8–24–01 Friday
Vol. 66 No. 165 Aug. 24, 2001
Pages 44521–44944

Federal Register

The **FEDERAL REGISTER** is published daily, Monday through Friday, except official holidays, by the Office of the Federal Register, National Archives and Records Administration, Washington, DC 20408, under the Federal Register Act (44 U.S.C. Ch. 15) and the regulations of the Administrative Committee of the Federal Register (1 CFR Ch. I). The Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402 is the exclusive distributor of the official edition.

The **Federal Register** provides a uniform system for making available to the public regulations and legal notices issued by Federal agencies. These include Presidential proclamations and Executive Orders, Federal agency documents having general applicability and legal effect, documents required to be published by act of Congress, and other Federal agency documents of public interest.

Documents are on file for public inspection in the Office of the Federal Register the day before they are published, unless the issuing agency requests earlier filing. For a list of documents currently on file for public inspection, see http://www.nara.gov/fedreg.

The seal of the National Archives and Records Administration authenticates the Federal Register as the official serial publication established under the Federal Register Act. Under 44 U.S.C. 1507, the contents of the **Federal Register** shall be judicially noticed.

The **Federal Register** is published in paper and on 24x microfiche. It is also available online at no charge as one of the databases on GPO Access, a service of the U.S. Government Printing Office.

The online edition of the **Federal Register** is issued under the authority of the Administrative Committee of the Federal Register as the official legal equivalent of the paper and microfiche editions (44 U.S.C. 4101 and 1 CFR 5.10). It is updated by 6 a.m. each day the **Federal Register** is published and it includes both text and graphics from Volume 59, Number 1 (January 2, 1994) forward.

GPO Access users can choose to retrieve online **Federal Register** documents as TEXT (ASCII text, graphics omitted), PDF (Adobe Portable Document Format, including full text and all graphics), or SUMMARY (abbreviated text) files. Users should carefully check retrieved material to ensure that documents were properly downloaded.

On the World Wide Web, connect to the **Federal Register** at http://www.access.gpo.gov/nara. Those without World Wide Web access can also connect with a local WAIS client, by Telnet to swais.access.gpo.gov, or by dialing (202) 512-1661 with a computer and modem. When using Telnet or modem, type swais, then log in as guest with no password.

For more information about GPO Access, contact the GPO Access User Support Team by E-mail at gpoaccess@gpo.gov; by fax at (202) 512–1262; or call (202) 512–1530 or 1–888–293–6498 (toll free) between 7 a.m. and 5 p.m. Eastern time, Monday–Friday, except Federal holidays.

The annual subscription price for the **Federal Register** paper edition is $638, or $697 for a combined **Federal Register,** Federal Register Index and List of CFR Sections Affected (LSA) subscription; the microfiche edition of the **Federal Register** including the Federal Register Index and LSA is $253. Six month subscriptions are available for one-half the annual rate. The charge for individual copies in paper form is $9.00 for each issue, or $9.00 for each group of pages as actually bound; or $2.00 for each issue in microfiche form. All prices include regular domestic postage and handling. International customers please add 25% for foreign handling. Remit check or money order, made payable to the Superintendent of Documents, or charge to your GPO Deposit Account, VISA, MasterCard or Discover. Mail to: New Orders, Superintendent of Documents, P.O. Box 371954, Pittsburgh, PA 15250–7954.

There are no restrictions on the republication of material appearing in the **Federal Register.**

How To Cite This Publication: Use the volume number and the page number. Example: 66 FR 12345.

Printed on recycled paper.

SUBSCRIPTIONS AND COPIES

PUBLIC

Subscriptions:

Paper or fiche	**202–512–1800**
Assistance with public subscriptions	**512–1806**

General online information **202–512–1530; 1–888–293–6498**

Single copies/back copies:

Paper or fiche	**512–1800**
Assistance with public single copies	**512–1803**

FEDERAL AGENCIES

Subscriptions:

Paper or fiche	**523–5243**
Assistance with Federal agency subscriptions	**523–5243**

Contents

Federal Register

Vol. 66, No. 165

Friday, August 24, 2001

Editorial Note: In the **Federal Register** table of contents of August 23, 2001, the final rule under Agriculture Department should have read:

Agriculture Department
RULES
Export sales reporting requirements:
Beef, 44291

Separate Parts In This Issue

Reader Aids
Consult the Reader Aids section at the end of this issue for phone numbers, online resources, finding aids, reminders, and notice of recently enacted public laws.

CFR PARTS AFFECTED IN THIS ISSUE

A cumulative list of the parts affected this month can be found in the Reader Aids section at the end of this issue.

Federal Register
Vol. 66, No. 165
Friday, August 24, 2001

Presidential Documents

Title 3—

The President

Presidential Determination No. 2001–23 of August 9, 2001

Waiver of Sanctions for the Export of Select U.S. Munitions List U.S.-Origin Helicopter and Armored Personnel Carrier Spare Parts and Ammunition from the United States to Pakistan

Memorandum for the Secretary of State

Pursuant to the authority vested in me as President of the United States, and consistent with Title IX of the Department of Defense Appropriations Act, 2000 (Public Law 106–79), I hereby waive the application of the restrictions contained in sections 101 and 102 of the Arms Export Control Act, as they have been applied under the International Traffic in Arms Regulations, and determine and certify to the Congress that the application of such restrictions would not be in the national security interests of the United States:

With respect to Pakistan, insofar as such restriction would otherwise apply to the sale of certain specified U.S.-origin helicopter and armored personnel carrier spare parts and ammunition to Pakistan for use in its deployment in Sierra Leone in support of UN peacekeeping operations.

You are authorized and directed to transmit this determination and certification to the appropriate committees of the Congress and to arrange for its publication in the **Federal Register**.



THE WHITE HOUSE,
Washington, August 9, 2001.

[FR Doc. 01–21586
Filed 8–23–01; 8:45 am]
Billing code 4710–10–M

Rules and Regulations

Federal Register
Vol. 66, No. 165
Friday, August 24, 2001

This section of the FEDERAL REGISTER contains regulatory documents having general applicability and legal effect, most of which are keyed to and codified in the Code of Federal Regulations, which is published under 50 titles pursuant to 44 U.S.C. 1510.

The Code of Federal Regulations is sold by the Superintendent of Documents. Prices of new books are listed in the first FEDERAL REGISTER issue of each week.

ADMINISTRATIVE COMMITTEE OF THE FEDERAL REGISTER

1 CFR Part 11

RIN 3095–ZA03

Prices and Availability of Federal Register Publications

AGENCY: Administrative Committee of the Federal Register.

ACTION: Final rule.

SUMMARY: The Administrative Committee of the **Federal Register** announces increases in the prices charged for the paper and microfiche editions of **Federal Register** publications. The price changes apply to the daily **Federal Register**, the **Federal Register** Index and LSA (List of CFR Sections Affected), the Code of Federal Regulations, and the Weekly Compilation of Presidential Documents. The Administrative Committee has determined that it is necessary to increase prices to enable the Government Printing Office to recover more of the cost of producing and distributing **Federal Register** publications.

DATES: This final rule is effective September 24, 2001.

FOR FURTHER INFORMATION CONTACT: Michael White at 202–275–4292, ext. 275.

SUPPLEMENTARY INFORMATION:

Background

Under the **Federal Register** Act (44 U.S.C. Chapter 15), the Administrative Committee of the **Federal Register** is responsible for establishing the prices charged for **Federal Register** publications. **Federal Register** publications are sold and distributed to the public by the Government Printing Office's (GPO) Superintendent of Documents. The Administrative Committee periodically reviews data submitted by the Superintendent of Documents to determine whether subscription rates and single copy prices of **Federal Register** publications produce sufficient revenue to keep pace with GPO's printing, handling and distribution costs, as well as postal rate increases. GPO receives no appropriation for any of the costs associated with producing **Federal Register** publications. Sales revenue supports the costs of the sales program.

In January 2001, the Administrative Committee reviewed data submitted by the Government Printing Office (GPO). The data indicates that sales revenue is insufficient to cover the program costs of certain **Federal Register** publications. The shortfall in sales revenue is attributable to declining paper subscriptions, increases in GPO employee pay scales and benefits, higher paper prices, and a 12.7 percent increase in postal rates in 2001. Although GPO has taken aggressive measures to achieve savings in its sales program, such as reducing full time equivalent employee costs by 29 percent since 1994, a number of other factors have combined to make it necessary to raise the price of paper publications. Part of the increased program costs can be attributed to a rise in the number of pages printed per subscription. The number of pages printed for each subscription to the **Federal Register** has increased by more than 10 percent since 1997 (66,934 pages in 1997 as compared with 77,234 pages in 2000). A sharp decline in the number of paid subscriptions has also contributed to the need for price increases. Since 1994, when the Administrative Committee began providing online access to the **Federal Register**, subscriptions have fallen by 73 percent. The decline in paper subscription revenue far exceeds the savings realized from reduced production costs. As a result, handling costs must be allocated over a much smaller base of orders, forcing increases in the prices of paper publications.

Based on this information, the Administrative Committee determined that it should propose price increases for certain publications to more accurately reflect the current costs of production and distribution. The Administrative Committee published a proposed rule on price changes for **Federal Register** publications on June 6, 2001 at 66 FR 30340. The proposed pricing schedule took into account the actual production, handling and distribution costs for paper publications over the past year and projected costs for the remainder of 2001. In this final rule, the Administrative Committee adopts without change the new subscription rates and single copy prices as set out in the proposed rule.

The price changes issued in the final rule are reflected in amendments to 1 CFR part 11. The following rates will be effective September 24, 2001. The annual subscription rate for the daily **Federal Register** paper edition increases from $638 to $699. For a combined **Federal Register**, **Federal Register** Index and LSA (List of CFR Sections Affected) subscription, the rate increases from $697 to $764. The price of a single copy of the daily **Federal Register** paper edition increases from $9 to $10. The annual subscription rate for the microfiche edition of the **Federal Register**, which includes the **Federal Register** Index and LSA, increases from $253 to $264. The annual subscription price for the **Federal Register** Index increases from $28 to $30. The annual subscription price for the monthly LSA increases from $31 to $35. The annual subscription rate for a full set of the CFR paper edition increases from $1094 to $1195. The annual subscription rate for the microfiche edition of the CFR increases from $290 to $298. The annual subscription rates for the Weekly Compilation of Presidential Documents increase from $92 to $103 for delivery by non-priority mail and from $151 to $169 for delivery by first-class mail.

The changes to subscription rates for the paper editions amount to a 9.6 percent increase in the price of the **Federal Register**, a 9.2 percent increase in the price of the CFR, and a 12 percent increase in the price of the Weekly Compilation of Presidential Documents. The single copy prices for the Weekly Compilation of Presidential Documents and the microfiche editions of the daily **Federal Register** and CFR will not change.

In the proposed rule, the Administrative Committee acknowledged that subscribers who prefer the convenience of having the paper editions of **Federal Register** publications delivered to their places of business would incur additional expenses. However, the Committee also stated that individuals and small

businesses would not be substantially affected because of the free access that is provided to the online editions on GPO Access and to the paper editions at Federal Depository libraries.

One person submitted a comment on the proposed rule. The commenter stated that the price increases did not adversely affect her ability to access Federal rules and policies. The commenter has relied on obtaining free access through a Depository library in the past and now uses the free online edition of the **Federal Register** on GPO Access. The commenter noted that having ready access to the online edition saves her the cost of driving at least 640 miles per year to a Depository library to do research and make photocopies.

Use of online **Federal Register** publications on the GPO Access service (http://www.access.gpo.gov/nara) has expanded rapidly since free service was introduced in late 1995. Information retrievals from the online edition of the **Federal Register** grew from just under 15 million documents in calendar year 1996 to over 61 million documents downloaded in calendar year 2000. Over the same period, information retrievals from the online edition of the CFR grew from about 725,000 documents to more than 93 million documents downloaded. The success of the online publications demonstrates that the Administrative Committee is fulfilling its mission to provide the public with essential information on the functions, actions, and regulatory requirements of the Federal government. At the same time, the Administrative Committee is constantly engaged in efforts to improve the quality of our online publications, including investments in new technology applications that will enhance e-government services to the public. In addition, GPO recently took new steps to significantly increase server capacity to meet the growing demand for online access to **Federal Register** publications. For members of the public who prefer to read the printed editions, GPO continues to provide free access to **Federal Register** publications at Federal Depository libraries located throughout the nation under funding provided by Congress.

Regulatory Analysis

Executive Order 12866

This rule has been drafted in accordance with Executive Order 12866, section 1(b), ''Principles of Regulation.'' The Administrative Committee consulted with the Office of Management and Budget (OMB) and determined that the rule does not meet the criteria for a significant regulatory action under Executive Order 12866. The annualized cost of the rule will be far less than $100 million and it does not meet any of the other criteria of section 3(f) of Executive Order 12866. Therefore, this final rule is not subject to OMB review.

Regulatory Flexibility Act

The Administrative Committee has determined that the Regulatory Flexibility Act, 5 U.S.C. 601 *et seq.*, does not apply to rate increases necessary to recover the costs to the Government for printing and distributing **Federal Register** publications. This rule will not have a significant impact on a substantial number of small entities since it imposes no substantive requirements, and any increased costs can be avoided by accessing **Federal Register** publications through the free GPO Access service on the Internet or at a Federal depository library. Therefore, a regulatory flexibility analysis as provided in the Regulatory Flexibility Act, as amended, is not required.

Federalism

This rule has no Federalism implications under Executive Order 13132. It does not impose compliance costs on State or local governments or preempt State law.

Congressional Review

This rule is not a major rule as defined by 5 U.S.C. 804(2). The Administrative Committee will submit a rule report, including a copy of this final rule, to each House of the Congress and to the Comptroller General of the United States as required under the congressional review provisions of the Small Business Regulatory Enforcement Fairness Act of 1986.

List of Subjects in 1 CFR Part 11

Code of Federal Regulations, **Federal Register,** Government publications, Weekly Compilation of Presidential Documents.

For the reasons discussed in the preamble, the Administrative Committee of the Federal Register amends part 11 of chapter I of title 1 of the Code of Federal Regulations as set forth below:

PART 11—SUBSCRIPTIONS

1. The authority citation for part 11 continues to read as follows:

Authority: 44 U.S.C. 1506; sec. 6, E.O. 10530, 19 FR 2709, 3 CFR, 1954–1958 Comp., p. 189.

2. In § 11.2, revise paragraph (a) to read as follows:

§ 11.2 Federal Register.

(a) The subscription price for the paper edition of the daily **Federal Register**, including postage, is $699 per year. A combined subscription to the daily **Federal Register**, the monthly **Federal Register** Index, and the monthly LSA (List of CFR Sections Affected), including postage, is $764 per year for the paper edition, or $264 per year for the microfiche edition. Six-month subscriptions to the paper and microfiche editions are also available at one-half the annual rate. Limited quantities of current or recent issues may be purchased for $10 per copy for the paper edition, or $2 per copy for the microfiche edition.

* * * * *

3. In § 11.3, revise paragraph (a) to read as follows:

§ 11.3 Code of Federal Regulations.

(a) The subscription price for a complete set of the Code of Federal Regulations, including postage, is $1195 per year for the bound, paper edition, or $298 per year for the microfiche edition. The Government Printing Office sells individual volumes of the paper edition of the Code of Federal Regulations at prices determined by the Superintendent of Documents under the general direction of the Administrative Committee. The price of a single volume of the microfiche edition is $2 per copy.

* * * * *

4. In § 11.6, revise paragraph (a) to read as follows:

§ 11.6 Weekly Compilation of Presidential Documents.

(a) The subscription price for the paper edition of the Weekly Compilation of Presidential Documents is $103 per year for delivery by non-priority mail, or $169 per year for delivery by first-class mail. The price of an individual copy is $4.

* * * * *

5. Revise § 11.7 to read as follows:

§ 11.7 Federal Register Index.

The annual subscription price for the monthly **Federal Register** Index, purchased separately, in paper form, is $30.

6. Revise § 11.8 to read as follows:

§ 11.8 LSA (List of CFR Sections Affected).

The annual subscription price for the monthly LSA (List of CFR Sections

Affected), purchased separately, in paper form, is $35.

John W. Carlin,
Chairman.
Michael F. Di Mario,
Member.
Rosemary Hart,
Member.
John D. Ashcroft,
Attorney General.
John W. Carlin,
Archivist of the United States.
[FR Doc. 01–21400 Filed 8–23–01; 8:45 am]
BILLING CODE 1505–02–P

FEDERAL RESERVE SYSTEM

12 CFR Part 220

[Regulation T]

Credit by Brokers and Dealers; List of Foreign Margin Stocks

AGENCY: Board of Governors of the Federal Reserve System.

ACTION: Final rule; determination of applicability of regulations.

SUMMARY: The List of Foreign Margin Stocks (Foreign List) is composed of certain foreign equity securities that qualify as *margin securities* under Regulation T. The Foreign List is published twice a year by the Board.

EFFECTIVE DATE: September 1, 2001.

FOR FURTHER INFORMATION CONTACT: Peggy Wolffrum, Financial Analyst, Division of Banking Supervision and Regulation, (202) 452–2837, or Scott Holz, Senior Counsel, Legal Division, (202) 452–2966, Board of Governors of the Federal Reserve System, Washington, DC 20551.

SUPPLEMENTARY INFORMATION: Listed below is a complete edition of the Board's Foreign List. The Foreign List was last published on February 22, 2001 (66 FR 11101), and became effective March 1, 2001.

The Foreign List is composed of foreign equity securities that qualify as margin securities under Regulation T by meeting the requirements of § 220.11(c) and (d). Additional foreign securities qualify as margin securities if they are deemed by the Securities and Exchange Commission (SEC) to have a ''ready market'' under SEC Rule 15c3–1 (17 CFR 240.15c3–1) or a ''no-action'' position issued thereunder. This includes all foreign stocks in the FTSE World Index Series.

It is unlawful for any creditor to make, or cause to be made, any representation to the effect that the inclusion of a security on the Foreign List is evidence that the Board or the SEC has in any way passed upon the merits of, or given approval to, such security or any transactions therein. Any statement in an advertisement or other similar communication containing a reference to the Board in connection with the Foreign List or the stocks thereon shall be an unlawful representation.

There are no additions to the Foreign List. The following three stocks are being removed because they no longer substantially meet the provisions of § 220.11(d) of Regulation T:

Hitachi Construction Machinery Co., Ltd.
¥50 par common
Nippon Trust Bank, Ltd.
¥50 par common
Tokyo Tomin Bank, Ltd.
¥500 par common

Public Comment and Deferred Effective Date

The requirements of 5 U.S.C. 553 with respect to notice and public participation were not followed in connection with the issuance of this amendment due to the objective character of the criteria for inclusion and continued inclusion on the Foreign List specified in § 220.11(c) and (d). No additional useful information would be gained by public participation. The full requirements of 5 U.S.C. 553 with respect to deferred effective date have not been followed in connection with the issuance of this amendment because the Board finds that it is in the public interest to facilitate investment and credit decisions based in whole or in part upon the composition of the Foreign List as soon as possible. The Board has responded to a request by the public and allowed approximately a one-week delay before the Foreign List is effective.

List of Subjects in 12 CFR Part 220

Brokers, Credit, Margin, Margin requirements, Investments, Reporting and recordkeeping requirements, Securities.

Accordingly, pursuant to the authority of sections 7 and 23 of the Securities Exchange Act of 1934, as amended (15 U.S.C. 78g and 78w), and in accordance with 12 CFR 220.2 and 220.11, there is set forth below a complete edition of the Foreign List.

Japan

Akita Bank, Ltd.
¥50 par common
Aomori Bank, Ltd.
¥50 par common
Asatsu-Dk Inc.
¥50 par common
Bandai Co., Ltd.
¥50 par common
Bank of Nagoya, Ltd.
¥50 par common
Chudenko Corp.
¥50 par common
Chugoku Bank, Ltd.
¥50 par common
Clarion Co., Ltd.
¥50 par common
Daihatsu Motor Co., Ltd.
¥50 par common
Dainippon Screen Mfg. Co., Ltd.
¥50 par common
Denki Kagaku Kogyo
¥50 par common
Eighteenth Bank, Ltd.
¥50 par common
Futaba Corp.
¥50 par common
Futaba Industrial Co., Ltd.
¥50 par common
Higo Bank, Ltd.
¥50 par common
Hitachi Software Engineering Co., Ltd.
¥50 par common
Hitachi Transport System, Ltd.
¥50 par common
Hokkoku Bank, Ltd.
¥50 par common
Hokuetsu Bank, Ltd.
¥50 par common
Hokuetsu Paper Mills, Ltd.
¥50 par common
Iyo Bank, Ltd.
¥50 par common
Japan Airport Terminal Co., Ltd.
¥50 par common
Juroku Bank, Ltd.
¥50 par common
Kagoshima Bank, Ltd.
¥50 par common
Kamigumi Co., Ltd.
¥50 par common
Katokichi Co., Ltd.
¥50 par common
Keisei Electric Railway Co., Ltd.
¥50 par common
Keiyo Bank, Ltd.
¥50 par common
Kiyo Bank, Ltd.
¥50 par common
Komori Corp.
¥50 par common
Konami Co., Ltd.
¥50 par common
Kyowa Exeo Corp.
¥50 par common
Matsushita Seiko Co., Ltd.
¥50 par common
Max Co., Ltd.
¥50 par common
Michinoku Bank, Ltd.
¥50 par common
Musashino Bank, Ltd.
¥500 par common
Namco, Ltd.
¥50 par common
Nichicon Corp.

¥50 par common
Nihon Unisys, Ltd.
¥50 par common
Nippon Comsys Corp.
¥50 par common
Nishi-Nippon Bank, Ltd.
¥50 par common
Nishi-Nippon Railroad Co., Ltd.
¥50 par common
Nissan Chemical Industries, Ltd.
¥50 par common
Ogaki Kyoritsu Bank, Ltd.
¥50 par common
Q.P. Corp.
¥50 par common
Rinnai Corporation
¥50 par common
Ryosan Co., Ltd.
¥50 par common
Sagami Railway Co., Ltd.
¥50 par common
Sakata Seed Corp.
¥50 par common
Santen Pharmaceutical Co., Ltd.
¥50 par common
Shimadzu Corp.
¥50 par common
Shimamura Co., Ltd.
¥50 par common
Sumitomo Rubber Industries, Ltd.
¥50 par common
Taiyo Yuden Co., Ltd.
¥50 par common
Takara Standard Co., Ltd.
¥50 par common
Takuma Co., Ltd.
¥50 par common
Toho Bank, Ltd.
¥50 par common
Toho Gas Co., Ltd.
¥50 par common
Tokyo Ohka Kogyo Co., Ltd.
¥50 par common
Uni-Charm Corp.
¥50 par common
Ushio, Inc.
¥50 par common
Yamaha Motor Co., Ltd.
¥50 par common
Yamanashi Chua Bank, Ltd.
¥50 par common

By order of the Board of Governors of the Federal Reserve System, acting by its Director of the Division of Banking Supervision and Regulation pursuant to delegated authority (12 CFR 265.7(f)(10)), August 20, 2001.

Jennifer J. Johnson,

Secretary of the Board.

[FR Doc. 01–21359 Filed 8–23–01; 8:45 am]

BILLING CODE 6210–01–P

DEPARTMENT OF THE TREASURY

Fiscal Service

31 CFR Part 357

[Department of the Treasury Circular, Public Debt Series, No. 2–86]

Regulations Governing Book-Entry Treasury Bonds, Notes, and Bills; Determination Regarding State Statute; South Carolina

AGENCY: Bureau of the Public Debt, Fiscal Service, Treasury.

ACTION: Determination of substantially identical state statute.

SUMMARY: The Department of the Treasury is announcing that it has reviewed the recently enacted South Carolina law adopting the 1994 Revision of Article 8 of the U.C.C. along with the conforming amendments from the 1998 Revision of Article 9 of the U.C.C. and has determined that it is substantially identical to the uniform version of Revised Article 8 for purposes of interpreting the rules in 31 CFR part 357, subpart B (the ''TRADES'' regulations).

EFFECTIVE DATE: August 24, 2001.

ADDRESSES: See Supplemental Information for electronic access.

FOR FURTHER INFORMATION CONTACT: Sandy Dyson, Attorney-Advisor (202) 691–3707, Walter T. Eccard, Chief Counsel (202) 691–3705 or Cynthia E. Reese, Deputy Chief Counsel (202) 691–3709.

SUPPLEMENTARY INFORMATION:

Electronic Access

Copies of this notice are available for downloading from the Bureau of the Public Debt home page at: *http://www.publicdebt.treas.gov.*

On August 23, 1996, The Department published a final rule to govern securities held in the commercial book-entry system, also referred to as the Treasury/Reserve Automated Debt Entry System (''TRADES''), 61 FR 43626.

In the commentary to the final regulations, Treasury stated that for the 28 states that had by then adopted Revised Article 8, the versions enacted were ''substantially identical'' to the uniform version for purposes of the rule. Therefore, for those states, that portion of the TRADES rule requiring application of Revised Article 8 was not invoked. Treasury also indicated in the commentary that as additional states adopt Revised Article 8, notice would be provided in the **Federal Register** as to whether the enactments are substantially identical to the uniform version so that the federal application of Revised Article 8 would no longer be in effect for those states. Treasury adopted this approach in an attempt to provide certainty in the application of the rule in response to public comments.

We have subsequently published notices setting forth our determination concerning 23 additional states' enactment of Revised Article 8. See 62 FR 26, January 2, 1997; 62 FR 34010, June 18, 1997; 62 FR 61912, November 20, 1997; 63 FR 20099, April 23, 1998; 63 FR 35807, July 1, 1998; 63 FR 50159, September 21, 1998; and 66 FR 33832, June 26, 2001. Thus, prior to this notice, a total of 51 jurisdictions (including the District of Columbia and Puerto Rico, which are treated as states), have enacted statutes deemed by Treasury as substantially identical to the uniform version of Revised Article 8.

We note that South Carolina's enactment of Article 8 includes conforming revisions made by Revised Article 9 (1998), which the state also enacted. The TRADES rules define ''Revised Article 8'' as the 1994 Official Text with conforming amendments (§ 357.2). Consistent with our notice published June 26, 2001 (66 FR 33832) concerning Revised Article 9, we have reviewed these changes and conclude that the law enacted by South Carolina is ''substantially identical'' to the 1994 version of Article 8 for purposes of the TRADES rules. Therefore, if either § 357.10(b) or § 357.11(b) directs a person to South Carolina, the provisions of §§ 357.10(c) and 357.11(d) of the TRADES rule are not applicable.

As noted in our June 26, 2001 notice, several technical or conforming changes to the TRADES regulations required by Revised Article 9 will be published in the near future.

Van Zeck,

Commissioner of the Public Debt.

[FR Doc. 01–21461 Filed 8–23–01; 8:45 am]

BILLING CODE 4810–39–P

DEPARTMENT OF COMMERCE

Patent and Trademark Office

37 CFR Part 10

[Docket No. 010724188–1188–01]

Interpretation of Registration of Agents and Representative for Director of Enrollment and Discipline in Disciplinary Proceedings

AGENCY: Patent and Trademark Office, Commerce.

ACTION: Interpretation of regulation.

SUMMARY: The United States Patent and Trademark Office (USPTO or ''Office'') implements an interpretation of certain regulatory provisions. These provisions concern the composition and operations of the Committee on Discipline and representation of the Director in disciplinary cases. The interpretation is necessary in view of the recent creation of the Office of General Counsel at the USPTO. The Patent and Trademark Office Efficiency Act (PTOEA) reestablished the Patent and Trademark Office as the United States Patent and Trademark Office, a performance-based organization with responsibility for its own operations. Consequently, the Office has responsibility for many functions formerly provided by the Department of Commerce.

EFFECTIVE DATE: The interpretation is issued August 24, 2001.

ADDRESSES: Director of the United States Patent and Trademark Office, Washington, D.C. 20231

FOR FURTHER INFORMATION CONTACT: Harry Moatz, by mail addressed to United States Patent and Trademark Office, Box OED, Washington, DC 20231, (Attn: OED Director) or by facsimile transmission to (703) 305–4631, or by electronic mail at harry.moatz@uspto.gov.

SUPPLEMENTARY INFORMATION: 37 CFR 10.140(b) relates to whom within the USPTO represents the Director of Enrollment and Discipline (OED Director) in disciplinary proceedings, and who shall be available as counsel to the Director of the United States Patent and Trademark Office (USPTO Director) in deciding such proceedings. For example, it states that at least two associate solicitors shall be designated to represent the OED Director. It also states that the Solicitor and Deputy Solicitor shall advise the USPTO Director.

Additionally, the last sentence of 37 CFR 10.4(b) identifies the USPTO employees that shall not participate in rendering a decision on disciplinary changes. Among those identified as not participating in rendering decisions are associate and assistant solicitors of the Office of the Solicitor. In addition, the PTOEA designated the head of the USPTO as Under Secretary of Commerce for Intellectual Property and Director of the USPTO. 35 U.S.C. 3(a)(1).

As a result, it is necessary and appropriate to interpret the last sentence of § 10.4(b) and § 10.140(b) in view of this reorganization. Because these are interpretive statements of rules, they are exempt from notice and comment rulemaking under 5 U.S.C. 553(b)(3)(A). For the reasons set forth in the preamble, the United States Patent and Trademark Office interprets §§ 10.4(b) and 10.140(b) as follows:

The last sentence of § 10.4(b) provides, ''When charges are brought against a practitioner, no member of the Committee on Discipline, employee under the direction of the Director, or associate solicitor or assistant solicitor in the Office of the Solicitor shall participate in rendering a decision on the charges.'' This sentence is construed as providing that when charges are brought against a practitioner, the designated attorneys in the Office of General Counsel (including assistant and associate solicitors, and associate counsel) shall not participate in rendering a decision on the charges.

The first sentence of § 10.140(b) provides, ''The Commissioner shall designate at least two associate solicitors in the Office of the Solicitor to act as representatives for the Director in disciplinary proceedings.'' This sentence is construed as authorizing the USPTO Director to designate at least two attorneys (including assistant and associate solicitors, and associate counsel) in the Office of General Counsel to act as representatives for the OED Director in disciplinary proceedings.

The second sentence of § 10.140(b) provides, ''In prosecuting disciplinary proceedings, the designated associate solicitors shall not involve the Solicitor or the Deputy Solicitor.'' This sentence is construed as providing that in prosecuting disciplinary proceedings, the designated attorneys in the Office of General Counsel (including assistant and associate solicitors, and associate counsel) shall not involve the General Counsel or the Deputy General Counsel for General Law.

The third sentence of § 10.140(b) provides, ''The Solicitor and the Deputy Solicitor shall remain insulated from the investigation and prosecution of all disciplinary proceedings in order that they shall be available as counsel to the Commissioner in deciding disciplinary proceedings.'' This is construed as providing that the General Counsel and the Deputy General Counsel for General Law shall remain insulated from the investigation and prosecution of all disciplinary proceedings in order that they shall be available as counsel to the USPTO Director in deciding disciplinary proceedings. However, the Deputy General Counsel for Intellectual Property Law and Solicitor shall not remain insulated from the investigation and prosecution of disciplinary proceedings, and thus shall not be available to counsel the USPTO Director in deciding such proceedings.

Dated: August 20, 2001.

Nicholas P. Godici,

Acting Under Secretary of Commerce for Intellectual Property and Acting Director of the United States Patent and Trademark Office.

[FR Doc. 01–21480 Filed 8–23–01; 8:45 am]

BILLING CODE 3510–16–U

DEPARTMENT OF VETERANS AFFAIRS

38 CFR Part 3

RIN 2900–AK96

Certification for Eligibility for Adaptive Equipment for Automobiles or Other Conveyances

AGENCY: Department of Veterans Affairs.

ACTION: Final rule.

SUMMARY: This document amends the Department of Veterans Affairs (VA) adjudication regulations concerning the criteria for certification for eligibility for financial assistance for adaptive equipment for automobiles or other conveyances by updating cross-references to pertinent medical regulations that have been recodified. These changes are made for clarity and accuracy.

DATES: Effective Date: August 24, 2001.

FOR FURTHER INFORMATION CONTACT: Randy A. McKevitt, Consultant, Regulations Staff, Compensation and Pension Service, Veterans Benefits Administration, 810 Vermont Avenue, NW., Washington, DC 20420, telephone (202) 273–7138.

SUPPLEMENTARY INFORMATION: This final rule consists of nonsubstantive changes and, therefore, is not subject to the notice and comment and effective date provisions of 5 U.S.C. 553.

The Secretary hereby certifies that this regulatory amendment will not have a significant economic impact on a substantial number of small entities as they are defined in the Regulatory Flexibility Act (RFA), 5 U.S.C. 601–612. This rule merely consists of nonsubstantive changes. Therefore, pursuant to 5 U.S.C. 605(b), this amendment is exempt from the initial and final regulatory flexibility analysis requirements of sections 603 and 604.

The Catalog of Federal Domestic Assistance program number is 64.100.

List of Subjects in 38 CFR Part 3

Administrative practice and procedure, Claims, Disability benefits, Health care, Pensions, Radioactive materials, Veterans, Vietnam.

Approved: August 17, 2001.

Anthony J. Principi,

Secretary of Veterans Affairs.

For the reasons set forth in the preamble, 38 CFR part 3 is amended as follows:

PART 3—ADJUDICATION

Subpart A—Pension, Compensation, and Dependency and Indemnity Compensation

1. The authority citation for part 3, subpart A continues to read as follows:

Authority: 38 U.S.C. 501(a), unless otherwise noted.

§ 3.808 [Amended]

2. In § 3.808, paragraph (d) is amended by removing ''17.119a through 17.119c'' and adding, in its place, ''17.156, 17.157, and 17.158''

[FR Doc. 01–21499 Filed 8–23–01; 8:45 am]

BILLING CODE 8320–01–P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 52

[PA–4136a; FRL–7035–8]

Approval and Promulgation of Air Quality Implementation Plans; Pennsylvania; VOC RACT Determinations for Nine Sources in the Pittsburgh-Beaver Valley Area

AGENCY: Environmental Protection Agency (EPA).

ACTION: Direct final rule.

SUMMARY: EPA is taking direct final action to approve revisions to the Commonwealth of Pennsylvania's State Implementation Plan (SIP). The revisions were submitted by the Pennsylvania Department of Environmental Protection (PADEP) to establish and require reasonably available control technology (RACT) for nine major sources of volatile organic compounds (VOC). These sources are located in the Pittsburgh-Beaver Valley ozone nonattainment area (the Pittsburgh area). EPA is approving these revisions to establish RACT requirements in the SIP in accordance with the Clean Air Act (CAA).

DATES: This rule is effective on October 9, 2001 without further notice, unless EPA receives adverse written comment by September 24, 2001. If EPA receives such comments, it will publish a timely withdrawal of the direct final rule in the **Federal Register** and inform the public that the rule will not take effect.

ADDRESSES: Written comments should be mailed to David L. Arnold, Chief, Air Quality Planning & Information Services Branch, Air Protection Division, Mailcode 3AP21, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103. Copies of the documents relevant to this action are available for public inspection during normal business hours at the Air Protection Division, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103; the Air and Radiation Docket and Information Center, U.S. Environmental Protection Agency, 401 M Street, SW, Washington, DC 20460; Allegheny County Health Department, Bureau of Environmental Quality, Division of Air Quality, 301 39th Street, Pittsburgh, Pennsylvania 15201 and the Pennsylvania Department of Environmental Protection, Bureau of Air Quality Control, P.O. Box 8468, 400 Market Street, Harrisburg, Pennsylvania 17105.

FOR FURTHER INFORMATION CONTACT: Rose Quinto at (215) 814–2182, the EPA Region III address above or by e-mail at *quinto.rose@epa.gov*. Please note that while questions may be posed via telephone and e-mail, formal comments must be submitted, in writing, as indicated in the **ADDRESSES** section of this document.

SUPPLEMENTARY INFORMATION:

I. Background

Pursuant to sections 182(b)(2) and 182(f) of the Clean Air Act (CAA), the Commonwealth of Pennsylvania (the Commonwealth or Pennsylvania) is required to establish and implement RACT for all major VOC and NO_X sources. The major source size is determined by its location, the classification of that area and whether it is located in the ozone transport region (OTR). Under section 184 of the CAA, RACT as specified in sections 182(b)(2) and 182(f)) applies throughout the OTR. The entire Commonwealth is located within the OTR. Therefore, RACT is applicable statewide in Pennsylvania.

State implementation plan revisions imposing reasonably available control technology (RACT) for three classes of VOC sources are required under section 182(b)(2). The categories are:

(1) All sources covered by a Control Technique Guideline (CTG) document issued between November 15, 1990 and the date of attainment;

(2) all sources covered by a CTG issued prior to November 15, 1990; and

(3) all major non-CTG sources. The regulations imposing RACT for these non-CTG major sources were to be submitted to EPA as SIP revisions by November 15, 1992 and compliance required by May of 1995.

The Pennsylvania SIP already includes approved RACT regulations for all sources and source categories covered by the CTGs. On February 4, 1994, PADEP submitted a revision to its SIP to require major sources of NO_X and additional major sources of VOC emissions (not covered by a CTG) to implement RACT. The February 4, 1994 submittal was amended on May 3, 1994 to correct and clarify certain presumptive NO_X RACT requirements. In the Pittsburgh area, a major source of VOC is defined as one having the potential to emit 50 tons per year (tpy) or more, and a major source of NO_X is defined as one having the potential to emit 100 tpy or more. Pennsylvania's RACT regulations require sources, in the Pittsburgh area, that have the potential to emit 50 tpy or more of VOC and sources which have the potential to emit 100 tpy or more of NO_X comply with RACT by May 31, 1995. The regulations contain technology-based or operational ''presumptive RACT emission limitations'' for certain major NO_X sources. For other major NO_X sources, and all major non-CTG VOC sources (not otherwise already subject to RACT under the Pennsylvania SIP), the regulations contain a ''generic'' RACT provision. A generic RACT regulation is one that does not, itself, specifically define RACT for a source or source categories but instead allows for case-by-case RACT determinations. The generic provisions of Pennsylvania's regulations allow for PADEP to make case-by case RACT determinations that are then to be submitted to EPA as revisions to the Pennsylvania SIP.

On March 23, 1998 EPA granted conditional limited approval to the Commonwealth's generic VOC and NO_X RACT regulations (63 FR 13789). In that action, EPA stated that the conditions of its approval would be satisfied once the Commonwealth either (1) certifies that it has submitted case-by-case RACT proposals for all sources subject to the RACT requirements currently known to PADEP; *or* (2) demonstrate that the emissions from any remaining subject sources represent a de minimis level of emissions as defined in the March 23, 1998 rulemaking. On April 22, 1999, PADEP made the required submittal to EPA certifying that it had met the terms and conditions imposed by EPA in its March 23, 1998 conditional limited approval of its VOC and NO_X RACT regulations by submitting 485 case-by-case VOC/ NO_X RACT determinations as SIP revisions and making the

demonstration described as condition 2, above. EPA determined that Pennsylvania's April 22, 1999 submittal satisfied the conditions imposed in its conditional limited approval published on March 23, 1998. On May 3, 2001 (66 FR 22123), EPA published a rulemaking action removing the conditional status of its approval of the Commonwealth's generic VOC and NO_X RACT regulations on a statewide basis. The regulation currently retains its limited approval status. Once EPA has approved the case-by-case RACT determinations submitted by PADEP to satisfy the conditional approval for subject sources located in Allegheny, Armstrong, Beaver, Butler, Fayette, Washington, and Westmoreland Counties; the limited approval of Pennsylvania's generic VOC and NO_X RACT regulations shall convert to a full approval for the Pittsburgh area.

It must be noted that the Commonwealth has adopted and is implementing additional ''post RACT requirements'' to reduce seasonal NO_X emissions in the form of a NO_X cap and trade regulation, 25 Pa Code Chapters 121 and 123, based upon a model rule developed by the States in the OTR. That rule's compliance date is May 1999. That regulation was approved as SIP revision on June 6, 2000 (65 FR 35842). Pennsylvania has also adopted regulations to satisfy Phase I of the NO_X SIP call and submitted those regulations to EPA for SIP approval. Pennsylvania's SIP revision to address the requirements of the NO_X SIP Call Phase I consists of the adoption of Chapter 145—Interstate Pollution Transport Reduction and amendments to Chapter 123—Standards for Contaminants. On May 29, 2001 (66 FR 29064), EPA proposed approval of the Commonwealth's NO_X SIP call rule SIP submittal. EPA expects to publish the final rulemaking in the **Federal Register** in the near future. Federal approval of a case-by-case RACT determination for a major source of NO_X in no way relieves that source from any applicable requirements found in 25 PA Code Chapters 121, 123 and 145.

On March 21, 1996, October 18, 1996, January 21, 1997, July 1, 1997, March 23, 2001, and April 19, 2001, PADEP submitted revisions to the Pennsylvania SIP which establish and impose RACT for several major sources of VOC. This rulemaking pertains to nine of those sources. The remaining sources are or have been the subject of separate rulemakings. The Commonwealth's submittals consist of operating permits (OPs) issued by PADEP and plan approval and agreement upon consent orders (Consent Orders or COs) issued by the Allegheny County Health Department (ACHD). These nine sources are located in the Pittsburgh area.

II. Summary of the SIP Revisions

The table below identifies the sources and individual OPs and COs which are the subject of this rulemaking. A summary of the VOC RACT determinations for each source follows the table.

PENNSYLVANIA—VOC RACT DETERMINATIONS FOR INDIVIDUAL SOURCES

Source	County	Consent order (CO#), operating permit (OP#)	Source type	''Major source'' pollutant
Armstrong World Industries, Inc.—Beaver Falls.	Beaver	OP 04–000–108	Ceiling tile manufacturing	VOC
Bacharach, Inc	Allegheny	CO 263	Gas detection equipment manufacturing	VOC
Bakerstown Container Corporation	Allegheny	CO 221	Steel drum reconditioning	VOC
Chestnut Ridge Foam, Inc	Westmoreland	OP 65–000–181	Foam product manufacturing	VOC
Flexsys America L. P., Monongahela Plant	Washington	OP 63–000–015	Crystex manufacturing	VOC
Haskell of Pittsburgh	Allegheny	CO 224	Steel office furniture manufacturing	VOC
Three Rivers Aluminum Company	Butler	OP 10–267	Aluminum window manufacturing	VOC
Tuscarora Plastics, Inc	Beaver	OP 04–000–497	Expandable polystyrene plant	VOC
Witco Corporation	Allegheny	CO 210	Lubricant manufacturing	VOC

A. Armstrong World Industries

Armstrong World Industries (AWI) manufactures commercial grade ceiling tile. This facility is located in Beaver Falls, Beaver County, Pennsylvania. AWI is a major VOC emitting facility. In this instance, RACT has been established and imposed by PADEP in an OP. On January 21, 1997, PADEP submitted this OP 04–000–108 to EPA as a SIP revision. OP 04–000–108 requires AWI and any associated air cleaning devices to be operated and maintained in a manner consistent with good operating and management practices. Under OP 04–000108, AWI must comply with the facility emission limit of 164 tons of VOC per year. AWI must not exceed a ceiling board production rate of 96 million square feet per year. AWI must maintain coating usage records. The production rate must be monitored and recorded to demonstrate compliance with the annual facility emission limit of 164 tons of VOC per year. Monitoring data will be recorded in log sheets, computer media, paper printouts, strip charts, or a combination of these for each production line. Summary reports of all required monitoring must be submitted by AWI to PADEP every 12 months. Compliance with annual limits must be met on a rolling monthly basis over very consecutive 12 month period.

B. Bacharach Inc.

Bacharach Inc. manufactures gas detection equipment and temperature and measurement devices. This facility is located in O'Hara Township, Allegheny County, Pennsylvania. Bacharach Inc. is a major VOC emitting facility. In this instance, RACT has been established and imposed by ACHD in CO 263. On April 19, 2001, PADEP submitted CO 263 to EPA on behalf of the ACHD as a SIP revision. Bacharach Inc. consists of two processes: (a) Vapor degreaser, and (2) spray paint booth and oven. Under CO 263, Bacharach Inc. is not allowed to exceed 50 tons per year of total combined annual facility wide emissions of VOCs. Also, under CO 263, Bacharach Inc. must maintain records to demonstrate compliance with this CO and Article XXI, section 2105.06. Recordkeeping requirements must include material purchase and consumption records. All records shall be retained for at least two years.

C. Bakerstown Container Corporation

Bakerstown Container Corporation (BCC) is a steel drum manufacturing facility located in Bakerstown, Allegheny County, Pennsylvania. BCC is a major VOC emitting facility. In this instance, RACT has been established and imposed by ACHD in CO 221. On July 1, 1997, PADEP submitted CO 221

to EPA on behalf of the ACHD as a SIP revision. BCC reconditions 55 gallon steel drums and consists of a drum drying furnace, drum interior and drum exterior coating processes, a curing oven and one boiler. Under CO 221, at no time shall BCC allow the drum burning furnace to operate unless the furnace and afterburner are properly maintained and operated within the following parameters: (1) Minimum afterburner operating temperature of 1600 degrees Fahrenheit, and (2) minimum afterburner residence time of 0.5 seconds. Also under CO 221, at no time shall BCC store containers of VOCs at the facility unless such containers are covered at all times, with the exceptions of the following: (a) the mixing of paint immediately prior to paint application, and (b) the transfer of material to different containers. CO 221 requires BCC at all times and as expeditiously as possible, to cleanup any liquid or dry material spilled at the facility. CO 221 also requires BCC to maintain records to demonstrate compliance with this CO and Article XXI, section 2105.06. Recordkeeping requirements must include the quantity, composition, and density of all coatings and solvents, including solvents used for cleanup and purging, used in each process. All records shall be retained for at least two years.

D. Chestnut Ridge Foam, Inc.

Chestnut Ridge Foam, Inc. (Chestnut) operates a facility for the manufacture of flame-resistant and specialty foam products located in East Huntington Township, Westmoreland County, Pennsylvania. Chestnut is a major VOC emitting facility. In this instance, RACT has been established and imposed by PADEP in an OP. On March 21, 1996, PADEP submitted OP 65–000–181 to EPA as a SIP revision. OP 654–000–181 requires that all processes and associated air cleaning devices be operated and maintained in a manner consistent with good operating and management practices. OP 654–000–181 is for the operation of the various VOC emitting sources: Dip Line, Lamination line, Ross Line, Glue Tables, Urethane Line, Boiler #1, Boiler #2, and Box Dryers. OP 654–000–181 requires Chestnut not to exceed 165.57 tons per year of VOC. All records shall be retained for at least two years. Recordkeeping includes monthly records on the quantity of VOC containing compounds used at the facility. Annual limits are to be met on a rolling monthly basis over every consecutive 12 month period.

E. Flexsys America L.P.

Flexsys America L.P. (Flexsys), Monongahela Plant, manufactures an insoluble sulfur additive called Crystex which is used in the making of rubber tires. The facility is located in Monongahela, Washington County, Pennsylvania. Flexsys is a major VOC emitting facility. In this instance, RACT has been established and imposed by PADEP in an OP. On April 19, 2001, PADEP submitted OP 63–000–015 to EPA as a SIP revision. OP 63–000–015 requires Flexsys' processes and any associated air cleaning devices to be operated and maintained in a manner consistent with good operating and management practices. Flexsys must maintain records in accordance with 25 PA Code section 129.95. Under OP 63–000–015, VOC emissions from this facility shall not exceed 170 tons per year to met on a rolling monthly basis over every consecutive 12 month period. In addition, VOC emissions from the Crystex process, shall not exceed 3.2 pounds per hour. The method of compliance with the VOC emission limitations above shall be the submittal of a yearly report to PADEP summarizing the actual and potential VOC emissions. This report shall describe in detail the methods used to calculate the emissions.

F. Haskell of Pittsburgh, Inc.

Haskell of Pittsburgh, Inc. (Haskell) is a steel office furniture manufacturing facility located in Verona, Allegheny County, Pennsylvania. Haskell is a major VOC emitting facility. In this instance, RACT has been established and imposed by ACHD in CO 224. On July 1, 1997, PADEP submitted CO 224 to EPA on behalf of the ACHD as a SIP revision. Haskell has six separate manufacturing processes along with miscellaneous facility maintenance operations. CO 224 requires Haskell the following:

(1) For the paint process: Utilize high solid paint coatings which have a VOC content not greater than 3.0 pounds per gallon, less water and exempt solvents, as applied; and utilize electrostatic spray equipment or equipment equal to or better in terms of VOC emission control.

(2) For the paint mixing room process: Utilize high solid paint coatings which have a VOC content not greater than 0.3 pounds per gallon, less water and exempt solvents, as applied; cover containers containing VOCs at all times, except during the transfer of material to different containers; and clean, as expeditiously as possible, any liquid or dry material spilled containing VOCs.

(3) For the paint storage rooms: Cover containers containing VOCs at all times, except during the transfer of material to different containers; and clean, as expeditiously as possible, any liquid or dry material spilled containing VOCs.

(4) For the burn-off oven: For the purpose of paint removal, maintain and operate its incinerator so that the minimum operating temperature of 1400 degrees Fahrenheit and minimum residence time of 0.5 seconds is maintained.

(5) For the xylene reclaim process: Utilize the still as a VOC control device, condensing the VOC containing vapors as a means of capturing VOCs.

(6) For the glue booth process operations: Utilize only glues which have a VOC content of not greater than 3.0 pounds per gallon, less water and exempt solvents, as applied.

(7) Operations with respect to the use of xylol in cleaning and maintenance: Maintain covers on all xylol containers except when in use, and clean any spilled xylol as expeditiously as possible.

CO 224 requires the VOC content of the booth peel used at the facility not to exceed 7.0 pounds per gallon, less water and exempt solvents, as applied. CO 224 requires Haskell to maintain records to demonstrate compliance with this CO and Article XXI, section 2105.06. Recordkeeping requirements must include the quantity, composition and density of all coatings and solvents in the paint process, and the glue both process, including solvents used for cleanup and purging in such processes. All records shall be retained for at least two years.

G. Three Rivers Aluminum Company

Three Rivers Aluminum Company (TRACO) manufactures commercial thermally improved operating and fixed windows, insulated glass, and custom and finished aluminum extrusions. The facility is located in Cranberry Township, Butler County, Pennsylvania. TRACO is a major VOC emitting facility. In this instance, RACT has been established and imposed by PADEP in an OP. On March 23, 2001, PADEP submitted OP 10–267 to EPA as a SIP revision. OP 10–267 requires TRACO to continue to investigate the use of substitute solvents; continue to improve procedures to reduce solvent usage and evaporative loss for assembly operations and continue to implement good work practices and mange solvent use and rags to minimize evaporation. All sources shall be operated and maintained in accordance with good air pollution control practices. OP 10–267 also requires TRACO to keep a log of all

solvents used in the assembly operations. The log requirements are: (a) To be maintained on a monthly basis specifying monthly VOC emissions from the assembly operations; and (b) to be maintained for a period of at least 5 years.

H. Tuscarora Plastics, Inc.

Tuscarora Plastics, Inc. (Tuscarora) is an expandable polystyrene plant located in New Brighton, Beaver County, Pennsylvania. Tuscarora manufactures various foam plastic products, including structural components, custom molded parts, foam plastic packaging and material handling constituents, Tuscarora is a major VOC emitting facility. In this instance, RACT has been established and imposed by PADEP in an OP. On October 18, 1996, PADEP submitted OP 04–000–497 to EPA as a SIP revision. OP 04–000–497 requires Tuscarora's processes and any associated air cleaning devices to be operated and maintained in a manner consistent with good operating and management practices. OP 04–000–497 requires the average VOC content of the raw material by weight shall not exceed 4.3 percent for the expandable polystyrene (EPS) beads and 8 percent for small quantities of polystyrene/polyethylene copolymer (ARCEL) beads. VOC emissions shall be limited to 4.17 pounds per 100 pounds of raw material processed for EPS, and 7.2 pounds per 100 pounds of raw material processes for ARCEL. The annual VOC emission rate shall not exceed 63 tons facility wide to met on a rolling monthly basis over every consecutive 12 month period. Records shall be maintained verifying emission rates and shall be retained for at least two years.

I. Witco Corporation

Witco Corporation (Witco) is a grease and other lubricants manufacturing facility located in Gibsonia, Allegheny County, Pennsylvania. Witco is a major VOC emitting facility. In this instance, RACT has been established and imposed by ACHD in CO 210. On July 1, 1997, PADEP submitted CO 210 to EPA on behalf of the ACHD as a SIP revision. CO 210 requires Witco not to conduct any process operations which generate emissions of VOCs at any time, unless all VOC emissions are processed by the facility's thermal oxidizer. The thermal oxidizer shall be properly maintained and operated with a minimum VOC destruction efficiency of 98.9 percent, a minimum retention of 0.5 seconds and a minimum operating temperature of 1500 degrees Fahrenheit at all times during process operations. The thermal oxidizer destruction efficiency shall be determined annually according to EPA approved test methods and section 2108.02.c of Article XXI. CO 210 requires Witco to maintain records to demonstrate compliance with this CO and Article XXI, section 2105.06. All records shall be retained for at least two years.

III. EPA's Evaluation of the SIP Revisions

EPA is approving these RACT SIP submittals because ACHD and PADEP established and imposed these RACT requirements in accordance with the criteria set forth in the SIP-approved RACT regulations applicable to these sources. The ACHD and PADEP has also imposed recordkeeping, monitoring, and testing requirements on these sources sufficient to determine compliance with the applicable RACT determinations.

IV. Final Action

EPA is approving the revisions to the Pennsylvania SIP submitted by PADEP to establish and require VOC RACT for nine major sources located in the Pittsburgh area. EPA is publishing this rule without prior proposal because the Agency views this as a noncontroversial amendment and anticipates no adverse comment. However, in the ''Proposed Rules'' section of today's **Federal Register**, EPA is publishing a separate document that will serve as the proposal to approve the SIP revision if adverse comments are filed. This rule will be effective on October 9, 2001 without further notice unless EPA receives adverse comment by September 24, 2001. If EPA receives adverse comment, EPA will publish a timely withdrawal in the **Federal Register** informing the public that the rule will not take effect. EPA will address all public comments in a subsequent final rule based on the proposed rule. EPA will not institute a second comment period on this action. Any parties interested in commenting must do so at this time. Please note that if adverse comment is received for a specific source or subset of sources covered by an amendment, section or paragraph of this rule, only that amendment, section, or paragraph for that source or subset of sources will be withdrawn.

V. Administrative Requirements

A. General Requirements

Under Executive Order 12866 (58 FR 51735, October 4, 1993), this action is not a ''significant regulatory action'' and therefore is not subject to review by the Office of Management and Budget. For this reason, this action is also not subject to Executive Order 13211, ''Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use.'' See 66 FR 28355, May 22, 2001. This action merely approves state law as meeting Federal requirements and imposes no additional requirements beyond those imposed by state law. Accordingly, the Administrator certifies that this rule will not have a significant economic impact on a substantial number of small entities under the Regulatory Flexibility Act (5 U.S.C. 601 *et seq.*). Because this rule approves pre-existing requirements under state law and does not impose any additional enforceable duty beyond that required by state law, it does not contain any unfunded mandate or significantly or uniquely affect small governments, as described in the Unfunded Mandates Reform Act of 1995 (Public Law 104–4). This rule also does not have a substantial direct effect on one or more Indian tribes, on the relationship between the Federal Government and Indian tribes, or on the distribution of power and responsibilities between the Federal Government and Indian tribes, as specified by Executive Order 13175 (65 FR 67249, November 9, 2000), nor will it have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132 (64 FR 43255, August 10, 1999), because it merely approves a state rule implementing a Federal standard, and does not alter the relationship or the distribution of power and responsibilities established in the Clean Air Act. This rule also is not subject to Executive Order 13045 (62 FR 19885, April 23, 1997), because it is not economically significant. In reviewing SIP submissions, EPA's role is to approve state choices, provided that they meet the criteria of the Clean Air Act. In this context, in the absence of a prior existing requirement for the State to use voluntary consensus standards (VCS), EPA has no authority to disapprove a SIP submission for failure to use VCS. It would thus be inconsistent with applicable law for EPA, when it reviews a SIP submission, to use VCS in place of a SIP submission that otherwise satisfies the provisions of the Clean Air Act. Thus, the requirements of section 12(d) of the National Technology Transfer and Advancement Act of 1995 (15 U.S.C. 272 note) do not apply. As required by section 3 of Executive Order 12988 (61 FR 4729, February 7, 1996), in issuing

this rule, EPA has taken the necessary steps to eliminate drafting errors and ambiguity, minimize potential litigation, and provide a clear legal standard for affected conduct. EPA has complied with Executive Order 12630 (53 FR 8859, March 15, 1988) by examining the takings implications of the rule in accordance with the ''Attorney General's Supplemental Guidelines for the Evaluation of Risk and Avoidance of Unanticipated Takings' issued under the executive order. This rule does not impose an information collection burden under the provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 *et seq.*).

B. Submission to Congress and the Comptroller General

The Congressional Review Act, 5 U.S.C. 801 *et seq.*, as added by the Small Business Regulatory Enforcement Fairness Act of 1996, generally provides that before a rule may take effect, the agency promulgating the rule must submit a rule report, which includes a copy of the rule, to each House of the Congress and to the Comptroller General of the United States. Section 804 exempts from section 801 the following types of rules: (1) Rules of particular applicability; (2) rules relating to agency management or personnel; and (3) rules of agency organization, procedure, or practice that do not substantially affect the rights or obligations of non-agency parties. 5 U.S.C. 804(3). EPA is not required to submit a rule report regarding today's action under section 801 because this is a rule of particular applicability establishing source-specific requirements for nine named sources.

C. Petitions for Judicial Review

Under section 307(b)(1) of the Clean Air Act, petitions for judicial review of this action must be filed in the United States Court of Appeals for the appropriate circuit by October 9, 2001. Filing a petition for reconsideration by the Administrator of this final rule does not affect the finality of this rule for the purposes of judicial review nor does it extend the time within which a petition for judicial review may be filed, and shall not postpone the effectiveness of such rule or action. This action approving the Commonwealth's source-specific RACT requirements to control VOC from nine individual sources in the Pittsburgh area Pennsylvania may not be challenged later in proceedings to enforce its requirements. (See section 307(b)(2).)

List of Subjects in 40 CFR Part 52

Environmental protection, Air pollution control, Hydrocarbons, Incorporation by reference, Ozone, Reporting and recordkeeping requirements.

Dated: August 9, 2001.

Thomas C. Voltaggio,

Deputy Regional Administrator, Region III.

40 CFR part 52 is amended as follows:

PART 52—[AMENDED]

1. The authority citation for Part 52 continues to read as follows:

Authority: 42 U.S.C. 7401 *et seq.*

Subpart NN—Pennsylvania

2. Section 52.2020 is amended by adding paragraph (c)(170) to read as follows:

§ 52.2020 Identification of plan.

* * * * *

(c) * * *

(170) Revisions pertaining to VOC RACT for major sources, located in the Pittsburgh-Beaver Valley ozone nonattainment area, submitted by the Pennsylvania Department of Environmental Protection on March 21, 1996, October 18, 1996, January 21, 1997, July 1, 1997, March 23, 2001, and April 19, 2001.

(i) Incorporation by reference.

(A) Letters dated March 21, 1996, October 18, 1996, January 21, 1997, July 1, 1997, March 23, 2001, and April 19, 2001, submitted by the Pennsylvania Department of Environmental Protection transmitting source-specific VOC RACT determinations.

(B) Operating Permits (OPs) and Plan Approval and Agreement Upon Consent Orders (COs) for the following sources:

(*1*) Armstrong World Industries, Beaver Falls Plant, OP 04–000–108, effective May 29, 1996.

(*2*) Bacharach, Inc., CO 263, effective October 10, 1997, except for condition 2.5.

(*3*) Bakerstown Container Corporation, CO 221, effective May 14, 1996, except for condition 2.5.

(*4*) Chestnut Ridge Foam, Inc., OP 65–000–181, effective December 29, 1995.

(*5*) Flexsys America L.P., Monongahela Plant, OP 63–000–015, effective March 23, 2001, except for the Permit Term.

(*6*) Haskell of Pittsburgh, Inc., CO 224, effective December 19, 1996, except for condition 2.4.

(*7*) Three Rivers Aluminum Company, OP 10–267, effective March 1, 2001.

(*8*) Tuscarora Plastics, Inc., OP 04–000–497, effective April 3, 1996.

(*9*) Witco Corporation, CO 210, effective May 14, 1996.

(ii) Additional Materials—Other materials submitted by the Commonwealth of Pennsylvania in support of and pertaining to the RACT determinations submitted for the sources listed in (i)(B), above.

[FR Doc. 01–21423 Filed 8–23–01; 8:45 am]

BILLING CODE 6560–50–P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 52

[PA–4133a; FRL–7037–4]

Approval and Promulgation of Air Quality Implementation Plans; Pennsylvania; VOC and NO_X RACT Determinations for Ten Individual Sources in the Pittsburgh-Beaver Valley Area

AGENCY: Environmental Protection Agency (EPA).

ACTION: Direct final rule.

SUMMARY: EPA is taking direct final action to approve revisions to the Commonwealth of Pennsylvania's State Implementation Plan (SIP). The revisions were submitted by the Pennsylvania Department of Environmental Protection (PADEP) to establish and require reasonably available control technology (RACT) for ten major sources of volatile organic compounds (VOC) and nitrogen oxides (NO_X). These sources are located in the Pittsburgh-Beaver Valley ozone nonattainment area (the Pittsburgh area). EPA is approving these revisions to establish RACT requirements in the SIP in accordance with the Clean Air Act (CAA).

DATES: This rule is effective on October 9, 2001 without further notice, unless EPA receives adverse written comment by September 24, 2001. If EPA receives such comments, it will publish a timely withdrawal of the direct final rule in the **Federal Register** and inform the public that the rule will not take effect.

ADDRESSES: Written comments should be mailed to David L. Arnold, Chief, Air Quality Planning & Information Services Branch, Air Protection Division, Mailcode 3AP21, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103. Copies of the documents relevant to this action are available for public inspection during normal business hours at the Air Protection Division, U.S. Environmental Protection Agency, Region III, 1650 Arch Street,

Philadelphia, Pennsylvania 19103; the Air and Radiation Docket and Information Center, U.S. Environmental Protection Agency, 401 M Street, SW, Washington, DC 20460; Allegheny County Health Department, Bureau of Environmental Quality, Division of Air Quality, 301 39th Street, Pittsburgh, Pennsylvania 15201 and the Pennsylvania Department of Environmental Protection, Bureau of Air Quality Control, P.O. Box 8468, 400 Market Street, Harrisburg, Pennsylvania 17105.

FOR FURTHER INFORMATION CONTACT: Janice Lewis at (215) 814–2185 or Betty Harris at (215) 2168, the EPA Region III address above or by e-mail at *lewis.janice@epa.gov* or *harris.betty@epa.gov.* Please note that while questions may be posed via telephone and e-mail, formal comments must be submitted, in writing, as indicated in the **ADDRESSES** section of this document.

SUPPLEMENTARY INFORMATION:

I. Background

Pursuant to sections 182(b)(2) and 182(f) of the Clean Air Act (CAA), the Commonwealth of Pennsylvania (the Commonwealth or Pennsylvania) is required to establish and implement RACT for all major VOC and NO_X sources. The major source size is determined by its location, the classification of that area and whether it is located in the ozone transport region (OTR).

Under section 184 of the CAA, RACT as specified in sections 182(b)(2) and 182(f) applies throughout the OTR. The entire Commonwealth is located within the OTR. Therefore, RACT is applicable statewide in Pennsylvania.

State implementation plan revisions imposing reasonably available control technology (RACT) for three classes of VOC sources are required under section 182(b)(2). The categories are: (1) All sources covered by a Control Technique Guideline (CTG) document issued between November 15, 1990 and the date of attainment; (2) all sources covered by a CTG issued prior to November 15, 1990; and (3) all major non-CTG sources. The regulations imposing RACT for these non-CTG major sources were to be submitted to EPA as SIP revisions by November 15, 1992 and compliance required by May of 1995.

The Pennsylvania SIP already includes approved RACT regulations for all sources and source categories covered by the CTGs. On February 4, 1994, PADEP submitted a revision to its SIP to require major sources of NO_X and additional major sources of VOC emissions (not covered by a CTG) to implement RACT. The February 4, 1994 submittal was amended on May 3, 1994 to correct and clarify certain presumptive NO_X RACT requirements. In the Pittsburgh area, a major source of VOC is defined as one having the potential to emit 50 tons per year (tpy) or more, and a major source of NO_X is defined as one having the potential to emit 100 tpy or more. Pennsylvania's RACT regulations require sources, in the Pittsburgh area, that have the potential to emit 50 tpy or more of VOC and sources which have the potential to emit 100 tpy or more of NO_X comply with RACT by May 31, 1995. The regulations contain technology-based or operational ''presumptive RACT emission limitations'' for certain major NO_X sources. For other major NO_X sources, and all major non-CTG VOC sources (not otherwise already subject to RACT under the Pennsylvania SIP), the regulations contain a ''generic'' RACT provision. A generic RACT regulation is one that does not, itself, specifically define RACT for a source or source categories but instead allows for case-by-case RACT determinations. The generic provisions of Pennsylvania's regulations allow for PADEP to make case-by case RACT determinations that are then to be submitted to EPA as revisions to the Pennsylvania SIP.

On March 23, 1998 EPA granted conditional limited approval to the Commonwealth's generic VOC and NO_X RACT regulations (63 FR 13789). In that action, EPA stated that the conditions of its approval would be satisfied once the Commonwealth either (1) certifies that it has submitted case-by-case RACT proposals for all sources subject to the RACT requirements currently known to PADEP; *or* (2) demonstrate that the emissions from any remaining subject sources represent a de minimis level of emissions as defined in the March 23, 1998 rulemaking. On April 22, 1999, PADEP made the required submittal to EPA certifying that it had met the terms and conditions imposed by EPA in its March 23, 1998 conditional limited approval of its VOC and NO_X RACT regulations by submitting 485 case-by-case VOC/NO_X RACT determinations as SIP revisions and making the demonstration described as condition 2, above. EPA determined that Pennsylvania's April 22, 1999 submittal satisfied the conditions imposed in its conditional limited approval published on March 23, 1998. On May 3, 2001 (66 FR 22123), EPA published a rulemaking action removing the conditional status of its approval of the Commonwealth's generic VOC and NO_X RACT regulations on a statewide basis. The regulation currently retains its limited approval status. Once EPA has approved the case-by-case RACT determinations submitted by PADEP to satisfy the conditional approval for subject sources located in Allegheny, Armstrong, Beaver, Butler, Fayette, Washington, and Westmoreland Counties; the limited approval of Pennsylvania's generic VOC and NO_X RACT regulations shall convert to a full approval for the Pittsburgh area.

It must be noted that the Commonwealth has adopted and is implementing additional ''post RACT requirements'' to reduce seasonal NO_X emissions in the form of a NO_X cap and trade regulation, 25 Pa Code Chapters 121 and 123, based upon a model rule developed by the States in the OTR. That rule's compliance date is May 1999. That regulation was approved as SIP revision on June 6, 2000 (65 FR 35842). Pennsylvania has also adopted regulations to satisfy Phase I of the NO_X SIP call and submitted those regulations to EPA for SIP approval. Pennsylvania's SIP revision to address the requirements of the NO_X SIP Call Phase I consists of the adoption of Chapter 145—Interstate Pollution Transport Reduction and amendments to Chapter 123—Standards for Contaminants. On May 29, 2001 (66 FR 29064), EPA proposed approval of the Commonwealth's NO_X SIP call rule SIP submittal. EPA expects to publish the final rulemaking in the **Federal Register** in the near future. Federal approval of a case by case RACT determination for a major source of NO_X in no way relieves that source from any applicable requirements found in 25 PA Code Chapters 121, 123 and 145.

On March 21, 1996, July 1, 1997, April 9, 1999, and April 19, 2001, PADEP submitted revisions to the Pennsylvania SIP which establish and impose RACT for several sources of VOC and/or NO_X. This rulemaking pertains to 10 of those sources. The remaining sources are or have been the subject of separate rulemakings. The Commonwealth's submittals consist of plan approvals (PAs) and operating permits (OPs) issued by PADEP, and agreement upon consent orders (COs) issued by the Allegheny County Health Department (ACHD) which impose VOC and/or NO_X RACT requirements for each source. These sources are all located in the Pittsburgh area.

II. Summary of the SIP Revisions

The table below identifies the sources and the individual PAs, OPs and COs which are the subject of this rulemaking. A summary of the VOC and

NO_X RACT determinations for each source follows the table.

PENNSYLVANIA—VOC AND NO_X RACT DETERMINATIONS FOR INDIVIDUAL SOURCES

Source	County	Plan approval (PA #) operating permit (OP #), consent order (CO #)	Source type	''Major source'' pollutant
Anchor Glass Container Corp	Fayette	PA–26–000–119	Glass Container Mfg	NO_X.
Anchor Hocking Specialty Glass Co	Beaver	OP–04–000–084	Pressed & Blown Glass Mfg	NO_X.
Corning Consumer Products Co	Washington	PA–63–000–110	Glassware Mfg	NO_X.
General Electric Company	Allegheny	CO 251	Glass Tubing Mfg	NO_X.
Glenshaw Glass Company, Inc	Allegheny	CO 270	Container Glass Mfg	NO_X.
Guardian Industries, Corp	Allegheny	CO 242	Float Glass Mfg	NO_X.
Allegheny County Sanitary Authority	Allegheny	CO 222	Wastewater Treatment	NO_X.
Browning-Ferris Ind	Allegheny	CO 231A	Municipal Landfill	VOC
Chambers Development Company	Allegheny	CO 253	Municipal Landfill	VOC
Kelly Run Sanitation	Allegheny	CO 236	Municipal Landfill	VOC

A. Anchor Glass Container Corporation

Anchor Glass Container Corporation (Anchor) is a glass manufacturer located in Connellsville, Pennsylvania. Anchor is a major source of NO_X. Anchor has three glass melting furnaces for the production of glass. On December 20, 1996, PADEP issued PA–26–000–119 to establish and impose RACT on Anchor. Under the PA, Anchor must meet NO_X emission limitations of 5.5 lbs/ton, 5.5 lbs/ton and 12.75 lbs/ton of glass processed at furnaces #1, #2, and #3, respectively. RACT for furnace ı3 also includes any NO_X reductions accomplished by energy efficient rebricking of the furnace. Compliance is to be demonstrated through annual stack testing in accordance with 25 Pa Code Chapter 139. Anchor is subject to the recordkeeping requirements of Pa Code section 129.95. Anchor must properly operate and maintain all process and associated emission control equipment according to good engineering and air pollution control practices in accordance with applicable PADEP regulations.

B. Anchor Hocking Speciality Glass Co.

The Anchor Hocking Speciality Glass Co. (Anchor Hocking) is a pressed and blown glass manufacturer located in Monaca, Pennsylvania. Anchor Hocking is a major source of NO_X. Anchor has three glass melting furnaces for the production of glass. On October 13, 1995, PADEP issued OP–04–000–084 to establish and impose RACT on Anchor Hocking. The OP requires RACT as the operation of Low-NO_X burners, underport firing, and low-excess air on the melter tank. It requires SIP-approved presumptive RACT requirements on the annealing, decorating and the quenching lehrs, and the removal of the niter (sodium nitrate) addition from the glass-making process. Under the OP, Anchor Hocking must maintain excess air at less 4.5 percent. The facility's NO_X emissions may not exceed 5.0lbs/ton of glass produced and shall not exceed 279 tons/year. Under OP–04–000–084, Anchor Hocking shall conduct a minimum of one stack test in accordance with 25 PA Code Section 139. Anchor Hocking must maintain records in accordance with the recordkeeping requirements of Pa Code Section 129.95. The following records shall be kept: operating hours and daily fuel consumption. These records shall be maintained on file for no less than two years. Units applicable to presumptive limits identified in Pa Code section 129.93 shall operate in accordance with manufacturer's specifications for installation, maintenance, and operation of these sources. Anchor Hocking must properly operate and maintain all process and emission control equipment according to good engineering and air pollution control practices in accordance with applicable PADEP regulations.

C. Corning Consumer Products Co.

Corning Consumer Products (Corning) is a glassware manufacturer located in Charleroi, Pennsylvania. Corning is a major source of NO_X. Corning has two glass melting tanks, one firing kiln and 12 small combustion units used in the production of glassware. On January 4, 1996, PADEP issued PA–63–000–110 to establish and impose RACT on Corning. The PA requires Tank #11 to convert gas/oxygen firing on all ports and electric boost to be increased to 30% on this unit. Tank #6 must continue the operation of gas/oxygen firing on all ports. RACT for the Tunnel kiln and the 12 small units shall be the operation and maintenance of these units in accordance with manufacturer's specifications and good air pollution control practices. Under the PA, Corning must meet the following emission limitations: (1) Tank #6, 22.8 lbs of NO_X/hr and 100 tons of NO_X/year, 0.35 lbs of VOC/hr and 1.53 tons of VOC /year; (2) Tank #11, 57.1 lbs of NO_X/hr and 250 tons of NO_X/year, 2.0 lbs of VOC/hr and 8.8 tons of VOC/year; (3) Tunnel kiln, 1.75 lbs of NO_X/hr and 7.7 tons of NO_X/year, 0.01 lbs of VOC/hr and 0.04 tons of VOC/year; and the combination of the 12 small units, 4.03 lbs of NO_X/hr and 17.66 tons of NO_X/year, 3.34 lbs of VOC/hr and 14.6 tons of VOC/year. Compliance is to be demonstrated thorough stack testing in accordance with 25 Pa Code Chapter 139. Annual limits are to be met on a rolling monthly basis for every consecutive 12 month period. Corning shall comply with the recordkeeping requirements of Pa Code section 129.95, including daily records on natural gas, oxygen, temperatures, electric consumption and tons of fill charged to Tanks #6 and #11. These records shall be maintained on file for at least two years. Corning must properly operate and maintain all process and emission control equipment according to good engineering and air pollution control practices in accordance with applicable PADEP regulations.

D. General Electric Company

The General Electric Company (GE) is a glass tubing manufacturing facility located in Collier, Pennsylvania. GE is a major source of NO_X. On December 19, 1996, Allegheny County Health Department (ACHD) issued CO 251 to establish and impose RACT on GE. The PADEP submitted CO 251, on behalf of the ACHD, to EPA as a SIP revision. GE produces glass in six glass melting furnaces, three cullet dryers, three natural gas boilers. There are two emergency generators used as back-up

for boilers. RACT for the Simplex furnace is the operation of ox-fuel combustion equipment. General Electric must maintain the baseline controls for the Fait furnace, Germicidal furnace and the 180 furnace including adherence to the furnace manufacturer's specifications and good engineering practices, low-excess oxygen for each furnace and the use of cullet as a batch ingredient for the180 furnace. All units are required to comply with manufacturer's specifications in accordance with good engineering and air pollution control practices. Additionally, GE must utilize electric boost as part of the baseline controls for the Gas/Electric and Special Furnaces. Under CO 251, the remaining sources (boilers, cullet dryers and emergency generators) must comply with manufacturer's specifications in accordance with good engineering and air pollution control practices. The CO requires that the NO_X emissions from the following units shall not exceed the following: (1) The Simplex furnace, 37.5lbs/hr and 165 tons/yr; (2) the 180 furnace, 27.72lbs/hr and 122 tons/yr. Under CO 251, GE is required to conduct emissions testing at least once every three years in accordance with applicable EPA approved test methods and Section 2108.02 of Article XXI of the ACHD's air pollution control regulations. Annual limits are to met on a rolling monthly basis for every consecutive 12 month period. Under CO 251, GE must maintain all records and testing data to demonstrate compliance with Section 2108.06 of Article XXI of the ACHD's air pollution control regulations. Record keeping requirements shall include the following: records of oxygen and fuel usage; production records for the Simplex furnace and; production usage and fuel usage of all other furnaces. All records shall be maintained for at least two years. Under CO 251, GE must operate and maintain all process and emission control equipment according to good engineering and air pollution control practices.

E. Glenshaw Glass Company

The Glenshaw Glass Company (Glenshaw) is a glass manufacturing facility located in Glenshaw, Pennsylvania. Glenshaw is a major source of NO_X. On March 10, 2000, the ACHD issued CO 270 to establish and impose RACT on Glenshaw. The PADEP submitted CO 270, on behalf of the ACHD, to EPA as a SIP revision. Glenshaw produces glass in four glass melting furnaces. The CO 270 limits NO_X emissions from the glass melting furnaces as the following:

(1) Furnace #1: 6.5lbs/ton glass and 267 tons/year ;
(2) Furnace #2: 6.5lbs/ton glass and 250 tons/yr;
(3) Furnace #3: 6.5lbs/ton glass and 190 tons/year; and
(4) Furnace #4: 6.5lbs/ton glass and 202 tons/year.

Under CO 270, Glenshaw is required to conduct emissions testing at least once every two years in accordance with applicable EPA approved test methods and Section 2108.02 of Article XXI of the ACHD's air pollution control regulations. Annual limits are to met on a rolling monthly basis for every consecutive 12 month period. Under CO 270, Glenshaw must maintain all records and testing data to demonstrate compliance with section 2105.06 of Article XXI of the ACHD's air pollution control regulations. Record keeping requirements shall include fuel use and production date per combustion unit. All records shall be maintained for at least two years. Under CO 270, Glenshaw must operate and maintain all process and emission control equipment according to good engineering and air pollution control practices.

F. Guardian Industries, Corp.

Guardian Industries, Corp. (Guardian) is a float glass manufacturing facility located in Floreffe, Pennsylvania. Guardian is a major source of NO_X. On August 27, 1996, ACHD issued CO 242 to establish and impose RACT on Guardian. The PADEP submitted CO 242, on behalf of the ACHD, to EPA as a SIP revision. Guardian produces glass in one glass melting furnace. The CO limits the NO_X emissions from the glass melting furnace to 40.0 lbs/ton glass and 2556 tons/year. Under CO 242, Guardian is required to conduct emissions testing at least once every two years in accordance with applicable EPA approved test methods and section 2108.02 of Article XXI of the ACHD's air pollution control regulations. The annual limit is to met on a rolling monthly basis for every consecutive 12 month period. Under CO 242, Guardian must maintain all records and testing data to demonstrate compliance with Section 2108.02 of Article XXI of the ACHD's air pollution control regulations. Record keeping requirements shall include fuel use and operating hours for the glass melting furnace; and all maintenance, inspection and repair activities, calibration and/or replacement of fuel-burning equipment for the glass melting furnace. Guardian must maintain daily records of information on the batch house and the glass melting furnace operations. All records shall be retained for at least two years. Under CO 242, Guardian must operate and maintain all process and emission control equipment according to good engineering and air pollution control practices.

G. Allegheny County Sanitary Authority

The Allegheny County Sanitary Authority (ALCOSAN) operates a publically owned wastewater treatment works facility located in Allegheny County, Pennsylvania. ALCOSAN is a major source of NO_X. On May 14, 1996, the ACHD issued CO 222 to establish and impose RACT on ALCOSAN. The PADEP submitted CO 222, on behalf of the ACHD, to EPA as a SIP revision. The CO 222 requires that the NO_X emissions from the entire facility shall not exceed 95 tons per year from two Fluidized bed incinerators (FBI) and one Multi-hearth incinerator. Under CO 222, the multi-hearth sludge incinerator shall not exceed annual operating hours of 3,665 per year. The annual limits are to met on a rolling monthly basis for every consecutive 12 month period. Under CO 222, ALCOSAN must maintain all records to demonstrate compliance, provide sufficient data and calculations with the requirements of Section 2105.06 of Article XXI of the ACHD's air pollution control regulations. Record keeping requirements shall include the fuel type and amount of fuel usage per combustion unit; hours of operation of combustion unit; and amount of sludge processed, in dry tons, for all the incinerators. All records shall be maintained for at least two years. Under CO 222, ALCOSAN must operate and maintain all process and emission control equipment according to good engineering and air pollution control practices.

H. Browning-Ferris Industries of PA, Inc.

Browning-Ferris Industries of PA, Inc. (BFI) is the operator of a solid waste municipal landfill located in Allegheny County, Pennsylvania. BFI is a major source of VOC. On April 28, 1997, the ACHD issued CO 231A to establish and impose RACT on BFI. The PADEP submitted CO 231A, on behalf of the ACHD, to EPA as a SIP revision. The CO requires a properly maintained and operated active landfill off gas collection system which collects off gas from each cell, area or group of cells in which initial solid waste has been placed for a period equal to or exceeding five (5) years if the subject cell, area or group of cells is active, with the exception of Area Seven (7), Phase Two (2), or two years if the subject cell, area or group of cells is closed or at grade. The average collection system efficiency of the active off gas collection

system shall be a minimum of seventy-five (75%) percent at all times. Compliance for the collection efficiency shall be determined by calculating the VOC emission rate from the cells, areas/groups of cells treated by the off gas collection system according to current approved EPA estimation procedures and the actual collection system off gas flow rate data. Such collection efficiency determinations must be conducted and reported annually. Except in emergency situations and for maintenance purposes requiring shutdown, BFI shall at all times, with the exception of Area Seven (7), Phase Two (2), have a properly maintained and operated off gas control system which shall process collected off gas and meet the following reduction efficiency criteria: (1) A minimum VOC destruction efficiency of ninety-eight (98%) percent, by weight percent; or (2) twenty parts per million (20ppm) as hexane by volume, dry basis at three percent (3%) oxygen or less. Compliance with the reduction criteria specified above shall be determined by emission testing conducted every five years according to applicable EPA approved test methods and Section 2108.02 of Article XXI of the ACHD's air pollution control regulations. The collection system must be operated with negative pressure at each wellhead at all times except (1) when a fire is present or when well temperatures indicate the possibility of a fire; (2) when a geomembrane or synthetic cover is in place; or (3) when a decommissioned well may experience static positive pressure after shutdown to accommodate declining off gas flows. Each interior wellhead shall operate with a landfill gas temperature of less than one-hundred and thirty-one (131) degrees Fahrenheit at all times with the exception of increased levels necessary to control offsite migration, a nitrogen level less than 20 percent or an oxygen level less then five percent. Each wellhead must be monitored monthly for temperature and nitrogen or oxygen levels according to EPA approved methods. Under CO 231A, BFI must maintain all records regarding gas monitoring data, tonnage records, a waste characterization with sufficient data and calculations to clearly demonstrate that all requirements of Section 2108.06 of Article XXI and CO231A are being met. Under CO 231A, all records shall be maintained for at least two years. BFI must operate and maintain all process and emission control equipment according to good engineering and air pollution control practices. Finally, it should be noted that CO 231A also requires that within one year after Area Seven (7), Phase Two (2) achieves final grade, BFI must install, operate and maintain a landfill gas collection and control system that meets, without exception, all the conditions of CO 231A.

I. Chambers Development Company

Chambers Development Company (Chambers) is the owner and operator of a solid waste municipal landfill located in Allegheny County, Pennsylvania. Chambers is a major source of VOC. On December 30, 1996, ACHD issued CO 253 to establish and impose RACT on Chambers. The PADEP submitted CO 253, on behalf of the ACHD, to EPA as a SIP revision. The CO requires a properly maintained and operated active landfill off gas collection system which collects off gas from each cell, area or group of cells in which initial solid waste has been placed for a period equal to or exceeding five (5) years if the subject cell, area or group of cells is active, or two years if the subject cell, area or group of cells is closed or at grade.

The average collection system efficiency of the active off gas collection system shall be a minimum of seventy-five (75%) percent at all times. Compliance for the collection efficiency shall be determined by calculating the VOC emission rate from the cells, areas/groups of cells treated by the off gas collection system according to current approved EPA estimation procedures and the actual collection system off gas flow rate data. Such collection efficiency determinations must be conducted and reported annually. Except in emergency situations and for maintenance purposes requiring shutdown, Chambers shall, at all times, have a properly maintained and operated off gas control system which shall process collected off gas and meet the following reduction efficiency criteria: (1) A minimum VOC destruction efficiency of ninety-eight (98%) percent, by weight percent; or (2) twenty parts per million (20ppm) as hexane by volume, dry basis at three percent (3%) oxygen or less. Compliance with the reduction criteria specified above shall be determined by emission testing conducted every five years according to applicable EPA approved test methods and Section 2108.02 of Article XXI of the ACHD's air pollution control regulations. The collection system must be operated with negative pressure at each wellhead at all times except (1) when a fire is present or when well temperatures indicate the possibility of a fire; (2) when a geomembrane or synthetic cover is in place; or (3) when a decommissioned well may experience static positive pressure after shutdown to accommodate declining off gas flows. Each interior wellhead shall operate with a landfill gas temperature of less than fifty-five (55) degrees centigrade at all times, with a nitrogen level less than 20 percent or an oxygen level less then five percent. Each wellhead must be monitored monthly for temperature and nitrogen or oxygen levels according to EPA approved methods. Under the CO, Chambers must maintain all records regarding gas monitoring data, tonnage records, a waste characterization with sufficient data and calculations to clearly demonstrate that all requirements of Section 2108.06 of Article XXI and CO 253 are being met. Under the CO, all records shall be maintained for at least two years. Chambers must operate and maintain all process and emission control equipment according to good engineering and air pollution control practices.

J. Kelly Run Sanitation

Kelly Run Sanitation (Kelly Run) operates a solid waste municipal landfill located in Allegheny County, Pennsylvania. Kelly Run is a major source of VOC. On January 23, 1997, ACHD issued CO 236 to establish and impose RACT on Kelly Run. The PADEP submitted CO 236, on behalf of the ACHD, to EPA as a SIP revision. The CO requires a properly maintained and operated active landfill off gas collection system which collects off gas from each cell, area or group of cells in which initial solid waste has been placed for a period equal to or exceeding five (5) years if the subject cell, area or group of cells is active, or two years if the subject cell, area or group of cells is closed or at grade. The average collection system efficiency of the active off gas collection system shall be a minimum of seventy-five (75%) percent at all times. Compliance for the collection efficiency shall be determined by calculating the VOC emission rate from the cells, areas/groups of cells treated by the off gas collection system. Such collection efficiency determinations must be conducted and reported annually. Except in emergency situations and for maintenance purposes requiring shutdown, Kelly Run shall, at all times, have a properly maintained and operated off gas control system which shall process collected off gas and meet a reduction efficiency criteria of a minimum VOC destruction efficiency of ninety-eight (98%) percent, by weight percent. Compliance with the reduction criteria specified above shall be

determined by emission testing conducted every five years according to applicable EPA approved test methods and Section 2108.02 of Article XXI of the ACHD's air pollution control regulations.

The collection system must be operated with negative pressure at each wellhead at all times except (1) when a fire is present or when well temperatures indicate the possibility of a fire; (2) when a geomembrane or synthetic cover is in place; or (3) when a decommissioned well may experience static positive pressure after shutdown to accommodate declining off gas flows. Each interior wellhead shall operate with a landfill gas temperature of less than fifty-five (55) degrees centigrade at all times, with a nitrogen level less than 20 percent or an oxygen level less then five percent. Each wellhead must be monitored monthly for temperature and nitrogen or oxygen levels according to EPA approved methods. Under the CO, Kelly Run must maintain all records regarding gas monitoring data, tonnage records, a waste characterization with sufficient data and calculations to clearly demonstrate that all requirements of Section 2108.06 of Article XXI and CO 236 are being met. Under the CO, all records shall be maintained for at least two years. Kelly Run must operate and maintain all process and emission control equipment according to good engineering and air pollution control practices.

III. EPA's Evaluation

EPA is approving these RACT SIP submittals because PADEP and ACHD established and imposed these RACT requirements in accordance with the criteria set forth in the SIP-approved RACT regulations applicable to these sources. The Commonwealth and the County have also imposed record-keeping, monitoring, and testing requirements on these sufficient to determine compliance with the applicable RACT determinations.

IV. Final Action

EPA is approving the revisions to the Pennsylvania SIP submitted by PADEP to establish and require VOC and NO_X RACT for ten major of sources located in the Pittsburgh area. EPA is publishing this rule without prior proposal because the Agency views this as a noncontroversial amendment and anticipates no adverse comment. However, in the ''Proposed Rules'' section of today's **Federal Register**, EPA is publishing a separate document that will serve as the proposal to approve the SIP revision if adverse comments are filed. This rule will be effective on October 9, 2001 without further notice unless EPA receives adverse comment by September 24, 2001. If EPA receives adverse comment, EPA will publish a timely withdrawal in the **Federal Register** informing the public that the rule will not take effect. EPA will address all public comments in a subsequent final rule based on the proposed rule. EPA will not institute a second comment period on this action. Any parties interested in commenting must do so at this time. Please note that if adverse comment is received for a specific source or subset of sources covered by an amendment, section or paragraph of this rule, only that amendment, section, or paragraph for that source or subset of sources will be withdrawn.

V. Administrative Requirements

A. General Requirements

Under Executive Order 12866 (58 FR 51735, October 4, 1993), this action is not a ''significant regulatory action'' and therefore is not subject to review by the Office of Management and Budget. For this reason, this action is also not subject to Executive Order 13211, ''Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use.'' See 66 FR 28355, May 22, 2001. This action merely approves state law as meeting Federal requirements and imposes no additional requirements beyond those imposed by state law. Accordingly, the Administrator certifies that this rule will not have a significant economic impact on a substantial number of small entities under the Regulatory Flexibility Act (5 U.S.C. 601 *et seq.*). Because this rule approves pre-existing requirements under state law and does not impose any additional enforceable duty beyond that required by state law, it does not contain any unfunded mandate or significantly or uniquely affect small governments, as described in the Unfunded Mandates Reform Act of 1995 (Public Law 104–4). This rule also does not have a substantial direct effect on one or more Indian tribes, on the relationship between the Federal Government and Indian tribes, or on the distribution of power and responsibilities between the Federal Government and Indian tribes, as specified by Executive Order 13175 (65 FR 67249, November 9, 2000), nor will it have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132 (64 FR 43255, August 10, 1999), because it merely approves a state rule implementing a Federal standard, and does not alter the relationship or the distribution of power and responsibilities established in the Clean Air Act. This rule also is not subject to Executive Order 13045 (62 FR 19885, April 23, 1997), because it is not economically significant. In reviewing SIP submissions, EPA's role is to approve state choices, provided that they meet the criteria of the Clean Air Act. In this context, in the absence of a prior existing requirement for the State to use voluntary consensus standards (VCS), EPA has no authority to disapprove a SIP submission for failure to use VCS. It would thus be inconsistent with applicable law for EPA, when it reviews a SIP submission, to use VCS in place of a SIP submission that otherwise satisfies the provisions of the Clean Air Act. Thus, the requirements of section 12(d) of the National Technology Transfer and Advancement Act of 1995 (15 U.S.C. 272 note) do not apply. As required by section 3 of Executive Order 12988 (61 FR 4729, February 7, 1996), in issuing this rule, EPA has taken the necessary steps to eliminate drafting errors and ambiguity, minimize potential litigation, and provide a clear legal standard for affected conduct. EPA has complied with Executive Order 12630 (53 FR 8859, March 15, 1988) by examining the takings implications of the rule in accordance with the ''Attorney General's Supplemental Guidelines for the Evaluation of Risk and Avoidance of Unanticipated Takings'' issued under the executive order. This rule does not impose an information collection burden under the provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 *et seq.*).

B. Submission to Congress and the Comptroller General

The Congressional Review Act, 5 U.S.C. 801 *et seq.*, as added by the Small Business Regulatory Enforcement Fairness Act of 1996, generally provides that before a rule may take effect, the agency promulgating the rule must submit a rule report, which includes a copy of the rule, to each House of the Congress and to the Comptroller General of the United States. Section 804 exempts from section 801 the following types of rules: (1) Rules of particular applicability; (2) rules relating to agency management or personnel; and (3) rules of agency organization, procedure, or practice that do not substantially affect the rights or obligations of non-agency parties. 5 U.S.C. 804(3). EPA is not required to submit a rule report regarding today's action under section

801 because this is a rule of particular applicability establishing source-specific requirements for ten named sources.

C. Petitions for Judicial Review

Under section 307(b)(1) of the Clean Air Act, petitions for judicial review of this action must be filed in the United States Court of Appeals for the appropriate circuit by October 23, 2001. Filing a petition for reconsideration by the Administrator of this final rule does not affect the finality of this rule for the purposes of judicial review nor does it extend the time within which a petition for judicial review may be filed, and shall not postpone the effectiveness of such rule or action. This action approving the Commonwealth's source-specific RACT requirements to control VOC and NO_X from ten individual sources in Pennsylvania may not be challenged later in proceedings to enforce its requirements. (See section 307(b)(2).)

List of Subjects in 40 CFR Part 52

Environmental protection, Air pollution control, Hydrocarbons, Incorporation by reference, Nitrogen Oxides, Ozone, Reporting and record keeping requirements.

Dated: August 10, 2001.

Judith Katz,

Acting Regional Administrator, Region III.

40 CFR part 52 is amended as follows:

PART 52—[AMENDED]

1. The authority citation for Part 52 continues to read as follows:

Authority: 42 U.S.C. 7401 *et seq.*

Subpart NN—Pennsylvania

2. Section 52.2020 is amended by adding paragraph (c)(167) to read as follows:

§ 52.2020 Identification of plan.

* * * * *

(c) * * *

(167) Revisions pertaining to VOC and NO_X RACT for major sources, located in the Pittsburgh-Beaver Valley ozone nonattainment area, submitted by the Pennsylvania Department of Environmental Protection on March 21, 1996, July 1, 1997, April 9, 1999 and April 19, 2001.

(i) Incorporation by reference.

(A) Letters dated March 21, 1996, July 1, 1997, April 9, 1999 and April 19, 2001 submitted by the Pennsylvania Department of Environmental Protection transmitting source-specific VOC and/or NO_X RACT determinations, in the form of plan approvals, operating permits, and consent orders.

(B) Plan approvals (PA), Operating permits (OP), or Consent Orders (CO) for the following sources:

(*1*) Anchor Glass Container Corporation, Plant 5, PA 26–000–119, effective December 20, 1996.

(*2*) Anchor Hocking Specialty Glass Co., Phoenix Glass Plant, OP 04–000–084, effective October 13, 1995.

(*3*) Corning Consumer Products Company, Charleroi Plant, PA 63–000–110, effective January 4, 1996, except for the third sentence of condition 3 (which references condition 13), and conditions 5, 6, 7, 13 in their entirety.

(*4*) General Electric Company, CO 251, effective December 19, 1996, except for condition 2.5.

(*5*) Glenshaw Glass Company, Inc., CO 270, effective March 10, 2000, except for condition 2.5.

(*6*) Guardian Industries, Corp., CO 242, effective August 27, 1996, except for conditions 2.5.

(*7*) Allegheny County Sanitary Authority, CO 222, effective May 14, 1996, except for condition 2.5.

(*8*) Browning-Ferris Industries of Pennsylvania Inc., Findlay Township Landfill, CO 231A, effective April 28, 1997, except for condition 2.5.

(*9*) Chambers Development Company, Monroville Borough Landfill, CO 253, effective December 30, 1996, except for condition 2.5.

(*10*) Kelly Run Sanitation, Forward Township Landfill, CO 236, effective January 23, 1997, except for condition 2.5.

(ii) Additional Materials—Other materials submitted by the Commonwealth of Pennsylvania in support of and pertaining to the RACT determinations for the sources listed in paragraph (c)(167)(i)(B) of this section.

[FR Doc. 01–21427 Filed 8–23–01; 8:45 am]

BILLING CODE 6560–50–P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 52

[PA–4144a; FRL–7041–1]

Approval and Promulgation of Air Quality Implementation Plans; Pennsylvania; VOC and NO_X RACT Determinations for Ten Individual Sources in the Pittsburgh-Beaver Valley Area

AGENCY: Environmental Protection Agency (EPA).

ACTION: Direct final rule.

SUMMARY: EPA is taking direct final action to approve revisions to the Commonwealth of Pennsylvania's State Implementation Plan (SIP). The revisions were submitted by the Pennsylvania Department of Environmental Protection (PADEP) to establish and require reasonably available control technology (RACT) for ten major sources of volatile organic compounds (VOC) and nitrogen oxides (NO_X). These sources are located in the Pittsburgh-Beaver Valley ozone nonattainment area (the Pittsburgh area). EPA is approving these revisions to establish RACT requirements in the SIP in accordance with the Clean Air Act (CAA).

DATES: This rule is effective on October 9, 2001 without further notice, unless EPA receives adverse written comment by September 24, 2001. If EPA receives such comments, it will publish a timely withdrawal of the direct final rule in the **Federal Register** and inform the public that the rule will not take effect.

ADDRESSES: Written comments should be mailed to David L. Arnold, Chief, Air Quality Planning & Information Services Branch, Air Protection Division, Mailcode 3AP21, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103. Copies of the documents relevant to this action are available for public inspection during normal business hours at the Air Protection Division, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103; the Air and Radiation Docket and Information Center, U.S. Environmental Protection Agency, 401 M Street, SW., Washington, DC 20460; Allegheny County Health Department, Bureau of Environmental Quality, Division of Air Quality, 301 39th Street, Pittsburgh, Pennsylvania 15201 and the Pennsylvania Department of Environmental Protection, Bureau of Air Quality Control, P.O. Box 8468, 400 Market Street, Harrisburg, Pennsylvania 17105.

FOR FURTHER INFORMATION CONTACT: Janice Lewis at (215) 814–2185 or Betty Harris at (215) 814–2168, the EPA Region III address above or by e-mail at *lewis.janice@epa.gov* or *harris.betty@epa.gov*. Please note that while questions may be posed via telephone and e-mail, formal comments must be submitted, in writing, as indicated in the **ADDRESSES** section of this document.

SUPPLEMENTARY INFORMATION:

I. Background

Pursuant to sections 182(b)(2) and 182(f) of the Clean Air Act (CAA), the Commonwealth of Pennsylvania (the

Commonwealth or Pennsylvania) is required to establish and implement RACT for all major VOC and NO_X sources. The major source size is determined by its location, the classification of that area and whether it is located in the ozone transport region (OTR). Under section 184 of the CAA, RACT as specified in sections 182(b)(2) and 182(f)) applies throughout the OTR. The entire Commonwealth is located within the OTR. Therefore, RACT is applicable statewide in Pennsylvania.

State implementation plan revisions imposing reasonably available control technology (RACT) for three classes of VOC sources are required under section 182(b)(2). The categories are: (1) All sources covered by a Control Technique Guideline (CTG) document issued between November 15, 1990 and the date of attainment; (2) all sources covered by a CTG issued prior to November 15, 1990; and (3) all major non-CTG sources. The regulations imposing RACT for these non-CTG major sources were to be submitted to EPA as SIP revisions by November 15, 1992 and compliance required by May of 1995.

The Pennsylvania SIP already includes approved RACT regulations for all sources and source categories covered by the CTGs. On February 4, 1994, PADEP submitted a revision to its SIP to require major sources of NO_X and additional major sources of VOC emissions (not covered by a CTG) to implement RACT. The February 4, 1994 submittal was amended on May 3, 1994 to correct and clarify certain presumptive NO_X RACT requirements. In the Pittsburgh area, a major source of VOC is defined as one having the potential to emit 50 tons per year (tpy) or more, and a major source of NO_X is defined as one having the potential to emit 100 tpy or more.

Pennsylvania's RACT regulations require sources, in the Pittsburgh area, that have the potential to emit 50 tpy or more of VOC and sources which have the potential to emit 100 tpy or more of NO_X comply with RACT by May 31, 1995. The regulations contain technology-based or operational ''presumptive RACT emission limitations'' for certain major NO_X sources. For other major NO_X sources, and all major non-CTG VOC sources (not otherwise already subject to RACT under the Pennsylvania SIP), the regulations contain a ''generic'' RACT provision. A generic RACT regulation is one that does not, itself, specifically define RACT for a source or source categories but instead allows for case-by-case RACT determinations. The generic provisions of Pennsylvania's regulations allow for PADEP to make case-by case RACT determinations that are then to be submitted to EPA as revisions to the Pennsylvania SIP.

On March 23, 1998 EPA granted conditional limited approval to the Commonwealth's generic VOC and NO_X RACT regulations (63 FR 13789). In that action, EPA stated that the conditions of its approval would be satisfied once the Commonwealth either (1) certifies that it has submitted case-by-case RACT proposals for all sources subject to the RACT requirements currently known to PADEP; *or* (2) demonstrate that the emissions from any remaining subject sources represent a de minimis level of emissions as defined in the March 23, 1998 rulemaking. On April 22, 1999, PADEP made the required submittal to EPA certifying that it had met the terms and conditions imposed by EPA in its March 23, 1998 conditional limited approval of its VOC and NO_X RACT regulations by submitting 485 case-by-case VOC/NO_X RACT determinations as SIP revisions and making the demonstration described as condition 2, above. EPA determined that Pennsylvania's April 22, 1999 submittal satisfied the conditions imposed in its conditional limited approval published on March 23, 1998. On May 3, 2001 (66 FR 22123), EPA published a rulemaking action removing the conditional status of its approval of the Commonwealth's generic VOC and NO_X RACT regulations on a statewide basis. The regulation currently retains its limited approval status. Once EPA has approved the case-by-case RACT determinations submitted by PADEP to satisfy the conditional approval for subject sources located in Allegheny, Armstrong, Beaver, Butler, Fayette, Washington, and Westmoreland Counties; the limited approval of Pennsylvania's generic VOC and NO_X RACT regulations shall convert to a full approval for the Pittsburgh area.

It must be noted that the Commonwealth has adopted and is implementing additional ''post RACT requirements'' to reduce seasonal NO_X emissions in the form of a NO_X cap and trade regulation, 25 Pa Code Chapters 121 and 123, based upon a model rule developed by the States in the OTR. That rule's compliance date is May 1999. That regulation was approved as SIP revision on June 6, 2000 (65 FR 35842). Pennsylvania has also adopted regulations to satisfy Phase I of the NO_X SIP call and submitted those regulations to EPA for SIP approval. Pennsylvania's SIP revision to address the requirements of the NO_X SIP Call Phase I consists of the adoption of Chapter 145—Interstate Pollution Transport Reduction and amendments to Chapter 123—Standards for Contaminants. On May 29, 2001 (66 FR 29064), EPA proposed approval of the Commonwealth's NO_X SIP call rule SIP submittal. EPA expects to publish the final rulemaking in the **Federal Register** in the near future. Federal approval of a case by case RACT determination for a major source of NO_X in no way relieves that source from any applicable requirements found in 25 PA Code Chapters 121, 123 and 145.

II. Summary of the SIP Revisions

On July 1, 1997, October 23, 1997, November 4, 1997, December 31, 1997, April 9, 1999, and August 9, 2000, PADEP submitted revisions to the Pennsylvania SIP which establish and impose RACT for several sources of VOC and/or NO_X. This rulemaking pertains to ten of those sources. The remaining sources are or have been the subject of separate rulemakings. The Commonwealth's submittals consist of operating permits and consent orders which impose VOC and/or NO_X RACT requirements for each source. These sources are all located in the Pittsburgh area. The table below identifies the sources and the individual operating permits (OPs), consent orders (COs), or enforcement orders (EOs) which are the subject of this rulemaking. A summary of the VOC and NO_X RACT determinations for each source follows the table.

PENNSYLVANIA—VOC AND NO_X RACT DETERMINATIONS FOR INDIVIDUAL SOURCES

Source	County	OP# or CO#	Source type	''Major source'' pollutant
Carbidie Corporation	Westmoreland	OP 65–000–720	Tungsten Carbide Products	VOC
Fansteel Hydro Carbide	Westmoreland	OP 65–000–860	Tungsten Carbide Products	VOC
Newcomer Products, Inc	Westmoreland	OP 65–000–851	Tungsten Carbide Products	VOC
Heinz USA—Pittsburgh	Allegheny	EO 211, CO 247	Food Processing	VOC

PENNSYLVANIA—VOC AND NO_X RACT DETERMINATIONS FOR INDIVIDUAL SOURCES—Continued

Source	County	OP# or CO#	Source type	''Major source'' pollutant
Nabisco Biscuit Company	Allegheny	CO 246	Food Processing	NO_X/VOC
Aristech Chemical Corporation	Allegheny	CO 232	Chemical Manufacturing	VOC
Dyno Nobel Inc.—Donora Plant	Washington	OP 63–000–070	Chemical Manufacturing	NO_X
General Carbide Corp	Westmoreland	OP 65–000–622	Powder Milling	VOC
Koppers Industries, Inc	Allegheny	CO 223	Chemical Manufacturing	VOC
Pressure Chemical Company	Allegheny	CO 261	Chemical Manufacturing	VOC

A. Carbidie Corporation

Carbidie Corporation (Carbidie) is a tools and parts tungsten carbide manufacturer located in Hempfield, Pennsylvania. Carbidie is a major source of VOC. On July 31, 1998, PADEP issued an operating permit (OP–65–000–720) to establish and impose RACT for Carbidie. Under OP 65–000–720, fixed lids and shaft seals on mixers and storage tanks must be monitored to insure that they are sealing properly sealed. A record of daily inspections shall be maintained as well. The temperature of the cool water chiller bath shall be maintained in the range of 55°–72° F. Under OP 65–000–720, a thermocouple must be installed, monitored, and maintained to ensure compliance. Dryers equipped with condensers must not be operated in the event that the condenser units are incapable of operation. Under OP 65–000–720, Carbidie, in accordance with 25 Pa Code 129.95, must retain sufficient records to demonstrate compliance with all conditions to meet RACT. This includes the following, but is not limited to: cool water chiller bath temperature (55°–72° F); total heptane consumption on a monthly basis; hours of operation; and all maintenance and repair operations to ensure compliance with all emission limits and restrictions. All records must be retained for at least two years. Carbidie must properly operate and maintain all equipment according to good engineering and air pollution control practices.

B. Fansteel Hydro Carbide

Fansteel Hydro Carbide (Fansteel) is a manufacturer of cemented tungsten carbide located in Latrobe, Pennsylvania. Fansteel is a major source of VOC. Fansteel has three 100SC attritors, five 30S attritors, two ballmills, and six vacuum dryers. The attritors will be controlled by a packaged chiller unit and the dryers are equipped with condensers. On December 12, 1997, PADEP issued an operating permit (OP–65–000–860) to establish and impose RACT on Fansteel. Under OP 65–000–860, the attritors must not be operated in the event that the package chiller unit is incapable of operation and the vacuum dryers shall not operate if the condensers are incapable of operation. Under OP 65–000–860, the coolant temperature exiting the package chiller unit must be maintained no at higher than 55 degrees Fahrenheit. The monitor on chiller unit shall visually show the inlet and outlet temperatures. These two readings along with time taken must be documented in a log book once a shift. These records must be retained on site for at least two years. The OP 65–000–860, requires Fansteel to operate an audible alarm in the milling room to ensure that the operators are aware if the chiller unit outlet water temperature is above the maximum temperature allowed (55 degrees Fahrenheit). Under OP 65–000–860, Fansteel must track and record hours of operation and all maintenance and repair operations to the attritor mills, package chiller unit, and vacuum dryers (condensers). All such recordkeeping must be done on a monthly basis. All such records shall be retained on site for at least two years. Under the OP, Fansteel must conduct a fugitive heptane leak detection and repair program patterned after that required for fugitive VOC sources at petroleum refineries under 25 Pa. Code 129.58. The facility shall record all spills of VOC-containing material. Spills must be cleaned-up to minimize atmospheric emissions. Emissions which occur as a result of spills must be estimated and recorded. Those spills which result in emissions exceeding 3 pounds of VOC /hr or 15lbs/day shall be immediately reported to PADEP and included in Fansteel's annual emissions inventory. Fansteel must document and maintain monthly records of the quantity of VOC-containing compound used at this facility. Fansteel must monitor in a logbook the weekly heptane consumed and recovered. Fansteel must maintain records in accordance with 129.95 and 129.91–.94 of Pennsylvania's SIP-approved regulations. Fansteel must properly operate and maintain all equipment according to good engineering and air pollution control practices.

C. Newcomer Products, Inc.

Newcomer Products, Inc. (Newcomer) is a tungsten carbide product manufacturer located in Latrobe, Pennsylvania. Newcomer is a major source of VOC. On August 7, 1997, PADEP issued an operating permit (OP–65–000–851) to establish and impose RACT on Newcomer. The OP 65–000–851 requires the installation of a Dry Mill (two 30SC attritors), Water Mill & Spray Dryer, and Vibratory Manufacturing System. This operation will be controlled by a new cyclone and baghouse. A monthly log must be kept of all VOC-containing materials purchased, consumed, and the inventory on hand at the facility. These records shall be maintained in a file for a period of no less than two years. Under OP 65–000–851, no heptane shall be used in the milling, powder making, and the carbide pellet making processes unless approved by PADEP. Newcomer must properly operate and maintain all equipment according to good engineering and air pollution control practices.

D. Heinz USA

Heinz USA (Heinz) is a food processing facility located in Pittsburgh, Pennsylvania. Heinz is a major source of VOC and NO_X. On March 8, 1996 and October 24, 1996, respectfully, the Allegheny County Health Department (ACHD) issued an Enforcement Order (EO 211) and a Plan Approval and Agreement Upon Consent Order (CO 247) to establish and impose RACT on Heinz. Under EO 211, the NO_X emissions from the seven boilers must not exceed the following:

Boiler No.	NO_X lbs/ MMBtu	TPY
Boiler #1	0.24	111
Boiler #2	0.24	111
Boiler #3	0.28	74
Boiler #4	0.28	74
Boiler #5	0.28	74
Boiler #7	0.20	74

Boiler No.	NO_X lbs/ MMBtu	TPY
Boiler #8	0.10	78

Under EO 211, Heinz at no time shall allow the combined annual NO_X emissions to exceed 596 tons per year. Under EO 211, compliance for each boiler must be determined through emission testing according to all applicable EPA approved test methods and section 2108.02 of Article XXI of the ACHD's air pollution control regulation. Heinz must conduct emissions monitoring for NO_X from boiler #8 according to 40 CFR part 60, subpart Db. Under EO 211, Heinz must maintain all records and testing data to demonstrate compliance with section 2105.06 of Article XXI of the ACHD's air pollution control regulations. Recordkeeping requirements must include (1) the fuel usage and steam load per unit; (2) all recording and reporting required by EPA's 40 CFR part 60, subpart Db for boiler #8. Under CO 211, Heinz must retain all records required by section 2105.06 of Article XXI. Under CO 247, Heinz must install a VOC absorption system, for the purposes of reducing VOC emissions from the vinegar production generators. Under CO 247, Heinz shall not operate the vinegar production generators unless the VOC absorption system is at all times properly maintained and operated within the following performance specifications: Minimum VOC stack removal efficiency by the absorption system of eighty percent (80%); and minimum overall VOC removal efficiency of sixty-four percent (64%). Under CO 247, Heinz must conduct a system performance test in order to demonstrate compliance with the performance specifications. Under CO 247, Heinz must determine the stack absorption system removal efficiency according to EPA approved test methods and section 2108.02 of Article XXI of the ACHD's air pollution control regulations. Also, Heinz must estimate the overall control efficiency through material balance calculations. Under CO 247, Heinz shall not, at any time, conduct ketchup production in the ketchup process mixing kettles unless the addition of vinegar to the kettles is through a hard-pipe system from the vinegar storage tanks and the kettles are immediately covered after the addition of all ingredients. Under EO 247, Heinz must not, at any time, use glue in the labeling and packaging process at the facility that exceeds a VOC content of on percent (1%), by weight. Under CO 247, Heinz must not, at any time, allow the annual average use of solvent borne inks to exceed seventy percent (70%) and the maximum VOC content of solvent borne inks to exceed ninety-five percent (95%). Under CO 247, Heinz must maintain all appropriate records to demonstrate compliance with the requirements of section 2150.06 of Article XXI of the ACHD's air pollution control regulations. All records must provided sufficient data and calculations to demonstrate that all requirements of section 2105.06 of Article XXI are met. Heinz must record data and information required to determine compliance for the facility in a time frame consistent with the averaging period of the requirements of section 2105.06 of Article XXI. All records for both (EO 211 and CO 247) must be retained for at least two years. Under EO 211 and CO 247, Heinz must operate and maintain all process and emission control equipment according to good engineering and air pollution control practices.

E. Nabisco Biscuit Company

Nabisco Biscuit Company (Nabisco) is a bakery facility located in Pittsburgh, Pennsylvania. Nabisco is a major source of VOC. On December 19, 1996, the ACHD issued CO 246 to establish and impose RACT on Nabisco. The PADEP submitted CO 246, on behalf of the ACHD, to EPA as a SIP revision. Under CO 246, at no time shall Nabisco allow the following equipment to operate unless each piece of equipment is being maintained and operated in accordance with good engineering practice and within the manufacturer's specifications: Boiler #1, Boiler #2; Propane vaporizer; and Bake ovens #2–#6. Under CO 246, Nabisco must maintain records of fuel type and fuel usage, certifications from fuel suppliers for all types of liquid fuel. For each shipment of distillate oils #1 or #2, a certification that the fuel complies with ASTM D396–78 ''Standard Specifications for Fuel Oils'' is required. For residual oils, minimum recordkeeping includes a certification from the fuel supplier of the nitrogen content of the fuel, and identification of the sampling method and protocol. Under CO 246, Nabisco must not at any time, allow the use of yeast-leaved dough in bake ovens three (#3), four (#4) and six (#6). Under CO 246, Nabisco must not allow the annual operation of bake ovens two (#2) and five (#5) to exceed eighty-four percent (84%) of their maximum operating capacity or 7, 360 hours per year, each for yeast-leavened dough. There shall be no limitation on the use of non-yeast leavened dough in bake ovens two (#2) or five (#5). Annual limits must be met on a rolling monthly basis over every consecutive 12 month period. Under CO 246, Nabisco must maintain all appropriate records to demonstrate compliance with section 2105.06 of Article XXI of the ACHD's air pollution control regulations. Record must provide sufficient data and calculations to clearly demonstrate that all requirements of section 2105.06 or Article XXI are met. Recordkeeping requirements must include the hours of operation, dough type (yeast or non-yeast) per bake oven. All records must be retained for at least two years. Under CO 246, Nabisco must operate and maintain all equipment according to good engineering and air pollution control practices.

F. Aristech Chemical Company

Aristech Chemical Company (Artistech) is a plasticizer manufacturing facility located in Pittsburgh, Pennsylvania. Artistech is a major source of VOC. On December 30, 1996, the ACHD issued CO 232 to establish and impose RACT on Aristech. The PADEP submitted CO 232, on behalf of the ACHD, to EPA as a SIP revision. Under CO 232, Aristech must properly maintain, at all times, the plasticizer manufacturing plant reactor vents and the stripper secondary jet water cooled condensers at an average annual coolant inlet temperature of 95° F, except in emergency situations. Under CO 232, Aristech must operate the alcohol measuring tanks for the plasticizer train #3 to operate a maximum operating temperature that shall not exceed 110 degrees centigrade and the maximum heating cycle must not exceed two hours. Under CO 232, Aristech must maintain all records and testing data to demonstrate compliance with section 2105.06 of Article XXI of the ACHD's air pollution control regulations. Recordkeeping requirements shall include the following, but not be limited to, production records and condenser inlet coolant temperatures. All records shall be maintained for at least two years. Under CO 232, Aristech must operate and maintain all equipment according to good engineering and air pollution control practices.

G. Dyno Nobel Inc.

Dyno Nobel Inc. (Dyno) is a manufacturer of ammonium nitrate located in Donora, Pennsylvania. Dyno is a major source of NO_X. On March 31, 1999, PADEP issued an operating permit (OP–63–000–070) to establish and impose RACT on Dyno. The OP 63–000–070 requires RACT for the entire facility not to exceed 460 tons/year in

any 12-month consecutive period as follows:

Process unit/units	TPY	lbs/hr.
Ammonia Oxidation Process	396	5.5 lbs/ton.
Cleaver Brooks #1 Boiler	31	7.1 lbs/hr.
Murray #2 Boiler	31	7.1 lbs/hr.

Under OP 63–000–070, Dyno must perform an annual adjustment or tune-up as required by 25 Pa Code Chapter 129.93 (b)(2) on each boiler with individual rated heat inputs between 20 and 50 MMBTU/hr as identified. Under OP 63–000–070, Dyno must maintain records for each adjustment conducted under the procedures outlined in 25 Pa Code Chapter 129.93(b)(2) (i–iii) for all identified combustion sources with rated heat inputs between 20 and 50 MMBtu/hr. All records must contain, at a minimum, the following: The date of the tuning procedure, the name of the service company and technicians, the final operating rate or load, the final NO_X emission rates, the final excess oxygen rate. Under OP 63–000–070, Dyno must maintain records including computerized records that may be necessary to comply with 23 Pa Code Chapter 135.21 (relating to reporting and emission statements). The records shall include production, fuel usage, maintenance of production or pollution control equipment, quantification of potential and actual air contaminant emissions. Under OP 63–000–070, Dyno shall maintain records in accordance with the record keeping requirements of 25 Pa Code Chapter 129.95. The records shall provide sufficient data and calculations to clearly demonstrate that the requirements of 25 Pa Code Chapter 129.91–94 are met. Data and information required to determine compliance shall be recorded and maintained in a time frame consistent with averaging periods to verify compliance. These records shall be retained for at least 5 years. Dyno must properly operate and maintain all equipment according to good engineering and air pollution control practices in accordance with applicable PADEP regulations.

H. General Carbide Corporation

General Carbide Corporation (General Carbide) processes metal carbide powders into tools and is located in Hempfield Township, Pennsylvania. General Carbide is a major source of VOC. On December 29, 1995, PADEP issued OP–65–000–622 to establish and impose RACT on General Carbide. Under OP 65–000–622, General Carbide may not operate unless its dryers and condensers are operational. Under OP 65–000–622, General Carbide must track and record hours of operation, total heptane consumption, all maintenance and repair operations to comply with the recordkeeping requirements. These record must be retained on site for at least two years. Under OP 65–000–622, General Carbide must conduct daily monitoring of the area that uses heptane. A heptane vapor monitor will be used to assure that the equipment is functioning properly and no leaks are occurring. If any leaks are detected from the storage tanks or process, General Carbide will notify PADEP immediately. OP 65–00–622 requires General Carbide to continue to officially document and maintain monthly records on the quantity of VOC containing compounds used at the facility. General Carbide must properly operate and maintain all processes according to good engineering and air pollution control practices in accordance with applicable PADEP regulations.

I. Koppers Industries, Inc.

Koppers Industries, Inc. (Koppers) is the owner and operator of crude tar feed and heavy, middle, and light distillates facilities in Clairton, Allegheny County, Pennsylvania. Koppers is a major source of VOC. On August 27, 1996, the ACHD issued CO 223 to establish and impose RACT on Koppers. The PADEP submitted CO 223, on behalf of the ACHD, to EPA as a SIP revision. Under CO 223, Koppers must not operate the tar distillation and refining unit unless the VOC emissions from this unit is processed by the existing natural gas blanketing system. Under CO 223, the natural gas blanketing system must be properly maintained and operated with a minimum VOC destruction efficiency of 95% at all times when the tar distillation and refining unit is operating. Under CO 223, the natural gas blanketing system destruction efficiency must be determined annually according to US EPA approved test methods and as required by section 2108.02(c) of Article XXI of the ACHD's air pollution control regulations. Under CO 223, Koppers must maintain all records and testing data to demonstrate compliance with section 2105.06 of Article XXI of the ACHD's air pollution control regulations. Under CO 223, all records must provide sufficient data and calculations to demonstrate that all requirements of section 2105.06 of Article XXI are being met. The data and information required to determine compliance must be recorded and maintained by the Koppers and shall include, but not limited to, throughput and operating hours of the tar refining process. All records shall be maintained for at least two years. Under CO 223, Koppers must operate and maintain all equipment according to good engineering and air pollution control practices.

J. Pressure Chemical Co.

Pressure Chemical Co. (Pressure Chemical) is a operator of a small batch chemical manufacturing facility located in Pittsburgh, Pennsylvania. Pressure Chemical is a major source of VOC. On June 11, 1997, the ACHD issued CO 261 to establish and impose RACT on Pressure Chemical. The PADEP submitted CO 261, on behalf of the ACHD, to EPA as a SIP revision. Under CO 261, Pressure Chemical must keep all storage containers containing VOCs covered at all times except during the transfer of materials and must clean any liquid or dry material spilled at the facility. Under CO 261, Pressure Chemical must at all times maintain the following records in order to calculated actual VOC emissions according to accepted mass balance methodology: (1) Purchase and inventory records of VOC containing materials; (2) annual throughput of VOC-containing materials; and (3) production records for all processes involving VOC containing materials. All records must be retained for at least two years. Under CO 261, Pressure Chemical must properly maintain and operate all existing process equipment according to good engineering and air pollution control practices.

III. EPA's Evaluation of the SIP Revisions

EPA is approving these RACT SIP submittals because the ACHD and PADEP established and imposed these RACT requirements in accordance with the criteria set forth in SIP-approved RACT regulations applicable to these

sources. The ACHD and PADEP have also imposed recordkeeping, monitoring, and testing requirements on these sufficient to determine compliance with the applicable RACT determinations.

IV. Final Action

EPA is approving the revisions to the Pennsylvania SIP submitted by PADEP to establish and require VOC and NO_X RACT for ten major of sources located in the Pittsburgh area. EPA is publishing this rule without prior proposal because the Agency views this as a noncontroversial amendment and anticipates no adverse comment. However, in the ''Proposed Rules'' section of today's **Federal Register**, EPA is publishing a separate document that will serve as the proposal to approve the SIP revision if adverse comments are filed. This rule will be effective on October 9, 2001 without further notice unless EPA receives adverse comment by September 24, 2001. If EPA receives adverse comment, EPA will publish a timely withdrawal in the **Federal Register** informing the public that the rule will not take effect. EPA will address all public comments in a subsequent final rule based on the proposed rule. EPA will not institute a second comment period on this action. Any parties interested in commenting must do so at this time. Please note that if adverse comment is received for a specific source or subset of sources covered by an amendment, section or paragraph of this rule, only that amendment, section, or paragraph for that source or subset of sources will be withdrawn.

V. Administrative Requirements

A. General Requirements

Under Executive Order 12866 (58 FR 51735, October 4, 1993), this action is not a ''significant regulatory action'' and therefore is not subject to review by the Office of Management and Budget. For this reason, this action is also not subject to Executive Order 13211, ''Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use.'' See 66 FR 28355, May 22, 2001. This action merely approves state law as meeting Federal requirements and imposes no additional requirements beyond those imposed by state law. Accordingly, the Administrator certifies that this rule will not have a significant economic impact on a substantial number of small entities under the Regulatory Flexibility Act (5 U.S.C. 601 *et seq.*). Because this rule approves pre-existing requirements under state law and does not impose any additional enforceable duty beyond that required by state law, it does not contain any unfunded mandate or significantly or uniquely affect small governments, as described in the Unfunded Mandates Reform Act of 1995 (Public Law 104–4). This rule also does not have a substantial direct effect on one or more Indian tribes, on the relationship between the Federal Government and Indian tribes, or on the distribution of power and responsibilities between the Federal Government and Indian tribes, as specified by Executive Order 13175 (65 FR 67249, November 9, 2000), nor will it have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132 (64 FR 43255, August 10, 1999), because it merely approves a state rule implementing a Federal standard, and does not alter the relationship or the distribution of power and responsibilities established in the Clean Air Act. This rule also is not subject to Executive Order 13045 (62 FR 19885, April 23, 1997), because it is not economically significant. In reviewing SIP submissions, EPA's role is to approve state choices, provided that they meet the criteria of the Clean Air Act. In this context, in the absence of a prior existing requirement for the State to use voluntary consensus standards (VCS), EPA has no authority to disapprove a SIP submission for failure to use VCS. It would thus be inconsistent with applicable law for EPA, when it reviews a SIP submission, to use VCS in place of a SIP submission that otherwise satisfies the provisions of the Clean Air Act. Thus, the requirements of section 12(d) of the National Technology Transfer and Advancement Act of 1995 (15 U.S.C. 272 note) do not apply. As required by section 3 of Executive Order 12988 (61 FR 4729, February 7, 1996), in issuing this rule, EPA has taken the necessary steps to eliminate drafting errors and ambiguity, minimize potential litigation, and provide a clear legal standard for affected conduct. EPA has complied with Executive Order 12630 (53 FR 8859, March 15, 1988) by examining the takings implications of the rule in accordance with the ''Attorney General's Supplemental Guidelines for the Evaluation of Risk and Avoidance of Unanticipated Takings'' issued under the executive order. This rule does not impose an information collection burden under the provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 *et seq.*).

B. Submission to Congress and the Comptroller General

The Congressional Review Act, 5 U.S.C. 801 *et seq.*, as added by the Small Business Regulatory Enforcement Fairness Act of 1996, generally provides that before a rule may take effect, the agency promulgating the rule must submit a rule report, which includes a copy of the rule, to each House of the Congress and to the Comptroller General of the United States. Section 804 exempts from section 801 the following types of rules: (1) Rules of particular applicability; (2) rules relating to agency management or personnel; and (3) rules of agency organization, procedure, or practice that do not substantially affect the rights or obligations of non-agency parties. 5 U.S.C. 804(3). EPA is not required to submit a rule report regarding today's action under section 801 because this is a rule of particular applicability establishing source-specific requirements for ten named sources.

C. Petitions for Judicial Review

Under section 307(b)(1) of the Clean Air Act, petitions for judicial review of this action must be filed in the United States Court of Appeals for the appropriate circuit by October 23, 2001. Filing a petition for reconsideration by the Administrator of this final rule does not affect the finality of this rule for the purposes of judicial review nor does it extend the time within which a petition for judicial review may be filed, and shall not postpone the effectiveness of such rule or action. This action approving the Commonwealth's source-specific RACT requirements to control VOC and/or NO_X from ten individual sources located in the Pittsburgh-Beaver Valley of Pennsylvania may not be challenged later in proceedings to enforce its requirements. (See section 307(b)(2).)

List of Subjects in 40 CFR Part 52

Environmental protection, Air pollution control, Hydrocarbons, Incorporation by reference, Nitrogen dioxide, Ozone, Reporting and recordkeeping requirements.

Dated: August 15, 2001.

Thomas C. Voltaggio,

Acting Regional Administrator, Region III.

40 CFR part 52 is amended as follows:

PART 52—[AMENDED]

1. The authority citation for part 52 continues to read as follows:

Authority: 42 U.S.C. 7401 *et seq.*

Subpart NN—Pennsylvania

2. Section 52.2020 is amended by adding paragraph (c)(178) to read as follows:

§ 52.2020 Identification of plan.

* * * * *

(c) * * *

(178) Revisions pertaining to VOC and/or NO_X RACT for major sources, located in the Pittsburgh-Beaver Valley ozone nonattainment area, submitted by the Pennsylvania Department of Environmental Protection on July 1, 1997, October 23, 1997, November 4, 1997, December 31, 1997, April 9, 1999 and August 9, 2000.

(i) Incorporation by reference.

(A) Letters dated July 1, 1997, October 23, 1997, November 4, 1997, December 31, 1997, April 9, 1999 and August 9, 2000 submitted by the Pennsylvania Department of Environmental Protection transmitting source-specific VOC and/or NO_X RACT determinations, in the form of operating permits, consent orders, and enforcement orders.

(B) Operating permits (OP), Consent Orders (CO) and Enforcement Orders (EO) for the following sources:

(*1*) Aristech Chemical Corporation, CO 232, effective December 30, 1996, except for condition 2.6.

(*2*) Heinz USA, EO 211, effective March 8, 1996, except for conditions 1.5, 2.4, and 2.5; and CO 247, effective October 24, 1996, except for conditions 1.11 and 2.7.

(*3*) Koppers Industries, Inc., CO 223, effective August 27, 1996, except for condition 2.5.

(*4*) Nabisco Biscuit Company, CO 246, effective December 19, 1996, except for condition 2.5.

(*5*) Pressure Chemical Company, CO 261, effective June 11, 1997, except for condition 2.8.

(*6*) General Carbide Corporation, OP 65–000–622, effective December 29, 1995, except for the Permit Term.

(*7*) Fansteel Hydro Carbide, OP 65–000–860, effective December 12, 1997.

(*8*) Carbidie Corporation, OP 65–000–720, effective July 31, 1998, except for the Permit Term, and Conditions 4, 5 and 11.

(*9*) Dyno Nobel, Inc., OP 63–000–070, effective March 31, 1999, except for the Permit Term.

(*10*) Newcomer Products, Inc., OP–65–000–851, effective August 7, 1997.

(ii) Additional Materials—Other materials submitted by the Commonwealth of Pennsylvania in support of and pertaining to the RACT determinations for the sources listed in paragraph (c)(178)(i)(B) of this section.

[FR Doc. 01–21425 Filed 8–23–01; 8:45 am]

BILLING CODE 6560–50–P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 52

[PA–4146a; FRL–7040–6]

Approval and Promulgation of Air Quality Implementation Plans; Pennsylvania; NO_X RACT Determination for Koppel Steel Corporation in the Pittsburgh-Beaver Valley Area

AGENCY: Environmental Protection Agency (EPA).

ACTION: Direct final rule.

SUMMARY: EPA is taking direct final action to approve a revision to the Commonwealth of Pennsylvania's State Implementation Plan (SIP). The revision was submitted by the Pennsylvania Department of Environmental Protection (PADEP) to establish and require reasonably available control technology (RACT) for the Koppel Steel Corporation's Ambridge Plant, a major source of nitrogen oxides (NO_X) located in the Pittsburgh-Beaver Valley ozone nonattainment area (the Pittsburgh area). EPA is approving this revision to establish RACT requirements in the SIP in accordance with the Clean Air Act (CAA).

DATES: This rule is effective on October 9, 2001 without further notice, unless EPA receives adverse written comment by September 24, 2001. If EPA receives such comments, it will publish a timely withdrawal of the direct final rule in the **Federal Register** and inform the public that the rule will not take effect.

ADDRESSES: Written comments should be mailed to David L. Arnold, Chief, Air Quality Planning & Information Services Branch, Air Protection Division, Mail code 3AP21, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103. Copies of the documents relevant to this action are available for public inspection during normal business hours at the Air Protection Division, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103; the Air and Radiation Docket and Information Center, U.S. Environmental Protection Agency, 401 M Street, SW., Washington, DC 20460; and the Pennsylvania Department of Environmental Protection, Bureau of Air Quality Control, P.O. Box 8468, 400 Market Street, Harrisburg, Pennsylvania 17105.

FOR FURTHER INFORMATION CONTACT: Michael Ioff at (215) 814–2166, the EPA Region III address above or by e-mail at *ioff.mike@epa.gov.* Please note that while questions may be posed via telephone and e-mail, formal comments must be submitted, in writing, as indicated in the **ADDRESSES** section of this document.

SUPPLEMENTARY INFORMATION:

I. Background

Pursuant to sections 182(b)(2) and 182(f) of the Clean Air Act (CAA), the Commonwealth of Pennsylvania (the Commonwealth or Pennsylvania) is required to establish and implement RACT for all major volatile organic compounds (VOC) and NO_X sources. The major source size is determined by its location, the classification of that area and whether it is located in the ozone transport region (OTR). Under section 184 of the CAA, RACT as specified in sections 182(b)(2) and 182(f) applies throughout the OTR. The entire Commonwealth is located within the OTR. Therefore, RACT is applicable statewide in Pennsylvania.

State implementation plan revisions imposing reasonably available control technology (RACT) for three classes of VOC sources are required under section 182(b)(2). The categories are: (1) All sources covered by a Control Technique Guideline (CTG) document issued between November 15, 1990 and the date of attainment; (2) All sources covered by a CTG issued prior to November 15, 1990; (3) All other major non-CTG rules were due by November 15, 1992. The Pennsylvania SIP has approved RACT regulations and requirements for all sources and source categories covered by the CTG's.

On February 4, 1994, the Pennsylvania Department of Environmental Protection (PADEP) submitted a revision to its SIP to require major sources of NO_X and additional major sources of VOC emissions (not covered by a CTG) to implement RACT. The February 4, 1994 submittal was amended on May 3, 1994 to correct and clarify certain presumptive NO_X RACT requirements. In the Pittsburgh area, a major source of VOC is defined as one having the potential to emit 50 tons per year (tpy) or more, and a major source of NO_X is defined as one having the potential to emit 100 tpy or more. Pennsylvania's RACT regulations require sources, in the Pittsburgh area, that have the potential to emit 50 tpy or more of VOC and sources which have

the potential to emit 100 tpy or more of NO_X comply with RACT by May 31, 1995. The regulations contain technology-based or operational ''presumptive RACT emission limitations'' for certain major NO_X sources. For other major NO_X sources, and all major non-CTG VOC sources (not otherwise already subject to RACT under the Pennsylvania SIP), the regulations contain a ''generic'' RACT provision. A generic RACT regulation is one that does not, itself, specifically define RACT for a source or source categories but instead allows for case-by-case RACT determinations. The generic provisions of Pennsylvania's regulations allow for PADEP to make case-by-case RACT determinations that are then to be submitted to EPA as revisions to the Pennsylvania SIP.

On March 23, 1998 EPA granted conditional limited approval to the Commonwealth's generic VOC and NO_X RACT regulations (63 FR 13789). In that action, EPA stated that the conditions of its approval would be satisfied once the Commonwealth either (1) certifies that it has submitted case-by-case RACT proposals for all sources subject to the RACT requirements currently known to PADEP; *or* (2) demonstrates that the emissions from any remaining subject sources represent a de minimis level of emissions as defined in the March 23, 1998 rulemaking. On April 22, 1999, PADEP made the required submittal to EPA certifying that it had met the terms and conditions imposed by EPA in its March 23, 1998 conditional limited approval of its VOC and NO_X RACT regulations by submitting 485 case-by-case VOC/NO_X RACT determinations as SIP revisions and making the demonstration described as condition 2, above. EPA determined that Pennsylvania's April 22, 1999 submittal satisfied the conditions imposed in its conditional limited approval published on March 23, 1998. On May 3, 2001 (66 FR 22123), EPA published a rulemaking action removing the conditional status of its approval of the Commonwealth's generic VOC and NO_X RACT regulations on a statewide basis. The regulation currently retains its limited approval status. Once EPA has approved the case-by-case RACT determinations submitted by PADEP to satisfy the conditional approval for subject sources located in Allegheny, Armstrong, Beaver, Butler, Fayette, Washington, and Westmoreland Counties; the limited approval of Pennsylvania's generic VOC and NO_X RACT regulations shall convert to a full approval for the Pittsburgh area.

II. Summary of the SIP Revision

On August 8, 2001, PADEP submitted revisions to the Pennsylvania SIP which establish and impose case-by-case RACT for several sources of VOC and/or NO_X. This rulemaking pertains to the Commonwealth's submittal of operating permit (OP) 04–000–227 which imposes NO_X RACT requirements for the Koppel Steel Corporation's Ambridge Plant, a major source of NO_X located in the Pittsburgh area. Remaining sources are the subject of separate rulemakings.

The Koppel Steel Corporation's Ambridge Plant is a producer of carbon and alloy tubular products located in Harmony Township, Beaver County, Pennsylvania. The Koppel's Ambridge facility receives steel billets and tube rounds from another Koppel facility located in Koppel, Pennsylvania. The Ambridge Plant is a steel processing facility which treats and shapes these billets and rounds into tubular products. The facility consists of eight installations/processes with potential NO_X emissions of 153.1 tons per year. It is, therefore, a major source of NO_X and subject to RACT. As the facility's potential VOC emissions are less than 50 tons per year, the facility is not a major source of VOC. The PADEP established NO_X RACT requirements in OP 04–000–227 for the eight installations/processes subject to Pennsylvania's RACT regulation.

A. Description of the NO_X Emitting Units/Processes at the Ambridge Plant

The eight installations/processes at Koppel Steel's Ambridge facility fall into two source types, heat treating furnaces and space heating units.

1. Heat Treating Furnaces

The heat treating furnaces include the Quench Furnace, Temper Furnace, Reheat Furnace, 5″ and 7.5″ upsetter furnaces, off-mill normalize furnace, and rotary hearth reheat furnace. The heating/reheat furnaces are used for heat-treating of steel to bring it to a uniform temperature suitable for hot working. Upsetter furnaces are small units used to heat treat the ends of the tubular products to the correct temperature prior to their upsetting. The normalizing furnace is used to refine the steel grain structure, to relieve stresses induced by hot or cold working, and to improve the mechanical properties of the steel. The quench and temper furnaces are used in the product's final finishing process, in order to achieve its proper physical properties, by cooling it under closely controlled thermal conditions. Heat treatment of the carbon and alloy steels is conducted at a slow rate and relatively low temperatures to minimize thermal stresses and to avoid distortion and cracking. All the heat treating furnaces at the Koppel's Ambridge facility are natural gas fired combustion units.

2. Miscellaneous Plant-wide Space Heating Units

Several natural gas fired space heaters are located throughout the plant. These units do not contribute significantly to the total plant-wide NO_X emissions. The gas space heaters are henceforth discussed collectively.

B. Description of the RACT Determination

Of the plant's eight major NO_X emitting installations/processes, four (the reheat furnace, 5″ and 7.5″ upsetter furnaces, and the gas space heaters) are units with rated heat input of less than 20 MMBTU/hr each. Pennsylvania has determined that these sources are subject to SIP-approved presumptive RACT requirements set forth in 25 Pa. Code Section 129.93(c)(1) which requires that the installation, maintenance, and operation of the source be done in accordance with manufacturer's specifications. Three of the four remaining sources (the quench, temper, and off-mill normalized furnaces) are natural gas fired combustion units with a rated heat inputs between 20 MMBTU/hr and 50 MMBTU/hr each. Pennsylvania has determined that these three sources are subject to SIP-approved presumptive RACT requirements set forth in 25 Pa. Code Section 129.93(b)(2) which require that an annual adjustment or tune-up of the combustion process be performed. Pennsylvania also requires that an annual test program be conducted utilizing a portable analyzer for nitrogen oxides, carbon monoxide, and VOC for the quench, temper, reheat, and off-mill normalize furnaces. In addition, in its OP 04–000–227 Pennsylvania has imposed a requirement that all sources, listed above, shall be operated and maintained in accordance with good air pollution control practices. The remaining NO_X emitting source is the rotary hearth reheat furnace with a rated heat input of 182 MMBTU/hr. The following NO_X control options were evaluated in a case-by-case RACT analysis: Selective Catalytic Reduction (SCR), Low NO_X Burners (LNB), Flue Gas Recirculation (FGR), Selective Non-Catalytic Reduction (SNCR), and Low Excess Air (LEA). Pennsylvania has determined that, as RACT, Koppel shall employ LEA at a percentage of approximately 10% to minimize NO_X formation. Pennsylvania also requires

that an annual test program be conducted utilizing a portable analyzer for nitrogen oxides, carbon monoxide, and VOC for this source. OP 04–000–227 also requires that a PADEP-approved stack test for oxides of nitrogen, carbon monoxide, and VOC be performed, and that the furnace shall be operated and maintained in accordance with good air pollution control practices.

III. EPA's Evaluation

EPA is approving Pennsylvania's SIP submittal to impose RACT for Koppel Steel Corporation's Ambridge Plant because OP 04–000–227 establishes and imposes RACT requirements in accordance with the criteria set forth in the SIP-approved RACT regulations and also imposes record-keeping, and testing requirements sufficient to determine compliance with the applicable RACT determinations.

IV. Final Action

EPA is approving OP 04–000–227 issued by the PADEP to impose RACT for Koppel Steel Corporation's Ambridge Plant as a revision to the Pennsylvania SIP. EPA is publishing this rule without prior proposal because the Agency views this as a noncontroversial amendment and anticipates no adverse comment. However, in the ''Proposed Rules'' section of today's **Federal Register**, EPA is publishing a separate document that will serve as the proposal to approve the SIP revision if adverse comments are filed. This rule will be effective on October 9, 2001 without further notice unless EPA receives adverse comment by September 24, 2001. If EPA receives adverse comment, EPA will publish a timely withdrawal in the **Federal Register** informing the public that the rule will not take effect. EPA will address all public comments in a subsequent final rule based on the proposed rule. EPA will not institute a second comment period on this action. Any parties interested in commenting must do so at this time.

V. Administrative Requirements

A. General Requirements

Under Executive Order 12866 (58 FR 51735, October 4, 1993), this action is not a ''significant regulatory action'' and therefore is not subject to review by the Office of Management and Budget. For this reason, this action is also not subject to Executive Order 13211, ''Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use.'' See 66 FR 28355, May 22, 2001. This action merely approves state law as meeting Federal requirements and imposes no additional requirements beyond those imposed by state law. Accordingly, the Administrator certifies that this rule will not have a significant economic impact on a substantial number of small entities under the Regulatory Flexibility Act (5 U.S.C. 601 *et seq.*). Because this rule approves pre-existing requirements under state law and does not impose any additional enforceable duty beyond that required by state law, it does not contain any unfunded mandate or significantly or uniquely affect small governments, as described in the Unfunded Mandates Reform Act of 1995 (Public Law 104–4). This rule also does not have a substantial direct effect on one or more Indian tribes, on the relationship between the Federal Government and Indian tribes, or on the distribution of power and responsibilities between the Federal Government and Indian tribes, as specified by Executive Order 13175 (65 FR 67249, November 9, 2000), nor will it have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132 (64 FR 43255, August 10, 1999), because it merely approves a state rule implementing a Federal standard, and does not alter the relationship or the distribution of power and responsibilities established in the Clean Air Act. This rule also is not subject to Executive Order 13045 (62 FR 19885, April 23, 1997), because it is not economically significant. In reviewing SIP submissions, EPA's role is to approve state choices, provided that they meet the criteria of the Clean Air Act. In this context, in the absence of a prior existing requirement for the State to use voluntary consensus standards (VCS), EPA has no authority to disapprove a SIP submission for failure to use VCS. It would thus be inconsistent with applicable law for EPA, when it reviews a SIP submission, to use VCS in place of a SIP submission that otherwise satisfies the provisions of the Clean Air Act. Thus, the requirements of section 12(d) of the National Technology Transfer and Advancement Act of 1995 (15 U.S.C. 272 note) do not apply. As required by section 3 of Executive Order 12988 (61 FR 4729, February 7, 1996), in issuing this rule, EPA has taken the necessary steps to eliminate drafting errors and ambiguity, minimize potential litigation, and provide a clear legal standard for affected conduct. EPA has complied with Executive Order 12630 (53 FR 8859, March 15, 1988) by examining the takings implications of the rule in accordance with the ''Attorney General's Supplemental Guidelines for the Evaluation of Risk and Avoidance of Unanticipated Takings'' issued under the executive order. This rule does not impose an information collection burden under the provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 *et seq.*).

B. Submission to Congress and the Comptroller General

The Congressional Review Act, 5 U.S.C. 801 *et seq.*, as added by the Small Business Regulatory Enforcement Fairness Act of 1996, generally provides that before a rule may take effect, the agency promulgating the rule must submit a rule report, which includes a copy of the rule, to each House of the Congress and to the Comptroller General of the United States. Section 804 exempts from section 801 the following types of rules: (1) Rules of particular applicability; (2) rules relating to agency management or personnel; and (3) rules of agency organization, procedure, or practice that do not substantially affect the rights or obligations of non-agency parties. 5 U.S.C. 804(3). EPA is not required to submit a rule report regarding today's action under section 801 because this is a rule of particular applicability establishing source-specific requirements for one named source.

C. Petitions for Judicial Review

Under section 307(b)(1) of the Clean Air Act, petitions for judicial review of this action must be filed in the United States Court of Appeals for the appropriate circuit by October 23, 2001. Filing a petition for reconsideration by the Administrator of this final rule does not affect the finality of this rule for the purposes of judicial review nor does it extend the time within which a petition for judicial review may be filed, and shall not postpone the effectiveness of such rule or action. This action approving the Commonwealth's source-specific RACT requirements to control NO_X emissions from Koppel Steel Corporation's Ambridge Plant may not be challenged later in proceedings to enforce its requirements. (See section 307(b)(2).)

List of Subjects in 40 CFR Part 52

Environmental protection, Air pollution control, Incorporation by reference, Nitrogen oxides, Ozone, Reporting and recordkeeping requirements.

Dated: August 15, 2001.

Thomas C. Voltaggio,

Acting Regional Administrator, Region III.

40 CFR part 52 is amended as follows:

PART 52—[AMENDED]

1. The authority citation for Part 52 continues to read as follows:

Authority: 42 U.S.C. 7401 et seq.

Subpart NN—Pennsylvania

2. Section 52.2020 is amended by adding paragraph (c)(180) to read as follows:

§ 52.2020 Identification of plan.

* * * * *

(c) * * *

(180) Revision pertaining to NO_X RACT for Koppel Steel Corporation's Ambridge Plant located in Harmony Township, Beaver County, Pennsylvania, submitted by the Pennsylvania Department of Environmental Protection on August 8, 2001.

(i) Incorporation by reference.

(A) Letter submitted on August 8, 2001 by the Pennsylvania Department of Environmental Protection transmitting several source-specific NO_X and/or VOC RACT determinations.

(B) Operating Permit 04–000–227, effective October 12, 2000, issued to Koppel Steel Corporation, Ambridge Plant.

(ii) Additional Materials—Other materials submitted by the Commonwealth of Pennsylvania in support of and pertaining to the RACT determination for the source listed in paragraph (c)(180)(i)(B) of this section.

[FR Doc. 01–21429 Filed 8–23–01; 8:45 am]

BILLING CODE 6560–50–P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 52

[PA 150–4150; FRL–7043–5]

Approval and Promulgation of Air Quality Implementation Plans; Pennsylvania; Conversion of the Conditional Approval of the 15 Percent Plan for the Pennsylvania Portion of the Philadelphia-Wilmington-Trenton Nonattainment Area to a Full Approval

AGENCY: Environmental Protection Agency (EPA).

ACTION: Final rule.

SUMMARY: EPA is converting its conditional approval of a State Implementation Plan (SIP) revision submitted by the Commonwealth of Pennsylvania to a full approval. The revision is the 15 percent reasonable further progress plan (15% plan) for Pennsylvania's portion of the Philadelphia-Wilmington-Trenton ozone nonattainment area (the Philadelphia area). EPA is converting its approval of this SIP revision from conditional to full approval because the Commonwealth has satisfied the conditions imposed by EPA's prior conditional approval of the Philadelphia 15% plan. The intended effect of this action is to convert EPA's conditional approval of Pennsylvania's 15% plan SIP for the Philadelphia area to a full approval.

EFFECTIVE DATE: This final rule is effective on September 24, 2001.

ADDRESSES: Copies of the documents relevant to this action are available for public inspection during normal business hours at the Air Protection Division, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103 or at the Pennsylvania Department of Environmental Protection, Bureau of Air Quality, P.O. Box 8468, 400 Market Street, Harrisburg, Pennsylvania 17105.

FOR FURTHER INFORMATION CONTACT: Brian Rehn at (215) 814–2176, or by e-mail at rehn.brian@epa.gov.

SUPPLEMENTARY INFORMATION:

I. Background

On May 16, 2001 (66 FR 27051), EPA published a notice of proposed rulemaking (NPR) for the Commonwealth of Pennsylvania. The NPR proposed the conversion of EPA's prior conditional approval of Pennsylvania's 15% plan SIP for the Philadelphia area to full approval. The basis for this proposed approval was a formal amendment to Pennsylvania's 15% plan SIP revision that was submitted by Pennsylvania on June 5, 1998. EPA is approving Pennsylvania's 15% plan for its portion of the Philadelphia area, which is based upon an overall air emissions target level of 487.9 tons per day of anthropogenic volatile organic compounds. EPA's rationale for approval of this SIP revision and the specific details of EPA's proposed action are explained in the NPR and will not be restated here. No public comments were submitted on the NPR.

II. Final Action

EPA is converting its prior conditional approval of Pennsylvania's 15% plan for its portion of the Philadelphia-Wilmington-Trenton ozone nonattainment area to a full approval. This action upon Pennsylvania's 15% plan SIP revision for the Philadelphia area serves to convert EPA's prior conditional approval of this SIP revision to a full approval.

III. Administrative Requirements

A. General Requirements

Under Executive Order 12866 (58 FR 51735, October 4, 1993), this action is not a ''significant regulatory action'' and therefore is not subject to review by the Office of Management and Budget. For this reason, this action is also not subject to Executive Order 13211, ''Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use'' (66 FR 28355, May 22, 2001). This action merely approves a state law as meeting Federal requirements and imposes no additional requirements beyond those imposed by state law. Accordingly, the Administrator certifies that this rule will not have a significant economic impact on a substantial number of small entities under the Regulatory Flexibility Act (5 U.S.C. 601 et seq.). Because this rule approves pre-existing requirements under state law and does not impose any additional enforceable duty beyond that required by state law, it does not contain any unfunded mandate or significantly or uniquely affect small governments, as described in the Unfunded Mandates Reform Act of 1995 (Pub. L. 104–4). This rule also does not have a substantial direct effect on one or more Indian tribes, on the relationship between the Federal Government and Indian tribes, or on the distribution of power and responsibilities between the Federal Government and Indian tribes, as specified by Executive Order 13175 (65 FR 67249, November 9, 2000), nor will it have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132 (64 FR 43255, August 10, 1999), because it merely approves a state rule implementing a Federal standard, and does not alter the relationship or the distribution of power and responsibilities established in the Clean Air Act. This rule also is not subject to Executive Order 13045 (62 FR 19885, April 23, 1997), because it is not economically significant. In reviewing SIP submissions, EPA's role is to approve state choices, provided that they meet the criteria of the Clean Air Act. In this context, in the absence of a prior existing requirement for the State to use voluntary consensus standards

(VCS), EPA has no authority to disapprove a SIP submission for failure to use VCS. It would thus be inconsistent with applicable law for EPA, when it reviews a SIP submission, to use VCS in place of a SIP submission that otherwise satisfies the provisions of the Clean Air Act. Thus, the requirements of section 12(d) of the National Technology Transfer and Advancement Act of 1995 (15 U.S.C. 272 note) do not apply. As required by section 3 of Executive Order 12988 (61 FR 4729, February 7, 1996), in issuing this rule, EPA has taken the necessary steps to eliminate drafting errors and ambiguity, minimize potential litigation, and provide a clear legal standard for affected conduct. EPA has complied with Executive Order 12630 (53 FR 8859, March 15, 1988) by examining the takings implications of the rule in accordance with the ''Attorney General's Supplemental Guidelines for the Evaluation of Risk and Avoidance of Unanticipated Takings'' issued under the executive order. This rule does not impose an information collection burden under the provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 *et seq.*).

B. Submission to Congress and the Comptroller General

The Congressional Review Act, 5 U.S.C. 801 *et seq.*, as added by the Small Business Regulatory Enforcement Fairness Act of 1996, generally provides that before a rule may take effect, the agency promulgating the rule must submit a rule report, which includes a copy of the rule, to each House of the Congress and to the Comptroller General of the United States. EPA will submit a report containing this rule and other required information to the U.S. Senate, the U.S. House of Representatives, and the Comptroller General of the United States prior to publication of the rule in the **Federal Register**. This rule is not a ''major rule'' as defined by 5 U.S.C. 804(2).

C. Petitions for Judicial Review

Under section 307(b)(1) of the Clean Air Act, petitions for judicial review of this action to convert EPA's prior conditional approval of the Philadelphia 15% plan to full approval must be filed in the United States Court of Appeals for the appropriate circuit by October 23, 2001. Filing a petition for reconsideration by the Administrator of this final rule does not affect the finality of this rule for the purposes of judicial review nor does it extend the time within which a petition for judicial review may be filed, and shall not postpone the effectiveness of such rule or action. This action may not be challenged later in proceedings to enforce its requirements. (See section 307(b)(2).)

List of Subjects in 40 CFR Part 52

Environmental protection, Air pollution control, Hydrocarbons, Ozone.

Dated: August 16, 2001.

Thomas C. Voltaggio,

Acting Regional Administrator, Region III.

40 CFR part 52 is amended as follows:

PART 52—[AMENDED]

1. The authority citation for part 52 continues to read as follows:

Authority: 42 U.S.C. 7401 *et seq.*

Subpart NN—Pennsylvania

2. In § 52.2038 the existing text is designated as paragraph (a) and paragraph (b) is added to read as follows:

§ 52.2038 Rate of progress plans: ozone.

* * * * *

(b) EPA grants full approval to the 15 Percent Rate of Progress Plan for Pennsylvania's portion of the Philadelphia-Wilmington-Trenton ozone nonattainment area. The area that is the subject of this action encompasses Bucks, Chester, Delaware, Philadelphia, and Montgomery Counties. The plan was formally submitted to EPA by the Secretary of the Pennsylvania Department of Environmental Protection on September 12, 1996, and was formally revised on April 10, 1997 and June 5, 1998.

§ 52.2026 [Removed and Reserved]

3. Section 52.2026 is removed and reserved.

[FR Doc. 01–21432 Filed 8–23–01; 8:45 am]

BILLING CODE 6560–50–U

FEDERAL COMMUNICATIONS COMMISSION

47 CFR Part 73

[DA 01–1910; MM Docket No. 01–95; RM–10093]

Radio Broadcasting Services; Naches, Sunnyside and Benton City, WA

AGENCY: Federal Communications Commission.

ACTION: Final rule.

SUMMARY: The Commission grants a petition for rule making filed by Butterfield Broadcasting Corporation (''petitioner'') licensee of Stations KZTA(FM), Naches, Washington and KZTB(FM), Sunnyside, Washington. *See* 66 FR 22498 (May 4, 2001). Channel 245C2 is substituted for 245A at Naches, and Channel 244A is reallotted from Sunnyside to Benton City, Washington, as the community's first local transmission service. Channel 245C2 is allotted at Naches in compliance with the Commission's minimum distance separation requirements at petitioner's requested site at coordinates NL 46–36–02 and WL 120–52–06. Channel 244A is reallotted from Sunnyside to Benton City in compliance with the Commission's minimum distance separation requirements at petitioner's requested site, at coordinates NL 46–14–48 and 120–25–40.

DATES: Effective September 24, 2001.

FOR FURTHER INFORMATION CONTACT: Victoria M. McCauley, Mass Media Bureau, and (202) 418–2180.

SUPPLEMENTARY INFORMATION: This is a synopsis of the Commission's Report and Order, MM Docket No. 01–95, adopted August 1, 2001 and released August 10, 2001. The full text of this Commission decision is available for inspection and copying during normal business hours in the FCC Reference Information Center (Room CY–A257), 445 12th Street, SW, Washington, DC. The complete text of this decision may also be purchased from the Commission's copy contractor, International Transcription Service, Inc., (202) 857–3800, 1231 20th Street, NW, Washington, DC 20036.

List of Subjects in 47 CFR Part 73

Radio broadcasting.

PART 73—RADIO BROADCAST SERVICES

1. The authority citation for part 73 continues to read as follows:

Authority: 47 U.S.C. 154, 303, 334 and 336.

§ 73.202 [Amended]

2. Section 73.202(b), the Table of FM Allotments under Washington is amended by removing Channel 245A at Naches and adding Channel 245C2 at Naches, and by removing Sunnyside, Channel 244A, and adding Benton City, Channel 244A.

Federal Communications Commission.

John A. Karousos,

Chief, Allocations Branch, Policy and Rules Division, Mass Media Bureau.

[FR Doc. 01–21409 Filed 8–23–01; 8:45 am]

BILLING CODE 6712–01–P

FEDERAL COMMUNICATIONS COMMISSION

47 CFR Part 73

[DA 01–1909; MM Docket No. 00–14; RM–9753]

Radio Broadcasting Services; Elkhorn City and Coal Run, KY

AGENCY: Federal Communications Commission.

ACTION: Final rule.

SUMMARY: The Commission, at the request of East Kentucky Broadcasting Corporation, reallots Channel 276A from Elkhorn City to Coal Run Kentucky, and modifies Station WPKE–FM license accordingly. *See* 65 FR 7816, February 16, 2000. Channel 276A can be reallotted to Coal Run in compliance with the Commission's minimum distance separation requirements with a site restriction of 13.4 kilometers (8.3 miles) south at petitioner's requested site. The coordinates for Channel 276A at Coal Run are 37–23–57 North Latitude and 82–30–32 West Longitude.

DATES: Effective September 24, 2001.

FOR FURTHER INFORMATION CONTACT: Sharon P. McDonald, Mass Media Bureau, (202) 418–2180.

SUPPLEMENTARY INFORMATION: This is a synopsis of the Commission's Report and Order, MM Docket No. 00–14 adopted August 1, 2001, and released August 10, 2001. The full text of this Commission decision is available for inspection and copying during normal business hours in the FCC Reference Information Center (Room CY–A257), 445 12th Street, SW., Washington, DC. The complete text of this decision may also be purchased from the Commission's copy contractors, International Transcription Service, Inc., (202) 857–3800, 1231 20th Street, NW., Washington, DC 20036.

List of Subjects in 47 CFR Part 73

Radio broadcasting.

Part 73 of title 47 of the Code of Federal Regulations is amended as follows:

PART 73—RADIO BROADCAST SERVICES

1. The authority citation for part 73 continues to read as follows:

Authority: 47 U.S.C. 54, 303, 334, and 336.

§ 73.202 [Amended]

2. Section 73.202(b), the Table of FM Allotments under Kentucky, is amended by adding Coal Run, Channel 276A; and removing Elkhorn City, Channel 276A.

Federal Communications Commission.

John A. Karousos,

Chief, Allocations Branch, Policy and Rules Division, Mass Media Bureau.

[FR Doc. 01–21412 Filed 8–23–01; 8:45 am]

BILLING CODE 6712–01–U

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

50 CFR Parts 223 and 224

[Docket No. 010820209–1209–01; I.D. 080901A]

RIN 0648–AP40

Endangered and Threatened Wildlife; Sea Turtle Conservation Requirements; Taking of Threatened or Endangered Species Incidental to Commercial Fishing Operations

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Interim final rule; request for comments.

SUMMARY: NMFS is issuing an interim final rule to prohibit fishing with drift gillnets in the California/Oregon (CA/OR) drift gillnet fishery from August 15 through November 15 in state and federal waters in Monterey Bay, CA and vicinity, north to the 45° N lat. intersect of the Oregon coast. NMFS has determined that the incidental take level of leatherback sea turtles by this fishery is dependent on the area and season being fished. The time and area closure will result in a take level reduction by the fishery and is necessary to avoid the likelihood of the CA/OR drift gillnet fishery jeopardizing the continued existence of the leatherback sea turtle population.

DATES: This interim final rule is effective August 24, 2001. Comments on this interim final rule must be postmarked or transmitted by facsimile by 5 p.m., Pacific Standard Time, on November 23, 2001. Comments transmitted via e-mail or the Internet will not be accepted.

ADDRESSES: Send comments on this interim final rule to Tim Price, National Marine Fisheries Service, Protected Resources Division, 501 West Ocean Boulevard, Suite 4200, Long Beach, California 90802–4213. Copies of the Environmental Assessment (EA) or biological opinion (BO) may be obtained from Tim Price, Protected Resources Division, National Marine Fisheries Service, Southwest Region, 501 West Ocean Blvd., Suite 4200, Long Beach, CA 90802–4213.

FOR FURTHER INFORMATION CONTACT: Tim Price (562) 980–4029.

SUPPLEMENTARY INFORMATION: On October 24, 2000 (65 FR 64670, October 30, 2000), NMFS issued a permit, for a period of 3 years, to authorize the incidental, but not intentional, taking of four stocks of threatened or endangered marine mammals (Fin whale, California/Oregon/Washington stock; Humpback whale, California/Oregon/Washington-Mexico stock; Steller sea lion, eastern stock; and Sperm whale, California/Oregon/Washington stock) by the CA/OR drift gillnet fishery under section 101(a)(5)(E) of the Marine Mammal Protection Act (MMPA) (16 U.S.C. 1371(a)(5)(E)).

To authorize the incidental take by this fishery of marine mammals listed under the Endangered Species Act (ESA), NMFS completed a formal consultation under section 7 of the ESA. On October 23, 2000, NMFS issued a BO in which it determined that the current operations of the CA/OR drift gillnet fishery are jeopardizing the continued existence of the leatherback and loggerhead sea turtle populations by appreciably reducing the likelihood of both the survival and recovery of these two species.

All sea turtles that occur in U.S. waters are listed as either endangered or threatened under the ESA. The leatherback (*Dermochelys coriacea*) is listed as endangered and the loggerhead (*Caretta caretta*) is listed as threatened. Under the ESA and its implementing regulations, taking sea turtles, even incidentally, is prohibited, with exceptions identified in 50 CFR 223.206. The incidental take of endangered species may only be legally authorized by an incidental take statement or an incidental take permit issued pursuant to section 7 or section 10 of the ESA. In order for an incidental take statement to be issued, the incidental take must not be likely to jeopardize the continued existence of listed species or destroy or adversely modify designated critical habitat.

To avoid the likelihood of the CA/OR drift gillnet fishery jeopardizing the continued existence of the leatherback and loggerhead sea turtles, NMFS developed a reasonable and prudent alternative in the BO which consists of three measures: a) a drift gillnet time and area closure to protect leatherback sea turtles; b) funding and supporting a Western Pacific conservation, education, and protection program aimed at protecting nesting females,

their eggs, and nesting beach habitat and addressing incidental capture in local fisheries; and c) a drift gillnet time and area closure to protect loggerhead sea turtles.

This interim final rule implements only the measure to protect leatherback sea turtles. For the reasons indicated later in this preamble, this measure must be implemented immediately.

The conservation, education, and protection program does not fall within U.S. regulatory authority and will be implemented through cooperative efforts with appropriate parties.

The measure to address the incidental take of loggerhead sea turtles by the CA/OR drift gillnet fishery will be implemented by a subsequent rulemaking. Observer data from July 1990 through January 2000 indicate that all the observed loggerhead sea turtle entanglements occurred during El Nino events. According to the most recent El Nino Watch Advisory, 2001–07, the existing west coast oceanographic conditions are consistent with a decay of the La Nina conditions and a prelude to a mild or moderate El Nino in the ensuing months. NOAA/National Environmental Satellite, Data and Information Services, Coast watch Program (http://cwatchwc.ucsd.edu) data indicate that an El Nino event is not imminent. Because the BO concluded that the CA/OR drift gillnet fishery would only jeopardize the continued existence of loggerhead sea turtles during El Nino events, there is adequate time to provide prior notice and an opportunity for public comment on the time and area closure to protect loggerhead sea turtles. Therefore, this measure was not included in this rulemaking but will be implemented in a separate rulemaking.

Measure to Reduce Leatherback Entanglements

The measure identified in the BO to address the incidental take of leatherback sea turtles by the CA/OR drift gillnet fishery consists of a time and area closure that would prohibit drift gillnet fishing activity in state and Federal ocean waters off of California and Oregon inside the area bounded by straight lines connecting Point Conception (34°27 N) to 34°27 N 129° W, to 45° N 129° W, to the point where 45° N intersects the Oregon coast, from August 15 to October 31, for a period of 3 years (2001–2003).

This measure would reduce the likelihood of the CA/OR drift gillnet fishery incidentally entangling leatherback turtles by 78 percent. Although the observer data do not indicate a specific, localized area where more leatherbacks are entangled, but rather a more widespread distribution, observed leatherback entanglement rates change as a function of latitude, with the most substantial increase in entanglement rates occurring north of 36°30 N. NMFS has observed 23 leatherback entanglements since the inception of the observer program in July 1990, 91 percent of which were recorded north of Point Conception. Takings of leatherbacks have been observed during the months of September, October, November, December and January, with approximately 60 percent of the entanglements occurring in October. Based on this information, NMFS expects this measure to prohibit fishing with drift gillnets in ocean waters north of Point Conception would avoid the likelihood of the CA/OR drift gillnet fishery jeopardizing the continued existence of the leatherback sea turtle species.

Alternative Measures to Reduce Leatherback Entanglements

Since the issuance of the BO on October 23, 2000, NMFS received comments from CA/OR drift gillnet commercial fishermen, recreational fishing organizations, and from the Pacific Offshore Cetacean Take Reduction Team (TROTTED) regarding the measure in the reasonable and prudent alternative to close the CA/OR drift gillnet fishery north of Point Conception from August 15 to October 31. The CA/OR drift gillnet fishermen have expressed a need to fish north of Point Conception to remain economically viable as a fishery. Recreational fishing organizations have expressed a concern that an increased number of drift gillnet vessels fishing south of Point Conception would cause a reduction in the number of striped marlin that recreational fishermen could catch. In response to the concern expressed by the fishermen on the effects of the closure on the fishery, the TROTTED evaluated whether there might be a measure other than the reasonable and prudent alternative measure identified in the BO, that would allow the fishermen to fish north of Point Conception and still provide the same level of protection to leatherback sea turtles and presented a consensus recommendation for consideration.

NMFS recognizes the merit and importance of the TROTTED recommendation. While NMFS was not able to conclude that the TROTTED recommendation provided a comparable level of protection for leatherback turtles, NMFS concluded that a modified version of the TROTTED recommendation would provide fishing opportunity north of Point Conception while providing the same level of protection for leatherback sea turtles as the BO.

In September 2000, NMFS tagged two leatherback turtles in Monterey Bay, CA with satellite transmitter tags. Shortly afterwards, the turtles departed the area, traveling in a southwesterly direction, presumably toward western Pacific nesting beaches. Based on this recent leatherback satellite telemetry data and historical observer data, NMFS is implementing a modified version of the TROTTED recommendation which will protect the potential migratory route of leatherback turtles departing Monterey, CA, in August, September, October and the first half of November. This alternative measure closes the area bounded by the straight lines from Point Sur (34°18.5 N) to 34°27 N 123°35 W, to 34°27 N 129° W, to 45° N 129° W, to the point 45° N intersects land, from August 15 to November 15. NMFS has determined that this alternative provides the same, if not greater, protection for leatherback turtles as the reasonable and prudent alternative measure identified in the BO. The NMFS Office of Protected Resources, which issued the BO, has concurred that this alternative would provide the same level of protection as the reasonable and prudent alternative measure identified in the BO and would avoid the likelihood of jeopardizing the continued existence of the leatherback sea turtle.

This determination is based on observer data that indicate that NMFS' alternative time and area closure described above provides the same level of protection for leatherback turtles (a 78–percent reduction in the likelihood of the CA/OR drift gillnet fishery incidentally entangling leatherback turtles) as the time and area closure identified in the reasonable and prudent alternative of the BO. In addition, based on leatherback satellite telemetry data, NMFS' alternative is expected to provide protection to migrating leatherback turtles departing Monterey, CA, in August, September, October and the first half of November.

Under this measure, drift gillnet vessels must continue to comply with existing state codes that regulate gear, equipment and fishing seasons and with Federal regulations that implement the Pacific Offshore Cetacean Take Reduction Plan (50 CFR 229.31).

Classification

NMFS prepared an EA for this interim final rule and concluded these

regulations would pose no significant adverse environmental impact.

The action implemented by this interim final rule is expected to impact approximately 81 California/Oregon drift gillnet vessel owners and operators, representing approximately 2,000 fishing sets annually. Four alternatives were evaluated in the EA prepared for this interim final rule, including a status quo alternative. For a description and a detailed economic analysis of the alternatives analyzed for the CA/OR drift gillnet fishery, readers should refer to the EA prepared for this interim final rule. The total cost to the CA/OR drift gillnet fleet resulting from the time and area closures in this interim final rule is estimated at $640K. This maximum cost estimate to the fishery is a worst case scenario based on the assumption that none of the fishing effort will shift to ocean areas that remain open to fishing. However, because the observed entanglement rate for swordfish in the leatherback closed area is similar to the swordfish entanglement rate in the open area along central California, NMFS expects most of the fishing effort will shift to the open ocean waters. Therefore, NMFS does not expect the leatherback time and area closure to have as much of an effect on ex-vessel gross revenue values as the worst case scenario estimate of $640K.

This interim final rule does not contain collection-of-information requirements subject to the Paperwork Reduction Act.

This interim final rule has been determined to be not significant for purposes of Executive Order 12866.

A BO on the issuance of a marine mammal permit under section 101 (a)(5)(E) of the MMPA was finalized on October 23, 2000. That BO concluded that issuance of a permit and continued operation of the CA/OR drift gillnet fishery was likely to jeopardize the continued existence of leatherback and loggerhead sea turtles. This interim final rule implements an alternative to the reasonable and prudent alternative measure in the BO to protect leatherback sea turtles. NMFS has determined that the alternative measure implemented by this interim final rule is as protective of leatherback sea turtles as the reasonable and prudent alternative measure in the BO. NMFS Office of Protected Resources, which issued the BO, has concurred that this alternative would provide the same level of protection as the reasonable and prudent alternative measure identified in the BO and would avoid the likelihood of jeopardizing the continued existence of the leatherback sea turtle. This alternative measure does not change the conclusions of the BO related to marine mammals listed under the ESA. Moreover, this interim final rule will have no adverse impacts on marine mammals that are not listed under the ESA.

Given the endangered status of the leatherback sea turtle, the fact that the fishery opened on August 15, and that the existing regulations are not sufficient to prevent entanglements, the Assistant Administrator for NOAA Fisheries (AA), for good cause, under 5 U.S.C. 553 (b)(3)(B), finds that delaying this closure action to allow for prior notice and an opportunity for public comment would be contrary to the public interest because such delay would not provide protection for leatherback sea turtles that would otherwise be taken by this fishery. For the same reasons, the AA finds good cause also under 5 U.S.C. 553 (d)(3) not to delay the effective date of this interim final rule for 30 days.

In developing the alternative closure for protection of leatherback sea turtles under this interim final rule, NMFS has considered, to the maximum extent practicable and consistent with the ESA, the concerns of the CA/OR drift gillnet fishery and Pacific Offshore Cetacean Take Reduction Team as previously described in this action. To ensure timely notice of this action, NMFS has scheduled mandatory skipper workshops for vessel operators and owners during the last week in August and first week in September to clarify issues related to the time and area closure to protect leatherback sea turtles and the Pacific Offshore Cetacean Take Reduction Plan. A fleet notice will be sent by certified mail to the vessel owners and operators notifying them of the leatherback time and area closure. NMFS will also coordinate with the U.S. Coast Guard to issue a Notice to Mariners on Channel 16, VHF radio as well as send notice through NOAA Weather radio.

As prior notice and opportunity for public comment are not required to be provided for this interim final rule by 5 U.S.C. 553, or by any other law, the analytical requirements of the Regulatory Flexibility Act, 5 U.S.C. 601 *et seq.*, are inapplicable.

In keeping with the intent of the Executive Order 13132 to provide continuing and meaningful dialogue on issues of mutual state and Federal interest, NMFS has conferred with the States of California and Oregon regarding the implementation of the reasonable and prudent alternative. Both California and Oregon have expressed support for the measures identified in the BO for the protection of leatherback and loggerhead sea turtle species. NMFS met with California Department of Fish and Game officials to decide which agency would implement the regulations to meet the requirement of the BO reasonable and prudent alternative. The State of California decided that NMFS should implement the regulations under the authority of the ESA. In addition, as a member of the TROTTED, the State of California was actively involved in the development of the alternative measure to protect leatherback sea turtles and participated in meetings about its implementation. NMFS intends to continue engaging in informal and formal contacts with the States of California and Oregon during the implementation of the measures in the BO and development of the highly migratory species fishery management plan that includes the CA/OR drift gillnet fishery.

Dated: August 21, 2001.

William T. Hogarth,

Acting Assistant Administrator for Fisheries, National Marine Fisheries Service.

List of Subjects

50 CFR Part 223

Endangered and threatened species, Exports, Imports, Marine mammals, Transportation.

50 CFR Part 224

Administrative practice and procedure, Endangered and threatened species, Exports, Imports, Reporting and recordkeeping requirements.

For the reasons set out in the preamble, 50 CFR parts 223 and 224 are amended to read as follows:

PART 223—THREATENED MARINE AND ANADROMOUS SPECIES

1. The authority citation for part 223 continues to read as follows:

Authority: 16 U.S.C. 1531–1543; subpart B, § 223.12 also issued under 16 U.S.C. 1361 *et seq.*

2. In § 223.206, add paragraph (d)(6) to read as follows:

§ 223.206 Exceptions to prohibitions relating sea turtles.

* * * * *

(d) * * *

(6) Restrictions applicable to the California/Oregon drift gillnet fishery--

(i) Pacific leatherback conservation area. No person may fish with, set, or haul back drift gillnet gear in U.S. waters of the Pacific Ocean from August 15 through November 15 in the area bounded by straight lines connecting the following coordinates in the order listed:

(A) Point Sur (36°18.5′ N) to 34°27′ N 123°35' W′;

(B) 34°27′ N 123°35′ W to 34°27′ N 129° W;

(C) 34°27′ N 129° W to 45° N 129° W;

(D) 45° N 129° W to the point 45° N intersects the Oregon coast.

(ii) [Reserved]

PART 224—ENDANGERED MARINE AND ANADROMOUS SPECIES

3. The authority citation for part 224 continues to reads as follows:

Authority: 16 U.S.C. 1531–1543 and 16 U.S.C. 1361 *et seq.*

4. In § 224.104, the section heading is revised to read as follows:

§ 224.104 Special requirements for fishing activities to protect endangered sea turtles.

5. In § 224.104, paragraph (c) is revised to read as follows:

* * * * *

(c) Special prohibitions relating to leatherback sea turtles are provided at § 223.206 (d)(2)(iv) and § 223.206 (d)(6) of this chapter.

[FR Doc. 01–21512 Filed 8–23–01; 8:45 am]

BILLING CODE 3510–22–S

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

50 CFR Part 660

[Docket No. 001226367–01; I.D. 081501A]

Fisheries off West Coast States and in the Western Pacific; Pacific Coast Groundfish Fishery; End of the Primary Season and Resumption of Trip Limits for the Shore-based Fishery for Pacific Whiting

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Fishing restrictions; request for comments.

SUMMARY: NMFS announces the end of the 2001 primary season for the shore-based fishery for Pacific whiting (whiting) and resumption of per-trip limits at 12 noon local time (l.t.) August 21, 2001, because the allocation is projected to be reached by that time. This action is intended to keep the harvest of whiting at the 2001 allocation levels.

DATES: Effective from 12 noon l.t. August 21, 2001, until the effective date of the 2002 specification and management measures for the Pacific Coast groundfish fishery which will be published in the **Federal Register**, unless modified, superseded or rescinded. Comments will be accepted through September 10, 2001.

ADDRESSES: Submit comments to Donna Darm, Acting Administrator, Northwest Region (Regional Administrator), NMFS, 7600 Sand Point Way NE., Seattle, WA 98115–0070; or Rod McInnis, Acting Regional Administrator, Southwest Region, NMFS, 501 West Ocean Blvd., Suite 4200, Long Beach, CA 90802–4213.

FOR FURTHER INFORMATION CONTACT: Becky Renko at 206–526–6110.

SUPPLEMENTARY INFORMATION: This action is authorized by regulations implementing the Pacific Coast Groundfish Fishery Management Plan (FMP), which governs the groundfish fishery off Washington, Oregon, and California. On January 11, 2001 (66 FR 2338), the levels of allowable biological catch (ABC), the optimum yield (OY) and the commercial OY (the OY minus the tribal allocation) for U.S. harvests of whiting were announced in the **Federal Register**. For 2001 the whiting ABC and OY are 190,400 metric tons (mt) and the commercial OY is 162,900 mt.

Regulations at 50 CFR 660.323(a)(4) divide the commercial OY into separate allocations for the catcher/processor, mothership, and shore-based sectors of the whiting fishery. The 2001 allocations, based on the 2001 commercial OY, are 55,386 mt (34 percent) for the catcher/processor sector, 39,096 mt (24 percent) for the mothership sector, and 68,418 mt (42 percent) for the shore-based sector. When each sector's allocation is reached, the primary season for that sector is ended.

The shore-based sector is composed of vessels that harvest whiting for delivery to land-based processors. The regulations at 50 CFR 660.323 (a)(3)(i) describe the primary season for the shore-based sector as the period(s) when the large-scale target fishery is conducted (when trip limits under § 660.323(b) are not in effect). Before and after the primary seasons, per-trip limits are in effect for whiting.

The best available information on August 21, 2001, indicates that 64,641 mt had been taken through August 18, 2001, and that the 68,418 mt shore-based allocation would be reached by 12 noon August 21, 2001. This **Federal Register** document announces the date that the primary season for the shore-based sector ends, and that per-trip limits are imposed. The per-trip limit is intended to accommodate small bait and fresh fish markets and bycatch in other fisheries. To minimize incidental catch of chinook salmon by vessels fishing shoreward of the 100 fm (183 m) contour in the Eureka area, at any time during a fishing trip, a limit of 10,000-lb (4,536 kg) of whiting is in effect year-round (unless landings of whiting are prohibited).

NMFS Action

For the reasons stated here, and in accordance with the regulations at 50 CFR 660.323(a)(4)(iii)(C), NMFS herein announces:

Effective 12 noon l.t. August 21, 2001, no more than 20,000-lb (9,072-kg) of whiting may be taken and retained, possessed or landed by a catcher vessel participating in the shore-based sector of the whiting fishery. If a vessel fishes shoreward of the 100 fm (183 m) contour in the Eureka area (43° - 40° 30′ N. lat.) at any time during a fishing trip, the 10,000-lb (4,536-kg) trip limit applies, as announced in the annual management measures at paragraph IV, B (3)(c)(ii).

Classification

This action is authorized by the regulations implementing the FMP. The determination to take this action is based on the most recent data available. The aggregate data upon which the determination is based are available for public inspection at the Office of the Regional Administrator (see **ADDRESSES**) during business hours. This action is taken under the authority of 50 CFR 660.323(a)(4)(iii)(C) and is exempt from review under Executive Order 12866.

Authority: 16 U.S.C. 1801 *et seq.*

August 20, 2001.

Bruce C. Morehead,

Acting Director, Office of Sustainable Fisheries, National Marine Fisheries Service.

[FR Doc. 01–21486 Filed 8–21–01; 3:07 pm]

BILLING CODE 3510–22–S

Proposed Rules

Federal Register
Vol. 66, No. 165
Friday, August 24, 2001

This section of the FEDERAL REGISTER contains notices to the public of the proposed issuance of rules and regulations. The purpose of these notices is to give interested persons an opportunity to participate in the rule making prior to the adoption of the final rules.

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. 2001–NM–198–AD]

RIN 2120–AA64

Airworthiness Directives; Boeing Model 767 Series Airplanes

AGENCY: Federal Aviation Administration, DOT.

ACTION: Notice of proposed rulemaking (NPRM).

SUMMARY: This document proposes the supersedure of an existing airworthiness directive (AD), applicable to certain Boeing Model 767 series airplanes, that currently requires inspections and various follow-on actions to detect cracking and corrosion of the aft trunnion of the outer cylinder of the main landing gear (MLG). That action also requires termination of the inspections by repairing the outer cylinder and installing new aft trunnion bushings. This action would prohibit the use of a particular corrosion inhibiting compound during accomplishment of the terminating action. This action is necessary to prevent the collapse of the MLG due to stress corrosion cracking of the aft trunnion of the outer cylinder. This action is intended to address the identified unsafe condition.

DATES: Comments must be received by September 24, 2001.

ADDRESSES: Submit comments in triplicate to the Federal Aviation Administration (FAA), Transport Airplane Directorate, ANM–114, Attention: Rules Docket No. 2001–NM–198–AD, 1601 Lind Avenue, SW., Renton, Washington 98055–4056. Comments may be inspected at this location between 9:00 a.m. and 3:00 p.m., Monday through Friday, except Federal holidays. Comments may be submitted via fax to (425) 227–1232. Comments may also be sent via the Internet using the following address: *9-anm-nprmcomment@faa.gov*. Comments sent via fax or the Internet must contain ''Docket No. 2001–NM–198–AD'' in the subject line and need not be submitted in triplicate. Comments sent via the Internet as attached electronic files must be formatted in Microsoft Word 97 for Windows or ASCII text.

The service information referenced in the proposed rule may be obtained from Boeing Commercial Airplane Group, P.O. Box 3707, Seattle, Washington 98124–2207. This information may be examined at the FAA, Transport Airplane Directorate, 1601 Lind Avenue, SW., Renton, Washington.

FOR FURTHER INFORMATION CONTACT: John Craycraft, Aerospace Engineer, Airframe Branch, ANM–120S, FAA, Seattle Aircraft Certification Office, 1601 Lind Avenue, SW., Renton, Washington 98055–4056; telephone (425) 227–2782; fax (425) 227–1181.

SUPPLEMENTARY INFORMATION:

Comments Invited

Interested persons are invited to participate in the making of the proposed rule by submitting such written data, views, or arguments as they may desire. Communications shall identify the Rules Docket number and be submitted in triplicate to the address specified above. All communications received on or before the closing date for comments, specified above, will be considered before taking action on the proposed rule. The proposals contained in this action may be changed in light of the comments received.

Submit comments using the following format:

- Organize comments issue-by-issue. For example, discuss a request to change the compliance time and a request to change the service bulletin reference as two separate issues.
- For each issue, state what specific change to the proposed AD is being requested.
- Include justification (e.g., reasons or data) for each request.

Comments are specifically invited on the overall regulatory, economic, environmental, and energy aspects of the proposed rule. All comments submitted will be available, both before and after the closing date for comments, in the Rules Docket for examination by interested persons. A report summarizing each FAA-public contact concerned with the substance of this proposal will be filed in the Rules Docket.

Commenters wishing the FAA to acknowledge receipt of their comments submitted in response to this action must submit a self-addressed, stamped postcard on which the following statement is made: ''Comments to Docket Number 2001–NM–198–AD.'' The postcard will be date stamped and returned to the commenter.

Availability of NPRMs

Any person may obtain a copy of this NPRM by submitting a request to the FAA, Transport Airplane Directorate, ANM–114, Attention: Rules Docket No. 2001–NM–198–AD, 1601 Lind Avenue, SW., Renton, Washington 98055–4056.

Discussion

On October 10, 1996, the FAA issued AD 96–21–06, amendment 39–9783 (61 FR 55080, October 24, 1996), applicable to certain Boeing Model 767 series airplanes, to require inspections and various follow-on actions to detect cracking and corrosion of the aft trunnion of the outer cylinder of the main landing gear (MLG). That action also requires termination of the inspections by repairing the outer cylinder and installing new aft trunnion bushings. That action was prompted by reports of failure of several MLG due to fracture of the aft trunnion outer cylinder. The requirements of that AD are intended to prevent the collapse of the MLG due to stress corrosion cracking of the aft trunnion of the outer cylinder.

Actions Since Issuance of Previous Rule

Since the issuance of that AD, the airplane manufacturer has received reports indicating that a particular corrosion inhibiting compound has caused severe corrosion in the Model 767 MLG aft trunnion of the outer cylinder. The corrosion was found on MLGs that were previously reworked using Desoto 823E508 (Titanine JC5A) corrosion inhibiting compound during accomplishment of Boeing Alert Service Bulletin 767–32A0148, dated December 21, 1995, or Revision 1, dated October 10, 1996 (which were referenced in AD 96–21–06 as the appropriate source of service information for accomplishing the terminating action).

Over time, that particular corrosion inhibiting compound deteriorates and becomes hard and dry. If moisture

enters the outer cylinder aft trunnion and mixes with Titanine JC5A, a series of chemical reactions occurs and the reaction products can degrade the primer and cadmium plating. This may lead to corrosion in the aft trunnion where Titanine JC5A was used. Such corrosion, if not corrected, could result in the collapse of the MLG due to stress corrosion cracking of the aft trunnion of the outer cylinder.

Explanation of Relevant Service Information

The FAA has reviewed and approved Boeing Service Bulletin 767–32A0148, Revision 2, dated November 30, 2000. This revised service bulletin is essentially identical to the original version and Revision 1 of the service bulletin. The only change effected by Revision 2 is to no longer allow the use of Desoto 823E508 (Titanine JC5A) as an option when incorporating that service bulletin. Revision 2 of the service bulletin adds Zip-Chem ZC–027L as an acceptable corrosion inhibiting compound. Zip-Chem ZC–027L and Mastinox 6856K are the only qualified BMS 3–27 products acceptable for use in incorporating that service bulletin. Accomplishment of the actions specified in the service bulletin is intended to adequately address the identified unsafe condition.

Explanation of Requirements of Proposed Rule

Since an unsafe condition has been identified that is likely to exist or develop on other products of this same type design, the proposed AD would supersede AD 96–21–06 to continue to require the actions specified by that AD. However, this proposed AD would prohibit the use of a particular corrosion inhibiting compound during accomplishment of the terminating action specified in AD 96–21–06. The actions would be required to be accomplished in accordance with the service bulletin described previously, as well as other service information specified in the existing AD.

Other Relevant Rulemaking

The manufacturer has issued a related service bulletin, Boeing Alert Service Bulletin 767–32A0192, dated May 31, 2001, which gives instructions for inspections of the MLG to detect corrosion or cracking; corrective actions, if necessary; application of an alternate corrosion inhibiting compound; and terminating action for the inspections and corrosion inhibiting compound, for airplanes on which Desoto 823E508 (Titanine JC5A) has been used. The FAA is considering the issuance of a separate rulemaking action to further address the identified unsafe condition on airplanes on which Desoto 823E508 (Titanine JC5A) was used.

Cost Impact

There are approximately 605 airplanes of the affected design in the worldwide fleet. The FAA estimates that 200 airplanes of U.S. registry would be affected by this proposed AD.

The actions that are currently required by AD 96–21–06 take approximately 252 work hours per airplane to accomplish, at an average labor rate of $60 per work hour. Required parts cost approximately $9,510 per airplane. Based on these figures, the cost impact of the currently required actions on U.S. operators is estimated to be $4,926,000, or $24,630 per airplane.

The prohibition of a certain corrosion inhibiting compound proposed in this AD action would not change the cost impact on U.S. operators from that imposed by the superseded AD.

The cost impact figure discussed above is based on assumptions that no operator has yet accomplished any of the proposed requirements of this AD action, and that no operator would accomplish those actions in the future if this proposed AD were not adopted. The cost impact figures discussed in AD rulemaking actions represent only the time necessary to perform the specific actions actually required by the AD. These figures typically do not include incidental costs, such as the time required to gain access and close up, planning time, or time necessitated by other administrative actions.

Regulatory Impact

The regulations proposed herein would not have a substantial direct effect on the States, on the relationship between the national Government and the States, or on the distribution of power and responsibilities among the various levels of government. Therefore, it is determined that this proposal would not have federalism implications under Executive Order 13132.

For the reasons discussed above, I certify that this proposed regulation (1) is not a ''significant regulatory action'' under Executive Order 12866; (2) is not a ''significant rule'' under the DOT Regulatory Policies and Procedures (44 FR 11034, February 26, 1979); and (3) if promulgated, will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act. A copy of the draft regulatory evaluation prepared for this action is contained in the Rules Docket. A copy of it may be obtained by contacting the Rules Docket at the location provided under the caption **ADDRESSES.**

List of Subjects in 14 CFR Part 39

Air transportation, Aircraft, Aviation safety, Safety.

The Proposed Amendment

Accordingly, pursuant to the authority delegated to me by the Administrator, the Federal Aviation Administration proposes to amend part 39 of the Federal Aviation Regulations (14 CFR part 39) as follows:

PART 39—AIRWORTHINESS DIRECTIVES

1. The authority citation for part 39 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40113, 44701.

§ 39.13 [Amended]

2. Section 39.13 is amended by removing amendment 39–9783 (61 FR 55080, October 24, 1996), and by adding a new airworthiness directive (AD), to read as follows:

Boeing: Docket 2001–NM–198–AD. Supersedes AD 96–21–06, amendment 39–9783.

Applicability: Model 767 series airplanes having line numbers 001 through 605 inclusive, on which the terminating action required by paragraph (e) of this AD has not been accomplished; certificated in any category.

Note 1: This AD applies to each airplane identified in the preceding applicability provision, regardless of whether it has been otherwise modified, altered, or repaired in the area subject to the requirements of this AD. For airplanes that have been modified, altered, or repaired so that the performance of the requirements of this AD is affected, the owner/operator must request approval for an alternative method of compliance in accordance with paragraph (i)(1) of this AD. The request should include an assessment of the effect of the modification, alteration, or repair on the unsafe condition addressed by this AD; and, if the unsafe condition has not been eliminated, the request should include specific proposed actions to address it.

Compliance: Required as indicated, unless accomplished previously.

To prevent collapse of the main landing gear (MLG) due to stress corrosion cracking of the aft trunnion of the outer cylinder, accomplish the following:

Note 2: This AD is merely a restatement of the requirements of AD 96–21–06, amendment 39–9783, with one exception: Only Revision 2, dated November 30, 2000, of Boeing Service Bulletin 767–32A0148, which disallows the use of Desoto 823E508 (Titanine JC5A) corrosion inhibiting compound, may be used after the effective date of this new AD. As allowed by the phrase, ''unless accomplished previously,'' if

those requirements of AD 96–21–06 have already been accomplished prior to the effective date of this AD in accordance with prior versions of that service bulletin, this AD does not require that those actions be repeated. The FAA is, however, considering the issuance of a separate rulemaking action to further address the identified unsafe condition on airplanes on which Desoto 823E508 (Titanine JC5A) was used.

Restatement of the Requirements of AD 96–21–06

Inspections and Various Follow-On Actions

(a) Perform the inspections described in paragraph III, Accomplishment Instructions, of Boeing Alert Service Bulletin 767–32A0151, dated November 30, 1995, or Revision 1, dated October 10, 1996, to detect cracking and corrosion of the aft trunnion of the outer cylinder of the MLG at the time specified in paragraph (a)(1), (a)(2), or (a)(3) of this AD, as applicable. These inspections are to be accomplished in accordance with Figure 1 of the alert service bulletin. Repeat these inspections thereafter at the intervals specified in that alert service bulletin. To determine the category in which an airplane falls, the age of the outer cylinder of the MLG is to be calculated as of February 16, 1996 (the effective date of AD 96–03–02 R1, amendment 39–9526). For airplanes on which the age of the right MLG differs from the age of the left MLG, an operator may place the airplane into a category that is the higher (numerically) of the two categories to ease its administrative burden, and to simplify the recordkeeping requirements imposed by this AD. Once the category into which an airplane falls is determined, operators must obtain approval from the Manager, Seattle Aircraft Certification Office (ACO), FAA, to move that airplane into another category.

Note 3: The broken (dash) lines used in Figure 1 of Boeing Alert Service Bulletin 767–32A0151, dated November 30, 1995, and Revision 1, dated October 10, 1996, denote ''go to'' actions for findings of discrepancies detected during any of the inspections required by this AD.

Note 4: Boeing Alert Service Bulletin 767–32A0151, dated November 30, 1995, and Revision 1, dated October 10, 1996, refer to Boeing Alert Service Bulletin 767–32A0148, dated December 21, 1995, and Revision 1, dated October 10, 1996, for procedures to repair the outer cylinder and replace the bushings in the outer cylinder of the MLG with new bushings.

(1) For airplanes identified as Category 3 in paragraph I.C. of Boeing Alert Service Bulletin 767–32A0151, dated November 30, 1995, or Revision 1, dated October 10, 1996: Perform the initial inspections within 30 days after February 16, 1996 (the effective date of AD 96–03–02 R1, amendment 39–9526).

(2) For airplanes identified as Category 2 in paragraph I.C. of Boeing Alert Service Bulletin 767–32A0151, dated November 30, 1995, or Revision 1, dated October 10, 1996: Perform the initial inspections within 90 days after February 16, 1996.

(3) For airplanes identified as Category 1 in paragraph I.C. of Boeing Alert Service Bulletin 767–32A0151, dated November 30, 1995, or Revision 1, dated October 10, 1996: Perform the initial inspections prior to the accumulation of 2½ years since the MLG outer cylinder was new or last overhauled, or within 150 days after February 16, 1996, whichever occurs later.

(b) If no cracking or corrosion is detected during the inspections required by paragraph (a) of this AD, accomplish the follow-on actions described in Boeing Alert Service Bulletin 767–32A0151, November 30, 1995, or Revision 1, dated October 10, 1996, at the time specified in the alert service bulletin. These follow-on actions are to be accomplished in accordance with that alert service bulletin.

(c) If any cracking is detected during the inspections required by paragraph (a) of this AD, prior to further flight, replace the outer cylinder with a new or serviceable outer cylinder in accordance with Boeing Alert Service Bulletin 767–32A0151, dated November 30, 1995, or Revision 1, dated October 10, 1996.

(d) If any corrosion is detected during the inspections required by paragraph (a) of this AD, accomplish the follow-on actions at the time specified in the ''Corrosion Flowchart,'' in Figure 1 of Boeing Alert Service Bulletin 767–32A0151, dated November 30, 1995, or Revision 1, dated October 10, 1996. The follow-on actions are to be accomplished in accordance with that alert service bulletin.

Terminating Action

(e) Unless previously accomplished in accordance with paragraph (e) of AD 96–21–06, at the time specified in either paragraph (e)(1) or (e)(2) of this AD, as applicable, repair the outer cylinder and replace the bushings in the aft trunnion and crossbolt of the MLG with new bushings, in accordance with Boeing Service Bulletin 767–32A0148, Revision 2, dated November 30, 2000. Accomplishment of this repair and replacement constitutes terminating action for this AD, and for the requirements of AD 95–19–10, amendment 39–9372; and AD 95–20–51, amendment 39–9398.

Note 5: Boeing Service Bulletin 767–32A0148, Revision 2, dated November 30, 2000, refers to Boeing Component Maintenance Manual (CMM) 32–11–40 for certain procedures.

(1) For airplanes identified as Category 3 in paragraph I.C. of Boeing Alert Service Bulletin 767–32A0151, dated November 30, 1995, or Revision 1, dated October 10, 1996: Accomplish the repair and replacement within 18 months after November 29, 1996 (the effective date of AD 96–21–06, amendment 39–9783).

(2) For airplanes identified as either Category 1 or Category 2 in paragraph I.C. of Boeing Alert Service Bulletin 767–32A0151, dated November 30, 1995, or Revision 1, dated October 10, 1996: Accomplish the repair and replacement at the time specified in either paragraph (e)(2)(i) or (e)(2)(ii) of this AD.

(i) Prior to the accumulation of 5½ years since the MLG outer cylinders were new or last overhauled, or within 18 months after November 29, 1996, whichever occurs later; or

(ii) Prior to the accumulation of 7 years since the MLG outer cylinders were new or last overhauled, provided that accomplishment of visual and non-destructive testing (NDT) inspections at the times specified in Figure 1 of the Accomplishment Instructions of Boeing Alert Service Bulletin 767–32A0151, dated November 30, 1995, or Revision 1, dated October 10, 1996, are repeated until the repair and replacement are accomplished.

(f) Accomplishment of the inspection requirements of this AD (in accordance with Boeing Alert Service Bulletin 767–32A0151, dated November 30, 1995, or Revision 1, dated October 10, 1996) is considered acceptable for compliance with AD 95–19–10, amendment 39–9372; and AD 95–20–51, amendment 39–9398.

New Requirement of This AD

(g) As of the effective date of this AD, only Revision 2, dated November 30, 2000, of Boeing Service Bulletin 767–32A0148 shall be used to accomplish the actions required by paragraph (e) of this AD.

Use of Titanine JC5A Prohibited

(h) As of the effective date of this AD, no person shall use the corrosion inhibiting compound Desoto 823E508 (Titanine JC5A) on any airplane.

Alternative Methods of Compliance

(i)(1) An alternative method of compliance or adjustment of the compliance time that provides an acceptable level of safety may be used if approved by the Manager, Seattle ACO. Operators shall submit their requests through an appropriate FAA Principal Maintenance Inspector, who may add comments and then send it to the Manager, Seattle ACO.

Note 6: Information concerning the existence of approved alternative methods of compliance with this AD, if any, may be obtained from the Seattle ACO.

(2) Alternative methods of compliance, approved in accordance with AD 96–03–02, amendment 39–9497; AD 96–03–02 R1, amendment 39–9526; AD 95–19–10, amendment 39–9372; or AD 95–20–51, amendment 39–9398; are approved as alternative methods of compliance with this AD except as required in paragraph (h) of this AD.

Special Flight Permits

(j) Special flight permits may be issued in accordance with sections 21.197 and 21.199 of the Federal Aviation Regulations (14 CFR 21.197 and 21.199) to operate the airplane to a location where the requirements of this AD can be accomplished.

Issued in Renton, Washington, on August 16, 2001.

Vi L. Lipski,

Manager, Transport Airplane Directorate, Aircraft Certification Service.

[FR Doc. 01–21224 Filed 8–23–01; 8:45 am]

BILLING CODE 4910–13–U

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. 2001–CE–09–AD]

RIN 2120–AA64

Airworthiness Directives; SOCATA—Groupe Aerospatiale Models TB 9, TB 10, TB 20, TB 21, and TB 200 Airplanes

AGENCY: Federal Aviation Administration, DOT.

ACTION: Notice of proposed rulemaking (NPRM).

SUMMARY: This document proposes to adopt a new airworthiness directive (AD) that would apply to all SOCATA—Groupe Aerospatiale (SOCATA) Models TB 9, TB 10, TB 20, TB 21, and TB 200 airplanes that do not have factory Modification 165, any edition, incorporated on the front seats. The proposed AD would require you to modify the front seats. The proposed AD is the result of mandatory continuing airworthiness information (MCAI) issued by the airworthiness authority for France. The actions specified by the proposed AD are intended to eliminate the potential for the front seats to inadvertently unlock from their fixed positions. Such uncontrolled movement could prevent the pilot from making the necessary flight maneuvers to control the airplane.

DATES: The Federal Aviation Administration (FAA) must receive any comments on this proposed rule on or before September 28, 2001.

ADDRESSES: Submit comments in triplicate to FAA, Central Region, Office of the Regional Counsel, Attention: Rules Docket No. 2001–CE–09–AD, 901 Locust, Room 506, Kansas City, Missouri 64106. Comments may be inspected at this location between 8 a.m. and 4 p.m., Monday through Friday, holidays excepted.

Service information that applies to the proposed AD may be obtained from SOCATA Groupe AEROSPATIALE, Customer Support, Aerodrome Tarbes-Ossun-Lourdes, BP 930—F65009 Tarbes Cedex, France; telephone: 011 33 5 62 41 73 00; facsimile: 011 33 5 62 41 76 54; or the Product Support Manager, SOCATA—Groupe AEROSPATIALE, North Perry Airport, 7501 Pembroke Road, Pembroke Pines, Florida 33023; telephone: (954) 894–1160; facsimile: (954) 964–4191. This information also may be examined at the Rules Docket at the address above.

FOR FURTHER INFORMATION CONTACT: Karl Schletzbaum, Aerospace Engineer, FAA, Small Airplane Directorate, 901 Locust, Room 301, Kansas City, Missouri 64106; telephone: (816) 329–4146; facsimile: (816) 329–4090.

SUPPLEMENTARY INFORMATION:

Comments Invited

How do I comment on the proposed AD? The FAA invites comments on this proposed rule. You may submit whatever written data, views, or arguments you choose. You need to include the rule's docket number and submit your comments in triplicate to the address specified under the caption ''**ADDRESSES.**'' The FAA will consider all comments received on or before the closing date. We may amend the proposed rule in light of comments received. Factual information that supports your ideas and suggestions is extremely helpful in evaluating the effectiveness of the proposed AD action and determining whether we need to take additional rulemaking action.

Are there any specific portions of the proposed AD I should pay attention to? The FAA specifically invites comments on the overall regulatory, economic, environmental, and energy aspects of the proposed rule that might suggest a need to modify the rule. You may examine all comments we receive before and after the closing date of the rule in the Rules Docket. We will file a report in the Rules Docket that summarizes each FAA contact with the public that concerns the substantive parts of the proposed AD.

We are re-examining the writing style we currently use in regulatory documents, in response to the Presidential memorandum of June 1, 1998. That memorandum requires federal agencies to communicate more clearly with the public. We are interested in your comments on whether the style of this document is clear, and any other suggestions you might have to improve the clarity of FAA communications that affect you. You can get more information about the Presidential memorandum and the plain language initiative at *http://www.plainlanguage.gov.*

How can I be sure FAA receives my comment? If you want us to acknowledge the receipt of your comments, you must include a self-addressed, stamped postcard. On the postcard, write ''Comments to Docket No. 2001–CE–09–AD.'' We will date stamp and mail the postcard back to you.

Discussion

What events have caused this proposed AD? The Direction Generale de l'Aviation Civile (DGAC), which is the airworthiness authority for France, recently notified FAA that an unsafe condition may exist on all SOCATA Models TB 9, TB 10, TB 20, TB 21, and TB 200 airplanes that do not have factory Modification 165 incorporated on the front seats. The DGAC reports cases where the seat pan interfered with the front seat locking mechanism. Interference with the seat locking mechanism could result in uncontrolled movement of the front seats.

This condition does not affect airplanes with factory Modification 165, any edition, incorporated. This modification consists of cutting a slot in the solid seat pan to eliminate the interference.

What are the consequences if the condition is not corrected? If this condition is not corrected, the front seats could inadvertently unlock from their fixed position. Such uncontrolled movement could prevent the pilot from making the necessary flight maneuvers to control the airplane.

Is there service information that applies to this subject? SOCATA has issued Service Bulletin SB 10–115 25, dated December, 2000.

What are the provisions of this service bulletin? The service bulletin includes procedures for modifying the front seat configuration.

What action did the DGAC take? The DGAC classified this service bulletin as mandatory and issued French AD 2001–005(A), dated January 10, 2001, in order to assure the continued airworthiness of these airplanes in France.

Was this in accordance with the bilateral airworthiness agreement? These airplane models are manufactured in France and are type certificated for operation in the United States under the provisions of section 21.29 of the Federal Aviation Regulations (14 CFR 21.29) and the applicable bilateral airworthiness agreement. Pursuant to this bilateral airworthiness agreement, the DGAC has kept FAA informed of the situation described above.

The FAA's Determination and an Explanation of the Provisions of the Proposed AD

What has FAA decided? The FAA has examined the findings of the DGAC; reviewed all available information, including the service information referenced above; and determined that:

—The unsafe condition referenced in this document exists or could develop on other SOCATA Models TB 9, TB 10, TB 20, TB 21, and TB 200 airplanes of the same type design;

—The actions specified in the previously-referenced service

information should be accomplished on the affected airplanes; and

—AD action should be taken in order to correct this unsafe condition.

What would the proposed AD require? This proposed AD would require you to incorporate the actions in the previously-referenced service bulletin.

Cost Impact

How many airplanes would the proposed AD impact? We estimate that the proposed AD affects 125 airplanes in the U.S. registry.

What would be the cost impact of the proposed AD on owners/operators of the affected airplanes? We estimate the following costs to accomplish the proposed modification:

Labor cost	Parts cost	Total cost per airplane	Total cost on U.S. operators
5 workhours × $60 per hour=$300	$58 ($29 per seat, 2 seats per airplane) ...	$358	$44,750

What are the differences between the French AD, the service bulletin and the proposed AD? French AD 2001–005(A) requires this action on airplanes registered in France at the next scheduled inspection. SOCATA Service Bulletin SB 10–115 25 also specifies the action at this time. We propose modification within 100 hours time-in-service (TIS) after the effective date of the AD. We cannot enforce a compliance time of ''at the next scheduled inspection.'' We have determined that 100 hours TIS will give the owners/operators of the affected airplanes enough time to have the proposed actions done without compromising the safety of the airplanes.

Regulatory Impact

Would this proposed AD impact various entities? The regulations proposed herein would not have a substantial direct effect on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government. Therefore, it is determined that this proposed rule would not have federalism implications under Executive Order 13132.

Would this proposed AD involve a significant rule or regulatory action? For the reasons discussed above, I certify that this proposed action (1) is not a ''significant regulatory action'' under Executive Order 12866; (2) is not a ''significant rule'' under DOT Regulatory Policies and Procedures (44 FR 11034, February 26, 1979); and (3) if promulgated, will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act. A copy of the draft regulatory evaluation prepared for this action has been placed in the Rules Docket. A copy of it may be obtained by contacting the Rules Docket at the location provided under the caption **ADDRESSES**.

List of Subjects in 14 CFR Part 39

Air transportation, Aircraft, Aviation safety, Safety.

The Proposed Amendment

Accordingly, under the authority delegated to me by the Administrator, the Federal Aviation Administration proposes to amend part 39 of the Federal Aviation Regulations (14 CFR part 39) as follows:

PART 39—AIRWORTHINESS DIRECTIVES

1. The authority citation for part 39 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40113, 44701.

§ 39.13 [Amended]

2. FAA amends § 39.13 by adding a new airworthiness directive (AD) to read as follows:

SOCATA—GROUPE AEROSPATIALE:

Docket No. 2001–CE–09–AD

(a) *What airplanes are affected by this AD?* This AD affects Models TB 9, TB 10, TB 20, TB 21, and TB 200 airplanes, all serial numbers, that:

(1) do not incorporate factory Modification 165, any edition. Modification 165 consists of cutting a slot in the solid seat pan to eliminate interference with the locking mechanism; and

(2) are certificated in any category.

(b) *Who must comply with this AD?* Anyone who wishes to operate any of the above airplanes must comply with this AD.

(c) *What problem does this AD address?* The actions specified by this AD are intended to eliminate the potential for the front seats to inadvertently unlock from their fixed positions. Such uncontrolled movement could prevent the pilot from making the necessary flight maneuvers to control the airplane.

(d) *What actions must I accomplish to address this problem?* To address this problem, you must accomplish the following:

Actions	Compliance	Procedures
(1) Modify the front seats	Within the next 100 hours time-in-service (TIS) after the effective date of the AD.	In accordance with the Accomplishment instructions section of SOCATA Service Bulletin SB 10–115 25, dated December 2000, and the applicable maintenance manual.
(2) Do not install any of the seats referenced in SOCATA Service Bulletin SB 10–115 25, dated December 2000 (or FAA-approved equivalent part numbers), without incorporating the modification reaquired by paragraph (d)(1) of this AD.	As of the effective date of this AD	In accordance with SOCATA Service Bulletin SB 10–115 25, dated December 2000.

(e) *Can I comply with this AD in any other way?* You may use an alternative method of compliance or adjust the compliance time if:

(1) Your alternative method of compliance provides an equivalent level of safety; and

(2) The Manager, Small Airplane Directorate, approves your alternative. Submit your request through an FAA Principal Maintenance Inspector, who may add comments and then send it to the Manager, Small Airplane Directorate.

Note 1: This AD applies to each airplane identified in paragraph (a) of this AD, regardless of whether it has been modified,

altered, or repaired in the area subject to the requirements of this AD. For airplanes that have been modified, altered, or repaired so that the performance of the requirements of this AD is affected, the owner/operator must request approval for an alternative method of compliance in accordance with paragraph (e) of this AD. The request should include an assessment of the effect of the modification, alteration, or repair on the unsafe condition addressed by this AD; and, if you have not eliminated the unsafe condition, specific actions you propose to address it.

(f) *Where can I get information about any already-approved alternative methods of compliance?* Contact Karl Schletzbaum, Aerospace Engineer, FAA, Small Airplane Directorate, 901 Locust, Room 301, Kansas City, Missouri 64106; telephone: (816) 329–4146; facsimile: (816) 329–4090.

(g) *What if I need to fly the airplane to another location to comply with this AD?* The FAA can issue a special flight permit under sections 21.197 and 21.199 of the Federal Aviation Regulations (14 CFR 21.197 and 21.199) to operate your airplane to a location where you can accomplish the requirements of this AD.

(h) *How do I get copies of the documents referenced in this AD?* You may obtain copies of the documents referenced in this AD from Socata Groupe Aerospatiale, Customer Support, Aerodrome Tarbes-Ossun-Lourdes, BP 930–F65009 Tarbes Cedex, France; telephone: 011 33 5 62 41 73 00; facsimile: 011 33 5 62 41 76 54; or the Product Support Manager, Socata-Groupe Aerospatiale, North Perry Airport, 7501 Pembroke Road, Pembroke Pines, Florida 33023; telephone: (954) 894–1160; facsimile: (954) 964–4191. You may examine these documents at FAA, Central Region, Office of the Regional Counsel, 901 Locust, Room 506, Kansas City, Missouri 64106.

Note 2: The subject of this AD is addressed in French AD 2001–005(A), dated January 10, 2001.

Issued in Kansas City, Missouri, on August 20, 2001.

Dorenda Baker,

Acting Manager, Small Airplane Directorate, Aircraft Certification Service.

[FR Doc. 01–21406 Filed 8–23–01; 8:45 am]

BILLING CODE 4910–13–U

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. 2001–CE–11–AD]

RIN 2120–AA64

Airworthiness Directives; SOCATA—Groupe AEROSPATIALE Model TBM 700 Airplanes

AGENCY: Federal Aviation Administration, DOT.

ACTION: Notice of proposed rulemaking (NPRM).

SUMMARY: This document proposes to adopt a new airworthiness directive (AD) that would apply to certain SOCATA—Groupe AEROSPATIALE (Socata) Model TBM 700 airplanes. The proposed AD would require you to inspect for defective Amendment A fuel tank air vent valves and replace with parts of improved design. The proposed AD is the result of mandatory continuing airworthiness information (MCAI) issued by the airworthiness authority for France. The actions specified by the proposed AD are intended to prevent in-flight damage to the wing skins caused by abnormal venting conditions of the wing fuel tank, which could result in severe handling problems or reduced structural capability. Continued operation with such structural deformation or handling problems could result in loss of control of the airplane.

DATES: The Federal Aviation Administration (FAA) must receive any comments on this proposed rule on or before September 24, 2001.

ADDRESSES: Submit comments in triplicate to FAA, Central Region, Office of the Regional Counsel, Attention: Rules Docket No. 2001–CE–11–AD, 901 Locust, Room 506, Kansas City, Missouri 64106. Comments may be inspected at this location between 8 a.m. and 4 p.m., Monday through Friday, holidays excepted.

Service information that applies to the proposed AD may be obtained from SOCATA Groupe AEROSPATIALE, Customer Support, Aerodrome Tarbes-Ossun-Lourdes, BP 930–F65009 Tarbes Cedex, France; telephone: 011 33 5 62 41 73 00; facsimile: 011 33 5 62 41 76 54; or the Product Support Manager, SOCATA—Groupe AEROSPATIALE, North Perry Airport, 7501 Pembroke Road, Pembroke Pines, Florida 33023; telephone: (954) 894–1160; facsimile: (954) 964–4191. This information also may be examined at the Rules Docket at the address above.

FOR FURTHER INFORMATION CONTACT: Karl Schletzbaum, Aerospace Engineer, FAA, Small Airplane Directorate, 901 Locust, Room 301, Kansas City, Missouri 64106; telephone: (816) 329–4146; facsimile: (816) 329–4090.

SUPPLEMENTARY INFORMATION:

Comments Invited

How do I comment on the proposed AD? The FAA invites comments on this proposed rule. You may submit whatever written data, views, or arguments you choose. You need to include the rule's docket number and submit your comments in triplicate to the address specified under the caption **ADDRESSES.** The FAA will consider all comments received on or before the closing date. We may amend the proposed rule in light of comments received. Factual information that supports your ideas and suggestions is extremely helpful in evaluating the effectiveness of the proposed AD action and determining whether we need to take additional rulemaking action.

Are there any specific portions of the proposed AD I should pay attention to? The FAA specifically invites comments on the overall regulatory, economic, environmental, and energy aspects of the proposed rule that might suggest a need to modify the rule. You may examine all comments we receive before and after the closing date of the rule in the Rules Docket. We will file a report in the Rules Docket that summarizes each FAA contact with the public that concerns the substantive parts of the proposed AD.

We are re-examining the writing style we currently use in regulatory documents, in response to the Presidential memorandum of June 1, 1998. That memorandum requires federal agencies to communicate more clearly with the public. We are interested in your comments on whether the style of this document is clear, and any other suggestions you might have to improve the clarity of FAA communications that affect you. You can get more information about the Presidential memorandum and the plain language initiative at *http://www.plainlanguage.gov.*

How can I be sure FAA receives my comment? If you want us to acknowledge the receipt of your comments, you must include a self-addressed, stamped postcard. On the postcard, write ''Comments to Docket No. 2001–CE–11–AD.'' We will date stamp and mail the postcard back to you.

Discussion

What events have caused this proposed AD? The Direction Générale de l'Aviation Civile (DGAC), which is the airworthiness authority for France, recently notified FAA that an unsafe condition may exist on certain Socata Model TBM 700 airplanes. The DGAC reports that Amendment A fuel tank air vent valve floats may block the air vent valve in the closed position making the valve defective. This condition is the result of a change in the manufacturing of the fuel tank air vent valve.

The DGAC reports one occurrence on a Socata Model TBM 700 airplane of abnormal venting conditions of the wing fuel tank due to a fuel tank air vent

valve float blocking the air vent valve in the closed position.

What are the consequences if the condition is not corrected? This condition, if not corrected, could result in severe handling problems or reduced structural capability. Continued operation with such structural deformation or handling problems could result in loss of control of the airplane.

Is there service information that applies to this subject? SOCATA has issued Service Bulletin SB 70–090, dated December 2000.

What are the provisions of this service bulletin? This service bulletin includes procedures for :

—Inspecting the fuel tank air vent valve to determine the Amendment level of the part; and

—Replacing the defective Amendment A fuel tank air vent valve with a part of improved design (Amendment B).

What action did DGAC take? The DGAC classified this service bulletin as mandatory and issued French AD 2001–004(A), dated January 10, 2001, in order to assure the continued airworthiness of these airplanes in France.

Was this in accordance with the bilateral airworthiness agreement? These airplane models are manufactured in France and are type certificated for operation in the United States under the provisions of section 21.29 of the Federal Aviation Regulations (14 CFR 21.29) and the applicable bilateral airworthiness agreement. Pursuant to this bilateral airworthiness agreement, the DGAC has kept FAA informed of the situation described above.

The FAA's Determination and an Explanation of the Provisions of the Proposed AD

What has FAA decided? The FAA has examined the findings of the DGAC; reviewed all available information, including the service information referenced above; and determined that:

—The unsafe condition referenced in this document exists or could develop on other SOCATA Model TBM 700 airplanes of the same type design;

—The actions specified in the previously-referenced service information should be accomplished on the affected airplanes; and

—AD action should be taken in order to correct this unsafe condition.

What would the proposed AD require? This proposed AD would require you to inspect the fuel tank air vent valve to determine the Amendment level of the part and replace the defective Amendment A fuel tank air vent valve with a part of improved design (Amendment B).

Cost Impact

How many airplanes would the proposed AD impact? We estimate that the proposed AD affects 38 airplanes in the U.S. registry.

What would be the cost impact of the proposed AD on owners/operators of the affected airplanes? We estimate the following costs to accomplish the proposed inspection:

Labor cost	Parts cost	Total cost per airplane	Total cost on U.S. operators
2 workhours × $60 per hour = $120	No parts required for the inspection	$120	$4,560

We estimate the following costs to accomplish the proposed replacement:

Labor cost	Parts cost	Total cost per airplane
2 workhours × $60 per hour = $120	No cost for parts	$120

Regulatory Impact

Would this proposed AD impact various entities? The regulations proposed herein would not have a substantial direct effect on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government. Therefore, it is determined that this proposed rule would not have federalism implications under Executive Order 13132.

Would this proposed AD involve a significant rule or regulatory action? For the reasons discussed above, I certify that this proposed action (1) Is not a ''significant regulatory action'' under Executive Order 12866; (2) is not a ''significant rule'' under DOT Regulatory Policies and Procedures (44 FR 11034, February 26, 1979); and (3) if promulgated, will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act. A copy of the draft regulatory evaluation prepared for this action has been placed in the Rules Docket. A copy of it may be obtained by contacting the Rules Docket at the location provided under the caption **ADDRESSES.**

List of Subjects in 14 CFR Part 39

Air transportation, Aircraft, Aviation safety, Safety.

The Proposed Amendment

Accordingly, under the authority delegated to me by the Administrator, the Federal Aviation Administration proposes to amend part 39 of the Federal Aviation Regulations (14 CFR part 39) as follows:

PART 39—AIRWORTHINESS DIRECTIVES

1. The authority citation for part 39 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40113, 44701.

§ 39.13 [Amended]

2. FAA amends § 39.13 by adding a new airworthiness directive (AD) to read as follows:

SOCATA—GROUPE AEROSPATIALE:

Docket No. 2001–CE–11–AD

(a) *What airplanes are affected by this AD?* This AD affects the following model TBM 700 airplanes that are certificated in any category:

Serial Nos.
114, 117, 118,
121 through 173,
175 through 177,
179 through 184,
186 and 187

(b) *Who must comply with this AD?* Anyone who wishes to operate any of the above airplanes must comply with this AD.

(c) *What problem does this AD address?* The actions specified by this AD are intended to prevent in-flight damage to the wing skins caused by abnormal venting conditions of the wing fuel tank, which could result in severe handling problems or reduced structural capability. Continued operation with such structural deformation could result in loss of control of the airplane.

(d) *What actions must I accomplish to address this problem?* To address this problem, you must accomplish the following:

Actions	Compliance	Procedures
(1) Inspect the upper surface of the fuel tank airvent valve for modification stamp ''Amdt A''.	Within the next 50 hours time-in-service (TIS) after the effective date of this AD.	In accordance with paragraph (B) of the ACCOMPLISHMENT INSTRUCTIONS in Socata Service Bulletin SB 70–090, dated December 2000, and the applicable maintenance manual.
(i) If the fuel tank air vent valve is stamped ''Amdt A'' on the upper surface, install a fuel tank air vent valve that incorporates Amendment B modifications. (ii) If modification stamp ''Amdt A'' is not on the upper surface of the fuel tank air vent valve, reinstall the valve and no further action is required by paragraph (d)(1) of this AD.	Prior to further flight after the inspection required in paragraph (d)(1) of this AD, unless ready accomplished.	
(2) Do not install any fuel tank air vent valve that does not have Amendment B incorporated (or FAA-approved equivalent part).	As of the effective date of this AD	Not applicable.

(e) *Can I comply with this AD in any other way?* You may use an alternative method of compliance or adjust the compliance time if:

(1) Your alternative method of compliance provides an equivalent level of safety; and

(2) The Manager, Small Airplane Directorate, approves your alternative. Submit your request through an FAA Principal Maintenance Inspector, who may add comments and then send it to the Manager, Small Airplane Directorate.

Note 1: This AD applies to each airplane identified in paragraph (a) of this AD, regardless of whether it has been modified, altered, or repaired in the area subject to the requirements of this AD. For airplanes that have been modified, altered, or repaired so that the performance of the requirements of this AD is affected, the owner/operator must request approval for an alternative method of compliance in accordance with paragraph (e) of this AD. The request should include an assessment of the effect of the modification, alteration, or repair on the unsafe condition addressed by this AD; and, if you have not eliminated the unsafe condition, specific actions you propose to address it.

(f) *Where can I get information about any already approved alternative methods of compliance?* Contact Karl Schletzbaum, Aerospace Engineer, FAA, Small Airplane Directorate, 901 Locust, Room 301, Kansas City, Missouri 64106; telephone: (816) 329–4146; facsimile: (816) 329–4090.

(g) *What if I need to fly the airplane to another location to comply with this AD?* The FAA can issue a special flight permit under sections 21.197 and 21.199 of the Federal Aviation Regulations (14 CFR 21.197 and 21.199) to operate your airplane to a location where you can accomplish the requirements of this AD.

(h) *How do I get copies of the documents referenced in this AD?* You may obtain copies of the documents referenced in this AD from SOCATA Groupe AEROSPATIALE, Customer Support, Aerodrome Tarbes-Ossun-Lourdes, BP 930–F65009 Tarbes Cedex, France; telephone: 011 33 5 62 41 73 00; facsimile: 011 33 5 62 41 76 54; or the Product Support Manager, SOCATA Groupe AEROSPATIALE, North Perry Airport, 7501 Pembroke Road, Pembroke Pines, Florida 33023; telephone: (954) 894–1160; facsimile: (954) 964–4191. You may examine these documents at FAA, Central Region, Office of the Regional Counsel, 901 Locust, Room 506, Kansas City, Missouri 64106.

Note 2: The subject of this AD is addressed in French AD 2001–004(A), dated January 10, 2001.

Issued in Kansas City, Missouri, on August 17, 2001.

Michael Gallagher,

Manager, Small Airplane Directorate, Aircraft Certification Service.

[FR Doc. 01–21397 Filed 8–23–01; 8:45 am]

BILLING CODE 4910–13–P

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. 99–NE–47–AD]

RIN 2120–AA64

Airworthiness Directives; Rolls-Royce Corporation (Formerly Allison Engine Company) 250–C18 and C–20 Series Turboshaft Engines

AGENCY: Federal Aviation Administration, DOT.

ACTION: Proposed rule; withdrawal.

SUMMARY: This action withdraws a notice of proposed rulemaking (NPRM) that proposed a new airworthiness directive (AD), applicable to Rolls-Royce Corporation (formerly Allison Engine Company) 250–C18 and C–20 series turboshaft engines. That action would have required a one-time visual inspection of the fuel nozzle screen for contamination. If contamination is found, the proposal would have required, prior to further flight, replacement of the fuel nozzle screen with a serviceable screen, visual inspection of the entire fuel system for contamination, and repair, if necessary. In addition, this proposal would have required reporting the results of the one-time inspection to the Federal Aviation Administration (FAA) to determine if repetitive inspections should be required by further rulemaking. This proposal was prompted by a report of fuel system contamination that caused an in-flight engine shutdown, autorotation, and forced landing. Since the issuance of the NPRM, the FAA and Rolls-Royce have determined that there have been no additional engine problems reported due to fuel nozzle screen contamination. Accordingly, the proposed rule is withdrawn.

FOR FURTHER INFORMATION CONTACT: John Tallarovic, Aerospace Engineer, Chicago Aircraft Certification Office, FAA, Small Airplane Directorate, 2300 E. Devon Ave., Des Plaines, IL 60018; telephone (847) 294–8180, fax (847) 294–7834.

SUPPLEMENTARY INFORMATION: A proposal to amend part 39 of the Federal Aviation Regulations (14 CFR part 39) to add a new AD that is applicable to Rolls-Royce Corporation (formerly Allison Engine Company) 250–C18 and C–20 series turboshaft engines was published in the **Federal Register** on April 25, 2000 (65 FR 24135). That action proposed to require a one-time visual inspection of the fuel nozzle screen for contamination. If contamination is found, that proposal would have required, prior to further flight, replacement of the fuel nozzle screen with a serviceable screen, visual inspection of the entire fuel system for contamination, and repair, if necessary. In addition, that proposal would have

required reporting the results of the one-time inspection to the Federal Aviation Administration (FAA) to determine if repetitive inspections should be required by further rulemaking. The actions specified by the proposal were intended to prevent an in-flight engine shutdown due to blockage of the fuel nozzle screen, which can result in autorotation and forced landing.

Since the issuance of that NPRM, the FAA and Rolls-Royce have determined that there have been no additional engine problems reported due to fuel nozzle screen contamination. Rolls-Royce further maintains that fuel nozzle contamination is a very rare event, varying between zero to 6.5 per 8,000 disassembled nozzles.

Since this problem first surfaced, Rolls-Royce and the FAA have taken the following actions:

• Because most accidents involving fuel nozzle contamination have occurred in Hawaii, Rolls-Royce Corporation conducted a training/fact finding mission to Hawaii in the spring of 1998 to assess the situation and to help educate users regarding the proper service of engine fuel systems.

• The FAA approved revised maintenance procedures for the Rolls-Royce model 250 engines. These procedures clarified the actions to be taken when fuel system contamination is suspected.

• Finally, the FAA published Special Airworthiness Information Bulletin (SAIB) No. CE–01–10 advising owners and operators of Rolls-Royce Corporation model 250–C18 series and 250–C20 series engines of the recent changes to the fuel system maintenance on how rotorcraft engine fuel nozzle screens be inspected.

Comments Received

Interested persons have been afforded an opportunity to participate in the making of this amendment. Due consideration has been given to the comments received.

Support

Two commenters either supported the NPRM or were neutral.

Opposition to NPRM

One commenter points out that there is already a requirement to inspect the fuel nozzle screen each 300 hours of operation if there is no airframe mounted fuel filter (otherwise inspect it at 1,500 hours); a 300 hour requirement to replace the fuel filter, and a 1,000 hour requirement to change the fuel control screen. The commenter expresses concern that the proposed actions in the NPRM would burden the majority of the operators who are already correctly performing the required maintenance checks. The FAA agrees and the NPRM is being withdrawn.

Another comment, by an aircraft owner and repair station owner employing over 200 Airframe and Powerplant mechanics, strongly opposes the actions proposed in the NPRM. The commenter emphasizes that efforts should be put into ensuring that clean fuel is used by operators, rather than mandating items that are already clearly covered by the Original Equipment Manufacturer's maintenance and operations manuals. The comment also notes that the rare cases of contamination they had witnessed resulted from operators refueling remotely out of 55-gallon drums. The commenter believes that this is an operational issue rather than an inherent design flaw with the rotorcraft fuel system. The FAA agrees. This observation is consistent with the FAA's inspection results confirming that accidents involved cases where the fuel supply was a problem (less than optimal conditions).

The final comment opposing the NPRM is from an owner/operator of 173 helicopters. This individual also points out that the actions proposed in the NPRM were already required by the engine maintenance manual. He expresses concern that in the course of complying with the proposed actions in the NPRM, mechanics will be removing and disassembling thousands of fuel nozzles in the field. It is his experience that these nozzles are best taken apart at a repair facility where they can be checked for proper reassembly after the inspection. Due to the critical nature of the assembly process, slight variations in the torque values can have a significant effect on the fuel flow and spray pattern of the nozzle. The net result would be an increase in service difficulties associated with the fuel nozzle. The FAA agrees and the proposed NPRM is being withdrawn.

After further consideration and review of this data, the FAA has determined that the unsafe condition no longer exists and is extremely unlikely to develop. Accordingly, the proposed rule is withdrawn.

Withdrawal of this notice of proposed rulemaking does not preclude the agency from issuing another notice in the future, nor does it commit the agency to any course of action in the future.

Since this action only withdraws a notice of proposed rulemaking, it is neither a proposed nor final rule, and, therefore, is not covered under Executive Order 12866, the Regulatory Flexibility Act, or DOT Regulatory Policies and Procedures (44 FR 11034, February 26, 1979).

List of Subjects in 14 CFR Part 39

Air transportation, Aircraft, Aviation safety, Safety.

The Withdrawal

Accordingly, the notice of proposed rulemaking, Docket No. 99–NE–47, published in the **Federal Register** on April 25, 2000 (65 FR 24135), is withdrawn.

Issued in Burlington, Massachusetts, on August 16, 2001.

Jay J. Pardee,

Manager, Engine and Propeller Directorate, Aircraft Certification Service.

[FR Doc. 01–21398 Filed 8–23–01; 8:45 am]

BILLING CODE 4910–13–P

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. 98–NM–353–AD]

RIN 2120–AA64

Airworthiness Directives; Boeing Model 737–100, –200, –300, –400, and –500 Series Airplanes

AGENCY: Federal Aviation Administration, DOT.

ACTION: Proposed rule; withdrawal.

SUMMARY: This action withdraws a notice of proposed rulemaking (NPRM) that proposed a new airworthiness directive (AD), applicable to certain Boeing Model 737–100, –200, –300, –400, and –500 series airplanes. That action would have required modification of certain filter module assemblies of the generator control units (GCU). Since the issuance of the NPRM, the Federal Aviation Administration (FAA) has received new data that indicate that the unsafe condition identified in the NPRM does not exist. Accordingly, the proposed rule is withdrawn.

FOR FURTHER INFORMATION CONTACT: Forrest Keller, Senior Aerospace Engineer, Systems and Equipment Branch, ANM–130S, FAA, Seattle Aircraft Certification Office, 1601 Lind Avenue, SW., Renton, Washington 98055–4056; telephone (425) 227–2790; fax (425) 227–1181.

SUPPLEMENTARY INFORMATION: A proposal to amend part 39 of the Federal Aviation Regulations (14 CFR part 39) to add a new airworthiness directive (AD),

applicable to certain Boeing Model 737–100, –200, –300, –400, and –500 series airplanes, was published in the **Federal Register** as a Notice of Proposed Rulemaking (NPRM) on March 5, 1999 (64 FR 10578). The proposed rule would have required modification of certain filter module assemblies of the generator control units (GCU). That action was prompted by reports of smoke and occasional fire in the flight compartment as a direct result of a GCU failure. The proposed actions were intended to prevent failure of the filter module assemblies of the GCUs due to overcurrent conditions, which could result in an increased risk of smoke, and/or fire in the flight compartment.

Actions Since Issuance of the NPRM

The NPRM proposed to require modification of certain filter module assemblies of the GCUs to prevent smoke and/or fire in the flight compartment due to overcurrent conditions in the GCUs. Since the issuance of the NPRM, the manufacturer has advised the FAA that there have been no reports of fire as a result of GCU overcurrent conditions. The manufacturer has further advised that GCUs that were examined and/or repaired by the supplier have shown no evidence of fire. In those cases where fires were reported, the manufacturer asserts that the erroneous identification of an actual fire had been inferred from the presence of smoke, which resulted from unrelated conditions and did not represent a hazard to the airplane.

In addition, the modifications proposed by the NPRM may have contributed, in part, to an event that occurred on a Model 737–200 series airplane during which all electrical power was lost in flight. As a result of that incident, the FAA issued AD 99–18–17, amendment 39–11283 (64 FR 47656, September 1, 1999), which was later superseded by AD 99–24–08, amendment 39–11432 (64 FR 66368, November 26, 1999), to require, among other things, repetitive testing of GCU diodes and repetitive replacement of airplane batteries. In this case, the attempt to minimize the incidence of smoke resulted in an increased probability of a total loss of electrical power. Total loss of electrical power represents a greater hazard to the airplane, and the information provided by the manufacturer indicates that the existing GCUs are adequate to ensure the safety of the fleet.

FAA's Conclusions

Upon further consideration of the above information, the FAA has determined that the hazard associated with GCU overcurrent conditions does not justify a requirement to modify the filter module. The FAA has further determined that incorporation of the proposed modifications could actually decrease the reliability of the electrical power system. Accordingly, the proposed rule is hereby withdrawn.

Withdrawal of this NPRM constitutes only such action, and does not preclude the agency from issuing another action in the future, nor does it commit the agency to any course of action in the future.

Regulatory Impact

Since this action only withdraws a notice of proposed rulemaking, it is neither a proposed nor a final rule and therefore is not covered under Executive Order 12866, the Regulatory Flexibility Act, or DOT Regulatory Policies and Procedures (44 FR 11034, February 26, 1979).

List of Subjects in 14 CFR Part 39

Air transportation, Aircraft, Aviation safety, Safety.

The Withdrawal

Accordingly, the notice of proposed rulemaking, Docket 98–NM–353–AD, published in the **Federal Register** on March 5, 1999 (64 FR 10578), is withdrawn.

Issued in Renton, Washington, on August 20, 2001.

Vi L. Lipski,

Manager, Transport Airplane Directorate, Aircraft Certification Service.

[FR Doc. 01–21496 Filed 8–23–01; 8:45 am]

BILLING CODE 4910–13–P

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. 2001–NM–99–AD]

RIN 2120–AA64

Airworthiness Directives; McDonnell Douglas Model DC–10–10, –10F, –15, –30, –30F (KC–10A and KDC–10), –40, and –40F Series Airplanes; and Model MD–10–10F and –30F Series Airplanes

AGENCY: Federal Aviation Administration, DOT.

ACTION: Notice of proposed rulemaking (NPRM).

SUMMARY: This document proposes the adoption of a new airworthiness directive (AD) that is applicable to certain McDonnell Douglas Model DC–10–10, –10F, –15, –30, –30F (KC–10A and KDC–10), –40, and –40F series airplanes; and Model MD–10–10F and –30F series airplanes. This proposal would require an inspection of the throttle control module on the center pedestal in the flight deck compartment to determine its part number and configuration, and modification of the throttle control module. This action is necessary to prevent chafing of wiring inside the throttle control module, fuel shutoff lever lights, and/or aft pedestal lightplates due to degradation of protective sleeving, which could result in electrical arcing and failure of the auto throttle/speed control system and consequent smoke and/or fire in the cockpit. This action is intended to address the identified unsafe condition.

DATES: Comments must be received by October 9, 2001.

ADDRESSES: Submit comments in triplicate to the Federal Aviation Administration (FAA), Transport Airplane Directorate, ANM–114, Attention: Rules Docket No. 2001–NM–99–AD, 1601 Lind Avenue, SW., Renton, Washington 98055–4056. Comments may be inspected at this location between 9:00 a.m. and 3:00 p.m., Monday through Friday, except Federal holidays. Comments may be submitted via fax to (425) 227–1232. Comments may also be sent via the Internet using the following address: 9-anm-nprmcomment@faa.gov. Comments sent via fax or the Internet must contain ''Docket No. 2001–NM–99–AD'' in the subject line and need not be submitted in triplicate. Comments sent via the Internet as attached electronic files must be formatted in Microsoft Word 97 for Windows or ASCII text.

The service information referenced in the proposed rule may be obtained from Boeing Commercial Aircraft Group, Long Beach Division, 3855 Lakewood Boulevard, Long Beach, California 90846, Attention: Data and Service Management, Dept. C1-L5A (D800–0024). This information may be examined at the FAA, Transport Airplane Directorate, 1601 Lind Avenue, SW., Renton, Washington; or at the FAA, Los Angeles Aircraft Certification Office, 3960 Paramount Boulevard, Lakewood, California.

FOR FURTHER INFORMATION CONTACT: Natalie Phan-Tran, Aerospace Engineer, Systems and Equipment Branch, ANM–130L, FAA, Los Angeles Aircraft Certification Office, 3960 Paramount Boulevard, Lakewood, California 90712–4137; telephone (562) 627–5343; fax (562) 627–5210.

SUPPLEMENTARY INFORMATION:

Comments Invited

Interested persons are invited to participate in the making of the proposed rule by submitting such written data, views, or arguments as they may desire. Communications shall identify the Rules Docket number and be submitted in triplicate to the address specified above. All communications received on or before the closing date for comments, specified above, will be considered before taking action on the proposed rule. The proposals contained in this action may be changed in light of the comments received.

Submit comments using the following format:

- Organize comments issue-by-issue. For example, discuss a request to change the compliance time and a request to change the service bulletin reference as two separate issues.
- For each issue, state what specific change to the proposed AD is being requested.
- Include justification (e.g., reasons or data) for each request.

Comments are specifically invited on the overall regulatory, economic, environmental, and energy aspects of the proposed rule. All comments submitted will be available, both before and after the closing date for comments, in the Rules Docket for examination by interested persons. A report summarizing each FAA-public contact concerned with the substance of this proposal will be filed in the Rules Docket.

Commenters wishing the FAA to acknowledge receipt of their comments submitted in response to this action must submit a self-addressed, stamped postcard on which the following statement is made: ''Comments to Docket Number 2001–NM–99–AD.'' The postcard will be date stamped and returned to the commenter.

Availability of NPRMs

Any person may obtain a copy of this NPRM by submitting a request to the FAA, Transport Airplane Directorate, ANM–114, Attention: Rules Docket No. 2001–NM–99–AD, 1601 Lind Avenue, SW., Renton, Washington 98055–4056.

Background

In July 1996, a Boeing Model 747 series airplane was involved in an accident. As part of re-examining all aspects of the service experience of the airplane involved in the accident, the FAA participated in design review and testing to determine possible sources of ignition in center fuel tanks. As part of the review, we examined fuel system wiring with regard to the possible effects that wire degradation may have on arc propagation.

In 1997 in a parallel preceding, at the recommendation of the White House Commission on Aviation Safety and Security, the FAA expanded its Aging Transport Program to include non-structural systems and assembled a team for evaluating these systems. This team performed visual inspections of certain transport category airplanes for which 20 years or more had passed since date of manufacture. In addition, the team gathered information from interviews with FAA Principal Maintenance Inspectors and meetings with representatives of airplane manufacturers. This evaluation revealed that the length of time in service is not the only cause of wire degradation; inadequate maintenance, contamination, improper repair, and mechanical damage are all contributing factors. From the compilation of this comprehensive information, we developed the Aging Transport Non-Structural Systems Plan to increase airplane safety by increasing knowledge of how non-structural systems degrade and how causes of degradation can be reduced.

In 1998, an accident occurred off the coast of Nova Scotia involving a McDonnell Douglas Model MD–11 series airplane. Investigation indicates that a fire broke out in the cockpit and first class overhead area. Although the ignition source of the fire has not been determined, the FAA, in conjunction with Boeing and operators of Model MD–11, DC–8, DC–9, DC–10, and DC–9–80 series airplanes, is reviewing all aspects of the service history of those airplanes to identify potential unsafe conditions associated with wire degradation due to various contributing factors (e.g., inadequate maintenance, contamination, improper repair, and mechanical damage) and to take appropriate corrective actions. We have issued a series of airworthiness directives (AD) that address unsafe conditions identified during that process. This process is continuing and we may consider additional rulemaking actions as further results of the review become available. The cause of the Nova Scotia MD–11 accident has not yet been determined.

In 1999, the FAA Administrator established a formal advisory committee to facilitate the implementation of the Aging Transport Non-Structural Systems Plan. This committee, the Aging Transport Systems Rulemaking Advisory Committee (ATSRAC), is made up of representatives of airplane manufacturers, operators, user groups, aerospace and industry associations, and government agencies. As part of its mandate, ATSRAC will recommend rulemaking to increase transport category airplane safety in cases where solutions to safety problems connected to aging systems have been found and must be applied. Detailed analyses of certain transport category airplanes that have been removed from service, studies of service bulletins pertaining to certain wiring systems, and reviews of previously issued ADs requiring repetitive inspections of certain wiring systems, have resulted in valuable information on the cause and prevention of wire degradation due to various contributing factors (e.g., inadequate maintenance, contamination, improper repair, and mechanical damage).

In summary, as a result of the investigations described above, the FAA has determined that corrective action may be necessary to minimize the potential hazards associated with wire degradation and related causal factors (e.g., inadequate maintenance, contamination, improper repair, and mechanical damage).

Identification of Unsafe Condition

The FAA has received reports of chafed electrical wires inside the throttle control module on certain McDonnell Douglas Model DC–10 series airplanes, which resulted in the failure of the auto throttle disconnect and takeoff/go around (TOGA) mode of the auto throttle/speed control system (AT/SC). Associated with the AT/SC wiring is the wiring of the fuel shutoff lever lights and aft pedestal lightplates, which also showed evidence of chafing. The cause of such chafing has been attributed to degradation of the existing protective sleeving on the wires during normal throttle actuation. Chafing of wiring inside the throttle control module, fuel shutoff lever lights, and/or aft pedestal lightplates, if not corrected, could result in electrical arcing and failure of the AT/SC and consequent smoke and/or fire in the cockpit.

The throttle control module on the center pedestal in the flight deck compartment on certain Model MD–10–10F and –30F series airplanes are identical to those on the affected Model DC–10 series airplanes. Therefore, all of these models may be subject to the same unsafe condition.

Other Related Rulemaking

This proposed AD is one of a series of actions identified as part of the ATSRAC program initiative to maintain continued operational safety of aging non-structural systems in transport category airplanes. The program is

continuing and the FAA may consider additional rulemaking actions as further results of the review become available.

Explanation of Relevant Service Information

The FAA has reviewed and approved Boeing Alert Service Bulletin DC10–76A048, dated August 6, 2001, which describes procedures for an inspection of the throttle control module on the center pedestal in the flight deck compartment to determine its part number and configuration and modification of the throttle control module. The modification includes removing material from the throttle lever and cover plates (as applicable) for engines 1, 2, and 3; replacing the existing guide assembly with an improved guide assembly inside the throttle control module; replacing the existing protective sleeving on the wire bundles; and removing previously installed spiral wrap tubing on the auto throttle/TOGA wiring; and reidentifying the coverplates and throttle control module; as applicable. Accomplishment of the actions specified in the service bulletin is intended to adequately address the identified unsafe condition.

Explanation of Requirements of Proposed Rule

Since an unsafe condition has been identified that is likely to exist or develop on other products of this same type design, the proposed AD would require accomplishment of the actions specified in the service bulletin described previously.

Cost Impact

There are approximately 399 Model DC–10–10, –10F, –15, –30, –30F (KC–10A and KDC–10), –40, and –40F series airplanes, and Model MD–10–10F and –30F series airplanes of the affected design in the worldwide fleet. The FAA estimates that 321 airplanes of U.S. registry would be affected by this proposed AD, that it would take approximately between 5 and 7 work hours per airplane depending on the airplane configuration to accomplish the proposed actions, and that the average labor rate is $60 per work hour. Required parts would cost approximately $1,712 per airplane. Based on these figures, the cost impact of the proposed AD on U.S. operators is estimated to be between $2,012 and $2,132, per airplane, depending on the airplane configuration.

The cost impact figure discussed above is based on assumptions that no operator has yet accomplished any of the proposed requirements of this AD action, and that no operator would accomplish those actions in the future if this proposed AD were not adopted. The cost impact figures discussed in AD rulemaking actions represent only the time necessary to perform the specific actions actually required by the AD. These figures typically do not include incidental costs, such as the time required to gain access and close up, planning time, or time necessitated by other administrative actions.

Regulatory Impact

The regulations proposed herein would not have a substantial direct effect on the States, on the relationship between the national Government and the States, or on the distribution of power and responsibilities among the various levels of government. Therefore, it is determined that this proposal would not have federalism implications under Executive Order 13132.

For the reasons discussed above, I certify that this proposed regulation (1) Is not a ''significant regulatory action'' under Executive Order 12866; (2) is not a ''significant rule'' under the DOT Regulatory Policies and Procedures (44 FR 11034, February 26, 1979); and (3) if promulgated, will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act. A copy of the draft regulatory evaluation prepared for this action is contained in the Rules Docket. A copy of it may be obtained by contacting the Rules Docket at the location provided under the caption **ADDRESSES.**

List of Subjects in 14 CFR Part 39

Air transportation, Aircraft, Aviation safety, Safety.

The Proposed Amendment

Accordingly, pursuant to the authority delegated to me by the Administrator, the Federal Aviation Administration proposes to amend part 39 of the Federal Aviation Regulations (14 CFR part 39) as follows:

PART 39—AIRWORTHINESS DIRECTIVES

1. The authority citation for part 39 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40113, 44701.

§ 39.13 [Amended]

2. Section 39.13 is amended by adding the following new airworthiness directive:

McDonnell Douglas: Docket 2001–NM–99–AD.

Applicability: Model DC–10–10, –10F, –15, –30, –30F (KC–10A and KDC–10), –40 and –40F series airplanes; and Model MD–10–10F and –30F series airplanes; as listed in Boeing Alert Service Bulletin DC10–76A048, dated August 6, 2001; certificated in any category.

Note 1: This AD applies to each airplane identified in the preceding applicability provision, regardless of whether it has been modified, altered, or repaired in the area subject to the requirements of this AD. For airplanes that have been modified, altered, or repaired so that the performance of the requirements of this AD is affected, the owner/operator must request approval for an alternative method of compliance in accordance with paragraph (b) of this AD. The request should include an assessment of the effect of the modification, alteration, or repair on the unsafe condition addressed by this AD; and, if the unsafe condition has not been eliminated, the request should include specific proposed actions to address it.

Compliance: Required as indicated, unless accomplished previously.

To prevent chafing of wiring inside the throttle control module, fuel shutoff lever lights, and/or aft pedestal lightplates due to degradation of protective sleeving, which could result in electrical arcing and failure of the auto throttle/speed control system and consequent smoke and/or fire in the cockpit, accomplish the following:

Inspection and Modification

(a) Within 18 months after the effective date of this AD, do the actions specified in paragraphs (a)(1) and (a)(2) of this AD, per Boeing Alert Service Bulletin DC10–76A048, dated August 6, 2001.

(1) Do an inspection of the throttle control module on the center pedestal in the flight deck compartment to determine its part number and configuration. This will identify the group applicability information.

(2) Modify the throttle control module on the center pedestal in the flight deck compartment per the applicable Figure in the service bulletin.

Alternative Methods of Compliance

(b) An alternative method of compliance or adjustment of the compliance time that provides an acceptable level of safety may be used if approved by the Manager, Los Angeles Aircraft Certification Office (ACO), FAA. Operators shall submit their requests through an appropriate FAA Principal Maintenance Inspector, who may add comments and then send it to the Manager, Los Angeles ACO.

Note 2: Information concerning the existence of approved alternative methods of compliance with this AD, if any, may be obtained from the Los Angeles ACO.

Special Flight Permit

(c) Special flight permits may be issued in accordance with sections 21.197 and 21.199 of the Federal Aviation Regulations (14 CFR 21.197 and 21.199) to operate the airplane to a location where the requirements of this AD can be accomplished.

Issued in Renton, Washington, on August 17, 2001.

Vi L. Lipski,

Manager, Transport Airplane Directorate, Aircraft Certification Service.

[FR Doc. 01–21497 Filed 8–23–01; 8:45 am]

BILLING CODE 4910–13–U

DEPARTMENT OF THE TREASURY

Internal Revenue Service

26 CFR Part 1

[REG–106431–01]

RIN 1545–AY76

Qualified Subchapter S Trust Election for Testamentary Trusts

AGENCY: Internal Revenue Service (IRS), Treasury.

ACTION: Notice of proposed rulemaking.

SUMMARY: This document contains proposed regulations relating to a qualified subchapter S trust election for testamentary trusts under section 1361 of the Internal Revenue Code. The Small Business Job Protection Act of 1996 and the Taxpayer Relief Act of 1997 made changes to the applicable law. These proposed regulations affect S corporations and their shareholders.

DATES: Written or electronic comments and requests for a public hearing must be received by November 23, 2001.

ADDRESSES: Send submissions to: CC:IT&A:RU (REG–106431–01), room 5226, Internal Revenue Service, POB 7604, Ben Franklin Station, Washington, DC 20044. Submissions may also be hand delivered Monday through Friday between the hours of 8 a.m. and 5 p.m. to: CC:IT&A:RU (REG–106431–01), Courier's desk, Internal Revenue Service, 1111 Constitution Avenue, NW., Washington, DC. Alternatively, taxpayers may submit comments electronically via the Internet by selecting the ''Tax Regs'' option on the IRS Home Page, or by submitting comments directly to the IRS Internet site at http://www.irs.gov/tax_regs/regslist.html.

FOR FURTHER INFORMATION CONTACT: Concerning the proposed regulations, Deane M. Burke, (202) 622–3070; concerning submissions of comments, Sonya Cruse, (202) 622–7180 (not toll-free numbers).

SUPPLEMENTARY INFORMATION:

Background

This document proposes to amend section 1361 of the Income Tax Regulations (26 CFR part 1) regarding a qualified subchapter S trust (QSST) election for testamentary trusts.

Section 1361(a) defines an S corporation as a small business corporation for which an election under section 1362(a) is in effect for the year. Section 1361(b) provides, in part, that a small business corporation is a domestic corporation which is not an ineligible corporation and which does not have as a shareholder a person (other than a trust described in section 1361(c)(2)) who is not an individual. Under section 1361(c)(2), subpart E trusts and testamentary trusts are permitted S corporation shareholders. A qualified subpart E trust is a trust, all of which is treated (under subpart E of part I of subchapter J, chapter 1) as owned by an individual who is a citizen or resident of the United States. A qualified subpart E trust that continues in existence after the death of the deemed owner (former qualified subpart E trust) is a permitted shareholder, but only for the 2-year period beginning on the day of the deemed owner's death. A testamentary trust is a trust to which S corporation stock is transferred pursuant to the terms of a will, but only for the 2-year period beginning on the day the stock is transferred to it.

Section 1303 of the Small Business Job Protection Act of 1996, Public Law 104–188 (110 Stat. 1779) (August 20, 1996) (1996 Act) amended section 1361 for taxable years beginning after December 31, 1996. Prior to the 1996 Act, a former qualified subpart E trust was a permitted shareholder for a 60-day period beginning on the day of the deemed owner's death. However, if the entire corpus of the trust was includible in the gross estate of the deemed owner, the trust was a permitted shareholder for a 2-year period beginning on the day of the deemed owner's death. Under the regulations, special rules applied if the trust consisted of community property. A testamentary trust was a permitted shareholder of an S corporation for a 60-day period beginning on the day that the S corporation stock was transferred to the trust.

After the 1996 Act, both a testamentary trust and a former qualified subpart E trust, whether or not the entire corpus is included in the deemed owner's gross estate, are permitted shareholders for a 2-year period. Because the entire corpus of a former qualified subpart E trust is not required to be included in the deemed owner's estate, it is no longer relevant whether the trust consists of community property for purposes of the trust's qualifying as a permitted shareholder for a 2-year period. However, whether a former qualified subpart E trust consists of community property is still relevant for purposes of determining the shareholders of S corporation stock held by the trust.

Explanation of Provisions

A. Incorporation of Changes From the 1996 Act

The proposed regulations incorporate changes from the 1996 Act regarding section 1361 to provide that a testamentary trust may be a permitted shareholder for a 2-year period. The proposed regulations also provide that a former qualified subpart E trust is a permitted shareholder for a 2-year period whether or not the entire corpus is included in the deemed owner's gross estate. The proposed regulations thus eliminate the special rules for determining whether trusts consisting of community property qualify for the 2-year period.

The proposed regulations also incorporate additional changes made to section 1361 by the 1996 Act. Section 1302 of the 1996 Act added a new type of trust, the electing small business trusts (ESBTs), to the types of trusts permitted to be S corporation shareholders under section 1361(c)(2). Section 1601(c) of the Taxpayer Relief Act of 1997, Public Law 105–34 (111 Stat. 1086) (August 5, 1997) made technical amendments to section 1361 affecting ESBTs and S corporation shareholders. A notice of proposed rulemaking (REG–251701–96, 2001–4 I.R.B. 396) regarding ESBTs was published in the **Federal Register** (65 FR 82963) on December 29, 2000. The proposed regulations refer to ESBTs and provide that certain former qualified subpart E trusts and testamentary trusts can continue as permitted shareholders after the end of the 2-year period by becoming ESBTs.

Section 1316 of the 1996 Act allowed certain exempt organizations to be S corporation shareholders for taxable years beginning after December 31, 1997, and section 1301 increased the number of permissible S corporation shareholders from 35 to 75. The proposed amendments incorporate these additional changes.

B. QSST Election for Testamentary Trusts

Section 1.1361–1(j)(6)(iii)(C) of the Income Tax Regulations provides guidance regarding when a QSST election is made for a former qualified subpart E trust that also satisfies the requirements of a QSST. Under the provision, a QSST election may be made for a former qualified subpart E trust at any time, but no later than the end of

the 16-day-and-2-month period beginning on the date on which the estate of the deemed owner ceases to be treated as a shareholder (as late as the end of the 2-year period). Thus, a former qualified subpart E trust can continue as a permitted shareholder after the end of the 2-year period by electing to be a QSST.

Section 1.1361–1(h)(3)(ii)(B) provides that if a testamentary trust continues to own S corporation stock after the expiration of the 60-day period (now 2-year period), the corporation's S election will terminate unless the trust otherwise qualifies as a permitted shareholder. The trust otherwise qualifies as a permitted shareholder if it satisfies the requirements of a QSST under section 1361(d)(3) and the trust income beneficiary makes a timely QSST election under section 1361(d)(2). The regulations, promulgated before 1996, do not address when a QSST election may be made for a testamentary trust during its 2-year period as a permitted shareholder. The IRS and the Treasury Department believe that the regulations should provide guidance similar to that for former qualified subpart E trusts clarifying when an income beneficiary of a testamentary trust may make a QSST election.

Accordingly, the proposed regulations clarify that a current income beneficiary of a testamentary trust that satisfies the QSST requirements may make a QSST election at any time during the 2-year period that the trust is a permitted shareholder or the 16-day-and-2-month period beginning on the date after the 2-year period ends. Under this provision, a testamentary trust continues as a permitted shareholder after the end of the 2-year period by becoming an electing QSST. Once the trust becomes an electing QSST, the beneficiary is treated as the shareholder of the S corporation as of the effective date of the QSST election.

Proposed Effective Date

The regulations are proposed to apply on and after the date that final regulations are published in the **Federal Register**.

Special Analyses

It has been determined that this notice of proposed rulemaking is not a significant regulatory action as defined in Executive Order 12866. It also has been determined that section 533(b) of the Administrative Procedures Act (5 U.S.C. chapter 5) does not apply to these regulations, and because these regulations do not impose a collection of information on small entities, the Regulatory Flexibility Act (5 U.S.C. chapter 6) does not apply. Therefore, a Regulatory Flexibility Analysis is not required. Pursuant to section 7805(f) of the Internal Revenue Code, this notice of proposed rulemaking will be submitted to the Chief Counsel for Advocacy of the Small Business Administration for comment on its impact on small business.

Comments and Request for a Public Hearing

Before these proposed regulations are adopted as final regulations, consideration will be given to any electronic and written comments (a signed original and eight (8) copies) that are submitted timely to the IRS. The IRS and the Treasury Department specifically request comments on the clarity of the proposed regulations and how they may be made easier to understand. All comments will be available for public inspection and copying. A public hearing will be scheduled if requested in writing by any person that timely submits written comments. If a public hearing is scheduled, notice of the date, time, and place for the public hearing will be published in the **Federal Register**.

Drafting Information

The principal author of these proposed regulations is Deane M. Burke, Office of the Associate Chief Counsel (Passthroughs & Special Industries). However, other personnel from the IRS and the Treasury Department participated in their development.

List of Subjects in 26 CFR Part 1

Income taxes, Reporting and recordkeeping requirements.

Proposed Amendments to the Regulations

Accordingly, 26 CFR part 1 is proposed to be amended as follows:

PART 1—INCOME TAXES

Paragraph 1. The authority citation for part 1 continues to read in part as follows:

Authority: 26 U.S.C. 7805 * * *

Par. 2. Section 1.1361–1 is amended as follows:

1. Revising paragraphs (b)(1)(ii), (f), (h)(1)(ii), (h)(1)(iv), (h)(3)(i)(B), and (h)(3)(i)(D). (The undesignated paragraph following paragraph (h)(3)(i)(B) is removed.)

2. Revising the second sentence of paragraph (h)(3)(ii)(A).

3. Revising paragraphs (h)(3)(ii)(B) and (j)(6)(iii)(C).

4. Redesignating paragraph (j)(6)(iii)(D) as paragraph (j)(6)(iii)(E).

5. Adding new paragraph (j)(6)(iii)(D).

6. Revising paragraph (j)(7)(ii).

7. Revising the fourth sentence of paragraph (k)(1) *Example 2*(ii).

8. Revising paragraph (k)(1) *Examples 3* and *4*(iii).

9. Adding a sentence to the end of paragraph (k)(2)(i).

The revisions and additions read as follows:

§ 1.1361–1 S corporation defined.

* * * * *

(b) * * *(1)* * *

(ii) As a shareholder, a person (other than an estate, a trust described in section 1361(c)(2), or, for taxable years beginning after December 31, 1997, an organization described in section 1361(c)(6)) who is not an individual;

* * * * *

(f) *Shareholder must be an individual or estate.* Except as otherwise provided in paragraph (e)(1) of this section (relating to nominees), paragraph (h) of this section (relating to certain trusts), and, for taxable years beginning after December 31, 1997, section 1361(c)(6) (relating to certain exempt organizations), a corporation in which any shareholder is a corporation, partnership, or trust does not qualify as a small business corporation.

* * * * *

(h)* * *(1)* * *

(ii) *Subpart E trust ceasing to be a qualified subpart E trust after the death of deemed owner.* A trust which was a qualified subpart E trust immediately before the death of the deemed owner and which continues in existence after the death of the deemed owner, but only for the 2-year period beginning on the day of the deemed owner's death. A trust is considered to continue in existence if the trust continues to hold the stock of the S corporation during the period of administration of the decedent's estate or if, after the period of administration, the trust continues to hold the stock pursuant to the terms of the will or the trust agreement. See § 1.641(b)–3 for rules concerning the termination of estates and trusts for federal income tax purposes.

* * * * *

(iv) *Testamentary trusts.* A trust (other than a qualified subpart E trust, an electing QSST, or an electing small business trust (ESBT)) to which S corporation stock is transferred pursuant to the terms of a will, but only for the 2-year period beginning on the day the stock is transferred to the trust.

* * * * *

(3)* * *

(i)* * *

(B) If stock is held by a trust defined in paragraph (h)(1)(ii) of this section, the

estate of the deemed owner is generally treated as the shareholder as of the day of the deemed owner's death. However, if stock is held by such a trust in a community property state, the decedent's estate is the shareholder only of the portion of the trust included in the decedent's gross estate (and the surviving spouse continues to be the shareholder of the portion of the trust owned by that spouse under the applicable state's community property law). The estate ordinarily will cease to be treated as the shareholder upon the earlier of the transfer of that stock by the trust or the expiration of the 2-year period beginning on the day of the deemed owner's death. If the trust qualifies and becomes an electing QSST, the beneficiary and not the estate is treated as the shareholder as of the effective date of the QSST election, and the rules provided in paragraph (j)(7) of this section apply. If the trust qualifies and becomes an ESBT, the shareholders are determined under provisions of REG–251701–96 in 2001–4 I.R.B. 396 (see § 601.601(d)(2) of this chapter) as of the effective date of the ESBT election.

* * * * *

(D) If stock is transferred to a testamentary trust described in paragraph (h)(1)(iv) of this section (other than a qualified subpart E trust, an electing QSST, or an ESBT), the estate of the testator is treated as the shareholder until the earlier of the transfer of that stock by the trust or the expiration of the 2-year period beginning on the day that the stock is transferred to the trust. If the trust qualifies and becomes an electing QSST, the beneficiary and not the estate is treated as the shareholder as of the effective date of the QSST election, and the rules provided in paragraph (j)(7) of this section apply. If the trust qualifies and becomes an ESBT, the shareholders are determined under provisions of REG–251701–96 in 2001–4 I.R.B. 396 (see § 601.601(d)(2) of this chapter) as of the effective date of the ESBT election.

* * * * *

(ii)* * *

(A)* * * If the trust continues to own the stock after the expiration of the 2-year period, the corporation's S election will terminate unless the trust is otherwise a permitted shareholder.* * *

(B) If stock is transferred to a testamentary trust described in paragraph (h)(1)(iv) of this section (other than a qualified subpart E trust, an electing QSST, or an ESBT), the trust is treated as the shareholder. If the trust continues to own the stock after the expiration of the 2-year period, the corporation's S election will terminate unless the trust otherwise qualifies as a permitted shareholder. If the trust qualifies as a QSST described in section 1361(d) and the income beneficiary of the trust makes a timely QSST election, the beneficiary and not the trust is treated as the shareholder from the effective date of the QSST election.

* * * * *

(j) * * *

(6) * * *

(iii) * * *

(C) If a trust ceases to be a qualified subpart E trust but also satisfies the requirements of a QSST, the QSST election must be filed within the 16-day-and-2-month period beginning on the date on which the trust ceases to be a qualified subpart E trust. If the estate of the deemed owner of the trust is treated as the shareholder under paragraph (h)(3)(i) of this section, the QSST election may be filed at any time, but no later than the end of the 16-day-and-2-month period beginning on the date on which the estate of the deemed owner ceases to be treated as a shareholder.

(D) If a testamentary trust is a permitted shareholder under paragraph (h)(1)(iv) of this section and also satisfies the requirements of a QSST, the QSST election may be filed at any time, but no later than the end of the 16-day-and-2-month period beginning on the date after the end of the 2-year period.

* * * * *

(7) * * *

(ii) If, upon the death of an income beneficiary, the trust continues in existence, continues to hold S corporation stock but no longer satisfies the QSST requirements, and is not a qualified subpart E trust, then, solely for purposes of section 1361(b)(1), as of the date of the income beneficiary's death, the estate of that income beneficiary is treated as the shareholder of the S corporation with respect to which the income beneficiary made the QSST election. The estate ordinarily will cease to be treated as the shareholder for purposes of section 1361(b)(1) upon the earlier of the transfer of that stock by the trust or the expiration of the 2-year period beginning on the day of the income beneficiary's death. During the period that the estate is treated as the shareholder for purposes of section 1361(b)(1), the trust is treated as the shareholder for purposes of sections 1366, 1367, and 1368. If, after the 2-year period, the trust continues to hold S corporation stock, the corporation's S election terminates. If the termination is inadvertent, the corporation may request relief under section 1362(f).

* * * * *

(k)(1) * * *

Example 2. * * *

(ii) * * * A's estate will cease to be treated as the shareholder for purposes of section 1361(b)(1) upon the earlier of the transfer of the Corporation M stock by the trust (other than to A's estate), the expiration of the 2-year period beginning on the day of A's death, or the effective date of a QSST election if the trust qualifies as a QSST.* * *

* * * * *

Example 3. 2-year rule under section 1361(c)(2)(A)(ii) and (iii). F owns stock of Corporation P, an S corporation. In addition, F is the deemed owner of a qualified subpart E trust that holds stock in Corporation O, an S corporation. F dies on July 1, 2001. The trust continues in existence after F's death but is no longer a qualified subpart E trust. On August 1, 2001, F's shares of stock in Corporation P are transferred to the trust pursuant to the terms of F's will. Because the stock of Corporation P was not held by the trust when F died, section 1361(c)(2)(A)(ii) does not apply with respect to that stock. Under section 1361(c)(2)(A)(iii), the last day on which F's estate could be treated as a permitted shareholder of Corporation P is July 31, 2003, (that is, the last day of the 2-year period that begins on the date of the transfer from the estate to the trust). With respect to the shares of stock in Corporation O held by the trust at the time of F's death, section 1361(c)(2)(A)(ii) applies and the last day on which F's estate could be treated as a permitted shareholder of Corporation O is June 30, 2003, (that is, the last day of the 2-year period that begins on the date of F's death).

Example 4. * * *

(iii) *QSST when a person other than the current income beneficiary may receive trust corpus.* Assume the same facts as in paragraph (i) of this *Example 4,* except that H dies on November 1, 2001. Under the terms of the trust, after H's death, L is the income beneficiary of the trust and the trustee is authorized to distribute trust corpus to L as well as to J. The trust ceases to be a QSST as of November 1, 2001, because corpus distributions may be made to someone other than L, the current (successive) income beneficiary. Under section 1361(c)(2)(B)(ii), H's estate (and not the trust) is considered to be the shareholder for purposes of section 1361(b)(1) for the 2-year period beginning on November 1, 2001. However, because the trust continues in existence after H's death and will receive any distributions from the corporation, the trust (and not H's estate) is treated as the shareholder for purposes of sections 1366, 1367, and 1368, during that 2-year period. After the 2-year period, the S election terminates and the trust continues as a shareholder of a C corporation. If the termination is inadvertent, Corporation Q may request relief under section 1362(f). However, the S election would not terminate if the trustee distributed all Corporation Q shares to L, J, or both before October 31, 2003, (the last day of the 2-year period) assuming that neither L nor J becomes the

76th shareholder of Corporation Q as a result of the distribution.

* * * * *

(2) * * * (i) * * * In addition, paragraphs (h)(1)(ii), (h)(1)(iv), (h)(3)(i)(B), (h)(3)(i)(D), (h)(3)(ii)(A) second sentence, (h)(3)(ii)(B), (j)(6)(iii)(C), (j)(6)(iii)(D), (j)(7)(ii), and (k)(1) *Example 2*(ii) fourth sentence, *Example 3,* and *Example 4*(iii) of this section apply on and after the date that final regulations are published in the **Federal Register**.

* * * * *

Robert E. Wenzel,

Deputy Commissioner of Internal Revenue.

[FR Doc. 01–21353 Filed 8–23–01; 8:45 am]

BILLING CODE 4830–01–P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 52

[PA 116/121/154/–4129; FRL–7043–6]

Approval and Promulgation of Air Quality Implementation Plans; Pennsylvania; Rate of Progress Plan for Pennsylvania Portion of the Philadelphia-Wilmington-Trenton Ozone Nonattainment Area

AGENCY: Environmental Protection Agency (EPA).

ACTION: Proposed rule.

SUMMARY: EPA is proposing to approve State Implementation Plan (SIP) revisions submitted by the Commonwealth of Pennsylvania consisting of the 1999, 2002, and 2005 rate of progress (ROP) plans for the Pennsylvania portion of the Philadelphia-Wilmington-Trenton Ozone Nonattainment Area (the Philadelphia area). Rate of progress plans are required by the Clean Air Act (the Act) to ensure progress in reducing emissions of ozone precursors. The intended effect of this action is to propose approval of the ROP plans submitted by the Pennsylvania Department of Environmental Protection (PADEP) to reduce volatile organic compounds (VOCs) and oxides of nitrogen (NO_X), which contribute to the formation of ground level ozone. EPA is withdrawing the previous proposed approval of the Pennsylvania post-1996 ROP plan, published on August 25, 1999.

DATES: Written comments must be received on or before September 24, 2001.

ADDRESSES: Written comments may be mailed to David L. Arnold, Chief, Air Quality Planning and Information Services Branch, Mailcode 3AP21, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103. Copies of the documents relevant to this action are available for public inspection during normal business hours at the Air Protection Division, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103; Pennsylvania Department of Environmental Protection, Bureau of Air Quality, P.O. Box 8468, 400 Market Street, Harrisburg, Pennsylvania 17105.

FOR FURTHER INFORMATION CONTACT: Jill Webster, (215) 814–2033 or by e-mail at Webster.Jill@epa.gov. Please note that while questions may be posed via telephone and e-mail, formal comments must be submitted, in writing, as indicated in the **ADDRESSES** section of this document.

SUPPLEMENTARY INFORMATION: The Commonwealth submitted the required ROP plans in two phases. The first plan, submitted on July 31, 1998, consists of a 9 percent reduction in ozone precursors from November 1996 to November 1999. On April 30, 1998, the Commonwealth submitted the second of the ROP plans, which consists of an additional 3 percent per year reduction in ozone precursors demonstrated for milestone years 2002 and 2005. The April 30, 1998 submittal also included an attainment demonstration for the Philadelphia area, which is the subject of a separate rulemaking action. On February 25, 2000, the Commonwealth amended the SIP pertaining to the motor vehicle emissions reductions and budgets for the Philadelphia area. Henceforth, each ROP plan shall be referred to by its respective milestone year, either 1999, 2002 and 2005; and the three plans collectively shall be referred to as the post-1996 ROP plans. These post-1996 plans collectively demonstrate ROP from November 1996 thorough November 2005.

I. Background

The Act requires serious and above ozone nonattainment areas to develop post-1996 ROP plans to reduce area-wide VOC emissions after 1996 by 3 percent per year averaged over consecutive 3-year periods, until the attainment year for that area. In this case, the Philadelphia area has submitted a SIP establishing an attainment date of 2005, the outside attainment date for areas classified as severe-15. This 3 percent per year reduction requirement is a continuation of the requirement for a 15 percent reduction in VOC by 1996. For the post-1996 ROP plans, the Act allows for the substitution of NO_X emission reductions in lieu of VOC emission reductions so long as reductions in both precursors are beneficial for reducing ozone levels. EPA has issued guidance applicable to the appropriate ratio of NO_X to VOC. Our assessment of the post-1996 ROP plans is to determine whether or not the 3 percent per year reduction requirement is met.

II. Calculation of the 3 Percent Per Year Reduction

An ROP plan consists of a plan to achieve a target level of emissions. There are several important emissions inventories and calculations associated with the plan. These include: The base year emission inventory, future year projection inventories, and target level calculations. Each of these is described below.

A. Base Year Emission Inventory

EPA approved the 1990 base year VOC emissions inventory for Pennsylvania's portion of the Philadelphia nonattainment area on June 9, 1997 (62 FR 31343). EPA approved the 1990 NO_X base year emission inventory for Pennsylvania's portion of the Philadelphia nonattainment area on June 17, 1999 (64 FR 32424).

B. Calculation of Needed Reductions and Target Levels

The process for the calculation of the required reductions is set forth in EPA's guidance document entitled ''Guidance on the Post-96 Rate of Progress Plans and the Attainment Demonstration,'' January 1994. The ''target level'' of emission represents the maximum amount of emissions that a nonattainment area can have in the given target year. Section 182(c)(2)(C) of the Act allows states to substitute NO_X emission reductions that occur after 1990 for VOC emission in the post-1996 ROP plans. EPA issued guidance for states to use in substituting NO_X for VOC reductions on December 15, 1993, ''NO_X Substitution Guidance'' and follow-up guidance on August 5, 1994, ''Clarification of Policy for Nitrogen (NO_X) Substitution.'' This guidance provides that the condition for meeting the ROP requirement is that the sum of all creditable VOC and NO_X emissions must equal 3 percent per year averaged over the three year periods up to the attainment year. If a state wishes to substitute NO_X reductions for VOC emission reductions, then a target level of emissions demonstrating a representative combined 9 percent

emission reduction in VOC and NO_X must be developed for each milestone year. In addition, in demonstrating ROP, projected growth in both VOC and NO_X emissions must be offset by emission reductions. Therefore, separate emission target levels must be developed for both VOC and NO_X emissions for each of the 1999, 2002, and 2005 milestone years. To calculate the target level of emissions, the required emission reduction is subtracted from the previous milestone's target level. For example, the 1999 ROP VOC target level is based upon the 1996 VOC target level calculated for the 15 percent plan.

EPA granted conditional approval of Pennsylvania's 15 percent plan for the Philadelphia area on June 9, 1997 (62 FR 31343). On May 16, 2001 (66 FR 27051), EPA published a notice of proposed rulemaking (NPR) to convert its prior conditional approval of Pennsylvania's 15 percent plan SIP for the Philadelphia area to full approval. No public comments were submitted on the NPR, and EPA expects to issue soon a final rule converting its conditional approval of the 15 percent plan to full approval. In its 15 percent plan, the PADEP calculated the 15 percent ROP target level to be 494 tons per day (TPD).

Pennsylvania has elected to substitute NO_X for VOC emissions reductions in the milestone years of 1999, 2002, and 2005 for the Philadelphia area. In Pennsylvania's plans, growth in VOC emissions is offset by VOC emissions reductions achieved by 2005. Similarly, growth in NO_X emissions is offset by NO_X emissions reductions achieved in that same time period. Pennsylvania did not calculate separate VOC and NO_X target levels. However, EPA has been able to calculate VOC and NO_X target levels using data in Pennsylvania's ROP plans. The calculations for the 1999 milestone year are shown in Table 1 below.

TABLE 1.—TARGET LEVEL AND EMISSION REDUCTION NEEDS FOR THE PHILADELPHIA AREA THROUGH 1999

[tons/day]

VOC	
1. 1990 ROP base year inventory = 1990 base year inventory—biogenic emissions	732 − 116 = 616
2. 1990 adjusted base year inventory = 1990 ROP base year inventory—1990 to 1999 FMVCP/RVP reductions	616 − 39 = 577
3. Required Reductions = 0.0% × 1990 adjusted base year inventory	0% × 576 = 0
4. 1999 target level = 1996 target—required reduction—fleet turnover correction	494–0–6 = 488
5. Reduction needed to offset VOC growth = 1999 uncontrolled emissions—1999 target	625 − 488 = 137
NO_X	
1. 1990 ROP base year inventory (sum of all point, area, and mobile source emission)	440
2. 1990 adjusted base year inventory = 1990 ROP base year inventory—1990 to 1999 FMVCP/RVP reductions	440 − 20 = 420
3. Required reduction = 9% × 1990 adjusted base year inventory	9% × 420 = 38
4. 1999 ROP target level = 1990 ROP base year inventory—required reduction—1990 to 1999 FMVCP/RVP reductions	440 − 38 − 20 = 382
5. Reductions needed for ROP and to offset NO_X growth = 1999 uncontrolled emissions—1999 target	455 − 382 = 73

Using the target levels calculated for 1999, EPA was able to calculate NO_X and VOC reductions needed for following milestone years 2002 and 2005. The calculations for each milestone are summarized in Table 2 below.

TABLE 2.—REDUCTIONS IN VOC AND NO_X NEEDED FOR MILESTONE YEARS 1999, 2002 AND 2005

[tons/day]

Milestone and Assumed Reduction	VOC	NO_X
1999 (9% ROP = 0% VOC + 9 % NO_X)	137	73
2002 (9% ROP = 5% VOC + 4% NO_X)	179	99
2005 (9% ROP = 4% VOC + 5% NO_X)	216	129

C. Growth Projections

States must include control measures in their ROP plans to offset the emissions growth projected to occur through the final milestone year. In this case, the Commonwealth must project growth in emissions that occur from 1996 through 2005. To meet the average 3 percent per year requirement, the Commonwealth must enact measures achieving sufficient emissions reductions to offset the projected growth in emissions, in addition to achieving a 3 percent per year reduction of NO_X/VOC emissions from 1996 through 2005. Growth must be determined separately for each source or source category, since sources typically grow at different rates. The post-1996 ROP plans submitted by PADEP for the Philadelphia area contain growth projections for stationary, area, on-road, and non-road sources using acceptable growth factor methodologies. A more detailed description of the Commonwealth's submittals and EPA's evaluation are included in a Technical Support Document (TSD) prepared in support of this rulemaking action. A copy of the TSD is available, upon request, from the EPA Regional Office listed in the **ADDRESSES** section of this document. EPA has determined that the Commonwealth's growth projection methodologies are acceptable for growth factor estimation.

III. The Control Strategies Included in the 1999, 2002, and 2005 ROP Plans

The purpose of the ROP plans is to demonstrate how the state has reduced emissions by 3 percent per year as averaged over each 3 year period between November 1996 and November 2005. In general, reductions toward ROP requirements are creditable, provided the control measure was implemented after 1990 and the resulting reductions are real, permanent, and Federally enforceable. Each control measure is described in detail in the TSD for this action. Table 3, below, summarizes the measures PADEP relies upon to demonstrate ROP for the applicable milestone years.

TABLE 3.—EMISSION REDUCTIONS IN THE PHILADELPHIA POST 1996 ROP PLANS

tons/day

Control measure	VOC			NO_X		
	1999	2002	2005	1999	2002	2005
RFG	22.56	35.24	36.59	0.47	7.17	7.45
I/M	58.69	61.44	65.38	32.22	32.73	33.89
FMVCP and Tier 1	6.95	13.12	20.35	14.11	22.59	27.36
Stage II Vapor Recovery	17.71	19.82	21.25	.....	.....	.....
OTC NO_X MOU	.....	.....	.....	27.37	30.82	34.20
RACT	9.82	10.11	10.42	3.63	3.72	3.81
Autobody Refinishing Coatings	5.95	6.07	6.12	.....	.....	.....
Consumer Products	4.12	4.16	4.20	.....	.....	.....
AIM coatings	7.33	7.38	7.43	.....	.....	.....
TSDFs	9.52	9.61	9.70	.....	.....	.....
Rule Effectiveness for Point Sources	.....	16.17	16.45	.....	.....	.....
Shutdowns	.....	2.59	2.79	.....	0.94	1.21
Compression-Ignition Engines	.....	.....	.....	.....	.....	44.00
Spark-Ignition Engines	.....	.....	15.79	.....	.....	.....
NLEV	.....	1.01	2.85	.....	1.69	4.71
Heavy-Duty Diesel Engine Standard	.....	.....	.....	.....	.....	0.38
Totals	142.65	186.72	219.32	77.8	99.66	157.01

Based upon the measures listed in the above table and EPA's analysis of each measure, EPA has determined the post 1996 ROP plans submitted by PADEP achieve the required reductions. Thus, the Commonwealth's 1999, 2002, and 2005 ROP plans meet the aggregate 27 percent emission reduction requirement of the Act, by achieving 9 percent emissions reductions over each successive 3 year period.

IV. The Transportation Conformity Budgets for the ROP Milestone Years

Under EPA's transportation conformity rule, August 15, 1997 (62 FR 43779), the post-1996 ROP plans are considered control strategy SIPs. A control strategy SIP establishes budgets to which Federally funded and approved transportation projects and plans must conform. The ROP plans establish VOC and NO_X budgets for the Philadelphia area that are applicable for 1999, 2002, and 2005. These budgets are applicable in later years in the absence of other applicable budgets. On February 25, 2000, the Commonwealth amended the motor vehicle emissions budgets for the applicable milestone years. Table 4, below, summarizes the revised motor vehicle emissions budgets of the ROP plans for the Philadelphia area. EPA determined the budgets identified below, adequate for use in conformity determinations on May 31, 2000 (65 FR 36438 published June 8, 2000). That determination became effective on June 23, 2000.

TABLE 4.—MOTOR VEHICLE EMISSIONS BUDGETS FOR THE PHILADELPHIA AREA

[tons/day]

Milestone year	VOC	NO_X
1999	88.6	109.6
2002	69.52	93.13
2005	61.76	86.42

V. EPA's Evaluation of the Commonwealth SIP Revisions

EPA's review of this material indicates that the Commonwealth has adopted, submitted and implemented adequate measures to achieve the post-1996 ROP reductions. EPA is proposing to approve the Pennsylvania post-1996 ROP plans submitted on April 30, 1998, July 31, 1998, and February 25, 2000 as SIP revisions. EPA is soliciting public comments on the issues concerning the post-1996 ROP plan. Any comments received before the close of the public comment period will be considered before taking final action. Interested parties may participate in the Federal rulemaking procedure by submitting written comments to the EPA Regional office listed in the **ADDRESSES** section of this document. This includes those who submitted comments on the NPR published on August 25, 1999 (64 FR 46325), if they believe their comments are still germane in light of this newly proposed action.

VI. Proposed Action

EPA is proposing to approve the 1999, 2002, and 2005 ROP plans submitted by the Commonwealth of Pennsylvania on April 30, 1998, July 31, 1998, and February 25, 2000. By proposing approval of the ROP plans submitted by the Commonwealth, EPA is also proposing to approve the motor vehicle emissions budgets contained in the February 25, 2000 SIP submittal for ROP and transportation conformity purposes. EPA is withdrawing the previous proposed approval of the Pennsylvania Post-1996 ROP plan, published on August 25, 1999 (64 FR 46325).

VII. Administrative Requirements

Under Executive Order 12866 (58 FR 51735, October 4, 1993), this proposed action is not a ''significant regulatory action'' and therefore is not subject to review by the Office of Management and Budget. For this reason, this action is also not subject to Executive Order 13211, ''Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use'' (66 FR 28355 (May 22, 2001)). This action merely proposes to approve state law as meeting Federal requirements and imposes no additional requirements beyond those imposed by state law. Accordingly, the Administrator certifies that this proposed rule will not have a significant economic impact on a substantial number of small entities under the Regulatory Flexibility Act (5 U.S.C. 601 *et seq.*). Because this rule proposes to approve pre-existing requirements under state law and does not impose any additional enforceable duty beyond that required by state law, it does not contain any unfunded mandate or significantly or uniquely affect small governments, as described in the Unfunded Mandates Reform Act of 1995 (Public Law 104–4). This proposed rule also does not have a substantial direct effect on one or more Indian tribes, on the relationship between the Federal

Government and Indian tribes, or on the distribution of power and responsibilities between the Federal Government and Indian tribes, as specified by Executive Order 13175 (65 FR 67249, November 9, 2000), nor will it have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132 (64 FR 43255, August 10, 1999), because it merely proposes to approve a state rule implementing a Federal standard, and does not alter the relationship or the distribution of power and responsibilities established in the Clean Air Act. This proposed rule also is not subject to Executive Order 13045 (62 FR 19885, April 23, 1997), because it is not economically significant. In reviewing SIP submissions, EPA's role is to approve state choices, provided that they meet the criteria of the Clean Air Act. In this context, in the absence of a prior existing requirement for the State to use voluntary consensus standards (VCS), EPA has no authority to disapprove a SIP submission for failure to use VCS. It would thus be inconsistent with applicable law for EPA, when it reviews a SIP submission, to use VCS in place of a SIP submission that otherwise satisfies the provisions of the Clean Air Act. Thus, the requirements of section 12(d) of the National Technology Transfer and Advancement Act of 1995 (15 U.S.C. 272 note) do not apply. As required by section 3 of Executive Order 12988 (61 FR 4729, February 7, 1996), in issuing this proposed rule, EPA has taken the necessary steps to eliminate drafting errors and ambiguity, minimize potential litigation, and provide a clear legal standard for affected conduct. EPA has complied with Executive Order 12630 (53 FR 8859, March 15, 1988) by examining the takings implications of the rule in accordance with the ''Attorney General's Supplemental Guidelines for the Evaluation of Risk and Avoidance of Unanticipated Takings'' issued under the executive order.

This proposed rule, regarding Pennsylvania's 1999, 2002, and 2005 ROP plans, does not impose an information collection burden under the provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 *et seq.*).

List of Subjects in 40 CFR Part 52

Environmental protection, Air pollution control, Hydrocarbons, Nitrogen dioxide, Ozone.

Authority: 42 U.S.C. 7401 *et seq.*

Dated: August 16, 2001.

Thomas C. Voltaggio,

Acting Regional Administrator, Region III.

[FR Doc. 01–21434 Filed 8–23–01; 8:45 am]

BILLING CODE 6560–50–P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 52

[PA117–4131; FRL–7043–4]

Approval and Promulgation of Air Quality Implementation Plans; Pennsylvania; One-Hour Ozone Attainment Demonstration Plan for the Philadelphia-Wilmington-Trenton Ozone Nonattainment Area

AGENCY: Environmental Protection Agency (EPA).

ACTION: Supplemental notice of proposed rule.

SUMMARY: On December 16, 1999, EPA proposed approval of the attainment demonstration plan submitted by the Pennsylvania Department of Environmental Protection (PADEP) for the Philadelphia-Wilmington-Trenton severe ozone nonattainment area. Among other things, EPA proposed approval of this SIP only if the Commonwealth of Pennsylvania submitted revised motor vehicle emissions budgets reflecting the benefits from the Tier 2/Sulfur rule and various enforceable commitments including a commitment to perform a mid-course review of the attainment demonstration. In this rulemaking, EPA is proposing to approve State Implementation Plan (SIP) revisions submitted by PADEP. These revisions satisfy the December 16, 1999 proposed rule's requisites for submittal of an enforceable commitment relating to the mid-course review and the need to revise the motor vehicle emissions budgets to reflect the benefits of the Tier 2/Sulfur rule. The intended effect of this proposed action is to supplement our December 16, 1999 proposed approval by opening a comment period on the enforceable commitment to a mid-course review and the revised motor vehicle emissions budgets. This action is being taken in accordance with the Clean Air Act.

DATES: Written comments must be received on or before September 24, 2001.

ADDRESSES: Written comments may be mailed to David L. Arnold, Chief, Air Quality Planning and Information Services, Mailcode 3AP21, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103. Copies of the documents relevant to this action are available for public inspection during normal business hours at the Air Protection Division, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103; and Pennsylvania Department of Environmental Protection, Bureau of Air Quality, P.O. Box 8468, 400 Market Street, Harrisburg, Pennsylvania 17105.

FOR FURTHER INFORMATION CONTACT: Christopher Cripps, (215) 814–2179. Or by e-mail at cripps.christopher@*epa.gov.* Please note that while questions may be posed via telephone and e-mail, formal comments must be submitted, in writing, as indicated in the **ADDRESSES** section of this document.

SUPPLEMENTARY INFORMATION: Throughout this document wherever ''we'', ''us'', or ''our'' are used we mean EPA.

I. Background

A. Previous Proposed Actions on the Attainment Demonstration SIP

On December 16, 1999 (64 FR 70428), we published a notice of proposed rulemaking (NPR) proposing approval of the attainment demonstration SIP revision submitted by the Commonwealth of Pennsylvania (the Commonwealth) for the Philadelphia-Wilmington-Trenton severe ozone nonattainment area (the Philadelphia area). The Philadelphia area is classified as severe nonattainment for ozone and its attainment date is 2005. Our approval was contingent upon certain actions by the Commonwealth for the Philadelphia area. These actions were that the Commonwealth had to adopt and submit the following: (1) Adequate motor vehicle emissions budgets including the benefits of the Tier 2/Sulfur rule (65 FR 6698, February 10, 2000); and (2) various enforceable commitments including one to perform a mid-course review of the attainment demonstration.

On December 16, 1999, EPA proposed approval of the attainment demonstrations for ten ozone nonattainment areas in the eastern United States (64 FR 70317). On July 28, 2000, we published a supplemental notice of proposed rulemaking (SNPR) on these attainment demonstrations (65 FR 46383). The comment period established by the July 28, 2000 SNPR concluded on August 28, 2000. In that SNPR, we clarified and expanded on two issues relating to the motor vehicle emissions budgets for the SIP revisions subject to all of the December 16, 1999

proposed actions. In the July 28, 2000 SNPR, we reopened the comment period to take comment on these two issues and, in the case of the Commonwealth's SIP for the Philadelphia area, to allow comment on all materials that were in the docket for the proposed action including those placed in the docket close to or after the conclusion of the initial comment period which closed on February 14, 2000. In general, the SNPR identified these materials as consisting of motor vehicle emissions budgets and revised or additional commitments submitted by the States (65 FR at 46387, July 28, 2000). On February 25, 2000 (prior to July 28, 2000 but after the February 14, 2000 close of the original comment period), PADEP submitted revised motor vehicle emissions budgets (which did not reflect the benefits from EPA's Tier 2/Sulfur rule) as well as enforceable commitments for its portion of the Philadelphia area. On May 31, 2000, EPA notified the Commonwealth that the motor vehicle emissions budgets submitted on February 25, 2000 were adequate (see 65 FR 36438, June 8, 2000). That adequacy finding included a condition precluding the use of the emission reduction benefits from the Tier 2/Sulfur rule in conformity determinations, since those budgets did not include the Tier 2/Sulfur benefits.

As we explained in the July 28, 2000 SNPR and reiterate here, we are proposing that the 2005 attainment motor vehicle emissions budgets that we are proposing to approve with the attainment demonstration will be effective for conformity purposes only until revised attainment motor vehicle emissions budgets developed using MOBILE6 or including additional measures to fill a shortfall are submitted and found adequate. The revised MOBILE6 attainment motor vehicle emissions budgets will then apply for conformity purposes as soon as we find them adequate. We are proposing to limit the duration of our approval in this manner because we are proposing to approve the attainment demonstration and its associated motor vehicle emissions budgets only because the Commonwealth has committed to revise them with MOBILE6, or if shortfall measures are submitted. The Commonwealth submitted the requisite commitment to revise these motor vehicle emissions budgets using MOBILE6 within one year of the issuance of that model, or if shortfall measures are submitted. This commitment was subject to the comment period established in the July 28, 2000 SNPR (65 FR 46383).

B. The Commonwealth's Additional Submissions of Revisions or Other Material Relevant to the Attainment Demonstration After August 28, 2000

On July 19, 2001, the Commonwealth submitted a SIP revision with revised attainment motor vehicle emissions budgets for the Pennsylvania portion of the Philadelphia area. These motor vehicle emissions budgets are for the year 2005 and incorporate the benefits of the Federal Tier 2/Sulfur rule. The Commonwealth submitted these motor vehicle emissions budgets in response to our proposed action on the Commonwealth's attainment demonstration SIP for the Philadelphia area (64 FR 70428, December 16, 1999). As previously explained, in that proposal we required that the benefits from the Federal Tier 2/Sulfur rule be incorporated into the 2005 attainment motor vehicle emissions budgets because the attainment demonstration for the Philadelphia area relies upon the benefits of this Federal rule.

In this July 19, 2001 submittal, the Commonwealth also included an amendment to the enforceable commitments it previously had submitted as provided in our December 16, 1999 proposed action. This amendment relates to the commitment by the Commonwealth to perform a mid-course review. The amendment clarifies that the Commonwealth will submit the mid-course review to EPA by December 31, 2003. In our December 16, 1999 NPR we proposed to approve the attainment demonstration if the Commonwealth committed to conduct and submit a mid-course review to EPA by December 31, 2003 (64 FR 70428 at 70442, December 16, 1999). The July 19, 2001 submittal also contains material relating to reasonably available control measures which will be the subject of a separate proposed rulemaking.

C. The Motor Vehicle Emissions Budgets Contained Within the July 19, 2001 Revision

The July 19, 2001 revision establishes the 2005 attainment year motor vehicle emissions budgets for the Pennsylvania portion of the Philadelphia area as 60.18 tons per day of volatile organic compounds (VOC) and 77.46 tons per day of nitrogen oxides (NO_X).

D. The Relationship of the Adequacy Review Process to the Motor Vehicle Emissions Budgets Incorporating the Tier 2/Sulfur Rule Benefits

On March 2, 1999, the D.C. Circuit Court ruled that budgets contained in submitted control strategy SIPs cannot be used for conformity determinations until EPA has affirmatively found them adequate. The relationship between determining the adequacy of motor vehicle emissions budgets in a SIP versus approval of a SIP with motor vehicle emission budgets is delineated in the EPA's May 14, 1999 memo titled ''Conformity Guidance on Implementation of March 2, 1999 Conformity Court Decision.'' Control strategy SIPs include rate-of-progress plans and attainment demonstrations. Affirmative adequacy determinations allow for the use of motor vehicle emissions budgets in submitted rate-of-progress plan SIPs and attainment demonstration SIPs for transportation conformity purposes . Motor vehicle emission budgets are actually approved, or disapproved, at the time EPA takes final action to approve or disapprove the SIP itself.

PADEP's July 19, 2001 submittal of revised 2005 motor vehicle emissions budgets is posted on EPA's conformity Web site (http://www.epa.gov/oms/transp/conform/currsips.htm) noting that EPA is taking comment on the adequacy and approvability of these budgets via rulemaking. We are forgoing the standard adequacy process because by October 15, 2001, we are currently required under a consent decree to sign either: (1) A final rule fully approving the attainment demonstration for the Philadelphia area, or (2) an action proposing a Federal implementation plan to remedy any gaps in the attainment demonstration. We have reviewed the 2005 motor vehicle emission budgets submitted by the Commonwealth on July 19, 2001. Based on our review, we conclude that the revised motor vehicle emissions budgets meet the adequacy criteria in section 93.118 of the Transportation Conformity Regulations, and we propose to find the budgets adequate as well as to approve them. If we sign a final action approving the attainment demonstration for the Philadelphia area by the date specified in the consent decree, such an action will have the effect of approving these motor vehicle emissions budgets into the SIP along with the attainment demonstration negating the need for a separate finding of adequacy.

We are seeking public comments on this proposed rule including the adequacy of the motor vehicle emissions budgets and will accept such comments provided they are submitted by as specified in the **DATES** and **ADDRESSES** sections of this document. We will not hold a separate comment period on the adequacy of these budgets through the conformity web process. We will address all comments in our final rulemaking on the attainment

demonstration. Because EPA's final rule on the 2005 attainment demonstration will, defacto, determine the approvability and adequacy of that SIP's motor vehicle emissions budgets, we will not publish a separate **Federal Register** notice announcing our adequacy findings.

E. The Submitted Motor Vehicle Emissions Budgets and the Prior Restrictions on the Use of the Benefits of Federal Tier 2/Sulfur Rule in Conformity Determinations

The December 16, 1999 NPR allowed States to submit motor vehicle emissions budgets that did not reflect the benefits of EPA's Tier 2/Sulfur rule. In the NPR, we explained that conformity analyses in the Philadelphia area could begin including Tier 2/Sulfur program benefits once EPA's Tier 2/Sulfur rule was promulgated, provided that the attainment demonstration SIP and associated motor vehicle emissions budgets include the Tier 2/Sulfur benefits. For an area that requires all or some portion of the Tier 2/Sulfur benefits to demonstrate attainment but have not yet included the benefits in the motor vehicle emissions budgets, in this NPR we noted that our adequacy finding will include a condition that conformity determinations may not take credit for Tier 2/Sulfur until the SIP budgets are revised to reflect Tier 2/Sulfur benefits.

As explained above, on February 25, 2000, the Commonwealth submitted 2005-year motor vehicle emissions budgets for its portion of the Philadelphia area that did not include the benefits from the Tier 2/Sulfur rule. The 2005-year motor vehicle emissions budgets applied to two separate types of control strategy SIP revisions: (1) Rate-of-progress and (2) attainment. On May 31, 2000, EPA notified the Commonwealth that the motor vehicle emissions budgets submitted on February 25, 2000 were adequate (see 65 FR 36438, June 8, 2000). That adequacy finding included a condition precluding the use of the emission reduction benefits from the Tier 2/Sulfur rule in conformity determinations.

The effect of today's proposed action on the 2005-year attainment motor vehicle emissions budgets submitted by PADEP on July 19, 2001 (which now reflect the Tier 2/Sulfur rule benefits), should we take final action to find them adequate and approve them, would be to supplant the attainment motor vehicle emissions budgets submitted on February 25, 2000. If approved, the motor vehicle emissions budgets in the Commonwealth's July 19, 2001 SIP revision would be the budgets for the Pennsylvania potion of the Philadelphia area to which all future transportation plans and transportation improvement programs (TIPs) must conform. Approval of the July 19, 2001 submittal's budgets would remove the restriction on the use of the benefits from the Federal Tier 2/Sulfur rule when demonstrating transportation plans and TIPs conform to the motor vehicle emissions budgets in the attainment demonstration SIP for the Philadelphia area. This proposed action is intended to have no effect on the rate-of-progress motor vehicle emissions budgets for 2005. Action on the rate-of-progress plans for the Pennsylvania portion of the Philadelphia area will be the subject of a separate rulemaking action.

F. Trigger to Redetermine Conformity Within 18-Months Under Section 93.104 of the Conformity Rule

Our conformity rule establishes the frequency by which transportation plans and transportation improvement programs must be found to conform to the SIP and includes trigger events tied to both submittal and approval of a SIP (40 CFR 93.104(e)). Both initial submission and approval can trigger a redetermination of conformity because it is not uncommon for the SIP to change between initial submission and final approval (61 FR 36112, July 9, 1996). Our proposed action, should it become final, will have the effect of approving motor vehicle emissions budgets for the attainment demonstration that are substantively different than those initially submitted on February 25, 2000. We are providing advance notice to affected transportation planning agencies that a final approval of the budgets in the July 19, 2001 SIP revision will require a redetermination that existing transportation plans and TIPs conform within 18 months of the date of any such approval of these motor vehicle emissions budgets.

II. Re-opening of the Public Comment Period

We are reopening the comment period for the Commonwealth's attainment demonstration SIP revision for the Philadelphia area to address the additional information that has been placed in the docket close to or after the conclusion of the last comment period established by the July 28, 2000 SNPR that concluded on August 28, 2000. These materials consist of actions that in the December 16, 1999 notice of proposed rulemaking discussed above EPA identified as necessary for approval of the attainment demonstration for the Pennsylvania portion of the Philadelphia area. Specifically these amendments are the revised motor vehicle emissions budgets and the amendment to the enforceable commitment for a mid-course review submitted by the Commonwealth on July 19, 2001.

We are proposing to approve and find adequate for conformity purposes the motor vehicle emissions budgets and revised enforceable commitment, which were submitted on July 19, 2001, as changes to the Commonwealth's attainment demonstration SIP for the Philadelphia area. We are soliciting public comment on the issues discussed in this document. Any comments received during the comment period will be considered before EPA takes final action. Interested parties may participate in the Federal rulemaking procedure by submitting written comments to the EPA Regional office listed in the **ADDRESSES** section of this document.

III. Proposed Action

EPA is proposing to approve the revisions to the attainment plan SIP for the Philadelphia-Wilmington-Trenton severe ozone nonattainment area submitted by the Commonwealth of Pennsylvania on July 19, 2001. Those revisions consist of motor vehicle emissions budgets which reflect the Tier 2/Sulfur rule and the enforceable commitment to submit a mid-course review by December 31, 2003.

IV. Administrative Requirements

Under Executive Order 12866 (58 FR 51735, October 4, 1993), this proposed action is not a ''significant regulatory action'' and therefore is not subject to review by the Office of Management and Budget. For this reason, this action is also not subject to Executive Order 13211, ''Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use'' (66 FR 28355 (May 22, 2001)). This action merely proposes to approve state law as meeting Federal requirements and imposes no additional requirements beyond those imposed by state law. Accordingly, the Administrator certifies that this proposed rule will not have a significant economic impact on a substantial number of small entities under the Regulatory Flexibility Act (5 U.S.C. 601 *et seq.*). Because this rule proposes to approve pre-existing requirements under state law and does not impose any additional enforceable duty beyond that required by state law, it does not contain any unfunded mandate or significantly or uniquely affect small governments, as described in the Unfunded Mandates Reform Act of 1995

(Public Law 104–4). This proposed rule also does not have a substantial direct effect on one or more Indian tribes, on the relationship between the Federal Government and Indian tribes, or on the distribution of power and responsibilities between the Federal Government and Indian tribes, as specified by Executive Order 13175 (65 FR 67249, November 9, 2000), nor will it have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132 (64 FR 43255, August 10, 1999), because it merely proposes to approve a state rule implementing a Federal standard, and does not alter the relationship or the distribution of power and responsibilities established in the Clean Air Act. This proposed rule also is not subject to Executive Order 13045 (62 FR 19885, April 23, 1997), because it is not economically significant. In reviewing SIP submissions, EPA's role is to approve state choices, provided that they meet the criteria of the Clean Air Act. In this context, in the absence of a prior existing requirement for the State to use voluntary consensus standards (VCS), EPA has no authority to disapprove a SIP submission for failure to use VCS. It would thus be inconsistent with applicable law for EPA, when it reviews a SIP submission, to use VCS in place of a SIP submission that otherwise satisfies the provisions of the Clean Air Act. Thus, the requirements of section 12(d) of the National Technology Transfer and Advancement Act of 1995 (15 U.S.C. 272 note) do not apply. As required by section 3 of Executive Order 12988 (61 FR 4729, February 7, 1996), in issuing this proposed rule, EPA has taken the necessary steps to eliminate drafting errors and ambiguity, minimize potential litigation, and provide a clear legal standard for affected conduct. EPA has complied with Executive Order 12630 (53 FR 8859, March 15, 1988) by examining the takings implications of the rule in accordance with the ''Attorney General's Supplemental Guidelines for the Evaluation of Risk and Avoidance of Unanticipated Takings' issued under the executive order. This supplemental proposed rule on the Commonwealth's attainment demonstration for the Philadelphia area to include motor vehicle emission budgets which reflect the benefits of the Federal Tier 2/Sulfur rule and enforceable commitment to a mid-course review as required by EPA's December 16, 1999 proposed rulemaking does not impose an information collection burden under the provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 *et seq.*).

List of Subjects in 40 CFR Part 52

Environmental protection, Air pollution control, Hydrocarbons, Intergovernmental relations, Nitrogen dioxide, Ozone.

Authority: 42 U.S.C. 7401 *et seq.*

Dated: August 16, 2001.

Thomas C. Voltaggio,

Acting Regional Administrator, Region III.

[FR Doc. 01–21433 Filed 8–23–01; 8:45 am]

BILLING CODE 6560–50–P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 52

[MD124–3075; FRL–7043–2]

Approval and Promulgation of Air Quality Implementation Plans; Maryland; Volatile Organic Compound Control Requirements for Aerospace Coating Operations and Kraft Pulp Mills

AGENCY: Environmental Protection Agency (EPA).

ACTION: Proposed rule.

SUMMARY: EPA is proposing to approve State Implementation Plan (SIP) revisions submitted by the State of Maryland. These revisions establish reasonably available control technology (RACT) requirements to reduce emissions of volatile organic compounds (VOCs) from aerospace coating operations and kraft pulp mills. The intended effect of this action is to propose approval of two regulations to reduce VOC emissions from aerospace coating operations and kraft pulp mills. This action is being taken under the Clean Air Act.

DATES: Written comments must be received on or before September 24, 2001.

ADDRESSES: Written comments may be mailed to David L. Arnold, Chief, Air Quality Planning and Information Services Branch, Mailcode 3AP21, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103. Copies of the documents relevant to this action are available for public inspection during normal business hours at the Air Protection Division, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103; and the Maryland Department of the Environment, 2500 Broening Highway, Baltimore, Maryland.

FOR FURTHER INFORMATION CONTACT: Kristeen Gaffney, (215) 814–2092, or via e-mail at gaffney.kristeen@epamail.epa.gov. Please note that while questions may be posed via telephone and e-mail, formal comments must be submitted, in writing, as indicated in the **ADDRESSES** section of this document.

SUPPLEMENTARY INFORMATION:

I. Background

On July 2, 2001, the Maryland Department of Environment (MDE) requested that EPA parallel process the approval of two proposed or draft state regulations as SIP revisions. These regulations control VOC emissions from (1) aerospace coating operations and (2) kraft pulp mills. The draft regulations impose RACT requirements for the control of VOC emissions at affected installations. To expedite the approval of these regulations as revisions to the Maryland SIP, EPA is using the parallel rulemaking process to propose approval of Maryland's regulations concurrently with the State's own process and procedures for adopting these regulations.

Maryland is adopting and submitting these regulations pursuant to the RACT requirements of sections 182 and 184 of the Clean Air Act (the Act). Section 182(b)(2) of the Act requires states to implement RACT on all source categories for which EPA has issued a Control Techniques Guideline (CTG) document and for all ''major'' sources of VOCs located in moderate or above ozone nonattainment areas. Major VOC sources are those with the potential to emit at least 50 tons per year in moderate and serious areas and 25 tons per year in severe areas. In addition, section 184(b)(1)(B) of the Act requires states in the Ozone Transport Region (OTR) to require RACT on all sources in the state that have the potential to emit 50 tons per year or more of VOC. Because Maryland is in the OTR, the State is required to implement RACT regulations for all major sources statewide.

II. Description of Maryland's SIP Revisions and EPA's Evaluation

On July 2, 2001, the MDE submitted a request to EPA to parallel process two draft/proposed regulations as revisions to the SIP: (1) Revisions to COMAR 26.11.19.13–1 for the control of VOC emissions from aerospace coatings operations; and (2) revisions to COMAR 26.11.14.06 to control of VOCs from

kraft pulp mills. Both of these regulations apply statewide.

A. Aerospace Coating Operations

Summary of the State Regulation

COMAR 26.11.19.13–1 establishes RACT standards to control VOC emissions from aerospace coating operations statewide that emit 20 pounds or more of VOCs per day. The coating application and cleaning processes are the significant sources of VOC emissions from aerospace facilities. Maryland's regulation establishes maximum allowable VOC contents for generally used topcoats, primers and chemical milling maskants as well as for 57 types of specialty coatings used specifically in the aerospace industry. In addition to VOC content limits, facilities subject to this regulation must comply with good maintenance and cleanup requirements that include: (1) Storing all VOC containing waste materials in closed containers; (2) maintaining lids on containers of surface preparation and cleanup materials when not in use; and (3) using enclosed containers or VOC recycling equipment to clean spray gun equipment.

Under Maryland's regulation, subject facilities are required to use the testing and compliance methods and coating averaging procedures specified in 40 CFR part 63, subpart GG, ''National Emissions Standards for Aerospace Manufacturing and Rework Facilities''. Specifically, affected facilities are subject to methods of compliance for VOC content limits found in subsections 63.745(a)–(e), 63.747(a)–(e) and 63.750, as applicable, and which are incorporated by reference into COMAR 26.11.19.13–1. Subject facilities are required to keep monthly records that contain the description, volume, total weight and VOC content of each coating used. Records must be maintained for three years and made available to the State upon request.

EPA's Evaluation

In September 1999, EPA adopted 40 CFR part 63, subpart GG, National Emission Standards for Aerospace Manufacturing and Rework Facilities (Aerospace NESHAP). The Aerospace NESHAP requires existing and new major source aerospace facilities to control emissions of hazardous air pollutants, many of which are also VOCs, to the level achievable through maximum achievable control technology (MACT) consistent with section 112(d) of the Act. The control techniques required by the Aerospace NESHAP result in reductions of VOC emissions.

Additionally, in December 1997, EPA issued a Control Technique Guideline (CTG) document, ''Control of Volatile Organic Compound Emissions from Coating Operations at Aerospace Manufacturing and Rework Operations' to provide guidance to the states in determining VOC RACT for the aerospace industry. The Aerospace CTG establishes EPA's recommended level of presumptive RACT for the control of VOC emissions from primer, topcoat and specialty coatings applications, maskant application, sealing and cleaning operations. The CTG does not recommend add-on emissions control devices as RACT for the aerospace coatings industry. According to the Aerospace CTG, the principal technique used by the aerospace industry to control VOC emissions from coating applications and cleaning is product substitution. VOC emissions are controlled when products containing high concentrations of VOC are replaced with those having reduced or eliminated VOC. The CTG describes available product substitutions for coatings and cleaning solvents. Presumptive RACT for coatings used on aerospace components and vehicles are based on VOC content. The Aerospace NESHAP sets limits for maximum HAP and VOC content for topcoats, primers, maskants, clean-up solvents and cleaning operations and the CTG recommends these same content limits as presumptive RACT limits for VOCs. Furthermore, the CTG recommends VOC content limits for 57 specialty coatings, which are not covered in the Aerospace NESHAP. The Aerospace NESHAP specifies detailed requirements for monitoring, testing, record keeping and reporting.

Maryland's aerospace regulation reflects the appropriate combination of the Aerospace NESHAP and the Aerospace CTG. The VOC coating content limits in Maryland's regulation for topcoats, primers and maskants are the same as those in the Aerospace NESHAP. Maryland's regulation also adopts the VOC content limit for the 57 specialty coatings recommended in the Aerospace CTG. The complete list of VOC content limits for all coating categories are shown below. Maryland's regulation contains definitions for each coating type with a specified limit. The allowable VOC content is expressed in both pounds per gallon and grams per liter of coating applied minus water.

Coating type	Pounds/gallon (grams/liter)
Topcoats	3.5 (420)
Self-priming topcoat	3.5 (420)
Primers	2.9 (350)
Chemical Milling Maskants	1.3 (160)
Exterior primer for large commercial aircraft	5.4 (650)
Primer for general aviation rework facilities	4.5 (540)
Specialty Coatings:	
Ablative Coating	5.0 (600)
Adhesion Promotor	7.42 (890)
Adhesive Bonding Primers:	
(Cured at 250 degrees F or below)	7.09 (850)
(Cured above 250 degrees F)	8.59 (1030)
Antichafe Coating	5.50 (660)
Bearing Coating	5.17 (620)
Bonding Maskant	10.26 (1,230)
Caulking and Smoothing Compounds	7.09 (850)
Chemical Agent-Resistant Coating	4.58 (550)
Clear Coating	6.00 (720)
Commercial Exterior Aerodynamic Structure Primer	5.42 (650)
Commercial Interior Adhesive	6.34 (760)
Compatible Substrate Primer	6.50 (780)
Corrosion Prevention Compound	5.92 (710)

	Pounds/gallon (grams/liter)
Critical Use and Line Sealer Maskant	8.51 (1,020)
Cryogenic Flexible Primer	5.38 (645)
Cryoprotective Coating	5.00 (600)
Cyanoacrylate Adhesive	8.51 (1,020)
Dry Lubricative Material	7.34 (880)
Electric or Radiation-Effect Coating	6.67 (800)
Electrostatic Discharge and Electromagnetic Interference (EMI) Coating	6.67 (800)
Elevated-Temperature Skydrol-Resistant Commercial Primer	6.17 (740)
Epoxy Polyamide Topcoat	5.50 (660)
Fire-Resistant (interior) Coating	6.67 (800)
Flexible Primer	5.34 (640)
Flight-Test Coatings Missile or Single Use Aircraft	3.50 (420)
Flight-Test Coatings All Other	7.0 (840)
Fuel Tank Adhesive	5.17 (620)
Fuel Tank Coating	6.00 (720)
High-Temperature Coating	7.09 (850)
Insulation Covering	6.17 (740)
Intermediate Release Coating	6.25 (750)
Lacquer	6.9 (830)
Metallized Epoxy Coating	6.17 (740)
Mold Release	6.50 (780)
Nonstructural Adhesive	3.00 (360)
Optical Antireflective Coating	6.25 (750)
Part Marking Coating	7.09 (850)
Pretreatment Coating	6.50 (780)
Rain Erosion-Resistant Coating	7.09 (850)
Rocket Motor Bonding Adhesive	7.42 (890)
Rocket Motor Nozzle Coating	5.50 (660)
Rubber-Based Adhesive	7.09 (850)
Scale Inhibitor	7.34 (880)
Screen Print Ink	7.00 (840)
Extrudable/Rollable/Brushable Sealants	2.33 (280)
Sprayable Sealant	5.0 (600)
Seal Coat Maskant	10.26 (1,230)
Silicone Insulation Material	7.09 (850)
Solid Film Lubricant	7.34 (880)
Specialized Function Coating	7.42 (890)
Structural Autoclavable Adhesive	0.50 (60)
Structural Nonautoclavable Adhesive	7.09 (850)
Temporary Protective Coating	2.67 (320)
Thermal Control Coating	6.67 (800)
Wet Fastener Installation Coating	5.63 (675)
Wing Coating	7.09 (850)

The Aerospace CTG also recommends good work practices and low VOC cleaning solvent composition to reduce emissions from solvent cleaning operations at aerospace facilities. Maryland's regulation contains adequate requirements to control fugitive VOC emissions associated with cleaning operations. For compliance (testing and monitoring), Maryland's regulation incorporates by reference the testing and compliance methods for VOCs in the Aerospace NESHAP. Maryland's regulation incorporates by reference the test methods and procedures for primers, topcoats and maskants found in 40 CFR 63.745, 63.747 and 63.750. Maryland's rule also requires all facilities subject to the rule to maintain monthly records containing a description and the volume of each coating, the total weight and the VOC content of each coating used. Subject facilities must retain records for not less than three years and provide them to the Department upon request. Maryland's regulation contains adequate testing and record keeping requirements to determine compliance with the regulation.

Maryland's proposed/draft regulation for the control of VOC emissions at aerospace coating operations (COMAR 26.11.19.13–1) meets the requirements of the Act and EPA guidance for implementing VOC RACT at aerospace coating installations and will result in the reduction of VOC emissions from the affected sources. EPA believes that the VOC control requirements of COMAR 26.11.19.13–1 constitute an acceptable level of RACT for aerospace coating operations.

B. Control of VOCs From Kraft Pulp Mills

Summary of the State Regulation

COMAR 26.11.14 is being expanded to add a new subsection 26.11.14.06 for the control of VOC emissions from kraft pulp mills. Existing sections of COMAR 26.11.14.01–.05 pertain to control requirements for total reduced sulfur compounds. Sections 26.11.14.03–.05 are specific control requirements for total sulfur compounds. These sections are not part of Maryland's SIP revision request. Only the sections of COMAR 26.11.14 that pertain to the control of VOC emissions, specifically sections 26.11.26.14.01, .02 and .06 are being requested for approval as revisions to the SIP. Section 26.11.14.01 contains definitions and section 26.11.14.02 covers applicability. New section 26.11.14.06 establishes RACT standards to control VOC emissions from kraft

pulp mill operations statewide that have actual emissions of 20 pounds or more of VOCs per day and the potential to emit total plant-wide VOC emissions of 25 tons or more per year.

Kraft pulp mills are facilities that use an alkaline sulfide solution containing sodium hydroxide and sodium sulfide for a cooking liquor in the wood pulping process. Maryland's regulation includes definitions for pulping processes and emissions streams, including definitions for: brown stock washers, black liquor, clean condensates, combusted, condensate, condensate steam stripper, digester, digester blow tank system, evaporator, foul condensates, knotters, recovery boiler and smelt dissolving tank. The VOC emissions emanate from the pulp, cooking liquors, condensates and non-condensable gases. The VOC emission sources at the facility include the digesters, washers, screen rooms, storage tanks, sewer vents, bleach rooms, black liquor oxidizer, recovery boilers and paper machines.

Requirements to control VOC emissions are as follows. Condensates from the digester blow tank system and evaporators are to be treated in a condensate steam stripper or other control system with a 90 percent control efficiency. Condensates from the steam stripper and non-condensable exhaust gases from the digester blow tank system and evaporator shall be collected and combusted in the boiler. Wash water for the brown stock washers and smelt dissolving tanks must use either fresh or clean water and/or clean condensates. A black liquor oxidation unit is required on the recovery boiler and at least 50 percent of the flue gas generated annually from the recovery boiler must be treated with a dry bottom precipitator with a salt cake mix tank. Fugitive VOC emissions from other miscellaneous processes at the installation will be controlled by processing pulp from the brown stock washers using clean condensates and fresh/clean wash water.

Annual tests are required to demonstrate the VOC removal efficiency of the condensate steam stripper using EPA Test Method 25D found in 40 CFR part 60. Other EPA approved VOC test methods 25, 25A or 25B shall be used to test other VOC emission streams. Installations are required to submit a test protocol to MDE for approval. Test results must be submitted to MDE within 60 days and retained for at least 5 years.

EPA Evaluation

EPA has not issued a CTG on RACT for VOC emissions generated from kraft pulp mills. Maryland's regulation includes control requirements to reduce VOC emissions from specific processes including the digester blow tank system and brown stock washers, which requires the installation and use of a condensate steam stripper to remove and destroy condensates with a control efficiency of 90 percent. The VOC emissions from other processes at the facility will be controlled by requiring the use of only clean wash water which will reduce fugitive emissions throughout the entire facility. Other VOC emission streams, including noncondensable gases not stripped in the steam stripper, are collected and vented to the facilities combustion boilers for destruction. Maryland's regulation results in an estimated 50 percent reduction in VOC emissions from several process points throughout the facility. EPA believes the VOC control requirements of COMAR 26.11.14.06 are reasonable and constitute and acceptable level of RACT for kraft pulp mill facilities. The regulation also contains adequate methods for determining compliance including EPA recommended test methods and record keeping requirements.

EPA's review of this material indicates Maryland's regulations for the control of VOC emissions at aerospace coating operations and kraft pulp mills define an appropriate level of RACT, meet the requirements of sections 182 and 184 of the Clean Air Act and strengthen the Maryland SIP. EPA proposing to approve the Maryland SIP revisions for aerospace coating operations and kraft pulp mills, which were submitted on July 2, 2001.

III. Proposed Action

EPA is proposing to approve revisions submitted by the State of Maryland on July 2, 2001 pertaining to RACT requirements to reduce VOC from aerospace coating operations (COMAR 26.11.19.13–1) and kraft pulp mills (COMAR 26.11.14.01, .02 and .06). EPA is soliciting public comments on the issues discussed in this document or on other relevant matters. These comments will be considered before taking final action. Interested parties may participate in the Federal rulemaking procedure by submitting written comments to the EPA Regional office listed in the **ADDRESSES** section of this document. This revision is being proposed under a procedure called parallel processing, whereby EPA proposes rulemaking action concurrently with the state's procedures for amending its regulations. If the proposed revision is substantially changed, EPA will evaluate those changes and may publish another notice of proposed rulemaking. If no substantial changes are made, EPA will publish a Final Rulemaking Notice on the revisions. The final rulemaking action by EPA will occur only after the SIP revision has been adopted by Maryland and submitted formally to EPA for incorporation into the SIP.

IV. Administrative Requirements

Under Executive Order 12866 (58 FR 51735, October 4, 1993), this proposed action is not a ''significant regulatory action'' and therefore is not subject to review by the Office of Management and Budget. For this reason, this action is also not subject to Executive Order 13211, ''Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use'' (66 FR 28355, May 22, 2001). This action merely proposes to approve state law as meeting Federal requirements and imposes no additional requirements beyond those imposed by state law. Accordingly, the Administrator certifies that this proposed rule will not have a significant economic impact on a substantial number of small entities under the Regulatory Flexibility Act (5 U.S.C. 601 *et seq.*). Because this rule proposes to approve pre-existing requirements under state law and does not impose any additional enforceable duty beyond that required by state law, it does not contain any unfunded mandate or significantly or uniquely affect small governments, as described in the Unfunded Mandates Reform Act of 1995 (Public Law 104–4). This rule also does not have a substantial direct effect on one or more Indian tribes, on the relationship between the Federal Government and Indian tribes, or on the distribution of power and responsibilities between the Federal Government and Indian tribes, as specified by Executive Order 13175 (65 FR 67249, November 9, 2000), nor will it have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132 (64 FR 43255, August 10, 1999), because it merely proposes to approve a state rule implementing a Federal standard, and does not alter the relationship or the distribution of power and responsibilities established in the Clean Air Act. This proposed rule also is not subject to Executive Order 13045 (62 FR 19885, April 23, 1997), because it is not economically significant. In reviewing SIP submissions, EPA's role is to approve state choices, provided that

they meet the criteria of the Clean Air Act. In this context, in the absence of a prior existing requirement for the State to use voluntary consensus standards (VCS), EPA has no authority to disapprove a SIP submission for failure to use VCS. It would thus be inconsistent with applicable law for EPA, when it reviews a SIP submission, to use VCS in place of a SIP submission that otherwise satisfies the provisions of the Clean Air Act. Thus, the requirements of section 12(d) of the National Technology Transfer and Advancement Act of 1995 (15 U.S.C. 272 note) do not apply. As required by section 3 of Executive Order 12988 (61 FR 4729, February 7, 1996), in issuing this proposed rule, EPA has taken the necessary steps to eliminate drafting errors and ambiguity, minimize potential litigation, and provide a clear legal standard for affected conduct. EPA has complied with Executive Order 12630 (53 FR 8859, March 15, 1988) by examining the takings implications of the rule in accordance with the ''Attorney General's Supplemental Guidelines for the Evaluation of Risk and Avoidance of Unanticipated Takings'' issued under the executive order. This proposed rule to approve RACT requirements to reduce VOC from aerospace coating operations and kraft pulp mills does not impose an information collection burden under the provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 *et seq.*).

List of Subjects in 40 CFR Part 52

Environmental protection, Air pollution control, Hydrocarbons, Ozone, Reporting and record-keeping requirements.

Authority: 42 U.S.C. 7401 *et seq.*

Dated: August 17, 2001.

Donald S. Welsh,

Regional Administrator, Region III.

[FR Doc. 01–21435 Filed 8–23–01; 8:45 am]

BILLING CODE 6560–50–P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 52

[PA041–4151; FRL–7042–8]

Approval and Promulgation of Air Quality Implementation Plans; Pennsylvania; Reasonably Available Control Technology Requirements for Volatile Organic Compounds and Nitrogen Oxides in the Pittsburgh-Beaver Valley Area

AGENCY: Environmental Protection Agency (EPA).

ACTION: Proposed rule.

SUMMARY: EPA is proposing to remove the limited status of its approval of the Commonwealth of Pennsylvania State Implementation Plan (SIP) revision that requires all major sources of volatile organic compounds (VOC) and nitrogen oxides (NO_X) to implement reasonably available control technology (RACT) as it applies in the Pittsburgh-Beaver Valley ozone nonattainment area (the Pittsburgh area). EPA is proposing to convert its limited approval of Pennsylvania's VOC and NO_X RACT regulations to full approval because EPA has approved or is currently conducting rulemaking to approve all of the case-by-case RACT determinations submitted by Pennsylvania for the affected sources located in the Pittsburgh area. The intended effect of this action is to remove the limited nature of EPA's approval of Pennsylvania's VOC and NO_X RACT regulations as they apply in the Pittsburgh area.

DATES: Written comments must be received on or before September 24, 2001.

ADDRESSES: Written comments should be mailed to Marcia L. Spink, Associate Director, Office of Air Programs, Mailcode 3AP20, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103. Copies of the documents relevant to this action are available for public inspection during normal business hours at the Air Protection Division, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103, and the Pennsylvania Department of Environmental Protection, Bureau of Air Quality, P.O. Box 8468, 400 Market Street, Harrisburg, Pennsylvania 17105.

FOR FURTHER INFORMATION CONTACT: Marcia L. Spink, (215) 814–2104, at the EPA Region III address above, or by e-mail at *spink.marcia@epa.gov*. Please note that while questions may be posed via telephone and e-mail, formal comments must be submitted, in writing, as indicated in the **ADDRESSES** section of this document.

SUPPLEMENTARY INFORMATION:

I. Background

Pursuant to sections 182(b)(2) and 182(f) of the Clean Air Act (CAA), the Commonwealth of Pennsylvania (the Commonwealth or Pennsylvania) is required to establish and implement RACT for all major VOC and NO_X sources. State implementation plan revisions imposing reasonably available control technology (RACT) for three classes of VOC sources are required under section 182(b)(2). The categories are all sources covered by a Control Technique Guideline (CTG) document issued between November 15, 1990 and the date of attainment; all sources covered by a CTG issued prior to November 15, 1990; and all other major non-CTG sources. Section 182(f) provides that the planning requirements applicable to major stationary sources of VOC in other provisions in part D, subpart 2 (including section 182) apply to major stationary sources of NO_X.

The Pennsylvania SIP already includes approved RACT regulations for sources and source categories of VOCs covered by the pre-1990 and post-1990 CTGs. Regulations requiring RACT for all major non-CTG sources of VOC and all major sources of NO_X were to be submitted to EPA as SIP revisions by November 15, 1992 and compliance required by May of 1995. On February 4, 1994, PADEP submitted a revision to its SIP consisting of 25 Pa Code Chapters 129.91 through 129.95 to require major sources of NO_X and additional major sources of VOC emissions (not covered by a CTG) to implement RACT (non-CTG RACT rules). The February 4, 1994 submittal was amended on May 3, 1994 to correct and clarify certain presumptive NO_X RACT requirements under Chapter 129.93. As described in more detail below, EPA granted conditional limited approval of the Commonwealth's VOC and NO_X RACT regulations on March 23, 1998 (63 FR 13789), and removed the conditional aspect of the approval on May 3, 2001 (66 FR 22123).

Under section 184 of the CAA, RACT as specified in sections 182(b)(2) and 182(f)) applies throughout the ozone transport region (OTR). The entire Commonwealth is located within the OTR. Therefore, RACT is applicable statewide in Pennsylvania. The major source size generally is determined by the classification of the area in which the source is located. However, for areas located in the OTR, the major source size for stationary sources of VOC is 50 tons per year (tpy) unless the area's classification prescribes a lower major source threshold. In the Pittsburgh area, which is classified as moderate, a major source of VOC is defined as one having the potential to emit 50 tpy or more, and a major source of NO_X is defined as one having the potential to emit 100 tpy or more. In the Pittsburgh area, Pennsylvania's RACT regulations require non-CTG sources that have the potential to emit 50 tpy or more of VOC and sources which have the potential to emit 100 tpy or more of NO_X comply with RACT. The regulations contain technology-based or operational

''presumptive RACT emission limitations'' for certain major NO_X sources. For other major NO_X sources, and all major non-CTG VOC sources (not otherwise already subject to RACT under the Pennsylvania SIP), the regulations contain a ''generic'' RACT provision. A generic RACT regulation is one that does not, itself, specifically define RACT for a source or source categories but instead allows for case-by-case RACT determinations. The generic provisions of Pennsylvania's regulations allow for PADEP to make case-by-case RACT determinations that are then to be submitted to EPA as revisions to the Pennsylvania SIP.

On March 23, 1998, EPA granted conditional limited approval to the Commonwealth's generic VOC and NO_X RACT regulations (63 FR 13789). In that action, EPA stated that the conditions of its approval would be satisfied once the Commonwealth either (1) certifies that it has submitted case-by-case RACT proposals for all sources subject to the RACT requirements currently known to PADEP; or (2) demonstrates that the emissions from any remaining subject sources represent a *de minimis* level of emissions as defined in the March 23, 1998 rulemaking.

On April 22, 1999, PADEP made the required submittal to EPA, certifying that it had met the terms and conditions imposed by EPA in the conditional limited approval by submitting 485 case-by-case VOC/ NO_X RACT determinations as SIP revisions and making the demonstration described as condition 2, above. On May 3, 2001 (66 FR 22123), EPA published a rulemaking determining that Pennsylvania had satisfied the conditions imposed in its conditional limited approval. Thus, in that rulemaking, EPA removed the conditional status of its approval of the Commonwealth's generic VOC and NO_X RACT regulations on a statewide basis. The final rule removing the conditional status of Pennsylvania's VOC and NO_X RACT regulations became effective on June 18, 2001. As of that time, Pennsylvania's generic VOC and NO_X RACT regulations retained a limited approval status.

EPA's review of PADEP's and the Allegheny County Health Departments's stationary source inventories for the Pittsburgh area indicates that there are no known major sources of NO_X and/or VOC for which the PADEP has failed to submit a case-by-case RACT determination as required by its generic RACT regulations.

It should be noted that the Commonwealth has adopted and is implementing additional ''post RACT requirements'' to reduce seasonal NO_X emissions in the form of a NO_X cap and trade regulation, 25 Pa Code Chapters 121 and 123, based upon a model rule developed by the States in the OTR. That rule's compliance date is May 1999. That regulation was approved as SIP revision on June 6, 2000 (65 FR 35842). This SIP-approved regulation is more stringent than the case-by-case RACT determinations submitted by Pennsylvania for the affected sources in that it requires more total reductions in NO_X emissions from that group of sources than does their combined case-by-case RACT submittals. Pennsylvania has also adopted regulations to satisfy Phase I of the NO_X SIP call and submitted those regulations to EPA for SIP approval. Pennsylvania's SIP revision to address the requirements of the NO_X SIP Call Phase I consists of the adoption of Chapter 145—Interstate Pollution Transport Reduction and amendments to Chapter 123—Standards for Contaminants. On May 29, 2001 (66 FR 29064), EPA proposed approval of the Commonwealth's NO_X SIP call rule SIP submittal. On August 10, 2001, EPA signed its final rule approving the Commonwealth's NO_X SIP call rule SIP submittal and expects it to be published in the **Federal Register** in the near future. Subsequent Federal approval of a case-by-case RACT determination for a major source of NO_X in no way relieves that source from any applicable, and previously SIP-approved, requirements found in 25 PA Code Chapters 121, 123 and 145.

II. EPA's Action

As EPA stated in its May 3, 2001 final rule (66 FR 22123), conversion from limited to full approval would occur when EPA has approved the case-by-case RACT determinations submitted by PADEP to satisfy the condition imposed by EPA in its March 23, 1998 (63 FR 13789) final rule. EPA has approved or is currently conducting rulemaking to approve all of the case-by-case RACT determinations submitted by PADEP to satisfy the condition imposed in EPA's March 23, 1998 (63 FR 13789) final rule for affected major sources of NO_X and/ or VOC sources located in Allegheny, Armstrong, Beaver, Butler, Fayette, Washington, and Westmoreland Counties, the seven counties that comprise the Pittsburgh area.

Proposed Action

EPA is proposing to convert its limited approval of Pennsylvania's generic VOC and NO_X RACT regulations, 25 Pa Code Chapter 129.91 through 129.95, to full approval as they apply in the seven-county Pittsburgh-Beaver Valley ozone nonattainment area. EPA has approved or is currently conducting rulemaking to approve all of the case-by-case RACT determinations submitted by PADEP to satisfy the condition imposed in EPA's March 23, 1998 (63 FR 13789) final rule for affected major sources of NO_X and/or VOC sources located in Allegheny, Armstrong, Beaver, Butler, Fayette, Washington, and Westmoreland Counties, the seven counties that comprise the Pittsburgh area. Final action converting the limited approval to full approval shall occur once EPA has completed rulemaking to approve either (1) the case-by-case RACT proposals for all sources subject to the RACT requirements currently known in the Pittsburgh-Beaver area; or (2) for a sufficient number of sources such that the emissions from any remaining subject sources represent a de minimis level of emissions as defined in the March 23, 1998 rulemaking (63 FR 13789).

III. Administrative Requirements

Under Executive Order 12866 (58 FR 51735, October 4, 1993), this proposed action is not a ''significant regulatory action'' and therefore is not subject to review by the Office of Management and Budget. For this reason, this action is also not subject to Executive Order 13211, ''Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use'' (66 FR 28355, May 22, 2001). This action merely proposes to approve state law as meeting Federal requirements and imposes no additional requirements beyond those imposed by state law. Accordingly, the Administrator certifies that this proposed rule will not have a significant economic impact on a substantial number of small entities under the Regulatory Flexibility Act (5 U.S.C. 601 *et seq.*). Because this rule proposes to approve pre-existing requirements under state law and does not impose any additional enforceable duty beyond that required by state law, it does not contain any unfunded mandate or significantly or uniquely affect small governments, as described in the Unfunded Mandates Reform Act of 1995 (Public Law 104–4). This proposed rule also does not have a substantial direct effect on one or more Indian tribes, on the relationship between the Federal Government and Indian tribes, or on the distribution of power and responsibilities between the Federal Government and Indian tribes, as specified by Executive Order 13175 (65 FR 67249, November 9, 2000), nor will it have substantial direct effects on the States, on the relationship between the national government and the States, or

on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132 (64 FR 43255, August 10, 1999), because it merely proposes to approve a state rule implementing a Federal standard, and does not alter the relationship or the distribution of power and responsibilities established in the Clean Air Act. This proposed rule also is not subject to Executive Order 13045 (62 FR 19885, April 23, 1997), because it is not economically significant. In reviewing SIP submissions, EPA's role is to approve state choices, provided that they meet the criteria of the Clean Air Act. In this context, in the absence of a prior existing requirement for the State to use voluntary consensus standards (VCS), EPA has no authority to disapprove a SIP submission for failure to use VCS. It would thus be inconsistent with applicable law for EPA, when it reviews a SIP submission, to use VCS in place of a SIP submission that otherwise satisfies the provisions of the Clean Air Act. Thus, the requirements of section 12(d) of the National Technology Transfer and Advancement Act of 1995 (15 U.S.C. 272 note) do not apply. As required by section 3 of Executive Order 12988 (61 FR 4729, February 7, 1996), in issuing this proposed rule, EPA has taken the necessary steps to eliminate drafting errors and ambiguity, minimize potential litigation, and provide a clear legal standard for affected conduct. EPA has complied with Executive Order 12630 (53 FR 8859, March 15, 1988) by examining the takings implications of the rule in accordance with the ''Attorney General's Supplemental Guidelines for the Evaluation of Risk and Avoidance of Unanticipated Takings,'' issued under the executive order. This proposed rule regarding Pennsylvania's generic VOC and NO_X RACT regulations as they apply in the Pittsburgh area does not impose an information collection burden under the provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 *et seq.*).

List of Subjects in 40 CFR Part 52

Environmental protection, Air pollution control, Hydrocarbons, Nitrogen dioxide, Ozone.

Authority: 42 U.S.C. 7401 *et seq.*

Dated: August 17, 2001.

W.C. Early,

Acting Regional Administrator, Region III.

[FR Doc. 01–21431 Filed 8–23–01; 8:45 am]

BILLING CODE 6560–50–P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 52

[PA–4136b; FRL–7035–9]

Approval and Promulgation of Air Quality Implementation Plans; Pennsylvania; VOC RACT Determinations for Nine Sources in the Pittsburgh-Beaver Valley Area

AGENCY: Environmental Protection Agency (EPA).

ACTION: Proposed rule.

SUMMARY: EPA proposes to approve the State Implementation Plan (SIP) revisions submitted by the Commonwealth of Pennsylvania for the purpose of establishing and requiring reasonably available control technology (RACT) for nine major sources of volatile organic compounds (VOC). These sources are located in the Pittsburgh-Beaver Valley ozone nonattainment area. In the Final Rules section of this **Federal Register**, EPA is approving the Commonwealth's SIP revisions as a direct final rule without prior proposal because the Agency views this as a noncontroversial submittal and anticipates no adverse comments. The rationale for the approval is set forth in the direct final rule. If no adverse comments are received in response to this action, no further activity is contemplated. If EPA receives adverse comments, the direct final rule will be withdrawn and all public comments received will be addressed in a subsequent final rule based on this proposed rule. EPA will not institute a second comment period. Any parties interested in commenting on this action should do so at this time. Please note that if adverse comment is received for a specific source or subset of sources covered by an amendment, section or paragraph of this rule, only that amendment, section, or paragraph for that source or subset of sources will be withdrawn.

DATES: Comments must be received in writing by September 24, 2001.

ADDRESSES: Written comments should be addressed to David L. Arnold, Chief, Air Quality Planning and Information Services Branch, Mailcode 3AP21, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103. Copies of the documents relevant to this action are available for public inspection during normal business hours at the Air Protection Division, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103; Allegheny County Health Department, Bureau of Environmental Quality, Division of Air Quality, 301 39th Street, Pittsburgh, Pennsylvania 15201 and the Pennsylvania Department of Environmental Resources Bureau of Air Quality Control, P.O. Box 8468, 400 Market Street, Harrisburg, Pennsylvania 17105.

FOR FURTHER INFORMATION CONTACT: Rose Quinto at (215) 814–2182, the EPA Region III address above or by e-mail at *quinto.rose@epa.gov*. Please note that while questions may be posed via telephone and e-mail, formal comments must be submitted, in writing, as indicated in the **ADDRESSES** section of this document.

SUPPLEMENTARY INFORMATION: For further information, please see the information provided in the direct final action, with the same title, that is located in the ''Rules and Regulations'' section of this **Federal Register** publication.

Dated: August 09, 2001.

Thomas C. Voltaggio,

Deputy Regional Administrator, Region III.

[FR Doc. 01–21424 Filed 8–24–01; 8:45 am]

BILLING CODE 6560–50–P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 52

[PA–4133b; FRL–7037–5]

Approval and Promulgation of Air Quality Implementation Plans; Pennsylvania; VOC and NO_X RACT Determinations for Ten Individual Sources in the Pittsburgh-Beaver Valley Area

AGENCY: Environmental Protection Agency (EPA).

ACTION: Proposed rule.

SUMMARY: EPA proposes to approve the State Implementation Plan (SIP) revisions submitted by the Commonwealth of Pennsylvania for the purpose of establishing and requiring reasonably available control technology (RACT) for ten major sources of volatile organic compounds (VOC) and nitrogen oxides (NO_X). These sources are located in the Pittsburgh-Beaver Valley ozone nonattainment area. In the Final Rules section of this **Federal Register**, EPA is approving the Commonwealth's SIP revisions as a direct final rule without prior proposal because the Agency views this as a noncontroversial submittal and anticipates no adverse comments. The rationale for the

approval is set forth in the direct final rule. If no adverse comments are received in response to this action, no further activity is contemplated. If EPA receives adverse comments, the direct final rule will be withdrawn and all public comments received will be addressed in a subsequent final rule based on this proposed rule. EPA will not institute a second comment period. Any parties interested in commenting on this action should do so at this time. Please note that if adverse comment is received for a specific source or subset of sources covered by an amendment, section or paragraph of this rule, only that amendment, section, or paragraph for that source or subset of sources will be withdrawn.

DATES: Comments must be received in writing by September 24, 2001.

ADDRESSES: Written comments should be addressed to David L. Arnold, Chief, Air Quality Planning and Information Services Branch, Mailcode 3AP21, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103. Copies of the documents relevant to this action are available for public inspection during normal business hours at the Air Protection Division, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103; Allegheny County Health Department, Bureau of Environmental Quality, Division of Air Quality, 301 39th Street, Pittsburgh, Pennsylvania 15201 and the Pennsylvania Department of Environmental Resources Bureau of Air Quality Control, P.O. Box 8468, 400 Market Street, Harrisburg, Pennsylvania 17105.

FOR FURTHER INFORMATION CONTACT: Janice Lewis at (215) 814–2185 or Betty Harris at (215) 814–2168, the EPA Region III address above or by e-mail at *lewis.janice@epa.gov* or *harris.betty@epa.gov*. Please note that while questions may be posed via telephone and e-mail, formal comments must be submitted, in writing, as indicated in the **ADDRESSES** section of this document.

SUPPLEMENTARY INFORMATION: For further information, please see the information provided in the direct final action, with the same title, that is located in the ''Rules and Regulations'' section of this **Federal Register** publication.

Dated: August 10, 2001.

Judith Katz,

Acting Regional Administrator, Region III.

[FR Doc. 01–21428 Filed 8–23–01; 8:45 am]

BILLING CODE 6560–50–P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 52

[PA–4144b; FRL–7041–2]

Approval and Promulgation of Air Quality Implementation Plans; Pennsylvania; VOC and NO_X RACT Determinations for Ten Individual Sources in the Pittsburgh-Beaver Valley Area

AGENCY: Environmental Protection Agency (EPA).

ACTION: Proposed rule.

SUMMARY: EPA proposes to approve the State Implementation Plan (SIP) revisions submitted by the Commonwealth of Pennsylvania for the purpose of establishing and requiring reasonably available control technology (RACT) for ten major sources of volatile organic compounds (VOC) and/or nitrogen oxides (NO_X). These sources are located in the Pittsburgh-Beaver Valley ozone nonattainment area. In the Final Rules section of this **Federal Register**, EPA is approving the Commonwealth's SIP revisions as a direct final rule without prior proposal because the Agency views this as a noncontroversial submittal and anticipates no adverse comments. The rationale for the approval is set forth in the direct final rule. If no adverse comments are received in response to this action, no further activity is contemplated. If EPA receives adverse comments, the direct final rule will be withdrawn and all public comments received will be addressed in a subsequent final rule based on this proposed rule. EPA will not institute a second comment period. Any parties interested in commenting on this action should do so at this time. Please note that if adverse comment is received for a specific source or subset of sources covered by an amendment, section or paragraph of this rule, only that amendment, section, or paragraph for that source or subset of sources will be withdrawn.

DATES: Comments must be received in writing by September 24, 2001.

ADDRESSES: Written comments should be addressed to David L. Arnold, Chief, Air Quality Planning and Information Services Branch, Mailcode 3AP21, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103. Copies of the documents relevant to this action are available for public inspection during normal business hours at the Air Protection Division, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103; Allegheny County Health Department, Bureau of Environmental Quality, Division of Air Quality, 301 39th Street, Pittsburgh, Pennsylvania 15201 and the Pennsylvania Department of Environmental Resources Bureau of Air Quality Control, P.O. Box 8468, 400 Market Street, Harrisburg, Pennsylvania 17105.

FOR FURTHER INFORMATION CONTACT: Janice Lewis at (215) 814–2185 or Betty Harris at (215) 814–2168, the EPA Region III address above or by e-mail at *lewis.janice@epa.gov* or harris.betty@epa.gov. Please note that while questions may be posed via telephone and e-mail, formal comments must be submitted, in writing, as indicated in the **ADDRESSES** section of this document.

SUPPLEMENTARY INFORMATION: For further information, please see the information provided in the direct final action, with the same title, that is located in the ''Rules and Regulations'' section of this **Federal Register** publication.

Dated: August 15, 2001.

Thomas C. Voltaggio,

Acting Regional Administrator, Region III.

[FR Doc. 01–21426 Filed 8–23–01; 8:45 am]

BILLING CODE 6560–50–P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 52

[PA–4146b; FRL–7040–7]

Approval and Promulgation of Air Quality Implementation Plans; Pennsylvania; NO_X RACT Determination for Koppel Steel Corporation in the Pittsburgh-Beaver Valley Area

AGENCY: Environmental Protection Agency (EPA).

ACTION: Proposed rule.

SUMMARY: EPA is proposing to approve a revision to the Commonwealth of Pennsylvania's State Implementation Plan (SIP). The revision was submitted by the Pennsylvania Department of Environmental Protection (PADEP) to establish and require reasonably available control technology (RACT) for the Koppel Steel Corporation's Ambridge Plant, a major source of nitrogen oxides (NO_X) located in the Pittsburgh-Beaver Valley ozone nonattainment area (the Pittsburgh area). In the Final Rules section of this

Federal Register, EPA is approving the Commonwealth's SIP revision as a direct final rule without prior proposal because the Agency views this as a noncontroversial submittal and anticipates no adverse comments. The rationale for the approval is set forth in the direct final rule. If no adverse comments are received in response to this action, no further activity is contemplated. If EPA receives adverse comments, the direct final rule will be withdrawn and all public comments received will be addressed in a subsequent final rule based on this proposed rule. EPA will not institute a second comment period. Any parties interested in commenting on this action should do so at this time.

DATES: Comments must be received in writing by September 24, 2001.

ADDRESSES: Written comments should be addressed to David L. Arnold, Chief, Air Quality Planning and Information Services Branch, Mailcode 3AP21, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103. Copies of the documents relevant to this action are available for public inspection during normal business hours at the Air Protection Division, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103; and the Pennsylvania Department of Environmental Resources Bureau of Air Quality Control, P.O. Box 8468, 400 Market Street, Harrisburg, Pennsylvania 17105.

FOR FURTHER INFORMATION CONTACT: Michael Ioff at (215) 814–2166, the EPA Region III address above or by e-mail at ioff.mike@epa.gov. Please note that while questions may be posed via telephone and e-mail, formal comments must be submitted, in writing, as indicated in the **ADDRESSES** section of this document.

SUPPLEMENTARY INFORMATION: For further information, please see the information provided in the direct final action, with the same title, that is located in the ''Rules and Regulations'' section of this **Federal Register** publication.

Dated: August 15, 2001.

Thomas C. Voltaggio,

Acting Regional Administrator, Region III.

[FR Doc. 01–21430 Filed 8–23–01; 8:45 am]

BILLING CODE 6560–01–P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Parts 52 and 62

[CT067–7224; A–1–FRL–7043–3]

Approval and Promulgation of Air Quality Implementation Plans; Connecticut; Revisions to State Plan for Municipal Waste Combustors and Incorporation of Regulation Into State Implementation Plan for Ozone

AGENCY: Environmental Protection Agency (EPA).

ACTION: Proposed rule.

SUMMARY: The EPA is proposing to approve revisions to Connecticut's State Plan for Municipal Waste Combustors (MWC) submitted by the Connecticut Department of Environmental Protection on November 28, 2000 and June 4, 2001. The MWC State Plan implements and enforces provisions at least as protective as the EPA's Emission Guidelines (EGs) applicable to existing MWC units with capacity to combust more than 250 tons per day of municipal solid waste. Further, the EPA is proposing to approve a State Implementation Plan (SIP) revision submitted by the State of Connecticut on June 4, 2001. This is a SIP-strengthening revision that incorporates the nitrogen oxide limits and related regulatory provisions of Connecticut's adopted Regulation Section 22a–174–38 Municipal Waste Combustors into the SIP to further reduce emissions of nitrogen oxides (NO_X) from MWC units. These actions are being taken under the Clean Air Act.

DATES: Written comments must be received on or before September 24, 2001.

ADDRESSES: Comments may be mailed to David Conroy, Unit Manager, Air Quality Planning Unit, Office of Ecosystem Protection (mail code CAQ), U.S. Environmental Protection Agency, EPA New England, One Congress Street, Suite 1100, Boston, MA 02114–2023. Copies of the State submittal and the EPA's technical support document are available for public inspection during normal business hours, by appointment at the Office of Ecosystem Protection, U.S. Environmental Protection Agency, EPA New England, One Congress Street, 11th floor, Boston, MA and the Bureau of Air Management, Department of Environmental Protection, State Office Building, 79 Elm Street, Hartford, CT 06106–1630.

FOR FURTHER INFORMATION CONTACT: Daniel Brown at (617) 918–1532 or *brown.dan@epa.gov.*

SUPPLEMENTARY INFORMATION: In the following text the terms ''we,'' ''us,'' or ''our'' mean the EPA. This notice is organized according to the following Table of Contents.

I. What Revisions to the MWC State Plan and Ozone State Implementation Plan Did Connecticut Submit to EPA?

A. Connecticut's November 28, 2000 Submittal

On November 28, 2000, the Connecticut Department of Environmental Protection (CT DEP) submitted a revision to its State Plan to implement the Municipal Waste Combustor Emission Guidelines and New Source Performance Standards. The November submittal consisted of the revised Connecticut regulation 22a–174–38 (Section 38) which CT DEP adopted and which became effective on October 26, 2000, a statement of changes made to Section 38, and documentation of a public hearing.

The changes made to Section 38 included revisions to the definitions, emission limits and compliance schedule as discussed below.

1. Definitions

There was a minor revision to the definition of ''NO_X emission reduction credit'' or ''ERC'' in Section 38 (a)(21) to make this definition consistent with other CT DEP usage.

2. Emission Limits

Emission limits in Section 38(c) Table 38–1 were revised to add sulfur dioxide (SO_2) limits for mass burn waterwall combustors for which construction commenced after December 20, 1989. The new emission limits are 29 ppmv SO^2 or an 80% reduction by weight or volume. These emission limits are more stringent than the federal requirements for SO_2 for MWCs constructed after December 20, 1989 (30 ppmv or 80% reduction).

Emissions limits in Section 38(c) Table 38–1 were revised to add hydrogen chloride (HCl) emission limits for mass burn waterwall combustors for which construction commenced after December 20, 1989. The HCl emission

limits are 25 ppmv or a 95 percent reduction by weight or volume. These emission limits are equivalent to the federal requirements for HCl for MWCs constructed after December 20, 1989.

Emissions limits in Section 38(c) Table 38–3 were revised to add NO_X emission limits for mass burn waterwall combustors for which construction commenced after December 20, 1989 and on or before September 20, 1994. The NO_X emission limits are 180 ppmv, which conforms with the federal requirements for NO_X for mass burn waterwall MWCs constructed after December 20, 1989.

B. Connecticut's June 4, 2001 Submittal

On June 4, 2001, the CT DEP submitted a request for parallel processing of proposed revisions to its State Implementation Plan for Ozone (SIP). Under the parallel processing procedure, we work closely with the CT DEP while it is developing its revision to its SIP. The State submits a copy of the proposed SIP revision to us concurrent with its public hearing. We review this proposed state action, and prepare a notice of proposed rulemaking to be published in the **Federal Register**. Thus, we provide for concurrent public comment periods on both the state action and Federal action. After the CT DEP submits the formal MWC Plan and SIP revision request (including a final state rule and response to all public comments raised during the State's public participation process), we will prepare a final rulemaking notice. If the CT DEP's formal SIP submittal contains changes which occur after the EPA's notice of proposed rulemaking, such changes must be described in our final rulemaking action. If the changes are significant, then we must decide whether it is appropriate to re-propose the state's action.

The June 4, 2001, request for parallel processing consisted of the revised Connecticut regulation 22a–174–38 (Section 38) which Connecticut adopted and which became effective on October 26, 2000, a request that the adopted Section 38 be incorporated into the SIP to further reduce NO_X emissions from MWC units, and a calculation of the additional NO_X reductions anticipated.

The revised Section 38 included additional NO_X emission limits and compliance schedules that were previously adopted in the state regulation but were never submitted to the EPA for approval. Specifically, emission limits in Section 38(c) were revised by adding a new ''Table 38–3a Additional Nitrogen Oxide Emission Limits.'' Table 38–3a adds more stringent NO_X limits that MWC owners and operators must comply with by May 1, 2003. These ''Phase II'' NO_X limits are more stringent than the federal requirements for NO_X for MWC units and are included in Table 1 along with the existing Phase I limits for comparison. In addition to the Phase II NO_X emission limits, the compliance schedule in Section 38(m) is revised to add a deadline of May 1, 2003, by which time MWC owners and operators must meet the new Phase II NO_X emission limits.

The Phase II NO_X emission limits and compliance schedule were adopted into Section 38, which became effective on October 26, 2000. However, the regulatory text was not submitted to the EPA with the November 28, 2000 SIP revision and CT DEP did not request this revision be made to MWC State Plan at that time. In its June 4, 2001 SIP submittal, CT DEP is now requesting that we approve these more stringent NO_X limits and compliance schedule into the MWC State Plan.

In addition, CT DEP requested that the NO_X limits and related regulatory provisions in its adopted Section 38 be incorporated into the SIP since the state will achieve further NO_X emission reductions from MWC units. The SIP submittal presented an analysis of the additional NO_X reductions expected from the Phase II NO_X limits. Connecticut DEP projected annual heat input for MWC units based on a projected utilization rate of 90 percent of the maximum rated capacity of the affected MWC units. The statewide NO_X reductions achieved by the Phase II NO_X limits were then calculated relative to reductions already achieved by Connecticut's NO_X Rule that requires reasonably available control technology (RACT) to be applied to major sources of NO_X. The reductions achieved by NO_X RACT have already been included in the SIP and, therefore, only Phase II reductions beyond NO_X RACT reductions are creditable as additional NO_X reductions. The Phase II limits are expected to achieve a creditable NO_X reduction of 592 tons per year, 248 tons per ozone season, and 1.62 tons per summer day.

TABLE 1.—EXISTING ''PHASE I'' NO_X EMISSION LIMITS AND ADDITIONAL ''PHASE II'' NO_X EMISSION LIMITS IN CONNECTICUT REG. SEC. 22A–174–38 TABLE 38–3 AND TABLE 38–3A

Municipal waste combustor yTechnology	NO_X emission limit (ppmv) [1]	
	Phase I	Phase II
Mass Burn Refractory Combustor	185	177
Mass Burn Waterwall Combustor for which construction commenced on or before December 20, 1989 [2]	205	200
Mass Burn Waterwall Combustor for which construction commenced after December 20, 1989 [3], and on or before September 20, 1994	180	177
Mass Burn Waterwall Combustor for which construction commenced after September 20, 1994:		
For one-year period following initial performance test	180	177
For period of time subsequent to one-year period above	150	150
Processed-Municipal Solid Waste Combustor	220	146
Reciprocating Grate Waste Tire Fired Incinerator/Boiler	79	N/A

[1] Corrected to seven percent oxygen, dry basis, or equivalent percentage carbon dioxide as specified In CT Sec. 22a–174–38.
[2] The Phase II Limits apply to combustors for which construction commenced on or before December 31, 1985.
[3] The Phase II Limits apply to combustors for which construction commenced after December 31, 1985.

II. Why Did Connecticut Submit Revisions to the MWC State Plan and SIP?

The CT DEP submitted attainment demonstrations for both the Southwest Connecticut nonattainment area and the Greater Connecticut nonattainment area on September 16, 1998. The EPA published proposed rulemaking regarding CT DEP's attainment demonstration for the Southwest Connecticut nonattainment area on December 16, 1999 (64 FR 70348). The proposal indicated that the attainment analysis for Southwest Connecticut did

not prove attainment by 2007. Specifically, the EPA calculated a 5 ppb shortfall between the future year modeled ozone values and the ozone standard. Based on this shortfall, we proposed conditional approval of the attainment demonstration and developed additional emission reduction targets of 3.8 percent VOC and 0.3 percent NO_X reductions from the 1990 baseline as one of the conditions for approval. These additional emission reductions needed for attainment are referred to as the ''shortfall.''

In response to the EPA's conditional approval of the attainment demonstration, CT DEP submitted a SIP revision concerning addenda to the ozone attainment demonstrations for Greater Connecticut and Southwest Connecticut on February 8, 2000. The February submittal committed to adopt additional NO_X emission limits applicable to MWC units and to submit these regulations to the EPA by December 31, 2000.

On November 28, 2000 CT DEP submitted a revision to the MWC Plan. The revision included revised Connecticut regulation 22a–174–38 which Connecticut adopted and which became effective on October 26, 2000. The revised regulation established more stringent ''Phase II'' NO_X limits for MWC units which MWC owners and operators must comply with no later than May 1, 2003. However, at that time, Connecticut did not request that the Phase II NO_X limits be incorporated into the MWC Plan and the provisions related to the Phase II standards were struck out of the regulatory text submitted to us.

On June 4, 2001, Connecticut submitted a revision to the MWC Plan and the SIP formally requesting that EPA incorporate the state adopted MWC regulations, including the Phase II NO_X limits, into the MWC Plan and the SIP. The Phase II NO_X standards further reduce emissions of NO_X from MWC units and partially addresses the shortfall of additional VOC and NO_X emission reductions needed for attainment of the ozone standard in Southwest Connecticut.

Connecticut's original MWC Plan was developed for implementing the MWC emission guidelines and was submitted to the EPA on October 12, 1999. On December 19, 1995, according to sections 111 and 129 of the Clean Air Act (Act), the EPA issued new source performance standards (NSPS) applicable to new MWCs and emissions guidelines (EG) applicable to existing MWCs. The NSPS and EG are codified at 40 CFR Part 60, Subparts Eb and Cb, respectively. *See* 60 FR 65387. Subparts Cb and Eb regulate the following: particulate matter, opacity, sulfur dioxide, hydrogen chloride, oxides of nitrogen, carbon monoxide, lead, cadmium, mercury, and dioxin and dibenzofurans. Subparts Eb and Cb apply only to MWC units with individual capacity to combust more than 250 tons/day of municipal solid waste (large MWC units).

Connecticut's October 1999 plan contained state regulation Sec. 22a–174–38 for MWC units (Section 38). Section 38 included ''Phase I'' NO_X emission limits (see Table 1) and a NO_X emission trading program. The regulation also included emission limits for particulate matter, cadmium, lead, mercury, sulfur dioxide, hydrogen chloride, dioxin/furan and opacity. The EPA approved the plan and Section 38 by a direct final rule on April 20, 2000 (65 FR 21354). Please refer to that notice for more information.

III. What Action Is the EPA Taking Today?

We are proposing to approve the revisions to the MWC Plan and SIP which were submitted by CT DEP on November 28, 2000 and June 4, 2001. Our review of Connecticut's November 28, 2000 and June 4, 2001 submittals indicates that the revisions to the MWC Plan are at least as protective as the emission guidelines applicable to existing MWC units with capacity to combust more than 250 tons per day of municipal solid waste. Connecticut's MWC Plan, as approved by EPA, covers only large, existing MWC units. Small and new units are not subject to the requirements of 40 CFR part 60, subpart Cb and are not subject to this approval of the MWC Plan under sections 111(d) and 129 of the Act. Connecticut's additional mercury emission limits of 0.028 mg/dscm or 85 percent reduction by weight are not proposed as part of the MWC Plan, and will not be federally enforceable. Connecticut's shutdown provisions for mass burn refractory units are also not proposed for inclusion in the MWC Plan.

We are proposing to approve the NO_X emission limits and related regulatory provisions of Connecticut's MWC rule sec. 22a–174–38 into Connecticut's ozone SIP. We are proposing approval of this SIP-strengthening revision under section 110 of the Act.

Connecticut DEP has demonstrated its legal authority to adopt emission standards and compliance schedules applicable to the designated facilities; enforce applicable laws, regulations, standards and compliance schedules; seek injunctive relief; obtain information necessary to determine compliance; require record keeping; conduct inspections and tests; require the use of monitors; require emission reports of owners and operators; and make emission data publicly available.

The November 28, 2000 submittal also included documentation of adequate public notice and public hearing. As indicated above, the June 4, 2001 submittal requested parallel processing to facilitate expeditious approval into the SIP by October 2001. Connecticut DEP issued a public hearing notice on June 1, 2001 and held a public hearing on July 10, 2001 and is preparing a final SIP revision concurrent with our proposed approval.

We are soliciting public comments on the revisions discussed in this notice or on other relevant matters. These comments will be considered before we take final action. Interested parties may participate in the Federal rulemaking procedure by submitting written comments to the EPA New England office listed in the **ADDRESSES** section of this action.

Nothing in this action should be construed as permitting or allowing or establishing a precedent for any future request for revision to any State implementation plan. Each request for revision to the State implementation plan shall be considered separately in light of specific technical, economic, and environmental factors and in relation to relevant statutory and regulatory requirements.

IV. What Are the Administrative Requirements?

Under Executive Order 12866 (58 FR 51735, October 4, 1993), this action is not a ''significant regulatory action'' and therefore is not subject to review by the Office of Management and Budget. For this reason, this action is also not subject to Executive Order 13211, ''Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use'' (66 FR 28355, May 22, 2001). This action merely approves state law as meeting federal requirements and imposes no additional requirements beyond those imposed by state law. Accordingly, the Administrator certifies that this rule will not have a significant economic impact on a substantial number of small entities under the Regulatory Flexibility Act (5 U.S.C. 601 *et seq.*). Because this rule approves pre-existing requirements under state law and does not impose any additional enforceable duty beyond that required by state law, it does not contain any unfunded mandate or significantly or uniquely affect small governments, as described in the

Unfunded Mandates Reform Act of 1995 (Public Law 104–4). This rule also does not have a substantial direct effect on one or more Indian tribes, on the relationship between the Federal Government and Indian tribes, or on the distribution of power and responsibilities between the Federal Government and Indian tribes, as specified by Executive Order 13175 (65 FR 67249, November 9, 2000), nor will it have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132 (64 FR 43255, August 10, 1999), because it merely approves a state rule implementing a federal standard, and does not alter the relationship or the distribution of power and responsibilities established in the Clean Air Act. This rule also is not subject to Executive Order 13045 (62 FR 19885, April 23, 1997), because it is not economically significant.

In reviewing SIP submissions, EPA's role is to approve state choices, provided that they meet the criteria of the Clean Air Act. In this context, in the absence of a prior existing requirement for the State to use voluntary consensus standards (VCS), EPA has no authority to disapprove a SIP submission for failure to use VCS. It would thus be inconsistent with applicable law for EPA, when it reviews a SIP submission, to use VCS in place of a SIP submission that otherwise satisfies the provisions of the Clean Air Act. Thus, the requirements of section 12(d) of the National Technology Transfer and Advancement Act of 1995 (15 U.S.C. 272 note) do not apply. As required by section 3 of Executive Order 12988 (61 FR 4729, February 7, 1996), in issuing this rule, EPA has taken the necessary steps to eliminate drafting errors and ambiguity, minimize potential litigation, and provide a clear legal standard for affected conduct. EPA has complied with Executive Order 12630 (53 FR 8859, March 15, 1988) by examining the takings implications of the rule in accordance with the ''Attorney General's Supplemental Guidelines for the Evaluation of Risk and Avoidance of Unanticipated Takings'' issued under the executive order. This rule does not impose an information collection burden under the provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 *et seq.*)

List of Subjects

40 CFR Part 52

Air pollution control, Intergovernmental relations, Nitrogen dioxide, Ozone, Reporting and recordkeeping requirements.

40 CFR Part 62

Administrative practice and Procedures, Air pollution control, Intergovernmental relations, Reporting and recordkeeping requirements, Waste treatment and disposal.

Authority: 42 U.S.C. 7401 *et seq.*

Dated: August 15, 2001.

Robert W. Varney,

Regional Administrator, EPA New England.

[FR Doc. 01–21442 Filed 8–23–01; 8:45 am]

BILLING CODE 6560–50–P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 140

[FRL–7043–1]

Extension of Comment Period for Proposed Rule To Establish a No Discharge Zone (NDZ) for State Waters Within the Boundaries of the Florida Keys National Marine Sanctuary (FKNMS)

AGENCY: Environmental Protection Agency (EPA).

ACTION: Proposed rule; extension of comment period.

SUMMARY: EPA is proposing to establish a NDZ for State Waters within the boundaries of the FKNMS pursuant to section 312(f)(4)(A) of the Clean Water Act. This proposed rule was published in the **Federal Register** on July 26, 2001 (66 FR 38967–38969). In response to concerns from the boating community, the comment period for this action will be extended for an additional 60 days, from August 27, 2001, to October 26, 2001.

DATES: Comments must now be submitted to EPA on or before October 26, 2001.

ADDRESSES: Written comments or requests for information may be submitted to Wesley B. Crum, Chief, Coastal Section, EPA Region 4, 61 Forsyth Street, Atlanta, Georgia 30303–8960.

FOR FURTHER INFORMATION CONTACT: Wesley B. Crum at (404) 562–9352.

A. Stanley Meiburg,

Acting Regional Administrator, Region 4.

[FR Doc. 01–21445 Filed 8–23–01; 8:45 am]

BILLING CODE 6560–50–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

42 CFR Parts 416, 482, and 485

[CMS–3070–CN]

RIN 0938–AK95

Medicare and Medicaid Programs; Hospital Conditions of Participation: Anesthesia Services

AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.

ACTION: Correction notice.

SUMMARY: This document corrects a technical error that appeared in the proposed rule published in the **Federal Register** on July 5, 2001 entitled, ''Medicare and Medicaid Programs; Hospital Conditions of Participation: Anesthesia Services.''

DATE: This correction is made on August 24, 2001.

FOR FURTHER INFORMATION CONTACT: Stephanie Dyson, RN (410) 786–9226; Jeannie Miller, RN (410) 786–3164.

SUPPLEMENTARY INFORMATION:

Background

In the July 5, 2001 proposed rule entitled, ''Hospital Conditions of Participation: Anesthesia Services,'' there was a technical error in the preamble.

In the first sentence of the **ADDRESSES** section, we listed an incorrect zip code for the mailing address for submission of written comments on the proposed regulation. We are correcting the zip code for the comments from 21207–8013 to 21244–8013. The complete address for written, mailed comments is: Health Care Financing Administration, Department of Health and Human Services, Attention: HCFA–3070–P, P.O. Box 8013, Baltimore, MD 21244–8013.

Correction of Errors

In FR Doc. 01–16964 of July 5, 2001 (66 FR 35395), we are making the following correction:

Corrections to Preamble

In the first sentence of the **ADDRESSES** section (page 35395), we are correcting the zip code for mailed comments from 21207–8013 to 21244–8013.

(Catalog of Federal Domestic Assistance Program No. 93.778, Medical Assistance Program)

(Catalog of Federal Domestic Assistance Program No. 93.733, Medicare—Hospital Insurance; and Program No.

93.744, Medicare—Supplementary Medical Insurance Program)

Dated: August 21, 2001.

Brian P. Burns,

Deputy Assistant Secretary of Information Resources Management.

[FR Doc. 01–21574 Filed 8–23–01; 8:45 am]

BILLING CODE 4120–01–P

FEDERAL COMMUNICATIONS COMMISSION

47 CFR Part 73

[DA 01–1862; MM Docket No. 01–179, RM–10199; MM Docket No. 01–180, RM–10200; MM Docket No. 01–181, RM–10201; MM Docket No. 01–182, RM–10202]

Radio Broadcasting Services; Port St. Joe, FL; Holdenville, OK; Wapanucka, OK; and Clarksville, TX

AGENCY: Federal Communications Commission.

ACTION: Proposed rule.

SUMMARY: This document proposes four allotments. The Commission requests comments on a petition filed by Cecil P. Staton, proposing the allotment of Channel 242A at Port St. Joe, Florida, as the community's second local aural transmission service. Channel 242A can be allotted to Port St. Joe in compliance with the Commission's minimum distance separation requirements with a site restriction of 2.1 km (1.3 miles) southeast of Port St. Joe. The coordinates for Channel 242A at Port St. Joe are 29–48–00 North Latitude and 85–17–03 West Longitude. The Commission requests comment on a petition filed by Katherine Pyeatt proposing the allotment of Channel 265A at Holdensville, Oklahoma, as the community's first local competing FM transmission service. Channel 265A can be allotted to Holdenville in compliance with the Commission's minimum distance separation requirements with a site restriction of 10.6 km (6.6 miles) west of Holdenville. The coordinates for Channel 265A at Holdenville are 35–04–53 North Latitude and 96–31–00 West Longitude.

The Commission further requests comment on a petition filed by Katherine Pyeatt proposing the allotment of Channel 298A at Wapanucka, Oklahoma, as the community's first local aural transmission service. Channel 298A can be allotted to Wapanucka in compliance with the Commission's minimum distance separation requirements with a site restriction of 2.9 km (1.8 miles) west of Wapanucka. The coordinates for Channel 298A at Wapanucka are 34–21–54 North Latitude and 96–23–47 West Longitude. The Commission further requests comment on a petition filed by Katherine Pyeatt proposing the allotment of Channel 294A at Clarksville, Texas, as the community's first local competing FM transmission service. Channel 294A can be allotted to Clarksville at center city coordinates in compliance with the Commission's minimum distance separation requirements. The coordinates for Channel 294A at Clarksville are 33–36–36 North Latitude and 95–03–06 West Longitude.

DATES: Comments must be filed on or before September 24, 2001, and reply comments on or before October 9, 2001.

ADDRESSES: Federal Communications Commission, Washington, DC 20554. In addition to filing comments with the FCC, interested parties should serve the petitioner, his counsel, or consultant, as follows: Cecil P. Staton, 6316 Peake Road, Macon, GA 31210; and Katherine Pyeatt, 6655 Aintree Circle, Dallas, TX 75214.

FOR FURTHER INFORMATION CONTACT: Deborah A. Dupont, Mass Media Bureau (202) 418–7072.

SUPPLEMENTARY INFORMATION: This is a synopsis of the Commission's Notice of Proposed Rule Making, MM Docket Nos. 01–179, 01–180, 01–181, and 01–182, adopted July 25, 2001, and released August 3, 2001. The full text of this Commission decision is available for inspection and copying during normal business hours in the FCC Reference Information Center (Room CY–A257), 445 12th Street, S.W., Washington, D.C. The complete text of this decision may also be purchased from the Commission's copy contractor, International Transcription Service, Inc., (202) 857–3800, 1231 20th Street, N.W., Washington, D.C. 20036.

The Provisions of the Regulatory Flexibility Act of 1980 do not apply to this proceeding. Members of the public should note that from the time a Notice of Proposed Rule Making is issued until the matter is no longer subject to Commission consideration or court review, all *ex parte* contacts are prohibited in Commission proceedings, such as this one, which involve channel allotments. See 47 CFR 1.1204(b) for rules governing permissible *ex parte* contacts.

For information regarding proper filing procedures for comments, see 47 CFR 1.415 and 1.420.

List of Subjects in 47 CFR Part 73

Radio broadcasting.

For the reasons discussed in the preamble, the Federal Communications Commission proposes to amend 47 CFR Part 73 as follows:

PART 73—RADIO BROADCAST SERVICES

1. The authority citation for Part 73 continues to read as follows:

Authority: 47 U.S.C. §§ 154, 303, 334 and 336.

§ 73.202 [Amended]

2. Section 73.202(b), the Table of FM Allotments under Florida, is amended by adding Channel 242A at Port St. Joe.

3. Section 73.202(b), the Table of FM Allotments under Oklahoma, is amended by adding Channel 265A at Holdenville and adding Wapanucka, Channel 298A.

4. Section 73.202(b), the Table of FM Allotments under Texas, is amended by adding Channel 294A at Clarksville.

Federal Communications Commission.

John A. Karousos,

Chief, Allocations Branch, Policy and Rules Division, Mass Media Bureau.

[FR Doc. 01–21408 Filed 8–23–01; 8:45 am]

BILLING CODE 6712–01–P

FEDERAL COMMUNICATIONS COMMISSION

47 CFR Part 73

[DA No. 01–1906; MM Docket No. 01–186, RM–9976]

Radio Broadcasting Services; Honor, Bear Lake, Ludington & Walhalla, MI

AGENCY: Federal Communications Commission.

ACTION: Proposed rule.

SUMMARY: This document requests comments on a petition filed by Northern Radio of Michigan, Inc. proposing the substitution of Channel 264C3 for Channel 264A at Honor, Michigan, and modification of the license for Station WIAR to specify operation on Channel 264C3. The coordinates for Channel 264C3 at Honor are 44–37–25 and 86–00–19. To accommodate the allotment at Honor, we shall propose the substitution of Channel 2291A for Channel 261A at Bear Lake, Michigan, and modification of the license for Station WSRQ to specify operation on Channel 291A at coordinates 44–17–30 and 86–13–30; substitution of Channel 254A for Channel 292A at Ludington, Michigan, and modification of the license for Station WKLA at coordinates 44–03–27 and 86–24–58; and substitution of

Channel 293A for vacant Channel 255A at Walhalla, Michigan, at coordinates 44–00–18 and 86–08–16. Canadian concurrence will be requested for the allotments at Honor, Bear Lake, Ludington and Walhalla, Michigan. In accordance with Section 1.420(g) of the Commission's Rules, we will not accept competing expressions of interest for the use of Channel 264C3 at Honor, or require petitioner to demonstrate the availability of an additional equivalent class channel for use by such parties.

DATES: Comments must be filed on or before October 1, 2001, and reply comments on or before October 16, 2001.

ADDRESSES: Federal Communications Commission, Washington, DC 20554.

In addition to filing comments with the FCC, interested parties should serve the petitioner's counsel, as follows: Harry C. Martin, Jennifer Dine Wagner, Fletcher, Heald & Hildreth, PLC, 1300 North 17th Street, 11th Floor, Arlington, Virginia 22209.

FOR FURTHER INFORMATION CONTACT: Kathleen Scheuerle, Mass Media Bureau, (202) 418–2180.

SUPPLEMENTARY INFORMATION: This is a summary of the Commission's Notice of Proposed Rule Making, MM Docket No. 01–186, adopted August 1, 2001, and released August 10, 2001. The full text of this Commission decision is available for inspection and copying during normal business hours in the Commission's Reference Center, Washington, DC. The complete text of this decision may also be purchased from the Commission's copy contractors, International Transcription Services, Inc., 1231 20th Street, NW., Washington, DC 20036, (202) 857–3800, facsimile (202) 857–3805.

Provisions of the Regulatory Flexibility Act of 1980 do not apply to this proceeding.

Members of the public should note that from the time a Notice of Proposed Rule Making is issued until the matter is no longer subject to Commission consideration or court review, all *ex parte* contacts are prohibited in Commission proceedings, such as this one, which involve channel allotments. See 47 CFR 1.1204(b) for rules governing permissible *ex parte* contact.

For information regarding proper filing procedures for comments, see 47 CFR 1.415 and 1.420.

List of Subjects in 47 CFR Part 73

Radio broadcasting.

For the reasons discussed in the preamble, the Federal Communications Commission proposes to amend 47 CFR part 73 as follows:

PART 73—RADIO BROADCAST SERVICES

1. The authority citation for part 73 continues to read as follows:

Authority: 47 U.S.C. 154, 303, 334 and 336.

§ 73.202 [Amended]

2. Section 73.202(b), the Table of FM Allotments under Michigan, is amended by removing Channel 264A and adding Channel 264C3 at Honor, by removing Channel 261A and adding Channel 291A at Bear Lake, by removing Channel 292A and adding Channel 254A at Ludington, and by removing Channel 255A and adding Channel 293A at Walhalla.

Federal Communications Commission.

John A. Karousos,

Chief, Allocations Branch, Policy and Rules Division, Mass Media Bureau.

[FR Doc. 01–21410 Filed 8–23–01; 8:45 am]

BILLING CODE 6712–01–P

FEDERAL COMMUNICATIONS COMMISSION

47 CFR Part 73

[DA No. 01–1908, MM Docket No. 01–187, RM–10174]

Radio Broadcasting Services; Sabinal, TX

AGENCY: Federal Communications Commission.

ACTION: Proposed rule.

SUMMARY: This document requests comments on a petition filed by Katherine Pyeatt requesting the allotment of Channel 296A at Sabinal, Texas. The coordinates for Channel 296A at Comfort are 29–20–17 and 99–29–00. There is a site restriction 2.9 kilometers (1.8 miles) northwest of the community. Mexican concurrence will be requested for the allotment of Channel 296A at Sabinal.

DATES: Comments must be filed on or before October 1, 2001, and reply comments on or before October 16, 2001.

ADDRESSES: Federal Communications Commission, 445 Twelfth Street, SW., Washington, DC 20554. In addition to filing comments with the FCC, interested parties should serve the petitioner, as follows: Katherine Pyeatt, 6655 Aintree Circle, Dallas, Texas 75214.

FOR FURTHER INFORMATION CONTACT: Kathleen Scheuerle, Mass Media Bureau, (202) 418–2180.

SUPPLEMENTARY INFORMATION: This is a summary of the Commission's Notice of Proposed Rule Making, MM Docket No. 01–187, adopted August 1, 2001, and released August 10, 2001. The full text of this Commission decision is available for inspection and copying during normal business hours in the Commission's Reference Information Center, 445 Twelfth Street, SW, Washington, DC 20554. The complete text of this decision may also be purchased from the Commission's copy contractors, International Transcription Services, Inc., 1231 20th Street, NW., Washington, DC. 20036, (202) 857–3800, facsimile (202) 857–3805.

Provisions of the Regulatory Flexibility Act of 1980 do not apply to this proceeding.

Members of the public should note that from the time a Notice of Proposed Rule Making is issued until the matter is no longer subject to Commission consideration or court review, all *ex parte* contacts are prohibited in Commission proceedings, such as this one, which involve channel allotments. See 47 CFR 1.1204(b) for rules governing permissible *ex parte* contact.

For information regarding proper filing procedures for comments, see 47 CFR 1.415 and 1.420.

List of Subjects in 47 CFR Part 73

Radio broadcasting.

For the reasons discussed in the preamble, the Federal Communications Commission proposes to amend 47 CFR part 73 as follows:

PART 73—RADIO BROADCAST SERVICES

1. The authority citation for part 73 continues to read as follows:

Authority: 47 U.S.C. 154, 303, 334 and 336.

§ 73.202 [Amended]

2. Section 73.202(b), the Table of FM Allotments under Texas, is amended by adding Sabinal, Channel 296A.

Federal Communications Commission.

John A. Karousos,

Chief, Allocations Branch, Policy and Rules Division, Mass Media Bureau.

[FR Doc. 01–21411 Filed 8–23–01; 8:45 am]

BILLING CODE 6712–01–U

FEDERAL COMMUNICATIONS COMMISSION

47 CFR Part 73

[DA 01–1907; MM Docket No. 01–188, RM–10203; MM Docket No. 01–189, RM–10204; MM Docket No. 01–190, RM–10210; and MM Docket No. 01–191, RM–10211]

Radio Broadcasting Services; Evant, TX; Winnsboro, TX; Comanche, TX; and Clayton, OK

AGENCY: Federal Communications Commission.

ACTION: Proposed rule.

SUMMARY: This document proposes four allotments. The Commission requests comment on a petition filed by Charles Crawford proposing the allotment of Channel 243A at Evant, Texas, as the community's first local aural transmission service. Channel 243A can be allotted to Evant in compliance with the Commission's minimum distance separation requirements with a site restriction of 0.8 km (0.5 miles) east of Evant. The coordinates for Channel 243A at Evant are 31–28–56 North Latitude and 98–09–19 West Longitude. The Commission requests comment on a petition filed by Katherine Pyeatt proposing the allotment of Channel 263A at Winnsboro, Texas, as the community's first local competing FM transmission service. Channel 263A can be allotted to Winnsboro in compliance with the Commission's minimum distance separation requirements with a site restriction of 7.9 km (4.9 miles) east of Winnsboro. The coordinates for Channel 263A at Winnsboro are 32–56–40 North Latitude and 95–12–27 West Longitude.

The Commission further requests comment on a petition filed by Jeraldine Anderson proposing the allotment of Channel 280A at Comanche, Texas, as the community's first local competing FM transmission service. Channel 280A can be allotted to Comanche at center city coordinates in compliance with the Commission's minimum distance separation requirements, with no site restriction. The coordinates for Channel 280A at Comanche are 31–53–50 North Latitude and 98–36–12 West Longitude.

The Commission requests comment on a petition filed by Maurice Salsa proposing the allotment of Channel 232C3 at Clayton, Oklahoma, as the community's first local aural transmission service. Channel 232C3 can be allotted to Clayton at center city coordinates in compliance with the Commission's minimum distance separation requirements, with no site restriction. The coordinates for Channel 232C3 at Clayton are 34–35–22 North Latitude and 95–21–09 West Longitude.

DATES: Comments must be filed on or before October 1, 2001, and reply comments on or before October 16, 2001.

ADDRESSES: Federal Communications Commission, Washington, DC 20554. In addition to filing comments with the FCC, interested parties should serve the petitioner, his or her counsel, or consultant, as follows: Charles Crawford, 4553 Bordeaux Avenue, Dallas, TX 75205; Katherine Pyeatt, 6655 Aintree Circle, Dallas, TX 75214; Jeraldine Anderson, 1702 Cypress Drive, Irving, TX 75061; and Maurice Salsa, 5615 Evergreen Valley Drive, Kingwood, TX 77345.

FOR FURTHER INFORMATION CONTACT: Deborah A. Dupont, Mass Media Bureau (202) 418–7072.

SUPPLEMENTARY INFORMATION: This is a synopsis of the Commission's Notice of Proposed Rule Making, MM Docket Nos. 01–188, 01–189, 01–190, and 01–191, adopted August 1, 2001, and released August 10, 2001. The full text of this Commission decision is available for inspection and copying during normal business hours in the FCC Reference Information Center (Room CY–A257), 445 12th Street, SW., Washington, DC. The complete text of this decision may also be purchased from the Commission's copy contractor, International Transcription Service, Inc., (202) 857–3800, 1231 20th Street, NW., Washington, DC 20036.

The Provisions of the Regulatory Flexibility Act of 1980 do not apply to this proceeding. Members of the public should note that from the time a Notice of Proposed Rule Making is issued until the matter is no longer subject to Commission consideration or court review, all *ex parte* contacts are prohibited in Commission proceedings, such as this one, which involve channel allotments. *See* 47 CFR 1.1204(b) for rules governing permissible *ex parte* contacts.

For information regarding proper filing procedures for comments, *see* 47 CFR 1.415 and 1.420.

List of Subjects in 47 CFR Part 73

Radio broadcasting.

For the reasons discussed in the preamble, the Federal Communications Commission proposes to amend 47 CFR Part 73 as follows:

PART 73—RADIO BROADCAST SERVICES

1. The authority citation for Part 73 continues to read as follows:

Authority: 47 U.S.C. 154, 303, 334 and 336.

§ 73.202 [Amended]

2. Section 73.202(b), the Table of FM Allotments under Texas, is amended by adding Channel 280A at Comanche, adding Evant, Channel 243A, and adding Channel 263A at Winnsboro.

3. Section 73.202(b), the Table of FM Allotments under Oklahoma, is amended by adding Clayton, Channel 232C3.

Federal Communications Commission.

John A. Karousos,

Chief, Allocations Branch, Policy and Rules Division, Mass Media Bureau.

[FR Doc. 01–21413 Filed 8–23–01; 8:45 am]

BILLING CODE 6712–01–P

DEPARTMENT OF DEFENSE

48 CFR Parts 232 and 252

[DFARS Case 2001–D012]

Defense Federal Acquisition Regulation Supplement; Customary Progress Payment Rate for Large Business Concerns

AGENCY: Department of Defense (DoD).

ACTION: Proposed rule with request for comments.

SUMMARY: DoD is proposing to amend the Defense Federal Acquisition Regulation Supplement (DFARS) to increase the customary uniform progress payment rate for large business concerns from 75 percent to 80 percent. The progress payment rate change will be applicable only to contract awards made on or after October 1, 2001, with final implementation contingent upon the approval of a DoD budget and outlay ceiling for Fiscal Year (FY) 2002 sufficient to accommodate the outlay impact of this proposed change. The Budget of the United States Government, FY 2002, submitted by the President, accommodates the outlay impact. Contracts awarded before October 1, 2001, will not be modified to include the 80 percent rate.

DATES: Comments on the proposed rule should be submitted to the address shown below on or before September 24, 2001 to be considered in the formation of the final rule.

ADDRESSES: Respondents may submit comments directly on the World Wide Web at *http://emissary.acq.osd.mil/dar/dfars.nsf/pubcomm.* As an alternative, respondents may e-mail comments to: *dfars@acq.osd.mil.* Please cite DFARS Case 2001–D012 in the subject line of e-mailed comments.

Respondents that cannot submit comments using either of the above

methods may submit comments to: Defense Acquisition Regulations Council, Attn: Ms. Sandra Haberlin, OUSD (AT&L) DP (DAR), IMD 3C132, 3062 Defense Pentagon, Washington, DC 20301–3062; facsimile (703) 602–0350. Please cite DFARS Case 2001–D012.

At the end of the comment period, interested parties may view public comments on the World Wide Web at *http://emissary.acq.osd.mil/dar/dfars.nsf.*

FOR FURTHER INFORMATION CONTACT: Ms. Sandra Haberlin, (703) 602–0289.

SUPPLEMENTARY INFORMATION:

A. Background

Pursuant to Section 8155 of the FY 1994 Defense Appropriations Act (Public Law 103–139), DoD reduced the customary progress payment rate for large business concerns from 85 percent to 75 percent, effective for solicitations issued on or after November 11, 1993. The rates for small business and small disadvantaged business concerns (90 percent and 95 percent, respectively) were not changed.

Despite changes to short term borrowing rates in subsequent years that have supported an increase in the progress payment rate for large business concerns, DoD has been unable to accommodate a rate increase within available funding outlays until FY 2002. This proposed DFARS change will conform the DoD customary uniform progress payment rate for large business concerns with the progress payment rate for large business concerns currently being used by other Executive agencies under FAR 32.501–1(a). The DoD rate will be applicable only to new contract awards made on or after October 1, 2001. Contracts awarded before October 1, 2001, will not be modified to include the 80 percent rate.

This rule was not subject to Office of Management and Budget review under Executive Order 12866, dated September 30, 1993.

B. Regulatory Flexibility Act

The proposed rule is not expected to have a significant economic impact on a substantial number of small entities within the meaning of the Regulatory Flexibility Act, 5 U.S.C. 601, et seq., because the progress payment rates for small and small disadvantaged business concerns are unchanged. Therefore, DoD has not performed an initial regulatory flexibility analysis. DoD invites comments from small businesses and other interested parties. DoD also will consider comments from small entities concerning the affected DFARS subparts in accordance with 5 U.S.C. 610. Such comments should be submitted separately and should cite DFARS Case 2001–D012.

C. Paperwork Reduction Act

The Paperwork Reduction Act does not apply because the rule does not impose any information collection requirements that require the approval of the Office of Management and Budget under 44 U.S.C. 3501, et seq.

List of Subjects in 48 CFR Parts 232 and 252

Government procurement.

Michele P. Peterson,

Executive Editor, Defense Acquisition Regulations Council.

Therefore, DoD proposes to amend 48 CFR Parts 232 and 252 as follows:

1. The authority citation for 48 CFR Parts 232 and 252 continues to read as follows:

Authority: 41 U.S.C. 421 and 48 CFR Chapter 1.

PART 232—CONTRACT FINANCING

2. Section 232.501–1 is revised to read as follows:

232.501–1 Customary progress payment rates.

(a) The customary progress payment rates for DoD contracts, including contracts that contain foreign military sales (FMS) requirements, are 80 percent for large business concerns, 90 percent for small business concerns, and 95 percent for small disadvantaged business concerns.

3. Section 232.502–4–70 is amended by revising paragraph (b) to read as follows:

232.502–4–70 Additional clauses.

* * * * *

(b) Use the clause at 252.232–7004, DoD Progress Payment Rates, instead of Alternate I of the clause at FAR 52.232–16, if the contractor is a small business or small disadvantaged business concern.

PART 252—SOLICITATION PROVISIONS AND CONTRACT CLAUSES

4. Section 252.232–7004 is revised to read as follows:

252.232–7004 DoD Progress Payment Rates.

As prescribed in 232.502–4–70(b), use the following clause:

DoD Progress Payment Rates (XXX 2001)

(a) If the contractor is a small business concern, the Progress Payments clause of this contract is modified to change each mention of the progress payment rate and liquidation rate (excepting paragraph (k), *Limitations on Undefinitized Contract Actions*) to 90 percent.

(b) If the contractor is a small disadvantaged business concern, the Progress Payments clause of this contract is modified to change each mention of the progress payment rate and liquidation rate (excepting paragraph (k), *Limitations on Undefinitized Contract Actions*) to 95 percent.

(End of clause)

[FR Doc. 01–21466 Filed 8–23–01; 8:45 am]

BILLING CODE 5000–04–M

Notices

Federal Register
Vol. 66, No. 165
Friday, August 24, 2001

This section of the FEDERAL REGISTER contains documents other than rules or proposed rules that are applicable to the public. Notices of hearings and investigations, committee meetings, agency decisions and rulings, delegations of authority, filing of petitions and applications and agency statements of organization and functions are examples of documents appearing in this section.

DEPARTMENT OF AGRICULTURE

Forest Service

Forest Transportation System; Interim Direction

AGENCY: Forest Service, USDA.

ACTION: Notice; request for comment.

SUMMARY: On January 12, 2001, corollary with adopting revisions to the Transportation System rules at 36 CFR part 212, the Forest Service adopted a revised administrative policy to guide transportation planning, analysis, and management, especially road management in the National Forest System. Following intensive training of field employees on implementing the new policy, the agency has determined that allowing only a six-month period, ending July 12, 2001, to prepare for use of the roads analysis process is insufficient. Also, the agency has concluded that decisions to extend the deadline for completing forest-scale roads analyses are best made on a case-by-case basis by the Regional Forester, not the Chief. These changes are embodied in Interim Directive No. 7710–2001–1 which the Chief signed on May 25, 2001. Because of the impending July 12, 2001, deadline, and the need for orderly adjustments in the local programs of work, it was not practicable to solicit public comment prior to implementing this Interim Directive. However, public comments are now invited and will be considered in developing any final policy.

DATES: Interim Directive No. 7710–2001–1 became effective May 31, 2001. Comments must be submitted on or before October 23, 2001.

ADDRESSES: Written comments concerning this Interim Directive (ID) should be sent to USFS CAT, Attention: Road Policy, P.O. Box 22914, Salt Lake City, UT, 84122; via email to roads_id@fs.fed.us; or via facsimile to 801–517–1021, Attention: Road Policy.

FOR FURTHER INFORMATION CONTACT: Mike Ash, Deputy Director, Engineering Staff, 703–605–4646.

SUPPLEMENTARY INFORMATION:

Current Rule and Policy

The Forest Service Road Management policy initiative resulted in adoption of a final rule at 36 CFR part 212, on January 12, 2001 (66 FR 3219). This rule directs the Responsible Official of each national forest, national grassland, experimental forest, and any other unit of the National Forest System to perform a comprehensive roads analysis on the transportation system within that unit and to document the forest transportation system in a transportation atlas. Concurrent with the rule, the Forest Service implemented an administrative policy that gives Forest Service employees more detailed instruction on building the road atlas and conducting road analyses. Issued as an amendment to Forest Service Manual Chapters 7700 Zero Code and 7710, the policy directs that decisions and final forest plan revisions or amendments adopted after July 12, 2001, must be informed by a roads analysis.

Need for Revision

Since adoption of the policy on January 12, 2001, the Forest Service has provided almost 1,000 employees in-depth training on how to conduct the roads analysis process and how to build the road atlas. Subsequently, many managers have informed the Chief's office that the deadlines for compliance are unworkable considering the level of detail, the variety of information required, and the amount of training necessary before the analysis can begin. Moreover, conducting roads analysis is often not compatible with meeting routine seasonal workload demands, especially in light of the need for restoration work after last year's devastating fire season. For these reasons, the Chief has determined that it is necessary to extend the deadline by which project and plan decisions must be informed by roads analysis from July 12, 2001, to January 12, 2002.

The administrative direction in FSM 7710 also directs all Forest Service units to complete a forest-scale roads analysis of their entire transportation system by January 12, 2003. As adopted, the policy provided that extensions to that deadline could be approved only by the Chief of the Forest Service. Requiring that only the Chief can approve extensions for completing the forest-scale roads analysis is not only inefficient but also inconsistent with the Chief's goal of encouraging and relying on local expertise and authority over forest-level issues as much as possible. The Chief has reconsidered this reservation of authority and concluded that Regional Foresters, to whom Forest Supervisors report, are in a better position to make judgments about local forest programs of work than the office of the Chief. Therefore, the Chief has redelegated to the Regional Foresters the authority to approve requests for extensions of forest-scale roads analysis beyond January 12, 2003. These changes have been issued in an Interim Directive to Forest Service Manual Chapter 7710, the text of which appears at the end of this notice.

Conclusion

The Forest Service is committed to providing adequate opportunities for the public to comment on all administrative directives that are of substantial public interest or controversy. However, because of the impending July 12, 2001, deadline, it was important to provide Forest Service units with sufficient advance notice of the changes so that they can adjust their plans of work in an orderly way. Accordingly, the agency issued the Interim Directive and made it effective immediately. However, as provided for in 36 CFR 216.7, the Forest Service is also requesting public comment on the Interim Directive. All comments will be reviewed and considered in determining a final policy.

Dated: June 28, 2001.

Dale N. Bosworth,

Chief.

Note: The Forest Service organizes its directive system by alphanumeric codes and subject headings. Only those sections of the FSM that are the subject of this notice are set forth here. Those who wish to see the entire chapter to which the Interim Direction (ID) applies may do so at *http://www.fs.fed.us/im/directives.*

FSM 7700—Transportation System

Chapter 7710—Transportation Atlas, Records, and Analysis

Interim Directive No.: 7710–2001–1.
Effective Date: May 31, 2001.

Duration: This interim directive expires on 11/30/2002.

Approved: Dale N. Bosworth, Chief.

Date Approved: 5/25/2001.

Posting Instructions: Interim directives are numbered consecutively by title and calendar year. Post by document at the end of the chapter.

Retain this transmittal as the first page(s) of this document. The last interim directive was 7710–99–2 to FSM 7710.

New Document	id__7710–2001–1	2 Pages
Superseded Document(s) (Interim Directive Number and Effective Date)	None.	

Digest:

7710.42—Delegates to the Regional Forester the responsibility previously reserved to the Chief to approve a Forest Supervisor request for additional time to complete forest-scale roads analysis (para. 6).

7712.15—Extends the deadlines for requiring roads analysis for road management decisions (para. 1a and 1b) and forest plan revisions or amendments (para. 2a) from July 12, 2001, to January 12, 2002. For clarity, subdivides paragraph 2a (as it appears in Amendment No. 7700–2001–2) into two paragraphs to distinguish deadlines applicable to those units that will complete a plan revision or amendments by January 12, 2002 (para. 2a) from those that have begun such amendments or revisions but will not be completed by January 12, 2002 (para. 2b). In new paragraph 2c (formerly para. 2b), permits Forest Supervisors to request that the Regional Forester grant an extension for completion of forest-scale roads analysis.

FSM 7700—Transportation System

Chapter 7710—Transportation Atlas, Records, and Analysis

7710.42—Regional Forester

6. Authority to approve, on a case-by-case basis, Forest Supervisor requests for additional time to complete forest-scale roads analysis.

7712.15—Deadlines for Completing Roads Analysis

1. *Analysis Needed to Inform Road Management Decisions.* Section 7712.13 identifies proposed road management decisions other than forest plan revisions or amendments that require roads analysis and provides guidance on the scope and scale of various levels of analysis that might inform those decisions. The following deadlines govern the application of roads analysis to the proposed road management decisions identified in sections 7712.13 through 7712.13c:

a. Decisions made before January 12, 2002, do not require a roads analysis.

b. Decisions made after January 12, 2002, must be informed by a roads analysis.

2. *Forest-Scale Road Analyses.* Every National Forest System administrative unit must have a forest-scale roads analysis completed by January 13, 2003, except as follows:

a. Those units that will complete a forest plan revision or amendment by January 12, 2002, do not need to complete a forest-scale roads analysis (FSM 7712.1) prior to adopting the plan revision or amendment. However, these units are still required to complete a forest-scale roads analysis by January 13, 2003.

b. Those units that have begun revision or amendment of their forest plans but will not adopt a final revision or final amendment by January 12, 2002, must complete a roads analysis prior to adoption of the final plan revision or amendment.

c. Where additional time is needed for completion of forest-scale roads analysis, a Forest Supervisor may request approval from the Regional Forester for an extension. In making such a request, the Forest Supervisor must provide a statement of the reason(s) the extension is needed.

[FR Doc. 01–21464 Filed 8–23–01; 8:45 am]

BILLING CODE 3410–11–U

COMMITTEE FOR PURCHASE FROM PEOPLE WHO ARE BLIND OR SEVERELY DISABLED

Procurement List; Proposed Addition

AGENCY: Committee for Purchase From People Who Are Blind or Severely Disabled.

ACTION: Proposed Addition to Procurement List.

SUMMARY: The Committee is proposing to add to the Procurement List commodity to be furnished by nonprofit agencies employing persons who are blind or have other severe disabilities.

COMMENTS MUST BE RECEIVED ON OR BEFORE: September 24, 2001

ADDRESSES: Committee for Purchase From People Who Are Blind or Severely Disabled, Jefferson Plaza 2, Suite 10800, 1421 Jefferson Davis Highway, Arlington, Virginia 22202–3259.

FOR FURTHER INFORMATION CONTACT: Louis R. Bartalot (703) 603–7740.

SUPPLEMENTARY INFORMATION:

This notice is published pursuant to 41 U.S.C. 47(a)(2) and 41 CFR 51–2.3. Its purpose is to provide interested persons an opportunity to submit comments on the possible impact of the proposed actions.

If the Committee approves the proposed addition, the entities of the Federal Government identified in this notice for each commodity will be required to procure the commodity listed below from nonprofit agencies employing persons who are blind or have other severe disabilities.

I certify that the following action will not have a significant impact on a substantial number of small entities. The major factors considered for this certification were:

1. The action will not result in any additional reporting, recordkeeping or other compliance requirements for small entities other than the small organizations that will furnish the commodity to the Government.

2. The action will result in authorizing small entities to furnish the commodity to the Government.

3. There are no known regulatory alternatives which would accomplish the objectives of the Javits-Wagner-O'Day Act (41 U.S.C. 46–48c) in connection with the commodity proposed for addition to the Procurement List. Comments on this certification are invited. Commenters should identify the statement(s) underlying the certification on which they are providing additional information.

The following commodity is proposed for addition to Procurement List for production by the nonprofit agencies listed:

Commodity

Strap, Chin

8475–01–142–7970

NPA: Cambria County Association f/t Blind & Handicapped, Johnstown, Pennsylvania.

Government Agency: Defense Supply Center Philadelphia.

Sheryl D. Kennerly,

Director, Information Management.

[FR Doc. 01–21467 Filed 8–23–01; 8:45 am]

BILLING CODE 6353–01–P

COMMITTEE FOR PURCHASE FROM PEOPLE WHO ARE BLIND OR SEVERELY DISABLED

Procurement List; Additions and Deletions

AGENCY: Committee for Purchase From People Who Are Blind or Severely Disabled.

ACTION: Additions to and Deletions from the Procurement List.

SUMMARY: This action adds to the Procurement List commodities and services to be furnished by nonprofit agencies employing persons who are blind or have other severe disabilities, and deletes from the Procurement List commodities and services previously furnished by such agencies.

EFFECTIVE DATE: September 24, 2001.

ADDRESSES: Committee for Purchase From People Who Are Blind or Severely Disabled, Jefferson Plaza 2, Suite 10800, 1421 Jefferson Davis Highway, Arlington, Virginia 22202–3259.

FOR FURTHER INFORMATION CONTACT: Louis R. Bartalot (703) 603–7740

SUPPLEMENTARY INFORMATION: On February 2, May 11, June 8, June 15, June 22 and June 29, 2001, the Committee for Purchase From People Who Are Blind or Severely Disabled published notices (66 FR 8776, 24100, 30884, 32598, 33520, 33521 and 34612) of proposed additions to and deletions from the Procurement List:

Additions

After consideration of the material presented to it concerning capability of qualified nonprofit agencies to provide the commodities and services and impact of the additions on the current or most recent contractors, the Committee has determined that the commodities and services listed below are suitable for procurement by the Federal Government under 41 U.S.C. 46–48c and 41 CFR 51–2.4.

I certify that the following action will not have a significant impact on a substantial number of small entities. The major factors considered for this certification were:

1. The action will not result in any additional reporting, recordkeeping or other compliance requirements for small entities other than the small organizations that will furnish the commodities and services to the Government.

2. The action will not have a severe economic impact on current contractors for the commodities and services.

3. The action will result in authorizing small entities to furnish the commodities and services to the Government.

4. There are no known regulatory alternatives which would accomplish the objectives of the Javits-Wagner-O'Day Act (41 U.S.C. 46–48c) in connection with the commodities and services proposed for addition to the Procurement List.

Accordingly, the following commodities and services are hereby added to the Procurement List:

Commodities

Air Freshener, Zooville Animal
M.R. 475
Broom, Swivel Head
M.R. 1043

Services

Janitorial/Custodial
U.S. Border Patrol Sector Headquarters
Ramey, Puerto Rico
Janitorial/Custodial
At the Following Base Exchanges:
Norfolk Naval Base
Norfolk, Virginia
Norfolk Naval Shipyard
Portsmouth, Virginia
Oceana Naval Air Station
Virginia Beach, Virginia
Dam Neck Fleet Combat Training Center Atlantic
Virginia Beach, Virginia
Little Creek Naval Amphibious Base
Norfolk, Virginia
Janitorial/Custodial
Defense Supply Center—Richmond
Richmond, Virginia
Janitorial/Custodial
U.S. Army Reserve Center
4828 West Silver Spring Drive
Milwaukee, Wisconsin
Mailroom and Records Management Services
Langley Air Force Base, Virginia
Operation of Environmental Remediation Service—Puget Sound Naval Shipyard, Bremerton, Washington
Transportation/Vehicle Operation Service—Brooks Air Force Base, Texas

This action does not affect current contracts awarded prior to the effective date of this addition or options that may be exercised under those contracts.

Deletions

I certify that the following action will not have a significant impact on a substantial number of small entities. The major factors considered for this certification were:

1. The action will not result in any additional reporting, recordkeeping or other compliance requirements for small entities.

2. The action will not have a severe economic impact on future contractors for the commodities and services.

3. The action will result in authorizing small entities to furnish the commodities and services to the Government.

4. There are no known regulatory alternatives which would accomplish the objectives of the Javits-Wagner-O'Day Act (41 U.S.C. 46–48c) in connection with the commodities and services deleted from the Procurement List.

After consideration of the relevant matter presented, the Committee has determined that the commodities and services listed below are no longer suitable for procurement by the Federal Government under 41 U.S.C. 46–48c and 41 CFR 51–2.4. Accordingly, the following commodities and services are hereby deleted from the Procurement List:

Commodities

Bag, Cargo 1670–01–065–3748
Winterization Kit 4240–00–065–0319
Strap, Webbing 5340–00–001–1266, 5340–01–147–3366, 5340–00–939–7062, 5340–01–219–2887, 5340–01–139–3197
Cap—Operating, Surgical 6532–00–083–6545
Original and Duplicate Microfiche, Program 1566–S 7690–00-NSH–0018
Mophead, Wet 7920–00–926–5497
Cleaner, Multi-Purpose 7930–01–393–6759
Box, Wood, Fiberboard 8115–00–L01–0679, 8115–00–L01–0680, 8115–00–L01–0681
Mask, Extreme Cold Weather 8415–01–006–3468, 8415–01–181–1398
Bag, Garment 8460–00–883–8673

Services

Janitorial/Custodial U.S. Army Reserve Center, 2513–15 Gravel Road, Fort Worth, Texas
Janitorial/Custodial U.S. Army Reserve Center, 2800 Crestline Road, Fort Worth, Texas

Sheryl D. Kennerly,

Director, Information Management.

[FR Doc. 01–21468 Filed 8–23–01; 8:45 am]

BILLING CODE 6353–01–P

COMMISSION ON CIVIL RIGHTS

Agenda and Notice of Public Meeting of the Oregon Advisory Committee

Notice is hereby given, pursuant to the provisions of the rules and regulations of the U.S. Commission on Civil Rights, that a meeting of the Oregon Advisory Committee to the Commission will convene at 11 a.m. and adjourn at 2 p.m. on Thursday, September 20, 2001, at the Doubletree Hotel—Columbia River, 1401 North Hayden Island Drive, Portland, Oregon 97217. The purpose of the meeting is to plan a forum on racial profiling in Oregon.

Persons desiring additional information, or planning a presentation to the Committee, should contact Philip Montez, Director of the Western Regional Office, 213–894–3437 (TDD 213–894–3435). Hearing-impaired persons who will attend the meeting and require the services of a sign language interpreter should contact the Regional Office at least ten (10) working days before the scheduled date of the meeting.

The meeting will be conducted pursuant to the provisions of the rules and regulations of the Commission.

Dated at Washington, DC, August 20, 2001.

Ivy L. Davis,

Chief, Regional Programs Coordination Unit.

[FR Doc. 01–21462 Filed 8–23–01; 8:45 am]

BILLING CODE 6335–01–P

DEPARTMENT OF COMMERCE

Submission for OMB Review; Comment Request

The Department of Commerce (DOC) has submitted to the Office of Management and Budget (OMB) for clearance the following proposal for collection of information under provisions of the Paperwork Reduction Act (44 U.S.C. Chapter 35).

Agency: Bureau of Export Administration (BXA).

Title: Procedures for Acceptance or Rejection of Rated Order.

Agency Form Number: None.

OMB Approval Number: 0694–0092.

Type of Request: Extension of a currently approved collection of information.

Burden: 21,963 hours.

Average Time Per Response: 1 to 15 minutes per response.

Number of Respondents: 18,000 respondents.

Needs and Uses: Because timely delivery or performance is critical under the Defense Priorities Allocation System, the information is used by the customer who placed the rated order with a supplier to help track the status of the rated order from initial receipt by the supplier to its shipment or performance of the needed goods or services. It also would be used by the Department of Defense and its associated agencies, the Department of Energy, and the Department of Commerce, as part of the information required to provide assistance to the customer in the event that the supplier can not or will not make timely delivery or performance of the needed goods or services.

Affected Public: Individuals, businesses or other for-profit institutions.

Respondent's Obligation: Required to obtain or retain benefits.

OMB Desk Officer: David Rostker.

Copies of the above information collection proposal can be obtained by calling or writing Madeleine Clayton, DOC Paperwork Clearance Officer, (202) 482–3129, Department of Commerce, Room 6086, 14th and Constitution Avenue, NW., Washington, DC 20230.

Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to David Rostker, OMB Desk Officer, Room 10202, New Executive Office Building, Washington, DC 20230.

Dated: August 21, 2001.

Madeleine Clayton,

Departmental Paperwork Clearance Officer, Office of the Chief Information Officer.

[FR Doc. 01–21506 Filed 8–23–01; 8:45 am]

BILLING CODE 3510–JT–P

DEPARTMENT OF COMMERCE

Submission for OMB Review; Comment Request

The Department of Commerce (DOC) has submitted to the Office of Management and Budget (OMB) for clearance the following proposal for collection of information under provisions of the Paperwork Reduction Act (44 U.S.C. Chapter 35).

Agency: Bureau of Export Administration (BXA).

Title: Five Year Records Retention Period.

Agency Form Number: None.

OMB Approval Number: 0694–0096.

Type of Request: Extension of a currently approved collection of information.

Burden: 249 hours.

Average Time Per Response: 0.01 second to 1.01 minute per response.

Number of Respondents: 200,000 respondents.

Needs and Uses: The five year records retention requirement enables BXA to detect violations from records up to five years old to correspond with the five year statute of limitations and prove that a violation did or did not take place. The documents can also provide exculpatory evidence for firms who have been accused of export control violations and are innocent.

Affected Public: Individuals, businesses or other for-profit institutions.

Respondent's Obligation: Required to obtain or retain benefits.

OMB Desk Officer: David Rostker.

Copies of the above information collection proposal can be obtained by calling or writing Madeleine Clayton, DOC Paperwork Clearance Officer, (202) 482–3129, Department of Commerce, Room 6086, 14th and Constitution Avenue, NW, Washington, DC 20230.

Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to David Rostker, OMB Desk Officer, Room 10202, New Executive Office Building, Washington, DC 20230.

Dated: August 21, 2001.

Madeleine Clayton,

Departmental Paperwork Clearance Officer, Office of the Chief Information Officer.

[FR Doc. 01–21507 Filed 8–23–01; 8:45 am]

BILLING CODE 3510–DT–P

DEPARTMENT OF COMMERCE

[I.D. 082101A]

Submission for OMB Review; Comment Request

The Department of Commerce has submitted to the Office of Management and Budget (OMB) for clearance the following proposal for collection of information under the provisions of the Paperwork Reduction Act (44 U.S.C. Chapter 35).

Agency: National Oceanic and Atmospheric Administration (NOAA).

Title: Fishermen's Contingency Fund

Form Number(s): NOAA Form 88–164 and 88–166.

OMB Approval Number: 0648–0082.

Type of Request: Regular submission.

Burden Hours: 2,017.

Number of Respondents: 200.

Average Hours Per Response: 10 hours for an application, 5 minutes for a 15–day report.

Needs and Uses: The Fishermen's Contingency Fund compensates U.S. commercial fishermen for loss of or damage to their fishing vessels or fishing gear, plus 50% of any gross

economic loss, caused by oil and gas industry activities on the U.S. Outer Continental Shelf. In order to be compensated, fishermen must file an application for claims to NOAA. In order to gain a presumption that damage was caused by an item related to oil and gas activities, a report needs to be filed within 15 days of the event. If a report is not filed, the application must provide evidence to the cause.

Affected Public: Individuals and households, business or other for-profit organizations.

Frequency: On occasion.

Respondent's Obligation: Required to obtain or retain a benefit.

OMB Desk Officer: David Rostker, (202) 395–3897.

Copies of the above information collection proposal can be obtained by calling or writing Madeleine Clayton, Departmental Paperwork Clearance Officer, (202) 482–3129, Department of Commerce, Room 6086, 14th and Constitution Avenue, NW, Washington, DC 20230 (or via the Internet at MClayton@doc.gov).

Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to David Rostker, OMB Desk Officer, Room 10202, New Executive Office Building, Washington, DC 20503.

Dated: August 17, 2001.

Gwellnar Banks,

Management Analyst, Office of the Chief Information Officer.

[FR Doc. 01–21510 Filed 8–23–01; 8:45 am]

BILLING CODE 3510–22–S

DEPARTMENT OF COMMERCE

Economic Development Administration

Notice of Petitions by Producing Firms for Determination of Eligibility To Apply for Trade Adjustment Assistance

AGENCY: Economic Development Administration, Commerce.

ACTION: To Give Firms an Opportunity to Comment.

Petitions have been accepted for filing on the dates indicated from the firms listed below.

LIST OF PETITION ACTION BY TRADE ADJUSTMENT ASSISTANCE FOR PERIOD 7/20/00—8/16/00

Firm name	Address	Date petition accepted	Product
New Holland Lingerie, Inc	494 W. Broad Street, New Holland, PA 17557.	07/23/01	Sportswear for adults and children.
Progressive Metal Manufacturing Company.	1300 Channing, Ferndale, MI 48220.	07/23/01	Ferrous and non-ferrous stampings for use in vehicles, i.e., metal brackets, battery boxes, rails, and supports.
Stroh Die Casting Co., Inc	11123 West Burleigh Street, Milwaukee, WI 53222.	07/26/01	Zinc die castings for automatic regulating and controlling instruments and office machines.
Catalina Tool & Mold, Inc	6230 S. Country Club Road, Tucson, AZ 85706.	07/26/01	Plastic injection molds.
Marlock, Inc	200 Raccoon Valley Road, Maynardville, TN 37807.	07/30/01	Mirror frames of polyurethane foam.
Owens & Hurst Lumber Co	2555 Highway 93 North, Eureka, MT 59917.	07/30/01	Dimension lumber, i.e., studs, and furring strips made of Douglas Fir, Larch, Spruce and Lodgepole Pine.
Precision Tool & Die Corp	1425 Wells Island Road, Shreveport, LA 71107.	08/06/01	Saw blade guides for the saw mill industry.
Frankoma Pottery	2400 Frankoma Road, Sapulpa, OK 74066.	08/06/01	Ceramic tableware and accent pieces.
Columbia Fruit	2526 Dike Road, Woodland, WA 98674.	08/06/01	Raspberries.
Woodline Products, Inc	892 Callendar Blvd., Painesville Twp., OH 44077.	08/06/01	Housings for lights for residential and commercial use.
Erath Veneer Corporation of Virginia.	160 Industrial Avenue, Rocky Mount, VA 24151.	08/06/01	Veneer panels made from wood logs for use by furniture, panel and door manufacturers.
Shirley Community Service and Development Corp.	Route 1, Box Zero, Shirley, AR 72153.	08/06/01	Shiitake mushrooms that are log-grown.
Seville Dyeing Co., Inc	229 First Street, Woonsocket, RI 02895.	08/06/01	Synthetic fiber fabrics and cotton blend fabrics for the women's garment industry.
Snake River Brewing Co., Inc	265 S. Millward, Jackson, WY 83001.	08/08/01	Beer.
Genesee Manufacturing Company, Inc.	566 Hollenbeck Street, Rochester, NY 14621.	08/08/01	Hollow mill cutting tools usually with carbide tipped blades.
Belco Tool & Manufacturing, Inc.	225 Terrace Street Ext., Meadville, PA 16335.	08/09/01	Tool and die for the automotive industry.
Jersey Plastic Molders, Inc	149–155 Shaw Avenue, Irvington, NJ 07111.	08/10/01	Plastic injection molds.
Glass Works WV, L.L.P	395 U.S. Highway 33 East, Weston, WV 26452.	08/14/01	Pressed and blown glass.
Ames Rubber Corporation	23–47 Ames Boulevard, Hamburg, NJ 07419.	08/15/01	Rubber products.
Coolbrook Corporation	150 Springfield Street, Avilla, MO 64833.	08/15/01	Gun cabinets, and entertainment and computer centers.
Remarque Manufacturing Corporation.	35 Research Drive, Hampton, VA 23666.	08/15/01	Electronic connectors.
PCB Acquisitions, Inc. dba Pronto Circuits Technologies.	1165 NW 55th Street, Ft. Lauderdale, FL 33309.	08/16/01	Printed circuit boards.

The petitions were submitted pursuant to Section 251 of the Trade Act of 1974 (19 U.S.C. 2341). Consequently, the United States Department of Commerce has initiated separate investigations to determine whether increased imports into the United States of articles like or directly competitive with those produced by each firm contributed importantly to total or partial separation of the firm's workers, or threat thereof, and to a decrease in sales or production of each petitioning firm.

Any party having a substantial interest in the proceedings may request a public hearing on the matter. A request for a hearing must be received by Trade Adjustment Assistance, Room 7315, Economic Development Administration, U.S. Department of Commerce, Washington, D.C. 20230, no later than the close of business of the tenth calendar day following the publication of this notice.

(The Catalog of Federal Domestic Assistance official program number and title of the program under which these petitions are submitted is 11.313, Trade Adjustment Assistance.)

Dated: August 17, 2001.

Anthony J. Meyer,

Coordinator, Trade Adjustment and Technical Assistance.

[FR Doc. 01–21402 Filed 8–23–01; 8:45 am]

BILLING CODE 3510–24–P

DEPARTMENT OF COMMERCE

Bureau of Export Administration

Materials Technical Advisory Committee; Notice of Partially Closed Meeting

The Materials Technical Advisory Committee will meet on September 10, 2001, 10:30 a.m., Herbert C. Hoover Building, Room 3884, 14th Street between Constitution & Pennsylvania Avenues, NW., Washington, DC. The Committee advises the Office of the Assistant Secretary for Export Administration with respect to technical questions that affect the level of export controls applicable to materials and related technology.

Agenda

Public Session

1. Opening remarks and introductions.
2. Presentation of papers and comments by the public.

Closed Session

3. Discussion of matters properly classified under Executive Order 12958, dealing with U.S. export control programs and strategic criteria related thereto.

A limited number of seats will be available during the public session of the meeting. Reservations are not accepted. To the extent time permits, members of the public may present oral statements to the Committee. Written statements may be submitted at any time before or after the meeting. However, to facilitate distribution of public presentation materials to Committee members, the materials should be forwarded prior to the meeting to the address below: Ms. Lee Ann Carpenter, OSIES/EA/BXA MS: 3876, U.S. Department of Commerce, 14th St. & Constitution Ave., NW., Washington, DC 20230.

The Assistant Secretary for Administration, with the concurrence of the delegate of the General Counsel, formally determined on March 7, 2000, pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, that the series of meetings or portions of meetings of the Committee and of any Subcommittee thereof dealing with the classified materials listed in 5 U.S.C. 552(c)(1) shall be exempt from the provisions relating to public meetings found in section 10(a)(1) and (a)(3) of the Federal Advisory Committee Act. The remaining series of meetings or portions thereof will be open to the public.

A copy of the Notice of Determination to close meetings or portions of meetings of the Committee is available for public inspection and copying in the Central Reference and Records Inspection Facility, Room 6020, U.S. Department of Commerce, Washington, DC. For more information or copies of the minutes call Ms. Lee Ann Carpenter at (202) 482–2583.

Dated: August 21, 2001.

Lee Ann Carpenter,

Committee Liaison Officer.

[FR Doc. 01–21416 Filed 8–23–01; 8:45 am]

BILLING CODE 3510–JT–M

DEPARTMENT OF COMMERCE

Bureau of Export Administration

Regulations and Procedures Technical Advisory Committee; Notice of Partially Closed Meeting

The Regulations and Procedures Technical Advisory Committee (RPTAC) will meet September 11, 2001, 9:00 a.m., Room 3884, in the Herbert C. Hoover Building, 14th Street between Constitution and Pennsylvania Avenues, N.W., Washington, D.C. The Committee advises the Office of the Assistant Secretary for Export Administration on implementation of the Export Administration Regulations (EAR) and provides for continuing review to update the EAR as needed.

Agenda

Public Session

1. Opening remarks by the Chairman.
2. Presentation of papers or comments by the public.
3. Update on pending regulations.
4. Work group activity reports and discussion.
5. Discussion on European export control developments.

Closed Session

6. Discussion of matters properly classified under Executive Order 12958, dealing with the U.S. export control program and strategic criteria related thereto.

A limited number of seats will be available for the public session. Reservations are not accepted. To the extent that time permits, members of the public may present oral statements to the Committee. The public may submit written statements at any time before or after the meeting. However, to facilitate the distribution of public presentation materials to the Committee members, the Committee suggests that presenters forward the public presentation materials prior to the meeting to the following address: Ms. Lee Ann Carpenter, OSIES/EA/BXA MS: 3876, 14th St. & Constitution Ave., N.W., U.S. Department of Commerce, Washington, D.C. 20230.

The Assistant Secretary for Administration, with the concurrence of the delegate of the General Counsel, formally determined on February 12, 2001, pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended, that the series of meetings or portions of meetings of the Committee and of any Subcommittees thereof, dealing with the classified materials listed in 5 U.S.C. 552b(c)(1) shall be exempt from the provisions relating to public meetings found in section 10(a)(1) and 10(a)(3) of the Federal Advisory Committee Act. The remaining series of meetings or portions thereof will be open to the public.

A copy of the Notice of Determination to close meetings or portions of meetings of the Committee is available for public inspection and copying the Central Reference and Records Inspection Facility, Room 6020, U.S. Department of Commerce, Washington, D.C. For more information, call Lee Ann Carpenter at (202) 482–2583.

Dated: August 21, 2001.

Lee Ann Carpenter,

Committee Liaison Officer.

[FR Doc. 01–21417 Filed 8–23–01; 8:45 am]

BILLING CODE 3510–JT–M

DEPARTMENT OF COMMERCE

International Trade Administration

[A–570–831]

Fresh Garlic From the People's Republic of China; Preliminary Results of Antidumping Duty New Shipper Review, Preliminary Results of Antidumping Duty Administrative Review, and Partial Rescission of Administrative Review

AGENCY: Import Administration, International Trade Administration, Department of Commerce.

ACTION: Notice of preliminary results of antidumping duty new shipper review, preliminary results of antidumping duty administrative review, and partial rescission of administrative review.

SUMMARY: In response to requests from interested parties, the Department of Commerce is conducting a new shipper review and an administrative review of the antidumping duty order on fresh garlic from the People's Republic of China. The period of review for the new shipper review, which concerns one new shipper, is June 1, 2000, through November 30, 2000. The period of review for the administrative review is November 1, 1999, through October 31, 2000. This review covers six manufacturers/exporters. At the request of the petitioner and the agreement of the new shipper, the two reviews have been aligned and are being performed simultaneously. With respect to the new shipper review, we find that the company has failed to provide the identity of garlic producers and other information key to an analysis of the factors of production and, therefore, a margin determination. Therefore, we preliminarily determine in the new shipper review that the respondent has not acted to the best of its ability and the usage of facts otherwise available for margin-calculation purposes is warranted. With respect to the administrative review, the requests for review have been withdrawn for two respondent-companies. We are therefore rescinding the review with respect to these companies. For the remaining four respondent-companies, we also have found that the respondents have not acted to the best of their ability in responding to our questionnaires. Therefore, we have preliminarily determined to use facts otherwise available for the determination of a margin.

We invite interested parties to comment on these preliminary results. Parties who submit comments are requested to submit with each argument: (1) a statement of the issue and (2) a brief summary of the argument.

EFFECTIVE DATE: August 24, 2001.

FOR FURTHER INFORMATION CONTACT: Hermes Pinilla or Richard Rimlinger, Office of Antidumping/Countervailing Duty Enforcement 3, Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue, NW., Washington, DC 20230; telephone (202) 482–3477 or (202) 482–4477, respectively, for information concerning the new shipper review. For information concerning the administrative review, please contact Edythe Artman or Mark Ross at the same address; telephone (202) 482–3931 or (202) 482–4794, respectively.

SUPPLEMENTARY INFORMATION:

The Applicable Statute and Regulations

Unless otherwise indicated, all citations to the Tariff Act of 1930, as amended (the Act), are references to the provisions effective January 1, 1995, the effective date of the amendments made to the Act by the Uruguay Round Agreements Act (URAA). In addition, unless otherwise indicated, all citations to the Department of Commerce's (the Department's) regulations are to 19 CFR part 351 (2000).

Background

On November 8, 2000, the Department published a notice of opportunity to request an administrative review of the antidumping duty order on fresh garlic from the People's Republic of China (PRC). See *Antidumping or Countervailing Duty Order, Finding, or Suspended Investigation; Opportunity to Request Administrative Review,* 65 FR 66965 (Nov. 8, 2000). On November 29, 2000, a legal representative submitted a request for a new shipper review in accordance with section 751(a)(2)(B) of the Act and section 351.214 (c) of the Department's regulations on behalf of Feidong Import and Export Company Ltd. (Feidong). On December 8, 2000, the representative submitted an amended request, in which Clipper Manufacturing Ltd. (Clipper) was identified as the new shipper. Because of circumstances concerning the request for review, the Department accepted the amendment as a timely submission. See ''Memorandum to the File'' regarding request for clarification concerning new shipper request (December 22, 2000). (All cited memoranda to the file and decision memoranda are on file in the Central Records Unit (CRU), Main Commerce Building, Room B–099.) We published a notice of initiation of new shipper review for Clipper on January 3, 2001. See *Fresh Garlic from the People's Republic of China: Initiation of New Shipper Antidumping Duty Review,* 66 FR 350 (January 3, 2001).

On November 27, 2000, Jinan Import and Export Co. (Jinan) requested an administrative review of exports of its merchandise to the United States. On November 30, 2000, Fook Huat Tong Kee Pte., Ltd., and Taian Fook Huat Tong Kee Foods Co., Ltd. (collectively FHTK), requested a review of their exports to the United States. On the same day, the petitioner, the Fresh Garlic Producers Association and its individual members, requested reviews of the following producers/exporters of the subject merchandise: FHTK; Rizhao Hanxi Fisheries and Comprehensive Development Co., Ltd. (Rizhao); Zhejiang Materials Industry (Zhejiang); Wo Hing (H.K.) Trading Co. (Wo Hing); Feidong; and an unidentified producer or exporter responsible for a shipment of fresh garlic imported by Good Time Produce, Inc. The Department determined that, in accordance with its past practice, it would not initiate a review of the latter respondent since the petitioner was unable to identify it by name. See ''Memorandum to the File'' regarding deficient request for administrative review (December 29, 2000). We published a notice of initiation of administrative review on December 28, 2000. See *Initiation of Antidumping and Countervailing Duty Administrative Reviews,* 65 FR 82322 (December 28, 2000).

On January 8, 2001, we issued a questionnaire to Clipper, each respondent in the administrative review, the Embassy of the PRC, the Ministry of Foreign Trade and Economic Cooperation (MOFTEC), and the China Chamber of Commerce for Import and Export of Foodstuffs, Native Produce, and Animal By-Products (China Chamber of Commerce). The questionnaire for Zhejiang was sent in care of MOFTEC since we were unable to obtain an address or phone number for that company. We did not receive a response to the questionnaire from the Embassy of the PRC, MOFTEC, or the China Chamber of Commerce.

On February 9, 2001, the petitioner submitted a request for alignment of the new shipper and administrative reviews. Clipper responded to the

Department that it did not object to the petitioner's request. See ''Memorandum to the File'' regarding alignment of new shipper and administrative reviews (February 19, 2001). Therefore, we are conducting the two reviews simultaneously.

Scope of the Order

The products subject to the antidumping duty order are all grades of garlic, whole or separated into constituent cloves, whether or not peeled, fresh, chilled, frozen, provisionally preserved, or packed in water or other neutral substance, but not prepared or preserved by the addition of other ingredients or heat processing. The differences between grades are based on color, size, sheathing, and level of decay.

The scope of this order does not include the following: (a) garlic that has been mechanically harvested and that is primarily, but not exclusively, destined for non-fresh use; or (b) garlic that has been specially prepared and cultivated prior to planting and then harvested and otherwise prepared for use as seed.

The subject merchandise is used principally as a food product and for seasoning. The subject garlic is currently classifiable under subheadings 0703.20.0010, 0703.20.0020, 0703.20.0090, 0710.80.7060, 0710.80.9750, 0711.90.6000, and 2005.90.9700 of the Harmonized Tariff Schedule of the United States (HTSUS). Although the HTSUS subheadings are provided for convenience and customs purposes, our written description of the scope of this proceeding is dispositive. In order to be excluded from the antidumping duty order, garlic entered under the HTSUS subheadings listed above that is (1) mechanically harvested and primarily, but not exclusively, destined for non-fresh use or (2) specially prepared and cultivated prior to planting and then harvested and otherwise prepared for use as seed must be accompanied by declarations to the Customs Service to that effect.

Partial Rescission of Administrative Review

On February 13, 2001, we received a letter from Jinan withdrawing its request for review. On the same day, we received a letter from Feidong in which it stated that it had made no shipments of subject merchandise to the United States during the period of review (POR). Prior to confirmation of this statement with the U.S. Customs Service, the petitioner sent us a letter in which it withdrew its request for review with respect to Feidong on March 5, 2001. Because the requests were withdrawn in a timely manner, we are rescinding the review with respect to Jinan and Feidong, in accordance with 19 CFR 351.213(d)(3).

Separate Rates

The Department has treated the PRC as a non-market-economy (NME) country in all past antidumping investigations (see, *e.g., Final Determination of Sales at Less Than Fair Value: Creatine Monohydrate from the People's Republic of China,* 64 FR 71104 (December 20, 1999), and *Final Determination of Sales at Less Than Fair Value: Certain Preserved Mushrooms from the People's Republic of China,* 63 FR 72255 (December 31, 1998)) and in prior segments of this proceeding. A designation as an NME remains in effect until it is revoked by the Department. See section 771(18)(C) of the Act. Accordingly, there is a rebuttable presumption that all companies within the PRC are subject to government control and, thus, should be assessed a single antidumping duty deposit rate.

It is the Department's standard policy to assign all exporters of the merchandise subject to review in NME countries a single rate, unless an exporter can affirmatively demonstrate an absence of government control, both in law (*de jure*) and in fact (*de facto*), with respect to exports. To establish whether a company is sufficiently independent to be entitled to a separate, company-specific rate, the Department analyzes each exporting entity in an NME country under the test established in the *Final Determination of Sales at Less Than Fair Value: Sparklers from the People's Republic of China,* 56 FR 20588 (May 6, 1991) (*Sparklers*), as amplified by the *Final Determination of Sales at Less Than Fair Value: Silicon Carbide from the People's Republic of China,* 59 FR 22585 (May 2, 1994).

Because Rizhao, Zhejiang, and Wo Hing did not provide responses to our request for information regarding separate rates, we preliminarily determine that these respondent-companies do not merit separate rates. See, *e.g., Natural Bristle Paint Brushes and Brush Heads from the People's Republic of China; Preliminary Results of Antidumping Duty Administrative Review,* 61 FR 57390 (November 6, 1996). Consequently, consistent with the statement in our notice of initiation, we find that, because these companies do not qualify for separate rates, they are deemed to be covered by the PRC-entity rate.

Clipper's submissions establish that it is a Hong Kong company. Because Hong Kong companies are treated as market-economy companies (see *Application of U.S. Antidumping and Countervailing Duty Laws to Hong Kong,* 62 FR 42965 (August 11, 1997)), we determine that no separate-rate analysis is required for Clipper. Consequently, Clipper qualifies for a company-specific rate.

FHTK's submissions establish that Taian Fook Huat Tong Kee Foods Co., Ltd., is a PRC-company that is wholly-owned by Fook Huat Tong Kee Pte., Ltd., a Singaporean company. Fook Huat Tong Kee Pte., Ltd., is wholly-owned by a Singaporean holding company that is publicly-traded. Because there is no PRC ownership of Taian Fook Huat Tong Kee Foods Co., Ltd., or Fook Huat Tong Kee Pte., Ltd., we determine that no separate-rate analysis is required for these companies because they are beyond the jurisdiction of the PRC government. See *Final Determinations of Sales at Less Than Fair Value: Disposable Pocket Lighters from the People's Republic of China,* 60 FR 22359, 22361 (May 5, 1995); *Bicycles from the People's Republic of China,* 61 FR 19026, 19027 (April 30, 1996). Consequently, FHTK qualifies for a company-specific rate.

Use of Facts Otherwise Available

Section 776(a)(2) of the Act provides that if an interested party or any other person: (A) Withholds information that has been requested by the administering authority; (B) fails to provide such information by the deadlines for the submission of the information or in the form and manner requested, subject to subsections (c)(1) and (e) of section 782; (C) significantly impedes a proceeding under this title; or (D) provides such information but the information cannot be verified as provided in section 782(i), the Department shall, subject to section 782(d), use the facts otherwise available in reaching the applicable determination under this title.

Where the Department determines that a response to a request for information does not comply with the request, section 782(d) of the Act provides that the Department will so inform the party submitting the response and will, to the extent practicable, provide that party the opportunity to remedy or explain the deficiency. If the party fails to remedy the deficiency within the applicable time limits, the Department may, subject to section 782(e) of the Act, disregard all or part of the original and subsequent responses, as appropriate. Section 782(e) of the Act provides that the Department ''shall not decline to consider information that is submitted by an interested party and is necessary to the determination but does not meet

all the applicable requirements established by the administering authority'' if the information is timely, can be verified, and is not so incomplete that it cannot be used, and if the interested party acted to the best of its ability in providing the information. Where all of these conditions are met, the statute requires the Department to use the information, if it can do so without undue difficulty.

According to section 776(b) of the Act, if the Department finds that an interested party ''has failed to cooperate by not acting to the best of its ability to comply with a request for information,'' the Department may use information that is adverse to the interests of the party as facts otherwise available. Adverse inferences are appropriate ''to ensure that the party does not obtain a more favorable result by failing to cooperate than if it had cooperated fully.'' See Statement of Administrative Action (SAA) accompanying the URAA, H.R. Doc. No. 316, 103d Cong., 2d Session at 870 (1994). Furthermore, ''an affirmative finding of bad faith on the part of the respondent is not required before the Department may make an adverse inference.'' *Antidumping Duties; Countervailing Duties; Final Rule,* 62 FR 27296, 27340 (May 19, 1997).

An adverse inference may include reliance on information derived from the petition, the final determination in the investigation, any previous review, or any other information placed on the record. See section 776(b) of the Act. However, section 776(c) provides that, when the Department relies on secondary information rather than on information obtained in the course of a review, the Department shall, to the extent practicable, corroborate that information from independent sources that are reasonably at its disposal. The SAA states that the independent sources may include published price lists, official import statistics and customs data, and information obtained from interested parties during the particular investigation or review. See SAA at 870. The SAA clarifies that ''corroborate'' means that the Department will satisfy itself that the secondary information to be used has probative value. *Id.* As noted in *Tapered Roller Bearings and Parts Thereof, Finished and Unfinished, from Japan, and Tapered Roller Bearings, Four Inches or Less in Outside Diameter, and Components Thereof, from Japan; Preliminary Results of Antidumping Duty Administrative Reviews and Partial Termination of Administrative Reviews,* 61 FR 57391, 57392 (Nov. 6, 1996) (*TRBs*), to corroborate secondary information, the Department will, to the extent practicable, examine the reliability and relevance of the information used. However, if there are no independent sources from which the Department can derive calculated dumping margins, then, unlike other types of information such as input costs or selling expenses, the only source for margins is previous administrative determinations.

A. New Shipper Review

Clipper submitted a response to section A of the questionnaire on February 12, 2001, and a response to sections C and D on February 28, 2001. Because Clipper failed to provide the Department with sufficient production and sales data in response to its questionnaire, the Department, pursuant to section 782(d) of the Act, sent Clipper a more specific supplemental questionnaire requesting the missing information. On May 17, 2001, Clipper sent its response to the Department. Clipper still failed to provide sufficient production and sales data in its supplemental response. Thus, the Department sent another supplemental questionnaire to Clipper on July 16, 2001. It submitted a response to this supplemental questionnaire on July 20, 2001. Therefore, we have provided the company with the opportunity to remedy or explain the deficiencies in its responses by responding to two supplemental questionnaires. Having reviewed the responses, we find that the supplemental questionnaire responses are incomplete and there is inconsistent information on the record. In response to our February 27, 2001, questionnaire, Clipper stated in an exhibit that the raw garlic was provided by ''local garlic growers.'' After further inquiry by the Department, Clipper again stated that ''the raw garlic was provided by local garlic growers'' in its May supplemental response but failed to provide the source of the garlic production. Finally, after our third inquiry in our July supplemental questionnaire, Clipper indicated yet again that raw garlic came from ''local growers,'' but it did not provide us with any source-specific information. In addition, at times in its responses, Clipper indicated that there may be one garlic grower or several garlic growers. Therefore, the Department knows nothing about Clipper's sources of garlic, not even the number of garlic growers.

The factors of production for growing garlic are critical to the accurate calculation of normal value. This is because information pertaining to garlic production in this case is key to a dumping analysis of Clipper's exports to the United States. See section 773(c)(1) of the Act. Further, because the information was both incomplete and unverifiable, the Department could not use the information actually provided by Clipper, pursuant to section 782(e) of the Act. Therefore, pursuant to section 776(a)(2) of the Act, we find it appropriate to resort to the use the facts otherwise available in our preliminary results of review. For a detailed analysis of our findings, see the ''Memorandum from Hermes Pinilla to Laurie Parkhill'' regarding the use of facts otherwise available and the corroboration of secondary information (August 14, 2001) (Facts-Available Memorandum I).

Furthermore, we find that Clipper could have complied with our requests for data but did not do so. Clipper gave every indication that it would comply with our requests for information and seemed to support this presumption by providing us with some factors-of-production information in response to a second supplemental questionnaire, albeit with data from unrevealed sources. Indeed, all of Clipper's representations suggest that Clipper itself believed it could comply with the requests for information. Section 776(b) of the Act requires a respondent to cooperate ''to the best of its ability'' in response to our requests for information during a review. We determine that Clipper did not act to the best of its ability in this case. With no source information pertaining to key factors-of-production information, the Department has no basis on which to conclude that Clipper's submissions are reliable and form a reasonable basis for a margin calculation. Therefore, because Clipper's responses are so incomplete that they could not provide a verifiable basis for determining a margin calculation, we find that Clipper did not act ''to the best of its ability,'' as required by the Act. Therefore, we find it appropriate, pursuant to section 776(b) of the Act, to use an adverse inference in selecting from the facts otherwise available. See Facts-Available Memorandum I.

The only rate that has ever been calculated in this proceeding is 376.67 percent, a rate that is currently the PRC-wide rate and that was calculated based on information contained in the petition. As detailed in the Facts-Available Memorandum I, the information contained in the petition was challenged during the less-than-fair-value investigation and that challenge was rejected by the Department. See *Notice of Final Determination of Sales at Less Than Fair Value: Fresh Garlic from the People's Republic of China,* 59 FR 49058, 49059 (September 26, 1994). The

rate was corroborated for the preliminary results of the first administrative review. See *Notice of Preliminary Results of Antidumping Duty Administrative Review,* 61 FR 68229, 68230 (December 27, 1996). We corroborated the information in subsequent reviews to the extent that we noted the history of corroboration and found that we had not received any information that warranted revisiting the issue. See *Fresh Garlic from the People's Republic of China: Preliminary Results of Antidumping Duty Administrative Review and Partial Rescission of Administrative Review,* 65 FR 48464 (Aug. 8, 2000). Similarly, no information has been presented in the current review that calls into question the reliability or the relevance of the information contained in the petition. We thus find that the information is reliable and relevant.

With respect to the relevance aspect of corroboration, the Department stated in *TRBs* that it will ''consider information reasonably at its disposal as to whether there are circumstances that would render a margin irrelevant. Where circumstances indicate that the selected margin is not appropriate as adverse facts available, the Department will disregard the margin and determine an appropriate margin.'' See *TRBs* at 61 FR 57392. See also *Fresh Cut Flowers from Mexico; Preliminary Results of Antidumping Duty Administrative Review,* 61 FR 6812, 6814 (Feb. 22, 1996) (disregarding the highest margin in the case as best information available because the margin was based on another company's uncharacteristic business expense resulting in an extremely high margin). There is no information on the record that the application of this rate would be inappropriate in the new shipper review or that the margin is not relevant; therefore for Clipper, we have applied, as adverse facts available, the 376.67 percent margin from a prior administrative review of this order and have satisfied the corroboration requirements under section 776(c) of the Act. See *Persulfates from the People's Republic of China: Preliminary Results of Antidumping Duty Administrative Review,* 66 FR 18439, 18441 (Apr. 9, 2001) (employing a petition rate used as adverse facts available in a previous segment as the adverse facts available in the current review). See Facts-Available Memorandum I.

B. Administrative Review

Rizhao, Zhejiang, and Wo Hing did not respond to our questionnaire. Consequently, we find it appropriate, under subsection 776(a)(2) of the Act, to use the facts otherwise available as the basis for our preliminary results of review for these three companies. For a detailed discussion of our determination, see the ''Memorandum from Edythe Artman to Laurie Parkhill'' regarding the use of facts otherwise available and the corroboration of secondary information (August 14, 2001) (Facts-Available Memorandum II).

As discussed in the ''Separate Rates'' section above, Rizhao, Zhejiang, and Wo Hing did not provide responses to our request for information regarding separate rates and, consequently, we preliminarily determine that these respondent-companies do not merit separate rates. See, *e.g., Natural Bristle Paint Brushes and Brush Heads from the People's Republic of China; Preliminary Results of Antidumping Duty Administrative Review,* 61 FR 57390 (November 6, 1996). We therefore find that, because these companies do not qualify for separate rates, they are deemed to be covered by the PRC-entity rate.

We find that, by not responding to our questionnaire, Rizhao, Zhejiang, and Wo Hing each failed to cooperate by not acting to the best of their ability to comply with a request for information. Therefore, we find it appropriate to use an inference that is adverse to the interests of each of these companies in selecting from among the facts otherwise available. By doing so, we ensure that the companies will not obtain a more favorable result by failing to cooperate than had they cooperated fully. See Facts-Available Memorandum II.

As discussed above, we find that the secondary information upon which the rate of 376.67 percent was based had been corroborated previously, pursuant to subsection 776(c) of the Act, and continues to have probative value. See Facts-Available Memorandum II. Therefore, we conclude that the margin of 376.67 percent should be used as the facts otherwise available for the preliminary results of review for Rizhao, Zhejiang, and Wo Hing.

FHTK submitted a response to section A of our questionnaire on February 21, 2001, and a response to sections C and D on February 28, 2001. Because FHTK failed to provide the Department with sufficient production and sales data in response to its questionnaires, the Department, pursuant to section 782(d) of the Act, sent FHTK a more specific supplemental questionnaire requesting the missing information. On May 15, 2001, FHTK sent its response to the Department. A great deal of necessary information was still not reported by FHTK. In fact, because the information was both incomplete and unverifiable, the Department could not use the information actually provided by FHTK, pursuant to section 782(e) of the Act.

We find that FHTK did not respond to these questionnaires to the best of its ability. As noted above, section 776(a)(2) of the Act permits the Department to apply facts otherwise available if a respondent has not provided sufficient responses to the Department's questionnaires. Section 776(b) of the Act allows the Department to draw an adverse inference if it determines that a party has not responded to the best of its ability. In this matter, therefore, we find that an adverse inference is warranted.

We find that FHTK's responses are so deficient as to preclude their use in the calculation of a dumping margin. FHTK failed to provide certain information on affiliation and FHTK's production and sales processes. Moreover, FHTK failed to submit financial statements for the two most recently completed fiscal years, as well as information on certain selling expenses. Finally, FHTK did not adequately explain certain factor data related to energy usage, labor, and packing materials. Without this information, we are unable to do a complete factors-of-production analysis. The deficiences in the responses are so significant and pervasive that we are neither able to calculate a dumping margin for FHTK based on its own data nor able to use ''gap fillers'' for the same reason. Therefore, we conclude that, pursuant to section 776(a)(2) of the Act, the use of total facts available is appropriate for our preliminary results of review for FHTK. We further find that the information in FHTK's responses is not sufficient for purposes of conducting a verification and, accordingly, we will not conduct a verification in this administrative review. See Facts-Available Memorandum II.

In addition, we find that, because the information provided by FHTK was incomplete or lacking in detail for purposes of conducting a verification or calculating a margin, FHTK did not cooperate to the best of its ability to comply with our requests for information. Furthemore, given FHTK's signficant resources and previous participation in antidumping proceedings, we find, at the least, that FHTK could have complied with our requests for information, but it did not do so. Accordingly, we find it appropriate to use an adverse inference in selecting from the facts otherwise available.

As discussed above, we find that the secondary information upon which the

rate of 376.67 percent was based has been corroborated previously, pursuant to subsection 776(c) of the Act, and continues to have probative value. Thus, we have preliminarily determined to apply 376.67 percent to the exports of subject merchandise by FHTK during the POR as the facts otherwise available. See Facts-Available Memorandum II.

Preliminary Results of the Reviews

As a result of our new shipper review, we preliminarily determine that a margin of 376.67 percent exists for all of Clipper's exports of the subject merchandise for the period June 1, 2000, through November 30, 2000. As a result of our administrative review, we preliminarily determine that a margin of 376.67 percent exists for FHTK and, as a PRC-entity rate, for all other producers/exporters of the subject merchandise for the period November 1, 1999, through October 31, 2000.

Interested parties may also submit written arguments in case briefs on these preliminary results within 30 days of the date of publication of this notice. Rebuttal briefs, limited to issues raised in case briefs, must be submitted no later than five days after the time limit for filing case briefs. Parties who submit arguments are requested to submit with each argument: (1) a statement of the issue, and (2) a brief summary of the argument. Case and rebuttal briefs must be served on interested parties in accordance with 19 CFR 351.303(f). Also, pursuant to 19 CFR 351.310, within 30 days of the date of publication of this notice, interested parties may request a public hearing on argument raised in the case and rebuttal briefs. Unless the Secretary specifies otherwise, the hearing, if requested, will be held three days after the scheduled date for submission of rebuttal briefs.

The Department will publish the final results of these reviews, including its analysis of issues raised in any case or rebuttal brief, not later than 120 days after the date of publication of this notice.

Upon completion of the final results in these reviews, the Department shall determine, and the Customs Service shall assess, antidumping duties on all appropriate entries.

Furthermore, upon publication of the final results of the reviews, the following deposit rates will be effective with respect to all shipments of fresh garlic from the PRC entered, or withdrawn from warehouse, for consumption on or after the publication date, as provided for by section 751(a)(2)(c) of the Act: (1) the cash deposit rate for the reviewed companies will be the rates for those firms established in the final results of this review; (2) for all other PRC exporters of subject merchandise, the cash deposit rate will be the PRC-wide rate of 376.67 percent; and (3) for non-PRC exporters of subject merchandise from the PRC not covered by this review, the less-than-fair-value investigation, or a previous review, the cash deposit rate will be the rate applicable to the PRC supplier of that exporter. These deposit requirements, when imposed, shall remain in effect until publication of the final results of the next administrative review.

Notification of Interested Parties

This notice serves as a preliminary reminder to importers of their responsibility under 19 CFR 351.402(f)(2) to file a certificate regarding the reimbursement of antidumping duties prior to liquidation of the relevant entries during the review periods. Failure to comply with this requirement could result in the Secretary's presumption that reimbursement of antidumping duties occurred and the subsequent assessment of double antidumping duties.

We are issuing these determinations and notice in accordance with sections 751(a)(1) and 777(i)(1) of the Act.

Dated: August 17, 2001.

Bernard T. Carreau,

Acting Assistant Secretary for Import Administration.

[FR Doc. 01–21469 Filed 8–23–01; 8:45 am]

BILLING CODE 3510–DS–P

DEPARTMENT OF COMMERCE

International Trade Administration

[A–583–827]

Static Random Access Memory Semiconductors From Taiwan: Notice of Extension of Time Limit for Final Results of Antidumping Duty Administrative Review

AGENCY: Import Administration, International Trade Administration, Department of Commerce.

SUMMARY: The Department of Commerce is extending the time limit of the final results of the antidumping duty administrative review on static random access memory semiconductors (SRAMs) from Taiwan. The review covers four producers/exporters of the subject merchandise to the United States. The period of review is April 1, 1999, through March 31, 2000.

EFFECTIVE DATE: August 24, 2001.

FOR FURTHER INFORMATION CONTACT: Irina Itkin at (202) 482–0656, Office of AD/CVD Enforcement, Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue, N.W., Washington, DC 20230.

The Applicable Statute

Unless otherwise indicated, all citations to the Tariff Act of 1930, as amended (the Act), are references to the provisions effective January 1, 1995, the effective date of the amendments made to the Act by the Uruguay Round Agreements Act. In addition, unless otherwise indicated, all citations to the Department's regulations are to 19 CFR part 351 (2000).

Extension of Time Limit for Final Results

Section 751(a)(3)(A) of the Act requires the Department to issue its final results within 120 days after the date on which the preliminary results are published. However, if it is not practicable to complete the final results within this time period, section 751(a)(3)(A) of the Act allows the Department to extend the 120 day time limit to 180 days.

The Department issued the preliminary results of the 1999–2000 administrative review of the antidumping duty order on SRAMs from Taiwan on May 4, 2001 (66 FR 22520). Due to the number of complex sales and cost issues raised by the parties in their case briefs (*e.g.*, the appropriate methodology for making sales and cost comparisons, the calculation of yield/loss ratios, etc.), we determine that it is not practicable to complete the final results of this review within the original time period. Therefore, the Department is extending the time limit for issuing the final results to no later than October 31, 2001.

Dated: August 17, 2001.

Susan Kuhbach,

Acting Deputy Assistant Secretary for Import Administration.

[FR Doc. 01–21470 Filed 8–23–01; 8:45 am]

BILLING CODE 3510–DS–P

DEPARTMENT OF COMMERCE

International Trade Administration

St. Louis Science Center; Notice of Decision on Application for Duty-Free Entry of Scientific Instrument

This decision is made pursuant to Section 6(c) of the Educational, Scientific, and Cultural Materials Importation Act of 1966 (Pub. L. 89–

651, 80 Stat. 897; 15 CFR part 301). Related records can be viewed between 8:30 A.M. and 5:00 P.M. in Room 4211, U.S. Department of Commerce, 14th and Constitution Avenue, NW., Washington, DC.

Docket Number: 01–001R. *Applicant:* St. Louis Science Center, St. Louis, MO 63110. *Instrument:* Universal Planetarium, Universarium Model IX. *Manufacturer:* Carl Zeiss, Germany. *Intended Use:* See notice at 66 FR 34154, June 27, 2001.

Comments: None received. *Decision:* Approved. No instrument of equivalent scientific value to the foreign instrument, for such purposes as it is intended to be used, is being manufactured in the United States. Reasons: The foreign instrument provides: (1) A unique fiber-optic system for projecting stars with high brightness, (2) ability to project the night sky in an environment with ambient lighting and (3) naturally appearing star scintillation. The National Air and Space Museum advised July 20, 2001 that (1) these capabilities are pertinent to the applicant's intended purpose and (2) it knows of no domestic instrument or apparatus of equivalent scientific value to the foreign instrument for the applicant's intended use.

We know of no other instrument or apparatus of equivalent scientific value to the foreign instrument which is being manufactured in the United States.

Gerald A. Zerdy,

Program Manager, Statutory Import Programs Staff.

[FR Doc. 01–21471 Filed 8–23–01; 8:45 am]

BILLING CODE 3510–DS–P

DEPARTMENT OF COMMERCE

National Institute of Standards and Technology

Visiting Committee on Advanced Technology; Meeting

AGENCY: National Institute of Standards and Technology, Department of Commerce.

ACTION: Notice of partially closed meeting.

SUMMARY: Pursuant to the Federal Advisory Committee Act, 5 U.S.C. app. 2, notice is hereby given that the Visiting Committee on Advanced Technology, National Institute of Standards and Technology (NIST), will meet Tuesday, September 11, 2001 from 8:25 a.m. to 5:30 p.m. and Wednesday, September 12, 2001 from 8:00 a.m. to 12:00 p.m. The Visiting Committee on Advanced Technology is composed of thirteen members appointed by the Director of NIST; who are eminent in such fields as business, research, new product development, engineering, labor, education, management consulting, environment, and international relations. The purpose of this meeting is to review and make recommendations regarding general policy for the Institute, its organization, its budget, and its programs within the framework of applicable national policies as set forth by the President and the Congress. The agenda will include an update on NIST programs; a cross-cut review of Healthcare; an overview of the NIST Industrial Liaison Office and Knowledge Net; a tour of the Boulder Facilities; a presentation on RF Emission Standards; and a Report from the Chair of the Board on Assessment. Discussions scheduled to begin at 5:00 p.m. and to end at 5:30 p.m. on September 11, 2001 and to begin at 8:00 a.m. and to end at 12:00 p.m. on September 12, 2001, on staffing of management positions at NIST, the NIST budget, including funding levels of the Advanced Technology Program and the Manufacturing Extension Partnership, and feedback sessions will be closed.

DATES: The meeting will convene September 11, 2001 at 8:25 a.m. and will adjourn at 12:00 p.m. on September 12, 2001.

ADDRESSES: The meeting will be held in the Radio Building, Room 1107 (seating capacity 60, includes 35 participants), National Institute of Standards and Technology, Boulder, Colorado.

FOR FURTHER INFORMATION CONTACT: Janet R. Russell, Administrative Coordinator, Visiting Committee on Advanced Technology, National Institute of Standards and Technology, Gaithersburg, MD 20899–1004, telephone number 301–975–2107, email: janet.russell@nist.gov.

SUPPLEMENTARY INFORMATION: The Assistant Secretary for Administration, with the concurrence of the General Counsel, formally determined on February 12, 2001, that portions of the meeting of the Visiting Committee on Advanced Technology which involve discussion of proposed funding of the Advanced Technology Program and the Manufacturing Extension Partnership Program may be closed in accordance with 5 U.S.C. 552b(c)(9)(B), because those portions of the meetings will divulge matters the premature disclosure of which would be likely to significantly frustrate implementation of proposed agency actions; and that portions of meetings which involve discussion of the staffing issues of management and other positions at NIST may be closed in accordance with 5 U.S.C. 552b(c)(6), because divulging information discussed in those portions of the meetings is likely to reveal information of a personal nature where disclosure would constitute a clearly unwarranted invasion of personal privacy.

Dated: August 13, 2001.

Karen H. Brown,

Acting Director.

[FR Doc. 01–21363 Filed 8–23–01; 8:45 am]

BILLING CODE 3510–13–M

DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

[Docket No. 010726192–1192–01]

RIN 0651–AB39

Notice of Electronic Products Available From the Information Products Division, Chief Information Officer, U.S. Patent and Trademark Office

AGENCY: United States Patent and Trademark Office, Commerce.

ACTION: Notice.

SUMMARY: The USPTO publishes a list of the electronic patent and trademark information products currently available from the Information Products Division, Office of the Chief Information Officer, U.S. Patent and Trademark Office. The products are made available in order to disseminate information on patents and trademarks to the public.

ADDRESSES: The products listed below can be ordered by contacting the Information Products Division, U.S. Patent and Trademark Office, Crystal Park 3, Suite 441, Washington, DC 20231. The 2001 USPTO Products and Services Catalog is available on the USPTO Web site at: *http://www.uspto.gov/web/offices/ac/ido/oeip/catalog/index.html*. The site provides more in-depth information about the individual products.

FOR FURTHER INFORMATION CONTACT: Information Products Division at 703–306–2600.

SUPPLEMENTARY INFORMATION: A list of the electronic patent and trademark information products currently available is given below. Included with the product title is the medium and price.

Product	Media	Price
Cassis Series of Optical Disc Products—Electronic Products Branch		
Cassis Sampler	CD–ROM	Free
Patents and Trademarks ASSIGN	DVD–ROM	$300/yr
Patents ASSIST	DVD–ROM	$200/yr
Patents BIB	DVD–ROM	$300/yr
Patents CLASS	DVD–ROM	$300/yr
Trademarks ASSIST	DVD–ROM	$50
Trademarks BIB	DVD–ROM	$500/yr
USAApp	DVD–ROM	$2400/yr
USAMark	CD–ROM	$200/yr
USAMark Back File	CD–ROM	$1180
USAPat	DVD–ROM	$2400/yr
USAPat Back File	DVD–ROM	$20,000
Patent and Trademark Data—Data Dissemination Branch		
Patent Bibliographic Data/SGML (Text Only)	Online (FTP)	Free
Patent Bibliographic/APS (Retrospective)	4 MM	$1500/yr
Patent Full-Text/APS (Retrospective)	DLT Cartridge	$28200/yr
Patent Grant Data/SGML (Text Only)	Online (FTP)	$8800/yr
Patent Grant Data/SGML (Text Only)	DLT Cartridge	$13300/yr
Patent Grant Data/SGML	DLT Cartridge	$25150/yr
Patent Application Data/XML (Text Only)	Online (FTP)	$7140/for 2001
Patent Application Data/XML (Text Only)	DLT Cartridge	$10752/for 2001
Patent Application Data/XML	DLT Cartridge	$20328/for 2001
Patent Image	3480 Cartridge Tape	$16550/yr
Patent Image	DLT Cartridge	$12400/yr
Patent Image/TIFF	DLT Cartridge	$12400/yr
Patent Image (Retrospective)	3480 Cartridge Tape	$373000
Patent Image/TIFF (Retrospective)	DLT Cartridge	$215350
Master Classification File (Patent Sequence)	Online (FTP)	$930/yr
Master Classification File (Patent Sequence)	DLT Cartridge	$1260/yr
Master Classification File (Class Sequence)	Online (FTP)	$930/yr
Master Classification File (Class Sequence)	DLT Cartridge	$1260/yr
Index to U.S. Patent Class	Online (FTP)	$312/yr
Index to U.S. Patent Class	DLT Cartridge	$312/yr
Manual of Classification	Online (FTP)	$312/yr
Manual of Classification	DLT Cartridge	$312/yr
Patent Assignment	DLT Cartridge	$1190/yr
Trademark Annual ASSIGN	Online (FTP)	$310/yr
Trademark Annual ASSIGN	DLT Cartridge	$415/yr
Trademark Annual DEAD	Online (FTP)	$1090/yr
Trademark Annual DEAD	DLT Cartridge	$1350/yr
Trademark Annual LIVE	Online (FTP)	$1190/yr
Trademark Annual LIVE	DLT Cartridge	$1450/yr
Trademark Annual TTAB	Online (FTP)	$210/yr
Trademark Annual TTAB	DLT Cartridge	$260/yr
Trademark Monthly Status	Online (FTP)	$624/yr
Trademark Monthly Status	DLT Cartridge	$1860/yr
Trademark Image Cropped Registrations	3480 Cartridge Tape	$12950/yr
Trademark Image Cropped Registrations	DLT Cartridge	$6530/yr
Trademark Image Cropped Registrations (Retro)	3480 Cartridge Tape	$620/yr
Trademark Image Cropped Registrations (Retro)	DLT Cartridge	$985/yr
Trademark Image Cropped Applications	3480 Cartridge Tape	$6475/yr
Trademark Image Cropped Applications	DLT Cartridge	$4715/yr
Trademark Image Cropped Applications (Retro)	3480 Cartridge Tape	$620/yr
Trademark Image Cropped Applications (Retro)	DLT Cartridge	$985/yr
Trademark Weekly Text	Online (FTP)	$2950/yr
Trademark Weekly Text	DLT Cartridge	$6370/yr
Trademark Application 24 Hour Box	Online (FTP)	$13000/yr
Patent and Trademark Statistical Reports—Technology Assessment and Forecast Branch		
Patenting Trends in the United States, 1999	Paper	$50
Patenting Trends in the United States, 1999	CD–ROM	$25
Patenting Trends in the United States, 1999—State/ Country Report	Paper	$50
Patenting Trends in the United States, 1999—State/ Country Report	CD–ROM	$25
U.S. Colleges and Universities—Utility Patent Grants, 1999	Paper	$50
U.S. Colleges and Universities—Utility Patent Grants, 1999	Diskette (2)	$25
Activity Index Report, 1999	Paper	$90
Activity Index Report, 1999	CD–ROM	$25
Activity Index Report, Corporate Patenting 1999	Paper	$90
Activity Index Report, Corporate Patenting 1999	CD–ROM	$25

Product	Media	Price
Activity Index Report, Utility Patent Applications 1999	Paper	$50
Activity Index Report, Utility Patent Applications 1999	CD–ROM	$25
Activity Index Report, Corporate Utility Patent Applications 1999	Paper	$50
Activity Index Report, Corporate Utility Patent Applications 1999	CD–ROM	$25
Buttons To Biotech, U.S. Patenting by Women, 1977 to 1996—updated through 1998.	Paper	$20
Selected Technologies Reports (variable lengths)	Paper	$20/report
General Statistical Reports—Issue Dates and Patent Numbers Since 1836.	Paper	$5
General Statistical Reports—Utility Patent Applications by Country of Origin Since 1965.	Paper	$5
General Statistical Reports—Patent Counts by Class by Year Report	Paper	$5/report
General Statistical Reports—Utility Patent Counts by State, County, and Metro Area.	Paper	$5
Concordance Between the Standard Industrial Classification System and the U.S. Patent Classification System (1999).	Paper	$80
Concordance Between the Standard Industrial Classification System and the U.S. Patent Classification System (1999).	Diskette (5MB compressed)	$25
Digital Media Having Information Contained in the TAF Database (Prices vary depending on the information wanted. Contact the TAF Branch office for prices and a description of what is available.).		
Inventor Mailing Labels	Paper	$50 plus $.35 per page of paper output
Inventor Mailing Labels	Self-stick labels	$50 plus $.70 per page of label stock output
Inventor Mailing Labels	Diskette (uncompressed electronic file output).	$50 plus $25/diskette
Custom Reports (Prices for custom reports vary according to the size and complexity of the requested report. Generally, report prices will be $50 per request plus $10 for every 30 single-sided report pages and $25 per diskette of uncompressed electronic file output. Custom report availability is subject to the availability of TAF resources.).		
Subclass Listings	Paper	$3/requested subclass on paper
Subclass Listings	Diskette	$3/requested subclass plus additional $25

This notice is issued under the authority of 35 U.S.C. 41(d), 35 U.S.C. 41(g) and 15 U.S.C. 1113.

Dated: August 20, 2001.

Nicholas P. Godici,

Acting Under Secretary of Commerce for Intellectual Property and Acting Director of the United States Patent and Trademark Office.

[FR Doc. 01–21481 Filed 8–23–01; 8:45 am]

BILLING CODE 3510–16–P

DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

[Docket No. 010723184–118401]

RIN 0651–AB30

Establishment of a Database Containing the Official Insignia of Federally and State Recognized Native American Tribes

AGENCY: United States Patent and Trademark Office, Commerce.

ACTION: Procedures for establishment and maintenance of a database of the official insignia of federally and state-recognized Native American tribes.

SUMMARY: The United States Patent and Trademark Office (USPTO) is announcing the procedures it will follow in creating and maintaining a database of the official insignia of federally and state-recognized Native American tribes. The database, recommended in a report required by the Trademark Law Treaty Implementation Act, will assist examining attorneys in their examinations of applications for registration.

SUPPLEMENTARY INFORMATION: The Trademark Law Treaty Implementation Act, Pub. L. 105–330, § 302, 112 Stat. 3071 (1998) required the USPTO to study issues surrounding protection of the official insignia of federally and state-recognized Native American tribes. The study was conducted, and a report was presented to the Chairman of the Committee on the Judiciary of the Senate and to the Chairman of the Committee on the Judiciary of the House of Representatives on November 30, 1999 (hereinafter ''the Report'').

One of the recommendations set forth in the Report was that the USPTO create and maintain an accurate and comprehensive database of the official insignia of Native American tribes.

On January 9, 2001, the USPTO published a notice in the **Federal Register** describing the proposed procedures for creating and maintaining the database (**Federal Register**, Vol. 66, No. 6), and requesting comments on these procedures.

Two parties submitted responses to the January 9, 2001 **Federal Register** Notice. One party submitted a comment regarding the proposed procedures for creating and maintaining the database, a request that the USPTO extend the time for submitting comments regarding the database, and a suggestion that the USPTO allow third parties to object to particular requests for entries of insignia in the database. Additionally, that party, as well as the other party that submitted a response, objected to the creation of the database.

Acceptable Form for Insignias

The proposed procedures published in the notice of January 9, 2001, provided that, if an insignia consists solely of a word or words, then the request to enter that insignia in the database should include a depiction of the word or words in uppercase letters.

Comment: One comment suggested that the proposed procedures should not

have allowed parties to submit requests to record matter comprised solely of words. This comment noted that the Report suggested that words, by themselves, could not function as official insignia of Native American tribes. Instead, the Report provided that insignia would be defined as ''flag or coat of arms or other emblem or device of any federally or state-recognized Native American tribe, as adopted by tribal resolution and notified to the U.S. Patent and Trademark Office.'' Accordingly, the comment suggested that the database not include entries of matter comprised solely of words.

Response: The suggestion has been adopted. The procedures for requesting entry of an insignia in the database have been modified to delete the reference to insignia composed solely of words, and to clarify that in order to be entered into the database, an insignia must consist of a flag or coat of arms or other emblem or device of any federally or state-recognized Native American tribe, as adopted by tribal resolution.

Propriety of Creating and Maintaining the Database of Insignia of Federally and State Recognized Native American Tribes

Two comments suggested that the USPTO should not establish a database of insignia of federally and state-recognized Native American Tribes. Both of these comments argued that the establishment of the database will confer rights on Native American Tribes that are not enjoyed by other groups. Additionally, both comments also argued that the USPTO would incur substantial costs in maintaining the database.

Response: The USPTO does not believe that entry of the official insignia of a Native American Tribe in the database will confer any rights on that tribe. The presence of an insignia in the database will not create any legal presumption of validity or priority, and none of the benefits of Federal trademark registration will accrue to a Native American tribe whose insignia is recorded pursuant to this notice. The sole function of the database will be to assist examining attorneys in their examination of applications for registration.

The USPTO believes that it currently has adequate resources to create and maintain the database. Additionally, it is noted that the database is being created pursuant to one of the recommendations of the Report. The Senate Appropriations Committee directed the USPTO to comply with this recommendation by creating and maintaining the database. See Senate Report 106–404 and H. Report 106–1005.

Time for Submitting Comments

One comment suggested that if comments regarding the proposed procedures were not received from each of the thirty-six entities who commented on the Report, then the USPTO should extend the period for commenting on the proposed procedures.

Response: The USPTO does not believe that it is necessary to extend the comment period. The USPTO believes that the thirty-day period provided for submitting comments was sufficient to allow all interested parties to prepare and submit comments.

Third Party Objections to Entry of Insignia

One comment suggested that establishment of the database would require the USPTO to accept and consider objections from third parties to the recordal of particular insignia.

Response: The USPTO does not believe that it should consider third party objections to entries of insignia in the database. The entry of an insignia will not confer any rights on the tribe that submitted the insignia. The sole function of the database will be to assist examining attorneys in their examination of applications for registration. Because no rights will accrue from entries of insignia into the database, it is unlikely that there can be any grounds for objecting to these entries.

Procedures for Submitting Requests for Entry of Insignia in the Database of Insignia of Federally and State Recognized Native American Tribes

All requests to enter an official insignia of a Native American tribe into the USPTO database must be in writing, addressed to the Commissioner for Trademarks, and must include the following:

(1) A depiction of the insignia. This depiction should not be larger than 4 inches by 4 inches (10.3 cm. by 10.3 cm.), and should be placed at or near the center of a sheet of white paper 8 to 8½ inches (20.3 to 21.6 cm.) wide and 11 inches (27.9 cm.) long. The paper should have a heading that includes the name of the tribe and the address for correspondence;

(2) A copy of the tribal resolution adopting the insignia in question as the official insignia of the tribe;

(3) A statement, signed by an official with authority to bind the tribe, confirming that the insignia included with the request is identical to the official insignia adopted by tribal resolution; and

(4) For all entities not recognized as Native American tribes by the Bureau of Indian Affairs (BIA), either: (a) a document issued by a state official that evidences the state's determination that the entity is a Native American tribe, or (b) a citation to a state statute designating the entity as a Native American tribe.

The request should be sent by facsimile to (703) 872–9192, or mailed to the Commissioner for Trademarks at the following address: P.O. Box 16471, Arlington, Virginia 22215.

The insignia must consist of a flag or coat of arms or other emblem or device of any federally or state-recognized Native American tribe, as adopted by tribal resolution. A word or words alone will not be considered an insignia, and will not be entered in the insignia database.

The USPTO will record any official insignia of a Native American tribe submitted in the manner described above, if the Commissioner determines that the entity that submitted the request is a Native American tribe recognized by the Federal Government or by one or more state governments.

The Commissioner will determine whether the entity that submitted the request is a federally recognized Native American tribe by consulting the list of Native American tribes maintained by the BIA.

If an entity seeking recordal of its insignia wishes to demonstrate that it is a state-recognized Native American tribe rather than a federally recognized Native American tribe, that entity must provide the Commissioner with either: (1) A document issued by a state official that evidences the state's determination that the entity is a Native American tribe, or (2) a citation to a state statute designating the entity as a Native American tribe.

The USPTO will begin to accept requests to record insignia one week after the publication of this notice.

Legal Significance of Recordal

The recordal of an official insignia of a Native American tribe at the USPTO will not be the equivalent of registering that insignia as a trademark pursuant to 15 U.S.C. 1051 *et seq.* Thus, including an insignia in the USPTO's database will not create any legal presumption of validity or priority, and none of the benefits of federal trademark registration will accrue to a Native American tribe whose insignia is recorded pursuant to this notice.

Acceptance of the insignia for recordal will not be a determination as

to whether a particular insignia for which recordal has been requested would be refused registration as a trademark pursuant to 15 U.S.C. 1051 *et seq.*, or to some provision of Chapter 37 of the Code of Federal Regulations, or to any requirement of the USPTO.

The USPTO will use the official insignia recorded by the USPTO as information useful in the examination of certain applications for registration of trademarks and as evidence of what a federally or state-recognized tribe considers to be its official insignia.

The database of official insignia of Native American tribes will be included, for informational purposes, within the USPTO's database of material that is not registered but is searched to make determinations regarding the registrability of marks. This database is available at the USPTO's web site. Inclusion of official insignia in this database will ensure that an examining attorney, who is searching a mark that is confusingly similar to an official insignia will find and consider the official insignia before making a determination of registrability.

For correspondence pertaining to the database of official insignia of Native American tribes, the Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office has waived the requirement of 37 CFR 1.1 that all correspondence intended for the United States Patent and Trademark Office be mailed to one of the addresses identified in 37 CFR 1.1.

The USPTO is in the process of requesting approval for establishment of the database under the Paperwork Reduction Act from the Office of Management and Budget.

The USPTO has determined that the proposed establishment of the database has no federalism implications affecting the relationship between the National Government and the State as outlined in Executive Order 13132. The USPTO has further determined that the proposed establishment of the database has no tribal implications as described in Executive Order 13175.

FOR FURTHER INFORMATION CONTACT: Ari Leifman by telephone at (703) 308–8900, or by mail addressed to: P.O. Box 16471, Arlington, Virginia, 22215, or by facsimile to (703) 872–9285, marked to the attention of Ari Leifman.

Dated: August 20, 2001.

Nicholas P. Godici,

Acting Under Secretary of Commerce for Intellectual Property and Acting Director of the United States Patent and Trademark Office.

[FR Doc. 01–21479 Filed 8–23–01; 8:45 am]

BILLING CODE 3510–16–P

CORPORATION FOR NATIONAL AND COMMUNITY SERVICE

Information Collection; Submission for OMB Review; Comment Request

AGENCY: Corporation for National and Community Service.

ACTION: Notice.

SUMMARY: The Corporation for National and Community Service (hereinafter the ''Corporation'') has submitted a public information collection request (ICR) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paper Reduction Act of 1995, Public Law 104–13, (44 U.S.C. Chapter 35). Copies of this ICR, with applicable supporting documentation, may be obtained by calling the Corporation for National and Community Service, Philip Shaw, at (202) 606–5000, extension 476. Individuals who use a telecommunications device for the deaf (TTY–TDD) may call (800) 833–3722 between the hours of 9:00 a.m. and 5:00 p.m. Eastern Standard Time, Monday through Friday.

Comments should be sent to the Office of Information and Regulatory Affairs, Attn: Ms. Brenda Aguilar, OMB Desk Officer for the Corporation for National and Community Service, Office of Management and Budget, Room 10235, Washington, DC, 20503, (202) 395–7316, within 30 days from the date of publication in this **Federal Register**.

The OMB is particularly interested in comments which:

• Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the Corporation, including whether the information will have practical utility;

• Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

• Propose ways to enhance the quality, utility and clarity of the information to be collected; and

• Propose ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submissions of responses.

The Corporation is soliciting comments concerning its proposed renewal of its AmeriCorps*NCCC Team Leader Application, OMB Control Number 3045–0005. This form Is due to expire on September 30, 2001.

Type of Review: Renewal.

Agency: Corporation for National and Community Service.

Title: AmeriCorps*NCCC Team Leader Application Form.

OMB Number: 3045–0005.

Agency Number: None.

Affected Public: Citizens of diverse ages and backgrounds who are committed to national service.

Total Respondents: 250.

Frequency: Bi-Annually.

Average Time Per Response: Two hours.

Estimated Total Burden Hours: 1,000 hours.

Total Burden Cost (capital/startup): None.

Total Burden Cost (operating/maintenance): None.

Description

This form is used to collect information that will be used by AmeriCorps*NCCC staff in the evaluation and selection of Team Leaders who wish to serve as Team Leaders at AmeriCorps*NCCC regional campuses. When revised, the form will include discussion concerning an additional application consideration period and will be used for the same purpose and in the same manner as the existing form.

Dated: August 20, 2001.

Fred Peters,

*Acting Director, AmeriCorps*National Civilian Community Corps.*

[FR Doc. 01–21458 Filed 8–23–01; 8:45 am]

BILLING CODE 6050–$$–P

DEPARTMENT OF DEFENSE

Reinstatement of Small Business Set-Asides and Unrestricted Competition for Certain Acquisitions Under the Small Business Competitiveness Demonstration Program

AGENCY: Department of Defense (DoD).

ACTION: Notice of reinstatement of small business set-asides and unrestricted competition under the Small Business Competitiveness Demonstration Program.

SUMMARY: The Director of Defense Procurement has reinstated the use of

small business set-aside procedures for certain non-nuclear ship repair acquisitions conducted by the Department of the Navy. Included in the reinstatement are solicitations issued under North American Industry Classification System (NAICS) Code 336611, Federal Service Code (FSC) J999 for the West Coast only. The Director of Defense Procurement has also reinstated the use of unrestricted competition for construction acquisitions in solicitations issued under NAICS Subsector 234 by the Departments of the Army and Navy and NAICS Code 23591 for the Department of the Navy.

EFFECTIVE DATE: August 13, 2001.

FOR FURTHER INFORMATION CONTACT: Mr. Tim J. Foreman, OUSD(AT&L), Deputy Director, Office of Small & Disadvantaged Business Utilization, 1777 North Kent Street, Rosslyn Plaza North, Suite 9100, Arlington, VA 22209; telephone (703) 588–8611.

SUPPLEMENTARY INFORMATION: The Office of Federal Procurement Policy and the Small Business Administration issued a final policy directive and implementation plan on June 2, 1999, for the Small Business Competitiveness Demonstration Program. The Program is further implemented in Subpart 19.10 of the Federal Acquisition Regulation (FAR) and Subpart 219.10 of the Defense FAR Supplement (DFARS).

Under the Program, small business set-asides were initially suspended for certain designated industry groups (DIGs) for certain participating agencies. The final policy directive and implementation plan, paragraph III.D.2.a. and IV.A.3., requires participating agencies to reinstate the use of small business set-asides whenever the small business awards under any DIG (to include Major Groups or Subsectors within Construction and East and West Coast Non-Nuclear Ship Repair) fall below 40 percent, or whenever small business awards under certain individual codes within the Construction and Architectural & Engineering Services DIGs fall below 35 percent. Reinstatement is to be limited to the organizational element that failed to meet the small business participation goals.

Participating agencies are required by paragraph III.D.2.b. and IV.A.3. of the final policy directive and implementation plan to reinstate the use of unrestricted competition upon determining, after an annual review, that their contract awards to small business concerns again meet the required goals. Accordingly, this notice is issued to reflect the results of small business participation in the DoD procurement data during Fiscal Year 2000 and supercedes the directives in the Director of Defense Procurement memorandum dated December 11, 1998 (63 FR 71272, December 24, 1998).

For the 12 months ending September 2000, DoD fell below the 40 percent goal in acquisitions under Standard Industrial Classification (SIC) Code 3731, FSC J999, for non-nuclear ship repairs on the West Coast. Effective October 1, 2000, the North American Industry Classification System (NAICS) Subsectors and Codes were substituted for SIC Major Groups and SIC Codes. Accordingly, pursuant to DFARS 219.1007(b)(1), the Director of Defense Procurement has directed the reinstatement of small business set-aside procedures in accordance with FAR Subpart 19.5 for all solicitations issued on or after August 13, 2001, or as soon thereafter as practicable, for:

Non-Nuclear Ship Repair, NAICS Code 336611, FSC J999—All Navy Activities

The Department-wide reinstatement of small business set-aside procedures for the Architectural & Engineering Services DIG remains in effect. Also, the emerging small business reserve amount of $50,000 for Architectural & Engineering Services remains in effect.

For the 12 months ending September 2000, DoD accomplished the 40 percent goal for participation of small businesses in construction acquisitions awarded under SIC Major Groups 16 and 17 (SIC Major Groups 16 and 17 are now referred to as NAICS Subsectors 234 and 235, respectively). DoD also exceeded the required 35 percent goal in all subcategories of SIC Major Group 17 (NAICS Subsector 235), including SIC Code 1791 (NAICS Code 23591). Accordingly, the Director of Defense Procurement has directed the reinstatement of unrestricted competition for all solicitations issued on or after August 13, 2001, or as soon thereafter as practicable, for:

Construction, NAICS Subsector 234—All Army and Navy Activities

Construction, NAICS Code 23591—All Navy Activities

To summarize, this results in unrestricted competition in Department-wide procurements for Construction NAICS Subsector 233 (SIC Major Group 15), NAICS Subsector 234 (SIC Major Group 16), NAICS Subsector 235 (SIC Major Group 17), Refuse Systems and Related Services, and for East Coast FSC J998 in the Non-Nuclear Ship Repair, NAICS 336611 (SIC 3731). Unrestricted competition is also in effect for the Army and Air Force for West Coast FSC J999 in the Non-Nuclear Ship Repair, NAICS 336611 (SIC 3731).

Consistent with the revised final policy directive and implementation plan, this reinstatement of set-asides and unrestricted competition will be reviewed annually for continuation.

Michele P. Peterson,

Executive Editor, Defense Acquisition Regulations Council.

[FR Doc. 01–21465 Filed 8–23–01; 8:45 am]

BILLING CODE 5000–04–M

DEPARTMENT OF DEFENSE

Department of the Air Force

Federal Advisory Committee for the End-to-End Review of the U.S. Nuclear Command and Control System

AGENCY: Department of the Air Force, DoD.

ACTION: Notice of Meeting.

SUMMARY: Pursuant to Public Law 92–463, notice is hereby given of forthcoming meetings of the Federal Advisory Committee for the End-to-End Review of the U.S. Nuclear Command and Control System (NCCS). The purpose of these meetings is to conduct a comprehensive and independent review of the NCCS positive measures to assure authorized use of nuclear weapons when directed by the President while assuring against unauthorized or inadvertent use. This meeting will be closed to the public.

DATES: September 11–12, 2001.

ADDRESSES: United States Strategic Command Headquarters, 901 SAC Blvd., Offutt Air Force Base, NE 68113.

FOR FURTHER INFORMATION CONTACT: Mr. William L. Jones, U.S. Nuclear Command and Control System Support Staff (NSS), Skyline 3, 5201 Leesburg Pike, Suite 500, Falls Church, Virginia 22041, (703) 681–8681.

Janet A. Long,

Air Force Federal Register Liaison Officer.

[FR Doc. 01–21371 Filed 8–23–01; 8:45 am]

BILLING CODE 5001–05–U

DEPARTMENT OF ENERGY

Office of Fossil Energy

[Docket Nos. FE C&E 01–82, et al.]

Certification Notice—204; Notice of Filings of Coal Capability of Pierce Power, LLC, et al.

AGENCY: Office of Fossil Energy, Department of Energy.

ACTION: Notice of Filing.

SUMMARY: Pierce Power LLC, Duke Energy Murray, LLC, Duke Energy Enterprise, LLC, Duke Energy Hot Spring, LLC, Duke Energy Southaven, LLC, Duke Energy Hinds, LLC, Cogen Power II, Whiting Clean Energy, Inc., Lone Oak Energy Center, LLC, Haywood Energy Center, LLC, and Calpine Construction Finance Company, L.P. submitted coal capability self-certifications pursuant to section 201 of the Powerplant and Industrial Fuel Use Act of 1978, as amended.

ADDRESSES: Copies of self-certification filings are available for public inspection, upon request, in the Office of Coal & Power Im/Ex, Fossil Energy, Room 4G–039, FE–27, Forrestal Building, 1000 Independence Avenue, SW., Washington, DC 20585.

FOR FURTHER INFORMATION CONTACT: Ellen Russell at (202) 586–9624.

SUPPLEMENTARY INFORMATION:

Title II of the Powerplant and Industrial Fuel Use Act of 1978 (FUA), as amended (42 U.S.C. 8301 *et seq.*), provides that no new baseload electric Powerplant may be constructed or operated without the capability to use coal or another alternate fuel as a primary energy source. In order to meet the requirement of coal capability, the owner or operator of such facilities proposing to use natural gas or petroleum as its primary energy source shall certify, pursuant to FUA section 201(d), to the Secretary of Energy prior to construction, or prior to operation as a base load Powerplant, that such Powerplant has the capability to use coal or another alternate fuel. Such certification establishes compliance with section 201(a) as of the date filed with the Department of Energy. The Secretary is required to publish a notice in the **Federal Register** that a certification has been filed. The following owners/operators of the proposed new baseload powerplants have filed a self-certification in accordance with section 201(d).

Owner: Pierce Power LLC [C&E 01–82].
Operator: Pierce Power LLC.
Location: Pierce County, Washington.
Plant Configuration: Simple cycle gas turbines.
Capacity: 170 MW.
Fuel: Natural Gas.
Purchasing Entities: Wholesale energy market.
In-Service Date: July 25, 2001.

Owner: Duke Energy Murray, LLC [C&E 01–83].
Operator: Duke Energy Murray, LLC.
Location: Murray County, GA.
Plant Configuration: Simple cycle gas turbines.
Capacity: 1240 MW.
Fuel: Natural gas.
Purchasing Entities: None.
In-Service Date: June 1, 2002.

Owner: Duke Energy Enterprise, LLC [C&E 01–84].
Operator: Duke Energy Enterprise, LLC.
Location: Clarke County, MS.
Plant Configuration: Simple-cycle gas turbines.
Capacity: 640 MW.
Fuel: Natural gas.
Purchasing Entities: None.
In-Service Date: June 1, 2002.

Owner: Duke Energy Hot Spring, LLC [C&E 01–85].
Operator: Duke Energy Hot Spring, LLC.
Location: Hot Spring County, AR.
Plant Configuration: Simple-cycle gas turbines.
Capacity: 620 MW.
Fuel: Natural gas.
Purchasing Entities: None.
In-Service Date: June 1, 2002

Owner: Duke Energy Southaven, LLC [C&E 01–86.
Operator: Duke Energy Southaven, LLC.
Location: DeSoto County, MS.
Plant Configuration: Simple cycle gas turbines.
Capacity: 640 MW.
Fuel: Natural gas.
Purchasing Entities: None.
In-Service Date: June 1, 2002.

Owner: Duke Energy Hinds, LLC [C&E 01–87].
Operator: Duke Energy Hinds, LLC.
Location: Hinds County, MS.
Plant Configuration: Simple-cycle gas turbines.
Capacity: 520 MW.
Fuel: Natural gas.
Purchasing Entities: None.
In-Service Date: June 1, 2001.

Owner: Cogen Power II, Inc. [C&E 01–88].
Operator: Quest Power.
Location: Cassia County, ID.
Plant Configuration: Combined cycle.
Capacity: 252 MW.
Fuel: Natural gas.
Purchasing Entities: Municipalities.
In-Service Date: Summer, 2003.

Owner: Whiting Clean Energy, Inc. [C&E 01–89].
Operator: Whiting Clean Energy, Inc..
Location: Whiting, IN.
Plant Configuration: Combined cycle.
Capacity: 545 MW.
Fuel: Natural gas.
Purchasing Entities: Wholesale power market.
In-Service Date: September 1, 2001.

Owner: Lone Oak Energy Center, L.L.C. [C&E 01–90].
Operator: Calpine Eastern Corporation.
Location: Lowndes County, MS.
Plant Configuration: Combined cycle.
Capacity: 920 MW.
Fuel: Natural gas.
Purchasing Entities: Wholesale power market.
In-Service Date: July, 2003.

Owner: Haywood Energy Center, L.L.C. [C&E 01–91].
Operator: Calpine Eastern Corporation.
Location: Haywood County, TN.
Plant Configuration: Combined cycle.
Capacity: 780 MW.
Fuel: Natural gas.
Purchasing Entities: Wholesale power market.
In-Service Date: November , 2003.

Owner: Calpine Construction Finance Company, L.P. [C&E 01–92].
Operator: Calpine Eastern Corporation.
Location: Polk County, FL.
Plant Configuration: Combined cycle.
Capacity: 585 MW.
Fuel: Natural gas.
Purchasing Entities: Wholesale power market.
In-Service Date: August, 2003.

Issued in Washington, D.C., August 20, 2001.

Anthony J. Como,

Deputy Director, Electric Power Regulation, Office of Coal & Power Im/Ex., Office of Coal & Power Systems, Office of Fossil Energy.

[FR Doc. 01–21419 Filed 8–23–01; 8:45 am]

BILLING CODE 6450–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. ER01–2401–000]

AES Red Oak, LLC; Notice of Issuance of Order

August 20, 2001.

AES Red Oak, LLC (AES Red Oak) submitted for filing a rate schedule under which AES Red Oak will engage in wholesale electric power and energy transactions at market-based rates. AES Red Oak also requested waiver of various Commission regulations. In particular, AES Red Oak requested that the Commission grant blanket approval under 18 CFR part 34 of all future issuances of securities and assumptions of liability by AES Red Oak.

On August 10, 2001, pursuant to delegated authority, the Director, Division of Corporate Applications, Office of Markets, Tariffs and Rates, granted requests for blanket approval under Part 34, subject to the following:

Within thirty days of the date of the order, any person desiring to be heard or to protest the blanket approval of issuances of securities or assumptions of liability by AES Red Oak should file a motion to intervene or protest with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with Rules 211 and 214 of the Commission's Rules of Practice and Procedure (18 CFR 385.211 and 385.214).

Absent a request to be heard in opposition within this period, AES Red Oak is authorized to issue securities and assume obligations or liabilities as a guarantor, indorser, surety, or otherwise in respect of any security of another person; provided that such issuance or assumption is for some lawful object within the corporate purposes of AES Red Oak and compatible with the public interest, and is reasonably necessary or appropriate for such purposes.

The Commission reserves the right to require a further showing that neither public nor private interests will be adversely affected by continued approval of AES Red Oak's issuances of securities or assumptions of liability.

Notice is hereby given that the deadline for filing motions to intervene or protests, as set forth above, is September 10, 2001.

Copies of the full text of the Order are available from the Commission's Public Reference Branch, 888 First Street, N.E., Washington, D.C. 20426. The Order may also be viewed on the web at *http://www.ferc.gov* using the ''RIMS'' link, select ''Docket#'' and follow the instructions (call 202–208–2222 for assistance). Comments, protests and interventions may be filed electronically via the Internet in lieu of paper. See, 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's web site under the ''e-Filing'' link.

David P. Boergers,

Secretary.

[FR Doc. 01–21386 Filed 8–23–01; 8:45 am]

BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket Nos. EL01–45–002, EL01–45–005, ER01–1385–003, and ER01–1385–006]

Consolidated Edison Company of New York, Inc.; Notice of Filing

August 17, 2001.

Take notice that on August 14, 2001, the New York Independent System Operator, Inc. (NYISO) filed a revised timetable for implementation of the revised Localized Market Power Mitigation Measures proposed by Consolidated Edison Company of New York, Inc., and approved by the Commission's order issued on July 20, 2001 in the above-captioned dockets.

The NYISO has served a copy of this filing upon parties on the official service lists maintained by the Commission for the above-captioned dockets.

Any person desiring to be heard or to protest such filing should file a motion to intervene or protest with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with Rules 211 and 214 of the Commission's Rules of Practice and Procedure (18 CFR 385.211 and 385.214). All such motions and protests should be filed on or before August 30, 2001. This date supercedes the August 20 date given in the Commission's previous notice in this docket. Protests will be considered by the Commission to determine the appropriate action to be taken, but will not serve to make protestants parties to the proceedings. Any person wishing to become a party must file a motion to intervene. Copies of this filing are on file with the Commission and are available for public inspection. This filing may also be viewed on the Commission's web site at *http://www.ferc.gov* using the ''RIMS'' link, select ''Docket#'' and follow the instructions (call 202–208–2222 for assistance). Comments, protests and interventions may be filed electronically via the internet in lieu of paper. See, 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's web site under the ''e-filing'' link.

David P. Boergers,

Secretary.

[FR Doc. 01–21377 Filed 8–23–01; 8:45 am]

BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. ER01–2397–000]

Electric City Energy Producers, LLC; Notice of Issuance of Order

August 20, 2001.

Electric City Energy Producers, LLC (ECEP) submitted for filing a rate schedule under which ECEP will engage in wholesale electric power and energy transactions at market-based rates. ECEP also requested waiver of various Commission regulations. In particular, ECEP requested that the Commission grant blanket approval under 18 CFR Part 34 of all future issuances of securities and assumptions of liability by ECEP.

On August 10, 2001, pursuant to delegated authority, the Director, Division of Corporate Applications, Office of Markets, Tariffs and Rates, granted requests for blanket approval under Part 34, subject to the following:

Within thirty days of the date of the order, any person desiring to be heard or to protest the blanket approval of issuances of securities or assumptions of liability by ECEP should file a motion to intervene or protest with the Federal Energy Regulatory Commission, 888 First Street, N.E., Washington, D.C. 20426, in accordance with Rules 211 and 214 of the Commission's Rules of Practice and Procedure (18 CFR 385.211 and 385.214).

Absent a request to be heard in opposition within this period, ECEP is authorized to issue securities and assume obligations or liabilities as a guarantor, indorser, surety, or otherwise in respect of any security of another person; provided that such issuance or assumption is for some lawful object within the corporate purposes of ECEP and compatible with the public interest, and is reasonably necessary or appropriate for such purposes.

The Commission reserves the right to require a further showing that neither public nor private interests will be adversely affected by continued approval of ECEP's issuances of securities or assumptions of liability.

Notice is hereby given that the deadline for filing motions to intervene or protests, as set forth above, is September 10, 2001.

Copies of the full text of the Order are available from the Commission's Public Reference Branch, 888 First Street, N.E., Washington, D.C. 20426. The Order may also be viewed on the web at *http://www.ferc.gov* using the ''RIMS'' link, select ''Docket#'' and follow the instructions (call 202–208–2222 for assistance). Comments, protests and interventions may be filed electronically via the Internet in lieu of paper. See, 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's web site under the ''e-Filing'' link.

David P. Boergers,

Secretary.

[FR Doc. 01–21385 Filed 8–23–01; 8:45 am]

BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. ER01–2439–000]

Equitec Power, LLC; Notice of Issuance of Order

August 20, 2001.

Equitec Power, LLC (Equitec Power) submitted for filing a rate schedule under which Equitec Power will engage in wholesale electric power and energy transactions at market-based rates. Equitec Power also requested waiver of various Commission regulations. In particular, Equitec Power requested that the Commission grant blanket approval under 18 CFR part 34 of all future issuances of securities and assumptions of liability by Equitec Power.

On August 10, 2001, pursuant to delegated authority, the Director, Division of Corporate Applications, Office of Markets, Tariffs and Rates, granted requests for blanket approval under part 34, subject to the following:

Within thirty days of the date of the order, any person desiring to be heard or to protest the blanket approval of issuances of securities or assumptions of liability by Equitec Power should file a motion to intervene or protest with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with Rules 211 and 214 of the Commission's Rules of Practice and Procedure (18 CFR 385.211 and 385.214).

Absent a request to be heard in opposition within this period, Equitec Power is authorized to issue securities and assume obligations or liabilities as a guarantor, indorser, surety, or otherwise in respect of any security of another person; provided that such issuance or assumption is for some lawful object within the corporate purposes of Equitec Power and compatible with the public interest, and is reasonably necessary or appropriate for such purposes.

The Commission reserves the right to require a further showing that neither public nor private interests will be adversely affected by continued approval of Equitec Power's issuances of securities or assumptions of liability.

Notice is hereby given that the deadline for filing motions to intervene or protests, as set forth above, is September 10, 2001.

Copies of the full text of the Order are available from the Commission's Public Reference Branch, 888 First Street, NE., Washington, DC 20426. The Order may also be viewed on the web at *http://www.ferc.gov* using the ''RIMS'' link, select ''Docket#'' and follow the instructions (call 202–208–2222 for assistance). Comments, protests and interventions may be filed electronically via the Internet in lieu of paper. See, 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's web site under the ''e-Filing'' link.

David P. Boergers,

Secretary.

[FR Doc. 01–21387 Filed 8–23–01; 8:45 am]

BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. ER01–2129–000]

Halt Company Ohio; Notice of Issuance of Order

August 20, 2001.

Halt Company of Ohio (Halt) submitted for filing a rate schedule under which Halt will engage in wholesale electric power and energy transactions at market-based rates. Halt also requested waiver of various Commission regulations. In particular, Halt requested that the Commission grant blanket approval under 18 CFR part 34 of all future issuances of securities and assumptions of liability by Halt.

On July 23, 2001, pursuant to delegated authority, the Director, Division of Corporate Applications, Office of Markets, Tariffs and Rates, granted requests for blanket approval under part 34, subject to the following:

Within thirty days of the date of the order, any person desiring to be heard or to protest the blanket approval of issuances of securities or assumptions of liability by Halt should file a motion to intervene or protest with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with Rules 211 and 214 of the Commission's Rules of Practice and Procedure (18 CFR 385.211 and 385.214).

Absent a request to be heard in opposition within this period, Halt is authorized to issue securities and assume obligations or liabilities as a guarantor, indorser, surety, or otherwise in respect of any security of another person; provided that such issuance or assumption is for some lawful object within the corporate purposes of Halt and compatible with the public interest, and is reasonably necessary or appropriate for such purposes.

The Commission reserves the right to require a further showing that neither public nor private interests will be adversely affected by continued approval of Halt's issuances of securities or assumptions of liability.

Notice is hereby given that the deadline for filing motions to intervene or protests, as set forth above, is September 17, 2001.

Copies of the full text of the Order are available from the Commission's Public Reference Branch, 888 First Street, NE, Washington, DC 20426. The Order may also be viewed on the on the web at *http://www.ferc.gov* using the ''RIMS'' link, select ''Docket#'' and follow the instructions (call 202–208–2222 for assistance). Comments, protests and interventions may be filed electronically via the Internet in lieu of paper. See, 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's web site under the ''e-Filing'' link.

David P. Boergers,

Secretary.

[FR Doc. 01–21382 Filed 8–23–01; 8:45 am]

BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. ER01–2563–000]

Jackson County Power, LLC; Notice of Issuance of Order

August 20, 2001.

Jackson County Power, LLC (Jackson County) submitted for filing a rate schedule under which Jackson County will engage in wholesale electric power and energy transactions at market-based rates. Jackson County also requested waiver of various Commission regulations. In particular, Jackson County requested that the Commission grant blanket approval under 18 CFR part 34 of all future issuances of securities and assumptions of liability by Jackson County.

On August 10, 2001, pursuant to delegated authority, the Director, Division of Corporate Applications, Office of Markets, Tariffs and Rates, granted requests for blanket approval under Part 34, subject to the following:

Within thirty days of the date of the order, any person desiring to be heard or to protest the blanket approval of issuances of securities or assumptions of liability by Jackson County should file a motion to intervene or protest with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with Rules 211 and 214 of the Commission's Rules of

Practice and Procedure (18 CFR 385.211 and 385.214).

Absent a request to be heard in opposition within this period, Jackson County is authorized to issue securities and assume obligations or liabilities as a guarantor, indorser, surety, or otherwise in respect of any security of another person; provided that such issuance or assumption is for some lawful object within the corporate purposes of Jackson County and compatible with the public interest, and is reasonably necessary or appropriate for such purposes.

The Commission reserves the right to require a further showing that neither public nor private interests will be adversely affected by continued approval of Jackson County's issuances of securities or assumptions of liability.

Notice is hereby given that the deadline for filing motions to intervene or protests, as set forth above, is September 10, 2001.

Copies of the full text of the Order are available from the Commission's Public Reference Branch, 888 First Street, NE., Washington, D.C. 20426. The Order may also be viewed on the web at *http://www.ferc.gov* using the ''RIMS'' link, select ''Docket#'' and follow the instructions (call 202–208–2222 for assistance). Comments, protests and interventions may be filed electronically via the Internet in lieu of paper. See, 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's web site under the ''e-Filing'' link.

David P. Boergers,

Secretary.

[FR Doc. 01–21389 Filed 8–23–01; 8:45 am]

BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. ER01–1690–001]

Megawatt Marketing, LLC; Notice of Issuance of Order

August 20, 2001.

Megawatt Marketing, LLC (Megawatt Marketing) submitted for filing a rate schedule under which Megawatt Marketing will engage in wholesale electric power and energy transactions at market-based rates. Megawatt Marketing also requested waiver of various Commission regulations. In particular, Megawatt Marketing requested that the Commission grant blanket approval under 18 CFR part 34 of all future issuances of securities and assumptions of liability by Megawatt Marketing.

On August 10, 2001, pursuant to delegated authority, the Director, Division of Corporate Applications, Office of Markets, Tariffs and Rates, granted requests for blanket approval under Part 34, subject to the following:

Within thirty days of the date of the order, any person desiring to be heard or to protest the blanket approval of issuances of securities or assumptions of liability by Megawatt Marketing should file a motion to intervene or protest with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with Rules 211 and 214 of the Commission's Rules of Practice and Procedure (18 CFR 385.211 and 385.214).

Absent a request to be heard in opposition within this period, Megawatt Marketing is authorized to issue securities and assume obligations or liabilities as a guarantor, indorser, surety, or otherwise in respect of any security of another person; provided that such issuance or assumption is for some lawful object within the corporate purposes of Megawatt Marketing and compatible with the public interest, and is reasonably necessary or appropriate for such purposes.

The Commission reserves the right to require a further showing that neither public nor private interests will be adversely affected by continued approval of Megawatt Marketing's issuances of securities or assumptions of liability.

Notice is hereby given that the deadline for filing motions to intervene or protests, as set forth above, is September 10, 2001.

Copies of the full text of the Order are available from the Commission's Public Reference Branch, 888 First Street, NE., Washington, DC 20426. The Order may also be viewed on the web at *http://www.ferc.gov* using the ''RIMS'' link, select ''Docket#'' and follow the instructions (call 202–208–2222 for assistance). Comments, protests and interventions may be filed electronically via the Internet in lieu of paper. See, 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's web site under the ''e-Filing'' link.

David P. Boergers,

Secretary.

[FR Doc. 01–21380 Filed 8–23–01; 8:45 am]

BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. ER01–2509–000]

Morrow Power, LLC; Notice of Issuance of Order

August 20, 2001.

Morrow Power, LLC (Morrow Power) submitted for filing a rate schedule under which Morrow Power will engage in wholesale electric power and energy transactions at market-based rates. Morrow Power also requested waiver of various Commission regulations. In particular, Morrow Power requested that the Commission grant blanket approval under 18 CFR part 34 of all future issuances of securities and assumptions of liability by Morrow Power.

On August 8, 2001, pursuant to delegated authority, the Director, Division of Corporate Applications, Office of Markets, Tariffs and Rates, granted requests for blanket approval under part 34, subject to the following:

Within thirty days of the date of the order, any person desiring to be heard or to protest the blanket approval of issuances of securities or assumptions of liability by Morrow Power should file a motion to intervene or protest with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with Rules 211 and 214 of the Commission's Rules of Practice and Procedure (18 CFR 385.211 and 385.214).

Absent a request to be heard in opposition within this period, Morrow Power is authorized to issue securities and assume obligations or liabilities as a guarantor, indorser, surety, or otherwise in respect of any security of another person; provided that such issuance or assumption is for some lawful object within the corporate purposes of Morrow Power and compatible with the public interest, and is reasonably necessary or appropriate for such purposes.

The Commission reserves the right to require a further showing that neither public nor private interests will be adversely affected by continued approval of Morrow Power's issuances of securities or assumptions of liability.

Notice is hereby given that the deadline for filing motions to intervene or protests, as set forth above, is September 7, 2001.

Copies of the full text of the Order are available from the Commission's Public Reference Branch, 888 First Street, NE., Washington, DC 20426. The Order may also be viewed on the web at *http://www.ferc.gov* using the ''RIMS''

link, select ''Docket#'' and follow the instructions (call 202–208–2222 for assistance). Comments, protests and interventions may be filed electronically via the Internet in lieu of paper. See, 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's web site under the ''e-Filing'' link.

David P. Boergers,

Secretary.

[FR Doc. 01–21388 Filed 8–23–01; 8:45 am]

BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. ER01–2115–000, Docket Nos. ER01–2192–000 and EL01–85–000, Docket No. ER01–2223–000, Docket No. ER01–2329–000, and Docket No. RT01–99–000]

New England Power Pool., ISO New England, Inc., New England Power Pool, New England Power Pool ISO New England, Inc., Regional Transmission Organizations; Notice Shortening Answer Period

August 20, 2001.

On August 17, 2001, ISO New England Inc. (ISO New England) filed a Request for Clarification (Request) in response to the Commission's Order on Standard Market Design issued July 25, 2001, in the above-docketed proceeding. ISO New England's filing also requested expedited consideration of its Request. By this notice, the period for the filing of answers to ISO New England's Request is hereby shortened to and including August 27, 2001.

David P. Boergers,

Secretary.

[FR Doc. 01–21374 Filed 8–23–01; 8:45 am]

BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. ER01–2224–000]

Nordic Energy Barge #1, L.L.C., Nordic Energy Barge #2, L.L.C.; Notice of Issuance of Order

August 20, 2001.

Nordic Energy Barge #1, L.L.C. and Nordic Energy Barge #2, L.L.C. (collectively, ''Nordic Energy'') submitted for filing a rate schedule under which Nordic Energy will engage in wholesale electric power and energy transactions at market-based rates. Nordic Energy also requested waiver of various Commission regulations. In particular, Nordic Energy requested that the Commission grant blanket approval under 18 CFR part 34 of all future issuances of securities and assumptions of liability by Nordic Energy.

On July 24, 2001, pursuant to delegated authority, the Director, Division of Corporate Applications, Office of Markets, Tariffs and Rates, granted requests for blanket approval under Part 34, subject to the following:

Within thirty days of the date of the order, any person desiring to be heard or to protest the blanket approval of issuances of securities or assumptions of liability by Nordic Energy should file a motion to intervene or protest with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with Rules 211 and 214 of the Commission's Rules of Practice and Procedure (18 CFR 385.211 and 385.214).

Absent a request to be heard in opposition within this period, Nordic Energy is authorized to issue securities and assume obligations or liabilities as a guarantor, indorser, surety, or otherwise in respect of any security of another person; provided that such issuance or assumption is for some lawful object within the corporate purposes of Nordic Energy and compatible with the public interest, and is reasonably necessary or appropriate for such purposes.

The Commission reserves the right to require a further showing that neither public nor private interests will be adversely affected by continued approval of Nordic Energy's issuances of securities or assumptions of liability.

Notice is hereby given that the deadline for filing motions to intervene or protests, as set forth above, is September 17, 2001.

Copies of the full text of the Order are available from the Commission's Public Reference Branch, 888 First Street, NE., Washington, DC 20426. The Order may also be viewed on the web at *http://www.ferc.gov* using the ''RIMS'' link, select ''Docket#'' and follow the instructions (call 202–208–2222 for assistance). Comments, protests and interventions may be filed electronically via the Internet in lieu of paper. See, 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's web site under the ''e-Filing'' link.

David P. Boergers,

Secretary.

[FR Doc. 01–21383 Filed 8–23–01; 8:45 am]

BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. ER01–2306–000]

Peoples Energy Services Corporation; Notice of Issuance of Order

August 20, 2001.

Peoples Energy Services Corporation (PESC) submitted for filing a rate schedule under which PESC will engage in wholesale electric power and energy transactions at market-based rates. PESC also requested waiver of various Commission regulations. In particular, PESC requested that the Commission grant blanket approval under 18 CFR Part 34 of all future issuances of securities and assumptions of liability by PESC.

On August 8, 2001, pursuant to delegated authority, the Director, Division of Corporate Applications, Office of Markets, Tariffs and Rates, granted requests for blanket approval under Part 34, subject to the following:

Within thirty days of the date of the order, any person desiring to be heard or to protest the blanket approval of issuances of securities or assumptions of liability by PESC should file a motion to intervene or protest with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with Rules 211 and 214 of the Commission's Rules of Practice and Procedure (18 CFR 385.211 and 385.214).

Absent a request to be heard in opposition within this period, PESC is authorized to issue securities and assume obligations or liabilities as a guarantor, indorser, surety, or otherwise in respect of any security of another person; provided that such issuance or assumption is for some lawful object within the corporate purposes of PESC and compatible with the public interest, and is reasonably necessary or appropriate for such purposes.

The Commission reserves the right to require a further showing that neither public nor private interests will be adversely affected by continued approval of PESC's issuances of securities or assumptions of liability.

Notice is hereby given that the deadline for filing motions to intervene or protests, as set forth above, is September 7, 2001.

Copies of the full text of the Order are available from the Commission's Public Reference Branch, 888 First Street, NE., Washington, DC 20426. The Order may also be viewed on the web at *http://www.ferc.gov* using the ''RIMS'' link, select ''Docket#'' and follow the

instructions (call 202–208–2222 for assistance). Comments, protests and interventions may be filed electronically via the Internet in lieu of paper. See, 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's web site under the ''e-Filing'' link.

David P. Boergers,

Secretary.

[FR Doc. 01–21384 Filed 8–23–01; 8:45 am]

BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. ER01–1714–000, ER01–1714–001]

Santa Rosa Energy, LLC; Notice of Issuance of Order

August 20, 2001.

Santa Rosa Energy, LLC (Santa Rosa) submitted for filing a rate schedule under which Santa Rosa will engage in wholesale electric power and energy transactions at market-based rates. Santa Rosa also requested waiver of various Commission regulations. In particular, Santa Rosa requested that the Commission grant blanket approval under 18 CFR Part 34 of all future issuances of securities and assumptions of liability by Santa Rosa.

On July 23, 2001, pursuant to delegated authority, the Director, Division of Corporate Applications, Office of Markets, Tariffs and Rates, granted requests for blanket approval under Part 34, subject to the following:

Within thirty days of the date of the order, any person desiring to be heard or to protest the blanket approval of issuances of securities or assumptions of liability by Santa Rosa should file a motion to intervene or protest with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with Rules 211 and 214 of the Commission's Rules of Practice and Procedure (18 CFR 385.211 and 385.214).

Absent a request to be heard in opposition within this period, Santa Rosa is authorized to issue securities and assume obligations or liabilities as a guarantor, indorser, surety, or otherwise in respect of any security of another person; provided that such issuance or assumption is for some lawful object within the corporate purposes of Santa Rosa and compatible with the public interest, and is reasonably necessary or appropriate for such purposes.

The Commission reserves the right to require a further showing that neither public nor private interests will be adversely affected by continued approval of Santa Rosa's issuances of securities or assumptions of liability.

Notice is hereby given that the deadline for filing motions to intervene or protests, as set forth above, is September 17, 2001.

Copies of the full text of the Order are available from the Commission's Public Reference Branch, 888 First Street, N.E., Washington, D.C. 20426. The Order may also be viewed on the web at *http://www.ferc.gov* using the ''RIMS'' link, select ''Docket#'' and follow the instructions (call 202–208–2222 for assistance). Comments, protests and interventions may be filed electronically via the Internet in lieu of paper. See, 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's web site under the ''e-Filing'' link

David P. Boergers,

Secretary.

[FR Doc. 01–21381 Filed 8–23–01; 8:45 am]

BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. ER01–2139–000]

Somerset Windpower, LLC; Notice of Issuance of Order

August 20, 2001.

Somerset Windpower, LLC (Somerset) submitted for filing a rate schedule under which Somerset will engage in wholesale electric power and energy transactions at market-based rates. Somerset also requested waiver of various Commission regulations. In particular, Somerset requested that the Commission grant blanket approval under 18 CFR part 34 of all future issuances of securities and assumptions of liability by Somerset.

On July 20, 2001, pursuant to delegated authority, the Director, Division of Corporate Applications, Office of Markets, Tariffs and Rates, granted requests for blanket approval under part 34, subject to the following:

Within thirty days of the date of the order, any person desiring to be heard or to protest the blanket approval of issuances of securities or assumptions of liability by Somerset should file a motion to intervene or protest with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with Rules 211 and 214 of the Commission's Rules of Practice and Procedure (18 CFR 385.211 and 385.214).

Absent a request to be heard in opposition within this period, Somerset is authorized to issue securities and assume obligations or liabilities as a guarantor, indorser, surety, or otherwise in respect of any security of another person; provided that such issuance or assumption is for some lawful object within the corporate purposes of Somerset and compatible with the public interest, and is reasonably necessary or appropriate for such purposes.

The Commission reserves the right to require a further showing that neither public nor private interests will be adversely affected by continued approval of Somerset's issuances of securities or assumptions of liability.

Notice is hereby given that the deadline for filing motions to intervene or protests, as set forth above, is September 17, 2001.

Copies of the full text of the Order are available from the Commission's Public Reference Branch, 888 First Street, NE., Washington, DC 20426. The Order may also be viewed on the web at http://www.ferc.gov using the ''RIMS'' link, select ''Docket#'' and follow the instructions (call 202–208–2222 for assistance). Comments, protests and interventions may be filed electronically via the Internet in lieu of paper. See, 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's web site under the ''e-Filing'' link.

David P. Boergers,

Secretary.

[FR Doc. 01–21378 Filed 8–23–01; 8:45 am]

BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. MG01–28–000]

Vector Pipeline L.P.; Notice of Filing

August 20, 2001.

On August 13, 2001, Vector Pipeline L.P. filed its initial standards of conduct.

Vector Pipeline L.P. states that it served copies of the filing on all customers and interested state commissions.

Any persons desiring to be heard or to protest said filing should file a motion to intervene or protest in this proceeding with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with Rules 211 and 214 of

the Commission's Rules of Practice and Procedure. (18 CFR 385.211 or 385.214) All such motions to intervene or protest should be filed on or before September 4, 2001. Protests will be considered by the Commission in determining the appropriate action to be taken but will not serve to make protestants parties to the proceeding. Any person wishing to become a party must file a motion to intervene. Copies of this filing are on file with the Commission and are available for public inspection. This filing may also be viewed on the web at *http://www.ferc.gov* using the ''RIMS'' link, select ''Docket#'' and follow the instructions (call 202–208–2222 for assistance). Comments, protests and interventions may be filed electronically via the Internet in lieu of paper. See, 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's web site under the ''e-Filing'' link.

David P. Boergers,

Secretary.

[FR Doc. 01–21390 Filed 8–23–01; 8:45 am]

BILLING CODE 6717–01–M

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. EG01–280–000, et al.]

American Ref-Fuel Company of Southeastern Connecticut, *et al;* Electric Rate and Corporate Regulation Filings

August 20, 2001.

Take notice that the following filings have been made with the Commission:

1. American Ref-Fuel Company of Southeastern Connecticut

[Docket No. EG01–280–000]

On August 15, 2001, American Ref-Fuel Company of Southeastern Connecticut (the Applicant), with its principal place of business at (c/o American Ref-Fuel Company) 15990 North Barker's Landing, Suite 200, Houston, Texas 77079, filed with the Federal Energy Regulatory Commission (Commission) an application for determination of exempt wholesale generator status pursuant to Part 365 of the Commission's regulations.

Comment date: September 5, 2001, in accordance with Standard Paragraph E at the end of this notice. The Commission will limit its consideration of comments to those that concern the adequacy or accuracy of the application.

2. Carolina Power & Light Company and Florida Power Corporation

[Docket No. ER01–1807–004]

Take notice that Carolina Power & Light Company and Florida Power Corporation on August 15, 2001 tendered for filing a modification to the compliance filing they made in response to the Commission's Order issued on June 25, 2001 in this docket, Carolina Power & Light Company and Florida Power Corporation, 5 FERC 61,429 (2001). The Company is submitting the revision following discussions with North Carolina Electric Membership Cooperative (NCEMC), the only customer of CP&L who is affected by the revision.

Copies of the filing were served upon the parties listed on the Commission's official service list and the North Carolina Utilities Commission, the South Carolina Public Service Commission and the Florida Public Service Commission and the filing was posted on the Companies' OASIS sites.

3. Otter Tail Power Company, a Division of Otter Tail Corporation

[Docket No. ER01–2207–001]

Take notice that on August 15, 2001, Otter Tail Power Company, a division of Otter Tail Corporation, filed a Response to the Commission's Order in Mid-Continent Area Power Pool, 96 FERC 61,111 (2001).

Comment date: September 5, 2001, in accordance with Standard Paragraph E at the end of this notice.

4. Montana-Dakota Utilities Co., a Division of MDU Resources Group, Inc.

[Docket No. ER01–2207–003]

Take notice that on August 15, 2001, Montana-Dakota Utilities Co., a Division of MDU Resources Group, Inc. (Montana-Dakota) tendered for filing a letter notifying the Federal Energy Regulatory Commission that the Montana-Dakota open access transmission tariff has been modified, effective July 16, 2001 to include the revised Mid-Continent Area Power Pool (MAPP) Transmission Loading Relief (TLR) procedures that incorporate the North American Electric Reliability Councils for curtailments of firm transmission, including generation to load service approved in Docket No. ER01–2207–000.

Comment date: September 15, 2001, in accordance with Standard Paragraph E at the end of this notice.

5. Virginia Electric and Power Company

[Docket No. ER01–2840–000]

Take notice that on August 15, 2001, Virginia Electric and Power Company (Dominion Virginia Power or the Company) tendered for filing the following Service Agreement for Firm Point-to-Point Transmission Service by Virginia Electric and Power Company to Ameren Energy, Inc., as agent for and on behalf of Union Electric Company doing business as Ameren UE, Ameren Energy Marketing Company and Ameren Energy Generating Company (Ameren) designated as Service Agreement No. 334 under the Company's FERC Electric Tariff, Second Revised Volume No. 5 and Service Agreement for Non-Firm Point-to-Point Transmission Service by Virginia Electric and Power Company to Ameren Energy, Inc., as agent for and on behalf of Union Electric Company doing business as Ameren UE, Ameren Energy Marketing Company and Ameren Energy Generating Company (''Ameren'') designated as Service Agreement No. 335 under the Company's FERC Electric Tariff, Second Revised Volume No. 5.

The foregoing Service Agreements are tendered for filing under the Open Access Transmission Tariff to Eligible Purchasers effective June 7, 2000. Under the tendered Service Agreements, Dominion Virginia Power will provide point-to-point service to Ameren under the rates, terms and conditions of the Open Access Transmission Tariff. Dominion Virginia Power requests an effective date August 15, 2001, the date of filing of the Service Agreements. Copies of the filing were served upon Ameren Energy, Inc., the Virginia State Corporation Commission, and the North Carolina Utilities Commission.

Comment date: September 15, 2001, in accordance with Standard Paragraph E at the end of this notice.

6. The Montana Power Company

[Docket No. ER01–2844–000]

Take notice that on August 15, 2001, The Montana Power Company (Montana) tendered for filing with the Federal Energy Regulatory Commission pursuant to 18 CFR 35.13 an unexecuted Network Integration Transmission Service Agreement with Express Pipeline LLC under Montana's FERC Electric Tariff, Fourth Revised Volume No. 5 (Open Access Transmission Tariff).

A copy of the filing was served upon Express Pipeline LLC.

Comment date: September 5, 2001, in accordance with Standard Paragraph E at the end of this notice.

7. American Transmission Company LLC

[Docket No. ER01–2845–000]

Take notice that on August 15, 2001, American Transmission Company LLC (ATCLLC) tendered for filing Firm and Non-Firm Point-to-Point Service Agreements for Detroit Edison Company and DTE Energy Trading, Inc. ATCLLC requests an effective date of August 1, 2001.

Comment date: September 5, 2001, in accordance with Standard Paragraph E at the end of this notice.

8. Southwestern Electric Power Company

[Docket No. ER01–2847–000]

Take notice that on August 15, 2001, Southwestern Electric Power Company (SWEPCO) submitted for filing a Restated and Amended Flint Creek Power Plant Power Coordination, Interchange and Transmission Service Agreement between Arkansas Electric Cooperative Corporation (AECC) and SWEPCO.

SWEPCO requests an effective date of July 1, 2000 for the Restated and Amended Agreement. Accordingly, to the extent necessary, SWEPCO seeks waiver of the Commission's filing requirements. SWEPCO has served copies of the filing on AECC and the Arkansas Public Service Commission. Copies of the filing are available for public inspection in SWEPCO's offices in Shreveport, Louisiana.

Comment date: September 5, 2001, in accordance with Standard Paragraph E at the end of this notice.

9. Commonwealth Edison Company

[Docket No. ER01–2850–000]

Take notice that Commonwealth Edison Company (ComEd) on August 15, 2001, tendered for filing pursuant to section 35.15 of the Federal Energy Regulatory Commission's regulations, 18 CFR 35.15 (2000), a Notice of Cancellation of Service Agreement Nos. 71 between ComEd and Illinova Energy Partners, Inc. (IEP) formerly Illinova Power Marketing, Inc.

ComEd requests an effective date of October 15, 2001 for the cancellation. ComEd served copies of the filing upon IEP.

Comment date: September 5, 2001, in accordance with Standard Paragraph E at the end of this notice.

10. Commonwealth Edison Company

[Docket No. ER01–2851–000]

Take notice that Commonwealth Edison Company (ComEd) on August 15, 2001, tendered for filing pursuant to section 35.15 of the Federal Energy Regulatory Commission's regulations, 18 CFR 35.15 (2000), a Notice of Cancellation of Service Agreement Nos. 368 between ComEd and Illinova Power Marketing, Inc (IPMI).

ComEd requests an effective date of October 15, 2001 for the cancellation. ComEd served copies of the filing upon IPMI.

Comment date: September 5, 2001, in accordance with Standard Paragraph E at the end of this notice.

11. Commonwealth Edison Company

[Docket No. ER01–2852–000]

Take notice that Commonwealth Edison Company (ComEd) on August 15, 2001, tendered for filing pursuant to section 35.15 of the Federal Energy Regulatory Commission's regulations, 18 CFR 35.15 (2000), a Notice of Cancellation of Service Agreement Nos. 348 between ComEd and Allegheny Power Service Corporation as agent for Monongahela Power Company, The Potomac Edison Company and West Penn Power Company, collectively d/b/a Allegheny Power under ComEd's Open Access Transmission Tariff (OATT). ComEd served copies of the filing upon Allegheny Power and Allegheny Energy.

ComEd requests an effective date of October 15, 2001 for the cancellation.

Comment date: September 5, 2001, in accordance with Standard Paragraph E at the end of this notice.

12. Virginia Electric and Power Company

[Docket No. ER01–2853–000]

Take notice that on August 15, 2001, Virginia Electric and Power Company (Dominion Virginia Power) tendered for filing Notices of Termination of Service Agreements with Ameren Services Company for Non-Firm and Firm Point-To-Point Transmission Service designated respectively as First Revised Service Nos. 221 and 222 under FERC Electric Tariff, Second Revised Volume No. 5. Dominion Virginia Power also respectfully requests an effective date of the termination of the Service Agreements of October 15, 2001, which is sixty (60) days from the date of filing of the Letter of Termination.

Copies of the filing were served upon Ameren Services Company, the Virginia State Corporation Commission and the North Carolina Utilities Commission.

Comment date: September 5, 2001, in accordance with Standard Paragraph E at the end of this notice.

Standard Paragraph

E. Any person desiring to be heard or to protest such filing should file a motion to intervene or protest with the Federal Energy Regulatory Commission, 888 First Street, N.E., Washington, D.C. 20426, in accordance with Rules 211 and 214 of the Commission's Rules of Practice and Procedure (18 CFR 385.211 and 385.214). All such motions or protests should be filed on or before the comment date. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceeding. Any person wishing to become a party must file a motion to intervene. Copies of this filing are on file with the Commission and are available for public inspection. This filing may also be viewed on the web at *http://www.ferc.gov* using the ''RIMS'' link, select ''[Docket#'' and follow the instructions (call 202–208–2222 for assistance). Comments, protests and interventions may be filed electronically via the Internet in lieu of paper. See, 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's web site under the ''e-Filing'' link.

David P. Boergers,

Secretary.

[FR Doc. 01–21375 Filed 8–23–01; 8:45 am]

BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. EC01–137–000, et al.]

DTE Energy Company, et al.; Electric Rate and Corporate Regulation Filings

August 17, 2001.

Take notice that the following filings have been made with the Commission:

1. DTE Energy Company, International Transmission Company

[Docket No. EC01–137–000]

Take notice that on August 10, 2001, DTE Energy Company and International Transmission Company tendered a joint application for authority to dispose of jurisdictional transmission facilities pursuant to section 203 of the Federal Power Act in accordance with the Commission's directive in International Transmission Co., 92 FERC 61,276 (2000).

Comment date: August 31, 2001, in accordance with Standard Paragraph E at the end of this notice.

2. Wisconsin Power and Light Company, Wisconsin Public Service Corporation

[Docket No. EC01–138–000]

Take notice that on August 9, 2001, Wisconsin Power and Light Company (WPL) and Wisconsin Public Service Corporation (WPSC) (collectively, the Applicants) filed an application under the provisions of Section 203 of the Federal Power Act for WPL to purchase a portion of WPSC's common equity interest in the Wisconsin River Power Company.

The Applicants state that copies of this application were served on the Public Service Commission, the Michigan Public Service Commission, the Illinois Commerce Commission, the U.S. Department of Justice, the Federal Trade Commission and Consolidated Water Power Company.

Comment date: August 29, 2001, in accordance with Standard Paragraph E at the end of this notice.

3. Southern Indiana Gas and Electric Company

[Docket No. EC01–139–000]

Take notice that on August 8, 2001, Southern Indiana Gas and Electric Company (SIGECO) filed with the Federal Energy Regulatory Commission an application pursuant to section 203 of the Federal Power Act for authorization of a disposition of jurisdictional facilitates whereby the SIGECO will transfer operational control of substantial portions of its jurisdictional transmission facilities to the Midwest Independent System Operator, Inc.

Comment date: August 29, 2001, in accordance with Standard Paragraph E at the end of this notice.

4. Mesquite Investors, L.L.C., Shady Hills Holding Company, L.L.C., Shady Hills Power Company, L.L.C., West Georgia Generating Company, L.L.C., Mirant Americas, Inc.

[Docket No. EC01–140–000]

Take notice that on August 14, 2001, Mesquite Investors, L.L.C. (Mesquite), Shady Hills Holding Company, L.L.C. (Shady Hills), Shady Hills Power Company, L.L.C. (Shady Hills Power), West Georgia Generating Company, L.L.C. (West Georgia), and Mirant Americas, Inc. (Mirant) (jointly Applicants) filed with the Federal Energy Regulatory Commission an application pursuant to Section 203 of the Federal Power Act for authorization of a disposition of jurisdictional facilities whereby Shady Hills will transfer its member interests in Shady Hills Power to Mirant and Mesquite will transfer its member interests in West Georgia to Mirant. Shady Hills Power owns a 480 MW generating facility under construction in New Port Richey, Florida. West Georgia owns and operates a 640 MW generating facility in Thomaston, Georgia. Applicants also request privileged treatment for certain exhibits pursuant to 18 CFR 33.9 and 388.112.

Comment date: September 4, 2001, in accordance with Standard Paragraph E at the end of this notice.

5. Richmond County Power, LLC

[Docket Nos. ER01–1417–002]

Take notice that on August 13, 2001, Richmond County Power, LLC tendered a compliance filing for authorization to sell energy, capacity and ancillary services at market-based rates.

Comment date: September 4, 2001, in accordance with Standard Paragraph E at the end of this notice.

6. Alliant Energy Corporate Services, Inc.

[Docket No. ER01–2207–002]

Take notice that on August 13 , 2001, Alliant Energy Corporate Services, Inc. tendered for filing a notice concerning the Commission's Order regarding the Incorporation of NERC Transmission Loading Relief Procedures, which were issued in ER01–2207–000.

A copy of this filing has been served upon the Illinois Commerce Commission, the Minnesota Public Utilities Commission, the Iowa Department of Commerce, and the Public Service Commission of Wisconsin.

Comment date: September 4, 2001, in accordance with Standard Paragraph E at the end of this notice.

7. Pro-Energy Development, LLC

[Docket No. ER01–2463–001

Take notice that on August 13, 2001, Pro Energy Development LLC petitioned the Commission for acceptance of Pro Energy Development LLC Rate Schedule FERC No.1; the granting of certain blanket approvals, including the authority to sell electricity at market based rates; and the waiver of certain Commission regulations.

Pro Energy Development LLC intends to engage in wholesale electric power and energy purchases and sales as a marketer. Pro Energy Development LLC is not in the business of generating or transmitting electric power.

Comment date: September 4, 2001, in accordance with Standard Paragraph E at the end of this notice.

8. Ameren Energy, Inc., on behalf of Union Electric Company d/b/a AmerenUE, Ameren Energy Marketing Company and Ameren Energy Generating Company

[Docket No. ER01–2500–000

Take notice that on August 13, 2001, Ameren Energy, Inc. (Ameren Energy), on behalf of Union Electric Company d/b/a AmerenUE, Ameren Energy Market Company, and Ameren Energy Generating Company (collectively, the Ameren Parties), pursuant to section 205 of the Federal Power Act, 16 U.S.C. 824d, filed a Notice of Withdrawal of a proposed *pro forma* umbrella power sales service agreement under the Ameren Parties' market rate authorizations that was filed in this proceeding on July 3, 2001. Ameren Energy states that no parties have intervened in this proceeding or protested the July 3 Filing, and that no party will be prejudiced or otherwise affected by the withdrawal. Ameren Energy requests that the Commission accept the Notice of Withdrawal effective as of July 4, 2001.

Copies of this filing were served on the public utilities commissions of Illinois and Missouri, and on all parties on the Commission's official service list in this proceeding.

Comment date: September 4, 2001, in accordance with Standard Paragraph E at the end of this notice.

9. Canastota Windpower, LLC

[Docket No. ER01–2692–001]

Canastota Windpower LLC (Canastota) filed an Amendment and Restated petition to the Commission on August 13, 2001, for authority to sell electricity at market-based rates under Section 205(a) of the Federal Power Act, 16 U.S.C. 824d(a); for granting of certain blanket approvals and for the waiver of certain Commission regulations. Canastota is a limited liability company that proposes to engage in the wholesale sale of electric power in the State of New York.

Comment date: September 4, 2001, in accordance with Standard Paragraph E at the end of this notice.

10. Arizona Public Service Company

[Docket No. ER01–2826–000]

Take notice that on August 13, 2001, Arizona Public Service Company (APS) tendered for filing umbrella Service Agreements to provide Short-Term Firm and Non-Firm Point-to-Point Transmission Service to PPL EnergyPlus, LLC under APS' Open Access Transmission Tariff.

A copy of this filing has been served on PPL EnergyPlus, LLC and the Arizona Corporation Commission.

Comment date: September 4, 2001, in accordance with Standard Paragraph E at the end of this notice.

11. UtiliCorp United Inc.

[Docket No. ER01–2827–000]

Take notice that on August 13, 2001, UtiliCorp United Inc. tendered for filing amendments to the open access transmission tariffs for its Missouri Public Service, WestPlains Energy-Kansas, and St. Joseph Power & Light operating divisions. The amendments incorporate the Mid-Continent Area Power Pool Transmission Loading Relief procedures for curtailments of firm transmission.

Comment date: September 4, 2001, in accordance with Standard Paragraph E at the end of this notice.

12. Ameren Services Company

[Docket No. ER01–2828–000]

Take notice that on August 13, 2001, Ameren Services Company (ASC) tendered for filing Service Agreements for Firm Point-to-Point Transmission Service Agreements and Non-Firm Point-to-Point Transmission Service Agreements between ASC and Calpine Energy Services, L.P. and Exelon Generation Company, LLP (the parties). ASC asserts that the purpose of the Agreements is to permit ASC to provide transmission service to the parties pursuant to Ameren's Open Access Transmission Tariff.

Comment date: September 4, 2001, in accordance with Standard Paragraph E at the end of this notice.

13. Progress Energy Inc. On behalf of Carolina Power & Light Company

[Docket No. ER01–2829–000]

Take notice that on August 13, 2001, Carolina Power & Light Company (CP&L) tendered for filing an executed Service Agreement between CP&L and the following eligible buyer, Enron Power Marketing, LLC. Service to this eligible buyer will be in accordance with the terms and conditions of CP&L's Market-Based Rates Tariff, FERC Electric Tariff No. 4, for sales of capacity and energy at market-based rates. Copies of the filing were served upon the North Carolina Utilities Commission and the South Carolina Public Service Commission.

CP&L requests an effective date of July 15, 2001 for this Service Agreement.

Comment date: September 4, 2001, in accordance with Standard Paragraph E at the end of this notice.

14. Roseburg Forest Products Company

[Docket No. ER01–2830–000]

Take notice that on August 13, 2001, Roseburg Forest Products Company (RFP) petitioned the Federal Energy Regulatory Commission for acceptance of Roseburg Forest Products Rate Schedule FERC No. 1; the granting of certain blanket approvals, including the authority to sell electricity at market-based rates; and the waiver of certain Commission regulations.

RFP intends to engage in wholesale electric power and energy sales as an independent power producer. RFP owns a 40 MW hog fuel facility in Dillard, Oregon (RFP Powerhouse). Other than the RFP Powerhouse, RFP is not engaged in the generation or transmission of electric power for sale at wholesale. RFP is a type C Corporation organized under the laws of the state of Oregon.

Comment date: September 4, 2001, in accordance with Standard Paragraph E at the end of this notice.

15. Tampa Electric Company

[Docket No. ER01–2831–000]

Take notice that on August 13, 2001, Tampa Electric Company (Tampa Electric) filed notices of cancellation of: (1) its Contract for the Purchase and Sale of Power and Energy with NP Energy Inc. (NP Energy); and (2) the Service Agreement with NP Energy for non-firm point-to-point transmission service under Tampa Electric's open access transmission tariff.

Tampa Electric proposes that the cancellations be made effective on August 13, 2001, and therefore requests waiver of the Commission's notice requirement.

Comment date: September 4, 2001, in accordance with Standard Paragraph E at the end of this notice.

16. Alcoa Power Generating Inc.

[Docket No. ER01–2832–000]

Take notice that on August 13, 2001, Alcoa Power Generating Inc. (APGI) tendered for filing a service agreement between Tenaska Power Services Co. (Tenaska) and APGI under APGI's Market Rate Tariff. This Tariff was accepted for filing by the Commission on July 13, 1999, in Docket No. ER99–2932–000. The service agreement with Tenaska is proposed to be effective August 1, 2001.

Comment date: September 4, 2001, in accordance with Standard Paragraph E at the end of this notice.

17. Allegheny Energy Service Corporation, On Behalf of Monongahela Power Company, The Potomac Edison Company, and West Penn Power Company (Allegheny Power)

[Docket No. ER01–2833–000]

Take notice that on August 14, 2001, Allegheny Energy Service Corporation on behalf of Monongahela Power Company, The Potomac Edison Company and West Penn Power Company (Allegheny Power), filed Service Agreement Nos. 359 and 360 to add Exelon Generation Company, LLC to Allegheny Power's Open Access Transmission Service Tariff which has been accepted for filing by the Federal Energy Regulatory Commission in Docket No. ER96–58–000.

The proposed effective date under the Service Agreements is September 1, 2001 or a date ordered by the Commission. Copies of the filing have been provided to the Public Utilities Commission of Ohio, the Pennsylvania Public Utility Commission, the Maryland Public Service Commission, the Virginia State Corporation Commission, and the West Virginia Public Service Commission.

Comment date: September 4, 2001, in accordance with Standard Paragraph E at the end of this notice.

18. Progress Energy On Behalf of Florida Power Corporation

[Docket No. ER01–2834–000]

Take notice that on August 14, 2001, Florida Power Corporation (FPC) filed a Service Agreement with Enron Power Marketing, Inc. under FPC's Short-Form Market-Based Wholesale Power Sales Tariff (SM–1), FERC Electric Tariff No. 10. A copy of this filing was served upon the Florida Public Service Commission.

FPC is requesting an effective date of July 15, 2001 for this Agreement.

Comment date: September 4, 2001, in accordance with Standard Paragraph E at the end of this notice.

19. Florida Power & Light Company

[Docket No. ER01–2835–000]

Take notice that on August 14, 2001 Florida Power & Light Company (FPL) tendered for filing proposed service agreements with Western Resources, Inc. for Non-Firm transmission service and Firm transmission service under FPL's Open Access Transmission Tariff. FPL states that this filing is in accordance with Section 35 of the Commission's regulations.

FPL requests that the proposed service agreements become effective on August 1, 2001.

Comment date: September 4, 2001, in accordance with Standard Paragraph E at the end of this notice.

20. Xcel Energy Services, Inc.

[Docket No. ER01–2837–000]

Take notice that on August 13, 2001, Xcel Energy Services Inc. (XES), on behalf of Public Service Company of Colorado (Public Service), submitted for filing a Short-Term Firm Point-to-Point Transmission Service Agreement between Public Service and Salt River Project under Xcel's Joint Open Access Transmission Service Tariff (Xcel FERC Electric Tariff, Original Volume No. 1). XES requests that this agreement, designated as Original Service Agreement No. 105–PSCo, become effective on June 12, 2001.

Comment date: September 4, 2001, in accordance with Standard Paragraph E at the end of this notice.

Standard Paragraph

E. Any person desiring to be heard or to protest such filing should file a motion to intervene or protest with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with Rules 211 and 214 of the Commission's Rules of Practice and Procedure (18 CFR 385.211 and 385.214). All such motions or protests should be filed on or before the comment date. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceeding. Any person wishing to become a party must file a motion to intervene. Copies of this filing are on file with the Commission and are available for public inspection. This filing may also be viewed on the web at *http://www.ferc.gov* using the ''RIMS'' link, select ''Docket#'' and follow the instructions (call 202–208–2222 for assistance). Comments, protests and interventions may be filed electronically via the Internet in lieu of paper. See, 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's web site under the ''e-Filing'' link.

David P. Boergers,

Secretary.

[FR Doc. 01–21376 Filed 8–23–01; 8:45 am]

BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[FERC Docket No. CP01–422–000, CA State Clearinghouse No. 2001071035, BLM Reference No. CA–17918]

Kern River Gas Transmission Company; Notice of Intent/Preparation To Prepare a Joint Environmental Impact Statement/Report for the Proposed Kern River 2003 Expansion Project; Request for Comments on Environmental Issues and Notice of Public Scoping Meetings and Site Visit

August 20, 2001.

The staffs of the Federal Energy Regulatory Commission (FERC or Commission) and the California State Lands Commission (CSLC) will jointly prepare an environmental impact statement/report (EIS/EIR) that will discuss the environmental impacts of Kern River Gas Transmission Company's (KRGT) proposed Kern River 2003 Expansion Project in Wyoming, Utah, Nevada, and California.[1] The proposed facilities would consist of 634.3 miles of 36-inch-diameter pipeline, 82.4 miles of 42-inch-diameter pipeline, 0.8 mile of 12-inch-diameter pipeline, and 163,700 horsepower (hp) of additional compression. The FERC will use the EIS/EIR in its decision-making process to determine whether the project is in the public convenience and necessity. The CSLC will use the document to consider KRGT's application for leasing the State's School Lands for the pipeline.

The FERC will be the lead Federal agency in the preparation of the EIS/EIR while the CSLC will be the State Lead Agency for California. The joint document, which will avoid much duplication of environmental analyses, will satisfy the requirements of both the National Environmental Policy Act (NEPA) and the California Environmental Quality Act (CEQA).

The proposed project would cross about 322.1 miles of Bureau of Land Management (BLM) land and 19.4 miles of the Dixie National Forest, which is under the jurisdiction of the Forest Service (FS). KRGT has filed a right-of-way application with the BLM and a special use permit application with the FS for the crossings of these Federal lands. As part of considering KRGT's applications, the BLM and the FS, Dixie National Forest have agreed to meet their NEPA responsibilities by participating as cooperating agencies in the preparation of the EIS/EIR.

This notice is being sent to landowners along KRGT's existing mainline and its proposed and alternative routes; Federal, state, and local government agencies; elected officials; environmental and public interest groups; Indian tribes that might attach religious and cultural significance to historic properties in the area of potential effect; local libraries and newspapers; other interested parties; and the FERC's official service list. Government representatives are encouraged to notify their constituents of this proposed action and encourage them to comment on their areas of concern. Additionally, with this notice we[2] are asking other Federal, state, local, and tribal agencies with jurisdiction and/or special expertise with respect to environmental issues to cooperate with us in the preparation of the EIS/EIR. These agencies may choose to participate once they have evaluated KRGT's proposal relative to their responsibilities. Agencies who would like to request cooperating status should follow the instructions for filing comments described later in this notice.

If you are a landowner receiving this notice, you may be contacted by a KRGT representative about the acquisition of an easement to construct, operate, and maintain the proposed facilities. The pipeline company would seek to negotiate a mutually acceptable agreement. However, if the project is approved by the FERC, that approval conveys with it the right of eminent domain. Therefore, if easement negotiations fail to produce an agreement, the pipeline company could initiate condemnation proceedings in accordance with applicable state laws in Wyoming, Utah, Nevada, and California.

A fact sheet prepared by the FERC entitled ''An Interstate Natural Gas Facility on My Land? What Do I Need To Know?'' should have been attached to the project notice KRGT provided to landowners. This fact sheet addresses a number of typically asked questions, including the use of eminent domain and how to participate in the FERC's proceedings. It is available for viewing on the FERC Internet website (*http://www.ferc.gov).*

Summary of the Proposed Project

KRGT proposes to build new natural gas pipeline and compression facilities to transport approximately 886 million cubic feet per day of natural gas from the Central Rocky Mountain region to

[1] KRGT's application in Docket No. CP01–422–000 was filed with the FERC under Sections 7(b) and 7(c) of the Natural Gas Act and Part 157 of the FERC's regulations.

[2] ''We,'' ''us,'' and ''our'' refer to the staffs of the FERC's Office of Energy Projects and the CSLC.

customers in Nevada and California. The natural gas would primarily supply existing and new power generation markets. KRGT's proposed action consists of the construction and operation of:

- 634.3 miles of 36-inch-diameter pipeline in 11 loops [3] adjacent to KRGT's existing Opal Lateral and existing mainline in Wyoming (Lincoln and Uinta Counties), Utah (Summit, Morgan, Salt Lake, Utah, Juab, Millard, Beaver, Iron, and Washington Counties), Nevada (Lincoln and Clark Counties), and California (San Bernardino County);
- 82.4 miles of 42-inch-diameter pipeline in one loop adjacent to the portion of KRGT's existing mainline that it jointly owns with Mojave Pipeline Company in California (San Bernardino and Kern Counties);
- 0.8 mile of 12-inch-diameter pipeline in Uinta County, Wyoming;
- Three new compressor stations, one each in Wyoming (Uinta County), Utah (Salt Lake County), and Nevada (Clark County) for a total of 60,000 hp of additional compression;
- Modifications to six existing compressor stations, one in Wyoming (Lincoln County), three in Utah (Utah, Millard, and Washington Counties), one in Nevada (Clark County), and one in California (San Bernardino County) for a total of 103,700 hp of additional compression;
- Modifications to one existing meter station in Wyoming (Lincoln County) and four existing meter stations in California (two each in San Bernardino and Kern Counties); and
- Various mainline block valves, pig [4] launcher/receiver facilities, and other appurtenances.

A general overview map of the major project facilities is shown on figure 1 in appendix 1.[5] Maps of each loop and associated facilities are provided on figure 2 sheets 1 through 9 in appendix 1. More detailed maps and copies of KRGT's FERC application are available for review at the centrally located public libraries listed in appendix 2.

As shown on the figures in appendix 1, there are two segments of the existing mainline between Opal, Wyoming and Mojave, California that would not be looped by this project. These unlooped areas are a 28.1-mile-long segment in Davis County, Salt Lake City, Utah and a 26.1-mile-long segment in Clark County, Las Vegas, Nevada. No construction is proposed in these areas; however, the operating pressure of the existing KRGT mainline would be higher due to the increased throughput of natural gas associated with the proposed project.

The Kern River 2003 Expansion Project is scheduled to be in service in May 2003. KRGT is requesting approval to begin construction in June 2002. The approximate duration of construction would be 11 months.

Land Requirements for Construction

Construction of KRGT's proposed pipeline facilities would require about 10,211 acres of land including the construction right-of-way, temporary extra workspaces, and contractor/pipe yards. The nominal construction right-of-way for the pipeline would be 75 feet wide for 36-inch-diameter pipe and 80 feet wide for 42-inch-diameter pipe. Additional right-of-way width and temporary extra workspace would be required at certain feature crossings and areas requiring topsoil segregation and special construction techniques.

The pipeline loops would be generally installed at the edge of the existing permanent right-of-way using a standard 25-foot offset from the existing KRGT mainline. At certain locations (*e.g.*, highway and waterbody crossings), a greater offset would be needed. In some areas, the proposed pipeline would deviate from the existing mainline right-of-way due to topographic or resource/land use constraints.

KRGT retains a 50-foot-wide permanent right-of-way for its existing mainline. Following construction of the proposed loops, KRGT would retain an additional 25-foot-wide new permanent right-of-way where the proposed pipeline is parallel to the existing pipeline. Where the proposed pipeline deviates from the existing mainline right-of-way, KRGT would retain a 50-foot-wide new permanent right-of-way. Total land requirements for the new permanent right-of-way would be approximately 2,435 acres.

KRGT proposes to acquire a total of about 81 acres of land for construction and operation of the new compressor stations. The modifications to the existing compressor and meter stations would be constructed within the existing facility sites, except for a 4-acre extra workspace that would be temporarily needed for one compressor station modification.

Mainline block valves would be installed within the permanent right-of-way at the beginning of each loop and at intermediate locations as necessary. The proposed mainline valves would be collocated with existing mainline valves and other aboveground facilities except in two locations. Pig launchers and receivers would be installed at the beginning and end points of each loop within other aboveground facility sites except in five locations. At each of these five locations, approximately 0.8 acre of land would be required for operation.

The EIS/EIR Process

NEPA requires the FERC to take into account the environmental impacts that could result from an action whenever it considers the issuance of a Certificate of Public Convenience and Necessity. The CSLC, as State Lead Agency for California, is required to consider the same potential impacts within the State of California under CEQA. The EIS/EIR we are preparing will give both the FERC and the CSLC the information we need to do that.

NEPA and CEQA also require us to discover and address concerns the public may have about proposals. We call this ''scoping.'' The main goal of the scoping process is to focus the analysis in the EIS/EIR on the important environmental issues and reasonable alternatives. All scoping comments received will be considered during the preparation of the EIS/EIR.

We began the scoping process for the Kern River 2003 Expansion Project on June 25–29, 2001. During that week, we met with agency representatives along the proposed pipeline route to discuss the project and allow them the opportunity to express issues and concerns that should be addressed in the EIS/EIR. After the agency scoping meetings, we provided a scoping summary document to the meeting participants.

On July 6, 2001, the CSLC issued a Notice of Preparation of a Draft EIR and Notice of Public Scoping Meeting (NOP). Issuance of the NOP opened a 30-day comment period for the CSLC to receive written comments on the scope and content of the environmental information and analysis that should be included in the EIR. The NOP announced a public scoping meeting in Barstow, California on August 2, 2001 that would also be used as the FERC's scoping meeting for the California portion of the proposed project. The

[3] A loop is a segment of pipeline that is usually installed adjacent to an existing pipeline and connected to it at both ends. The loop allows more gas to be moved through the system.

[4] A pig is an internal tool used to inspect a pipeline for potential leaks or damage.

[5] The appendices referenced in this notice are not being printed in the **Federal Register**. Copies are available on the FERC's website (http://www.ferc.gov) at the ''RIMS'' link or from the Commission's Public Reference and Files Maintenance Branch, 888 First Street, NE., Room 2A, Washington, DC 20426, or call (202) 208–1371. For instructions on connecting to RIMS, refer to page 12 of this notice. Copies of the appendices were sent to all those receiving this notice in the mail.

comment period on the CSLC's NOP closed on August 6, 2001.

By this notice, we are requesting additional agency and public comments on the scope of the issues to be analyzed and presented in the EIS/EIR. If you provided comments on the agency scoping summary document discussed above or in response to the CSLC's NOP, you do not need to resubmit your comments.

Our independent analysis of the issues will be included in the Draft EIS/EIR. The Draft EIS/EIR will be mailed to Federal, state, and local government agencies; elected officials; environmental and public interest groups; Indian tribes; affected landowners; local libraries and newspapers; other interested parties; and the FERC's official service list for this proceeding. We will consider all comments on the Draft EIS/EIR and revise the document, as necessary, before issuing a Final EIS/EIR. The Final EIS/EIR will include our response to all comments received.

Currently Identified Environmental Issues

The EIS/EIR will discuss impacts that could occur as a result of the construction and operation of the proposed project. We have already identified a number of issues and alternatives that we think deserve attention based on a preliminary review of the proposed facilities, the environmental information provided by KRGT, and the scoping comments received to date. This preliminary list of issues and alternatives may be changed based on your comments and our additional analysis.

- Geology and Soils
  - —Assessment of potential geological hazards.
  - —Impact on mineral resources.
  - —Impacts resulting from blasting.
  - —Erosion and sedimentation control.
  - —Right-of-way restoration.
- Water Resources
  - —Impact on groundwater and surface water supplies.
  - —Impact on wetland hydrology.
  - —Effect of pipeline crossings on perennial and intermittent streams, canals, and washes.
  - —Assessment of special measures for the crossings of the Bear and Weber Rivers, and Yellow, Oak, Mogatsu, and Moody Creeks.
  - —Assessment of hydrostatic test water sources and discharge locations.
- Fish, Wildlife, and Vegetation
  - —Effect on coldwater and sensitive fisheries.
  - —Effect on wildlife resources and their habitat.
  - —Effect on big game crucial winter ranges and migration corridors.
  - —Effect on migratory birds.
  - —Assessment of construction time window restrictions.
  - —Effect on agave, cacti, yucca (including Joshua trees), and mesquite.
  - —Control of noxious weeds within the right-of-way.
  - —Assessment of measures to successfully revegetate the right-of-way.
- Endangered and Threatened Species
  - —Potential effect on nine federally listed or proposed species (including the desert tortoise) and one Federal candidate species (blue diamond cholla).
  - —Assessment of mitigation for impacts on the desert tortoise and its designated habitat.
  - —Potential effect on state-listed, BLM-designated, and FS-designated sensitive species (including sage grouse and raptors).
- Cultural Resources
  - —Assessment of survey methodologies.
  - —Effect on historic and prehistoric sites.
  - —Native American and tribal concerns.
- Paleontological Resources
  - —Effect on paleontological resources.
- Land Use, Recreation and Special Interest Areas, and Visual Resources
  - —Impacts on about 626.8 miles of rangeland.
  - —Permanent conversion of about 84.7 acres of land from rangeland to industrial use.
  - —Impact on 15 residences within 50 feet of the construction work area.
  - —Effect on about 391.4 miles of public land.
  - —Impact on special use areas, including the Dixie National Forest, Moapa River Indian Reservation, Red Rock Canyon National Conservation Area, Humboldt-Toiyabe National Forest/Spring Mountain National Recreation Area, and military bases.
  - —Evaluation of the project's consistency with regional and local land use management plans.
  - —Assessment of potential increased off-highway vehicle use in prohibited or environmentally sensitive areas.
  - —Visual impacts.
- Socioeconomics
  - —Effects on transportation and traffic.
  - —Effects of construction workforce demands on public services and temporary housing.
- Air Quality and Noise
  - —Effects on local air quality and noise environment from construction and operation of the proposed facilities.
  - —Evaluation of potential effect on Prevention of Significant Deterioration Class I areas.
- Reliability and Safety
  - —Assessment of hazards associated with natural gas pipelines.
- Alternatives
  - —Assessment of the use of existing systems to reduce or avoid environmental impacts.
  - —Assessment of the potential to add compression to eliminate or minimize pipeline construction.
  - —Evaluation of route alternatives at Cumberland Gap, Pinnacle Pass, the Mojave National Preserve, and Edwards Air Force Base.
  - —Identification of measures to lessen or avoid impacts on the various resource and special interest areas.
- Cumulative Impact
  - —Assessment of the effect of the proposed project when combined with other past, present, or future actions in the same region.

Public Participation

You can make a difference by providing us with your specific comments or concerns about the project. By becoming a commentor, your concerns will be addressed in the EIS/EIR and considered by the FERC, the CSLC, the BLM, and the FS. You should focus on the potential environmental effects of the proposal, alternatives to the proposal (including alternative locations and routes), and measures to avoid or lessen environmental impact. The more specific your comments, the more useful they will be. Please carefully follow these instructions to ensure that your comments are received in time and properly recorded:

- Send an original and two copies of your letter to: David P. Boergers, Secretary, Federal Energy Regulatory Commission, 888 First St., NE., Room 1A, Washington, DC 20426;
- Reference Docket No. CP01–422–000;
- Label one copy of your comments for the attention of the Gas Group 1;
- Mail your comments so that they will be received in Washington, DC on or before September 24, 2001.

Comments may also be filed electronically via the Internet in lieu of paper. See 18 CFR 385.2001(a)(1)(iii) and the instructions on the FERC's website under the ''e-Filing'' link.

- Send an additional copy of your letter to the following individual: Cy Oggins, California State Lands

Commission, 100 Howe Ave., Suite 100 South, Sacramento, CA 95825.

Everyone who responds to this notice, responded to the CSLC's NOP, or provides comments throughout the EIS/EIR process will be retained on our mailing list. If you do not want to send comments at this time but still want to stay informed and receive copies of the Draft and Final EIS/EIR, you must return the Information Request (appendix 4). If you do not send comments or return the Information Request or the CSLC's form asking to remain on the mailing list, you will be taken off the mailing list.

Public Scoping Meetings and Site Visit

In addition to or in lieu of sending written comments, we invite you to attend the public scoping meetings that the FERC, the CSLC, and the BLM will conduct in the project area. All meetings will begin at 7 pm, and are scheduled as follows:

Date	Location
Monday, September 17, 2001	Best Western Inn, 1601 Harrison Drive, Evanston, Wyoming, (307) 789–3770
Tuesday, September 18, 2001	Crystal Inn, 2254 City Center Court, West Valley City, Utah, (801) 736–2000
Wednesday, September 19, 2001	Best Western Paradise Inn, 1025 North Main Street, Fillmore, Utah, (435) 743–6895
Thursday, September 20, 2001	Best Western Abbey Inn, 1129 South Bluff Street, Saint George, Utah, (435) 652–1234
Friday, September 21, 2001	Clark County Government Center, ETD Room 3, 500 South Grand Central Parkway, Las Vegas, Nevada, (702) 455–3121

The public scoping meetings are designed to provide you with more detailed information and another opportunity to offer your comments on the proposed project. KRGT representatives will be present at the scoping meetings to describe their proposal. Interested groups and individuals are encouraged to attend the meetings and to present comments on the environmental issues they believe should be addressed in the EIS/EIR. A transcript of each meeting will be made so that your comments will be accurately recorded.

On the dates of the meetings, we will also be conducting limited site visits to the project area. Anyone interested in participating in the site visits may contact the FERC's Office of External Affairs identified at the end of this notice for more details and must provide their own transportation.

Becoming an Intervenor

In addition to involvement in the EIS/EIR scoping process, you may want to become an official party to the proceeding, known as an ''intervenor.'' Intervenors play a more formal role in the process. Among other things, intervenors have the right to receive copies of case-related Commission documents and filings by other intervenors. Likewise, each intervenor must provide 14 copies of its filings to the Secretary of the Commission and must send a copy of its filings to all other parties on the Commission's service list for this proceeding. If you want to become an intervenor you must file a motion to intervene according to Rule 214 of the Commission's Rules of Practice and Procedure (18 CFR 385.214) (see appendix 3). Only intervenors have the right to seek rehearing of the Commission's decision.

Affected landowners and parties with environmental concerns may be granted intervenor status upon showing good cause by stating that they have a clear and direct interest in this proceeding that would not be adequately represented by any other parties. You do not need intervenor status to have your environmental comments considered.

Availability of Additional Information

Additional information about the proposed project is available from Cy Oggins at the CSLC at (916) 574–1884, or on the CSLC website at *http://www.slc.ca.gov,* or from the FERC's Office of External Affairs at (202) 208–1088, or on the FERC website at *http://www.ferc.gov* using the ''RIMS'' link, select ''Docket#'' and follow the instructions (call (202) 208–2222 for assistance). Access to the texts of formal documents issued by the FERC with regard to these dockets, such as orders and notices, is also available on the FERC website using the ''CIPS'' link. For assistance with access to CIPS, the CIPS helpline can be reached at (202) 208–2474.

Information concerning the involvement of the BLM in the EIS/EIR process is available from Jerry Crockford, BLM Project Manager, at (505) 599–6333. Information concerning the involvement of the FS in the EIS/EIR process is available from David Swank, Environmental Studies Coordinator, at (435) 865–3231.

David P. Boergers,

Secretary.

[FR Doc. 01–21379 Filed 8–23–01; 8:45 am]

BILLING CODE 6717–01–P

ENVIRONMENTAL PROTECTION AGENCY

[ER–FRL–6621–2]

Environmental Impact Statements; Notice of Availability

Responsible Agency: Office of Federal Activities, General Information (202) 564–7167 or *www.epa.gov/oeca/ofa.*

Weekly receipt of Environmental Impact Statements Filed August 13, 2001 Through August 17, 2001 Pursuant to 40 CFR 1506.9.

EIS No. 010305, Draft Supplement, FAA, MN, Flying Cloud Airport, Substantive Changes to Alternatives and New Information, Extension of the Runways 9R/27L and 9L/27R, Long-Term Comprehensive Development, In the City of Eden Prairie, Hennepin County, MN, Comment Period Ends: October 09, 2001, Contact: Glen Orcutt (612) 713–4354.

EIS No. 010306, Draft EIS, AFS, MT, Beaverhead-DeerLodge National Forest, Noxious Weed Control Program, Implementation, Integrated Weed Management, Dillon County, MT, Comment Period Ends: October 09, 2001, Contact: Peri Suenram (406) 683–3967. This document is available on the Internet at: www.fs.fed.us/rl/b-d/.

EIS No. 010307, Final EIS, BLM, WY, North Jacobs Ranch Coal Lease Application (WYW 146744), Federal Coal Tract, Located in the Powder River Basin, Campbell County, WY, Wait Period Ends: September 24, 2001, Contact: Nancy Doelger (307) 261–7627.

EIS No. 010308, Draft EIS, BOP, PA, Northumberland County Federal Correctional Institution Construction and Operation, Site Locations: Coal Township, Mt. Carmel Township, Natalie East or The Sagon,

Northumberland County, PA, Comment Period Ends: October 09, 2001, Contact: David J. Dorworth (202) 514–6470.

EIS No. 010309, Final EIS, AFS, MT, Hemlock Point Access Project, Construction of 860 feet of Low Standard Road, Plum Creek, Swan Valley, Flathead National Forest, Missoula County, MT, Wait Period Ends: September 24, 2001, Contact: Dennis Mc Carthy (406) 758–5239.

EIS No. 010310, Draft EIS, FHW, CA, CA–905 Freeway or Tollway Construction Project, Route Location, Adoption and Construction, Otay Mesa Port of Entry to I–805, Funding and US Army COE Section 404 Permit Issuance, San Diego County, CA, Comment Period Ends: October 16, 2001, Contact: Jeffrey W. Kolb (916) 498–5037.

EIS No. 010311, Final EIS COE, RI, Providence River and Harbor Maintenance Dredging Project, To Restore the Navigation Efficiency, Providence River Shipping Channel, Narragansett Bay, RI, Wait Period Ends: October 01, 2001, Contact: Edward O'Donnell (978) 318–8375.

EIS No. 010312, Draft EIS, BLM, AZ, Las Cienegas Resource Management Plan, Implementation, Las Cienegas National Conservation Area (NCA) and Sonoita Valley Acquisition Planning District, AZ, Comment Period Ends: November 23, 2001, Contact: Karen Simms (520) 258–7200.

EIS No. 010313, Final EIS, FHW, TN, TN–385 (Collierville-Arlington Parkway) Improvement Project, Construction from Mt. Pleasant Road to South of Interstate 40, Shelby and Fayette Counties, TN, Wait Period Ends: September 24, 2001, Contact: Charles Boyd (615) 781–5770.

EIS No. 010314, Final EIS, FHW, AR, Southeast Arkansas I–69 Connector Construction, US–278 in the vicinity of Monticello to I–530 in Pine Bluff, Funding and US Army COE Section 404 and NPDES Permits Issuance, Drew, Lincoln, Cleveland and Jefferson Counties, AR, Wait Period Ends: October 01, 2001, Contact: Army H. Helfin (501) 324–6435.

EIS No. 010315, Draft EIS, FHW, WA, I–405 Corridor Transportation Improvements, I–5 in the City of Tukwila to I–5 in Snohomish County, Funding and Possible COE Section 404 Permits Issuance, King and Snohomish Counties, CA, Comment Period Ends: October 09, 2001, Contact: James Leonard (FHWA) (360) 753–9408.

The US Department of Transportation's Federal Highway Administration and Federal Transit Authority (FTA) are Joint Lead Agencies for the above project. John Witmar is the Contact for FTA, phone No. 206–220–7964.

EIS No. 010316, Final EIS, EPA Proposed Rule on Environmental Impact Assessment of Nongovernmental Activities in Antarctica, To Implement the Protocol on Environmental Protection to the Antarctic Treaty of 1959, Wait Period Ends: September 24, 2001, Contact: Katherine Biggs (202) 564–7144. This document is available on the Internet at: http://es.epa.gov/oeca/ofa/index/html.

EIS No. 010317, Final EIS, AFS, MT, Pink Stone Fire Recovery and Associated Activities, Reduction of Existing and Expected Future Fuel Accumulations, Kootena National Forest, Rexford Ranger District, Lincoln County, MT, Wait Period Ends: September 24, 2001, Contact: Annie Dueker (406) 296–2536.

EIS No. 010318, Final EIS, AFS, CO, Baylor Park Blowdown Project, Salvage and Treat Down and Damaged Timber, To Reduce Impact of Spruce Bettles, Implementation, White River National Forest, Sopris and Rifle Ranger Districts, Garfield, Mesa, and Pitkin Counties, CO, Wait Period Ends: September 24, 2001, Contact: Jan Spencer (970) 945–2521.

EIS No. 010319, Draft EIS, DOE, OR, Umatilla Generating Project, Construction and Operation, Gas-Fired Combined Cycle Electric Power Generation Plant, Nominal Generation Capacity of 550 megawatts (MW) Connection to the Regional Grid at McNary Substation, Umatilla County, AZ, Comment Period Ends: October 15, 2001, Contact: Inez Graetzer (503) 230–3786. This document is available on the Internet at: www.efw.bpa.gov

EIS No. Final EIS, FAA, GA, Hartsfield Atlanta International Airport, Construction and Operation of the 9,000-Foot Fifth Runway and Associated Projects, Approval of Airport Layout Plan (ALP), City of Atlanta, Fulton and Clayton Counties, GA, Wait Period Ends: September 24, 2001, Contact: Donna M. Meyer (404) 305–7150.

Amended Notices

EIS No. 010142, Draft EIS, AFS, UT, Uinta National Forest Revised Land and Resource Management Plan, Implementation, Juab, Sanpete, Tooele, Utah and Wasatch Counties, UT, Due: September 17, 2001, Contact: Peter W. Karp (801) 377–5780.

Revision of FR Notice Published on 05/04/2001: CEQ Review Period Ending on 08/02/2001 has been Extended to 09/17/2001.

Dated: August 21, 2001.

Joseph C. Montgomery,

Director, NEPA Compliance Division, Office of Federal Activities.

[FR Doc. 01–21449 Filed 8–23–01; 8:45 am]

BILLING CODE 6560–50–M

ENVIRONMENTAL PROTECTION AGENCY

[ER–FRL–6621–3]

Environmental Impact Statements and Regulations; Availability of EPA Comments

Availability of EPA comments prepared pursuant to the Environmental Review Process (ERP), under Section 309 of the Clean Air Act and Section 102(2)(c) of the National Environmental Policy Act as amended. Requests for copies of EPA comments can be directed to the Office of Federal Activities at (202) 260–5076. An explanation of the ratings assigned to draft environmental impact statements (EISs) was published in FR dated May 18, 2001 (66 FR 27164).

DRAFT EISs

ERP No. D–COE–K36135–CA Rating EC2, White Slough Flood Control Study, To Improve Tidal Circulation, Continuing Authorities Program Section 205, Vallejo Sanitation and Flood Control District, City of Vallejo, Solano County, CA.

Summary: EPA expressed concerns, and requested additional information on the project's purpose and need, alternatives considered, and impacts to habitat, water quality, biological resources, air quality, community growth and traffic.

ERP No. D–DOE–K03024–AZ Rating EC2, Big Sandy Energy Project, Construction and Operation a 720-megawatt (MW) Natural Gas-Fired Combined-Cycle Power Plants, Right-of-Way Grant, Mohave County, AZ.

Summary: EPA expressed concerns regarding water quality, wetlands, air quality, hazardous material and threatened and endangered species. EPA urged avoidance of impacts versus relying on mitigation measures to reduce impacts to a level of insignificance, a commitment to directional drilling for the pipeline crossing of the Big Sandy River, and an evaluation of the need for additional generation capacity.

ERP No. D–FRC–L05221–WA Rating EC2, Cowlitz River Hydroelectric Project (No. 2016–044), Relicensing of the Existing 462-megawatt, Cowlitz River, City of Tacoma, WA.

Summary: EPA identified concerns related to potential effects to water quality, fisheries and flood control and the narrow range of alternatives evaluated in the EIS. EPA recommended additional information related to those concerns as well as the duration of the proposed license and the purpose and need for the project.

ERP No. D–NPS–G03019–TX Rating EC2, Lake Meredith National Recreation Area and Alibates Flint Quarries National Monument Oil and Gas Management Plan, Hutchinson, Moore and Potter Counties, TX.

Summary: EPA expressed environmental concerns and requested that the FEIS further address socioeconomics, environmental justice, and visitor use.

ERP No. DS–BLM–J67019–MT Rating LO, Zortman and Landusky Mines Reclamation Plan, Modifications and Mine Life Extensions, Updated Information To Analyze Additional Reclamation Alternatives, Approval of Mine Operation, Mine Reclamation and COE Section 404 Permit, Little Rocky Mountains, Phillip County, MT.

Summary: EPA has no objections to the preferred alternative which will take $22 million to implement. However, EPA would have environmental objections to the other less expensive alternatives should this funding not be available given that they do not adequately control the generation of acid mine drainage.

Dated: August 21, 2001.

Joseph C. Montgomery,

Director, NEPA Compliance Division, Office of Federal Activities.

[FR Doc. 01–21450 Filed 8–23–01; 8:45 am]

BILLING CODE 6560–50–P

ENVIRONMENTAL PROTECTION AGENCY

[AD–FRL–7042–9]

Public Meeting on Monitoring and Reporting Requirements for Combustion Turbines

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

SUMMARY: This document announces that EPA is inviting stakeholders to participate at a public meeting regarding monitoring and reporting requirements under 40 CFR part 75 and 40 CFR part 60 for combustion turbines, that will take place in Washington, DC, on October 9, 2001, to gather stakeholder input and recommendations regarding ways to improve and better harmonize those requirements.

DATES: The meeting will be held on October 9, 2001, in Washington, DC, from 9:30 am to 4:30 p.m. If you are planning to attend, please inform Dr. Ruben Deza, *deza.ruben@epa.gov*, by September 21, 2001. Written comments may also be provided and should be postmarked by September 21, 2001.

ADDRESSES: The meeting will be held in Washington, DC, at the 7th floor conference room of the Clean Air Markets Division at 633 3rd Street, N.W. building.

Comments should be submitted to Ruben D. Deza, PhD, e-mail: deza.ruben@epa.gov, Fax: 202–564–7372, Mailing Address: U.S. Environmental Protection Agency, Ariel Rios Building (6204N), 1200 Pennsylvania Avenue, NW, Washington, DC 20460, Office Location and FedEx Delivery: 633 3rd Street NW, 7 Floor, Washington, DC 20001.

FOR FURTHER INFORMATION CONTACT: Dr. Ruben Deza, Clean Air Markets Division, US Environmental Agency, Ariel Rios Building (6204N), 1200 Pennsylvania Avenue, NW, Washington, DC 20460, Phone: 202–564–3956, Fax: 202–564–7372, e-mail: deza.ruben@epa.gov.

SUPPLEMENTARY INFORMATION: EPA's Clean Air Markets Division (CAMD) is responsible for implementing Title IV (Acid Deposition Control) of the Clean Air Act Amendments (CAAA) of 1990. Part 75 of the Code of Federal Regulations (CFR) establishes continuous emission monitoring (CEM) requirements for facilities affected by Title IV. Combustion turbines are among the affected facilities. To meet the rising demand for electrical generating capacity in the United States, a large number of combustion turbines are expected to be built in the immediate future. CAMD expects that the number of combustion turbines reporting under part 75 will increase from approximately 400 to more than 1,000 in the next few years. Several stakeholders have noted to CAMD that some of the requirements in part 75 and in part 60 (the CFR provision dealing with performance of new sources) could be more efficiently implemented, if harmonized. In addition, the technology, operating characteristics, and emissions controls of turbines have changed dramatically since the introduction of the original rules. Resulting emissions of NO_X from many new combustion turbine units are substantially less than those observed in the past. Consequently, there may be quality assurance procedures that are difficult to implement at newer turbines. For all these reasons, and EPA's continuous commitment to reduce the information burden, the Agency is seeking to identify emissions neutral opportunities to streamline the monitoring, testing and reporting requirements for combustion turbines under these rules.

To assist in this process, CAMD will hold a public meeting to solicit comments from interested parties. The purpose of the meeting is to identify opportunities for revising the part 75 and part 60 regulations for combustion turbines and secure stakeholder input on these recommendations and other needed changes to the regulations. CAMD is particularly interested in comments on duplicative requirements; inconsistencies; recommended improvements and enhancements; problems in emissions monitoring, reporting, and testing requirements; conflicts with state permitting authorities; and the need for separate requirements for different models of combustion turbines, subclasses of turbines, add-on controls, and operating conditions.

The meeting will be held on October 9, 2001, in Washington, DC. While this is an open forum for discussion of issues, some agenda time will be reserved for participants to make presentations. Participants seeking to make presentations should contact Dr. Deza at the above address and provide a brief abstract of their intended discussion. Written comments and data submission are also encouraged. A final agenda will be posted on the CAMD web page prior to the meeting.

Dated: August 16, 2001

Paul Stolpman,

Director, Office of Atmospheric Programs.

[FR Doc. 01–21444 Filed 8–23–01; 8:45 am]

BILLING CODE 6560–50–P

ENVIRONMENTAL PROTECTION AGENCY

[OPP–00736; FRL–6798–9]

Tribal Pesticide Program Council (TPPC) Fourth Meeting; Notice of Meeting

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

SUMMARY: The Tribal Pesticide Program Council (TPPC) will hold a 2–day meeting, beginning on September 20, 2001, and ending September 21, 2001. This notice announces the location and times for the meeting and sets forth the tentative agenda topics.

DATES: The meeting will be held on Thursday, September 20, 2001, from 8

a.m. to 5 p.m. and Friday, September 21, 2001, from 8 a.m. to 5 p.m.

ADDRESS: This meeting will be held at the Harrah's Ak Chin Casino Resort, 42507 West Peters and Nall Road, Maricopa, AZ 85239.

Comments may be submitted by mail, electronically, or in person. Please follow the detailed instructions for each method as provided in Unit I. of the **SUPPLEMENTARY INFORMATION.** To ensure proper receipt by EPA, it is imperative that you identify docket control number OPP–00736 in the subject line on the first page of your response.

FOR FURTHER INFORMATION CONTACT: Georgia A. McDuffie, Field and External Affairs Division (7506C), Office of Pesticide Programs, Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460; telephone number: (703) 605–0195; fax number: (703) 308–1850; e-mail address: mcduffie.georgia@epa.gov.

Lillian A. Wilmore, Native Ecology Initiative, Coordinator for the TPPC, P.O. Box 470829, Brookline Village, MA 02447–0829; telephone number: (617) 232–5742; fax (617) 277–1656; e-mail: naecology@aol.com

SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this Action Apply to Me?

This action is directed to the public in general. This action may, however, be of interest to all parties interested in TPPC's information exchange relationship with EPA, regarding important issues related to human health, environmental exposure to pesticides, and insight into EPA's decision-making process are invited and encouraged to attend the meetings and participate as appropriate. Since other entities may also be interested, the Agency has not attempted to describe all the specific entities that may be affected by this action. If you have any questions regarding the applicability of this action to a particular entity, consult the person listed under **FOR FURTHER INFORMATION CONTACT**.

B. How Can I Get Additional Information, Including Copies of this Document and Other Related Documents?

1. *Electronically*. You may obtain electronic copies of this document, and certain other related documents that might be available electronically, from the EPA Internet Home Page at *http://www.epa.gov/*. To access this document, on the Home Page select ''Laws and Regulations,'' ''Regulations and Proposed Rules,'' and then look up the entry for this document under the ''**Federal Register**—Environmental Documents.'' You can also go directly to the **Federal Register** listings at *http://www.epa.gov/fedrgstr/*.

2. *In person*. The Agency has established an official record for this action under docket control number OPP–00736. The official record consists of the documents specifically referenced in this action, any public comments received during an applicable comment period, and other information related to this action, including any information claimed as Confidential Business Information (CBI). This official record includes the documents that are physically located in the docket, as well as the documents that are referenced in those documents. The public version of the official record does not include any information claimed as CBI. The public version of the official record, which includes printed, paper versions of any electronic comments submitted during an applicable comment period, is available for inspection in the Public Information and Records Integrity Branch (PIRIB), Rm. 119, Crystal Mall #2, 1921 Jefferson Davis Hwy., Arlington, VA, from 8:30 a.m. to 4 p.m., Monday through Friday, excluding legal holidays. The PIRIB telephone number is (703) 305–5805.

C. How and to Whom Do I Submit Comments?

You may submit comments through the mail, in person, or electronically. To ensure proper receipt by EPA, it is imperative that you identify docket control number OPP–00736 in the subject line on the first page of your response.

1. *By mail*. Submit your comments to: Public Information and Records Integrity Branch (PIRIB), Information Resources and Services Division (7502C), Office of Pesticide Programs (OPP), Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460.

2. *In person or by courier*. Deliver your comments to: Public Information and Records Integrity Branch (PIRIB), Information Resources and Services Division (7502C), Office of Pesticide Programs (OPP), Environmental Protection Agency, Rm. 119, Crystal Mall #2, 1921 Jefferson Davis Hwy., Arlington, VA. The PIRIB is open from 8:30 a.m. to 4 p.m., Monday through Friday, excluding legal holidays. The PIRIB telephone number is (703) 305–5805.

3. *Electronically*. You may submit your comments electronically by e-mail to: opp-docket@epa.gov, or you can submit a computer disk as described above. Do not submit any information electronically that you consider to be CBI. Avoid the use of special characters and any form of encryption. Electronic submissions will be accepted in WordPerfect 6.1/8.0 or ASCII file format. All comments in electronic form must be identified by docket control number OPP–00736. Electronic comments may also be filed online at many Federal Depository Libraries.

D. How Should I Handle CBI that I Want to Submit to the Agency?

Do not submit any information electronically that you consider to be CBI. You may claim information that you submit to EPA in response to this document as CBI by marking any part or all of that information as CBI. Information so marked will not be disclosed except in accordance with procedures set forth in 40 CFR part 2. In addition to one complete version of the comment that includes any information claimed as CBI, a copy of the comment that does not contain the information claimed as CBI must be submitted for inclusion in the public version of the official record. Information not marked confidential will be included in the public version of the official record without prior notice. If you have any questions about CBI or the procedures for claiming CBI, please consult the person listed under **FOR FURTHER INFORMATION CONTACT**.

E. What Should I Consider as I Prepare My Comments for EPA?

You may find the following suggestions helpful for preparing your comments:

1. Explain your views as clearly as possible.

2. Describe any assumptions that you used.

3. Provide copies of any technical information and/or data you used that support your views.

4. If you estimate potential burden or costs, explain how you arrived at the estimate that you provide.

5. Provide specific examples to illustrate your concerns.

6. Offer alternative ways to improve the notice or collection activity.

7. Make sure to submit your comments by the deadline in this notice.

8. To ensure proper receipt by EPA, be sure to identify the docket control number assigned to this action in the subject line on the first page of your response. You may also provide the name, date, and **Federal Register** citation.

II. Tentative Agenda

This unit provides tentative agenda topics for the 2–day meeting.

1. FIFRA sections 18 and 24(c)/tribal authority under FIFRA.
2. Basic elements of tribal pesticide.
3. Native American Graves Protection and Repatriation Act issues and updates.
4. Integrated Pest Management (IPM)/ focus on schools and structural.
5. Federal inspector credentials.
6. Worker protection presentation.
7. Presentation by Gila River Indian Community Pesticide Program Reports from TPPC Working Groups.
8. Office of Pesticide Program up-date on funding awards for special projects and water quality.
9. Office of Enforcement and Compliance Assurance up-date on funding, data collections issues, and training.

List of Subjects

Environmental protection, Pesticides.

Dated: August 14, 2001.

Jay Ellenberger,

Acting Division Director, Field and External Affairs Division, Office of Pesticide Programs.

[FR Doc. 01–21446 Filed 8–23–01; 8:45 am]

BILLING CODE 6560–50–S

ENVIRONMENTAL PROTECTION AGENCY

[PF–1038; FRL–6796–7]

Notice of Filing a Pesticide Petition to Establish a Tolerance for a Certain Pesticide Chemical in or on Food

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

SUMMARY: This notice announces the initial filing of a pesticide petition proposing the establishment of regulations for residues of a certain pesticide chemical in or on various food commodities.

DATES: Comments, identified by docket control number PF–1038, must be received on or before September 24, 2001.

ADDRESSES: Comments may be submitted by mail, electronically, or in person. Please follow the detailed instructions for each method as provided in Unit I.C. of the **SUPPLEMENTARY INFORMATION**. To ensure proper receipt by EPA, it is imperative that you identify docket control number PF–1038 in the subject line on the first page of your response.

FOR FURTHER INFORMATION CONTACT: By mail: Hoyt Jamerson, Registration Support Branch, Registration Division (7505C), Office of Pesticide Programs, Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460; telephone number: (703) 308–9368; e-mail address: jamerson.hoyt@epa.gov.

SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this Action Apply to Me?

You may be affected by this action if you are an agricultural producer, food manufacturer or pesticide manufacturer. Potentially affected categories and entities may include, but are not limited to:

Categories	NAICS codes	Examples of potentially affected entities
Industry	111 112 311 32532	Crop production Animal production Food manufacturing Pesticide manufacturing

This listing is not intended to be exhaustive, but rather provides a guide for readers regarding entities likely to be affected by this action. Other types of entities not listed in the table could also be affected. The North American Industrial Classification System (NAICS) codes have been provided to assist you and others in determining whether or not this action might apply to certain entities. If you have questions regarding the applicability of this action to a particular entity, consult the person listed under **FOR FURTHER INFORMATION CONTACT**.

B. How Can I Get Additional Information, Including Copies of this Document and Other Related Documents?

1. *Electronically*. You may obtain electronic copies of this document, and certain other related documents that might be available electronically, from the EPA Internet Home Page at http://www.epa.gov/. To access this document, on the Home Page select ''Laws and Regulations'' ''Regulation and Proposed Rules,'' and then look up the entry for this document under the ''**Federal Register**—Environmental Documents.'' You can also go directly to the **Federal Register** listings at http://www.epa.gov/fedrgstr/.

2. *In person*. The Agency has established an official record for this action under docket control number PF–1038. The official record consists of the documents specifically referenced in this action, any public comments received during an applicable comment period, and other information related to this action, including any information claimed as confidential business information (CBI). This official record includes the documents that are physically located in the docket, as well as the documents that are referenced in those documents. The public version of the official record does not include any information claimed as CBI. The public version of the official record, which includes printed, paper versions of any electronic comments submitted during an applicable comment period, is available for inspection in the Public Information and Records Integrity Branch (PIRIB), Rm. 119, Crystal Mall #2, 1921 Jefferson Davis Highway, Arlington, VA, from 8:30 a.m. to 4 p.m., Monday through Friday, excluding legal holidays. The PIRIB telephone number is (703) 305–5805.

C. How and to Whom Do I Submit Comments?

You may submit comments through the mail, in person, or electronically. To ensure proper receipt by EPA, it is imperative that you identify docket control number PF–1038 in the subject line on the first page of your response.

1. *By mail*. Submit your comments to: Public Information and Records Integrity Branch (PIRIB), Information Resources and Services Division (7502C), Office of Pesticide Programs (OPP), Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460.

2. *In person or by courier*. Deliver your comments to: Public Information and Records Integrity Branch (PIRIB), Information Resources and Services Division (7502C), Office of Pesticide Programs (OPP), Environmental Protection Agency, Rm. 119, Crystal Mall #2, 1921 Jefferson Davis Highway, Arlington, VA. The PIRIB is open from 8:30 a.m. to 4 p.m., Monday through Friday, excluding legal holidays. The PIRIB telephone number is (703) 305–5805.

3. *Electronically*. You may submit your comments electronically by e-mail to: opp-docket@epa.gov, or you can submit a computer disk as described above. Do not submit any information electronically that you consider to be CBI. Avoid the use of special characters and any form of encryption. Electronic submissions will be accepted in Wordperfect 6.1/8.0 or ASCII file format. All comments in electronic form must be identified by docket control number PF–1038. Electronic comments

may also be filed online at many Federal Depository Libraries.

D. How Should I Handle CBI That I Want to Submit to the Agency?

Do not submit any information electronically that you consider to be CBI. You may claim information that you submit to EPA in response to this document as CBI by marking any part or all of that information as CBI. Information so marked will not be disclosed except in accordance with procedures set forth in 40 CFR part 2. In addition to one complete version of the comment that includes any information claimed as CBI, a copy of the comment that does not contain the information claimed as CBI must be submitted for inclusion in the public version of the official record. Information not marked confidential will be included in the public version of the official record without prior notice. If you have any questions about CBI or the procedures for claiming CBI, please consult the person identified under **FOR FURTHER INFORMATION CONTACT**.

E. What Should I Consider as I Prepare My Comments for EPA?

You may find the following suggestions helpful for preparing your comments:

1. Explain your views as clearly as possible.
2. Describe any assumptions that you used.
3. Provide copies of any technical information and/or data you used that support your views.
4. If you estimate potential burden or costs, explain how you arrived at the estimate that you provide.
5. Provide specific examples to illustrate your concerns.
6. Make sure to submit your comments by the deadline in this notice.
7. To ensure proper receipt by EPA, be sure to identify the docket control number assigned to this action in the subject line on the first page of your response. You may also provide the name, date, and **Federal Register** citation.

II. What Action is the Agency Taking?

EPA has received a pesticide petition as follows proposing the establishment and/or amendment of regulations for residues of a certain pesticide chemical in or on various food commodities under section 408 of the Federal Food, Drug, and Cosmetic Act (FFDCA), 21 U.S.C. 346a. EPA has determined that this petition contains data or information regarding the elements set forth in section 408(d)(2); however, EPA has not fully evaluated the sufficiency of the submitted data at this time or whether the data support granting of the petition. Additional data may be needed before EPA rules on the petition.

List of Subjects

Environmental protection, Agricultural commodities, Feed additives, Food additives, Pesticides and pests, Reporting and recordkeeping requirements.

Dated:August 9, 2001.

James Jones,

Director, Registration Division, Office of Pesticide Programs.

Summary of Petition

The petitioner summary of the pesticide petition is printed below as required by section 408(d)(3) of the FFDCA. The summary of the petition was prepared by the petitioner and represents the view of the petitioner. EPA is publishing the petition summary verbatim without editing it in any way. The petition summary announces the availability of a description of the analytical methods available to EPA for the detection and measurement of the pesticide chemical residues or an explanation of why no such method is needed.

EPA has received pesticide petitions [0E6202 and 1E6249] from the Interregional Research Project Number 4 (IR-4), 681 U.S. Highway #1 South, North Brunswick, NJ 08902 proposing, pursuant to section 408(d) of the Federal Food, Drug, and Cosmetic Act (FFDCA), 21 U.S.C. 346a(d), to amend 40 CFR part 180 by establishing tolerances for residues of the herbicide chemical clethodim, (E)-(±)-2-1-[(3-chloro-2-propenyl)oxy]imino]propyl]-5-2(ethylthio) propyl]-3-hydroxy-2-cyclohexen-1-one and its metabolites containing the 5-(2-ethylthio-propyl) cyclohexene-3-one and 5-(2-ethylthiopropyl)-5-hydroxycyclohexene-3-one moieties and their sulfoxides and sulfones, all expressed as clethodim] in or on the raw agricultural commodities: (1) pesticide petition (1E6249) proposes tolerances for green onions and leaf lettuce at 2.0 ppm, and head and stem Brassica (Crop subgroup 5A) at 3.0 parts per million (ppm), (2) pesticide petition (0E6202) proposes tolerances for flax seed at 0.50 ppm, flax meal at 1.0 ppm, and mustard seed at 0.50 ppm.

EPA has determined that the petition contain data or information regarding the elements set forth in section 408(d)(2) of the FFDCA; however, EPA has not fully evaluated the sufficiency of the submitted data at this time or whether the data supports granting of the petitions. Additional data may be needed before EPA rules on the petitions.

Interregional Research Project Number 4 (IR-4)

PP 0E6202 and 1E6249

A. Background Information and Use Profile

Clethodim is the active ingredient in SELECT 2 EC Herbicide (EPA Reg. No. 59639–3), SELECT Herbicide (also known as PRISM Herbicide, EPA Reg. No. 59639–78), and SELECT SUPER Herbicide (EPA Reg. No. 59639-102) post-emergence herbicides effective against a wide range of annual and perennial grasses. Clethodim Technical is registered by the EPA (EPA Reg. No. 59639–2) as a technical grade active ingredient for manufacturing use. SELECT 2 EC Herbicide is registered for use on alfalfa; cotton; dry beans; peanuts; onions, garlic, and shallots (all dry bulb); soybeans; sugar beets; tomatoes; and is an emulsifiable concentrate containing 2 pounds per gallon (26.4%) of active ingredient. SELECT Herbicide is registered for the same uses and is an emulsifiable concentrate containing 0.94 pounds per gallon (12.6%) of active ingredient. PRISM Herbicide is an alternate brand name for SELECT Herbicide. For optimum grass weed control, both SELECT 2EC and SELECT Herbicides require that adjuvant or crop oil concentrate be added to the spray solution. SELECT SUPER Herbicide is also an emulsifiable concentrate that includes the required adjuvant. SELECT SUPER Herbicide contains 1.0 pound per gallon (13.2%) of active ingredient and is registered on cotton, soybeans and sugar beets only. These products are applied to registered crops via broadcast foliar applications at rates up to 0.25 lb. Active ingredient/Acre (ai/A). For more difficult to control grass weeds, a second application within about 14 days is allowed. The maximum seasonal use rate is 0.5 lb. ai/A.

B. Residue Chemistry

1. *Plant and animal metabolism*. The metabolism of ^{14}C-clethodim labeled in the ring structure and in the side chain has been studied in carrots, soybeans, and cotton as well as in lactating goats and laying hens. The major metabolic pathway in plants is initial sulfoxidation, forming clethodim sulfoxide, followed by further oxidation to form clethodim sulfone. These reactions are apparently followed by elimination of the chloroallyloxy side

chain to give the imine sulfoxide and sulfone, with further hydroxylation to form the 5-OH sulfoxide and 5-OH sulfone. Clethodim sulfoxide and clethodim sulfone conjugates were also detected as major or minor metabolites, depending on plant species and subfractions. Once the side chain is cleaved from clethodim, the chloroallyloxy moiety undergoes extensive metabolism to eliminate chlorine and incorporate three-carbon moieties into natural plant components.

Ruminant and poultry metabolism studies demonstrated that transfer of administered ^{14}C-clethodim residues to tissues was low. Total ^{14}C-residues in goat milk, muscle and tissues accounted for less than 0.5% of the administered dose (24 ppm in diet for 3 days), and were less than 0.4 ppm in all cases. In poultry treated at 2.2 milligram/kilogram/day (mg/kg/day) for 5 days, total ^{14}C residues in eggs, muscle and most tissues were less than 0.3 ppm, although higher in liver, kidney and the gastrointestinal tract (GI tract). Residues in eggs were less than 0.2 ppm.

Comparing metabolites detected and quantified from plant and animal metabolism studies shows that there are no significant aglycones in plants which are not also present in the excreta or tissues of animals. Based on these metabolism studies, the residues of concern in crops and animal products are clethodim and its metabolites containing the cyclohexene moiety, and their sulfoxides and sulfones.

2. *Analytical method*. Practical analytical methods for detecting and measuring levels of clethodim and its metabolites have been developed and validated in/on all appropriate agricultural commodities, respective processing fractions, milk, animal tissues, and environmental samples. The extraction methodology has been validated using aged radio chemical residue samples from ^{14}C-metabolism studies. The methods have been validated at independent laboratories, and EPA has successfully performed an analytical method trial. For most commodities, the primary enforcement method is EPA-RM-26D-3, an high performance liquid chromotography (HPLC) method capable of distinguishing clethodim from the structurally related herbicide sethoxydim. However, for milk, natural interferences prevent adequate quantitation of clethodim moieties and the common-moiety method (RM-26B-2) is the primary enforcement method with EPA-RM-26D-3 as the secondary method if needed to differentiate clethodim from sethoxydim.

3. *Magnitude of residues*. A summary of field residue data supporting the proposed tolerances on green onion, leaf lettuce, head and stem brassica vegetables, flax and mustard seed is presented below.

(a) Green Onion: In three (3) field trials, onions (green) were treated with two post-emergent applications of 0.24 to 0.34 lb. a.i./A and harvested 13 to 15 days after the application. The trials were performed in EPA regions 3, 6, and 10. Residues in onions (green) ranged from <0.20 ppm to 0.87 ppm total clethodim. These residue data support a tolerance for green onion of 2.0 ppm.

(b) Leaf Lettuce: In six (6) field trials conducted in EPA regions 2, 3, and 10, leaf lettuce was treated with two post-emergent applications of 0.23 to 0.32 lb. a.i./A each. Lettuce was harvested 13–16 days after the last application. Clethodim residues ranged from <0.25 to <1.10 ppm total clethodim. These residue data support a tolerance for leaf lettuce of 2.0 ppm.

(c) Head and Stem Brassica: Proposed tolerances for Crop Subgroup 4B are supported by field residue studies in broccoli and cabbage. In six (6) field trials, broccoli was treated with two post-emergent applications of 0.24 to 0.34 lb. a.i./A each, 13–14 days apart, and harvested 29–31 days after the last application. Residues in broccoli ranged from <0.1 ppm to 1.20 ppm total clethodim. In seven (7) field trials, cabbage was treated with two post-emergent applications of 0.25 to 0.37 lb. a.i./A each, 14 days apart, and harvested 28–31 days after the last application. Residues in cabbage ranged from <0.24 ppm to 1.17 ppm total clethodim. These data support a tolerance of 3.0 ppm in head and stem brassica.

(d) Flax: In two (2) field trials, flax was treated with one post-emergent application of 0.09 lb. a.i./A and harvested approximately 84 to 108 days after the last application. These residue trials were performed in Canada in growing regions adjacent to the U.S. areas where flax is grown. These data were used to support a maximum residue level in Canada and are being cited in order to harmonize maximum residue levels between the U.S. and Canada and to remove the existing trade barrier. Clethodim residues ranged from <0.05 to 0.06 ppm total clethodim and support a tolerance for flax seed at 0.50 ppm.

(e) Mustard Seed: Tolerances for mustard seed are supported by residue field trials on flax, summarized above, and a similar oilseed crop, canola. In 18 field trials, canola or rape was treated with one post-emergent application of 0.11 to 0.32 lb. a.i./A and harvested approximately 70 to 98 days after the application. Most of these trials were performed in Canada in growing regions adjacent to the U.S. areas where canola is grown. These data were used to support a maximum residue level in Canada and were cited in a previous petition (7F4873) to harmonize maximum residue levels for canola between the U.S. and Canada and to remove the existing trade barrier. Residues in canola seed samples ranged from < 0.05 ppm to 0.54 ppm. The highest average field trial (HAFT) residue was 0.505 ppm. The averageresidue value for all trials, including samples less than the limit of detection at one-half the limit, was 0.16 ppm (number of samples = 31, standard deviation, n-1 degrees of freedom = 0.14 ppm). Since the highest residues were the result of application rates (0.19 lb. a.i./A) higher than those proposed for the U.S. (0.08 lb. a.i./A), these data support tolerances of 0.50 ppm in mustard seed.

Secondary Residues: The single feed item associated with these uses, flax meal, has potential anticipated clethodim residues well below other feed items with existing tolerances. Thus, clethodim residues in/on this proposed feed item does not effect the theoretical maximum dietary burden for the various livestock diets, and thus does not effect the magnitude of secondary residue tolerances. Therefore, no changes in existing secondary residue tolerances is being proposed.

Rotational Crops: The results of a confined rotational crops accumulation study indicate that no rotational crop tolerances are required.

C. Toxicological Profile

A full battery of toxicology testing including studies of acute, sub-acute, and chronic toxicity; carcinogenicity; developmental and reproductive toxicity; mutagenicity; and rat metabolism is available for clethodim. The acute toxicity of clethodim is low by all routes. Clethodim is not a developmental or reproductive toxicant, and is not mutagenic or carcinogenic. EPA has established a reference dose (RfD) for clethodim of 0.01 mg/kg bwt/day, based on alterations in hematology and increased absolute and relative liver weights at 75 mg/kg/day observed in a chronic toxicity study in dogs with a no observed adverse effect level (NOAEL) of 1 mg/kg/day. An uncertainty factor of 100 is used in calculating the reference dose RfD to account for both inter- and intra-species variations. EPA has (not) identified toxicity endpoints of concern for acute exposures.

1. *Acute toxicity*. Clethodim technical is slightly toxic to animals following acute oral (Toxicity Category III), dermal (Toxicity Category IV), or inhalation exposure (Toxicity Category IV). Clethodim is a moderate eye irritant (Category III), a skin irritant (Category II), and does not cause skin sensitization in the modified Buehler test in guinea pigs. In addition, an acute oral no-observed effect level (NOAEL) has been determined in rats to be 300 mg/kg.

2. *Genotoxicity*. Clethodim does not present a genetic hazard. Clethodim technical did not induce gene mutation in microbial *in vitro* assays. A weak response in an *in vitro* assay for chromosome aberrations was not confirmed when clethodim was tested in an *in vivo* cytogenetics assay up to the maximally tolerated dose level, nor was the response observed *in vitro* using technical material of a higher purity. No evidence of unscheduled DNA synthesis was seen following *in vitro*exposure up to a dose level near the LD_{50} (1.5 g/kg). This evidence indicates that clethodim does not present a genetic hazard to intact animal systems.

3. *Reproductive and developmental toxicity*. No reproductive toxicity was observed with clethodim technical at feeding levels up to 2,500 ppm. Developmental toxicity was observed in 2 rodent species, but only at maternally toxic dose levels. Clethodim is therefore not considered a reproductive or developmental hazard. These studies indicate no unique toxicity to the developing fetus or young, growing animals.

The developmental toxicity study conducted with clethodim technical in the rat resulted in a developmental and maternal NOAEL and lowest observed adverse effect level (LOAEL) of 100 and 350 mg/kg/day, respectively. The NOAEL and LOAEL for developmental toxicity were based on reductions in fetal body weight and increases in skeletal abnormalies.

The developmental toxicity study conducted with clethodim technical in the rabbit resulted in a maternal toxicity NOAEL and LOAEL of 25 and 100 mg/kg/day, respectively. Maternal toxicity was manifested as clinical signs of toxicity and reduced weight gain and food consumption duringtreatment. Developmental toxicity was not observed, and therefore the developmental toxicity NOAEL was 300 mg/kg/day, highest dose tested (HDT).

The 2–generation reproduction study conducted with clethodim technical in the rat resulted in parental toxicity NOAEL and LOAEL of 500 and 2,500 ppm, respectively, based on reductions in body weight in males, and decreased food consumption in both generations. The NOAEL for reproductive toxicity was 2,500 ppm, HDT.

4. *Subchronic toxicity*. Subchronic oral toxicity studies conducted with clethodim technical in the rat and dog indicate a low level of toxicity. Effects observed at high dose levels consisted primarily of decreased body weights, increased liver size (increased weight and cell hypertrophy), and anemia (decreased erythrocyte counts, hemoglobin, or hematocrit) in rats and dogs. The NOAELs from these studies were 500 ppm (ca. 25 mg/kg bw/day) in rats and 25 mg/kg bwt/day in dogs.

A 21–day dermal toxicity study in rats with clethodim technical showed a LOAEL at 100 mg/kg bwt/day and a NOAEL at 1,000 mg/kg bwt/day, the highest dose tested.

5. *Chronic toxicity*. Clethodim technical has been tested in chronic studies with dogs, rats and mice. In chronic studies compound-related effects noted at high doses included decreased body weight, increased liver size (liver weight and hypertrophy), and anemia (decreased hemoglobin, hematocrit, and erythrocyte count). Bone marrow hyperplasia was observed in dogs at the highest dose tested. No treatment-related increases in incidence of neoplasms were observed in any study. Chronic NOAELs were 200 ppm for an 18–month feeding study in mice and 500 ppm for a 24–month study in rats. EPA has established a reference dose (RfD) for clethodim of 0.01 mg/kg bwt/day, based on the NOAEL in the 1–year oral dog study and an uncertainty factor of 100. Effects cited by EPA include, alterations in hematology and increased absolute and relative liver weights at 75 mg/kg/day.

Clethodim technical is not a carcinogen. Studies with clethodim have shown that repeated high dose exposures produced signs of toxicity, but did not produce cancer in test animals. No oncogenic response was observed in a rat 2–year chronic feeding/carcinogenicity study or in a 18–month study on mice. The carcinogenicity classification of clethodim is ''E'' no evidence of carcinogenicity for humans.

A 1–year feeding study with clethodim technical in the dog resulted in a systemic NOAEL of 1 mg/kg/day in both sexes and an LOAEL of 75 mg/kg/day based on increased absolute and relative liver weights, and alteration and clinical chemistry.

An 18–month mouse carcinogenicity feeding study showed clethodim technical to be non-carcinogenic to mice under the conditions of the study. The systemic NOAEL was 200 ppm (8 mg/kg bwt/day), and the systemic LOAEL was 1,000 ppm (50 mg/kg bwt/day) based on treatment-related effects on survival, red cell mass, absolute and relative liver weights, and microscopic findings in liver and lung.

A 2–year chronic toxicity/carcinogenicity feeding study performed in the rat found clethodim technical to be noncarcinogenic to rats under the conditions of the study. The systemic NOAEL was 500 ppm (approximately 19 mg/kg bwt/day), and the systemic LOAEL was 2,500 ppm (approximately 100 mg/kg bwt/day) based on the observed body weight gain, the increases in liver weights, and the presence of centrilobular hepatic hypertrophy.

6. *Animal metabolism*. The absorption, tissue distribution, metabolism and excretion of ring- and side chain-labeled ^{14}C- clethodim were studied in rats after single oral doses of 468 or 4.4 mg/kg/ bwt, and after a single oral dose of 4.8 mg/kg bwt $_{14}C$-clethodim following 14 daily oral doses at 4.5 mg/kg bwt of unlabelled material. For all dose groups, most $_{14}C$-clethodim (88–96%) of the administered radiolabel was excreted in the urine and feces within 2 days after radiolabeled test material dosing, and 92–98% of the administered dose was excreted within seven days. The low dose groups eliminated clethodim slightly faster than the high dose group, and repeated exposure to clethodim prior to radiolabel dosing did not affect the rate of elimination or distribution of recovered radiolabel. There were no apparent sex differences with respect to elimination or distribution of metabolites. Seven days after dosing, tissue residues were generally low, accounting for no more than 0.3% of the dosed ^{14}C. Radiocarbon concentrations in fat were the higher than in other tissues analyzed. Recovery in tissues over time indicates that the potential for bioaccumulation is minimal. The primary excretory metabolites were identified as clethodim sulfoxide (48–63%), clethodim S-methyl sulfoxide (6–12%), clethodim imine sulfoxide (7–10%), and clethodim 5-hydroxy sulfoxide (3–5%). Minor metabolites included clethodim oxazole sulfoxide (2–3%), clethodim trione sulfoxide (1%), clethodim (1%), clethodim 5-hydroxy sulfone (0.3–1%), clethodim sulfone (0.1–1%), aromatic sulfone (0.2–0.7%), and S-methyl sulfone (0–0.4%).

7. *Metabolite toxicology*. Metabolism studies of clethodim in rats, crop plants, goats and hens demonstrate that the parent is very rapidly metabolized and, in animals, eliminated. Because parent and metabolites are not retained in the

body, the potential for acute toxicity from *in situ* formed metabolites is low. The potential for chronic toxicity is adequately tested by chronic exposure to the parent at the MTD and consequent chronic exposure to the internally formed metabolites. Two metabolites of clethodim, clethodim imine sulfone and clethodim 5-hydroxy sulfone, have been tested in toxicity screening studies to evaluate the potential impact of these metabolites on the toxicity of clethodim. In general, these metabolites were found to be less toxic than Clethodim Technical for acute and oral toxicity studies; reproduction and teratology screening studies; and several mutagenicity studies.

8. *Dermal Penetration*. The dermal penetration of SELECT 2 EC Herbicide, the end-use product, was tested on unabraded, shaved skin of rats. Single doses of approximately 0.05, 0.5, and 5.0 mg of radiolabeled ^{14}C-clethodim) SELECT 2 EC Herbicide, were applied topically to 10 cm2 sites on the dorsal trunk. Clethodim was found to be slowly absorbed through the skin in a time-dependent manner. The percent of dose absorbed increased with length of exposure and decreased with increasing dose. Ten-hour absorption rates ranged from 7.5% to 30.0%. Most of the absorbed material was found in the urine and carcass, and most of the unabsorbed material was found in the skin scrubbings indicating that material was still on the skin surface.

9. *Endocrine disruption*. No special studies to investigate the potential for estrogenic or other endocrine effects of clethodim have been performed. However, as summarized above, a large and detailed toxicology data base exists for the compound including studies acceptable to the Agency in all required categories. These studies include acute, sub-chronic, chronic, developmental, and reproductive toxicology studies including detailed histology and histopathology of numerous tissues, including endocrine organs, following repeated or long term exposure. These studies are considered capable of revealing endocrine effects, and the results of all of these studies show no evidence of any endocrine-mediated effects and no pathology of the endocrine organs. Consequently, it is concluded that clethodim does not possess estrogenic or endocrine disrupting properties.

C. Aggregate Exposure

1. *Dietary exposure*. EPA has established a RfD for clethodim of 0.01 mg/kg bwt/day, based on the NOAEL in the 1–year oral dog study and an uncertainty factor of 100. Effects cited by EPA include, alterations in hematology and increased absolute and relative liver weights at 75 mg/kg/day. Toxic endpoints of concern have not been identified for acute or short-term exposures by any route, or chronic endpoints of concern by any route other than oral. Therefore, only aggregate chronic dietary risk analyses are required.

i. *Food*. Chronic dietary exposure to clethodim residues was calculated for established and pending uses of clethodim for the U.S. population and 26 population subgroups using anticipated residues (average residues from field residue studies) and accounting for the percent of the crop treated.

ii. *Drinking water*. Since clethodim is applied outdoors postemergence to growing agricultural crops, the potential exists for clethodim and/or its metabolites to reach ground or surface water that may be used for drinking water. To model very conservative estimates of the potential concentrations of clethodim and its sulfoxide metabolite in drinking water, the Agency used screening concentration in ground water (SCI-GROW), and generic expected environmental concentration (GENEEC) for surface water. The sum of the parent and metabolite estimated concentrations in surface water greatly exceeded those in groundwater. Dividing the GENEEC derived 56–day average concentration by three gives 10 micrograms per liter (ppb) as the Agency's worse case estimate for drinking water contamination [Federal Register 63(67): 1701–8 (April 8, 1998). Using standard assumptions about body weight and water consumption, the chronic exposure from this drinking water would be 0.00029 and 0.001 mg/kg bwt/day for adults and children, respectively; 10% of the RfD for children. Based on this worse case analysis, the contribution of water to the chronic dietary risk exceeds food, but is still acceptable.

2. *Non-dietary exposure*. Clethodim is currently registered for use as a broadcast application on winter dormant perennial turf to control annual grasses. It is conceivable that this outdoor uses could result in acute or short- and/or intermediate- term residential exposure. Under current EPA criteria, the registered and proposed uses of clethodim would not constitute a chronic residential exposure scenario. Because toxic endpoints of concern have not been identified for short- or intermediate-term exposure, these risk analyses are not necessary.

D. Cumulative Effects

Section 408(b)(2)(D)(v) requires that the Agency must consider ''available information'' concerning the cumulative effects of a particular pesticide's residues and ''other substances that have a common mechanism of toxicity.'' Available information in this context include not only toxicity, chemistry, and exposure data, but also scientific policies and methodologies for understanding common mechanisms of toxicity and conducting cumulative risk assessments. For most pesticides, although the Agency has some information in its files that may turn out to be helpful in eventually determining whether a pesticide shares a common mechanism of toxicity with any other substances, EPA does not at this time have the methodologies to resolve the complex scientific issues concerning common mechanism of toxicity in a meaningful way.

There are other pesticidal compounds that are structurally related to clethodim including sethoxydim, cycloxydim, and tralkoxydim. Analytical methods convert some of these herbicides and their metabolites to common moieties. Plant and animal metabolism data demonstrates that no common metabolites are formed. In consideration of potential cumulative effects of clethodim and other substances that may have a common mechanism of toxicity, there are currently no available data or other reliable information indicating that any toxic effects produced by clethodim would be cumulative with those of other chemical compounds. Thus, only the potential risks of clethodim have been considered in this assessment of aggregate exposure and effects.

Valent will submit information for EPA to consider concerning potential cumulative effects of clethodim consistent with the schedule established by EPA at 62 Federal Register 42020 (August 4, 1997) and other subsequent EPA publications pursuant to the Food Quality Protection Act (FQPA).

E. Safety Determination

An acute dietary endpoint was not identified. Thus, the risk from acute aggregate dietary exposure to clethodim is considered to be negligible. Aggregate chronic dietary exposure to various sub-populations of children and adults demonstrate acceptable risk. Aggregate chronic exposures to clethodim for all population subgroups occupy considerably less than 100% of the RfD. It should be noted that the bulk of the calculated aggregate chronic exposures consist of very conservatively estimated

concentrations of clethodim and its sulfoxide metabolite in drinking water. Because there are no identified short- or intermediate-term dermal toxic endpoints of concern, these risk analyses are not necessary.

It can be concluded that there is a reasonable certainty that no harm will result to individuals in the U.S. population or in any sub-group of the U.S. population, including infants and children, from aggregate chronic exposures to clethodim residues resulting from approved and pending uses.

1. *U.S. population*. Using the dietary exposure assessment procedures described above for clethodim, calculated chronic dietary exposure — taking into account percent of crop treated and using anticipated residues — from existing and proposed uses of clethodim is minimal. The estimated chronic dietary exposure from food for the overall U.S. population and many non-child/infant subgroups is 0.000174 to 0.000204 mg/kg bwt/day, 1.7 to 2.0% of the RfD. Addition of the small but worse case potential chronic exposure from drinking water (calculated above) increases exposure by 0.0003 mg/kg bwt/day and the maximum occupancy of the RfD from 2.0 per cent to 5.0%. Generally, the Agency has no cause for concern if total residue contribution is less than 100% of the RfD. It can be concluded that there is a reasonable certainty that no harm will result to the overall U.S. Population and many non-child/infant subgroups from aggregate, chronic exposure to clethodim residues.

2. *Infants and children*. Safety Factor for Infants and Children: In assessing the potential for additional sensitivity of infants and children to residues of clethodim, FFDCA section 408 provides that EPA shall apply an additional margin of safety, up to ten-fold, for added protection for infants and children in the case of threshold effects unless EPA determines that a different margin of safety will be safe for infants and children.

The toxicological data base for evaluating pre- and post-natal toxicity for clethodim is complete with respect to current data requirements. There are no special pre- or post-natal toxicity concerns for infants and children, based on the results of the rat and rabbit developmental toxicity studies or the 3–generation reproductive toxicity study in rats. Reliable data support use of the standard 100-fold uncertainty factor and an additional uncertainty factor is not needed for clethodim to be further protective of infants and children.

Chronic Exposure and Risk — Infant and child sub-populations: Using the conservative exposure assumptions described above (anticipated residues and percent of crop treated), the percentage of the RfD that will be utilized by dietary (food only) exposure to residues of clethodim ranges from 0.7% for nursing infants (<1 year old), up to 4.8 % for children (1–6 years). Adding the worse case potential incremental exposure to infants and children from clethodim in drinking water (0.001 mg/kg bwt/day) greatly increases the aggregate, chronic dietary exposure and the occupancy of the RfD by 10.0 % to 14.8 % for Children (1–6 years). EPA generally has no concern for exposures below 100% of the RfD because the RfD represents the level at or below which daily aggregate dietary exposure over a lifetime will not pose appreciable risks to human health. It can be concluded that there is a reasonable certainty that no harm will result to infants and children from aggregate, chronic exposure to clethodim residues.

F. International Tolerances

Although some have been proposed, there are no Canadian, Mexican, or Codex tolerances or maximum residue limits established for clethodim. There are no conflicts between this proposed action and international residue limits.

[FR Doc. 01–21447 Filed 8–23–01; 8:45 am]

BILLING CODE 6560–50–S

ENVIRONMENTAL PROTECTION AGENCY

[PF–1039; FRL–6796–2]

Notice of Filing a Pesticide Petition to Establish a Tolerance for a Certain Pesticide Chemical in or on Food

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

SUMMARY: This notice announces the initial filing of a pesticide petition proposing the establishment of regulations for residues of a certain pesticide chemical in or on various food commodities.

DATES: Comments, identified by docket control number PF–1039, must be received on or before September 24, 2001.

ADDRESSES: Comments may be submitted by mail, electronically, or in person. Please follow the detailed instructions for each method as provided in Unit I.C. of the **SUPPLEMENTARY INFORMATION**. To ensure proper receipt by EPA, it is imperative that you identify docket control number PF–1039 in the subject line on the first page of your response.

FOR FURTHER INFORMATION CONTACT: By mail: Joseph M. Tavano, Registration Division (7505W), Office of Pesticide Programs, Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460; telephone number: (703) 305–6411; e-mail address: tavano.joseph@epa.gov.

SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this Action Apply to Me?

You may be affected by this action if you are an agricultural producer, food manufacturer, or pesticide manufacturer. Potentially affected categories and entities may include, but are not limited to:

Categories	NAICS codes	Examples of potentially affected entities
Industry	111	Crop production
	112	Animal production
	311	Food manufacturing
	32532	Pesticide manufacturing

This listing is not intended to be exhaustive, but rather provides a guide for readers regarding entities likely to be affected by this action. Other types of entities not listed in the table could also be affected. The North American Industrial Classification System (NAICS) codes have been provided to assist you and others in determining whether or not this action might apply to certain entities. If you have questions regarding the applicability of this action to a particular entity, consult the person listed under **FOR FURTHER INFORMATION CONTACT**.

B. How Can I Get Additional Information, Including Copies of this Document and Other Related Documents?

1. *Electronically*. You may obtain electronic copies of this document, and certain other related documents that might be available electronically, from the EPA Internet Home Page at http://www.epa.gov/. To access this document, on the Home Page select ''Laws and Regulations,'' ''Regulations and Proposed Rules,'' and then look up the entry for this document under the ''**Federal Register**—Environmental Documents.'' You can also go directly to the **Federal Register** listings at http://www.epa.gov/fedrgstr/.

2. *In person*. The Agency has established an official record for this action under docket control number PF–1039. The official record consists of the documents specifically referenced in this action, any public comments received during an applicable comment period, and other information related to this action, including any information claimed as confidential business information (CBI). This official record includes the documents that are physically located in the docket, as well as the documents that are referenced in those documents. The public version of the official record does not include any information claimed as CBI. The public version of the official record, which includes printed, paper versions of any electronic comments submitted during an applicable comment period, is available for inspection in the Public Information and Records Integrity Branch (PIRIB), Rm. 119, Crystal Mall #2, 1921 Jefferson Davis Highway, Arlington, VA, from 8:30 a.m. to 4 p.m., Monday through Friday, excluding legal holidays. The PIRIB telephone number is (703) 305–5805.

C. How and to Whom Do I Submit Comments?

You may submit comments through the mail, in person, or electronically. To ensure proper receipt by EPA, it is imperative that you identify docket control number PF–1039 in the subject line on the first page of your response.

1. *By mail*. Submit your comments to: Public Information and Records Integrity Branch (PIRIB), Information Resources and Services Division (7502C), Office of Pesticide Programs (OPP), Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460.

2. *In person or by courier*. Deliver your comments to: Public Information and Records Integrity Branch (PIRIB), Information Resources and Services Division (7502C), Office of Pesticide Programs (OPP), Environmental Protection Agency, Rm. 119, Crystal Mall #2, 1921 Jefferson Davis Highway, Arlington, VA. The PIRIB is open from 8:30 a.m. to 4 p.m., Monday through Friday, excluding legal holidays. The PIRIB telephone number is (703) 305–5805.

3. *Electronically*. You may submit your comments electronically by e-mail to: opp-docket@epa.gov, or you can submit a computer disk as described above. Do not submit any information electronically that you consider to be CBI. Avoid the use of special characters and any form of encryption. Electronic submissions will be accepted in Wordperfect 6.1/8.0 or ASCII file format. All comments in electronic form must be identified by docket control number PF–1039. Electronic comments may also be filed online at many Federal Depository Libraries.

D. How Should I Handle CBI That I Want to Submit to the Agency?

Do not submit any information electronically that you consider to be CBI. You may claim information that you submit to EPA in response to this document as CBI by marking any part or all of that information as CBI. Information so marked will not be disclosed except in accordance with procedures set forth in 40 CFR part 2. In addition to one complete version of the comment that includes any information claimed as CBI, a copy of the comment that does not contain the information claimed as CBI must be submitted for inclusion in the public version of the official record. Information not marked confidential will be included in the public version of the official record without prior notice. If you have any questions about CBI or the procedures for claiming CBI, please consult the person identified under **FOR FURTHER INFORMATION CONTACT**.

E. What Should I Consider as I Prepare My Comments for EPA?

You may find the following suggestions helpful for preparing your comments:

1. Explain your views as clearly as possible.

2. Describe any assumptions that you used.

3. Provide copies of any technical information and/or data you used that support your views.

4. If you estimate potential burden or costs, explain how you arrived at the estimate that you provide.

5. Provide specific examples to illustrate your concerns.

6. Make sure to submit your comments by the deadline in this notice.

7. To ensure proper receipt by EPA, be sure to identify the docket control number assigned to this action in the subject line on the first page of your response. You may also provide the name, date, and **Federal Register** citation.

II. What Action is the Agency Taking?

EPA has received a pesticide petition as follows proposing the establishment and/or amendment of regulations for residues of a certain pesticide chemical in or on various food commodities under section 408 of the Federal Food, Drug, and Cosmetic Act (FFDCA), 21 U.S.C. 346a. EPA has determined that this petition contains data or information regarding the elements set forth in section 408(d)(2); however, EPA has not fully evaluated the sufficiency of the submitted data at this time or whether the data support granting of the petition. Additional data may be needed before EPA rules on the petition.

List of Subjects

Environmental protection, Agricultural commodities, Feed additives, Food additives, Pesticides and pests, Reporting and recordkeeping requirements.

Dated: August 14, 2001.

Peter Caulkins,

Acting Director, Registration Division, Office of Pesticide Programs.

Summary of Petition

The petitioner summary of the pesticide petition is printed below as required by section 408(d)(3) of the FFDCA. The summary of the petition was prepared by the petitioner and represents the view of the petitioner. EPA is publishing the petition summary verbatim without editing it in any way. The petition summary announces the availability of a description of the analytical methods available to EPA for the detection and measurement of the pesticide chemical residues or an explanation of why no such method is needed.

Rohm and Haas Company

1F6287

EPA has received a pesticide petition (1F6287) from Rohm and Haas Company, 100 Independence Mall West, Philadelphia, PA 19106–2399 proposing, pursuant to section 408(d) of the Federal Food, Drug, and Cosmetic Act (FFDCA), 21 U.S.C. 346a(d), to amend 40 CFR part 180 by establishing a tolerance for residues of methoxyfenozide [benzoic acid, 3-methoxy-2-methyl-, 2-(3,5-dimethylbenzoyl)-2-(1,1-dimethylethyl) hydrazide] in or on the raw agricultural commodity tree nut crop group and almond hulls at 0.1 and 45 parts per million (ppm), respectively. EPA has determined that the petition contains data or information regarding the elements set forth in section 408(d)(2) of the FFDCA; however, EPA has not fully evaluated the sufficiency of the submitted data at this time or whether the data support granting of the petition. Additional data may be needed before EPA rules on the petition.

A. Residue Chemistry

1. *Plant metabolism*. The qualitative nature of methoxyfenozide residues in plants and animals is adequately understood and was previously published in the **Federal Register** of July 5, 2000, (65 FR 41355) (FRL–6496–5).

2. *Analytical method*. A high performance liquid chromotography/ using ultra-violet detection (HPLC/UV) Method TR 34–00–107 for the enforcement of tolerances in tree nuts and almond hulls has been developed. Confirmatory method validation data have been submitted for this method. The validated limit of quantitation (LOQ) of the analytical method was 0.02 ppm in all nut matrices and 0.05 ppm for almond hulls.

3. *Magnitude of residues*. Magnitude of residue, geographically representative field trials with methoxyfenozide 80WP and 2F formulations were conducted to support the proposed crop group tolerance for the tree nut representative crops pecans and almonds. The results of the field trials indicate that residues of methoxyfenozide will not exceed the proposed crop group tolerance of 0.1 ppm for tree nuts or 45 ppm for almond hulls.

B. Toxicological Profile

The toxicological profile and endpoints for methoxyfenozide which supports this petition to establish tolerances were previously published in the **Federal Register** of July 5, 2000 (65 FR 41355) (FRL–6496–5).

C. Aggregate Exposure

i. *Food—Acute exposure and risk*. Acute dietary risk assessments are performed for a food-use pesticide if a toxicological study has indicated the possibility of an effect of concern occurring as a result of a 1–day or single exposure. No appropriate toxicological endpoint attributable to a single exposure was identified in the available toxicology studies on methoxyfenozide including the acute neurotoxicity study in rats, the developmental toxicity study in rats, and the developmental toxicity study in rabbits. Since no acute toxicological endpoints were established, Rohm and Haas considers acute aggregate risk to be negligible.

ii. *Chronic exposure and risk*. Rohm and Haas used the dietary exposure evaluation model (DEEM) software for conducting a chronic dietary (food) risk analysis. DEEM is a dietary exposure analysis system that is used to estimate exposure to a pesticide chemical in foods comprising the diets of the U.S. population, including population subgroups. DEEM contains food consumption data as reported by respondents in the United States Department of Agriculture (USDA) continuing surveys of food intake by individuals conducted in 1994–1996. Rohm and Haas assumed 100% of crops would be treated and contain methoxyfenozide residues at the tolerance level. The following tolerance levels were used in the analysis:

Commodity	Tolerance Level ppm
Almond hulls	45 ppm
Bulb vegetables	0.1 ppm
Corn, aspirated grain fractions	1.0 ppm
Corn, field, forage	15 ppm
Corn, field, grain	0.05 ppm
Corn, field, stover (fodder)	105 ppm
Corn, oil	0.2 ppm
Corn, silage	5.0 ppm
Corn, sweet, forage	30 ppm
Corn, sweet (K+CWHR)	0.05 ppm
Corn, sweet, stover (fodder)	60 ppm
Cotton, undelinted seed	2.0 ppm
Fat*	0.5 ppm
Fruiting vegetables	2.0 ppm
Grapes	1.0 ppm
Head and stem Brassica (5A)	6.5 ppm
Herbs and spices	8 ppm
Leaf petioles (4B)	10.0 ppm
Leafy Brassica greens (5B)	20.0 ppm
Leafy vegetables (4A)	25 ppm
Leaves of root and tuber vegetables	0.1 ppm
Legume vegetables	0.05 ppm
Liver	0.4 ppm
Meat*	0.02 ppm
Meat byproducts* (except liver)	0.1 ppm
Milk	0.1 ppm
Pome fruit	1.5 ppm
Prunes	7.0 ppm
Raisins	1.5 ppm
Root and tuber vegetables	0.05 ppm
Stone fruits	5.0 ppm
Tree nuts	0.1 ppm

*Of cattle, goats, hogs, horses, and sheep.

Processing factors were also applied to grape juice (1.2x), grape juice concentrate (3.6x), apple juice/cider (1.3x), apple juice concentrate (3.9x), dried apples (8x), dried pears (6.25x), tomato juice (1.5x), tomato puree (3.3x), tomato paste (5.4x), tomato catsup (2.5x), dried tomatoes (14.3x), dehydrated onions (9x), white dry potatoes (6.5x), sprouted soybean seeds (0.33x), corn grain sugar (high, fructose corn syrup 1.5x), dried beef (1.92x), dried veal (1.92x), dried apricots (6.0x), dried cherries (4.0x), cherry juice (1.5x), dried peaches (7.0x), dried plums (5.0x), and plum/prune juice (1.4x). The processing factors are default values from DEEM.

As shown in the following table, the resulting dietary food exposures occupy up to 37.6% of the chronic PAD (cPAD) for the most highly exposed population subgroup, children 1 to 6 years old. These results should be viewed as conservative (health protective) risk estimates. Refinements such as use of percent crop-treated information and/or anticipated residue values would yield even lower estimates of chronic dietary exposure.

SUMMARY: CHRONIC DIETARY EXPOSURE ANALYSIS BY DEEM (TIER 1)

Population Subgroup	Exposure milligrams/ kilograms (mg/kg/day)	% of cPAD
U.S. population (48 contiguous States)	0.0189	18.9
All infants (<1 year old)	0.0315	31.5
Nursing infants (<1 year old)	0.0134	13.4
Non-nursing infants (<1 year old)	0.0368	36.8
Children (1 to 6 years old)	0.0376	37.6

SUMMARY: CHRONIC DIETARY EXPOSURE ANALYSIS BY DEEM (TIER 1)—Continued

Population Subgroup	Exposure milligrams/kilograms (mg/kg/day)	% of cPAD
Children (7 to 12 years old)	0.0216	21.6
Females 13+ (nursing)	0.0191	19.1
U.S. population (autumn season)	0.0191	19.1
U.S. population (spring season)	0.0190	19.0
Northeast region	0.0206	20.6
Western region	0.0210	21.0
Hispanics	0.0191	19.1
Non-Hispanic/non- white/non-black	0.0249	24.9

Percent cPAD = (Exposure divided by cPAD) x 100%.

The subgroups listed are:

- The U.S. population (total).
- Those for infants and children.
- The other subgroup(s), if any, for which the percentage of the cPAD occupied is greater than that occupied by the subgroup U.S. population (total).
- The most highly exposed of the females subgroups (in this case, females (13+ years, nursing).

iii. *Drinking water.* There is no water-related exposure data from monitoring to complete a quantitative drinking water exposure analysis and risk assessment for methoxyfenozide. Generic expected environmental concentration (GENEEC) and/or pesticide root zone model/exposure analysis modeling system (PRZM/EXAMS) (both produce estimates of pesticide concentration in a farm pond) are used to generate estimated environmental concentrations (EECs) for surface water and screening concentration in ground water (SCI-GROW) (an empirical model based upon actual monitoring data collected for a number of pesticides that serve as benchmarks) predicts EECs in ground water. These models take into account the use patterns and the environmental profile of a pesticide, but do not include consideration of the impact that processing raw water for distribution as drinking water would likely have on the removal of pesticides from the source water. The primary use of these models at this stage is to provide a coarse screen for assessing whether a pesticide is likely to be present in drinking water at concentrations which would exceed human health levels of concern.

A drinking water level of comparison (DWLOC) is the concentration of a pesticide in drinking water that would be acceptable as a theoretical upper limit in light of total aggregate exposure to that pesticide from food, water, and residential uses. HED uses DWLOCs internally in the risk assessment process as a surrogate measure of potential exposure associated with pesticide exposure through drinking water. In the absence of monitoring data for a pesticide, the DWLOC is used as a point of comparison against the conservative EECs provided by computer modeling (SCI-GROW, GENEEC, PRZM/EXAMS).

a. *Acute exposure and risk.* Because no acute dietary endpoint was determined, Rohm and Haas concludes that there is a reasonable certainty of no harm from acute exposure from drinking water.

b. *Chronic exposure and risk.* Tier II screening-level assessments can be conducted using the simulation models SCI-GROW and PRZM/EXAMS to generate EECs for ground and surface water, respectively. The modeling was conducted based on the environmental profile and the maximum seasonal application rate proposed for methoxyfenozide (1.0 lb active iingredient/acre/season). PRZM/EXAMS was used to generate the surface water EECs, because it can factor the persistent nature of the chemical into the estimates.

The EECs for assessing chronic aggregate dietary risk used by HED are 6 parts per billion (ppb) (in ground water, based on SCI-GROW) and 98.5 ppb (in surface water, based on the PRZM/EXAMS, long-term mean). The back-calculated DWLOCs for assessing chronic aggregate dietary risk range from 624 ppb for the most highly exposed population subgroup (children 1 to 6 years old) to 2,839 ppb for the U.S. population (48 contiguous States—all seasons).

The SCI-GROW and PRZM/EXAMS chronic EECs are less than the Agency's level of comparison (the DWLOC value for each population subgroup) for methoxyfenozide residues in drinking water as a contribution to chronic aggregate exposure. Rohm and Haas thus concludes with reasonable certainty that residues of methoxyfenozide in drinking water will not contribute significantly to the aggregate chronic human health risk and that the chronic aggregate exposure from methoxyfenozide residues in food and drinking water will not exceed the Agency's level of concern (100% of the cPAD) for chronic dietary aggregate exposure by any population subgroup. EPA generally has no concern for exposures below 100% of the cPAD, because it is a level at or below which daily aggregate dietary exposure over a lifetime will not pose appreciable risks to the health and safety of any population subgroup. This risk assessment is considered high confidence, conservative, and very protective of human health.

DRINKING WATER LEVELS OF COMPARISON FOR CHRONIC EXPOSURE TO METHOXYFENOZIDE

Population Subgroup	cPAD (mg/kg/day)	Food Exposure (mg/kg/day)	Maximum Water Exposure (mg/kg/day)	SCI-GROW (µg/L)	GENEEC 56–Day Average (µg/L)	DWLOC (µg/L)
U.S. population (48 contiguous States)		0.0189	0.0811			2839
Females 13+ (nursing)		0.0191	0.0809			2427
Non-nursing Infants <1 year old	0.10	0.0368	0.0632	6	98.5	632

DRINKING WATER LEVELS OF COMPARISON FOR CHRONIC EXPOSURE TO METHOXYFENOZIDE—Continued

Population Sub-group	cPAD (mg/kg/day)	Food Exposure (mg/kg/day)	Maximum Water Exposure (mg/kg/day)	SCI-GROW (µg/L)	GENEEC 56–Day Average (µg/L)	DWLOC (µg/L)
Children (1 to 6 years old)		0.0376	0.0624			624
Children (7 to 12 years old)		0.0216	0.0784			784

Maximum water exposure (mg/kg/day) = cPAD (mg/kg/day) - chronic food exposure DWLOC (µg/L) = maximum water exposure (mg/kg/day) x body weight kg divided by 1/1,000 mg/µg x water consumed daily (L/day). Body weights for adults is 70 kg, for females 13+ is 60 kg, and for all children is 10 kg. Drinking water consumption is 2 liters per day for adults and 1 liter per day for children.

2. *Non-dietary exposure*. Methoxyfenozide is not currently registered for use on any residential non-food sites. Therefore, there is no non-dietary acute, chronic, short-or intermediate-term exposure.

D. Cumulative Effects

Section 408(b)(2)(D)(v) requires that, when considering whether to establish, modify, or revoke a tolerance, the Agency consider ''available information'' concerning the cumulative effects of a particular pesticide's residue and ''other substances that have a common mechanism of toxicity.''

EPA does not have, at this time, available data to determine whether methoxyfenozide has a common mechanism of toxicity with other substances or how to include this pesticide in a cumulative risk assessment. Unlike other pesticides for which EPA has followed a cumulative risk approach based on a common mechanism of toxicity, methoxyfenozide does not appear to produce a toxic metabolite produced by other substances. For the purposes of this tolerance action, therefore, it is assumed that methoxyfenozide does not have a common mechanism of toxicity with other substances.

E. Safety Determination

1. *U.S. population*. Using the DEEM exposure assumptions described in this unit, Rohm and Haas has concluded that aggregate exposure to methoxyfenozide from food will utilize 18.9% of the cPAD for the U.S. population. The major identifiable subgroup with the highest aggregate exposure is children 1 to 6 years old at 37.6% of the cPAD and is discussed below. EPA generally has no concern for exposures below 100% of the cPAD because the cPAD represents the level at or below which daily aggregate dietary exposure over a lifetime will not pose appreciable risks to human health. Despite the potential for exposure to methoxyfenozide in drinking water, the aggregate exposure is not expected to exceed 100% of the cPAD. Rohm and Haas concludes that there is a reasonable certainty that no harm will result from aggregate exposure to methoxyfenozide residues.

2. *Infants and children*. In assessing the potential for additional sensitivity of infants and children to residues of methoxyfenozide, EPA considered data from developmental toxicity studies in the rat and rabbit and a 2–generation reproduction study in the rat. The developmental toxicity studies are designed to evaluate adverse effects on the developing organism resulting from maternal pesticide exposure during gestation. Reproduction studies provide information relating to effects from exposure to the pesticide on the reproductive capability of mating animals and data on systemic toxicity.

FFDCA section 408 provides that EPA shall apply an additional ten-fold margin of safety for infants and children in the case of threshold effects to account for prenatal and postnatal toxicity and the completeness of the data base unless EPA determines that a different margin of safety will be safe for infants and children. Margins of safety are incorporated into EPA risk assessments either directly through use of a margin of exposure (MOE) analysis or through using uncertainty (safety) factors in calculating a dose level that poses no appreciable risk to humans. EPA believes that reliable data support using the standard uncertainty factor (usually 100 for combined interspecies and intraspecies variability) and not the additional ten-fold MOE/UF when EPA has a complete data base under existing guidelines and when the severity of the effect in infants or children or the potency or unusual toxic properties of a compound do not raise concerns regarding the adequacy of the standard MOE/safety factor.

The toxicology data base for methoxyfenozide included acceptable developmental toxicity studies in both rats and rabbits as well as a 2–generation reproductive toxicity study in rats. The data provided no indication of increased sensitivity of rats or rabbits to *in utero* and/or postnatal exposure to methoxyfenozide.

3. *Conclusion*. There is a complete toxicity data base for methoxyfenozide and exposure data are complete or are estimated based on data that reasonably accounts for potential exposures. Based on the completeness of the data base and the lack of prenatal and postnatal toxicity, EPA determined that an additional safety factor was not needed for the protection of infants and children.

Since no acute toxicological endpoints were established, acute aggregate risk is considered to be negligible.

Using the exposure assumptions described in this unit, Rohm and Haas has concluded that aggregate exposure to methoxyfenozide from food will utilize 37.6% of the cPAD for infants and children. EPA generally has no concern for exposures below 100% of the cPAD because the cPAD represents the level at or below which daily aggregate dietary exposure over a lifetime will not pose appreciable risks to human health. Despite the potential for exposure to methoxyfenozide in drinking water, Rohm and Haas does not expect the aggregate exposure to exceed 100% of the cPAD.

Short and intermediate term risks are judged to be negligible due to the lack of significant toxicological effects observed.

Based on these risk assessments, Rohm and Haas concludes that there is a reasonable certainty that no harm will result to infants and children from aggregate exposure to methoxyfenozide residues.

F. International Tolerances

There are no established or proposed Codex, Canadian or Mexican limits for residues of methoxyfenozide in/on plant or animal commodities. Therefore, no compatibility issues exist with regard to

the proposed U.S. tolerances discussed in this petition review.

[FR Doc. 01–21448 Filed 8–23–01; 8:45 am]

BILLING CODE 6560–50–S

ENVIRONMENTAL PROTECTION AGENCY

[FRL–7042–3]

Proposed CERCLA Administrative Cost Recovery Settlement; Atlantic Richfield Company, International Smelter Site, Tooele, Utah

AGENCY: Environmental Protection Agency.

ACTION: Notice; request for public comment.

SUMMARY: In accordance with section 122(i) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended (''CERCLA''), 42 U.S.C. 9622(i), notice is hereby given of a proposed administrative settlement for recovery of past response costs concerning the International Smelter site in Tooele, Utah, with Atlantic Richfield Company. The settlement requires the settling party to pay $185,066 to the Hazardous Substance Superfund and to perform and fund the remedial investigation/feasibility study for the site. The settlement includes a covenant not to sue the settling party pursuant to section 107(a) of CERCLA, 42 U.S.C. 9607(a). For thirty (30) days following the date of publication of this notice, the Agency will receive written comments relating to the settlement. The Agency will consider all comments received and may modify or withdraw its consent to the settlement if comments received disclose facts or considerations which indicate that the settlement is inappropriate, improper, or inadequate.

DATES: Comments must be submitted on or before September 24, 2001.

ADDRESSES: Written comments may be mailed to Dawn Tesorero, Technical Enforcement Program, 8ENF–T, Environmental Protection Agency (EPA), Region 8, 999 18th Street, Suite 300, Denver, Colorado, 80202. Comments should reference the International Smelter Site, Tooele, Utah. Copies of the documents relevant to this settlement are available for public inspection at the Superfund Records Center, EPA, Region 8, 999 18th Street, Suite 300, Denver, Colorado, 80202.

FOR FURTHER INFORMATION CONTACT: Dawn Tesorero, EPA, Technical Enforcement Program, (303) 312–6883 at the earlier mentioned address.

Dated: August 9, 2001.

Carol Rushin,

Assistant Regional Administrator, Office of Enforcement, Compliance, and Environmental Justice, Region 8.

[FR Doc. 01–21443 Filed 8–23–01; 8:45 am]

BILLING CODE 6560–50–P

FEDERAL COMMUNICATIONS COMMISSION

Notice of Public Information Collection(s) Being Reviewed by the Federal Communications Commission, Comments Requested

August 17, 2001.

SUMMARY: The Federal Communications Commission, as part of its continuing effort to reduce paperwork burden invites the general public and other Federal agencies to take this opportunity to comment on the following information collection, as required by the Paperwork Reduction Act of 1995, Public Law 104–13. An agency may not conduct or sponsor a collection of information unless it displays a currently valid control number. No person shall be subject to any penalty for failing to comply with a collection of information subject to the Paperwork Reduction Act (PRA) that does not display a valid control number. Comments are requested concerning (a) whether the proposed collection of information is necessary for the proper performance of the functions of the Commission, including whether the information shall have practical utility; (b) the accuracy of the Commission's burden estimate; (c) ways to enhance the quality, utility, and clarity of the information collected; and (d) ways to minimize the burden of the collection of information on the respondents, including the use of automated collection techniques or other forms of information technology.

DATES: Written comments should be submitted on or before October 23, 2001. If you anticipate that you will be submitting comments, but find it difficult to do so within the period of time allowed by this notice, you should advise the contact listed below as soon as possible.

ADDRESSES: Direct all comments to Les Smith, Federal Communications Commissions, 445 12th Street, S.W., Room 1-A804, Washington, DC 20554 or via the Internet to *lesmith@fcc.gov.*

FOR FURTHER INFORMATION CONTACT: For additional information or copies of the information collections contact Les Smith at (202) 418–0217 or via the Internet at *lesmith@fcc.gov.*

SUPPLEMENTARY INFORMATION:

OMB Approval No.: 3060–0991.

Title: AM Measurement Data.

Form No.: n/a.

Type of Review: Extension of currently approved collection.

Respondents: Businesses or other for-profit.

Number of Respondents: 1,900.

Estimated Hours Per Response: 0.5–25 hours.

Frequency of Response: recordkeeping, third party disclosure, reporting, on occasion.

Cost to Respondents: $72,500.

Estimated Total Annual Burden: 29,180.

Needs and Uses: In order to control interference between stations and assure adequate community coverage, AM stations must conduct various engineering measurements to demonstrate that the antenna system operates as authorized. The data is used by station engineers to correct the operating parameters of an antenna. The data is also used by FCC staff in field operations to ensure that stations are in compliance with the technical requirements of the Commission's rules.

OMB Approval Number: 3060–0798.

Title: FCC Application for Wireless Telecommunications Bureau Radio Service Authorization.

Form No.: FCC 601.

Type of Review: Revision of an existing collection..

Respondents: Individuals or households; Business or other for-profit; Not-for-profit institutions; State, Local or Tribal Government.

Number of Respondents: 240,576.

Estimated Time Per Response: 1.25 hours.

Total Annual Burden: 210,504 hours.

Needs and Uses: FCC 601 is used as the general application (long form) for market based licensing and site-by-site licensing in the Wireless Telecommunications Radio Services. The purpose of this revision is to make the necessary form changes for radio communication services in the 900 MHz band for Multiple Address Systems, for 700 MHz band State License for public safety services, to make the necessary adjustments to the instructions for implementation of Aviation Radio Service and to further clarify various instructions for the applicants. We are seeking emergency clearance on these changes in order to allow form changes to be in place for the auctions scheduled for the middle of November.

The information is used by the Commission to determine whether the applicant is legally, technically and financially qualified to be licensed.

Respondent costs are estimated to be $48,115,200 which includes application filing fees.

OMB Approval Number: 3060–0799.

Title: FCC Ownership Disclosure Information for the Wireless Telecommunications Services.

Form No.: FCC 602.

Type of Review: Extension & Revision of Currently Approved Collection.

Respondents: Individuals or households; Business or other for-profit; not-for-profit institutions; State, Local or Tribal Government.

Number of Respondents: 10,000.

Estimated Time Per Response: 2 hours.

Total Annual Burden: 20,000 hours.

Needs and Uses: This form is required to be filed by applicants who have acquired their license by participation in an FCC auction or who are applying for a license in a service which is subject to Part 1, Subpart Q of the Commission's Rules, or by Common Carrier licensees whether or not the service was originally subject to auction, under the following circumstances:

(1) Applicants for a new license or authorization who do not have a current FCC Form 602 on file with the FCC;

(2) Applicants filing to renew an existing license if there is no current FCC Form 602 on file with the FCC;

(3) Applicants for a transfer of control of a license or assignment of authorization who do not have a current FCC Form 602 on file with the FCC;

(4) Applicants who are going to participate in an FCC auction and do not have a current FCC Form 602 on file.

The purpose for the information collection is to obtain the identity of the applicant and to elicit information required by Section 1.2112 of the Commission's rules regarding:

(1) Persons or entities holding a 10% or greater direct or indirect ownership interest in the applicant;

(2) All affiliates of the applicant pursuant to Section 1.2110;

(3) All general partners in any general partnership in the applicant's chain of ownership, and;

(4) All the members of any limited liability corporation in applicant's chain of ownership.

FCC 602 consists of a Main Form and associated schedules for technical information. Filers will use multiple copies of Form 602 as needed to list each direct and indirect owner and associated information. The data will be used by the FCC to determine whether the applicant is legally, technically and financially qualified to be licensed.

The data collected on this form includes Taxpayer Identification Numbers for the Applicant/Licensee, any Related FCC Regulated Businesses of the Applicant/Licensee, Disclosable Interest Holders and any Related FCC Regulated Businesses of Disclosable Interest Holders. These numbers will not be displayed to the public.

This form has been revised to include FCC Registration Number (FRN).

There is no change to the estimated average burden or number of respondents.

OMB Approval Number: 3060–0800.

Title: FCC Wireless Telecommunications Bureau Application for Assignments of Authorization and Transfers of Control.

Form No.: FCC 603.

Type of Review: Extension and Revision to an Existing Collection.

Respondents: Individuals or households; Business or other for-profit; Not-for-profit institutions; State, Local or Tribal Government.

Number of Respondents: 3,500.

Estimated Time Per Response: 4 hours.

Total Annual Burden: 14,000 hours.

Needs and Uses: Form 603 is a multi-purpose form used to apply for approval of assignment or transfer of control of licenses in the Wireless Radio Services. The data collected on this form is used by the FCC to determine whether the public interest would be served by approval of the requested assignment or transfer. This form is also used to notify the Commission of consummated assignments and transfers of wireless licenses that have previously been consented to by the Commission or for which notification but not prior consent is required. This form is used by applicants/licensees in the Public Mobile Services, Personal Communications Services, Private Land Mobile Radio Services, Broadcast Auxiliary Services, Fixed Microwave Services, Maritime Services (excluding ships), and Aviation Services (excluding aircraft).

The purpose of this form is to obtain information sufficient to identify the parties to the proposed assignment or transfer, establish the parties' basic eligibility and qualifications, classify the filing, and determine the nature of the proposed service. Various technical schedules are required along with the main form applicable to Auctioned Services, Partitioning and Disaggregation, Undefined Geographical Area Partitioning, Notification of Consummation or Request for Extension of Time for Consummation.

The data collected on this form includes the Taxpayer Identification Numbers of the Licensee/Assignor, Transferor and the Assignee/Transferee. These numbers will not be displayed to the public.

This form is replacing FCC Forms 490, 702, 703, 704 and 1046. After an initial transition period for use of the Form 603, the other forms will be obsoleted in the Wireless Telecommunications Bureau.

This form is being revised to include FCC Registration Number (FRN).

There is no change to the estimated average burden or number of respondents.

OMB Approval Number: 3060–0054.

Title: Application For Exemption From Ship Station Requirements.

Form No.: FCC 820.

Type of Review: Extension and Revision to an existing collection.

Respondents: Business or other for-profit; Small Businesses or Organization; Individuals or Households.

Number of Respondents: 250.

Estimated Time Per Response: 1.166 hour.

Total Annual Burden: 291.5 hours.

Needs and Uses: FCC Rules require this collection of information when exemptions from radio provisions of statute, treaty or international agreements are requested. The data is used by examiners to determine the applicants qualifications for the requested exemption.

The data collected on this form includes the applicant's Taxpayer Identification Number. However, this information will be redacted from public view.

This form has been revised to include FCC Registration Number (FRN) and to correct mailing addresses in the general instructions, where to file completed applications and filing for emergency requests.

The estimated average burden and number of respondents has been corrected based on receipts for the past 2 years.

Federal Communications Commission.

Magalie Roman Salas,

Secretary.

[FR Doc. 01–21415 Filed 8–23–01; 8:45 am]

BILLING CODE 6712–01–P

FEDERAL COMMUNICATIONS COMMISSION

[CC Docket No. 98–146; FCC 01–223]

Inquiry Concerning the Deployment of Advanced Telecommunications Capability to All Americans in a Reasonable and Timely Fashion, and Possible Steps To Accelerate Such Deployment Pursuant to Section 706 of the Telecommunications Act of 1996

AGENCY: Federal Communications Commission.

ACTION: Notice.

SUMMARY: In this document, the Federal Communications Commission begins its third inquiry into whether advanced telecommunications capability is being deployed to all Americans in a reasonable and timely fashion.

DATES: Comments are due September 24, 2001. Reply comments are due October 9, 2001.

ADDRESSES: Filings must be sent to the Commission's Secretary, Magalie Roman Salas, Office of the Secretary, Federal Communications Commission, 445 12th St., SW., Room TW B–204, Washington, DC 20554.

FOR FURTHER INFORMATION CONTACT: Ellen Blackler, Special Assistant to the Bureau Chief, Common Carrier Bureau, (202) 418–0491, TTY: (202) 418–0484.

SUPPLEMENTARY INFORMATION: This is a summary of the Commission's Third Notice of Inquiry (Notice) in CC Docket No. 98–146 released on August 10, 2001. The full text of the Notice is available for public inspection and copying during normal business hours in the FCC Reference Center, Room CY–A257, 445 Twelfth Street, SW., Washington, DC 20554.

Synopsis of the Inquiry

1. This Notice begins our third inquiry under section 706 of the Telecommunications Act of 1996 into ''whether advanced telecommunications capability is being deployed to all Americans in a reasonable and timely fashion.'' To help inform this inquiry, we are simultaneously releasing our most recent data on subscribership to high-speed services. Our first and second inquiries concluded that the deployment of advanced telecommunications capability was reasonable and timely on a general, nationwide basis. Our Second Report cautioned, however, that certain groups of consumers might be particularly vulnerable to not receiving timely deployment of advanced telecommunications capability by market forces alone. Notwithstanding our conclusion that deployment is occurring in a reasonable and timely basis, we continue to take steps to remove any barriers to deployment; to remove any barriers to investment in technologies that can deliver advanced services; and to vigorously promote a competitive marketplace. In this inquiry, we re-examine the marketplace in order to determine whether advanced telecommunications capability is being deployed to all Americans in a reasonable and timely manner. This inquiry will build on the information we have collected through our previous inquiries, our continuing dialogue with the Joint Federal-State Conference on Advanced Services (Joint Conference), the Joint Conference's database of community deployment efforts, and the records developed in our proceedings designed to increase competition and promote deployment.

2. Specifically, the Notice seeks comment on four areas: (1) Whether the Commission's definition of advanced telecommunications capability remains appropriate; (2) whether advanced telecommunications capability is being deployed to all Americans; (3) whether the deployment of advanced telecommunications capability is reasonable and timely; and (4) if deployment of advanced telecommunications capability is not reasonable and timely, the actions that will accelerate deployment. Once the Commission has gathered this information, it will release a Report within 180 days detailing its findings.

Ordering Clause

3. Accordingly, it is ordered that, pursuant to section 706 of the Telecommunications Act of 1996, this Notice of Inquiry is adopted.

Federal Communications Commission.

Magalie Roman Salas,

Secretary.

[FR Doc. 01–21414 Filed 8–23–01; 8:45 am]

BILLING CODE 6712–01–P

FEDERAL DEPOSIT INSURANCE CORPORATION

Notice of Agency Meeting

Pursuant to the provisions of the ''Government in the Sunshine Act'' (5 U.S.C. 552b), notice is hereby given that at 10 a.m. on Tuesday, August 21, 2001, the Board of Directors of the Federal Deposit Insurance Corporation met in closed session to consider matters relating to the Corporation's enforcement, corporate, resolution and supervisory activities.

In calling the meeting, the Board determined, on motion of Director Ellen S. Seidman (Director, Office of Thrift Supervision) seconded by Leann Britton, acting in the place and stead of Director John D. Hawke, Jr. (Comptroller of the Currency), and concurred in by Acting Chairman John M. Reich, that Corporation business required its consideration of the matters on less than seven days' notice to the public; that no notice of the meeting earlier than August 17, 2001 was practicable; that the public interest did not require consideration of the matters in a meeting open to public observation; and that the matters could be considered in a closed meeting by authority of subsections (c)(2), (c)(4), (c)(6), (c)(8), (c)(9)(A)(ii), and (c)(9)(B) of the ''Government in the Sunshine Act'' (5 U.S.C. 552b(c)(2), (c)(4), (c)(6), (c)(8), (c)(9)(A)(ii), and (c)(9)(B)).

The meeting was held in the Board Room of the FDIC Building located at 550—17th Street, NW., Washington, DC.

Dated: August 21, 2001.

Federal Deposit Insurance Corporation.

James D. LaPierre,

Deputy Executive Secretary.

[FR Doc. 01–21537 Filed 8–22–01; 10:06 am]

BILLING CODE 6714–01–M

FEDERAL RESERVE SYSTEM

Change in Bank Control Notices; Acquisition of Shares of Bank or Bank Holding Companies

The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices also will be available for inspection at the office of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than September 7, 2001.

A. Federal Reserve Bank of Atlanta (Cynthia C. Goodwin, Vice President) 1000 Peachtree Street, N.E., Atlanta, Georgia 30309–4470:

1. Paul B. Landry, Jr. Charitable Remainder Trust, Port Allen, Louisiana; Herman Joseph Lowe, Port Allen, Louisiana; and Sylvia Rodriguez

Landry, Baton Rouge, Louisiana; to collectively retain 16.60 percent of the outstanding voting shares of West Baton Rouge Bancshares, Inc., and its subsidiary, Bank of West Baton Rouge, both of Port Allen, Louisiana.

B. Federal Reserve Bank of Minneapolis (JoAnne F. Lewellen, Assistant Vice President) 90 Hennepin Avenue, Minneapolis, Minnesota 55480–0291:

1. Robert L. Frei, Wagner, South Dakota; to acquire voting shares of Commercial Holding Company, Wagner, South Dakota, and thereby indirectly acquire voting shares of Commercial State Bank of Wagner, Wagner, South Dakota.

Board of Governors of the Federal Reserve System, August 20, 2001.

Jennifer J. Johnson,

Secretary of the Board.

[FR Doc. 01–21459 Filed 8–23–01; 8:45 am]

BILLING CODE 6210–01–S

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center website at www.ffiec.gov/nic/.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than September 18, 2001.

A. Federal Reserve Bank of Richmond (A. Linwood Gill, III, Vice President) 701 East Byrd Street, Richmond, Virginia 23261–4528:

1. FNB Corporation, Christiansburg, Virginia; to acquire 100 percent of the voting shares of FNB Southwest, National Association, Roanoke, Virginia (successor by charter conversion to Southwest Virginia Savings Bank, FSB, Roanoke, Virginia).

B. Federal Reserve Bank of Dallas (W. Arthur Tribble, Vice President) 2200 North Pearl Street, Dallas, Texas 75201–2272:

1. International Bancshares Corporation, Laredo, Texas, and IBC Subsidiary Corporation, Wilmington, Delaware; to acquire 100 percent of the voting shares of National Bancshares Corporation of Texas, San Antonio, Texas; and thereby indirectly acquire NBT of Delaware, Inc., Wilmington, Delaware; and NBC Bank, National Association, Eagle Pass, Texas.

Board of Governors of the Federal Reserve System, August 20, 2001.

Jennifer J. Johnson,

Secretary of the Board.

[FR Doc. 01–21460 Filed 8–23–01; 8:45 am]

BILLING CODE 6210–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Program Announcement (PA) #01187, Counseling & Testing in Emergency Room & Ambulatory Care; PA #01188, Social & Environmental Interventions To Prevent HIV, and PA #01191, Efficacy of Condom Skills Building Demonstrations

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting.

Name: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): PA #01187, Counseling & Testing in Emergency Room & Ambulatory Care; PA #01188, Social & Environmental Interventions to Prevent HIV; and PA #01191, Efficacy of Condom Skills Building Demonstrations, meeting.

Times and Date: 8 a.m.–9 a.m., September 11, 2001 (Open); 9 a.m.–5 p.m., September 11, 2001 (Closed); 8 a.m.–5 p.m., September 12, 2001 (Closed).

Place: The Double Tree Hotel Atlanta Buckhead, 3342 Peachtree Road, NE, Atlanta, Georgia 30326.

Status: Portions of the meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Deputy Director for Program Management, CDC, pursuant to Public Law 92–463.

Matters To Be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcements 01187, 01188, and 01191.

For Further Information Contact: Beth Wolfe, Prevention Support Office, National Center for HIV, STD, and TB Prevention, CDC, Corporate Square Office Park, 8 Corporate Square Boulevard, M/S E07, Atlanta, Georgia 30329, telephone 404/639–8025.

The Director, Management Analysis and Services office has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: August 20, 2001.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention CDC.

[FR Doc. 01–21403 Filed 8–23–01; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Blood Products Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Blood Products Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on September 20, 2001, from 8 a.m. to 5 p.m., and on September 21, 2001, from 8 a.m. to 3:30 p.m.

Location: Hilton DC North—Gaithersburg, 620 Perry Pkwy., Gaithersburg, MD.

Contact: Linda A. Smallwood, Center for Biologics Evaluation and Research

(HFM–302), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301–827–3514, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 19516. Please call the Information Line for up-to-date information on this meeting.

Agenda: On September 20, 2001, the following committee updates are tentatively scheduled: (1) Transmissible spongiform encephalopathies guidance; hepatitis B surface antigen lot release guidance; human immunodeficiency virus (HIV) and hepatitis C virus nucleic acid testing; Clinical Laboratory Improvement Act waiver for HIV rapid tests; and (2) compliance quality control oversight. In the morning, the committee will hear presentations, discuss and make recommendations on potential concerns for simian foamy virus transmission by blood and blood products. In the afternoon, the committee will hear presentations, discuss and make recommendations on the leukocyte reduction guidance. On September 21, 2001, the committee will hear presentations, discuss and make recommendations on human cells, tissues and cellular and tissue-based products: risk factors for semen donation.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by September 4, 2001. Oral presentations from the public will be scheduled between approximately 12 noon and 12:30 p.m., and 3:45 p.m. and 4:45 p.m. on September 20, 2001; and between approximately 11:30 a.m. and 1 p.m. on September 21, 2001. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before September 4, 2001, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: August 16, 2001.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 01–21361 Filed 8–23–01; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Medical Devices Dispute Resolution Panel of the Medical Devices Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Medical Devices Dispute Resolution Panel of the Medical Devices Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on scientific disputes between the Center for Devices and Radiological Health and sponsors, applicants, and manufacturers.

Date and Time: The meeting, which is rescheduled from June 4, 2001, will be held on September 6, 2001, from 8 a.m. to 6 p.m.

Location: Marriott, Salons E, F, and G, 9751 Washingtonian Blvd., Gaithersburg, MD.

Contact: Les Weinstein, Center for Devices and Radiological Health (HFZ–5), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301–443–6220, ext. 119, FAX 301–827–2565, lsw@cdrh.fda.gov, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 10232. Please call the Information Line for up-to-date information on this meeting.

Agenda: The committee will discuss, make recommendations, and vote regarding a scientific dispute between the agency and Lifecore Biomedical, Inc., related to the approvability of a premarket approval application for Intergel, an adhesion prevention solution for use in gynecologic pelvic surgery. Background information and questions for the committee will be available to the public on September 5, 2001, on the Internet at http://www.fda.gov/cdrh/panelmtg.html.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by September 4, 2001. Oral presentations from the public will be scheduled between approximately 8 a.m. and 8:30 a.m. on September 6, 2001. Near the end of the committee deliberations, a 30-minute open public session will be conducted for interested persons to address issues specific to the dispute before the committee. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before September 4, 2001, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

FDA regrets that it was unable to publish this notice 15 days prior to the Medical Devices Dispute Resolution Panel of the Medical Devices Advisory Committee meeting. Because the agency believes that there is some urgency to bring this issue to public discussion and qualified members of the Medical Devices Dispute Resolution Panel of the Medical Devices Advisory Committee were available at this time, the Commissioner of Food and Drugs concluded that it was in the public interest to hold this meeting even if there was not sufficient time for the customary 15-day public notice.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: August 16, 2001.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 01–21360 Filed 8–23–01; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of Biotechnology Activities; Recombinant DNA Research: Proposed Actions Under the NIH Guidelines

AGENCY: National Institutes of Health (NIH), PHS, DHHS.

ACTION: Notice of proposed actions under the NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines).

SUMMARY: The NIH is proposing to amend the provisions of the NIH Guidelines relating to the Recombinant DNA Advisory Committee (RAC) by authorizing a minimum of 15 voting members and establishing the charter of the committee as the controlling document for the membership and procedures of the RAC.

DATES: The public is encouraged to submit written comments on the

proposed change. Comments may be submitted to the NIH Office of Biotechnology Activities (OBA) in paper or electronic form. Comments received on or before September 24, 2001 will be considered by NIH.

All comments received in response to this notice will be available for public inspection in the NIH OBA office, 6705 Rockledge Drive, Suite 750, MSC 7985, Bethesda, MD 20892–7985, 301–496–9838, weekdays between the hours of 8:30 a.m. and 5 p.m.

FOR FURTHER INFORMATION CONTACT: If you have questions, or want additional information about these proposed changes, please contact OBA by e-mail at *oba@od.nih.gov* or telephone at 301–496–9838. Comments should be addressed to the Dockets Manager and may be submitted to the same e-mail address, by fax to 301–496–9839, or by mail to the Office of Biotechnology Activities address above.

SUPPLEMENTARY INFORMATION

Section IV–C–2 of the NIH Guidelines provides that the RAC consists of 15 voting members including the Chair, appointed by the DHHS Secretary or designee, at least 8 of whom are selected from authorities knowledgeable in the fields of molecular genetics, molecular biology, recombinant DNA research, or other scientific fields. At least 4 members of RAC shall be persons knowledgeable in applicable law, standards of professional conduct and practice, public attitudes, the environment, public health, occupational health, or related fields. Representatives from designated Federal agencies serve as nonvoting members.

On January 23, 1997, the NIH Guidelines were amended to reduce the RAC from 25 to 15 voting members. This change was made in conjunction with the discontinuation of RAC's role in recommending approval or disapproval of individual gene transfer protocols. As stated in the November 22, 1996, Notice of Proposed Actions that included this reduction of RAC membership (61 FR 59725), the reduction was intended to ''increase efficiency while ensuring sufficient representation from scientific, ethical, and legal communities.'' Although RAC members no longer recommend approval or disapproval of gene transfer protocols, they review them to determine if they raise scientific, medical, safety, or ethical issues that require public discussion at a meeting of the RAC (see Appendix M and Appendix M–I–B–2 of the NIH Guidelines).

In the years since the number of RAC members was reduced, the number of gene transfer trials has dramatically increased, and those trials now encompass a broader array of clinical applications. Current trials address cancer, inborn errors of metabolism, cardiovascular diseases, autoimmune disorders, and neurologic diseases. In addition, current trials employ an increasing array of viral vectors, including vaccinia, fowl pox, canary pox, herpes simplex virus, adeno-associated virus, adenovirus, and retroviruses.

Thus, a broader range of expertise is needed on the RAC in order to adequately assess the issues raised by the many and increasingly varied proposed gene transfer trials submitted to the NIH. Given the dynamism of the field, flexibility in how this expertise is achieved is key to the effective and efficient functioning of the RAC. To this end, the NIH is proposing to amend Section IV–C–2 of the NIH Guidelines to authorize a minimum of 15 voting members with no maximum number of voting members specified. The maximum number of voting members will be established through the charter for the RAC, which is the controlling document for the membership and procedures of the RAC, in the event of any conflict with the NIH Guidelines. This will enable NIH to respond promptly to the need for additional expertise on the RAC through appropriate amendments to the charter.

Section IV–C–2 would also be amended to establish the RAC charter as the controlling document for the membership and functions of the RAC. In addition, the listing of specific types of knowledge for members who are not biomedical scientists would be broadened by changing ''applicable law'' to ''law,'' and ''standards of professional conduct and practice'' to ''ethics.''

Section IV–C–2 currently refers to the charter of the RAC, but it does not indicate that the charter sets forth the membership and procedures of the RAC, as well as its functions, or establish the charter as the controlling document in the event of a conflict with the NIH Guidelines. Under the proposed change, the NIH Guidelines would establish a minimum number of RAC members and the size of the RAC could vary according to need. The broad discretion of the Director, NIH, to choose members knowledgeable in certain fields would be retained, but the types of knowledge listed may periodically be changed.

Proposed Amendments to the NIH Guidelines

I. For the reasons stated above, it is proposed to amend Section IV-C–2 Recombinant DNA Advisory Committee (RAC) to state:

Section IV–C–2. Recombinant DNA Advisory Committee (RAC)

The RAC is responsible for carrying out the functions specified in the NIH Guidelines, as well as others specified in its charter or assigned by the Secretary of Health and Human Services or the NIH Director. The RAC membership and procedures, in addition to those set forth in the NIH Guidelines, are specified in the charter for the RAC, which is filed as provided in the General Services Administration Federal Advisory Committee Management regulations, 41 CFR Parts 101–6 and 102–3, and is available on the OBA website, http://www4.od.nih.gov/oba/rac/. In the event of a conflict between the NIH Guidelines and the charter, the charter shall control.

The RAC will consist of not less than 15 voting members, including the Chair, appointed under the procedures of the NIH and the Department of Health and Human Services. The maximum number and expertise of voting members will be established in the charter of the RAC. A majority of the voting members must be knowledgeable in relevant scientific fields, e.g., molecular genetics, molecular biology, recombinant DNA research, including clinical gene transfer research. At least 4 members of the RAC must be knowledgeable in fields such as public health, laboratory safety, occupational health, protection of human subjects of research, the environment, ethics, law, public attitudes or related fields. Representatives of the Federal agencies listed in the charter shall serve as nonvoting members. Nominations for RAC members may be submitted to the Office of Biotechnology Activities, National Institutes of Health, 6705 Rockledge Drive, Suite 750, MSC 7985, Bethesda, MD 20892–7985 (20817 for non-USPS mail), 301–496–9838, 301–496–9838 (fax).

All meetings of the RAC shall be announced in the **Federal Register**, including tentative agenda items, at least 15 calendar days before the meeting. Final agendas, if modified, shall be available at least 72 hours before the meeting. No item defined as a Major Action under Section IV–C–1–b–(1) may be added to an agenda following **Federal Register** publication.

OMB's ''Mandatory Information Requirement for Federal Assistance Program Announcements'' (45 FR 39592) requires a statement concerning the official Government programs contained in the Catalog of Federal

Domestic Assistance. Normally, NIH lists in its announcements the number and title of affected individual programs for the guidance of the public. Because the proposed guidance in this notice covers virtually every NIH and Federal research program in which recombinant DNA techniques could be used, it has been determined not to be cost effective or in the public interest to attempt to list these programs. In addition, NIH could not be certain that every Federal program would be included as many Federal agencies, as well as private organizations, both national and international, have elected to follow the NIH Guidelines. In lieu of the individual program listing, NIH invites readers to direct questions to the information address above about whether individual programs listed in the Catalog of Federal Domestic Assistance are affected.

Dated: August 16, 2001.

Ruth L. Kirschstein,

Acting Director, National Institutes of Health.

[FR Doc. 01–21392 Filed 8–23–01; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR–4650–N–62]

Notice of Submission of Proposed Information Collection to OMB; Compliance Inspection Report—HUD–92051 Mortgagee's Assurance of Completion—HUD–92300

AGENCY: Office of the Chief Information Officer, HUD.

ACTION: Notice.

SUMMARY: The proposed information collection requirement described below has been submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal.

DATES: *Comments Due Date:* September 24, 2001.

ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB approval number (2502–0189) and should be sent to: Joseph F. Lackey, Jr., OMB Desk Officer, Office of Management and Budget, Room 10235, New Executive Office Building, Washington, DC 20503.

FOR FURTHER INFORMATION CONTACT: Wayne Eddins, Reports Management Officer, Q, Department of Housing and Urban Development, 451 Seventh Street, SW., Washington, DC 20410; e-mail Wayne_Eddins@HUD.gov; telephone (202) 708–2374. This is not a toll-free number. Copies of the proposed forms and other available documents submitted to OMB may be obtained from Mr. Eddins.

SUPPLEMENTARY INFORMATION: The Department has submitted the proposal for the collection of information, as described below, to OMB for review, as required by the Paperwork Reduction Act (44 U.S.C. Chapter 35). The Notice lists the following information: (1) The title of the information collection proposal; (2) the office of the agency to collect the information; (3) the OMB approval number, if applicable; (4) the description of the need for the information and its proposed use; (5) the agency form number, if applicalbe; (6) what members of the public will be affected by the proposal; (7) how frequently information submissions will be required; (8) an estimate of the total number of hours needed to prepare the information submission including number of respondents, frequency of response, and hours of response; (9) whether the proposal is new, an extension, reinstatement, or revision of an information collection requirement; and (10) the name and telephone number of an agency official familiar with the proposal and of the OMB Desk Officer for the Department.

This Notice also lists the following information:

Title of Proposal: Compliance Inspection Report—HUD–92051; Mortgagee's Assurance of Completion—HUD–92300.

OMB Approval Number: 2502–0189.

Form Numbers: HUD–92051 and HUD–92300.

Description of the Need for the Information and Its Proposed Use: The Compliance Inspection Report (HUD–92051) is used by staff and private inspectors and appraisers. The Mortgagee's Assurance of Completion (HUD–92300) is used by mortgage companies for establishing escrow for incomplete repairs or construction. HUD staff review and approve these forms and use them in monitoring and training.

Respondents: Business or other for-profit.

Frequency of Submission: On occasion.

	Number of respondents	x	Frequency of response	x	Hours per response	=	Burden hours
Reporting Burden	14,500		251		0.25		909,875

Total Estimated Burden Hours: 909,875.

Status: Reinstatement, without change.

Authority: Section 3507 of the Paperwork Reduction Act of 1995, 44 U.S.C. 35, as amended.

Dated: August 17, 2001.

Wayne Eddins,

Departmental Reports Management Officer, Office of the Chief Information Officer.

[FR Doc. 01–21399 Filed 8–23–01; 8:45 am]

BILLING CODE 4210–72–M

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[WO–320–1330–PB–24 1A]

Extension of Approved Information Collection, OMB Approval Number 1004–0169

AGENCY: Bureau of Land Management, Interior.

ACTION: Notice and request for comments.

SUMMARY: In accordance with the Paperwork Reduction Act of 1995, the Bureau of Land Management (BLM) is requesting the Office of Management and Budget (OMB) to extend an existing approval to collect information from mining claimants concerning use and occupancy of their mining claims on public lands. BLM collects this information to analyze and approve proposed mining development activities on public lands. The nonform information under 43 CFR 3715 authorizes BLM to manage the use and occupancy on public lands for developing the mineral deposits by mining claimants.

DATES: You must submit your comments to BLM at the address below on or before October 23, 2001. BLM will not

necessarily consider any comments received after the above date.

ADDRESSES: You may mail comments to: Regulatory Affairs Group (630), Bureau of Land Management, Mailstop 401LS, 1849 C Street, NW, Washington, DC 20240.

You may send comments via Internet to: *WOComment@blm.gov.* Please include ''ATTN; 1004–0169'' and your name and return address in your Internet message.

You may deliver comments to the Bureau of Land Management, Administrative Record, Room 401, 1620 L Street, NW, Washington, DC.

Comments will be available for public review at the L Street address during regular business hours (7:45 a.m. to 4:15 p.m.) Monday through Friday.

FOR FURTHER INFORMATION CONTACT: You may contact Richard E. Deery on (202) 452–0353 (Commercial or FTS). Persons who use a telecommunication device for the deaf (TDD) may call the Federal Information Relay Service (FIRS) on 1–800–877–8330, 24 hours a day, seven days a week, to contact Mr. Deery.

SUPPLEMENTARY INFORMATION: 5 CFR 1320.12(a) requires that we provide a 60-day notice in the **Federal Register** concerning a collection of information to solicit comments on:

(a) Whether the collection of information is necessary for the proper functioning of the agency, including whether the information will have practical utility;

(b) The accuracy of our estimates of the information collection burden, including the validity of the methodology and assumptions we use;

(c) Ways to enhance the quality, utility, and clarity of the information collected; and

(d) Ways to minimize the information collection burden on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

The General Mining Law (30 U.S.C. 612), Federal Land Policy and Management Act of 1976 (43 U.S.C. 1733), and the regulations under 43 CFR 3715 authorizes BLM to manage use and occupancy of mining claims on public lands. The nonform information in the regulations under 43 CFR 3715 authorizes BLM to collect information concerning proposed mining development activities on public lands. Without this information, BLM would not be able to analyze and approve proposed use and occupancy activities on public lands by mining claimants. Also, BLM would not be able to carry out the mandate of the Federal Land Policy and Management Act of 1976.

Mining claimants planning to occupy their mining claims on public lands under the mining laws must submit the following information to BLM:

(1) A detailed map that identifies the site and shows the place of temporary and permanent structures for occupancy, the location of and reason for the structures intended to exclude the public, and the location of reasonable public passage or access routes through or around the area adjacent to public lands;

(2) A written description of the proposed occupancy that describes in detail how the proposed occupancy is reasonably incident to mining and how the proposed occupancy meets the conditions of 43 CFR 3715.2 and 3715.2–1; and

(3) An estimate of the period of use of the structures which excludes the public and a schedule for their removal and reclamation when the operations end.

Based upon BLM experience with mining claims use and occupancy activity, we estimate the public reporting information collection burden takes 2 hours to complete. The respondents are mining claimants and operators of prospecting, exploration, mining, and processing operations. The estimated number of responses per year is 280 and the total annual burden is 560 hours.

BLM will summarize all responses to this notice and include them in the request for OMB approval. All comments will become a matter of public record.

Dated: July 30, 2001.

Michael H. Schwartz,

BLM Information Collection Clearance Officer.

[FR Doc. 01–21472 Filed 8–23–01; 8:45 am]

BILLING CODE 4310–84–M

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[WO–310–1310–PB–24 1A]

Extension of Approved Information Collection, OMB Approval Number 1004–0145

AGENCY: Bureau of Land Management, Interior.

ACTION: Notice and request for comments.

SUMMARY: In accordance with the Paperwork Reduction Act of 1995, the Bureau of Land Management (BLM) is requesting the Office of Management and Budget (OMB) to extend an existing approval to collect information from lessees, record title holders, operating rights owners, and operators on oil and gas leasing and exploration activities. BLM collects this information to determine compliance with the terms and conditions of the oil and gas lease and to monitor oil and gas leasing and exploration activities BLM approves. The nonform information under 43 CFR 3000–3120 authorizes BLM to manage oil and gas leasing and exploration activities.

DATES: You must submit your comments to BLM at the address below on or before October 23, 2001. BLM will not necessarily consider any comments received after the above date.

ADDRESSES: You may mail comments to: Regulatory Affairs Group (630), Bureau of Land Management, Mailstop 401LS, 1849 C Street, NW., Washington, DC 20240.

You may send comments via Internet to: *WOComment@blm.gov*. Please include ''ATTN: 1004–0145'' and your name and return address in your Internet message.

You may deliver comments to the Bureau of Land Management, Administrative Record, Room 401, 1620 L Street, NW., Washington DC.

Comments will be available for public review at the L Street address during regular business hours (7:45 a.m. to 4:15 p.m.) Monday through Friday.

FOR FURTHER INFORMATION CONTACT: You may contact Barbara Gamble on (202) 452–0338 (Commercial or FTS). Persons who use a telecommunication device for the deaf (TDD) may call the Federal Information Relay Service (FIRS) on 1–800–877–8330, 24 hours a day, seven days a week, to contact Ms. Gamble.

SUPPLEMENTARY INFORMATION: 5 CFR 1320.12(a) requires that we provide a 60-day notice in the **Federal Register** concerning a collection of information to solicit comments on:

(a) Whether the collection of information is necessary for the proper functioning of the agency, including whether the information will have practical utility;

(b) the accuracy of our estimates of the information collection burden, including the validity of the methodology and assumptions we use;

(c) ways to enhance the quality, utility, and clarity of the information collected; and

ways to minimize the information collection burden on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological

collection techniques or other forms of information technology.

The Mineral Leasing Act of 1920 (MLA), 30 U.S.C. 191 *et seq.*, gives the Secretary of the Interior responsibility for oil and gas leasing on approximately 570 million acres of public lands and national forests, and private lands where the mineral rights are reserved by the Federal Government. The Act of May 21, 1930 (30 U.S.C. 301–306), authorizes the leasing of oil and gas deposits under railroads and other rights-of-way. The Act of August 7, 1947 (Mineral Leasing Act of Acquired Lands), authorizes the Secretary to lease lands acquired by the United States (30 U.S.C. 341–359). The regulations under 43 CFR 3000–3120 authorize BLM to manage the oil and gas leasing and exploration activities. Without the information, BLM would not be able to analyze and approve oil and gas leasing and exploration activities.

BLM collects nonform information on oil and gas leasing and exploration activities when the lessee, record title holder, operating rights owner, or operator files any of the following information for BLM to adjudicate:

Information collection on oil and gas leasing and exploration activities	Estimated burden hours
1. Notice of option holdings for acreage chargeability option statement	1
2. Petition requesting additional time to divest excess acreage	1
3. Statement showing date, acreage, State in which leases are held	1
4. Statement showing unit agreement entered into if lease is for lands within an approved unit	1.5
5. Application for waiver, suspension, or reduction of rental or royalty	1
6. Copy of communitization or drilling agreement interest held in operating, drilling, or development contracts	2
7. Application to combine operations or transport oil	2
8. Application for subsurface storage of oil and gas	2
9. Statement that heirs and devisees are qualified to hold lease	1
10. Reporting a change of name	1
11. Notification of corporate merger	2
12. Application for renewing lease	1
13. Application to relinquish lease	0.5
14. Application to reinstate lease	0.5
15. Application for lease located within a right-of-way	1
16. Application for oil and gas exploration permit in Alaska	1
17. Reporting date of exploration activities	1
18. Reporting completion of operations	1

Based upon BLM experience with managing the oil and gas leasing and exploration activities, we estimate the above public reporting information collection burden. The estimated number of responses per year is 1,400 and the total annual burden is 1,400 hours.

BLM will summarize all responses to this notice and include them in the request for OMB approval. All comments will become a matter of public record.

Dated: July 30, 2001.

Michael H. Schwartz,

BLM Information Collection Clearance Officer.

[FR Doc. 01–21473 Filed 8–23–01; 8:45 am]

BILLING CODE 4310–84–M

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[WO–350–1430–PF–01–24 1A]

Extension of Approved Information Collection, OMB Approval Number 1004–0190

AGENCY: Bureau of Land Management, Interior.

ACTION: Notice and request for comments.

SUMMARY: In accordance with the Paperwork Reduction Act of 1995, the Bureau of Land Management (BLM) is requesting the Office of Management and Budget (OMB) to extend an existing approval to collect certain information from Indians eligible to apply for an allotment with the BLM office that has jurisdiction over the lands covered by the application. BLM uses Form 2530–3, Indian Allotment Application, to collect this information to determine if the Indian applicant qualifies for an Indian allotment on public lands and public domain lands within national forests. The regulations under 43 CFR 2530 authorize BLM to issue an Indian allotment to eligible Indians who apply and qualify.

DATES: You must submit your comments to BLM at the address below on or before October 23, 2001. BLM will not necessarily consider any comments received after the above date.

ADDRESSES: You may mail comments to: Regulatory Affairs Group (630), Bureau of Land Management, Mailstop 401LS, 1849 C Street, NW, Washington, DC 20240.

You may send comments via Internet to: *WOCComment@blm.gov.* Please include ''ATTN: 1004–0190'' and your name and return address in your Internet message.

You may deliver comments to the Bureau of Land Management, Administrative Record, Room 401, 1620 L Street, NW, Washington, DC.

Comments will be available for public review at the L Street address during regular business hours (7:45 a.m. to 4:15 p.m.) Monday through Friday.

FOR FURTHER INFORMATION CONTACT: You may contact Alzata L. Ransom, Realty Use Group, on (202) 452–7772 (Commercial or FTS). Persons who use a telecommunication device for the deaf (TDD) may call the Federal Information Relay Service (FIRS) on 1–800–877–8330, 24 hours a day, seven days a week, to contact Ms. Ransom.

SUPPLEMENTARY INFORMATION: 5 CFR 1320.12(a) requires that we provide a 60-day notice in the **Federal Register** concerning a collection of information to solicit comments on:

(a) Whether the collection of information is necessary for the proper functioning of the agency, including whether the information will have practical utility;

(b) The accuracy of our estimates of the information collection burden, including the validity of the methodology and assumptions we use;

(c) Ways to enhance the quality, utility, and clarity of the information collected; and

(d) Ways to minimize the information collection burden on those who are to respond, including the use of appropriate automated, electronic,

mechanical, or other technological collection techniques or other forms of information technology.

Section 4 of the Indian General Allotment Act of February 8, 1887 (43 U.S.C. 1740) provides that, if you are an Indian eligible for an allotment, you may apply for an allotment. To establish you are eligible, you must furnish documentation from the Bureau of Indian Affairs (BIA) showing you are an Indian who meets the requirements of the Act. If you are eligible, your minor child also qualifies to file for an allotment under the Act. You must apply to the BLM office having jurisdiction over the lands covered by your application.

BLM uses Form 2530–3 to collect the following information:

(1) The name and address of the applicant; if a minor child, the name, age of child, and the applicant's relationship to the child;

(2) The name of the Indian tribe to which the applicant belongs or is eligible to belong;

(3) A Certificate of Indian Blood from the BIA and the name of the recognized Indian tribe to which you claim membership or be eligible for membership to a recognized Indian tribe;

(4) A legal land description of the lands applied for (by township, range, meridian, section, subdivision, and State);

(5) A plan of development that describes the proposed agricultural or grazing land use and a description of the improvements that the applicant plans to place on the lands;

(6) Any allotments that the applicant received previously from BLM; and

(7) The applicant must certify their knowledge of the lands, is the person named in the BIA Certificate of Indian Blood, and makes true, accurate, and good faith statements on the application.

BLM uses the information to determine whether or not to issue an Indian allotment. Without this information, BLM would not be able to properly administer Indian allotments on public lands and public domain lands within national forests.

Based upon BLM experience and recent tabulations of activity, we process approximately 16 applications each year. The public reporting information collection burden varies from 30 minutes to 2 hours to complete. The estimated number of responses per year is 16. The estimated total annual burden is 13 hours.

BLM will summarize all responses to this notice and include them in the request for OMB approval. All comments will become a matter of public record.

Dated: July 31, 2001.

Michael H. Schwartz,

BLM Information Collection Clearance Officer.

[FR Doc. 01–21474 Filed 8–23–01; 8:45 am]

BILLING CODE 4310–84–M

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[AZ–957–1310–01; AZA–028337]

Arizona: Proposed Reinstatement of Terminated Oil and Gas Lease

Under the provisions of Public Law 97–451, a petition for reinstatement of oil and gas lease AZA 028337 for lands in Apache County, Arizona, was timely filed and was accompanied by all required rentals and royalties accruing from October 1, 1999, the date of termination.

No valid lease has been issued affecting the lands. The lessee has agreed to new lease terms for rentals and royalties at the rate of $5.00 per acre or fraction thereof and 16⅔ percent, respectively. The lessee has paid the required $500.00 administrative fee and has reimbursed the Bureau of Land Management for the cost of this **Federal Register** notice.

The lessee has met all the requirements for reinstatement of the lease as set out in Sections 31(d) and (e) of the Mineral Leasing Act of 1920 (30 USC 188), and the Bureau of Land Management is proposing to reinstate the lease effective October 1, 1999, subject to the original terms and conditions of the lease and the increased rental and royalty rates cited above.

For further information, contact Dominic R. Sarracino, Land Law Examiner, Lands and Minerals Adjudication at (602) 417–9346.

Dated: August 7, 2001.

Ivy J. Garcia.

Group Administrator, Lands & Minerals Adjudication.

[FR Doc. 01–21478 Filed 8–23–01; 8:45 am]

BILLING CODE 4310–32–P

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[NM–930–1310–01; NMNM 97833]

New Mexico: Proposed Reinstatement of Terminated Oil and Gas Lease NMNM 97833

Under the provisions of Public Law 97–451, a petition for reinstatement of oil and gas lease NMNM 97833 for lands in Sandoval County, New Mexico, was timely filed and was accompanied by all required rentals and royalties accruing from December 1, 2000, the date of termination.

No valid lease has been issued affecting the lands. The lessee has agreed to new lease terms for rentals and royalties at rates of $10.00 per acre or fraction thereof and 16 ⅔ percent, respectively. The lessee has paid the required $500.00 administrative fee and has reimbursed the Bureau of Land Management for the cost of this **Federal Register** notice.

The Lessee has met all the requirements for reinstatement of the lease as set out in Sections 31(d) and (e) of the Mineral Leasing Act of 1920 (30 USC 188), and the Bureau of Land Management is proposing to reinstate the lease effective December 1, 2000, subject to the original terms and conditions of the lease and the increased rental and royalty rates cited above.

For further information contact: Bernadine T. Martinez, BLM, New Mexico State Office, (505) 438–7530.

Dated: August 3, 2001.

Bernadine T. Martinez,

Land Law Examiner, Fluids Adjudication Team.

[FR Doc. 01–21476 Filed 8–23–01; 8:45 am]

BILLING CODE 4310–FB–P

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[NMNM 94897]

Public Land Order No. 7495; Partial Modification of an Executive Order and Transfer of Jurisdiction; New Mexico

AGENCY: Bureau of Land Management, Interior.

ACTION: Public Land Order.

SUMMARY: This order modifies an Executive Order insofar as it affects approximately 903 acres of land by changing the reservation of the land for military purposes to a reservation of the land for Bureau of Indian Affairs programs and establishing a 20-year

term. Jurisdiction of the land is transferred from the Secretary of Defense/Secretary of the Army to the Secretary of the Interior for management by the Bureau of Indian Affairs. The land will remain closed to surface entry and mining to protect an area having cultural, historical, geological and archeological significance to the Navajo Nation and the Pueblo of Zuni.

EFFECTIVE DATE: August 24, 2001.

FOR FURTHER INFORMATION CONTACT: Debby Lucero, BLM Albuquerque Field Office, 435 Montano Road NE, Albuquerque, New Mexico 87107, 505–761–8787.

SUPPLEMENTARY INFORMATION: By virtue of the authority vested in the Secretary of the Interior by Section 204 of the Federal Land Policy and Management Act of 1976, 43 U.S.C. 1714 (1994), it is ordered as follows:

1. The Executive Order dated February 18, 1870, which withdrew and reserved public land for use by the War Department for Fort Wingate is hereby modified to establish a 20-year term for the land described below. Jurisdiction of the following described land is hereby transferred from the Secretary of Defense/Secretary of the Army to the Secretary of the Interior and reserved for use and administration by the Bureau of Indian Affairs:

Parcel 15 and Parcel 17 of the administrative survey plat titled ''ADMINISTRATIVE SURVEY OF CERTAIN PARCELS WITHIN FORT WINGATE ARMY DEPOT, NEW MEXICO,'' approved and dated September 18, 2000, on file at the Bureau of Land Management's New Mexico State Office, Santa Fe, New Mexico; excluding the area identified as ''Right-of-Way'' on the survey plat titled ''TOWNSHIP 15 NORTH, RANGE 16 WEST OF THE NEW MEXICO PRINCIPLE MERIDIAN, NEW MEXICO, WITHIN THE FORT WINGATE ARMY DEPOT, ADMINISTRATIVE RIGHT-OF-WAY SURVEY,'' dated and approved October 10, 2000, on file at the New Mexico State Office.

The areas of Parcel 15 and Parcel 17 aggregate approximately 903 acres.

2. The land described in Paragraph 1 continues to be withdrawn from settlement, sale, location, or entry under the general land laws, including the Unites States mining laws (30 U.S.C. Ch.2 (1994)), but not from leasing under the mineral leasing laws, to protect an area having cultural, historical, geological and archeological significance to the Navajo Nation and the Pueblo of Zuni. The withdrawn land is to be managed by the Bureau of Indian Affairs for these values, as well as other compatible uses.

3. The land and resources shall be managed by the Bureau of Indian Affairs, its successors or assigns, in accordance with the Memorandum of Agreement between the Ballistic Missile Defense Organization and the Department of the Interior dated June 13, 2000. The Memorandum of Agreement shall be incorporated into any future land transfers for the life of the Memorandum of Agreement. The Memorandum of Agreement may be reviewed and amended by the agencies as necessary.

4. The Department of the Army and its officers, agents, employees, contractors, and subcontractors will have the right of access, upon reasonable notice, to enter the land described in this order for the purpose of activities related to the Fort Wingate Depot Activity Installation Restoration Program and other environmentally related compliance programs and to construct, operate, maintain or undertake response and remedial actions to implement this program.

5. The Department of the Army represents that, to the best of its knowledge, no unexploded ordnance are currently present on the land described in this order. Due to the former use of the land as an active military installation, there is a possibility that unexploded ordnance may exist on the land. Upon due notice, the Army agrees to remove any such remaining unexploded ordnance discovered on the land, as required under applicable law and regulations, as expeditiously as is reasonable and practicable, subject to the availability of funds.

6. This withdrawal will expire 20 years from the effective date of this order unless, as a result of a review conducted before the expiration date pursuant to Section 204(f) of the Federal Land Policy and Management Act of 1976, 43 U.S.C. 1714(f) (1994), the Secretary determines that the withdrawal shall be extended.

Dated: August 10, 2001.

J. Steven Griles,

Deputy Secretary.

[FR Doc. 01–21453 Filed 8–23–01; 8:45 am]

BILLING CODE 4310–02–P

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[NM–030–1430–ES; NMNM–104131]

Notice of Realty Action; Recreation and Public Purposes (R&PP) Act Classification; New Mexico

AGENCY: Bureau of Land Management (BLM), Interior.

ACTION: Notice.

SUMMARY: The following public land in Dona County, New Mexico has been examined and found suitable for classification for lease or conveyance to New Mexico State University (NMSU) under the provisions of the Recreation and Public Purposes (R&PP) Act; as amended (43 U.S.C. 869 *et seq.*). NMSU proposes to use the land to construct the East Mesa Center of the Dona Ana Branch Community College. The land is described as follows:

New Mexico Principal Meridian

T. 22 S., R. 2 E., sec. 33, SE¼NE¼, E½SW¼NE¼.

Containing 60 acres more or less.

The land is not needed for Federal purposes. Lease or conveyance is consistent with current BLM land use planning and would be in the public interest.

City, County, and State government will receive a copy of this Notice of Realty Action/Classification as required by 43 CFR 2742.4(b).

DATES: Comments regarding the proposed lease/conveyance or classification must be submitted on or before October 9, 2001.

ADDRESSES: Comments should be sent to BLM, Las Cruces Field Office, 1800 Marquess, Las Cruces, New Mexico, 88005.

FOR FURTHER INFORMATION CONTACT: Juan Padilla at (505) 525–4376.

SUPPLEMENTARY INFORMATION: The lease/patent, when issued, will be subject to the following terms, conditions, and reservations:

1. Provisions of the R&PP Act and to all applicable regulations of the Secretary of the Interior.

2. A right-of-way for ditches and canals constructed by the authority of the United States.

3. All minerals shall be reserved to the United States, together with the right to prospect for, mine, and remove the minerals.

4. Those rights for a 345 kV transmission line granted to the El Paso Electric Company by Right-of-Way Grant No. NM 0554552.

5. Rights-of-way for streets, roads, and utilities in accordance with the City of

Las Cruces Metropolitan Planning Organization (MPO) transportation plan.

Detailed information concerning this action is available for review at the BLM, Las Cruces Field Office, 1800 Marquess, Las Cruces, New Mexico. Upon publication of this notice in the **Federal Register**, the land will be segregated from all other forms of appropriation under the public land laws, including the general mining laws, except for lease or conveyance under the Recreation and Public Purposes Act and leasing under the mineral leasing laws. On or before October 9, 2001, interested persons may submit comments regarding the proposed lease/conveyance or classification of the land to the Field Office Manager, Las Cruces Field Office, 1800 Marquess, Las Cruces, New Mexico, 88005.

Classification Comments

Interested parties may submit comments involving the suitability of the land for a community college. Comments on the classification are restricted to whether the land is physically suited for the proposal, whether the use will maximize the future use or uses of the land, whether the use is consistent with local planning and zoning, or if the use is consistent with State and Federal programs.

Application Comments

Interested parties may submit comments regarding the specific use proposed in the application and plan of development, whether the BLM followed proper administrative procedures in reaching the decision, or any other factor not directly related to the suitability of the land for a community college.

Any adverse comments will be reviewed by the State Director. In the absence of any adverse comments, the classification will become effective on October 23, 2001.

Dated: August 8, 2001.

Amy L. Lueders,

Field Manager, Las Cruces.

[FR Doc. 01–21475 Filed 8–23–01; 8:45 am]

BILLING CODE 4310–VC–P

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

Notice of Realty Action; Recreation and Public Purposes (R&PP) Act Classification; Utah [UT045–1430–ES; UTU–45941]

AGENCY: Bureau of Land Management (BLM), DOI.

SUMMARY: The following public lands, located in the city of St. George in Washington County, Utah, have been examined and found suitable for classification for lease or conveyance to the Washington County School District under the provisions of the Recreation and Public Purposes Act, as amended (43 U.S.C. 869 *et.seq.*):

Salt Lake Meridian, Utah

T. 43 S., R. 15 W.,
Sec. 8, S1/2N1/2SE1/4SW1/4NW1/4, S1/2SE1/4SW1/4NW1/4; containing 7.50 acres.

SUPPLEMENTARY INFORMATION: The Washington County School District currently leases land from the Bureau of Land Management for a bus garage and elementary school site in the Bloomington Hills area of St. George City. Additional space is needed for bus maintenance and parking. The School District proposes to expand their site to give them additional space. They have also proposed to construct a driver training course. Leasing or conveying title to these public land is consistent with current BLM land use planning and would be in the public interest.

The lease or patent, when issued, would be subject to the following terms, conditions, and reservations:

1. Provisions of the Recreation and Public Purposes Act and all applicable regulations of the Secretary of the Interior.

2. A right-of-way for ditches and canals constructed by the authority of the United States.

3. All minerals shall be reserved to the United States, together with the right to prospect for, mine, and remove the minerals.

Detailed information concerning this action is available at the office of the Bureau of Land Management, St. George Field Office, 345 E. Riverside Drive, St. George, Utah 84790.

Upon publication of this notice in the **Federal Register**, the land will be segregated from all other forms of appropriation under the public land laws, including the general mining laws, except for leasing or conveyance under the Recreation and Public Purposes Act and leasing under the mineral leasing laws. For a period of 45 days from the date of publication of this notice in the **Federal Register**, interested persons may submit comments regarding the proposed classification, leasing or conveyance of the land to the Field Office Manager, St. George Field Office.

Classification Comments: Interested parties may submit comments concerning the suitability of the lands for school purposes. Comments on the classification are restricted to whether the land is physically suited for the proposal, whether the use will maximize the future use or uses of the land, whether the use is consistent with local planning and zoning, or if the use is consistent with State and Federal programs.

Application Comments: Interested parties may submit comments regarding the specific use proposed in the Washington County School District's application and plan of development, whether the BLM followed proper administrative procedures in reaching the decision, or any other factor not directly related to the suitability of the land for recreation and public purposes.

Any adverse comments will be reviewed by the State Director. In the absence of any adverse comments, the classification will become effective 60 days from the date of publication of this notice.

Dated: August 7, 2001.

James D. Crisp,

Field Office Manager.

[FR Doc. 01–21477 Filed 8–23–01; 8:45 am]

BILLING CODE 4310–DQ–U

DEPARTMENT OF JUSTICE

Notice of Lodging of Consent Decree Under the Comprehensive Environmental Response, Compensation, and Liability Act (''CERCLA'')

In accordance with Departmental policy, *see* 28 CFR 50.7, 38 FR 19029, and 42 U.S.C. 9622(d)(2), notice is hereby given that on July 31, 2001, a proposed Consent Decree in *United States* v. *Commerce Holding Company, Inc.*, No. 00–CV–1249 (DRH/ETB) (E.D.N.Y.), was lodged with the United States District Court for the Eastern District of New York. The proposed Consent Decree settles the United States's claims for past response costs against the Commerce Holding Company, Inc. (''Commerce'') for the Tronic Plating Superfund Site (''the Site'') under Section 107 of the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA), 42 U.S.C. 9607. Under the terms of the proposed consent decree, Commerce will pay at least $631,442.02 and up to $650,000, depending on the timing of the payment, to the United States as reimbursement for the past response costs the United States incurred at the Site.

The Department of Justice will receive, for a period of thirty (30) days

from the date of this publication, comments relating to the proposed consent decree. Comments should be addressed to the Assistant Attorney General for the Environment and Natural Resources Division, Department of Justice, P.O. Box 7611, Ben Franklin Station, Washington, D.C. 20044–7611, and should refer to *United States* v. *Commerce Holding Company, Inc.*, No. 00–CV–1249 (DRH/ETB) (E.D.N.Y.) D.J. Ref. 90–11–3–06298. Copies of all comments should also be sent to Alan Vinegrad, United States Attorney for the Eastern District of New York, F. Franklin Amanat, Assistant United States Attorney, One Pierrepont Plaza, 16th Floor, Brooklyn, NY 11201–2776.

The proposed consent decree may be examined at EPA Region II, Office of the Environmental Protection Agency, 290 Broadway, New York, New York 10007–1866. A copy of the consent decree may also be obtained by mail from the Department of Justice Consent Decree Library, P.O. Box 7611, Washington, DC 20044. In requesting a copy, please enclose a check in the amount of $4.50 (25 cents per page reproduction cost) payable to the Consent Decree Library.

Ronald G. Gluck,

Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division—U.S. Department of Justice.

[FR Doc. 01–21373 Filed 8–23–01; 8:45 am]

BILLING CODE 4410–15–M

DEPARTMENT OF JUSTICE

Notice of Lodging of a Consent Decree Pursuant to the Comprehensive Environmental Response, Compensation, and Liability Act

Notice is hereby given that a proposed consent decree in *United States* v. *Continental Equities, Inc.,* Civil Action No. 99–619–CIV–Seitz-Garber, was lodged on August 9, 2001, with the United States District Court for the Southern District of Florida. The proposed Consent Decree would resolve certain claims under sections 106 and 107 of the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, 42 U.S.C. 9606 and 9607, as amended brought against Continental Equities, Inc. to recover response costs incurred by the Environmental Protection Agency in connection with the release of hazardous substances at the Anodyne National Priorities List Superfund Site (''Site'') in Miami, Florida. The United States alleges that Settling Defendant is liable as a person who currently owns and owned a portion of the Site at the time of disposal of a hazardous substance. Under the proposed Consent Decree, the Settling Defendant will pay $350,000 to the Hazardous Substances Superfund to reimburse the United States for response costs incurred and to be incurred at the Site.

The Department of Justice will receive, for a period of thirty (30) days from the date of this publication, comments relating to the proposed Consent Decree. Comments should be addressed to the Assistant Attorney General for the Environment and Natural Resources Division, Department of Justice, P.O. Box 7611, Washington, DC 20530, and should refer to *United States* v. *Continental Equities, Inc.,* Civil Action No. 99–619–CIV (S.D.FL.), DOJ Ref. #90–11–2–881.

The Consent Decree may be examined at the Region 4 Office of the Environmental Protection Agency, 61 Forsyth Street, Atlanta, GA 30303 and the United States Attorney's Office for the Southern District of Florida, 99 NE. 4th Street, Miami, Florida, 33132 c/o Assistant U.S. Attorney Barbara Junge. A copy of the proposed consent decree may be obtained by mail from the Consent Decree Library, Post Office Box 7611, Washington, DC 20044. In requesting copies please refer to the referenced case and enclose a check in the amount of $12.00 (25 cents per page reproduction costs), payable to the Consent Decree Library.

Ellen Mahan,

Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division.

[FR Doc. 01–21372 Filed 8–23–01; 8:45 am]

BILLING CODE 4410–15–M

DEPARTMENT OF JUSTICE

Immigration and Naturalization Service

[INS No. 2159–01]

Detained Aliens Requesting Release Under Zadvydas v. Davis

AGENCY: Immigration and Naturalization Service, Justice.

ACTION: Notice.

SUMMARY: This notice promulgates the address of the office of the Immigration and Naturalization Service (Service) to which a detained alien must submit, in writing, a request for release on the ground that there is no significant likelihood that the Service will be able to remove the alien in the reasonably foreseeable future, in accordance with the judgment of the Supreme Court in *Zadvydas* v. *Davis,* 533 U.S. __, 121 S.Ct. 2491 (2001).

EFFECTIVE DATE: This notice is effective August 24, 2001.

FOR FURTHER INFORMATION CONTACT: David J. Venturella, Headquarters, Office of Detention and Removals, Immigration and Naturalization Service, 801 I Street NW., Suite 900, Washington, DC 20536, telephone (202) 514–1970.

SUPPLEMENTARY INFORMATION: On July 24, 2001, at 66 FR 38433, the Department of Justice published in the **Federal Register** the text of a memorandum issued by the Attorney General in response to the Supreme Court's judgment in *Zadvydas* v. *Davis,* 533 U.S. __, 121 S.Ct. 2491 (2001). The Memorandum directed the former Acting Commissioner of the Service, among other things, to begin accepting written requests for release for detained aliens subject to removal orders who contend that there is no significant likelihood that the Service will be able to remove them in the reasonably foreseeable future. These interim procedures apply to aliens who are subject to final orders of removal, except that the procedures do not apply to detained arriving aliens, including arriving aliens who have been paroled into the United States under section 212(d)(5)(A) of the Immigration and Nationality Act.

Any detained alien who believes that he or she may be eligible for release under the *Zadvydas* decision, should submit a written request for release, along with supporting documentation, to: U.S. Department of Justice, Immigration and Naturalization Service, Headquarters, Post-Order Detention Unit, 801 I Street NW., Suite 900, Washington DC 20536.

Dated: August 13, 2001.

James W. Ziglar,

Commissioner, Immigration and Naturalization Service.

[FR Doc. 01–21401 Filed 8–23–01; 8:45 am]

BILLING CODE 4410–10–M

DEPARTMENT OF LABOR

Office of the Secretary

Submission for OMB Review; Comment Request

August 13, 2001.

The Department of Labor (DOL) has submitted the following public information collection requests (ICRs) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork

Reduction Act of 1995 (Pub. L. 104–13, 44 U.S.C. Chapter 35). A copy of each individual ICR, with applicable supporting documentation, may be obtained by calling the Department of Labor. To obtain documentation contact Marlene Howze at (202) 219–8904 or Email *Howze-Marlene@dol.gov*.

Comments should be sent to Office of Information and Regulatory Affairs, Attn: OMB Desk Officer for ESA, Office of Management and Budget, Room 10235, Washington, DC 20503 ((202) 395–7316), within 30 days from the date of this publication in the **Federal Register**.

The OMB is particularly interested in comments which:

• Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

• Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumption used;

• Enhance the quality, utility, and clarity of the information to be collected; and minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses.

Type of Review: Extension of a currently approved collection.

Agency: Employment Standards Administration (ESA).

Title: Request for State or Federal Workers' Compensation Information.

OMB Number: 1215–0060.

Affected Public: Federal Government and State, Local or Tribal Government.

Frequency: On Occasion.

Number of Respondents: 3,522.

Number of Annual Responses: 3,522.

Estimated Time Per Response: 15 minutes.

Total Burden Hours: 881.

Total Annualized Capital/Startup Costs: $0.

Total Annual Costs (operating/maintaining systems or purchasing services): $11,799.

Description: The Federal Mine Safety and Health Act of 1977, as amended, 30 USC 922(b) and 20 CFR 725.535 directs that DOL Black Lung benefit payments to a beneficiary for any month be reduced by any other payments of state or Federal benefits for workers' compensation due to pneumoconiosis. To ensure compliance with this mandate DCMWC must collect information regarding the status of any state or Federal workers' compensation claim, including dates of payments, weekly or lump sum amounts paid, and other fees or expenses paid out of this award, such as attorney fees and related expenses associated with pneumoconiosis. A social security number is required for the information collection per Public Law 106–113.

Ira L. Mills,

Departmental Clearance Officer.

[FR Doc. 01–21482 Filed 8–23–01; 8:45 am]

BILLING CODE 4510–CK–M

DEPARTMENT OF LABOR

Employment Standards Administration

Proposed Collection; Comment Request

ACTION: Notice.

SUMMARY: The Department of Labor, as part of its continuing effort to reduce paperwork and respondent burden, conducts a preclearance consultation program to provide the general public and Federal agencies with an opportunity to comment on proposed and/or continuing collections of information in accordance with the Paperwork Reduction Act of 1995 (PRA95) (44 U.S.C. 3506(c)(2)(A)). This program helps to ensure that requested data can be provided in the desired format, reporting burden (time and financial resources) is minimized, collection instruments are clearly understood, and the impact of collection requirements on respondents can be properly assessed. Currently, the Employment Standards Administration is soliciting comments concerning the proposed extension of Payment of Compensation Without Award (LS–206).

DATES: Written comments must be submitted to the office listed in the **ADDRESSES** section below on or before October 23, 2001.

ADDRESSES: Ms. Patricia A. Forkel, U.S. Department of Labor, 200 Constitution Ave., NW., Room S–3201, Washington, DC 20210, telephone (202) 693–0339 (this is not a toll-free number), fax (202) 693–1451.

SUPPLEMENTARY INFORMATION:

I. Background

The Office of Workers' Compensation Programs (OWCP) administers the Longshore and Harbor Workers' Compensation Act (LSWCA). The Act provides benefits to workers injured in maritime employment on the navigable waters of the United States or in an adjoining area customarily used by an employer in loading, unloading, repairing, or building a vessel. Under section 14(b) and (c) of the Act, a self-insured employer or insurance carrier is required to pay compensation within 14 days after the employer has knowledge of the injury or death. Upon making the first payment, the employer or carrier shall immediately notify the district director of payment. Form LS–206 has been designated as the form on which report of first payment is to be made.

II. Review Focus

The Department of Labor is particularly interested in comments which:

• Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

• Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

• Enhance the quality, utility and clarity of the information to be collected; and

• Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submissions of responses.

III. Current Actions

The Department of Labor seeks the approval of the extension of this information collection in order to carry out its responsibility to meet the statutory requirements to ensure payment of compensation or death benefits under the Act.

Type of Review: Extension.

Agency: Employment Standards Administration.

Title: Payment of Compensation Without Award.

OMB Number: 1215–0022.

Agency Number: LS–206.

Affected Public: Businesses or other for-profit.

Frequency: On occasion.

Total Respondents: 900.

Total Annual Responses: 26,100.

Time Per Response: 15 minutes.

Estimated Total Burden Hours: 6,525.

Total Burden Cost (capital/startup): $0.

Total Burden Cost (operating/maintenance): $10,224.25.

Comments submitted in response to this notice will be summarized and/or included in the request for Office of Management and Budget approval of the information collection request; they will also become a matter of public record.

Dated: August 10, 2001.

Margaret J. Sherrill,

Chief, Branch of Management Review and Internal Control, Division of Financial Management, Office of Management, Administration and Planning, Employment Standards Administration.

[FR Doc. 01–21483 Filed 8–23–01; 8:45 am]

BILLING CODE 4510–CF–P

DEPARTMENT OF LABOR

Employment Standards Administration

Proposed Collection; Comment Request

ACTION: Notice.

SUMMARY: The Department of Labor, as part of its continuing effort to reduce paperwork and respondent burden, conducts a preclearance consultation program to provide the general public and Federal agencies with an opportunity to comment on proposed and/or continuing collections of information in accordance with the Paperwork Reduction Act of 1995 (PRA95) (44 U.S.C. 3506(c)(2)(A)). This program helps to ensure that requested data can be provided in the desired format, reporting burden (time and financial resources) is minimized, collection instruments are clearly understood, and the impact of collection requirements on respondents can be properly assessed. Currently, the Employment Standards Administration is soliciting comments concerning the proposed extension of two information collections: (1) Provider Enrollment Form and (2) Request for Information on Earnings, Dual Benefits, Dependents, and Third Party Settlements.

DATES: Written comments must be submitted to the office listed in the **ADDRESSES** section below on or before October 23, 2001.

ADDRESSES: Ms. Patricia A. Forkel, U.S. Department of Labor, 200 Constitution Ave., NW., Room S–3201, Washington, DC 20210, telephone (202) 693–0339 (this is not a toll-free number), fax (202) 693–1451.

SUPPLEMENTARY INFORMATION:

Provider Enrollment Form

I. Background

Two programs in the Office of Workers' Compensation Programs are responsible for maintaining a list of authorized treating physicians and medical facilities in the area of the claimant's residence and for payment of certain medical bills for services and supplies, provided to miners under the Black Lung Benefits Act (30 U.S.C. 901 *et seq.*, 20 CFR 725.703(a) and 725.704(b)) and claimants under the Division of Energy Employees Occupational Illness Compensation Program Act (Pub.L. 106–398 and 20 CFR 30.701). Both of these programs maintain a list of registered providers who wish to participate in rendering services and supplies for the Program beneficiaries. Provider information on the form is used to carry out the payment process and to ensure that claimants can be referred to approved providers upon request.

II. Review Focus

The Department of Labor is particularly interested in comments which:

• Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

• Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

• Enhance the quality, utility and clarity of the information to be collected; and

• Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submissions of responses.

III. Current Actions

The Department of Labor seeks the approval of this information collection in order to carry out a wide range of full automated medical bill edits, such as, cross-checks of provider specialty against type of service, status of case reporting, and compilation of historical data on selected providers. This information is also utilized to furnish timely and detailed reports to providers on the status of previous bills. The form is also used to up-date provider billing information.

Type of Review: Extension.

Agency: Employment Standards Administration.

Title: Provider Enrollment Form.

OMB Number: 1215–0137.

Agency Number: OWCP–1168.

Affected Public: Business or other for-profit.

Frequency: Annual.

Total Respondents: 9,000.

Total Annual Responses: 9,000.

Average Time per Response: 6 minutes.

Estimated Total Burden Hours: 1,017.

Total Burden Cost (capital/startup): $0.

Total Burden Cost (operating/maintenance): $3,330.00.

Request for Information on Earnings, Dual Benefits, Dependents, and Third Party Settlements

I. Background

The collection of this information is necessary under provisions of the Federal Employees' Compensation Act (FECA) which states: (1) Compensation must be adjusted to reflect a claimant's earnings while in receipt of benefits (5 U.S.C. 8106); (2) compensation is payable at the augmented rate of 75 percent only if the claimant has one or more dependents as defined by the FECA (5 U.S.C. 8110); (3) compensation may not be paid concurrently with certain benefits from other Federal Agencies, such as the Office of Personnel Management, Social Security, and the Veterans Administration (5 U.S.C. 8116); (4) compensation must be adjusted to reflect any settlement from a third party responsible for the injury for which the claimant is being paid compensation (5 U.S.C. 8132); (5) an individual convicted of any violation related to fraud in the application for, or receipt of, any compensation benefit, forfeits (as of the date of such conviction) any entitlement to such benefits, for any injury occurring on or before the date of conviction (5 U.S.C. 8148 (a)); and, (6) no Federal compensation benefit can be paid to any individual for any period during which such individual is incarcerated for any felony offense (5 U.S.C. 8148 (b)(1)). The information collected through Form CA–1032 is used to ensure that compensation being paid on the periodic roll is correct.

II. Review Focus

The Department of Labor is particularly interested in comments which:

• Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

• Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information,

including the validity of the methodology and assumptions used;

• Enhance the quality, utility and clarity of the information to be collected; and

• Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submissions of responses.

III. Current Actions

The Department of Labor seeks the approval of this information collection in order to ensure that compensation being paid on the periodic roll is correct.

Type of Review: Extension.

Agency: Employment Standards Administration.

Title: Request for Information on Earnings, Dual Benefits, Dependents, and Third Party Settlements.

OMB Number: 1215–0151.

Agency Number: CA–1032.

Affected Public: Businesses or other for-profit.

Frequency: Annual.

Total Respondents: 50,000.

Total Annual Responses: 50,000.

Time per Response: 20 minutes.

Estimated Total Burden Hours: 16,667.

Total Burden Cost (capital/startup): $0.

Total Burden Cost (operating/maintenance): $18,500.00.

Comments submitted in response to this notice will be summarized and/or included in the request for Office of Management and Budget approval of the information collection request; they will also become a matter of public record.

Dated: August 16, 2001.

Margaret J. Sherrill,

Chief, Branch of Management Review and Internal Control, Division of Financial Management, Office of Management, Administration and Planning, Employment Standards Administration.

[FR Doc. 01–21484 Filed 8–23–01; 8:45 am]

BILLING CODE 4510–CH–P

DEPARTMENT OF LABOR

Employment Standards Administration Wage and Hour Division

Minimum Wages for Federal and Federally Assisted Construction; General Wage Determination Decisions

General Wage determination decisions of the Secretary of Labor are issued in accordance with applicable law and are based on the information obtained by the Department of Labor from its study of local wage conditions and data made available from other sources. They specify the basic hourly wage rates and fringe benefits which are determined to be prevailing for the described classes of laborers and mechanics employed on construction projects of a similar character and in the localities specified therein.

The determinations in these decisions of prevailing rates and fringe benefits have been made in accordance with 29 CFR Part 1, by authority of the Secretary of Labor pursuant to the provisions of the Davis-Bacon Act of March 3, 1931, as amended (46 Stat. 1494, as amended, 40 U.S.C. 276a) and of other Federal statutes referred to in 29 CFR part 1, appendix, as well as such additional statues as may from time to time be enacted containing provisions for the payment of wages determined to be prevailing by the Secretary of Labor in accordance with the Davis-Bacon Act. The prevailing rates and fringe benefits determined in these decisions shall, in accordance with the provisions of the foregoing statutes, constitute the minimum wages payable on Federal and federally assisted construction projects to laborers and mechanics of the specified classes engaged on contract work of the character and in the localities described therein.

Good cause is hereby found for not utilizing notice and public comment procedure thereon prior to the issuance of these determinations as prescribed in 5 U.S.C. 553 and not providing for delay in the effective date as prescribed in that section, because the necessity to issue current construction industry wage determinations frequently and in large volume causes procedures to be impractical and contrary to the public interest.

General wage determination decisions, and modifications and supersede as decisions thereto, contain no expiration dates and are effective from their date of notice in the **Federal Register**, or on the date written notice is received by the agency, whichever is earlier. These decisions are to be used in accordance with the provisions of 29 CFR Parts 1 and 5. Accordingly, the applicable decision, together with any modifications issued, must be made a part of every contract for performance of the described work within the geographic area indicated as required by an applicable Federal prevailing wage law and 28 CFR Part 5. The wage rates and fringe benefits, notice of which is published therein, and which are contained in the Government Printing Office (GPO) document entitled ''General Wage Determinations Issued Under The Davis-Bacon And Related Acts,'' shall be the minimum paid by contractors and subcontractors to laborers and mechanics.

Any person, organization, or governmental agency having an interest in the rates determined as prevailing is encouraged to submit wage rate and fringe benefit information for consideration by the Department.

Further information and self-explanatory forms for the purpose of submitting this data may be obtained by writing to the U.S. Department of Labor, Employment Standards Administration, Wage and Hour Division, Division of Wage Determinations, 200 Constitution Avenue, NW., Room S–3014, Washington, DC 20210.

Withdrawn General Wage Determination Decision

This is to advise all interested parties that the Department of Labor is withdrawing, from the date of this notice, General Wage Determination No. WV010010. See WV010009.

Contracts for which bids have been opened shall not be effected by this notice. Also, consistent with 29 CFR 1.6(c)(2)(i)(A), when the opening of bids is less than ten (10) days from the date of this notice, this action shall be effective unless the agency finds that there is insufficient time to notify bidders of the change and the finding is documented in the contract file.

Modification to General Wage Determination Decisions

The number of decisions listed to the Government Printing Office document entitled ''General Wage determinations Issued Under the Davis-Bacon and related Acts'' being modified are listed by Volume and State. Dates of publication in the **Federal Register** are in parentheses following the decisions being modified.

Volume I

New Hampshire
NH010001 (Mar. 2, 2001)
NH010005 (Mar. 2, 2001)
NH010007 (Mar. 2, 2001)
New Jersey
NJ10001 (Mar. 2, 2001)
NJ10002 (Mar. 2, 2001)
NJ10003 (Mar. 2, 2001)
New Jersey
NJ010004 (Mar. 02, 2001)
New Jersey
NJ010005 (Mar. 02, 2001)
New Jersey
NJ010007 (Mar. 02, 2001)
New Jersey
NJ010009 (Mar. 02, 2001)

Volume II

West Virginia
WV010009 (Mar. 02, 2001)

Volume III

Florida
FL010017 (Mar. 02, 2001)

Volume IV

Illinois
IL010001 (Mar. 02, 2001)
Illinois
IL010002 (Mar. 02, 2001)
Illinois
IL010003 (Mar. 02, 2001)
Illinois
IL010004 (Mar. 02, 2001)
Illinois
IL010005 (Mar. 02, 2001)
Illinois
IL010006 (Mar. 02, 2001)
Illinois
IL010007 (Mar. 02, 2001)
Illinois
IL010008 (Mar. 02, 2001)
Illinois
IL010009 (Mar. 02, 2001)
Illinois
IL010011 (Mar. 02, 2001)
Illinois
IL010012 (Mar. 02, 2001)
Illinois
IL010013 (Mar. 02, 2001)
Illinois
IL010014 (Mar. 02, 2001)
Illinois
IL010017 (Mar. 02, 2001)
Illinois
IL010019 (Mar. 02, 2001)
Illinois
IL010020 (Mar. 02, 2001)
Illinois
IL010030 (Mar. 02, 2001)
Illinois
IL010034 (Mar. 02, 2001)
Illinois
IL010036 (Mar. 02, 2001)
Illinois
IL010039 (Mar. 02, 2001)
Illinois
IL010040 (Mar. 02, 2001)
Illinois
IL010042 (Mar. 02, 2001)
Illinois
IL010049 (Mar. 02, 2001)
Illinois
IL010052 (Mar. 02, 2001)
Illinois
IL010060 (Mar. 02, 2001)
Illinois
IL010063 (Mar. 02, 2001)
Michigan
MI010001 (Mar. 02, 2001)
Michigan
MI010003 (Mar. 02, 2001)
Michigan
MI010004 (Mar. 02, 2001)
Michigan
MI010005 (Mar. 02, 2001)
Michigan
MI010007 (Mar. 02, 2001)
Michigan
MI010013 (Mar. 02, 2001)
Michigan
MI010016 (Mar. 02, 2001)
Michigan
MI010027 (Mar. 02, 2001)
Michigan
MI010030 (Mar. 02, 2001)
Michigan
MI010031 (Mar. 02, 2001)
Michigan
MI010040 (Mar. 02, 2001)
Michigan
MI010046 (Mar. 02, 2001)
Michigan
MI010047 (Mar. 02, 2001)
Michigan
MI010049 (Mar. 02, 2001)

Volume V

None

Volume VI

Montana
MT010001 (Mar. 02, 2001)
Montana
MT010003 (Mar. 02, 2001)
Montana
MT010004 (Mar. 02, 2001)
Montana
MT010034 (Mar. 02, 2001)

Volume VII

None

General Wage Determination Publication

General wage determinations issued under the Davis-Bacon and related Acts, including those noted above, may be found in the Government Printing Office (GPO) document entitled ''General Wage Determinations Issued Under The Davis-Bacon And Related Acts''. This publication is available at each of the 50 Regional Government Depository Libraries and many of the 1,400 Government Depository Libraries across the country.

General wage determinations issued under the Davis-Bacon and related Acts are available electronically at no cost on the Government Printing Office site at *www.access.gpo.gov/davisbacon.* They are also available electronically by subscription to the FedWorld Bulletin Board System of the National Technical Information Service (NTIS) of the U.S. Department of Commerce at 1–800–363–2068.

Hard-copy subscriptions may be purchased from: Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 20402, (202) 512–1800.

When ordering hard-copy subscription(s), be sure to specify the State(s) of interest, since subscriptions may be ordered for any or all of the six separate volumes, arranged by State. Subscriptions include an annual edition (issued in January or February) which includes all current general wage determinations for the States covered by each volume. Throughout the remainder of the year, regular weekly updates will be distributed to subscribers.

Signed at Washington DC this 16th day of August 2001.

Carl J. Poleskey,

Chief, Branch of Construction Wage Determinations.

[FR Doc. 01–21125 Filed 8–23–01; 8:45 am]

BILLING CODE 4510–27–M

INTERNATIONAL BOUNDARY AND WATER COMMISSION

Implement International Agreement for Deliveries to Tijuana, Baja California, of a Part of Mexico's Colorado River Waters Through the Southern California Aqueducts; Notice of Final Finding of No Significant Impact

AGENCY: United States Section, International Boundary and Water Commission, United States and Mexico.

ACTION: Notice of availability of a final Finding of No Significant Impact and a final Environmental Assessment.

SUMMARY: Based on the draft Environmental Assessment (EA) and the comments received, the United States Section (U.S.) finds that the proposed action of implementing an international agreement with the Government of Mexico through the International Boundary and Water Commission (IBWC) to provide emergency deliveries to Tijuana, Baja California, of a part of Mexico's Colorado River water allotment through the Southern California aqueducts, is not a major federal action that would have a significant adverse effect on the quality of the human environment. An environmental impact statement will not be prepared for the project. The final Finding of No Significant Impact (FONSI) and final EA have been forwarded to the United States Environmental Protection Agency and various Federal, State and local agencies and interested parties for information only. No comments are requested. The Notice of Availability of a FONSI is being published in the **Federal Register**. The documents are on the USIBWC Home Page at *http://www.ibwc.state.gov* under ''What's New'' and are at the San Diego Central Library, 820 ''E'' St.; City of San Diego, Environmental Services Library, Ste. 130, 9601 Ridgehaven Court; Otay Mesa Branch Library, 3003

Coronado Ave., San Diego; San Ysidro Public Library, 101 West San Ysidro Blvd.; Civic Center Branch Library, Eastlake Public Library, 365 F St., Chula Vista; and San Diego County Libraries at the Casa de Oro Branch, 9628 Campo Road # L, Spring Valley and at 1043 Elkelton Blvd., Spring Valley. A limited number of hard copies are available upon request from Mr. Fox at the above address, e-mail *stevefox@ibwc.state.gov* or at (915) 832–4736.

The purpose of the proposed action is to arrange emergency deliveries of a portion of Mexico's Colorado River water allocation through the Southern California aqueduct system to the Tijuana water distribution system under the terms of an international agreement. The proposed action would alleviate some of the current water shortage in Tijuana, with a population of about 1.3 million, and conditions that could lead to serious public health and economic problems that may impact inhabitants on both sides of the international boundary.

The emergency water deliveries would be made under the terms of a Minute of the IBWC utilizing the existing facilities in the United States. A minute is an international agreement of the IBWC. The agreement will provide terms and conditions for the emergency deliveries. The IBWC may conclude such agreements under the terms of the United States/Mexico Treaty of 1944 (1944 Water Treaty). The U.S. Commissioner of the IBWC is authorized to arrange such agreements in the United States by the Act of August 19, 1935 (U.S. Congress, 1935) and the American—Mexican Treaty Act of September 13, 1950, (U.S. Congress, 1950).

The alternative is no action. The City of Tijuana is considering improvements to their system. The Southern California agencies that operate and maintain the Southern California aqueducts are willing and able to make deliveries under emergency conditions.

The proposed five year emergency water deliveries would begin during 2002 and would consist of deliveries to Tijuana of a portion of the waters allotted to Mexico under the 1944 Water Treaty. The waters are for use in Tijuana, Baja California. Conveyance will be by means of aqueducts owned and operated by the Metropolitan Water District (MWD) and the San Diego County Water Authority (SDCWA). Emergency water deliveries to Mexico from the Southern California aqueducts will be through pipelines and other facilities, including those belonging to the Otay Water District (OWD), up to a maximum rate of 0.6 m^3/sec (14 mgd) during peak demand periods in Tijuana. The delivery to Mexico, based on Mexico's request, not to exceed conveyance system capacity, would use the existing emergency connection located at the international boundary about 6.3 miles (10.1 km) east of the Otay port-of-entry, on Otay Mesa, San Diego, California.

The final conveyance point to Mexico requires use of an existing line to be replaced at Mexico's expense. This line to Mexico requires the replacement of an approximately 80-foot segment of existing 14-inch pipeline that was initially installed as a temporary measure. Up to about 120 feet of deteriorated 24-inch pipeline will also be replaced. Therefore, a maximum of approximately 200 linear feet of pipeline will be replaced, in the area of the OWD meter and in the area between the international boundary fence and the secondary fence, with 24-inch pipeline consistent with the remainder of the OWD pipeline. The project work includes the upgrade in diameter of the 14-inch diameter section of pipeline and the installation of a meter and backflow prevention facility on a small (approximately 1,300 square foot) concrete pad with security fence. All pipeline and backflow prevention construction, as well as completed facilities, will be located within the existing 30-foot wide OWD easement on the site which is accessible by existing roads. This improvement facilitates the City of Tijuana's peak demand of approximately 4.0 m^3/sec (91 mgd) by the Comision Estatal de Servicios Publicos de Tijuana's (CESPT) system. The surface area of the above ground structures will be approximately 1,300 ft^2 (121 m^2) and the area of the temporary land disturbance (i.e., construction) will be about 3,050 ft^2 (283 m^2).

Under the no action alternative, the City of Tijuana could experience a water supply shortage lasting upwards of several days. There could be the public health risk of illnesses attributed to water shortages which could have an impact on communities on both sides of the international boundary. Under another alternative, not considered in the EA, is that for water supply expansion in the City of Tijuana by Mexico. The responsible agencies in Mexico are evaluating alternative sources of water for the region such that emergency water deliveries would be needed until they can be constructed. Of the alternatives considered, the proposed action is most compatible with the responsibilities and powers of the United States Section, IBWC, in implementing United States/Mexico agreements of the IBWC and does not significantly affect the environmental resources.

The detailed air quality analysis indicated project-related pollutants will be at the threshold for some of the criteria pollutants. The proposed action will be in compliance with San Diego Air Pollution Control District (APCD) Rules and Regulations. The overall air emissions impacts will be consistent with applicable ambient air quality standards. An application was submitted by the OWD to the APCD in May 2000 for a permit to increase operation of the three natural gas engines that will be required to deliver the water to Mexico. The staff plans to purchase specific equipment to continue the District's practice of equipment standardization and to obtain the best, proven engine and air pollution control technology. The APCD adopted revisions to Rule 69.4.1 in November 2000, six months after submittal of the original permit application to APCD. The revisions to APCD Rule 69.4.1 implement more stringent California state-mandated Best Available Retrofit Control Technology (BARCT) requirements to further reduce nitrogen oxide (NO_X) emissions in San Diego County that will take full effect in 2002. OWD has determined that retrofitting existing engines to meet the new emission guidelines and deliver the water to Mexico will be cost prohibitive; therefore, OWD will purchase new engines with Best Available Control Technology (BACT)[(i.e., with new Caterpillar engines and non-selective catalytic reduction (NSCR) and NO_X emissions controls)] that will more reliably and cost-effectively meet these new emission standards. OWD has committed to purchasing equipment that is the best, proven technology for accomplishing OWD purposes that will meet APCD requirements. OWD is currently in the process of purchasing the necessary engines and BACT in order to deliver the water to Mexico; however, due to the timing of the APCD mandate relative to Rule 69.4.1 and the date when water will need to be delivered to Mexico, OWD will be required to obtain a variance from APCD in order to operate the existing engines without BARCT until the new engines with BACT are installed, tested, and permitted. OWD will off-set or otherwise mitigate the emissions allowed during the APCD variance consistent with the terms and conditions of the variance as well as existing APCD rules and regulations. The mitigation is for use of the old

pumps while new pumps are installed, tested and permitted.

Based on the conformity determination made under 40 Code of Federal Regulations (CFR) Part 51.858, the Federal action will be in conformity with the specific requirements and the purposes of the California Ambient Air Quality Standards pursuant to the United States Section's affirmative obligation under Section 176(c) of the Clean Air Act in accordance with the requirements of 40 CFR, Ch. 1, Part 51, Subpart W. The Federal action will be in compliance with the Clean Air Act and California's compliance requirements for air quality resources.

The proposed project complies with all requirements of Federal Statutes, executive orders and other statutes, regulations and applicable permits, including the National Environmental Policy Act (NEPA), the United States Section's NEPA implementing procedures and the California Environmental Quality Act (CEQA) because there will be no significant project impacts. Project coordination on air quality and all other resources, including cultural, biological, and any Federally threatened and endangered species or habitats is being completed by United States Section and SDCWA for NEPA and CEQA compliance.

This final EA, ''Implement International Agreement for Deliveries to Tijuana, Baja California, of a Part of Mexico's Colorado River Waters Through the Southern California Aqueducts'' documents the assessment of the potential impacts of the proposed action and its alternatives. No significant adverse affects to the resources of the connecting facilities, Otay Mesa, delivery facilities, Colorado River, City of Tijuana, biological, archaeological, historical and other cultural resources, water, air quality, environmental justice, energy, and induced growth are expected by implementing the proposed action.

Based upon the results of the final Environmental Assessment, it has been determined that the proposed action will not have a significant adverse effect on the environment and an Environmental Impact Statement is not warranted.

August 15, 2001.

William A. Wilcox, Jr.

Attorney-Advisor (General).

[FR Doc. 01–21404 Filed 8–23–01; 8:45 am]

BILLING CODE 7010–01–P

NATIONAL AERONAUTICS AND SPACE ADMINISTRATION

[Notice (01–099)]

NASA Advisory Council; Meeting

AGENCY: National Aeronautics and Space Administration.

ACTION: Notice of Meeting.

SUMMARY: In accordance with the Federal Advisory Committee Act, Pub. L. 92–463, as amended, the National Aeronautics and Space Administration announces a meeting of the NASA Advisory Council.

DATES: Tuesday, September 11, 2001, 8:30 a.m. to 3:15 p.m.; and Wednesday, September 12, 2001, 8:00 a.m. to 11:15 a.m.

ADDRESSES: Ames Research Center (AMES), National Aeronautics and Space Administration, The Moffett Field Training and Conference Center, Bldg 3., Moffett Field, CA 94035–1000.

FOR FURTHER INFORMATION CONTACT: Ms. Kathy Dakon, Code Z, National Aeronautics and Space Administration, Washington, DC 20546, 202/358–0732.

SUPPLEMENTARY INFORMATION: The meeting will be open to the public up to the seating capacity of the room. The agenda for the meeting is as follows:

—Soft Adaptive Computing
—NASA Supercomputing Program
—Global Modeling
—Biology and Nanotechnology Research
—Restructured Aeronautics Program
—Committee/TaskForce/Working Group Reports
—Discussion of Findings and Recommendations

It is imperative that the meeting be held on these dates to accommodate the scheduling priorities of the key participants. Visitors will be requested to sign a visitor register.

Beth M. McCormick,

Advisory Committee Management Officer, National Aeronautics and Space Administration.

[FR Doc. 01–21367 Filed 8–23–01; 8:45 am]

BILLING CODE 7510–01–P

NATIONAL FOUNDATION ON THE ARTS AND THE HUMANITIES

National Endowment for the Arts

Fellowships Advisory Panel

Pursuant to Section 10(a)(2) of the Federal Advisory Committee Act (Public Law 92–463), as amended, notice is hereby given that a meeting of the Fellowships Advisory Panel, Literature Section (Creative Writing Fellowships category) to the National Council on the Arts will be held on September 10–13, 2001 at the Nancy Hanks Center, 1100 Pennsylvania Avenue, NW, (Room M–07) Washington, DC 20506. A portion of this meeting, from 11:00 a.m. to 12:30 p.m. on September 13th, will be open to the public for policy discussion. The remaining portions of this meeting, from 9:00 a.m. to 6:00 p.m. on September 10th, from 9:00 a.m. to 6:30 p.m. on September 11th and 12th, and from 9:00 a.m. to 11:00 a.m. and 12:30 p.m. to 5:00 p.m. on September 13th, will be closed.

The closed portions of these meetings are for the purpose of Panel review, discussion, evaluation, and recommendation on applications for financial assistance under the National Foundation on the Arts and the Humanities Act of 1965, as amended, including information given in confidence to the agency by grant applicants. In accordance with the determination of the Chairman of May 22, 2001, these sessions will be closed to the public pursuant to (c)(4)(6) and (9)(B) of section 552b of Title 5, United States Code.

Any person may observe meetings, or portions thereof, of advisory panels that are open to the public, and, if time allows, may be permitted to participate in the panel's discussions at the discretion of the panel chairman and with the approval of the full-time Federal employee in attendance.

If you need special accommodations due to a disability, please contact the Office of AccessAbility, National Endowment for the Arts, 1100 Pennsylvania Avenue, NW., Washington, DC 20506, 202/682–5532, TDY–TDD 202/682–5496, at least seven (7) days prior to the meeting.

Further information with reference to this meeting can be obtained from Ms. Kathy Plowitz-Worden, Office of Guidelines & Panel Operations, National Endowment for the Arts, Washington, DC 20506, or call 202/682–5691.

Dated: August 17, 2001.

Kathy Plowitz-Worden,

Panel Coordinator.

[FR Doc. 01–21407 Filed 8–23–01; 8:45 am]

BILLING CODE 7537–01–P

NUCLEAR REGULATORY COMMISSION

[Docket No. 50–410]

Niagara Mohawk Power Corporation; Notice of Consideration of Issuance of Amendment to Facility Operating License, Proposed No Significant Hazards Consideration Determination, and Opportunity for a Hearing

The U.S. Nuclear Regulatory Commission (the Commission) is considering issuance of an amendment to Facility Operating License No. NPF–69, issued to Niagara Mohawk Power Corporation (NMPC, the licensee), for operation of the Nine Mile Point Nuclear Station, Unit No. 2 (NMP2), located in Scriba, New York.

The proposed amendment would revise Technical Specification (TS) Section 3.6.1.7, ''Suppression Chamber-to-Drywell Vacuum Breakers,'' to allow an exception to the periodic functional testing requirements for two specific vacuum breakers (cycling the vacuum breakers open and closed). Specifically, the proposed change revises Surveillance Requirement 3.6.1.7.2 such that the functional testing requirement would not apply to vacuum breakers 2ISC*RV35A and 2ISC*RV35B for the remainder of Cycle 8 (the current operating cycle).

The licensee found that limit switch(es) on vacuum breaker 2ISC*RV35A began operating intermittently during the last functional test. The limit switches provide position indication to verify that vacuum breaker 2ISC*RV35A is closed. The limit switches also provide input to a permissive logic that allows opening vacuum breaker 2ISC*RV35B when vacuum breaker 2ISC*RV35A is confirmed closed. An alternate pressure test method for verifying that vacuum breaker 2ISC*RV35A is closed is available for use only if vacuum breaker 2ISC*RV35B can be opened. Currently, both vacuum breakers 2ISC*RV35A and 2ISC*RV35B are verified closed. Future performance of functional tests on vacuum breaker 2ISC*RV35A could cause failure of the position indication, which is the normal method for verifying the vacuum breaker is closed. Furthermore, because the permissive logic inputs from vacuum breaker 2ISC*RV35A are not operating correctly, exercising vacuum breaker 2ISC*RV35B may not be possible in order to satisfy its functional testing requirement. Loss of the capability to exercise vacuum breaker 2ISC*RV35B would prohibit use of the alternate pressure testing method for verifying that vacuum breaker 2ISC*RV35A is closed.

Thus, failure of the limit switch would require NMP2 to be placed in Mode 3 within 84 hours and Mode 4 within the following 24 hours due to a loss of position indication for verifying vacuum breaker 2ISC*RV35A is closed and the inability to perform a pressure test. The degradation of the limit switches was observed during the last functional testing surveillance conducted on July 30, 2001. The limit switches are located in the drywell and cannot be accessed for repair or replacement during power operation due to the inerted environment. Per the TSs, the next functional test of the vacuum breakers must be performed by September 6, 2001 (31 days plus 25 percent).

The licensee stated that the limit switches for the vacuum breakers are currently replaced every other refueling outage (RFO). The limit switches for vacuum breakers 2ISC*RV35A and 2ISC*RV35B were replaced during the last RFO7. The eight vacuum breakers had all passed their 31-day functional tests since RFO7 with no evidence of impending failure until the last tests on July 30, 2001. Therefore, there was no prior indication that the limit switches would degrade.

Before issuance of the proposed license amendment, the Commission will have made findings required by the Atomic Energy Act of 1954, as amended (the Act) and the Commission's regulations.

Pursuant to 10 CFR 50.91(a)(6) for amendments to be granted under exigent circumstances, the NRC staff must determine that the amendment request involves no significant hazards consideration. Under the Commission's regulations in 10 CFR 50.92, this means that operation of the facility in accordance with the proposed amendment would not (1) involve a significant increase in the probability or consequences of an accident previously evaluated; or (2) create the possibility of a new or different kind of accident from any accident previously evaluated; or (3) involve a significant reduction in a margin of safety. As required by 10 CFR 50.91(a), the licensee has provided its analysis of the issue of no significant hazards consideration, which is presented below:

The operation of Nine Mile Point Unit 2, in accordance with the proposed amendment, will not involve a significant increase in the probability or consequences of an accident previously evaluated.

Proper functioning of the suppression chamber-to-drywell vacuum breakers is required for accident mitigation. Failure of the vacuum breakers is not assumed as an accident initiator for any accident previously evaluated. Therefore, any potential failure of a vacuum breaker to perform when necessary will not affect the probability of an accident previously evaluated.

During a LOCA [loss-of-coolant accident], the vacuum breakers are assumed to initially be closed to limit drywell-to-suppression chamber bypass leakage and must be capable of reclosing following a suppression pool swell event. The vacuum breakers open to prevent an excessive negative differential pressure across the suppression chamber-to-drywell boundary. The proposed change will not affect the capability of the vacuum breakers to perform their open and closed safety functions. Therefore, all four vacuum breaker pairs will remain operable and available to mitigate the consequences of a LOCA. Accordingly, the proposed amendment will not significantly increase the consequences of an accident previously evaluated.

The operation of Nine Mile Point Unit 2, in accordance with the proposed amendment, will not create the possibility of a new or different kind of accident from any accident previously evaluated.

The suppression chamber-to-drywell vacuum breakers are used to mitigate the potential consequences of an accident. The proposed change does not affect the capability of the vacuum breakers to perform their open and closed safety functions. Thus, the initial conditions assumed in the accident analysis are not affected. Since the vacuum breakers have demonstrated high reliability, proper functioning of the four vacuum breaker pairs is assured in order to satisfy the current accident analysis. The proposed amendment does not involve a change to plant design and does not involve any new modes of operation or testing methods. Accordingly, the vacuum breakers will continue to perform their accident mitigation safety functions as previously evaluated. Therefore, operation with the proposed amendment will not create the possibility of a new or different kind of accident from any accident previously evaluated.

The operation of Nine Mile Point Unit 2, in accordance with the proposed amendment, will not involve a significant reduction in a margin of safety.

The deferral of functional testing for one vacuum breaker pair for the remainder of Cycle 8 is not risk significant, in that the increase in core damage frequency and large early release frequency were found to be less that 10^{-8}/yr. The vacuum breakers are not modified by the proposed amendment. Reviews of vacuum breaker failure history show that the vacuum breakers have a high reliability to open or close when necessary. Thus, both vacuum breakers in each of the four vacuum breaker lines are expected to remain available to perform their accident mitigation safety functions. Furthermore, the 14-day surveillance that verifies the vacuum breakers are closed will continue to be performed to ensure a potential bypass leakage path is not present. Accordingly, all four vacuum breaker pairs are considered operable. The accident analysis assumptions for the closed safety functions of the vacuum

breakers are satisfied when at least one vacuum breaker in each of the four vacuum breaker lines are fully closed and capable of reclosing following a suppression pool swell event. The additional vacuum breaker in each line satisfies the single failure criterion. The open safety function of the vacuum breakers is satisfied when three of the four vacuum breaker pairs open during a design basis accident. The fourth vacuum breaker pair satisfies the single failure criterion. Since all of the vacuum breakers are considered operable and available to perform their open and closed safety functions, the proposed change will not involve a significant reduction in a margin of safety.

The NRC staff has reviewed the licensee's analysis and, based on this review, it appears that the three standards of 10 CFR 50.92(c) are satisfied. Therefore, the NRC staff proposes to determine that the amendment request involves no significant hazards consideration.

The Commission is seeking public comments on this proposed determination. Any comments received within 14 days after the date of publication of this notice will be considered in making any final determination.

Normally, the Commission will not issue the amendment until the expiration of the 14-day notice period. However, should circumstances change during the notice period, such that failure to act in a timely way would result, for example, in derating or shutdown of the facility, the Commission may issue the license amendment before the expiration of the 14-day notice period, provided that its final determination is that the amendment involves no significant hazards consideration. The final determination will consider all public and State comments received. Should the Commission take this action, it will publish in the **Federal Register** a notice of issuance. The Commission expects that the need to take this action will occur very infrequently.

Written comments may be submitted by mail to the Chief, Rules and Directives Branch, Division of Administrative Services, Office of Administration, U.S. Nuclear Regulatory Commission, Washington, DC 20555–0001, and should cite the publication date and page number of this **Federal Register** notice. Written comments may also be delivered to Room 6D59, Two White Flint North, 11545 Rockville Pike, Rockville, Maryland, from 7:30 a.m. to 4:15 p.m. Federal workdays. Documents may be examined, and/or copied for a fee, at the NRC's Public Document Room, located at One White Flint North, 11555 Rockville Pike (first floor), Rockville, Maryland.

The filing of requests for hearing and petitions for leave to intervene is discussed below.

By September 24, 2001, the licensee may file a request for a hearing with respect to issuance of the amendment to the subject facility operating license and any person whose interest may be affected by this proceeding and who wishes to participate as a party in the proceeding must file a written request for a hearing and a petition for leave to intervene. Requests for a hearing and a petition for leave to intervene shall be filed in accordance with the Commission's ''Rules of Practice for Domestic Licensing Proceedings'' in 10 CFR part 2. Interested persons should consult a current copy of 10 CFR 2.714, which is available at the Commission's Public Document Room, located at One White Flint North, 11555 Rockville Pike (first floor), Rockville, Maryland, or electronically on the Internet at the NRC Web site *http://www.nrc.gov/NRC/CFR/index.html*. If there are problems in accessing the document, contact the Public Document Room Reference staff at 1–800–397–4209, 301–415–4737 or by email to *pdr@nrc.gov*. If a request for a hearing or petition for leave to intervene is filed by the above date, the Commission or an Atomic Safety and Licensing Board, designated by the Commission or by the Chairman of the Atomic Safety and Licensing Board Panel, will rule on the request and/or petition; and the Secretary or the designated Atomic Safety and Licensing Board will issue a notice of hearing or an appropriate order.

As required by 10 CFR 2.714, a petition for leave to intervene shall set forth with particularity the interest of the petitioner in the proceeding, and how that interest may be affected by the results of the proceeding. The petition should specifically explain the reasons why intervention should be permitted with particular reference to the following factors: (1) The nature of the petitioner's right under the Act to be made a party to the proceeding; (2) the nature and extent of the petitioner's property, financial, or other interest in the proceeding; and (3) the possible effect of any order which may be entered in the proceeding on the petitioner's interest. The petition should also identify the specific aspect(s) of the subject matter of the proceeding as to which petitioner wishes to intervene. Any person who has filed a petition for leave to intervene or who has been admitted as a party may amend the petition without requesting leave of the Board up to 15 days prior to the first prehearing conference scheduled in the proceeding, but such an amended petition must satisfy the specificity requirements described above.

Not later than 15 days prior to the first prehearing conference scheduled in the proceeding, a petitioner shall file a supplement to the petition to intervene which must include a list of the contentions which are sought to be litigated in the matter. Each contention must consist of a specific statement of the issue of law or fact to be raised or controverted. In addition, the petitioner shall provide a brief explanation of the bases of the contention and a concise statement of the alleged facts or expert opinion which support the contention and on which the petitioner intends to rely in proving the contention at the hearing. The petitioner must also provide references to those specific sources and documents of which the petitioner is aware and on which the petitioner intends to rely to establish those facts or expert opinion. Petitioner must provide sufficient information to show that a genuine dispute exists with the applicant on a material issue of law or fact. Contentions shall be limited to matters within the scope of the amendment under consideration. The contention must be one which, if proven, would entitle the petitioner to relief. A petitioner who fails to file such a supplement which satisfies these requirements with respect to at least one contention will not be permitted to participate as a party.

Those permitted to intervene become parties to the proceeding, subject to any limitations in the order granting leave to intervene, and have the opportunity to participate fully in the conduct of the hearing, including the opportunity to present evidence and cross-examine witnesses.

If the amendment is issued before the expiration of the 30-day hearing period, the Commission will make a final determination on the issue of no significant hazards consideration. If a hearing is requested, the final determination will serve to decide when the hearing is held.

If the final determination is that the amendment request involves no significant hazards consideration, the Commission may issue the amendment and make it immediately effective, notwithstanding the request for a hearing. Any hearing held would take place after issuance of the amendment.

If the final determination is that the amendment request involves a significant hazards consideration, any hearing held would take place before the issuance of any amendment.

A request for a hearing or a petition for leave to intervene must be filed with the Secretary of the Commission, U.S.

Nuclear Regulatory Commission, Washington, DC 20555–0001, Attention: Rulemakings and Adjudications Staff, or may be delivered to the Commission's Public Document Room, located at One White Flint North, 11555 Rockville Pike (first floor), Rockville, Maryland, by the above date. A copy of the petition should also be sent to the Office of the General Counsel, U.S. Nuclear Regulatory Commission, Washington, DC 20555–0001, and to Mark J. Wetterhahn, Esquire, Winston & Strawn, 1400 L Street, NW., Washington, DC 20005–3502, attorney for the licensee.

Nontimely filings of petitions for leave to intervene, amended petitions, supplemental petitions and/or requests for hearing will not be entertained absent a determination by the Commission, the presiding officer or the presiding Atomic Safety and Licensing Board that the petition and/or request should be granted based upon a balancing of the factors specified in 10 CFR 2.714(a)(1)(i)–(v) and 2.714(d).

For further details with respect to this action, see the application for amendment dated August 17, 2001, which is available for public inspection at the Commission's Public Document Room, located at One White Flint North, 11555 Rockville Pike (first floor), Rockville, Maryland. Publicly available records will be accessible electronically from the Agencywide Documents Access and Management Systems (ADAMS) Public Electronic Reading Room on the Internet at the NRC web site, *http://www.nrc.gov/NRC/ADAMS/index.html.* If you do not have access to ADAMS or if there are problems in accessing the documents located in ADAMS, contact the NRC Public Document Room Reference staff at 1–800–397–4209, 301–415–4737 or by email to pdr@nrc.gov.

Dated at Rockville, Maryland, this 20th day of August 2001.

For the Nuclear Regulatory Commission.

Donna M. Skay,

Project Manager, Section 1, Project Directorate I, Division of Licensing Project Management, Office of Nuclear Reactor Regulation.

[FR Doc. 01–21436 Filed 8–23–01; 8:45 am]

BILLING CODE 7590–01–P

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34–44717; File No. SR–CBOE–2001–43]

Self-Regulatory Organizations; Notice of Filing and Immediate Effectiveness of Proposed Rule Change by the Chicago Board Options Exchange, Inc. Regarding Its Marketing Fee

August 16, 2001.

Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (''Act'')[1] and Rule 19b–4 thereunder,[2] notice is hereby given that on August 1, 2001, the Chicago Board Options Exchange, Inc. (''CBOE'') filed with the Securities and Exchange Commission (''Commission'') the proposed rule change as described in Items I, II, and III below, which Items the CBOE has prepared. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.

I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change

The CBOE proposes to reduce the amount of its marketing fee from $0.40 per contract to $0.00. The text of the proposed rule change is available at the CBOE and at the Commission.

II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, the CBOE included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. The CBOE has prepared summaries, set forth in Sections A, B, and C below, of the most significant aspects of such statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In July 2000, the CBOE imposed a $0.40 per contract marketing fee to collect funds to be used by the appropriate Designated Primary Market Maker (''DPM'') to attract order flow to the CBOE.[3] The CBOE now proposes to reduce the amount of the marketing fee, effective August 1, 2001, to $0.00 per contract. The effect of this fee reduction is that the CBOE is suspending the assessment of the marketing fee. The CBOE is reserving the right to reinstate the marketing fee at a future date. Any reinstatement of the fee would be done pursuant to a rule filing with the Commission.[4]

The CBOE will continue to perform administrative functions under the current marketing fee program until all previously collected funds are distributed. The CBOE also will continue to pay interest on the funds in the DPM marketing fee accounts until these funds are distributed. Effective September 1, 2001, the CBOE also proposes to suspend the $10,000 monthly fee that has been imposed to help cover expenses related to its administration of the marketing fee program.[5] The CBOE expects that this administrative fee will remain suspended until such time as the CBOE determines, if at all, to reinstate the marketing fee described above.[6]

The CBOE believes that the proposed rule change is consistent with Section 6(b) of the Act[7] and furthers the objectives of Section 6(b)(4) of the Act[8] in that it is designed to provide for the equitable allocation of reasonable dues, fees, and other changes among CBOE members.

B. Self-Regulatory Organization's Statement on Burden on Competition

The CBOE does not believe that the proposed rule change will impose any burden on competition not necessary or appropriate in furtherance of purposes of the Act.

C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others

The CBOE neither solicited nor received comments with respect to the proposed rule change.

III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission

Because the CBOE has designated the foregoing proposed rule change as a fee change pursuant to Section 19(b)(3)(A)

[1] 15 U.S.C. 78s(b)(1).

[2] 17 CFR 240.19b–4.

[3] *See* Securities Exchange Act Release No. 43112 (August 3, 2000) 65 FR 49040 (August 10, 2000) (File No. SR–CBOE–2000–28).

[4] The CBOE notes that if it were to reinstate the marketing fee, it could establish a per-contract fee different from the $0.40 currently charged.

[5] *See* Securities Exchange Act Release No. 44469 (June 22, 2001) 66 FR 35301 (July 3, 2001) (File No. SR–CBOE–2001–25).

[6] The CBOE states that any decision to reinstate the administrative fee would be filed with the Commission as a rule change.

[7] 15 U.S.C. 78f(b).

[8] 15 U.S.C. 78f(b)(4).

of the Act [9] and Rule 19b–4(f)(2) thereunder,[10] the proposal has become effective immediately upon filing with the Commission. At any time within 60 days after the filing of this proposed rule change, the Commission may summarily abrogate the rule change if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act.

IV. Solicitation of Comments

The Commission invites interested persons to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549–0609. Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission's Public Reference Room. Copies of such filing will also be available for inspection and copying at the principal office of the CBOE. All submissions should refer to SR–CBOE–2001–43 and should be submitted by September 14, 2001.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority.[11]

Jonathan G. Katz,

Secretary.

[FR Doc. 01–21368 Filed 8–23–01; 8:45 am]

BILLING CODE 8010–01–M

[9] 15 U.S.C. 78s(b)(3)(A).

[10] 17 CFR 240.19b–4(f)(2).

[11] 17 CFR 200.30–3(a)(12).

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34–44719; File No. SR–DTC–2001–01]

Self-Regulatory Organizations; The Depository Trust Company; Notice of Filing and Immediate Effectiveness of Proposed Rule Change Relating to the Filing of Five Service Guides

August 17, 2001.

Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (''Act''),[1] notice is hereby given that on January 24, 2001, The Depository Trust Company (''DTC'') filed with the Securities and Exchange Commission (''Commission'') the proposed rule change as described in Items I, II, and III below, which items have been prepared primarily by DTC. The Commission is publishing this notice to solicit comments on the proposed rule change from interested parties.

1. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change

The proposed rule change consists of the implementation of five Service Guides, which constitute a restatement of certain sections of the Participant Operating Procedures (''POP'') and Participant Terminal System (''PTS'') Manual of DTC. Such sections are being retitled as Service Guides for DTC Custody, Dividend, Reorganization, Settlement, and Underwriting services.[2]

II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, DTC included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. DTC has prepared summaries, set forth in sections (A), (B) and (C) below, of the most significant aspects of these statements.[3]

(A) Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

DTC's POP constitutes procedures of DTC adopted pursuant to its Rule 27. It is a hardcopy multivolume manual that, among other things, provides participants with procedures and information pertaining to a number of DTC services. DTC's PTS Manual, also a hardcopy multivolume manual, describes and documents each function (or user application) of PTS. It serves as a navigational tool or operational guide for authorized users.

DTC determined that both POP and the PTS Manual would better serve participants and other authorized users if they were restated together utilizing modern electronic media. As a result, DTC is developing Service Guides to replace all POP and PTS documentation.

With this proposed rule filing, DTC is filing Service Guides for the following DTC services; Custody, Dividend, Reorganization, Settlement, and Underwriting. DTC intends to file additional Service Guides with the Commission when they are completed. Existing sections of POP and PTS documentation will remain in effect only until such time as they are restated as Service Guides. No substantive changes in the procedures of DTC are being made at this time.

Service Guides are currently organized into four sections:

1. *Using This Guide* contains copyright and disclaimer information plus information on document conventions and the structure and organization of the Service Guide. The language in this section is the same for all Service Guides regardless of service.

2. *About DTC's [Service Name] Guide* is a restatement of POP and contains product overviews, definitions, important dates, and legal information. It has links to the various PTS functions used by the particular service. (See Section 4 below.)

3. *About the Participant Terminal System* provides general PTS overview information such as directions about the use of passwords, logging on and off, and common function keys. The language in this section is the same for all Service Guides regardless of service.

4. *[Service Name] Functions* is a restatement of the PTS Manual. It provides information for each PTS function, including step-by-step PTS procedures together with screen and field definitions. The ''Functions'' and ''About'' sections of every Service Guide are linked.

The five Service Guides will be implemented upon filing and are available to participants and other authorized users via CD ROM (which is comprised of current Service Guide, POP, and PTS Manual information) and the Internet at DTC's web site: *http://*

[1] 15 U.S.C. 78s(b)(1).

[2] A copy of the text of DTC's proposed rule change and the attached exhibit are available at the Commission's Public Reference Section or through DTC.

[3] The Commission has modified the text of the summaries prepared by DTC.

www.dtc.org/. The two formats contain the same information and are similar in functionality. At this time, DTC updates such information on its web site on a monthly basis and distributes CD ROM updates on a quarterly basis.[4]

The proposed rule change is consistent with the requirements of Section 17A of the Act[5] and the rules and regulations thereunder applicable to DTC because the proposed rule change will contribute to the ease of use of DTC's services and PTS. The proposed rule change will be implemented consistently with the safeguarding of securities and funds in DTC's custody or control or for which it is responsible because the proposed rule change enhances the utilization of DTC's existing services.

(B) Self-Regulatory Organization's Statement on Burden on Competition

DTC perceives no adverse impact on competition by reason of the proposed rule change.

(C) Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants or Others

The proposed rule change has been developed through discussions with a number of participants. Written comments from participants or others have not been solicited or received on the proposed rule change.

III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action

The foregoing rule change has become effective pursuant to Section 19(b)(3)(A)(i)[6] of the Act and Rule 19b–4(f)(1)[7] promulgated thereunder because the proposal constitutes a stated policy, practice, or interpretation with respect to the meaning, administration, or enforcement of an existing rule. At any time within sixty days of the filing of such proposed rule change, the Commission may summarily abrogate such rule change if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act.

[4] DTC will provide the Commission with above-mentioned CD ROMs upon issuance each quarter. The Commission has been granted access to those screens on DTC's web site which contain the Service Guides and related information.

[5] 15 U.S.C. 78q–1.

[6] 15 U.S.C. 78s(b)(3)(A)(i).

[7] 17 CFR 240.19b–4(f)(1).

IV. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW., Washington, DC 20549–0609. Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission's Public Reference Section, 450 Fifth Street, NW., Washington, DC 20549. Copies of such filing also will be available for inspection and copying at the principal office of DTC. All submissions should refer to File No. SR–DTC–2001–01 and should be submitted by September 14, 2001.

For the Commission by the Division of Market Regulation, pursuant to delegated authority.[8]

Jonathan G. Katz,

Secretary.

[FR Doc. 01–21370 Filed 8–23–01; 8:45 am]

BILLING CODE 8010–01–M

[8] 17 CFR 200.30–3(a)(12).

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34–44720; File No. SR–NASD–2001–46]

Self-Regulatory Organizations; Notice of Filing of Proposed Rule Change by the National Association of Securities Dealers, Inc. Relating to Electronic Filings With the Corporate Financing Department

August 17, 2001.

Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (''Act''),[1] and Rule 19b–4 thereunder,[2] notice is hereby given that on August 6, 2001, the National Association of Securities Dealers, Inc. (''NASD''), through its wholly-owned subsidiary NASD Regulation, Inc. (''NASD Regulation''), filed with the Securities and Exchange Commission (''SEC'' or ''Commission'') the proposed rule change as described in Items I, II, and III below, which Items have been prepared by NASD Regulation. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.

[1] 15 U.S.C. 78s(b)(1).

[2] 17 CFR 240.19b–4.

I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change

NASD Regulation is proposing to amend Rule 2710 of the Conduct Rules of the NASD (''Corporate Financing Rule'' or ''Rule'') to: (i) require electronic filing of certain information with the Corporate Financing Department (''Department'') with respect to offerings subject to Rules 2710, 2720, and 2810; (ii) provide that all public offering documents that are filed with the Commission's Electronic Data Gathering and Retrieval System (''EDGAR'') will be treated as filed with the Association; and (iii) reduce the number of offering documents that are required to be filed with the Association for members that file manually with the Commission instead of electronically through EDGAR. Below is the text of the proposed rule change. Proposed new language is in italics; proposed deletions are in brackets.

2710. Corporate Financing Rule—Underwriting Terms and Arrangements

(a) No Change.

(b) Filing Requirements

(1)–(4) No Change.

(5) Documents To Be Filed

(A) The following documents relating to all proposed public offerings of securities *that are required to be filed under subparagraph (b)(4) above* shall be filed *with the Association* for review:

([A]*i*) [Five (5)] *Three* copies of the registration statement, offering circular, offering memorandum, notification of filing, notice of intention, application for conversion and/or any other document used to offer securities to the public;

([B]*ii*) Three ([3)] copies of any proposed underwriting agreement, agreement among underwriters, selected dealers agreement, agency agreement, purchase agreement, letter of intent, consulting agreement, partnership agreement, underwriter's warrant agreement, escrow agreement, and any other document which describes the underwriting or other arrangements in connection with or related to the distribution, and the terms and conditions relating thereto; and any other information or documents which

may be material to or part of the said arrangements, terms and conditions and which may have a bearing on the Association's review;

([C]*iii*) [Five (5) *Three* copies of each pre- and post-effective amendment to the registration statement or other offering document, one copy marked to show changes; and three [(3)] copies of any other amended document previously filed pursuant to subparagraphs ([A])*i*) and ([B]*ii*) above, one copy marked to show changes; and

([D]*iv*) Three [(3)] copies of the final registration statement declared effective by the Commission or equivalent final offering docment and a list of the members of the underwriting syndicate, if not indicated therein, and one ([1)] copy of the executed form of the final underwriting documents and any other document submitted to the Association for review.

(B) All documents that are filed with the Commission through the Commission's Electronic Data Gathering and Retrieval System shall be treated as filed with the Association.

(6) Information Required To Be Filed

(A) Any person filing documents [pursuant to subparagraph] *that are required to be filed under paragraph (b)*(4) above shall provide the following information with respect to the offering *through the Association's electronic filing system:*

(i) An estimate of the maximum public offering price;

(ii) An estimate of the maximum underwriting discount or commission; maximum reimbursement of underwriter's expenses, and underwriter's counsel's fees (except for reimbursement of ''blue sky'' fees); maximum financial consulting and/or advisory fees to the underwriter and related persons; maximum finder's fees; and a statement of any other type and amount of compensation which may accrue to the underwriter and related persons;

(iii) a statement of the association or affiliation with any member of any officer, director or security holder of the issuer in an initial public offering of equity securities, and with respect to any other offering provide such information with respect to any officer, director or security holder of five percent or more of any class of the issuer's securities, to include:

a. The identity of the person;

b. The identity of the member and whether such member is participating in any capacity in the public offering; and

c. The number of equity securities or the face value of debt securities owned by such person, the date such securities were acquired, and the price paid for such securities.

(iv) a statement addressing the factors in subparagraphs (c)(4) (C) and (D), where applicable;

(v) a detailed explanation of any other arrangement entered into during the 12-month period immediately preceding the filing of the offering, which arrangement provides for the receipt of any item of value and/or the transfer of any warrants, options, or other securities from the issuer to the underwriter and related persons; [and]

(vi) a detailed explanation and any documents related to the modification of any item of compensation subsequent to the review and approval of such compensation by the Association; [3] *and*

(vii) any other information required by the Association's electronic filing system.

(B) Any person filing documents pursuant to paragraph *(b)*(5) above shall [file with the Association written notice] *notify the association through its electronic filing system* that the offering has been declared effective or approved by the Commission or other agency no later than one business day following such declaration or approval or that the offering has been withdrawn or abandoned within three business days following the withdrawal decision to abandon the offering.

II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, NASD Regulation included statements concerning the purpose of, and basis for, the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. NASD Regulation has prepared summaries, set forth in Sections A, B, and C below, of the most significant aspects of such statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

1. Purpose

Background

The Corporate Financing Rule regulate the underwriting terms and arrangements of public offerings of securities. The Rule requires members to file multiple copies of documents such as registration statements and other supplemental information with the Corporate Financing Department for most public offerings.

The Department reviews the filings to ensure compliance with NASD Rules, including Rules 2710, 2720, and 2810.[4] These rules require underwriters and their counsel to submit specified documents to the Department, such as registration statements and other documents describing the underwriting and other arrangements relating to distributions. The Department receives thousands of packages and letters each year in paper form from underwriters and their counsel. Before the Department deployed its electronic filing system, members and their counsel had to send these documents and information by regular mail, courier or fax.

In June 1999, the Department deployed the Corporate Offerings Business Regulatory Analysis System (''COBRA'') to permit members and their counsel to file information electronically with the Department and to permit the staff to access any documents filed with the SEC through EDGAR. On April 30, 2001, the Department deployed a Web-based application of the COBRA system. The system consists of an internal software application used by the Department and ''Web COBRADesk,'' a user interface that permits members and their counsel to file offerings from their offices over the Internet.

Members' use of the electronic filing system has greatly facilitated the Department's review of filings. Filings made through Web COBRADesk automatically enter the Department's database for review by the staff. By contrast, for paper filings, the staff must manually enter information into the COBRA system, which delays its review.

Web COBRADesk eliminates the need for members to file registration statements with the Department if the registration statement already has been filed with the SEC using EDGAR. Filers simply provide the Department with an EDGAR accession number when they file the original registration statement, subsequent amendments, and final prospectus. COBRA allows the staff to link to each document for review. Using COBRADesk significantly reduces members' printing and delivery expenses related to Corporate Financing

[3] Subparagraphs (i)–(vi) are proposed to be amended in SR–NASD–00–04. *See* Securities Exchange Act Release Nos. 42619 (April 4, 2000), 65 FR 19409 (April 11, 2000); 44044 (March 6, 2001), 66 FR 14949 (March 14, 2001).

[4] NASD Rule 2720 regulates corporate public offerings of securities where a participating member may have a conflict of interest. NASD Rule 2810 regulates public offerings of direct participation program securities.

review. In addition, the system provides each filer with a local electronic database of the information it has filed with the Department. NASD Regulation District examiners, Enforcement staff and other internal users also can access the filing information as needed.

Since its implementation, COBRA has improved the efficiency of the review process for electronic filings, decreased review time, and reduced the amount of paper correspondence and documents that members must file with the Department. The system has operated as a faster and more efficient mechanism for communication between filers and NASD Regulation.

Description of Proposed Amendments

NASD Regulation is proposing to amend NASD Rule 2710(b)(6) to require members to file information required by subparagraph (b)(6) with the Department through its electronic filing system. The obligation to file information electronically that is proposed in subparagraph (b)(6) would apply to all offerings subject to the Rule's filing requirements, regardless of whether the offering is exempt from registration with the SEC or is submitted confidentially to the SEC for review.

NASD Regulation also is proposing to adopt new subparagraph (b)(5)(B) of Rule 2710 to provide that all documents that are filed with the SEC through the EDGAR system shall be treated as filed with the Association. Members that do not file documents with the SEC through EDGAR would remain obligated to continue to submit multiple copies of any required documents in paper format. However, NASD Regulation is proposing to amend NASD Rule 2710(b)(5)(A) (ii) and (iii) to reduce the number of required copies of these documents from five to three.

Implementation

NASD Regulation has hosted several training sessions to provide opportunities for members and their counsel to learn how to file offerings using COBRADesk. In addition, certain Department staff members are dedicated to assisting filers when they access and navigate the system. Prior to and following Commission approval of the proposed rule change, the Department will provide additional training sessions and providing continuing support and assistance to members and their counsel who have questions and are unfamiliar with the system.

The NASD will publish a Notice To Members within 30 days of Commission approval announcing the proposed rule change and providing an effective date within 60 days of Commission approval.

2. Statutory Basis

NASD Regulation believes that the proposed rule change is consistent with the provisions of Section 15A(b)(6) of the Act,[5] which requires, among other things, that the Association's rules be designed to prevent fraudulent and manipulative acts and practices, to promote just and equitable principles of trade, and, in general, to protect investors and the public interest. NASD Regulation believes that the proposed rule change will facilitate the Association's review of public offerings of securities and assist the Association to maintain a confidential, nonpublic database of information related to such filings.

B. Self-Regulatory Organization's Statement on Burden on Competition

NASD Regulation does not believe that the proposed rule change will result in any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act.

C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others

Written comments were neither solicited nor received.

III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action

Within 35 days of the date of publication of this notice in the **Federal Register** or within such longer period (i) as the Commission may designate up to 90 days of such date if it finds such longer period to be appropriate and publishes its reasons for so finding or (ii) as to which NASD Regulation consents, the Commission will:

(A) by order approve such proposed rule change, or

(B) institute proceedings to determine whether the proposed rule change should be disapproved.

IV. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposal is consistent with the Act. Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW., Washington, DC 20549–0609. Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission's Public Reference Room. Copies of the filing will also be available for inspection and copying at the principal office of the NASD. All submissions should refer to the File No. SR–NASD–2001–46 and should be submitted by September 14, 2001.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority.[6]

Jonathan G. Katz,

Secretary.

[FR Doc. 01–21369 Filed 8–23–01; 8:45 am]

BILLING CODE 8010–01–M

[5] 15 U.S.C. 78*o*–3.

[6] 17 CFR 200.30–3(a)(12).

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34–44723; File No. SR–OCC–2001–03]

Self-Regulatory Organizations; The Options Clearing Corporation; Notice of Filing of Proposed Rule Change To Rescind Concentration Restrictions on Letters of Credit Issued by Certain Non-U.S. Institutions

August 20, 2001.

Pursuant to section 19(b)(1) of the Securities Exchange Act of 1934 (''Act''),[1] notice is hereby given that on April 11, 2001, the Options Clearing Corporation (''OCC'') filed with the Securities and Exchange Commission (''Commission'') the proposed rule change as described in Items I, II, and III below, which items have been prepared primarily by OCC.[2] The Commission is publishing this notice to solicit comments on the proposed rule change from interested parties.

I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change

The proposed rule change would rescind the concentration restrictions on letters of credit issued by certain non-U.S. institutions.

[1] 15 U.S.C. 78s(b)(1).

[2] A copy of OCC's proposed rule change is available at the Commission's Public Reference Section or through OCC.

II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, OCC included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. OCC has prepared summaries, set forth in sections (A), (B), and (C) below, of the most significant aspects of these statements.[3]

(A) Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

The purpose of the proposed rule change is to rescind the concentration restrictions placed upon letters of credit issued by a non-U.S. institution where the issuing institution has qualified as a financial holding company under Regulation Y of the Board of Governors of the Federal Reserve System (''Fed'') or is an institution owned by or under the control of such a financial holding company.

OCC began accepting letters of credit from non-U.S. institutions in January 1983 in response to concerns that U.S. institutions were increasing their fees to clearing members or were otherwise reducing their overall commitment to financing clearing members. A combination of factors led OCC to impose more stringent qualification standards on non-U.S. institutions than on U.S. institutions issuing letters of credit for the benefit of OCC.[4] The qualification standards generally are found in Sections .01 through .08 of the Interpretations and Policies under OCC Rule 604.

OCC has recently completed a reassessment of these standards to ensure that they remain appropriate and achieve their intended purposes. We have concluded that with the enactment of the Gramm-Leach-Bliley financial Modernization Act of 1999 (''GLB'')[5] and the Fed amendments to Regulation Y implementing GLB, the concentration restrictions found in Interpretations and Policies .02 should be rescinded for certain non-U.S. institutions.

GLB created a new type of holding company called a ''financial holding company'' and specified certain eligibility requirements for such institutions.[6] To become a financial holding company, GLB requires a bank holding company to submit a declaration to the Fed that the company elects to be a financial holding company and a certification that all of the depository institutions controlled by the company are well capitalized and well managed. Under GLB, foreign banks are specifically permitted to qualify as financial holding companies. GLB also requires the Fed to apply comparable capital and management standards to such banks that are comparable to those applied to U.S. banks owned by a financial holding company, giving due regard to certain enumerated principles.

The Fed has amended Regulation Y in order to implement provisions of the GLB Act governing the creation and conduct of financial holding companies.[7] Section 225.90 sets forth requirements that a foreign bank must meet for purposes of qualifying as a financial holding company, including capitalization and management tests.[8] The well-capitalized test includes risk based capital assessments.[9] The well-managed test requires the foreign bank to receive satisfactory Fed regulatory ratings, to receive the consent of its home country supervisor to the expansion of its U.S. activities, and to meet management standards comparable to those required of a U.S. bank owned by a financial holding company.[10] A foreign bank's election to be treated as a financial holding company is effective on the thirty-first day after the date that the election was received by the appropriate Federal Reserve Bank unless the applicant receives prior written notice that its election is effective or the applicant is notified that the election is ineffective.[11]

OCC believes that the Fed's regulatory policies governing the qualification of foreign banks as financial holding companies provide sufficient safeguards as to the creditworthiness of such institutions and the collectibility of letters of credit issued by them to warrant rescinding the concentration restrictions currently imposed on such institutions. Letters of credit issued by non-U.S. institutions currently represent only 3.2% of total margin deposits,[12] and OCC does not believe that rescinding the concentration requirements for qualified non-U.S. financial holding companies will materially increase its exposure to letters of credit issued by non-U.S. institutions specifically or letters of credit generally.

The proposed rule change is consistent with section 17A of the Act because it would facilitate the prompt and accurate clearance and settlement of securities transactions and should allow OCC to safely keep funds and securities while allowing non-U.S. institutions that have qualified as financial holding companies to compete on an equal footing with U.S. institutions for purposes of issuing letters of credit on behalf of clearing members.

(B) Self-Regulatory Organization's Statement on Burden on Competition

OCC does not believe that the proposed rule change would impose any burden on competition.

(C) Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants or Others

Written comments were not and are not intended to be solicited with respect to the proposed rule change, and none have been received.

III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action

Within thirty-five days of the date of publication of this notice in the **Federal Register** or within such longer period (i) as the Commission may designate up to ninety days of such date if it finds such longer period to be appropriate and publishes its reasons for so finding or (ii) as to which the self-regulatory

[3] The Commission has modified the text of the summaries prepared by OCC.

[4] Those factors included concerns about the diversity of regulatory structures, exposure to economic or political risk outside of the United States, and OCC's relative inexperience in dealing with non-U.S. institutions. Securities Exchange Act Release No. 19422 (January 12, 1983), 48 FR 2481 [File No. SR–OCC–82–8] (formalizing certain OCC criteria for approving domestic and foreign banks as issuers of letters of credit for margin purposes).

[5] Gramm-Leach-Bliley Financial Modernization Act of 1999, Pub. L. No. 106–102, 113 Stat. 1338 (1999).

[6] Qualified financial holding companies may engage in securities, insurance, and other activities that are financial in nature or incidental to a financial activity. 50 FR 14433.

[7] See 66 FR 399 (January 3, 2001) (Board of Governors of the Federal Reserve Board adopting a final rule to amend Regulation Y to implement the financial holding company provisions of the GLB).

[8] Section 225.93 sets forth provisions that are applicable should a foreign bank fail to meet the applicable capital and management standards and specifies the consequences of such failure. Consequences include being required to execute an agreement with the Fed providing for a schedule of actions to be taken by the foreign bank to become compliant and, if the foreign bank is unable to meet such schedule, being subjected to an order requiring the divestiture or termination of certain business in the United States. Section 12 CFR 225.93 (2000).

[9] Section 12 CFR 225.90(b) (2000).

[10] Section 12 CFR 225.90(c) (2000).

[11] Section 12 CFR 225.92 (2000). The Fed publishes a list of effective financial holding company elections on its web site. As of January 2001, 13 out of 32 non-U.S. Institutions approved by OCC to issue letters of credit have qualified as financial holding companies.

[12] Letters of credit currently represent only 11.9% of total margin deposits.

organization consents, the Commission will:

(A) by order approve such proposed rule change or

(B) institute proceedings to determine whether the proposed rule change should be disapproved.

IV. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW., Washington, DC 20549–0609. Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission's Public Reference Section, 450 Fifth Street, NW., Washington, DC 20549. Copies of such filing also will be available for inspection and copying at the principal office of OCC. All submissions should refer to File No. SR–OCC–2001–03 and should be submitted by September 14, 2001.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority.

Jonathan G. Katz,

Secretary.

[FR Doc. 01–21421 Filed 8–23–01; 8:45 am]

BILLING CODE 8010–01–M

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34–44722; File No. SR–SCCP–2001–04]

Self-Regulatory Organizations; The Stock Clearing Corporation of Philadelphia; Order Granting Approval of a Proposed Rule Change Establishing Fines for Late Margin Call Payments and an Appeal for Such Fines

August 20, 2001.

On February 27, 2001, the Stock Clearing Corporation of Philadelphia (''SCCP'') filed with the Securities and Exchange Commission (''Commission'') a proposed rule change (File No. SR–SCCP–2001–04) pursuant to section 19(b)(1) of the Securities Exchange Act of 1934 (''Act'').[1] Notice of the proposed rule change was published in the **Federal Register** on May 29, 2001.[2] No comment letters were received. For the reasons discussed below, the Commission is granting approval of the proposed rule change.

I. Description

The purpose of the filing is to implement a fine schedule for SCCP margin members who are late meeting a margin call payment. The proposed rule change is intended to encourage the timely payments of margin calls. Rule 9 provides, in part, that SCCP will provide margin accounts for margin members that clear and settle their transactions through SCCP's omnibus clearance and settlement account. SCCP provides margin for such accounts based on its procedures and Regulation T of the Board of Governors of the Federal Reserve System. Margin members who are designated as specialists or alternate specialists in a security receive margin credit of 15% with respect to positions in that security held in their specialist accounts. Members holding positions for which they are not designated as a specialist or alternate specialist receive non-specialist margin credit of 50%. SCCP may issue margin calls to any margin member when the margin requirement exceeds the account equity. Pursuant to SCCP procedures, margin call payments are due by 12:00 p.m. EST the business day of the call. Late margin payments are not currently subject to a specific late fine although members may be subject to possible disciplinary action pursuant to SCCP Rule 22.

SCCP believes that implementation of the proposed fine schedule will reduce the number of incidents of later margin call payments by members. Notwithstanding the late margin call payment fine, members would continue to be subject to possible disciplinary action pursuant to SCCP Rule 22.

Currently, Rule 23 provides, in relevant part, a SCCP participant[3] with the right to appeal from any decision or decisions of SCCP resulting in sanctions or penalties imposed under Rule 20 or 22.[4] SCCP proposes to include fines imposed under Rule 9 to the list of applicable actions specified in Rule 23.

II. Discussion

Section 17A(b)(3)(F) of the Act requires that the rules of a clearing agency be designed to assure the safeguarding of securities and funds which are in the clearing agency's custody or control or for which it is responsible. The rule change allows SCCP to fine members for making later margin payments. Implementing the fine schedule should encourage margin members to submit margin payments in a timely manner thereby providing SCCP with adequate collections so that it may fulfill its safeguarding obligations. Therefore, the Commission finds that SCCP's proposed rule change is consistent with section 17A of the Act and the rules and regulations thereunder.

III. Conclusion

On the basis of the foregoing, the Commission finds that the proposed rule change is consistent with the requirements of the Act and in particular section 17A of the Act and the rules and regulations thereunder.

It Is Therefore Ordered, pursuant to section 19(b)(2) of the Act, that the proposed rule change (File No. SR–SCCP–2001–04) be and hereby is approved.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority.[5]

Jonathan G. Katz,

Secretary.

[FR Doc. 01–21420 Filed 8–23–01; 8:45 am]

BILLING CODE 8010–01–M

[1] 15 U.S.C. 78s(b)(1).

[2] Securities Exchange Act Release No. 44334 (May 22, 2001), 66 FR 29199.

[3] The term ''participants'' means persons or organizations which have qualified for membership in SCCP pursuant to SCCP Rules 2 and 3. Participants are also referred to in SCCP Rules as ''members.''

[4] SCCP Rule 23 Section 1(c).

[5] 17 CFR 200.30–3(a)(12).

SMALL BUSINESS ADMINISTRATION

Office of the National Ombudsman

Tri-Regional Regulatory Fairness Board Town Hall Meeting

The Office of the National Ombudsman, U.S. Small Business Administration, will convene a Town Hall Meeting on Wednesday, August 29, 2001, from 3:00–5:30 pm EST, at the Hyatt Regency, One Goat Island, Newport, RI, 02840, to hear comments and/or complaints from small businesses and representatives of trade associations concerning potentially unfair regulatory enforcement or compliance actions taken by Federal agencies.

Anyone wishing to attend and make comments must contact James Van

Wert, Acting National Ombudsman, U.S. Small Business Administration, 409 3rd Street, SW, Washington, DC 20416, no later than August 24, 2001 via telephone (202) 205–2417 e-mail ombudsman@sba.gov or fax (202) 481–5719.

Steve Tupper,

Committee Management Officer.

[FR Doc. 01–21350 Filed 8–23–01; 8:45 am]

BILLING CODE 8025–01–P

DEPARTMENT OF TRANSPORTATION

Maritime Administration

[Docket No. MARAD–2001–10456]

Information Collection Available for Public Comments and Recommendations

ACTION: Notice and request for comments.

SUMMARY: In accordance with the Paperwork Reduction Act of 1995, this notice announces the Maritime Administration's (MARAD's) intentions to request extension of approval for three years of a currently approved information collection.

DATES: Comments should be submitted on or before October 23, 2001.

FOR FURTHER INFORMATION CONTACT: Philip Budwick, Maritime Administration, MAR 226, 400 Seventh Street, SW., Washington, DC 20590. Telephone: 202–366–5167 or FAX: 202–366–7485. Copies of this collection can also be obtained from that office.

SUPPLEMENTARY INFORMATION:

Title of Collection: Requirements for Establishing U.S. Citizenship.

Type of Request: Extension of currently approved information collection.

OMB Control Number: 2133–0012.

Form Numbers: Special Format.

Expiration Date of Approval: March 31, 2002.

Summary of Collection of Information: In accordance with the Merchant Marine Act, 1936, participants in the various programs offered by the Maritime Administration (MARAD) must be citizens of the United States within the meaning of Section 2 of the Shipping Act, 1916, as amended. In addition, the participants in the programs must file annually an affidavit with MARAD attesting to their continuing citizenship.

Need and Use of the Information: MARAD will review the Affidavits of U.S. Citizenship to determine if the applicants are eligible to participate in the programs offered by agency.

Annual Responses: 300.

Annual Burden: 1,500 hours.

Comments: Comments should refer to the docket number that appears at the top of this document. Written comments may be submitted to the Docket Clerk, U.S. DOT Dockets, Room PL–401, 400 Seventh Street, SW., Washington, DC 20590. Comments may also be submitted by electronic means via the Internet at *http://dmses.dot.gov/submit.* Specifically address whether this information collection is necessary for proper performance of the functions of the agency and will have practical utility, accuracy of the burden estimates, ways to minimize this burden, and ways to enhance the quality, utility, and clarity of the information to be collected. All comments received will be available for examination at the above address between 10 a.m. and 5 p.m. EDT, Monday through Friday, except Federal Holidays. An electronic version of this document is available on the World Wide Web at *http://dms.dot.gov.*

Dated: August 20, 2001.

By order of the Maritime Administrator.

Joel C. Richard,

Secretary.

[FR Doc. 01–21463 Filed 8–23–01; 8:45 am]

BILLING CODE 4910–81–P

DEPARTMENT OF TRANSPORTATION

National Highway Traffic Safety Administration

[Docket NHTSA–99–5087]

Safety Performance Standards Program Meeting

AGENCY: National Highway Traffic Safety Administration (DOT).

ACTION: Notice of NHTSA Rulemaking Status Meeting.

SUMMARY: This notice announces a public meeting at which NHTSA will answer questions from the public and the automobile industry regarding the agency's vehicle regulatory program.

DATES: The Agency's regular public meeting relating to its vehicle regulatory program will be held on Wednesday, November 14, 2001, beginning at 9:45 a.m. and ending at approximately 12:00 p.m. at the Best Western Gateway International Hotel, 9191 Wickham, Romulus, Michigan. Questions relating to the vehicle regulatory program must be submitted in writing with a diskette (Microsoft Word) by Monday, October 22, 2001, to the address shown below or by e-mail. If sufficient time is available, questions received after October 22, may be answered at the meeting. The individual, group or company submitting a questions(s) does not have to be present for the questions(s) to be answered. A consolidated list of the questions submitted by October 22, 2001, and the issues to be discussed, will be posted on NHTSA's web site (www.nhtsa.dot.gov) by Friday, November 9, 2001, and also will be available at the meeting. The agency will hold a second public meeting on November 14, devoted exclusively to a presentation of research and development programs. This meeting will begin at 1:30 p.m. and end at approximately 5:00 p.m. This meeting is described more fully in a separate announcement. The next NHTSA Public Meeting will take place on Thursday, March 14, 2002, at the Best Western Gateway International Hotel, 9191 Wickham, Romulus, Michigan.

ADDRESSES: Questions for the November 14, NHTSA Rulemaking Status Meeting, relating to the agency's vehicle regulatory program, should be submitted to Delia Lopez, NPS–01, National Highway Traffic Safety Administration, Room 5401, 400 Seventh Street, SW., Washington, DC 20590, Fax Number 202–366–4329, e-mail dlopez@nhtsa.dot.gov. The meeting will be held at the Best Western Gateway International Hotel, 9191 Wickham, Romulus, Michigan. The telephone number for the Gateway International Hotel is 734–728–2800.

FOR FURTHER INFORMATION CONTACT: Delia Lopez, (202) 366–1810.

SUPPLEMENTARY INFORMATION: NHTSA holds regular public meetings to answer questions from the public and the regulated industries regarding the agency's vehicle regulatory program. Questions on aspects of the agency's research and development activities that relate directly to ongoing regulatory actions should be submitted, as in the past, to the agency's Safety Performance Standards Office. Transcripts of these meetings will be available for public inspection in the DOT Docket in Washington, DC, within four weeks after the meeting. Copies of the transcript will then be available at ten cents a page, (length has varied from 80 to 150 pages) upon request to DOT Docket, Room PL–401, 400 Seventh Street, SW., Washington, DC 20590. The DOT Docket is open to the public from 10:00 a.m. to 5:00 p.m. The transcript may also be accessed electronically at *http://dms.dot.gov,* at docket NHTSA–99–5087. Questions to be answered at the public meeting should be organized by categories to help us process the

questions into an agenda form more efficiently.

Sample format:

I. Rulemaking
A. Crash avoidance
B. Crashworthiness
C. Other Rulemakings
II. Consumer Information
III. Miscellaneous

NHTSA will provide auxiliary aids to participants as necessary. Any person desiring assistance of ''auxiliary aids'' (*e.g.* sign-language interpreter, telecommunications devices for deaf persons (TDDs), readers, taped texts, brailled materials, or large print materials and/or a magnifying device), please contact Delia Lopez on (202) 366–1810, by COB Friday, November 9, 2001.

Issued: August 20, 2001.

Stephen R. Kratzke,

Associate Administrator for Safety Performance Standards.

[FR Doc. 01–21456 Filed 8–23–01; 8:45 am]

BILLING CODE 4910–59–P

DEPARTMENT OF TRANSPORTATION

National Highway Traffic Safety Administration

[Docket No. NHTSA 2001–10382; Notice 1]

International Truck and Engine Corporation; Receipt of Application for Decision of Inconsequential Noncompliance

International Truck and Engine Corporation (International) of Fort Wayne, Indiana, has determined that approximately 801 vehicles produced from January 1, 1986, through January 16, 2001, are noncompliant with paragraphs 5.1.1 of Federal Motor Vehicle Safety Standard (FMVSS) No. 120, ''Tire Selection and Rims for Motor Vehicles Other Than Passenger Cars.''

Pursuant to 49 U.S.C. 30118(d) and 30120(h), International has petitioned for a determination that this noncompliance is inconsequential to motor vehicle safety and has filed an appropriate report pursuant to 49 CFR Part 573, ''Defect and Noncompliance Reports.''

This notice of receipt of an application is published under 49 U.S.C. 30118 and 30120 and does not represent any agency decision or other exercise of judgment concerning the merits of the application.

International built 801 vehicles with 295/75R22.5 tires mounted on 7.50-inch wide rims. Paragraph S5.1.1 of FMVSS No. 120 requires that vehicles be equipped with rims that are listed as suitable for use with the tires that are mounted on them in accordance with paragraph S5.1 of FMVSS No. 119, ''New Pneumatic Tires for Vehicles other than Passenger Cars.'' Paragraph S 5.1 of FMVSS No. 119 requires that a listing of the dimensions of the rims that may be used with each tire be provided to the public. This requirement is met if the information concerning tire and rim size matching is published in ''The Tire and Rim Association, Inc.'' (T&RA) Yearbook. According to T&RA, the approved rim widths for the 295/75/R22.5 tires are 8.25—9.00 inches.

International states that the T&RA approved rim widths are based on an engineering guideline that the rim width should be 70 to 80 percent of the tire section width. It also cites a statement in the T&RA Yearbook that the effect of using rims of different than the design rim width is to change the tire section width by 0.1 inch for each 0.25 inch change in rim width. Consequently the 7.5 inch rim width is 67 percent of the reduced tire section width of 11.13 inches. International concludes that the 7.5 inch rim width provides 95 percent of the recommended rim width for the tire.

The petitioner has corrected its tire wheel assembly instruction charts and, as of January 17, 2001, no longer produces this noncompliant tire and wheel combination.

International states that the noncompliance of the 295/75R22.5 tires being mounted on the 7.5'' wheel is inconsequential as it relates to motor vehicle safety for the following reasons:

1. International customers have operated vehicles of various model types for 15 years, with this combination of tire and wheel, with no reported problems.

2. International has corrected its tire wheel assembly instruction charts and as of 1/17/01, will no longer produce this non-compliant tire and wheel combination.

3. Many of these vehicles may have likely gone through several tire replacement cycles without reported problems.

Interested persons are invited to submit written data, views, and arguments on the application described above. Comments should refer to the docket and notice number and be submitted to: U.S. Department of Transportation, Docket Management, Room PL–401, 400 Seventh Street, SW, Washington, DC, 20590. It is requested that two copies be submitted.

All comments received before the close of business on the closing date indicated below will be considered. The application and supporting materials, and all comments received after the closing date, will also be filed and will be considered to the extent possible. When the application is granted or denied, a notice will be published in the **Federal Register** pursuant to the authority indicated below. Comment closing date: September 24, 2001.

(49 U.S.C. 301118, 301120; delegations of authority at 49 CFR 1.50 and 501.8)

Issued on: August 20, 2001.

Stephen R. Kratzke,

Associate Administrator for Safety Performance Standards.

[FR Doc. 01–21455 Filed 8–23–01; 8:45 am]

BILLING CODE 4910–59–P

DEPARTMENT OF TRANSPORTATION

National Highway Traffic Safety Administration

[DOCKET No. NHTSA–01–10411; NOTICE 1]

Reliance Trailer Company, LLC ; Receipt of Application for Decision of Inconsequential Noncompliance

Reliance Trailer Company, LLC, of Spokane, Washington, determined that 26 of its dump body trailers failed to comply with Federal Motor Vehicle Safety Standard (FMVSS) No. 224, ''Rear Impact Protection,'' and has applied to be exempted from the notification and remedy requirements of 49 U.S.C. Chapter 301 ''Motor Vehicle Safety'' on the basis that the noncompliance is inconsequential to motor vehicle safety. Reliance has filed an appropriate report of noncompliance pursuant to 49 CFR Part 573 ''Defects and Noncompliance Reports.''

This notice of receipt of an application is published under 49 U.S.C. 30118 and 30120 and does not represent any agency decision or other exercise of judgement concerning the merits of the application.

On May 29, 2001, Reliance filed a petition for inconsequential noncompliance after it determined that 26 dump body trailers it manufactured may not comply with FMVSS No. 224, ''because their wheels were located farther ahead of the 12″ wheels back dimension.''

Description of Noncompliance and Reasons of Exemption

Reliance stated:

We are a small, Pacific Northwest, custom trailer manufacturer (LLC in Washington State) with a small (38 person) operation, in Western Washington, that builds aggregate hauling equipment for road building and construction industries.

1. FMVSS 224 Compliance Problems

Asphalt laydown equipment have hoppers into which our vehicle dumps the hot mix and the various types require our rear axles to be set ahead of the trailer rear 16″–18.″ This location is farther than the 12″ ''wheels back'' measurement, so an under-ride device should be installed. However, any device behind the tires will interfere with this operation unless it can be moved out of the way when this dumping takes place.

Currently, no one has been able to get paver manufacturers to revise, or users to retrofit all their equipment so the under-ride could be accommodated. Additionally, no vehicle manufacturer has come up with a reasonably durable, cost effective, movable guard that is not too heavy, too expensive to maintain.

2. Competitors' Exemption

Docket #NHTSA–98–3848, Notice 2, Grant of Petition

Docket #NHTSA–98–3848, Notice 3, Petition for Renewal

Docket #NHTSA–98–3848, Notice 4, Grant of Petition

Beall Trailers of Washington, Inc. was granted an exemption. All the details in those dockets are similar to ours and we compete with them directly for this type of business.

3. Similar ''Paver'' Exemption

Docket #NHTSA–2001–8827 Notice 2, Grant of Petition

Dan Hill and Associates, Inc. and Red River Manufacturing, Inc. received an exemption published April 18, 2001, which expires April, 2003, for trailers those two competitors build. They have similar interference problems with paving equipment. Their experiences in designing and constructing guards, that will work, show how difficult this is.

4. Vehicle Use and Exposure on Highways

Very small quantities of these vehicles are built each year. Typical hauls are short and have minimal amount of time traveling on highways compared with most freight trailers.

Asphalt batch plants are typically set up close to the paving activities so vehicles spend little time traveling on roads to the paving site. Often, special temporary access, off highways, is provided for paving operations, which also diminishes the exposure for these vehicles.

We know of no rear end collisions, involving injuries, with this type of trailer.

5. Under-ride Guard and Research Activities

We are beginning a review of paving equipment that these trailers mate with to determine if they can be retrofitted or modified to accommodate trailers with tires located within 12″ of the rear. With this survey, we will determine how a fixed rear guard interferes and what requirements will be necessary for swing up or retractable guards.

Based on this, Reliance will aggressively proceed to design, build, test and provide prototypes to determine the feasibility and usefulness of these devices.

Hot asphalt build-up on any moving parts may require frequent cleaning or maintenance and will need to be analyzed carefully so these devices will work.

Frequent impacts, while contacting the paver, are a serious consideration that can affect the integrity of the guard.

Based upon the foregoing, we are asking to be granted an Exemption for Inconsequential Noncompliance.

Separately, Reliance submitted a Petition for a Temporary Exemption from FMVSS No. 224 (66 FR 36989).

Interested persons are invited to submit written data, views and arguments on the petition of Reliance, described above. Comments should refer to the Docket Number and be submitted to: Docket Management, National Highway Traffic Safety Administration, Room PL 401, 400 Seventh Street, SW., Washington, DC 20590. It is requested that two copies be submitted.

All comments received before the close of business on the closing date indicated below will be considered. The application and supporting materials, and all comments received after the closing date will also be filed and will be considered to the extent practicable. When the application is granted or denied, a notice will be published in the **Federal Register** pursuant to the authority indicated below.

Comment closing date: September 24, 2001.

(49 U.S.C. 30118, 30120; delegations of authority at 49 CFR 1.50 and 49 CFR 501.8)

Issued on: August 20, 2001.

Stephen R. Kratzke,

Associate Administrator for Safety Performance Standards.

[FR Doc. 01–21454 Filed 8–23–01; 8:45 am]

BILLING CODE 4910–59–P

DEPARTMENT OF TRANSPORTATION

Surface Transportation Board

[STB Docket No. AB–55 (Sub–No. 596X)]

CSX Transportation, Inc.—Abandonment Exemption—in Lorain County, OH

CSX Transportation, Inc. (CSXT) has filed a notice of exemption under 49 CFR 1152 Subpart F—*Exempt Abandonments* to abandon a 1.17-mile line of railroad between milepost BJ–161.00 and milepost BJ–162.17 in Lorain, Lorain County, OH. The line traverses United States Postal Service Zip Code 44052.

CSXT has certified that: (1) no local traffic has moved over the line for at least 2 years; (2) there has been no overhead traffic on the line; (3) no formal complaint filed by a user of rail service on the line (or by a state or local government entity acting on behalf of such user) regarding cessation of service over the line either is pending with the Surface Transportation Board (Board) or with any U.S. District Court or has been decided in favor of complainant within the 2-year period; and (4) the requirements at 49 CFR 1105.7 (environmental reports), 49 CFR 1105.8 (historic reports), 49 CFR 1105.11 (transmittal letter), 49 CFR 1105.12 (newspaper publication), and 49 CFR 1152.50(d)(1) (notice to governmental agencies) have been met.

As a condition to this exemption, any employee adversely affected by the abandonment and discontinuance shall be protected under *Oregon Short Line R. Co.—Abandonment—Goshen,* 360 I.C.C. 91 (1979). To address whether this condition adequately protects affected employees, a petition for partial revocation under 49 U.S.C. 10502(d) must be filed. Provided no formal expression of intent to file an offer of financial assistance (OFA) has been received, this exemption will be effective on September 25, 2001, unless stayed pending reconsideration. Petitions to stay that do not involve environmental issues,[1] formal expressions of intent to file an OFA under 49 CFR 1152.27(c)(2),[2] and trail use/rail banking requests under 49 CFR 1152.29 must be filed by September 4, 2001. Petitions to reopen or requests for public use conditions under 49 CFR 1152.28 must be filed by September 13, 2001, with: Surface Transportation Board, Office of the Secretary, Case Control Unit, 1925 K Street, N.W., Washington, DC 20423.

A copy of any petition filed with the Board should be sent to CSXT's representative: Natalie S. Rosenberg, Counsel, CSX Transportation, Inc., 500 Water Street J150, Jacksonville, FL 32202.

If the verified notice contains false or misleading information, the exemption is void *ab initio.*

CSXT has filed an environmental report which addresses the effects, if any, of the abandonment and discontinuance on the environment and historic resources. SEA will issue an environmental assessment (EA) by

[1] The Board will grant a stay if an informed decision on environmental issues (whether raised by a party or by the Board's Section of Environmental Analysis (SEA) in its independent investigation) cannot be made before the exemption's effective date. *See Exemption of Out-of-Service Rail Lines,* 5 I.C.C.2d 377 (1989). Any request for a stay should be filed as soon as possible so that the Board may take appropriate action before the exemption's effective date.

[2] Each offer of financial assistance must be accompanied by the filing fee, which currently is set at $1000. *See* 49 CFR 1002.2(f)(25).

August 31, 2001. Interested persons may obtain a copy of the EA by writing to SEA (Room 500, Surface Transportation Board, Washington, DC 20423) or by calling SEA, at (202) 565–1545. Comments on environmental and historic preservation matters must be filed within 15 days after the EA becomes available to the public.

Environmental, historic preservation, public use, or trail use/rail banking conditions will be imposed, where appropriate, in a subsequent decision.

Pursuant to the provisions of 49 CFR 1152.29(e)(2), CSXT shall file a notice of consummation with the Board to signify that it has exercised the authority granted and fully abandoned its line. If consummation has not been effected by CSXT's filing of a notice of consummation by August 24, 2002, and there are no legal or regulatory barriers to consummation, the authority to abandon will automatically expire.

Board decisions and notices are available on our website at *www.stb.dot.gov.*

Decided: August 16, 2001.

By the Board, David M. Konschnik, Director, Office of Proceedings.

Vernon A. Williams,

Secretary.

[FR Doc. 01–21332 Filed 8–23–01; 8:45 am]

BILLING CODE 4915–00–P

DEPARTMENT OF THE TREASURY

Submission for OMB Review; Comment Request

August 17, 2001.

The Department of Treasury has submitted the following public information collection requirement(s) to OMB for review and clearance under the Paperwork Reduction Act of 1995, Public Law 104–13. Copies of the submission(s) may be obtained by calling the Treasury Bureau Clearance Officer listed. Comments regarding this information collection should be addressed to the OMB reviewer listed and to the Treasury Department Clearance Officer, Department of the Treasury, Room 2110, 1425 New York Avenue, NW., Washington, DC 20220.

DATES: Written comments should be received on or before September 24, 2001 to be assured of consideration.

Financial Crimes Enforcement Network (FinCEN)

OMB Number: 1506–0006.

Form Number: TD F 90–22.49.

Type of Review: Extension.

Title: Suspicious Activity Report by Casinos.

Description: Nevada casinos will file Form TD F 90–22.49 after a customer or individual conducts a potentially suspicious transaction or activity, pursuant to Nevada Commission Regulation 6A, Section 100, authorities, during the course of investigations involving financial crimes.

Respondents: Individuals or households, Business or other for-profit.

Estimated Number of Respondents/ Recordkeepers: 110.

Estimated Burden Hours Per Respondent/Recordkeeping: 31 minutes.

Frequency of Response: Other (as required).

Estimated Total Reporting/ Recordkeeping Burden: 64 hours.

Clearance Officer: Lois K. Holland, Departmental Offices, Room 2110, 1425 New York Avenue, NW., Washington, DC 20220; (202) 622–1563.

OMB Reviewer: Alexander T. Hunt, Office of Management and Budget, Room 10202, New Executive Office Building, Washington, DC 20503; (202) 395–7860.

Lois K. Holland,

Departmental Reports, Management Officer.

[FR Doc. 01–21364 Filed 8–23–01; 8:45 am]

BILLING CODE 4810–31–P

DEPARTMENT OF THE TREASURY

Submission for OMB Review; Comment Request

August 16, 2001.

The Department of Treasury has submitted the following public information collection requirement(s) to OMB for review and clearance under the Paperwork Reduction Act of 1995, Public Law 104–13. Copies of the submission(s) may be obtained by calling the Treasury Bureau Clearance Officer listed. Comments regarding this information collection should be addressed to the OMB reviewer listed and to the Treasury Department Clearance Officer, Department of the Treasury, Room 2110, 1425 New York Avenue, NW., Washington, DC 20220.

DATES: Written comments should be received on or before September 24, 2001 to be assured of consideration.

Internal Revenue Service

OMB Number: 1545–0074.

Form Number: IRS Form 1040 and Schedules A, B, C, C–EZ, D, D–1, E, EIC, F, H, J, R, and SE.

Type of Review: Revision.

Title: U.S. Individual Income Tax Return.

Description: Form 1040 and schedules are used by individuals to report their income tax liability. The data is used to verify that the items reported on the forms are correct, and also for general statistical use.

Respondents: Individuals or households.

Estimated Number of Respondents/ Recordkeepers: 71,097,253.

Estimated Burden Hours Per Respondent/Recordkeeper:

Form/Schedule	Recordkeeper	Learning about the law or the form	Preparing the form	Copying, assembling, and sending the form
Form 1010	2 hr., 46 min	3 hr., 29 min	4 hr., 1 min	34 min.
Schedule A	3 hr., 4 min	39 min	1 hr., 34 min	20 min.
Schedule B	33 min	8 min	25 min	20 min.
Schedule C	6 hr., 4 min	1 hr., 31 min	2 hr., 19 min	41 min.
Schedule C–EZ	45 min	3 min	35 min	20 min.
Schedule D	1 hr., 29 min	2 hr., 59 min	2 hr., 34 min	34 min.
Schedule D–1	13 min	1 min	11 min	34 min.
Schedule E	3 hr., 0 min	1 hr., 0 min	1 hr., 24 min	34 min.
Schedule EIC		1 min	13 min	20 min
Schedule F:				
Cash Method	3 hr., 29 min	36 min	1 hr., 27 min	20 min.
Accrual Method	3 hr., 36 min	26 min	1 hr., 25 min	20 min.
Schedule H	1 hr., 38 min	30 min	53 min	34 min.
Schedule J	19 min	11 min	1 hr., 32 min	20 min.

Form/Schedule	Recordkeeper	Learning about the law or the form	Preparing the form	Copying, assembling, and sending the form
Schedule R	19 min	15 min	30 min	34 min.
Schedule SE:				
Short	13 min	14 min	12 min	13 min.
Long	26 min	20 min	33 min	20 min.

Frequency of Response: Annually.

Estimated Total Reporting/ Recordkeeping Burden: 1,454,784,038 hours.

Clearance Officer: Garrick Shear, Internal Revenue Service, Room 5244, 1111 Constitution Avenue, NW., Washington, DC 20224.

OMB Reviewer: Alexander T. Hunt, (202) 395–7860, Office of Management and Budget, Room 10202, New Executive Office Building, Washington, DC 20503.

Lois K. Holland,

Departmental Reports, Management Officer.

[FR Doc. 01–21365 Filed 8–23–01; 8:45 am]

BILLING CODE 4830–01–P

DEPARTMENT OF THE TREASURY

Submission for OMB Review; Comment Request

August 17, 2001.

The Department of Treasury has submitted the following public information collection requirement(s) to OMB for review and clearance under the Paperwork Reduction Act of 1995, Public Law 104–13. Copies of the submission(s) may be obtained by calling the Treasury Bureau Clearance Officer listed. Comments regarding this information collection should be addressed to the OMB reviewer listed and to the Treasury Department Clearance Officer, Department of the Treasury, Room 2110, 1425 New York Avenue, NW., Washington, DC 20220.

DATES: Written comments should be received on or before September 24, 2001 to be assured of consideration.

Internal Revenue Service (IRS)

OMB Number: 1545–0085.

Form Number: IRS Form 1040A and Schedules 1, 2, 3, and EIC.

Type of Review: Revision.

Title: U.S. Individual Income Tax Return.

Description: This form is used by individuals to report their income subject to income tax and to compute their correct tax liability. The data are used to verify that the income reported on the form is correct and are also for statistical use.

Respondents: Individuals or households.

Estimated Number of Respondents/ Recordkeepers: 29,434,276.

Estimated Burden Hours Per Respondent/Recordkeeper:

Form/schedule	Recordkeeping	Learning about the law or the form	Preparing the form	Copying, assembling, and sending the form
Form 1040A	1 hr., 10 min	3 hr., 9 min	5 hr., 15 min	34 min.
Schedule 1	19 min	4 min	13 min	20 min.
Schedule 2	33 min	10 min	52 min	31 min.
Schedule 3	13min	14 min	28 min	34 min.
Schedule EIC	0 min	1 min	13 min	20 min.

Frequency of Response: Annually.

Estimated Total Reporting/ Recordkeeping Burden: 303,833,720 hours.

Clearance Officer: Garrick Shear, Internal Revenue Service, Room 5244, 1111 Constitution Avenue, NW., Washington, DC 20224

OMB Reviewer: Alexander T. Hunt, Office of Management and Budget, Room 10202, New Executive Office Building, Washington, DC 20503; phone, (202) 395–7860.

Lois K. Holland,

Departmental Reports, Management Officer.

[FR Doc. 01–21366 Filed 8–23–01; 8:45 am]

BILLING CODE 4830–01–P

DEPARTMENT OF THE TREASURY

United States Secret Service

Appointment of Performance Review Board (PRB) Members

This notice announces the appointment of members of the Senior Executive Service Performance Review Boards in accordance with 5 U.S.C. 4314(c)(4) for the rating period beginning October 1, 2000, and ending September 30, 2001. Each PRB will be composed of at least three of the Senior Executive Service members listed below.

Name and Title

Larry L. Cockell, Deputy Director, U.S. Secret Service

James E. Bauer, Assistant Director, Investigations (USSS)

Carlton D. Spriggs, Assistant Director, Protective Operations (USSS)

Barbara S. Riggs, Assistant Director, Protective Research (USSS)

Dana A. Brown, Assistant Director, Administration (USSS)

George D. Rogers, Assistant Director, Inspection (USSS)

Donald A. Flynn, Assistant Director, Human Resources and Training (USSS)

H. Terrence Samway, Assistant Director, Government Liaison & Public Affairs (USSS)

John J. Kelleher, Chief Counsel (USSS)

FOR FURTHER INFORMATION CONTACT: Sheila M. Lumsden, Chief, Personnel Division, 950 H St., NW., Suite 7400,

Washington, DC 20223, Telephone No. (202) 406–5635.

Brian L. Stafford,

Director.

[FR Doc. 01–21362 Filed 8–23–01; 8:45 am]

BILLING CODE 4810–42–M

DEPARTMENT OF VETERANS AFFAIRS

[OMB Control No. 2900–0393]

Proposed Information Collection Activity: Proposed Collection; Comment Request

AGENCY: Office of Acquisition and Materiel Management, Department of Veterans Affairs

ACTION: Notice.

SUMMARY: The Office of Acquisition and Materiel Management (OA&MM), Department of Veterans Affairs (VA), is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act (PRA) of 1995, Federal agencies are required to publish notice in the **Federal Register** concerning each proposed collection of information, including each proposed reinstatement, with change, of a previously approved collection for which approval has expired, and allow 60 days for public comment in response to the notice. This notice solicits comments on the information needed to allow VA to issue purchase orders for the acquisition of the goods and services used for operation of the Department.

DATES: Written comments and recommendations on the proposed collection of information should be received on or before October 23, 2001.

ADDRESSES: Submit written comments on the collection of information to Donald E. Kaliher, Office of Acquisition and Materiel Management (95A), Department of Veterans Affairs, 810 Vermont Avenue, NW, Washington, DC 20420 or e-mail *donald.kaliher@mail.va.gov.* Please refer to ''OMB Control No. 2900–0393'' in any correspondence.

FOR FURTHER INFORMATION CONTACT: Donald E. Kaliher at (202) 273–8819.

SUPPLEMENTARY INFORMATION: Under the PRA of 1995 (Pub. L. 104–13; 44 U.S.C., 3501–3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. This request for comment is being made pursuant to Section 3506(c)(2)(A) of the PRA.

With respect to the following collection of information, OA&MM invites comments on: (1) Whether the proposed collection of information is necessary for the proper performance of OA&MM's functions, including whether the information will have practical utility; (2) the accuracy of OA&MM's estimate of the burden of the proposed collection of information; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or the use of other forms of information technology.

Title: VA Acquisition Regulation (VAAR) Part 813.

OMB Control Number: 2900–0393.

Type of Review: Reinstatement, with change, of a previously approved collection for which approval has expired.

Abstract: VA issues requests for quotations (RFQs) under the procedures of the Federal Acquisition Regulation (FAR) Part 13 and VAAR Part 813 for the acquisition of the goods and services necessary to operate the Department. In addition, VA requests information from vendors for the purpose of establishing blanket purchase agreements (BPAs). Any individual or business wishing to submit an offer on an RFQ or respond to a request for the establishment of a BPA may do so. VA will use the information to determine to which business or individual VA should issue a purchase order for the acquisition of goods or services or to determine with which business or individual VA should establish a BPA. This collection of information covers only those acquisition-related actions conducted under the procedures of FAR Part 13 and VAAR Part 813 that affect 10 or more persons and are, therefore, subject to the PRA. Such actions include open market competitive acquisitions between $25,000 and $100,000 and, for commercial items, acquisitions between $100,000 and $5 million where simplified procedures are used.

Affected Public: Business or other for-profit; individuals and households; and not-for-profit institutions.

Estimated Annual Burden: 10,650 hours.

Estimated Average Burden Per Respondent: 1 hour.

Frequency of Response: On occasion.

Estimated Number of Respondents: 10,650.

Dated: August 7, 2001.

By direction of the Secretary.

Donald L. Neilson,

Director, Information Management Service.

[FR Doc. 01–21500 Filed 8–23–01; 8:45 am]

BILLING CODE 8320–01–U

DEPARTMENT OF VETERANS AFFAIRS

[OMB Control No. 2900–0500]

Proposed Information Collection Activity: Proposed Collection; Comment Request

AGENCY: Veterans Benefits Administration, Department of Veterans Affairs.

ACTION: Notice.

SUMMARY: The Veterans Benefits Administration (VBA), Department of Veterans Affairs (VA), is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act (PRA) of 1995, Federal agencies are required to publish notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension of a currently approved collection and allow 60 days for public comment in response to the notice. This notice solicits comments on information needed to determine dependents continued entitlement to benefits.

DATES: Written comments and recommendations on the proposed collection of information should be received on or before October 23, 2001.

ADDRESSES: Submit written comments on the collection of information to Nancy J. Kessinger, Veterans Benefits Administration (20S52), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420 or e-mail *irmnkess@vba.va.gov.* Please refer to ''OMB Control No. 2900–0500'' in any correspondence.

FOR FURTHER INFORMATION CONTACT: Nancy J. Kessinger at (202) 273–7079 or FAX (202) 275–5947.

SUPPLEMENTARY INFORMATION: Under the PRA of 1995 (Pub. L. 104–13; 44 U.S.C., 3501–3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. This request for comment is being made pursuant to Section 3506(c)(2)(A) of the PRA.

With respect to the following collection of information, VBA invites comments on: (1) Whether the proposed collection of information is necessary for the proper performance of VBA's functions, including whether the

information will have practical utility; (2) the accuracy of VBA's estimate of the burden of the proposed collection of information; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or the use of other forms of information technology.

Title: Status of Dependents Questionnaire, VA Form 21–0538.

OMB Control Number: 2900–0500.

Type of Review: Extension of a currently approved collection.

Abstract: The form is used to request certification of the status of dependents for whom additional compensation is being paid. Without the information, continued entitlement to the benefits for dependents could not be determined.

Affected Public: Individuals or households.

Estimated Annual Burden: 14,083 hours.

Estimated Average Burden Per Respondent: 10 minutes.

Frequency of Response: On occasion.

Estimated Number of Respondents: 84,500.

Dated: August 13, 2001.

By direction of the Secretary.

Donald L. Neilson,

Director, Information Management Service.

[FR Doc. 01–21503 Filed 8–23–01; 8:45 am]

BILLING CODE 8320–01–P

DEPARTMENT OF VETERANS AFFAIRS

[OMB Control No. 2900–0159]

Proposed Information Collection Activity: Proposed Collection; Comment Request

AGENCY: Veterans Benefits Administration, Department of Veterans Affairs.

ACTION: Notice.

SUMMARY: The Veterans Benefits Administration (VBA), Department of Veterans Affairs (VA), is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act (PRA) of 1995, Federal agencies are required to publish notice in the **Federal Register** concerning each proposed collection of information, including each extension of a currently approved collection, and allow 60 days for public comment in response to the notice. This notice solicits comments on information needed to determine the disposition of proceeds of a matured endowment policy.

DATES: Written comments and recommendations on the proposed collection of information should be received on or before October 23, 2001.

ADDRESSES: Submit written comments on the collection of information to Nancy J. Kessinger, Veterans Benefits Administration (20S52), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420 or e-mail *irmnkess@vba.va.gov*. Please refer to ''OMB Control No. 2900–0159'' in any correspondence.

FOR FURTHER INFORMATION CONTACT: Nancy J. Kessinger at (202) 273–7079 or FAX (202) 275–5947.

SUPPLEMENTARY INFORMATION: Under the PRA of 1995 (Pub. L. 104–13; 44 U.S.C., 3501–3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. This request for comment is being made pursuant to Section 3506(c)(2)(A) of the PRA.

With respect to the following collection of information, VBA invites comments on: (1) Whether the proposed collection of information is necessary for the proper performance of VBA's functions, including whether the information will have practical utility; (2) the accuracy of VBA's estimate of the burden of the proposed collection of information; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or the use of other forms of information technology.

Title: Matured Endowment Notification, VA Form 29–5767.

OMB Control Number: 2900–0159.

Type of Review: Extension of a currently approved collection.

Abstract: The form is used to notify the insured that his/her endowment policy has matured and to elicit their desired disposition of the proceeds of the policy. The information is used by VA to process the insured's request.

Affected Public: Individuals or households.

Estimated Annual Burden: 2,867 hours.

Estimated Average Burden Per Respondent: 20 minutes.

Frequency of Response: On occasion.

Estimated Number of Respondents: 8,600.

Dated: August 15, 2001.

By direction of the Secretary.

Donald L. Neilson,

Director, Information Management Service.

[FR Doc. 01–21504 Filed 8–23–01; 8:45 am]

BILLING CODE 8320–01–U

DEPARTMENT OF VETERANS AFFAIRS

[OMB Control No. 2900–0036]

Proposed Information Collection Activity: Proposed Collection; Comment Request

AGENCY: Veterans Benefits Administration, Department of Veterans Affairs.

ACTION: Notice.

SUMMARY: The Veterans Benefits Administration (VBA), Department of Veterans Affairs (VA), is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act (PRA) of 1995, Federal agencies are required to publish notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension of a currently approved collection and allow 60 days for public comment in response to the notice. This notice solicits comments on information needed to determine if a decision of presumptive death can be made for benefit payment purposes.

DATES: Written comments and recommendations on the proposed collection of information should be received on or before October 23, 2001.

ADDRESSES: Submit written comments on the collection of information to Nancy J. Kessinger, Veterans Benefits Administration (20S52), Department of Veterans Affairs, 810 Vermont Avenue, NW, Washington, DC 20420 or e-mail *irmnkess@vba.va.gov*. Please refer to ''OMB Control No. 2900–0036'' in any correspondence.

FOR FURTHER INFORMATION CONTACT: Nancy J. Kessinger at (202) 273–7079 or FAX (202) 275–5947.

SUPPLEMENTARY INFORMATION: Under the PRA of 1995 (Pub. L. 104–13; 44 U.S.C., 3501—3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. This request for comment is being made pursuant to Section 3506(c)(2)(A) of the PRA.

With respect to the following collection of information, VBA invites comments on: (1) Whether the proposed collection of information is necessary for the proper performance of VBA's

functions, including whether the information will have practical utility; (2) the accuracy of VBA's estimate of the burden of the proposed collection of information; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or the use of other forms of information technology.

Title: Statement of Disappearance, VA Form 21–1775.

OMB Control Number: 2900–0036.

Type of Review: Extension of a currently approved collection.

Abstract: Title 38, U.S.C., Section 108, requires a formal presumption of death when a veteran has been missing for seven years. VA Form 21–1775 is used to gather the necessary information for proper decisions regarding the unexplained absence of an individual. Without this information, it would not be possible for VA to authorize death benefits.

Affected Public: Individuals or households.

Estimated Annual Burden: 2,000 hours.

Estimated Average Burden Per Respondent: 2 hours 45 minutes.

Frequency of Response: On occasion.

Estimated Number of Respondents: 5,500.

Dated: August 15, 2001.

By direction of the Secretary.

Donald L. Neilson,

Director, Information Management Service.

[FR Doc. 01–21505 Filed 8–23–01; 8:45 am]

BILLING CODE 8320–01–P

DEPARTMENT OF VETERANS AFFAIRS

[OMB Control No. 2900–0111]

Agency Information Collection Activities Under OMB Review

AGENCY: Veterans Benefits Administration, Department of Veterans Affairs

ACTION: Notice.

SUMMARY: In compliance with the Paperwork Reduction Act (PRA) of 1995 (44 U.S.C., 3501 *et seq.*), this notice announces that the Veterans Benefits Administration (VBA), Department of Veterans Affairs, has submitted the collection of information abstracted below to the Office of Management and Budget (OMB) for review and comment. The PRA submission describes the nature of the information collection and its expected cost and burden; it includes the actual data collection instrument.

DATES: Comments must be submitted on or before September 24, 2001.

FOR FURTHER INFORMATION OR A COPY OF THE SUBMISSION CONTACT: Denise McLamb, Information Management Service (045A4), Department of Veterans Affairs, 810 Vermont Avenue, NW, Washington, DC 20420, (202) 273–8030, FAX (202) 273–5981 or e-mail: *denise.mclamb.va.gov.* Please refer to ''OMB Control No. 2900–0111.''

SUPPLEMENTARY INFORMATION: *Title:* Statement of Purchaser or Owner Assuming Seller's Loan, VA Form 26–6382.

OMB Control Number: 2900–0111.

Type of Review: Extension of a currently approved collection.

Abstract: VA Form 26–6382 is completed by purchasers who are assuming veterans' guaranteed, insured, and direct home loans. The information collected on the form is essential for VA to make determinations for release of liability as well as for credit underwriting determinations for substitution of entitlement cases.

An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. The **Federal Register** Notice with a 60-day comment period soliciting comments on this collection of information was published on June 14, 2001, at page 32414—32415.

Affected Public: Individuals or households.

Estimated Annual Burden: 2,250 hours.

Estimated Average Burden Per Respondent: 15 minutes.

Frequency of Response: On occasion.

Estimated Number of Respondents: 9,000.

Send comments and recommendations concerning any aspect of the information collection to VA's OMB Desk Officer, OMB Human Resources and Housing Branch, New Executive Office Building, Room 10235, Washington, DC 20503 (202) 395–7316. Please refer to ''OMB Control No. 2900–0111'' in any correspondence.

Dated: August 16, 2001.

By direction of the Secretary.

Donald L. Neilson,

Director, Information Management Service.

[FR Doc. 01–21501 Filed 8–23–01; 8:45 am]

BILLING CODE 8320–01–P

DEPARTMENT OF VETERANS AFFAIRS

[OMB Control No. 2900–0521]

Agency Information Collection Activities Under OMB Review

AGENCY: Veterans Benefits Administration, Department of Veterans Affairs.

ACTION: Notice.

SUMMARY: In compliance with the Paperwork Reduction Act (PRA) of 1995 (44 U.S.C. 3501 *et seq.*), this notice announces that the Veterans Benefits Administration (VBA), Department of Veterans Affairs, has submitted the collection of information abstracted below to the Office of Management and Budget (OMB) for review and comment. The PRA submission describes the nature of the information collection and its expected cost and burden; it includes the actual data collection instrument.

DATES: Comments must be submitted on or before September 24, 2001.

FOR FURTHER INFORMATION OR A COPY OF THE SUBMISSION CONTACT: Denise McLamb, Information Management Service (045A4), Department of Veterans Affairs, 810 Vermont Avenue, NW, Washington, DC 20420, (202) 273–8030, FAX (202) 273–5981 or e-mail: *denise.mclamb@mail.va.gov.* Please refer to ''OMB Control No. 2900–0521.''

SUPPLEMENTARY INFORMATION: *Title:* Credit Underwriting Standards and Procedures for Processing VA Guaranteed Loans.

OMB Control Number: 2900–0521.

Type of Review: Reinstatement, without change, of a previously approved collection for which approval has expired.

Abstract: VA sets forth, in regulatory form, standards to be used by lenders in underwriting VA-guaranteed loans and to obtain credit information. Lenders must collect certain specific information concerning the veteran and the veteran's credit history (and spouse or other co-borrower, as applicable), in order to underwrite the veteran's loan. A loan may not be guaranteed unless the veteran is a satisfactory credit risk. VA requires the lender to provide the Department with the credit information to assure itself that applications for VA-guaranteed loans are underwritten in a reasonable and prudent manner.

An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. The **Federal Register** Notice with a 60-day comment period soliciting comments on this collection

of information was published on August 31, 2000, at pages 53092–53093.

Affected Public: Individuals or households and business or other for-profit.

Estimated Annual Burden: 1 hour.

Estimated Average Burden Per Respondent: 45 minutes.

Frequency of Response: On occasion.

Estimated Number of Respondents: 300,000.

Send comments and recommendations concerning any aspect of the information collection to VA's Desk Officer, OMB Human Resources and Housing Branch, New Executive Office Building, Room 10235, Washington, DC 20503, (202) 395–7316. Please refer to ''OMB Control No. 2900–0521'' in any correspondence.

Dated: August 8, 2001.

By direction of the Secretary.

Donald L. Neilson,

Director, Information Management Service.

[FR Doc. 01–21502 Filed 8–23–01; 8:45 am]

BILLING CODE 8320–01–U

Federal Register

Friday,

August 24, 2001

Part II

Department of Health and Human Services

Centers for Medicare & Medicaid Services

42 CFR Part 413, et al.

Medicare Program; Changes to the Hospital Outpatient Prospective Payment System and Calendar Year 2002 Payment Rates; Proposed Rule

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

42 CFR Parts 413, 419, and 489

[CMS–1159–P]

RIN 0938–AK54

Medicare Program; Changes to the Hospital Outpatient Prospective Payment System and Calendar Year 2002 Payment Rates

AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.

ACTION: Proposed rule.

SUMMARY: This proposed rule would revise the Medicare hospital outpatient prospective payment system to implement applicable statutory requirements, including relevant provisions of the Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000 and changes arising from our continuing experience with this system. In addition, it would describe proposed changes to the amounts and factors used to determine the payment rates for Medicare hospital outpatient services paid under the prospective payment system. These changes would be applicable to services furnished on or after January 1, 2002.

DATES: We will consider comments if we receive them at the appropriate address, as provided below, no later than 5 p.m. on October 3, 2001.

ADDRESSES: In commenting, please refer to file code CMS–1159–P. Because of staff and resource limitations, we cannot accept comments by facsimile (FAX) transmission. Mail written comments (one original and three copies) to the following address only: Centers for Medicare & Medicaid Services, Department of Health and Human Services, Attention: CMS–1159–P, P.O. Box 8017, Baltimore, MD 21244–8017.

To ensure that mailed comments are received in time for us to consider them, please allow for possible delays in delivery.

If you prefer, you may deliver (by hand or courier) your written comments (one original and three copies) to one of the following addresses:

Room 443–G, Hubert H. Humphrey Building, 200 Independence Avenue, SW., Washington, DC 20201, or

Room C5–16–03, 7500 Security Boulevard, Baltimore, MD 21244–1850.

Comments mailed to the addresses indicated as appropriate for hand or courier delivery may be delayed and received too late for us to consider them.

For information on viewing public comments, see the beginning of the **SUPPLEMENTARY INFORMATION** section.

When ordering copies of the **Federal Register** containing this document, see the **SUPPLEMENTARY INFORMATION** section.

FOR FURTHER INFORMATION CONTACT: George Morey (410) 786–4653, for provider-based issues; and Nancy Edwards (410) 786–0378, for all other issues.

SUPPLEMENTARY INFORMATION:

Inspection of Public Comments

Comments received timely will be available for public inspection as they are received, generally beginning approximately 3 weeks after publication of a document, at the headquarters of the Centers for Medicare & Medicaid Services, 7500 Security Blvd., Baltimore, MD 21244–1850 on Monday through Friday of each week from 8:30 a.m. to 4 p.m. To schedule an appointment to view public comments, please call (410) 786–7195 or (410) 786–4668.

Availability of Copies and Electronic Access

Copies: To order copies of the **Federal Register** containing this document, send your request to: New Orders, Superintendent of Documents, P.O. Box 371954, Pittsburgh, PA 15250–7954. Specify the date of the issue requested and enclose a check or money order payable to the Superintendent of Documents, or enclose your Visa or Master Card number and expiration date. Credit card orders can also be placed by calling the order desk at (202) 512–1800 or by faxing to (202) 512–2250. The cost for each copy is $9. As an alternative, you can view and photocopy the **Federal Register** document at most libraries designated as Federal Depository Libraries and at many other public and academic libraries throughout the country that receive the **Federal Register**.

This **Federal Register** document is also available from the **Federal Register** online database through GPO Access, a service of the U.S. Government Printing Office. The Website address is: *http://www.access.gpo.gov/nara/index.html.* To assist readers in referencing sections contained in this document, we are providing the following table of contents.

Outline of Contents

Alphabetical List of Acronyms Appearing in the Proposed Rule

APC Ambulatory payment classification
APG Ambulatory patient group
ASC Ambulatory surgical center
AWP Average wholesale price
BBA 1997 Balanced Budget Act of 1997
BIPA 2000 Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000
BBRA 1999 Balanced Budget Refinement Act of 1999
CAH Critical access hospital
CAT Computerized axial tomography
CCI Correct Coding Initiative
CCR Cost center specific cost-to-charge ratio
CMHC Community mental health center
CMS Centers for Medicare & Medicaid Services (Formerly known as the Health Care Financing Administration)
CORF Comprehensive outpatient rehabilitation facility
CPI Consumer Price Index
CPT (Physician's) Current Procedural Terminology, Fourth Edition, 2001, copyrighted by the American Medical Association
DME Durable medical equipment
DMEPOS DME, prosthetics (which include prosthetic devices and implants) orthotics, and supplies
DRG Diagnosis-related group
EMTALA Emergency Medical Treatment and Active Labor Act
FDA Food and Drug Administration
FQHC Federally qualified health center
HCPCS Healthcare Common Procedure Coding System
HHA Home health agency
ICD–9–CM International Classification of Diseases, Ninth Edition, Clinical Modification
IME Indirect medical education
JCAHO Joint Commission on Accreditation of Healthcare Organizations
MRI Magnetic resonance imaging
MSA Metropolitan statistical area
NECMA New England County Metropolitan Area
OPPS Hospital outpatient prospective payment system
PPS Prospective payment system
RFA Regulatory Flexibility Act
RHC Rural health clinic
RRC Rural referral center
SCH Sole community hospital
SNF Skilled nursing facility

I. Background

A. Authority

When the Medicare statute was originally enacted, Medicare payment for hospital outpatient services was based on hospital-specific costs. In an effort to ensure that Medicare and its beneficiaries pay appropriately for services and to encourage more efficient delivery of care, the Congress mandated replacement of the cost-based payment methodology with a prospective payment system (PPS). The Balanced Budget Act of 1997 (BBA) (Pub. L. 105–33), enacted on August 5, 1997, added section 1833(t) to the Social Security Act (the Act) authorizing implementation of a PPS for hospital outpatient services. The Balanced Budget Refinement Act of 1999 (BBRA) (Pub. L. 106–113), enacted on November 29, 1999, made major changes that affected the hospital outpatient PPS (OPPS). The Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000 (BIPA) (Pub. L. 106–554), enacted on December 21, 2000, made further changes in the OPPS. The BIPA provisions that affect the OPPS are summarized below, in section I.C. The OPPS was first implemented for services furnished on or after August 1, 2000.

B. Summary of Rulemaking

- On September 8, 1998, we published a proposed rule (63 FR 47552) to establish in regulations a PPS for hospital outpatient services, to eliminate the formula-driven overpayment for certain hospital outpatient services, and to extend reductions in payment for costs of hospital outpatient services. On June 30, 1999, we published a correction notice (64 FR 35258) to correct a number of technical and typographic errors in the September 1998 proposed rule including the proposed amounts and factors used to determine the payment rates.
- On April 7, 2000, we published a final rule with comment period (65 FR 18438) that addressed the provisions of the PPS for hospital outpatient services scheduled to be effective for services furnished on or after July 1, 2000. Under this system, Medicare payment for hospital outpatient services included in the PPS is made at a predetermined, specific rate. These outpatient services are classified according to a list of ambulatory payment classifications (APCs). The April 7 final rule with comment period also established requirements for provider departments and provider-based entities and prohibited Medicare payment for non-physician services furnished to a hospital outpatient by a provider or supplier other than a hospital unless the services are furnished under arrangement. In addition, this rule extended reductions in payment for costs of hospital outpatient services as required by the BBA of 1997 and

amended by the BBRA of 1999. Medicare regulations governing the hospital OPPS are set forth at 42 CFR 419.

- On June 30, 2000, we published a notice (65 FR 40535) announcing a delay in implementation of the OPPS from July 1, 2000 to August 1, 2000.
- On August 3, 2000, we published an interim final rule with comment period (65 FR 47670) that modified criteria that we use to determine which medical devices are eligible for transitional pass-through payments. The August 3, 2000 rule also corrected and clarified certain provider-based provisions included in the April 7, 2000 rule.
- On November 13, 2000, we published an interim final rule with comment period (65 FR 67798). This rule provided for the annual update to the amounts and factors for OPPS payment rates effective for services furnished on or after January 1, 2001. We also responded to public comments on those portions of the April 7, 2000 final rule that implemented related provisions of the BBRA and public comments on the August 3, 2000 rule.

C. Summary of Relevant Provisions of the BIPA

The BIPA, which was enacted on December 21, 2000, made the following changes to the Act relating to OPPS.

1. Accelerated Reduction of Beneficiary Copayment

Section 111 amended section 1833(t)(8)(C) of the Act to limit the national copayment rate for OPPS services to 57 percent of the OPPS payment rate for services furnished in 2001 on or after April 1, 2001; 55 percent for services in 2002 and 2003; 50 percent for services furnished in 2004; 45 percent for services furnished in 2005; and 40 percent for services furnished in 2006 and thereafter.

Section 111 also specifies that nothing in BIPA 2000 or the Act, shall be viewed as preventing a hospital from waiving the amount of any beneficiary coinsurance for outpatient hospital services that may have been increased as a result of implementation of the OPPS.

2. Revision of Payment Update

Section 401 amended section 1833(t)(3)(C) of the Act to provide in 2001 an update equal to the full rate of increase in the market basket index. The 2002 update factor remains as it was under the law before the enactment of BIPA, that is, the market basket index percentage increase minus 1 percentage point.

3. Process and Standards for Determining Eligibility of Devices for Transitional Pass-Through Payments

Section 402 amended section 1833(t)(6) of the Act to require that the determination of eligibility for transitional pass-through payments be based on categories of devices (previously, eligibility was determined on a device-specific basis). The establishment of an initial set of categories was required effective for services furnished on or after April 1, 2001. This provision was implemented on March 22, 2001 in Program Memorandum (PM) No. A–01–41, which set forth a list of 96 initial categories.

Section 402 of the BIPA also provides that the Secretary must establish criteria to use in creating additional device categories. These criteria will be set forth in an interim final rule with comment period that will be published in the **Federal Register** at a later date.

Related to this issue is the issue of pro rata reductions of transitional pass through payments for new technology. A discussion of this can be found later in this document in Section VII. B.

4. Application of Transitional Corridor Payments to Certain Hospitals That Did Not Submit a 1996 Cost Report

Section 403 amended section 1833(t)(7)(F)(ii)(I) of the Act to allow transitional corridor payments to hospitals subject to the OPPS that did not have a 1996 cost report by authorizing the use of the first available cost reporting period ending after 1996 and before 2001.

5. Treatment of Children's Hospitals

Section 405 amended section 1833(t) of the Act to give children's hospitals the same permanent hold harmless protection as cancer hospitals under the OPPS.

6. Transitional Pass-Through Payment for Temperature Monitored Cryoablation

Section 406 amended section 1833(t)(6)(A)(ii) of the Act to include devices of temperature monitored cryoablation as eligible for transitional pass-through payments. This provision will be included in the interim final rule concerning changes in eligibility of devices for transitional pass-through payments mentioned above.

7. Contrast Enhanced Diagnostic Procedures

Section 430 amended section 1833(t)(2) of the Act to require that procedures that use contrast agents be classified in groups that are separate from those to which procedures not using contrast agents are assigned. We implemented this provision in PM No. A–01–73, issued on June 1, 2001. In addition, section 430 amended section 1861(t)(1) of the Act to expand the definition of drugs to include contrast agents effective for contrast agents furnished on or after July 1, 2001.

8. Other Changes

In addition to the provisions directly related to OPPS, BIPA included the following provisions that will require revision in the services assigned to APCs in the OPPS:

- Section 102 amended section 1861(s)(2) of the Act to allow coverage of glaucoma screening for certain high risk individuals effective for services furnished on or after January 1, 2002.
- Section 104(d)(2) directed the Secretary to determine if HCPCS codes are appropriate to describe mammography that uses new technology. The Secretary has created these codes for 2002.

Throughout this proposed rule, we discuss these various provisions and the changes we are proposing to make in the OPPS for them.

II. Proposed Changes to the APC Groups and Relative Weights

Under the OPPS, we pay for hospital outpatient services on a rate per service basis that varies according to the APC group to which the service is assigned. Each APC weight represents the median hospital cost of the services included in that APC relative to the median hospital cost of the services included in APC 0601, Mid-Level Clinic Visits. As described in the April 7, 2000 final rule (65 FR 18484), the APC weights are scaled to APC 0601 because a mid-level clinic visit is one of the most frequently performed services in the outpatient setting.

Section 1833(t)(9)(A) of the Act requires the Secretary to review the components of the OPPS not less often than annually and to revise the groups and related payment adjustment factors to take into account changes in medical practice, changes in technology, and the addition of the new services, new cost data, and other relevant information. Section 1833(t)(9)(A) of the Act requires the Secretary, beginning in 2001, to consult with an outside panel of experts when annually reviewing and updating the APC groups and the relative weights.

Finally, section 1833(t)(2) of the Act provides that, subject to certain exceptions, the items and services within an APC group cannot be considered comparable with respect to

the use of resources if the highest median or mean cost item or service in the group is more than 2 times greater than the lowest median or mean cost item or service within the same group (referred to as the ''2 times rule''). We use the median cost of the item or service in implementing this provision. The statute authorizes the Secretary to make exceptions to the 2 times rule ''in unusual cases, such as low volume items and services.''

The APC groups that we are proposing in this rule as the basis for payment in 2002 under the OPPS have been analyzed within this statutory framework.

A. Recommendations of the Advisory Panel on APC Groups

1. Establishment of the Advisory Panel

Section 1833(t)(9)(A) of the Act, which requires that we consult with an outside panel of experts when annually reviewing and updating the APC groups and the relative weights, specifies that the panel will act in an advisory capacity. The expert panel, which is to be composed of representatives of providers, is to review and advise us about the clinical integrity of the APC groups and their weights. The panel is not restricted to using our data and may use data collected or developed by organizations outside the Department in conducting its review.

On November 21, 2000, the Secretary signed the charter establishing an ''Advisory Panel on APC Groups'' (the Panel). The Panel is technical in nature and is governed by the provisions of the Federal Advisory Committee Act (FACA) as amended (Public Law 92–463). To establish the Panel, we solicited members in a notice published in the **Federal Register** on December 5, 2000 (65 FR 75943). We received applications from more than 115 individuals nominating either themselves or a colleague. After carefully reviewing the applications, CMS chose 15 highly qualified individuals to serve on the panel. The Panel was convened for the first time on February 27, February 28, and March 1, 2001. We published a notice in the **Federal Register** on February 12, 2001 (66 FR 9857) to announce the location and time of the Panel meeting, a list of agenda items, and that the meeting was open to the public. We also provided additional information through a press release and our website.

2. Specific Recommendations of the Advisory Panel and Our Responses

In this section of the proposed rule, we summarize the issues considered by the Panel, the Panel's APC recommendations, and our subsequent action with regard to the Panel's recommendations. The data used by the Panel in making its recommendation are the 1996 claims that were used to set the APC weights and payment rates for CY 2000 and 2001.

As discussed below, the Panel sometimes declined to recommend a change in an APC even though the APC violated the 2 times rule. In section II.C.3 of this preamble, we discuss our proposals regarding the 2 times rule based on the data we are using to recalibrate the 2002 APC relative weights (that is, claims for services furnished on or after July 1, 1999 and before July 1, 2000). That section also details the criteria we use in deciding to make an exception to the 2 times rule. We asked the Panel to review many of the exceptions we implemented in 2000 and 2001. The exceptions are referred to as ''violations of the 2 times'' rule in the following discussion.

APC 0016: Level V Debridement & Destruction

APC 0017: Level VI Debridement & Destruction

We asked the Panel to review the current placement of CPT code 56501, Destruction of lesion(s), vulva; simple, any method, in APC 0016 because the APC violates the 2 times rule. Because the procedure is a simple destruction of skin and superficial subcutaneous tissues, we would not expect it to have a median cost of $500. Thus, we believe that the higher costs associated with this code were the result of incorrect coding. To ensure that procedures in APC 0016 comply with the 2 times rule, we asked the Panel to consider one of the following clinical options:

- Move CPT code 56501 to APC 0017.
- Retain CPT code 56501 in APC 0016 but split APC 0016 into three APCs to distinguish simple destruction lesions from extensive destruction lesions.

The Panel rejected the option to split APC 0016 into three different APCs. The members stated that there was no validity in taking that approach because simple versus extensive destruction of lesions had greater significance in relation to physician work than in measuring facility resource use. They believed that many of the procedures assigned to APC 0016 are performed in a procedure room rather than in the operating room. The Panel considered factors such as the use of anesthesia and the method used to destroy the lesions as indicators of differences in facility resource consumption between simple and extensive destruction of lesions. The Panel agreed that the simple destruction of lesions should be assigned to the same APC as the extensive destruction of lesions if a laser is used to remove simple lesions. In this case, the Panel stated that the similarity in resource use is based on the method or technique used to perform the procedure.

The Panel also noted that CPT code 11042, Debridement; skin, subcutaneous tissue, and muscle, is the most frequently performed procedure in APC 0016, accounting for approximately 85 percent of this APC's total volume. The Panel noted that this code had probably been billed incorrectly because of widespread misunderstanding about its definition.

The Panel also reviewed procedures assigned to APCs 0014 (Level III Debridement & Destruction) and 0015 (Level IV Debridement & Destruction) and compared similarities and differences among those procedures and the ones assigned to APCs 0016 and 0017. During this comparative review, the Panel compared CPT code 56501 to the following two CPT codes: 46917, Destruction of lesion(s), anus, simple; laser surgery, which is assigned to APC 0014, and 54055, Destruction of lesion(s), penis, simple; electrodesiccation, which is assigned to APC 0016. In reviewing these three procedures, the Panel questioned whether the resources involved supported their current APC assignments. After considerable discussion, the Panel recommended the following:

- Move CPT code 56501 from APC 0016 to APC 0017.
- Move CPT code 46917 from APC 0014 to APC 0017.

The Panel recommended these changes to achieve clinical coherence and resource similarity among the procedures assigned to these APCs. Because CPT code 46917 is performed using laser equipment and requires anesthesia, the Panel believed it appropriate to move this procedure to APC 0017. Although the Panel considered the reassignment of CPT code 54055 to APC 0017, it did not recommend this change. The Panel's recommended changes would group in APC 0017 simple destruction of lesion procedures that use laser or surgical techniques with extensive destruction of lesion procedures.

We propose to accept the Panel's recommendation regarding CPT code 56501 and to revise the APC accordingly. However, as shown below in Table 3, we are proposing to make

additional changes to these APCs because of the 2 times rule.

APC 0024: Level I Skin Repair

APC 0025: Level II Skin Repair

APC 0026: Level III Skin Repair

APC 0027: Level IV Skin Repair

The composition of procedures in APCs 0025 and 0027 results in these APCs violating the 2 times rule. Therefore, we requested the Panel's advice in exploring other clinical options for reconfiguring the four skin repair APCs to achieve clinical and resource homogeneity among the procedures assigned to APCs 0025 and 0027 while retaining clinical and resource homogeneity for APCs 0024 and 0026. We asked the Panel to consider the following clinical options to achieve this result:

- Rearrange the procedures assigned to APCs 0024 through 0027 based on the size or the length of the skin incision.
- Rearrange the procedures assigned to APCs 0024 through 0027 based on the complexity of the repair, such as distinguishing repairs that involve layers of skin, flaps, or grafts from those that do not.

The Panel reviewed the various options presented, which were modeled based on the 1996 claims data used in constructing the current APC groups and payment rates. Using these data, the Panel discussed size and complexity of the various repairs, considered the clinical differences in performing the repairs on different anatomical sites, and the clinical differences involved in making skin repairs using flaps and grafts versus layers of skin. As a result of its review, the Panel stated that they found no compelling clinical advantages in the options presented. The Panel also agreed that more current data would be needed to make appropriate recommendations about the actual merits and benefits of the various options. For these reasons, the Panel recommended the following:

- Make no changes to APCs 0024 and 0027.
- Reevaluate these APCs with new data when the Panel meets in 2002.
- The Panel, in preparation for the 2002 meeting, will discuss with and gather clinical and utilization information from their respective hospitals regarding these procedures.

We propose to accept the Panel's recommendations. However, as shown in Table 3, we are proposing to make changes to these APCs based on the use of new data and application of the 2 times rule.

APC 0058: Level I Strapping and Casting Application

APC 0059: Level II Strapping and Casting Application

APC 0058 (which consists of the simpler casting, splinting, and strapping procedures) violates the 2 times rule. The median costs for high volume procedures in APC 0058 vary widely, ranging from $27 to $83. The median costs associated with presumably more resource-intensive procedures in APC 0059 are fairly uniform, ranging from $69 to $119. To limit the cost variation in APC 0058, we asked the Panel to consider the following options:

- Move the following four codes from APC 0058 to APC 0059: CPT code 29515, Application of short splint (calf to foot); CPT code 29520, Strapping; hip; CPT code 29530, Strapping; knee; and CPT code 29590, Denis-Brown splint strapping.
- Create a new APC to include a third level of strapping and casting application procedures by regrouping all procedures assigned to both APCs 0058 and 0059 based on the following clinical distinctions: Removal/revision, strapping/splinting, and casting.
- Package certain CPT codes assigned to APC 0058 with relevant procedures.

The Panel discussion revealed that codes grouped in APC 0058 are not always appropriately billed by hospitals. The Panel pointed out that code descriptors such as ''strapping of the hip'' are not commonly understood by hospital staff. The Panel noted that before implementation of OPPS, hospitals billed the items described by these codes as supplies (without a CPT code) when they were billed as anything other than an emergency room visit. They also stated that the use of these codes has been confused with the use of some codes associated with durable medical equipment. For these reasons, the Panel believed that the procedure costs reflected in our data are skewed. As a result, the Panel recommended that we do the following:

- Make no changes to APC 0058.
- Provide appropriate education and guidance to hospitals regarding appropriate use and billing of codes in APC 0058.
- Resubmit APC 0058 to the Panel for reevaluation when later data are available.

We propose to accept the Panel's recommendations except that we propose to move CPT code 29515 to APC 0059 due to the 2 times rule and the newer data we are using for this proposed rule.

APC 0079: Ventilation Initiation and Management

The codes in APC 0079 represent respiratory treatment and support provided in the outpatient setting. The cost variation among the assigned procedures in this APC raises concern about hospital coding practices. The median costs for these procedures range from $40 to $315. We asked the Panel to clarify whether these procedures are performed on outpatients or if they are performed on patients who come to the emergency room and are later admitted to the hospital as inpatients.

The Panel acknowledged that there are major problems associated with appropriately assigning codes to these procedures which results in incorrect billing. The Panel concluded that additional information is necessary to better understand the issues raised. The Panel also advised that CPT code 94660, Continuous positive airway pressure ventilation (CPAP), initiation and management, is a sleep apnea procedure used in the treatment of obesity and is clinically different from all other procedures in APC 0079. For these reasons, the Panel recommended the following:

- Remove CPT code 94660 from APC 0079 and create a new APC for this one procedure.

We propose to accept the Panel's recommendation by creating a new APC 0065, CPAP Initiation.

APC 0094: Resuscitation and Cardioversion

We requested the Panel's assistance in determining whether it is clinically appropriate to remove the cardioversion procedures from APC 0094 because the rest of the procedures assigned to APC 0094 are emergency procedures rather than elective. We proposed that the Panel consider the creation of a new APC for the cardioversion procedures or reassignment of the procedures to another APC that would be more appropriate in terms of clinical coherence and resource similarity. Splitting APC 0094 into two distinct groups, one for resuscitation procedures and the other for internal and external electrical cardioversion procedures, would not result in a significant difference in the APC payment rate for either of the new APCs.

The Panel considered whether it was clinically appropriate to combine internal and external cardioversion procedures (CPT codes 92960 and 92961, respectively) in the same APC. The Panel also questioned the conditions under which internal cardioversion procedures would be performed on an outpatient basis.

The Panel recommended that the only action we should take is to move CPT code 92961, Cardioversion, elective, electrical conversion of arrhythmia; internal (separate procedure), from APC 0094 to APC 0087, Cardiac Electrophysiology Recording/Mapping.

We propose to accept the APC Panel recommendation.

APC 0102: Electronic Analysis of Pacemakers/Other Devices

The neurologic procedures included in APC 0102 (CPT codes 95970 through 95975), are significantly more complex than the routine cardiac pacemaker programming codes also assigned to this APC. Because we believe these codes are clinically different, we asked the Panel to consider the following:

- Create a new APC for the neurologic codes.
- Move the neurologic codes to APC 0215, Level I Nerve and Muscle Tests.

One presenter appearing before the Panel stated that APC 0102 involves clinical functions related to four different categories of devices; that is, pacemakers, defibrillators, infusion pumps, and neurostimulators. The presenter, who represented a device manufacturers' association, contended that these four categories of devices differ clinically. The presenter also stated that patients receiving these devices are clinically different and are even treated by different hospital departments. The presenter recommended the following:

- Split APC 0102 into two APCs: One APC for electronic analysis of pacemakers and other cardiac devices and a separate APC for electronic analysis of infusion pumps and neurostimulators.
- The APC created for electronic analysis of infusion pumps and neurostimulators would include the following CPT codes:

Code	Descriptor
62367 ..	Analyze spine infusion pump.
62368 ..	Analyze spine infusion pump.
95970 ..	Analyze neurostim, no prog.
95971 ..	Analyze neurostim, simple.
95972 ..	Analyze neurostim, complex.
95973 ..	Analyze neurostim, complex.
95974 ..	Cranial neurostim, complex.
95975 ..	Cranial neurostim, complex.

- The APC created for electronic analysis of pacemakers and other cardiac devices would include the following CPT codes:

Code	Descriptor
93727 ..	Analyze ilr system.
93731 ..	Analyze pacemaker system.
93732 ..	Analyze pacemaker system.
93733 ..	Telephone analy, pacemaker.
93734 ..	Analyze pacemaker system.
93735 ..	Analyze pacemaker system.
93736 ..	Telephone analy, pacemaker.
93737 ..	Analyze cardio/defibrillator.
93738 ..	Analyze cardio/defibrillator.
93741 ..	Analyze ht pace device sngl.
93742 ..	Analyze ht pace device single.
93743 ..	Analyze ht pace device dual.
93744 ..	Analyze ht pace device dual.

The presenter stated that reorganizing APC 0102 as recommended would establish groups that are more clinically and resource similar than the current grouping. The presenter believes that APC 0102 as currently configured violates the 2 times rule. The median costs for the 21 procedures currently included in APC 0102 vary from $19 to $145. Other presenters clarified clinical aspects of the procedures, identified which practitioners perform them, the time it takes to perform them, and how they are to be billed. Yet another presenter speaking on behalf of a specialty society noted that the society had previously commented on this APC and requested that we remove CPT codes 93737 and 93738 from APC 0102.

The Panel noted that because most of the codes are new, having been established since 1996 (the base year of data available to the Panel), these newer procedures could not have been included in the data file used to create the current APC payment rates. In the absence of frequency and median cost data for many of these procedures, the Panel was concerned about reorganizing the codes in this APC. Nonetheless, the Panel recommended the following reorganization of APC 0102 to better reflect clinical coherence:

- APC 0102 be split into four new APCs: One APC for analysis and programming of infusion pumps and CSF shunts; a second for analysis and programming of neurostimulators; a third for analysis and programming of pacemakers and internal loop recorders; and a fourth for analysis and programming of cardioverter-defibrillators.

We propose to accept the Panel's recommendations and propose to create four new APCs as follows:

APC 0689: Electronic Analysis of Cardioverter-Defibrillator

APC 0690: Electronic Analysis of Pacemakers and Other Cardiac Devices

APC 0691: Electronic Analysis of Programmable Shunts/Pumps

APC 0692: Electronic Analysis of Neurostimulator Pulse Generators.

APC 0110: Transfusion

APC 0111: Blood Product Exchange

APC 0112: Extracorporeal Photopheresis

The procedures included in APC 0110 are those related only to the services associated with performing the blood transfusion and monitoring the patient during the transfusion; the costs associated with the blood products themselves are not included in APC 0110. We advised the Panel that we were not certain that cost data for blood transfusions excluded the costs of the blood products because the APC 0110 median cost of $289 seemed excessive. We expressed concern about hospital coding and billing practices for blood products, blood processing, storage, and transportation charges as represented in the 1996 data. We asked the Panel to advise us on how to clarify hospital billing and coding practices for blood transfusions; we also asked if the Panel members believe that the median costs for transfusion procedures include the costs for blood products and, if so, how the procedures should be adjusted to eliminate these costs.

A presenter representing a device manufacturers' association noted that these issues were examined extensively by several specialty societies that sent considerable data to us on the actual cost of the transfusion procedures before publication of the April 7, 2000 final rule (65 FR 18434). The presenter stated that the median costs for transfusion procedures that we used in calculating the final payment rate for APC 0110 was somewhat lower than the costs submitted by the specialty societies. The presenter believes that our experience under the APC system is too limited for us to make a judgment concerning the validity of the median costs. The presenter also believes that the payment rate for APC 0110 should have been adjusted to include costs for blood safety tests, such as the hepatitis and HIV look-back tests mandated by the FDA over the past several years, because these costs were not included in the 1996 data used to construct the APC rates. The presenter stated that these tests are expensive and that they increase the hospitals' costs to provide the blood. However, it was unclear whether these tests are separately billable under the lab fee schedule.

In addition, the presenter explained that blood centers do not charge hospitals for blood because it is voluntarily donated, not manufactured. The presenter stated that blood centers charge hospitals what it costs them to provide the blood and that hospitals bill

acquisition and processing charges rather than charges for the blood itself. Based on the information provided, the presenter urged the Panel not to revise APC 0110 until more data become available.

For APC 0111, another representative of a specialty society recommended that CPT code 36521, Therapeutic apheresis; with extracorporeal affinity column absorption and plasma reinfusion, be moved from APC 0111 to APC 0112. The presenter stated that CPT code 36521 is more similar clinically and in resource use to 36522, Photopheresis, extracorporeal which is in APC 0112. The presenter stated that a major difference between the procedure represented by CPT codes 36521 and 36520, Therapeutic Apheresis; plasma and/or cell exchange, which is also assigned to APC 0111, and the other procedures codes assigned to APC 0111, is that hospitals can bill separately for blood products such as the plasma or albumin used in performing plasma exchange procedures. The presenter described CPT code 36521 as a ''self-contained'' procedure not requiring the use of albumin or plasma, because the patient's own blood is processed through a machine and returned to the patient. The presenter stated that the materials and equipment used to perform this procedure make it much more costly than the other procedures assigned to APC 0111. The presenter, citing cost data from two medical centers where CPT code 36521 is frequently performed, stated that the total cost of the procedure, including the cost of the adsorption column, is approximately $2000. At this time, the commenter noted, only one of the adsorption columns (Prosorba) used for this procedure is eligible for transitional pass-through payments, which means that payments for this procedure, which are based upon the APC payment alone, are too low when one of the other columns is used and no additional pass-through payment is made. It was stated that the cost of many of the adsorption columns is over $1000 per column. The presenter concluded that moving CPT code 36521 from APC 0111 to APC 0112 would comply with the statutory requirements for clinical coherence and resource similarity among procedures in the same APC.

The Panel discussed various adsorption devices used in performing CPT code 36521, their eligibility for transitional pass-through payments, as well as the clinical and resource use difference between CPT codes 36520 and 36551. After considerable discussion, the Panel recommended the following:

- Take no action on APC 0110.
- Move CPT code 36521 from APC 0111 to APC 0112 to achieve clinical coherence and resource similarity with photopheresis procedures included in APC 0112. However, the Panel cautioned that the payment for APC 0112 captured the cost of the entire procedure including the cost of the adsorption column. For this reason, any additional payment for the adsorption column through the transitional pass-through payment mechanism would be a duplicate payment. Therefore, the panel asked that CMS address this problem when considering their recommendation.

We propose to accept the Panel's recommendations. We note that effective April 1, 2001, the Prosorba column is no longer eligible for a transitional pass-through payment (see PMA–01–40 issued on March 27, 2001).

APC 0116: Chemotherapy Administration by Other Technique Except Infusion

APC 0117: Chemotherapy Administration by Infusion Only

APC 0118: Chemotherapy Administration by Both Infusion and Other Technique

We had received several comments requesting that oral delivery of chemotherapy and delivery of chemotherapy by infusion pumps and reservoirs be recognized for payment under the OPPS. We asked the Panel to examine this issue.

With regard to oral administration of chemotherapy, the Panel heard several presenters discuss the need for extensive beneficiary education prior to administration of oral anticancer agents. The Panel agreed that the beneficiaries actually self-administer the drug and that beneficiary education was appropriately billed as a clinic visit. The Panel stated that this would be true whether the education involved cancer chemotherapy, diabetes management, or congestive heart failure management. Therefore, the Panel recommended that no new codes be created to specifically recognize oral administration of chemotherapy.

With regard to recognizing chemotherapy administration through infusion pumps and ports, the Panel heard several presentations that this is becoming a common method of administering not only cancer chemotherapy but also for administering other types of pharmaceuticals. It was pointed out that because CPT codes 96520, Refilling and maintenance of portable pump, and 96530, Refilling and maintenance of implantable pump or reservoir, were excluded from the OPPS it was impossible for hospitals to be paid when performing these services. After lengthy discussion, the Panel recommended that refilling and maintenance of pumps and reservoirs be assigned to an APC.

The Panel also discussed the current HCPCS Q codes for chemotherapy administration and concluded that these codes should continue to be recognized in the OPPS. In addition, the Panel discussed whether a new Q code should be developed for extended chemotherapy infusions.

In summary, the Panel recommended the following:

- Hospitals be allowed to bill for patient education under the appropriate clinic codes.
- CPT codes 96520 and 96530 be assigned to a new APC.
- The current HCPCS Level II Q codes for chemotherapy administration should continue to be used.
- There is no need to develop a new HCPCS code for ''extended chemotherapy infusions.''
- CMS should consider developing a new HCPCS code for flushing of ports and reservoirs.

We propose to accept all the Panel recommendations except for the recommendation regarding flushing of ports and reservoirs. Flushing is performed in conjunction with either a chemotherapy administration service or an outpatient clinic visit. In the first case, flushing is part of the chemotherapy administration and its costs are adequately captured in the costs of the chemotherapy administration code. In the second case, we believe that the costs of flushing are adequately captured in the costs of the clinic visit and need not be paid separately. We are proposing to create a new APC 0125, Refilling of Infusion Pump.

APC 0123: Bone Marrow Harvesting and Bone Marrow/Stem Cell Transplant

In APC 0123, the 1996 median cost for CPT code 38230, Bone marrow harvesting for transplantation, was only $15. We believe that this cost is lower than the actual cost of the procedure. Further, we do not have sufficient data to determine how often bone marrow and stem cell transplant procedures are performed on an outpatient basis. For these reasons, we requested the Panel's advice in clarifying the resources used in performing the procedures assigned to APC 0123, and the extent to which these procedures are performed on an outpatient basis.

The Panel noted that these transplant and stem cell harvesting procedures are

being increasingly performed on an outpatient basis. One presenter representing a specialty society stated that 95 percent of these procedures are performed in the hospital outpatient setting. The presenter shared cost data from the bone marrow transplant unit of an academic medical center that showed the cost to harvest bone marrow to be about $1,800. The presenter observed that this cost is significantly higher than the APC payment rate of about $205 for APC 0123. Another presenter representing a group of hospitals stated that the supply costs alone for bone marrow harvesting are more than the current APC payment for the procedure. The presenter suggested that miscoding may have contributed to the low $15 median cost reflected in our database. After discussion, the Panel recommended the following:

- Make no changes in the procedures assigned to APC 0123 in the absence of sufficient data to support such modifications.
- The two presenters on this APC issue submit cost data for the Panel to use in reevaluating this issue at its 2002 meeting.

We note that our analysis of the more recent claims data we are using to reclassify and recalibrate the APCs in this proposed rule reveals a significant increase in costs for this APC resulting in a proposed payment rate that is double the current rate. However, very few procedures (fewer than 20) were billed on an outpatient basis. We will have the Panel review this APC again at their next meeting.

APC 0142: Small Intestine Endoscopy

APC 0143: Lower GI Endoscopy

APC 0145: Therapeutic Anoscopy

APC 0147: Level II Sigmoidoscopy

APC 0148: Level I Anal/Rectal Procedures

APC 0149: Level II Anal/Rectal Procedures

APC 0150: Level III Anal/Rectal Procedures

We presented these seven APCs to the Panel because of the inconsistencies in the median costs for some procedures included in APCs 0142, 0143, 0145, and 0147. We advised the Panel that our cost data do not show a progression of median costs proportional to increases in clinical complexity as we would expect. For example, the data indicate that a therapeutic anoscopy assigned to APC 0145 costs more than twice as much as a flexible or rigid sigmoidoscopy assigned to APC 0147. We stated our concern that cost disparity could provide incentives to use inappropriate procedures. Because of these concerns, we asked the Panel's advice in determining whether one of the following actions should be taken:

- Divide the codes in APC 0142 into separate APCs representing ileoscopy and small intestine procedures.
- Combine diagnostic anoscopy and Level I sigmoidoscopy.
- Merge APCs 0143, 0145, and 0147 into one APC.

We also asked the Panel whether the costs associated with codes in APC 0145 appeared to be valid.

During the Panel discussion, it was noted that the data distributed to the Panel for these APCs indicated that most of the procedures are billed as single procedures only 50 percent of the time. This raised questions as to whether the data include procedures such as flexible sigmoidoscopies that were miscoded as rigid sigmoidoscopies, colonoscopies, and anoscopies. In examining the data, the Panel considered what impact this miscoding would have on the cost data, and discussed the clinical approaches used to perform some of the procedures, what type of practitioners perform them, and other procedures and supplies that would be billed with them. As a result of this discussion, the Panel concluded that the data anomalies were probably attributable to miscoding because hospitals have not received sufficient guidance and information on appropriately coding procedures included in these APCs. The Panel also agreed that it would need more current data before it could consider reconfiguring these APCs. Therefore, the Panel recommended that we do the following:

- Make no changes to APCs 0142, 0143, 0145, and 0147.
- Provide information and guidance to better assist hospitals in understanding how to bill appropriately for services included in APCs 0142, 0143, 0145, and 0147.
- Resubmit these APCs to the Panel for review when newer data are available.

We propose to accept the Panel's recommendations.

APC 0151: Endoscopic Retrograde Cholangio-Pancreatography (ERCP)

We advised the Panel that we have received comments that indicate that it is inappropriate to assign both diagnostic and therapeutic ERCP procedures to the same APC. The commenters allege that virtually every hospital performs diagnostic ERCPs but only teaching hospitals perform therapeutic ERCPs. Based on our current data, if we created two APCs for ERCP procedures, the APC payment rate for therapeutic ERCPs would be lower than that for diagnostic ERCPs (approximately $526 and $535, respectively). Therefore, we requested the Panel's advice to help us determine whether to create separate APCs for diagnostic and therapeutic ERCP procedures.

A presenter speaking on behalf of a specialty society made the following points:

- ERCP is the most complex endoscopy procedure to perform and is usually performed by gastroenterologists.
- ERCP is usually performed at large hospitals.
- The most complex ERCP procedures are usually performed in teaching hospitals.
- Current payments for ERCP are lower than the costs to perform the procedure (based on cost and frequency data gathered from several teaching hospitals).
- Single claims should not be used to calculate an APC payment rate for ERCP services because a single ERCP procedure usually consists of several components, each with its own CPT code (e.g., sphincterotomy and stent placement). Therefore, an ERCP billed as a single CPT code would represent aberrant billing and would not accurately reflect the costs of an ERCP.

The OPPS data distributed to the Panel verified that the vast majority of the ERCP procedures are performed as multiple procedures. The Panel agreed that the use of single claims data could possibly skew the APC payment rate for ERCP services.

The Panel recommended that we do the following:

- Do not reconfigure the ERCP procedures in APC 0151.
- Resubmit this issue to the Panel for review when more recent data are available.
- Explore the feasibility of using multiple claims rather than single claims to calculate appropriate APC payment rates for ERCP procedures.

We propose to accept the Panel's recommendations. We are currently reviewing the potential for using multiple claims data for determining payment rates for ERCP procedures. As a first step in the process, in this proposed rule, we have determined a payment rate for ERCP procedures based on both single claims for ERCP procedures and, because ERCP procedures are typically done under radiologic guidance, on claims that included both an ERCP procedure and a radiologic supervision or guidance

procedure in this APC. Using these additional claims has resulted in significantly increasing the number of claims used to determine the payment rate for this APC and in a much higher proposed payment rate (about $825).

APC 0160: Level I Cystourethroscopy and other Genitourinary Procedures

APC 0161: Level II Cystourethroscopy and other Genitourinary Procedures

APC 0162: Level III Cystourethroscopy and other Genitourinary Procedures

APC 0163: Level IV Cystourethroscopy and other Genitourinary Procedures

APC 0169: Lithotripsy

We advised the Panel that we had received a number of comments that advocated moving CPT code 52337, Cystoscopy, with ureteroscopy and/or pyeloscopy; with lithotripsy (ureteral catheterization is included), from APC 0162 to APC 0163. (We note that CPT code 52337 was deleted for 2001 and replaced with an identical CPT code, 52353. We will use the new code in the following discussion.) Because of these comments, we sought the Panel's advice in examining the clinical and resource distinctions between CPT code 52353 and other procedures assigned to APC 0162. Other information shared with the Panel noted that most of the procedures included in APC 0162 are complicated cystourethroscopies while those assigned to APC 0163 are largely prostate procedures.

One presenter representing a device manufacturer discussed the merits of reassigning CPT code 52353 to either APC 0163 or 0169 (APC 0169 contains a single CPT code, 50590, Lithotripsy, extracorporeal shock wave (ESWL)). The presenter was concerned that our decision to assign the cystourethroscopic procedure to APC 0162 rather to APC 0163 was not explained in our April 7, 2000 final rule.

Furthermore, the presenter noted that this decision resulted in a 40 percent decline in payment for the procedure which will make it difficult for hospitals to provide this service because the capital equipment, probes, and fibers required to perform the procedure are expensive. Moreover, the probes and fibers are ineligible for transitional pass-through payments because they are not single-use items. At the Panel's request, the presenter discussed the clinical differences between CPT codes 52353 and 50590. The presenter stated that code 50590 is a noninvasive procedure that involves breaking up kidney stones using shock waves produced outside the patient while code 52353 is an invasive procedure that requires the urologist to insert different instruments through a cystoscope and a uretheroscope to access stones in the upper urinary tract (the ureter and kidney).

The presenter also compared the cost of performing CPT code 52353 with that for CPT code 52352, which involves the mechanical removal of stones. The presenter asked the Panel to consider the following two options to resolve this issue:

- Reassign CPT code 52353 to APC 0169, Lithotripsy. The presenter believes that this would be the most appropriate assignment clinically and from a cost perspective because both involve lithotripsy and require expensive capital equipment, fibers, and probes. Also, other payers using a similar procedure grouping system, ambulatory procedure groups (APGs), have grouped these procedures together.
- Restore CPT code 52353 to its original APC assignment, APC 0163.

In addition, the presenter expressed concern that the large number of procedures assigned to APC 0162 makes it difficult to achieve clinical homogeneity within the APC. The presenter asked that we work with appropriate groups to reconfigure APC 0162 because, as constituted, it appears to violate the 2 times rule.

The Panel had a lengthy discussion regarding whether to move CPT code 52353 to APC 0163 or to APC 0169. The Panel considered the resources used for procedures in APCs 0163 and 0169 and noted that the lithotriptor used for code 50590 may be purchased or leased and that lease rates for lithotriptors have frequently been inflated. Furthermore, it noted that much of the equipment and resource use required for code 52353 is similar to the resource use of other procedures in APC 0163. In spite of these considerations, the Panel voted eight to seven to recommend moving CPT code 52353 from APC 0162 to APC 0169 because both codes 52353 and 50590 are lithotripsy procedures.

We reviewed the panel discussion very carefully and noted the close vote. After careful consideration, we propose to disagree with the Panel's recommendation and move code 52353 to APC 0163. The 1999–2000 cost data, which contains over 400 single claims for code 52353 and over 6,000 single claims for code 50590, show that the median cost for code 52353 is much more similar to the median cost of other procedures in APC 0163 than it is to the median cost of APC 0169. Although both codes involve lithotripsy, the type of equipment used in the two procedures is very different. Clinically, the surgical approach used for code 52353 and the resources used (e.g., anesthesia and operating room costs) are much more similar to other procedures in APC 0163 than to those for code 50590. Additionally, the median cost for code 50590, which is $700 higher than that of code 52353, is dependent on the widely variable arrangements hospitals make for use of the extracorporeal lithotriptor. Therefore, we believe that placing code 52353 in APC 0163 maintains its clinical coherence and similar use of resources.

APC 0191: Level I Female Reproductive Procedures

APC 0192: Level II Female Reproductive Procedures

APC 0193: Level III Female Reproductive Procedures

APC 0194: Level IV Female Reproductive Procedures

APC 0195: Level V Female Reproductive Procedures

This group of APCs was presented to the Panel because APC 0195 violates the 2 times rule. To facilitate the Panel's review of this issue, we distributed cost data on all the female reproductive procedures assigned to these five APCs. These data showed that the median costs for procedures assigned to APC 0195 ranged from a low of $365 to a high of $1,817. The CPT code 57288, Sling operation for stress incontinence (e.g., fascia or synthetic), which is assigned to APC 0195, has the highest median cost of the procedures in this group. We discussed with the Panel two clinical options for rearranging the procedures assigned to APC 0195 to comply with the 2 times rule. The first option would split APC 0195 into two separate APCs by separating vaginal procedures from abdominal procedures. The second option would split APC 0195 into three distinct APCs by retaining the separate APCs for abdominal and vaginal procedures and further distinguishing vaginal procedures based on whether they are simple or complex.

The Panel discussed the rapid increase in the rate at which CPT code 57288 is performed on an outpatient basis. The Panel stated that this procedure is becoming more routine and replacing many of the older, more complex urinary dysfunctional procedures. Questions were raised about the frequency with which this procedure is performed alone as opposed to being performed as one of several procedures. The Panel was advised that the sling material and the relevant anchors used in performing

CPT code 57288 are eligible for transitional pass-through payments.

One presenter, speaking on behalf of a device manufacturer, supported our proposal to divide APC 0195 into different clinical groupings. The presenter's testimony was limited to a discussion of CPT code 57288. The presenter concurred with the Panel's assessment of the current utilization trends for CPT code 57288, emphasized the high costs associated with performing this procedure, and highlighted the wide variation in techniques and devices used to perform it. Because of these factors, the presenter believes that the procedure is underpaid and that the 1996 cost data may not fully reflect the actual costs associated with performing CPT code 57288.

The Panel also closely reviewed the other four APCs for female reproductive procedures to ensure each was clinically homogeneous. As a result of this review, the Panel recommended a number of changes for these APCs. These recommendations and those for APC 0195 are as follows:

- Move CPT codes 56350, Hysteroscopy, diagnostic, and 58555, Hysteroscopy, diagnostic/separate procedure, from APC 0191 to APC 0194 (In 2001, CPT code 56350 was replaced with CPT code 58555.)
- Divide APC 0195 into two APCs to distinguish vaginal procedures from abdominal procedures.
- Retain the following vaginal procedures in APC 0195:

CPT code	Descriptor
57555	Excision of cervical stump, vaginal approach: with anterior and/or posterior repair.
58800	Drainage of ovarian cyst(s), unilateral or bilateral, (separate procedure); vaginal approach.
58820	Drainage of ovarian abscess; vaginal approach, open.
57310	Closure of urethrovaginal fistula.
57320	Closure of vesicovaginal fistula; vaginal approach.
57530	Trachelectomy (cervicectomy), amputation of cervix (separate procedure).
57291	Construction of artificial vagina; without graft.
57220	Plastic operation on urethral sphincter, vaginal approach (e.g., Kelly urethral plication).
57550	Excision of cervical stump, vaginal approach.
57556	Excision of cervical stump, vaginal approach; with repair of enterocele.
57289	Pereyra procedure, including anterior colporrhaphy.
57300	Closure of rectovaginal fistula; vaginal or transanal approach.
57284	Paravaginal defect repair (including repair of cystocele, stress urinary incontinence, and/or incomplete vaginal prolapse).
57265	Combined anteroposterior colporrhaphy; with enterocele repair.
57268	Repair of enterocele vaginal approach (separate procedure).
56625	Vulvectomy simple; complete.
58145	Myomectomy excision of fibroid tumor of uterus, single or multiple (separate procedure); vaginal approach.
57260	Combined anteroposterior colporrhaphy.
57240	Anterior colporrhaphy, repair of cystocele with or without repair of urethrocele.
57250	Posterior colporrhaphy, repair of rectocele with or without perineorrhaphy.
56620	Vulvectomy simple; partial.
57522	Conization of cervix, with or without fulguration, with or without dilation and curettage, with or without repair; loop electrode excision.

- Include the following abdominal procedures in a new APC titled ''Level VI Female Reproductive Procedures.''

CPT code	Descriptor
58920	Wedge resection or bisection of ovary, unilateral or bilateral.
58900	Biopsy of ovary, unilateral or bilateral (separate procedure).
58925	Ovarian cystectomy, unilateral or bilateral.
57288	Sling operation for stress incontinence (e.g., fascia or synthetic).
57287	Removal or revision of sling for stress incontinence (e.g., fascia or synthetic).

- Move CPT code 57107 from APC 0194 to APC 0195, Level V Female Reproductive Procedures.
- Move CPT code 57109, Vaginectomy with removal of paravaginal tissue (radical vaginectomy) with bilateral total pelvic lympadenectomy and para-oortic lymph node sampling (biopsy), from APC 0194 to the new APC, Level VI Female Reproductive Procedures.

We propose to accept all of these Panel recommendations. These APCs would be reconfigured and renumbered as APCs 0188 to 0194. We are also proposing to add new APCs for Level VII and Level VIII Female Reproductive Procedures (APCs 0195 and 0202, respectively) based on the 1999–2000 claims data and the 2 times rule.

APC 0210: Spinal Tap

APC 0211: Level I Nervous System Injections

APC 0212: Level II Nervous System Injections

The Panel heard testimony from two presenters regarding the merits of modifying these three APCs. The first presenter, speaking on behalf of a manufacturer, discussed CPT code 64614, Chemodenervation of muscles; extremities and/or trunk muscles (e.g., for dystonia, cerebral palsy, multiple sclerosis). The presenter advised the Panel that although this is a new code for 2001, the procedure is well established and formerly coded using CPT code 64640, Destruction by neurolytic agent; other peripheral nerve or branch. The new code was created to distinguish chemodenervation of limb and trunk muscles from other chemodenervation procedures. The presenter claimed that this code is similar both clinically and in terms of resource use to the other chemodenervation procedures assigned to APC 0211, so it should be assigned to that APC instead of APC 0971, New Technology—Level II, where it is currently assigned.

The second presenter, representing a specialty society, proposed regrouping the procedures assigned to APCs 0210, 0211, and 0212 based on similar levels of complexity and median costs. The presenter's proposal also included reassignment to these APCs of interventional pain procedures

currently assigned to APCs 040, Arthrocenteris and Ligament/Tendon Injection, 0105, Revision/Removal of Pacemakers, AICD, or Vascular Device, and 0971. The presenter contended that it was essential to reconfigure these APCs because of disparity in resource use among procedures currently assigned to the same APC. The presenter also claimed that many of these procedures are being underpaid in their current APC and, for that reason, a number of hospitals have chosen not to perform them in the outpatient setting. The presenter proposed establishing the following five levels of interventional pain procedures by regrouping the procedures into new APCs as stated below:

• Level I Nerve Injections (to include Trigger Point, Joint, Other Injections, and Lower Complexity Nerve Blocks):

CPT code	Reassigned from APC
20550	040
20600	040
20605	040
20610	040
64612	0211
64613	0211
64614	0971
64400–64418	0211
64425	0211
64430	0211
64435	0211
64445	0211
64450	0211
64505	0211
64508	0211

• Level II Nerve Injections (to include Moderate Complexity Nerve Blocks and Epidurals):

CPT code	Reassigned from APC
27096	0210
62270	0210
62272	0210
62273	0212
62310–62319	0212

Level III Nerve Injections (to include Moderately High Complexity Epidurals, Facet Blocks, and Disk Injections):

CPT code	Reassigned from APC
62280–62282	0212
62290	Currently Packaged.
62291	Currently Packaged.
64420–64421	0211
64470	0211
64472	0211
64475–64476	0211
64479	0211
64480	0211
64483–64484	0211
64510	0211
64520	0211
64530	0211
64630	0211
64640	0211

• Level IV Nerve Injections (to include High Complexity Lysis of Adhesions, Neurolytic Procedures, Removal of Implantable Pumps and Stimulators):

CPT code	Reassigned from APC
62263	0212
64600	0211
64605	0211
64610	0211
64620	0211
64622–64623	0211
64626–64627	0211
64680	0211
62355	0105
62365	0105

• Level V Nerve Injections (to include Highest Complexity Disk and Spinal Endoscopies): CPT code 62287, Aspiration or decompression procedure, percutaneous, of nucleus pulposus of invertebral disk, any method, single or multiple levels, lumbar (e.g., manual or automated percutaneous diskectomy, percutaneous laser diskectomy), reassigned from APC 0220, Level I Nerve Procedures.

The Panel recommended reassignment of CPT code 64614 from APC 0971 to APC 0211.

Concerning the suggested regrouping of interventional pain procedures, the Panel agreed that the recommended division of these procedures by clinical complexity would reflect resource use and was a reasonable approach to take. It was pointed out to the Panel that the costs for CPT codes 62290, Injection procedure for diskography, each level; lumbar, and 62291, Injection procedure for diskography, each level; cervical or thoracic, were packaged into the procedures with which they were billed. Therefore, the Panel concurred with the regrouping of procedures to establish Levels I, II, III, and IV with the following exceptions:

• The Panel recommended that CPT codes 62290 and 62291 not be included in Level III because they are packaged injections and should not be unpackaged and paid separately.

• The Panel opposed moving CPT codes 62355, Removal of previously implanted intrathecal or epidural catheter, and 62365, Removal of subcutaneous reservoir or pump, previously implanted for intrathecal or epidural infusion, from APC 0105 to Level IV Nerve Injections because they were neither clinically similar nor similar in resource use to the other codes assigned to this proposed APC.

• The Panel opposed the creation of Level V Nerve Tests as it included only one code and recommended that CPT code 62287 remain in APC 220.

We propose to accept the Panel's recommendations for these services. We propose to create new APCs 0203, 0204, 0206, and 0207 to accommodate these proposed changes.

APC 0215: Level I Nerve and Muscle Tests

APC 0216: Level II Nerve and Muscle Tests

APC 0217: Level III Nerve and Muscle Tests

We advised the Panel that we had received a comment contending that assignment of CPT code 95863, Needle electromyography, three extremities with or without related paraspinal areas, to APC 0216 created an inappropriate incentive to perform tests on three extremities rather than two or four extremities. The payment of about $144 for APC 0216 is greater than the payment of about $58 for the same tests when performed on one, two, or four extremities. This is due to the fact that CPT codes 95860, 95861, and 95864, Needle electromyography, one, two, and four extremities with or without related paraspinal areas, respectively, are assigned to APC 0215. We distributed data to the Panel that showed a median cost of about $141 for CPT code 95863, which is more than 3 times that of the median cost of $41 for CPT code 95864. We asked the Panel to consider the reassignment of CPT code 95863 from APC 0216 to APC 0215 and advised the Panel that, based on cost data available at the time of our meeting, this change could potentially reduce the payment for APC 0216. It was also noted that this change could result in a payment increase for APC 0215.

The Panel reviewed the cost data for APCs 0215 and 0216 and noted that the median costs for both CPT codes 95863 and 95864 appeared aberrant. Based on the information presented, the Panel recommended that we move CPT code 95863 from APC 0216 to APC 0215.

We propose to accept the Panel's recommendation with one exception. We are proposing to revise these APCs based on the 1999–2000 cost data and the 2 times rule, and CPT code 95863 would be assigned to a reconfigured APC for Level II Nerve and Muscle Tests (APC 0218).

APC 0237: Level III Posterior Segment Eye Procedures

We advised the Panel that procedures assigned to APC 0237 are high volume procedures and rank among the top outpatient procedures billed under Medicare. We have received a number of comments disagreeing with the assignment of CPT code 67027, Implantation of intravitreal drug delivery system (e.g., ganciclovoir implant), which includes concomitant removal of vitreous, to APC 0237. This procedure was added to the CPT coding system after 1996 and, therefore, was not included in the 1996 data. We advised the Panel that ganciclovoir, the drug implanted during this procedure, is paid separately as a transitional pass-through item. Because the drug is paid separately, it should not be included in determining whether the resources associated with the surgical procedure are similar to the resources required to perform the other procedures assigned to APC 0237. We advised the Panel that, of the procedures assigned to APC 0237, we believe that CPT code 67027 is related to codes 65260, 65265, and 67005, all of which involve removal of foreign bodies and vitreous from the eye. To ensure that CPT code 67027 is assigned to the appropriate APC, we asked the Panel to consider creation of a new APC, Level IV Posterior Segment Eye Procedures, for CPT codes 65260, 65265, 67005, and 67027. Based on the APC rates effective January 1, 2001, the suggested change could lower the APC rate for the four procedures by $400.

The Panel reviewed the data and did not believe it was sufficient to support the creation of a new APC for these four procedures. Therefore, the Panel recommended that APC 0237 remain intact and that more recent claims data be analyzed to determine whether CPT code 67027 is similar to the other procedures assigned to APC 0237.

Based on the 1999–2000 claims data, we have determined that the resources used for code 67027 are similar to other procedures in APC 0237. However, we will present APCs 0235, 0236, and 0237 to the Panel at their next meeting to determine whether any further changes should be made. We are proposing to make various other changes to these APCs based on the new data and the 2 times rule.

APC 0251: Level I ENT Procedures

This APC violates the 2 times rule because it consists of a wide variety of minor ENT procedures, many of which are low volume services or codes for nonspecific procedures. In order to correct this problem, we proposed to the Panel that this APC be split by surgical site (e.g., nasal and oral). After reviewing cost data, the Panel agreed that the APC should be split but that current data were insufficient to determine how that split should be made. Therefore, the Panel asked that this APC, along with more recent cost data, be placed on the agenda at the next meeting.

We agree that this APC should be reviewed by the Panel at its next meeting. However, our review of the more recent cost data indicates that significant violations of the 2 times rule still exist. In order to correct this problem, but keep the APC as intact as possible, we propose to move CPT codes 30300, Remove foreign body, intranasal; office type procedure, 40804, Removal of embedded foreign body, vestiblue of mouth; simple, and 42809, Removal of foreign body from pharynx, to APC 0340, Minor Ancillary Procedures. This APC consists of procedures such as removal of earwax that require similar resources.

APC 0264: Level II Miscellaneous Radiology Procedures

We asked the panel to review this APC because it violated the 2 times rule and consisted of a wide variety of unrelated procedures. Specifically, we believe that the costs associated with CPT codes 74740, Hysterosalpingography, radiological supervision and interpretation, and 76102, Radiologic examination, complex motion (e.g., hypercycloidal) body section (e.g., mastoid polytomography), other than with urography; bilateral, were aberrant and that we would significantly underpay these procedures if we moved them into a lower paying APC. We also asked the Panel to determine whether this APC and APC 0263, Level I Miscellaneous Radiology Procedures, should be reconfigured by body system. After considerable discussion, the Panel agreed that the procedures in these APCs were not clinically homogeneous; however, it recommended that we leave these APCs intact because the data do not support any more coherent reorganization. The Panel requested that this APC be placed on the agenda for the 2002 meeting.

We agree with the Panel with the following revisions. First, BIPA requires us to assign procedures requiring contrast into different APCs from procedures not requiring contrast. This required changes to a number of radiologic APCs including APCs 0263 and 0264. In addition, in this proposed rule, we would move CPT code 75940, Percutaneous Placement of IVC filter, radiologic supervision and interpretation, to a new APC 0187, Placement/Reposition Miscellaneous Catheters, because its costs were significantly higher than the costs of the procedures remaining in APC 0264.

APC 0269: Echocardiogram except Transesophageal

APC 0270: Transesophageal Echocardiogram

We asked the Panel to consider splitting these APCs based on whether or not 2D imaging is employed. After review of the data, the Panel recommended that we leave these APCs intact.

We propose to leave APC 0270 intact except for the addition of two new codes for transesophageal echocardiography. We also propose to split APC 0269 into two APCs, APC 0269, Level I Echocardiogram Except Transesophageal and APC 0697, Level II Echocardiogram Except Transesophageal. One APC (0697) would include comprehensive echocardiograms and the other APC (0269) would include limited/follow-up echocardiograms and doppler add-on procedures.

APC 0274: Myelography

We advised the Panel that APC 0274 is clinically homogeneous but that it violates the 2 times rule. Procedures assigned to this APC include radiological supervision and interpretation of diagnostic studies of central nervous system structures (e.g., spinal cord and spinal nerves) performed after injection of contrast material. We shared data with the Panel that showed the median costs for the procedures assigned to this APC ranged from a low of about $109 to a high of about $295. We asked the Panel's recommendation for reconfiguring APC 0274 to comply with the 2 times rule.

We informed the Panel members that we packaged the costs associated with radiologic injection codes into the radiological supervision and interpretation codes with which they were reported. The reason for doing this is that hospitals incur expenses for providing both services and they typically perform both an injection and a supervision and interpretation procedure on the same patient. Therefore, since neither an injection code nor a supervision and interpretation code should be billed alone, it would not be appropriate for us to use single claims data to determine the costs of performing these procedures. However, we are using single claims data in order to accurately

determine the costs of performing procedures. Therefore, in order to accurately determine the costs of a complete radiologic procedure, we had to package the costs of the injection component into the cost of the supervision and interpretation component with which it was billed. The Panel believed that, in 1996, hospitals generally did not bill the injection code when performing myelography. Furthermore, in 1996, some hospitals kept patients overnight after a myelogram. More recently, postmyelogram recovery time has decreased to about 6 hours. For these reasons, the Panel believed that the median costs of $109 and $174 probably do not represent the actual resources used for CPT codes 70010, Myelography, posterior fossa, radiological supervision and interpretation, and 70015, Cisternography, positive contrast, radiological supervision and interpretation. Therefore, the Panel recommended the following:

- Make no changes to APC 0274.
- Review new cost data to determine whether payment would increase for APC 0274.

We propose to accept the Panel's recommendations.

APC 0279: Level I Diagnostic Angiography and Venography

APC 0280: Level II Diagnostic Angiography and Venography

We presented these codes to the Panel for several reasons. APC 0279 fails the 2 times rule, there are numerous codes in these APCs with no cost data, there are numerous ''add on'' codes in these APCs, and many of these procedures were performed infrequently in the outpatient setting in 1996.

The Panel reviewed the clinical coherence of both APCs as well as the resources required to perform all these procedures. The Panel believed that it would be unusual for many of these procedures to be performed separately and that we would need to look at multiple claims to get accurate data. The Panel recommended the following:

- Create a new APC (APC 0287, Complex Venography) with the following CPT codes: 75831, 75840, 75842, 75860, 75870, 75872, and 75880.
- Move CPT codes 75960, 75961, 75964, 75968, 75970, 75978, 75992, and 75995 from APC 0279 to APC 0280.

We propose to accept the Panel's recommendations. We note that, as proposed, APC 0279 violates the 2 times rule because of the low cost data for CPT code 75660, Angiography, external carotid, unilateral selective, radiological supervision and interpretation. We believe that, for these procedures, these cost data are aberrant. This code is clinically similar to the other codes in APC 0279 and moving code 75660 to an APC with a lower weight could be an inappropriate APC assignment. Therefore, we believe that an exception to the 2 times rule is warranted.

APC 0300: Level I Radiation Therapy

APC 0302: Level III Radiation Therapy

We presented this APC to the Panel because we received comments that the assignment of CPT code 61793, Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator), one or more sessions, to APC 0302 would result in inappropriate payment of this service. Many commenters wrote that stereotactic radiosurgery and intensity modulated radiation therapy (IMRT) required significantly more staff time, treatment time, and resources than other types of radiation therapy. Other commenters disagreed with our decision, effective January 1, 2001, to discontinue recognizing CPT code 61793, and to create two HCPCS level 2 codes, G0173, Stereotactic radiosurgery, complete course of therapy in one session, and G0174 Intensity modulated radiation therapy (IMRT) plan, per session, to report both stereotactic radiosurgery and IMRT.

We reported to the Panel that the APC assignment of these G codes and their payment rate was based on our understanding that stereotactic radiosurgery was generally performed on an inpatient basis and delivered a complete course of treatment in a single session, while IMRT was performed on an outpatient basis and required several sessions to deliver a complete course of treatment. We also explained to the Panel that it was our understanding that multiple CPT codes were billed for each session of stereotactic radiosurgery and IMRT. Therefore, we believed that the payment for APC 0302 was only a fraction of the total payment a hospital received for performing stereotactic radiosurgery or IMRT on an outpatient basis.

Radiosurgery equipment manufacturers, physician groups, and patient advocacy groups have both submitted comments to us and provided testimony to the APC Panel on these issues. These comments have convinced us that we did not clearly understand either the relationship of IMRT to stereotactic radiosurgery or the various types of equipment used to perform these services.

We are proposing to set forth a proposed new coding structure that more accurately reflects the clinical use of these services and the resources required to perform them. Our understanding of these services, based on review of the comments, the testimony before the Panel, the Panel discussion and recommendations, and meetings with knowledgeable stakeholders, is described below.

Recent developments in the field of radiation oncology include the ability to deliver high doses of radiation to abnormal tissues (e.g., tumors) while minimizing delivery of radiation to adjacent normal tissues. Collectively, these procedures are called stereotactic radiosurgery and IMRT.

Clinically, there are essentially two services required to deliver stereotactic radiosurgery and IMRT. First, there is ''treatment planning,'' which includes such activities as determining the location of all normal and abnormal tissues, determining the amount of radiation to be delivered to the abnormal tissue, determining the dose tolerances of normal tissues, and determining how to deliver the required dose to abnormal tissue while delivering a dose to adjacent normal tissues within their range of tolerance. These activities include the ability to manufacture various treatment devices for protection of normal tissue as well as the ability to ensure that the plan will deliver the intended doses to normal and abnormal tissue by simulating the treatment. Second, there is ''treatment delivery,'' which is the actual delivery of radiation to the patient in accordance with the treatment plan. Treatment delivery includes such activities as adjusting the collimator (a device that filters the radiation beams), doing setup and verification images, treating one or more areas, and performing quality control.

Treatment planning requires specialized equipment including a duplicate of the actual equipment used to deliver the treatment, the ability to perform a CT scan, various disposable supplies, and involvement of various staff such as the physician, the physicist, the dosimetrist, and the radiation technologist. Treatment delivery requires specialized equipment to deliver the treatment and the involvement of the radiation technologist. The physician and physicist provide general oversight of this process.

Although there are several types of equipment, produced by several manufacturers, used to accomplish this treatment, it is the consensus of the commenters and the Panel that the most useful way to categorize stereotactic radiosurgery and IMRT is by the source of radiation used for the treatment and

not by the type of equipment used. One reason for this is that the clinical indications for stereotactic radiosurgery and IMRT overlap. Therefore, a single disease process can be treated by either modality but the cost of treatment varies by source of radiation used for the treatment. Second, while both stereotactic radiosurgery and IMRT can deliver a complete course of treatment in either one or multiple sessions, the cost of treatment delivery per session is relatively fixed, and is closely related to the source of radiation used for the treatment. Therefore, we believe that appropriate APC assignment and payment can be made by creating a small number of HCPCS codes to describe these services. The proposed codes are as follows:

- GXXX1 Multi-source photon stereotactic radiosurgery (Cobalt 60 multi-source converging beams) plan, including dose volume histograms for target and critical structure tolerances, plan optimization performed for highly conformal distributions, plan positional accuracy and dose verification, all lesions treated, per course of treatment.
- GXXX2 Multi-source photon stereotactic radiosurgery, delivery including collimator changes and custom plugging, complete course of treatment, per lesion.
- G0174 Intensity modulated radiation therapy (IMRT) delivery to one or more treatment areas, multiple couch angles/fields/arcs custom collimated pencil-beams with treatment setup and verification images, complete course of therapy requiring more than one session, per session.
- G0178 Intensity modulated radiation therapy (IMRT) plan, including dose volume histograms for target and critical structure partial tolerances, inverse plan optimization performed for highly conformal distributions, plan positional accuracy and dose verification, per course of treatment.

We propose that HCPCS codes GXXX1, G0174, and G0178 have status indicators of S, while GXXX2 have a status indicator of T. We believe these are the correct status indicators because G0178 has a ''per session'' designation, while GXXX2 has a ''per lesion'' designation. Furthermore, it is our understanding that GXXX1 would not be billed on a ''per lesion'' basis as the planning process would take into account all lesions being treated and it would be extremely difficult to determine resource utilization for planning on a ''per lesion'' basis. Because the costs of performing GXXX1 will vary based on the number of lesions treated, payment would reflect a weighted average.

It is our understanding that single-source photon stereotactic radiosurgery (or LINAC) planning and delivery are similar to IMRT planning and delivery in terms of clinical use and resource requirements. Therefore, we propose to require coding for single-source photon stereotactic radiosurgery under HCPCS codes G0174 and G0178.

Further, we are aware that the AMA is establishing codes for IMRT planning and treatment delivery for 2002 and we propose to retire G0174 and G0178 (with the usual 90-day phase out) and recognize the applicable CPT codes when they are established in January 2002.

We believe that all activities required to perform stereotactic radiosurgery and IMRT are included in the codes described above. In order to avoid confusion and to optimize tracking of these services in terms of both utilization and cost, we propose to discontinue the use of any other radiation therapy codes for activities involved with planning and delivery of stereotactic radiosurgery and IMRT for purposes of hospital billing in OPPS. Thus, we would continue to not recognize CPT code 61793 for hospital billing purposes.

We believe the coding requirements set forth above not only simplify the reporting process for hospitals, but appropriately recognize the clinical practice and resource requirements for stereotactic radiosurgery and IMRT.

We seek comments on our proposal, including the code titles, descriptors, and coding requirements discussed above. We also request information regarding appropriate APC assignment and payment rates to inform our decision-making. In particular, we would like information regarding the costs of treatment delivery including any differences between the cost of a complete treatment in single versus multiple sessions.

We also note that several commenters requested placement of the stereotactic delivery codes in surgical APCs and we request clarification and support for these comments within the context of our coding proposal. Specifically, we are concerned that appropriate payment be made for GXXX2, which has a ''per lesion'' descriptor.

We believe that while the APC Panel did not make any specific recommendations regarding these codes, the concerns expressed by the Panel are addressed by our proposal.

APC 0311: Radiation Physics Services

APC 0312: Radio Element Application

APC 0313: Brachytherapy

We presented APC 0311 to the Panel because we believed our cost data for CPT codes 77336, Continuing medical physics consultation, including assessment of treatment parameters, quality assurance of dose delivery, and review of patient treatment documentation in support of the radiation oncologist, reported per week of therapy; 77370, Special medical radiation physics consultation; and 77399, Unlisted procedure, medical radiation physics, dosimetry, and treatment devices, and special services, were inaccurate. We were concerned that these procedures, particularly code 77370, were not being paid appropriately in APC 0311.

Presenters pointed out that, as with all radiation oncology services, the usual practice is to bill multiple CPT codes on the same date of service. Therefore, single claims were likely to be inaccurate bills and did not represent the true costs of the procedure. For this reason, presenters believe that using single claims to set payment rates for radiation oncology procedures was inappropriate and that we needed to develop a methodology that allowed the use of multiple claims data to set payment rates for these services.

With regard to radiation physics consultation, presenters stated that the staff costs associated with CPT code 77370 were significantly greater than the costs of CPT codes 77336 and 77399. Therefore, they recommended that CPT codes 77336 and 77399 be moved from APC 0311 to APC 0304, Level I Therapeutic Radiation Treatment Preparation, and CPT code 77370 be moved from APC 0311 to APC 0305, Level II Therapeutic Radiation Treatment Preparation. The Panel agreed with this recommendation and we propose to accept the Panel's recommendation. We also agree that we should review the use of single claims to set payment rates for radiation oncology services. We plan to present this issue again at the 2002 Panel meeting.

We presented APCs 0312 and 0313 to the Panel because commenters were concerned that the payment rates were too low for the procedures assigned to the APCs and that there were insufficient data to set payment rates for these APCs. The Panel agreed that the issue regarding the use of single claim data affected the payment rates for these services. However, there were insufficient data for the Panel to make

any recommendations regarding these APCs. The Panel did request to look at the issue of radiation oncology at its 2002 meeting.

Therefore, we are proposing to make no changes to APCs 0312 and 0313 but will address radiation oncology issues at the Panel's 2002 meeting. We note that our updated claims data show very few single claims for procedures in these APCs. However, moving any of these procedures into other radiation oncology APCs would lower their payment rates.

APC 0371: Allergy Injections

We presented this APC to the Panel because it violates the 2 times rule. The median costs for CPT codes 95115, Professional Services for allergen immunotherapy not including provision of allergenic extracts; single injection, and 95117, Professional Services for allergen immunotherapy not including provision of allergenic extracts; two or more injections, were lower than the median costs for the other services in this APC.

The Panel agreed that because codes 95115 and 95117 included administration of an injection only, the resource utilization for these services was lower than for the other services. The other services involve preparation of antigen and require more staff time and hospital resources to perform.

In order to create clinical and resource homogeneity, the Panel recommended that we create a new APC for codes 95115 and 95117 and that we leave the other services in APC 0371. We propose to accept the Panel recommendation and create a new APC 0353, Level II Allergy Injections, and revise the title of APC 0371 to Level I Allergy Injections.

Observation Services

See the discussion on observation services in section II.C.4 of this preamble for a summary of the Panel discussion and recommendations and our proposal.

Inpatient Procedure List

See the discussion of the inpatient procedures list in section II.C.5 of this preamble for a summary of the Panel discussion and recommendations and our proposal.

B. Additional APC Changes Resulting from BIPA Provisions

1. Coverage of Glaucoma Screening

Section 102 of the BIPA amended section 1861(s)(2) of the Act to provide payment for glaucoma screening for eligible Medicare beneficiaries, specifically, those with diabetes mellitus or a family history of glaucoma, and certain other individuals found to be at high risk for glaucoma as specified by our rulemaking. The implementation of this provision is discussed in detail in a separate proposed rule concerning the revisions in the physician payment policy for CY 2002.

In order to implement section 102 of BIPA, we have established two new HCPCS codes for glaucoma screening:

G0117—Glaucoma screening for high risk patients furnished by an ophthalmologist or optometrist.

G0118—Glaucoma screening for high risk patients furnished under the direct supervision of an ophthalmologist or optometrist.

We are proposing to assign the glaucoma screening codes to APC 0230, Level I Eye Tests. We further propose to instruct our fiscal intermediaries to make payment for glaucoma screening only if it is the sole ophthalmologic service for which the hospital submits a bill for a visit. That is, the services included in glaucoma screening (a dilated eye examination with an intraocular pressure measurement and direct opthalmoscopy or slit-lamp biomicroscopy) would generally be performed during the delivery of another opthalmologic service that is furnished on the same day. If the beneficiary receives only a screening service, however, we would pay for it under APC 0230.

2. APCs for Contrast Enhanced Diagnostic Procedures

Section 430 of the BIPA amended section 1833(t)(2) of the Act to require the Secretary to create additional APC groups to classify procedures that utilize contrast agents separately from those that do not, effective for items and services furnished on or after July 1, 2001. On June 1, 2001, we issued a Program Memorandum, Transmittal A–01–73, in which we made numerous coding and grouping changes to implement this provision. (This transmittal can be found at www.hcfa.gov/pubforms/transmit/AO173.pdf) We removed the radiological procedures whose descriptors included either ''without contrast material'' or ''without contrast material followed by contrast material'' from APC groups 0282, Level I, Computerized Axial Tomography; APC 0283, Level II, Computerized Axial Tomography; and APC 0284, Magnetic Resonance Imaging. As a result, APCs 0283 and 0284 now include only imaging procedures that are performed with contrast materials. Additionally, reconfigured APC 0282 no longer includes radiological procedures that use contrast agents.

Effective for items or services furnished on or after July 1, 2001, we created six new APC groups for the procedures removed from APCs 0282, 0283, and 0284, as shown below. (Effective October 1, 2001, we will eliminate APC 0338. Refer to Transmittal A–01–73 for a detailed description of this change.) For services furnished on or after July 1, 2001 and before January 1, 2002, the payment rates for the new imaging APCs are the same as those associated with the APCs from which the procedures were moved. In this proposed rule, the weights for the new APCs are recalibrated based on the data we are using to set the weights for 2002.

TABLE 1.—APC GROUPS RECONFIGURED TO SEPARATE IMAGING PROCEDURES THAT USE CONTRAST MATERIAL FROM PROCEDURES THAT DO NOT USE CONTRAST MATERIAL

APC	SI	APC title
0282	S	Miscellaneous Computerized Axial Tomography.
0283	S	Computerized Axial Tomography with Contrast.
0284	S	Magnetic Resonance Imaging and Angiography with Contrast.
0332	S	Computerized Axial Tomography w/o Contrast.
0333	S	CT Angio and Computerized Axial Tomography w/o Contrast followed by with Contrast.
0335	S	Magnetic Resonance Imaging, Temporomandibular Joint.
0336	S	Magnetic Resonance Angiography and Imaging without Contrast.
0337	S	Magnetic Resonance Imaging and Angiography w/o Contrast followed by with Contrast.
0338	S	Magnetic Resonance Angiography, Chest and Abdomen with or w/o Contrast.

The HCPCS codes that are reassigned to the new imaging APCs in this proposed rule are as follows:

APC	HCPCS	SI	Short descriptor
0282	76370	S	CAT scan for therapy guide.
	76375	S	3d/holograph reconstr add-on.
	76380	S	CAT scan for follow-up study.
	G0131	S	Ct scan, bone density study.
	G0132	S	Ct scan, bone density study.
0283	70460	S	Ct head/brain w/dye.
	70481	S	Ct orbit/ear/fossa w/dye.
	70487	S	Ct maxillofacial w/dye.
	70491	S	Ct soft tissue neck w/dye.
	71260	S	Ct thorax w/dye.
	72126	S	Ct neck spine w/dye.
	72129	S	Ct chest spine w/dye.
	72132	S	Ct lumbar spine w/dye.
	72193	S	Ct pelvis w/dye.
	73201	S	Ct upper extremity w/dye.
	73701	S	Ct lower extremity w/dye.
	74160	S	Ct abdomen w/dye.
	76355	S	CAT scan for localization.
	76360	S	CAT scan for needle biopsy.
0284	70542	S	MRI orbit/face/neck w/dye.
	70545	S	Mr angiography head w/dye.
	70548	S	Mr angiography neck w/dye.
	70552	S	MRI brain w/dye.
	71551	S	MRI chest w/dye.
	72142	S	MRI neck spine w/dye.
	72147	S	MRI chest spine w/dye.
	72149	S	MRI lumbar spine w/dye.
	72196	S	MRI pelvis w/dye.
	73219	S	MRI upper extremity w/dye.
	73222	S	MRI joint upr extrem w/dye.
	73719	S	MRI lower extremity w/dye.
	73722	S	MRI joint of lwr extr w/dye.
	74182	S	MRI abdomen w/dye.
	75553	S	Heart MRI for morph w/dye.
	C8900	S	MRA w/cont, abd.
	C8903	S	MRI w/cont, breast, uni.
	C8906	S	MRI w/cont, breast, bi.
	C8909	S	MRA w/cont, chest.
	C8912	S	MRA w/cont, lwr ext.
0332	70450	S	CAT scan of head or brain.
	70480	S	Ct orbit/ear/fossa w/o dye.
	70486	S	Ct maxillofacial w/o dye.
	70490	S	Ct soft tissue neck w/o dye.
	71250	S	Ct thorax w/o dye.
	72125	S	Ct neck spine w/o dye.
	72128	S	Ct chest spine w/o dye.
	72131	S	Ct lumbar spine w/o dye.
	72192	S	Ct pelvis w/o dye.
	73200	S	Ct upper extremity w/o dye.
	73700	S	Ct lower extremity w/o dye.
	74150	S	Ct abdomen w/o dye.
0333	70470	S	Ct head/brain w/o&w dye.
	70482	S	Ct orbit/ear/fossa w/o&w dye.
	70488	S	Ct maxillofacial w/o&w dye.
	70492	S	Ct sft tsue nck w/o & w/dye.
	70496	S	Ct angiography, head.
	70498	S	Ct angiography, neck.
	71270	S	Ct thorax w/o&w dye.
	71275	S	Ct angiography, chest.
	72127	S	Ct neck spine w/o&w dye.
	72130	S	Ct chest spine w/o&w dye.
	72133	S	Ct lumbar spine w/o&w dye.
	72191	S	Ct angiograph pelv w/o&w dye.
	72194	S	Ct pelvis w/o&w dye.
	73202	S	Ct uppr extremity w/o&w dye.
	73206	S	Ct angio upr extrm w/o&w dye.
	73702	S	Ct lwr extremity w/o&w dye.
	73706	S	Ct angio lwr extr w/o&w dye.
	74170	S	Ct abdomen w/o&w dye.
	74175	S	Ct angio abdom w/o&w dye.
	75635	S	Ct angio abdominal arteries.
0335	70336	S	Magnetic image, jaw joint.
	75554	S	Cardiac mri/function.
	75555	S	Cardiac mri/limited study.

APC	HCPCS	SI	Short descriptor
	76390	S	Mr spectroscopy.
	76400	S	Magnetic image, bone marrow.
0336	70540	S	MRI orbit/face/neck w/o dye.
	70544	S	Mr angiography head w/o dye.
	70547	S	Mr angiography neck w/o dye.
	70551	S	MRI brain w/o dye.
	71550	S	MRI chest w/o dye.
	72141	S	MRI neck spine w/o dye.
	72146	S	MRI chest spine w/o dye.
	72148	S	MRI lumbar spine w/o dye.
	72195	S	MRI pelvis w/o dye.
	73218	S	MRI upper extremity w/o dye.
	73221	S	MRI joint upr extrem w/o dye.
	73718	S	MRI lower extremity w/o dye.
	73721	S	MRI joint of lwr extre w/o dye.
	74181	S	MRI abdomen w/o dye.
	75552	S	Heart MRI for morph w/o dye.
	C8901	S	MRA w/o cont, abd.
	C8904	S	MRI w/o cont, breast, uni.
	C8910	S	MRA w/o cont, chest.
	C8913	S	MRA w/o cont, lwr ext.
0337	70543	S	MRI orbt/fac/nck w/o&w dye.
	70546	S	Mr angiograph head w/o&w dye.
	70549	S	Mr angiograph neck w/o&w dye.
	70553	S	MRI brain w/o&w dye.
	71552	S	MRI chest w/o&w dye.
	72156	S	MRI neck spine w/o&w dye.
	72157	S	MRI chest spine w/o&w dye.
	72158	S	MRI lumbar spine w/o&w dye.
	72197	S	MRI pelvis w/o&w dye.
	73220	S	MRI uppr extremity w/o&w dye.
	73223	S	MRI joint upr extr w/o&w dye.
	73720	S	MRI lwr extremity w/o&w dye.
	73723	S	MRI joint lwr extr w/o&w dye.
	74183	S	MRI abdomen w/o&w dye.
	C8902	S	MRA w/o fol w/cont, abd.
	C8905	S	MRI w/o fol w/cont, brst, uni.
	C8908	S	MRI w/o fol w/cont, breast, bi.
	C8911	S	MRA w/o fol w/cont, chest.
	C8914	S	MRA w/o fol w/cont, lwr ext.

Refer to Addendum A or Addendum B for the updated weights, payment rates, national unadjusted copayment, and minimum unadjusted copayment that we are proposing for all of the procedures listed above.

C. Other Changes Affecting the APCs

1. Changes in Revenue Code Packaging

In the April 7, 2000 final rule, we described how, in calculating the per procedure and per visit costs to determine the median cost of an APC (and therefore its relative weight), we used the charges billed using the revenue codes that contained items that were integral to performing the procedure or visit (65 FR 18483). For example, in calculating the cost of a surgical procedure, we included charges for revenue codes such as operating room, treatment rooms, recovery, observation, medical and surgical supplies, pharmacy, anesthesia, casts and splints, and donor tissue, bone, and organ. For medical visit costs, we included charges for items such as medical and surgical supplies, drugs, and observation. The complete list of the revenue centers by type of APC group was printed in the April 7, 2000 rule (65 FR 18484).

In the November 13, 2000 interim final rule, we made some changes to the list of revenue codes to reflect the charges associated with implantable devices (65 FR 67806 and 67825). As we stated in that rule, charges included in revenue codes 274 (prosthetic/orthotic devices), 275 (pacemaker), and 278 (other implants) were not included in the initial APC payment rates because, before enactment of BBRA, we were proposing to pay these devices outside of the OPPS, and, after the enactment of the BBRA, it was not feasible to revise our database to include these revenue codes in developing the April 7, 2000 final rule. As discussed in the November 13, 2000 interim final rule, we were later able to incorporate these revenue codes in our database, and effective January 1, 2001, we updated the APC payment rates to reflect inclusion of this information.

We have continued to review and revise the list of revenue codes to be included in the database and we are proposing several changes to the list of revenue codes that are packaged with the costs used to calculate the proposed APC rates. Some of these changes reflect the addition of revenue codes and others are a further refinement of our methodology. The following are the specific changes we are proposing to make:

- Package additional revenue centers that may be used to bill for implantable devices (including durable medical equipment (DME) and brachytherapy seeds) with surgical procedures. These additional centers are revenue codes 280 (oncology), 289 (other oncology), 290 (DME), and 624 (investigational devices).
- Package revenue codes 280, 289, and 624 with other diagnostic and radiology services.
- Package the revenue codes for medical social services, 560 (medical social services) and 569 (other medical social services). These services are not

paid separately in the hospital outpatient setting but often constitute discharge-planning services if provided with an outpatient service.

• Package revenue code 637 (self-administered drug (insulin administered in an emergency diabetic coma)) with medical visits. Although this is a self-administrable drug, it is covered when administered as described.

• Remove revenue code 723 (circumcision) from the list of packaged revenue codes because circumcision is a payable procedure under OPPS and should not be packaged.

• Package revenue code 942 (education/training) with medical visits and the category of ''All Other APC Groups.'' Patient training and education are generally not paid as a separate service under Medicare, but may be included as part of an otherwise payable service such as a medical visit. We believe that training and education services generally occur as part of a medical visit or psychiatric service.

• Remove the revenue codes in the range of 890 through 899 (donor bank), as these are no longer valid revenue codes.

2. Special Revenue Code Packaging for Specific Types of Procedures

We are proposing that the same packaging used for surgical procedures be used for corneal tissue implant procedures in APC 0244, Corneal Transplant, except that organ acquisition revenue codes and the revenue codes used to bill implantable devices are not packaged with corneal implants.

There are certain other diagnostic procedures with CPT codes that are similar to surgical procedures. The cost of these procedures (HCPCS codes 92980–92996, 93501–93505, and 93510–93536) reflects both the revenue code packaging for ambulatory surgical center (ASC) and other surgery, as well as the revenue code packaging for other diagnostic services.

A complete listing of the revenue codes that we are proposing in this rule and that we used for purposes of calculating median costs of services are shown below in Table 2.

Table 2.—Packaged Services by Revenue Code

Surgery

250 PHARMACY
251 GENERIC
252 NONGENERIC
257 NONPRESCRIPTION DRUGS
258 IV SOLUTIONS
259 OTHER PHARMACY
260 IV THERAPY, GENERAL CLASS
262 IV THERAPY/PHARMACY SERVICES
263 IV THERAPY/DRUG SUPPLY/DELIVERY
264 IV THERAPY/SUPPLIES
269 OTHER IV THERAPY
270 M&S SUPPLIES
271 NONSTERILE SUPPLIES
272 STERILE SUPPLIES
274 PROSTHETIC/ORTHOTIC DEVICES
275 PACEMAKER DRUG
276 INTRAOCULAR LENS SOURCE DRUG
278 OTHER IMPLANTS
279 OTHER M&S SUPPLIES
280 ONCOLOGY
289 OTHER ONCOLOGY
290 DURABLE MEDICAL EQUIPMENT
370 ANESTHESIA
379 OTHER ANESTHESIA
390 BLOOD STORAGE AND PROCESSING
399 OTHER BLOOD STORAGE AND PROCESSING
560 MEDICAL SOCIAL SERVICES
569 OTHER MEDICAL SOCIAL SERVICES
624 INVESTIGATIONAL DEVICE (IDE)
630 DRUGS REQUIRING SPECIFIC IDENTIFICATION, GENERAL CLASS
631 SINGLE SOURCE
632 MULTIPLE
633 RESTRICTIVE PRESCRIPTION
700 CAST ROOM
709 OTHER CAST ROOM
710 RECOVERY ROOM
719 OTHER RECOVERY ROOM
720 LABOR ROOM
721 LABOR
762 OBSERVATION ROOM
810 ORGAN AQUISITION
819 OTHER ORGAN ACQUISITION

Medical Visit

250 PHARMACY
251 GENERIC
252 NONGENERIC
257 NONPRESCRIPTION DRUGS
258 IV SOLUTIONS
259 OTHER PHARMACY
270 M&S SUPPLIES
271 NONSTERILE SUPPLIES
272 STERILE SUPPLIES
279 OTHER M&S SUPPLIES
560 MEDICAL SOCIAL SERVICES
569 OTHER MEDICAL SOCIAL SERVICES
630 DRUGS REQUIRING SPECIFIC IDENTIFICATION, GENERAL CLASS
631 SINGLE SOURCE DRUG
632 MULTIPLE SOURCE DRUG
633 RESTRICTIVE PRESCRIPTION
637 SELF-ADMINISTERED DRUG (INSULIN ADMIN. IN EMERGENCY DIABETIC COMA)
700 CAST ROOM
709 OTHER CAST ROOM
762 OBSERVATION ROOM
942 EDUCATION/TRAINING

Other Diagnostic

254 PHARMACY INCIDENT TO OTHER DIAGNOSTIC
280 ONCOLOGY
289 OTHER ONCOLOGY
372 ANESTHESIA INCIDENT TO OTHER DIAGNOSTIC
560 MEDICAL SOCIAL SERVICES
569 OTHER MEDICAL SOCIAL SERVICES
622 SUPPLIES INCIDENT TO OTHER DIAGNOSTIC
624 INVESTIGATIONAL DEVICE (IDE)
710 RECOVERY ROOM
719 OTHER RECOVERY ROOM
762 OBSERVATION ROOM

Radiology

255 PHARMACY INCIDENT TO RADIOLOGY
280 ONCOLOGY
289 OTHER ONCOLOGY
371 ANESTHESIA INCIDENT TO RADIOLOGY
560 MEDICAL SOCIAL SERVICES
710 RECOVERY ROOM
719 OTHER RECOVERY ROOM
569 OTHER MEDICAL SOCIAL SERVICES
621 SUPPLIES INCIDENT TO RADIOLOGY
624 INVESTIGATIONAL DEVICE (IDE)
762 OBSERVATION ROOM

All Other APC Groups

250 PHARMACY
251 GENERIC
252 NONGENERIC
257 NONPRESCRIPTION DRUGS
258 IV SOLUTIONS
259 OTHER PHARMACY
260 IV THERAPY, GENERAL CLASS
262 IV THERAPY PHARMACY SERVICES
263 IV THERAPY/DRUG/SUPPLY/DELIVERY
264 IV THERAPY SUPPLIES
269 OTHER IV THERAPY
270 M&S SUPPLIES
271 NONSTERILE SUPPLIES
272 STERILE SUPPLIES
279 OTHER M&S SUPPLIES
560 MEDICAL SOCIAL SERVICES
569 OTHER MEDICAL SOCIAL SERVICES
630 DRUG REQUIRING SPECIFIC IDENTIFICATION, GENERAL CLASS
631 SINGLE SOURCE DRUG
632 MULTIPLE SOURCE DRUG
633 RESTRICTIVE PRESCRIPTION
762 OBSERVATION ROOM
942 EDUCATION/TRAINING

3. Limit on Variation of Costs of Services Classified Within a Group

Section 1833(t)(2) of the Act provides that the items and services within an APC group cannot be considered comparable with respect to the use of resources if the highest cost item or service within a group is more than 2 times greater than the lowest cost item or service within the same group, but the Secretary may make exceptions to this limit on the variation of costs within each group in unusual cases such as low volume items and services. No exception may be made, however, in the case of a drug or biological that has been designated as an orphan drug under section 526 of the Federal Food, Drug, and Cosmetic Act.

Based on the proposed APC changes discussed above in this section of this preamble and the use of more current data to calculate the median cost of procedures classified to APCs, we reviewed all the APCs to determine which of them would not meet the 2 times limit. We use the following

criteria when deciding whether to make exceptions to the 2 times rule for affected APCs:

- Resource homogeneity.
- Clinical homogeneity.
- Hospital concentration.
- Frequency of service (volume).
- Opportunity for upcoding and code fragmentation.

For a detailed discussion of these criteria, refer to the April 7, 2000 final rule (65 FR 18457).

The following list contains APCs that we propose to except from the 2 times rule based on the criteria cited above. In cases in which compliance with the 2 times rule appeared to conflict with a recommendation of the APC Advisory Panel, we generally accepted the Panel recommendation. This was because Panel recommendations were based on explicit consideration of resource use, clinical homogeneity, hospital specialization, and the quality of the data used to determine payment rates.

0001 Photochemotherapy
0041 Arthroscopy
0044 Closed Treatment Fracture/Dislocation Except Finger/Toe/Trunk
0047 Arthroplasty without Prosthesis
0058 Level I Strapping and Cast Application
0077 Level I Pulmonary Treatment
0093 Vascular Repair/Fistula Construction
0096 Noninvasive Vascular Studies
0097 Cardiac Monitoring for 30 days
0115 Cannula/Access Device Procedures
0121 Level I Tube Changes and Repositioning
0140 Esophageal Dilation without Endoscopy
0147 Level II Sigmoidoscopy
0164 Level I Urinary and Anal Procedures
0165 Level II Urinary and Anal Procedures
0182 Insertion of Penile Prosthesis
0198 Pregnancy and Neonatal Care Procedures
0203 Level V Nerve Injections
0204 Level VI Nerve Injections
0207 Level IV Nerve Injections
0213 Extended EEG Studies and Sleep Studies
0215 Level I Nerve and Muscle Tests
0231 Level II Eye Tests
0238 Level I Repair and Plastic Eye Procedures
0251 Level I ENT Procedures
0260 Level I Plain Film Except Teeth
0265 Level I Diagnostic Ultrasound Except Vascular
0279 Level I Angiography and Venography except Extremity
0285 Positron Emission Tomography (PET)
0305 Level II Therapeutic Radiation Preparation
0322 Brief Individual Psychotherapy
0345 Level I Transfusion Lab Procedures
0349 Miscellaneous Lab Procedures
0354 Administration of Influenza/Pneumonia Vaccine
0356 Level II Immunizations
0363 Otorhinolaryngologic Function Tests
0364 Level I Audiometry
0373 Neuropsychological Testing
0602 High Level Clinic Visits
0694 Level III Excision/Biopsy
0697 Level II Transesophageal Procedures

4. Observation Services

Observation services have a long intertwined clinical and payment history. For many years, beneficiaries have been placed in ''observation status'' in order to receive treatment or be monitored before making a decision concerning their next placement (that is, admit to the hospital or discharge to home). This occurs most frequently after surgery or a visit to the emergency department. Typically, beneficiaries placed in observation have failed to respond to initial emergency department treatment for their condition (for example, exacerbation of asthma), have symptoms placing them at significant risk for mortality (for example, chest pains with the possibility of myocardial infarction), or have received anesthesia for a surgical procedure and need to be monitored postoperatively. Clinically, most beneficiaries do not require more than 24 hours of observation before a decision concerning admission or discharge can be made. Therefore, it is rare that it is clinically justifiable to keep a patient in observation for more than 24 to 48 hours. The location where observation services are provided is facility-specific, and sometimes individual-specific. It is not uncommon for beneficiaries to be observed in the emergency department, in a designated unit near the emergency department, or in an intensive care or other unit in the facility.

After implementation of the Medicare hospital inpatient PPS in 1983, peer review organizations (PROs) began to review inpatient admissions to determine whether the admission and the length of stay were appropriate. Because ''observation care'' is considered to be an outpatient service, facilities began using ''observation'' as an administrative mechanism to care for beneficiaries who, if admitted as inpatients, might have their admission questioned by the PRO. Moreover, before the implementation of the OPPS, the payment for observation care was on a reasonable cost basis, which frequently gave hospitals a financial incentive to keep beneficiaries in ''observation status'' even though they were clinically being treated as inpatients. Occasionally, beneficiaries were kept in observation for days and weeks resulting in both excessive payments from the Medicare program and excessive copayments from the beneficiary. In response to this practice, Medicare revised its manuals in November 1996, limiting covered observation services to no more than 48 hours (section 456 of the Hospital Manual and section 3663 of the Intermediary Manual).

The costs for all observation services provided in the outpatient setting, even those provided in excess of 48 hours, were included in the initial APC payment rates. Currently, observation services are not paid separately, that is, they are not assigned to a separate APC. Instead, costs for observation services are packaged into payments for services with which the observation was billed in 1996. Observation was most frequently billed with emergency department visits, clinic visits, and surgical procedures. The payments for all APCs include the costs of observation to the extent that it was billed in 1996. In the 1996 data, we identified and packaged a total of $392 million from revenue codes 760, 761, 762, and 769, which represented observation services.

In the April 7, 2000 final rule (65 FR 18448), we responded to numerous comments concerning observation services. Even though commenters acknowledged that being paid separately for observation services following a surgical procedure was unnecessary, many commenters requested that we pay separately for observation services following emergency department visits. Among those commenters requesting separate payment for observation, some requested separate payment for specific medical conditions, and others requested payment for all medical conditions. Some commenters provided articles and books containing clinical research on the value and cost effectiveness of observation for certain patients. Although we did not decide to create a separate APC for observation services, we did include this topic in the agenda for our APC Panel, which met from February 27 to March 1, 2001. While individual Panel members agreed that use of observation services had been abused in the past by hospitals seeking to maximize payment, the Panel also agreed that observation services following clinic and emergency room visits should be paid separately. In addition, the Panel believed that observation following surgery should be packaged into the payment for the surgical procedure. The Panel did not dispute that the vast majority of patients are admitted to the hospital or discharged home from observation in less than 24 hours, and Panel members judged that a rule limiting separate payment to 24 hours of observation

would be reasonable. The Panel also noted that because Medicare currently allows hospitals to report observation services up to 48 hours, hospital staff and coders would have to be educated were we to change the current standard.

Since the Panel meeting, we have reviewed all comments we have received on this issue. In determining whether we should pay separately for observation services, our primary concern is to ensure that Medicare beneficiaries have access to medically necessary observation care. We also want to ensure that payment be made only for beneficiaries actually receiving observation care, and that payment be restricted to clinically appropriate observation care. We paid particular attention to the Qualcare criteria (severity of illness and intensity of service criteria used by some insurance plans to determine whether it is appropriate for a patient to receive observation care) for observation services and to those comments providing medical evidence on the value and cost effectiveness of observation care. We also carefully considered logistical and administrative issues related to delivering observation care such as whether payment for emergency services should be bundled into observation services, the potential for overuse of the services, and the need for treatment guidelines. We also considered how to most appropriately define the starting time, discharge time, and minimum length of stay for observation care.

Finally, in considering whether to make a separate payment for observation care, we had to balance the issues of access, medical necessity, potential for abuse, and need to ensure appropriate payment. As a threshold requirement for candidate medical conditions, we sought published criteria regarding the following:

- Risk stratification of patients to determine which patient sub-populations benefit from observation care.
- Which patients should be admitted to observation.
- Which patients should be discharged home from observation.
- When patients should be admitted to the hospital from observation.
- Patient management.

We found that these criteria were met for chest pain, asthma, and congestive heart failure.

The fulfillment of these criteria ensured that, for these conditions, observation care avoided significant morbidity and mortality from inappropriate discharge to home while at the same time avoiding unnecessary inpatient admissions. For example, the use of observation for selected patients with asthma and congestive heart failure can reduce the rate of return emergency visits and subsequent admission. The literature clearly shows that for these patients, observation care requires prolonged physiologic monitoring and intensive treatment to result in the beneficial outcomes.

After careful consideration, we are proposing—

- To continue to package observation services into surgical procedures; and
- To create a single APC, APC 0339, Observation, to make separate payment for observation services for three medical conditions, chest pain, asthma, and congestive heart failure, when certain criteria (as described below) are met.

We are further proposing to instruct hospitals that payment under APC 0339 for observation services would be subject to the following billing requirements and conditions:

- An emergency department visit (APC 0610, 0611, or 0612) or a clinic visit (APC 0600, 0601, or 0602) is billed in conjunction with each bill for observation services.
- Observation care is billed hourly for a minimum of 8 hours up to a maximum of 48 hours. We would not pay separately for any hours a beneficiary spends in observation over 24 hours, but all costs beyond 24 hours would be packaged into the APC payment for observation services.
- Observation time begins at the clock time appearing on the nurse's observation admission note. (We note that this coincides with the initiation of observation care or with the time of the patient's arrival in the observation unit.)
- Observation time ends at the clock time documented in the physician's discharge orders, or, in the absence of such a documented time, the clock time when the nurse or other appropriate person signs off on the physician's discharge order. (This time coincides with the end of the patient's period of monitoring or treatment in observation.)
- The beneficiary is under the care of a physician during the period of observation, as documented in the medical record by admission, discharge, and other appropriate progress notes, timed, written, and signed by the physician.
- The medical record includes documentation that the physician used risk stratification criteria to determine that the beneficiary would benefit from observation care. (These criteria may be either published generally accepted medical standards or established hospital-specific standards.)
- The hospital furnishes certain other diagnostic services along with observation services to ensure that separate payment is made only for those beneficiaries truly requiring observation care. We believe that these tests are typically performed on beneficiaries requiring observation care for the three specified conditions and they are medically necessary to determine whether a beneficiary will benefit from being admitted to observation care and the appropriate disposition of a patient in observation care. The diagnostic tests are as follows:
- For chest pain, at least two sets of cardiac enzymes and two sequential electrocardiograms.
- For asthma, a peak expiratory flow rate (PEFR) (CPT code 94010) and nebulizer treatments.
- For congestive heart failure, a chest x-ray, an electrocardiogram, and pulse oximetry.

We are proposing to make payment for APC 0339 only if the tests described above are billed on the same claim as the observation service.

(We are not proposing to require telemetry and other ongoing monitoring services as criteria to make separate payment for observation services. Although these services are often medically necessary to ensure prompt diagnosis of cardiac arrhythmias and other disorders, we do not believe they are necessary to support separate payment for observation services.)

We propose to require that, in order to receive payment for APC 0339, the hospital must include one of the ICD–9–CM diagnosis codes listed below in the diagnosis field of the bill. We propose the following diagnosis codes to indicate a symptom or condition that would require observation:

For Chest Pain

411.1 Intermediate coronary syndrome
411.81 Coronary occlusion without myocardial infarction
411.0 Postmyocardial infarction syndrome
411.89 Other acute ischemic heart disease
413.0 Angina decubitus
413.1 Prinzmetal angina
413.9 Other and unspecified angina pectoris
786.05 Shortness of breath
786.50 Chest pain, unspecified
786.51 Precordial pain
786.52 Painful respiration
786.59 Other chest pain

For Asthma

493.01 Extrinsic asthma with status asthmaticus
493.02 Extrinsic asthma with acute exacerbation

493.11 Intrinsic asthma with status asthmaticus
493.12 Intrinsic asthma with acute exacerbation
493.21 Chronic obstructive asthma with status asthmaticus
493.22 Chronic obstructive asthma with acute exacerbation
493.91 Asthma, unspecified with status asthmaticus
493.92 Asthma, unspecified with acute exacerbation

For Congestive Heart Failure

428.0 Congestive heart failure
428.1 Left heart failure
428.9 Heart failure, unspecified

We used the following process to identify the appropriate median cost for APC 0339. First, we identified in the 1999–2000 claims data all hospital outpatient claims for observation using revenue codes 760, 761, 762, and 769. We then selected the subset of these claims that were billed for patients with chest pain, asthma, and congestive heart failure. Because no standard method for coding these claims was in place in 1996, we identified all diagnosis codes that could reasonably have been used to classify beneficiaries as having chest pain, asthma, and congestive heart failure. We then verified that these beneficiaries received appropriate observation care for chest pain, asthma, or congestive heart failure by identifying the claims in which one or more of the tests identified above were performed. The median costs of these claims were used to establish the median costs of APC 0339.

We appreciate that there are other medical conditions for which selected beneficiaries may benefit from observation care and we are interested in comments on whether we should make separate payment for observation care for other conditions. We will consider medical research submitted to support the benefits of observation services for these conditions. This information will assist us in determining whether these other conditions meet the criteria we used to select the three conditions we have proposed to include in APC 0339.

5. List of Procedures That Will Be Paid Only as Inpatient Procedures

Before implementation of the OPPS, Medicare paid reasonable costs for services provided in the outpatient department. The claims submitted were subject to medical review by the fiscal intermediaries to determine the appropriateness of providing certain services in the outpatient setting. We did not specify in regulations those services that were appropriate to provide only in the inpatient setting and that, therefore, should be payable only when provided in that setting.

Section 1833(t)(1)(B)(i) of the Social Security Act gave the Secretary broad authority to determine the services to be covered and paid for under the OPPS. In the September 8, 1998 OPPS proposed rule, we defined a set of services that are typically provided only in an inpatient setting and, hence, would not be paid by Medicare under the OPPS. This set of services is referred to as the ''inpatient list.''

We received numerous comments on the inpatient list. In the April 7, 2000 final rule, we revised the proposed list by removing a number of services and we discussed in greater detail the criteria we will use to define which services will be included on the inpatient list (65 FR 18455). These are services that require inpatient care because of the invasive nature of the procedure, the need for at least 24 hours of postoperative recovery time or monitoring before the patient can be safely discharged, or the underlying physical condition of the patient.

After publication of the April 7 final rule, we received information from a number of groups demonstrating that certain services are routinely provided safely in the outpatient setting. As a result, in the November 13, 2000 interim final rule, we removed 44 procedures from the list (65 FR 67826). In that rule, we also stated that we would update the list at least quarterly to reflect advances in medical practice that permit procedures to be routinely performed in the outpatient setting. And, on June 1, 2001, we issued Program Memorandum A–01–73 in which we moved an additional 23 procedures from the inpatient list.

At its February 2001 meeting, the APC Advisory Panel discussed the existence of the inpatient list. The Advisory Panel generally favored its elimination. In this instance, we disagree with the position taken by the Panel. Rather, we propose to continue the current policy of reviewing the HCPCS codes on the inpatient list and eliminating procedures from the list if they can be appropriately performed on the Medicare population in the outpatient setting. Our medical and policy staff, supplemented as appropriate by the APC Advisory Panel, would review comments submitted by the public and consider advances in medical practice in making decisions to remove codes from the list. We would continue to use the following criteria, which we discussed in the April 7, 2000 final rule, when deciding to remove codes from the list:

- Most outpatient departments are equipped to provide the services to the Medicare population.
- The simplest procedure described by the code may be performed in most outpatient departments.
- The procedure is related to codes we have already moved off the inpatient list (for example, the radiologic part of an interventional cardiology procedure).

We would continue to update the list in response to comments as often as quarterly through program memoranda to reflect current advances in medical practice. We believe that the current list addresses the concerns of previous commenters and reflects a general consensus about those services that hospitals and physicians agree are not routinely performed in the outpatient setting. Therefore, at this time, we are proposing no further changes to the inpatient list, which is set forth in Addendum E to this proposed rule.

6. Additional New Technology APC Groups

In the April 7, 2000 final rule, we created 15 new technology APC groups to pay for new technologies that do not meet the statutory requirements for transitional pass-through payments and for which we have little or no data upon which to base assignment to an appropriate APC. APC groups 0970 through 0984 are the current new technology APCs. We currently assign services to a new technology APC for 2 to 3 years based solely on costs, without regard to clinical factors. This method of paying for new technologies allows us to gather data on their use for subsequent assignment to a clinically-based APC. Payment rates for the new technology APCs are based on the midpoint of ranges of possible costs.

After evaluating the costs of services in the new technology APCs, we are proposing that APC 0982, which covers a range of costs from $2500 to $3500, be split into two APCs, as follows: APC 0982, which would encompass services whose costs fall between $2500 and $3000, and APC 0983, which would encompass those services whose costs fall between $3000 and $3500. APC 0984 would then encompass services whose costs fall between $3500 and $5000 and we would create a new APC, 0985, for services whose costs fall between $5000 and $6000. We believe that subdividing the current range of costs within APC 0982 would allow us to pay more accurately for the services in that cost range.

In section VI.G of this preamble, we describe several modifications and refinements to the criteria and process

for assigning services to new technology APCs that we are proposing in this rule.

Table 3 below, lists all of the APC groups that we are proposing to change for 2002.

TABLE 3.—APC GROUPS PROPOSED TO BE CHANGED IN 2002

APC	Title	SI	APC panel	2 times	Other
0002	Fine needle Biopsy/Aspiration	T		X	
0004	Level I Needle Biopsy/Aspiration Except Bone Marrow	T		X	
0006	Level I Incision & Drainage	T		X	
0007	Level II Incision & Drainage	T		X	
0008	Level III Incision & Drainage	T		X	
0012	Level I Debridement & Destruction	T		X	
0013	Level II Debridement & Destruction	T		X	
0014	Level III Debridement and Destruction	T		X	
0015	Level IV Debridement & Destruction	T		X	
0016	Level V Debridement & Destruction	T	X	X	
0017	Level VI Debridement & Destruction	T	X	X	
0018	Biopsy of Skin/Puncture of Lesion	T		X	
0019	Level I Excision/Biopsy	T		X	
0020	Level II Excision/Biopsy	T		X	
0021	Level IV Excision/Biopsy	T		X	
0022	Level V Excision/Biopsy	T		X	
0026	Level III Skin Repair	T		X	
0027	Level IV Skin Repair	T		X	
0029	Level II Incision/Excision Breast	T		X	
0030	Level I Breast Reconstruction	T		X	
0032	Insertion of Central Venous/Arterial Catheter	T		X	
0035	Placement of Arterial/Central Venous Catheter	T		X	
0043	Closed Treatment Fracture Finger/Toe/Trunk	T		X	
0044	Closed Treatment Fracture/Dislocation except Finger/Toe/Trunk	T		X	
0045	Bone/Joint Manipulation Under Anesthesia	T		X	
0049	Level I Musculoskeletal Procedures Except Hand and Foot	T		X	
0050	Level II Musculoskeletal Procedures Except Hand and Foot	T		X	
0058	Level I Strapping and Cast Application	S		X	
0059	Level II Strapping and Cast Application	S		X	
0068	CPAP Initiation	S	X		
0069	Thoracoscopy	T		X	
0074	Level IV Endoscopy Upper Airway	T		X	
0075	Level V Endoscopy Upper Airway	T		X	
0076	Endoscopy Lower Airway	T		X	
0079	Ventilation Initiation and Management	S	X		
0082	Coronary Atherectomy	T		X	
0083	Coronary Angioplasty	T		X	
0087	Cardiac Electrophysiologic Recording/Mapping	S	X		
0088	Thrombectomy	T		X	
0093	Vascular Repair/Fistula Construction	T		X	
0094	Resuscitation and Cardioversion	S	X		
0097	Cardiac Monitoring for 30 days	T		X	
0102	Electronic Analysis of Pacemakers/other Devices	S	X		
0105	Revision/Removal of Pacemakers, AICD, or Vascular Device	T	X		
0111	Blood Product Exchange	S	X		
0112	Apheresis, Photopheresis, and Plasmapheresis	S	X		
0115	Cannula/Access Device Procedures	T		X	
0125	Refilling of Infusion Pump	T	X		
0130	Level I Laparoscopy	T		X	
0131	Level II Laparoscopy	T		X	
0148	Level I Anal/Rectal Procedure	T		X	
0149	Level III Anal/Rectal Procedure	T		X	
0150	Level IV Anal/Rectal Procedure	T		X	
0155	Level II Anal/Rectal Procedure	T		X	
0156	Level II Urinary and Anal Procedures	T		X	
0160	Level I Cystourethroscopy and other Genitourinary Procedures	T		X	
0161	Level II Cystourethroscopy and other Genitourinary Procedures	T		X	
0162	Level III Cystourethroscopy and other Genitourinary Procedures	T		X	
0163	Level IV Cystourethroscopy and other Genitourinary Procedures	T		X	
0164	Level I Urinary and Anal Procedures	T		X	
0165	Level III Urinary and Anal Procedures	T		X	
0188	Level II Female Reproductive Proc	T	X	X	
0189	Level III Female Reproductive Proc	T	X	X	
0191	Level I Female Reproductive Proc	T	X	X	
0192	Level IV Female Reproductive Proc	T	X	X	
0193	Level V Female Reproductive Proc	T	X	X	
0194	Level VI Female Reproductive Proc	T	X	X	
0195	Level VII Female Reproductive Proc	T	X	X	

TABLE 3.—APC GROUPS PROPOSED TO BE CHANGED IN 2002—Continued

APC	Title	SI	APC panel	2 times	Other
0196	Dilation and Curettage	T		X	
0203	Level V Nerve Injections	T	X		
0204	Level VI Nerve Injections	T	X		
0206	Level III Nerve Injections	T	X		
0207	Level IV Nerve Injections	T	X		
0208	Laminotomies and Laminectomies	T	X		
0209	Level II Extended EEG Studies and Sleep Studies	S		X	
0212	Level II Nervous System Injections	T	X		
0213	Level I Extended EEG Studies and Sleep Studies	S		X	
0215	Level I Nerve and Muscle Tests	S	X	X	
0216	Level III Nerve and Muscle Tests	S	X	X	
0217	Level III Nerve and Muscle Tests	S		X	
0218	Level II Nerve and Muscle Tests	S		X	
0230	Level I Eye Tests & Treatments	S		X	X
0231	Level III Eye Tests & Treatments	S		X	
0232	Level I Anterior Segment Eye	S		X	
0233	Level II Anterior Segment Eye	T		X	
0234	Level III Anterior Segment Eye Procedures	T		X	
0235	Level I Posterior Segment Eye Procedures	T		X	
0236	Level II Posterior Segment Eye Procedures	T		X	
0237	Level III Posterior Segment Eye Procedures	T		X	
0238	Level I Repair and Plastic Eye Procedures	T		X	
0239	Level II Repair and Plastic Eye Procedures	T		X	
0245	Level I Cataract Procedures without IOL Insert	T		X	
0249	Level II Cataract Procedures without IOL Insert	T		X	
0251	Level I ENT Procedures	T		X	
0252	Level II ENT Procedures	T		X	
0253	Level III ENT Procedures	T		X	
0254	Level IV ENT Procedures	T		X	
0256	Level V ENT Procedures	T		X	
0259	Level VI ENT Procedures	T		X	
0260	Level I Plain Film Except Teeth	X		X	
0261	Level II Plain Film Except Teeth Including Bone Density Measurement	X		X	
0263	Level I Miscellaneous Radiology Procedures	X		X	
0264	Level II Miscellaneous Radiology Procedures	X		X	
0265	Level I Diagnostic Ultrasound Except Vascular	X		X	
0266	Level II Diagnostic Ultrasound Except Vascular	S		X	
0269	Level I Echocardiogram Except Transesophageal	S		X	
0271	Mammography	S			X
0272	Level I Fluoroscopy	X		X	
0279	Level I Angiography and Venography except Extremity	S	X		
0280	Level II Angiography and Venography	S	X		
0282	Miscellaneous Computerized Axial Tomography	S		X	X
0283	Computerized Axial Tomography with Contrast	S			X
0284	Magnetic Resonance Imaging and Angiography with Contrast	S			X
0287	Complex Venography	S	X		
0288	CT, Bone Density	S		X	
0289	Needle Localization for Breast Biopsy	X	X		
0291	Level I Diagnostic Nuclear Medicine Excluding Myocardial Scans	S		X	
0292	Level II Diagnostic Nuclear Medicine Excluding Myocardial Scans	S		X	
0300	Level I Radiation Therapy	S		X	
0301	Level II Radiation Therapy	S		X	
0302	Level III Radiation Therapy	S		X	
0304	Level I Therapeutic Radiation Treatment Preparation	X	X		
0305	Level II Therapeutic Radiation Treatment Preparation	X	X		
0312	Radioelement Applications	S	X		
0332	Computerized Axial Tomography w/o Contrast	S		X	X
0333	CT Angio and Computerized Axial Tomography w/o Contrast followed by with Contrast.	S		X	X
0335	Magnetic Resonance Imaging, Temporomandular Joint	S			X
0336	Magnetic Resonance Angiography and Imaging without Contrast	S		X	X
0337	Magnetic Resonance Imaging and Angiography w/o Contrast followed by with Contrast.	S			X
0338	Magnetic Resonance Angiography, Chest and Abdomen with or w/o Contrast	S			X
0339	Observation	X	X		
0340	Minor Ancillary Procedures	X		X	
0345	Level I Transfusion Laboratory Procedures	X		X	
0346	Level II Transfusion Laboratory Procedures	X		X	
0347	Level III Transfusion Laboratory Procedures	X		X	
0352	Level II Injections	X		X	
0353	Level II Allergy Injections	X	X		
0355	Level I Immunizations	K		X	

TABLE 3.—APC GROUPS PROPOSED TO BE CHANGED IN 2002—Continued

APC	Title	SI	APC panel	2 times	Other
0356	Level II Immunizations	K		X	
0359	Level I Injections	K		X	
0360	Level I Alimentary Tests	X		X	
0361	Level II Alimentary Tests	X		X	
0364	Level I Audiometry	X		X	
0365	Level II Audiometry	X		X	
0367	Level I Pulmonary Test	X		X	
0368	Level II Pulmonary Tests	X		X	
0369	Level III Pulmonary Tests	X		X	
0371	Level I Allergy Injections	X	X		
0689	Electronic Analysis of Cardioverter-Defibrillators	S	X		
0690	Electronic Analysis of Pacemakers and other Cardiac Devices	S	X		
0691	Electronic Analysis of Programmable Shunts/Pumps	S	X		
0692	Electronic Analysis of Neurostimulator Pulse Generators	S	X		
0693	Level II Breast Reconstruction	T		X	
0694	Level III Excision/Biopsy	T		X	
0695	Level VII Debridement & Destruction	T		X	
0696	Repair/Replacement of Cardioverter-Defibrillators	T	X		
0697	Level II Echocardiogram Except Transesophageal	S		X	
0698	Level II Eye Tests & Treatments	S		X	
0699	Level IV Eye Tests & Treatment	T		X	
0982	New Technology—Level XII ($2500–3000)	T			X
0983	New Technology—Level XIV ($3000–3500)	T			X
0984	New Technology—Level XV ($3500–5000)	T			X
0985	New Technology—Level XVI ($5000–6000)	T			X

D. Recalibration of APC Weights for CY 2002

Section 1833(t)(9)(A) of the Act requires that the Secretary review and revise the relative payment weights for APCs at least annually beginning in 2001 for application in 2002. In the April 7, 2000 final rule (65 FR 18482), we explained in detail how we calculated the relative payment weights that were implemented on August 1, 2000 for each APC group. Except for some reweighting due to APC changes, these relative weights continued to be in effect for 2001. (See the November 13, 2000 interim final rule (65 FR 67824–67827).)

To recalibrate the relative APC weights for services furnished on or after January 1, 2002 and before January 1, 2003, we are proposing to use the same basic methodology that we described in the April 7, 2000 final rule to recalibrate the relative weights for 2002. That is, we would recalibrate the weights based on claims and cost report data for outpatient services. We propose to use the most recent available data to construct the database for calculating APC group weights. For the purpose of recalibrating APC relative weights for 2002, the most recent available claims data are the approximately 98 million final action claims for hospital outpatient department services furnished on or after July 1, 1999 and before July 1, 2000. We matched these claims to the most recent cost report filed by the individual hospitals represented in our claims data. The APC relative weights would continue to be based on the median hospital costs for services in the APC groups.

The methodology we followed to calculate the APC relative weights proposed for CY 2002 is as follows:

- We excluded from the data approximately 15.4 million claims for those bill and claim types that would not be paid under the OPPS (for example, bill type 72X for dialysis services for patients with ESRD).
- Using the most recent available cost report from each hospital, we converted billed charges to costs and aggregated them to the procedure or visit level first by identifying the cost-to-charge ratio specific to each hospital's cost centers (''cost center specific cost-to-charge ratios'' or CCRs) and then by matching the CCRs to revenue centers used on the hospital's 1999–2000 outpatient bills. The CCRs included operating and capital costs but excluded costs paid on a reasonable cost basis that are described elsewhere of this preamble.
- We eliminated from the hospital CCR data 283 hospitals that we identified as having reported charges on their cost reports that were not actual charges (for example, they make uniform charges for all services).
- We calculated the geometric mean of the total operating CCRs of hospitals remaining in the CCR data. We removed from the CCR data 67 hospitals whose total operating CCR exceeded the geometric mean by more than 3 standard deviations.
- We excluded from our data approximately 1.8 million claims from the hospitals that we removed or trimmed from the hospital CCR data.
- We matched revenue centers from the remaining universe of approximately 80.8 million claims to CCRs of 5,653 hospitals.
- We separated the 80.8 million claims that we had matched with a cost report into two distinct groups: single-procedure claims and multiple-procedure claims. Single-procedure claims were those that included only one HCPCS code (other than laboratory and incidentals such as packaged drugs and venipuncture) that could be grouped to an APC. Multiple-procedure claims included more than one HCPCS code that could be mapped to an APC. There were approximately 36.4 million single-procedure claims and 44.4 million multiple-procedure claims.
- To calculate median costs for services within an APC, we used only single-procedure bills. We did not use multiple-procedure claims because we are not able to specifically allocate charges or costs for packaged items and services such as anesthesia, recovery room, drugs, or supplies to a particular procedure when more than one significant procedure or medical visit is billed on a claim. Use of the single-procedure bills minimizes the risk of improperly assigning costs to the wrong procedure or visit.
- For each single-procedure claim, we calculated a cost for every billed line item charge by multiplying each

revenue center charge by the appropriate hospital-specific CCR. If the appropriate cost center did not exist for a given hospital, we crosswalked the revenue center to a secondary cost center when possible, or to the hospital's overall cost-to-charge ratio for outpatient department services. We excluded from this calculation all charges associated with HCPCS codes previously defined as not paid under the OPPS (for example, laboratory, ambulance, and therapy services).

• To calculate the per-service costs, we used the charges shown in the revenue centers that contained items integral to performing the service. These included those items that we previously discussed as being subject to our proposed packaging provision. For instance, in calculating the surgical procedure cost, we included charges for the operating room, treatment rooms, recovery, observation, medical and surgical supplies, pharmacy, anesthesia, casts and splints, and donor tissue, bone, and organ. For medical visit cost estimates, we included charges for items such as medical and surgical supplies, drugs, and observation in those instances where it is still packaged. See sections II.C.1 and II.C.2 of this preamble for a discussion and complete listing of the revenue centers that we are proposing to use to calculate per-service costs.

• We standardized costs for geographic wage variation by dividing the labor-related portion of the operating and capital costs for each billed item by the current FY 2001 hospital inpatient prospective payment system wage index published in the **Federal Register** on August 1, 2000 (65 FR 47054). We used 60 percent to represent our estimate of that portion of costs attributable, on average, to labor. A more detailed discussion of wage index adjustments is found in section III of this preamble.

• We summed the standardized labor-related cost and the nonlabor-related cost component for each billed item to derive the total standardized cost for each procedure or medical visit.

• We removed extremely unusual costs that appeared to be errors in the data using a trimming methodology analogous to what we use in calculating the DRG weights for the hospital inpatient PPS. That is, we eliminated any bills with costs outside of 3 standard deviations from the geometric mean.

• After trimming the procedure and visit level costs, we mapped each procedure or visit cost to its assigned APC, including, to the extent possible, the proposed APC changes described elsewhere in this preamble.

• We calculated the median cost, weighted by procedure volume, for each APC.

• Using the weighted median APC costs, we calculated the relative payment weights for each APC. We scaled all the relative payment weights to APC 0601, Mid-level clinic visit, because it is one of the most frequently performed services in the hospital outpatient setting. This approach is consistent with that used in developing relative value units for the Medicare physician fee schedule. We assigned APC 0601 a relative payment weight of 1.00 and divided the median cost for each APC by the median cost for APC 0601, to derive the relative payment weight for each APC. The median cost for APC 0601 is $54.00.

Section 1833(t)(9)(B) of the Act requires that APC reclassification and recalibration changes and wage index changes be made in a manner that assures that aggregate payments under the OPPS for 2002 are neither greater than nor less than the aggregate payments that would have been made without the changes. To comply with this requirement concerning the APC changes, we compared aggregate payments using the CY 2001 relative weights to aggregate payments using the CY 2002 proposed weights. Based on this comparison, we are proposing to make an adjustment of 1.022 to the weights. The weights that we are proposing for 2002, which incorporate the recalibration adjustments explained in this section, are listed in Addendum A and Addendum B.

III. Wage Index Changes

Under section 1833(t)(2)(D) of the Act, we are required to determine a wage adjustment factor to adjust for geographic wage differences, in a budget neutral manner, that portion of the OPPS payment rate and copayment amount that is attributable to labor and labor-related costs.

We used the proposed Federal fiscal year (FY) 2002 hospital inpatient PPS wage index to make wage adjustments in determining the proposed payment rates set forth in this proposed rule. The proposed FY 2002 hospital inpatient wage index published in the May 4, 2001 **Federal Register** (66 FR 22821) is reprinted in this proposed rule as Addendum H, Wage Index for Urban Areas; Addendum I, Wage Index for Rural Areas; and Addendum J, Wage Index for Hospitals That Are Reclassified. We propose to use the final FY 2002 hospital inpatient wage index to calculate the payment rates and coinsurance amounts that we will publish in the final rule implementing the OPPS for calendar year (CY) 2002.

IV. Copayment Changes

We note that in section 1833(t) of the Act, the terms ''copayment'' and ''coinsurance'' appear to be used interchangeably. To be consistent with CMS usage, we make a distinction between the two terms throughout this preamble. We propose to make conforming changes to part 419 of the regulations to reflect the following usage:

• ''Coinsurance'' means the percent of the Medicare-approved amount that beneficiaries pay for a service furnished in the hospital outpatient department (after they meet the Part B deductible).

• ''Copayment'' means the set dollar amount that beneficiaries pay under the OPPS. For example, if the payment rate for an APC is $200 and the beneficiary is responsible for paying $50, the copayment is $50 and the coinsurance is 25 percent.

A. BIPA 2000 Coinsurance Limit

As discussed in section I.C of this preamble, certain provisions of BIPA 2000 affect beneficiary copayment amounts under the OPPS. Section 111 of the BIPA added section 1833(t)(8)(C)(ii) of the Act, to accelerate the reduction of beneficiary copayment amounts, providing that, for services furnished on or after April 1, 2001 and before January 1, 2002, the national unadjusted coinsurance for an APC cannot exceed 57 percent of the APC payment rate. The statute provides for further reductions in future years so that the national unadjusted coinsurance for an APC cannot exceed 55 percent in 2002 and 2003, 50 percent in 2004, 45 percent in 2005, and 40 percent in 2006 and thereafter.

We implemented the reduction in beneficiary copayments for 2001 effective April 1, 2001 through changes to the OPPS PRICER software used to calculate OPPS payments to hospitals from the Medicare Program and beneficiary copayments.

We would revise § 419.41 to conform the regulations text to this provision.

B. Impact of BIPA 2000 Payment Rate Increase on Coinsurance

Under the statute as enacted by BBA 1997, APC payment rates for 2001 were to be based on the payment rates for 2000 increased by the inpatient hospital market basket percentage increase minus 1 percentage point; however, section 401 of the BIPA 2000 increased APC payment rates for 2001 to reflect an update based on the full market basket

percentage increase. The Congress intended for the increased payment to be in effect for the entire calendar year 2001; however, to provide us sufficient time to make the change, the Congress adopted a special payment rule for 2001. Under section 401(c) of the BIPA, the payment rates in effect for services furnished on or after January 1, 2001 and before April 1, 2001 are the rates as determined under the statute prior to the enactment of BIPA. For services furnished on or after April 1, 2001 and before January 1, 2002 the payment rates reflect the full market basket update and are further increased by 0.32 percent to account for the timing delay in implementing the full market basket update for 2001. The 0.32 percent increase is a temporary increase that applies only to the period April 1 through December 31, 2001 and is not considered in updating the OPPS conversion factor for 2002. The increase in APC payment rates for 2001 was implemented effective April 1, 2001 through changes to the OPPS PRICER software. We would revise § 419.32 to conform to the statute.

The section 401 increase to the APC payment rates affected beneficiary copayments in several ways. In cases for which the beneficiary coinsurance was already based on 20 percent of the APC payment rate, the increase in the APC payment rate caused a corresponding increase in the copayment for the APC. For all other APCs, the copayment amount remained at the same level. In addition, because the minimum copayment amount for an APC, which is the lowest amount a provider may elect to charge, if it chooses to reduce copayments for an APC, is based on 20 percent of the APC amount, the increase to an APC payment rate under section 401 of BIPA, resulted in an increase to the minimum copayment amount for each APC.

C. Coinsurance and Copayment Changes Resulting From Change in an APC Group

National unadjusted copayment amounts for the original APCs that went into effect on August 1, 2000 were, by statute, based on 20 percent of the national median charge billed for services in the APC group during calendar year 1996, trended forward to 1999, but could be no lower than 20 percent of the APC payment rate. Although the BBA 1997 specified how copayments were to be determined initially, the statute does not specify how copayments are to be determined in the future as the APC groups are recalibrated or as individual services are reclassified from one APC group to another. In this section, we are proposing the method we intend to apply in determining copayments for new APCs (that is, those created after 2001) and for APCs that are revised because of recalibration and reclassification.

In developing a proposed approach to be used in determining copayments for new or revised APCs, we took into account the following:

- One of the Congress's goals in authorizing an OPPS is to reduce beneficiary copayment liability until the copayment for every hospital outpatient service equals 20 percent of the prospectively determined payment rate for that service. Therefore, when given two possible copayment amounts or coinsurance percentages for a service as the result of an APC change, we should opt for the lower value.
- In general, we should use the coinsurance percentage (that is, the percentage of the total payment rate represented by the copayment amount) as the factor for comparison of the old versus the new copayment amount rather than a copayment dollar amount.
- Notwithstanding any changes, the coinsurance for an APC cannot be lower than 20 percent of the payment rate for an APC group.
- Notwithstanding any changes, the coinsurance for an APC cannot exceed 55 percent of the payment rate for an APC in 2002 or the applicable copayment limits under section 1833(t)(8)(C)(ii) of the Act in subsequent years.

The following describes how we propose to determine copayment amounts for new and revised APCs for 2002 and subsequent years:

1. If a newly created APC group consists of services that were not included in the 1996 data base or whose charges were not separately calculated in that data base (that is, the services were excluded or packaged) the unadjusted copayment amount would be 20 percent of the APC payment rate.

2. If recalibrating the relative payment weights results in an APC having a decrease in its payment rate for a subsequent year, the unadjusted copayment amount will be calculated so that the coinsurance percentage for the APC remains the same that it was before the payment rate decrease. For example, assume the APC had a payment rate of $100 and an unadjusted copayment amount of $50, resulting in a coinsurance percentage of 50 percent. If the new payment rate for the APC is lowered to $80, the copayment amount is calculated using the prior coinsurance percentage of 50 percent; therefore, the new copayment amount would be 50 percent of $80 or $40.

3. If recalibrating the relative payment weights results in an APC having an increase in its payment rate for a subsequent year, the unadjusted copayment amount would be calculated so that the copayment dollar amount for the APC remains the same as it was before the payment rate increase. That is, the unadjusted copayment amount would not change. For example, assume the APC had a payment rate of $100 and an unadjusted copayment amount of $60 (a coinsurance percentage of 60 percent). If the new payment rate for the APC is increased to $150, the unadjusted copayment amount would remain at $60 (a coinsurance percentage of 40 percent).

4. If a newly created APC group consists of services from two or more existing APCs, the unadjusted copayment amount would be calculated based on the lowest coinsurance percentage of the contributing APCs. For example, a new APC is created by moving some or all of the services from two existing APCs into the new APC. Assume that one contributing APC had a payment rate of $100 and an unadjusted copayment amount of $40, coinsurance percentage of 40 percent. Assume the other contributing APC had a payment rate of $150 and an unadjusted copayment amount of $75, a coinsurance percentage of 50 percent. If the new APC had a payment rate of $130, the unadjusted copayment amount for the new APC would be based on a coinsurance percentage of 40. The unadjusted copayment amount for the new APC would be 40 percent of $130, or $52.

5. If an APC payment rate is increased due to a conversion factor update, the unadjusted copayment amount for the APC would not change.

V. Outlier Policy Changes

For OPPS services furnished before January 1, 2002, section 1833(t)(5)(D) of the Act explicitly authorizes the Secretary to apply the outlier payment provision based upon all of the OPPS services on a bill. We exercised that authority and, since the beginning of the OPPS on August 1, 2000, we have calculated outlier payments in the aggregate for all OPPS services that appear on a bill. Under this proposed rule, beginning January 1, 2002, we will calculate outlier payments based on each individual OPPS service. We propose to revise the aggregate method that we are currently using to calculate outlier payments and begin to determine outliers on a service-by-service basis for

OPPS services furnished on or after January 1, 2002.

One difficulty we face with calculating outliers based on individual services is how to treat the charges for packaged services (for example, drugs, supplies, anesthesia, and equipment) when more than one OPPS service appears on a bill. These packaged services do not in themselves generate an APC payment but their charges must be taken into account to determine the cost of a service such as a surgical or diagnostic procedure or medical visit that does generate an APC payment. When more than one HCPCS code that will result in an APC payment appears on a bill, it is currently impossible to determine which packaged service is associated with an individual OPPS payable service. For example, when multiple surgical procedures are performed on the same day, we cannot determine how much of the operating room, drug, supply, anesthesia, or recovery room charge is attributable to each procedure. Similarly, if a medical visit and a surgical procedure occur on the same day, we cannot accurately determine how much of the charge for any drug, supply, or other packaged service that appears on the bill is attributable to each individual OPPS service.

One solution would be to require hospitals to submit separate bills for each OPPS service so that we can be certain that the correct packaged services attributable to the individual OPPS service will be taken into account in determining an outlier payment for that service. We believe, however, such a requirement would be excessively burdensome to hospitals and would greatly increase fiscal intermediary workloads. In addition, billing of individual services for the same day on separate bills would prohibit us from applying the correct coding edits. Finally, we believe that the limit on outlier payments (up to 2.5 percent of the total OPPS payments in each year before 2004 and up to 3 percent for subsequent years) does not justify the burden that would result from requiring separate bills for each OPPS service.

Another approach we considered is to allocate the charges for any packaged service among the individual OPPS services that appear on the bill. We considered two possible ways to do this. First, we could divide the packaged charges equally among the OPPS services so that if there were three services that generated APC payments, one third of the charges for the packaged services would be assigned to each OPPS service. We also considered dividing the total packaged charges among the OPPS services based on the ratio of the APC payment rate for an individual OPPS service to the total APC payment rates for all services on the bill. Thus, if a service resulted in an APC rate of $200 and the total APC payment rates for all services on the bill were $2,000, that individual APC would be allocated 10 percent of the packaged charges appearing on the bill.

We prefer using one of the approaches that would allocate packaged charges among the APCs on a bill to avoid disruptive billing changes. Of the two ways to allocate charges for packaged services, we are proposing that charges be allocated to each OPPS service based on the percent the APC payment rate for that service bears to the total APC rates for all OPPS services on the bill. We believe that this allocation method is somewhat more precise than simply dividing evenly the total packaged charges by the number of APCs on the bill.

We also propose to convert charges to costs for calculating outlier payments by continuing to apply a single overall hospital-specific cost-to-charge ratio instead of applying hospital-specific departmental cost-to-charge ratios. There is no universal crosswalk of revenue codes to cost report cost centers that is used by all hospitals. Although departmental cost-to-charge ratios are more precise for purposes of determining costs of specific services, hospitals have considerable discretion in assigning charges billed under specific revenue codes to specific departments on their cost reports. Therefore, we do not have a way of defining, in a uniform manner that is accurate for all hospitals, which department cost-to-charge ratio to apply to a revenue code billed by a hospital. We considered establishing a basic crosswalk that we would apply uniformly to every hospital, but this could result in a distorted or inaccurate model of how some hospitals actually assign charges. Given the appropriate resources, we could gather data from hospitals upon which to base a crosswalk specific to every hospital paid under the OPPS. But collecting these data would impose significant burden and administrative costs on hospitals and on our contractors. Given that outliers represent only 2 to 3 percent of total OPPS expenditures, we believe that the increased accuracy in calculating outlier payments that we could gain would not be sufficient to justify the significant additional administrative burden and cost that would be required. For this reason, we are proposing to continue to apply a single hospital-specific outpatient cost-to-charge ratio to convert billed charges to costs for calculating outlier payments.

As explained in the April 7, 2000 final rule (65 FR 18498), we set a target for outlier payments at 2.0 percent of total payments. We also explained, for purposes of simulating payments to calculate outlier thresholds, that we set the parameters for determining outlier payments as if the target were 2.5 percent. We believed that it would be likely that using simulation 1996 claims data would overstate the percentage of payments that would be made. Based on the simulations, we set a threshold for outlier payments at 2.5 times the claim cost and a payment percent of 75 percent of the cost above the threshold for both 2000 and 2001.

In setting the 2002 outlier threshold and payment percentage, we account for the charge to service level rather than claim level outlier calculation. In this proposed rule, we would again set the target for outlier payment at 2.0 percent. However, because we believe that the claims data we are using to set the 2002 proposed payment rates reflect much better coding of services than did the 1996 data, we would set these parameters to reach a target of 2.0 percent (rather than 2.5 percent). Based on our simulations, the proposed threshold for 2002 is 3 times the service costs and the proposed payment percentage for costs above that threshold is set at 50 percent.

VI. Other Policy Decisions and Proposed Changes

A. Change in Services Covered Within the Scope of the OPPS

Section 1833(t)(1)(B) of the Act defines the term ''covered OPD services'' that are to be paid under the OPPS. ''Covered OPD services'' are ''hospital outpatient services designated by the Secretary'' and include ''inpatient hospital services designated by the Secretary that are covered under this part and furnished to a hospital inpatient who (i) is entitled to benefits under part A but has exhausted benefits for inpatient hospital services during a spell of illness, or (ii) is not so entitled'' (that is, ''Part B-only'' services). ''Part B-only'' services are certain ancillary services furnished to inpatients for which the hospital receives payment under Medicare Part B. Section 3110 of the Medicare Intermediary Manual and section 2255C of the Medicare Carriers Manual specify these services as diagnostic tests; X-ray and radioactive isotope therapy; surgical dressings, splints and casts; prosthetic devices; and limb braces and trusses and artificial limbs and eyes.

In the April 7, 2000 final rule, we included inpatient ''Part B-only'' services within the definition of services payable under the OPPS (68 FR 18543). We have subsequently been approached by representatives of some hospitals that do not have outpatient departments and that, therefore, do no billing for Part B services except for a relatively few ''Part B-only'' services that they furnish to their inpatients. That is, the only bills these hospitals would ever submit for Part B payment are for the ancillary services designated as ''Part B-only'' services. These hospitals are concerned about the administrative burden and prohibitive costs they would incur if they were to change their billing systems to accommodate OPPS requirements solely to receive payment for ''Part B-only'' services.

We recognize that there are certain hospitals that do not have outpatient departments and that do not provide outpatient department services but that do provide inpatient services to Medicare beneficiaries. The only services these hospitals bill under OPPS are services furnished to inpatients. That is, these are special billings under the Part B-only benefit for limited ancillary services provided to beneficiaries who are admitted to the hospital as inpatients and who are not receiving services on an outpatient basis. We further acknowledge that the expense of converting their billing systems to accommodate the OPPS is disproportionate to the Part B revenues that these hospitals receive. Therefore, we are proposing to revise § 419.22 by adding subparagraph (r) to exclude from payment under the OPPS Part B-only services that are furnished to inpatients of hospitals that do no other billing for hospital outpatient services under Part B.

Under this proposed revision of the regulations, hospitals with outpatient departments would continue to bill under the OPPS for Part B-only services that they furnish to their inpatients. However, a hospital that does not have an outpatient department would be unable to bill under the OPPS for any Part B-only service the hospital furnished to its inpatients because those services would not fall within the scope of covered OPD services. If a hospital with no outpatient department is currently billing under the OPPS, the hospital would have to revert to its previous payment methodology for services furnished on or after January 1, 2002. That methodology would be an all-inclusive rate for hospitals paid that way prior to the implementation of OPPS and reasonable cost for other hospitals.

We do not know at this time, and are not sure it would be possible to ascertain, the potential number of hospitals that would be affected by this regulatory change. However, we expect the financial impact on the program to be small, because this revised rule would apply only to the relatively few hospitals that are billing for the very limited range of Part B-only services for a small number of beneficiaries.

B. Categories of Hospitals Subject to and Excluded From the OPPS

In § 419.20(b) of the regulations, certain hospitals in Maryland that qualify under section 1814(b)(3) of the Act for payment under the State's payment system are excluded from the OPPS. Critical access hospitals (CAHs) that are paid under a reasonable cost-based system as required under section 1834(g) of the Act are also excluded. In addition, we stated in the April 7, 2000 final rule that the outpatient services provided by the hospitals of the Indian Health Services (IHS) will continue to be paid under separately established rates. We also noted that we intended to consult with the IHS and develop a plan to transition these hospitals into OPPS. With these exceptions, the OPPS applies to all other hospitals that participate in the Medicare program.

It has been brought to our attention that under the statute, hospitals located in Guam, Saipan, American Samoa, and the Virgin Islands are excluded from the hospital inpatient PPS. These hospitals currently lack a charge structure for billing and, in some cases, are not equipped to prepare a cost report. They furnish very few services that would be subject to the OPPS. In addition, we believe that because of their distant locations, they incur costs that might not be adequately recognized by a PPS. Prior to implementation of the OPPS, each of the hospitals in Guam, American Samoa, Saipan, and the Virgin Islands had its own unique Medicare payment methodology for the outpatient services they furnish. In light of these factors, we are proposing to revise § 419.20 of the regulations by adding paragraph (b)(3) to exclude these hospitals from OPPS consistent with their treatment under inpatient PPS. In addition, we would revise that section to include the hospitals of the IHS so that it is clear that they are excluded until we develop a plan to include them. We would note that it may also be possible to include the hospitals in the territories in the OPPS in the future.

C. Conforming Changes: Additional Payments on a Reasonable Cost Basis

Hospitals subject to the OPPS are paid for certain items and services that are outside the scope of the OPPS on a reasonable cost or other basis. Payments for the following services are made on a reasonable cost basis or otherwise applicable methodology:

a. The direct costs of medical education as described in § 413.86.

b. The costs of nursing and allied health programs as described in § 413.85.

c. The costs associated with interns and residents not in approved teaching programs as described in § 415.202.

d. The costs of teaching physicians attributable to Part B services for hospitals that elect cost-based payment for teaching physicians under § 415.160.

e. The costs of anesthesia services furnished to hospital outpatients by qualified nonphysician anesthetists (certified registered nurse anesthetists and anesthesiologists' assistants) employed by the hospital or obtained under arrangements, for hospitals that meet the requirements under § 412.113(c).

f. Bad debts for uncollectible deductible and coinsurance amounts as described in § 413.80(b).

g. Organ acquisition costs paid under Part B. Interim payments for these services are made on a biweekly basis and final payments are determined at cost report settlement.

We would revise § 419.2(c) to make conforming changes that reflect the exclusion of these costs from the OPPS rates.

D. Hospital Coding for Evaluation and Management (E/M) Services

In the April 7, 2000 final rule, we emphasized the importance of each facility accurately assessing the intensity, resource use, and charges for evaluation and management (E/M) services, in order to ensure proper reporting of the service provided. We stated that ''the billing information that the hospitals report during the first years of implementation of the hospital outpatient PPS will be vitally important to our revision of weights and other adjustments that affect payment in future years.'' (65 FR 18451)

We went on to state, ''We realize that while these HCPCS codes appropriately represent different levels of physician effort, they do not adequately describe nonphysician resources. However, * * * the same concept can be applied to each code in terms of the differences in resource utilization. Therefore, each facility should develop a system for

mapping the provided services or combination of services furnished to the different levels of effort represented by the codes * * *. We will hold each facility accountable for following its own system for assigning the different levels of HCPCS codes. As long as the services furnished are documented and medically necessary and the facility is following its own system, which reasonably relates the intensity of hospital resources to the different levels of HCPCS codes, we will assume that it is in compliance with these reporting requirements as they relate to the clinic/emergency department visit code reported on the bill. Therefore, we would not expect to see a high degree of correlation between the code reported by the physician and that reported by the facility * * *. We will work with the American Hospital Association and the American Medical Association to propose the establishment of appropriate facility-based patient visit codes * * *.''

We understand that facilities have developed several different systems for determining resource consumption to assign proper E/M codes. Some of these systems are based on clinical (''condition'') criteria, and others are based on weighted scoring criteria. We continue to believe that proper facility coding of E/M services is critical for assuring appropriate payments. In order to achieve this, we are interested in developing and implementing a standardized coding process for facility reporting of E/M services. This process could include the use of current HCPCS codes or the establishment of new HCPCS codes in conjunction with guidelines for facility coding.

At this time, we are soliciting comments from hospitals and other interested parties on this issue. We will submit these comments to the APC Advisory Panel and ask for the Panel's recommendations regarding the development and implementation of a facility coding process for E/M services. In order to ensure consideration by the Panel, comments must be received by November 1, 2001. Send comments regarding facility coding of E/M services to: OPPS–E/M coding, Centers for Medicare & Medicaid Services, Mailstop C4–05–17, 7500 Security Boulevard, Baltimore, Maryland 21244–1850. CMS will review both the public comments and the recommendations from the Panel and propose a coding process in the proposed rule for 2003.

E. Annual Drug Pricing Update

Under the OPPS, we pay for drugs and biologicals in one of three ways.

1. Packaged Payment

As we explain in the April 7, 2000 final rule, we generally package the cost of drugs, biologicals, and pharmaceuticals into the APC payment rate for the primary procedure or treatment with which the drugs are usually furnished (65 FR 18450). No separate payment is made under the OPPS for drugs, biologicals, and pharmaceuticals whose costs are packaged into the APCs with which they are associated.

2. Transitional Pass-Through Payments for Eligible Drugs and Biologicals

As we explain in the April 7, 2000 final rule and in section VII of this preamble, the BBRA 1999 provided for special transitional pass-through payments for a period of 2 to 3 years for the following drugs and biologicals:

- Current orphan drugs, as designated under section 526 of the Federal Food, Drug, and Cosmetic Act;
- Current drugs and biologic agents used for treatment of cancer;
- Current radiopharmaceutical drugs and biological products; and
- New drugs and biologic agents in instances where the item was not being paid for as a hospital outpatient service as of December 31, 1996, and where the cost of the item is ''not insignificant'' in relation to the hospital outpatient PPS payment amount.

In this context, ''current'' refers to those items for which hospital outpatient payment was being made on August 1, 2000, the date on which the OPPS was implemented. A ''new'' drug or biological is a product that was not paid as a hospital outpatient service prior to January 1, 1997 and for which the cost is not insignificant in relation to the payment for the APC to which it is assigned.

Section 1833(t)(6)(D)(i) of the Act sets the payment rate for pass-through eligible drugs as the amount determined under section 1842(o) of the Act, that is, 95 percent of the applicable average wholesale price (AWP). Section 1833(t)(6)(D)(i) of the Act also sets the amount of additional payment for pass-through-eligible drugs and biologicals (the pass-through payment amount). The pass-through payment amount is the difference between 95 percent of the applicable AWP and the portion of the otherwise applicable fee schedule amount (that is, the APC payment rate) that the Secretary determines is associated with the drug or biological. Therefore, as we explain in the April 7 final rule (65 FR 18481), in order to determine the correct pass-through payment amount, we first had to determine the cost that was packaged for the drug or biological within its related APC. In order to determine this amount, we used the following methodology, which we also explain in the April 7 final rule.

When we implemented the OPPS on August 1, 2000, costs for drugs and biologicals eligible for transitional pass-through payment were, to the extent possible, not included in the payment rates for the APC groups into which they had been packaged prior to enactment of the BBRA 1999. That is, to the extent feasible, we removed from the APC groups into which they were packaged, the costs of as many of the pass-through eligible drugs and biologicals as we could identify in the 1996 claims data. Then, we assigned each drug and biological eligible for a pass-through payment to its own, separate APC group, the total payment rate for which was set at 95 percent of the applicable AWP.

Next, in order to establish the applicable beneficiary copayment amount and pass-through payment amount, we had to determine the cost of the pass-through eligible drug or biological that would have been included in the payment rate for its associated APC had the drug or biological been packaged. We used hospital acquisition costs as a proxy for the amount that would have been packaged, based on data taken from an external survey of hospital drug costs. (See the April 7, 2000 final rule (65 FR 18481)).

We imputed the acquisition cost for the various drugs and biologicals in pass-through APCs by multiplying their applicable AWP by one of the following ratios. The following ratios are based on the survey data, and they represent, on average, hospital drug acquisition cost relative to AWP:

- For drugs with one manufacturer (sole-source), the ratio of acquisition cost to AWP equals 0.68.
- For drugs with more than one manufacturer (multi-source), the ratio of acquisition cost to AWP equals 0.61.
- For drugs with more than one manufacturer and with generic competitors, the ratio of acquisition cost to AWP equals 0.43.

In accordance with section 1833(t)(7) of the Act, we base beneficiary copayment amounts for pass-through drugs only on that portion of the drug's cost that would have been included in the payment amount for an associated APC had the drug been packaged. Therefore, having determined the hospital acquisition cost of the drug based on the ratios described above, we multiply the acquisition cost by 20

percent to calculate the beneficiary copayment for the pass-through drug or biological APCs. Finally, to calculate the actual pass-through payment amount, we subtract from the applicable 95 percent of AWP the hospital acquisition cost less the beneficiary copayment amount.

To illustrate this payment methodology, consider a current sole source drug with an average wholesale price (AWP) of $100 per dose. Under section 1842(o) of the Act, the total allowed payment for the drug is $95, that is, 95 percent of AWP. We impute the cost of the drug based on survey data, which indicate hospital acquisition costs for this type of drug on average to be 68 percent of its AWP (or $68). In the absence of the pass-through provisions, this cost would be packaged into the APC payment for the procedure or service with which the drug or biological is furnished. Therefore, we define the beneficiary coinsurance as 20 percent of the imputed cost of $68, resulting in a copayment amount $13.60. The pass-through payment amount is $27 (the difference between 95 percent of AWP ($95) and the portion of the APC payment that is based on the cost of the drug ($68)). The total Medicare program payment in this example equals $81.40 (cost of the drug in the APC ($68) less beneficiary copay ($13.60) plus pass-through payment ($27)).

In this proposed rule, we are clarifying that, for purposes of calculating transitional pass-through payment amounts, we make no distinction between new and current drugs and biologicals. Rather, we assume that drugs and biologicals defined as ''new'' under section 1833(t)(6)(A)(iv)(I) of the Act, that is, for which payment was not being made as of December 31, 1996, nonetheless replace or are alternatives to drugs, biologicals, or therapies whose costs would have been reflected in our 1996 claims data and, thus, have been packaged into an associated APC. Therefore, we assume that our imputed acquisition cost, based on the external survey data, represents that portion of the APC payment attributable to new as well as current drugs and biologicals. For that reason, we are discontinuing use of the payment status indicator ''J'' that we introduced in the November 13, 2000 final rule to designate a ''new'' drug/biological pass-through. Instead, we would assign payment status indicator ''G'' to both current and new drugs that are eligible for pass-through payment under the OPPS. (Addendum D lists the definition of the OPPS payment status indicators.)

3. Separate APCs for Drugs Not Eligible for Transitional Pass-Through Payment

There are some drugs and biologicals for which we did not have adequate cost data yet that are not eligible for transitional pass-through payments. Beginning with the April 7, 2000 final rule, we created separate APCs for these drugs and biologicals. For example, we did not package into the emergency room visit APCs the various drugs classified as tissue plasminogen activators (tPAs) and other thrombolytic agents, which are used to treat patients with myocardial infarctions. Rather, we created individual APC groups for these drugs to allow separate payment so as not to discourage their use where appropriate.

We based the payment rate for these APCs on median hospital acquisition costs. To determine the hospital acquisition cost for the drugs, we imputed a cost using the same ratios of drug acquisition cost to AWP that we discuss in section VI.E.2. in connection with calculating acquisition costs for transitional pass-through drug payments. That is, we multiplied the AWP for the drug by the applicable ratio (sole or multi-source drug) based on data collected in an external survey of hospital drug acquisition costs.

We set beneficiary co-payment amounts for these drug APCs at 20 percent of the imputed acquisition cost. We use status indicator ''K'' to denote the APCs for drugs, biologicals, and pharmaceuticals that are paid separately from and in addition to the procedure or treatment with which they are associated yet are not eligible for transitional pass-through payment. Refer to Addendum A to identify these APCs.

4. Annual Drug Pricing Update

a. Drugs Eligible for Pass-Through Payments. We used the AWPs reported in the Drug Topics Red Book to determine the payment rates for the pass-through drugs and biologicals. In the November 13, 2000 interim final rule (65 FR 67809), in response to a comment that we update the AWPs for pass-through drugs on a quarterly basis, we stated that, due to the complexity of the new payment system, we would be able to update the rates only on an annual basis. We also noted that the new rates would be effective for the quarter following the publication of the updated AWP values in the Red Book. It was our understanding that, although there are quarterly updates to the AWPs in the Red Book, the annual update is published in April of each year. It was our intention to update the AWPs for drugs each July 1, the quarter following the annual publication, and we did use the April 2001 version of the Red Book to update the APC rates for drugs eligible for pass-through payments. The pass-through payment rates for drugs and biologicals updated for 2001 went into effect July 1, 2001 (Program Memorandum A–01–73, issued on June 1, 2001).

We found that doing an update for all the pass-through drugs and biologicals at mid-year was disruptive to both our computer systems and pricing software. Because it is now our understanding that even though the April publication is the annual printed version of the Red Book, there are quarterly updates available that we can use to update the AWPs. In fact, we have found that since the implementation of the pass-through payments in OPPS, many manufacturers have availed themselves of the Red Book quarterly update system to make frequent and large increases to their AWPs. Therefore, we do not believe it is necessary to wait until publication of the annual Red Book to do an update to the pass-through rates for drugs and biologicals to reflect the most recent AWPs.

Thus, we are proposing to update the APC rates for drugs that are eligible for pass-through payments in 2002 using the July 2001 or October 2001 version of Red Book (depending upon which is available when we develop the final rule). The updated rates effective January 1, 2002 would remain in effect until we implement the next annual update in 2003, when we would again update the AWPs based on the latest quarterly version of the Red Book. This would place the update of pass-through drug prices on the same calendar year schedule as the other annual OPPS updates.

b. Drugs in Separate APCs Not Eligible for Pass-Through Payments. We used the conversion factor published in the November 13, 2000 final rule (65 FR 67827) to update, effective January 1, 2001, the APC rates for the drugs that are not eligible for pass-through payments that are in separate APCs. We also made payment adjustments to these APC groups effective April 1, 2001, as required by section 401(c) of the BIPA, which sets forth a special payment rule that had the effect of providing a full market basket update in 2001.

For 2002, we propose to recalibrate the weights for the APCs for drugs that are not pass-through items and make the other adjustments applicable to the APC groups that we discuss in sections III, IV, and VIII of this proposed rule.

F. Definition of Single-Use Devices

Our definition of a device eligible for pass-through payment includes a criterion whereby eligible devices are used for one patient only and are single use (65 FR 47674, August 3, 2000). In the November 13, 2000 interim final rule, we stated, in response to a comment, that additional pass-through payments would not be made for devices that are reprocessed or reused because they are not single-use items. We further indicated that hospitals submitting pass-through claims for these devices might be considered to be engaging in fraudulent billing practices (65 FR 67822).

Since publishing our November 13, 2000 rule, much has come to our attention regarding reprocessed single-use devices. Reprocessors and professional associations using reprocessed devices commented that, under certain circumstances, the FDA considers reprocessed devices to be single-use devices. The FDA corroborated that it considers previously used single-use devices that have been appropriately reprocessed to be considered to be a single-use device. The reprocessing industry also indicated that reprocessed single use devices are of much lower cost to hospitals than original equipment manufactured single-use devices.

We have learned that the FDA published guidance for the reprocessing of single-use devices (FDA's ''Enforcement Priorities for Single-Use Devices Reprocessed by Third Parties and Hospitals,'' issued August 14, 2000). This document presents a phased-in regulatory scheme for reprocessed devices. As such, we are proposing to follow FDA's guidance on reprocessed single-use device. We would consider reprocessed single-use devices that are otherwise eligible for pass-through payment as part of a category of devices to be eligible for that payment if they meet FDA's most recent regulatory criteria on single-use devices. Also, reprocessed devices must meet any FDA guidance or other regulatory requirements in the future regarding single use. Reprocessed devices adhering to these guidelines would be considered as having met our criterion of approval or clearance by the FDA. We have met with and will continue to meet and coordinate with the FDA concerning that Federal agency's definition and regulation of single-use devices.

Parties advise us that reprocessed devices reduce the costs to hospitals substantially. Therefore, we would expect that the hospital charges on claims submitted for pass-through payments for reprocessed single-use devices would reflect the lower cost of these devices.

G. Criteria for New Technology APCs

1. Background

In the April 7, 2000 final rule (68 FR 18477), we created a set of new technology APCs to pay for certain new technology services under the OPPS. These APCs are intended to pay for new technology services that were not addressed by the transitional pass-through provisions of the BBRA 1999. We indicated that the new technology APCs would be defined on the basis of costs and not the clinical characteristics of a service.

We initially established groups 0970 through 0984 as the new technology APCs with costs ranging from less than $50 to $6,000. The payment rate for each of these APCs is based on the midpoint of a range of costs. For example, the payment for new technology APC 0974, which includes services that cost from $300 to $500, is set at $400.

The new technology APCs that were implemented on August 1, 2000 were populated with 11 new technology services. We state in the April 7, 2000 rule that we will pay for an item or service under a new technology APC for at least 2 years but no more than 3 years, consistent with the term of transitional pass-through payments. After that period of time, during the annual APC update cycle, we stated that we will move the item or service into the existing APC structure based on its clinical attributes and, based on claims data, its resource costs. For a new technology APC, the beneficiary coinsurance is 20 percent of the APC payment rate.

In the April 7, 2000 rule, we specified an application process and the information that must be supplied for us to consider a request for payment under the new technology APCs (65 FR 18478). We also described the five criteria we would use to determine whether a service is eligible for assignment to a new technology APC group. These criteria, which we are currently using, are as follows:

- The item or service is one that could not have been billed to the Medicare program in 1996 or, if it was available in 1996, the costs of the service could not have been adequately represented in 1996 data.
- The item or service does not qualify for an additional payment under the transitional pass-through payments provided for by section 1833(t)(6) of the Act as a current orphan drug, as a current cancer therapy drug or biological or brachytherapy, as a current radiopharmaceutical drug or biological product, or as a new medical device, drug, or biological.
- The item or service has a HCPCS code.
- The item or service falls within the scope of Medicare benefits under section 1832(a) of the Act.
- The item or service is determined to be reasonable and necessary in accordance with section 1862(a)(1)(A) of the Act.

2. Proposed Modifications to the Criteria and Process for Assigning Services to New Technology APCs

Based on the experience we have gained and data we have collected since publication of the April 7, 2000 final rule, we are proposing to revise—(a) the definition of what is appropriately paid for under the new technology APCs; (b) the criteria for determining whether a service may be paid under the new technology APCs; (c) the information that we will require to determine eligibility for assignment to a new technology APC; and (d) the length of time we will pay for a service in a new technology APC.

a. Services Paid Under New Technology APCs. We propose to limit eligibility for placement in new technology APCs to complete services or procedures. That is, the following are not eligible for placement in a new technology APC: items, materials, supplies, apparatuses, instruments, implements, or equipment that are used to accomplish a more comprehensive service or procedure.

We would continue to exclude devices or any drug, biologic, radiopharmaceutical, product, or commodity for which payment could be made under the transitional pass-through provisions. We believe that the new technology APCs should be reserved for only those comprehensive services or procedures that are truly new. Individual components of a service or procedure that do not meet the transitional pass-through payment criteria should be incorporated into a current APC and as hospitals begin to use the new items, supplies, or equipment the costs will become incorporated into the weight of the APC. To the extent possible, we believe that hospitals should be making the decision on what items, supplies, and equipment on the basis of efficiency and appropriate treatment of the patient. However, we believe it is appropriate to incorporate truly new services and procedures that replace much less

expensive services or procedures into a new technology APC to afford access to our beneficiaries.

Furthermore, we wish to clarify that we do not consider that merely being a different approach to an existing treatment or procedure qualifies a service for assignment to a new technology APC. As new approaches to existing procedures and services are adopted and performed, we expect the costs associated with these variations and improvements to be reflected in the claims data that we use to annually update the APC relative weights.

b. Criteria for Assignment to New Technology APC. In light of the experience we have gained over the past year in reviewing requests for new technology and transitional pass-through status, developing criteria to define new medical services and technologies under the inpatient PPS, and determining categories of new devices under the transitional pass-through provisions, we are proposing that the following criteria be used to determine whether a service be assigned to a new technology APC. These modifications are based on changes in data (we are no longer using 1996 data to set payment rates) and our continuing experience with the system of assigning new technology APCs.

- The service is one that could not have been adequately represented in the claims data being used for the most current annual payment update. (Current criterion based on 1996 data.)
- The service does not qualify for an additional payment under the transitional pass-through provisions. (This criterion is unchanged.)
- The service cannot reasonably be placed in an existing APC group that is appropriate in terms of clinical characteristics and resource costs. We believe it is unnecessary to assign a new service to a new technology APC if it may be appropriately placed in a current APC.
- The service falls within the scope of Medicare benefits under section 1832(a) of the Act. (This criterion is unchanged.)
- The service is determined to be reasonable and necessary in accordance with section 1862(a)(1)(A) of the Act. (This criterion is unchanged.)

We would delete the criterion that the service must have a HCPCS code. In the absence of an appropriate HCPCS code, we would consider creating a HCPCS code that describes the procedure or service. These HCPCS codes would be solely for hospitals to use when billing under the OPPS.

c. Revision of Application for New Technology Status. We also propose to change the information that interested parties must submit to have a service or procedure considered for assignment to a new technology APC. Based on our experience over the past year in reviewing new technology APC applications, we believe that the criteria would better assist us in determining eligibility for these APCs than do the current criteria. Specifically, to be considered, we propose to require that requests include the following information:

- The name by which the service is most commonly known. We currently require only the trade/brand name.
- A clinical vignette, including patient diagnoses that the service is intended to treat, the typical patient, and a description of what resources are used to furnish the service by both the facility and the physician. For example, for a surgical procedure this would include staff, operating room, and recovery room services as well as equipment, supplies, and devices, etc. This criterion would replace the criterion that requires a detailed description of the clinical application of the service. We believe we need a fuller description to help us understand how the service is furnished in hospitals.
- A list of any drugs or devices used as part of the service that require approval from the Food and Drug Administration (FDA) and information to document receipt of FDA approval/clearances and the date obtained. This would be a refinement of the current requirement for demonstrating FDA approval.
- A description of where the service is currently being performed (by location) and the approximate number of patients receiving the service in each location. This criterion and the one that follows would help inform our analysis by providing us with medical contacts.
- An estimate of the number of physicians who are furnishing the service nationally and the specialties they represent.
- Information about the clinical use and efficacy of the service such as peer-reviewed articles. Again, this criterion would assist us in our clinical review of the procedure.
- The CPT or HCPCS Level II code(s) that are currently being used to report the service and an explanation of why use of these HCPCS codes is inadequate to report the service under the OPPS. This criterion and the three that follow are refinements of the current HCPCS requirement.
- A list of the CPT or HCPCS Level II codes for all items and procedures that are an integral part of the service. This list should include codes for all procedures and services that, if coded in addition to the code for the service under consideration for new technology status, would represent unbundling.
- A list of all CPT and HCPCS Level II codes that would typically be reported in addition to the service.
- A proposal for a new HCPCS code, including a descriptor and rationale for why the descriptor is appropriate. The proposal should include the reason why the service does not have a CPT or HCPCS Level II code, and why the CPT or HCPCS Level II code or codes currently used to describe the service are inadequate.
- An itemized list of the costs incurred by a hospital to furnish the new technology service, including labor, equipment, supplies, overhead, etc. (This criterion is unchanged.)
- The name, address, and telephone number of the party making the request. (This criterion is unchanged.)
- Other information as CMS may require to evaluate specific requests. (This criterion is unchanged.)

d. Length of Time in a New Technology APC. We are also proposing to change the period of time during which a service may be paid under a new technology APC. Although section 1833(t)(6)(B) of the Act, as amended by section 201 of BBRA 1999, sets a 2 to 3 year period of payment for transitional pass-through payments, this requirement does not extend to new technology APCs. In the April 7, 2000 final rule we stated our intention to adopt the same period of payment for new technology APCs for consistency. However, the experience we have gained during the first year of the OPPS has led us to the conclusion that a more flexible payment period would be preferable. Therefore, we are proposing to modify the time frame that we established for new technology APCs in the April 7, 2000 final rule and to retain a service within a new technology APC group until we have acquired adequate data that allow us to assign the service to a clinically appropriate APC. This would allow us to move a service from a new technology APC in less than 2 years if the data were available and would also allow us to retain a service in a new technology APC for more than 3 years if these data were not available.

We invite comment on the changes to the definition, criteria, application process, and timeframe that we are proposing for services and procedures that may qualify for assignment to a new technology APC under the OPPS.

VII. Transitional Pass-Through Payment Issues

A. Background

Section 1833(t)(6) of the Act provides for temporary additional payments or ''transitional pass-through payments'' for certain innovative medical devices, drugs, and biologicals. As originally enacted by the BBRA, this provision required the Secretary to make additional payments to hospitals for current orphan drugs, as designated under section 526 of the Federal Food, Drug, and Cosmetic Act; current drugs, biologic agents, and brachytherapy devices used for the treatment of cancer; and current radiopharmaceutical drugs and biological products. Transitional pass-through payments are also required for new medical devices, drugs, and biologic agents that were not being paid for as a hospital outpatient service as of December 31, 1996 and whose cost is ''not insignificant'' in relation to the OPPS payment for the procedures or services associated with the new device, drug, or biological. Under the statute, transitional pass-through payments are to be made for at least 2 years but not more than 3 years.

Section 402 of BIPA, which was enacted on December 21, 2000, made several changes to section 1833(t)(6) of the Act. First, section 1833(t)(6)(B)(i) of the Act, as amended, requires us to establish by April 1, 2001, initial categories to be used for purposes of determining which medical devices are eligible for transitional pass-through payments. We fulfilled this requirement through the issuance on March 22, 2001 of two Program Memoranda, Transmittals A–01–40 and A–01–41. These Program Memoranda can be found on the CMS homepage at *www.hcfa.gov/pubforms/transmit/A0140.pdf* and *www.hcfa.gov/pubforms/transmit/A0141.pdf,* respectively. We note that section 1833(t)(6)(B)(i)(II) of the Act explicitly authorizes the Secretary to establish initial categories by program memorandum.

Transmittal A–01–41 includes a list of the initial device categories and a crosswalk of all the item-specific C-codes for individual devices that were approved for transitional pass-through payments as of January 20, 2001 to the initial category code by which the device is to be billed beginning April 1, 2001.

Section 1833(t)(6)(B)(ii) of the Act also requires us to establish, through rulemaking, criteria that will be used to create additional categories, other than those established initially. The criteria for new categories are the subject of a separate interim final rule with comment period, which will be published at a later date.

Transitional pass-through categories are for devices only; they do not apply to drugs or biologicals. The regulations governing transitional pass-through payments for eligible drugs and biologicals remain unchanged. The process to apply for transitional pass-through payment for eligible drugs and biological agents, including radiopharmaceuticals, can be found in the April 7, 2000 **Federal Register** (65 FR 18481) and on the CMS web site at *http://www.hcfa.gov/medlearn/appdead.htm.* If we revise the application instructions in any way, we will post the revisions on our web site and submit the changes for the Office of Management and Budget (OMB) review under the Paperwork Reduction Act.

B. Discussion of Pro Rata Reduction

Section 1833(t)(6)(E) of the Act limits the total projected amount of transitional pass-through payments for a given year to an ''applicable percentage'' of projected total payments under the hospital OPPS. For a year before 2004, the applicable percentage is 2.5 percent; for 2004 and subsequent years, the applicable percentage is specified by the Secretary up to 2.0 percent. If the Secretary estimates before the beginning of the calendar year that the total amount of pass-through payments in that year would exceed the applicable percentage, section 1833(t)(6)(E)(iii) of the Act requires a (prospective) uniform reduction in the amount of each of the transitional pass-through payments made in that year to ensure that the limit is not exceeded.

In order to prepare for making an estimate, we have constructed an extensive database that includes outpatient claims data submitted by hospitals for services furnished on or after July 1, 1999 and before July 1, 2000. We are also collecting device cost and utilization data that were provided by manufacturers. We are extracting device cost and utilization data from applications for pass-through status submitted by manufacturers, hospitals, specialty societies, and other entities. In their applications for pass-through status, manufacturers have supplied information on the expected cost to hospitals of devices and the procedures with which the devices are commonly used.

The information that we have collected thus far suggests that a significant pro rata reduction could be required for 2002 in order to meet the statutory limit on the amount of the pass-through payments. Given the potential magnitude of the reductions, we are reviewing our data and methodology to identify any flaws or weaknesses in them and to determine whether a significant reduction would actually be required under the statute. We are also considering the appropriateness of a number of possible alternative approaches to different technical aspects of estimating payments that would have the effect of minimizing the amount of any potential reduction in these payments. Below is a discussion of the methodology that we contemplate employing in developing our estimate.

We are considering a number of possible approaches to different technical aspects of estimating payments. As is always the case in making these types of estimates, it is necessary to make a number of assumptions in interpreting the data. We are tentatively contemplating using the following assumptions and techniques in developing our methodology:

1. Data and Methodology

We plan to base the estimate of 2002 pass-through expenditures on the claims we would use to set payment rates for 2002, 2001 pass-through amounts for drugs and radiopharmaceuticals, and device cost and use data from pass-through applications submitted by manufacturers, hospitals, specialty societies, and other entities. Projections to CY 2002 would employ price, volume, and service-mix inflators consistent with our baseline for OPPS spending. Estimates for drugs, radiopharmaceuticals, and devices would be made separately and combined for the final projection of pass-through spending.

2. Drugs and Biologicals

We would identify those drugs eligible for pass-through status that have been separately billed to the Medicare program on the claims that we intend to employ for the estimate. We would multiply the frequency of use for each of these drugs (that is, the number of line items multiplied by the number of units billed as shown in the claims data) by its 2001 pass-through payment amount. If any drugs are not reflected in the claims data, we would make an appropriate adjustment. Such an adjustment might take into account the extent to which the non-coded items are classified as orphan drugs and therefore would likely be used infrequently.

3. Radiopharmaceutical Drugs and Biological Products

Similar to the drug estimate, we would identify those

radiopharmaceuticals eligible for pass-through status that were separately billed to Medicare in the claims data file. We would estimate expenditures for these radiopharmaceuticals directly as described above. For radiopharmaceutical drugs, we would multiply the frequency of use for each item by the 2001 pass-through amount. We would estimate expenditures for the remaining items by using the frequency counts for all nuclear medicine procedures not billed with one of these radiopharmaceuticals.

4. Medical Devices

We would estimate the transitional pass-through payments attributable to devices by linking the frequencies for all device-related procedures in the claims data file with the cost and use data supplied by the manufacturers or other entities as part of their applications for pass-through status. We would match each device eligible as of January 2001 with the procedures with which it would be used. We would then calculate an average cost for each device or device package associated with a procedure.

The statute requires that we calculate transitional pass-through payments for devices by adjusting the hospital's charge for the device to cost and then subtracting an amount that reflects the device costs already included in the payment for the associated APC. As we explained in the April 7, 2000 final rule (65 FR 18481) we were not able to implement these subtractions at the time of implementation of the system. For 2001, as we explain in section III.C. of this preamble, we made these deductions for pacemakers and neurostimulators but not other devices because it was not feasible to make the deductions for the other devices at that time. As also explained in section III.C., we are proposing to make these subtractions for most other devices beginning in 2002. For the purpose of doing this estimation, we would deduct these amounts from each device package before multiplying that cost by the procedure frequencies. In total, we project the deductions to be $450 million. (See section III.C. for a discussion of how we calculated the deductions.)

5. Projecting to 2002

After making the three estimates as determined above, we plan to project prices and quantities in the estimates to 2002 using actuarial projections of price, volume, and service increase consistent with the OPPS baseline. We would add the three separate results for drugs, radiopharmaceuticals, and devices to determine an estimate of total pass-through spending.

A. Reducing Transitional Pass-Through Payments to Offset Costs Packaged Into APC Groups

1. Background

As discussed above in section II.C.1. of this preamble, in the November 13, 2000 interim final rule (65 FR 67806 and 67825), we explained that we originally excluded costs in revenue codes 274 (Prosthetic/orthotic devices), 275 (Pacemaker), and 278 (Other implants) from the calculation of APC payment rates because, before enactment of the BBRA 1999, we had proposed to pay for implantable devices outside of the OPPS and after the enactment of the BBRA, it was not feasible to revise our database to include these revenue codes in developing the April 7, 2000 final rule. We were able to make the necessary revisions and adjustments in time for implementation on January 1, 2001. When we packaged costs from these revenue codes to recalculate APC rates for 2001, to comply with the BBRA 1999 requirement, the median costs for a handful of procedures related to pacemakers and neurostimulators significantly increased. Therefore, we restructured the affected APCs to account for these changes in procedure level median costs.

Under section 1833(t)(6)(D)(ii) of the Act, as added by the BBRA 1999 and redesignated by BIPA, the amount of additional payment for an eligible device is the amount by which the hospital's cost exceeds the portion of the otherwise applicable APC payment amount that the Secretary determines is associated with the device. Thus, beginning January 1, 2001, for eligible devices, we deducted from transitional pass-through payments the dollar increase in the rates for the new APCs for procedures associated with the devices. Effective April 1, 2001, we revised our policy to subtract the dollar amount from the otherwise applicable pass-through payment for each category of device. The dollar amount subtracted in 2001 from transitional pass-through payments for affected categories of devices is as follows:

TABLE 4.—CY 2001 REDUCTIONS TO PASS-THROUGH PAYMENTS TO OFFSET DEVICE-RELATED COSTS PACKAGED IN ASSOCIATED APC GROUPS

For item billed under HCPCS code. * * *	Subtract from the pass-through payment the following amount:
C1767 Generator, neurostimulator (implantable)	$643.73
C1778 Lead, neurostimulator (implantable)	501.27
C1785 Pacemaker, dual chamber, rate-responsive (implantable)	2,843.00
C1786 Pacemaker, single chamber, rate-responsive (implantable)	2,843.00
C1816 Receiver and/or transmitter, neurostimulator (implantable)	537.83
C2619 Pacemaker, dual chamber, non rate-responsive (implantable)	2,843.00
C2620 Pacemaker, single chamber, non rate-responsive (implantable)	2,843.00

The increase in certain APC rates for device costs on January 1, 2001 was offset by the simultaneous reduction of the associated pass-through payments. Payments for the procedures in the affected APCs that did not include a pass-through device increased for 2001 and for procedures that did include devices, total payment for the procedure plus the device or devices did not change.

For 2002, in this proposed rule we are estimating the portion of each APC rate that could reasonably be attributed to the cost of associated devices that are eligible for pass-through payments. This amount will be deducted from the pass-through payments for those devices as required by the statute. Since the deductions to the pass-through payments for costs included in APCs for 2002 are included in the recalibration of the weights and the fixed pool of dollars for outpatient services, the total payment for the procedure plus device or devices will be reduced rather than remain constant as they did in 2001.

2. Proposed Reductions for 2002

First, we reviewed the APCs to determine which of them contained services that are associated with a category of devices eligible for a transitional pass-through payment. We then estimated the portion of the costs in those APCs that could reasonably be attributed to the cost of pass-through devices as follows:

• For each procedure associated with a pass-through device or devices, we examined all single-service bills (that is, bills that include services payable only under one APC) to determine utilization patterns for specific revenue centers that would reasonably be used for device-related charges in revenue codes 272 (sterile supplies), 275 (pacemakers), and 278 (other implants).

• We removed the costs in those revenue codes to calculate a cost for the bill net of device-related costs (reduced cost). For example, the average bill cost (in 1999–2000 dollars) for insertion of a cardiac pacemaker (CPT 33208) was $5,733. The average cost associated with revenue code 275 was $4,163, so the reduced cost for the procedure was $1,570. We calculated the ratio of the reduced cost ($1,570) to the full bill costs ($5,733), and we applied that ratio to the costs on any bills for CPT 33208 that did not use revenue code 275 to establish reduced cost at the procedure code level across all claims.

• To determine the reduced cost at the APC level and that portion of the APC payment rate associated with device costs, we calculated the median cost of the reduced cost bills for each relevant APC. For this calculation of the median, we allowed the full costs of bills for services in the APC that were not associated with pass-through devices.

• We calculated, for the APC, the percentage difference between the APC median of full cost or unreduced bills and the APC median where some or all of the bills had reduced costs. We applied this percent difference to the proposed APC payment rate in order to calculate the share of that rate attributable to the device or devices associated with procedures in the APC. In Table 5, we show the amount that we propose to subtract from the pass-through payment for an eligible device that is billed with the related APCs.

TABLE 5.—PROPOSED REDUCTION TO PASS-THROUGH PAYMENT TO OFFSET DEVICE-RELATED COSTS PACKAGED IN ASSOCIATED APC GROUPS

APC	Description	Percent differences	Device-related cost to be subtracted from pass-through payment for eligible device
00032	Insertion of Central Venous/Arterial Catheter	20.11	$73
00080	Diagnostic Cardiac Catheterization	9.99	164
00081	Non-Coronary Angioplasty or Atherectomy	27.06	303
00082	Coronary Atherectomy	6.95	462
00083	Coronary Angioplasty	19.85	506
00088	Thrombectomy	10.86	161
00089	Insertion/Replacement of Permanent Pacemaker and Electrodes	72.69	3,052
00090	Insertion/Replacement of Pacemaker Pulse Generator	77.13	2,877
00104	Transcatheter Placement of Intracoronary Stents	11.64	422
00106	Insertion/Replacement/Repair of Pacemaker and/or Electrodes	79.55	640
00107	Insertion of Cardioverter-Defibrillator	81.69	6,449
0108	Insertion/Replacement/Repair of Cardioverter-Defibrillator Leads	71.16	5,768
0122	Level II Tube Changes and Repositioning	24.92	72
0151	Endoscopic Retrograde Cholangio-Pancreatography (ERCP)	7.35	61
0152	Percutaneous Biliary Endoscopic Procedures	12.05	107
0154	Hernia/Hydrocele Procedures	8.80	108
0182	Insertion of Penile Prosthesis	57.22	2,500
0185	Removal or Repair of Penile Prosthesis	56.82	1,652
0202	Level VIII Female Reproductive Procedures	25.02	503
0222	Implantation of Neurological Device	75.70	4,330
0223	Implantation of Pain Management Device	79.51	359
0225	Implantation of Neurotransmitter Electrodes	67.25	1,154
0227	Implantation of Drug Infusion Device	80.23	3,871
0229	Transcatheter Placement of Intravascular Shunts	35.46	1,083
0246	Cataract Procedures with IOL Insert	12.87	146

VIII. Conversion Factor Update for CY 2002

Section 1833(t)(3)(C)(ii) of the Act requires us to update the conversion factor used to determine payment rates under the OPPS on an annual basis. Section 1833(t)(3)(C)(iv) of the Act, as redesignated by section 401 of the BIPA, provides that for 2002, the update is equal to the hospital inpatient market basket percentage increase applicable to hospital discharges under section 1886(b)(3)(B)(iii) of the Act, reduced by one percentage point. Further, section 401 of the BIPA increased the conversion factor for 2001 to reflect an update equal to the full market basket percentage increase amount.

The most recent forecast of the hospital market basket increase for FY 2002 is 3.3 percent. To set the proposed OPPS conversion factor for 2002, we increased the 2001 conversion factor of $50.080, which reflects the BIPA provision of the full market basket update, by 2.3 percent, that is, the 3.3 percentage increase minus 1 percentage point.

In accordance with section 1833(t)(9)(B) of the Act, we further adjusted the proposed conversion factor for 2002 to ensure that the revisions we are proposing to update the wage index are made on a budget-neutral basis. A budget neutrality factor of 0.9924 was calculated for wage index changes by comparing total payments from our simulation model using the proposed FY 2002 hospital inpatient PPS wage

index values to those payments using the current (FY 2001) wage index values.

The increase factor of 2.3 percent for 2002 and the required wage index budget neutrality adjustment of 0.9924 result in a proposed conversion factor for 2002 of $50.842.

IX. Summary of and Responses to MedPac Recommendations

The Medicare Payment Advisory Commission (MedPAC) offered several recommendations dealing with the OPPS in its March 2001 Report to Congress. Below we summarize each recommendation and respond to it.

MedPAC Recommendation: MedPAC has offered two recommendations regarding the update to the conversion factor in the OPPS. The first recommendation is that the Secretary should not use an expenditure target to update the conversion factor. The second recommendation is that Congress should require an annual update of the conversion factor in the OPPS that is based on the relevant factors influencing the costs of efficiently providing hospital outpatient care, and not just the change in input prices.

Response: Section 1833(t)(3)(C)(ii) of the Act requires the Secretary to update the conversion factor annually. Under section 1833(t)(3)(C)(iv) of the Act the update is equal to the hospital market basket percentage increase applicable under the hospital inpatient PPS, minus one percentage point for the years 2000 and 2002. The Secretary has the authority under section 1833(t)(3)(C)(iv) of the Act to substitute a market basket that is specific to hospital outpatient services. Finally, section 1833(t)(2)(F) of the Act requires the Secretary to develop a method for controlling unnecessary increases in the volume of covered hospital outpatient services, and section 1833(t)(9)(C) of the Act authorizes the Secretary to adjust the update to the conversion factor if the volume of services increased beyond the amount established under section 1833(t)(2)(F) of the Act.

In the September 8, 1998 proposed rule on the OPPS, we indicated that we were considering the option of developing an outpatient-specific market basket and invited comments on possible sources of data suitable for constructing one (63 FR 47579). We received no comments in response to this invitation, and we therefore announced in the April 7, 2000 final rule that we would update the conversion factor by the hospital inpatient market basket increase, minus one percentage point, for the years 2000, 2001, and 2002 (65 FR 18502). As required by section 401(c) of the BIPA, we made payment adjustments effective April 1, 2001 under a special payment rule that has had the effect of providing a full market basket update in 2001. We are, however, working with a contractor to study the option of developing an outpatient-specific market basket and would welcome comments and recommendations regarding appropriate data sources. We will also study the feasibility of developing appropriate adjustments for factors that influence the costs of efficiently providing hospital outpatient care, such as productivity increases and the introduction of new technologies, and the availability of appropriate sources of data for calculating the factors.

In the September 8, 1998 proposed rule on the OPPS, we proposed employing a modified version of the physicians' sustainable growth rate system (SGR) as an adjustment in the update framework to control for excess increases in the volume of covered outpatient services (63 FR 47586–47587). In response to comments on this proposal, we announced in the April 7, 2000 final rule that we had decided to delay implementation of a volume control mechanism, and to continue to study the options with a contractor (65 FR 18503). We will take MedPAC's recommendation into consideration in making a decision, and before implementing volume control mechanism we will publish a proposed rule with an opportunity for public comment.

MedPAC Recommendation: MedPAC recommends that the Secretary should develop formalized procedures in the OPPS for expeditiously assigning codes, updating relative weights, and investigating the need for service classification changes to recognize the costs of new and substantially improved technologies.

Response: Beginning with the April 7, 2000 final rule implementing the OPPS, we have outlined a comprehensive process to recognize the costs of new technology in the new system. One component of this process is the provision for pass-through payments for devices, drugs, and biologicals (see the discussion in conjunction with the next MedPAC recommendation). The other component is the creation of new APC groups to accommodate payment for new technology services that are not eligible for transitional pass-through payments. We assign new technology services that cannot be appropriately placed within existing APC groups to new technology APC groups, using costs alone (rather than costs plus clinical coherence) as the basis for the assignment. We describe revised criteria for assignment to a new technology group in section VI.G. of this preamble. When it is necessary, creation of new technology APC groups involves establishment of new codes. New codes are established through a well-ordered process that operates on an annual cycle. The cycle starts with submission of information by interested parties no later than April 1 of each year and ends with the announcement of new codes in October. As we stated previously, in the absence of an appropriate HCPCS code, we would consider creating a HCPCS code that describes the procedure or service. These codes would be solely for hospitals to use when billing under the OPPS.

We have also provided a mechanism for moving these services from the new technology APCs to clinically related APCs as part of the annual update of the APC groups. As described in section VI of this preamble, a service is retained within a new technology APC group until we have acquired adequate data that allow us to assign the service to an appropriate APC. We use the annual APC update cycle to assign the service to an existing APC that is similar both clinically and in terms of resource costs. If no such APC exists, we create a new APC for the service.

MedPAC Recommendation: MedPAC recommends that pass-through payments for specific technologies should be made in the OPPS only when a technology is new or substantially improved and adds substantially to the cost of care in an APC. MedPAC believes that the definition of ''new'' should not include items whose costs were included in the 1996 data used to set the OPPS payment rates.

Response: The statute requires that, under the OPPS, transitional pass-through payments are made for certain drugs, devices, and biologicals. The items designated by the statute to receive these pass-through payments include the following:

- Current orphan drugs, as designated under section 526 of the Federal Food, Drug, and Cosmetic Act.
- Current drugs and biologicals used for the treatment of cancer, and brachytherapy and temperature monitored cryoablation devices used for the treatment of cancer.
- Current radiopharmaceutical drugs and biologicals.
- New drugs and biologicals in instances in which the item was not being paid as a hospital outpatient service as of December 31, 1996, and when the cost of the item is ''not insignificant'' in relation to the OPPS payment amount.
- Effective April 1, 2001, categories of Medical devices when the cost of the

category is not insignificant'' in relation to the OPPS payment amount.

We are publishing a separate interim final rule in which we lay out the criteria for establishing categories of devices eligible for pass-through payments.

Section 1833(t)(6) of the Act provides that once a category is established, a specific device may receive a pass-through payment for 2 to 3 years if the device is described by an existing category, regardless of whether it was being paid as a hospital outpatient service as of December 31, 1996 or its cost meets the ''not insignificant'' criterion. Thus, the statute allows for certain devices that do not meet MedPAC's recommended limitation on a ''new'' device to receive transitional pass-through payments. However, no categories are created on the basis of devices that were paid for on or before December 31, 1996. That is, while devices paid for on or before December 31, 1996 can be included in a category, we would establish a category only on the basis of devices that were not being paid as hospital outpatient services as of December 31, 1996.

MedPAC Recommendation: MedPAC recommends that pass-through payments for specific technologies in the OPPS should be made on a budget-neutral basis and that the costs of new or substantially improved technologies should be factored into the update of the outpatient conversion factor.

Response: The statute requires that the transitional pass-through payments for drugs, devices, and biologicals be made on a budget neutral basis. Estimated pass-through payments are limited under the statute to 2.5 percent (and up to 2.0 percent for 2004 and thereafter) of estimated total program payments for covered hospital outpatient services. We adjust the conversion factor to account for the proportion of total program payments for covered hospital outpatient services, up to the statutory limit, that we estimate will be made in pass-through payments. As we have discussed in response to MedPAC's recommendation concerning an update framework for the OPPS conversion factor, we will study the feasibility of including appropriate adjustments for factors, including introduction of new technologies, that influence the costs of efficiently providing hospital outpatient care within such a framework.

MedPAC Recommendation: MedPAC recommends that the Congress should continue the reduction in outpatient coinsurance to achieve a 20 percent coinsurance rate by 2010.

Response: For most services that Medicare covers, the program is responsible for 80 percent of the total payment amount, and beneficiaries pay 20 percent. However, under the cost-based payment system in place for outpatient services before the OPPS, beneficiaries paid 20 percent of the hospital's charges for these services. As a result, coinsurance was often more than 20 percent of the total payment amount for the services.

The BBA established a formula under the OPPS that was designed to reduce coinsurance gradually to 20 percent of the total payment amount. Under this formula, a national copayment amount was set for each service category, and that amount is to remain frozen as payment rates increase until the coinsurance percentage falls to 20 percent for all services. On average, beneficiaries have paid about 16 percent less in copayments for hospital outpatient services during 2000 under the OPPS than they would have paid under the previous system. However, it is true that the coinsurance remains higher than 20 percent of the Medicare payment amount for many services.

Subsequent legislation has placed caps on the coinsurance percentages to speed up this process. Specifically, section 111 of BIPA amended section 1833(t)(8)(C)(ii) of the Act to reduce beneficiary coinsurance liability by phasing in a cap on the coinsurance percentage for each service. Starting on April 1, 2001, coinsurance for a single service furnished in 2001 cannot exceed 57 percent of the total payment amount for the service. The cap will be 55 percent in 2002 and 2003, and will be reduced by 5 percentage points each year from 2004 to 2006 until coinsurance is limited to 40 percent of the total payment for each service. The underlying process for decreasing coinsurance will also continue during this period (see discussion in section IV.A. of this preamble). However, MedPAC projects that under current law, it would take until 2029 to reach the goal of 20 percent coinsurance for all services.

We agree with MedPAC's goal of continuing the reduction in outpatient coinsurance, and we would welcome enactment of a practical measure to do so.

X. Provider-Based Issues

A. Background and April 7, 2000 Regulations

On April 7, 2000, we published a final rule specifying the criteria that must be met for a determination regarding provider-based status (65 FR 18504). Since the beginning of the Medicare program, some providers, which we refer to as ''main providers,'' have functioned as a single entity while owning and operating multiple departments, locations, and facilities. Having clear criteria for provider-based status is important because this designation can result in additional Medicare payments for services furnished at the provider-based facility, and may also increase the coinsurance liability of Medicare for those services.

The regulations at § 413.65 define provider-based status as ''the relationship between a main provider and a provider-based entity or a department of a provider, remote location of a hospital, or satellite facility, that complies with the provisions of this section.'' Section 413.65(b)(2) states that before a main provider may bill for services of a facility as if the facility is provider-based, or before it includes costs of those services on its cost report, the facility must meet the criteria listed in the regulations at § 413.65(d). Among these criteria are the requirements that the main provider and the facility must have common licensure (when appropriate), the facility must operate under the ownership and control of the main provider, and the facility must be located in the immediate vicinity of the main provider.

The effective date of these regulations was originally set at October 10, 2000, but was subsequently delayed and is now in effect for cost reporting periods beginning on or after January 10, 2001. Program instructions on provider-based status issued prior to that date, found in Section 2446 of the Provider Reimbursement Manual—Part 1 (PRM–1), Section 2004 of the Medicare State Operations Manual (SOM), and CMS Program Memorandum (PM) A–99–24, will apply to any facility for periods before the new regulations become applicable to it. (Some of these instructions will not be applied because they have been superseded by specific legislation on provider-based status, as described in item C below).

B. Provider-Based Issues/Frequently Asked Questions

Following publication of the April 7, 2000 final rule, we received many requests for clarification of policies on specific issues related to provider-based status. In response, we published a list of ''Frequently Asked Questions'' and the answers to them on the CMS web site at *www.hcfa.gov/medlearn/provqa.htm.* (This document can also be obtained by contacting the CMS (Formerly, HCFA) Regional Office.)

These Qs and As did not revise the regulatory criteria, but do provide subregulatory guidance for their implementation.

C. Benefits Improvement and Protection Act of 2000 (Pub. L. 106–554)

On December 21 2000, the Benefits Improvement and Protection Act (BIPA) of 2000 (Pub. L. 106–554) was enacted. Section 404 of BIPA contains provisions that significantly affect the provider-based regulations at § 413.65. Section 404 includes a grandfathering provision for facilities treated as provider-based on October 1, 2000; alternative criteria for meeting the geographic location requirement; and criteria for temporary treatment as provider-based.

1. Two-Year ''Grandfathering''

Under section 404(a) of BIPA, any facilities or organizations that were ''treated'' as provider-based in relation to any hospital or CAH on October 1, 2000 will continue to be treated as such until October 1, 2002. For the purpose of this provision, we interpret ''treated as provider-based'' to include those facilities with formal CMS determinations, as well as those facilities without formal CMS determinations that were being paid as provider-based as of October 1, 2000. As a result, existing provider-based facilities and organizations may retain that status without meeting the criteria in the regulations under §§ 413.65(d), (e), (f), and (h) until October 1, 2002. These provisions concern provider-based status requirements, joint ventures, management contracts, and services under arrangement. Thus, the provider-based facilities and organizations affected under section 404(a) are not required to submit an application for or obtain a provider-based status determination in order to continue receiving reimbursement as provider-based during this period.

These provider-based facilities and organizations will not be exempt from the Emergency Medical Treatment and Active Labor Act (EMTALA) requirements for provider-based facilities and organizations (revised § 489.24(b) and new § 489.24(i)) or from the obligations of hospital outpatient departments and hospital-based entities in § 413.65(g), such as the requirement that off-campus facilities provide written notices to Medicare beneficiaries of coinsurance liability. These requirements become effective for hospitals on the first day of the hospital's cost reporting period beginning on or after January 10, 2001.

We are aware that many hospitals and physicians continue to have significant concerns with our policy on the applicability of EMTALA to provider-based facilities and organizations. We intend to re-examine these regulations and, in particular, reconsider the appropriateness of applying EMTALA to off-campus locations. At the same time, we want to assure that those departments that Medicare pays as hospital-based departments are appropriately integrated with the hospital as a whole. We intend to publish a proposed rule to address these issues more fully.

2. Geographic Location Criteria

Section 404(b) of BIPA provides that those facilities or organizations that are not included in the grandfathering provision at section 404(a) are deemed to comply with the ''immediate vicinity'' requirements of the new regulations under § 413.65(d)(7) if they are located not more than 35 miles from the main campus of the hospital or critical access hospital. Therefore, those facilities located within 35 miles of the main provider satisfy the immediate vicinity requirement as an alternative to meeting the ''75/75 test'' under § 413.65(d)(7).

In addition, BIPA provides that certain facilities or organizations are deemed to comply with the requirements for geographic proximity (either the ''75/75 test'' or the ''35-mile test'') if they are owned and operated by a main provider that is a hospital with a disproportionate share adjustment percentage greater than 11.75 percent and is (1) owned or operated by a unit of State or local government, (2) a public or private nonprofit corporation that is formally granted governmental powers by a unit of State or local government, or (3) a private hospital that has a contract with a state or local government that includes the operation of clinics of the hospital to assure access in a well-defined service area to health care services for low-income individuals who are not entitled to benefits under Medicare or Medicaid.

These geographic location criteria are permanent. While those facilities or organizations treated as provider-based on October 1, 2000 are covered by the two-year grandfathering provision noted above, the geographic location criteria at section 404(b) of BIPA and the regulations at § 413.65(d)(7) will apply to facilities or organizations not treated as provider-based as of that date, effective with the hospital's cost reporting period beginning on or after January 10, 2001. Beginning October 1, 2002, these criteria will also apply to the grandfathered facilities.

3. Criteria for Temporary Treatment as Provider-Based

Finally, section 404(c) of BIPA also provides that a facility or organization that seeks a determination of provider-based status on or after October 1, 2000 and before October 1, 2002 may not be treated as not having provider-based status for any period before a determination is made. Thus, recovery for overpayments will not be made retroactively for noncompliance with the provider-based criteria once a request for a determination during that time period has been made. For hospitals that do not qualify for grandfathering under section 404(a), until a uniform application is available, a request for provider-based status should be submitted to the appropriate CMS Regional Office (RO). At a minimum, the request should include the identity of the main provider and the facility or organization for which provider-based status is being sought and supporting documentation to demonstrate compliance with the provider-based status criteria in effect at the time the application is submitted. Once such a request has been submitted on or after October 1, 2000, and before October 1, 2002, CMS will treat the facility or organization as being provider-based from the date it began operating as provider-based (as long as that date is on or after October 1, 2000) until the effective date of a CMS determination that the facility or organization is not provider-based.

Facilities requesting a provider-based status determination on or after October 1, 2002 will not be covered by the provision concerning temporary treatment as provider-based in section 404(c) of BIPA. Thus, as stated in § 413.65(n), CMS ROs will make provider-based status applicable as of the earliest date on which a request for determination has been made and all requirements for provider-based status in effect as of the date of the request are shown to have been met, not on the date of the formal CMS determination. If a facility or organization does not qualify for provider-based status and CMS learns that the provider has treated the facility or organization as provider-based without having obtained a provider-based determination under applicable regulations, CMS will review all payments and may seek recovery for overpayments in accordance with the regulations at § 413.65(j), including overpayments made for the period of time between submission of the request or application for provider-based status and the issuance of a formal CMS determination.

D. Proposed Changes to Provider-Based Regulations

To fully implement the provisions of section 404 of BIPA and to codify the clarifications currently stated only in the Q&As on provider-based status, as described above, we are proposing to revise the regulations as follows.

1. Clarification of Requirements for Adequate Cost Data and Cost Finding (§ 413.24(d))

As part of the April 7, 2000, final rule implementing the prospective payment system for hospital outpatient services to Medicare beneficiaries, under § 413.24, Adequate Cost Data and Cost Finding, we added a new paragraph (d)(6), entitled ''Management Contracts.'' Since publication of the final rule, we have received several questions concerning the new paragraph.

In response to these questions, we are proposing changes in wording to clarify the meaning of that paragraph. In addition, for further clarity, we are revising the coding and title of that material. Under our proposal, § 413.24(d)(6)(i) would become § 413.24(d)(6) and § 413.24(d)(6)(ii) would become § 413.24(d)(7). As revised, paragraph (d)(6) would address the situation when the main provider in a provider-based complex purchases services for a provider-based entity or for a department of the provider through a contract for services (for example, a management contract), directly assigning the costs to the provider-based entity or department and reporting the costs directly in the cost center for that entity or department. In any situation in which costs are directly assigned to a cost center, there is a risk of excess cost in that cost center resulting from the directly assigned costs plus a share of overhead improperly allocated to the cost center which duplicates the directly assigned costs. This duplication could result in improper Medicare payment to the provider. Therefore, where a provider has purchased services for a provider-based entity or for a provider department, like general service costs of the provider (for example, like costs in the administrative and general cost center) must be separately identified to ensure that they are not improperly allocated to the entity or the department. If the like costs of the provider cannot be separately identified, the costs of the services purchased through a contract for the provider-based entity or provider department must be reclassified to the main provider and allocated among the main provider's benefiting cost centers.

For costs of services furnished to free-standing entities, we would also clarify in revised § 413.24(d)(7), that the costs that a provider incurs to furnish services to free-standing entities with which it is associated are not allowable costs of that provider. Any costs of services furnished to a free-standing entity must be identified and eliminated from the allowable costs of the servicing provider, to prevent Medicare payment to that provider for those costs. This may be done by including the free-standing entity on the cost report as a nonreimbursable cost center for the purpose of allocating overhead costs to that entity. If this method would not result in an accurate allocation of costs to the entity, the provider must develop detailed work papers showing how the cost of services furnished by the provider to the entity were determined. These costs are removed from the applicable cost centers of the servicing provider.

This revision is not a change in the policy, but instead is a clarification to the policy set forth in the April 7, 2000 final rule.

2. Scope and Definitions (§ 413.65(a))

In Q/A 9 published on the CMS (Formerly, HCFA) web site at *www.hcfa.gov/medlearn/provqa.htm*, we identified specific types of facilities for which provider-based determinations would not be made, since their status would not affect either Medicare payment levels or beneficiary liability. (This document may also be obtained by contacting the CMS (Formerly, HCFA) Regional Office.) The facilities identified in Q/A 9 are ambulatory Surgical Centers (ASCs), comprehensive outpatient rehabilitation facilities (CORFs); home health agencies (HHAs); skilled nursing facilities (SNFs); hospices; inpatient rehabilitation units that are excluded from the inpatient PPS for acute hospital services; independent diagnostic testing facilities and any other facilities that furnish only clinical diagnostic laboratory tests; facilities furnishing only physical, occupational or speech therapy to ambulatory patients, for as long as the $1500 annual cap on coverage of physical, occupational, and speech therapy, as described in section 1833(g)(2) of the Act, remains suspended by the action of subsequent legislation; and end-stage renal disease (ESRD) facilities. Determinations for ESRD facilities are made under § 413.174.

We propose to revise the regulations at § 413.65(a) to clarify that these facilities are not subject to the provider-based requirements and that provider-based determinations will not be made for them.

3. BIPA Provisions on Grandfathering and Temporary Treatment as Provider-Based (§§ 413.65(b)(2) and (b)(5))

Current regulations at § 413.65(b)(2) state that a main provider or a facility must contact CMS (Formerly, HCFA) and the facility must be determined by CMS (Formerly, HCFA) to be provider-based before the main provider bills for services of the facility as if the facility were provider-based, or before it includes costs of those services on its cost report. However, as explained earlier, sections 404(a) and (c) of BIPA require that certain facilities be grandfathered for a 2-year period, and that facilities applying between October 1, 2000 and October 1, 2002 for provider-based status with respect to a hospital be given provider-based status on a temporary basis, pending a decision on their applications. To implement these provisions, we propose to revise the regulations in § 413.65(b)(2) to state that if a facility was treated as provider-based in relation to a hospital or CAH on October 1, 2000, it will continue to be considered provider-based in relation to that hospital or CAH until October 1, 2002, and the requirements, limitations, and exclusions specified in paragraphs (d), (e), (f), and (h) of § 413.65 will not apply to that hospital or CAH with respect to that facility until October 1, 2002. We would further state that for purposes of paragraph (b)(2), a facility will be considered to have been treated as provider-based on October 1, 2000, if on that date it either had a written determination from CMS (Formerly, HCFA) that it was provider-based as of that date, or was billing and being paid as a provider-based department or entity of the hospital.

We would also propose to add a new § 413.65(b)(2) to state that a facility for which a determination of provider-based status in relation to a hospital or CAH is requested on or after October 1, 2000 and before October 1, 2002 will be treated as provider-based in relation to the hospital or CAH from the first date on or after October 1, 2000 on which the facility was licensed (to the extent required by the State), staffed and equipped to treat patients until the date on which CMS (Formerly, HCFA) determines that the facility does not qualify for provider-based status.

4. Reporting (§ 413.65(c)(1))

Current regulations at § 413.65(c) state that a main provider that creates or acquires a facility or organization for which it wishes to claim provider-based

status, including any physician offices that a hospital wishes to operate as a hospital outpatient department or clinic, must report its acquisition of the facility or organization to CMS (Formerly, HCFA) if the facility or organization is located off the campus of the provider, or inclusion of the costs of the facility or organization in the provider's cost report would increase the total costs on the provider's cost report by at least 5 percent, and must furnish all information needed for a determination as to whether the facility or organization meets the requirements in paragraph (d) of this section for provider-based status. Concern has been expressed that such reporting would duplicate the requirement for obtaining approval of a facility as provider-based before billing its services that way or including its costs on the cost report of the main provider (current § 413.65(b)(2)). To prevent any unnecessary duplicate reporting, we propose to delete the current requirement from § 413.65(c)(1). We would, however, retain the requirement that a main provider that has had one or more facilities considered provider-based also report to CMS (Formerly, HCFA) any material change in the relationship between it and any provider-based facility, such as a change in ownership of the facility or entry into a new or different management contract that could affect the provider-based status of the facility.

5. Geographic Location Criteria (§ 413.65(d)(7))

As explained earlier in C.2 of this section, section 404(b) of BIPA mandates that facilities seeking provider-based status be considered to meet any geographic location criteria if they are located not more than 35 miles from the main campus of the hospital or CAH to which they wish to be based, or meet other specific criteria relating to their ownership and operation. To implement this provision, we propose to revise § 413.65(d)(7) to state that facility will meet provider-based location criteria if it and the main provider are located on the same campus, or if one of the following three criteria are met:

- The facility or organization is located within a 35-mile radius of the main campus of the hospital or CAH that is the potential main provider;
- The facility or organization is owned and operated by a hospital or CAH that—

(A) Is owned or operated by a unit of State or local government;

(B) Is a public or nonprofit corporation that is formally granted governmental powers by a unit of State or local government; or,

(C) Is a private hospital that has a contract with a State or local government that includes the operation of clinics located off the main campus of the hospital to assure access in a well-defined service area to health care services to low-income individuals who are not entitled to benefits under Medicare (or medical assistance under a Medicaid State plan); and

(D) Has a disproportionate share adjustment (as determined under § 412.106 of this chapter) greater than 11.75 percent or is described in § 412.106(c)(2) of this chapter implementing section 1886(d)(5)(F)(i)(II) of the Act.

- The facility meets the criteria currently set forth in § 413.65(d)(7)(i) for service to the same patient population as the main provider.

6. Notice to Beneficiaries of Coinsurance Liability (§ 413.65(g)(7))

Current regulations at § 413.65(g)(7) state that when a Medicare beneficiary is treated in a hospital outpatient department or hospital-based entity (other than an RHC) that is not located on the main provider's campus, the hospital has a duty to provide written notice to the beneficiary, prior to the delivery of services, of the amount of the beneficiary's potential financial liability (that is, of the fact that the beneficiary will incur a coinsurance liability for an outpatient visit to the hospital as well as for the physician service, and of the amount of that liability). The notice must be one that the beneficiary can read and understand.

Some concern had been expressed that providing notice of a beneficiary's exact liability might be difficult in cases where the treating physician was in the process of diagnosing the patient's condition and was unsure of exactly what services might be required. In response to this concern we clarified in the preamble to an interim final rule with comment period published on August 3, 2000 (65 FR 47670) that if the exact type and extent of care needed is not known, the hospital may furnish a written notice to the patient that explains the fact that the beneficiary will incur a coinsurance liability to the hospital that they would not incur if the facility were not provider-based. The interim final rule preamble § 413.65(g)(7)) further explained that the hospital may furnish an estimate based on typical or average charges for visits to the facility, while stating that the patient's actual liability will depend upon the actual services furnished by the hospital. If the beneficiary is unconscious, under great duress, or for any other reason unable to read a written notice and understand and act on his or her own rights, the notice must be provided, prior to the delivery of services, to the beneficiary's authorized representative.

We are proposing to amend § 413.65(g)(7) to include this clarifying language.

7. Clarification of Protocols for Off-Campus Departments (§ 489.24(i)(2)(ii))

Current regulations at § 489.24(i) specify the antipatient dumping obligations that hospitals have with respect to individuals who come to off-campus hospital departments for the examination or treatment of a potential emergency medical conditions. These obligations are sometimes known as EMTALA obligations, after the Emergency Medical Treatment and Active Labor Act, which is the legislation that first imposed the obligations. Currently, hospitals are responsible for ensuring that personnel at their off-campus departments are trained and given appropriate protocols for the handling of emergency cases.

In the case of off-campus departments not routinely staffed with physicians, RNs, or LPNs, the department's personnel must be given protocols that direct them to contact emergency personnel at the main hospital campus before arranging an appropriate transfer to a medical facility other than the main hospital.

Some concern had been expressed that taking the time needed to make such contacts might inappropriately delay the appropriate transfer of emergency patients in cases where the patient's condition was deteriorating rapidly. In response to this concern we clarified in the preamble to the interim final rule with comment period published on August 3, 2000 cited above (65 FR 47670) that in any case of the kind described in § 489.24(i)(2)(ii) the contact with emergency personnel at the main hospital campus should be made either concurrently with or after the actions needed to arrange an appropriate transfer, if doing otherwise would significantly jeopardize the individual's life or health. This does not relieve the off-campus department of the responsibility for making the contact, but only clarifies that the contact may be delayed in specific cases where doing otherwise would endanger a patient subject to EMTALA protection.

We are proposing to amend § 489.24(i)(2)(ii) to include this clarifying language.

8. Other Changes

In addition to the changes cited above, we are proposing to make the following conforming and clarifying changes:

• We are correcting date references in §§ 413.65(i)(1)(i) and (i)(2), in order to take into account the effective date of the current regulations.

• We are substituting ''CMS'' for ''HCFA'' throughout the revised sections of part 413, to reflect the renaming of the Health Care Financing Administration (HCFA) as the Centers for Medicare & Medicaid Services (CMS).

XI. Summary of Proposed Changes for 2002

A. Changes Required by BIPA 2000

We are proposing the following changes to the OPPS, to implement the provisions of BIPA 2000:

• Limit coinsurance to a specified percentage of APC payment amounts.

• Provide hold-harmless transitional corridor payments to children's hospitals.

• Provide separate APCs for services that use contrast agents and those that do not.

• Pay for glaucoma screening as a covered service.

• Pay for certain new technology used in screening and diagnostic mammograms.

B. Additional Changes

We are proposing the following additional changes to the OPPS:

• Add APCs, delete APCs, and modify the composition of services within some existing APCs.

• Add an APC group that would provide payment for observation services in limited circumstances to patients having specific diagnoses.

• Recalibrate the relative payment weights of the APCs.

• Update the conversion factor and wage index.

• Revise the APC payment amounts to reflect the APC reclassifications, the recalibration of payment weights and the other required updates and adjustments.

• Make reductions in pass-through payments for specific drugs and categories of devices to account for the drug and device costs that are included in the APC payment for associated procedures and services.

• Apply a standard procedure to calculate copayment amounts when new APCs are created or when APC payment rates are increased or decreased as a result of recalibrated weights.

• Calculate outlier payments on a service-by-service basis beginning in 2002. We also propose a methodology for allocating packaged services to individual APCs in determining costs of a service and we propose to use a hospital's overall outpatient cost-to-charge ratio to convert charges to costs.

• Change the threshold for outlier payments to require costs to exceed 3 times the APC payment amount, and pay 50 percent of any excess costs above the threshold as an outlier payment.

• Exclude hospitals located outside the 50 states, the District of Columbia and Puerto Rico from the OPPS.

• Exclude from payment under the OPPS certain services that are furnished to inpatients of hospitals that do not submit claims for outpatient services under Medicare Part B.

• Exclude from the OPPS certain items and services (for example, bad debts, direct medical education and certain certified registered nurse anesthetists services) that are paid on a cost basis.

• Propose to update the payments for pass-through radiopharmaceuticals, drugs, and biologicals on a calendar year basis to reflect increases in AWP.

• Allow reprocessed single use devices to be considered eligible for pass-through payments if the reprocessing process for single use devices meets the FDA's most recent criteria.

• Revise the criteria we will use to determine whether a procedure or service is eligible to be assigned to a new technology APC.

• Revise the list of information that must be submitted to request assignment of a service or procedure to a new technology APC.

• Provide more flexibility in the amount of time a service may be paid under a new technology APC.

C. Technical Corrections

We are proposing to make conforming changes to the regulations in 42 CFR parts 413, 419 and 489.

In part 413 we would—

• Revise § 413.24(d)(6) and (d) (7) to clarify requirements for adequate cost data and cost findings and clarify the meaning of the paragraph.

• Revise § 413.65(a)(1) to clarify the specified types of facilities identified in this section that are not subject to the provider-based requirements and that provider-based determinations will not be made for them.

• Revise the definition of ''Provider-based entity'' in § 413.65(a)(2).

• Revise § 413.65(b) to implement the BIPA provisions on grandfathering and temporary treatment of a facility as provider-based.

• Delete the existing requirement in § 413.65(c)(1) in order to prevent unnecessary duplicate reporting.

• Specify in § 413.65(d)(7) that a facility will meet provider-based geographic location criteria if it and the main provider are located on the same campus, or if a facility meets one of the three criteria specified in this paragraph.

• Clarify in § 413.65(g)(7) that the hospital may furnish an estimate based on typical or average charges for visits to the facility, while stating that the patient's actual liability will depend upon the actual services furnished by the hospital.

• Correct date references in §§ 413.65(i)(1)(ii) and (i)(2), in order to take into account the effective date of the current regulations.

In part 419, we would—

• Revise § 419.2 to clarify the costs that are excluded from the OPPS rates.

• Revise the reference to the effective date of the OPPS to August 1, 2000 in § 419.20(a).

• Add new §§ 419.20(b)(3) and (b)(4) to specify that a hospital located outside one of the 50 States, the District of Columbia, or Puerto Rico, or a hospital of the Indian Health Service is excluded from the hospital outpatient prospective payment system.

• Add a new § 419.22(r) to specify that services defined in § 419.21(b) that are furnished to inpatients of hospitals that do not submit claims for outpatients services under Medicare Part B are not paid for under the hospital OPPS.

• Revise § 419.32 to reflect the revised update to the payment rates, as required by section 401 of BIPA.

• Replace the word ''coinsurance'' each time it appears in §§ 419.40, 419.41, 419.42 and 419.43 with the word ''copayment.''

• Redesignate existing § 419.41(c)(4)(ii) as paragraph (c)(4)(iv), and add paragraphs (c)(4)(ii) and (c)(4)(iii) to include the provisions of section 1833(t)(8)(C)(ii) of the Act. This section would specify that, effective for services furnished from April 1, 2001 through December 31, 2001, the national unadjusted coinsurance rate for an APC cannot exceed 57 percent of the prospective rate for that APC and the national unadjusted coinsurance rate for an APC cannot exceed 55 percent in calendar year 2004, 45 percent in calendar year 2005, and 40 percent in calendar year 2006 and thereafter.

• Revise § 419.70(d) to give children's hospitals the same permanent hold harmless protection as cancer hospitals under the OPPS, as required by section 405 of BIPA.

• Revise § 489.24(i)(2)(ii) to clarify that, for the purposes of arranging an appropriate transfer of a patient from an off-campus department, staff at the off-campus department may delay contacting the emergency personnel at the main hospital campus in the specific cases where doing otherwise would endanger a patient.

XII. Collection of Information Requirements

Under the Paperwork Reduction Act of 1995, we are required to provide 60-day notice in the **Federal Register** and solicit public comment before a collection of information requirement is submitted to the Office of Management and Budget (OMB) for review and approval. In order to fairly evaluate whether an information collection should be approved by OMB, section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 requires that we solicit comment on the following issues:

• The need for the information collection and its usefulness in carrying out the proper functions of our agency.

• The accuracy of our estimate of the information collection burden.

• The quality, utility, and clarity of the information to be collected.

• Recommendations to minimize the information collection burden on the affected public, including automated collection techniques.

Sections 413.65 and 419.42 of this proposed regulation contain information collection requirements that are subject to review by OMB under the Paperwork Reduction Act of 1995. However, §§ 413.65 and 419.42 have been approved by OMB under approval number 0938–0798, with a current expiration date of August 31, 2003 and OMB approval number 0938–0802, with a current expiration date of August 31, 2001.

XIII. Response to Public Comments

Because of the large number of items of correspondence we normally receive on a proposed rule, we are not able to acknowledge or respond to them individually. However, in preparing the final rule, we will consider all comments concerning the provisions of this proposed rule that we receive by the date and time specified in the **DATES** section of this preamble and respond to those comments in the preamble to that rule.

Modification of 60-day Comment Period

The highly complex analysis surrounding the possibility of a significant pro rata reduction has caused a delay in the publication of the proposed rule. It is essential for this rule to become effective by January 1, 2002 for hospital outpatient departments to receive appropriate higher payments and to ensure that beneficiaries receive the benefits of further reductions in beneficiary copayments. Congress has directed us to update payment rates annually, at the beginning of each calendar year. If the increased provider payments and reduced beneficiary copayments do not become effective by the statutory effective date of January 1, 2002, enormous uncertainty and administrative difficulties will result for beneficiaries, providers, and intermediaries. In addition, any delay in receiving increased provider payments or reduced beneficiary copayments will cause harm to providers and beneficiaries. Consequently, in order to avoid imposing this uncertainty and harm on beneficiaries, providers, and intermediaries and to meet the January 1, 2002 statutory effective date for the update to the OPPS payment rates, we find we must shorten the comment period to 40 days. For the reasons discussed above, we find there is good cause to modify the 60-day comment period. We further find that this comment cycle will give parties sufficient opportunity to comment adequately on our proposed rule. In addition, we are immediately posting this proposed rule on our website at http://www.hcfa.gov/regs/cms1159p.htm pending publication in the **Federal Register** to ensure the maximum possible opportunity for public comment.

XIV. Regulatory Impact Analysis

A. General

We have examined the impacts of this proposed rule as required by Executive Order 12866 (September 1993, Regulatory Planning and Review) and the Regulatory Flexibility Act (RFA) (September 19, 1980 Public Law 96–354). Executive Order 12866 directs agencies to assess all costs and benefits of available regulatory alternatives and, if regulation is necessary, to select regulatory approaches that maximize net benefits (including potential economic, environmental, public health and safety effects, distributive impacts, and equity). A regulatory impact analysis (RIA) must be prepared for major rules with economically significant effects ($100 million or more annually).

The statutory effects of the provisions that would be implemented by this proposed rule result in expenditures exceeding $100 million per year. We estimate the total impact of these changes for CY 2002 payments compared to CY 2001 payments to be approximately a $450 million increase. Therefore, this proposed rule is an economically significant rule under Executive Order 12866, and a major rule under 5 U.S.C. 804(2).

The RFA requires agencies to determine whether a rule will have a significant economic impact on a substantial number of small entities. For purposes of the RFA, small entities include small businesses, nonprofit organizations and government agencies. Most hospitals and most other providers and suppliers are small entities, either by nonprofit status of by having revenues of $5 to $25 million or less annually (see 65 FR 69432). For purposes of the RFA, all providers of hospital outpatient services are considered small entities. Individuals and States are not included in the definition of a small entity.

In addition, section 1102(b) of the Act requires us to prepare a regulatory impact analysis if a rule may have a significant impact on the operations of a substantial number of small rural hospitals. This analysis must conform to the provisions of section 603 of the RFA. With the exception of hospitals located in certain New England counties, for purposes of section 1102(b) of the Act, we define a small rural hospital as a hospital that is located outside of a Metropolitan Statistical Area (MSA) and has fewer than 100 beds, or New England County Metropolitan Area (NECMA). Section 601(g) of the Social Security Amendments of 1983 (Pub. L. 98–21) designated hospitals in certain New England counties as belonging to the adjacent NECMA. Thus, for purposes of the OPPS, we classify these hospitals as urban hospitals.

It is clear that the changes in this proposed rule would affect both a substantial number of rural hospitals as well as other classes of hospitals, and the effects on some may be significant. Therefore, the discussion below, in combination with the rest of this proposed rule, constitutes a regulatory impact analysis.

Section 202 of the Unfunded Mandate Reform Act of 1995 (Pub. L. 104–4) also requires that agencies assess anticipated costs and benefits before issuing any rule that may result in an expenditure in any one year by State, local, or tribal governments, in the aggregate, or by the private sector, of $110 million. This proposed rule would not mandate any requirements for State, local, or tribal governments.

Executive Order 13132 establishes certain requirements that an agency must meet when it publishes a proposed

rule (and subsequent final rule) that imposes substantial direct costs on State and local governments, preempts State law, or otherwise has Federalism implications.

We have examined this proposed rule in accordance with Executive Order 13132, Federalism, and have determined that it will not have any negative impact on the rights, roles, and responsibilities of State, local or tribal governments.

B. Changes in This Proposed Rule

We are proposing several changes to the OPPS that are required by the statute. We are required under section 1833(t)(3)(C)(ii) of the Act to update annually the conversion factor used to determine the APC payment rates. We are also required under section 1833(t)(8)(A) of the Act to revise, not less often than annually, the wage index and other adjustments. In addition, we must review the clinical integrity of payment groups and weights at least annually. Accordingly, in this proposed rule, we are updating the conversion factor and the wage index adjustment for hospital outpatient services furnished beginning January 1, 2002. We are also proposing revisions to the relative APC payment weights based on claims data from July 1, 1999 through June 30, 2000. Finally, we are proposing to begin calculating outlier payments on an APC-specific basis rather than the current method of calculating outlier payments for each claim.

The projected aggregate impact of updating the conversion factor is to increase total payments to hospitals by 2.3 percent. As described in the preamble, budget neutrality adjustments are made to the conversion factor and the weights to assure that the revisions in the wage index, APC groups, and relative weights do not affect aggregate payments. In addition, the determination of the parameters for outlier payments have been modified so that projected outlier payments for 2002 are equivalent to the established policy target of 2.0 percent of total payments. Because we are not revising the target percentage, there is no estimated aggregate impact from modifying the method of determining outlier payments.

The impact of the wage, recalibration and outlier changes do vary somewhat by hospital group. Estimates of these impacts are displayed on Table 6.

C. Limitations of Our Analysis

The distributional impacts represent the projected effects of the proposed policy changes, as well as statutory changes effective for 2002, on various hospital groups. We estimate the effects of individual policy changes by estimating payments per service while holding all other payment policies constant. We use the best data available but do not attempt to predict behavioral responses to our policy changes. In addition, we do not make adjustments for future changes in variables such as service volume, service mix, or number of encounters.

D. Estimated Impacts of This Proposed Rule

Column 5 in Table 6 represents the full impact on each hospital group of all the changes for 2002. Columns 2 through 4 in the table reflect the independent effects of the proposed change in the wage index, the APC reclassification and recalibration changes and the change in outlier method, respectively.

In general, the wage index changes favor rural hospitals, particularly the largest in bed size and volume. The only rural hospitals that would experience a negative impact due to wage index changes are those in the Middle Atlantic and Pacific Regions, a decrease of 0.3 percent for each. Conversely, the urban hospitals are generally negatively affected by these changes, with the largest effect on those with 500 or more beds (0.6 percent decrease) and those in the Middle Atlantic (1.7 percent decrease) and West South Central Regions (1.5 percent decrease).

We estimate that the APC reclassification and recalibration changes have generally an opposite impact from the wage index, causing increases for all urban hospitals except those with under 200 beds and volumes of fewer than 21,000 services per year and those located in the New England (a 0.1 percent decrease), Middle Atlantic (a 0.7 percent decrease), East North Central (a 0.55 percent decrease), and Puerto Rico (a 5.6 percent decrease) Regions.

The change in outlier policy to an APC-specific payment has a slight negative effect on rural hospitals as a group (a 0.2 percent decrease), no effect on urban hospitals as a group, and slight negative effects on all smaller hospitals as well as those with lower volumes of services.

The overall projected increase in payments for urban hospitals is slightly greater (2.4 percent) than the average increase for all hospitals while the increase for rural hospitals is somewhat less than the average increase (1.9 percent). Rural hospitals gain 1.2 percent from the wage index change, but lose a combined 1.7 percent from the APC changes and the change in method of determining outlier payments.

In both urban and rural areas, hospitals that provide a higher volume of outpatient services are projected to receive a larger increase in payments than lower volume hospitals. In rural areas, hospitals with volumes of fewer than 5000 services are projected to experience a small decline in payments (−0.1 percent). The less favorable impact for the low volume hospitals is attributable to the APC changes and the change in outlier method. For example, rural hospitals providing fewer than 5000 services are projected to lose a combined 3 percent due to these changes.

Urban hospitals in the Middle Atlantic region are projected to receive no increase in payments, and we estimate a decline of 0.1 percent for rural hospitals in this region. Both the urban and rural hospitals lose 2.4 percent due to the wage index change and APC changes. The urban hospitals are affected more by the wage index change (−1.7 percent), while rural hospitals are affected more by the recalibration (−2.1 percent). Urban hospitals in the East South Central Region are projected to experience the largest increase in payments (5.5 percent).

Major teaching hospitals are projected to experience a smaller increase in payments (1.3 percent) than the aggregate for all hospitals due to negative impacts of the wage index (−0.7 percent), recalibration (−0.1 percent), and outlier changes (−0.2 percent). Hospitals with less intensive teaching programs are projected to experience an overall increase (3.0 percent) that is larger than the average for all hospitals. This is attributable to the fact that there is no impact on this group for the wage index change and positive impacts for both the APC changes (0.6 percent) and outlier changes (0.1). There is little difference in impact among hospitals with varying shares of low-income patients.

TABLE 6.—IMPACT OF CHANGES FOR CY 2002 HOSPITAL OUTPATIENT PROSPECTIVE PAYMENT SYSTEM

[Percent changes in total payments (program and beneficiary)]

	Number of hospitals [1] (1)	New wage index [2] (2)	APC recalib. [3] (3)	New outlier policy [4] (4)	All CY 2002 changes [5] (5)
ALL HOSPITALS	5,077	0.0	0.0	0.0	2.3
NON–TEFRA HOSPITALS	4,701	0.0	0.0	0.0	2.3
URBAN HOSPS	2,608	−0.3	0.4	0.0	2.4
LARGE URBAN (GT 1 MILL.)	1,495	−0.5	0.1	0.0	1.9
OTHER URBAN (LE 1 MILL.)	1,113	−0.1	0.7	0.1	3.1
RURAL HOSPS	2,093	1.2	−1.5	−0.2	1.9
BEDS (URBAN):					
0–99 BEDS	661	0.0	−1.9	−0.1	0.3
100–199 BEDS	918	−0.3	−0.4	0.1	1.8
200–299 BEDS	510	−0.3	0.6	0.0	2.6
300–499 BEDS	374	−0.3	1.1	0.1	3.2
500 + BEDS	145	−0.6	1.1	0.0	2.7
BEDS (RURAL):					
0—49 BEDS	1,249	0.4	−2.4	−0.6	−0.2
50–99 BEDS	506	0.7	−2.2	−0.2	0.6
100–149 BEDS	198	1.6	−0.7	0.0	3.2
150–199 BEDS	74	1.6	−1.0	−0.1	2.8
200 + BEDS	66	2.6	−0.2	0.1	4.8
VOLUME (URBAN):					
LT 5,000	363	−0.5	−0.5	−0.3	1.0
5,000–10,999	496	−0.3	−1.1	0.0	0.9
11,000–20,999	605	−0.4	−0.4	0.1	1.7
21,000–42,999	746	−0.4	0.6	0.1	2.6
GT 42,999	398	−0.2	0.6	0.0	2.7
VOLUME (RURAL):					
LT 5,000	1,000	0.4	−2.0	−1.0	−0.1
5,000–10,999	569	0.5	−2.3	−0.2	0.2
11,000–20,999	322	1.1	−1.7	−0.1	1.6
21,000–42,999	171	1.7	−0.9	0.0	3.0
GT 42,999	31	2.8	−0.3	0.0	4.8
REGION (URBAN):					
NEW ENGLAND	136	1.0	−0.1	−0.2	3.0
MIDDLE ATLANTIC	380	−1.7	−0.7	0.0	0.0
SOUTH ATLANTIC	429	0.4	1.3	0.1	4.1
EAST NORTH CENT	444	−0.4	−0.5	0.1	1.5
EAST SOUTH CENT	154	1.3	1.8	0.1	5.5
WEST NORTH CENT	183	−0.1	0.2	0.1	2.5
WEST SOUTH CENT	323	−1.5	1.6	0.0	2.3
MOUNTAIN	129	0.1	1.2	0.0	3.6
PACIFIC	391	−0.2	0.4	0.0	2.5
PUERTO RICO	39	1.2	−5.6	−0.2	−2.3
REGION (RURAL):					
NEW ENGLAND	51	0.4	−2.3	−0.4	0.0
MIDDLE ATLANTIC	72	−0.3	−2.1	0.1	−0.1
SOUTH ATLANTIC	276	1.8	−0.8	−0.1	3.2
EAST NORTH CENT	275	1.5	−2.5	−0.1	1.2
EAST SOUTH CENT	250	1.5	−0.9	−0.1	2.8
WEST NORTH CENT	501	1.3	−2.1	−0.3	1.2
WEST SOUTH CENT	326	1.4	−0.2	−0.2	3.2
MOUNTAIN	200	1.6	−1.1	−0.5	2.4
PACIFIC	137	−0.3	−1.2	−0.2	0.6
PUERTO RICO	5	4.2	−3.1	−0.3	3.0
TEACHING STATUS:					
NON–TEACHING	3,594	0.2	−0.4	0.0	2.1
MINOR	812	0.0	0.6	0.1	3.0
MAJOR	294	−0.7	−0.1	−0.2	1.3
DSH PATIENT PERCENT:					
0	27	0.0	−1.1	−0.7	0.7
GT 0–0.10	1,298	−0.1	−0.3	0.0	2.0
0.10–0.16	1,047	0.2	−0.2	0.1	2.3
0.16–0.23	822	−0.1	0.3	0.0	2.5
0.23–0.35	812	0.1	0.2	0.0	2.6
GE 0.35	695	−0.2	0.1	−0.3	2.0
URBAN IME/DSH:					
IME & DSH	1,012	−0.4	0.5	0.0	2.4
IME/NO DSH	4	−0.1	−2.2	−1.2	−1.0
NO IME/DSH	1,578	−0.2	0.2	0.1	2.4
NO IME/NO DSH	14	0.1	0.9	0.7	4.0

TABLE 6.—IMPACT OF CHANGES FOR CY 2002 HOSPITAL OUTPATIENT PROSPECTIVE PAYMENT SYSTEM—Continued

[Percent changes in total payments (program and beneficiary)]

	Number of hospitals [1] (1)	New wage index [2] (2)	APC recalib. [3] (3)	New outlier policy [4] (4)	All CY 2002 changes [5] (5)
RURAL HOSP. TYPES:					
NO SPECIAL STATUS	797	0.5	−2.0	−0.2	0.6
RRC	171	2.3	−0.5	0.1	4.2
SCH/EACH	656	0.7	−2.2	−0.4	0.5
MDH	327	0.2	−2.5	−0.5	−0.4
SCH AND RRC	70	2.1	−0.9	−0.1	3.4
TYPE OF OWNERSHIP:					
VOLUNTARY	2,808	−0.1	−0.1	0.0	2.2
PROPRIETARY	761	0.0	0.9	0.2	3.4
GOVERNMENT	1,132	0.4	−0.4	−0.2	2.1
SPECIALTY HOSPITALS:					
EYE AND EAR	12	0.1	−8.3	0.6	−5.3
TRAUMA	154	−0.2	−0.1	−0.1	1.9
CANCER	10	−1.7	2.3	−1.6	1.2
TEFRA HOSPITALS (NOT INCLUDED ON OTHER LINES):					
REHAB	164	−1.8	10.0	−1.0	8.9
PSYCH	88	−1.4	−0.6	−3.5	−3.1
LTC	83	−0.7	−2.3	−0.2	−1.0
CHILDREN	41	−0.6	−2.0	−2.2	−2.2

[1] Some data necessary to classify hospitals by category were missing; thus, the total number of hospitals in each category may not equal the national total.

[2] This column shows the impact of updating the wage index used to calculate payment using the proposed FY 2002 hospital inpatient wage index after geographic reclassification by the Medicare Geographic Classification Review Board. The hospital inpatient proposed rule for FY 2002 was published in the **Federal Register** on May 4, 2001.

[3] This column shows the impact of recalibrating the APC weights based on 1999–2000 hospital claims data and of the reassignment of some HCPCs to APCs as discussed in this rule.

[4] This column shows the difference in calculating outliers on an APC-specific rather than bill basis.

[5] This column shows changes in total payment from CY 2001 to CY 2002. It incorporates all of the changes reflected in columns 2, 3, and 4. In addition, it shows the impact of the CY 2002 payment update. The sum of the columns may be different from the percentage changes shown here due to rounding.

In accordance with the provisions of Executive Order 12866, this proposed rule was reviewed by the Office of Management and Budget.

List of Subjects

42 CFR Part 413

Health facilities, Kidney diseases, Medicare, Puerto Rico, Reporting and recordkeeping requirements.

42 CFR Part 419

Hospitals, Medicare, Reporting and recordkeeping requirements.

42 CFR Part 489

Health facilities, Medicare, Reporting and recordkeeping requirements.

For the reasons set forth in the preamble, the Centers for Medicare & Medicaid Services proposes to amend 42 CFR chapter IV as follows:

PART 413—PRINCIPLES OF REASONABLE COST REIMBURSEMENT; PAYMENT FOR END-STAGE RENAL DISEASE SERVICES; PROSPECTIVELY DETERMINED PAYMENT RATES FOR SKILLED NURSING FACILITIES

A. Part 413 is amended as set forth below:

1. The authority citation for part 413 continues to read as follows:

Authority: Secs. 1102, 1812(d), 1814(b), 1815, 1833(a), (i), and (n), 1871, 1881, 1883, and 1886 of the Social Security Act (42 U.S.C. 1302, 1395f(b), 1395g, 1395l, 1395l(a), (i), and (n), 1395x(v), 1395hh, 1395rr, 1395tt, and 1395ww).

Subpart B—Accounting Records and Reports

2. In § 413.24, the heading to paragraph (d) is republished, paragraph (d)(6) is revised, and a new paragraph (d)(7) is added, to read as follows:

§ 413.24 Adequate cost data and cost finding.

* * * * *

(d) *Cost finding methods.* * * *

(6) *Provider-based entities and departments: Preventing duplication of cost.* In some situations, the main provider in a provider-based complex may purchase services for a provider-based entity or for a department of the provider through a contract for services (for example, a management contract), directly assigning the costs to the provider-based entity or department and reporting the costs directly in the cost center for that entity or department. In any situation in which costs are directly assigned to a cost center, there is a risk of excess cost in that cost center resulting from the directly assigned costs plus a share of overhead improperly allocated to the cost center which duplicates the directly assigned costs. This duplication could result in improper Medicare payment to the provider. Where a provider has purchased services for a provider-based entity or for a provider department, like general service costs of the provider (for example, like costs in the administrative and general cost center) must be separately identified to ensure that they are not improperly allocated to the entity or the department. If the like costs of the main provider cannot be separately identified, the costs of the services purchased through a contract

must be reclassified to the main provider and allocated among the main provider's benefiting cost centers.

Example: A provider-based complex is composed of a hospital and a hospital-based rural health clinic (RHC). The hospital furnishes the entirety of its own administrative and general costs internally. The RHC, however, is managed by an independent contractor through a management contract. The management contract provides a full array of administrative and general services, with the exception of patient billing. The hospital directly assigns the costs of the RHC's management contract to the RHC cost center (for example, Form HCFA 2552–96, Worksheet A, Line 71). A full allocation of the hospital's administrative and general costs to the RHC cost center would duplicate most of the RHC's administrative and general costs. However, an allocation of the hospital's cost (included in hospital administrative and general costs) of its patient billing function to the RHC would be appropriate. Therefore, the hospital must include the costs of the patient billing function in a separate cost center to be allocated to the benefiting cost centers, including the RHC cost center. The remaining hospital administrative and general costs would be allocated to all cost centers, excluding the RHC cost center. If the hospital is unable to isolate the costs of the patient billing function, the costs of the RHC's management contract must be reclassified to the hospital administrative and general cost center to be allocated among all cost centers, as appropriate.

(7) *Costs of services furnished to free-standing entities.* The costs that a provider incurs to furnish services to free-standing entities with which it is associated are not allowable costs of that provider. Any costs of services furnished to a free-standing entity must be identified and eliminated from the allowable costs of the servicing provider, to prevent Medicare payment to that provider for those costs. This may be done by including the free-standing entity on the cost report as a nonreimbursable cost center for the purpose of allocating overhead costs to that entity. If this method would not result in an accurate allocation of costs to the entity, the provider must develop detailed work papers showing how the cost of services furnished by the provider to the entity were determined. These costs are removed from the applicable cost centers of the servicing provider.

* * * * *

Subpart E—Payments to Providers

3. Section 413.65 is amended as follows:

A. Revising paragraph (a)(1).

B. Revising the definition of ''Provider-based entity'' in paragraph (a)(2).

C. Revising paragraph (b).

D. Revising paragraph (c).

E. Revising the introductory text to paragraph (d).

F. Revising paragraph (d)(7).

G. Revising paragraph (g)(7).

H. Revising the introductory text to paragraph (i)(1).

I. Revising paragraph (i)(1)(ii).

J. Revising paragraph (i)(2).

The revisions read as follows:

§ 413.65 Requirements for a determination that a facility or an organization has provider-based status.

(a) *Scope and definitions.* (1) *Scope.* (i) This section applies to all facilities for which provider-based status is sought, including remote locations of hospitals, as defined in paragraph (a)(2) of this section and satellite facilities as defined in § 412.22(h)(1) and § 412.25(e)(1) of this chapter, other than facilities described in paragraph (a)(1)(ii) of this section.

(ii) This section does not apply to the following facilities:

(A) Ambulatory surgical centers (ASCs).

(B) Comprehensive outpatient rehabilitation facilities (CORFs).

(C) Home health agencies (HHAs).

(D) Skilled nursing facilities (SNFs).

(E) Hospices.

(F) Inpatient rehabilitation units that are excluded from the inpatient PPS for acute hospital services.

(G) Independent diagnostic testing facilities and any other facilities that furnish only clinical diagnostic laboratory tests.

(H) Facilities furnishing only physical, occupational, or speech therapy to ambulatory patients, for as long as the $1,500 annual cap on coverage of physical, occupational, and speech therapy, as described in section 1833(g)(2) of the Act, remains suspended by the action of subsequent legislation.

(I) ESRD facilities (determinations for ESRD facilities are made under § 413.174 of this chapter).

(2) *Definitions.* * * *

* * * * *

Provider-based entity means a provider of health care services, or an RHC as defined in § 405.2401(b) of this chapter, that is either created by, or acquired by, a main provider for the purpose of furnishing health care services of a different type from those of the main provider under the name, ownership, and administrative and financial control of the main provider, in accordance with the provisions of this section.

* * * * *

(b) *Provider-based determinations.* (1) A facility or organization is not entitled to be treated as provider-based simply because it or the main provider believe it is provider-based.

(2) If a facility was treated as provider-based in relation to a hospital or CAH on October 1, 2000, it will continue to be considered provider-based in relation to that hospital or CAH until October 1, 2002, and the requirements, limitations, and exclusions specified in paragraphs (d), (e), (f), and (h) of this section will not apply to that hospital or CAH for that facility until October 1, 2002. For purposes of this paragraph, a facility will be considered to have been treated as provider-based on October 1, 2000, if on that date it either had a written determination from CMS that it was provider-based as of that date, or was billing and being paid as a provider-based department or entity of the hospital.

(3) Except as specified in paragraphs (b)(2) and (b)(5) of this section, a main provider or a facility must contact CMS, and the facility must be determined by CMS to be provider-based, before the main provider bills for services of the facility as if the facility were provider-based, or before it includes costs of those services on its cost report.

(4) A facility that is not located on the campus of a hospital and that is used as a site where physician services of the kind ordinarily furnished in physician offices are furnished is presumed to be a free-standing facility, unless it is determined by CMS to have provider-based status.

(5) A facility for which a determination of provider-based status in relation to a hospital or CAH is requested on or after October 1, 2000 and before October 1, 2002 will be treated as provider-based in relation to the hospital or CAH from the first date on or after October 1, 2000 on which the facility was licensed (to the extent required by the State), staffed and equipped to treat patients until the date on which CMS determines that the facility does not qualify for provider-based status.

(c) *Reporting.* A main provider that has had one or more facilities considered provider-based also must report to CMS any material change in the relationship between it and any

provider-based facility, such as a change in ownership of the facility or entry into a new or different management contract that could affect the provider-based status of the facility.

(d) *Requirements.* An entity must meet all of the following requirements to be determined by CMS to have provider-based status.

* * * * *

(7) *Location in immediate vicinity.* The facility or organization and the main provider are located on the same campus, except when the requirements in paragraphs (d)(7)(i), (d)(7)(ii), or (d)(7)(iii) of this section are met:

(i) The facility or organization is located within a 35-mile radius of the main campus of the hospital or CAH that is the potential main provider;

(ii) The facility or organization is owned and operated by a hospital or CAH that has a disproportionate share adjustment (as determined under § 412.106 of this chapter) greater than 11.75 percent or is described in § 412.106(c)(2) of this chapter implementing section 1886(d)(5)(F)(i)(II) of the Act and is—

(A) Owned or operated by a unit of State or local government;

(B) A public or nonprofit corporation that is formally granted governmental powers by a unit of State or local government; or

(C) A private hospital that has a contract with a State or local government that includes the operation of clinics located off the main campus of the hospital to assure access in a well-defined service area to health care services to low-income individuals who are not entitled to benefits under Medicare (or medical assistance under a Medicaid State plan).

(iii) The facility or organization demonstrates a high level of integration with the main provider by showing that it meets all of the other provider-based criteria and demonstrates that it serves the same patient population as the main provider, by submitting records showing that, during the 12-month period immediately preceding the first day of the month in which the application for provider-based status is filed with CMS, and for each subsequent 12-month period—

(A) At least 75 percent of the patients served by the facility or organization reside in the same zip code areas as at least 75 percent of the patients served by the main provider;

(B) At least 75 percent of the patients served by the facility or organization who required the type of care furnished by the main provider received that care from that provider (for example, at least 75 percent of the patients of an RHC seeking provider-based status received inpatient hospital services from the hospital that is the main provider); or

(C) If the facility or organization is unable to meet the criteria in paragraph (d)(7)(i)(A) or (d)(7)(i)(B) of this section because it was not in operation during all of the 12-month period described in the previous sentence, the facility or organization is located in a zip code area included among those that, during all of the 12-month period described in the previous sentence, accounted for at least 75 percent of the patients served by the main provider.

(iv) A facility or organization is not considered to be in the ''immediate vicinity'' of the main provider unless the facility or organization and the main provider are located in the same State or, when consistent with the laws of both States, adjacent States.

(v) An RHC that is otherwise qualified as a provider-based entity of a hospital that is located in a rural area, as defined in § 412.62(f)(1)(iii) of this chapter, and has fewer than 50 beds, as determined under § 412.105(b) of this chapter, is not subject to the criteria in paragraphs (d)(7)(i) through (d)(7)(iv) of this section.

* * * * *

(g) *Obligations of hospital outpatient departments and hospital-based entities.* * * *

* * * * *

(7) When a Medicare beneficiary is treated in a hospital outpatient department or hospital-based entity (other than an RHC) that is not located on the main provider's campus, the hospital has a duty to provide written notice to the beneficiary, before the delivery of services, of the amount of the beneficiary's potential financial liability (that is, of the fact that the beneficiary will incur a coinsurance liability for an outpatient visit to the hospital as well as for the physician service, and of the amount of that liability). The notice must be one that the beneficiary can read and understand. If the exact type and extent of care needed is not known, the hospital may furnish a written notice to the patient that explains the fact that the beneficiary will incur a coinsurance liability to the hospital that he or she would not incur if the facility were not provider-based. The hospital may furnish an estimate based on typical or average charges for visits to the facility, while stating that the patient's actual liability will depend upon the actual services furnished by the hospital. If the beneficiary is unconscious, under great duress, or for any other reason unable to read a written notice and understand and act on his or her own rights, the notice must be provided, before the delivery of services, to the beneficiary's authorized representative.

* * * * *

(i) *Inappropriate treatment of a facility or organization as provider-based.* (1) *Determination and review.* If CMS learns that a provider has treated a facility or organization as provider-based and the provider had not obtained a determination of provider-based status under this section, CMS will—

* * * * *

(ii) Investigate and determine whether the requirements in paragraph (d) of this section (or, for periods before the beginning of the hospital's first cost reporting period beginning or or after January 10, 2001, the requirements in applicable program instructions) were met; and

* * * * *

(2) *Recovery of overpayments.* If CMS finds that payments for services at the facility or organization have been made as if the facility or organization were provider-based, even though CMS had not previously determined that the facility or organization qualified for provider-based status, CMS will recover the difference between the amount of payments that actually were made and the amount of payments that CMS estimates should have been made in the absence of a determination of provider-based status, except that recovery will not be made for any period before the beginning of the hospital's first cost reporting period beginning or or after January 10, 2001 if during all of that period the management of the entity made a good faith effort to operate it as a provider-based facility or organization, as described in paragraph (h)(3) of this section.

* * * * *

PART 419—PROSPECTIVE PAYMENT SYSTEM FOR HOSPITAL OUTPATIENT DEPARTMENT SERVICES

B. Part 419 is amended as set forth below:

1. The authority citation for part 419 continues to read as follows:

Authority: Secs. 1102, 1833(t), and 1871 of the Social Security Act (42 U.S.C. 1302, 1395l(t), and 1395hh).

Subpart A—General Provisions

2. In § 419.2, paragraph (c) is revised to read as follows:

§ 419.2 Basis of payment.

* * * * *

(c) *Determination of hospital outpatient prospective payment rates: Excluded costs.* The following costs are excluded from the hospital outpatient prospective payment system.

(1) The costs of direct graduate medical education activities as described in § 413.86 of this chapter.

(2) The costs of nursing and allied health programs as described in § 413.85 of this chapter.

(3) The costs associated with interns and residents not in approved teaching programs as described in § 415.202 of this chapter.

(4) The costs of teaching physicians attributable to Part B services for hospitals that elect cost-based reimbursement for teaching physicians under § 415.160.

(5) The reasonable costs of anesthesia services furnished to hospital outpatients by qualified nonphysician anesthetists (certified registered nurse anesthetists and anesthesiologists' assistants) employed by the hospital or obtained under arrangements, for hospitals that meet the requirements under § 412.113(c) of this chapter.

(6) Bad debts for uncollectible deductibles and coinsurances as described in § 413.80(b) of this chapter.

(7) Organ acquisition costs paid under Part B.

(8) Corneal tissue acquisition costs.

Subpart B—Categories of Hospitals and Services Subject to and Excluded From the Hospital Outpatient Prospective Payment System

3. In § 419.20, paragraph (a) is revised, and paragraphs (b)(3) and (b)(4) are added to read as follows:

§ 419.20 Hospitals subject to the hospital outpatient prospective payment system.

(a) *Applicability.* The hospital outpatient prospective payment system is applicable to any hospital participating in the Medicare program, except those specified in paragraph (b) of this section, for services furnished on or after August 1, 2000.

(b) *Hospitals excluded from the outpatient prospective payment system.*

* * * * *

(3) A hospital located outside one of the 50 States, the District of Columbia, and Puerto Rico is excluded from the hospital outpatient prospective payment system.

(4) A hospital of the Indian Health Service.

4. In § 419.22, the introductory text is republished, and paragraph (r) is added to read as follows:

§ 419.22 Hospital outpatient services excluded from payment under the hospital outpatient prospective payment system.

The following services are not paid for under the hospital outpatient prospective payment system:

* * * * *

(r) Services defined in § 419.21(b) that are furnished to inpatients of hospitals that do not submit claims for outpatient services under Medicare Part B.

Subpart C—Basic Methodology for Determining Prospective Payment Rates for Hospital Outpatient Services

5. In § 419.32, paragraph (b)(1) is revised to read as follows:

§ 419.32 Calculation of prospective payment rates for hospital outpatient services.

* * * * *

(b) *Conversion factor for calendar year 2000 and subsequent years.* (1) Subject to paragraph (b)(2) of this section, the conversion factor for a calendar year is equal to the conversion factor calculated for the previous year adjusted as follows:

(i) For calendar year 2000, by the hospital inpatient market basket percentage increase applicable under section 1886(b)(3)(B)(iii) of the Act reduced by one percentage point.

(ii) For calendar year 2001—

(A) For services furnished on or after January 1, 2001 and before April 1, 2001, by the hospital inpatient market basket percentage increase applicable under section 1886(b)(3)(B)(iii) of the Act reduced by one percentage point; and

(B) For services furnished on or after April 1, 2001 and before January 1, 2002, by the hospital inpatient market basket percentage increase applicable under section 1886(b)(3)(B)(iii) of the Act, and increased by a transitional percentage allowance equal to 0.32 percent.

(iii) For calendar year 2002, by the hospital inpatient market basket percentage increase applicable under section 1886(b)(3)(B)(iii) of the Act reduced by one percentage point, without taking into account the transitional percentage allowance referenced in § 419.32(b)(ii)(B).

(iv) For calendar year 2003 and subsequent years, by the hospital inpatient market basket percentage increase applicable under section 1886(b)(3)(B)(iii) of the Act.

* * * * *

Subpart D—Payments to Hospitals

6. In § 419.40, the word ''coinsurance'' is removed and the word ''copayment'' is added in its place as follows:

§ 419.40 Payment concepts.

(a) In addition to the payment rate described in § 419.32, for each APC group there is a predetermined beneficiary copayment amount as described in § 419.41(a). The Medicare program payment amount for each APC group is calculated by applying the program payment percentage as described in § 419.41(b).

(b) For purposes of this section—

(1) Coinsurance percentage is calculated as the difference between the program payment percentage and 100 percent. The coinsurance percentage in any year is thus defined for each APC group as the greater of the following: the ratio of the APC group unadjusted copayment amount to the annual APC group payment rate, or 20 percent.

(2) Program payment percentage is calculated as the lower of the following: the ratio of the APC group payment rate minus the APC group unadjusted copayment amount, to the APC group payment rate, or 80 percent.

(3) Unadjusted copayment amount is calculated as 20 percent of the wage-adjusted national median of charges for services within an APC group furnished during 1996, updated to 1999 using an actuarial projection of charge increases for hospital outpatient department services during the period 1996 to 1999.

(c) *Limitation of copayment amount to inpatient hospital deductible amount.* The copayment amount for a procedure performed in a year cannot exceed the amount of the inpatient hospital deductible established under section 1813(b) of the Act for that year.

7. Amend § 419.41 as follows:

A. The section heading is revised.

B. The word ''coinsurance'' is removed each time it appears, and the word ''copayment'' is added in its place.

C. Paragraph (c)(4)(ii) is redesignated as paragraph (c)(4)(iv).

D. Paragraphs (c)(4)(ii) and (c)(4)(iii) are added as follows:

§ 419.41 Calculation of national beneficiary copayment amounts and national Medicare program payment amounts.

(c) * * *

(4) * * *

(i) Effective for services furnished from April 1, 2001 through December 31, 2001, the national unadjusted coinsurance rate for an APC cannot exceed 57 percent of the prospective payment rate for that APC.

(ii) The national unadjusted coinsurance rate for an APC cannot exceed 55 percent in calendar years

2002 and 2003; 50 percent in calendar year 2004; 45 percent in calendar year 2005; and 40 percent in calendar year 2006 and thereafter.

* * * * *

8. In § 419.42 paragraph (a), (c), and (e) are revised as follows:

§ 419.42 Hospital election to reduce coinsurance.

(a) A hospital may elect to reduce coinsurance for any or all APC groups on a calendar year basis. A hospital may not elect to reduce copayment amounts for some, but not all, services within the same group.

* * * * *

(c) The hospital's election must be properly documented. It must specifically identify the APCs to which it applies and the copayment amount (within the limits identified below) that the hospital has selected for each group.

* * * * *

(e) In electing reduced coinsurance, a hospital may elect a copayment amount that is less than that year's wage-adjusted copayment amount for the group but not less than 20 percent of the APC payment rate as determined in § 419.32.

* * * * *

§ 419.43 [Amended]

9. Section 419.43 is amended by removing the word ''coinsurance'' from the section heading and from paragraph (a), and adding the word ''copayment'' in its place.

Subpart G—Transitional Corridors

10. In § 419.70, paragraph (d)(2) is revised to read as follows:

§ 419.70 Transitional adjustment to limit decline in payment.

* * * * *

(d) *Hold harmless provisions* * * *

* * * * *

(2) *Permanent treatment for cancer hospitals and children's hospitals.* In the case of a hospital described in § 412.23(d) or § 412.23(f) of this chapter for which the prospective payment system amount is less than the pre-BBA amount for covered hospital outpatient services, the amount of payment under this part is increased by the amount of this difference.

* * * * *

PART 489—PROVIDER AGREEMENTS AND SUPPLIER APPROVAL

C. Part 489 is amended as set forth below:

1. The authority citation to part 489 continues to read as follows:

Authority: Secs. 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395hh).

Subpart B—Essentials of Provider Agreements

2. In § 489.24, paragraph (i)(2)(ii) is revised to read as follows:

§ 489.24 Special responsibilities of Medicare hospitals in emergency cases.

* * * * *

(i) *Off-campus departments.* * * *

(2) *Protocols for off-campus departments.* * * *

* * * * *

(ii) If the off-campus department is a physical therapy, radiology, or other facility not routinely staffed with physicians, RNs, or LPNs, the department's personnel must be given protocols that direct them to contact emergency personnel at the main hospital campus for direction. Under this direction, and in accordance with protocols established in advance by the hospital, the personnel at the off-campus department must describe patient appearance and report symptoms and, if appropriate, either arrange transportation of the individual to the main hospital campus in accordance with paragraph (i)(3)(i) of this section or assist in an appropriate transfer as described in paragraphs (i)(3)(ii) and (d)(2) of this section. Any contact with emergency personnel at the main hospital campus should either be made after or concurrently with the actions needed to arrange an appropriate transfer under paragraph (i)(3)(ii) of this section if doing otherwise would significantly jeopardize the life or health of the individual.

* * * * *

(Catalog of Federal Domestic Assistance Program No. 93.773, Medicare—Hospital Insurance; and Program No. 93.774, Medicare—Supplementary Medical Insurance Program)

Dated: August 3, 2001.

Thomas A. Scully,

Administrator, Centers for Medicare & Medicaid Services.

Approved: August 3, 2001.

Tommy G. Thompson,

Secretary.

ADDENDUM A.—LIST OF AMBULATORY PAYMENT CLASSIFICATIONS (APCS) WITH STATUS INDICATORS, RELATIVE WEIGHTS, PAYMENT RATES, AND COPAYMENT AMOUNTS CALENDAR YEAR 2002

APC	Group Title	Status Indicator	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
0001	Photochemotherapy	S	0.45	$22.88	$8.24	$4.58
0002	Fine needle Biopsy/Aspiration	T	0.47	$23.90	$13.14	$4.78
0003	Bone Marrow Biopsy/Aspiration	T	1.11	$56.43	$27.99	$11.29
0004	Level I Needle Biopsy/ Aspiration Except Bone Marrow	T	3.00	$152.53	$32.57	$30.51
0005	Level II Needle Biopsy /Aspiration Except Bone Marrow	T	6.71	$341.15	$119.75	$68.23
0006	Level I Incision & Drainage	T	2.36	$119.99	$33.95	$24.00
0007	Level II Incision & Drainage	T	7.28	$370.13	$74.03	$74.03
0008	Level III Incision and Drainage	T	11.36	$577.57	$115.51	$115.51
0009	Nail Procedures	T	0.68	$34.57	$8.99	$6.91
0010	Level I Destruction of Lesion	T	0.71	$36.10	$9.86	$7.22
0011	Level II Destruction of Lesion	T	1.57	$79.82	$29.53	$15.96
0012	Level I Debridement & Destruction	T	0.72	$36.61	$9.18	$7.32
0013	Level II Debridement & Destruction	T	1.51	$76.77	$17.66	$15.35
0015	Level IV Debridement & Destruction	T	2.29	$116.43	$31.20	$23.29
0016	Level V Debridement & Destruction	T	3.31	$168.29	$70.68	$33.66
0017	Level VI Debridement & Destruction	T	10.51	$534.35	$245.80	$106.87
0018	Biopsy of Skin/Puncture of Lesion	T	1.16	$58.98	$17.66	$11.80
0019	Level I Excision/ Biopsy	T	4.56	$231.84	$78.91	$46.37
0020	Level II Excision/ Biopsy	T	8.56	$435.21	$130.53	$87.04
0021	Level IV Excision/ Biopsy	T	12.74	$647.73	$236.51	$129.55
0022	Level V Excision/ Biopsy	T	15.07	$766.19	$292.94	$153.24
0023	Exploration Penetrating Wound	T	2.18	$110.84	$40.37	$22.17
0024	Level I Skin Repair	T	2.48	$126.09	$44.50	$25.22
0025	Level II Skin Repair	T	3.71	$188.62	$70.66	$37.72

ADDENDUM A.—LIST OF AMBULATORY PAYMENT CLASSIFICATIONS (APCs) WITH STATUS INDICATORS, RELATIVE WEIGHTS, PAYMENT RATES, AND COPAYMENT AMOUNTS CALENDAR YEAR 2002—Continued

APC	Group Title	Status Indicator	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
0026	Level III Skin Repair	T	13.51	$686.88	$277.92	$137.38
0027	Level IV Skin Repair	T	19.31	$981.76	$383.10	$196.35
0028	Level I Incision/Excision Breast	T	14.95	$760.09	$303.74	$152.02
0029	Level II Incision/Excision Breast	T	35.93	$1,826.75	$820.79	$365.35
0030	Level I Breast Reconstruction	T	25.95	$1,319.35	$646.48	$263.87
0032	Insertion of Central Venous/Arterial Catheter	T	7.16	$364.03	$119.52	$72.81
0033	Partial Hospitalization	P	4.17	$212.01	.....	$42.40
0035	Placement of Arterial or Central Venous Catheter	T	0.13	$6.61	$2.18	$1.32
0041	Arthroscopy	T	26.18	$1,331.04	$592.08	$266.21
0042	Arthroscopically-Aided Procedures	T	39.39	$2,002.67	$804.74	$400.53
0043	Closed Treatment Fracture Finger/Toe/Trunk	T	4.13	$209.98	$42.00	$42.00
0044	Closed Treatment Fracture/Dislocation Except Finger/Toe/Trunk	T	2.73	$138.80	$38.08	$27.76
0045	Bone/Joint Manipulation Under Anesthesia	T	12.91	$656.37	$277.12	$131.27
0046	Open/Percutaneous Treatment Fracture or Dislocation	T	25.36	$1,289.35	$535.76	$257.87
0047	Arthroplasty without Prosthesis	T	28.54	$1,451.03	$537.03	$290.21
0048	Arthroplasty with Prosthesis	T	32.37	$1,645.76	$725.94	$329.15
0049	Level I Musculoskeletal Procedures Except Hand and Foot	T	17.07	$867.87	$356.95	$173.57
0050	Level II Musculoskeletal Procedures Except Hand and Foot	T	22.31	$1,134.29	$513.86	$226.86
0051	Level III Musculoskeletal Procedures Except Hand and Foot	T	30.94	$1,573.05	$675.24	$314.61
0052	Level IV Musculoskeletal Procedures Except Hand and Foot	T	38.88	$1,976.74	$930.91	$395.35
0053	Level I Hand Musculoskeletal Procedures	T	12.67	$644.17	$253.49	$128.83
0054	Level II Hand Musculoskeletal Procedures	T	20.84	$1,059.55	$472.33	$211.91
0055	Level I Foot Musculoskeletal Procedures	T	16.77	$852.62	$355.34	$170.52
0056	Level II Foot Musculoskeletal Procedures	T	19.20	$976.17	$405.81	$195.23
0057	Bunion Procedures	T	21.11	$1,073.27	$496.65	$214.65
0058	Level I Strapping and Cast Application	S	1.36	$69.15	$19.27	$13.83
0059	Level II Strapping and Cast Application	S	2.34	$118.97	$29.59	$23.79
0060	Manipulation Therapy	S	0.25	$12.71	$2.54	$2.54
0068	CPAP Initiation	S	3.33	$169.30	$93.12	$33.86
0069	Thoracoscopy	T	25.62	$1,302.57	$612.21	$260.51
0070	Thoracentesis/Lavage Procedures	T	4.11	$208.96	$79.60	$41.79
0071	Level I Endoscopy Upper Airway	T	1.08	$54.91	$14.22	$10.98
0072	Level II Endoscopy Upper Airway	T	1.29	$65.59	$36.08	$13.12
0073	Level III Endoscopy Upper Airway	T	3.54	$179.98	$79.19	$36.00
0074	Level IV Endoscopy Upper Airway	T	14.62	$743.31	$347.54	$148.66
0075	Level V Endoscopy Upper Airway	T	19.08	$970.07	$467.29	$194.01
0076	Endoscopy Lower Airway	T	8.22	$417.92	$197.05	$83.58
0077	Level I Pulmonary Treatment	S	0.42	$21.35	$11.74	$4.27
0078	Level II Pulmonary Treatment	S	0.93	$47.28	$20.33	$9.46
0079	Ventilation Initiation and Management	S	0.62	$31.52	$17.34	$6.30
0080	Diagnostic Cardiac Catheterization	T	32.20	$1,637.11	$838.92	$327.42
0081	Non-Coronary Angioplasty or Atherectomy	T	22.04	$1,120.56	$549.07	$224.11
0082	Coronary Atherectomy	T	130.89	$6,654.71	$1,351.74	$1,330.94
0083	Coronary Angioplasty	T	50.15	$2,549.73	$794.30	$509.95
0084	Level I Electrophysiologic Evaluation	S	4.94	$251.16	$82.88	$50.23
0085	Level II Electrophysiologic Evaluation	S	27.39	$1,392.56	$654.48	$278.51
0086	Ablate Heart Dysrhythm Focus	S	47.13	$2,396.18	$1,265.37	$479.24
0087	Cardiac Electrophysiologic Recording/Mapping	S	14.89	$757.04	$214.72	$151.41
0088	Thrombectomy	T	29.11	$1,480.01	$678.68	$296.00
0089	Insertion/Replacement of Permanent Pacemaker and Electrodes	T	82.60	$4,199.55	$2,246.59	$839.91
0090	Insertion/Replacement of Pacemaker Pulse Generator	T	73.37	$3,730.28	$2,014.35	$746.06
0091	Level I Vascular Ligation	T	22.17	$1,127.17	$348.23	$225.43
0092	Level II Vascular Ligation	T	21.43	$1,089.54	$505.37	$217.91
0093	Vascular Repair/Fistula Construction	T	15.05	$765.17	$277.34	$153.03
0094	Resuscitation and Cardioversion	S	5.69	$289.29	$105.29	$57.86
0095	Cardiac Rehabilitation	S	0.66	$33.56	$16.98	$6.71
0096	Non-Invasive Vascular Studies	S	1.87	$95.07	$52.29	$19.01
0097	Cardiac Monitoring for 30 days	X	0.87	$44.23	$24.33	$8.85
0098	Injection of Sclerosing Solution	T	1.34	$68.13	$20.88	$13.63
0099	Electrocardiograms	S	0.38	$19.32	$10.63	$3.86
0100	Stress Tests and Continuous ECG	X	1.63	$82.87	$45.58	$16.57
0101	Tilt Table Evaluation	S	4.03	$204.89	$112.69	$40.98
0103	Miscellaneous Vascular Procedures	T	10.91	$554.69	$249.61	$110.94
0104	Transcatheter Placement of Intracoronary Stents	T	71.42	$3,631.14	$726.23	$726.23
0105	Revision/Removal of Pacemakers, AICD, or Vascular Device	T	16.56	$841.94	$372.32	$168.39
0106	Insertion/Replacement/Repair of Pacemaker and/or Electrodes	T	15.82	$804.32	$426.29	$160.86
0107	Insertion of Cardioverter-Defibrillator	T	155.27	$7,894.24	$4,224.27	$1,578.85
0108	Insertion/Replacement/Repair of Cardioverter-Defibrillator Leads	T	159.42	$8,105.23	$4,214.72	$1,621.05
0109	Removal of Implanted Devices	T	6.57	$334.03	$133.51	$66.81
0110	Transfusion	S	5.76	$292.85	$122.70	$58.57
0111	Blood Product Exchange	S	16.69	$848.55	$300.74	$169.71
0112	Apheresis, Photopheresis, and Plasmapheresis	S	39.75	$2,020.97	$663.65	$404.19
0113	Excision Lymphatic System	T	16.87	$857.70	$326.55	$171.54
0114	Thyroid/Lymphadenectomy Procedures	T	30.50	$1,550.68	$493.78	$310.14
0115	Cannula/Access Device Procedures	T	19.06	$969.05	$503.91	$193.81
0116	Chemotherapy Administration by Other Technique Except Infusion	S	0.98	$49.83	$9.97	$9.97
0117	Chemotherapy Administration by Infusion Only	S	3.48	$176.93	$52.69	$35.39
0118	Chemotherapy Administration by Both Infusion and Other Technique	S	3.52	$178.96	$72.03	$35.79

ADDENDUM A.—LIST OF AMBULATORY PAYMENT CLASSIFICATIONS (APCs) WITH STATUS INDICATORS, RELATIVE WEIGHTS, PAYMENT RATES, AND COPAYMENT AMOUNTS CALENDAR YEAR 2002—Continued

APC	Group Title	Status Indicator	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
0119	Implantation of Devices	T	14.37	$730.60	$161.50	$146.12
0120	Infusion Therapy Except Chemotherapy	T	2.35	$119.48	$42.67	$23.90
0121	Level I Tube changes and Repositioning	T	2.42	$123.04	$52.53	$24.61
0122	Level II Tube changes and Repositioning	T	5.69	$289.29	$114.93	$57.86
0123	Bone Marrow Harvesting and Bone Marrow/Stem Cell Transplant	S	10.12	$514.52	$102.90	$102.90
0124	Revision of Implanted Infusion Pump	T	25.84	$1,313.76	$722.57	$262.75
0125	Refilling of Infusion Pump	T	3.20	$162.69	.....	$32.54
0130	Level I Laparoscopy	T	27.92	$1,419.51	$659.53	$283.90
0131	Level II Laparoscopy	T	39.80	$2,023.51	$1,052.23	$404.70
0132	Level III Laparoscopy	T	60.31	$3,066.28	$1,239.22	$613.26
0140	Esophageal Dilation without Endoscopy	T	5.73	$291.32	$107.24	$58.26
0141	Upper GI Procedures	T	7.46	$379.28	$184.67	$75.86
0142	Small Intestine Endoscopy	T	7.61	$386.91	$162.42	$77.38
0143	Lower GI Endoscopy	T	7.87	$400.13	$198.46	$80.03
0144	Diagnostic Anoscopy	T	1.97	$100.16	$44.07	$20.03
0145	Therapeutic Anoscopy	T	12.11	$615.70	$179.39	$123.14
0146	Level I Sigmoidoscopy	T	2.95	$149.98	$65.15	$30.00
0147	Level II Sigmoidoscopy	T	6.15	$312.68	$146.96	$62.54
0148	Level I Anal/Rectal Procedure	T	2.58	$131.17	$43.59	$26.23
0149	Level III Anal/Rectal Procedure	T	14.49	$736.70	$293.06	$147.34
0150	Level IV Anal/Rectal Procedure	T	19.58	$995.49	$437.12	$199.10
0151	Endoscopic Retrograde Cholangio-Pancreatography (ERCP)	T	16.22	$824.66	$245.46	$164.93
0152	Percutaneous Biliary Endoscopic Procedures	T	17.44	$886.68	$207.38	$177.34
0153	Peritoneal and Abdominal Procedures	T	22.44	$1,140.89	$496.31	$228.18
0154	Hernia/Hydrocele Procedures	T	24.09	$1,224.78	$556.98	$244.96
0155	Level II Anal/Rectal Procedure	T	5.73	$291.32	$96.14	$58.26
0156	Level II Urinary and Anal Procedures	T	2.62	$133.21	$39.96	$26.64
0157	Colorectal Cancer Screening: Barium Enema	S	2.14	$108.80	.....	$27.20
0158	Colorectal Cancer Screening: Colonoscopy	S	7.00	$355.89	.....	$88.97
0159	Colorectal Cancer Screening: Flexible Sigmoidoscopy	S	2.51	$127.61	.....	$31.90
0160	Level I Cystourethroscopy and other Genitourinary Procedures	T	5.98	$304.04	$110.11	$60.81
0161	Level II Cystourethroscopy and other Genitourinary Procedures	T	16.45	$836.35	$249.36	$167.27
0162	Level III Cystourethroscopy and other Genitourinary Procedures	T	19.86	$1,009.72	$427.49	$201.94
0163	Level IV Cystourethroscopy and other Genitourinary Procedures	T	30.27	$1,538.99	$792.58	$307.80
0164	Level I Urinary and Anal Procedures	T	0.98	$49.83	$14.95	$9.97
0165	Level III Urinary and Anal Procedures	T	5.36	$272.51	$91.76	$54.50
0166	Level I Urethral Procedures	T	13.02	$661.96	$218.73	$132.39
0167	Level II Urethral Procedures	T	24.18	$1,229.36	$555.84	$245.87
0168	Level III Urethral Procedures	T	31.68	$1,610.67	$536.11	$322.13
0169	Lithotripsy	T	42.65	$2,168.41	$1,192.63	$433.68
0170	Dialysis for Other Than ESRD Patients	S	1.08	$54.91	$12.08	$10.98
0180	Circumcision	T	16.29	$828.22	$304.87	$165.64
0181	Penile Procedures	T	24.07	$1,223.77	$673.07	$244.75
0182	Insertion of Penile Prosthesis	T	85.94	$4,369.36	$1,492.28	$873.87
0183	Testes/Epididymis Procedures	T	20.37	$1,035.65	$448.94	$207.13
0184	Prostate Biopsy	T	5.23	$265.90	$122.96	$53.18
0185	Removal or Repair of Penile Prosthesis	T	57.17	$2,906.64	$906.36	$581.33
0187	Placement/Repositioning Misc Catheters	T	4.54	$230.82	$113.10	$46.16
0188	Level II Female Reproductive Proc	T	0.83	$42.20	$12.24	$8.44
0189	Level III Female Reproductive Proc	T	1.38	$70.16	$17.54	$14.03
0190	Surgical Hysteroscopy	T	18.27	$928.88	$443.89	$185.78
0191	Level I Female Reproductive Proc	T	0.27	$13.73	$3.98	$2.75
0192	Level IV Female Reproductive Proc	T	2.73	$138.80	$35.33	$27.76
0193	Level V Female Reproductive Proc	T	12.17	$618.75	$171.13	$123.75
0194	Level VI Female Reproductive Proc	T	17.18	$873.47	$395.94	$174.69
0195	Level VII Female Reproductive Proc	T	22.22	$1,129.71	$483.80	$225.94
0196	Dilation and Curettage	T	14.62	$743.31	$357.98	$148.66
0197	Infertility Procedures	T	2.58	$131.17	$49.55	$26.23
0198	Pregnancy and Neonatal Care Procedures	T	1.42	$72.20	$33.03	$14.44
0199	Vaginal Delivery	T	4.20	$213.54	$59.79	$42.71
0200	Therapeutic Abortion	T	13.74	$698.57	$373.23	$139.71
0201	Spontaneous Abortion	T	14.89	$757.04	$329.65	$151.41
0202	Level VIII Female Reproductive Proc	T	39.56	$2,011.31	$864.86	$402.26
0203	Level V Nerve Injections	T	7.62	$387.42	$166.59	$77.48
0204	Level VI Nerve Injections	T	2.44	$124.05	$47.14	$24.81
0206	Level III Nerve Injections	T	3.88	$197.27	$82.85	$39.45
0207	Level IV Nerve Injections	T	4.13	$209.98	$94.49	$42.00
0208	Laminotomies and Laminectomies	T	30.93	$1,572.54	$314.51	$314.51
0209	Extended EEG Studies and Sleep Studies, Level II	S	11.73	$596.38	$310.12	$119.28
0212	Level II Nervous System Injections	T	4.17	$212.01	$88.78	$42.40
0213	Extended EEG Studies and Sleep Studies, Level I	S	2.95	$149.98	$77.99	$30.00
0214	Electroencephalogram	S	2.27	$115.41	$57.71	$23.08
0215	Level I Nerve and Muscle Tests	S	0.66	$33.56	$17.45	$6.71
0216	Level III Nerve and Muscle Tests	S	2.91	$147.95	$64.69	$29.59
0218	Level II Nerve and Muscle Tests	S	1.09	$55.42	$23.83	$11.08
0220	Level I Nerve Procedures	T	14.76	$750.43	$326.21	$150.09
0221	Level II Nerve Procedures	T	22.68	$1,153.10	$463.62	$230.62
0222	Implantation of Neurological Device	T	112.50	$5,719.73	$2,688.27	$1,143.95

ADDENDUM A.—LIST OF AMBULATORY PAYMENT CLASSIFICATIONS (APCs) WITH STATUS INDICATORS, RELATIVE WEIGHTS, PAYMENT RATES, AND COPAYMENT AMOUNTS CALENDAR YEAR 2002—Continued

APC	Group Title	Status Indicator	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
0223	Implantation of Pain Management Device	T	8.87	$450.97	$154.27	$90.19
0224	Implantation of Reservoir/Pump/Shunt	T	29.95	$1,522.72	$453.41	$304.54
0225	Implantation of Neurostimulator Electrodes	T	33.75	$1,715.92	$408.33	$343.18
0226	Implantation of Drug Infusion Reservoir	T	8.91	$453.00	$109.42	$90.60
0227	Implantation of Drug Infusion Device	T	94.89	$4,824.40	$964.88	$964.88
0228	Creation of Lumbar Subarachnoid Shunt	T	47.98	$2,439.40	$696.46	$487.88
0229	Transcatherter Placement of Intravascular Shunts	T	60.07	$3,054.08	$996.86	$610.82
0230	Level I Eye Tests & Treatments	S	0.64	$32.54	$14.97	$6.51
0231	Level III Eye Tests & Treatments	S	2.27	$115.41	$51.94	$23.08
0232	Level I Anterior Segment Eye Procedures	T	3.69	$187.61	$82.55	$37.52
0233	Level II Anterior Segment Eye Procedures	T	11.78	$598.92	$287.48	$119.78
0234	Level III Anterior Segment Eye Procedures	T	20.56	$1,045.31	$502.16	$209.06
0235	Level I Posterior Segment Eye Procedures	T	5.39	$274.04	$78.91	$54.81
0236	Level II Posterior Segment Eye Procedures	T	17.75	$902.45	$180.49	$180.49
0237	Level III Posterior Segment Eye Procedures	T	33.56	$1,706.26	$852.68	$341.25
0238	Level I Repair and Plastic Eye Procedures	T	2.84	$144.39	$58.96	$28.88
0239	Level II Repair and Plastic Eye Procedures	T	6.25	$317.76	$123.42	$63.55
0240	Level III Repair and Plastic Eye Procedures	T	14.86	$755.51	$315.31	$151.10
0241	Level IV Repair and Plastic Eye Procedures	T	19.20	$976.17	$384.47	$195.23
0242	Level V Repair and Plastic Eye Procedures	T	25.31	$1,286.81	$597.36	$257.36
0243	Strabismus/Muscle Procedures	T	19.22	$977.18	$431.39	$195.44
0244	Corneal Transplant	T	41.43	$2,106.38	$851.42	$421.28
0245	Level I Cataract Procedures without IOL Insert	T	10.75	$546.55	$256.88	$109.31
0246	Cataract Procedures with IOL Insert	T	22.36	$1,136.83	$534.31	$227.37
0247	Laser Eye Procedures Except Retinal	T	4.73	$240.48	$110.62	$48.10
0248	Laser Retinal Procedures	T	4.15	$210.99	$94.05	$42.20
0249	Level II Cataract Procedures without IOL Insert	T	23.51	$1,195.30	$561.79	$239.06
0250	Nasal Cauterization/Packing	T	2.27	$115.41	$38.54	$23.08
0251	Level I ENT Procedures	T	2.71	$137.78	$27.99	$27.56
0252	Level II ENT Procedures	T	6.53	$332.00	$114.24	$66.40
0253	Level III ENT Procedures	T	13.27	$674.67	$284.00	$134.93
0254	Level IV ENT Procedures	T	19.11	$971.59	$272.41	$194.32
0256	Level V ENT Procedures	T	28.82	$1,465.27	$623.05	$293.05
0258	Tonsil and Adenoid Procedures	T	18.86	$958.88	$462.81	$191.78
0259	Level VI ENT Procedures	T	306.15	$15,565.28	$6,537.42	$3,113.06
0260	Level I Plain Film Except Teeth	X	0.76	$38.64	$21.25	$7.73
0261	Level II Plain Film Except Teeth Including Bone Density Measurement	X	1.31	$66.60	$36.63	$13.32
0262	Plain Film of Teeth	X	0.66	$33.56	$10.90	$6.71
0263	Level I Miscellaneous Radiology Procedures	X	1.74	$88.47	$45.88	$17.69
0264	Level II Miscellaneous Radiology Procedures	X	2.51	$127.61	$70.19	$25.52
0265	Level I Diagnostic Ultrasound Except Vascular	S	1.02	$51.86	$28.52	$10.37
0266	Level II Diagnostic Ultrasound Except Vascular	S	1.67	$84.91	$46.70	$16.98
0267	Vascular Ultrasound	S	2.58	$131.17	$72.14	$26.23
0269	Level I Echocardiogram Except Transesophageal	S	4.31	$219.13	$113.95	$43.83
0270	Transesophageal Echocardiogram	S	5.83	$296.41	$150.26	$59.28
0271	Mammography	S	0.64	$32.54	$17.90	$6.51
0272	Level I Fluoroscopy	X	1.47	$74.74	$39.00	$14.95
0274	Myelography	S	5.69	$289.29	$128.12	$57.86
0275	Arthrography	S	2.82	$143.37	$72.26	$28.67
0276	Level I Digestive Radiology	S	1.63	$82.87	$45.58	$16.57
0277	Level II Digestive Radiology	S	2.35	$119.48	$65.71	$23.90
0278	Diagnostic Urography	S	2.56	$130.16	$71.59	$26.03
0279	Level I Angiography and Venography except Extremity	S	8.37	$425.55	$174.57	$85.11
0280	Level II Angiography and Venography except Extremity	S	14.40	$732.12	$373.38	$146.42
0281	Venography of Extremity	S	4.64	$235.91	$115.16	$47.18
0282	Miscellaneous Computerized Axial Tomography	S	1.63	$82.87	$45.58	$16.57
0283	Computerized Axial Tomography with Contrast Material	S	4.89	$248.62	$136.74	$49.72
0284	Magnetic Resonance Imaging and Magnetic Resonance Angiography with Contrast Material.	S	7.80	$396.57	$218.11	$79.31
0285	Positron Emission Tomography (PET)	S	20.07	$1,020.40	$415.21	$204.08
0286	Myocardial Scans	S	5.85	$297.43	$163.58	$59.49
0287	Complex Venography	S	4.33	$220.15	$90.26	$44.03
0288	CT, Bone Density	S	1.27	$64.57	$35.51	$12.91
0289	Needle Localization for Breast Biopsy	X	1.22	$62.03	$32.25	$12.41
0290	Standard Non-Imaging Nuclear Medicine	S	1.91	$97.11	$53.41	$19.42
0291	Level I Diagnostic Nuclear Medicine Excluding Myocardial Scans	S	3.78	$192.18	$90.20	$38.44
0292	Level II Diagnostic Nuclear Medicine Excluding Myocardial Scans	S	4.56	$231.84	$124.85	$46.37
0294	Level I Therapeutic Nuclear Medicine	S	5.45	$277.09	$144.06	$55.42
0295	Level II Therapeutic Nuclear Medicine	S	13.97	$710.26	$390.64	$142.05
0296	Level I Therapeutic Radiologic Procedures	S	3.52	$178.96	$98.43	$35.79
0297	Level II Therapeutic Radiologic Procedures	S	7.80	$396.57	$172.51	$79.31
0300	Level I Radiation Therapy	S	2.25	$114.39	$47.72	$22.88
0301	Level II Radiation Therapy	S	5.85	$297.43	$59.49	$59.49
0302	Level III Radiation Therapy	S	11.96	$608.07	$216.55	$121.61
0303	Treatment Device Construction	X	3.98	$202.35	$69.28	$40.47
0304	Level I Therapeutic Radiation Treatment Preparation	X	1.80	$91.52	$41.52	$18.30
0305	Level II Therapeutic Radiation Treatment Preparation	X	4.40	$223.70	$97.50	$44.74
0310	Level III Therapeutic Radiation Treatment Preparation	X	17.14	$871.43	$339.05	$174.29

ADDENDUM A.—LIST OF AMBULATORY PAYMENT CLASSIFICATIONS (APCs) WITH STATUS INDICATORS, RELATIVE WEIGHTS, PAYMENT RATES, AND COPAYMENT AMOUNTS CALENDAR YEAR 2002—Continued

APC	Group Title	Status Indicator	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
0312	Radioelement Applications	S	7.77	$395.04	$109.65	$79.01
0313	Brachytherapy	S	16.31	$829.23	$165.85	$165.85
0314	Hyperthermic Therapies	S	5.16	$262.34	$133.80	$52.47
0320	Electroconvulsive Therapy	S	4.20	$213.54	$80.06	$42.71
0321	Biofeedback and Other Training	S	1.02	$51.86	$23.86	$10.37
0322	Brief Individual Psychotherapy	S	1.25	$63.55	$13.35	$12.71
0323	Extended Individual Psychotherapy	S	1.89	$96.09	$22.48	$19.22
0324	Family Psychotherapy	S	3.13	$159.14	$31.83	$31.83
0325	Group Psychotherapy	S	1.49	$75.75	$19.70	$15.15
0330	Dental Procedures	S	7.68	$390.47	$78.09	$78.09
0332	Computerized Axial Tomography and Computerized Angiography without Contrast Material.	S	3.51	$178.46	$98.15	$35.69
0333	Computerized Axial Tomography and Computerized Angiography without Contrast Material followed by Contrast Material.	S	5.66	$287.77	$158.27	$57.55
0335	Magnetic Resonance Imaging, Miscellaneous	S	5.91	$300.48	$165.26	$60.10
0336	Magnetic Resonance Imaging and Magnetic Resonance Angiography without Contrast Material.	S	6.85	$348.27	$191.55	$69.65
0337	Magnetic Resonance Imaging and Magnetic Resonance Angiography without Contrast Material followed by Contrast Material.	S	9.26	$470.80	$258.94	$94.16
0339	Observation	X	7.38	$375.21	.....	$75.04
0340	Minor Ancillary Procedures	X	0.91	$46.27	$11.57	$9.25
0341	Immunology Tests	X	0.11	$5.59	$3.08	$1.12
0342	Level I Pathology	X	0.22	$11.19	$6.15	$2.24
0343	Level II Pathology	X	0.42	$21.35	$11.53	$4.27
0344	Level III Pathology	X	0.60	$30.51	$16.78	$6.10
0345	Level I Transfusion Laboratory Procedures	X	0.29	$14.74	$5.37	$2.95
0346	Level II Transfusion Laboratory Procedures	X	0.83	$42.20	$12.03	$8.44
0347	Level III Transfusion Laboratory Procedures	X	1.73	$87.96	$20.13	$17.59
0348	Fertility Laboratory Procedures	X	0.85	$43.22	$8.64	$8.64
0349	Miscellaneous Laboratory Procedures	X	0.34	$17.29	$3.46	$3.46
0352	Level II Injections	X	0.45	$22.88	$4.58	$4.58
0353	Level II Allergy Injections	X	0.27	$13.73	$2.75	$2.75
0354	Administration of Influenza/Pneumonia Vaccine	K	0.11	$5.59	.....	.....
0355	Level I Immunizations	K	0.20	$10.17	.....	$2.03
0356	Level II Immunizations	K	1.20	$61.01	.....	$12.20
0359	Level II Injections	X	1.91	$97.11	$19.42	$19.42
0360	Level I Alimentary Tests	X	1.40	$71.18	$34.75	$14.24
0361	Level II Alimentary Tests	X	3.52	$178.96	$88.09	$35.79
0362	Fitting of Vision Aids	X	0.83	$42.20	$9.63	$8.44
0363	Otorhinolaryngologic Function Tests	X	2.06	$104.73	$38.75	$20.95
0364	Level I Audiometry	X	0.55	$27.96	$10.91	$5.59
0365	Level II Audiometry	X	1.42	$72.20	$21.66	$14.44
0367	Level I Pulmonary Test	X	0.76	$38.64	$19.32	$7.73
0368	Level II Pulmonary Tests	X	1.53	$77.79	$39.67	$15.56
0369	Level III Pulmonary Tests	X	3.99	$202.86	$58.50	$40.57
0370	Allergy Tests	X	0.87	$44.23	$11.81	$8.85
0371	Level I Allergy Injections	X	0.76	$38.64	$7.73	$7.73
0372	Therapeutic Phlebotomy	X	0.57	$28.98	$10.09	$5.80
0373	Neuropsychological Testing	X	1.11	$56.43	$15.80	$11.29
0374	Monitoring Psychiatric Drugs	X	0.96	$48.81	$10.74	$9.76
0600	Low Level Clinic Visits	V	0.93	$47.28	$9.46	$9.46
0601	Mid Level Clinic Visits	V	1.02	$51.86	$10.37	$10.37
0602	High Level Clinic Visits	V	1.49	$75.75	$15.15	$15.15
0610	Low Level Emergency Visits	V	1.34	$68.13	$20.65	$13.63
0611	Mid Level Emergency Visits	V	2.33	$118.46	$36.47	$23.69
0612	High Level Emergency Visits	V	3.75	$190.66	$54.14	$38.13
0620	Critical Care	S	9.13	$464.19	$152.78	$92.84
0689	Electronic Analysis of Cardioverter-defibrillators	S	0.49	$24.91	$13.70	$4.98
0690	Electronic Analysis of Pacemakers and other Cardiac Devices	S	0.40	$20.34	$11.19	$4.07
0691	Electronic Analysis of Programmable Shunts/Pumps	S	3.36	$170.83	$93.96	$34.17
0692	Electronic Analysis of Neurostimulator Pulse Generators	S	1.73	$87.96	$48.38	$17.59
0693	Level II Breast Reconstruction	T	33.16	$1,685.92	$826.10	$337.18
0694	Level III Excision/Biopsy	T	4.28	$217.60	$65.28	$43.52
0695	Level VII Debridement & Destruction	T	17.06	$867.36	$398.99	$173.47
0697	Level II Echocardiogram Except Transesophageal	S	2.00	$101.68	$52.88	$20.34
0698	Level II Eye Tests & Treatments	S	1.09	$55.42	$24.94	$11.08
0699	Level IV Eye Tests & Treatment	T	6.91	$351.32	$158.09	$70.26
0701	SR 89 chloride, per mCi	G	.....	$963.42	.....	$137.92
0702	SM 153 lexidronam, 50 mCi	G	.....	$1,020.00	.....	$146.02
0704	IN 111 Satumomab pendetide per dose	G	.....	$831.25	.....	$119.00
0705	TC 99M tetrofosmin, per dose	G	.....	$129.96	.....	$18.60
0725	Leucovorin calcium inj, 50 mg	G	.....	$4.98	.....	$.45
0726	Dexrazoxane hcl injection, 250 mg	G	.....	$194.53	.....	$27.85
0727	Etidronate disodium inj 300 mg	G	.....	$63.65	.....	$9.11
0728	Filgrastim 300 mcg injection	G	.....	$179.08	.....	$25.64
0730	Pamidronate disodium , 30 mg	G	.....	$253.68	.....	$32.58
0731	Sargramostim injection 50 mcg	G	.....	$29.06	.....	$4.16
0732	Mesna injection 200 mg	G	.....	$40.44	.....	$5.79

ADDENDUM A.—LIST OF AMBULATORY PAYMENT CLASSIFICATIONS (APCs) WITH STATUS INDICATORS, RELATIVE WEIGHTS, PAYMENT RATES, AND COPAYMENT AMOUNTS CALENDAR YEAR 2002—Continued

APC	Group Title	Status Indicator	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
0733	Non esrd epoetin alpha inj, 1000 u	G		$11.85		$1.52
0750	Dolasetron mesylate, 10 mg	G		$16.45		$2.11
0754	Metoclopramide hcl injection up to 10 mg	G		$1.55		$.20
0755	Thiethylperazine maleate inj up to 10 mg	G		$5.43		$.70
0762	Dronabinol 2.5mg oral	G		$3.28		$.42
0763	Dolasetron mesylate oral, 100 mg	G		$69.64		$8.94
0764	Granisetron hcl injection 10 mcg	G		$18.54		$2.38
0765	Granisetron hcl 1 mg oral	G		$44.70		$5.74
0768	Ondansetron hcl injection 1 mg	G		$3.92		$.50
0769	Ondansetron hcl 8mg oral	G		$25.15		$3.23
0800	Leuprolide acetate, 3.75 mg	G		$81.60		$7.39
0801	Cyclophosphamide oral 25 mg	G		$2.23		$.32
0802	Etoposide oral 50 mg	G		$50.89		$7.29
0803	Melphalan oral 2 mg	G		$2.18		$.31
0807	Aldesleukin/single use vial	G		$641.25		$91.80
0809	Bcg live intravesical vac	G		$166.44		$21.37
0810	Goserelin acetate implant 3.6 mg	G		$446.49		$63.92
0811	Carboplatin injection 50 mg	G		$111.11		$15.91
0812	Carmus bischl nitro inj 100 mg	G		$114.41		$16.38
0813	Cisplatin 10 mg injection	G		$47.12		$6.75
0814	Asparaginase injection 10,000 u	G		$59.70		$8.55
0815	Cyclophosphamide 100 mg inj	G		$5.98		$.77
0816	Cyclophosphamide lyophilized 100 mg	G		$6.13		$.79
0817	Cytarabine hcl 100 mg inj	G		$4.75		$.43
0818	Dactinomycin 0.5 mg	G		$13.23		$1.89
0819	Dacarbazine 100 mg inj	G		$11.28		$1.02
0820	Daunorubicin 10 mg	G		$76.62		$6.94
0821	Daunorubicin citrate liposom 10 mg	G		$64.60		$9.25
0822	Diethylstilbestrol injection 250 mg	G		$3.99		$.57
0823	Docetaxel, 20 mg	G		$297.83		$42.64
0824	Etoposide 10 mg inj	G		$3.86		$.35
0826	Methotrexate Oral 2.5 mg	G		$2.73		$.25
0827	Floxuridine injection 500 mg	G		$129.56		$11.73
0828	Gemcitabine HCL 200 mg	G		$102.13		$14.62
0830	Irinotecan injection 20 mg	G		$125.47		$17.96
0831	Ifosfomide injection 1 gm	G		$156.65		$22.43
0832	Idarubicin hcl injection 5 mg	G		$412.21		$59.01
0833	Interferon alfacon-1, 1 mcg	G		$4.10		$.59
0834	Interferon alfa-2a inj recombinant 3 million u	G		$34.87		$4.99
0836	Interferon alfa-2b inj recombinant, 1 million	G		$12.98		$1.67
0838	Interferon gamma 1-b inj, 3 million u	G		$285.64		$40.89
0839	Mechlorethamine hcl inj 10 mg	G		$11.88		$1.70
0840	Melphalan hydrochl 50 mg	G		$381.65		$54.64
0841	Methotrexate sodium inj 5 mg	G		$.41		$.04
0842	Fludarabine phosphate inj 50 mg	G		$258.88		$37.06
0843	Pegaspargase, singl dose vial	G		$1,255.57		$179.74
0844	Pentostatin injection, 10 mg	G		$1,654.14		$236.80
0847	Doxorubicin hcl 10 mg vl chemo	G		$9.00		$1.29
0849	Rituximab, 100 mg	G		$454.55		$65.07
0850	Streptozocin injection, 1 gm	G		$117.64		$16.84
0851	Thiotepa injection, 15 mg	G		$116.97		$16.75
0852	Topotecan, 4 mg	G		$632.56		$90.56
0853	Vinblastine sulfate inj, 1 mg	G		$4.11		$.37
0854	Vincristine sulfate 1 mg inj	G		$30.16		$2.73
0855	Vinorelbine tartrate, 10 mg	G		$79.28		$11.35
0856	Porfimer sodium, 75 mg	G		$2,603.67		$372.74
0857	Bleomycin sulfate injection 15 u	G		$289.37		$41.43
0858	Cladribine, 1mg	G		$56.08		$8.03
0859	Fluorouracil injection 500 mg	G		$1.48		$.13
0860	Plicamycin (mithramycin) inj 2.5 mg	G		$93.80		$13.43
0861	Leuprolide acetate injection 1 mg	G		$26.15		$2.37
0862	Mitomycin 5 mg inj	G		$121.65		$11.01
0863	Paclitaxel injection, 30 mg	G		$164.08		$21.07
0864	Mitoxantrone hcl, 5 mg	G		$244.20		$34.96
0865	Interferon alfa-n3 inj, human leukocyte derived, 250,000 iu	G		$7.86		$1.12
0884	Rho d immune globulin inj, 1 dose pkg	G		$34.11		$4.38
0886	Azathioprine oral 50mg	G		$1.24		$.16
0887	Azathioprine parenteral 100 mg	G		$.75		$.10
0888	Cyclosporine oral 100 mg	G		$5.23		$.47
0889	Cyclosporin parenteral 250mg	G		$25.08		$2.27
0890	Lymphocyte immune globulin 250 mg	G		$249.47		$32.04
0891	Tacrolimus oral per 1 mg	G		$2.91		$.42
0900	Alglucerase injection, per 10 u	G		$37.53		$5.37
0901	Alpha 1 proteinase inhibitor, 10 mg	G		$2.09		$.30
0902	Botulinum toxin a, per unit	G		$4.39		$.56
0903	Cytomegalovirus imm IV, 50 mg	G		$656.27		$84.28
0905	Immune globulin 500 mg	G		$25.92		$3.33
0906	RSV-ivig, 50 mg	G		$406.34		$58.17

ADDENDUM A.—LIST OF AMBULATORY PAYMENT CLASSIFICATIONS (APCs) WITH STATUS INDICATORS, RELATIVE WEIGHTS, PAYMENT RATES, AND COPAYMENT AMOUNTS CALENDAR YEAR 2002—Continued

APC	Group Title	Status Indicator	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
0907	Ganciclovir Sodium 500 mg injection	K	0.46	$23.39	.....	$4.51
0908	Tetanus immune globulin inj up to 250 u	G	.....	$102.60	.....	$14.69
0909	Interferon beta-1a, 33 mcg	G	.....	$225.23	.....	$32.24
0910	Interferon beta-1b , .25 mg	G	.....	$54.15	.....	$7.75
0911	Streptokinase per 250,000 iu	K	1.80	$91.52	.....	$17.68
0913	Ganciclovir long act implant 4.5 mg	G	.....	$4,750.00	.....	$680.00
0916	Imiglucerase, unit	G	.....	$3.75	.....	$.54
0917	Pharmacologic stressors	K	0.37	$18.81	.....	$3.62
0925	Factor viii per iu	G	.....	$.87	.....	$.11
0926	Factor VIII (porcine) per iu	G	.....	$2.09	.....	$.30
0927	Factor viii recombinant per iu	G	.....	$1.19	.....	$.15
0928	Factor ix complex per iu	G	.....	$.68	.....	$.09
0929	Anti-inhibitor per iu	G	.....	$1.43	.....	$.18
0930	Antithrombin iii injection per iu	G	.....	$1.05	.....	$.15
0931	Factor IX non-recombinant, per iu	G	.....	$.76	.....	$.10
0932	Factor IX recombinant, per iu	G	.....	$1.12	.....	$.16
0949	Plasma, Pooled Multiple Donor, Solvent/Detergent Treated, Frozen	K	3.00	$152.53	.....	$30.51
0950	Blood (Whole) For Transfusion	K	2.13	$108.29	.....	$21.66
0952	Cryoprecipitate	K	0.72	$36.61	.....	$7.32
0954	RBC leukocytes reduced	K	2.89	$146.93	.....	$29.39
0955	Plasma, Fresh Frozen	K	2.31	$117.45	.....	$23.49
0956	Plasma Protein Fraction	K	1.29	$65.59	.....	$13.12
0957	Platelet Concentrate	K	1.00	$50.84	.....	$10.17
0958	Platelet Rich Plasma	K	1.19	$60.50	.....	$12.10
0959	Red Blood Cells	K	2.09	$106.26	.....	$21.25
0960	Washed Red Blood Cells	K	3.89	$197.78	.....	$39.56
0961	Infusion, Albumin (Human) 5%, 50 ml	K	2.24	$113.89	.....	$22.78
0962	Infusion, Albumin (Human) 25%, 10 ml	K	1.12	$56.94	.....	$11.39
0970	New Technology - Level I ($0 - $50)	T	0.47	$23.90	.....	$4.78
0971	New Technology - Level II ($50 - $100)	S	1.42	$72.20	.....	$14.44
0972	New Technology - Level III ($100 - $200)	T	2.84	$144.39	.....	$28.88
0973	New Technology - Level IV ($200 - $300)	T	4.73	$240.48	.....	$48.10
0974	New Technology - Level V ($300 - $500)	S	7.57	$384.87	.....	$76.97
0975	New Technology - Level VI ($500 - $750)	T	11.83	$601.46	.....	$120.29
0976	New Technology - Level VII ($750 - $1000)	S	16.56	$841.94	.....	$168.39
0977	New Technology - Level VIII ($1000 - $1250)	T	21.30	$1,082.93	.....	$216.59
0978	New Technology - Level IX ($1250 - $1500)	T	26.03	$1,323.42	.....	$264.68
0979	New Technology - Level X ($1500 - $1750)	T	30.76	$1,563.90	.....	$312.78
0980	New Technology - Level XI ($1750 - $2000)	T	35.49	$1,804.38	.....	$360.88
0981	New Technology - Level XII ($2000 - $2500)	S	42.59	$2,165.36	.....	$433.07
0982	New Technology - Level XIII ($2500 - $3000)	T	52.06	$2,646.83	.....	$529.37
0983	New Technology-Level XIV ($3000- $3500)	T	61.52	$3,127.80	.....	.....
0984	New Technology - Level XV ($3500 - $5000)	T	80.45	$4,090.24	.....	$818.05
0985	New Technology - Level XVI ($5000 - $6000)	T	104.11	$5,293.16	.....	$1,058.63
1002	Cochlear Implant System	H	.....	.....	.....	.....
1009	Cryoprecip reduced plasma	K	0.88	$44.74	.....	$8.95
1010	Blood, L/R, CMV-neg	K	2.94	$149.48	.....	$29.90
1011	Platelets, HLA-m, L/R, unit	K	12.12	$616.21	.....	$123.24
1012	Platelet concentrate, L/R, irradiated, unit	K	1.96	$99.65	.....	$19.93
1013	Platelet concentrate, L/R, unit	K	1.20	$61.01	.....	$12.20
1014	Platelets, aph/pher, L/R, unit	K	9.13	$464.19	.....	$92.84
1016	Blood, L/R, froz/deglycerol/washed	K	7.31	$371.66	.....	$74.33
1017	Platelets, aph/pher, L/R, CMV-neg, unit	K	9.53	$484.52	.....	$96.90
1018	Blood, L/R, irradiated	K	3.20	$162.69	.....	$32.54
1019	Platelets, aph/pher, L/R, irradiated, unit	K	9.85	$500.79	.....	$100.16
1024	Quinupristin/dalfopristin	G	.....	$102.05	.....	$14.61
1045	Iobenguane sulfate i-131	G	.....	$495.65	.....	$44.87
1059	Cultured chondrocytes implnt	G	.....	$14,250.00	.....	$2,040.00
1079	CO 57/58 0.5 mCi	G	.....	$253.84	.....	$36.34
1084	Denileukin diftitox, 300 MCG	G	.....	$999.88	.....	$143.14
1086	Temozolomide,oral 5 mg	G	.....	$5.93	.....	$.85
1087	I-123 per uci, dx use	G	.....	$.65	.....	$.09
1089	Cyanocobalamin cobalt co57	G	.....	$97.85	.....	$14.01
1090	IN 111 Chloride, per mCi	G	.....	$152.00	.....	$21.76
1091	IN 111 Oxyquinoline, per 5 mCi	G	.....	$482.84	.....	$69.12
1092	IN 111 Pentetate, per 1.5 mCi	G	.....	$769.50	.....	$110.16
1094	TC 99M Albumin aggr, per vial	G	.....	$33.09	.....	$4.74
1095	TC 99M Depreotide, per vial	G	.....	$760.00	.....	$108.80
1096	TC 99M Exametazime, per dose	G	.....	$423.04	.....	$60.56
1097	TC 99M Mebrofenin, per vial	G	.....	$51.43	.....	$7.36
1098	TC 99M Pentetate, per vial	G	.....	$22.64	.....	$2.76
1099	TC 99M Pyrophosphate, per vial	G	.....	$42.75	.....	$6.12
1122	TC 99M arcitumomab, per vial	G	.....	$1,235.00	.....	$176.80
1166	Cytarabine liposomal, 10 mg	G	.....	$371.45	.....	$53.18
1167	Epirubicin hcl, 2 mg	G	.....	$24.94	.....	$3.57
1178	Busulfan IV, 6 mg	G	.....	$26.49	.....	$3.79
1188	I-131 per uci, dx use	G	.....	$.78	.....	$.10
1200	TC 99M Sodium Glucoheptonate, per vial	G	.....	$107.40	.....	$15.37

ADDENDUM A.—LIST OF AMBULATORY PAYMENT CLASSIFICATIONS (APCs) WITH STATUS INDICATORS, RELATIVE WEIGHTS, PAYMENT RATES, AND COPAYMENT AMOUNTS CALENDAR YEAR 2002—Continued

APC	Group Title	Status Indicator	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
1201	TC 99M succimer, per vial	G		$135.66		$19.42
1202	TC 99M Sulfur Colloid, per dose	G		$36.10		$3.27
1203	Verteporfin for injection	G		$1,458.25		$208.76
1205	Technetium tc99m disofenin	G		$85.50		$7.74
1207	Octreotide acetate depot 1mg	G		$140.37		$20.10
1305	Apligraf	G		$1,157.81		$165.75
1348	I-131 per mci sol, rx use	G		$146.57		$20.98
1400	Diphenhydramine hcl 50mg	G		$.12		$.01
1401	Prochlorperazine maleate 5mg	G		$.57		$.05
1402	Promethazine hcl 12.5mg oral	G		$.03		$.00
1403	Chlorpromazine hcl 10mg oral	G		$.07		$.01
1404	Trimethobenzamide hcl 250mg	G		$.36		$.03
1405	Thiethylperazine maleate10mg	G		$.56		$.08
1406	Perphenazine 4mg oral	G		$.62		$.06
1407	Hydroxyzine pamoate 25mg	G		$.20		$.02
1409	Factor viia recombinant, per 1.2 mg	G		$1,596.00		$228.48
1600	TC 99M sestamibi, per syringe	G		$115.90		$16.59
1601	TC 99M medronate, per dose	G		$36.46		$3.30
1602	TC 99M apcitide, per vial	G		$45.13		$6.46
1603	TL 201, mCi	G		$29.45		$3.78
1604	IN 111 capromab pendetide, per dose	G		$1,128.13		$161.50
1605	Abciximab injection, 10 mg	G		$513.02		$73.44
1606	Anistreplase, 30 u	G		$2,559.11		$366.36
1607	Eptifibatide injection, 5 mg	G		$13.58		$1.94
1608	Etanercept injection, 25 mg	G		$140.98		$20.18
1609	Rho(D) immune globulin h, sd, 100 iu	G		$20.64		$2.65
1611	Hylan G-F 20 injection, 16 mg	G		$213.86		$30.62
1612	Daclizumab, parenteral, 25 mg	G		$397.29		$56.88
1613	Trastuzumab, 10 mg	G		$52.83		$7.56
1614	Valrubicin, 200 mg	G		$423.23		$60.59
1615	Basiliximab, 20 mg	G		$1,348.76		$193.09
1616	Histrelin Acetate, 0.5 mg	G		$14.16		$2.03
1617	Lepirdin, 50 mg	G		$131.96		$18.89
1618	Von Willebrand factor, per iu	G		$.95		$.14
1619	Ga 67, per mCi	G		$24.38		$3.13
1620	TC 99M Bicisate, per vial	G		$384.75		$55.08
1621	Xe 133, per mCi	G		$29.93		$3.84
1622	TC 99M Mertiatide, per vial	G		$176.53		$25.27
1623	TC 99M Gluceptate	G		$22.61		$3.24
1624	P32 sodium, per mCi	G		$81.10		$11.61
1625	IN 111 Pentetreotide, per mCi	G		$935.75		$133.96
1626	TC 99M Oxidronate, per vial	G		$36.74		$5.26
1627	TC-99 labeled red blood cell, per test	G		$40.90		$5.85
1628	P32 phosphate chromic, per mCi	G		$150.86		$21.60
1713	Anchor/screw bn/bn,tis/bn	H				
1714	Cath, trans atherectomy, dir	H				
1715	Brachytherapy needle	H				
1716	Brachytx seed, Gold 198	H				
1717	Brachytx seed, HDR Ir-192	H				
1718	Brachytx seed, Iodine 125	H				
1719	Brachytxseed, Non-HDR Ir-192	H				
1720	Brachytx seed, Palladium 103	H				
1721	AICD, dual chamber	H				
1722	AICD, single chamber	H				
1723	Cath, ablation, non-cardiac	H				
1724	Cath, trans atherec,rotation	H				
1725	Cath, translumin non-laser	H				
1726	Cath, bal dil, non-vascular	H				
1727	Cath, bal tis dis, non-vas	H				
1728	Cath, brachytx seed adm	H				
1729	Cath, drainage	H				
1730	Cath, EP, 19 or fewer elect	H				
1731	Cath, EP, 20 or more elec	H				
1732	Cath, EP, diag/abl, 3D/vect	H				
1733	Cath, EP, othr than cool-tip	H				
1750	Cath, hemodialysis,long-term	H				
1751	Cath, inf, per/cent/midline	H				
1752	Cath, hemodialysis,short-term	H				
1753	Cath, intravas ultrasound	H				
1754	Catheter, intradiscal	H				
1755	Catheter, intraspinal	H				
1756	Cath, pacing, transesoph	H				
1757	Cath, thrombectomy/embolect	H				
1758	Cath, ureteral	H				
1759	Cath, intra echocardiography	H				
1760	Closure dev, vasc, imp/insert	H				
1762	Conn tiss, human (inc fascia)	H				
1763	Conn tiss, non-human	H				

ADDENDUM A.—LIST OF AMBULATORY PAYMENT CLASSIFICATIONS (APCS) WITH STATUS INDICATORS, RELATIVE WEIGHTS, PAYMENT RATES, AND COPAYMENT AMOUNTS CALENDAR YEAR 2002—Continued

APC	Group Title	Status Indicator	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
1764	Event recorder, cardiac	H				
1765	Adhesion barrier	H				
1766	Intro/sheath,strble,non-peel	H				
1767	Generator, neurostim, imp	H				
1768	Graft, vascular	H				
1769	Guide wire	H				
1770	Imaging coil, MR, insertable	H				
1771	Rep dev, urinary, w/sling	H				
1772	Infusion pump, programmable	H				
1773	Retrieval dev, insert	H				
1776	Joint device (implantable)	H				
1777	Lead, AICD, endo single coil	H				
1778	Lead, neurostimulator	H				
1779	Lead, pmkr, transvenous VDD	H				
1780	Lens, intraocular	H				
1781	Mesh (implantable)	H				
1782	Morcellator	H				
1784	Ocular dev, intraop, det ret	H				
1785	Pmkr, dual, rate-resp	H				
1786	Pmkr, single, rate-resp	H				
1787	Patient progr, neurostim	H				
1788	Port, indwelling, imp	H				
1789	Prosthesis, breast, imp	H				
1813	Prosthesis, penile, inflatab	H				
1815	Pros, urinary sph, imp	H				
1816	Receiver/transmitter, neuro	H				
1817	Septal defect imp sys	H				
1874	Stent, coated/cov w/del sys	H				
1875	Stent, coated/cov w/o del sy	H				
1876	Stent, non-coa/no-cov w/del	H				
1877	Stent, non-coat/cov w/o del	H				
1878	Matrl for vocal cord	H				
1879	Tissue marker, imp	H				
1880	Vena cava filter	H				
1881	Dialysis access system	H				
1882	AICD, other than sing/dual	H				
1883	Adapt/ext, pacing/neuro lead	H				
1885	Cath, translumin angio laser	H				
1887	Catheter, guiding	H				
1891	Infusion pump,non-prog,perm	H				
1892	Intro/sheath,fixed,peel-away	H				
1893	Intro/sheath,fixed,non-peel	H				
1894	Intro/sheath, non-laser	H				
1895	Lead, AICD, endo dual coil	H				
1896	Lead, AICD, non sing/dual	H				
1897	Lead, neurostim test kit	H				
1898	Lead, pmkr, other than trans	H				
1899	Lead, pmkr/AICD combination	H				
2615	Sealant, pulmonary, liquid	H				
2616	Brachytx seed, Yttrium-90	H				
2617	Stent, non-cor, tem w/o del	H				
2618	Probe, cryoablation	H				
2619	Pmkr, dual, non rate-resp	H				
2620	Pmkr, single, non rate-resp	H				
2621	Pmkr, other than sing/dual	H				
2622	Prosthesis, penile, non-inf	H				
2625	Stent, non-cor, tem w/del sys	H				
2626	Infusion pump, non-prog,temp	H				
2627	Cath, suprapubic/cystoscopic	H				
2628	Catheter, occlusion	H				
2629	Intro/sheath, laser	H				
2630	Cath, EP, cool-tip	H				
2631	Rep dev, urinary, w/o sling	H				
7000	Amifostine, 500 mg	G		$392.06		$56.13
7001	Amphotericin B lipid complex, 50 mg	G		$109.25		$15.64
7003	Epoprostenol injection 0.5 mg	G		$17.37		$2.49
7005	Gonadorelin hydroch, 100 mcg	G		$38.47		$5.51
7007	Milrinone lactate, per 5 ml, inj	K	0.48	$24.40		$4.88
7010	Morphine sulfate (preservative free) 10 mg	G		$7.41		$.95
7011	Oprelvekin injection, 5 mg	G		$236.31		$33.83
7014	Fentanyl citrate inj up 2 ml	G		$1.40		$.18
7015	Busulfan, oral, 2 mg	G		$1.81		$.23
7019	Aprotinin, 10,000 kiu	G		$2.06		$.30
7022	Elliot's B solution, per ml	G		$14.25		$2.04
7023	Treatment for bladder calculi, per 500 ml	G		$24.70		$3.54
7024	Corticorelin ovine triflutate, per 0.1 mg	G		$368.03		$52.69
7025	Digoxin immune FAB (Ovine), 40 mg vial	G		$551.66		$78.97
7026	Ethanolamine oleate, 100 mg	G		$39.73		$5.69

ADDENDUM A.—LIST OF AMBULATORY PAYMENT CLASSIFICATIONS (APCS) WITH STATUS INDICATORS, RELATIVE WEIGHTS, PAYMENT RATES, AND COPAYMENT AMOUNTS CALENDAR YEAR 2002—Continued

APC	Group Title	Status Indicator	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
7027	Fomepizole, 1.5 mg	G		$1.09		$.16
7028	Fosphenytoin, 50 mg	G		$9.55		$1.37
7029	Glatiramer acetate, 20 mg	G		$30.07		$4.30
7030	Hemin, 1 mg	G		$.99		$.14
7031	Octreotide acetate injection 1mg	G		$125.65		$17.99
7032	Sermorelin acetate, 0.5 mg	G		$15.78		$2.26
7033	Somatrem, 5 mg	G		$209.48		$29.99
7034	Somatropin, 1 mg (any derivation)	G		$39.90		$5.12
7035	Teniposide, 50 mg	G		$216.32		$30.97
7037	Urofollitropin, 75 I.U.	G		$73.29		$9.41
7038	Muromonab-CD3, 5 mg	G		$777.31		$111.28
7039	Pegademase bovine inj 25 I.U	G		$139.33		$19.95
7040	Pentastarch 10% inj, 100 ml	G		$15.11		$2.16
7041	Tirofiban hydrochloride 12.5 mg	G		$435.27		$62.31
7042	Capecitabine, oral, 150 mg	G		$2.43		$.35
7043	Infliximab injection 10 mg	G		$63.23		$9.05
7045	Trimetrexate glucoronate 25 mg	G		$86.09		$12.32
7046	Doxorubicin hcl liposome inj 10 mg	G		$358.95		$51.39
7047	Droperidol/fentanyl inj	G		$6.67		$.95
7048	Alteplase recombinant	K	0.39	$19.83		$3.97
7049	Filgrastim 480 mcg injection	G		$285.38		$40.85
7050	Prednisone oral	G		$.07		$.01
7315	Sodium hyaluronate, 20 mg	G		$136.80		$19.58
9000	Na chromate Cr51, per 0.25mCi	G		$.32		$.05
9001	Linezolid inj, 200mg	G		$34.14		$4.89
9002	Tenecteplase, 50mg/vial	G		$2,612.50		$374.00
9003	Palivizumab, per 50mg	G		$664.49		$95.13
9004	Gemtuzumab ozogamicin inj,5mg	G		$1,929.69		$276.25
9005	Reteplase injection	G		$1,306.25		$187.00
9006	Tacrolimus inj, per 5mg (1 amp)	G		$113.15		$16.20
9007	Baclofen Intrathecal kit-1amp	G		$79.80		$11.42
9008	Baclofen Refill Kit--500mcg	G		$233.70		$33.46
9009	Baclofen Refill Kit--2000mcg	G		$491.15		$70.31
9010	Baclofen Refill Kit--4000mcg	G		$861.65		$123.35
9011	Caffeine Citrate, inj, 1ml	G		$12.22		$1.75
9012	Arsenic Trioxide, 1mg/kg	G		$237.50		$34.00
9013	Co 57 Cobaltous Cl, 1 ml	G		$10.02		$1.43
9015	Mycophenolate mofetil oral	G		$2.40		$.34
9016	Echocardiography contrast	G		$39.58		$5.67
9018	Botulinum tox B, per 100 u	G		$8.79		$1.26
9019	Caspofungin acetate, 50 mg	G		$34.20		$4.90
9020	Sirolimus tablet, 1 mg	G		$6.51		$.89
9100	Iodinated I-131 Albumin	G		$9.84		$1.41
9102	51 Na chromate, 50mCi	G		$.65		$.09
9103	Na Iothalamate I-125, 10uCi	G		$11.66		$1.67
9104	Anti-thymocyte globulin,25mg	G		$251.75		$36.04
9105	Hep B imm glob, per 1 ml	G		$135.43		$12.26
9106	Sirolimus, oral	G		$6.51		$.93
9108	Thyrotropin alfa, 1.1 mg	G		$531.05		$76.02
9109	Tirofliban hcl, 6.25 mg	G		$217.64		$31.16
9217	Leuprolide acetate suspnsion	G		$564.92		$51.14
9500	Platelets, irradiated	K	1.81	$92.02		$18.40
9501	Platelets, pheresis	K	9.91	$503.84		$100.77
9502	Platelet pheresis irradiated	K	10.75	$546.55		$109.31
9503	Fresh frozen plasma, ea unit	K	1.69	$85.92		$17.18
9504	RBC deglycerolized	K	4.45	$226.25		$45.25
9505	RBC irradiated	K	2.64	$134.22		$26.84

ADDENDUM D.—PAYMENT STATUS INDICATORS FOR THE HOSPITAL OUTPATIENT PROSPECTIVE PAYMENT SYSTEM

Indicator	Service	Status
A	Pulmonary Rehabilitation Clinical Trial	Not Paid Under Outpatient PPS
A	Durable Medical Equipment, Prosthetics and Orthotics	DMEPOS Fee Schedule
A	Physical, Occupational and Speech Therapy	Physician Fee Schedule
A	Ambulance	Ambulance Fee Schedule
A	EPO for ESRD Patients	National Rate
A	Clinical Diagnostic Laboratory Services	Laboratory Fee Schedule
A	Physician Services for ESRD Patients	Physician Fee Schedule
A	Screening Mammography	Lower of Charges or National Rate
C	Inpatient Procedures	Admit Patient
E	Non-Covered Items and Services	Not Paid Under Outpatient PPS
F	Acquisition of Corneal Tissue	Paid at Reasonable Cost
G	Drug/Biological Pass-Through	Additional Payment
H	Device Pass-Through	Additional Payment
K	Non Pass-Through Drug/Biological	Paid Under Outpatient PPS
N	Incidental Services, packaged into APC Rate	Packaged
P	Partial Hospitalization	Paid Per Diem APC

ADDENDUM D.—PAYMENT STATUS INDICATORS FOR THE HOSPITAL OUTPATIENT PROSPECTIVE PAYMENT SYSTEM—Continued

Indicator	Service	Status
S	Significant Procedure, Not Discounted When Multiple	Paid Under Outpatient PPS
T	Significant Procedure, Multiple Procedure Reduction Applies	Paid Under Outpatient PPS
V	Visit to Clinic or Emergency Department	Paid Under Outpatient PPS
X	Ancillary Service	Paid Under Outpatient PPS

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
00100	N	Anesth, salivary gland					
00103	N	Anesth, blepharoplasty					
00104	N	Anesth, electroshock					
00120	N	Anesth, ear surgery					
00124	N	Anesth, ear exam					
00126	N	Anesth, tympanotomy					
00140	N	Anesth, procedures on eye					
00142	N	Anesth, lens surgery					
00144	N	Anesth, corneal transplant					
00145	N	Anesth, vitreoretinal surg					
00147	N	Anesth, iridectomy					
00148	N	Anesth, eye exam					
00160	N	Anesth, nose/sinus surgery					
00162	N	Anesth, nose/sinus surgery					
00164	N	Anesth, biopsy of nose					
00170	N	Anesth, procedure on mouth					
00172	N	Anesth, cleft palate repair					
00174	N	Anesth, pharyngeal surgery					
00176	N	Anesth, pharyngeal surgery					
00190	N	Anesth, face/skull bone surg					
00192	N	Anesth, facial bone surgery					
00210	N	Anesth, open head surgery					
00212	N	Anesth, skull drainage					
00214	N	Anesth, skull drainage					
00215	N	Anesth, skull repair/fract					
00216	N	Anesth, head vessel surgery					
00218	N	Anesth, special head surgery					
00220	N	Anesth, spinal fluid shunt					
00222	N	Anesth, head nerve surgery					
00300	N	Anesth, head/neck/ptrunk					
00320	N	Anesth, neck organ surgery					
00322	N	Anesth, biopsy of thyroid					
00350	N	Anesth, neck vessel surgery					
00352	N	Anesth, neck vessel surgery					
00400	N	Anesth, skin, ext/per/atrunk					
00402	N	Anesth, surgery of breast					
00404	N	Anesth, surgery of breast					
00406	N	Anesth, surgery of breast					
00410	N	Anesth, correct heart rhythm					
00450	N	Anesth, surgery of shoulder					
00452	N	Anesth, surgery of shoulder					
00454	N	Anesth, collar bone biopsy					
00470	N	Anesth, removal of rib					
00472	N	Anesth, chest wall repair					
00474	N	Anesth, surgery of rib(s)					
00500	N	Anesth, esophageal surgery					
00520	N	Anesth, chest procedure					
00522	N	Anesth, chest lining biopsy					
00524	N	Anesth, chest drainage					
00528	N	Anesth, chest partition view					
00530	N	Anesth, pacemaker insertion					
00532	N	Anesth, vascular access					
00534	N	Anesth, cardioverter/defib					
00537	N	Anesth, cardiac electrophys					
00540	N	Anesth, chest surgery					
00542	N	Anesth, release of lung					
00544	N	Anesth, chest lining removal					
00546	N	Anesth, lung,chest wall surg					
00548	N	Anesth, trachea,bronchi surg					
00550	N	Anesth, sternal debridement					
00560	N	Anesth, open heart surgery					
00562	N	Anesth, open heart surgery					
00563	N	Anesth, heart proc w/pump					
00566	N	Anesth, cabg w/o pump					
00580	N	Anesth heart/lung transplant					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
00600	N	Anesth, spine, cord surgery					
00604	N	Anesth, sitting procedure					
00620	N	Anesth, spine, cord surgery					
00622	N	Anesth, removal of nerves					
00630	N	Anesth, spine, cord surgery					
00632	N	Anesth, removal of nerves					
00634	N	Anesth for chemonucleolysis					
00635	N	Anesth, lumbar puncture					
00670	N	Anesth, spine, cord surgery					
00700	N	Anesth, abdominal wall surg					
00702	N	Anesth, for liver biopsy					
00730	N	Anesth, abdominal wall surg					
00740	N	Anesth, upper gi visualize					
00750	N	Anesth, repair of hernia					
00752	N	Anesth, repair of hernia					
00754	N	Anesth, repair of hernia					
00756	N	Anesth, repair of hernia					
00770	N	Anesth, blood vessel repair					
00790	N	Anesth, surg upper abdomen					
00792	N	Anesth, hemorr/excise liver					
00794	N	Anesth, pancreas removal					
00796	N	Anesth, for liver transplant					
00800	N	Anesth, abdominal wall surg					
00802	N	Anesth, fat layer removal					
00810	N	Anesth, low intestine scope					
00820	N	Anesth, abdominal wall surg					
00830	N	Anesth, repair of hernia					
00832	N	Anesth, repair of hernia					
00840	N	Anesth, surg lower abdomen					
00842	N	Anesth, amniocentesis					
00844	N	Anesth, pelvis surgery					
00846	N	Anesth, hysterectomy					
00848	N	Anesth, pelvic organ surg					
00850	N	Anesth, cesarean section					
00855	N	Anesth, hysterectomy					
00857	N	Analgesia, labor & c-section					
00860	N	Anesth, surgery of abdomen					
00862	N	Anesth, kidney/ureter surg					
00864	N	Anesth, removal of bladder					
00865	N	Anesth, removal of prostate					
00866	N	Anesth, removal of adrenal					
00868	N	Anesth, kidney transplant					
00870	N	Anesth, bladder stone surg					
00872	N	Anesth kidney stone destruct					
00873	N	Anesth kidney stone destruct					
00880	N	Anesth, abdomen vessel surg					
00882	N	Anesth, major vein ligation					
00884	N	Anesth, major vein revision					
00902	N	Anesth, anorectal surgery					
00904	N	Anesth, perineal surgery					
00906	N	Anesth, removal of vulva					
00908	N	Anesth, removal of prostate					
00910	N	Anesth, bladder surgery					
00912	N	Anesth, bladder tumor surg					
00914	N	Anesth, removal of prostate					
00916	N	Anesth, bleeding control					
00918	N	Anesth, stone removal					
00920	N	Anesth, genitalia surgery					
00922	N	Anesth, sperm duct surgery					
00924	N	Anesth, testis exploration					
00926	N	Anesth, removal of testis					
00928	N	Anesth, removal of testis					
00930	N	Anesth, testis suspension					
00932	N	Anesth, amputation of penis					
00934	N	Anesth, penis, nodes removal					
00936	N	Anesth, penis, nodes removal					
00938	N	Anesth, insert penis device					
00940	N	Anesth, vaginal procedures					
00942	N	Anesth, surg on vag/urethal					
00944	N	Anesth, vaginal hysterectomy					
00946	N	Anesth, vaginal delivery					
00948	N	Anesth, repair of cervix					
00950	N	Anesth, vaginal endoscopy					
00952	N	Anesth, hysteroscope/graph					
00955	N	Analgesia, vaginal delivery					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
01112	N	Anesth, bone aspirate/bx					
01120	N	Anesth, pelvis surgery					
01130	N	Anesth, body cast procedure					
01140	N	Anesth, amputation at pelvis					
01150	N	Anesth, pelvic tumor surgery					
01160	N	Anesth, pelvis procedure					
01170	N	Anesth, pelvis surgery					
01180	N	Anesth, pelvis nerve removal					
01190	N	Anesth, pelvis nerve removal					
01200	N	Anesth, hip joint procedure					
01202	N	Anesth, arthroscopy of hip					
01210	N	Anesth, hip joint surgery					
01212	N	Anesth, hip disarticulation					
01214	N	Anesth, replacement of hip					
01215	N	Anesth, revise hip repair					
01220	N	Anesth, procedure on femur					
01230	N	Anesth, surgery of femur					
01232	N	Anesth, amputation of femur					
01234	N	Anesth, radical femur surg					
01250	N	Anesth, upper leg surgery					
01260	N	Anesth, upper leg veins surg					
01270	N	Anesth, thigh arteries surg					
01272	N	Anesth, femoral artery surg					
01274	N	Anesth, femoral embolectomy					
01320	N	Anesth, knee area surgery					
01340	N	Anesth, knee area procedure					
01360	N	Anesth, knee area surgery					
01380	N	Anesth, knee joint procedure					
01382	N	Anesth, knee arthroscopy					
01390	N	Anesth, knee area procedure					
01392	N	Anesth, knee area surgery					
01400	N	Anesth, knee joint surgery					
01402	N	Anesth, replacement of knee					
01404	N	Anesth, amputation at knee					
01420	N	Anesth, knee joint casting					
01430	N	Anesth, knee veins surgery					
01432	N	Anesth, knee vessel surg					
01440	N	Anesth, knee arteries surg					
01442	N	Anesth, knee artery surg					
01444	N	Anesth, knee artery repair					
01462	N	Anesth, lower leg procedure					
01464	N	Anesth, ankle arthroscopy					
01470	N	Anesth, lower leg surgery					
01472	N	Anesth, achilles tendon surg					
01474	N	Anesth, lower leg surgery					
01480	N	Anesth, lower leg bone surg					
01482	N	Anesth, radical leg surgery					
01484	N	Anesth, lower leg revision					
01486	N	Anesth, ankle replacement					
01490	N	Anesth, lower leg casting					
01500	N	Anesth, leg arteries surg					
01502	N	Anesth, lwr leg embolectomy					
01520	N	Anesth, lower leg vein surg					
01522	N	Anesth, lower leg vein surg					
01610	N	Anesth, surgery of shoulder					
01620	N	Anesth, shoulder procedure					
01622	N	Anesth, shoulder arthroscopy					
01630	N	Anesth, surgery of shoulder					
01632	N	Anesth, surgery of shoulder					
01634	N	Anesth, shoulder joint amput					
01636	N	Anesth, forequarter amput					
01638	N	Anesth, shoulder replacement					
01650	N	Anesth, shoulder artery surg					
01652	N	Anesth, shoulder vessel surg					
01654	N	Anesth, shoulder vessel surg					
01656	N	Anesth, arm-leg vessel surg					
01670	N	Anesth, shoulder vein surg					
01680	N	Anesth, shoulder casting					
01682	N	Anesth, airplane cast					
01710	N	Anesth, elbow area surgery					
01712	N	Anesth, uppr arm tendon surg					
01714	N	Anesth, uppr arm tendon surg					
01716	N	Anesth, biceps tendon repair					
01730	N	Anesth, uppr arm procedure					
01732	N	Anesth, elbow arthroscopy					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
01740	N	Anesth, upper arm surgery					
01742	N	Anesth, humerus surgery					
01744	N	Anesth, humerus repair					
01756	N	Anesth, radical humerus surg					
01758	N	Anesth, humeral lesion surg					
01760	N	Anesth, elbow replacement					
01770	N	Anesth, uppr arm artery surg					
01772	N	Anesth, uppr arm embolectomy					
01780	N	Anesth, upper arm vein surg					
01782	N	Anesth, uppr arm vein repair					
01810	N	Anesth, lower arm surgery					
01820	N	Anesth, lower arm procedure					
01830	N	Anesth, lower arm surgery					
01832	N	Anesth, wrist replacement					
01840	N	Anesth, lwr arm artery surg					
01842	N	Anesth, lwr arm embolectomy					
01844	N	Anesth, vascular shunt surg					
01850	N	Anesth, lower arm vein surg					
01852	N	Anesth, lwr arm vein repair					
01860	N	Anesth, lower arm casting					
01904	N	Anesth, skull x-ray inject					
01906	N	Anesth, lumbar myelography					
01908	N	Anesth, cervical myelography					
01910	N	Anesth, skull myelography					
01912	N	Anesth, lumbar diskography					
01914	N	Anesth, cervical diskography					
01916	N	Anesth, head arteriogram					
01918	N	Anesth, limb arteriogram					
01920	N	Anesth, catheterize heart					
01921	N	Anesth, vessel surgery					
01922	N	Anesth, cat or MRI scan					
01951	N	Anesth, burn, less 1 percent					
01952	N	Anesth, burn, 1-9 percent					
01953	N	Anesth, burn, each 9 percent					
01990	N	Support for organ donor					
01995	N	Regional anesthesia, limb					
01996	N	Manage daily drug therapy					
01999	N	Unlisted anesth procedure					
10040	T	Acne surgery of skin abscess	0006	2.36	$119.99	$33.95	$24.00
10060	T	Drainage of skin abscess	0006	2.36	$119.99	$33.95	$24.00
10061	T	Drainage of skin abscess	0006	2.36	$119.99	$33.95	$24.00
10080	T	Drainage of pilonidal cyst	0006	2.36	$119.99	$33.95	$24.00
10081	T	Drainage of pilonidal cyst	0007	7.28	$370.13	$74.03	$74.03
10120	T	Remove foreign body	0006	2.36	$119.99	$33.95	$24.00
10121	T	Remove foreign body	0020	8.56	$435.21	$130.53	$87.04
10140	T	Drainage of hematoma/fluid	0007	7.28	$370.13	$74.03	$74.03
10160	T	Puncture drainage of lesion	0018	1.16	$58.98	$17.66	$11.80
10180	T	Complex drainage, wound	0007	7.28	$370.13	$74.03	$74.03
11000	T	Debride infected skin	0015	2.29	$116.43	$31.20	$23.29
11001	T	Debride infected skin add-on	0013	1.51	$76.77	$17.66	$15.35
11010	T	Debride skin, fx	0022	15.07	$766.19	$292.94	$153.24
11011	T	Debride skin/muscle, fx	0022	15.07	$766.19	$292.94	$153.24
11012	T	Debride skin/muscle/bone, fx	0022	15.07	$766.19	$292.94	$153.24
11040	T	Debride skin, partial	0015	2.29	$116.43	$31.20	$23.29
11041	T	Debride skin, full	0015	2.29	$116.43	$31.20	$23.29
11042	T	Debride skin/tissue	0016	3.31	$168.29	$70.68	$33.66
11043	T	Debride tissue/muscle	0016	3.31	$168.29	$70.68	$33.66
11044	T	Debride tissue/muscle/bone	0017	10.51	$534.35	$245.80	$106.87
11055	T	Trim skin lesion	0012	0.72	$36.61	$9.18	$7.32
11056	T	Trim skin lesions, 2 to 4	0012	0.72	$36.61	$9.18	$7.32
11057	T	Trim skin lesions, over 4	0012	0.72	$36.61	$9.18	$7.32
11100	T	Biopsy of skin lesion	0018	1.16	$58.98	$17.66	$11.80
11101	T	Biopsy, skin add-on	0018	1.16	$58.98	$17.66	$11.80
11200	T	Removal of skin tags	0013	1.51	$76.77	$17.66	$15.35
11201	T	Remove skin tags add-on	0015	2.29	$116.43	$31.20	$23.29
11300	T	Shave skin lesion	0012	0.72	$36.61	$9.18	$7.32
11301	T	Shave skin lesion	0012	0.72	$36.61	$9.18	$7.32
11302	T	Shave skin lesion	0013	1.51	$76.77	$17.66	$15.35
11303	T	Shave skin lesion	0015	2.29	$116.43	$31.20	$23.29
11305	T	Shave skin lesion	0013	1.51	$76.77	$17.66	$15.35
11306	T	Shave skin lesion	0013	1.51	$76.77	$17.66	$15.35
11307	T	Shave skin lesion	0013	1.51	$76.77	$17.66	$15.35
11308	T	Shave skin lesion	0013	1.51	$76.77	$17.66	$15.35
11310	T	Shave skin lesion	0013	1.51	$76.77	$17.66	$15.35
11311	T	Shave skin lesion	0013	1.51	$76.77	$17.66	$15.35

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
11312	T	Shave skin lesion	0013	1.51	$76.77	$17.66	$15.35
11313	T	Shave skin lesion	0016	3.31	$168.29	$70.68	$33.66
11400	T	Removal of skin lesion	0019	4.56	$231.84	$78.91	$46.37
11401	T	Removal of skin lesion	0019	4.56	$231.84	$78.91	$46.37
11402	T	Removal of skin lesion	0019	4.56	$231.84	$78.91	$46.37
11403	T	Removal of skin lesion	0020	8.56	$435.21	$130.53	$87.04
11404	T	Removal of skin lesion	0020	8.56	$435.21	$130.53	$87.04
11406	T	Removal of skin lesion	0021	12.74	$647.73	$236.51	$129.55
11420	T	Removal of skin lesion	0019	4.56	$231.84	$78.91	$46.37
11421	T	Removal of skin lesion	0019	4.56	$231.84	$78.91	$46.37
11422	T	Removal of skin lesion	0019	4.56	$231.84	$78.91	$46.37
11423	T	Removal of skin lesion	0020	8.56	$435.21	$130.53	$87.04
11424	T	Removal of skin lesion	0020	8.56	$435.21	$130.53	$87.04
11426	T	Removal of skin lesion	0022	15.07	$766.19	$292.94	$153.24
11440	T	Removal of skin lesion	0019	4.56	$231.84	$78.91	$46.37
11441	T	Removal of skin lesion	0019	4.56	$231.84	$78.91	$46.37
11442	T	Removal of skin lesion	0019	4.56	$231.84	$78.91	$46.37
11443	T	Removal of skin lesion	0020	8.56	$435.21	$130.53	$87.04
11444	T	Removal of skin lesion	0020	8.56	$435.21	$130.53	$87.04
11446	T	Removal of skin lesion	0022	15.07	$766.19	$292.94	$153.24
11450	T	Removal, sweat gland lesion	0022	15.07	$766.19	$292.94	$153.24
11451	T	Removal, sweat gland lesion	0022	15.07	$766.19	$292.94	$153.24
11462	T	Removal, sweat gland lesion	0022	15.07	$766.19	$292.94	$153.24
11463	T	Removal, sweat gland lesion	0022	15.07	$766.19	$292.94	$153.24
11470	T	Removal, sweat gland lesion	0022	15.07	$766.19	$292.94	$153.24
11471	T	Removal, sweat gland lesion	0022	15.07	$766.19	$292.94	$153.24
11600	T	Removal of skin lesion	0019	4.56	$231.84	$78.91	$46.37
11601	T	Removal of skin lesion	0019	4.56	$231.84	$78.91	$46.37
11602	T	Removal of skin lesion	0019	4.56	$231.84	$78.91	$46.37
11603	T	Removal of skin lesion	0020	8.56	$435.21	$130.53	$87.04
11604	T	Removal of skin lesion	0020	8.56	$435.21	$130.53	$87.04
11606	T	Removal of skin lesion	0021	12.74	$647.73	$236.51	$129.55
11620	T	Removal of skin lesion	0019	4.56	$231.84	$78.91	$46.37
11621	T	Removal of skin lesion	0019	4.56	$231.84	$78.91	$46.37
11622	T	Removal of skin lesion	0019	4.56	$231.84	$78.91	$46.37
11623	T	Removal of skin lesion	0020	8.56	$435.21	$130.53	$87.04
11624	T	Removal of skin lesion	0020	8.56	$435.21	$130.53	$87.04
11626	T	Removal of skin lesion	0022	15.07	$766.19	$292.94	$153.24
11640	T	Removal of skin lesion	0019	4.56	$231.84	$78.91	$46.37
11641	T	Removal of skin lesion	0019	4.56	$231.84	$78.91	$46.37
11642	T	Removal of skin lesion	0019	4.56	$231.84	$78.91	$46.37
11643	T	Removal of skin lesion	0020	8.56	$435.21	$130.53	$87.04
11644	T	Removal of skin lesion	0020	8.56	$435.21	$130.53	$87.04
11646	T	Removal of skin lesion	0022	15.07	$766.19	$292.94	$153.24
11719	T	Trim nail(s)	0009	0.68	$34.57	$8.99	$6.91
11720	T	Debride nail, 1-5	0009	0.68	$34.57	$8.99	$6.91
11721	T	Debride nail, 6 or more	0009	0.68	$34.57	$8.99	$6.91
11730	T	Removal of nail plate	0013	1.51	$76.77	$17.66	$15.35
11732	T	Remove nail plate, add-on	0012	0.72	$36.61	$9.18	$7.32
11740	T	Drain blood from under nail	0009	0.68	$34.57	$8.99	$6.91
11750	T	Removal of nail bed	0019	4.56	$231.84	$78.91	$46.37
11752	T	Remove nail bed/finger tip	0022	15.07	$766.19	$292.94	$153.24
11755	T	Biopsy, nail unit	0019	4.56	$231.84	$78.91	$46.37
11760	T	Repair of nail bed	0024	2.48	$126.09	$44.50	$25.22
11762	T	Reconstruction of nail bed	0024	2.48	$126.09	$44.50	$25.22
11765	T	Excision of nail fold, toe	0015	2.29	$116.43	$31.20	$23.29
11770	T	Removal of pilonidal lesion	0021	12.74	$647.73	$236.51	$129.55
11771	T	Removal of pilonidal lesion	0022	15.07	$766.19	$292.94	$153.24
11772	T	Removal of pilonidal lesion	0022	15.07	$766.19	$292.94	$153.24
11900	T	Injection into skin lesions	0012	0.72	$36.61	$9.18	$7.32
11901	T	Added skin lesions injection	0012	0.72	$36.61	$9.18	$7.32
11920	T	Correct skin color defects	0024	2.48	$126.09	$44.50	$25.22
11921	T	Correct skin color defects	0024	2.48	$126.09	$44.50	$25.22
11922	T	Correct skin color defects	0024	2.48	$126.09	$44.50	$25.22
11950	T	Therapy for contour defects	0024	2.48	$126.09	$44.50	$25.22
11951	T	Therapy for contour defects	0024	2.48	$126.09	$44.50	$25.22
11952	T	Therapy for contour defects	0024	2.48	$126.09	$44.50	$25.22
11954	T	Therapy for contour defects	0024	2.48	$126.09	$44.50	$25.22
11960	T	Insert tissue expander(s)	0026	13.51	$686.88	$277.92	$137.38
11970	T	Replace tissue expander	0026	13.51	$686.88	$277.92	$137.38
11971	T	Remove tissue expander(s)	0022	15.07	$766.19	$292.94	$153.24
11975	E	Insert contraceptive cap	.....	.....	.....	.....	.....
11976	T	Removal of contraceptive cap	0019	4.56	$231.84	$78.91	$46.37
11977	E	Removal/reinsert contra cap	.....	.....	.....	.....	.....
11980	X	Implant hormone pellet(s)	0340	0.91	$46.27	$11.57	$9.25

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
12001	T	Repair superficial wound(s)	0024	2.48	$126.09	$44.50	$25.22
12002	T	Repair superficial wound(s)	0024	2.48	$126.09	$44.50	$25.22
12004	T	Repair superficial wound(s)	0024	2.48	$126.09	$44.50	$25.22
12005	T	Repair superficial wound(s)	0024	2.48	$126.09	$44.50	$25.22
12006	T	Repair superficial wound(s)	0024	2.48	$126.09	$44.50	$25.22
12007	T	Repair superficial wound(s)	0024	2.48	$126.09	$44.50	$25.22
12011	T	Repair superficial wound(s)	0024	2.48	$126.09	$44.50	$25.22
12013	T	Repair superficial wound(s)	0024	2.48	$126.09	$44.50	$25.22
12014	T	Repair superficial wound(s)	0024	2.48	$126.09	$44.50	$25.22
12015	T	Repair superficial wound(s)	0024	2.48	$126.09	$44.50	$25.22
12016	T	Repair superficial wound(s)	0024	2.48	$126.09	$44.50	$25.22
12017	T	Repair superficial wound(s)	0024	2.48	$126.09	$44.50	$25.22
12018	T	Repair superficial wound(s)	0024	2.48	$126.09	$44.50	$25.22
12020	T	Closure of split wound	0024	2.48	$126.09	$44.50	$25.22
12021	T	Closure of split wound	0024	2.48	$126.09	$44.50	$25.22
12031	T	Layer closure of wound(s)	0024	2.48	$126.09	$44.50	$25.22
12032	T	Layer closure of wound(s)	0024	2.48	$126.09	$44.50	$25.22
12034	T	Layer closure of wound(s)	0024	2.48	$126.09	$44.50	$25.22
12035	T	Layer closure of wound(s)	0024	2.48	$126.09	$44.50	$25.22
12036	T	Layer closure of wound(s)	0024	2.48	$126.09	$44.50	$25.22
12037	T	Layer closure of wound(s)	0026	13.51	$686.88	$277.92	$137.38
12041	T	Layer closure of wound(s)	0024	2.48	$126.09	$44.50	$25.22
12042	T	Layer closure of wound(s)	0024	2.48	$126.09	$44.50	$25.22
12044	T	Layer closure of wound(s)	0024	2.48	$126.09	$44.50	$25.22
12045	T	Layer closure of wound(s)	0024	2.48	$126.09	$44.50	$25.22
12046	T	Layer closure of wound(s)	0024	2.48	$126.09	$44.50	$25.22
12047	T	Layer closure of wound(s)	0026	13.51	$686.88	$277.92	$137.38
12051	T	Layer closure of wound(s)	0024	2.48	$126.09	$44.50	$25.22
12052	T	Layer closure of wound(s)	0024	2.48	$126.09	$44.50	$25.22
12053	T	Layer closure of wound(s)	0024	2.48	$126.09	$44.50	$25.22
12054	T	Layer closure of wound(s)	0024	2.48	$126.09	$44.50	$25.22
12055	T	Layer closure of wound(s)	0024	2.48	$126.09	$44.50	$25.22
12056	T	Layer closure of wound(s)	0024	2.48	$126.09	$44.50	$25.22
12057	T	Layer closure of wound(s)	0026	13.51	$686.88	$277.92	$137.38
13100	T	Repair of wound or lesion	0025	3.71	$188.62	$70.66	$37.72
13101	T	Repair of wound or lesion	0025	3.71	$188.62	$70.66	$37.72
13102	T	Repair wound/lesion add-on	0025	3.71	$188.62	$70.66	$37.72
13120	T	Repair of wound or lesion	0025	3.71	$188.62	$70.66	$37.72
13121	T	Repair of wound or lesion	0025	3.71	$188.62	$70.66	$37.72
13122	T	Repair wound/lesion add-on	0025	3.71	$188.62	$70.66	$37.72
13131	T	Repair of wound or lesion	0025	3.71	$188.62	$70.66	$37.72
13132	T	Repair of wound or lesion	0025	3.71	$188.62	$70.66	$37.72
13133	T	Repair wound/lesion add-on	0025	3.71	$188.62	$70.66	$37.72
13150	T	Repair of wound or lesion	0026	13.51	$686.88	$277.92	$137.38
13151	T	Repair of wound or lesion	0025	3.71	$188.62	$70.66	$37.72
13152	T	Repair of wound or lesion	0025	3.71	$188.62	$70.66	$37.72
13153	T	Repair wound/lesion add-on	0025	3.71	$188.62	$70.66	$37.72
13160	T	Late closure of wound	0026	13.51	$686.88	$277.92	$137.38
14000	T	Skin tissue rearrangement	0026	13.51	$686.88	$277.92	$137.38
14001	T	Skin tissue rearrangement	0026	13.51	$686.88	$277.92	$137.38
14020	T	Skin tissue rearrangement	0026	13.51	$686.88	$277.92	$137.38
14021	T	Skin tissue rearrangement	0026	13.51	$686.88	$277.92	$137.38
14040	T	Skin tissue rearrangement	0026	13.51	$686.88	$277.92	$137.38
14041	T	Skin tissue rearrangement	0026	13.51	$686.88	$277.92	$137.38
14060	T	Skin tissue rearrangement	0026	13.51	$686.88	$277.92	$137.38
14061	T	Skin tissue rearrangement	0026	13.51	$686.88	$277.92	$137.38
14300	T	Skin tissue rearrangement	0026	13.51	$686.88	$277.92	$137.38
14350	T	Skin tissue rearrangement	0026	13.51	$686.88	$277.92	$137.38
15000	T	Skin graft	0026	13.51	$686.88	$277.92	$137.38
15001	T	Skin graft add-on	0026	13.51	$686.88	$277.92	$137.38
15050	T	Skin pinch graft	0026	13.51	$686.88	$277.92	$137.38
15100	T	Skin split graft	0026	13.51	$686.88	$277.92	$137.38
15101	T	Skin split graft add-on	0026	13.51	$686.88	$277.92	$137.38
15120	T	Skin split graft	0026	13.51	$686.88	$277.92	$137.38
15121	T	Skin split graft add-on	0026	13.51	$686.88	$277.92	$137.38
15200	T	Skin full graft	0026	13.51	$686.88	$277.92	$137.38
15201	T	Skin full graft add-on	0026	13.51	$686.88	$277.92	$137.38
15220	T	Skin full graft	0026	13.51	$686.88	$277.92	$137.38
15221	T	Skin full graft add-on	0026	13.51	$686.88	$277.92	$137.38
15240	T	Skin full graft	0026	13.51	$686.88	$277.92	$137.38
15241	T	Skin full graft add-on	0026	13.51	$686.88	$277.92	$137.38
15260	T	Skin full graft	0026	13.51	$686.88	$277.92	$137.38
15261	T	Skin full graft add-on	0026	13.51	$686.88	$277.92	$137.38
15342	T	Cultured skin graft, 25 cm	0025	3.71	$188.62	$70.66	$37.72
15343	T	Culture skn graft addl 25 cm	0025	3.71	$188.62	$70.66	$37.72

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
15350	T	Skin homograft	0026	13.51	$686.88	$277.92	$137.38
15351	T	Skin homograft add-on	0026	13.51	$686.88	$277.92	$137.38
15400	T	Skin heterograft	0026	13.51	$686.88	$277.92	$137.38
15401	T	Skin heterograft add-on	0026	13.51	$686.88	$277.92	$137.38
15570	T	Form skin pedicle flap	0026	13.51	$686.88	$277.92	$137.38
15572	T	Form skin pedicle flap	0026	13.51	$686.88	$277.92	$137.38
15574	T	Form skin pedicle flap	0026	13.51	$686.88	$277.92	$137.38
15576	T	Form skin pedicle flap	0026	13.51	$686.88	$277.92	$137.38
15600	T	Skin graft	0026	13.51	$686.88	$277.92	$137.38
15610	T	Skin graft	0026	13.51	$686.88	$277.92	$137.38
15620	T	Skin graft	0026	13.51	$686.88	$277.92	$137.38
15630	T	Skin graft	0026	13.51	$686.88	$277.92	$137.38
15650	T	Transfer skin pedicle flap	0026	13.51	$686.88	$277.92	$137.38
15732	T	Muscle-skin graft, head/neck	0027	19.31	$981.76	$383.10	$196.35
15734	T	Muscle-skin graft, trunk	0027	19.31	$981.76	$383.10	$196.35
15736	T	Muscle-skin graft, arm	0027	19.31	$981.76	$383.10	$196.35
15738	T	Muscle-skin graft, leg	0027	19.31	$981.76	$383.10	$196.35
15740	T	Island pedicle flap graft	0027	19.31	$981.76	$383.10	$196.35
15750	T	Neurovascular pedicle graft	0027	19.31	$981.76	$383.10	$196.35
15756	C	Free muscle flap, microvasc					
15757	C	Free skin flap, microvasc					
15758	C	Free fascial flap, microvasc					
15760	T	Composite skin graft	0027	19.31	$981.76	$383.10	$196.35
15770	T	Derma-fat-fascia graft	0027	19.31	$981.76	$383.10	$196.35
15775	T	Hair transplant punch grafts	0026	13.51	$686.88	$277.92	$137.38
15776	T	Hair transplant punch grafts	0026	13.51	$686.88	$277.92	$137.38
15780	T	Abrasion treatment of skin	0022	15.07	$766.19	$292.94	$153.24
15781	T	Abrasion treatment of skin	0022	15.07	$766.19	$292.94	$153.24
15782	T	Abrasion treatment of skin	0022	15.07	$766.19	$292.94	$153.24
15783	T	Abrasion treatment of skin	0016	3.31	$168.29	$70.68	$33.66
15786	T	Abrasion, lesion, single	0013	1.51	$76.77	$17.66	$15.35
15787	T	Abrasion, lesions, add-on	0013	1.51	$76.77	$17.66	$15.35
15788	T	Chemical peel, face, epiderm	0012	0.72	$36.61	$9.18	$7.32
15789	T	Chemical peel, face, dermal	0015	2.29	$116.43	$31.20	$23.29
15792	T	Chemical peel, nonfacial	0012	0.72	$36.61	$9.18	$7.32
15793	T	Chemical peel, nonfacial	0013	1.51	$76.77	$17.66	$15.35
15810	T	Salabrasion	0016	3.31	$168.29	$70.68	$33.66
15811	T	Salabrasion	0016	3.31	$168.29	$70.68	$33.66
15819	T	Plastic surgery, neck	0026	13.51	$686.88	$277.92	$137.38
15820	T	Revision of lower eyelid	0026	13.51	$686.88	$277.92	$137.38
15821	T	Revision of lower eyelid	0026	13.51	$686.88	$277.92	$137.38
15822	T	Revision of upper eyelid	0026	13.51	$686.88	$277.92	$137.38
15823	T	Revision of upper eyelid	0026	13.51	$686.88	$277.92	$137.38
15824	T	Removal of forehead wrinkles	0027	19.31	$981.76	$383.10	$196.35
15825	T	Removal of neck wrinkles	0026	13.51	$686.88	$277.92	$137.38
15826	T	Removal of brow wrinkles	0026	13.51	$686.88	$277.92	$137.38
15828	T	Removal of face wrinkles	0027	19.31	$981.76	$383.10	$196.35
15829	T	Removal of skin wrinkles	0026	13.51	$686.88	$277.92	$137.38
15831	T	Excise excessive skin tissue	0022	15.07	$766.19	$292.94	$153.24
15832	T	Excise excessive skin tissue	0022	15.07	$766.19	$292.94	$153.24
15833	T	Excise excessive skin tissue	0022	15.07	$766.19	$292.94	$153.24
15834	T	Excise excessive skin tissue	0022	15.07	$766.19	$292.94	$153.24
15835	T	Excise excessive skin tissue	0026	13.51	$686.88	$277.92	$137.38
15836	T	Excise excessive skin tissue	0019	4.56	$231.84	$78.91	$46.37
15837	T	Excise excessive skin tissue	0019	4.56	$231.84	$78.91	$46.37
15838	T	Excise excessive skin tissue	0019	4.56	$231.84	$78.91	$46.37
15839	T	Excise excessive skin tissue	0019	4.56	$231.84	$78.91	$46.37
15840	T	Graft for face nerve palsy	0027	19.31	$981.76	$383.10	$196.35
15841	T	Graft for face nerve palsy	0027	19.31	$981.76	$383.10	$196.35
15842	T	Flap for face nerve palsy	0027	19.31	$981.76	$383.10	$196.35
15845	T	Skin and muscle repair, face	0027	19.31	$981.76	$383.10	$196.35
15850	T	Removal of sutures	0016	3.31	$168.29	$70.68	$33.66
15851	T	Removal of sutures	0013	1.51	$76.77	$17.66	$15.35
15852	T	Dressing change,not for burn	0013	1.51	$76.77	$17.66	$15.35
15860	N	Test for blood flow in graft					
15876	T	Suction assisted lipectomy	0027	19.31	$981.76	$383.10	$196.35
15877	T	Suction assisted lipectomy	0027	19.31	$981.76	$383.10	$196.35
15878	T	Suction assisted lipectomy	0027	19.31	$981.76	$383.10	$196.35
15879	T	Suction assisted lipectomy	0027	19.31	$981.76	$383.10	$196.35
15920	T	Removal of tail bone ulcer	0022	15.07	$766.19	$292.94	$153.24
15922	T	Removal of tail bone ulcer	0027	19.31	$981.76	$383.10	$196.35
15931	T	Remove sacrum pressure sore	0022	15.07	$766.19	$292.94	$153.24
15933	T	Remove sacrum pressure sore	0022	15.07	$766.19	$292.94	$153.24
15934	T	Remove sacrum pressure sore	0027	19.31	$981.76	$383.10	$196.35
15935	T	Remove sacrum pressure sore	0027	19.31	$981.76	$383.10	$196.35

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
15936	T	Remove sacrum pressure sore	0027	19.31	$981.76	$383.10	$196.35
15937	T	Remove sacrum pressure sore	0027	19.31	$981.76	$383.10	$196.35
15940	T	Remove hip pressure sore	0022	15.07	$766.19	$292.94	$153.24
15941	T	Remove hip pressure sore	0022	15.07	$766.19	$292.94	$153.24
15944	T	Remove hip pressure sore	0027	19.31	$981.76	$383.10	$196.35
15945	T	Remove hip pressure sore	0027	19.31	$981.76	$383.10	$196.35
15946	T	Remove hip pressure sore	0027	19.31	$981.76	$383.10	$196.35
15950	T	Remove thigh pressure sore	0022	15.07	$766.19	$292.94	$153.24
15951	T	Remove thigh pressure sore	0022	15.07	$766.19	$292.94	$153.24
15952	T	Remove thigh pressure sore	0027	19.31	$981.76	$383.10	$196.35
15953	T	Remove thigh pressure sore	0027	19.31	$981.76	$383.10	$196.35
15956	T	Remove thigh pressure sore	0027	19.31	$981.76	$383.10	$196.35
15958	T	Remove thigh pressure sore	0027	19.31	$981.76	$383.10	$196.35
15999	T	Removal of pressure sore	0022	15.07	$766.19	$292.94	$153.24
16000	T	Initial treatment of burn(s)	0013	1.51	$76.77	$17.66	$15.35
16010	T	Treatment of burn(s)	0016	3.31	$168.29	$70.68	$33.66
16015	T	Treatment of burn(s)	0017	10.51	$534.35	$245.80	$106.87
16020	T	Treatment of burn(s)	0013	1.51	$76.77	$17.66	$15.35
16025	T	Treatment of burn(s)	0013	1.51	$76.77	$17.66	$15.35
16030	T	Treatment of burn(s)	0015	2.29	$116.43	$31.20	$23.29
16035	C	Incision of burn scab, initi	.....	.....	.....	.....	.....
16036	C	Incise burn scab, addl incis	.....	.....	.....	.....	.....
17000	T	Destroy benign/premal lesion	0010	0.71	$36.10	$9.86	$7.22
17003	T	Destroy lesions, 2-14	0010	0.71	$36.10	$9.86	$7.22
17004	T	Destroy lesions, 15 or more	0011	1.57	$79.82	$29.53	$15.96
17106	T	Destruction of skin lesions	0011	1.57	$79.82	$29.53	$15.96
17107	T	Destruction of skin lesions	0011	1.57	$79.82	$29.53	$15.96
17108	T	Destruction of skin lesions	0011	1.57	$79.82	$29.53	$15.96
17110	T	Destruct lesion, 1-14	0010	0.71	$36.10	$9.86	$7.22
17111	T	Destruct lesion, 15 or more	0011	1.57	$79.82	$29.53	$15.96
17250	T	Chemical cautery, tissue	0013	1.51	$76.77	$17.66	$15.35
17260	T	Destruction of skin lesions	0013	1.51	$76.77	$17.66	$15.35
17261	T	Destruction of skin lesions	0013	1.51	$76.77	$17.66	$15.35
17262	T	Destruction of skin lesions	0013	1.51	$76.77	$17.66	$15.35
17263	T	Destruction of skin lesions	0013	1.51	$76.77	$17.66	$15.35
17264	T	Destruction of skin lesions	0013	1.51	$76.77	$17.66	$15.35
17266	T	Destruction of skin lesions	0016	3.31	$168.29	$70.68	$33.66
17270	T	Destruction of skin lesions	0013	1.51	$76.77	$17.66	$15.35
17271	T	Destruction of skin lesions	0012	0.72	$36.61	$9.18	$7.32
17272	T	Destruction of skin lesions	0013	1.51	$76.77	$17.66	$15.35
17273	T	Destruction of skin lesions	0015	2.29	$116.43	$31.20	$23.29
17274	T	Destruction of skin lesions	0016	3.31	$168.29	$70.68	$33.66
17276	T	Destruction of skin lesions	0016	3.31	$168.29	$70.68	$33.66
17280	T	Destruction of skin lesions	0013	1.51	$76.77	$17.66	$15.35
17281	T	Destruction of skin lesions	0013	1.51	$76.77	$17.66	$15.35
17282	T	Destruction of skin lesions	0015	2.29	$116.43	$31.20	$23.29
17283	T	Destruction of skin lesions	0015	2.29	$116.43	$31.20	$23.29
17284	T	Destruction of skin lesions	0016	3.31	$168.29	$70.68	$33.66
17286	T	Destruction of skin lesions	0013	1.51	$76.77	$17.66	$15.35
17304	T	Chemosurgery of skin lesion	0694	4.28	$217.60	$65.28	$43.52
17305	T	2nd stage chemosurgery	0694	4.28	$217.60	$65.28	$43.52
17306	T	3rd stage chemosurgery	0694	4.28	$217.60	$65.28	$43.52
17307	T	Followup skin lesion therapy	0694	4.28	$217.60	$65.28	$43.52
17310	T	Extensive skin chemosurgery	0694	4.28	$217.60	$65.28	$43.52
17340	T	Cryotherapy of skin	0012	0.72	$36.61	$9.18	$7.32
17360	T	Skin peel therapy	0012	0.72	$36.61	$9.18	$7.32
17380	T	Hair removal by electrolysis	0017	10.51	$534.35	$245.80	$106.87
17999	T	Skin tissue procedure	0004	3.00	$152.53	$32.57	$30.51
19000	T	Drainage of breast lesion	0004	3.00	$152.53	$32.57	$30.51
19001	T	Drain breast lesion add-on	0004	3.00	$152.53	$32.57	$30.51
19020	T	Incision of breast lesion	0008	11.36	$577.57	$115.51	$115.51
19030	N	Injection for breast x-ray	.....	.....	.....	.....	.....
19100	T	Bx breast percut w/o image	0005	6.71	$341.15	$119.75	$68.23
19101	T	Biopsy of breast, open	0028	14.95	$760.09	$303.74	$152.02
19102	T	Bx breast percut w/image	0005	6.71	$341.15	$119.75	$68.23
19103	S	Bx breast percut w/device	0974	7.57	$384.87	.....	$76.97
19110	T	Nipple exploration	0028	14.95	$760.09	$303.74	$152.02
19112	T	Excise breast duct fistula	0028	14.95	$760.09	$303.74	$152.02
19120	T	Removal of breast lesion	0028	14.95	$760.09	$303.74	$152.02
19125	T	Excision, breast lesion	0028	14.95	$760.09	$303.74	$152.02
19126	T	Excision, addl breast lesion	0028	14.95	$760.09	$303.74	$152.02
19140	T	Removal of breast tissue	0028	14.95	$760.09	$303.74	$152.02
19160	T	Removal of breast tissue	0028	14.95	$760.09	$303.74	$152.02
19162	T	Remove breast tissue, nodes	0693	33.16	$1,685.92	$826.10	$337.18
19180	T	Removal of breast	0030	25.95	$1,319.35	$646.48	$263.87

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
19182	T	Removal of breast	0030	25.95	$1,319.35	$646.48	$263.87
19200	C	Removal of breast					
19220	C	Removal of breast					
19240	T	Removal of breast	0029	35.93	$1,826.75	$820.79	$365.35
19260	T	Removal of chest wall lesion	0021	12.74	$647.73	$236.51	$129.55
19271	C	Revision of chest wall					
19272	C	Extensive chest wall surgery					
19290	N	Place needle wire, breast					
19291	N	Place needle wire, breast					
19295	N	Place breast clip, percut					
19316	T	Suspension of breast	0030	25.95	$1,319.35	$646.48	$263.87
19318	T	Reduction of large breast	0693	33.16	$1,685.92	$826.10	$337.18
19324	T	Enlarge breast	0693	33.16	$1,685.92	$826.10	$337.18
19325	T	Enlarge breast with implant	0693	33.16	$1,685.92	$826.10	$337.18
19328	T	Removal of breast implant	0030	25.95	$1,319.35	$646.48	$263.87
19330	T	Removal of implant material	0030	25.95	$1,319.35	$646.48	$263.87
19340	T	Immediate breast prosthesis	0030	25.95	$1,319.35	$646.48	$263.87
19342	T	Delayed breast prosthesis	0693	33.16	$1,685.92	$826.10	$337.18
19350	T	Breast reconstruction	0030	25.95	$1,319.35	$646.48	$263.87
19355	T	Correct inverted nipple(s)	0030	25.95	$1,319.35	$646.48	$263.87
19357	T	Breast reconstruction	0693	33.16	$1,685.92	$826.10	$337.18
19361	C	Breast reconstruction					
19364	C	Breast reconstruction					
19366	T	Breast reconstruction	0030	25.95	$1,319.35	$646.48	$263.87
19367	C	Breast reconstruction					
19368	C	Breast reconstruction					
19369	C	Breast reconstruction					
19370	T	Surgery of breast capsule	0030	25.95	$1,319.35	$646.48	$263.87
19371	T	Removal of breast capsule	0030	25.95	$1,319.35	$646.48	$263.87
19380	T	Revise breast reconstruction	0030	25.95	$1,319.35	$646.48	$263.87
19396	T	Design custom breast implant	0029	35.93	$1,826.75	$820.79	$365.35
19499	T	Breast surgery procedure	0029	35.93	$1,826.75	$820.79	$365.35
20000	T	Incision of abscess	0006	2.36	$119.99	$33.95	$24.00
20005	T	Incision of deep abscess	0049	17.07	$867.87	$356.95	$173.57
20100	T	Explore wound, neck	0023	2.18	$110.84	$40.37	$22.17
20101	T	Explore wound, chest	0026	13.51	$686.88	$277.92	$137.38
20102	T	Explore wound, abdomen	0026	13.51	$686.88	$277.92	$137.38
20103	T	Explore wound, extremity	0023	2.18	$110.84	$40.37	$22.17
20150	T	Excise epiphyseal bar	0051	30.94	$1,573.05	$675.24	$314.61
20200	T	Muscle biopsy	0020	8.56	$435.21	$130.53	$87.04
20205	T	Deep muscle biopsy	0021	12.74	$647.73	$236.51	$129.55
20206	T	Needle biopsy, muscle	0005	6.71	$341.15	$119.75	$68.23
20220	T	Bone biopsy, trocar/needle	0019	4.56	$231.84	$78.91	$46.37
20225	T	Bone biopsy, trocar/needle	0020	8.56	$435.21	$130.53	$87.04
20240	T	Bone biopsy, excisional	0022	15.07	$766.19	$292.94	$153.24
20245	T	Bone biopsy, excisional	0022	15.07	$766.19	$292.94	$153.24
20250	T	Open bone biopsy	0049	17.07	$867.87	$356.95	$173.57
20251	T	Open bone biopsy	0049	17.07	$867.87	$356.95	$173.57
20500	T	Injection of sinus tract	0251	2.71	$137.78	$27.99	$27.56
20501	N	Inject sinus tract for x-ray					
20520	T	Removal of foreign body	0019	4.56	$231.84	$78.91	$46.37
20525	T	Removal of foreign body	0022	15.07	$766.19	$292.94	$153.24
20550	T	Inject tendon/ligament/cyst	0204	2.44	$124.05	$47.14	$24.81
20600	T	Drain/inject, joint/bursa	0204	2.44	$124.05	$47.14	$24.81
20605	T	Drain/inject, joint/bursa	0204	2.44	$124.05	$47.14	$24.81
20610	T	Drain/inject, joint/bursa	0204	2.44	$124.05	$47.14	$24.81
20615	T	Treatment of bone cyst	0004	3.00	$152.53	$32.57	$30.51
20650	T	Insert and remove bone pin	0049	17.07	$867.87	$356.95	$173.57
20660	C	Apply,remove fixation device					
20661	C	Application of head brace					
20662	C	Application of pelvis brace					
20663	C	Application of thigh brace					
20664	C	Halo brace application					
20665	N	Removal of fixation device					
20670	T	Removal of support implant	0021	12.74	$647.73	$236.51	$129.55
20680	T	Removal of support implant	0022	15.07	$766.19	$292.94	$153.24
20690	T	Apply bone fixation device	0050	22.31	$1,134.29	$513.86	$226.86
20692	T	Apply bone fixation device	0050	22.31	$1,134.29	$513.86	$226.86
20693	T	Adjust bone fixation device	0049	17.07	$867.87	$356.95	$173.57
20694	T	Remove bone fixation device	0049	17.07	$867.87	$356.95	$173.57
20802	C	Replantation, arm, complete					
20805	C	Replant, forearm, complete					
20808	C	Replantation hand, complete					
20816	C	Replantation digit, complete					
20822	C	Replantation digit, complete					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
20824	C	Replantation thumb, complete					
20827	C	Replantation thumb, complete					
20838	C	Replantation foot, complete					
20900	T	Removal of bone for graft	0050	22.31	$1,134.29	$513.86	$226.86
20902	T	Removal of bone for graft	0050	22.31	$1,134.29	$513.86	$226.86
20910	T	Remove cartilage for graft	0026	13.51	$686.88	$277.92	$137.38
20912	T	Remove cartilage for graft	0026	13.51	$686.88	$277.92	$137.38
20920	T	Removal of fascia for graft	0026	13.51	$686.88	$277.92	$137.38
20922	T	Removal of fascia for graft	0026	13.51	$686.88	$277.92	$137.38
20924	T	Removal of tendon for graft	0050	22.31	$1,134.29	$513.86	$226.86
20926	T	Removal of tissue for graft	0026	13.51	$686.88	$277.92	$137.38
20930	C	Spinal bone allograft					
20931	C	Spinal bone allograft					
20936	C	Spinal bone autograft					
20937	C	Spinal bone autograft					
20938	C	Spinal bone autograft					
20950	T	Fluid pressure, muscle	0008	11.36	$577.57	$115.51	$115.51
20955	C	Fibula bone graft, microvasc					
20956	C	Iliac bone graft, microvasc					
20957	C	Mt bone graft, microvasc					
20962	C	Other bone graft, microvasc					
20969	C	Bone/skin graft, microvasc					
20970	C	Bone/skin graft, iliac crest					
20972	C	Bone/skin graft, metatarsal					
20973	C	Bone/skin graft, great toe					
20974	A	Electrical bone stimulation					
20975	T	Electrical bone stimulation	0049	17.07	$867.87	$356.95	$173.57
20979	E	Us bone stimulation					
20999	N	Musculoskeletal surgery					
21010	T	Incision of jaw joint	0254	19.11	$971.59	$272.41	$194.32
21015	T	Resection of facial tumor	0252	6.53	$332.00	$114.24	$66.40
21025	T	Excision of bone, lower jaw	0256	28.82	$1,465.27	$623.05	$293.05
21026	T	Excision of facial bone(s)	0256	28.82	$1,465.27	$623.05	$293.05
21029	T	Contour of face bone lesion	0256	28.82	$1,465.27	$623.05	$293.05
21030	T	Removal of face bone lesion	0254	19.11	$971.59	$272.41	$194.32
21031	T	Remove exostosis, mandible	0254	19.11	$971.59	$272.41	$194.32
21032	T	Remove exostosis, maxilla	0254	19.11	$971.59	$272.41	$194.32
21034	T	Removal of face bone lesion	0256	28.82	$1,465.27	$623.05	$293.05
21040	T	Removal of jaw bone lesion	0254	19.11	$971.59	$272.41	$194.32
21041	T	Removal of jaw bone lesion	0256	28.82	$1,465.27	$623.05	$293.05
21044	T	Removal of jaw bone lesion	0256	28.82	$1,465.27	$623.05	$293.05
21045	C	Extensive jaw surgery					
21050	T	Removal of jaw joint	0256	28.82	$1,465.27	$623.05	$293.05
21060	T	Remove jaw joint cartilage	0256	28.82	$1,465.27	$623.05	$293.05
21070	T	Remove coronoid process	0256	28.82	$1,465.27	$623.05	$293.05
21076	T	Prepare face/oral prosthesis	0254	19.11	$971.59	$272.41	$194.32
21077	T	Prepare face/oral prosthesis	0256	28.82	$1,465.27	$623.05	$293.05
21079	T	Prepare face/oral prosthesis	0256	28.82	$1,465.27	$623.05	$293.05
21080	T	Prepare face/oral prosthesis	0256	28.82	$1,465.27	$623.05	$293.05
21081	T	Prepare face/oral prosthesis	0256	28.82	$1,465.27	$623.05	$293.05
21082	T	Prepare face/oral prosthesis	0256	28.82	$1,465.27	$623.05	$293.05
21083	T	Prepare face/oral prosthesis	0256	28.82	$1,465.27	$623.05	$293.05
21084	T	Prepare face/oral prosthesis	0256	28.82	$1,465.27	$623.05	$293.05
21085	T	Prepare face/oral prosthesis	0253	13.27	$674.67	$284.00	$134.93
21086	T	Prepare face/oral prosthesis	0256	28.82	$1,465.27	$623.05	$293.05
21087	T	Prepare face/oral prosthesis	0256	28.82	$1,465.27	$623.05	$293.05
21088	T	Prepare face/oral prosthesis	0256	28.82	$1,465.27	$623.05	$293.05
21089	T	Prepare face/oral prosthesis	0253	13.27	$674.67	$284.00	$134.93
21100	T	Maxillofacial fixation	0256	28.82	$1,465.27	$623.05	$293.05
21110	T	Interdental fixation	0252	6.53	$332.00	$114.24	$66.40
21116	N	Injection, jaw joint x-ray					
21120	T	Reconstruction of chin	0254	19.11	$971.59	$272.41	$194.32
21121	T	Reconstruction of chin	0254	19.11	$971.59	$272.41	$194.32
21122	T	Reconstruction of chin	0254	19.11	$971.59	$272.41	$194.32
21123	T	Reconstruction of chin	0254	19.11	$971.59	$272.41	$194.32
21125	T	Augmentation, lower jaw bone	0254	19.11	$971.59	$272.41	$194.32
21127	T	Augmentation, lower jaw bone	0256	28.82	$1,465.27	$623.05	$293.05
21137	T	Reduction of forehead	0254	19.11	$971.59	$272.41	$194.32
21138	T	Reduction of forehead	0256	28.82	$1,465.27	$623.05	$293.05
21139	T	Reduction of forehead	0256	28.82	$1,465.27	$623.05	$293.05
21141	C	Reconstruct midface, lefort					
21142	C	Reconstruct midface, lefort					
21143	C	Reconstruct midface, lefort					
21145	C	Reconstruct midface, lefort					
21146	C	Reconstruct midface, lefort					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
21147	C	Reconstruct midface, lefort					
21150	C	Reconstruct midface, lefort					
21151	C	Reconstruct midface, lefort					
21154	C	Reconstruct midface, lefort					
21155	C	Reconstruct midface, lefort					
21159	C	Reconstruct midface, lefort					
21160	C	Reconstruct midface, lefort					
21172	C	Reconstruct orbit/forehead					
21175	C	Reconstruct orbit/forehead					
21179	C	Reconstruct entire forehead					
21180	C	Reconstruct entire forehead					
21181	T	Contour cranial bone lesion	0254	19.11	$971.59	$272.41	$194.32
21182	C	Reconstruct cranial bone					
21183	C	Reconstruct cranial bone					
21184	C	Reconstruct cranial bone					
21188	C	Reconstruction of midface					
21193	C	Reconst lwr jaw w/o graft					
21194	C	Reconst lwr jaw w/graft					
21195	C	Reconst lwr jaw w/o fixation					
21196	C	Reconst lwr jaw w/fixation					
21198	T	Reconstr lwr jaw segment	0256	28.82	$1,465.27	$623.05	$293.05
21199	T	Reconstr lwr jaw w/advance	0256	28.82	$1,465.27	$623.05	$293.05
21206	T	Reconstruct upper jaw bone	0256	28.82	$1,465.27	$623.05	$293.05
21208	T	Augmentation of facial bones	0256	28.82	$1,465.27	$623.05	$293.05
21209	T	Reduction of facial bones	0256	28.82	$1,465.27	$623.05	$293.05
21210	T	Face bone graft	0256	28.82	$1,465.27	$623.05	$293.05
21215	T	Lower jaw bone graft	0256	28.82	$1,465.27	$623.05	$293.05
21230	T	Rib cartilage graft	0256	28.82	$1,465.27	$623.05	$293.05
21235	T	Ear cartilage graft	0254	19.11	$971.59	$272.41	$194.32
21240	T	Reconstruction of jaw joint	0256	28.82	$1,465.27	$623.05	$293.05
21242	T	Reconstruction of jaw joint	0256	28.82	$1,465.27	$623.05	$293.05
21243	T	Reconstruction of jaw joint	0256	28.82	$1,465.27	$623.05	$293.05
21244	T	Reconstruction of lower jaw	0256	28.82	$1,465.27	$623.05	$293.05
21245	T	Reconstruction of jaw	0256	28.82	$1,465.27	$623.05	$293.05
21246	T	Reconstruction of jaw	0256	28.82	$1,465.27	$623.05	$293.05
21247	C	Reconstruct lower jaw bone					
21248	T	Reconstruction of jaw	0256	28.82	$1,465.27	$623.05	$293.05
21249	T	Reconstruction of jaw	0256	28.82	$1,465.27	$623.05	$293.05
21255	C	Reconstruct lower jaw bone					
21256	C	Reconstruction of orbit					
21260	T	Revise eye sockets	0256	28.82	$1,465.27	$623.05	$293.05
21261	T	Revise eye sockets	0256	28.82	$1,465.27	$623.05	$293.05
21263	T	Revise eye sockets	0256	28.82	$1,465.27	$623.05	$293.05
21267	T	Revise eye sockets	0256	28.82	$1,465.27	$623.05	$293.05
21268	C	Revise eye sockets					
21270	T	Augmentation, cheek bone	0256	28.82	$1,465.27	$623.05	$293.05
21275	T	Revision, orbitofacial bones	0256	28.82	$1,465.27	$623.05	$293.05
21280	T	Revision of eyelid	0256	28.82	$1,465.27	$623.05	$293.05
21282	T	Revision of eyelid	0253	13.27	$674.67	$284.00	$134.93
21295	T	Revision of jaw muscle/bone	0252	6.53	$332.00	$114.24	$66.40
21296	T	Revision of jaw muscle/bone	0254	19.11	$971.59	$272.41	$194.32
21299	T	Cranio/maxillofacial surgery	0253	13.27	$674.67	$284.00	$134.93
21300	T	Treatment of skull fracture	0253	13.27	$674.67	$284.00	$134.93
21310	T	Treatment of nose fracture	0253	13.27	$674.67	$284.00	$134.93
21315	T	Treatment of nose fracture	0253	13.27	$674.67	$284.00	$134.93
21320	T	Treatment of nose fracture	0253	13.27	$674.67	$284.00	$134.93
21325	T	Treatment of nose fracture	0254	19.11	$971.59	$272.41	$194.32
21330	T	Treatment of nose fracture	0254	19.11	$971.59	$272.41	$194.32
21335	T	Treatment of nose fracture	0254	19.11	$971.59	$272.41	$194.32
21336	T	Treat nasal septal fracture	0046	25.36	$1,289.35	$535.76	$257.87
21337	T	Treat nasal septal fracture	0253	13.27	$674.67	$284.00	$134.93
21338	T	Treat nasoethmoid fracture	0254	19.11	$971.59	$272.41	$194.32
21339	T	Treat nasoethmoid fracture	0254	19.11	$971.59	$272.41	$194.32
21340	T	Treatment of nose fracture	0256	28.82	$1,465.27	$623.05	$293.05
21343	C	Treatment of sinus fracture					
21344	C	Treatment of sinus fracture					
21345	T	Treat nose/jaw fracture	0254	19.11	$971.59	$272.41	$194.32
21346	C	Treat nose/jaw fracture					
21347	C	Treat nose/jaw fracture					
21348	C	Treat nose/jaw fracture					
21355	T	Treat cheek bone fracture	0256	28.82	$1,465.27	$623.05	$293.05
21356	C	Treat cheek bone fracture					
21360	C	Treat cheek bone fracture					
21365	C	Treat cheek bone fracture					
21366	C	Treat cheek bone fracture					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
21385	C	Treat eye socket fracture					
21386	C	Treat eye socket fracture					
21387	C	Treat eye socket fracture					
21390	C	Treat eye socket fracture					
21395	C	Treat eye socket fracture					
21400	T	Treat eye socket fracture	0252	6.53	$332.00	$114.24	$66.40
21401	T	Treat eye socket fracture	0253	13.27	$674.67	$284.00	$134.93
21406	T	Treat eye socket fracture	0256	28.82	$1,465.27	$623.05	$293.05
21407	T	Treat eye socket fracture	0256	28.82	$1,465.27	$623.05	$293.05
21408	C	Treat eye socket fracture					
21421	T	Treat mouth roof fracture	0254	19.11	$971.59	$272.41	$194.32
21422	C	Treat mouth roof fracture					
21423	C	Treat mouth roof fracture					
21431	C	Treat craniofacial fracture					
21432	C	Treat craniofacial fracture					
21433	C	Treat craniofacial fracture					
21435	C	Treat craniofacial fracture					
21436	C	Treat craniofacial fracture					
21440	T	Treat dental ridge fracture	0254	19.11	$971.59	$272.41	$194.32
21445	T	Treat dental ridge fracture	0254	19.11	$971.59	$272.41	$194.32
21450	T	Treat lower jaw fracture	0251	2.71	$137.78	$27.99	$27.56
21451	T	Treat lower jaw fracture	0252	6.53	$332.00	$114.24	$66.40
21452	T	Treat lower jaw fracture	0253	13.27	$674.67	$284.00	$134.93
21453	T	Treat lower jaw fracture	0256	28.82	$1,465.27	$623.05	$293.05
21454	T	Treat lower jaw fracture	0254	19.11	$971.59	$272.41	$194.32
21461	T	Treat lower jaw fracture	0256	28.82	$1,465.27	$623.05	$293.05
21462	T	Treat lower jaw fracture	0256	28.82	$1,465.27	$623.05	$293.05
21465	T	Treat lower jaw fracture	0256	28.82	$1,465.27	$623.05	$293.05
21470	T	Treat lower jaw fracture	0256	28.82	$1,465.27	$623.05	$293.05
21480	T	Reset dislocated jaw	0251	2.71	$137.78	$27.99	$27.56
21485	T	Reset dislocated jaw	0253	13.27	$674.67	$284.00	$134.93
21490	T	Repair dislocated jaw	0256	28.82	$1,465.27	$623.05	$293.05
21493	T	Treat hyoid bone fracture	0252	6.53	$332.00	$114.24	$66.40
21494	T	Treat hyoid bone fracture	0252	6.53	$332.00	$114.24	$66.40
21495	C	Treat hyoid bone fracture					
21497	T	Interdental wiring	0253	13.27	$674.67	$284.00	$134.93
21499	T	Head surgery procedure	0253	13.27	$674.67	$284.00	$134.93
21501	T	Drain neck/chest lesion	0008	11.36	$577.57	$115.51	$115.51
21502	T	Drain chest lesion	0049	17.07	$867.87	$356.95	$173.57
21510	C	Drainage of bone lesion					
21550	T	Biopsy of neck/chest	0019	4.56	$231.84	$78.91	$46.37
21555	T	Remove lesion, neck/chest	0022	15.07	$766.19	$292.94	$153.24
21556	T	Remove lesion, neck/chest	0022	15.07	$766.19	$292.94	$153.24
21557	C	Remove tumor, neck/chest					
21600	T	Partial removal of rib	0050	22.31	$1,134.29	$513.86	$226.86
21610	T	Partial removal of rib	0050	22.31	$1,134.29	$513.86	$226.86
21615	C	Removal of rib					
21616	C	Removal of rib and nerves					
21620	C	Partial removal of sternum					
21627	C	Sternal debridement					
21630	C	Extensive sternum surgery					
21632	C	Extensive sternum surgery					
21700	T	Revision of neck muscle	0008	11.36	$577.57	$115.51	$115.51
21705	C	Revision of neck muscle/rib					
21720	T	Revision of neck muscle	0008	11.36	$577.57	$115.51	$115.51
21725	T	Revision of neck muscle	0008	11.36	$577.57	$115.51	$115.51
21740	C	Reconstruction of sternum					
21750	C	Repair of sternum separation					
21800	T	Treatment of rib fracture	0043	4.13	$209.98	$42.00	$42.00
21805	T	Treatment of rib fracture	0046	25.36	$1,289.35	$535.76	$257.87
21810	C	Treatment of rib fracture(s)					
21820	T	Treat sternum fracture	0044	2.73	$138.80	$38.08	$27.76
21825	C	Treat sternum fracture					
21899	T	Neck/chest surgery procedure	0252	6.53	$332.00	$114.24	$66.40
21920	T	Biopsy soft tissue of back	0020	8.56	$435.21	$130.53	$87.04
21925	T	Biopsy soft tissue of back	0022	15.07	$766.19	$292.94	$153.24
21930	T	Remove lesion, back or flank	0022	15.07	$766.19	$292.94	$153.24
21935	T	Remove tumor, back	0022	15.07	$766.19	$292.94	$153.24
22100	C	Remove part of neck vertebra					
22101	C	Remove part, thorax vertebra					
22102	C	Remove part, lumbar vertebra					
22103	C	Remove extra spine segment					
22110	C	Remove part of neck vertebra					
22112	C	Remove part, thorax vertebra					
22114	C	Remove part, lumbar vertebra					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
22116	C	Remove extra spine segment					
22210	C	Revision of neck spine					
22212	C	Revision of thorax spine					
22214	C	Revision of lumbar spine					
22216	C	Revise, extra spine segment					
22220	C	Revision of neck spine					
22222	C	Revision of thorax spine					
22224	C	Revision of lumbar spine					
22226	C	Revise, extra spine segment					
22305	T	Treat spine process fracture	0043	4.13	$209.98	$42.00	$42.00
22310	T	Treat spine fracture	0043	4.13	$209.98	$42.00	$42.00
22315	T	Treat spine fracture	0043	4.13	$209.98	$42.00	$42.00
22318	C	Treat odontoid fx w/o graft					
22319	C	Treat odontoid fx w/graft					
22325	C	Treat spine fracture					
22326	C	Treat neck spine fracture					
22327	C	Treat thorax spine fracture					
22328	C	Treat each add spine fx					
22505	T	Manipulation of spine	0045	12.91	$656.37	$277.12	$131.27
22520	T	Percut vertebroplasty thor	0050	22.31	$1,134.29	$513.86	$226.86
22521	T	Percut vertebroplasty lumb	0050	22.31	$1,134.29	$513.86	$226.86
22522	T	Percut vertebroplasty addl	0050	22.31	$1,134.29	$513.86	$226.86
22548	C	Neck spine fusion					
22554	C	Neck spine fusion					
22556	C	Thorax spine fusion					
22558	C	Lumbar spine fusion					
22585	C	Additional spinal fusion					
22590	C	Spine & skull spinal fusion					
22595	C	Neck spinal fusion					
22600	C	Neck spine fusion					
22610	C	Thorax spine fusion					
22612	C	Lumbar spine fusion					
22614	C	Spine fusion, extra segment					
22630	C	Lumbar spine fusion					
22632	C	Spine fusion, extra segment					
22800	C	Fusion of spine					
22802	C	Fusion of spine					
22804	C	Fusion of spine					
22808	C	Fusion of spine					
22810	C	Fusion of spine					
22812	C	Fusion of spine					
22818	C	Kyphectomy, 1-2 segments					
22819	C	Kyphectomy, 3 or more					
22830	C	Exploration of spinal fusion					
22840	C	Insert spine fixation device					
22841	C	Insert spine fixation device					
22842	C	Insert spine fixation device					
22843	C	Insert spine fixation device					
22844	C	Insert spine fixation device					
22845	C	Insert spine fixation device					
22846	C	Insert spine fixation device					
22847	C	Insert spine fixation device					
22848	C	Insert pelv fixation device					
22849	C	Reinsert spinal fixation					
22850	C	Remove spine fixation device					
22851	C	Apply spine prosth device					
22852	C	Remove spine fixation device					
22855	C	Remove spine fixation device					
22899	T	Spine surgery procedure	0043	4.13	$209.98	$42.00	$42.00
22900	T	Remove abdominal wall lesion	0022	15.07	$766.19	$292.94	$153.24
22999	T	Abdomen surgery procedure	0022	15.07	$766.19	$292.94	$153.24
23000	T	Removal of calcium deposits	0021	12.74	$647.73	$236.51	$129.55
23020	T	Release shoulder joint	0051	30.94	$1,573.05	$675.24	$314.61
23030	T	Drain shoulder lesion	0008	11.36	$577.57	$115.51	$115.51
23031	T	Drain shoulder bursa	0008	11.36	$577.57	$115.51	$115.51
23035	C	Drain shoulder bone lesion					
23040	T	Exploratory shoulder surgery	0050	22.31	$1,134.29	$513.86	$226.86
23044	T	Exploratory shoulder surgery	0050	22.31	$1,134.29	$513.86	$226.86
23065	T	Biopsy shoulder tissues	0021	12.74	$647.73	$236.51	$129.55
23066	T	Biopsy shoulder tissues	0022	15.07	$766.19	$292.94	$153.24
23075	T	Removal of shoulder lesion	0021	12.74	$647.73	$236.51	$129.55
23076	T	Removal of shoulder lesion	0022	15.07	$766.19	$292.94	$153.24
23077	T	Remove tumor of shoulder	0022	15.07	$766.19	$292.94	$153.24
23100	T	Biopsy of shoulder joint	0049	17.07	$867.87	$356.95	$173.57
23101	T	Shoulder joint surgery	0050	22.31	$1,134.29	$513.86	$226.86

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
23105	T	Remove shoulder joint lining	0050	22.31	$1,134.29	$513.86	$226.86
23106	T	Incision of collarbone joint	0050	22.31	$1,134.29	$513.86	$226.86
23107	T	Explore treat shoulder joint	0050	22.31	$1,134.29	$513.86	$226.86
23120	T	Partial removal, collar bone	0051	30.94	$1,573.05	$675.24	$314.61
23125	C	Removal of collar bone					
23130	T	Remove shoulder bone, part	0051	30.94	$1,573.05	$675.24	$314.61
23140	T	Removal of bone lesion	0049	17.07	$867.87	$356.95	$173.57
23145	T	Removal of bone lesion	0050	22.31	$1,134.29	$513.86	$226.86
23146	T	Removal of bone lesion	0050	22.31	$1,134.29	$513.86	$226.86
23150	T	Removal of humerus lesion	0050	22.31	$1,134.29	$513.86	$226.86
23155	T	Removal of humerus lesion	0050	22.31	$1,134.29	$513.86	$226.86
23156	T	Removal of humerus lesion	0050	22.31	$1,134.29	$513.86	$226.86
23170	T	Remove collar bone lesion	0050	22.31	$1,134.29	$513.86	$226.86
23172	T	Remove shoulder blade lesion	0050	22.31	$1,134.29	$513.86	$226.86
23174	T	Remove humerus lesion	0050	22.31	$1,134.29	$513.86	$226.86
23180	T	Remove collar bone lesion	0050	22.31	$1,134.29	$513.86	$226.86
23182	T	Remove shoulder blade lesion	0050	22.31	$1,134.29	$513.86	$226.86
23184	T	Remove humerus lesion	0050	22.31	$1,134.29	$513.86	$226.86
23190	T	Partial removal of scapula	0050	22.31	$1,134.29	$513.86	$226.86
23195	C	Removal of head of humerus					
23200	C	Removal of collar bone					
23210	C	Removal of shoulder blade					
23220	C	Partial removal of humerus					
23221	C	Partial removal of humerus					
23222	C	Partial removal of humerus					
23330	T	Remove shoulder foreign body	0019	4.56	$231.84	$78.91	$46.37
23331	T	Remove shoulder foreign body	0022	15.07	$766.19	$292.94	$153.24
23332	C	Remove shoulder foreign body					
23350	N	Injection for shoulder x-ray					
23395	C	Muscle transfer,shoulder/arm					
23397	C	Muscle transfers					
23400	C	Fixation of shoulder blade					
23405	T	Incision of tendon & muscle	0050	22.31	$1,134.29	$513.86	$226.86
23406	T	Incise tendon(s) & muscle(s)	0050	22.31	$1,134.29	$513.86	$226.86
23410	T	Repair of tendon(s)	0052	38.88	$1,976.74	$930.91	$395.35
23412	T	Repair of tendon(s)	0052	38.88	$1,976.74	$930.91	$395.35
23415	T	Release of shoulder ligament	0051	30.94	$1,573.05	$675.24	$314.61
23420	T	Repair of shoulder	0052	38.88	$1,976.74	$930.91	$395.35
23430	T	Repair biceps tendon	0052	38.88	$1,976.74	$930.91	$395.35
23440	C	Remove/transplant tendon					
23450	T	Repair shoulder capsule	0052	38.88	$1,976.74	$930.91	$395.35
23455	T	Repair shoulder capsule	0052	38.88	$1,976.74	$930.91	$395.35
23460	T	Repair shoulder capsule	0052	38.88	$1,976.74	$930.91	$395.35
23462	T	Repair shoulder capsule	0052	38.88	$1,976.74	$930.91	$395.35
23465	T	Repair shoulder capsule	0052	38.88	$1,976.74	$930.91	$395.35
23466	T	Repair shoulder capsule	0052	38.88	$1,976.74	$930.91	$395.35
23470	C	Reconstruct shoulder joint					
23472	C	Reconstruct shoulder joint					
23480	T	Revision of collar bone	0051	30.94	$1,573.05	$675.24	$314.61
23485	T	Revision of collar bone	0051	30.94	$1,573.05	$675.24	$314.61
23490	T	Reinforce clavicle	0051	30.94	$1,573.05	$675.24	$314.61
23491	T	Reinforce shoulder bones	0051	30.94	$1,573.05	$675.24	$314.61
23500	T	Treat clavicle fracture	0043	4.13	$209.98	$42.00	$42.00
23505	T	Treat clavicle fracture	0043	4.13	$209.98	$42.00	$42.00
23515	T	Treat clavicle fracture	0046	25.36	$1,289.35	$535.76	$257.87
23520	T	Treat clavicle dislocation	0044	2.73	$138.80	$38.08	$27.76
23525	T	Treat clavicle dislocation	0043	4.13	$209.98	$42.00	$42.00
23530	T	Treat clavicle dislocation	0046	25.36	$1,289.35	$535.76	$257.87
23532	T	Treat clavicle dislocation	0046	25.36	$1,289.35	$535.76	$257.87
23540	T	Treat clavicle dislocation	0044	2.73	$138.80	$38.08	$27.76
23545	T	Treat clavicle dislocation	0043	4.13	$209.98	$42.00	$42.00
23550	T	Treat clavicle dislocation	0046	25.36	$1,289.35	$535.76	$257.87
23552	T	Treat clavicle dislocation	0046	25.36	$1,289.35	$535.76	$257.87
23570	T	Treat shoulder blade fx	0043	4.13	$209.98	$42.00	$42.00
23575	T	Treat shoulder blade fx	0044	2.73	$138.80	$38.08	$27.76
23585	T	Treat scapula fracture	0046	25.36	$1,289.35	$535.76	$257.87
23600	T	Treat humerus fracture	0044	2.73	$138.80	$38.08	$27.76
23605	T	Treat humerus fracture	0044	2.73	$138.80	$38.08	$27.76
23615	T	Treat humerus fracture	0046	25.36	$1,289.35	$535.76	$257.87
23616	T	Treat humerus fracture	0046	25.36	$1,289.35	$535.76	$257.87
23620	T	Treat humerus fracture	0044	2.73	$138.80	$38.08	$27.76
23625	T	Treat humerus fracture	0044	2.73	$138.80	$38.08	$27.76
23630	T	Treat humerus fracture	0046	25.36	$1,289.35	$535.76	$257.87
23650	T	Treat shoulder dislocation	0043	4.13	$209.98	$42.00	$42.00
23655	T	Treat shoulder dislocation	0045	12.91	$656.37	$277.12	$131.27

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
23660	T	Treat shoulder dislocation	0046	25.36	$1,289.35	$535.76	$257.87
23665	T	Treat dislocation/fracture	0044	2.73	$138.80	$38.08	$27.76
23670	T	Treat dislocation/fracture	0046	25.36	$1,289.35	$535.76	$257.87
23675	T	Treat dislocation/fracture	0044	2.73	$138.80	$38.08	$27.76
23680	T	Treat dislocation/fracture	0046	25.36	$1,289.35	$535.76	$257.87
23700	T	Fixation of shoulder	0045	12.91	$656.37	$277.12	$131.27
23800	T	Fusion of shoulder joint	0051	30.94	$1,573.05	$675.24	$314.61
23802	T	Fusion of shoulder joint	0051	30.94	$1,573.05	$675.24	$314.61
23900	C	Amputation of arm & girdle					
23920	C	Amputation at shoulder joint					
23921	T	Amputation follow-up surgery	0026	13.51	$686.88	$277.92	$137.38
23929	T	Shoulder surgery procedure	0043	4.13	$209.98	$42.00	$42.00
23930	T	Drainage of arm lesion	0008	11.36	$577.57	$115.51	$115.51
23931	T	Drainage of arm bursa	0008	11.36	$577.57	$115.51	$115.51
23935	T	Drain arm/elbow bone lesion	0049	17.07	$867.87	$356.95	$173.57
24000	T	Exploratory elbow surgery	0050	22.31	$1,134.29	$513.86	$226.86
24006	T	Release elbow joint	0050	22.31	$1,134.29	$513.86	$226.86
24065	T	Biopsy arm/elbow soft tissue	0020	8.56	$435.21	$130.53	$87.04
24066	T	Biopsy arm/elbow soft tissue	0021	12.74	$647.73	$236.51	$129.55
24075	T	Remove arm/elbow lesion	0021	12.74	$647.73	$236.51	$129.55
24076	T	Remove arm/elbow lesion	0022	15.07	$766.19	$292.94	$153.24
24077	T	Remove tumor of arm/elbow	0022	15.07	$766.19	$292.94	$153.24
24100	T	Biopsy elbow joint lining	0049	17.07	$867.87	$356.95	$173.57
24101	T	Explore/treat elbow joint	0050	22.31	$1,134.29	$513.86	$226.86
24102	T	Remove elbow joint lining	0050	22.31	$1,134.29	$513.86	$226.86
24105	T	Removal of elbow bursa	0049	17.07	$867.87	$356.95	$173.57
24110	T	Remove humerus lesion	0049	17.07	$867.87	$356.95	$173.57
24115	T	Remove/graft bone lesion	0050	22.31	$1,134.29	$513.86	$226.86
24116	T	Remove/graft bone lesion	0050	22.31	$1,134.29	$513.86	$226.86
24120	T	Remove elbow lesion	0049	17.07	$867.87	$356.95	$173.57
24125	T	Remove/graft bone lesion	0050	22.31	$1,134.29	$513.86	$226.86
24126	T	Remove/graft bone lesion	0050	22.31	$1,134.29	$513.86	$226.86
24130	T	Removal of head of radius	0050	22.31	$1,134.29	$513.86	$226.86
24134	T	Removal of arm bone lesion	0050	22.31	$1,134.29	$513.86	$226.86
24136	T	Remove radius bone lesion	0050	22.31	$1,134.29	$513.86	$226.86
24138	T	Remove elbow bone lesion	0050	22.31	$1,134.29	$513.86	$226.86
24140	T	Partial removal of arm bone	0050	22.31	$1,134.29	$513.86	$226.86
24145	T	Partial removal of radius	0050	22.31	$1,134.29	$513.86	$226.86
24147	T	Partial removal of elbow	0050	22.31	$1,134.29	$513.86	$226.86
24149	C	Radical resection of elbow					
24150	C	Extensive humerus surgery					
24151	C	Extensive humerus surgery					
24152	C	Extensive radius surgery					
24153	C	Extensive radius surgery					
24155	T	Removal of elbow joint	0051	30.94	$1,573.05	$675.24	$314.61
24160	T	Remove elbow joint implant	0050	22.31	$1,134.29	$513.86	$226.86
24164	T	Remove radius head implant	0050	22.31	$1,134.29	$513.86	$226.86
24200	T	Removal of arm foreign body	0019	4.56	$231.84	$78.91	$46.37
24201	T	Removal of arm foreign body	0021	12.74	$647.73	$236.51	$129.55
24220	N	Injection for elbow x-ray					
24301	T	Muscle/tendon transfer	0050	22.31	$1,134.29	$513.86	$226.86
24305	T	Arm tendon lengthening	0050	22.31	$1,134.29	$513.86	$226.86
24310	T	Revision of arm tendon	0049	17.07	$867.87	$356.95	$173.57
24320	T	Repair of arm tendon	0051	30.94	$1,573.05	$675.24	$314.61
24330	T	Revision of arm muscles	0051	30.94	$1,573.05	$675.24	$314.61
24331	T	Revision of arm muscles	0051	30.94	$1,573.05	$675.24	$314.61
24340	T	Repair of biceps tendon	0051	30.94	$1,573.05	$675.24	$314.61
24341	T	Repair arm tendon/muscle	0051	30.94	$1,573.05	$675.24	$314.61
24342	T	Repair of ruptured tendon	0051	30.94	$1,573.05	$675.24	$314.61
24350	T	Repair of tennis elbow	0050	22.31	$1,134.29	$513.86	$226.86
24351	T	Repair of tennis elbow	0050	22.31	$1,134.29	$513.86	$226.86
24352	T	Repair of tennis elbow	0050	22.31	$1,134.29	$513.86	$226.86
24354	T	Repair of tennis elbow	0050	22.31	$1,134.29	$513.86	$226.86
24356	T	Revision of tennis elbow	0050	22.31	$1,134.29	$513.86	$226.86
24360	T	Reconstruct elbow joint	0047	28.54	$1,451.03	$537.03	$290.21
24361	T	Reconstruct elbow joint	0048	32.37	$1,645.76	$725.94	$329.15
24362	T	Reconstruct elbow joint	0048	32.37	$1,645.76	$725.94	$329.15
24363	T	Replace elbow joint	0048	32.37	$1,645.76	$725.94	$329.15
24365	T	Reconstruct head of radius	0047	28.54	$1,451.03	$537.03	$290.21
24366	T	Reconstruct head of radius	0048	32.37	$1,645.76	$725.94	$329.15
24400	T	Revision of humerus	0050	22.31	$1,134.29	$513.86	$226.86
24410	T	Revision of humerus	0050	22.31	$1,134.29	$513.86	$226.86
24420	T	Revision of humerus	0051	30.94	$1,573.05	$675.24	$314.61
24430	T	Repair of humerus	0051	30.94	$1,573.05	$675.24	$314.61
24435	T	Repair humerus with graft	0051	30.94	$1,573.05	$675.24	$314.61

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
24470	T	Revision of elbow joint	0051	30.94	$1,573.05	$675.24	$314.61
24495	T	Decompression of forearm	0050	22.31	$1,134.29	$513.86	$226.86
24498	T	Reinforce humerus	0051	30.94	$1,573.05	$675.24	$314.61
24500	T	Treat humerus fracture	0044	2.73	$138.80	$38.08	$27.76
24505	T	Treat humerus fracture	0044	2.73	$138.80	$38.08	$27.76
24515	T	Treat humerus fracture	0046	25.36	$1,289.35	$535.76	$257.87
24516	T	Treat humerus fracture	0046	25.36	$1,289.35	$535.76	$257.87
24530	T	Treat humerus fracture	0044	2.73	$138.80	$38.08	$27.76
24535	T	Treat humerus fracture	0044	2.73	$138.80	$38.08	$27.76
24538	T	Treat humerus fracture	0046	25.36	$1,289.35	$535.76	$257.87
24545	T	Treat humerus fracture	0046	25.36	$1,289.35	$535.76	$257.87
24546	T	Treat humerus fracture	0046	25.36	$1,289.35	$535.76	$257.87
24560	T	Treat humerus fracture	0044	2.73	$138.80	$38.08	$27.76
24565	T	Treat humerus fracture	0044	2.73	$138.80	$38.08	$27.76
24566	T	Treat humerus fracture	0046	25.36	$1,289.35	$535.76	$257.87
24575	T	Treat humerus fracture	0046	25.36	$1,289.35	$535.76	$257.87
24576	T	Treat humerus fracture	0044	2.73	$138.80	$38.08	$27.76
24577	T	Treat humerus fracture	0044	2.73	$138.80	$38.08	$27.76
24579	T	Treat humerus fracture	0046	25.36	$1,289.35	$535.76	$257.87
24582	T	Treat humerus fracture	0046	25.36	$1,289.35	$535.76	$257.87
24586	T	Treat elbow fracture	0046	25.36	$1,289.35	$535.76	$257.87
24587	T	Treat elbow fracture	0046	25.36	$1,289.35	$535.76	$257.87
24600	T	Treat elbow dislocation	0044	2.73	$138.80	$38.08	$27.76
24605	T	Treat elbow dislocation	0045	12.91	$656.37	$277.12	$131.27
24615	T	Treat elbow dislocation	0046	25.36	$1,289.35	$535.76	$257.87
24620	T	Treat elbow fracture	0044	2.73	$138.80	$38.08	$27.76
24635	T	Treat elbow fracture	0046	25.36	$1,289.35	$535.76	$257.87
24640	T	Treat elbow dislocation	0044	2.73	$138.80	$38.08	$27.76
24650	T	Treat radius fracture	0044	2.73	$138.80	$38.08	$27.76
24655	T	Treat radius fracture	0044	2.73	$138.80	$38.08	$27.76
24665	T	Treat radius fracture	0046	25.36	$1,289.35	$535.76	$257.87
24666	T	Treat radius fracture	0046	25.36	$1,289.35	$535.76	$257.87
24670	T	Treat ulnar fracture	0044	2.73	$138.80	$38.08	$27.76
24675	T	Treat ulnar fracture	0044	2.73	$138.80	$38.08	$27.76
24685	T	Treat ulnar fracture	0046	25.36	$1,289.35	$535.76	$257.87
24800	T	Fusion of elbow joint	0051	30.94	$1,573.05	$675.24	$314.61
24802	T	Fusion/graft of elbow joint	0051	30.94	$1,573.05	$675.24	$314.61
24900	C	Amputation of upper arm	.....	.....	.....	.....	.....
24920	C	Amputation of upper arm	.....	.....	.....	.....	.....
24925	T	Amputation follow-up surgery	0049	17.07	$867.87	$356.95	$173.57
24930	C	Amputation follow-up surgery	.....	.....	.....	.....	.....
24931	C	Amputate upper arm & implant	.....	.....	.....	.....	.....
24935	T	Revision of amputation	0052	38.88	$1,976.74	$930.91	$395.35
24940	C	Revision of upper arm	.....	.....	.....	.....	.....
24999	T	Upper arm/elbow surgery	0044	2.73	$138.80	$38.08	$27.76
25000	T	Incision of tendon sheath	0049	17.07	$867.87	$356.95	$173.57
25020	T	Decompression of forearm	0049	17.07	$867.87	$356.95	$173.57
25023	T	Decompression of forearm	0050	22.31	$1,134.29	$513.86	$226.86
25028	T	Drainage of forearm lesion	0049	17.07	$867.87	$356.95	$173.57
25031	T	Drainage of forearm bursa	0049	17.07	$867.87	$356.95	$173.57
25035	T	Treat forearm bone lesion	0049	17.07	$867.87	$356.95	$173.57
25040	T	Explore/treat wrist joint	0050	22.31	$1,134.29	$513.86	$226.86
25065	T	Biopsy forearm soft tissues	0021	12.74	$647.73	$236.51	$129.55
25066	T	Biopsy forearm soft tissues	0022	15.07	$766.19	$292.94	$153.24
25075	T	Removal of forearm lesion	0020	8.56	$435.21	$130.53	$87.04
25076	T	Removal of forearm lesion	0022	15.07	$766.19	$292.94	$153.24
25077	T	Remove tumor, forearm/wrist	0022	15.07	$766.19	$292.94	$153.24
25085	T	Incision of wrist capsule	0049	17.07	$867.87	$356.95	$173.57
25100	T	Biopsy of wrist joint	0049	17.07	$867.87	$356.95	$173.57
25101	T	Explore/treat wrist joint	0050	22.31	$1,134.29	$513.86	$226.86
25105	T	Remove wrist joint lining	0050	22.31	$1,134.29	$513.86	$226.86
25107	T	Remove wrist joint cartilage	0050	22.31	$1,134.29	$513.86	$226.86
25110	T	Remove wrist tendon lesion	0049	17.07	$867.87	$356.95	$173.57
25111	T	Remove wrist tendon lesion	0053	12.67	$644.17	$253.49	$128.83
25112	T	Reremove wrist tendon lesion	0053	12.67	$644.17	$253.49	$128.83
25115	T	Remove wrist/forearm lesion	0049	17.07	$867.87	$356.95	$173.57
25116	T	Remove wrist/forearm lesion	0049	17.07	$867.87	$356.95	$173.57
25118	T	Excise wrist tendon sheath	0050	22.31	$1,134.29	$513.86	$226.86
25119	T	Partial removal of ulna	0050	22.31	$1,134.29	$513.86	$226.86
25120	T	Removal of forearm lesion	0050	22.31	$1,134.29	$513.86	$226.86
25125	T	Remove/graft forearm lesion	0050	22.31	$1,134.29	$513.86	$226.86
25126	T	Remove/graft forearm lesion	0050	22.31	$1,134.29	$513.86	$226.86
25130	T	Removal of wrist lesion	0050	22.31	$1,134.29	$513.86	$226.86
25135	T	Remove & graft wrist lesion	0050	22.31	$1,134.29	$513.86	$226.86
25136	T	Remove & graft wrist lesion	0050	22.31	$1,134.29	$513.86	$226.86

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
25145	T	Remove forearm bone lesion	0050	22.31	$1,134.29	$513.86	$226.86
25150	T	Partial removal of ulna	0050	22.31	$1,134.29	$513.86	$226.86
25151	T	Partial removal of radius	0050	22.31	$1,134.29	$513.86	$226.86
25170	C	Extensive forearm surgery	.....	.....	.....	.....	.....
25210	T	Removal of wrist bone	0054	20.84	$1,059.55	$472.33	$211.91
25215	T	Removal of wrist bones	0054	20.84	$1,059.55	$472.33	$211.91
25230	T	Partial removal of radius	0050	22.31	$1,134.29	$513.86	$226.86
25240	T	Partial removal of ulna	0050	22.31	$1,134.29	$513.86	$226.86
25246	N	Injection for wrist x-ray	.....	.....	.....	.....	.....
25248	T	Remove forearm foreign body	0049	17.07	$867.87	$356.95	$173.57
25250	T	Removal of wrist prosthesis	0050	22.31	$1,134.29	$513.86	$226.86
25251	T	Removal of wrist prosthesis	0050	22.31	$1,134.29	$513.86	$226.86
25260	T	Repair forearm tendon/muscle	0050	22.31	$1,134.29	$513.86	$226.86
25263	T	Repair forearm tendon/muscle	0050	22.31	$1,134.29	$513.86	$226.86
25265	T	Repair forearm tendon/muscle	0050	22.31	$1,134.29	$513.86	$226.86
25270	T	Repair forearm tendon/muscle	0050	22.31	$1,134.29	$513.86	$226.86
25272	T	Repair forearm tendon/muscle	0050	22.31	$1,134.29	$513.86	$226.86
25274	T	Repair forearm tendon/muscle	0050	22.31	$1,134.29	$513.86	$226.86
25280	T	Revise wrist/forearm tendon	0050	22.31	$1,134.29	$513.86	$226.86
25290	T	Incise wrist/forearm tendon	0050	22.31	$1,134.29	$513.86	$226.86
25295	T	Release wrist/forearm tendon	0049	17.07	$867.87	$356.95	$173.57
25300	T	Fusion of tendons at wrist	0050	22.31	$1,134.29	$513.86	$226.86
25301	T	Fusion of tendons at wrist	0050	22.31	$1,134.29	$513.86	$226.86
25310	T	Transplant forearm tendon	0051	30.94	$1,573.05	$675.24	$314.61
25312	T	Transplant forearm tendon	0051	30.94	$1,573.05	$675.24	$314.61
25315	T	Revise palsy hand tendon(s)	0051	30.94	$1,573.05	$675.24	$314.61
25316	T	Revise palsy hand tendon(s)	0051	30.94	$1,573.05	$675.24	$314.61
25320	T	Repair/revise wrist joint	0051	30.94	$1,573.05	$675.24	$314.61
25332	T	Revise wrist joint	0047	28.54	$1,451.03	$537.03	$290.21
25335	T	Realignment of hand	0051	30.94	$1,573.05	$675.24	$314.61
25337	T	Reconstruct ulna/radioulnar	0051	30.94	$1,573.05	$675.24	$314.61
25350	T	Revision of radius	0051	30.94	$1,573.05	$675.24	$314.61
25355	T	Revision of radius	0051	30.94	$1,573.05	$675.24	$314.61
25360	T	Revision of ulna	0050	22.31	$1,134.29	$513.86	$226.86
25365	T	Revise radius & ulna	0050	22.31	$1,134.29	$513.86	$226.86
25370	T	Revise radius or ulna	0051	30.94	$1,573.05	$675.24	$314.61
25375	T	Revise radius & ulna	0051	30.94	$1,573.05	$675.24	$314.61
25390	C	Shorten radius or ulna	.....	.....	.....	.....	.....
25391	C	Lengthen radius or ulna	.....	.....	.....	.....	.....
25392	C	Shorten radius & ulna	.....	.....	.....	.....	.....
25393	C	Lengthen radius & ulna	.....	.....	.....	.....	.....
25400	T	Repair radius or ulna	0050	22.31	$1,134.29	$513.86	$226.86
25405	T	Repair/graft radius or ulna	0050	22.31	$1,134.29	$513.86	$226.86
25415	T	Repair radius & ulna	0050	22.31	$1,134.29	$513.86	$226.86
25420	C	Repair/graft radius & ulna	.....	.....	.....	.....	.....
25425	T	Repair/graft radius or ulna	0051	30.94	$1,573.05	$675.24	$314.61
25426	T	Repair/graft radius & ulna	0051	30.94	$1,573.05	$675.24	$314.61
25440	T	Repair/graft wrist bone	0051	30.94	$1,573.05	$675.24	$314.61
25441	T	Reconstruct wrist joint	0048	32.37	$1,645.76	$725.94	$329.15
25442	T	Reconstruct wrist joint	0048	32.37	$1,645.76	$725.94	$329.15
25443	T	Reconstruct wrist joint	0048	32.37	$1,645.76	$725.94	$329.15
25444	T	Reconstruct wrist joint	0048	32.37	$1,645.76	$725.94	$329.15
25445	T	Reconstruct wrist joint	0048	32.37	$1,645.76	$725.94	$329.15
25446	T	Wrist replacement	0048	32.37	$1,645.76	$725.94	$329.15
25447	T	Repair wrist joint(s)	0047	28.54	$1,451.03	$537.03	$290.21
25449	T	Remove wrist joint implant	0047	28.54	$1,451.03	$537.03	$290.21
25450	T	Revision of wrist joint	0051	30.94	$1,573.05	$675.24	$314.61
25455	T	Revision of wrist joint	0051	30.94	$1,573.05	$675.24	$314.61
25490	T	Reinforce radius	0051	30.94	$1,573.05	$675.24	$314.61
25491	T	Reinforce ulna	0051	30.94	$1,573.05	$675.24	$314.61
25492	T	Reinforce radius and ulna	0051	30.94	$1,573.05	$675.24	$314.61
25500	T	Treat fracture of radius	0044	2.73	$138.80	$38.08	$27.76
25505	T	Treat fracture of radius	0044	2.73	$138.80	$38.08	$27.76
25515	T	Treat fracture of radius	0046	25.36	$1,289.35	$535.76	$257.87
25520	T	Treat fracture of radius	0044	2.73	$138.80	$38.08	$27.76
25525	T	Treat fracture of radius	0046	25.36	$1,289.35	$535.76	$257.87
25526	T	Treat fracture of radius	0046	25.36	$1,289.35	$535.76	$257.87
25530	T	Treat fracture of ulna	0044	2.73	$138.80	$38.08	$27.76
25535	T	Treat fracture of ulna	0044	2.73	$138.80	$38.08	$27.76
25545	T	Treat fracture of ulna	0046	25.36	$1,289.35	$535.76	$257.87
25560	T	Treat fracture radius & ulna	0044	2.73	$138.80	$38.08	$27.76
25565	T	Treat fracture radius & ulna	0044	2.73	$138.80	$38.08	$27.76
25574	T	Treat fracture radius & ulna	0046	25.36	$1,289.35	$535.76	$257.87
25575	T	Treat fracture radius/ulna	0046	25.36	$1,289.35	$535.76	$257.87
25600	T	Treat fracture radius/ulna	0044	2.73	$138.80	$38.08	$27.76

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
25605	T	Treat fracture radius/ulna	0044	2.73	$138.80	$38.08	$27.76
25611	T	Treat fracture radius/ulna	0046	25.36	$1,289.35	$535.76	$257.87
25620	T	Treat fracture radius/ulna	0046	25.36	$1,289.35	$535.76	$257.87
25622	T	Treat wrist bone fracture	0044	2.73	$138.80	$38.08	$27.76
25624	T	Treat wrist bone fracture	0044	2.73	$138.80	$38.08	$27.76
25628	T	Treat wrist bone fracture	0046	25.36	$1,289.35	$535.76	$257.87
25630	T	Treat wrist bone fracture	0044	2.73	$138.80	$38.08	$27.76
25635	T	Treat wrist bone fracture	0044	2.73	$138.80	$38.08	$27.76
25645	T	Treat wrist bone fracture	0046	25.36	$1,289.35	$535.76	$257.87
25650	T	Treat wrist bone fracture	0044	2.73	$138.80	$38.08	$27.76
25660	T	Treat wrist dislocation	0044	2.73	$138.80	$38.08	$27.76
25670	T	Treat wrist dislocation	0046	25.36	$1,289.35	$535.76	$257.87
25675	T	Treat wrist dislocation	0044	2.73	$138.80	$38.08	$27.76
25676	T	Treat wrist dislocation	0046	25.36	$1,289.35	$535.76	$257.87
25680	T	Treat wrist fracture	0044	2.73	$138.80	$38.08	$27.76
25685	T	Treat wrist fracture	0046	25.36	$1,289.35	$535.76	$257.87
25690	T	Treat wrist dislocation	0044	2.73	$138.80	$38.08	$27.76
25695	T	Treat wrist dislocation	0046	25.36	$1,289.35	$535.76	$257.87
25800	T	Fusion of wrist joint	0051	30.94	$1,573.05	$675.24	$314.61
25805	T	Fusion/graft of wrist joint	0051	30.94	$1,573.05	$675.24	$314.61
25810	T	Fusion/graft of wrist joint	0051	30.94	$1,573.05	$675.24	$314.61
25820	T	Fusion of hand bones	0053	12.67	$644.17	$253.49	$128.83
25825	T	Fuse hand bones with graft	0054	20.84	$1,059.55	$472.33	$211.91
25830	T	Fusion, radioulnar jnt/ulna	0051	30.94	$1,573.05	$675.24	$314.61
25900	C	Amputation of forearm					
25905	C	Amputation of forearm					
25907	T	Amputation follow-up surgery	0049	17.07	$867.87	$356.95	$173.57
25909	C	Amputation follow-up surgery					
25915	C	Amputation of forearm					
25920	C	Amputate hand at wrist					
25922	T	Amputate hand at wrist	0049	17.07	$867.87	$356.95	$173.57
25924	C	Amputation follow-up surgery					
25927	C	Amputation of hand					
25929	T	Amputation follow-up surgery	0026	13.51	$686.88	$277.92	$137.38
25931	C	Amputation follow-up surgery					
25999	T	Forearm or wrist surgery	0044	2.73	$138.80	$38.08	$27.76
26010	T	Drainage of finger abscess	0006	2.36	$119.99	$33.95	$24.00
26011	T	Drainage of finger abscess	0007	7.28	$370.13	$74.03	$74.03
26020	T	Drain hand tendon sheath	0053	12.67	$644.17	$253.49	$128.83
26025	T	Drainage of palm bursa	0053	12.67	$644.17	$253.49	$128.83
26030	T	Drainage of palm bursa(s)	0053	12.67	$644.17	$253.49	$128.83
26034	T	Treat hand bone lesion	0053	12.67	$644.17	$253.49	$128.83
26035	T	Decompress fingers/hand	0053	12.67	$644.17	$253.49	$128.83
26037	T	Decompress fingers/hand	0053	12.67	$644.17	$253.49	$128.83
26040	T	Release palm contracture	0054	20.84	$1,059.55	$472.33	$211.91
26045	T	Release palm contracture	0054	20.84	$1,059.55	$472.33	$211.91
26055	T	Incise finger tendon sheath	0053	12.67	$644.17	$253.49	$128.83
26060	T	Incision of finger tendon	0053	12.67	$644.17	$253.49	$128.83
26070	T	Explore/treat hand joint	0053	12.67	$644.17	$253.49	$128.83
26075	T	Explore/treat finger joint	0053	12.67	$644.17	$253.49	$128.83
26080	T	Explore/treat finger joint	0053	12.67	$644.17	$253.49	$128.83
26100	T	Biopsy hand joint lining	0053	12.67	$644.17	$253.49	$128.83
26105	T	Biopsy finger joint lining	0053	12.67	$644.17	$253.49	$128.83
26110	T	Biopsy finger joint lining	0053	12.67	$644.17	$253.49	$128.83
26115	T	Removal of hand lesion	0022	15.07	$766.19	$292.94	$153.24
26116	T	Removal of hand lesion	0022	15.07	$766.19	$292.94	$153.24
26117	T	Remove tumor, hand/finger	0022	15.07	$766.19	$292.94	$153.24
26121	T	Release palm contracture	0054	20.84	$1,059.55	$472.33	$211.91
26123	T	Release palm contracture	0054	20.84	$1,059.55	$472.33	$211.91
26125	T	Release palm contracture	0054	20.84	$1,059.55	$472.33	$211.91
26130	T	Remove wrist joint lining	0053	12.67	$644.17	$253.49	$128.83
26135	T	Revise finger joint, each	0054	20.84	$1,059.55	$472.33	$211.91
26140	T	Revise finger joint, each	0053	12.67	$644.17	$253.49	$128.83
26145	T	Tendon excision, palm/finger	0053	12.67	$644.17	$253.49	$128.83
26160	T	Remove tendon sheath lesion	0053	12.67	$644.17	$253.49	$128.83
26170	T	Removal of palm tendon, each	0053	12.67	$644.17	$253.49	$128.83
26180	T	Removal of finger tendon	0053	12.67	$644.17	$253.49	$128.83
26185	T	Remove finger bone	0053	12.67	$644.17	$253.49	$128.83
26200	T	Remove hand bone lesion	0053	12.67	$644.17	$253.49	$128.83
26205	T	Remove/graft bone lesion	0054	20.84	$1,059.55	$472.33	$211.91
26210	T	Removal of finger lesion	0053	12.67	$644.17	$253.49	$128.83
26215	T	Remove/graft finger lesion	0053	12.67	$644.17	$253.49	$128.83
26230	T	Partial removal of hand bone	0053	12.67	$644.17	$253.49	$128.83
26235	T	Partial removal, finger bone	0053	12.67	$644.17	$253.49	$128.83
26236	T	Partial removal, finger bone	0053	12.67	$644.17	$253.49	$128.83

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
26250	T	Extensive hand surgery	0053	12.67	$644.17	$253.49	$128.83
26255	T	Extensive hand surgery	0054	20.84	$1,059.55	$472.33	$211.91
26260	T	Extensive finger surgery	0053	12.67	$644.17	$253.49	$128.83
26261	T	Extensive finger surgery	0053	12.67	$644.17	$253.49	$128.83
26262	T	Partial removal of finger	0053	12.67	$644.17	$253.49	$128.83
26320	T	Removal of implant from hand	0020	8.56	$435.21	$130.53	$87.04
26350	T	Repair finger/hand tendon	0054	20.84	$1,059.55	$472.33	$211.91
26352	T	Repair/graft hand tendon	0054	20.84	$1,059.55	$472.33	$211.91
26356	T	Repair finger/hand tendon	0054	20.84	$1,059.55	$472.33	$211.91
26357	T	Repair finger/hand tendon	0054	20.84	$1,059.55	$472.33	$211.91
26358	T	Repair/graft hand tendon	0054	20.84	$1,059.55	$472.33	$211.91
26370	T	Repair finger/hand tendon	0054	20.84	$1,059.55	$472.33	$211.91
26372	T	Repair/graft hand tendon	0054	20.84	$1,059.55	$472.33	$211.91
26373	T	Repair finger/hand tendon	0054	20.84	$1,059.55	$472.33	$211.91
26390	T	Revise hand/finger tendon	0054	20.84	$1,059.55	$472.33	$211.91
26392	T	Repair/graft hand tendon	0054	20.84	$1,059.55	$472.33	$211.91
26410	T	Repair hand tendon	0053	12.67	$644.17	$253.49	$128.83
26412	T	Repair/graft hand tendon	0054	20.84	$1,059.55	$472.33	$211.91
26415	T	Excision, hand/finger tendon	0054	20.84	$1,059.55	$472.33	$211.91
26416	T	Graft hand or finger tendon	0054	20.84	$1,059.55	$472.33	$211.91
26418	T	Repair finger tendon	0053	12.67	$644.17	$253.49	$128.83
26420	T	Repair/graft finger tendon	0054	20.84	$1,059.55	$472.33	$211.91
26426	T	Repair finger/hand tendon	0054	20.84	$1,059.55	$472.33	$211.91
26428	T	Repair/graft finger tendon	0054	20.84	$1,059.55	$472.33	$211.91
26432	T	Repair finger tendon	0053	12.67	$644.17	$253.49	$128.83
26433	T	Repair finger tendon	0053	12.67	$644.17	$253.49	$128.83
26434	T	Repair/graft finger tendon	0054	20.84	$1,059.55	$472.33	$211.91
26437	T	Realignment of tendons	0053	12.67	$644.17	$253.49	$128.83
26440	T	Release palm/finger tendon	0053	12.67	$644.17	$253.49	$128.83
26442	T	Release palm & finger tendon	0054	20.84	$1,059.55	$472.33	$211.91
26445	T	Release hand/finger tendon	0053	12.67	$644.17	$253.49	$128.83
26449	T	Release forearm/hand tendon	0054	20.84	$1,059.55	$472.33	$211.91
26450	T	Incision of palm tendon	0053	12.67	$644.17	$253.49	$128.83
26455	T	Incision of finger tendon	0053	12.67	$644.17	$253.49	$128.83
26460	T	Incise hand/finger tendon	0053	12.67	$644.17	$253.49	$128.83
26471	T	Fusion of finger tendons	0053	12.67	$644.17	$253.49	$128.83
26474	T	Fusion of finger tendons	0053	12.67	$644.17	$253.49	$128.83
26476	T	Tendon lengthening	0053	12.67	$644.17	$253.49	$128.83
26477	T	Tendon shortening	0053	12.67	$644.17	$253.49	$128.83
26478	T	Lengthening of hand tendon	0053	12.67	$644.17	$253.49	$128.83
26479	T	Shortening of hand tendon	0053	12.67	$644.17	$253.49	$128.83
26480	T	Transplant hand tendon	0054	20.84	$1,059.55	$472.33	$211.91
26483	T	Transplant/graft hand tendon	0054	20.84	$1,059.55	$472.33	$211.91
26485	T	Transplant palm tendon	0054	20.84	$1,059.55	$472.33	$211.91
26489	T	Transplant/graft palm tendon	0054	20.84	$1,059.55	$472.33	$211.91
26490	T	Revise thumb tendon	0054	20.84	$1,059.55	$472.33	$211.91
26492	T	Tendon transfer with graft	0054	20.84	$1,059.55	$472.33	$211.91
26494	T	Hand tendon/muscle transfer	0054	20.84	$1,059.55	$472.33	$211.91
26496	T	Revise thumb tendon	0054	20.84	$1,059.55	$472.33	$211.91
26497	T	Finger tendon transfer	0054	20.84	$1,059.55	$472.33	$211.91
26498	T	Finger tendon transfer	0054	20.84	$1,059.55	$472.33	$211.91
26499	T	Revision of finger	0054	20.84	$1,059.55	$472.33	$211.91
26500	T	Hand tendon reconstruction	0053	12.67	$644.17	$253.49	$128.83
26502	T	Hand tendon reconstruction	0054	20.84	$1,059.55	$472.33	$211.91
26504	T	Hand tendon reconstruction	0054	20.84	$1,059.55	$472.33	$211.91
26508	T	Release thumb contracture	0053	12.67	$644.17	$253.49	$128.83
26510	T	Thumb tendon transfer	0054	20.84	$1,059.55	$472.33	$211.91
26516	T	Fusion of knuckle joint	0054	20.84	$1,059.55	$472.33	$211.91
26517	T	Fusion of knuckle joints	0054	20.84	$1,059.55	$472.33	$211.91
26518	T	Fusion of knuckle joints	0054	20.84	$1,059.55	$472.33	$211.91
26520	T	Release knuckle contracture	0053	12.67	$644.17	$253.49	$128.83
26525	T	Release finger contracture	0053	12.67	$644.17	$253.49	$128.83
26530	T	Revise knuckle joint	0047	28.54	$1,451.03	$537.03	$290.21
26531	T	Revise knuckle with implant	0048	32.37	$1,645.76	$725.94	$329.15
26535	T	Revise finger joint	0047	28.54	$1,451.03	$537.03	$290.21
26536	T	Revise/implant finger joint	0048	32.37	$1,645.76	$725.94	$329.15
26540	T	Repair hand joint	0053	12.67	$644.17	$253.49	$128.83
26541	T	Repair hand joint with graft	0054	20.84	$1,059.55	$472.33	$211.91
26542	T	Repair hand joint with graft	0053	12.67	$644.17	$253.49	$128.83
26545	T	Reconstruct finger joint	0054	20.84	$1,059.55	$472.33	$211.91
26546	T	Repair nonunion hand	0054	20.84	$1,059.55	$472.33	$211.91
26548	T	Reconstruct finger joint	0054	20.84	$1,059.55	$472.33	$211.91
26550	T	Construct thumb replacement	0054	20.84	$1,059.55	$472.33	$211.91
26551	C	Great toe-hand transfer	.....	.....	.....	.....	.....
26553	C	Single transfer, toe-hand	.....	.....	.....	.....	.....

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
26554	C	Double transfer, toe-hand	.....	.....	.....	.....	.....
26555	T	Positional change of finger	0054	20.84	$1,059.55	$472.33	$211.91
26556	C	Toe joint transfer	.....	.....	.....	.....	.....
26560	T	Repair of web finger	0053	12.67	$644.17	$253.49	$128.83
26561	T	Repair of web finger	0054	20.84	$1,059.55	$472.33	$211.91
26562	T	Repair of web finger	0054	20.84	$1,059.55	$472.33	$211.91
26565	T	Correct metacarpal flaw	0054	20.84	$1,059.55	$472.33	$211.91
26567	T	Correct finger deformity	0054	20.84	$1,059.55	$472.33	$211.91
26568	T	Lengthen metacarpal/finger	0054	20.84	$1,059.55	$472.33	$211.91
26580	T	Repair hand deformity	0054	20.84	$1,059.55	$472.33	$211.91
26585	T	Repair finger deformity	0054	20.84	$1,059.55	$472.33	$211.91
26587	T	Reconstruct extra finger	0053	12.67	$644.17	$253.49	$128.83
26590	T	Repair finger deformity	0054	20.84	$1,059.55	$472.33	$211.91
26591	T	Repair muscles of hand	0054	20.84	$1,059.55	$472.33	$211.91
26593	T	Release muscles of hand	0053	12.67	$644.17	$253.49	$128.83
26596	T	Excision constricting tissue	0054	20.84	$1,059.55	$472.33	$211.91
26597	T	Release of scar contracture	0054	20.84	$1,059.55	$472.33	$211.91
26600	T	Treat metacarpal fracture	0044	2.73	$138.80	$38.08	$27.76
26605	T	Treat metacarpal fracture	0044	2.73	$138.80	$38.08	$27.76
26607	T	Treat metacarpal fracture	0044	2.73	$138.80	$38.08	$27.76
26608	T	Treat metacarpal fracture	0046	25.36	$1,289.35	$535.76	$257.87
26615	T	Treat metacarpal fracture	0046	25.36	$1,289.35	$535.76	$257.87
26641	T	Treat thumb dislocation	0044	2.73	$138.80	$38.08	$27.76
26645	T	Treat thumb fracture	0044	2.73	$138.80	$38.08	$27.76
26650	T	Treat thumb fracture	0046	25.36	$1,289.35	$535.76	$257.87
26665	T	Treat thumb fracture	0046	25.36	$1,289.35	$535.76	$257.87
26670	T	Treat hand dislocation	0044	2.73	$138.80	$38.08	$27.76
26675	T	Treat hand dislocation	0044	2.73	$138.80	$38.08	$27.76
26676	T	Pin hand dislocation	0046	25.36	$1,289.35	$535.76	$257.87
26685	T	Treat hand dislocation	0046	25.36	$1,289.35	$535.76	$257.87
26686	T	Treat hand dislocation	0046	25.36	$1,289.35	$535.76	$257.87
26700	T	Treat knuckle dislocation	0043	4.13	$209.98	$42.00	$42.00
26705	T	Treat knuckle dislocation	0044	2.73	$138.80	$38.08	$27.76
26706	T	Pin knuckle dislocation	0044	2.73	$138.80	$38.08	$27.76
26715	T	Treat knuckle dislocation	0046	25.36	$1,289.35	$535.76	$257.87
26720	T	Treat finger fracture, each	0043	4.13	$209.98	$42.00	$42.00
26725	T	Treat finger fracture, each	0043	4.13	$209.98	$42.00	$42.00
26727	T	Treat finger fracture, each	0046	25.36	$1,289.35	$535.76	$257.87
26735	T	Treat finger fracture, each	0046	25.36	$1,289.35	$535.76	$257.87
26740	T	Treat finger fracture, each	0043	4.13	$209.98	$42.00	$42.00
26742	T	Treat finger fracture, each	0044	2.73	$138.80	$38.08	$27.76
26746	T	Treat finger fracture, each	0046	25.36	$1,289.35	$535.76	$257.87
26750	T	Treat finger fracture, each	0043	4.13	$209.98	$42.00	$42.00
26755	T	Treat finger fracture, each	0043	4.13	$209.98	$42.00	$42.00
26756	T	Pin finger fracture, each	0046	25.36	$1,289.35	$535.76	$257.87
26765	T	Treat finger fracture, each	0046	25.36	$1,289.35	$535.76	$257.87
26770	T	Treat finger dislocation	0043	4.13	$209.98	$42.00	$42.00
26775	T	Treat finger dislocation	0045	12.91	$656.37	$277.12	$131.27
26776	T	Pin finger dislocation	0046	25.36	$1,289.35	$535.76	$257.87
26785	T	Treat finger dislocation	0046	25.36	$1,289.35	$535.76	$257.87
26820	T	Thumb fusion with graft	0054	20.84	$1,059.55	$472.33	$211.91
26841	T	Fusion of thumb	0054	20.84	$1,059.55	$472.33	$211.91
26842	T	Thumb fusion with graft	0054	20.84	$1,059.55	$472.33	$211.91
26843	T	Fusion of hand joint	0054	20.84	$1,059.55	$472.33	$211.91
26844	T	Fusion/graft of hand joint	0054	20.84	$1,059.55	$472.33	$211.91
26850	T	Fusion of knuckle	0054	20.84	$1,059.55	$472.33	$211.91
26852	T	Fusion of knuckle with graft	0054	20.84	$1,059.55	$472.33	$211.91
26860	T	Fusion of finger joint	0054	20.84	$1,059.55	$472.33	$211.91
26861	T	Fusion of finger jnt, add-on	0054	20.84	$1,059.55	$472.33	$211.91
26862	T	Fusion/graft of finger joint	0054	20.84	$1,059.55	$472.33	$211.91
26863	T	Fuse/graft added joint	0054	20.84	$1,059.55	$472.33	$211.91
26910	T	Amputate metacarpal bone	0054	20.84	$1,059.55	$472.33	$211.91
26951	T	Amputation of finger/thumb	0053	12.67	$644.17	$253.49	$128.83
26952	T	Amputation of finger/thumb	0053	12.67	$644.17	$253.49	$128.83
26989	T	Hand/finger surgery	0043	4.13	$209.98	$42.00	$42.00
26990	T	Drainage of pelvis lesion	0049	17.07	$867.87	$356.95	$173.57
26991	T	Drainage of pelvis bursa	0049	17.07	$867.87	$356.95	$173.57
26992	C	Drainage of bone lesion	.....	.....	.....	.....	.....
27000	T	Incision of hip tendon	0049	17.07	$867.87	$356.95	$173.57
27001	T	Incision of hip tendon	0050	22.31	$1,134.29	$513.86	$226.86
27003	T	Incision of hip tendon	0050	22.31	$1,134.29	$513.86	$226.86
27005	C	Incision of hip tendon	.....	.....	.....	.....	.....
27006	C	Incision of hip tendons	.....	.....	.....	.....	.....
27025	C	Incision of hip/thigh fascia	.....	.....	.....	.....	.....
27030	C	Drainage of hip joint	.....	.....	.....	.....	.....

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
27033	T	Exploration of hip joint	0051	30.94	$1,573.05	$675.24	$314.61
27035	C	Denervation of hip joint					
27036	C	Excision of hip joint/muscle					
27040	T	Biopsy of soft tissues	0021	12.74	$647.73	$236.51	$129.55
27041	T	Biopsy of soft tissues	0022	15.07	$766.19	$292.94	$153.24
27047	T	Remove hip/pelvis lesion	0022	15.07	$766.19	$292.94	$153.24
27048	T	Remove hip/pelvis lesion	0022	15.07	$766.19	$292.94	$153.24
27049	T	Remove tumor, hip/pelvis	0022	15.07	$766.19	$292.94	$153.24
27050	T	Biopsy of sacroiliac joint	0049	17.07	$867.87	$356.95	$173.57
27052	T	Biopsy of hip joint	0049	17.07	$867.87	$356.95	$173.57
27054	C	Removal of hip joint lining					
27060	T	Removal of ischial bursa	0049	17.07	$867.87	$356.95	$173.57
27062	T	Remove femur lesion/bursa	0049	17.07	$867.87	$356.95	$173.57
27065	T	Removal of hip bone lesion	0049	17.07	$867.87	$356.95	$173.57
27066	T	Removal of hip bone lesion	0050	22.31	$1,134.29	$513.86	$226.86
27067	T	Remove/graft hip bone lesion	0050	22.31	$1,134.29	$513.86	$226.86
27070	C	Partial removal of hip bone					
27071	C	Partial removal of hip bone					
27075	C	Extensive hip surgery					
27076	C	Extensive hip surgery					
27077	C	Extensive hip surgery					
27078	C	Extensive hip surgery					
27079	C	Extensive hip surgery					
27080	T	Removal of tail bone	0050	22.31	$1,134.29	$513.86	$226.86
27086	T	Remove hip foreign body	0019	4.56	$231.84	$78.91	$46.37
27087	T	Remove hip foreign body	0049	17.07	$867.87	$356.95	$173.57
27090	C	Removal of hip prosthesis					
27091	C	Removal of hip prosthesis					
27093	N	Injection for hip x-ray					
27095	N	Injection for hip x-ray					
27096	N	Inject sacroiliac joint					
27097	T	Revision of hip tendon	0050	22.31	$1,134.29	$513.86	$226.86
27098	T	Transfer tendon to pelvis	0050	22.31	$1,134.29	$513.86	$226.86
27100	T	Transfer of abdominal muscle	0051	30.94	$1,573.05	$675.24	$314.61
27105	T	Transfer of spinal muscle	0051	30.94	$1,573.05	$675.24	$314.61
27110	T	Transfer of iliopsoas muscle	0051	30.94	$1,573.05	$675.24	$314.61
27111	T	Transfer of iliopsoas muscle	0051	30.94	$1,573.05	$675.24	$314.61
27120	C	Reconstruction of hip socket					
27122	C	Reconstruction of hip socket					
27125	C	Partial hip replacement					
27130	C	Total hip replacement					
27132	C	Total hip replacement					
27134	C	Revise hip joint replacement					
27137	C	Revise hip joint replacement					
27138	C	Revise hip joint replacement					
27140	C	Transplant femur ridge					
27146	C	Incision of hip bone					
27147	C	Revision of hip bone					
27151	C	Incision of hip bones					
27156	C	Revision of hip bones					
27158	C	Revision of pelvis					
27161	C	Incision of neck of femur					
27165	C	Incision/fixation of femur					
27170	C	Repair/graft femur head/neck					
27175	C	Treat slipped epiphysis					
27176	C	Treat slipped epiphysis					
27177	C	Treat slipped epiphysis					
27178	C	Treat slipped epiphysis					
27179	C	Revise head/neck of femur					
27181	C	Treat slipped epiphysis					
27185	C	Revision of femur epiphysis					
27187	C	Reinforce hip bones					
27193	T	Treat pelvic ring fracture	0044	2.73	$138.80	$38.08	$27.76
27194	T	Treat pelvic ring fracture	0045	12.91	$656.37	$277.12	$131.27
27200	T	Treat tail bone fracture	0044	2.73	$138.80	$38.08	$27.76
27202	T	Treat tail bone fracture	0046	25.36	$1,289.35	$535.76	$257.87
27215	C	Treat pelvic fracture(s)					
27216	C	Treat pelvic ring fracture					
27217	C	Treat pelvic ring fracture					
27218	C	Treat pelvic ring fracture					
27220	T	Treat hip socket fracture	0044	2.73	$138.80	$38.08	$27.76
27222	C	Treat hip socket fracture					
27226	C	Treat hip wall fracture					
27227	C	Treat hip fracture(s)					
27228	C	Treat hip fracture(s)					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
27230	T	Treat thigh fracture	0044	2.73	$138.80	$38.08	$27.76
27232	C	Treat thigh fracture					
27235	C	Treat thigh fracture					
27236	C	Treat thigh fracture					
27238	T	Treat thigh fracture	0044	2.73	$138.80	$38.08	$27.76
27240	C	Treat thigh fracture					
27244	C	Treat thigh fracture					
27245	C	Treat thigh fracture					
27246	T	Treat thigh fracture	0043	4.13	$209.98	$42.00	$42.00
27248	C	Treat thigh fracture					
27250	T	Treat hip dislocation	0044	2.73	$138.80	$38.08	$27.76
27252	T	Treat hip dislocation	0045	12.91	$656.37	$277.12	$131.27
27253	C	Treat hip dislocation					
27254	C	Treat hip dislocation					
27256	T	Treat hip dislocation	0043	4.13	$209.98	$42.00	$42.00
27257	T	Treat hip dislocation	0045	12.91	$656.37	$277.12	$131.27
27258	C	Treat hip dislocation					
27259	C	Treat hip dislocation					
27265	T	Treat hip dislocation	0044	2.73	$138.80	$38.08	$27.76
27266	T	Treat hip dislocation	0047	28.54	$1,451.03	$537.03	$290.21
27275	T	Manipulation of hip joint	0045	12.91	$656.37	$277.12	$131.27
27280	C	Fusion of sacroiliac joint					
27282	C	Fusion of pubic bones					
27284	C	Fusion of hip joint					
27286	C	Fusion of hip joint					
27290	C	Amputation of leg at hip					
27295	C	Amputation of leg at hip					
27299	T	Pelvis/hip joint surgery	0043	4.13	$209.98	$42.00	$42.00
27301	T	Drain thigh/knee lesion	0008	11.36	$577.57	$115.51	$115.51
27303	C	Drainage of bone lesion					
27305	T	Incise thigh tendon & fascia	0049	17.07	$867.87	$356.95	$173.57
27306	T	Incision of thigh tendon	0049	17.07	$867.87	$356.95	$173.57
27307	T	Incision of thigh tendons	0049	17.07	$867.87	$356.95	$173.57
27310	T	Exploration of knee joint	0050	22.31	$1,134.29	$513.86	$226.86
27315	T	Partial removal, thigh nerve	0220	14.76	$750.43	$326.21	$150.09
27320	T	Partial removal, thigh nerve	0220	14.76	$750.43	$326.21	$150.09
27323	T	Biopsy, thigh soft tissues	0021	12.74	$647.73	$236.51	$129.55
27324	T	Biopsy, thigh soft tissues	0022	15.07	$766.19	$292.94	$153.24
27327	T	Removal of thigh lesion	0022	15.07	$766.19	$292.94	$153.24
27328	T	Removal of thigh lesion	0022	15.07	$766.19	$292.94	$153.24
27329	T	Remove tumor, thigh/knee	0022	15.07	$766.19	$292.94	$153.24
27330	T	Biopsy, knee joint lining	0050	22.31	$1,134.29	$513.86	$226.86
27331	T	Explore/treat knee joint	0050	22.31	$1,134.29	$513.86	$226.86
27332	T	Removal of knee cartilage	0050	22.31	$1,134.29	$513.86	$226.86
27333	T	Removal of knee cartilage	0050	22.31	$1,134.29	$513.86	$226.86
27334	T	Remove knee joint lining	0050	22.31	$1,134.29	$513.86	$226.86
27335	T	Remove knee joint lining	0050	22.31	$1,134.29	$513.86	$226.86
27340	T	Removal of kneecap bursa	0049	17.07	$867.87	$356.95	$173.57
27345	T	Removal of knee cyst	0049	17.07	$867.87	$356.95	$173.57
27347	T	Remove knee cyst	0049	17.07	$867.87	$356.95	$173.57
27350	T	Removal of kneecap	0050	22.31	$1,134.29	$513.86	$226.86
27355	T	Remove femur lesion	0050	22.31	$1,134.29	$513.86	$226.86
27356	T	Remove femur lesion/graft	0050	22.31	$1,134.29	$513.86	$226.86
27357	T	Remove femur lesion/graft	0050	22.31	$1,134.29	$513.86	$226.86
27358	T	Remove femur lesion/fixation	0050	22.31	$1,134.29	$513.86	$226.86
27360	T	Partial removal, leg bone(s)	0050	22.31	$1,134.29	$513.86	$226.86
27365	C	Extensive leg surgery					
27370	N	Injection for knee x-ray					
27372	T	Removal of foreign body	0022	15.07	$766.19	$292.94	$153.24
27380	T	Repair of kneecap tendon	0049	17.07	$867.87	$356.95	$173.57
27381	T	Repair/graft kneecap tendon	0049	17.07	$867.87	$356.95	$173.57
27385	T	Repair of thigh muscle	0049	17.07	$867.87	$356.95	$173.57
27386	T	Repair/graft of thigh muscle	0049	17.07	$867.87	$356.95	$173.57
27390	T	Incision of thigh tendon	0049	17.07	$867.87	$356.95	$173.57
27391	T	Incision of thigh tendons	0049	17.07	$867.87	$356.95	$173.57
27392	T	Incision of thigh tendons	0049	17.07	$867.87	$356.95	$173.57
27393	T	Lengthening of thigh tendon	0050	22.31	$1,134.29	$513.86	$226.86
27394	T	Lengthening of thigh tendons	0050	22.31	$1,134.29	$513.86	$226.86
27395	T	Lengthening of thigh tendons	0051	30.94	$1,573.05	$675.24	$314.61
27396	T	Transplant of thigh tendon	0050	22.31	$1,134.29	$513.86	$226.86
27397	T	Transplants of thigh tendons	0051	30.94	$1,573.05	$675.24	$314.61
27400	T	Revise thigh muscles/tendons	0051	30.94	$1,573.05	$675.24	$314.61
27403	T	Repair of knee cartilage	0050	22.31	$1,134.29	$513.86	$226.86
27405	T	Repair of knee ligament	0051	30.94	$1,573.05	$675.24	$314.61
27407	T	Repair of knee ligament	0051	30.94	$1,573.05	$675.24	$314.61

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
27409	T	Repair of knee ligaments	0051	30.94	$1,573.05	$675.24	$314.61
27418	T	Repair degenerated kneecap	0051	30.94	$1,573.05	$675.24	$314.61
27420	T	Revision of unstable kneecap	0051	30.94	$1,573.05	$675.24	$314.61
27422	T	Revision of unstable kneecap	0051	30.94	$1,573.05	$675.24	$314.61
27424	T	Revision/removal of kneecap	0051	30.94	$1,573.05	$675.24	$314.61
27425	T	Lateral retinacular release	0050	22.31	$1,134.29	$513.86	$226.86
27427	T	Reconstruction, knee	0052	38.88	$1,976.74	$930.91	$395.35
27428	T	Reconstruction, knee	0052	38.88	$1,976.74	$930.91	$395.35
27429	T	Reconstruction, knee	0052	38.88	$1,976.74	$930.91	$395.35
27430	T	Revision of thigh muscles	0051	30.94	$1,573.05	$675.24	$314.61
27435	T	Incision of knee joint	0051	30.94	$1,573.05	$675.24	$314.61
27437	T	Revise kneecap	0047	28.54	$1,451.03	$537.03	$290.21
27438	T	Revise kneecap with implant	0048	32.37	$1,645.76	$725.94	$329.15
27440	T	Revision of knee joint	0047	28.54	$1,451.03	$537.03	$290.21
27441	T	Revision of knee joint	0047	28.54	$1,451.03	$537.03	$290.21
27442	T	Revision of knee joint	0047	28.54	$1,451.03	$537.03	$290.21
27443	T	Revision of knee joint	0047	28.54	$1,451.03	$537.03	$290.21
27445	C	Revision of knee joint					
27446	T	Revision of knee joint	0047	28.54	$1,451.03	$537.03	$290.21
27447	C	Total knee replacement					
27448	C	Incision of thigh					
27450	C	Incision of thigh					
27454	C	Realignment of thigh bone					
27455	C	Realignment of knee					
27457	C	Realignment of knee					
27465	C	Shortening of thigh bone					
27466	C	Lengthening of thigh bone					
27468	C	Shorten/lengthen thighs					
27470	C	Repair of thigh					
27472	C	Repair/graft of thigh					
27475	C	Surgery to stop leg growth					
27477	C	Surgery to stop leg growth					
27479	C	Surgery to stop leg growth					
27485	C	Surgery to stop leg growth					
27486	C	Revise/replace knee joint					
27487	C	Revise/replace knee joint					
27488	C	Removal of knee prosthesis					
27495	C	Reinforce thigh					
27496	T	Decompression of thigh/knee	0049	17.07	$867.87	$356.95	$173.57
27497	T	Decompression of thigh/knee	0049	17.07	$867.87	$356.95	$173.57
27498	T	Decompression of thigh/knee	0049	17.07	$867.87	$356.95	$173.57
27499	T	Decompression of thigh/knee	0049	17.07	$867.87	$356.95	$173.57
27500	T	Treatment of thigh fracture	0044	2.73	$138.80	$38.08	$27.76
27501	T	Treatment of thigh fracture	0044	2.73	$138.80	$38.08	$27.76
27502	T	Treatment of thigh fracture	0044	2.73	$138.80	$38.08	$27.76
27503	T	Treatment of thigh fracture	0044	2.73	$138.80	$38.08	$27.76
27506	C	Treatment of thigh fracture					
27507	C	Treatment of thigh fracture					
27508	T	Treatment of thigh fracture	0044	2.73	$138.80	$38.08	$27.76
27509	T	Treatment of thigh fracture	0046	25.36	$1,289.35	$535.76	$257.87
27510	T	Treatment of thigh fracture	0044	2.73	$138.80	$38.08	$27.76
27511	C	Treatment of thigh fracture					
27513	C	Treatment of thigh fracture					
27514	C	Treatment of thigh fracture					
27516	T	Treat thigh fx growth plate	0044	2.73	$138.80	$38.08	$27.76
27517	T	Treat thigh fx growth plate	0043	4.13	$209.98	$42.00	$42.00
27519	C	Treat thigh fx growth plate					
27520	T	Treat kneecap fracture	0044	2.73	$138.80	$38.08	$27.76
27524	T	Treat kneecap fracture	0046	25.36	$1,289.35	$535.76	$257.87
27530	T	Treat knee fracture	0044	2.73	$138.80	$38.08	$27.76
27532	T	Treat knee fracture	0044	2.73	$138.80	$38.08	$27.76
27535	C	Treat knee fracture					
27536	C	Treat knee fracture					
27538	T	Treat knee fracture(s)	0043	4.13	$209.98	$42.00	$42.00
27540	C	Treat knee fracture					
27550	T	Treat knee dislocation	0044	2.73	$138.80	$38.08	$27.76
27552	T	Treat knee dislocation	0045	12.91	$656.37	$277.12	$131.27
27556	C	Treat knee dislocation					
27557	C	Treat knee dislocation					
27558	C	Treat knee dislocation					
27560	T	Treat kneecap dislocation	0044	2.73	$138.80	$38.08	$27.76
27562	T	Treat kneecap dislocation	0045	12.91	$656.37	$277.12	$131.27
27566	T	Treat kneecap dislocation	0046	25.36	$1,289.35	$535.76	$257.87
27570	T	Fixation of knee joint	0045	12.91	$656.37	$277.12	$131.27
27580	C	Fusion of knee					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
27590	C	Amputate leg at thigh					
27591	C	Amputate leg at thigh					
27592	C	Amputate leg at thigh					
27594	T	Amputation follow-up surgery	0049	17.07	$867.87	$356.95	$173.57
27596	C	Amputation follow-up surgery					
27598	C	Amputate lower leg at knee					
27599	T	Leg surgery procedure	0044	2.73	$138.80	$38.08	$27.76
27600	T	Decompression of lower leg	0049	17.07	$867.87	$356.95	$173.57
27601	T	Decompression of lower leg	0049	17.07	$867.87	$356.95	$173.57
27602	T	Decompression of lower leg	0049	17.07	$867.87	$356.95	$173.57
27603	T	Drain lower leg lesion	0008	11.36	$577.57	$115.51	$115.51
27604	T	Drain lower leg bursa	0049	17.07	$867.87	$356.95	$173.57
27605	T	Incision of achilles tendon	0055	16.77	$852.62	$355.34	$170.52
27606	T	Incision of achilles tendon	0049	17.07	$867.87	$356.95	$173.57
27607	T	Treat lower leg bone lesion	0049	17.07	$867.87	$356.95	$173.57
27610	T	Explore/treat ankle joint	0050	22.31	$1,134.29	$513.86	$226.86
27612	T	Exploration of ankle joint	0050	22.31	$1,134.29	$513.86	$226.86
27613	T	Biopsy lower leg soft tissue	0020	8.56	$435.21	$130.53	$87.04
27614	T	Biopsy lower leg soft tissue	0022	15.07	$766.19	$292.94	$153.24
27615	T	Remove tumor, lower leg	0046	25.36	$1,289.35	$535.76	$257.87
27618	T	Remove lower leg lesion	0021	12.74	$647.73	$236.51	$129.55
27619	T	Remove lower leg lesion	0022	15.07	$766.19	$292.94	$153.24
27620	T	Explore/treat ankle joint	0050	22.31	$1,134.29	$513.86	$226.86
27625	T	Remove ankle joint lining	0050	22.31	$1,134.29	$513.86	$226.86
27626	T	Remove ankle joint lining	0050	22.31	$1,134.29	$513.86	$226.86
27630	T	Removal of tendon lesion	0049	17.07	$867.87	$356.95	$173.57
27635	T	Remove lower leg bone lesion	0050	22.31	$1,134.29	$513.86	$226.86
27637	T	Remove/graft leg bone lesion	0050	22.31	$1,134.29	$513.86	$226.86
27638	T	Remove/graft leg bone lesion	0050	22.31	$1,134.29	$513.86	$226.86
27640	T	Partial removal of tibia	0051	30.94	$1,573.05	$675.24	$314.61
27641	T	Partial removal of fibula	0050	22.31	$1,134.29	$513.86	$226.86
27645	C	Extensive lower leg surgery					
27646	C	Extensive lower leg surgery					
27647	T	Extensive ankle/heel surgery	0051	30.94	$1,573.05	$675.24	$314.61
27648	N	Injection for ankle x-ray					
27650	T	Repair achilles tendon	0051	30.94	$1,573.05	$675.24	$314.61
27652	T	Repair/graft achilles tendon	0051	30.94	$1,573.05	$675.24	$314.61
27654	T	Repair of achilles tendon	0051	30.94	$1,573.05	$675.24	$314.61
27656	T	Repair leg fascia defect	0049	17.07	$867.87	$356.95	$173.57
27658	T	Repair of leg tendon, each	0049	17.07	$867.87	$356.95	$173.57
27659	T	Repair of leg tendon, each	0049	17.07	$867.87	$356.95	$173.57
27664	T	Repair of leg tendon, each	0049	17.07	$867.87	$356.95	$173.57
27665	T	Repair of leg tendon, each	0050	22.31	$1,134.29	$513.86	$226.86
27675	T	Repair lower leg tendons	0049	17.07	$867.87	$356.95	$173.57
27676	T	Repair lower leg tendons	0050	22.31	$1,134.29	$513.86	$226.86
27680	T	Release of lower leg tendon	0050	22.31	$1,134.29	$513.86	$226.86
27681	T	Release of lower leg tendons	0050	22.31	$1,134.29	$513.86	$226.86
27685	T	Revision of lower leg tendon	0050	22.31	$1,134.29	$513.86	$226.86
27686	T	Revise lower leg tendons	0050	22.31	$1,134.29	$513.86	$226.86
27687	T	Revision of calf tendon	0050	22.31	$1,134.29	$513.86	$226.86
27690	T	Revise lower leg tendon	0051	30.94	$1,573.05	$675.24	$314.61
27691	T	Revise lower leg tendon	0051	30.94	$1,573.05	$675.24	$314.61
27692	T	Revise additional leg tendon	0051	30.94	$1,573.05	$675.24	$314.61
27695	T	Repair of ankle ligament	0050	22.31	$1,134.29	$513.86	$226.86
27696	T	Repair of ankle ligaments	0050	22.31	$1,134.29	$513.86	$226.86
27698	T	Repair of ankle ligament	0050	22.31	$1,134.29	$513.86	$226.86
27700	T	Revision of ankle joint	0047	28.54	$1,451.03	$537.03	$290.21
27702	C	Reconstruct ankle joint					
27703	C	Reconstruction, ankle joint					
27704	T	Removal of ankle implant	0049	17.07	$867.87	$356.95	$173.57
27705	T	Incision of tibia	0051	30.94	$1,573.05	$675.24	$314.61
27707	T	Incision of fibula	0049	17.07	$867.87	$356.95	$173.57
27709	T	Incision of tibia & fibula	0050	22.31	$1,134.29	$513.86	$226.86
27712	C	Realignment of lower leg					
27715	C	Revision of lower leg					
27720	C	Repair of tibia					
27722	C	Repair/graft of tibia					
27724	C	Repair/graft of tibia					
27725	C	Repair of lower leg					
27727	C	Repair of lower leg					
27730	T	Repair of tibia epiphysis	0050	22.31	$1,134.29	$513.86	$226.86
27732	T	Repair of fibula epiphysis	0050	22.31	$1,134.29	$513.86	$226.86
27734	T	Repair lower leg epiphyses	0050	22.31	$1,134.29	$513.86	$226.86
27740	T	Repair of leg epiphyses	0050	22.31	$1,134.29	$513.86	$226.86
27742	T	Repair of leg epiphyses	0051	30.94	$1,573.05	$675.24	$314.61

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
27745	T	Reinforce tibia	0051	30.94	$1,573.05	$675.24	$314.61
27750	T	Treatment of tibia fracture	0044	2.73	$138.80	$38.08	$27.76
27752	T	Treatment of tibia fracture	0044	2.73	$138.80	$38.08	$27.76
27756	T	Treatment of tibia fracture	0046	25.36	$1,289.35	$535.76	$257.87
27758	T	Treatment of tibia fracture	0046	25.36	$1,289.35	$535.76	$257.87
27759	T	Treatment of tibia fracture	0046	25.36	$1,289.35	$535.76	$257.87
27760	T	Treatment of ankle fracture	0044	2.73	$138.80	$38.08	$27.76
27762	T	Treatment of ankle fracture	0044	2.73	$138.80	$38.08	$27.76
27766	T	Treatment of ankle fracture	0046	25.36	$1,289.35	$535.76	$257.87
27780	T	Treatment of fibula fracture	0044	2.73	$138.80	$38.08	$27.76
27781	T	Treatment of fibula fracture	0044	2.73	$138.80	$38.08	$27.76
27784	T	Treatment of fibula fracture	0046	25.36	$1,289.35	$535.76	$257.87
27786	T	Treatment of ankle fracture	0044	2.73	$138.80	$38.08	$27.76
27788	T	Treatment of ankle fracture	0044	2.73	$138.80	$38.08	$27.76
27792	T	Treatment of ankle fracture	0046	25.36	$1,289.35	$535.76	$257.87
27808	T	Treatment of ankle fracture	0044	2.73	$138.80	$38.08	$27.76
27810	T	Treatment of ankle fracture	0044	2.73	$138.80	$38.08	$27.76
27814	T	Treatment of ankle fracture	0046	25.36	$1,289.35	$535.76	$257.87
27816	T	Treatment of ankle fracture	0044	2.73	$138.80	$38.08	$27.76
27818	T	Treatment of ankle fracture	0044	2.73	$138.80	$38.08	$27.76
27822	T	Treatment of ankle fracture	0046	25.36	$1,289.35	$535.76	$257.87
27823	T	Treatment of ankle fracture	0046	25.36	$1,289.35	$535.76	$257.87
27824	T	Treat lower leg fracture	0044	2.73	$138.80	$38.08	$27.76
27825	T	Treat lower leg fracture	0044	2.73	$138.80	$38.08	$27.76
27826	T	Treat lower leg fracture	0046	25.36	$1,289.35	$535.76	$257.87
27827	T	Treat lower leg fracture	0046	25.36	$1,289.35	$535.76	$257.87
27828	T	Treat lower leg fracture	0046	25.36	$1,289.35	$535.76	$257.87
27829	T	Treat lower leg joint	0046	25.36	$1,289.35	$535.76	$257.87
27830	T	Treat lower leg dislocation	0044	2.73	$138.80	$38.08	$27.76
27831	T	Treat lower leg dislocation	0044	2.73	$138.80	$38.08	$27.76
27832	T	Treat lower leg dislocation	0046	25.36	$1,289.35	$535.76	$257.87
27840	T	Treat ankle dislocation	0044	2.73	$138.80	$38.08	$27.76
27842	T	Treat ankle dislocation	0045	12.91	$656.37	$277.12	$131.27
27846	T	Treat ankle dislocation	0046	25.36	$1,289.35	$535.76	$257.87
27848	T	Treat ankle dislocation	0046	25.36	$1,289.35	$535.76	$257.87
27860	T	Fixation of ankle joint	0045	12.91	$656.37	$277.12	$131.27
27870	T	Fusion of ankle joint	0051	30.94	$1,573.05	$675.24	$314.61
27871	T	Fusion of tibiofibular joint	0051	30.94	$1,573.05	$675.24	$314.61
27880	C	Amputation of lower leg	.....	.....	.....	.....	.....
27881	C	Amputation of lower leg	.....	.....	.....	.....	.....
27882	C	Amputation of lower leg	.....	.....	.....	.....	.....
27884	T	Amputation follow-up surgery	0049	17.07	$867.87	$356.95	$173.57
27886	C	Amputation follow-up surgery	.....	.....	.....	.....	.....
27888	C	Amputation of foot at ankle	.....	.....	.....	.....	.....
27889	T	Amputation of foot at ankle	0050	22.31	$1,134.29	$513.86	$226.86
27892	T	Decompression of leg	0049	17.07	$867.87	$356.95	$173.57
27893	T	Decompression of leg	0049	17.07	$867.87	$356.95	$173.57
27894	T	Decompression of leg	0049	17.07	$867.87	$356.95	$173.57
27899	T	Leg/ankle surgery procedure	0044	2.73	$138.80	$38.08	$27.76
28001	T	Drainage of bursa of foot	0008	11.36	$577.57	$115.51	$115.51
28002	T	Treatment of foot infection	0049	17.07	$867.87	$356.95	$173.57
28003	T	Treatment of foot infection	0049	17.07	$867.87	$356.95	$173.57
28005	T	Treat foot bone lesion	0055	16.77	$852.62	$355.34	$170.52
28008	T	Incision of foot fascia	0055	16.77	$852.62	$355.34	$170.52
28010	T	Incision of toe tendon	0055	16.77	$852.62	$355.34	$170.52
28011	T	Incision of toe tendons	0055	16.77	$852.62	$355.34	$170.52
28020	T	Exploration of foot joint	0055	16.77	$852.62	$355.34	$170.52
28022	T	Exploration of foot joint	0055	16.77	$852.62	$355.34	$170.52
28024	T	Exploration of toe joint	0055	16.77	$852.62	$355.34	$170.52
28030	T	Removal of foot nerve	0220	14.76	$750.43	$326.21	$150.09
28035	T	Decompression of tibia nerve	0220	14.76	$750.43	$326.21	$150.09
28043	T	Excision of foot lesion	0021	12.74	$647.73	$236.51	$129.55
28045	T	Excision of foot lesion	0055	16.77	$852.62	$355.34	$170.52
28046	T	Resection of tumor, foot	0055	16.77	$852.62	$355.34	$170.52
28050	T	Biopsy of foot joint lining	0055	16.77	$852.62	$355.34	$170.52
28052	T	Biopsy of foot joint lining	0055	16.77	$852.62	$355.34	$170.52
28054	T	Biopsy of toe joint lining	0055	16.77	$852.62	$355.34	$170.52
28060	T	Partial removal, foot fascia	0056	19.20	$976.17	$405.81	$195.23
28062	T	Removal of foot fascia	0056	19.20	$976.17	$405.81	$195.23
28070	T	Removal of foot joint lining	0056	19.20	$976.17	$405.81	$195.23
28072	T	Removal of foot joint lining	0056	19.20	$976.17	$405.81	$195.23
28080	T	Removal of foot lesion	0055	16.77	$852.62	$355.34	$170.52
28086	T	Excise foot tendon sheath	0055	16.77	$852.62	$355.34	$170.52
28088	T	Excise foot tendon sheath	0055	16.77	$852.62	$355.34	$170.52
28090	T	Removal of foot lesion	0055	16.77	$852.62	$355.34	$170.52

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
28092	T	Removal of toe lesions	0055	16.77	$852.62	$355.34	$170.52
28100	T	Removal of ankle/heel lesion	0055	16.77	$852.62	$355.34	$170.52
28102	T	Remove/graft foot lesion	0056	19.20	$976.17	$405.81	$195.23
28103	T	Remove/graft foot lesion	0056	19.20	$976.17	$405.81	$195.23
28104	T	Removal of foot lesion	0055	16.77	$852.62	$355.34	$170.52
28106	T	Remove/graft foot lesion	0056	19.20	$976.17	$405.81	$195.23
28107	T	Remove/graft foot lesion	0056	19.20	$976.17	$405.81	$195.23
28108	T	Removal of toe lesions	0055	16.77	$852.62	$355.34	$170.52
28110	T	Part removal of metatarsal	0057	21.11	$1,073.27	$496.65	$214.65
28111	T	Part removal of metatarsal	0055	16.77	$852.62	$355.34	$170.52
28112	T	Part removal of metatarsal	0055	16.77	$852.62	$355.34	$170.52
28113	T	Part removal of metatarsal	0055	16.77	$852.62	$355.34	$170.52
28114	T	Removal of metatarsal heads	0055	16.77	$852.62	$355.34	$170.52
28116	T	Revision of foot	0055	16.77	$852.62	$355.34	$170.52
28118	T	Removal of heel bone	0055	16.77	$852.62	$355.34	$170.52
28119	T	Removal of heel spur	0055	16.77	$852.62	$355.34	$170.52
28120	T	Part removal of ankle/heel	0055	16.77	$852.62	$355.34	$170.52
28122	T	Partial removal of foot bone	0055	16.77	$852.62	$355.34	$170.52
28124	T	Partial removal of toe	0055	16.77	$852.62	$355.34	$170.52
28126	T	Partial removal of toe	0055	16.77	$852.62	$355.34	$170.52
28130	T	Removal of ankle bone	0055	16.77	$852.62	$355.34	$170.52
28140	T	Removal of metatarsal	0055	16.77	$852.62	$355.34	$170.52
28150	T	Removal of toe	0055	16.77	$852.62	$355.34	$170.52
28153	T	Partial removal of toe	0055	16.77	$852.62	$355.34	$170.52
28160	T	Partial removal of toe	0055	16.77	$852.62	$355.34	$170.52
28171	T	Extensive foot surgery	0055	16.77	$852.62	$355.34	$170.52
28173	T	Extensive foot surgery	0055	16.77	$852.62	$355.34	$170.52
28175	T	Extensive foot surgery	0055	16.77	$852.62	$355.34	$170.52
28190	T	Removal of foot foreign body	0019	4.56	$231.84	$78.91	$46.37
28192	T	Removal of foot foreign body	0021	12.74	$647.73	$236.51	$129.55
28193	T	Removal of foot foreign body	0021	12.74	$647.73	$236.51	$129.55
28200	T	Repair of foot tendon	0055	16.77	$852.62	$355.34	$170.52
28202	T	Repair/graft of foot tendon	0056	19.20	$976.17	$405.81	$195.23
28208	T	Repair of foot tendon	0055	16.77	$852.62	$355.34	$170.52
28210	T	Repair/graft of foot tendon	0055	16.77	$852.62	$355.34	$170.52
28220	T	Release of foot tendon	0055	16.77	$852.62	$355.34	$170.52
28222	T	Release of foot tendons	0055	16.77	$852.62	$355.34	$170.52
28225	T	Release of foot tendon	0055	16.77	$852.62	$355.34	$170.52
28226	T	Release of foot tendons	0055	16.77	$852.62	$355.34	$170.52
28230	T	Incision of foot tendon(s)	0055	16.77	$852.62	$355.34	$170.52
28232	T	Incision of toe tendon	0055	16.77	$852.62	$355.34	$170.52
28234	T	Incision of foot tendon	0055	16.77	$852.62	$355.34	$170.52
28238	T	Revision of foot tendon	0056	19.20	$976.17	$405.81	$195.23
28240	T	Release of big toe	0055	16.77	$852.62	$355.34	$170.52
28250	T	Revision of foot fascia	0056	19.20	$976.17	$405.81	$195.23
28260	T	Release of midfoot joint	0056	19.20	$976.17	$405.81	$195.23
28261	T	Revision of foot tendon	0056	19.20	$976.17	$405.81	$195.23
28262	T	Revision of foot and ankle	0056	19.20	$976.17	$405.81	$195.23
28264	T	Release of midfoot joint	0056	19.20	$976.17	$405.81	$195.23
28270	T	Release of foot contracture	0055	16.77	$852.62	$355.34	$170.52
28272	T	Release of toe joint, each	0055	16.77	$852.62	$355.34	$170.52
28280	T	Fusion of toes	0055	16.77	$852.62	$355.34	$170.52
28285	T	Repair of hammertoe	0055	16.77	$852.62	$355.34	$170.52
28286	T	Repair of hammertoe	0055	16.77	$852.62	$355.34	$170.52
28288	T	Partial removal of foot bone	0056	19.20	$976.17	$405.81	$195.23
28289	T	Repair hallux rigidus	0056	19.20	$976.17	$405.81	$195.23
28290	T	Correction of bunion	0057	21.11	$1,073.27	$496.65	$214.65
28292	T	Correction of bunion	0057	21.11	$1,073.27	$496.65	$214.65
28293	T	Correction of bunion	0057	21.11	$1,073.27	$496.65	$214.65
28294	T	Correction of bunion	0057	21.11	$1,073.27	$496.65	$214.65
28296	T	Correction of bunion	0057	21.11	$1,073.27	$496.65	$214.65
28297	T	Correction of bunion	0057	21.11	$1,073.27	$496.65	$214.65
28298	T	Correction of bunion	0057	21.11	$1,073.27	$496.65	$214.65
28299	T	Correction of bunion	0057	21.11	$1,073.27	$496.65	$214.65
28300	T	Incision of heel bone	0056	19.20	$976.17	$405.81	$195.23
28302	T	Incision of ankle bone	0056	19.20	$976.17	$405.81	$195.23
28304	T	Incision of midfoot bones	0056	19.20	$976.17	$405.81	$195.23
28305	T	Incise/graft midfoot bones	0056	19.20	$976.17	$405.81	$195.23
28306	T	Incision of metatarsal	0056	19.20	$976.17	$405.81	$195.23
28307	T	Incision of metatarsal	0056	19.20	$976.17	$405.81	$195.23
28308	T	Incision of metatarsal	0056	19.20	$976.17	$405.81	$195.23
28309	T	Incision of metatarsals	0056	19.20	$976.17	$405.81	$195.23
28310	T	Revision of big toe	0055	16.77	$852.62	$355.34	$170.52
28312	T	Revision of toe	0055	16.77	$852.62	$355.34	$170.52
28313	T	Repair deformity of toe	0055	16.77	$852.62	$355.34	$170.52

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
28315	T	Removal of sesamoid bone	0055	16.77	$852.62	$355.34	$170.52
28320	T	Repair of foot bones	0056	19.20	$976.17	$405.81	$195.23
28322	T	Repair of metatarsals	0056	19.20	$976.17	$405.81	$195.23
28340	T	Resect enlarged toe tissue	0055	16.77	$852.62	$355.34	$170.52
28341	T	Resect enlarged toe	0055	16.77	$852.62	$355.34	$170.52
28344	T	Repair extra toe(s)	0056	19.20	$976.17	$405.81	$195.23
28345	T	Repair webbed toe(s)	0056	19.20	$976.17	$405.81	$195.23
28360	T	Reconstruct cleft foot	0056	19.20	$976.17	$405.81	$195.23
28400	T	Treatment of heel fracture	0044	2.73	$138.80	$38.08	$27.76
28405	T	Treatment of heel fracture	0044	2.73	$138.80	$38.08	$27.76
28406	T	Treatment of heel fracture	0046	25.36	$1,289.35	$535.76	$257.87
28415	T	Treat heel fracture	0046	25.36	$1,289.35	$535.76	$257.87
28420	T	Treat/graft heel fracture	0046	25.36	$1,289.35	$535.76	$257.87
28430	T	Treatment of ankle fracture	0044	2.73	$138.80	$38.08	$27.76
28435	T	Treatment of ankle fracture	0044	2.73	$138.80	$38.08	$27.76
28436	T	Treatment of ankle fracture	0046	25.36	$1,289.35	$535.76	$257.87
28445	T	Treat ankle fracture	0046	25.36	$1,289.35	$535.76	$257.87
28450	T	Treat midfoot fracture, each	0044	2.73	$138.80	$38.08	$27.76
28455	T	Treat midfoot fracture, each	0044	2.73	$138.80	$38.08	$27.76
28456	T	Treat midfoot fracture	0046	25.36	$1,289.35	$535.76	$257.87
28465	T	Treat midfoot fracture, each	0046	25.36	$1,289.35	$535.76	$257.87
28470	T	Treat metatarsal fracture	0044	2.73	$138.80	$38.08	$27.76
28475	T	Treat metatarsal fracture	0044	2.73	$138.80	$38.08	$27.76
28476	T	Treat metatarsal fracture	0046	25.36	$1,289.35	$535.76	$257.87
28485	T	Treat metatarsal fracture	0046	25.36	$1,289.35	$535.76	$257.87
28490	T	Treat big toe fracture	0044	2.73	$138.80	$38.08	$27.76
28495	T	Treat big toe fracture	0044	2.73	$138.80	$38.08	$27.76
28496	T	Treat big toe fracture	0046	25.36	$1,289.35	$535.76	$257.87
28505	T	Treat big toe fracture	0046	25.36	$1,289.35	$535.76	$257.87
28510	T	Treatment of toe fracture	0043	4.13	$209.98	$42.00	$42.00
28515	T	Treatment of toe fracture	0043	4.13	$209.98	$42.00	$42.00
28525	T	Treat toe fracture	0046	25.36	$1,289.35	$535.76	$257.87
28530	T	Treat sesamoid bone fracture	0044	2.73	$138.80	$38.08	$27.76
28531	T	Treat sesamoid bone fracture	0046	25.36	$1,289.35	$535.76	$257.87
28540	T	Treat foot dislocation	0044	2.73	$138.80	$38.08	$27.76
28545	T	Treat foot dislocation	0045	12.91	$656.37	$277.12	$131.27
28546	T	Treat foot dislocation	0046	25.36	$1,289.35	$535.76	$257.87
28555	T	Repair foot dislocation	0046	25.36	$1,289.35	$535.76	$257.87
28570	T	Treat foot dislocation	0044	2.73	$138.80	$38.08	$27.76
28575	T	Treat foot dislocation	0043	4.13	$209.98	$42.00	$42.00
28576	T	Treat foot dislocation	0046	25.36	$1,289.35	$535.76	$257.87
28585	T	Repair foot dislocation	0046	25.36	$1,289.35	$535.76	$257.87
28600	T	Treat foot dislocation	0044	2.73	$138.80	$38.08	$27.76
28605	T	Treat foot dislocation	0043	4.13	$209.98	$42.00	$42.00
28606	T	Treat foot dislocation	0046	25.36	$1,289.35	$535.76	$257.87
28615	T	Repair foot dislocation	0046	25.36	$1,289.35	$535.76	$257.87
28630	T	Treat toe dislocation	0044	2.73	$138.80	$38.08	$27.76
28635	T	Treat toe dislocation	0045	12.91	$656.37	$277.12	$131.27
28636	T	Treat toe dislocation	0046	25.36	$1,289.35	$535.76	$257.87
28645	T	Repair toe dislocation	0046	25.36	$1,289.35	$535.76	$257.87
28660	T	Treat toe dislocation	0043	4.13	$209.98	$42.00	$42.00
28665	T	Treat toe dislocation	0045	12.91	$656.37	$277.12	$131.27
28666	T	Treat toe dislocation	0046	25.36	$1,289.35	$535.76	$257.87
28675	T	Repair of toe dislocation	0046	25.36	$1,289.35	$535.76	$257.87
28705	T	Fusion of foot bones	0056	19.20	$976.17	$405.81	$195.23
28715	T	Fusion of foot bones	0056	19.20	$976.17	$405.81	$195.23
28725	T	Fusion of foot bones	0056	19.20	$976.17	$405.81	$195.23
28730	T	Fusion of foot bones	0056	19.20	$976.17	$405.81	$195.23
28735	T	Fusion of foot bones	0056	19.20	$976.17	$405.81	$195.23
28737	T	Revision of foot bones	0055	16.77	$852.62	$355.34	$170.52
28740	T	Fusion of foot bones	0056	19.20	$976.17	$405.81	$195.23
28750	T	Fusion of big toe joint	0055	16.77	$852.62	$355.34	$170.52
28755	T	Fusion of big toe joint	0055	16.77	$852.62	$355.34	$170.52
28760	T	Fusion of big toe joint	0056	19.20	$976.17	$405.81	$195.23
28800	C	Amputation of midfoot	.....	.....	.....	.....	.....
28805	C	Amputation thru metatarsal	.....	.....	.....	.....	.....
28810	T	Amputation toe & metatarsal	0055	16.77	$852.62	$355.34	$170.52
28820	T	Amputation of toe	0055	16.77	$852.62	$355.34	$170.52
28825	T	Partial amputation of toe	0055	16.77	$852.62	$355.34	$170.52
28899	T	Foot/toes surgery procedure	0043	4.13	$209.98	$42.00	$42.00
29000	S	Application of body cast	0059	2.34	$118.97	$29.59	$23.79
29010	S	Application of body cast	0059	2.34	$118.97	$29.59	$23.79
29015	S	Application of body cast	0059	2.34	$118.97	$29.59	$23.79
29020	S	Application of body cast	0059	2.34	$118.97	$29.59	$23.79
29025	S	Application of body cast	0059	2.34	$118.97	$29.59	$23.79

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
29035	S	Application of body cast	0058	1.36	$69.15	$19.27	$13.83
29040	S	Application of body cast	0059	2.34	$118.97	$29.59	$23.79
29044	S	Application of body cast	0059	2.34	$118.97	$29.59	$23.79
29046	S	Application of body cast	0059	2.34	$118.97	$29.59	$23.79
29049	S	Application of figure eight	0059	2.34	$118.97	$29.59	$23.79
29055	S	Application of shoulder cast	0059	2.34	$118.97	$29.59	$23.79
29058	S	Application of shoulder cast	0059	2.34	$118.97	$29.59	$23.79
29065	S	Application of long arm cast	0059	2.34	$118.97	$29.59	$23.79
29075	S	Application of forearm cast	0058	1.36	$69.15	$19.27	$13.83
29085	S	Apply hand/wrist cast	0058	1.36	$69.15	$19.27	$13.83
29105	S	Apply long arm splint	0058	1.36	$69.15	$19.27	$13.83
29125	S	Apply forearm splint	0058	1.36	$69.15	$19.27	$13.83
29126	S	Apply forearm splint	0058	1.36	$69.15	$19.27	$13.83
29130	S	Application of finger splint	0058	1.36	$69.15	$19.27	$13.83
29131	S	Application of finger splint	0058	1.36	$69.15	$19.27	$13.83
29200	S	Strapping of chest	0058	1.36	$69.15	$19.27	$13.83
29220	S	Strapping of low back	0059	2.34	$118.97	$29.59	$23.79
29240	S	Strapping of shoulder	0058	1.36	$69.15	$19.27	$13.83
29260	S	Strapping of elbow or wrist	0058	1.36	$69.15	$19.27	$13.83
29280	S	Strapping of hand or finger	0058	1.36	$69.15	$19.27	$13.83
29305	S	Application of hip cast	0058	1.36	$69.15	$19.27	$13.83
29325	S	Application of hip casts	0059	2.34	$118.97	$29.59	$23.79
29345	S	Application of long leg cast	0059	2.34	$118.97	$29.59	$23.79
29355	S	Application of long leg cast	0059	2.34	$118.97	$29.59	$23.79
29358	S	Apply long leg cast brace	0059	2.34	$118.97	$29.59	$23.79
29365	S	Application of long leg cast	0059	2.34	$118.97	$29.59	$23.79
29405	S	Apply short leg cast	0058	1.36	$69.15	$19.27	$13.83
29425	S	Apply short leg cast	0059	2.34	$118.97	$29.59	$23.79
29435	S	Apply short leg cast	0058	1.36	$69.15	$19.27	$13.83
29440	S	Addition of walker to cast	0059	2.34	$118.97	$29.59	$23.79
29445	S	Apply rigid leg cast	0059	2.34	$118.97	$29.59	$23.79
29450	S	Application of leg cast	0059	2.34	$118.97	$29.59	$23.79
29505	S	Application, long leg splint	0059	2.34	$118.97	$29.59	$23.79
29515	S	Application lower leg splint	0059	2.34	$118.97	$29.59	$23.79
29520	S	Strapping of hip	0058	1.36	$69.15	$19.27	$13.83
29530	S	Strapping of knee	0058	1.36	$69.15	$19.27	$13.83
29540	S	Strapping of ankle	0058	1.36	$69.15	$19.27	$13.83
29550	S	Strapping of toes	0058	1.36	$69.15	$19.27	$13.83
29580	S	Application of paste boot	0058	1.36	$69.15	$19.27	$13.83
29590	S	Application of foot splint	0058	1.36	$69.15	$19.27	$13.83
29700	S	Removal/revision of cast	0058	1.36	$69.15	$19.27	$13.83
29705	S	Removal/revision of cast	0058	1.36	$69.15	$19.27	$13.83
29710	S	Removal/revision of cast	0058	1.36	$69.15	$19.27	$13.83
29715	S	Removal/revision of cast	0058	1.36	$69.15	$19.27	$13.83
29720	S	Repair of body cast	0058	1.36	$69.15	$19.27	$13.83
29730	S	Windowing of cast	0058	1.36	$69.15	$19.27	$13.83
29740	S	Wedging of cast	0058	1.36	$69.15	$19.27	$13.83
29750	S	Wedging of clubfoot cast	0058	1.36	$69.15	$19.27	$13.83
29799	N	Casting/strapping procedure	.....	.....	.....	.....	.....
29800	T	Jaw arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29804	T	Jaw arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29815	T	Shoulder arthroscopy	0041	26.18	$1,331.04	$592.08	$266.21
29819	T	Shoulder arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29820	T	Shoulder arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29821	T	Shoulder arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29822	T	Shoulder arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29823	T	Shoulder arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29825	T	Shoulder arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29826	T	Shoulder arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29830	T	Elbow arthroscopy	0041	26.18	$1,331.04	$592.08	$266.21
29834	T	Elbow arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29835	T	Elbow arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29836	T	Elbow arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29837	T	Elbow arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29838	T	Elbow arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29840	T	Wrist arthroscopy	0041	26.18	$1,331.04	$592.08	$266.21
29843	T	Wrist arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29844	T	Wrist arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29845	T	Wrist arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29846	T	Wrist arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29847	T	Wrist arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29848	T	Wrist endoscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29850	T	Knee arthroscopy/surgery	0042	39.39	$2,002.67	$804.74	$400.53
29851	T	Knee arthroscopy/surgery	0042	39.39	$2,002.67	$804.74	$400.53
29855	T	Tibial arthroscopy/surgery	0042	39.39	$2,002.67	$804.74	$400.53

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
29856	T	Tibial arthroscopy/surgery	0042	39.39	$2,002.67	$804.74	$400.53
29860	T	Hip arthroscopy, dx	0041	26.18	$1,331.04	$592.08	$266.21
29861	T	Hip arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29862	T	Hip arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29863	T	Hip arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29870	T	Knee arthroscopy, dx	0041	26.18	$1,331.04	$592.08	$266.21
29871	T	Knee arthroscopy/drainage	0041	26.18	$1,331.04	$592.08	$266.21
29874	T	Knee arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29875	T	Knee arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29876	T	Knee arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29877	T	Knee arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29879	T	Knee arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29880	T	Knee arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29881	T	Knee arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29882	T	Knee arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29883	T	Knee arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29884	T	Knee arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29885	T	Knee arthroscopy/surgery	0042	39.39	$2,002.67	$804.74	$400.53
29886	T	Knee arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29887	T	Knee arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29888	T	Knee arthroscopy/surgery	0042	39.39	$2,002.67	$804.74	$400.53
29889	T	Knee arthroscopy/surgery	0042	39.39	$2,002.67	$804.74	$400.53
29891	T	Ankle arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29892	T	Ankle arthroscopy/surgery	0042	39.39	$2,002.67	$804.74	$400.53
29893	T	Scope, plantar fasciotomy	0055	16.77	$852.62	$355.34	$170.52
29894	T	Ankle arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29895	T	Ankle arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29897	T	Ankle arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29898	T	Ankle arthroscopy/surgery	0041	26.18	$1,331.04	$592.08	$266.21
29909	T	Arthroscopy of joint	0041	26.18	$1,331.04	$592.08	$266.21
30000	T	Drainage of nose lesion	0251	2.71	$137.78	$27.99	$27.56
30020	T	Drainage of nose lesion	0251	2.71	$137.78	$27.99	$27.56
30100	T	Intranasal biopsy	0252	6.53	$332.00	$114.24	$66.40
30110	T	Removal of nose polyp(s)	0253	13.27	$674.67	$284.00	$134.93
30115	T	Removal of nose polyp(s)	0253	13.27	$674.67	$284.00	$134.93
30117	T	Removal of intranasal lesion	0253	13.27	$674.67	$284.00	$134.93
30118	T	Removal of intranasal lesion	0254	19.11	$971.59	$272.41	$194.32
30120	T	Revision of nose	0253	13.27	$674.67	$284.00	$134.93
30124	T	Removal of nose lesion	0252	6.53	$332.00	$114.24	$66.40
30125	T	Removal of nose lesion	0256	28.82	$1,465.27	$623.05	$293.05
30130	T	Removal of turbinate bones	0253	13.27	$674.67	$284.00	$134.93
30140	T	Removal of turbinate bones	0254	19.11	$971.59	$272.41	$194.32
30150	T	Partial removal of nose	0256	28.82	$1,465.27	$623.05	$293.05
30160	T	Removal of nose	0256	28.82	$1,465.27	$623.05	$293.05
30200	T	Injection treatment of nose	0253	13.27	$674.67	$284.00	$134.93
30210	T	Nasal sinus therapy	0252	6.53	$332.00	$114.24	$66.40
30220	T	Insert nasal septal button	0252	6.53	$332.00	$114.24	$66.40
30300	X	Remove nasal foreign body	0340	0.91	$46.27	$11.57	$9.25
30310	T	Remove nasal foreign body	0253	13.27	$674.67	$284.00	$134.93
30320	T	Remove nasal foreign body	0253	13.27	$674.67	$284.00	$134.93
30400	T	Reconstruction of nose	0256	28.82	$1,465.27	$623.05	$293.05
30410	T	Reconstruction of nose	0256	28.82	$1,465.27	$623.05	$293.05
30420	T	Reconstruction of nose	0256	28.82	$1,465.27	$623.05	$293.05
30430	T	Revision of nose	0254	19.11	$971.59	$272.41	$194.32
30435	T	Revision of nose	0256	28.82	$1,465.27	$623.05	$293.05
30450	T	Revision of nose	0256	28.82	$1,465.27	$623.05	$293.05
30460	T	Revision of nose	0256	28.82	$1,465.27	$623.05	$293.05
30462	T	Revision of nose	0256	28.82	$1,465.27	$623.05	$293.05
30465	T	Repair nasal stenosis	0256	28.82	$1,465.27	$623.05	$293.05
30520	T	Repair of nasal septum	0256	28.82	$1,465.27	$623.05	$293.05
30540	T	Repair nasal defect	0256	28.82	$1,465.27	$623.05	$293.05
30545	T	Repair nasal defect	0256	28.82	$1,465.27	$623.05	$293.05
30560	T	Release of nasal adhesions	0251	2.71	$137.78	$27.99	$27.56
30580	T	Repair upper jaw fistula	0256	28.82	$1,465.27	$623.05	$293.05
30600	T	Repair mouth/nose fistula	0256	28.82	$1,465.27	$623.05	$293.05
30620	T	Intranasal reconstruction	0256	28.82	$1,465.27	$623.05	$293.05
30630	T	Repair nasal septum defect	0254	19.11	$971.59	$272.41	$194.32
30801	T	Cauterization, inner nose	0252	6.53	$332.00	$114.24	$66.40
30802	T	Cauterization, inner nose	0253	13.27	$674.67	$284.00	$134.93
30901	T	Control of nosebleed	0250	2.27	$115.41	$38.54	$23.08
30903	T	Control of nosebleed	0250	2.27	$115.41	$38.54	$23.08
30905	T	Control of nosebleed	0250	2.27	$115.41	$38.54	$23.08
30906	T	Repeat control of nosebleed	0250	2.27	$115.41	$38.54	$23.08
30915	T	Ligation, nasal sinus artery	0091	22.17	$1,127.17	$348.23	$225.43
30920	T	Ligation, upper jaw artery	0092	21.43	$1,089.54	$505.37	$217.91

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
30930	T	Therapy, fracture of nose	0253	13.27	$674.67	$284.00	$134.93
30999	T	Nasal surgery procedure	0251	2.71	$137.78	$27.99	$27.56
31000	T	Irrigation, maxillary sinus	0251	2.71	$137.78	$27.99	$27.56
31002	T	Irrigation, sphenoid sinus	0252	6.53	$332.00	$114.24	$66.40
31020	T	Exploration, maxillary sinus	0254	19.11	$971.59	$272.41	$194.32
31030	T	Exploration, maxillary sinus	0256	28.82	$1,465.27	$623.05	$293.05
31032	T	Explore sinus,remove polyps	0256	28.82	$1,465.27	$623.05	$293.05
31040	T	Exploration behind upper jaw	0254	19.11	$971.59	$272.41	$194.32
31050	T	Exploration, sphenoid sinus	0256	28.82	$1,465.27	$623.05	$293.05
31051	T	Sphenoid sinus surgery	0256	28.82	$1,465.27	$623.05	$293.05
31070	T	Exploration of frontal sinus	0254	19.11	$971.59	$272.41	$194.32
31075	T	Exploration of frontal sinus	0256	28.82	$1,465.27	$623.05	$293.05
31080	T	Removal of frontal sinus	0256	28.82	$1,465.27	$623.05	$293.05
31081	T	Removal of frontal sinus	0256	28.82	$1,465.27	$623.05	$293.05
31084	T	Removal of frontal sinus	0256	28.82	$1,465.27	$623.05	$293.05
31085	T	Removal of frontal sinus	0256	28.82	$1,465.27	$623.05	$293.05
31086	T	Removal of frontal sinus	0256	28.82	$1,465.27	$623.05	$293.05
31087	T	Removal of frontal sinus	0256	28.82	$1,465.27	$623.05	$293.05
31090	T	Exploration of sinuses	0256	28.82	$1,465.27	$623.05	$293.05
31200	T	Removal of ethmoid sinus	0256	28.82	$1,465.27	$623.05	$293.05
31201	T	Removal of ethmoid sinus	0256	28.82	$1,465.27	$623.05	$293.05
31205	T	Removal of ethmoid sinus	0256	28.82	$1,465.27	$623.05	$293.05
31225	C	Removal of upper jaw					
31230	C	Removal of upper jaw					
31231	T	Nasal endoscopy, dx	0071	1.08	$54.91	$14.22	$10.98
31233	T	Nasal/sinus endoscopy, dx	0072	1.29	$65.59	$36.08	$13.12
31235	T	Nasal/sinus endoscopy, dx	0074	14.62	$743.31	$347.54	$148.66
31237	T	Nasal/sinus endoscopy, surg	0074	14.62	$743.31	$347.54	$148.66
31238	T	Nasal/sinus endoscopy, surg	0074	14.62	$743.31	$347.54	$148.66
31239	T	Nasal/sinus endoscopy, surg	0075	19.08	$970.07	$467.29	$194.01
31240	T	Nasal/sinus endoscopy, surg	0074	14.62	$743.31	$347.54	$148.66
31254	T	Revision of ethmoid sinus	0075	19.08	$970.07	$467.29	$194.01
31255	T	Removal of ethmoid sinus	0075	19.08	$970.07	$467.29	$194.01
31256	T	Exploration maxillary sinus	0075	19.08	$970.07	$467.29	$194.01
31267	T	Endoscopy, maxillary sinus	0075	19.08	$970.07	$467.29	$194.01
31276	T	Sinus endoscopy, surgical	0075	19.08	$970.07	$467.29	$194.01
31287	T	Nasal/sinus endoscopy, surg	0075	19.08	$970.07	$467.29	$194.01
31288	T	Nasal/sinus endoscopy, surg	0075	19.08	$970.07	$467.29	$194.01
31290	C	Nasal/sinus endoscopy, surg					
31291	C	Nasal/sinus endoscopy, surg					
31292	C	Nasal/sinus endoscopy, surg					
31293	C	Nasal/sinus endoscopy, surg					
31294	C	Nasal/sinus endoscopy, surg					
31299	T	Sinus surgery procedure	0252	6.53	$332.00	$114.24	$66.40
31300	T	Removal of larynx lesion	0256	28.82	$1,465.27	$623.05	$293.05
31320	T	Diagnostic incision, larynx	0256	28.82	$1,465.27	$623.05	$293.05
31360	C	Removal of larynx					
31365	C	Removal of larynx					
31367	C	Partial removal of larynx					
31368	C	Partial removal of larynx					
31370	C	Partial removal of larynx					
31375	C	Partial removal of larynx					
31380	C	Partial removal of larynx					
31382	C	Partial removal of larynx					
31390	C	Removal of larynx & pharynx					
31395	C	Reconstruct larynx & pharynx					
31400	T	Revision of larynx	0256	28.82	$1,465.27	$623.05	$293.05
31420	T	Removal of epiglottis	0256	28.82	$1,465.27	$623.05	$293.05
31500	S	Insert emergency airway	0094	5.69	$289.29	$105.29	$57.86
31502	T	Change of windpipe airway	0121	2.42	$123.04	$52.53	$24.61
31505	T	Diagnostic laryngoscopy	0072	1.29	$65.59	$36.08	$13.12
31510	T	Laryngoscopy with biopsy	0074	14.62	$743.31	$347.54	$148.66
31511	T	Remove foreign body, larynx	0072	1.29	$65.59	$36.08	$13.12
31512	T	Removal of larynx lesion	0074	14.62	$743.31	$347.54	$148.66
31513	T	Injection into vocal cord	0073	3.54	$179.98	$79.19	$36.00
31515	T	Laryngoscopy for aspiration	0074	14.62	$743.31	$347.54	$148.66
31520	T	Diagnostic laryngoscopy	0072	1.29	$65.59	$36.08	$13.12
31525	T	Diagnostic laryngoscopy	0074	14.62	$743.31	$347.54	$148.66
31526	T	Diagnostic laryngoscopy	0074	14.62	$743.31	$347.54	$148.66
31527	T	Laryngoscopy for treatment	0075	19.08	$970.07	$467.29	$194.01
31528	T	Laryngoscopy and dilatation	0074	14.62	$743.31	$347.54	$148.66
31529	T	Laryngoscopy and dilatation	0074	14.62	$743.31	$347.54	$148.66
31530	T	Operative laryngoscopy	0075	19.08	$970.07	$467.29	$194.01
31531	T	Operative laryngoscopy	0075	19.08	$970.07	$467.29	$194.01
31535	T	Operative laryngoscopy	0075	19.08	$970.07	$467.29	$194.01

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
31536	T	Operative laryngoscopy	0075	19.08	$970.07	$467.29	$194.01
31540	T	Operative laryngoscopy	0075	19.08	$970.07	$467.29	$194.01
31541	T	Operative laryngoscopy	0075	19.08	$970.07	$467.29	$194.01
31560	T	Operative laryngoscopy	0075	19.08	$970.07	$467.29	$194.01
31561	T	Operative laryngoscopy	0075	19.08	$970.07	$467.29	$194.01
31570	T	Laryngoscopy with injection	0074	14.62	$743.31	$347.54	$148.66
31571	T	Laryngoscopy with injection	0075	19.08	$970.07	$467.29	$194.01
31575	T	Diagnostic laryngoscopy	0071	1.08	$54.91	$14.22	$10.98
31576	T	Laryngoscopy with biopsy	0074	14.62	$743.31	$347.54	$148.66
31577	T	Remove foreign body, larynx	0073	3.54	$179.98	$79.19	$36.00
31578	T	Removal of larynx lesion	0075	19.08	$970.07	$467.29	$194.01
31579	T	Diagnostic laryngoscopy	0073	3.54	$179.98	$79.19	$36.00
31580	T	Revision of larynx	0256	28.82	$1,465.27	$623.05	$293.05
31582	C	Revision of larynx					
31584	C	Treat larynx fracture					
31585	T	Treat larynx fracture	0253	13.27	$674.67	$284.00	$134.93
31586	T	Treat larynx fracture	0256	28.82	$1,465.27	$623.05	$293.05
31587	C	Revision of larynx					
31588	T	Revision of larynx	0256	28.82	$1,465.27	$623.05	$293.05
31590	T	Reinnervate larynx	0256	28.82	$1,465.27	$623.05	$293.05
31595	T	Larynx nerve surgery	0256	28.82	$1,465.27	$623.05	$293.05
31599	T	Larynx surgery procedure	0254	19.11	$971.59	$272.41	$194.32
31600	T	Incision of windpipe	0254	19.11	$971.59	$272.41	$194.32
31601	T	Incision of windpipe	0254	19.11	$971.59	$272.41	$194.32
31603	T	Incision of windpipe	0252	6.53	$332.00	$114.24	$66.40
31605	T	Incision of windpipe	0253	13.27	$674.67	$284.00	$134.93
31610	T	Incision of windpipe	0254	19.11	$971.59	$272.41	$194.32
31611	T	Surgery/speech prosthesis	0254	19.11	$971.59	$272.41	$194.32
31612	T	Puncture/clear windpipe	0254	19.11	$971.59	$272.41	$194.32
31613	T	Repair windpipe opening	0254	19.11	$971.59	$272.41	$194.32
31614	T	Repair windpipe opening	0256	28.82	$1,465.27	$623.05	$293.05
31615	T	Visualization of windpipe	0076	8.22	$417.92	$197.05	$83.58
31622	T	Dx bronchoscope/wash	0076	8.22	$417.92	$197.05	$83.58
31623	T	Dx bronchoscope/brush	0076	8.22	$417.92	$197.05	$83.58
31624	T	Dx bronchoscope/lavage	0076	8.22	$417.92	$197.05	$83.58
31625	T	Bronchoscopy with biopsy	0076	8.22	$417.92	$197.05	$83.58
31628	T	Bronchoscopy with biopsy	0076	8.22	$417.92	$197.05	$83.58
31629	T	Bronchoscopy with biopsy	0076	8.22	$417.92	$197.05	$83.58
31630	T	Bronchoscopy with repair	0076	8.22	$417.92	$197.05	$83.58
31631	T	Bronchoscopy with dilation	0076	8.22	$417.92	$197.05	$83.58
31635	T	Remove foreign body, airway	0076	8.22	$417.92	$197.05	$83.58
31640	T	Bronchoscopy & remove lesion	0076	8.22	$417.92	$197.05	$83.58
31641	T	Bronchoscopy, treat blockage	0076	8.22	$417.92	$197.05	$83.58
31643	T	Diag bronchoscope/catheter	0076	8.22	$417.92	$197.05	$83.58
31645	T	Bronchoscopy, clear airways	0076	8.22	$417.92	$197.05	$83.58
31646	T	Bronchoscopy, reclear airway	0076	8.22	$417.92	$197.05	$83.58
31656	T	Bronchoscopy, inj for xray	0076	8.22	$417.92	$197.05	$83.58
31700	T	Insertion of airway catheter	0072	1.29	$65.59	$36.08	$13.12
31708	N	Instill airway contrast dye					
31710	N	Insertion of airway catheter					
31715	N	Injection for bronchus x-ray					
31717	T	Bronchial brush biopsy	0073	3.54	$179.98	$79.19	$36.00
31720	T	Clearance of airways	0072	1.29	$65.59	$36.08	$13.12
31725	C	Clearance of airways					
31730	T	Intro, windpipe wire/tube	0073	3.54	$179.98	$79.19	$36.00
31750	T	Repair of windpipe	0256	28.82	$1,465.27	$623.05	$293.05
31755	T	Repair of windpipe	0256	28.82	$1,465.27	$623.05	$293.05
31760	C	Repair of windpipe					
31766	C	Reconstruction of windpipe					
31770	C	Repair/graft of bronchus					
31775	C	Reconstruct bronchus					
31780	C	Reconstruct windpipe					
31781	C	Reconstruct windpipe					
31785	C	Remove windpipe lesion					
31786	C	Remove windpipe lesion					
31800	C	Repair of windpipe injury					
31805	C	Repair of windpipe injury					
31820	T	Closure of windpipe lesion	0253	13.27	$674.67	$284.00	$134.93
31825	T	Repair of windpipe defect	0254	19.11	$971.59	$272.41	$194.32
31830	T	Revise windpipe scar	0254	19.11	$971.59	$272.41	$194.32
31899	T	Airways surgical procedure	0076	8.22	$417.92	$197.05	$83.58
32000	T	Drainage of chest	0070	4.11	$208.96	$79.60	$41.79
32002	T	Treatment of collapsed lung	0070	4.11	$208.96	$79.60	$41.79
32005	T	Treat lung lining chemically	0070	4.11	$208.96	$79.60	$41.79
32020	T	Insertion of chest tube	0070	4.11	$208.96	$79.60	$41.79

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
32035	C	Exploration of chest					
32036	C	Exploration of chest					
32095	C	Biopsy through chest wall					
32100	C	Exploration/biopsy of chest					
32110	C	Explore/repair chest					
32120	C	Re-exploration of chest					
32124	C	Explore chest free adhesions					
32140	C	Removal of lung lesion(s)					
32141	C	Remove/treat lung lesions					
32150	C	Removal of lung lesion(s)					
32151	C	Remove lung foreign body					
32160	C	Open chest heart massage					
32200	C	Drain, open, lung lesion					
32201	C	Drain, percut, lung lesion					
32215	C	Treat chest lining					
32220	C	Release of lung					
32225	C	Partial release of lung					
32310	C	Removal of chest lining					
32320	C	Free/remove chest lining					
32400	T	Needle biopsy chest lining	0005	6.71	$341.15	$119.75	$68.23
32402	C	Open biopsy chest lining					
32405	T	Biopsy, lung or mediastinum	0005	6.71	$341.15	$119.75	$68.23
32420	T	Puncture/clear lung	0070	4.11	$208.96	$79.60	$41.79
32440	C	Removal of lung					
32442	C	Sleeve pneumonectomy					
32445	C	Removal of lung					
32480	C	Partial removal of lung					
32482	C	Bilobectomy					
32484	C	Segmentectomy					
32486	C	Sleeve lobectomy					
32488	C	Completion pneumonectomy					
32491	C	Lung volume reduction					
32500	C	Partial removal of lung					
32501	C	Repair bronchus add-on					
32520	C	Remove lung & revise chest					
32522	C	Remove lung & revise chest					
32525	C	Remove lung & revise chest					
32540	C	Removal of lung lesion					
32601	T	Thoracoscopy, diagnostic	0069	25.62	$1,302.57	$612.21	$260.51
32602	T	Thoracoscopy, diagnostic	0069	25.62	$1,302.57	$612.21	$260.51
32603	T	Thoracoscopy, diagnostic	0069	25.62	$1,302.57	$612.21	$260.51
32604	T	Thoracoscopy, diagnostic	0069	25.62	$1,302.57	$612.21	$260.51
32605	T	Thoracoscopy, diagnostic	0069	25.62	$1,302.57	$612.21	$260.51
32606	T	Thoracoscopy, diagnostic	0069	25.62	$1,302.57	$612.21	$260.51
32650	C	Thoracoscopy, surgical					
32651	C	Thoracoscopy, surgical					
32652	C	Thoracoscopy, surgical					
32653	C	Thoracoscopy, surgical					
32654	C	Thoracoscopy, surgical					
32655	C	Thoracoscopy, surgical					
32656	C	Thoracoscopy, surgical					
32657	C	Thoracoscopy, surgical					
32658	C	Thoracoscopy, surgical					
32659	C	Thoracoscopy, surgical					
32660	C	Thoracoscopy, surgical					
32661	C	Thoracoscopy, surgical					
32662	C	Thoracoscopy, surgical					
32663	C	Thoracoscopy, surgical					
32664	C	Thoracoscopy, surgical					
32665	C	Thoracoscopy, surgical					
32800	C	Repair lung hernia					
32810	C	Close chest after drainage					
32815	C	Close bronchial fistula					
32820	C	Reconstruct injured chest					
32850	C	Donor pneumonectomy					
32851	C	Lung transplant, single					
32852	C	Lung transplant with bypass					
32853	C	Lung transplant, double					
32854	C	Lung transplant with bypass					
32900	C	Removal of rib(s)					
32905	C	Revise & repair chest wall					
32906	C	Revise & repair chest wall					
32940	C	Revision of lung					
32960	T	Therapeutic pneumothorax	0070	4.11	$208.96	$79.60	$41.79
32997	C	Total lung lavage					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
32999	T	Chest surgery procedure	0070	4.11	$208.96	$79.60	$41.79
33010	T	Drainage of heart sac	0070	4.11	$208.96	$79.60	$41.79
33011	T	Repeat drainage of heart sac	0070	4.11	$208.96	$79.60	$41.79
33015	C	Incision of heart sac					
33020	C	Incision of heart sac					
33025	C	Incision of heart sac					
33030	C	Partial removal of heart sac					
33031	C	Partial removal of heart sac					
33050	C	Removal of heart sac lesion					
33120	C	Removal of heart lesion					
33130	C	Removal of heart lesion					
33140	C	Heart revascularize (tmr)					
33141	C	Heart tmr w/other procedure					
33200	C	Insertion of heart pacemaker					
33201	C	Insertion of heart pacemaker					
33206	T	Insertion of heart pacemaker	0089	82.60	$4,199.55	$2,246.59	$839.91
33207	T	Insertion of heart pacemaker	0089	82.60	$4,199.55	$2,246.59	$839.91
33208	T	Insertion of heart pacemaker	0089	82.60	$4,199.55	$2,246.59	$839.91
33210	T	Insertion of heart electrode	0106	15.82	$804.32	$426.29	$160.86
33211	T	Insertion of heart electrode	0106	15.82	$804.32	$426.29	$160.86
33212	T	Insertion of pulse generator	0090	73.37	$3,730.28	$2,014.35	$746.06
33213	T	Insertion of pulse generator	0090	73.37	$3,730.28	$2,014.35	$746.06
33214	T	Upgrade of pacemaker system	0089	82.60	$4,199.55	$2,246.59	$839.91
33216	T	Revise eltrd pacing-defib	0106	15.82	$804.32	$426.29	$160.86
33217	T	Revise eltrd pacing-defib	0106	15.82	$804.32	$426.29	$160.86
33218	T	Revise eltrd pacing-defib	0106	15.82	$804.32	$426.29	$160.86
33220	T	Revise eltrd pacing-defib	0106	15.82	$804.32	$426.29	$160.86
33222	T	Revise pocket, pacemaker	0026	13.51	$686.88	$277.92	$137.38
33223	T	Revise pocket, pacing-defib	0026	13.51	$686.88	$277.92	$137.38
33233	T	Removal of pacemaker system	0105	16.56	$841.94	$372.32	$168.39
33234	T	Removal of pacemaker system	0105	16.56	$841.94	$372.32	$168.39
33235	T	Removal pacemaker electrode	0105	16.56	$841.94	$372.32	$168.39
33236	C	Remove electrode/thoracotomy					
33237	C	Remove electrode/thoracotomy					
33238	C	Remove electrode/thoracotomy					
33240	T	Insert pulse generator	0107	155.27	$7,894.24	$4,224.27	$1,578.85
33241	T	Remove pulse generator	0105	16.56	$841.94	$372.32	$168.39
33243	C	Remove eltrd/thoracotomy					
33244	T	Remove eltrd, transven	0105	16.56	$841.94	$372.32	$168.39
33245	C	Insert epic eltrd pace-defib					
33246	C	Insert epic eltrd/generator					
33249	T	Eltrd/insert pace-defib	0108	159.42	$8,105.23	$4,214.72	$1,621.05
33250	C	Ablate heart dysrhythm focus					
33251	C	Ablate heart dysrhythm focus					
33253	C	Reconstruct atria					
33261	C	Ablate heart dysrhythm focus					
33282	S	Implant pat-active ht record	0974	7.57	$384.87		$76.97
33284	T	Remove pat-active ht record	0109	6.57	$334.03	$133.51	$66.81
33300	C	Repair of heart wound					
33305	C	Repair of heart wound					
33310	C	Exploratory heart surgery					
33315	C	Exploratory heart surgery					
33320	C	Repair major blood vessel(s)					
33321	C	Repair major vessel					
33322	C	Repair major blood vessel(s)					
33330	C	Insert major vessel graft					
33332	C	Insert major vessel graft					
33335	C	Insert major vessel graft					
33400	C	Repair of aortic valve					
33401	C	Valvuloplasty, open					
33403	C	Valvuloplasty, w/cp bypass					
33404	C	Prepare heart-aorta conduit					
33405	C	Replacement of aortic valve					
33406	C	Replacement of aortic valve					
33410	C	Replacement of aortic valve					
33411	C	Replacement of aortic valve					
33412	C	Replacement of aortic valve					
33413	C	Replacement of aortic valve					
33414	C	Repair of aortic valve					
33415	C	Revision, subvalvular tissue					
33416	C	Revise ventricle muscle					
33417	C	Repair of aortic valve					
33420	C	Revision of mitral valve					
33422	C	Revision of mitral valve					
33425	C	Repair of mitral valve					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
33426	C	Repair of mitral valve					
33427	C	Repair of mitral valve					
33430	C	Replacement of mitral valve					
33460	C	Revision of tricuspid valve					
33463	C	Valvuloplasty, tricuspid					
33464	C	Valvuloplasty, tricuspid					
33465	C	Replace tricuspid valve					
33468	C	Revision of tricuspid valve					
33470	C	Revision of pulmonary valve					
33471	C	Valvotomy, pulmonary valve					
33472	C	Revision of pulmonary valve					
33474	C	Revision of pulmonary valve					
33475	C	Replacement, pulmonary valve					
33476	C	Revision of heart chamber					
33478	C	Revision of heart chamber					
33496	C	Repair, prosth valve clot					
33500	C	Repair heart vessel fistula					
33501	C	Repair heart vessel fistula					
33502	C	Coronary artery correction					
33503	C	Coronary artery graft					
33504	C	Coronary artery graft					
33505	C	Repair artery w/tunnel					
33506	C	Repair artery, translocation					
33510	C	CABG, vein, single					
33511	C	CABG, vein, two					
33512	C	CABG, vein, three					
33513	C	CABG, vein, four					
33514	C	CABG, vein, five					
33516	C	Cabg, vein, six or more					
33517	C	CABG, artery-vein, single					
33518	C	CABG, artery-vein, two					
33519	C	CABG, artery-vein, three					
33521	C	CABG, artery-vein, four					
33522	C	CABG, artery-vein, five					
33523	C	Cabg, art-vein, six or more					
33530	C	Coronary artery, bypass/reop					
33533	C	CABG, arterial, single					
33534	C	CABG, arterial, two					
33535	C	CABG, arterial, three					
33536	C	Cabg, arterial, four or more					
33542	C	Removal of heart lesion					
33545	C	Repair of heart damage					
33572	C	Open coronary endarterectomy					
33600	C	Closure of valve					
33602	C	Closure of valve					
33606	C	Anastomosis/artery-aorta					
33608	C	Repair anomaly w/conduit					
33610	C	Repair by enlargement					
33611	C	Repair double ventricle					
33612	C	Repair double ventricle					
33615	C	Repair, modified fontan					
33617	C	Repair single ventricle					
33619	C	Repair single ventricle					
33641	C	Repair heart septum defect					
33645	C	Revision of heart veins					
33647	C	Repair heart septum defects					
33660	C	Repair of heart defects					
33665	C	Repair of heart defects					
33670	C	Repair of heart chambers					
33681	C	Repair heart septum defect					
33684	C	Repair heart septum defect					
33688	C	Repair heart septum defect					
33690	C	Reinforce pulmonary artery					
33692	C	Repair of heart defects					
33694	C	Repair of heart defects					
33697	C	Repair of heart defects					
33702	C	Repair of heart defects					
33710	C	Repair of heart defects					
33720	C	Repair of heart defect					
33722	C	Repair of heart defect					
33730	C	Repair heart-vein defect(s)					
33732	C	Repair heart-vein defect					
33735	C	Revision of heart chamber					
33736	C	Revision of heart chamber					
33737	C	Revision of heart chamber					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
33750	C	Major vessel shunt					
33755	C	Major vessel shunt					
33762	C	Major vessel shunt					
33764	C	Major vessel shunt & graft					
33766	C	Major vessel shunt					
33767	C	Major vessel shunt					
33770	C	Repair great vessels defect					
33771	C	Repair great vessels defect					
33774	C	Repair great vessels defect					
33775	C	Repair great vessels defect					
33776	C	Repair great vessels defect					
33777	C	Repair great vessels defect					
33778	C	Repair great vessels defect					
33779	C	Repair great vessels defect					
33780	C	Repair great vessels defect					
33781	C	Repair great vessels defect					
33786	C	Repair arterial trunk					
33788	C	Revision of pulmonary artery					
33800	C	Aortic suspension					
33802	C	Repair vessel defect					
33803	C	Repair vessel defect					
33813	C	Repair septal defect					
33814	C	Repair septal defect					
33820	C	Revise major vessel					
33822	C	Revise major vessel					
33824	C	Revise major vessel					
33840	C	Remove aorta constriction					
33845	C	Remove aorta constriction					
33851	C	Remove aorta constriction					
33852	C	Repair septal defect					
33853	C	Repair septal defect					
33860	C	Ascending aortic graft					
33861	C	Ascending aortic graft					
33863	C	Ascending aortic graft					
33870	C	Transverse aortic arch graft					
33875	C	Thoracic aortic graft					
33877	C	Thoracoabdominal graft					
33910	C	Remove lung artery emboli					
33915	C	Remove lung artery emboli					
33916	C	Surgery of great vessel					
33917	C	Repair pulmonary artery					
33918	C	Repair pulmonary atresia					
33919	C	Repair pulmonary atresia					
33920	C	Repair pulmonary atresia					
33922	C	Transect pulmonary artery					
33924	C	Remove pulmonary shunt					
33930	C	Removal of donor heart/lung					
33935	C	Transplantation, heart/lung					
33940	C	Removal of donor heart					
33945	C	Transplantation of heart					
33960	C	External circulation assist					
33961	C	External circulation assist					
33968	C	Remove aortic assist device					
33970	C	Aortic circulation assist					
33971	C	Aortic circulation assist					
33973	C	Insert balloon device					
33974	C	Remove intra-aortic balloon					
33975	C	Implant ventricular device					
33976	C	Implant ventricular device					
33977	C	Remove ventricular device					
33978	C	Remove ventricular device					
33999	T	Cardiac surgery procedure	0070	4.11	$208.96	$79.60	$41.79
34001	C	Removal of artery clot					
34051	C	Removal of artery clot					
34101	T	Removal of artery clot	0088	29.11	$1,480.01	$678.68	$296.00
34111	T	Removal of arm artery clot	0088	29.11	$1,480.01	$678.68	$296.00
34151	C	Removal of artery clot					
34201	T	Removal of artery clot	0088	29.11	$1,480.01	$678.68	$296.00
34203	T	Removal of leg artery clot	0088	29.11	$1,480.01	$678.68	$296.00
34401	C	Removal of vein clot					
34421	T	Removal of vein clot	0088	29.11	$1,480.01	$678.68	$296.00
34451	C	Removal of vein clot					
34471	T	Removal of vein clot	0088	29.11	$1,480.01	$678.68	$296.00
34490	T	Removal of vein clot	0088	29.11	$1,480.01	$678.68	$296.00
34501	T	Repair valve, femoral vein	0088	29.11	$1,480.01	$678.68	$296.00

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
34502	C	Reconstruct vena cava					
34510	T	Transposition of vein valve	0088	29.11	$1,480.01	$678.68	$296.00
34520	T	Cross-over vein graft	0088	29.11	$1,480.01	$678.68	$296.00
34530	T	Leg vein fusion	0088	29.11	$1,480.01	$678.68	$296.00
34800	C	Endovasc abdo repair w/tube					
34802	C	Endovasc abdo repr w/device					
34804	C	Endovasc abdo repr w/device					
34808	C	Endovasc abdo occlud device					
34812	C	Xpose for endoprosth, aortic					
34813	C	Xpose for endoprosth, femorl					
34820	C	Xpose for endoprosth, iliac					
34825	C	Endovasc extend prosth, init					
34826	C	Endovasc exten prosth, addl					
34830	C	Open aortic tube prosth repr					
34831	C	Open aortoiliac prosth repr					
34832	C	Open aortofemor prosth repr					
35001	C	Repair defect of artery					
35002	C	Repair artery rupture, neck					
35005	C	Repair defect of artery					
35011	T	Repair defect of artery	0093	15.05	$765.17	$277.34	$153.03
35013	C	Repair artery rupture, arm					
35021	C	Repair defect of artery					
35022	C	Repair artery rupture, chest					
35045	C	Repair defect of arm artery					
35081	C	Repair defect of artery					
35082	C	Repair artery rupture, aorta					
35091	C	Repair defect of artery					
35092	C	Repair artery rupture, aorta					
35102	C	Repair defect of artery					
35103	C	Repair artery rupture, groin					
35111	C	Repair defect of artery					
35112	C	Repair artery rupture,spleen					
35121	C	Repair defect of artery					
35122	C	Repair artery rupture, belly					
35131	C	Repair defect of artery					
35132	C	Repair artery rupture, groin					
35141	C	Repair defect of artery					
35142	C	Repair artery rupture, thigh					
35151	C	Repair defect of artery					
35152	C	Repair artery rupture, knee					
35161	C	Repair defect of artery					
35162	C	Repair artery rupture					
35180	T	Repair blood vessel lesion	0093	15.05	$765.17	$277.34	$153.03
35182	C	Repair blood vessel lesion					
35184	T	Repair blood vessel lesion	0093	15.05	$765.17	$277.34	$153.03
35188	T	Repair blood vessel lesion	0088	29.11	$1,480.01	$678.68	$296.00
35189	C	Repair blood vessel lesion					
35190	T	Repair blood vessel lesion	0093	15.05	$765.17	$277.34	$153.03
35201	T	Repair blood vessel lesion	0093	15.05	$765.17	$277.34	$153.03
35206	T	Repair blood vessel lesion	0093	15.05	$765.17	$277.34	$153.03
35207	T	Repair blood vessel lesion	0088	29.11	$1,480.01	$678.68	$296.00
35211	C	Repair blood vessel lesion					
35216	C	Repair blood vessel lesion					
35221	C	Repair blood vessel lesion					
35226	T	Repair blood vessel lesion	0093	15.05	$765.17	$277.34	$153.03
35231	T	Repair blood vessel lesion	0093	15.05	$765.17	$277.34	$153.03
35236	T	Repair blood vessel lesion	0093	15.05	$765.17	$277.34	$153.03
35241	C	Repair blood vessel lesion					
35246	C	Repair blood vessel lesion					
35251	C	Repair blood vessel lesion					
35256	T	Repair blood vessel lesion	0093	15.05	$765.17	$277.34	$153.03
35261	T	Repair blood vessel lesion	0093	15.05	$765.17	$277.34	$153.03
35266	T	Repair blood vessel lesion	0093	15.05	$765.17	$277.34	$153.03
35271	C	Repair blood vessel lesion					
35276	C	Repair blood vessel lesion					
35281	C	Repair blood vessel lesion					
35286	T	Repair blood vessel lesion	0093	15.05	$765.17	$277.34	$153.03
35301	C	Rechanneling of artery					
35311	C	Rechanneling of artery					
35321	T	Rechanneling of artery	0093	15.05	$765.17	$277.34	$153.03
35331	C	Rechanneling of artery					
35341	C	Rechanneling of artery					
35351	C	Rechanneling of artery					
35355	C	Rechanneling of artery					
35361	C	Rechanneling of artery					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
35363	C	Rechanneling of artery					
35371	C	Rechanneling of artery					
35372	C	Rechanneling of artery					
35381	C	Rechanneling of artery					
35390	C	Reoperation, carotid add-on					
35400	C	Angioscopy					
35450	C	Repair arterial blockage					
35452	C	Repair arterial blockage					
35454	C	Repair arterial blockage					
35456	C	Repair arterial blockage					
35458	T	Repair arterial blockage	0081	22.04	$1,120.56	$549.07	$224.11
35459	T	Repair arterial blockage	0081	22.04	$1,120.56	$549.07	$224.11
35460	T	Repair venous blockage	0081	22.04	$1,120.56	$549.07	$224.11
35470	T	Repair arterial blockage	0081	22.04	$1,120.56	$549.07	$224.11
35471	T	Repair arterial blockage	0081	22.04	$1,120.56	$549.07	$224.11
35472	T	Repair arterial blockage	0081	22.04	$1,120.56	$549.07	$224.11
35473	T	Repair arterial blockage	0081	22.04	$1,120.56	$549.07	$224.11
35474	T	Repair arterial blockage	0081	22.04	$1,120.56	$549.07	$224.11
35475	T	Repair arterial blockage	0081	22.04	$1,120.56	$549.07	$224.11
35476	T	Repair venous blockage	0081	22.04	$1,120.56	$549.07	$224.11
35480	C	Atherectomy, open					
35481	T	Atherectomy, open	0081	22.04	$1,120.56	$549.07	$224.11
35482	C	Atherectomy, open					
35483	C	Atherectomy, open					
35484	T	Atherectomy, open	0081	22.04	$1,120.56	$549.07	$224.11
35485	T	Atherectomy, open	0081	22.04	$1,120.56	$549.07	$224.11
35490	T	Atherectomy, percutaneous	0081	22.04	$1,120.56	$549.07	$224.11
35491	T	Atherectomy, percutaneous	0081	22.04	$1,120.56	$549.07	$224.11
35492	T	Atherectomy, percutaneous	0081	22.04	$1,120.56	$549.07	$224.11
35493	T	Atherectomy, percutaneous	0081	22.04	$1,120.56	$549.07	$224.11
35494	T	Atherectomy, percutaneous	0081	22.04	$1,120.56	$549.07	$224.11
35495	T	Atherectomy, percutaneous	0081	22.04	$1,120.56	$549.07	$224.11
35500	T	Harvest vein for bypass	0081	22.04	$1,120.56	$549.07	$224.11
35501	C	Artery bypass graft					
35506	C	Artery bypass graft					
35507	C	Artery bypass graft					
35508	C	Artery bypass graft					
35509	C	Artery bypass graft					
35511	C	Artery bypass graft					
35515	C	Artery bypass graft					
35516	C	Artery bypass graft					
35518	C	Artery bypass graft					
35521	C	Artery bypass graft					
35526	C	Artery bypass graft					
35531	C	Artery bypass graft					
35533	C	Artery bypass graft					
35536	C	Artery bypass graft					
35541	C	Artery bypass graft					
35546	C	Artery bypass graft					
35548	C	Artery bypass graft					
35549	C	Artery bypass graft					
35551	C	Artery bypass graft					
35556	C	Artery bypass graft					
35558	C	Artery bypass graft					
35560	C	Artery bypass graft					
35563	C	Artery bypass graft					
35565	C	Artery bypass graft					
35566	C	Artery bypass graft					
35571	C	Artery bypass graft					
35582	C	Vein bypass graft					
35583	C	Vein bypass graft					
35585	C	Vein bypass graft					
35587	C	Vein bypass graft					
35600	C	Harvest artery for cabg					
35601	C	Artery bypass graft					
35606	C	Artery bypass graft					
35612	C	Artery bypass graft					
35616	C	Artery bypass graft					
35621	C	Artery bypass graft					
35623	C	Bypass graft, not vein					
35626	C	Artery bypass graft					
35631	C	Artery bypass graft					
35636	C	Artery bypass graft					
35641	C	Artery bypass graft					
35642	C	Artery bypass graft					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
35645	C	Artery bypass graft					
35646	C	Artery bypass graft					
35650	C	Artery bypass graft					
35651	C	Artery bypass graft					
35654	C	Artery bypass graft					
35656	C	Artery bypass graft					
35661	C	Artery bypass graft					
35663	C	Artery bypass graft					
35665	C	Artery bypass graft					
35666	C	Artery bypass graft					
35671	C	Artery bypass graft					
35681	C	Composite bypass graft					
35682	C	Composite bypass graft					
35683	C	Composite bypass graft					
35691	C	Arterial transposition					
35693	C	Arterial transposition					
35694	C	Arterial transposition					
35695	C	Arterial transposition					
35700	C	Reoperation, bypass graft					
35701	C	Exploration, carotid artery					
35721	C	Exploration, femoral artery					
35741	C	Exploration popliteal artery					
35761	T	Exploration of artery/vein	0115	19.06	$969.05	$503.91	$193.81
35800	C	Explore neck vessels					
35820	C	Explore chest vessels					
35840	C	Explore abdominal vessels					
35860	T	Explore limb vessels	0093	15.05	$765.17	$277.34	$153.03
35870	C	Repair vessel graft defect					
35875	T	Removal of clot in graft	0088	29.11	$1,480.01	$678.68	$296.00
35876	T	Removal of clot in graft	0088	29.11	$1,480.01	$678.68	$296.00
35879	T	Revise graft w/vein	0088	29.11	$1,480.01	$678.68	$296.00
35881	T	Revise graft w/vein	0088	29.11	$1,480.01	$678.68	$296.00
35901	C	Excision, graft, neck					
35903	T	Excision, graft, extremity	0115	19.06	$969.05	$503.91	$193.81
35905	C	Excision, graft, thorax					
35907	C	Excision, graft, abdomen					
36000	N	Place needle in vein					
36005	N	Injection, venography					
36010	N	Place catheter in vein					
36011	N	Place catheter in vein					
36012	N	Place catheter in vein					
36013	N	Place catheter in artery					
36014	N	Place catheter in artery					
36015	N	Place catheter in artery					
36100	N	Establish access to artery					
36120	N	Establish access to artery					
36140	N	Establish access to artery					
36145	N	Artery to vein shunt					
36160	N	Establish access to aorta					
36200	N	Place catheter in aorta					
36215	N	Place catheter in artery					
36216	N	Place catheter in artery					
36217	N	Place catheter in artery					
36218	N	Place catheter in artery					
36245	N	Place catheter in artery					
36246	N	Place catheter in artery					
36247	N	Place catheter in artery					
36248	N	Place catheter in artery					
36260	T	Insertion of infusion pump	0119	14.37	$730.60	$161.50	$146.12
36261	T	Revision of infusion pump	0124	25.84	$1,313.76	$722.57	$262.75
36262	T	Removal of infusion pump	0109	6.57	$334.03	$133.51	$66.81
36299	N	Vessel injection procedure					
36400	N	Drawing blood					
36405	N	Drawing blood					
36406	N	Drawing blood					
36410	N	Drawing blood					
36415	E	Drawing blood					
36420	T	Establish access to vein	0035	0.13	$6.61	$2.18	$1.32
36425	T	Establish access to vein	0035	0.13	$6.61	$2.18	$1.32
36430	S	Blood transfusion service	0110	5.76	$292.85	$122.70	$58.57
36440	S	Blood transfusion service	0110	5.76	$292.85	$122.70	$58.57
36450	S	Exchange transfusion service	0110	5.76	$292.85	$122.70	$58.57
36455	S	Exchange transfusion service	0110	5.76	$292.85	$122.70	$58.57
36460	S	Transfusion service, fetal	0110	5.76	$292.85	$122.70	$58.57
36468	T	Injection(s), spider veins	0098	1.34	$68.13	$20.88	$13.63

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
36469	T	Injection(s), spider veins	0098	1.34	$68.13	$20.88	$13.63
36470	T	Injection therapy of vein	0098	1.34	$68.13	$20.88	$13.63
36471	T	Injection therapy of veins	0098	1.34	$68.13	$20.88	$13.63
36481	N	Insertion of catheter, vein					
36488	T	Insertion of catheter, vein	0032	7.16	$364.03	$119.52	$72.81
36489	T	Insertion of catheter, vein	0032	7.16	$364.03	$119.52	$72.81
36490	T	Insertion of catheter, vein	0032	7.16	$364.03	$119.52	$72.81
36491	T	Insertion of catheter, vein	0032	7.16	$364.03	$119.52	$72.81
36493	T	Repositioning of cvc	0187	4.54	$230.82	$113.10	$46.16
36500	N	Insertion of catheter, vein					
36510	C	Insertion of catheter, vein					
36520	S	Plasma and/or cell exchange	0111	16.69	$848.55	$300.74	$169.71
36521	S	Apheresis w/ adsorp/reinfuse	0112	39.75	$2,020.97	$663.65	$404.19
36522	S	Photopheresis	0112	39.75	$2,020.97	$663.65	$404.19
36530	T	Insertion of infusion pump	0119	14.37	$730.60	$161.50	$146.12
36531	T	Revision of infusion pump	0124	25.84	$1,313.76	$722.57	$262.75
36532	T	Removal of infusion pump	0109	6.57	$334.03	$133.51	$66.81
36533	T	Insertion of access device	0115	19.06	$969.05	$503.91	$193.81
36534	T	Revision of access device	0103	10.91	$554.69	$249.61	$110.94
36535	T	Removal of access device	0109	6.57	$334.03	$133.51	$66.81
36540	N	Collect blood venous device					
36550	T	Declot vascular device	0970	0.47	$23.90		$4.78
36600	N	Withdrawal of arterial blood					
36620	N	Insertion catheter, artery					
36625	N	Insertion catheter, artery					
36640	T	Insertion catheter, artery	0032	7.16	$364.03	$119.52	$72.81
36660	C	Insertion catheter, artery					
36680	T	Insert needle, bone cavity	0120	2.35	$119.48	$42.67	$23.90
36800	T	Insertion of cannula	0115	19.06	$969.05	$503.91	$193.81
36810	T	Insertion of cannula	0115	19.06	$969.05	$503.91	$193.81
36815	T	Insertion of cannula	0115	19.06	$969.05	$503.91	$193.81
36819	T	Av fusion by basilic vein	0088	29.11	$1,480.01	$678.68	$296.00
36821	T	Av fusion direct any site	0088	29.11	$1,480.01	$678.68	$296.00
36822	C	Insertion of cannula(s)					
36823	C	Insertion of cannula(s)					
36825	T	Artery-vein graft	0088	29.11	$1,480.01	$678.68	$296.00
36830	T	Artery-vein graft	0088	29.11	$1,480.01	$678.68	$296.00
36831	T	Av fistula excision, open	0088	29.11	$1,480.01	$678.68	$296.00
36832	T	Av fistula revision, open	0088	29.11	$1,480.01	$678.68	$296.00
36833	T	Av fistula revision	0088	29.11	$1,480.01	$678.68	$296.00
36834	T	Repair A-V aneurysm	0088	29.11	$1,480.01	$678.68	$296.00
36835	T	Artery to vein shunt	0115	19.06	$969.05	$503.91	$193.81
36860	T	External cannula declotting	0115	19.06	$969.05	$503.91	$193.81
36861	T	Cannula declotting	0115	19.06	$969.05	$503.91	$193.81
36870	T	Av fistula revision, open	0093	15.05	$765.17	$277.34	$153.03
37140	C	Revision of circulation					
37145	C	Revision of circulation					
37160	C	Revision of circulation					
37180	C	Revision of circulation					
37181	C	Splice spleen/kidney veins					
37195	C	Thrombolytic therapy, stroke					
37200	T	Transcatheter biopsy	0005	6.71	$341.15	$119.75	$68.23
37201	T	Transcatheter therapy infuse	0120	2.35	$119.48	$42.67	$23.90
37202	T	Transcatheter therapy infuse	0120	2.35	$119.48	$42.67	$23.90
37203	T	Transcatheter retrieval	0103	10.91	$554.69	$249.61	$110.94
37204	T	Transcatheter occlusion	0103	10.91	$554.69	$249.61	$110.94
37205	T	Transcatheter stent	0229	60.07	$3,054.08	$996.86	$610.82
37206	T	Transcatheter stent add-on	0229	60.07	$3,054.08	$996.86	$610.82
37207	T	Transcatheter stent	0229	60.07	$3,054.08	$996.86	$610.82
37208	T	Transcatheter stent add-on	0229	60.07	$3,054.08	$996.86	$610.82
37209	T	Exchange arterial catheter	0103	10.91	$554.69	$249.61	$110.94
37250	T	Iv us first vessel add-on	0103	10.91	$554.69	$249.61	$110.94
37251	T	Iv us each add vessel add-on	0103	10.91	$554.69	$249.61	$110.94
37565	T	Ligation of neck vein	0093	15.05	$765.17	$277.34	$153.03
37600	T	Ligation of neck artery	0093	15.05	$765.17	$277.34	$153.03
37605	T	Ligation of neck artery	0091	22.17	$1,127.17	$348.23	$225.43
37606	T	Ligation of neck artery	0091	22.17	$1,127.17	$348.23	$225.43
37607	T	Ligation of a-v fistula	0092	21.43	$1,089.54	$505.37	$217.91
37609	T	Temporal artery procedure	0020	8.56	$435.21	$130.53	$87.04
37615	T	Ligation of neck artery	0091	22.17	$1,127.17	$348.23	$225.43
37616	C	Ligation of chest artery					
37617	C	Ligation of abdomen artery					
37618	C	Ligation of extremity artery					
37620	T	Revision of major vein	0091	22.17	$1,127.17	$348.23	$225.43
37650	T	Revision of major vein	0091	22.17	$1,127.17	$348.23	$225.43

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
37660	C	Revision of major vein					
37700	T	Revise leg vein	0091	22.17	$1,127.17	$348.23	$225.43
37720	T	Removal of leg vein	0092	21.43	$1,089.54	$505.37	$217.91
37730	T	Removal of leg veins	0092	21.43	$1,089.54	$505.37	$217.91
37735	T	Removal of leg veins/lesion	0092	21.43	$1,089.54	$505.37	$217.91
37760	T	Revision of leg veins	0091	22.17	$1,127.17	$348.23	$225.43
37780	T	Revision of leg vein	0091	22.17	$1,127.17	$348.23	$225.43
37785	T	Revise secondary varicosity	0091	22.17	$1,127.17	$348.23	$225.43
37788	C	Revascularization, penis					
37790	T	Penile venous occlusion	0181	24.07	$1,223.77	$673.07	$244.75
37799	T	Vascular surgery procedure	0020	8.56	$435.21	$130.53	$87.04
38100	C	Removal of spleen, total					
38101	C	Removal of spleen, partial					
38102	C	Removal of spleen, total					
38115	C	Repair of ruptured spleen					
38120	T	Laparoscopy, splenectomy	0131	39.80	$2,023.51	$1,052.23	$404.70
38129	T	Laparoscope proc, spleen	0130	27.92	$1,419.51	$659.53	$283.90
38200	N	Injection for spleen x-ray					
38230	S	Bone marrow collection	0123	10.12	$514.52	$102.90	$102.90
38231	S	Stem cell collection	0111	16.69	$848.55	$300.74	$169.71
38240	S	Bone marrow/stem transplant	0123	10.12	$514.52	$102.90	$102.90
38241	S	Bone marrow/stem transplant	0123	10.12	$514.52	$102.90	$102.90
38300	T	Drainage, lymph node lesion	0008	11.36	$577.57	$115.51	$115.51
38305	T	Drainage, lymph node lesion	0008	11.36	$577.57	$115.51	$115.51
38308	T	Incision of lymph channels	0113	16.87	$857.70	$326.55	$171.54
38380	C	Thoracic duct procedure					
38381	C	Thoracic duct procedure					
38382	C	Thoracic duct procedure					
38500	T	Biopsy/removal, lymph nodes	0113	16.87	$857.70	$326.55	$171.54
38505	T	Needle biopsy, lymph nodes	0005	6.71	$341.15	$119.75	$68.23
38510	T	Biopsy/removal, lymph nodes	0113	16.87	$857.70	$326.55	$171.54
38520	T	Biopsy/removal, lymph nodes	0113	16.87	$857.70	$326.55	$171.54
38525	T	Biopsy/removal, lymph nodes	0113	16.87	$857.70	$326.55	$171.54
38530	T	Biopsy/removal, lymph nodes	0113	16.87	$857.70	$326.55	$171.54
38542	T	Explore deep node(s), neck	0114	30.50	$1,550.68	$493.78	$310.14
38550	T	Removal, neck/armpit lesion	0113	16.87	$857.70	$326.55	$171.54
38555	T	Removal, neck/armpit lesion	0114	30.50	$1,550.68	$493.78	$310.14
38562	C	Removal, pelvic lymph nodes					
38564	C	Removal, abdomen lymph nodes					
38570	T	Laparoscopy, lymph node biop	0131	39.80	$2,023.51	$1,052.23	$404.70
38571	T	Laparoscopy, lymphadenectomy	0132	60.31	$3,066.28	$1,239.22	$613.26
38572	T	Laparoscopy, lymphadenectomy	0131	39.80	$2,023.51	$1,052.23	$404.70
38589	T	Laparoscope proc, lymphatic	0130	27.92	$1,419.51	$659.53	$283.90
38700	C	Removal of lymph nodes, neck					
38720	T	Removal of lymph nodes, neck	0114	30.50	$1,550.68	$493.78	$310.14
38724	C	Removal of lymph nodes, neck					
38740	T	Remove armpit lymph nodes	0114	30.50	$1,550.68	$493.78	$310.14
38745	T	Remove armpit lymph nodes	0114	30.50	$1,550.68	$493.78	$310.14
38746	C	Remove thoracic lymph nodes					
38747	C	Remove abdominal lymph nodes					
38760	T	Remove groin lymph nodes	0114	30.50	$1,550.68	$493.78	$310.14
38765	C	Remove groin lymph nodes					
38770	C	Remove pelvis lymph nodes					
38780	C	Remove abdomen lymph nodes					
38790	N	Inject for lymphatic x-ray					
38792	N	Identify sentinel node					
38794	N	Access thoracic lymph duct					
38999	T	Blood/lymph system procedure	0008	11.36	$577.57	$115.51	$115.51
39000	C	Exploration of chest					
39010	C	Exploration of chest					
39200	C	Removal chest lesion					
39220	C	Removal chest lesion					
39400	T	Visualization of chest	0069	25.62	$1,302.57	$612.21	$260.51
39499	C	Chest procedure					
39501	C	Repair diaphragm laceration					
39502	C	Repair paraesophageal hernia					
39503	C	Repair of diaphragm hernia					
39520	C	Repair of diaphragm hernia					
39530	C	Repair of diaphragm hernia					
39531	C	Repair of diaphragm hernia					
39540	C	Repair of diaphragm hernia					
39541	C	Repair of diaphragm hernia					
39545	C	Revision of diaphragm					
39560	C	Resect diaphragm, simple					
39561	C	Resect diaphragm, complex					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
39599	C	Diaphragm surgery procedure	.....	.....	.....	.....	.....
40490	T	Biopsy of lip	0251	2.71	$137.78	$27.99	$27.56
40500	T	Partial excision of lip	0253	13.27	$674.67	$284.00	$134.93
40510	T	Partial excision of lip	0254	19.11	$971.59	$272.41	$194.32
40520	T	Partial excision of lip	0253	13.27	$674.67	$284.00	$134.93
40525	T	Reconstruct lip with flap	0254	19.11	$971.59	$272.41	$194.32
40527	T	Reconstruct lip with flap	0254	19.11	$971.59	$272.41	$194.32
40530	T	Partial removal of lip	0254	19.11	$971.59	$272.41	$194.32
40650	T	Repair lip	0252	6.53	$332.00	$114.24	$66.40
40652	T	Repair lip	0252	6.53	$332.00	$114.24	$66.40
40654	T	Repair lip	0252	6.53	$332.00	$114.24	$66.40
40700	T	Repair cleft lip/nasal	0256	28.82	$1,465.27	$623.05	$293.05
40701	T	Repair cleft lip/nasal	0256	28.82	$1,465.27	$623.05	$293.05
40702	T	Repair cleft lip/nasal	0256	28.82	$1,465.27	$623.05	$293.05
40720	T	Repair cleft lip/nasal	0256	28.82	$1,465.27	$623.05	$293.05
40761	T	Repair cleft lip/nasal	0256	28.82	$1,465.27	$623.05	$293.05
40799	T	Lip surgery procedure	0253	13.27	$674.67	$284.00	$134.93
40800	T	Drainage of mouth lesion	0251	2.71	$137.78	$27.99	$27.56
40801	T	Drainage of mouth lesion	0252	6.53	$332.00	$114.24	$66.40
40804	X	Removal, foreign body, mouth	0340	0.91	$46.27	$11.57	$9.25
40805	T	Removal, foreign body, mouth	0252	6.53	$332.00	$114.24	$66.40
40806	T	Incision of lip fold	0251	2.71	$137.78	$27.99	$27.56
40808	T	Biopsy of mouth lesion	0251	2.71	$137.78	$27.99	$27.56
40810	T	Excision of mouth lesion	0253	13.27	$674.67	$284.00	$134.93
40812	T	Excise/repair mouth lesion	0252	6.53	$332.00	$114.24	$66.40
40814	T	Excise/repair mouth lesion	0253	13.27	$674.67	$284.00	$134.93
40816	T	Excision of mouth lesion	0254	19.11	$971.59	$272.41	$194.32
40818	T	Excise oral mucosa for graft	0251	2.71	$137.78	$27.99	$27.56
40819	T	Excise lip or cheek fold	0252	6.53	$332.00	$114.24	$66.40
40820	T	Treatment of mouth lesion	0253	13.27	$674.67	$284.00	$134.93
40830	T	Repair mouth laceration	0251	2.71	$137.78	$27.99	$27.56
40831	T	Repair mouth laceration	0252	6.53	$332.00	$114.24	$66.40
40840	T	Reconstruction of mouth	0254	19.11	$971.59	$272.41	$194.32
40842	T	Reconstruction of mouth	0254	19.11	$971.59	$272.41	$194.32
40843	T	Reconstruction of mouth	0254	19.11	$971.59	$272.41	$194.32
40844	T	Reconstruction of mouth	0256	28.82	$1,465.27	$623.05	$293.05
40845	T	Reconstruction of mouth	0256	28.82	$1,465.27	$623.05	$293.05
40899	T	Mouth surgery procedure	0252	6.53	$332.00	$114.24	$66.40
41000	T	Drainage of mouth lesion	0253	13.27	$674.67	$284.00	$134.93
41005	T	Drainage of mouth lesion	0251	2.71	$137.78	$27.99	$27.56
41006	T	Drainage of mouth lesion	0254	19.11	$971.59	$272.41	$194.32
41007	T	Drainage of mouth lesion	0253	13.27	$674.67	$284.00	$134.93
41008	T	Drainage of mouth lesion	0253	13.27	$674.67	$284.00	$134.93
41009	T	Drainage of mouth lesion	0251	2.71	$137.78	$27.99	$27.56
41010	T	Incision of tongue fold	0253	13.27	$674.67	$284.00	$134.93
41015	T	Drainage of mouth lesion	0251	2.71	$137.78	$27.99	$27.56
41016	T	Drainage of mouth lesion	0252	6.53	$332.00	$114.24	$66.40
41017	T	Drainage of mouth lesion	0252	6.53	$332.00	$114.24	$66.40
41018	T	Drainage of mouth lesion	0252	6.53	$332.00	$114.24	$66.40
41100	T	Biopsy of tongue	0252	6.53	$332.00	$114.24	$66.40
41105	T	Biopsy of tongue	0253	13.27	$674.67	$284.00	$134.93
41108	T	Biopsy of floor of mouth	0252	6.53	$332.00	$114.24	$66.40
41110	T	Excision of tongue lesion	0253	13.27	$674.67	$284.00	$134.93
41112	T	Excision of tongue lesion	0253	13.27	$674.67	$284.00	$134.93
41113	T	Excision of tongue lesion	0253	13.27	$674.67	$284.00	$134.93
41114	T	Excision of tongue lesion	0254	19.11	$971.59	$272.41	$194.32
41115	T	Excision of tongue fold	0252	6.53	$332.00	$114.24	$66.40
41116	T	Excision of mouth lesion	0253	13.27	$674.67	$284.00	$134.93
41120	T	Partial removal of tongue	0256	28.82	$1,465.27	$623.05	$293.05
41130	C	Partial removal of tongue	.....	.....	.....	.....	.....
41135	C	Tongue and neck surgery	.....	.....	.....	.....	.....
41140	C	Removal of tongue	.....	.....	.....	.....	.....
41145	C	Tongue removal, neck surgery	.....	.....	.....	.....	.....
41150	C	Tongue, mouth, jaw surgery	.....	.....	.....	.....	.....
41153	C	Tongue, mouth, neck surgery	.....	.....	.....	.....	.....
41155	C	Tongue, jaw, & neck surgery	.....	.....	.....	.....	.....
41250	T	Repair tongue laceration	0251	2.71	$137.78	$27.99	$27.56
41251	T	Repair tongue laceration	0252	6.53	$332.00	$114.24	$66.40
41252	T	Repair tongue laceration	0252	6.53	$332.00	$114.24	$66.40
41500	T	Fixation of tongue	0254	19.11	$971.59	$272.41	$194.32
41510	T	Tongue to lip surgery	0253	13.27	$674.67	$284.00	$134.93
41520	T	Reconstruction, tongue fold	0252	6.53	$332.00	$114.24	$66.40
41599	T	Tongue and mouth surgery	0251	2.71	$137.78	$27.99	$27.56
41800	T	Drainage of gum lesion	0251	2.71	$137.78	$27.99	$27.56
41805	T	Removal foreign body, gum	0254	19.11	$971.59	$272.41	$194.32

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
41806	T	Removal foreign body,jawbone	0253	13.27	$674.67	$284.00	$134.93
41820	T	Excision, gum, each quadrant	0252	6.53	$332.00	$114.24	$66.40
41821	T	Excision of gum flap	0252	6.53	$332.00	$114.24	$66.40
41822	T	Excision of gum lesion	0253	13.27	$674.67	$284.00	$134.93
41823	T	Excision of gum lesion	0254	19.11	$971.59	$272.41	$194.32
41825	T	Excision of gum lesion	0253	13.27	$674.67	$284.00	$134.93
41826	T	Excision of gum lesion	0253	13.27	$674.67	$284.00	$134.93
41827	T	Excision of gum lesion	0254	19.11	$971.59	$272.41	$194.32
41828	T	Excision of gum lesion	0253	13.27	$674.67	$284.00	$134.93
41830	T	Removal of gum tissue	0253	13.27	$674.67	$284.00	$134.93
41850	T	Treatment of gum lesion	0253	13.27	$674.67	$284.00	$134.93
41870	T	Gum graft	0254	19.11	$971.59	$272.41	$194.32
41872	T	Repair gum	0253	13.27	$674.67	$284.00	$134.93
41874	T	Repair tooth socket	0254	19.11	$971.59	$272.41	$194.32
41899	T	Dental surgery procedure	0253	13.27	$674.67	$284.00	$134.93
42000	T	Drainage mouth roof lesion	0251	2.71	$137.78	$27.99	$27.56
42100	T	Biopsy roof of mouth	0252	6.53	$332.00	$114.24	$66.40
42104	T	Excision lesion, mouth roof	0253	13.27	$674.67	$284.00	$134.93
42106	T	Excision lesion, mouth roof	0253	13.27	$674.67	$284.00	$134.93
42107	T	Excision lesion, mouth roof	0254	19.11	$971.59	$272.41	$194.32
42120	T	Remove palate/lesion	0256	28.82	$1,465.27	$623.05	$293.05
42140	T	Excision of uvula	0252	6.53	$332.00	$114.24	$66.40
42145	T	Repair palate, pharynx/uvula	0254	19.11	$971.59	$272.41	$194.32
42160	T	Treatment mouth roof lesion	0253	13.27	$674.67	$284.00	$134.93
42180	T	Repair palate	0251	2.71	$137.78	$27.99	$27.56
42182	T	Repair palate	0256	28.82	$1,465.27	$623.05	$293.05
42200	T	Reconstruct cleft palate	0256	28.82	$1,465.27	$623.05	$293.05
42205	T	Reconstruct cleft palate	0256	28.82	$1,465.27	$623.05	$293.05
42210	T	Reconstruct cleft palate	0256	28.82	$1,465.27	$623.05	$293.05
42215	T	Reconstruct cleft palate	0256	28.82	$1,465.27	$623.05	$293.05
42220	T	Reconstruct cleft palate	0256	28.82	$1,465.27	$623.05	$293.05
42225	T	Reconstruct cleft palate	0256	28.82	$1,465.27	$623.05	$293.05
42226	T	Lengthening of palate	0256	28.82	$1,465.27	$623.05	$293.05
42227	T	Lengthening of palate	0256	28.82	$1,465.27	$623.05	$293.05
42235	T	Repair palate	0253	13.27	$674.67	$284.00	$134.93
42260	T	Repair nose to lip fistula	0254	19.11	$971.59	$272.41	$194.32
42280	T	Preparation, palate mold	0251	2.71	$137.78	$27.99	$27.56
42281	T	Insertion, palate prosthesis	0253	13.27	$674.67	$284.00	$134.93
42299	T	Palate/uvula surgery	0251	2.71	$137.78	$27.99	$27.56
42300	T	Drainage of salivary gland	0253	13.27	$674.67	$284.00	$134.93
42305	T	Drainage of salivary gland	0253	13.27	$674.67	$284.00	$134.93
42310	T	Drainage of salivary gland	0251	2.71	$137.78	$27.99	$27.56
42320	T	Drainage of salivary gland	0251	2.71	$137.78	$27.99	$27.56
42325	T	Create salivary cyst drain	0251	2.71	$137.78	$27.99	$27.56
42326	T	Create salivary cyst drain	0252	6.53	$332.00	$114.24	$66.40
42330	T	Removal of salivary stone	0252	6.53	$332.00	$114.24	$66.40
42335	T	Removal of salivary stone	0253	13.27	$674.67	$284.00	$134.93
42340	T	Removal of salivary stone	0253	13.27	$674.67	$284.00	$134.93
42400	T	Biopsy of salivary gland	0004	3.00	$152.53	$32.57	$30.51
42405	T	Biopsy of salivary gland	0253	13.27	$674.67	$284.00	$134.93
42408	T	Excision of salivary cyst	0253	13.27	$674.67	$284.00	$134.93
42409	T	Drainage of salivary cyst	0253	13.27	$674.67	$284.00	$134.93
42410	T	Excise parotid gland/lesion	0256	28.82	$1,465.27	$623.05	$293.05
42415	T	Excise parotid gland/lesion	0256	28.82	$1,465.27	$623.05	$293.05
42420	T	Excise parotid gland/lesion	0256	28.82	$1,465.27	$623.05	$293.05
42425	T	Excise parotid gland/lesion	0256	28.82	$1,465.27	$623.05	$293.05
42426	C	Excise parotid gland/lesion	.....	.....	.....	.....	.....
42440	T	Excise submaxillary gland	0256	28.82	$1,465.27	$623.05	$293.05
42450	T	Excise sublingual gland	0254	19.11	$971.59	$272.41	$194.32
42500	T	Repair salivary duct	0254	19.11	$971.59	$272.41	$194.32
42505	T	Repair salivary duct	0256	28.82	$1,465.27	$623.05	$293.05
42507	T	Parotid duct diversion	0256	28.82	$1,465.27	$623.05	$293.05
42508	T	Parotid duct diversion	0256	28.82	$1,465.27	$623.05	$293.05
42509	T	Parotid duct diversion	0256	28.82	$1,465.27	$623.05	$293.05
42510	T	Parotid duct diversion	0256	28.82	$1,465.27	$623.05	$293.05
42550	N	Injection for salivary x-ray	.....	.....	.....	.....	.....
42600	T	Closure of salivary fistula	0253	13.27	$674.67	$284.00	$134.93
42650	T	Dilation of salivary duct	0252	6.53	$332.00	$114.24	$66.40
42660	T	Dilation of salivary duct	0252	6.53	$332.00	$114.24	$66.40
42665	T	Ligation of salivary duct	0254	19.11	$971.59	$272.41	$194.32
42699	T	Salivary surgery procedure	0253	13.27	$674.67	$284.00	$134.93
42700	T	Drainage of tonsil abscess	0251	2.71	$137.78	$27.99	$27.56
42720	T	Drainage of throat abscess	0253	13.27	$674.67	$284.00	$134.93
42725	T	Drainage of throat abscess	0256	28.82	$1,465.27	$623.05	$293.05
42800	T	Biopsy of throat	0252	6.53	$332.00	$114.24	$66.40

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
42802	T	Biopsy of throat	0253	13.27	$674.67	$284.00	$134.93
42804	T	Biopsy of upper nose/throat	0253	13.27	$674.67	$284.00	$134.93
42806	T	Biopsy of upper nose/throat	0254	19.11	$971.59	$272.41	$194.32
42808	T	Excise pharynx lesion	0253	13.27	$674.67	$284.00	$134.93
42809	X	Remove pharynx foreign body	0340	0.91	$46.27	$11.57	$9.25
42810	T	Excision of neck cyst	0254	19.11	$971.59	$272.41	$194.32
42815	T	Excision of neck cyst	0256	28.82	$1,465.27	$623.05	$293.05
42820	T	Remove tonsils and adenoids	0258	18.86	$958.88	$462.81	$191.78
42821	T	Remove tonsils and adenoids	0258	18.86	$958.88	$462.81	$191.78
42825	T	Removal of tonsils	0258	18.86	$958.88	$462.81	$191.78
42826	T	Removal of tonsils	0258	18.86	$958.88	$462.81	$191.78
42830	T	Removal of adenoids	0258	18.86	$958.88	$462.81	$191.78
42831	T	Removal of adenoids	0258	18.86	$958.88	$462.81	$191.78
42835	T	Removal of adenoids	0258	18.86	$958.88	$462.81	$191.78
42836	T	Removal of adenoids	0258	18.86	$958.88	$462.81	$191.78
42842	C	Extensive surgery of throat					
42844	T	Extensive surgery of throat	0256	28.82	$1,465.27	$623.05	$293.05
42845	C	Extensive surgery of throat					
42860	T	Excision of tonsil tags	0258	18.86	$958.88	$462.81	$191.78
42870	T	Excision of lingual tonsil	0258	18.86	$958.88	$462.81	$191.78
42890	T	Partial removal of pharynx	0256	28.82	$1,465.27	$623.05	$293.05
42892	T	Revision of pharyngeal walls	0256	28.82	$1,465.27	$623.05	$293.05
42894	C	Revision of pharyngeal walls					
42900	T	Repair throat wound	0252	6.53	$332.00	$114.24	$66.40
42950	T	Reconstruction of throat	0254	19.11	$971.59	$272.41	$194.32
42953	C	Repair throat, esophagus					
42955	T	Surgical opening of throat	0254	19.11	$971.59	$272.41	$194.32
42960	T	Control throat bleeding	0250	2.27	$115.41	$38.54	$23.08
42961	C	Control throat bleeding					
42962	T	Control throat bleeding	0256	28.82	$1,465.27	$623.05	$293.05
42970	T	Control nose/throat bleeding	0250	2.27	$115.41	$38.54	$23.08
42971	C	Control nose/throat bleeding					
42972	T	Control nose/throat bleeding	0253	13.27	$674.67	$284.00	$134.93
42999	T	Throat surgery procedure	0252	6.53	$332.00	$114.24	$66.40
43020	T	Incision of esophagus	0252	6.53	$332.00	$114.24	$66.40
43030	C	Throat muscle surgery					
43045	C	Incision of esophagus					
43100	C	Excision of esophagus lesion					
43101	C	Excision of esophagus lesion					
43107	C	Removal of esophagus					
43108	C	Removal of esophagus					
43112	C	Removal of esophagus					
43113	C	Removal of esophagus					
43116	C	Partial removal of esophagus					
43117	C	Partial removal of esophagus					
43118	C	Partial removal of esophagus					
43121	C	Partial removal of esophagus					
43122	C	Parital removal of esophagus					
43123	C	Partial removal of esophagus					
43124	C	Removal of esophagus					
43130	T	Removal of esophagus pouch	0254	19.11	$971.59	$272.41	$194.32
43135	C	Removal of esophagus pouch					
43200	T	Esophagus endoscopy	0141	7.46	$379.28	$184.67	$75.86
43202	T	Esophagus endoscopy, biopsy	0141	7.46	$379.28	$184.67	$75.86
43204	T	Esophagus endoscopy & inject	0141	7.46	$379.28	$184.67	$75.86
43205	T	Esophagus endoscopy/ligation	0141	7.46	$379.28	$184.67	$75.86
43215	T	Esophagus endoscopy	0141	7.46	$379.28	$184.67	$75.86
43216	T	Esophagus endoscopy/lesion	0141	7.46	$379.28	$184.67	$75.86
43217	T	Esophagus endoscopy	0141	7.46	$379.28	$184.67	$75.86
43219	T	Esophagus endoscopy	0141	7.46	$379.28	$184.67	$75.86
43220	T	Esoph endoscopy, dilation	0141	7.46	$379.28	$184.67	$75.86
43226	T	Esoph endoscopy, dilation	0141	7.46	$379.28	$184.67	$75.86
43227	T	Esoph endoscopy, repair	0141	7.46	$379.28	$184.67	$75.86
43228	T	Esoph endoscopy, ablation	0141	7.46	$379.28	$184.67	$75.86
43231	T	Esoph endoscopy w/us exam	0141	7.46	$379.28	$184.67	$75.86
43232	T	Esoph endoscopy w/us fn bx	0141	7.46	$379.28	$184.67	$75.86
43234	T	Upper GI endoscopy, exam	0141	7.46	$379.28	$184.67	$75.86
43235	T	Uppr gi endoscopy, diagnosis	0141	7.46	$379.28	$184.67	$75.86
43239	T	Upper GI endoscopy, biopsy	0141	7.46	$379.28	$184.67	$75.86
43240	T	Esoph endoscope w/drain cyst	0141	7.46	$379.28	$184.67	$75.86
43241	T	Upper GI endoscopy with tube	0141	7.46	$379.28	$184.67	$75.86
43242	T	Uppr gi endoscopy w/us fn bx	0141	7.46	$379.28	$184.67	$75.86
43243	T	Upper gi endoscopy & inject	0141	7.46	$379.28	$184.67	$75.86
43244	T	Upper GI endoscopy/ligation	0141	7.46	$379.28	$184.67	$75.86
43245	T	Operative upper GI endoscopy	0141	7.46	$379.28	$184.67	$75.86

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
43246	T	Place gastrostomy tube	0141	7.46	$379.28	$184.67	$75.86
43247	T	Operative upper GI endoscopy	0141	7.46	$379.28	$184.67	$75.86
43248	T	Uppr gi endoscopy/guide wire	0141	7.46	$379.28	$184.67	$75.86
43249	T	Esoph endoscopy, dilation	0141	7.46	$379.28	$184.67	$75.86
43250	T	Upper GI endoscopy/tumor	0141	7.46	$379.28	$184.67	$75.86
43251	T	Operative upper GI endoscopy	0141	7.46	$379.28	$184.67	$75.86
43255	T	Operative upper GI endoscopy	0141	7.46	$379.28	$184.67	$75.86
43256	T	Uppr gi endoscopy w stent	0141	7.46	$379.28	$184.67	$75.86
43258	T	Operative upper GI endoscopy	0141	7.46	$379.28	$184.67	$75.86
43259	T	Endoscopic ultrasound exam	0141	7.46	$379.28	$184.67	$75.86
43260	T	Endo cholangiopancreatograph	0151	16.22	$824.66	$245.46	$164.93
43261	T	Endo cholangiopancreatograph	0151	16.22	$824.66	$245.46	$164.93
43262	T	Endo cholangiopancreatograph	0151	16.22	$824.66	$245.46	$164.93
43263	T	Endo cholangiopancreatograph	0151	16.22	$824.66	$245.46	$164.93
43264	T	Endo cholangiopancreatograph	0151	16.22	$824.66	$245.46	$164.93
43265	T	Endo cholangiopancreatograph	0151	16.22	$824.66	$245.46	$164.93
43267	T	Endo cholangiopancreatograph	0151	16.22	$824.66	$245.46	$164.93
43268	T	Endo cholangiopancreatograph	0151	16.22	$824.66	$245.46	$164.93
43269	T	Endo cholangiopancreatograph	0151	16.22	$824.66	$245.46	$164.93
43271	T	Endo cholangiopancreatograph	0151	16.22	$824.66	$245.46	$164.93
43272	T	Endo cholangiopancreatograph	0151	16.22	$824.66	$245.46	$164.93
43280	T	Laparoscopy, fundoplasty	0132	60.31	$3,066.28	$1,239.22	$613.26
43289	T	Laparoscope proc, esoph	0130	27.92	$1,419.51	$659.53	$283.90
43300	C	Repair of esophagus					
43305	C	Repair esophagus and fistula					
43310	C	Repair of esophagus					
43312	C	Repair esophagus and fistula					
43320	C	Fuse esophagus & stomach					
43324	C	Revise esophagus & stomach					
43325	C	Revise esophagus & stomach					
43326	C	Revise esophagus & stomach					
43330	C	Repair of esophagus					
43331	C	Repair of esophagus					
43340	C	Fuse esophagus & intestine					
43341	C	Fuse esophagus & intestine					
43350	C	Surgical opening, esophagus					
43351	C	Surgical opening, esophagus					
43352	C	Surgical opening, esophagus					
43360	C	Gastrointestinal repair					
43361	C	Gastrointestinal repair					
43400	C	Ligate esophagus veins					
43401	C	Esophagus surgery for veins					
43405	C	Ligate/staple esophagus					
43410	C	Repair esophagus wound					
43415	C	Repair esophagus wound					
43420	C	Repair esophagus opening					
43425	C	Repair esophagus opening					
43450	T	Dilate esophagus	0140	5.73	$291.32	$107.24	$58.26
43453	T	Dilate esophagus	0140	5.73	$291.32	$107.24	$58.26
43456	T	Dilate esophagus	0140	5.73	$291.32	$107.24	$58.26
43458	T	Dilate esophagus	0140	5.73	$291.32	$107.24	$58.26
43460	C	Pressure treatment esophagus					
43496	C	Free jejunum flap, microvasc					
43499	T	Esophagus surgery procedure	0140	5.73	$291.32	$107.24	$58.26
43500	C	Surgical opening of stomach					
43501	C	Surgical repair of stomach					
43502	C	Surgical repair of stomach					
43510	C	Surgical opening of stomach					
43520	C	Incision of pyloric muscle					
43600	T	Biopsy of stomach	0141	7.46	$379.28	$184.67	$75.86
43605	C	Biopsy of stomach					
43610	C	Excision of stomach lesion					
43611	C	Excision of stomach lesion					
43620	C	Removal of stomach					
43621	C	Removal of stomach					
43622	C	Removal of stomach					
43631	C	Removal of stomach, partial					
43632	C	Removal of stomach, partial					
43633	C	Removal of stomach, partial					
43634	C	Removal of stomach, partial					
43635	C	Removal of stomach, partial					
43638	C	Removal of stomach, partial					
43639	C	Removal of stomach, partial					
43640	C	Vagotomy & pylorus repair					
43641	C	Vagotomy & pylorus repair					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
43651	T	Laparoscopy, vagus nerve	0132	60.31	$3,066.28	$1,239.22	$613.26
43652	T	Laparoscopy, vagus nerve	0132	60.31	$3,066.28	$1,239.22	$613.26
43653	T	Laparoscopy, gastrostomy	0131	39.80	$2,023.51	$1,052.23	$404.70
43659	T	Laparoscope proc, stom	0130	27.92	$1,419.51	$659.53	$283.90
43750	T	Place gastrostomy tube	0141	7.46	$379.28	$184.67	$75.86
43752	E	Nasal/orogastric w/stent					
43760	T	Change gastrostomy tube	0121	2.42	$123.04	$52.53	$24.61
43761	T	Reposition gastrostomy tube	0121	2.42	$123.04	$52.53	$24.61
43800	C	Reconstruction of pylorus					
43810	C	Fusion of stomach and bowel					
43820	C	Fusion of stomach and bowel					
43825	C	Fusion of stomach and bowel					
43830	T	Place gastrostomy tube	0141	7.46	$379.28	$184.67	$75.86
43831	T	Place gastrostomy tube	0141	7.46	$379.28	$184.67	$75.86
43832	C	Place gastrostomy tube					
43840	C	Repair of stomach lesion					
43842	C	Gastroplasty for obesity					
43843	C	Gastroplasty for obesity					
43846	C	Gastric bypass for obesity					
43847	C	Gastric bypass for obesity					
43848	C	Revision gastroplasty					
43850	C	Revise stomach-bowel fusion					
43855	C	Revise stomach-bowel fusion					
43860	C	Revise stomach-bowel fusion					
43865	C	Revise stomach-bowel fusion					
43870	T	Repair stomach opening	0025	3.71	$188.62	$70.66	$37.72
43880	C	Repair stomach-bowel fistula					
43999	T	Stomach surgery procedure	0121	2.42	$123.04	$52.53	$24.61
44005	C	Freeing of bowel adhesion					
44010	C	Incision of small bowel					
44015	C	Insert needle cath bowel					
44020	C	Exploration of small bowel					
44021	C	Decompress small bowel					
44025	C	Incision of large bowel					
44050	C	Reduce bowel obstruction					
44055	C	Correct malrotation of bowel					
44100	T	Biopsy of bowel	0141	7.46	$379.28	$184.67	$75.86
44110	C	Excision of bowel lesion(s)					
44111	C	Excision of bowel lesion(s)					
44120	C	Removal of small intestine					
44121	C	Removal of small intestine					
44125	C	Removal of small intestine					
44130	C	Bowel to bowel fusion					
44132	C	Enterectomy, cadaver donor					
44133	C	Enterectomy, live donor					
44135	C	Intestine transplnt, cadaver					
44136	C	Intestine transplant, live					
44139	C	Mobilization of colon					
44140	C	Partial removal of colon					
44141	C	Partial removal of colon					
44143	C	Partial removal of colon					
44144	C	Partial removal of colon					
44145	C	Partial removal of colon					
44146	C	Partial removal of colon					
44147	C	Partial removal of colon					
44150	C	Removal of colon					
44151	C	Removal of colon/ileostomy					
44152	C	Removal of colon/ileostomy					
44153	C	Removal of colon/ileostomy					
44155	C	Removal of colon/ileostomy					
44156	C	Removal of colon/ileostomy					
44160	C	Removal of colon					
44200	T	Laparoscopy, enterolysis	0131	39.80	$2,023.51	$1,052.23	$404.70
44201	T	Laparoscopy, jejunostomy	0131	39.80	$2,023.51	$1,052.23	$404.70
44202	C	Laparo, resect intestine					
44209	T	Laparoscope proc, intestine	0130	27.92	$1,419.51	$659.53	$283.90
44300	C	Open bowel to skin					
44310	C	Ileostomy/jejunostomy					
44312	T	Revision of ileostomy	0026	13.51	$686.88	$277.92	$137.38
44314	C	Revision of ileostomy					
44316	C	Devise bowel pouch					
44320	C	Colostomy					
44322	C	Colostomy with biopsies					
44340	T	Revision of colostomy	0026	13.51	$686.88	$277.92	$137.38
44345	C	Revision of colostomy					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
44346	C	Revision of colostomy					
44360	T	Small bowel endoscopy	0142	7.61	$386.91	$162.42	$77.38
44361	T	Small bowel endoscopy/biopsy	0142	7.61	$386.91	$162.42	$77.38
44363	T	Small bowel endoscopy	0142	7.61	$386.91	$162.42	$77.38
44364	T	Small bowel endoscopy	0142	7.61	$386.91	$162.42	$77.38
44365	T	Small bowel endoscopy	0142	7.61	$386.91	$162.42	$77.38
44366	T	Small bowel endoscopy	0142	7.61	$386.91	$162.42	$77.38
44369	T	Small bowel endoscopy	0142	7.61	$386.91	$162.42	$77.38
44370	T	Small bowel endoscopy/stent	0142	7.61	$386.91	$162.42	$77.38
44372	T	Small bowel endoscopy	0142	7.61	$386.91	$162.42	$77.38
44373	T	Small bowel endoscopy	0142	7.61	$386.91	$162.42	$77.38
44376	T	Small bowel endoscopy	0142	7.61	$386.91	$162.42	$77.38
44377	T	Small bowel endoscopy/biopsy	0142	7.61	$386.91	$162.42	$77.38
44378	T	Small bowel endoscopy	0142	7.61	$386.91	$162.42	$77.38
44379	T	S bowel endoscope w/stent	0142	7.61	$386.91	$162.42	$77.38
44380	T	Small bowel endoscopy	0142	7.61	$386.91	$162.42	$77.38
44382	T	Small bowel endoscopy	0142	7.61	$386.91	$162.42	$77.38
44383	T	Ileoscopy w/stent	0142	7.61	$386.91	$162.42	$77.38
44385	T	Endoscopy of bowel pouch	0143	7.87	$400.13	$198.46	$80.03
44386	T	Endoscopy, bowel pouch/biop	0143	7.87	$400.13	$198.46	$80.03
44388	T	Colon endoscopy	0143	7.87	$400.13	$198.46	$80.03
44389	T	Colonoscopy with biopsy	0143	7.87	$400.13	$198.46	$80.03
44390	T	Colonoscopy for foreign body	0143	7.87	$400.13	$198.46	$80.03
44391	T	Colonoscopy for bleeding	0143	7.87	$400.13	$198.46	$80.03
44392	T	Colonoscopy & polypectomy	0143	7.87	$400.13	$198.46	$80.03
44393	T	Colonoscopy, lesion removal	0143	7.87	$400.13	$198.46	$80.03
44394	T	Colonoscopy w/snare	0143	7.87	$400.13	$198.46	$80.03
44397	T	Colonoscopy w stent	0143	7.87	$400.13	$198.46	$80.03
44500	T	Intro, gastrointestinal tube	0121	2.42	$123.04	$52.53	$24.61
44602	C	Suture, small intestine					
44603	C	Suture, small intestine					
44604	C	Suture, large intestine					
44605	C	Repair of bowel lesion					
44615	C	Intestinal stricturoplasty					
44620	C	Repair bowel opening					
44625	C	Repair bowel opening					
44626	C	Repair bowel opening					
44640	C	Repair bowel-skin fistula					
44650	C	Repair bowel fistula					
44660	C	Repair bowel-bladder fistula					
44661	C	Repair bowel-bladder fistula					
44680	C	Surgical revision, intestine					
44700	C	Suspend bowel w/prosthesis					
44799	T	Intestine surgery procedure	0142	7.61	$386.91	$162.42	$77.38
44800	C	Excision of bowel pouch					
44820	C	Excision of mesentery lesion					
44850	C	Repair of mesentery					
44899	C	Bowel surgery procedure					
44900	C	Drain app abscess, open					
44901	C	Drain app abscess, percut					
44950	C	Appendectomy					
44955	C	Appendectomy add-on					
44960	C	Appendectomy					
44970	T	Laparoscopy, appendectomy	0130	27.92	$1,419.51	$659.53	$283.90
44979	T	Laparoscope proc, app	0130	27.92	$1,419.51	$659.53	$283.90
45000	T	Drainage of pelvic abscess	0149	14.49	$736.70	$293.06	$147.34
45005	T	Drainage of rectal abscess	0148	2.58	$131.17	$43.59	$26.23
45020	T	Drainage of rectal abscess	0149	14.49	$736.70	$293.06	$147.34
45100	T	Biopsy of rectum	0149	14.49	$736.70	$293.06	$147.34
45108	T	Removal of anorectal lesion	0150	19.58	$995.49	$437.12	$199.10
45110	C	Removal of rectum					
45111	C	Partial removal of rectum					
45112	C	Removal of rectum					
45113	C	Partial proctectomy					
45114	C	Partial removal of rectum					
45116	C	Partial removal of rectum					
45119	C	Remove rectum w/reservoir					
45120	C	Removal of rectum					
45121	C	Removal of rectum and colon					
45123	C	Partial proctectomy					
45126	C	Pelvic exenteration					
45130	C	Excision of rectal prolapse					
45135	C	Excision of rectal prolapse					
45150	T	Excision of rectal stricture	0150	19.58	$995.49	$437.12	$199.10
45160	T	Excision of rectal lesion	0150	19.58	$995.49	$437.12	$199.10

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
45170	T	Excision of rectal lesion	0150	19.58	$995.49	$437.12	$199.10
45190	T	Destruction, rectal tumor	0150	19.58	$995.49	$437.12	$199.10
45300	T	Proctosigmoidoscopy dx	0146	2.95	$149.98	$65.15	$30.00
45303	T	Proctosigmoidoscopy dilate	0146	2.95	$149.98	$65.15	$30.00
45305	T	Protosigmoidoscopy w/bx	0146	2.95	$149.98	$65.15	$30.00
45307	T	Protosigmoidoscopy fb	0146	2.95	$149.98	$65.15	$30.00
45308	T	Protosigmoidoscopy removal	0147	6.15	$312.68	$146.96	$62.54
45309	T	Protosigmoidoscopy removal	0147	6.15	$312.68	$146.96	$62.54
45315	T	Protosigmoidoscopy removal	0147	6.15	$312.68	$146.96	$62.54
45317	T	Protosigmoidoscopy bleed	0146	2.95	$149.98	$65.15	$30.00
45320	T	Protosigmoidoscopy ablate	0147	6.15	$312.68	$146.96	$62.54
45321	T	Protosigmoidoscopy volvul	0147	6.15	$312.68	$146.96	$62.54
45327	T	Proctosigmoidoscopy w/stent	0147	6.15	$312.68	$146.96	$62.54
45330	T	Diagnostic sigmoidoscopy	0146	2.95	$149.98	$65.15	$30.00
45331	T	Sigmoidoscopy and biopsy	0146	2.95	$149.98	$65.15	$30.00
45332	T	Sigmoidoscopy w/fb removal	0146	2.95	$149.98	$65.15	$30.00
45333	T	Sigmoidoscopy & polypectomy	0147	6.15	$312.68	$146.96	$62.54
45334	T	Sigmoidoscopy for bleeding	0147	6.15	$312.68	$146.96	$62.54
45337	T	Sigmoidoscopy & decompress	0147	6.15	$312.68	$146.96	$62.54
45338	T	Sigmoidoscpy w/tumr remove	0147	6.15	$312.68	$146.96	$62.54
45339	T	Sigmoidoscopy w/ablate tumr	0147	6.15	$312.68	$146.96	$62.54
45341	T	Sigmoidoscopy w/ultrasound	0147	6.15	$312.68	$146.96	$62.54
45342	T	Sigmoidoscopy w/us guide bx	0147	6.15	$312.68	$146.96	$62.54
45345	T	Sigmodoscopy w/stent	0147	6.15	$312.68	$146.96	$62.54
45355	T	Surgical colonoscopy	0143	7.87	$400.13	$198.46	$80.03
45378	T	Diagnostic colonoscopy	0143	7.87	$400.13	$198.46	$80.03
45379	T	Colonoscopy w/fb removal	0143	7.87	$400.13	$198.46	$80.03
45380	T	Colonoscopy and biopsy	0143	7.87	$400.13	$198.46	$80.03
45382	T	Colonoscopy/control bleeding	0143	7.87	$400.13	$198.46	$80.03
45383	T	Lesion removal colonoscopy	0143	7.87	$400.13	$198.46	$80.03
45384	T	Lesion remove colonoscopy	0143	7.87	$400.13	$198.46	$80.03
45385	T	Lesion removal colonoscopy	0143	7.87	$400.13	$198.46	$80.03
45387	T	Colonoscopy w/stent	0143	7.87	$400.13	$198.46	$80.03
45500	T	Repair of rectum	0150	19.58	$995.49	$437.12	$199.10
45505	T	Repair of rectum	0150	19.58	$995.49	$437.12	$199.10
45520	T	Treatment of rectal prolapse	0098	1.34	$68.13	$20.88	$13.63
45540	C	Correct rectal prolapse	.....	.....	.....	.....	.....
45541	C	Correct rectal prolapse	.....	.....	.....	.....	.....
45550	C	Repair rectum/remove sigmoid	.....	.....	.....	.....	.....
45560	T	Repair of rectocele	0150	19.58	$995.49	$437.12	$199.10
45562	C	Exploration/repair of rectum	.....	.....	.....	.....	.....
45563	C	Exploration/repair of rectum	.....	.....	.....	.....	.....
45800	C	Repair rect/bladder fistula	.....	.....	.....	.....	.....
45805	C	Repair fistula w/colostomy	.....	.....	.....	.....	.....
45820	C	Repair rectourethral fistula	.....	.....	.....	.....	.....
45825	C	Repair fistula w/colostomy	.....	.....	.....	.....	.....
45900	T	Reduction of rectal prolapse	0148	2.58	$131.17	$43.59	$26.23
45905	T	Dilation of anal sphincter	0149	14.49	$736.70	$293.06	$147.34
45910	T	Dilation of rectal narrowing	0149	14.49	$736.70	$293.06	$147.34
45915	T	Remove rectal obstruction	0148	2.58	$131.17	$43.59	$26.23
45999	T	Rectum surgery procedure	0148	2.58	$131.17	$43.59	$26.23
46030	T	Removal of rectal marker	0149	14.49	$736.70	$293.06	$147.34
46040	T	Incision of rectal abscess	0155	5.73	$291.32	$96.14	$58.26
46045	T	Incision of rectal abscess	0150	19.58	$995.49	$437.12	$199.10
46050	T	Incision of anal abscess	0148	2.58	$131.17	$43.59	$26.23
46060	T	Incision of rectal abscess	0150	19.58	$995.49	$437.12	$199.10
46070	T	Incision of anal septum	0155	5.73	$291.32	$96.14	$58.26
46080	T	Incision of anal sphincter	0149	14.49	$736.70	$293.06	$147.34
46083	T	Incise external hemorrhoid	0148	2.58	$131.17	$43.59	$26.23
46200	T	Removal of anal fissure	0150	19.58	$995.49	$437.12	$199.10
46210	T	Removal of anal crypt	0149	14.49	$736.70	$293.06	$147.34
46211	T	Removal of anal crypts	0150	19.58	$995.49	$437.12	$199.10
46220	T	Removal of anal tab	0149	14.49	$736.70	$293.06	$147.34
46221	T	Ligation of hemorrhoid(s)	0155	5.73	$291.32	$96.14	$58.26
46230	T	Removal of anal tabs	0149	14.49	$736.70	$293.06	$147.34
46250	T	Hemorrhoidectomy	0150	19.58	$995.49	$437.12	$199.10
46255	T	Hemorrhoidectomy	0150	19.58	$995.49	$437.12	$199.10
46257	T	Remove hemorrhoids & fissure	0150	19.58	$995.49	$437.12	$199.10
46258	T	Remove hemorrhoids & fistula	0150	19.58	$995.49	$437.12	$199.10
46260	T	Hemorrhoidectomy	0150	19.58	$995.49	$437.12	$199.10
46261	T	Remove hemorrhoids & fissure	0150	19.58	$995.49	$437.12	$199.10
46262	T	Remove hemorrhoids & fistula	0150	19.58	$995.49	$437.12	$199.10
46270	T	Removal of anal fistula	0150	19.58	$995.49	$437.12	$199.10
46275	T	Removal of anal fistula	0150	19.58	$995.49	$437.12	$199.10
46280	T	Removal of anal fistula	0150	19.58	$995.49	$437.12	$199.10

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
46285	T	Removal of anal fistula	0150	19.58	$995.49	$437.12	$199.10
46288	T	Repair anal fistula	0150	19.58	$995.49	$437.12	$199.10
46320	T	Removal of hemorrhoid clot	0155	5.73	$291.32	$96.14	$58.26
46500	T	Injection into hemorrhoids	0155	5.73	$291.32	$96.14	$58.26
46600	N	Diagnostic anoscopy					
46604	T	Anoscopy and dilation	0144	1.97	$100.16	$44.07	$20.03
46606	T	Anoscopy and biopsy	0145	12.11	$615.70	$179.39	$123.14
46608	T	Anoscopy/ remove for body	0144	1.97	$100.16	$44.07	$20.03
46610	T	Anoscopy/remove lesion	0145	12.11	$615.70	$179.39	$123.14
46611	T	Anoscopy	0145	12.11	$615.70	$179.39	$123.14
46612	T	Anoscopy/ remove lesions	0145	12.11	$615.70	$179.39	$123.14
46614	T	Anoscopy/control bleeding	0145	12.11	$615.70	$179.39	$123.14
46615	T	Anoscopy	0145	12.11	$615.70	$179.39	$123.14
46700	T	Repair of anal stricture	0150	19.58	$995.49	$437.12	$199.10
46705	C	Repair of anal stricture					
46715	C	Repair of anovaginal fistula					
46716	C	Repair of anovaginal fistula					
46730	C	Construction of absent anus					
46735	C	Construction of absent anus					
46740	C	Construction of absent anus					
46742	C	Repair of imperforated anus					
46744	C	Repair of cloacal anomaly					
46746	C	Repair of cloacal anomaly					
46748	C	Repair of cloacal anomaly					
46750	T	Repair of anal sphincter	0150	19.58	$995.49	$437.12	$199.10
46751	C	Repair of anal sphincter					
46753	T	Reconstruction of anus	0150	19.58	$995.49	$437.12	$199.10
46754	T	Removal of suture from anus	0149	14.49	$736.70	$293.06	$147.34
46760	T	Repair of anal sphincter	0150	19.58	$995.49	$437.12	$199.10
46761	T	Repair of anal sphincter	0150	19.58	$995.49	$437.12	$199.10
46762	T	Implant artificial sphincter	0150	19.58	$995.49	$437.12	$199.10
46900	T	Destruction, anal lesion(s)	0016	3.31	$168.29	$70.68	$33.66
46910	T	Destruction, anal lesion(s)	0017	10.51	$534.35	$245.80	$106.87
46916	T	Cryosurgery, anal lesion(s)	0013	1.51	$76.77	$17.66	$15.35
46917	T	Laser surgery, anal lesions	0695	17.06	$867.36	$398.99	$173.47
46922	T	Excision of anal lesion(s)	0695	17.06	$867.36	$398.99	$173.47
46924	T	Destruction, anal lesion(s)	0695	17.06	$867.36	$398.99	$173.47
46934	T	Destruction of hemorrhoids	0155	5.73	$291.32	$96.14	$58.26
46935	T	Destruction of hemorrhoids	0155	5.73	$291.32	$96.14	$58.26
46936	T	Destruction of hemorrhoids	0149	14.49	$736.70	$293.06	$147.34
46937	T	Cryotherapy of rectal lesion	0149	14.49	$736.70	$293.06	$147.34
46938	T	Cryotherapy of rectal lesion	0150	19.58	$995.49	$437.12	$199.10
46940	T	Treatment of anal fissure	0149	14.49	$736.70	$293.06	$147.34
46942	T	Treatment of anal fissure	0149	14.49	$736.70	$293.06	$147.34
46945	T	Ligation of hemorrhoids	0155	5.73	$291.32	$96.14	$58.26
46946	T	Ligation of hemorrhoids	0155	5.73	$291.32	$96.14	$58.26
46999	T	Anus surgery procedure	0149	14.49	$736.70	$293.06	$147.34
47000	T	Needle biopsy of liver	0005	6.71	$341.15	$119.75	$68.23
47001	C	Needle biopsy, liver add-on					
47010	C	Open drainage, liver lesion					
47011	C	Percut drain, liver lesion					
47015	C	Inject/aspirate liver cyst					
47100	C	Wedge biopsy of liver					
47120	C	Partial removal of liver					
47122	C	Extensive removal of liver					
47125	C	Partial removal of liver					
47130	C	Partial removal of liver					
47133	C	Removal of donor liver					
47134	C	Partial removal, donor liver					
47135	C	Transplantation of liver					
47136	C	Transplantation of liver					
47300	C	Surgery for liver lesion					
47350	C	Repair liver wound					
47360	C	Repair liver wound					
47361	C	Repair liver wound					
47362	C	Repair liver wound					
47379	T	Laparoscope procedure, liver	0130	27.92	$1,419.51	$659.53	$283.90
47399	T	Liver surgery procedure	0005	6.71	$341.15	$119.75	$68.23
47400	C	Incision of liver duct					
47420	C	Incision of bile duct					
47425	C	Incision of bile duct					
47460	C	Incise bile duct sphincter					
47480	C	Incision of gallbladder					
47490	C	Incision of gallbladder					
47500	N	Injection for liver x-rays					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
47505	N	Injection for liver x-rays					
47510	T	Insert catheter, bile duct	0152	17.44	$886.68	$207.38	$177.34
47511	T	Insert bile duct drain	0152	17.44	$886.68	$207.38	$177.34
47525	T	Change bile duct catheter	0122	5.69	$289.29	$114.93	$57.86
47530	T	Revise/reinsert bile tube	0121	2.42	$123.04	$52.53	$24.61
47550	C	Bile duct endoscopy add-on					
47552	T	Biliary endoscopy thru skin	0152	17.44	$886.68	$207.38	$177.34
47553	T	Biliary endoscopy thru skin	0152	17.44	$886.68	$207.38	$177.34
47554	T	Biliary endoscopy thru skin	0152	17.44	$886.68	$207.38	$177.34
47555	T	Biliary endoscopy thru skin	0152	17.44	$886.68	$207.38	$177.34
47556	T	Biliary endoscopy thru skin	0152	17.44	$886.68	$207.38	$177.34
47560	T	Laparoscopy w/cholangio	0130	27.92	$1,419.51	$659.53	$283.90
47561	T	Laparo w/cholangio/biopsy	0130	27.92	$1,419.51	$659.53	$283.90
47562	T	Laparoscopic cholecystectomy	0131	39.80	$2,023.51	$1,052.23	$404.70
47563	T	Laparo cholecystectomy/graph	0131	39.80	$2,023.51	$1,052.23	$404.70
47564	T	Laparo cholecystectomy/explr	0131	39.80	$2,023.51	$1,052.23	$404.70
47570	C	Laparo cholecystoenterostomy					
47579	T	Laparoscope proc, biliary	0130	27.92	$1,419.51	$659.53	$283.90
47600	C	Removal of gallbladder					
47605	C	Removal of gallbladder					
47610	C	Removal of gallbladder					
47612	C	Removal of gallbladder					
47620	C	Removal of gallbladder					
47630	T	Remove bile duct stone	0152	17.44	$886.68	$207.38	$177.34
47700	C	Exploration of bile ducts					
47701	C	Bile duct revision					
47711	C	Excision of bile duct tumor					
47712	C	Excision of bile duct tumor					
47715	C	Excision of bile duct cyst					
47716	C	Fusion of bile duct cyst					
47720	C	Fuse gallbladder & bowel					
47721	C	Fuse upper gi structures					
47740	C	Fuse gallbladder & bowel					
47741	C	Fuse gallbladder & bowel					
47760	C	Fuse bile ducts and bowel					
47765	C	Fuse liver ducts & bowel					
47780	C	Fuse bile ducts and bowel					
47785	C	Fuse bile ducts and bowel					
47800	C	Reconstruction of bile ducts					
47801	C	Placement, bile duct support					
47802	C	Fuse liver duct & intestine					
47900	C	Suture bile duct injury					
47999	T	Bile tract surgery procedure	0121	2.42	$123.04	$52.53	$24.61
48000	C	Drainage of abdomen					
48001	C	Placement of drain, pancreas					
48005	C	Resect/debride pancreas					
48020	C	Removal of pancreatic stone					
48100	C	Biopsy of pancreas					
48102	T	Needle biopsy, pancreas	0005	6.71	$341.15	$119.75	$68.23
48120	C	Removal of pancreas lesion					
48140	C	Partial removal of pancreas					
48145	C	Partial removal of pancreas					
48146	C	Pancreatectomy					
48148	C	Removal of pancreatic duct					
48150	C	Partial removal of pancreas					
48152	C	Pancreatectomy					
48153	C	Pancreatectomy					
48154	C	Pancreatectomy					
48155	C	Removal of pancreas					
48160	E	Pancreas removal/transplant					
48180	C	Fuse pancreas and bowel					
48400	C	Injection, intraop add-on					
48500	C	Surgery of pancreas cyst					
48510	C	Drain pancreatic pseudocyst					
48511	C	Drain pancreatic pseudocyst					
48520	C	Fuse pancreas cyst and bowel					
48540	C	Fuse pancreas cyst and bowel					
48545	C	Pancreatorrhaphy					
48547	C	Duodenal exclusion					
48550	E	Donor pancreatectomy					
48554	E	Transpl allograft pancreas					
48556	C	Removal, allograft pancreas					
48999	T	Pancreas surgery procedure	0005	6.71	$341.15	$119.75	$68.23
49000	C	Exploration of abdomen					
49002	C	Reopening of abdomen					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
49010	C	Exploration behind abdomen					
49020	C	Drain abdominal abscess					
49021	C	Drain abdominal abscess					
49040	C	Drain, open, abdom abscess					
49041	C	Drain, percut, abdom abscess					
49060	C	Drain, open, retrop abscess					
49061	C	Drain, percut, retroper absc					
49062	C	Drain to peritoneal cavity					
49080	T	Puncture, peritoneal cavity	0070	4.11	$208.96	$79.60	$41.79
49081	T	Removal of abdominal fluid	0070	4.11	$208.96	$79.60	$41.79
49085	T	Remove abdomen foreign body	0153	22.44	$1,140.89	$496.31	$228.18
49180	T	Biopsy, abdominal mass	0005	6.71	$341.15	$119.75	$68.23
49200	C	Removal of abdominal lesion					
49201	C	Removal of abdominal lesion					
49215	C	Excise sacral spine tumor					
49220	C	Multiple surgery, abdomen					
49250	T	Excision of umbilicus	0153	22.44	$1,140.89	$496.31	$228.18
49255	C	Removal of omentum					
49320	T	Diag laparo separate proc	0130	27.92	$1,419.51	$659.53	$283.90
49321	T	Laparoscopy, biopsy	0130	27.92	$1,419.51	$659.53	$283.90
49322	T	Laparoscopy, aspiration	0130	27.92	$1,419.51	$659.53	$283.90
49323	T	Laparo drain lymphocele	0130	27.92	$1,419.51	$659.53	$283.90
49329	T	Laparo proc, abdm/per/oment	0130	27.92	$1,419.51	$659.53	$283.90
49400	N	Air injection into abdomen					
49420	T	Insert abdominal drain	0153	22.44	$1,140.89	$496.31	$228.18
49421	T	Insert abdominal drain	0153	22.44	$1,140.89	$496.31	$228.18
49422	T	Remove perm cannula/catheter	0105	16.56	$841.94	$372.32	$168.39
49423	T	Exchange drainage catheter	0153	22.44	$1,140.89	$496.31	$228.18
49424	N	Assess cyst, contrast inject					
49425	C	Insert abdomen-venous drain					
49426	T	Revise abdomen-venous shunt	0153	22.44	$1,140.89	$496.31	$228.18
49427	N	Injection, abdominal shunt					
49428	C	Ligation of shunt					
49429	T	Removal of shunt	0105	16.56	$841.94	$372.32	$168.39
49495	T	Repair inguinal hernia, init	0154	24.09	$1,224.78	$556.98	$244.96
49496	T	Repair inguinal hernia, init	0154	24.09	$1,224.78	$556.98	$244.96
49500	T	Repair inguinal hernia	0154	24.09	$1,224.78	$556.98	$244.96
49501	T	Repair inguinal hernia, init	0154	24.09	$1,224.78	$556.98	$244.96
49505	T	Repair inguinal hernia	0154	24.09	$1,224.78	$556.98	$244.96
49507	T	Repair inguinal hernia	0154	24.09	$1,224.78	$556.98	$244.96
49520	T	Rerepair inguinal hernia	0154	24.09	$1,224.78	$556.98	$244.96
49521	T	Repair inguinal hernia, rec	0154	24.09	$1,224.78	$556.98	$244.96
49525	T	Repair inguinal hernia	0154	24.09	$1,224.78	$556.98	$244.96
49540	T	Repair lumbar hernia	0154	24.09	$1,224.78	$556.98	$244.96
49550	T	Repair femoral hernia	0154	24.09	$1,224.78	$556.98	$244.96
49553	T	Repair femoral hernia, init	0154	24.09	$1,224.78	$556.98	$244.96
49555	T	Repair femoral hernia	0154	24.09	$1,224.78	$556.98	$244.96
49557	T	Repair femoral hernia, recur	0154	24.09	$1,224.78	$556.98	$244.96
49560	T	Repair abdominal hernia	0154	24.09	$1,224.78	$556.98	$244.96
49561	T	Repair incisional hernia	0154	24.09	$1,224.78	$556.98	$244.96
49565	T	Rerepair abdominal hernia	0154	24.09	$1,224.78	$556.98	$244.96
49566	T	Repair incisional hernia	0154	24.09	$1,224.78	$556.98	$244.96
49568	T	Hernia repair w/mesh	0154	24.09	$1,224.78	$556.98	$244.96
49570	T	Repair epigastric hernia	0154	24.09	$1,224.78	$556.98	$244.96
49572	T	Repair epigastric hernia	0154	24.09	$1,224.78	$556.98	$244.96
49580	T	Repair umbilical hernia	0154	24.09	$1,224.78	$556.98	$244.96
49582	T	Repair umbilical hernia	0154	24.09	$1,224.78	$556.98	$244.96
49585	T	Repair umbilical hernia	0154	24.09	$1,224.78	$556.98	$244.96
49587	T	Repair umbilical hernia	0154	24.09	$1,224.78	$556.98	$244.96
49590	T	Repair abdominal hernia	0154	24.09	$1,224.78	$556.98	$244.96
49600	T	Repair umbilical lesion	0154	24.09	$1,224.78	$556.98	$244.96
49605	C	Repair umbilical lesion					
49606	C	Repair umbilical lesion					
49610	C	Repair umbilical lesion					
49611	C	Repair umbilical lesion					
49650	T	Laparo hernia repair initial	0131	39.80	$2,023.51	$1,052.23	$404.70
49651	T	Laparo hernia repair recur	0131	39.80	$2,023.51	$1,052.23	$404.70
49659	T	Laparo proc, hernia repair	0131	39.80	$2,023.51	$1,052.23	$404.70
49900	C	Repair of abdominal wall					
49905	C	Omental flap					
49906	C	Free omental flap, microvasc					
49999	T	Abdomen surgery procedure	0121	2.42	$123.04	$52.53	$24.61
50010	C	Exploration of kidney					
50020	C	Renal abscess, open drain					
50021	C	Renal abscess, percut drain					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
50040	C	Drainage of kidney					
50045	C	Exploration of kidney					
50060	C	Removal of kidney stone					
50065	C	Incision of kidney					
50070	C	Incision of kidney					
50075	C	Removal of kidney stone					
50080	T	Removal of kidney stone	0163	30.27	$1,538.99	$792.58	$307.80
50081	T	Removal of kidney stone	0163	30.27	$1,538.99	$792.58	$307.80
50100	C	Revise kidney blood vessels					
50120	C	Exploration of kidney					
50125	C	Explore and drain kidney					
50130	C	Removal of kidney stone					
50135	C	Exploration of kidney					
50200	T	Biopsy of kidney	0005	6.71	$341.15	$119.75	$68.23
50205	C	Biopsy of kidney					
50220	C	Removal of kidney					
50225	C	Removal of kidney					
50230	C	Removal of kidney					
50234	C	Removal of kidney & ureter					
50236	C	Removal of kidney & ureter					
50240	C	Partial removal of kidney					
50280	C	Removal of kidney lesion					
50290	C	Removal of kidney lesion					
50300	C	Removal of donor kidney					
50320	C	Removal of donor kidney					
50340	C	Removal of kidney					
50360	C	Transplantation of kidney					
50365	C	Transplantation of kidney					
50370	C	Remove transplanted kidney					
50380	C	Reimplantation of kidney					
50390	T	Drainage of kidney lesion	0005	6.71	$341.15	$119.75	$68.23
50392	T	Insert kidney drain	0161	16.45	$836.35	$249.36	$167.27
50393	T	Insert ureteral tube	0160	5.98	$304.04	$110.11	$60.81
50394	N	Injection for kidney x-ray					
50395	T	Create passage to kidney	0160	5.98	$304.04	$110.11	$60.81
50396	T	Measure kidney pressure	0164	0.98	$49.83	$14.95	$9.97
50398	T	Change kidney tube	0122	5.69	$289.29	$114.93	$57.86
50400	C	Revision of kidney/ureter					
50405	C	Revision of kidney/ureter					
50500	C	Repair of kidney wound					
50520	C	Close kidney-skin fistula					
50525	C	Repair renal-abdomen fistula					
50526	C	Repair renal-abdomen fistula					
50540	C	Revision of horseshoe kidney					
50541	T	Laparo ablate renal cyst	0130	27.92	$1,419.51	$659.53	$283.90
50544	T	Laparoscopy, pyeloplasty	0130	27.92	$1,419.51	$659.53	$283.90
50545	C	Laparo radical nephrectomy					
50546	C	Laparoscopic nephrectomy					
50547	C	Laparo removal donor kidney					
50548	C	Laparo remove k/ureter					
50549	T	Laparoscope proc, renal	0130	27.92	$1,419.51	$659.53	$283.90
50551	T	Kidney endoscopy	0161	16.45	$836.35	$249.36	$167.27
50553	T	Kidney endoscopy	0161	16.45	$836.35	$249.36	$167.27
50555	T	Kidney endoscopy & biopsy	0161	16.45	$836.35	$249.36	$167.27
50557	T	Kidney endoscopy & treatment	0161	16.45	$836.35	$249.36	$167.27
50559	T	Renal endoscopy/radiotracer	0161	16.45	$836.35	$249.36	$167.27
50561	T	Kidney endoscopy & treatment	0161	16.45	$836.35	$249.36	$167.27
50570	C	Kidney endoscopy					
50572	C	Kidney endoscopy					
50574	C	Kidney endoscopy & biopsy					
50575	C	Kidney endoscopy					
50576	C	Kidney endoscopy & treatment					
50578	C	Renal endoscopy/radiotracer					
50580	C	Kidney endoscopy & treatment					
50590	T	Fragmenting of kidney stone	0169	42.65	$2,168.41	$1,192.63	$433.68
50600	C	Exploration of ureter					
50605	C	Insert ureteral support					
50610	C	Removal of ureter stone					
50620	C	Removal of ureter stone					
50630	C	Removal of ureter stone					
50650	C	Removal of ureter					
50660	C	Removal of ureter					
50684	N	Injection for ureter x-ray					
50686	T	Measure ureter pressure	0164	0.98	$49.83	$14.95	$9.97
50688	T	Change of ureter tube	0121	2.42	$123.04	$52.53	$24.61

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
50690	N	Injection for ureter x-ray					
50700	C	Revision of ureter					
50715	C	Release of ureter					
50722	C	Release of ureter					
50725	C	Release/revise ureter					
50727	C	Revise ureter					
50728	C	Revise ureter					
50740	C	Fusion of ureter & kidney					
50750	C	Fusion of ureter & kidney					
50760	C	Fusion of ureters					
50770	C	Splicing of ureters					
50780	C	Reimplant ureter in bladder					
50782	C	Reimplant ureter in bladder					
50783	C	Reimplant ureter in bladder					
50785	C	Reimplant ureter in bladder					
50800	C	Implant ureter in bowel					
50810	C	Fusion of ureter & bowel					
50815	C	Urine shunt to bowel					
50820	C	Construct bowel bladder					
50825	C	Construct bowel bladder					
50830	C	Revise urine flow					
50840	C	Replace ureter by bowel					
50845	C	Appendico-vesicostomy					
50860	C	Transplant ureter to skin					
50900	C	Repair of ureter					
50920	C	Closure ureter/skin fistula					
50930	C	Closure ureter/bowel fistula					
50940	C	Release of ureter					
50945	T	Laparoscopy ureterolithotomy	0131	39.80	$2,023.51	$1,052.23	$404.70
50947	T	Laparo new ureter/bladder	0131	39.80	$2,023.51	$1,052.23	$404.70
50948	T	Laparo new ureter/bladder	0131	39.80	$2,023.51	$1,052.23	$404.70
50949	T	Laparoscope proc, ureter	0130	27.92	$1,419.51	$659.53	$283.90
50951	T	Endoscopy of ureter	0162	19.86	$1,009.72	$427.49	$201.94
50953	T	Endoscopy of ureter	0162	19.86	$1,009.72	$427.49	$201.94
50955	T	Ureter endoscopy & biopsy	0162	19.86	$1,009.72	$427.49	$201.94
50957	T	Ureter endoscopy & treatment	0162	19.86	$1,009.72	$427.49	$201.94
50959	T	Ureter endoscopy & tracer	0162	19.86	$1,009.72	$427.49	$201.94
50961	T	Ureter endoscopy & treatment	0162	19.86	$1,009.72	$427.49	$201.94
50970	T	Ureter endoscopy	0162	19.86	$1,009.72	$427.49	$201.94
50972	T	Ureter endoscopy & catheter	0162	19.86	$1,009.72	$427.49	$201.94
50974	T	Ureter endoscopy & biopsy	0162	19.86	$1,009.72	$427.49	$201.94
50976	T	Ureter endoscopy & treatment	0162	19.86	$1,009.72	$427.49	$201.94
50978	T	Ureter endoscopy & tracer	0162	19.86	$1,009.72	$427.49	$201.94
50980	T	Ureter endoscopy & treatment	0162	19.86	$1,009.72	$427.49	$201.94
51000	T	Drainage of bladder	0165	5.36	$272.51	$91.76	$54.50
51005	T	Drainage of bladder	0156	2.62	$133.21	$39.96	$26.64
51010	T	Drainage of bladder	0165	5.36	$272.51	$91.76	$54.50
51020	T	Incise & treat bladder	0162	19.86	$1,009.72	$427.49	$201.94
51030	T	Incise & treat bladder	0162	19.86	$1,009.72	$427.49	$201.94
51040	T	Incise & drain bladder	0162	19.86	$1,009.72	$427.49	$201.94
51045	T	Incise bladder/drain ureter	0162	19.86	$1,009.72	$427.49	$201.94
51050	T	Removal of bladder stone	0162	19.86	$1,009.72	$427.49	$201.94
51060	C	Removal of ureter stone					
51065	T	Removal of ureter stone	0162	19.86	$1,009.72	$427.49	$201.94
51080	T	Drainage of bladder abscess	0007	7.28	$370.13	$74.03	$74.03
51500	T	Removal of bladder cyst	0154	24.09	$1,224.78	$556.98	$244.96
51520	T	Removal of bladder lesion	0162	19.86	$1,009.72	$427.49	$201.94
51525	C	Removal of bladder lesion					
51530	C	Removal of bladder lesion					
51535	C	Repair of ureter lesion					
51550	C	Partial removal of bladder					
51555	C	Partial removal of bladder					
51565	C	Revise bladder & ureter(s)					
51570	C	Removal of bladder					
51575	C	Removal of bladder & nodes					
51580	C	Remove bladder/revise tract					
51585	C	Removal of bladder & nodes					
51590	C	Remove bladder/revise tract					
51595	C	Remove bladder/revise tract					
51596	C	Remove bladder/create pouch					
51597	C	Removal of pelvic structures					
51600	N	Injection for bladder x-ray					
51605	N	Preparation for bladder xray					
51610	N	Injection for bladder x-ray					
51700	T	Irrigation of bladder	0156	2.62	$133.21	$39.96	$26.64

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
51705	T	Change of bladder tube	0121	2.42	$123.04	$52.53	$24.61
51710	T	Change of bladder tube	0121	2.42	$123.04	$52.53	$24.61
51715	T	Endoscopic injection/implant	0167	24.18	$1,229.36	$555.84	$245.87
51720	T	Treatment of bladder lesion	0156	2.62	$133.21	$39.96	$26.64
51725	T	Simple cystometrogram	0165	5.36	$272.51	$91.76	$54.50
51726	T	Complex cystometrogram	0165	5.36	$272.51	$91.76	$54.50
51736	T	Urine flow measurement	0164	0.98	$49.83	$14.95	$9.97
51741	T	Electro-uroflowmetry, first	0164	0.98	$49.83	$14.95	$9.97
51772	T	Urethra pressure profile	0165	5.36	$272.51	$91.76	$54.50
51784	T	Anal/urinary muscle study	0164	0.98	$49.83	$14.95	$9.97
51785	T	Anal/urinary muscle study	0156	2.62	$133.21	$39.96	$26.64
51792	T	Urinary reflex study	0156	2.62	$133.21	$39.96	$26.64
51795	T	Urine voiding pressure study	0165	5.36	$272.51	$91.76	$54.50
51797	T	Intraabdominal pressure test	0165	5.36	$272.51	$91.76	$54.50
51800	C	Revision of bladder/urethra					
51820	C	Revision of urinary tract					
51840	C	Attach bladder/urethra					
51841	C	Attach bladder/urethra					
51845	C	Repair bladder neck					
51860	C	Repair of bladder wound					
51865	C	Repair of bladder wound					
51880	T	Repair of bladder opening	0162	19.86	$1,009.72	$427.49	$201.94
51900	C	Repair bladder/vagina lesion					
51920	C	Close bladder-uterus fistula					
51925	C	Hysterectomy/bladder repair					
51940	C	Correction of bladder defect					
51960	C	Revision of bladder & bowel					
51980	C	Construct bladder opening					
51990	T	Laparo urethral suspension	0131	39.80	$2,023.51	$1,052.23	$404.70
51992	T	Laparo sling operation	0132	60.31	$3,066.28	$1,239.22	$613.26
52000	T	Cystoscopy	0160	5.98	$304.04	$110.11	$60.81
52005	T	Cystoscopy & ureter catheter	0161	16.45	$836.35	$249.36	$167.27
52007	T	Cystoscopy and biopsy	0161	16.45	$836.35	$249.36	$167.27
52010	T	Cystoscopy & duct catheter	0160	5.98	$304.04	$110.11	$60.81
52204	T	Cystoscopy	0161	16.45	$836.35	$249.36	$167.27
52214	T	Cystoscopy and treatment	0161	16.45	$836.35	$249.36	$167.27
52224	T	Cystoscopy and treatment	0161	16.45	$836.35	$249.36	$167.27
52234	T	Cystoscopy and treatment	0162	19.86	$1,009.72	$427.49	$201.94
52235	T	Cystoscopy and treatment	0162	19.86	$1,009.72	$427.49	$201.94
52240	T	Cystoscopy and treatment	0163	30.27	$1,538.99	$792.58	$307.80
52250	T	Cystoscopy and radiotracer	0162	19.86	$1,009.72	$427.49	$201.94
52260	T	Cystoscopy and treatment	0161	16.45	$836.35	$249.36	$167.27
52265	T	Cystoscopy and treatment	0160	5.98	$304.04	$110.11	$60.81
52270	T	Cystoscopy & revise urethra	0161	16.45	$836.35	$249.36	$167.27
52275	T	Cystoscopy & revise urethra	0161	16.45	$836.35	$249.36	$167.27
52276	T	Cystoscopy and treatment	0161	16.45	$836.35	$249.36	$167.27
52277	T	Cystoscopy and treatment	0162	19.86	$1,009.72	$427.49	$201.94
52281	T	Cystoscopy and treatment	0160	5.98	$304.04	$110.11	$60.81
52282	T	Cystoscopy, implant stent	0162	19.86	$1,009.72	$427.49	$201.94
52283	T	Cystoscopy and treatment	0161	16.45	$836.35	$249.36	$167.27
52285	T	Cystoscopy and treatment	0161	16.45	$836.35	$249.36	$167.27
52290	T	Cystoscopy and treatment	0161	16.45	$836.35	$249.36	$167.27
52300	T	Cystoscopy and treatment	0161	16.45	$836.35	$249.36	$167.27
52301	T	Cystoscopy and treatment	0161	16.45	$836.35	$249.36	$167.27
52305	T	Cystoscopy and treatment	0161	16.45	$836.35	$249.36	$167.27
52310	T	Cystoscopy and treatment	0160	5.98	$304.04	$110.11	$60.81
52315	T	Cystoscopy and treatment	0161	16.45	$836.35	$249.36	$167.27
52317	T	Remove bladder stone	0162	19.86	$1,009.72	$427.49	$201.94
52318	T	Remove bladder stone	0162	19.86	$1,009.72	$427.49	$201.94
52320	T	Cystoscopy and treatment	0162	19.86	$1,009.72	$427.49	$201.94
52325	T	Cystoscopy, stone removal	0162	19.86	$1,009.72	$427.49	$201.94
52327	T	Cystoscopy, inject material	0161	16.45	$836.35	$249.36	$167.27
52330	T	Cystoscopy and treatment	0162	19.86	$1,009.72	$427.49	$201.94
52332	T	Cystoscopy and treatment	0162	19.86	$1,009.72	$427.49	$201.94
52334	T	Create passage to kidney	0162	19.86	$1,009.72	$427.49	$201.94
52341	T	Cysto w/ureter stricture tx	0162	19.86	$1,009.72	$427.49	$201.94
52342	T	Cysto w/up stricture tx	0162	19.86	$1,009.72	$427.49	$201.94
52343	T	Cysto w/renal stricture tx	0162	19.86	$1,009.72	$427.49	$201.94
52344	T	Cysto/uretero, stone remove	0162	19.86	$1,009.72	$427.49	$201.94
52345	T	Cysto/uretero w/up stricture	0162	19.86	$1,009.72	$427.49	$201.94
52346	T	Cystouretero w/renal strict	0162	19.86	$1,009.72	$427.49	$201.94
52351	T	Cystouretro & or pyeloscope	0161	16.45	$836.35	$249.36	$167.27
52352	T	Cystouretro w/stone remove	0162	19.86	$1,009.72	$427.49	$201.94
52353	T	Cystouretero w/lithotripsy	0163	30.27	$1,538.99	$792.58	$307.80
52354	T	Cystouretero w/biopsy	0162	19.86	$1,009.72	$427.49	$201.94

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
52355	T	Cystouretero w/excise tumor	0162	19.86	$1,009.72	$427.49	$201.94
52400	T	Cystouretero w/congen repr	0162	19.86	$1,009.72	$427.49	$201.94
52450	T	Incision of prostate	0162	19.86	$1,009.72	$427.49	$201.94
52500	T	Revision of bladder neck	0162	19.86	$1,009.72	$427.49	$201.94
52510	T	Dilation prostatic urethra	0161	16.45	$836.35	$249.36	$167.27
52601	T	Prostatectomy (TURP)	0163	30.27	$1,538.99	$792.58	$307.80
52606	T	Control postop bleeding	0162	19.86	$1,009.72	$427.49	$201.94
52612	T	Prostatectomy, first stage	0163	30.27	$1,538.99	$792.58	$307.80
52614	T	Prostatectomy, second stage	0163	30.27	$1,538.99	$792.58	$307.80
52620	T	Remove residual prostate	0163	30.27	$1,538.99	$792.58	$307.80
52630	T	Remove prostate regrowth	0163	30.27	$1,538.99	$792.58	$307.80
52640	T	Relieve bladder contracture	0162	19.86	$1,009.72	$427.49	$201.94
52647	T	Laser surgery of prostate	0163	30.27	$1,538.99	$792.58	$307.80
52648	T	Laser surgery of prostate	0163	30.27	$1,538.99	$792.58	$307.80
52700	T	Drainage of prostate abscess	0162	19.86	$1,009.72	$427.49	$201.94
53000	T	Incision of urethra	0166	13.02	$661.96	$218.73	$132.39
53010	T	Incision of urethra	0166	13.02	$661.96	$218.73	$132.39
53020	T	Incision of urethra	0166	13.02	$661.96	$218.73	$132.39
53025	T	Incision of urethra	0166	13.02	$661.96	$218.73	$132.39
53040	T	Drainage of urethra abscess	0166	13.02	$661.96	$218.73	$132.39
53060	T	Drainage of urethra abscess	0166	13.02	$661.96	$218.73	$132.39
53080	T	Drainage of urinary leakage	0166	13.02	$661.96	$218.73	$132.39
53085	C	Drainage of urinary leakage	.....	.....	.....	.....	.....
53200	T	Biopsy of urethra	0166	13.02	$661.96	$218.73	$132.39
53210	T	Removal of urethra	0168	31.68	$1,610.67	$536.11	$322.13
53215	T	Removal of urethra	0168	31.68	$1,610.67	$536.11	$322.13
53220	T	Treatment of urethra lesion	0168	31.68	$1,610.67	$536.11	$322.13
53230	T	Removal of urethra lesion	0168	31.68	$1,610.67	$536.11	$322.13
53235	T	Removal of urethra lesion	0168	31.68	$1,610.67	$536.11	$322.13
53240	T	Surgery for urethra pouch	0168	31.68	$1,610.67	$536.11	$322.13
53250	T	Removal of urethra gland	0166	13.02	$661.96	$218.73	$132.39
53260	T	Treatment of urethra lesion	0166	13.02	$661.96	$218.73	$132.39
53265	T	Treatment of urethra lesion	0166	13.02	$661.96	$218.73	$132.39
53270	T	Removal of urethra gland	0167	24.18	$1,229.36	$555.84	$245.87
53275	T	Repair of urethra defect	0166	13.02	$661.96	$218.73	$132.39
53400	T	Revise urethra, stage 1	0168	31.68	$1,610.67	$536.11	$322.13
53405	T	Revise urethra, stage 2	0168	31.68	$1,610.67	$536.11	$322.13
53410	T	Reconstruction of urethra	0168	31.68	$1,610.67	$536.11	$322.13
53415	C	Reconstruction of urethra	.....	.....	.....	.....	.....
53420	T	Reconstruct urethra, stage 1	0168	31.68	$1,610.67	$536.11	$322.13
53425	T	Reconstruct urethra, stage 2	0168	31.68	$1,610.67	$536.11	$322.13
53430	T	Reconstruction of urethra	0168	31.68	$1,610.67	$536.11	$322.13
53440	T	Correct bladder function	0182	85.94	$4,369.36	$1,492.28	$873.87
53442	T	Remove perineal prosthesis	0166	13.02	$661.96	$218.73	$132.39
53443	C	Reconstruction of urethra	.....	.....	.....	.....	.....
53445	T	Correct urine flow control	0182	85.94	$4,369.36	$1,492.28	$873.87
53447	T	Remove artificial sphincter	0168	31.68	$1,610.67	$536.11	$322.13
53449	T	Correct artificial sphincter	0168	31.68	$1,610.67	$536.11	$322.13
53450	T	Revision of urethra	0168	31.68	$1,610.67	$536.11	$322.13
53460	T	Revision of urethra	0168	31.68	$1,610.67	$536.11	$322.13
53502	T	Repair of urethra injury	0166	13.02	$661.96	$218.73	$132.39
53505	T	Repair of urethra injury	0167	24.18	$1,229.36	$555.84	$245.87
53510	T	Repair of urethra injury	0166	13.02	$661.96	$218.73	$132.39
53515	T	Repair of urethra injury	0168	31.68	$1,610.67	$536.11	$322.13
53520	T	Repair of urethra defect	0168	31.68	$1,610.67	$536.11	$322.13
53600	T	Dilate urethra stricture	0156	2.62	$133.21	$39.96	$26.64
53601	T	Dilate urethra stricture	0164	0.98	$49.83	$14.95	$9.97
53605	T	Dilate urethra stricture	0161	16.45	$836.35	$249.36	$167.27
53620	T	Dilate urethra stricture	0165	5.36	$272.51	$91.76	$54.50
53621	T	Dilate urethra stricture	0164	0.98	$49.83	$14.95	$9.97
53660	T	Dilation of urethra	0164	0.98	$49.83	$14.95	$9.97
53661	T	Dilation of urethra	0164	0.98	$49.83	$14.95	$9.97
53665	T	Dilation of urethra	0166	13.02	$661.96	$218.73	$132.39
53670	N	Insert urinary catheter	.....	.....	.....	.....	.....
53675	T	Insert urinary catheter	0156	2.62	$133.21	$39.96	$26.64
53850	T	Prostatic microwave thermotx	0982	52.06	$2,646.83	.....	$529.37
53852	T	Prostatic rf thermotx	0982	52.06	$2,646.83	.....	$529.37
53899	T	Urology surgery procedure	0165	5.36	$272.51	$91.76	$54.50
54000	T	Slitting of prepuce	0166	13.02	$661.96	$218.73	$132.39
54001	T	Slitting of prepuce	0166	13.02	$661.96	$218.73	$132.39
54015	T	Drain penis lesion	0008	11.36	$577.57	$115.51	$115.51
54050	T	Destruction, penis lesion(s)	0013	1.51	$76.77	$17.66	$15.35
54055	T	Destruction, penis lesion(s)	0017	10.51	$534.35	$245.80	$106.87
54056	T	Cryosurgery, penis lesion(s)	0012	0.72	$36.61	$9.18	$7.32
54057	T	Laser surg, penis lesion(s)	0017	10.51	$534.35	$245.80	$106.87

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
54060	T	Excision of penis lesion(s)	0017	10.51	$534.35	$245.80	$106.87
54065	T	Destruction, penis lesion(s)	0695	17.06	$867.36	$398.99	$173.47
54100	T	Biopsy of penis	0020	8.56	$435.21	$130.53	$87.04
54105	T	Biopsy of penis	0021	12.74	$647.73	$236.51	$129.55
54110	T	Treatment of penis lesion	0181	24.07	$1,223.77	$673.07	$244.75
54111	T	Treat penis lesion, graft	0181	24.07	$1,223.77	$673.07	$244.75
54112	T	Treat penis lesion, graft	0181	24.07	$1,223.77	$673.07	$244.75
54115	T	Treatment of penis lesion	0008	11.36	$577.57	$115.51	$115.51
54120	T	Partial removal of penis	0181	24.07	$1,223.77	$673.07	$244.75
54125	C	Removal of penis					
54130	C	Remove penis & nodes					
54135	C	Remove penis & nodes					
54150	T	Circumcision	0180	16.29	$828.22	$304.87	$165.64
54152	T	Circumcision	0180	16.29	$828.22	$304.87	$165.64
54160	T	Circumcision	0180	16.29	$828.22	$304.87	$165.64
54161	T	Circumcision	0180	16.29	$828.22	$304.87	$165.64
54200	T	Treatment of penis lesion	0156	2.62	$133.21	$39.96	$26.64
54205	T	Treatment of penis lesion	0181	24.07	$1,223.77	$673.07	$244.75
54220	T	Treatment of penis lesion	0156	2.62	$133.21	$39.96	$26.64
54230	N	Prepare penis study					
54231	T	Dynamic cavernosometry	0165	5.36	$272.51	$91.76	$54.50
54235	T	Penile injection	0164	0.98	$49.83	$14.95	$9.97
54240	T	Penis study	0164	0.98	$49.83	$14.95	$9.97
54250	T	Penis study	0165	5.36	$272.51	$91.76	$54.50
54300	T	Revision of penis	0181	24.07	$1,223.77	$673.07	$244.75
54304	T	Revision of penis	0181	24.07	$1,223.77	$673.07	$244.75
54308	T	Reconstruction of urethra	0181	24.07	$1,223.77	$673.07	$244.75
54312	T	Reconstruction of urethra	0181	24.07	$1,223.77	$673.07	$244.75
54316	T	Reconstruction of urethra	0181	24.07	$1,223.77	$673.07	$244.75
54318	T	Reconstruction of urethra	0181	24.07	$1,223.77	$673.07	$244.75
54322	T	Reconstruction of urethra	0181	24.07	$1,223.77	$673.07	$244.75
54324	T	Reconstruction of urethra	0181	24.07	$1,223.77	$673.07	$244.75
54326	T	Reconstruction of urethra	0181	24.07	$1,223.77	$673.07	$244.75
54328	T	Revise penis/urethra	0181	24.07	$1,223.77	$673.07	$244.75
54332	C	Revise penis/urethra					
54336	C	Revise penis/urethra					
54340	T	Secondary urethral surgery	0181	24.07	$1,223.77	$673.07	$244.75
54344	T	Secondary urethral surgery	0181	24.07	$1,223.77	$673.07	$244.75
54348	T	Secondary urethral surgery	0181	24.07	$1,223.77	$673.07	$244.75
54352	T	Reconstruct urethra/penis	0181	24.07	$1,223.77	$673.07	$244.75
54360	T	Penis plastic surgery	0181	24.07	$1,223.77	$673.07	$244.75
54380	T	Repair penis	0181	24.07	$1,223.77	$673.07	$244.75
54385	T	Repair penis	0181	24.07	$1,223.77	$673.07	$244.75
54390	C	Repair penis and bladder					
54400	T	Insert semi-rigid prosthesis	0182	85.94	$4,369.36	$1,492.28	$873.87
54401	T	Insert self-contd prosthesis	0182	85.94	$4,369.36	$1,492.28	$873.87
54402	T	Remove penis prosthesis	0185	57.17	$2,906.64	$906.36	$581.33
54405	T	Insert multi-comp prosthesis	0182	85.94	$4,369.36	$1,492.28	$873.87
54407	T	Remove multi-comp prosthesis	0185	57.17	$2,906.64	$906.36	$581.33
54409	T	Revise penis prosthesis	0185	57.17	$2,906.64	$906.36	$581.33
54420	T	Revision of penis	0181	24.07	$1,223.77	$673.07	$244.75
54430	C	Revision of penis					
54435	T	Revision of penis	0181	24.07	$1,223.77	$673.07	$244.75
54440	T	Repair of penis	0181	24.07	$1,223.77	$673.07	$244.75
54450	T	Preputial stretching	0156	2.62	$133.21	$39.96	$26.64
54500	T	Biopsy of testis	0005	6.71	$341.15	$119.75	$68.23
54505	T	Biopsy of testis	0183	20.37	$1,035.65	$448.94	$207.13
54510	T	Removal of testis lesion	0183	20.37	$1,035.65	$448.94	$207.13
54512	T	Excise lesion testis	0183	20.37	$1,035.65	$448.94	$207.13
54520	T	Removal of testis	0183	20.37	$1,035.65	$448.94	$207.13
54522	T	Orchiectomy, partial	0183	20.37	$1,035.65	$448.94	$207.13
54530	T	Removal of testis	0154	24.09	$1,224.78	$556.98	$244.96
54535	C	Extensive testis surgery					
54550	T	Exploration for testis	0154	24.09	$1,224.78	$556.98	$244.96
54560	C	Exploration for testis					
54600	T	Reduce testis torsion	0183	20.37	$1,035.65	$448.94	$207.13
54620	T	Suspension of testis	0183	20.37	$1,035.65	$448.94	$207.13
54640	T	Suspension of testis	0154	24.09	$1,224.78	$556.98	$244.96
54650	C	Orchiopexy (Fowler-Stephens)					
54660	T	Revision of testis	0183	20.37	$1,035.65	$448.94	$207.13
54670	T	Repair testis injury	0183	20.37	$1,035.65	$448.94	$207.13
54680	T	Relocation of testis(es)	0183	20.37	$1,035.65	$448.94	$207.13
54690	T	Laparoscopy, orchiectomy	0131	39.80	$2,023.51	$1,052.23	$404.70
54692	T	Laparoscopy, orchiopexy	0132	60.31	$3,066.28	$1,239.22	$613.26
54699	T	Laparoscope proc, testis	0130	27.92	$1,419.51	$659.53	$283.90

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
54700	T	Drainage of scrotum	0183	20.37	$1,035.65	$448.94	$207.13
54800	T	Biopsy of epididymis	0004	3.00	$152.53	$32.57	$30.51
54820	T	Exploration of epididymis	0183	20.37	$1,035.65	$448.94	$207.13
54830	T	Remove epididymis lesion	0183	20.37	$1,035.65	$448.94	$207.13
54840	T	Remove epididymis lesion	0183	20.37	$1,035.65	$448.94	$207.13
54860	T	Removal of epididymis	0183	20.37	$1,035.65	$448.94	$207.13
54861	T	Removal of epididymis	0183	20.37	$1,035.65	$448.94	$207.13
54900	T	Fusion of spermatic ducts	0183	20.37	$1,035.65	$448.94	$207.13
54901	T	Fusion of spermatic ducts	0183	20.37	$1,035.65	$448.94	$207.13
55000	T	Drainage of hydrocele	0004	3.00	$152.53	$32.57	$30.51
55040	T	Removal of hydrocele	0154	24.09	$1,224.78	$556.98	$244.96
55041	T	Removal of hydroceles	0154	24.09	$1,224.78	$556.98	$244.96
55060	T	Repair of hydrocele	0183	20.37	$1,035.65	$448.94	$207.13
55100	T	Drainage of scrotum abscess	0007	7.28	$370.13	$74.03	$74.03
55110	T	Explore scrotum	0183	20.37	$1,035.65	$448.94	$207.13
55120	T	Removal of scrotum lesion	0183	20.37	$1,035.65	$448.94	$207.13
55150	T	Removal of scrotum	0183	20.37	$1,035.65	$448.94	$207.13
55175	T	Revision of scrotum	0183	20.37	$1,035.65	$448.94	$207.13
55180	T	Revision of scrotum	0183	20.37	$1,035.65	$448.94	$207.13
55200	T	Incision of sperm duct	0183	20.37	$1,035.65	$448.94	$207.13
55250	T	Removal of sperm duct(s)	0183	20.37	$1,035.65	$448.94	$207.13
55300	N	Prepare, sperm duct x-ray					
55400	T	Repair of sperm duct	0183	20.37	$1,035.65	$448.94	$207.13
55450	T	Ligation of sperm duct	0183	20.37	$1,035.65	$448.94	$207.13
55500	T	Removal of hydrocele	0183	20.37	$1,035.65	$448.94	$207.13
55520	T	Removal of sperm cord lesion	0183	20.37	$1,035.65	$448.94	$207.13
55530	T	Revise spermatic cord veins	0183	20.37	$1,035.65	$448.94	$207.13
55535	T	Revise spermatic cord veins	0154	24.09	$1,224.78	$556.98	$244.96
55540	T	Revise hernia & sperm veins	0154	24.09	$1,224.78	$556.98	$244.96
55550	T	Laparo ligate spermatic vein	0131	39.80	$2,023.51	$1,052.23	$404.70
55559	T	Laparo proc, spermatic cord	0130	27.92	$1,419.51	$659.53	$283.90
55600	C	Incise sperm duct pouch					
55605	C	Incise sperm duct pouch					
55650	C	Remove sperm duct pouch					
55680	T	Remove sperm pouch lesion	0183	20.37	$1,035.65	$448.94	$207.13
55700	T	Biopsy of prostate	0184	5.23	$265.90	$122.96	$53.18
55705	T	Biopsy of prostate	0184	5.23	$265.90	$122.96	$53.18
55720	T	Drainage of prostate abscess	0162	19.86	$1,009.72	$427.49	$201.94
55725	T	Drainage of prostate abscess	0162	19.86	$1,009.72	$427.49	$201.94
55801	C	Removal of prostate					
55810	C	Extensive prostate surgery					
55812	C	Extensive prostate surgery					
55815	C	Extensive prostate surgery					
55821	C	Removal of prostate					
55831	C	Removal of prostate					
55840	C	Extensive prostate surgery					
55842	C	Extensive prostate surgery					
55845	C	Extensive prostate surgery					
55859	T	Percut/needle insert, pros	0163	30.27	$1,538.99	$792.58	$307.80
55860	T	Surgical exposure, prostate	0165	5.36	$272.51	$91.76	$54.50
55862	C	Extensive prostate surgery					
55865	C	Extensive prostate surgery					
55870	T	Electroejaculation	0197	2.58	$131.17	$49.55	$26.23
55873	T	Cryoablate prostate	0163	30.27	$1,538.99	$792.58	$307.80
55899	T	Genital surgery procedure	0164	0.98	$49.83	$14.95	$9.97
55970	E	Sex transformation, M to F					
55980	E	Sex transformation, F to M					
56405	T	I & D of vulva/perineum	0192	2.73	$138.80	$35.33	$27.76
56420	T	Drainage of gland abscess	0192	2.73	$138.80	$35.33	$27.76
56440	T	Surgery for vulva lesion	0194	17.18	$873.47	$395.94	$174.69
56441	T	Lysis of labial lesion(s)	0193	12.17	$618.75	$171.13	$123.75
56501	T	Destruction, vulva lesion(s)	0017	10.51	$534.35	$245.80	$106.87
56515	T	Destruction, vulva lesion(s)	0695	17.06	$867.36	$398.99	$173.47
56605	T	Biopsy of vulva/perineum	0019	4.56	$231.84	$78.91	$46.37
56606	T	Biopsy of vulva/perineum	0019	4.56	$231.84	$78.91	$46.37
56620	T	Partial removal of vulva	0195	22.22	$1,129.71	$483.80	$225.94
56625	T	Complete removal of vulva	0195	22.22	$1,129.71	$483.80	$225.94
56630	C	Extensive vulva surgery					
56631	C	Extensive vulva surgery					
56632	C	Extensive vulva surgery					
56633	C	Extensive vulva surgery					
56634	C	Extensive vulva surgery					
56637	C	Extensive vulva surgery					
56640	C	Extensive vulva surgery					
56700	T	Partial removal of hymen	0194	17.18	$873.47	$395.94	$174.69

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
56720	T	Incision of hymen	0193	12.17	$618.75	$171.13	$123.75
56740	T	Remove vagina gland lesion	0194	17.18	$873.47	$395.94	$174.69
56800	T	Repair of vagina	0194	17.18	$873.47	$395.94	$174.69
56805	T	Repair clitoris	0194	17.18	$873.47	$395.94	$174.69
56810	T	Repair of perineum	0194	17.18	$873.47	$395.94	$174.69
57000	T	Exploration of vagina	0194	17.18	$873.47	$395.94	$174.69
57010	T	Drainage of pelvic abscess	0194	17.18	$873.47	$395.94	$174.69
57020	T	Drainage of pelvic fluid	0193	12.17	$618.75	$171.13	$123.75
57022	T	I &d vaginal hematoma, ob	0007	7.28	$370.13	$74.03	$74.03
57023	T	I &d vag hematoma, trauma	0007	7.28	$370.13	$74.03	$74.03
57061	T	Destruction vagina lesion(s)	0194	17.18	$873.47	$395.94	$174.69
57065	T	Destruction vagina lesion(s)	0194	17.18	$873.47	$395.94	$174.69
57100	T	Biopsy of vagina	0193	12.17	$618.75	$171.13	$123.75
57105	T	Biopsy of vagina	0194	17.18	$873.47	$395.94	$174.69
57106	T	Remove vagina wall, partial	0194	17.18	$873.47	$395.94	$174.69
57107	T	Remove vagina tissue, part	0195	22.22	$1,129.71	$483.80	$225.94
57109	T	Vaginectomy partial w/nodes	0202	39.56	$2,011.31	$864.86	$402.26
57110	C	Remove vagina wall, complete					
57111	C	Remove vagina tissue, compl					
57112	C	Vaginectomy w/nodes, compl					
57120	T	Closure of vagina	0194	17.18	$873.47	$395.94	$174.69
57130	T	Remove vagina lesion	0194	17.18	$873.47	$395.94	$174.69
57135	T	Remove vagina lesion	0194	17.18	$873.47	$395.94	$174.69
57150	T	Treat vagina infection	0191	0.27	$13.73	$3.98	$2.75
57160	T	Insert pessary/other device	0188	0.83	$42.20	$12.24	$8.44
57170	T	Fitting of diaphragm/cap	0191	0.27	$13.73	$3.98	$2.75
57180	T	Treat vaginal bleeding	0192	2.73	$138.80	$35.33	$27.76
57200	T	Repair of vagina	0194	17.18	$873.47	$395.94	$174.69
57210	T	Repair vagina/perineum	0194	17.18	$873.47	$395.94	$174.69
57220	T	Revision of urethra	0195	22.22	$1,129.71	$483.80	$225.94
57230	T	Repair of urethral lesion	0194	17.18	$873.47	$395.94	$174.69
57240	T	Repair bladder & vagina	0195	22.22	$1,129.71	$483.80	$225.94
57250	T	Repair rectum & vagina	0195	22.22	$1,129.71	$483.80	$225.94
57260	T	Repair of vagina	0195	22.22	$1,129.71	$483.80	$225.94
57265	T	Extensive repair of vagina	0195	22.22	$1,129.71	$483.80	$225.94
57268	T	Repair of bowel bulge	0195	22.22	$1,129.71	$483.80	$225.94
57270	C	Repair of bowel pouch					
57280	C	Suspension of vagina					
57282	C	Repair of vaginal prolapse					
57284	T	Repair paravaginal defect	0195	22.22	$1,129.71	$483.80	$225.94
57287	T	Revise/remove sling repair	0202	39.56	$2,011.31	$864.86	$402.26
57288	T	Repair bladder defect	0202	39.56	$2,011.31	$864.86	$402.26
57289	T	Repair bladder & vagina	0195	22.22	$1,129.71	$483.80	$225.94
57291	T	Construction of vagina	0195	22.22	$1,129.71	$483.80	$225.94
57292	C	Construct vagina with graft					
57300	T	Repair rectum-vagina fistula	0195	22.22	$1,129.71	$483.80	$225.94
57305	C	Repair rectum-vagina fistula					
57307	C	Fistula repair & colostomy					
57308	C	Fistula repair, transperine					
57310	T	Repair urethrovaginal lesion	0195	22.22	$1,129.71	$483.80	$225.94
57311	C	Repair urethrovaginal lesion					
57320	T	Repair bladder-vagina lesion	0195	22.22	$1,129.71	$483.80	$225.94
57330	T	Repair bladder-vagina lesion	0195	22.22	$1,129.71	$483.80	$225.94
57335	C	Repair vagina					
57400	T	Dilation of vagina	0194	17.18	$873.47	$395.94	$174.69
57410	T	Pelvic examination	0194	17.18	$873.47	$395.94	$174.69
57415	T	Remove vaginal foreign body	0194	17.18	$873.47	$395.94	$174.69
57452	T	Examination of vagina	0189	1.38	$70.16	$17.54	$14.03
57454	T	Vagina examination & biopsy	0192	2.73	$138.80	$35.33	$27.76
57460	T	Cervix excision	0193	12.17	$618.75	$171.13	$123.75
57500	T	Biopsy of cervix	0192	2.73	$138.80	$35.33	$27.76
57505	T	Endocervical curettage	0192	2.73	$138.80	$35.33	$27.76
57510	T	Cauterization of cervix	0193	12.17	$618.75	$171.13	$123.75
57511	T	Cryocautery of cervix	0189	1.38	$70.16	$17.54	$14.03
57513	T	Laser surgery of cervix	0193	12.17	$618.75	$171.13	$123.75
57520	T	Conization of cervix	0194	17.18	$873.47	$395.94	$174.69
57522	T	Conization of cervix	0195	22.22	$1,129.71	$483.80	$225.94
57530	T	Removal of cervix	0195	22.22	$1,129.71	$483.80	$225.94
57531	C	Removal of cervix, radical					
57540	C	Removal of residual cervix					
57545	C	Remove cervix/repair pelvis					
57550	T	Removal of residual cervix	0195	22.22	$1,129.71	$483.80	$225.94
57555	T	Remove cervix/repair vagina	0195	22.22	$1,129.71	$483.80	$225.94
57556	T	Remove cervix, repair bowel	0195	22.22	$1,129.71	$483.80	$225.94
57700	T	Revision of cervix	0194	17.18	$873.47	$395.94	$174.69

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
57720	T	Revision of cervix	0194	17.18	$873.47	$395.94	$174.69
57800	T	Dilation of cervical canal	0192	2.73	$138.80	$35.33	$27.76
57820	T	D & c of residual cervix	0196	14.62	$743.31	$357.98	$148.66
58100	T	Biopsy of uterus lining	0188	0.83	$42.20	$12.24	$8.44
58120	T	Dilation and curettage	0196	14.62	$743.31	$357.98	$148.66
58140	C	Removal of uterus lesion					
58145	T	Removal of uterus lesion	0195	22.22	$1,129.71	$483.80	$225.94
58150	C	Total hysterectomy					
58152	C	Total hysterectomy					
58180	C	Partial hysterectomy					
58200	C	Extensive hysterectomy					
58210	C	Extensive hysterectomy					
58240	C	Removal of pelvis contents					
58260	C	Vaginal hysterectomy					
58262	C	Vaginal hysterectomy					
58263	C	Vaginal hysterectomy					
58267	C	Hysterectomy & vagina repair					
58270	C	Hysterectomy & vagina repair					
58275	C	Hysterectomy/revise vagina					
58280	C	Hysterectomy/revise vagina					
58285	C	Extensive hysterectomy					
58300	E	Insert intrauterine device					
58301	T	Remove intrauterine device	0189	1.38	$70.16	$17.54	$14.03
58321	T	Artificial insemination	0197	2.58	$131.17	$49.55	$26.23
58322	T	Artificial insemination	0197	2.58	$131.17	$49.55	$26.23
58323	T	Sperm washing	0197	2.58	$131.17	$49.55	$26.23
58340	N	Catheter for hysterography					
58345	T	Reopen fallopian tube	0194	17.18	$873.47	$395.94	$174.69
58350	T	Reopen fallopian tube	0194	17.18	$873.47	$395.94	$174.69
58353	T	Endometr ablate, thermal	0193	12.17	$618.75	$171.13	$123.75
58400	C	Suspension of uterus					
58410	C	Suspension of uterus					
58520	C	Repair of ruptured uterus					
58540	C	Revision of uterus					
58550	T	Laparo-asst vag hysterectomy	0132	60.31	$3,066.28	$1,239.22	$613.26
58551	T	Laparoscopy, remove myoma	0131	39.80	$2,023.51	$1,052.23	$404.70
58555	T	Hysteroscopy, dx, sep proc	0194	17.18	$873.47	$395.94	$174.69
58558	T	Hysteroscopy, biopsy	0190	18.27	$928.88	$443.89	$185.78
58559	T	Hysteroscopy, lysis	0190	18.27	$928.88	$443.89	$185.78
58560	T	Hysteroscopy, resect septum	0190	18.27	$928.88	$443.89	$185.78
58561	T	Hysteroscopy, remove myoma	0190	18.27	$928.88	$443.89	$185.78
58562	T	Hysteroscopy, remove fb	0190	18.27	$928.88	$443.89	$185.78
58563	T	Hysteroscopy, ablation	0190	18.27	$928.88	$443.89	$185.78
58578	T	Laparo proc, uterus	0190	18.27	$928.88	$443.89	$185.78
58579	T	Hysteroscope procedure	0190	18.27	$928.88	$443.89	$185.78
58600	T	Division of fallopian tube	0194	17.18	$873.47	$395.94	$174.69
58605	C	Division of fallopian tube					
58611	C	Ligate oviduct(s) add-on					
58615	T	Occlude fallopian tube(s)	0194	17.18	$873.47	$395.94	$174.69
58660	T	Laparoscopy, lysis	0131	39.80	$2,023.51	$1,052.23	$404.70
58661	T	Laparoscopy, remove adnexa	0131	39.80	$2,023.51	$1,052.23	$404.70
58662	T	Laparoscopy, excise lesions	0131	39.80	$2,023.51	$1,052.23	$404.70
58670	T	Laparoscopy, tubal cautery	0131	39.80	$2,023.51	$1,052.23	$404.70
58671	T	Laparoscopy, tubal block	0131	39.80	$2,023.51	$1,052.23	$404.70
58672	T	Laparoscopy, fimbrioplasty	0131	39.80	$2,023.51	$1,052.23	$404.70
58673	T	Laparoscopy, salpingostomy	0131	39.80	$2,023.51	$1,052.23	$404.70
58679	T	Laparo proc, oviduct-ovary	0130	27.92	$1,419.51	$659.53	$283.90
58700	C	Removal of fallopian tube					
58720	C	Removal of ovary/tube(s)					
58740	C	Revise fallopian tube(s)					
58750	C	Repair oviduct					
58752	C	Revise ovarian tube(s)					
58760	C	Remove tubal obstruction					
58770	C	Create new tubal opening					
58800	T	Drainage of ovarian cyst(s)	0195	22.22	$1,129.71	$483.80	$225.94
58805	C	Drainage of ovarian cyst(s)					
58820	T	Drain ovary abscess, open	0195	22.22	$1,129.71	$483.80	$225.94
58822	C	Drain ovary abscess, percut					
58823	C	Drain pelvic abscess, percut					
58825	C	Transposition, ovary(s)					
58900	T	Biopsy of ovary(s)	0195	22.22	$1,129.71	$483.80	$225.94
58920	T	Partial removal of ovary(s)	0202	39.56	$2,011.31	$864.86	$402.26
58925	T	Removal of ovarian cyst(s)	0202	39.56	$2,011.31	$864.86	$402.26
58940	C	Removal of ovary(s)					
58943	C	Removal of ovary(s)					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
58950	C	Resect ovarian malignancy					
58951	C	Resect ovarian malignancy					
58952	C	Resect ovarian malignancy					
58960	C	Exploration of abdomen					
58970	T	Retrieval of oocyte	0194	17.18	$873.47	$395.94	$174.69
58974	T	Transfer of embryo	0197	2.58	$131.17	$49.55	$26.23
58976	T	Transfer of embryo	0197	2.58	$131.17	$49.55	$26.23
58999	T	Genital surgery procedure	0019	4.56	$231.84	$78.91	$46.37
59000	T	Amniocentesis	0198	1.42	$72.20	$33.03	$14.44
59012	T	Fetal cord puncture,prenatal	0198	1.42	$72.20	$33.03	$14.44
59015	T	Chorion biopsy	0198	1.42	$72.20	$33.03	$14.44
59020	T	Fetal contract stress test	0198	1.42	$72.20	$33.03	$14.44
59025	T	Fetal non-stress test	0198	1.42	$72.20	$33.03	$14.44
59030	T	Fetal scalp blood sample	0198	1.42	$72.20	$33.03	$14.44
59050	T	Fetal monitor w/report	0198	1.42	$72.20	$33.03	$14.44
59051	E	Fetal monitor/interpret only					
59100	C	Remove uterus lesion					
59120	C	Treat ectopic pregnancy					
59121	C	Treat ectopic pregnancy					
59130	C	Treat ectopic pregnancy					
59135	C	Treat ectopic pregnancy					
59136	C	Treat ectopic pregnancy					
59140	C	Treat ectopic pregnancy					
59150	T	Treat ectopic pregnancy	0131	39.80	$2,023.51	$1,052.23	$404.70
59151	T	Treat ectopic pregnancy	0131	39.80	$2,023.51	$1,052.23	$404.70
59160	T	D & c after delivery	0196	14.62	$743.31	$357.98	$148.66
59200	T	Insert cervical dilator	0189	1.38	$70.16	$17.54	$14.03
59300	T	Episiotomy or vaginal repair	0193	12.17	$618.75	$171.13	$123.75
59320	T	Revision of cervix	0194	17.18	$873.47	$395.94	$174.69
59325	C	Revision of cervix					
59350	C	Repair of uterus					
59400	E	Obstetrical care					
59409	T	Obstetrical care	0199	4.20	$213.54	$59.79	$42.71
59410	E	Obstetrical care					
59412	T	Antepartum manipulation	0199	4.20	$213.54	$59.79	$42.71
59414	T	Deliver placenta	0199	4.20	$213.54	$59.79	$42.71
59425	E	Antepartum care only					
59426	E	Antepartum care only					
59430	E	Care after delivery					
59510	E	Cesarean delivery					
59514	C	Cesarean delivery only					
59515	E	Cesarean delivery					
59525	C	Remove uterus after cesarean					
59610	E	Vbac delivery					
59612	T	Vbac delivery only	0199	4.20	$213.54	$59.79	$42.71
59614	E	Vbac care after delivery					
59618	E	Attempted vbac delivery					
59620	C	Attempted vbac delivery only					
59622	E	Attempted vbac after care					
59812	T	Treatment of miscarriage	0201	14.89	$757.04	$329.65	$151.41
59820	T	Care of miscarriage	0201	14.89	$757.04	$329.65	$151.41
59821	T	Treatment of miscarriage	0201	14.89	$757.04	$329.65	$151.41
59830	C	Treat uterus infection					
59840	T	Abortion	0200	13.74	$698.57	$373.23	$139.71
59841	T	Abortion	0200	13.74	$698.57	$373.23	$139.71
59850	C	Abortion					
59851	C	Abortion					
59852	C	Abortion					
59855	C	Abortion					
59856	C	Abortion					
59857	C	Abortion					
59866	T	Abortion (mpr)	0198	1.42	$72.20	$33.03	$14.44
59870	T	Evacuate mole of uterus	0201	14.89	$757.04	$329.65	$151.41
59871	T	Remove cerclage suture	0194	17.18	$873.47	$395.94	$174.69
59898	T	Laparo proc, ob care/deliver	0130	27.92	$1,419.51	$659.53	$283.90
59899	T	Maternity care procedure	0198	1.42	$72.20	$33.03	$14.44
60000	T	Drain thyroid/tongue cyst	0252	6.53	$332.00	$114.24	$66.40
60001	T	Aspirate/inject thyriod cyst	0004	3.00	$152.53	$32.57	$30.51
60100	T	Biopsy of thyroid	0004	3.00	$152.53	$32.57	$30.51
60200	T	Remove thyroid lesion	0114	30.50	$1,550.68	$493.78	$310.14
60210	T	Partial thyroid excision	0114	30.50	$1,550.68	$493.78	$310.14
60212	T	Parital thyroid excision	0114	30.50	$1,550.68	$493.78	$310.14
60220	T	Partial removal of thyroid	0114	30.50	$1,550.68	$493.78	$310.14
60225	T	Partial removal of thyroid	0114	30.50	$1,550.68	$493.78	$310.14
60240	T	Removal of thyroid	0114	30.50	$1,550.68	$493.78	$310.14

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
60252	T	Removal of thyroid	0256	28.82	$1,465.27	$623.05	$293.05
60254	C	Extensive thyroid surgery					
60260	T	Repeat thyroid surgery	0256	28.82	$1,465.27	$623.05	$293.05
60270	C	Removal of thyroid					
60271	C	Removal of thyroid					
60280	T	Remove thyroid duct lesion	0114	30.50	$1,550.68	$493.78	$310.14
60281	T	Remove thyroid duct lesion	0114	30.50	$1,550.68	$493.78	$310.14
60500	T	Explore parathyroid glands	0256	28.82	$1,465.27	$623.05	$293.05
60502	C	Re-explore parathyroids					
60505	C	Explore parathyroid glands					
60512	T	Autotransplant parathyroid	0021	12.74	$647.73	$236.51	$129.55
60520	C	Removal of thymus gland					
60521	C	Removal of thymus gland					
60522	C	Removal of thymus gland					
60540	C	Explore adrenal gland					
60545	C	Explore adrenal gland					
60600	C	Remove carotid body lesion					
60605	C	Remove carotid body lesion					
60650	C	Laparoscopy adrenalectomy					
60659	T	Laparo proc, endocrine	0130	27.92	$1,419.51	$659.53	$283.90
60699	T	Endocrine surgery procedure	0004	3.00	$152.53	$32.57	$30.51
61000	T	Remove cranial cavity fluid	0212	4.17	$212.01	$88.78	$42.40
61001	T	Remove cranial cavity fluid	0212	4.17	$212.01	$88.78	$42.40
61020	T	Remove brain cavity fluid	0212	4.17	$212.01	$88.78	$42.40
61026	T	Injection into brain canal	0212	4.17	$212.01	$88.78	$42.40
61050	T	Remove brain canal fluid	0212	4.17	$212.01	$88.78	$42.40
61055	T	Injection into brain canal	0212	4.17	$212.01	$88.78	$42.40
61070	T	Brain canal shunt procedure	0212	4.17	$212.01	$88.78	$42.40
61105	C	Twist drill hole					
61107	C	Drill skull for implantation					
61108	C	Drill skull for drainage					
61120	C	Burr hole for puncture					
61140	C	Pierce skull for biopsy					
61150	C	Pierce skull for drainage					
61151	C	Pierce skull for drainage					
61154	C	Pierce skull & remove clot					
61156	C	Pierce skull for drainage					
61210	C	Pierce skull, implant device					
61215	T	Insert brain-fluid device	0224	29.95	$1,522.72	$453.41	$304.54
61250	C	Pierce skull & explore					
61253	C	Pierce skull & explore					
61304	C	Open skull for exploration					
61305	C	Open skull for exploration					
61312	C	Open skull for drainage					
61313	C	Open skull for drainage					
61314	C	Open skull for drainage					
61315	C	Open skull for drainage					
61320	C	Open skull for drainage					
61321	C	Open skull for drainage					
61330	T	Decompress eye socket	0256	28.82	$1,465.27	$623.05	$293.05
61332	C	Explore/biopsy eye socket					
61333	C	Explore orbit/remove lesion					
61334	C	Explore orbit/remove object					
61340	C	Relieve cranial pressure					
61343	C	Incise skull (press relief)					
61345	C	Relieve cranial pressure					
61440	C	Incise skull for surgery					
61450	C	Incise skull for surgery					
61458	C	Incise skull for brain wound					
61460	C	Incise skull for surgery					
61470	C	Incise skull for surgery					
61480	C	Incise skull for surgery					
61490	C	Incise skull for surgery					
61500	C	Removal of skull lesion					
61501	C	Remove infected skull bone					
61510	C	Removal of brain lesion					
61512	C	Remove brain lining lesion					
61514	C	Removal of brain abscess					
61516	C	Removal of brain lesion					
61518	C	Removal of brain lesion					
61519	C	Remove brain lining lesion					
61520	C	Removal of brain lesion					
61521	C	Removal of brain lesion					
61522	C	Removal of brain abscess					
61524	C	Removal of brain lesion					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
61526	C	Removal of brain lesion					
61530	C	Removal of brain lesion					
61531	C	Implant brain electrodes					
61533	C	Implant brain electrodes					
61534	C	Removal of brain lesion					
61535	C	Remove brain electrodes					
61536	C	Removal of brain lesion					
61538	C	Removal of brain tissue					
61539	C	Removal of brain tissue					
61541	C	Incision of brain tissue					
61542	C	Removal of brain tissue					
61543	C	Removal of brain tissue					
61544	C	Remove & treat brain lesion					
61545	C	Excision of brain tumor					
61546	C	Removal of pituitary gland					
61548	C	Removal of pituitary gland					
61550	C	Release of skull seams					
61552	C	Release of skull seams					
61556	C	Incise skull/sutures					
61557	C	Incise skull/sutures					
61558	C	Excision of skull/sutures					
61559	C	Excision of skull/sutures					
61563	C	Excision of skull tumor					
61564	C	Excision of skull tumor					
61570	C	Remove foreign body, brain					
61571	C	Incise skull for brain wound					
61575	C	Skull base/brainstem surgery					
61576	C	Skull base/brainstem surgery					
61580	C	Craniofacial approach, skull					
61581	C	Craniofacial approach, skull					
61582	C	Craniofacial approach, skull					
61583	C	Craniofacial approach, skull					
61584	C	Orbitocranial approach/skull					
61585	C	Orbitocranial approach/skull					
61586	C	Resect nasopharynx, skull					
61590	C	Infratemporal approach/skull					
61591	C	Infratemporal approach/skull					
61592	C	Orbitocranial approach/skull					
61595	C	Transtemporal approach/skull					
61596	C	Transcochlear approach/skull					
61597	C	Transcondylar approach/skull					
61598	C	Transpetrosal approach/skull					
61600	C	Resect/excise cranial lesion					
61601	C	Resect/excise cranial lesion					
61605	C	Resect/excise cranial lesion					
61606	C	Resect/excise cranial lesion					
61607	C	Resect/excise cranial lesion					
61608	C	Resect/excise cranial lesion					
61609	C	Transect artery, sinus					
61610	C	Transect artery, sinus					
61611	C	Transect artery, sinus					
61612	C	Transect artery, sinus					
61613	C	Remove aneurysm, sinus					
61615	C	Resect/excise lesion, skull					
61616	C	Resect/excise lesion, skull					
61618	C	Repair dura					
61619	C	Repair dura					
61624	C	Occlusion/embolization cath					
61626	C	Occlusion/embolization cath					
61680	C	Intracranial vessel surgery					
61682	C	Intracranial vessel surgery					
61684	C	Intracranial vessel surgery					
61686	C	Intracranial vessel surgery					
61690	C	Intracranial vessel surgery					
61692	C	Intracranial vessel surgery					
61697	C	Brain aneurysm repr, complx					
61698	C	Brain aneurysm repr, complx					
61700	C	Brain aneurysm repr , simple					
61702	C	Inner skull vessel surgery					
61703	C	Clamp neck artery					
61705	C	Revise circulation to head					
61708	C	Revise circulation to head					
61710	C	Revise circulation to head					
61711	C	Fusion of skull arteries					
61720	C	Incise skull/brain surgery					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
61735	C	Incise skull/brain surgery					
61750	C	Incise skull/brain biopsy					
61751	C	Brain biopsy w/ ct/mr guide					
61760	C	Implant brain electrodes					
61770	C	Incise skull for treatment					
61790	T	Treat trigeminal nerve	0220	14.76	$750.43	$326.21	$150.09
61791	C	Treat trigeminal tract					
61793	S	Focus radiation beam	0302	11.96	$608.07	$216.55	$121.61
61795	S	Brain surgery using computer	0302	11.96	$608.07	$216.55	$121.61
61850	C	Implant neuroelectrodes					
61860	C	Implant neuroelectrodes					
61862	C	Implant neurostimul, subcort					
61870	C	Implant neuroelectrodes					
61875	C	Implant neuroelectrodes					
61880	T	Revise/remove neuroelectrode	0105	16.56	$841.94	$372.32	$168.39
61885	T	Implant neurostim one array	0222	112.50	$5,719.73	$2,688.27	$1,143.95
61886	T	Implant neurostim arrays	0222	112.50	$5,719.73	$2,688.27	$1,143.95
61888	T	Revise/remove neuroreceiver	0105	16.56	$841.94	$372.32	$168.39
62000	C	Treat skull fracture					
62005	C	Treat skull fracture					
62010	C	Treatment of head injury					
62100	C	Repair brain fluid leakage					
62115	C	Reduction of skull defect					
62116	C	Reduction of skull defect					
62117	C	Reduction of skull defect					
62120	C	Repair skull cavity lesion					
62121	C	Incise skull repair					
62140	C	Repair of skull defect					
62141	C	Repair of skull defect					
62142	C	Remove skull plate/flap					
62143	C	Replace skull plate/flap					
62145	C	Repair of skull & brain					
62146	C	Repair of skull with graft					
62147	C	Repair of skull with graft					
62180	C	Establish brain cavity shunt					
62190	C	Establish brain cavity shunt					
62192	C	Establish brain cavity shunt					
62194	T	Replace/irrigate catheter	0121	2.42	$123.04	$52.53	$24.61
62200	C	Establish brain cavity shunt					
62201	C	Establish brain cavity shunt					
62220	C	Establish brain cavity shunt					
62223	C	Establish brain cavity shunt					
62225	T	Replace/irrigate catheter	0121	2.42	$123.04	$52.53	$24.61
62230	T	Replace/revise brain shunt	0224	29.95	$1,522.72	$453.41	$304.54
62252	S	Csf shunt reprogram	0691	3.36	$170.83	$93.96	$34.17
62256	C	Remove brain cavity shunt					
62258	C	Replace brain cavity shunt					
62263	T	Lysis epidural adhesions	0203	7.62	$387.42	$166.59	$77.48
62268	T	Drain spinal cord cyst	0212	4.17	$212.01	$88.78	$42.40
62269	T	Needle biopsy, spinal cord	0005	6.71	$341.15	$119.75	$68.23
62270	T	Spinal fluid tap, diagnostic	0206	3.88	$197.27	$82.85	$39.45
62272	T	Drain spinal fluid	0206	3.88	$197.27	$82.85	$39.45
62273	T	Treat epidural spine lesion	0206	3.88	$197.27	$82.85	$39.45
62280	T	Treat spinal cord lesion	0207	4.13	$209.98	$94.49	$42.00
62281	T	Treat spinal cord lesion	0207	4.13	$209.98	$94.49	$42.00
62282	T	Treat spinal canal lesion	0207	4.13	$209.98	$94.49	$42.00
62284	N	Injection for myelogram					
62287	T	Percutaneous diskectomy	0220	14.76	$750.43	$326.21	$150.09
62290	N	Inject for spine disk x-ray					
62291	N	Inject for spine disk x-ray					
62292	T	Injection into disk lesion	0212	4.17	$212.01	$88.78	$42.40
62294	T	Injection into spinal artery	0212	4.17	$212.01	$88.78	$42.40
62310	T	Inject spine c/t	0206	3.88	$197.27	$82.85	$39.45
62311	T	Inject spine l/s (cd)	0206	3.88	$197.27	$82.85	$39.45
62318	T	Inject spine w/cath, c/t	0206	3.88	$197.27	$82.85	$39.45
62319	T	Inject spine w/cath l/s (cd)	0206	3.88	$197.27	$82.85	$39.45
62350	T	Implant spinal canal cath	0223	8.87	$450.97	$154.27	$90.19
62351	C	Implant spinal canal cath					
62355	T	Remove spinal canal catheter	0105	16.56	$841.94	$372.32	$168.39
62360	T	Insert spine infusion device	0226	8.91	$453.00	$109.42	$90.60
62361	T	Implant spine infusion pump	0227	94.89	$4,824.40	$964.88	$964.88
62362	T	Implant spine infusion pump	0227	94.89	$4,824.40	$964.88	$964.88
62365	T	Remove spine infusion device	0105	16.56	$841.94	$372.32	$168.39
62367	S	Analyze spine infusion pump	0691	3.36	$170.83	$93.96	$34.17
62368	S	Analyze spine infusion pump	0691	3.36	$170.83	$93.96	$34.17

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
63001	T	Removal of spinal lamina	0208	30.93	$1,572.54	$314.51	$314.51
63003	T	Removal of spinal lamina	0208	30.93	$1,572.54	$314.51	$314.51
63005	T	Removal of spinal lamina	0208	30.93	$1,572.54	$314.51	$314.51
63011	T	Removal of spinal lamina	0208	30.93	$1,572.54	$314.51	$314.51
63012	T	Removal of spinal lamina	0208	30.93	$1,572.54	$314.51	$314.51
63015	T	Removal of spinal lamina	0208	30.93	$1,572.54	$314.51	$314.51
63016	T	Removal of spinal lamina	0208	30.93	$1,572.54	$314.51	$314.51
63017	T	Removal of spinal lamina	0208	30.93	$1,572.54	$314.51	$314.51
63020	T	Neck spine disk surgery	0208	30.93	$1,572.54	$314.51	$314.51
63030	T	Low back disk surgery	0208	30.93	$1,572.54	$314.51	$314.51
63035	T	Spinal disk surgery add-on	0208	30.93	$1,572.54	$314.51	$314.51
63040	T	Laminotomy, single cervical	0208	30.93	$1,572.54	$314.51	$314.51
63042	T	Laminotomy, single lumbar	0208	30.93	$1,572.54	$314.51	$314.51
63043	C	Laminotomy, addl cervical					
63044	C	Laminotomy, addl lumbar					
63045	T	Removal of spinal lamina	0208	30.93	$1,572.54	$314.51	$314.51
63046	T	Removal of spinal lamina	0208	30.93	$1,572.54	$314.51	$314.51
63047	T	Removal of spinal lamina	0208	30.93	$1,572.54	$314.51	$314.51
63048	T	Remove spinal lamina add-on	0208	30.93	$1,572.54	$314.51	$314.51
63055	T	Decompress spinal cord	0208	30.93	$1,572.54	$314.51	$314.51
63056	T	Decompress spinal cord	0208	30.93	$1,572.54	$314.51	$314.51
63057	T	Decompress spine cord add-on	0208	30.93	$1,572.54	$314.51	$314.51
63064	T	Decompress spinal cord	0208	30.93	$1,572.54	$314.51	$314.51
63066	T	Decompress spine cord add-on	0208	30.93	$1,572.54	$314.51	$314.51
63075	C	Neck spine disk surgery					
63076	C	Neck spine disk surgery					
63077	C	Spine disk surgery, thorax					
63078	C	Spine disk surgery, thorax					
63081	C	Removal of vertebral body					
63082	C	Remove vertebral body add-on					
63085	C	Removal of vertebral body					
63086	C	Remove vertebral body add-on					
63087	C	Removal of vertebral body					
63088	C	Remove vertebral body add-on					
63090	C	Removal of vertebral body					
63091	C	Remove vertebral body add-on					
63170	C	Incise spinal cord tract(s)					
63172	C	Drainage of spinal cyst					
63173	C	Drainage of spinal cyst					
63180	C	Revise spinal cord ligaments					
63182	C	Revise spinal cord ligaments					
63185	C	Incise spinal column/nerves					
63190	C	Incise spinal column/nerves					
63191	C	Incise spinal column/nerves					
63194	C	Incise spinal column & cord					
63195	C	Incise spinal column & cord					
63196	C	Incise spinal column & cord					
63197	C	Incise spinal column & cord					
63198	C	Incise spinal column & cord					
63199	C	Incise spinal column & cord					
63200	C	Release of spinal cord					
63250	C	Revise spinal cord vessels					
63251	C	Revise spinal cord vessels					
63252	C	Revise spinal cord vessels					
63265	C	Excise intraspinal lesion					
63266	C	Excise intraspinal lesion					
63267	C	Excise intraspinal lesion					
63268	C	Excise intraspinal lesion					
63270	C	Excise intraspinal lesion					
63271	C	Excise intraspinal lesion					
63272	C	Excise intraspinal lesion					
63273	C	Excise intraspinal lesion					
63275	C	Biopsy/excise spinal tumor					
63276	C	Biopsy/excise spinal tumor					
63277	C	Biopsy/excise spinal tumor					
63278	C	Biopsy/excise spinal tumor					
63280	C	Biopsy/excise spinal tumor					
63281	C	Biopsy/excise spinal tumor					
63282	C	Biopsy/excise spinal tumor					
63283	C	Biopsy/excise spinal tumor					
63285	C	Biopsy/excise spinal tumor					
63286	C	Biopsy/excise spinal tumor					
63287	C	Biopsy/excise spinal tumor					
63290	C	Biopsy/excise spinal tumor					
63300	C	Removal of vertebral body					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
63301	C	Removal of vertebral body					
63302	C	Removal of vertebral body					
63303	C	Removal of vertebral body					
63304	C	Removal of vertebral body					
63305	C	Removal of vertebral body					
63306	C	Removal of vertebral body					
63307	C	Removal of vertebral body					
63308	C	Remove vertebral body add-on					
63600	T	Remove spinal cord lesion	0220	14.76	$750.43	$326.21	$150.09
63610	T	Stimulation of spinal cord	0220	14.76	$750.43	$326.21	$150.09
63615	T	Remove lesion of spinal cord	0220	14.76	$750.43	$326.21	$150.09
63650	T	Implant neuroelectrodes	0225	33.75	$1,715.92	$408.33	$343.18
63655	C	Implant neuroelectrodes					
63660	T	Revise/remove neuroelectrode	0105	16.56	$841.94	$372.32	$168.39
63685	T	Implant neuroreceiver	0222	112.50	$5,719.73	$2,688.27	$1,143.95
63688	T	Revise/remove neuroreceiver	0105	16.56	$841.94	$372.32	$168.39
63700	C	Repair of spinal herniation					
63702	C	Repair of spinal herniation					
63704	C	Repair of spinal herniation					
63706	C	Repair of spinal herniation					
63707	C	Repair spinal fluid leakage					
63709	C	Repair spinal fluid leakage					
63710	C	Graft repair of spine defect					
63740	C	Install spinal shunt					
63741	T	Install spinal shunt	0228	47.98	$2,439.40	$696.46	$487.88
63744	T	Revision of spinal shunt	0228	47.98	$2,439.40	$696.46	$487.88
63746	T	Removal of spinal shunt	0109	6.57	$334.03	$133.51	$66.81
64400	T	Injection for nerve block	0204	2.44	$124.05	$47.14	$24.81
64402	T	Injection for nerve block	0204	2.44	$124.05	$47.14	$24.81
64405	T	Injection for nerve block	0204	2.44	$124.05	$47.14	$24.81
64408	T	Injection for nerve block	0204	2.44	$124.05	$47.14	$24.81
64410	T	Injection for nerve block	0204	2.44	$124.05	$47.14	$24.81
64412	T	Injection for nerve block	0204	2.44	$124.05	$47.14	$24.81
64413	T	Injection for nerve block	0204	2.44	$124.05	$47.14	$24.81
64415	T	Injection for nerve block	0204	2.44	$124.05	$47.14	$24.81
64417	T	Injection for nerve block	0204	2.44	$124.05	$47.14	$24.81
64418	T	Injection for nerve block	0204	2.44	$124.05	$47.14	$24.81
64420	T	Injection for nerve block	0207	4.13	$209.98	$94.49	$42.00
64421	T	Injection for nerve block	0207	4.13	$209.98	$94.49	$42.00
64425	T	Injection for nerve block	0204	2.44	$124.05	$47.14	$24.81
64430	T	Injection for nerve block	0204	2.44	$124.05	$47.14	$24.81
64435	T	Injection for nerve block	0204	2.44	$124.05	$47.14	$24.81
64445	T	Injection for nerve block	0204	2.44	$124.05	$47.14	$24.81
64450	T	Injection for nerve block	0204	2.44	$124.05	$47.14	$24.81
64470	T	Inj paravertebral c/t	0207	4.13	$209.98	$94.49	$42.00
64472	T	Inj paravertebral c/t add-on	0207	4.13	$209.98	$94.49	$42.00
64475	T	Inj paravertebral l/s	0207	4.13	$209.98	$94.49	$42.00
64476	T	Inj paravertebral l/s add-on	0207	4.13	$209.98	$94.49	$42.00
64479	T	Inj foramen epidural c/t	0207	4.13	$209.98	$94.49	$42.00
64480	T	Inj foramen epidural add-on	0207	4.13	$209.98	$94.49	$42.00
64483	T	Inj foramen epidural l/s	0207	4.13	$209.98	$94.49	$42.00
64484	T	Inj foramen epidural add-on	0207	4.13	$209.98	$94.49	$42.00
64505	T	Injection for nerve block	0204	2.44	$124.05	$47.14	$24.81
64508	T	Injection for nerve block	0204	2.44	$124.05	$47.14	$24.81
64510	T	Injection for nerve block	0207	4.13	$209.98	$94.49	$42.00
64520	T	Injection for nerve block	0207	4.13	$209.98	$94.49	$42.00
64530	T	Injection for nerve block	0207	4.13	$209.98	$94.49	$42.00
64550	A	Apply neurostimulator					
64553	T	Implant neuroelectrodes	0225	33.75	$1,715.92	$408.33	$343.18
64555	T	Implant neuroelectrodes	0225	33.75	$1,715.92	$408.33	$343.18
64560	T	Implant neuroelectrodes	0225	33.75	$1,715.92	$408.33	$343.18
64565	T	Implant neuroelectrodes	0225	33.75	$1,715.92	$408.33	$343.18
64573	T	Implant neuroelectrodes	0225	33.75	$1,715.92	$408.33	$343.18
64575	T	Implant neuroelectrodes	0225	33.75	$1,715.92	$408.33	$343.18
64577	T	Implant neuroelectrodes	0225	33.75	$1,715.92	$408.33	$343.18
64580	T	Implant neuroelectrodes	0225	33.75	$1,715.92	$408.33	$343.18
64585	T	Revise/remove neuroelectrode	0105	16.56	$841.94	$372.32	$168.39
64590	T	Implant neuroreceiver	0222	112.50	$5,719.73	$2,688.27	$1,143.95
64595	T	Revise/remove neuroreceiver	0105	16.56	$841.94	$372.32	$168.39
64600	T	Injection treatment of nerve	0203	7.62	$387.42	$166.59	$77.48
64605	T	Injection treatment of nerve	0203	7.62	$387.42	$166.59	$77.48
64610	T	Injection treatment of nerve	0203	7.62	$387.42	$166.59	$77.48
64612	T	Destroy nerve, face muscle	0204	2.44	$124.05	$47.14	$24.81
64613	T	Destroy nerve, spine muscle	0204	2.44	$124.05	$47.14	$24.81
64614	T	Destroy nerve, extrem musc	0206	3.88	$197.27	$82.85	$39.45

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
64620	T	Injection treatment of nerve	0203	7.62	$387.42	$166.59	$77.48
64622	T	Destr paravertebrl nerve l/s	0203	7.62	$387.42	$166.59	$77.48
64623	T	Destr paravertebral n add-on	0203	7.62	$387.42	$166.59	$77.48
64626	T	Destr paravertebrl nerve c/t	0203	7.62	$387.42	$166.59	$77.48
64627	T	Destr paravertebral n add-on	0203	7.62	$387.42	$166.59	$77.48
64630	T	Injection treatment of nerve	0207	4.13	$209.98	$94.49	$42.00
64640	T	Injection treatment of nerve	0207	4.13	$209.98	$94.49	$42.00
64680	T	Injection treatment of nerve	0203	7.62	$387.42	$166.59	$77.48
64702	T	Revise finger/toe nerve	0220	14.76	$750.43	$326.21	$150.09
64704	T	Revise hand/foot nerve	0220	14.76	$750.43	$326.21	$150.09
64708	T	Revise arm/leg nerve	0220	14.76	$750.43	$326.21	$150.09
64712	T	Revision of sciatic nerve	0220	14.76	$750.43	$326.21	$150.09
64713	T	Revision of arm nerve(s)	0220	14.76	$750.43	$326.21	$150.09
64714	T	Revise low back nerve(s)	0220	14.76	$750.43	$326.21	$150.09
64716	T	Revision of cranial nerve	0220	14.76	$750.43	$326.21	$150.09
64718	T	Revise ulnar nerve at elbow	0220	14.76	$750.43	$326.21	$150.09
64719	T	Revise ulnar nerve at wrist	0220	14.76	$750.43	$326.21	$150.09
64721	T	Carpal tunnel surgery	0220	14.76	$750.43	$326.21	$150.09
64722	T	Relieve pressure on nerve(s)	0220	14.76	$750.43	$326.21	$150.09
64726	T	Release foot/toe nerve	0220	14.76	$750.43	$326.21	$150.09
64727	T	Internal nerve revision	0220	14.76	$750.43	$326.21	$150.09
64732	T	Incision of brow nerve	0220	14.76	$750.43	$326.21	$150.09
64734	T	Incision of cheek nerve	0220	14.76	$750.43	$326.21	$150.09
64736	T	Incision of chin nerve	0220	14.76	$750.43	$326.21	$150.09
64738	T	Incision of jaw nerve	0220	14.76	$750.43	$326.21	$150.09
64740	T	Incision of tongue nerve	0220	14.76	$750.43	$326.21	$150.09
64742	T	Incision of facial nerve	0220	14.76	$750.43	$326.21	$150.09
64744	T	Incise nerve, back of head	0220	14.76	$750.43	$326.21	$150.09
64746	T	Incise diaphragm nerve	0220	14.76	$750.43	$326.21	$150.09
64752	C	Incision of vagus nerve					
64755	C	Incision of stomach nerves					
64760	C	Incision of vagus nerve					
64761	T	Incision of pelvis nerve	0220	14.76	$750.43	$326.21	$150.09
64763	C	Incise hip/thigh nerve					
64766	C	Incise hip/thigh nerve					
64771	T	Sever cranial nerve	0220	14.76	$750.43	$326.21	$150.09
64772	T	Incision of spinal nerve	0220	14.76	$750.43	$326.21	$150.09
64774	T	Remove skin nerve lesion	0220	14.76	$750.43	$326.21	$150.09
64776	T	Remove digit nerve lesion	0220	14.76	$750.43	$326.21	$150.09
64778	T	Digit nerve surgery add-on	0220	14.76	$750.43	$326.21	$150.09
64782	T	Remove limb nerve lesion	0220	14.76	$750.43	$326.21	$150.09
64783	T	Limb nerve surgery add-on	0220	14.76	$750.43	$326.21	$150.09
64784	T	Remove nerve lesion	0220	14.76	$750.43	$326.21	$150.09
64786	T	Remove sciatic nerve lesion	0221	22.68	$1,153.10	$463.62	$230.62
64787	T	Implant nerve end	0220	14.76	$750.43	$326.21	$150.09
64788	T	Remove skin nerve lesion	0220	14.76	$750.43	$326.21	$150.09
64790	T	Removal of nerve lesion	0220	14.76	$750.43	$326.21	$150.09
64792	T	Removal of nerve lesion	0221	22.68	$1,153.10	$463.62	$230.62
64795	T	Biopsy of nerve	0220	14.76	$750.43	$326.21	$150.09
64802	C	Remove sympathetic nerves					
64804	C	Remove sympathetic nerves					
64809	C	Remove sympathetic nerves					
64818	C	Remove sympathetic nerves					
64820	C	Remove sympathetic nerves					
64831	T	Repair of digit nerve	0221	22.68	$1,153.10	$463.62	$230.62
64832	T	Repair nerve add-on	0221	22.68	$1,153.10	$463.62	$230.62
64834	T	Repair of hand or foot nerve	0221	22.68	$1,153.10	$463.62	$230.62
64835	T	Repair of hand or foot nerve	0221	22.68	$1,153.10	$463.62	$230.62
64836	T	Repair of hand or foot nerve	0221	22.68	$1,153.10	$463.62	$230.62
64837	T	Repair nerve add-on	0221	22.68	$1,153.10	$463.62	$230.62
64840	T	Repair of leg nerve	0221	22.68	$1,153.10	$463.62	$230.62
64856	T	Repair/transpose nerve	0221	22.68	$1,153.10	$463.62	$230.62
64857	T	Repair arm/leg nerve	0221	22.68	$1,153.10	$463.62	$230.62
64858	T	Repair sciatic nerve	0221	22.68	$1,153.10	$463.62	$230.62
64859	T	Nerve surgery	0221	22.68	$1,153.10	$463.62	$230.62
64861	T	Repair of arm nerves	0221	22.68	$1,153.10	$463.62	$230.62
64862	T	Repair of low back nerves	0221	22.68	$1,153.10	$463.62	$230.62
64864	T	Repair of facial nerve	0221	22.68	$1,153.10	$463.62	$230.62
64865	T	Repair of facial nerve	0221	22.68	$1,153.10	$463.62	$230.62
64866	C	Fusion of facial/other nerve					
64868	C	Fusion of facial/other nerve					
64870	T	Fusion of facial/other nerve	0221	22.68	$1,153.10	$463.62	$230.62
64872	T	Subsequent repair of nerve	0221	22.68	$1,153.10	$463.62	$230.62
64874	T	Repair & revise nerve add-on	0221	22.68	$1,153.10	$463.62	$230.62
64876	T	Repair nerve/shorten bone	0221	22.68	$1,153.10	$463.62	$230.62

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
64885	T	Nerve graft, head or neck	0221	22.68	$1,153.10	$463.62	$230.62
64886	T	Nerve graft, head or neck	0221	22.68	$1,153.10	$463.62	$230.62
64890	T	Nerve graft, hand or foot	0221	22.68	$1,153.10	$463.62	$230.62
64891	T	Nerve graft, hand or foot	0221	22.68	$1,153.10	$463.62	$230.62
64892	T	Nerve graft, arm or leg	0221	22.68	$1,153.10	$463.62	$230.62
64893	T	Nerve graft, arm or leg	0221	22.68	$1,153.10	$463.62	$230.62
64895	T	Nerve graft, hand or foot	0221	22.68	$1,153.10	$463.62	$230.62
64896	T	Nerve graft, hand or foot	0221	22.68	$1,153.10	$463.62	$230.62
64897	T	Nerve graft, arm or leg	0221	22.68	$1,153.10	$463.62	$230.62
64898	T	Nerve graft, arm or leg	0221	22.68	$1,153.10	$463.62	$230.62
64901	T	Nerve graft add-on	0221	22.68	$1,153.10	$463.62	$230.62
64902	T	Nerve graft add-on	0221	22.68	$1,153.10	$463.62	$230.62
64905	T	Nerve pedicle transfer	0221	22.68	$1,153.10	$463.62	$230.62
64907	T	Nerve pedicle transfer	0221	22.68	$1,153.10	$463.62	$230.62
64999	T	Nervous system surgery	0204	2.44	$124.05	$47.14	$24.81
65091	T	Revise eye	0242	25.31	$1,286.81	$597.36	$257.36
65093	T	Revise eye with implant	0241	19.20	$976.17	$384.47	$195.23
65101	T	Removal of eye	0242	25.31	$1,286.81	$597.36	$257.36
65103	T	Remove eye/insert implant	0242	25.31	$1,286.81	$597.36	$257.36
65105	T	Remove eye/attach implant	0242	25.31	$1,286.81	$597.36	$257.36
65110	T	Removal of eye	0242	25.31	$1,286.81	$597.36	$257.36
65112	T	Remove eye/revise socket	0242	25.31	$1,286.81	$597.36	$257.36
65114	T	Remove eye/revise socket	0242	25.31	$1,286.81	$597.36	$257.36
65125	T	Revise ocular implant	0240	14.86	$755.51	$315.31	$151.10
65130	T	Insert ocular implant	0241	19.20	$976.17	$384.47	$195.23
65135	T	Insert ocular implant	0241	19.20	$976.17	$384.47	$195.23
65140	T	Attach ocular implant	0242	25.31	$1,286.81	$597.36	$257.36
65150	T	Revise ocular implant	0241	19.20	$976.17	$384.47	$195.23
65155	T	Reinsert ocular implant	0242	25.31	$1,286.81	$597.36	$257.36
65175	T	Removal of ocular implant	0240	14.86	$755.51	$315.31	$151.10
65205	S	Remove foreign body from eye	0231	2.27	$115.41	$51.94	$23.08
65210	S	Remove foreign body from eye	0231	2.27	$115.41	$51.94	$23.08
65220	S	Remove foreign body from eye	0231	2.27	$115.41	$51.94	$23.08
65222	S	Remove foreign body from eye	0231	2.27	$115.41	$51.94	$23.08
65235	T	Remove foreign body from eye	0233	11.78	$598.92	$287.48	$119.78
65260	T	Remove foreign body from eye	0237	33.56	$1,706.26	$852.68	$341.25
65265	T	Remove foreign body from eye	0236	17.75	$902.45	$180.49	$180.49
65270	T	Repair of eye wound	0240	14.86	$755.51	$315.31	$151.10
65272	T	Repair of eye wound	0233	11.78	$598.92	$287.48	$119.78
65273	C	Repair of eye wound	.....	.....	.....	.....	.....
65275	T	Repair of eye wound	0233	11.78	$598.92	$287.48	$119.78
65280	T	Repair of eye wound	0234	20.56	$1,045.31	$502.16	$209.06
65285	T	Repair of eye wound	0234	20.56	$1,045.31	$502.16	$209.06
65286	T	Repair of eye wound	0233	11.78	$598.92	$287.48	$119.78
65290	T	Repair of eye socket wound	0243	19.22	$977.18	$431.39	$195.44
65400	T	Removal of eye lesion	0233	11.78	$598.92	$287.48	$119.78
65410	T	Biopsy of cornea	0233	11.78	$598.92	$287.48	$119.78
65420	T	Removal of eye lesion	0233	11.78	$598.92	$287.48	$119.78
65426	T	Removal of eye lesion	0234	20.56	$1,045.31	$502.16	$209.06
65430	S	Corneal smear	0230	0.64	$32.54	$14.97	$6.51
65435	T	Curette/treat cornea	0239	6.25	$317.76	$123.42	$63.55
65436	T	Curette/treat cornea	0233	11.78	$598.92	$287.48	$119.78
65450	T	Treatment of corneal lesion	0232	3.69	$187.61	$82.55	$37.52
65600	T	Revision of cornea	0240	14.86	$755.51	$315.31	$151.10
65710	T	Corneal transplant	0244	41.43	$2,106.38	$851.42	$421.28
65730	T	Corneal transplant	0244	41.43	$2,106.38	$851.42	$421.28
65750	T	Corneal transplant	0244	41.43	$2,106.38	$851.42	$421.28
65755	T	Corneal transplant	0244	41.43	$2,106.38	$851.42	$421.28
65760	E	Revision of cornea	.....	.....	.....	.....	.....
65765	E	Revision of cornea	.....	.....	.....	.....	.....
65767	E	Corneal tissue transplant	.....	.....	.....	.....	.....
65770	T	Revise cornea with implant	0244	41.43	$2,106.38	$851.42	$421.28
65771	E	Radial keratotomy	.....	.....	.....	.....	.....
65772	T	Correction of astigmatism	0233	11.78	$598.92	$287.48	$119.78
65775	T	Correction of astigmatism	0233	11.78	$598.92	$287.48	$119.78
65800	T	Drainage of eye	0233	11.78	$598.92	$287.48	$119.78
65805	T	Drainage of eye	0233	11.78	$598.92	$287.48	$119.78
65810	T	Drainage of eye	0233	11.78	$598.92	$287.48	$119.78
65815	T	Drainage of eye	0234	20.56	$1,045.31	$502.16	$209.06
65820	T	Relieve inner eye pressure	0232	3.69	$187.61	$82.55	$37.52
65850	T	Incision of eye	0234	20.56	$1,045.31	$502.16	$209.06
65855	T	Laser surgery of eye	0247	4.73	$240.48	$110.62	$48.10
65860	T	Incise inner eye adhesions	0247	4.73	$240.48	$110.62	$48.10
65865	T	Incise inner eye adhesions	0233	11.78	$598.92	$287.48	$119.78
65870	T	Incise inner eye adhesions	0234	20.56	$1,045.31	$502.16	$209.06

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
65875	T	Incise inner eye adhesions	0234	20.56	$1,045.31	$502.16	$209.06
65880	T	Incise inner eye adhesions	0233	11.78	$598.92	$287.48	$119.78
65900	T	Remove eye lesion	0233	11.78	$598.92	$287.48	$119.78
65920	T	Remove implant from eye	0233	11.78	$598.92	$287.48	$119.78
65930	T	Remove blood clot from eye	0234	20.56	$1,045.31	$502.16	$209.06
66020	T	Injection treatment of eye	0233	11.78	$598.92	$287.48	$119.78
66030	T	Injection treatment of eye	0233	11.78	$598.92	$287.48	$119.78
66130	T	Remove eye lesion	0234	20.56	$1,045.31	$502.16	$209.06
66150	T	Glaucoma surgery	0233	11.78	$598.92	$287.48	$119.78
66155	T	Glaucoma surgery	0234	20.56	$1,045.31	$502.16	$209.06
66160	T	Glaucoma surgery	0234	20.56	$1,045.31	$502.16	$209.06
66165	T	Glaucoma surgery	0234	20.56	$1,045.31	$502.16	$209.06
66170	T	Glaucoma surgery	0234	20.56	$1,045.31	$502.16	$209.06
66172	T	Incision of eye	0234	20.56	$1,045.31	$502.16	$209.06
66180	T	Implant eye shunt	0234	20.56	$1,045.31	$502.16	$209.06
66185	T	Revise eye shunt	0234	20.56	$1,045.31	$502.16	$209.06
66220	T	Repair eye lesion	0236	17.75	$902.45	$180.49	$180.49
66225	T	Repair/graft eye lesion	0234	20.56	$1,045.31	$502.16	$209.06
66250	T	Follow-up surgery of eye	0233	11.78	$598.92	$287.48	$119.78
66500	T	Incision of iris	0232	3.69	$187.61	$82.55	$37.52
66505	T	Incision of iris	0232	3.69	$187.61	$82.55	$37.52
66600	T	Remove iris and lesion	0233	11.78	$598.92	$287.48	$119.78
66605	T	Removal of iris	0234	20.56	$1,045.31	$502.16	$209.06
66625	T	Removal of iris	0233	11.78	$598.92	$287.48	$119.78
66630	T	Removal of iris	0233	11.78	$598.92	$287.48	$119.78
66635	T	Removal of iris	0234	20.56	$1,045.31	$502.16	$209.06
66680	T	Repair iris & ciliary body	0234	20.56	$1,045.31	$502.16	$209.06
66682	T	Repair iris & ciliary body	0234	20.56	$1,045.31	$502.16	$209.06
66700	T	Destruction, ciliary body	0233	11.78	$598.92	$287.48	$119.78
66710	T	Destruction, ciliary body	0233	11.78	$598.92	$287.48	$119.78
66720	T	Destruction, ciliary body	0233	11.78	$598.92	$287.48	$119.78
66740	T	Destruction, ciliary body	0233	11.78	$598.92	$287.48	$119.78
66761	T	Revision of iris	0247	4.73	$240.48	$110.62	$48.10
66762	T	Revision of iris	0247	4.73	$240.48	$110.62	$48.10
66770	T	Removal of inner eye lesion	0247	4.73	$240.48	$110.62	$48.10
66820	T	Incision, secondary cataract	0232	3.69	$187.61	$82.55	$37.52
66821	T	After cataract laser surgery	0247	4.73	$240.48	$110.62	$48.10
66825	T	Reposition intraocular lens	0234	20.56	$1,045.31	$502.16	$209.06
66830	T	Removal of lens lesion	0232	3.69	$187.61	$82.55	$37.52
66840	T	Removal of lens material	0245	10.75	$546.55	$256.88	$109.31
66850	T	Removal of lens material	0249	23.51	$1,195.30	$561.79	$239.06
66852	T	Removal of lens material	0249	23.51	$1,195.30	$561.79	$239.06
66920	T	Extraction of lens	0249	23.51	$1,195.30	$561.79	$239.06
66930	T	Extraction of lens	0249	23.51	$1,195.30	$561.79	$239.06
66940	T	Extraction of lens	0245	10.75	$546.55	$256.88	$109.31
66982	T	Cataract surgery, complex	0246	22.36	$1,136.83	$534.31	$227.37
66983	T	Cataract surg w/iol, 1 stage	0246	22.36	$1,136.83	$534.31	$227.37
66984	T	Cataract surg w/iol, i stage	0246	22.36	$1,136.83	$534.31	$227.37
66985	T	Insert lens prosthesis	0246	22.36	$1,136.83	$534.31	$227.37
66986	T	Exchange lens prosthesis	0246	22.36	$1,136.83	$534.31	$227.37
66999	T	Eye surgery procedure	0247	4.73	$240.48	$110.62	$48.10
67005	T	Partial removal of eye fluid	0237	33.56	$1,706.26	$852.68	$341.25
67010	T	Partial removal of eye fluid	0237	33.56	$1,706.26	$852.68	$341.25
67015	T	Release of eye fluid	0237	33.56	$1,706.26	$852.68	$341.25
67025	T	Replace eye fluid	0236	17.75	$902.45	$180.49	$180.49
67027	T	Implant eye drug system	0237	33.56	$1,706.26	$852.68	$341.25
67028	T	Injection eye drug	0235	5.39	$274.04	$78.91	$54.81
67030	T	Incise inner eye strands	0236	17.75	$902.45	$180.49	$180.49
67031	T	Laser surgery, eye strands	0247	4.73	$240.48	$110.62	$48.10
67036	T	Removal of inner eye fluid	0237	33.56	$1,706.26	$852.68	$341.25
67038	T	Strip retinal membrane	0237	33.56	$1,706.26	$852.68	$341.25
67039	T	Laser treatment of retina	0237	33.56	$1,706.26	$852.68	$341.25
67040	T	Laser treatment of retina	0237	33.56	$1,706.26	$852.68	$341.25
67101	T	Repair detached retina	0235	5.39	$274.04	$78.91	$54.81
67105	T	Repair detached retina	0248	4.15	$210.99	$94.05	$42.20
67107	T	Repair detached retina	0237	33.56	$1,706.26	$852.68	$341.25
67108	T	Repair detached retina	0237	33.56	$1,706.26	$852.68	$341.25
67110	T	Repair detached retina	0235	5.39	$274.04	$78.91	$54.81
67112	T	Rerepair detached retina	0237	33.56	$1,706.26	$852.68	$341.25
67115	T	Release encircling material	0236	17.75	$902.45	$180.49	$180.49
67120	T	Remove eye implant material	0236	17.75	$902.45	$180.49	$180.49
67121	T	Remove eye implant material	0237	33.56	$1,706.26	$852.68	$341.25
67141	T	Treatment of retina	0235	5.39	$274.04	$78.91	$54.81
67145	T	Treatment of retina	0248	4.15	$210.99	$94.05	$42.20
67208	S	Treatment of retinal lesion	0231	2.27	$115.41	$51.94	$23.08

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
67210	T	Treatment of retinal lesion	0248	4.15	$210.99	$94.05	$42.20
67218	T	Treatment of retinal lesion	0237	33.56	$1,706.26	$852.68	$341.25
67220	T	Treatment of choroid lesion	0235	5.39	$274.04	$78.91	$54.81
67221	T	Ocular photodynamic ther	0235	5.39	$274.04	$78.91	$54.81
67227	T	Treatment of retinal lesion	0235	5.39	$274.04	$78.91	$54.81
67228	T	Treatment of retinal lesion	0248	4.15	$210.99	$94.05	$42.20
67250	T	Reinforce eye wall	0240	14.86	$755.51	$315.31	$151.10
67255	T	Reinforce/graft eye wall	0237	33.56	$1,706.26	$852.68	$341.25
67299	T	Eye surgery procedure	0248	4.15	$210.99	$94.05	$42.20
67311	T	Revise eye muscle	0243	19.22	$977.18	$431.39	$195.44
67312	T	Revise two eye muscles	0243	19.22	$977.18	$431.39	$195.44
67314	T	Revise eye muscle	0243	19.22	$977.18	$431.39	$195.44
67316	T	Revise two eye muscles	0243	19.22	$977.18	$431.39	$195.44
67318	T	Revise eye muscle(s)	0243	19.22	$977.18	$431.39	$195.44
67320	T	Revise eye muscle(s) add-on	0243	19.22	$977.18	$431.39	$195.44
67331	T	Eye surgery follow-up add-on	0243	19.22	$977.18	$431.39	$195.44
67332	T	Rerevise eye muscles add-on	0243	19.22	$977.18	$431.39	$195.44
67334	T	Revise eye muscle w/suture	0243	19.22	$977.18	$431.39	$195.44
67335	T	Eye suture during surgery	0243	19.22	$977.18	$431.39	$195.44
67340	T	Revise eye muscle add-on	0243	19.22	$977.18	$431.39	$195.44
67343	T	Release eye tissue	0243	19.22	$977.18	$431.39	$195.44
67345	T	Destroy nerve of eye muscle	0238	2.84	$144.39	$58.96	$28.88
67350	T	Biopsy eye muscle	0699	6.91	$351.32	$158.09	$70.26
67399	T	Eye muscle surgery procedure	0243	19.22	$977.18	$431.39	$195.44
67400	T	Explore/biopsy eye socket	0241	19.20	$976.17	$384.47	$195.23
67405	T	Explore/drain eye socket	0241	19.20	$976.17	$384.47	$195.23
67412	T	Explore/treat eye socket	0241	19.20	$976.17	$384.47	$195.23
67413	T	Explore/treat eye socket	0241	19.20	$976.17	$384.47	$195.23
67414	T	Explr/decompress eye socket	0242	25.31	$1,286.81	$597.36	$257.36
67415	T	Aspiration, orbital contents	0239	6.25	$317.76	$123.42	$63.55
67420	T	Explore/treat eye socket	0242	25.31	$1,286.81	$597.36	$257.36
67430	T	Explore/treat eye socket	0242	25.31	$1,286.81	$597.36	$257.36
67440	T	Explore/drain eye socket	0242	25.31	$1,286.81	$597.36	$257.36
67445	T	Explr/decompress eye socket	0242	25.31	$1,286.81	$597.36	$257.36
67450	T	Explore/biopsy eye socket	0242	25.31	$1,286.81	$597.36	$257.36
67500	S	Inject/treat eye socket	0231	2.27	$115.41	$51.94	$23.08
67505	T	Inject/treat eye socket	0238	2.84	$144.39	$58.96	$28.88
67515	T	Inject/treat eye socket	0239	6.25	$317.76	$123.42	$63.55
67550	T	Insert eye socket implant	0242	25.31	$1,286.81	$597.36	$257.36
67560	T	Revise eye socket implant	0241	19.20	$976.17	$384.47	$195.23
67570	T	Decompress optic nerve	0242	25.31	$1,286.81	$597.36	$257.36
67599	T	Orbit surgery procedure	0239	6.25	$317.76	$123.42	$63.55
67700	T	Drainage of eyelid abscess	0238	2.84	$144.39	$58.96	$28.88
67710	T	Incision of eyelid	0239	6.25	$317.76	$123.42	$63.55
67715	T	Incision of eyelid fold	0240	14.86	$755.51	$315.31	$151.10
67800	T	Remove eyelid lesion	0238	2.84	$144.39	$58.96	$28.88
67801	T	Remove eyelid lesions	0239	6.25	$317.76	$123.42	$63.55
67805	T	Remove eyelid lesions	0238	2.84	$144.39	$58.96	$28.88
67808	T	Remove eyelid lesion(s)	0240	14.86	$755.51	$315.31	$151.10
67810	T	Biopsy of eyelid	0238	2.84	$144.39	$58.96	$28.88
67820	T	Revise eyelashes	0238	2.84	$144.39	$58.96	$28.88
67825	T	Revise eyelashes	0238	2.84	$144.39	$58.96	$28.88
67830	T	Revise eyelashes	0239	6.25	$317.76	$123.42	$63.55
67835	T	Revise eyelashes	0240	14.86	$755.51	$315.31	$151.10
67840	T	Remove eyelid lesion	0239	6.25	$317.76	$123.42	$63.55
67850	T	Treat eyelid lesion	0239	6.25	$317.76	$123.42	$63.55
67875	T	Closure of eyelid by suture	0239	6.25	$317.76	$123.42	$63.55
67880	T	Revision of eyelid	0233	11.78	$598.92	$287.48	$119.78
67882	T	Revision of eyelid	0240	14.86	$755.51	$315.31	$151.10
67900	T	Repair brow defect	0240	14.86	$755.51	$315.31	$151.10
67901	T	Repair eyelid defect	0240	14.86	$755.51	$315.31	$151.10
67902	T	Repair eyelid defect	0240	14.86	$755.51	$315.31	$151.10
67903	T	Repair eyelid defect	0240	14.86	$755.51	$315.31	$151.10
67904	T	Repair eyelid defect	0240	14.86	$755.51	$315.31	$151.10
67906	T	Repair eyelid defect	0240	14.86	$755.51	$315.31	$151.10
67908	T	Repair eyelid defect	0240	14.86	$755.51	$315.31	$151.10
67909	T	Revise eyelid defect	0240	14.86	$755.51	$315.31	$151.10
67911	T	Revise eyelid defect	0240	14.86	$755.51	$315.31	$151.10
67914	T	Repair eyelid defect	0240	14.86	$755.51	$315.31	$151.10
67915	T	Repair eyelid defect	0239	6.25	$317.76	$123.42	$63.55
67916	T	Repair eyelid defect	0240	14.86	$755.51	$315.31	$151.10
67917	T	Repair eyelid defect	0240	14.86	$755.51	$315.31	$151.10
67921	T	Repair eyelid defect	0240	14.86	$755.51	$315.31	$151.10
67922	T	Repair eyelid defect	0239	6.25	$317.76	$123.42	$63.55
67923	T	Repair eyelid defect	0240	14.86	$755.51	$315.31	$151.10

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
67924	T	Repair eyelid defect	0240	14.86	$755.51	$315.31	$151.10
67930	T	Repair eyelid wound	0240	14.86	$755.51	$315.31	$151.10
67935	T	Repair eyelid wound	0240	14.86	$755.51	$315.31	$151.10
67938	T	Remove eyelid foreign body	0238	2.84	$144.39	$58.96	$28.88
67950	T	Revision of eyelid	0240	14.86	$755.51	$315.31	$151.10
67961	T	Revision of eyelid	0240	14.86	$755.51	$315.31	$151.10
67966	T	Revision of eyelid	0240	14.86	$755.51	$315.31	$151.10
67971	T	Reconstruction of eyelid	0241	19.20	$976.17	$384.47	$195.23
67973	T	Reconstruction of eyelid	0241	19.20	$976.17	$384.47	$195.23
67974	T	Reconstruction of eyelid	0241	19.20	$976.17	$384.47	$195.23
67975	T	Reconstruction of eyelid	0240	14.86	$755.51	$315.31	$151.10
67999	T	Revision of eyelid	0240	14.86	$755.51	$315.31	$151.10
68020	T	Incise/drain eyelid lining	0240	14.86	$755.51	$315.31	$151.10
68040	T	Treatment of eyelid lesions	0238	2.84	$144.39	$58.96	$28.88
68100	T	Biopsy of eyelid lining	0233	11.78	$598.92	$287.48	$119.78
68110	T	Remove eyelid lining lesion	0699	6.91	$351.32	$158.09	$70.26
68115	T	Remove eyelid lining lesion	0239	6.25	$317.76	$123.42	$63.55
68130	T	Remove eyelid lining lesion	0233	11.78	$598.92	$287.48	$119.78
68135	T	Remove eyelid lining lesion	0239	6.25	$317.76	$123.42	$63.55
68200	S	Treat eyelid by injection	0230	0.64	$32.54	$14.97	$6.51
68320	T	Revise/graft eyelid lining	0240	14.86	$755.51	$315.31	$151.10
68325	T	Revise/graft eyelid lining	0242	25.31	$1,286.81	$597.36	$257.36
68326	T	Revise/graft eyelid lining	0241	19.20	$976.17	$384.47	$195.23
68328	T	Revise/graft eyelid lining	0241	19.20	$976.17	$384.47	$195.23
68330	T	Revise eyelid lining	0233	11.78	$598.92	$287.48	$119.78
68335	T	Revise/graft eyelid lining	0241	19.20	$976.17	$384.47	$195.23
68340	T	Separate eyelid adhesions	0240	14.86	$755.51	$315.31	$151.10
68360	T	Revise eyelid lining	0234	20.56	$1,045.31	$502.16	$209.06
68362	T	Revise eyelid lining	0234	20.56	$1,045.31	$502.16	$209.06
68399	T	Eyelid lining surgery	0239	6.25	$317.76	$123.42	$63.55
68400	T	Incise/drain tear gland	0238	2.84	$144.39	$58.96	$28.88
68420	T	Incise/drain tear sac	0240	14.86	$755.51	$315.31	$151.10
68440	T	Incise tear duct opening	0238	2.84	$144.39	$58.96	$28.88
68500	T	Removal of tear gland	0241	19.20	$976.17	$384.47	$195.23
68505	T	Partial removal, tear gland	0241	19.20	$976.17	$384.47	$195.23
68510	T	Biopsy of tear gland	0240	14.86	$755.51	$315.31	$151.10
68520	T	Removal of tear sac	0241	19.20	$976.17	$384.47	$195.23
68525	T	Biopsy of tear sac	0240	14.86	$755.51	$315.31	$151.10
68530	T	Clearance of tear duct	0240	14.86	$755.51	$315.31	$151.10
68540	T	Remove tear gland lesion	0241	19.20	$976.17	$384.47	$195.23
68550	T	Remove tear gland lesion	0242	25.31	$1,286.81	$597.36	$257.36
68700	T	Repair tear ducts	0241	19.20	$976.17	$384.47	$195.23
68705	T	Revise tear duct opening	0238	2.84	$144.39	$58.96	$28.88
68720	T	Create tear sac drain	0242	25.31	$1,286.81	$597.36	$257.36
68745	T	Create tear duct drain	0241	19.20	$976.17	$384.47	$195.23
68750	T	Create tear duct drain	0242	25.31	$1,286.81	$597.36	$257.36
68760	T	Close tear duct opening	0238	2.84	$144.39	$58.96	$28.88
68761	S	Close tear duct opening	0231	2.27	$115.41	$51.94	$23.08
68770	T	Close tear system fistula	0240	14.86	$755.51	$315.31	$151.10
68801	S	Dilate tear duct opening	0231	2.27	$115.41	$51.94	$23.08
68810	T	Probe nasolacrimal duct	0699	6.91	$351.32	$158.09	$70.26
68811	T	Probe nasolacrimal duct	0240	14.86	$755.51	$315.31	$151.10
68815	T	Probe nasolacrimal duct	0240	14.86	$755.51	$315.31	$151.10
68840	T	Explore/irrigate tear ducts	0699	6.91	$351.32	$158.09	$70.26
68850	N	Injection for tear sac x-ray	.....	.....	.....	.....	.....
68899	T	Tear duct system surgery	0699	6.91	$351.32	$158.09	$70.26
69000	T	Drain external ear lesion	0006	2.36	$119.99	$33.95	$24.00
69005	T	Drain external ear lesion	0007	7.28	$370.13	$74.03	$74.03
69020	T	Drain outer ear canal lesion	0006	2.36	$119.99	$33.95	$24.00
69090	E	Pierce earlobes	.....	.....	.....	.....	.....
69100	T	Biopsy of external ear	0019	4.56	$231.84	$78.91	$46.37
69105	T	Biopsy of external ear canal	0253	13.27	$674.67	$284.00	$134.93
69110	T	Remove external ear, partial	0020	8.56	$435.21	$130.53	$87.04
69120	T	Removal of external ear	0254	19.11	$971.59	$272.41	$194.32
69140	T	Remove ear canal lesion(s)	0254	19.11	$971.59	$272.41	$194.32
69145	T	Remove ear canal lesion(s)	0020	8.56	$435.21	$130.53	$87.04
69150	C	Extensive ear canal surgery	.....	.....	.....	.....	.....
69155	C	Extensive ear/neck surgery	.....	.....	.....	.....	.....
69200	X	Clear outer ear canal	0340	0.91	$46.27	$11.57	$9.25
69205	T	Clear outer ear canal	0022	15.07	$766.19	$292.94	$153.24
69210	X	Remove impacted ear wax	0340	0.91	$46.27	$11.57	$9.25
69220	T	Clean out mastoid cavity	0012	0.72	$36.61	$9.18	$7.32
69222	T	Clean out mastoid cavity	0253	13.27	$674.67	$284.00	$134.93
69300	T	Revise external ear	0254	19.11	$971.59	$272.41	$194.32
69310	T	Rebuild outer ear canal	0256	28.82	$1,465.27	$623.05	$293.05

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
69320	T	Rebuild outer ear canal	0256	28.82	$1,465.27	$623.05	$293.05
69399	T	Outer ear surgery procedure	0251	2.71	$137.78	$27.99	$27.56
69400	T	Inflate middle ear canal	0251	2.71	$137.78	$27.99	$27.56
69401	N	Inflate middle ear canal					
69405	T	Catheterize middle ear canal	0252	6.53	$332.00	$114.24	$66.40
69410	T	Inset middle ear (baffle)	0252	6.53	$332.00	$114.24	$66.40
69420	T	Incision of eardrum	0251	2.71	$137.78	$27.99	$27.56
69421	T	Incision of eardrum	0253	13.27	$674.67	$284.00	$134.93
69424	T	Remove ventilating tube	0252	6.53	$332.00	$114.24	$66.40
69433	T	Create eardrum opening	0252	6.53	$332.00	$114.24	$66.40
69436	T	Create eardrum opening	0253	13.27	$674.67	$284.00	$134.93
69440	T	Exploration of middle ear	0254	19.11	$971.59	$272.41	$194.32
69450	T	Eardrum revision	0256	28.82	$1,465.27	$623.05	$293.05
69501	T	Mastoidectomy	0256	28.82	$1,465.27	$623.05	$293.05
69502	C	Mastoidectomy					
69505	T	Remove mastoid structures	0256	28.82	$1,465.27	$623.05	$293.05
69511	T	Extensive mastoid surgery	0256	28.82	$1,465.27	$623.05	$293.05
69530	T	Extensive mastoid surgery	0256	28.82	$1,465.27	$623.05	$293.05
69535	C	Remove part of temporal bone					
69540	T	Remove ear lesion	0253	13.27	$674.67	$284.00	$134.93
69550	T	Remove ear lesion	0256	28.82	$1,465.27	$623.05	$293.05
69552	T	Remove ear lesion	0256	28.82	$1,465.27	$623.05	$293.05
69554	C	Remove ear lesion					
69601	T	Mastoid surgery revision	0256	28.82	$1,465.27	$623.05	$293.05
69602	T	Mastoid surgery revision	0256	28.82	$1,465.27	$623.05	$293.05
69603	T	Mastoid surgery revision	0256	28.82	$1,465.27	$623.05	$293.05
69604	T	Mastoid surgery revision	0256	28.82	$1,465.27	$623.05	$293.05
69605	T	Mastoid surgery revision	0256	28.82	$1,465.27	$623.05	$293.05
69610	T	Repair of eardrum	0254	19.11	$971.59	$272.41	$194.32
69620	T	Repair of eardrum	0254	19.11	$971.59	$272.41	$194.32
69631	T	Repair eardrum structures	0256	28.82	$1,465.27	$623.05	$293.05
69632	T	Rebuild eardrum structures	0256	28.82	$1,465.27	$623.05	$293.05
69633	T	Rebuild eardrum structures	0256	28.82	$1,465.27	$623.05	$293.05
69635	T	Repair eardrum structures	0256	28.82	$1,465.27	$623.05	$293.05
69636	T	Rebuild eardrum structures	0256	28.82	$1,465.27	$623.05	$293.05
69637	T	Rebuild eardrum structures	0256	28.82	$1,465.27	$623.05	$293.05
69641	T	Revise middle ear & mastoid	0256	28.82	$1,465.27	$623.05	$293.05
69642	T	Revise middle ear & mastoid	0256	28.82	$1,465.27	$623.05	$293.05
69643	T	Revise middle ear & mastoid	0256	28.82	$1,465.27	$623.05	$293.05
69644	T	Revise middle ear & mastoid	0256	28.82	$1,465.27	$623.05	$293.05
69645	T	Revise middle ear & mastoid	0256	28.82	$1,465.27	$623.05	$293.05
69646	T	Revise middle ear & mastoid	0256	28.82	$1,465.27	$623.05	$293.05
69650	T	Release middle ear bone	0254	19.11	$971.59	$272.41	$194.32
69660	T	Revise middle ear bone	0256	28.82	$1,465.27	$623.05	$293.05
69661	T	Revise middle ear bone	0256	28.82	$1,465.27	$623.05	$293.05
69662	T	Revise middle ear bone	0256	28.82	$1,465.27	$623.05	$293.05
69666	T	Repair middle ear structures	0256	28.82	$1,465.27	$623.05	$293.05
69667	T	Repair middle ear structures	0256	28.82	$1,465.27	$623.05	$293.05
69670	T	Remove mastoid air cells	0256	28.82	$1,465.27	$623.05	$293.05
69676	T	Remove middle ear nerve	0256	28.82	$1,465.27	$623.05	$293.05
69700	T	Close mastoid fistula	0256	28.82	$1,465.27	$623.05	$293.05
69710	E	Implant/replace hearing aid					
69711	T	Remove/repair hearing aid	0256	28.82	$1,465.27	$623.05	$293.05
69714	T	Implant temple bone w/stimul	0256	28.82	$1,465.27	$623.05	$293.05
69715	T	Temple bne implnt w/stimulat	0256	28.82	$1,465.27	$623.05	$293.05
69717	T	Temple bone implant revision	0256	28.82	$1,465.27	$623.05	$293.05
69718	T	Revise temple bone implant	0256	28.82	$1,465.27	$623.05	$293.05
69720	T	Release facial nerve	0256	28.82	$1,465.27	$623.05	$293.05
69725	T	Release facial nerve	0256	28.82	$1,465.27	$623.05	$293.05
69740	T	Repair facial nerve	0256	28.82	$1,465.27	$623.05	$293.05
69745	T	Repair facial nerve	0256	28.82	$1,465.27	$623.05	$293.05
69799	T	Middle ear surgery procedure	0253	13.27	$674.67	$284.00	$134.93
69801	T	Incise inner ear	0256	28.82	$1,465.27	$623.05	$293.05
69802	T	Incise inner ear	0256	28.82	$1,465.27	$623.05	$293.05
69805	T	Explore inner ear	0256	28.82	$1,465.27	$623.05	$293.05
69806	T	Explore inner ear	0256	28.82	$1,465.27	$623.05	$293.05
69820	T	Establish inner ear window	0256	28.82	$1,465.27	$623.05	$293.05
69840	T	Revise inner ear window	0256	28.82	$1,465.27	$623.05	$293.05
69905	T	Remove inner ear	0256	28.82	$1,465.27	$623.05	$293.05
69910	T	Remove inner ear & mastoid	0256	28.82	$1,465.27	$623.05	$293.05
69915	T	Incise inner ear nerve	0256	28.82	$1,465.27	$623.05	$293.05
69930	T	Implant cochlear device	0259	306.15	$15,565.28	$6,537.42	$3,113.06
69949	T	Inner ear surgery procedure	0253	13.27	$674.67	$284.00	$134.93
69950	C	Incise inner ear nerve					
69955	T	Release facial nerve	0256	28.82	$1,465.27	$623.05	$293.05

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
69960	T	Release inner ear canal	0256	28.82	$1,465.27	$623.05	$293.05
69970	C	Remove inner ear lesion	.....	.....	.....	.....	.....
69979	T	Temporal bone surgery	0251	2.71	$137.78	$27.99	$27.56
69990	N	Microsurgery add-on	.....	.....	.....	.....	.....
70010	S	Contrast x-ray of brain	0274	5.69	$289.29	$128.12	$57.86
70015	S	Contrast x-ray of brain	0274	5.69	$289.29	$128.12	$57.86
70030	X	X-ray eye for foreign body	0260	0.76	$38.64	$21.25	$7.73
70100	X	X-ray exam of jaw	0260	0.76	$38.64	$21.25	$7.73
70110	X	X-ray exam of jaw	0260	0.76	$38.64	$21.25	$7.73
70120	X	X-ray exam of mastoids	0260	0.76	$38.64	$21.25	$7.73
70130	X	X-ray exam of mastoids	0260	0.76	$38.64	$21.25	$7.73
70134	X	X-ray exam of middle ear	0261	1.31	$66.60	$36.63	$13.32
70140	X	X-ray exam of facial bones	0260	0.76	$38.64	$21.25	$7.73
70150	X	X-ray exam of facial bones	0260	0.76	$38.64	$21.25	$7.73
70160	X	X-ray exam of nasal bones	0260	0.76	$38.64	$21.25	$7.73
70170	X	X-ray exam of tear duct	0263	1.74	$88.47	$45.88	$17.69
70190	X	X-ray exam of eye sockets	0260	0.76	$38.64	$21.25	$7.73
70200	X	X-ray exam of eye sockets	0260	0.76	$38.64	$21.25	$7.73
70210	X	X-ray exam of sinuses	0260	0.76	$38.64	$21.25	$7.73
70220	X	X-ray exam of sinuses	0260	0.76	$38.64	$21.25	$7.73
70240	X	X-ray exam, pituitary saddle	0260	0.76	$38.64	$21.25	$7.73
70250	X	X-ray exam of skull	0260	0.76	$38.64	$21.25	$7.73
70260	X	X-ray exam of skull	0261	1.31	$66.60	$36.63	$13.32
70300	X	X-ray exam of teeth	0262	0.66	$33.56	$10.90	$6.71
70310	X	X-ray exam of teeth	0262	0.66	$33.56	$10.90	$6.71
70320	X	Full mouth x-ray of teeth	0262	0.66	$33.56	$10.90	$6.71
70328	X	X-ray exam of jaw joint	0260	0.76	$38.64	$21.25	$7.73
70330	X	X-ray exam of jaw joints	0260	0.76	$38.64	$21.25	$7.73
70332	S	X-ray exam of jaw joint	0275	2.82	$143.37	$72.26	$28.67
70336	S	Magnetic image, jaw joint	0335	5.91	$300.48	$165.26	$60.10
70350	X	X-ray head for orthodontia	0260	0.76	$38.64	$21.25	$7.73
70355	X	Panoramic x-ray of jaws	0260	0.76	$38.64	$21.25	$7.73
70360	X	X-ray exam of neck	0260	0.76	$38.64	$21.25	$7.73
70370	X	Throat x-ray & fluoroscopy	0272	1.47	$74.74	$39.00	$14.95
70371	X	Speech evaluation, complex	0272	1.47	$74.74	$39.00	$14.95
70373	X	Contrast x-ray of larynx	0263	1.74	$88.47	$45.88	$17.69
70380	X	X-ray exam of salivary gland	0260	0.76	$38.64	$21.25	$7.73
70390	X	X-ray exam of salivary duct	0263	1.74	$88.47	$45.88	$17.69
70450	S	Ct head/brain w/o dye	0332	3.51	$178.46	$98.15	$35.69
70460	S	Ct head/brain w/dye	0283	4.89	$248.62	$136.74	$49.72
70470	S	Ct head/brain w/o&w dye	0333	5.66	$287.77	$158.27	$57.55
70480	S	Ct orbit/ear/fossa w/o dye	0332	3.51	$178.46	$98.15	$35.69
70481	S	Ct orbit/ear/fossa w/dye	0283	4.89	$248.62	$136.74	$49.72
70482	S	Ct orbit/ear/fossa w/o&w dye	0333	5.66	$287.77	$158.27	$57.55
70486	S	Ct maxillofacial w/o dye	0332	3.51	$178.46	$98.15	$35.69
70487	S	Ct maxillofacial w/dye	0283	4.89	$248.62	$136.74	$49.72
70488	S	Ct maxillofacial w/o&w dye	0333	5.66	$287.77	$158.27	$57.55
70490	S	Ct soft tissue neck w/o dye	0332	3.51	$178.46	$98.15	$35.69
70491	S	Ct soft tissue neck w/dye	0283	4.89	$248.62	$136.74	$49.72
70492	S	Ct sft tsue nck w/o & w/dye	0333	5.66	$287.77	$158.27	$57.55
70496	S	Ct angiography, head	0333	5.66	$287.77	$158.27	$57.55
70498	S	Ct angiography, neck	0333	5.66	$287.77	$158.27	$57.55
70540	S	Mri orbit/face/neck w/o dye	0336	6.85	$348.27	$191.55	$69.65
70542	S	Mri orbit/face/neck w/dye	0284	7.80	$396.57	$218.11	$79.31
70543	S	Mri orbt/fac/nck w/o&w dye	0337	9.26	$470.80	$258.94	$94.16
70544	S	Mr angiography head w/o dye	0336	6.85	$348.27	$191.55	$69.65
70545	S	Mr angiography head w/dye	0284	7.80	$396.57	$218.11	$79.31
70546	S	Mr angiograph head w/o&w dye	0337	9.26	$470.80	$258.94	$94.16
70547	S	Mr angiography neck w/o dye	0336	6.85	$348.27	$191.55	$69.65
70548	S	Mr angiography neck w/dye	0284	7.80	$396.57	$218.11	$79.31
70549	S	Mr angiograph neck w/o&w dye	0337	9.26	$470.80	$258.94	$94.16
70551	S	Mri brain w/o dye	0336	6.85	$348.27	$191.55	$69.65
70552	S	Mri brain w/dye	0284	7.80	$396.57	$218.11	$79.31
70553	S	Mri brain w/o&w dye	0337	9.26	$470.80	$258.94	$94.16
71010	X	Chest x-ray	0260	0.76	$38.64	$21.25	$7.73
71015	X	Chest x-ray	0260	0.76	$38.64	$21.25	$7.73
71020	X	Chest x-ray	0260	0.76	$38.64	$21.25	$7.73
71021	X	Chest x-ray	0260	0.76	$38.64	$21.25	$7.73
71022	X	Chest x-ray	0260	0.76	$38.64	$21.25	$7.73
71023	X	Chest x-ray and fluoroscopy	0272	1.47	$74.74	$39.00	$14.95
71030	X	Chest x-ray	0260	0.76	$38.64	$21.25	$7.73
71034	X	Chest x-ray and fluoroscopy	0272	1.47	$74.74	$39.00	$14.95
71035	X	Chest x-ray	0260	0.76	$38.64	$21.25	$7.73
71040	X	Contrast x-ray of bronchi	0263	1.74	$88.47	$45.88	$17.69
71060	X	Contrast x-ray of bronchi	0263	1.74	$88.47	$45.88	$17.69

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
71090	X	X-ray & pacemaker insertion	0272	1.47	$74.74	$39.00	$14.95
71100	X	X-ray exam of ribs	0260	0.76	$38.64	$21.25	$7.73
71101	X	X-ray exam of ribs/chest	0260	0.76	$38.64	$21.25	$7.73
71110	X	X-ray exam of ribs	0260	0.76	$38.64	$21.25	$7.73
71111	X	X-ray exam of ribs/ chest	0261	1.31	$66.60	$36.63	$13.32
71120	X	X-ray exam of breastbone	0260	0.76	$38.64	$21.25	$7.73
71130	X	X-ray exam of breastbone	0260	0.76	$38.64	$21.25	$7.73
71250	S	Ct thorax w/o dye	0332	3.51	$178.46	$98.15	$35.69
71260	S	Ct thorax w/dye	0283	4.89	$248.62	$136.74	$49.72
71270	S	Ct thorax w/o&w dye	0333	5.66	$287.77	$158.27	$57.55
71275	S	Ct angiography, chest	0333	5.66	$287.77	$158.27	$57.55
71550	S	Mri chest w/o dye	0336	6.85	$348.27	$191.55	$69.65
71551	S	Mri chest w/dye	0284	7.80	$396.57	$218.11	$79.31
71552	S	Mri chest w/o&w dye	0337	9.26	$470.80	$258.94	$94.16
71555	E	Mri angio chest w or w/o dye					
72010	X	X-ray exam of spine	0261	1.31	$66.60	$36.63	$13.32
72020	X	X-ray exam of spine	0260	0.76	$38.64	$21.25	$7.73
72040	X	X-ray exam of neck spine	0260	0.76	$38.64	$21.25	$7.73
72050	X	X-ray exam of neck spine	0261	1.31	$66.60	$36.63	$13.32
72052	X	X-ray exam of neck spine	0261	1.31	$66.60	$36.63	$13.32
72069	X	X-ray exam of trunk spine	0260	0.76	$38.64	$21.25	$7.73
72070	X	X-ray exam of thoracic spine	0260	0.76	$38.64	$21.25	$7.73
72072	X	X-ray exam of thoracic spine	0260	0.76	$38.64	$21.25	$7.73
72074	X	X-ray exam of thoracic spine	0260	0.76	$38.64	$21.25	$7.73
72080	X	X-ray exam of trunk spine	0260	0.76	$38.64	$21.25	$7.73
72090	X	X-ray exam of trunk spine	0261	1.31	$66.60	$36.63	$13.32
72100	X	X-ray exam of lower spine	0260	0.76	$38.64	$21.25	$7.73
72110	X	X-ray exam of lower spine	0261	1.31	$66.60	$36.63	$13.32
72114	X	X-ray exam of lower spine	0261	1.31	$66.60	$36.63	$13.32
72120	X	X-ray exam of lower spine	0260	0.76	$38.64	$21.25	$7.73
72125	S	Ct neck spine w/o dye	0332	3.51	$178.46	$98.15	$35.69
72126	S	Ct neck spine w/dye	0283	4.89	$248.62	$136.74	$49.72
72127	S	Ct neck spine w/o&w dye	0333	5.66	$287.77	$158.27	$57.55
72128	S	Ct chest spine w/o dye	0332	3.51	$178.46	$98.15	$35.69
72129	S	Ct chest spine w/dye	0283	4.89	$248.62	$136.74	$49.72
72130	S	Ct chest spine w/o&w dye	0333	5.66	$287.77	$158.27	$57.55
72131	S	Ct lumbar spine w/o dye	0332	3.51	$178.46	$98.15	$35.69
72132	S	Ct lumbar spine w/dye	0283	4.89	$248.62	$136.74	$49.72
72133	S	Ct lumbar spine w/o&w dye	0333	5.66	$287.77	$158.27	$57.55
72141	S	Mri neck spine w/o dye	0336	6.85	$348.27	$191.55	$69.65
72142	S	Mri neck spine w/dye	0284	7.80	$396.57	$218.11	$79.31
72146	S	Mri chest spine w/o dye	0336	6.85	$348.27	$191.55	$69.65
72147	S	Mri chest spine w/dye	0284	7.80	$396.57	$218.11	$79.31
72148	S	Mri lumbar spine w/o dye	0336	6.85	$348.27	$191.55	$69.65
72149	S	Mri lumbar spine w/dye	0284	7.80	$396.57	$218.11	$79.31
72156	S	Mri neck spine w/o&w dye	0337	9.26	$470.80	$258.94	$94.16
72157	S	Mri chest spine w/o&w dye	0337	9.26	$470.80	$258.94	$94.16
72158	S	Mri lumbar spine w/o&w dye	0337	9.26	$470.80	$258.94	$94.16
72159	E	Mr angio spine w/o&w dye					
72170	X	X-ray exam of pelvis	0260	0.76	$38.64	$21.25	$7.73
72190	X	X-ray exam of pelvis	0260	0.76	$38.64	$21.25	$7.73
72191	S	Ct angiograph pelv w/o&w dye	0333	5.66	$287.77	$158.27	$57.55
72192	S	Ct pelvis w/o dye	0332	3.51	$178.46	$98.15	$35.69
72193	S	Ct pelvis w/dye	0283	4.89	$248.62	$136.74	$49.72
72194	S	Ct pelvis w/o&w dye	0333	5.66	$287.77	$158.27	$57.55
72195	S	Mri pelvis w/o dye	0336	6.85	$348.27	$191.55	$69.65
72196	S	Mri pelvis w/dye	0284	7.80	$396.57	$218.11	$79.31
72197	S	Mri pelvis w/o & w dye	0337	9.26	$470.80	$258.94	$94.16
72198	E	Mr angio pelvis w/o&w dye					
72200	X	X-ray exam sacroiliac joints	0260	0.76	$38.64	$21.25	$7.73
72202	X	X-ray exam sacroiliac joints	0260	0.76	$38.64	$21.25	$7.73
72220	X	X-ray exam of tailbone	0260	0.76	$38.64	$21.25	$7.73
72240	S	Contrast x-ray of neck spine	0274	5.69	$289.29	$128.12	$57.86
72255	S	Contrast x-ray, thorax spine	0274	5.69	$289.29	$128.12	$57.86
72265	S	Contrast x-ray, lower spine	0274	5.69	$289.29	$128.12	$57.86
72270	S	Contrast x-ray of spine	0274	5.69	$289.29	$128.12	$57.86
72275	S	Epidurography	0274	5.69	$289.29	$128.12	$57.86
72285	S	X-ray c/t spine disk	0274	5.69	$289.29	$128.12	$57.86
72295	S	X-ray of lower spine disk	0274	5.69	$289.29	$128.12	$57.86
73000	X	X-ray exam of collar bone	0260	0.76	$38.64	$21.25	$7.73
73010	X	X-ray exam of shoulder blade	0260	0.76	$38.64	$21.25	$7.73
73020	X	X-ray exam of shoulder	0260	0.76	$38.64	$21.25	$7.73
73030	X	X-ray exam of shoulder	0260	0.76	$38.64	$21.25	$7.73
73040	S	Contrast x-ray of shoulder	0275	2.82	$143.37	$72.26	$28.67
73050	X	X-ray exam of shoulders	0260	0.76	$38.64	$21.25	$7.73

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
73060	X	X-ray exam of humerus	0260	0.76	$38.64	$21.25	$7.73
73070	X	X-ray exam of elbow	0260	0.76	$38.64	$21.25	$7.73
73080	X	X-ray exam of elbow	0260	0.76	$38.64	$21.25	$7.73
73085	S	Contrast x-ray of elbow	0275	2.82	$143.37	$72.26	$28.67
73090	X	X-ray exam of forearm	0260	0.76	$38.64	$21.25	$7.73
73092	X	X-ray exam of arm, infant	0260	0.76	$38.64	$21.25	$7.73
73100	X	X-ray exam of wrist	0260	0.76	$38.64	$21.25	$7.73
73110	X	X-ray exam of wrist	0260	0.76	$38.64	$21.25	$7.73
73115	S	Contrast x-ray of wrist	0275	2.82	$143.37	$72.26	$28.67
73120	X	X-ray exam of hand	0260	0.76	$38.64	$21.25	$7.73
73130	X	X-ray exam of hand	0260	0.76	$38.64	$21.25	$7.73
73140	X	X-ray exam of finger(s)	0260	0.76	$38.64	$21.25	$7.73
73200	S	Ct upper extremity w/o dye	0332	3.51	$178.46	$98.15	$35.69
73201	S	Ct upper extremity w/dye	0283	4.89	$248.62	$136.74	$49.72
73202	S	Ct uppr extremity w/o&w dye	0333	5.66	$287.77	$158.27	$57.55
73206	S	Ct angio upr extrm w/o&w dye	0333	5.66	$287.77	$158.27	$57.55
73218	S	Mri upper extremity w/o dye	0336	6.85	$348.27	$191.55	$69.65
73219	S	Mri upper extremity w/dye	0284	7.80	$396.57	$218.11	$79.31
73220	S	Mri uppr extremity w/o&w dye	0337	9.26	$470.80	$258.94	$94.16
73221	S	Mri joint upr extrem w/o dye	0336	6.85	$348.27	$191.55	$69.65
73222	S	Mri joint upr extrem w/ dye	0284	7.80	$396.57	$218.11	$79.31
73223	S	Mri joint upr extr w/o&w dye	0337	9.26	$470.80	$258.94	$94.16
73225	E	Mr angio upr extr w/o&w dye	.....	.....	.....	.....	.....
73500	X	X-ray exam of hip	0260	0.76	$38.64	$21.25	$7.73
73510	X	X-ray exam of hip	0260	0.76	$38.64	$21.25	$7.73
73520	X	X-ray exam of hips	0260	0.76	$38.64	$21.25	$7.73
73525	S	Contrast x-ray of hip	0275	2.82	$143.37	$72.26	$28.67
73530	X	X-ray exam of hip	0261	1.31	$66.60	$36.63	$13.32
73540	X	X-ray exam of pelvis & hips	0260	0.76	$38.64	$21.25	$7.73
73542	S	X-ray exam, sacroiliac joint	0275	2.82	$143.37	$72.26	$28.67
73550	X	X-ray exam of thigh	0260	0.76	$38.64	$21.25	$7.73
73560	X	X-ray exam of knee, 1 or 2	0260	0.76	$38.64	$21.25	$7.73
73562	X	X-ray exam of knee, 3	0260	0.76	$38.64	$21.25	$7.73
73564	X	X-ray exam, knee, 4 or more	0260	0.76	$38.64	$21.25	$7.73
73565	X	X-ray exam of knees	0260	0.76	$38.64	$21.25	$7.73
73580	S	Contrast x-ray of knee joint	0275	2.82	$143.37	$72.26	$28.67
73590	X	X-ray exam of lower leg	0260	0.76	$38.64	$21.25	$7.73
73592	X	X-ray exam of leg, infant	0261	1.31	$66.60	$36.63	$13.32
73600	X	X-ray exam of ankle	0260	0.76	$38.64	$21.25	$7.73
73610	X	X-ray exam of ankle	0260	0.76	$38.64	$21.25	$7.73
73615	S	Contrast x-ray of ankle	0275	2.82	$143.37	$72.26	$28.67
73620	X	X-ray exam of foot	0260	0.76	$38.64	$21.25	$7.73
73630	X	X-ray exam of foot	0260	0.76	$38.64	$21.25	$7.73
73650	X	X-ray exam of heel	0260	0.76	$38.64	$21.25	$7.73
73660	X	X-ray exam of toe(s)	0260	0.76	$38.64	$21.25	$7.73
73700	S	Ct lower extremity w/o dye	0332	3.51	$178.46	$98.15	$35.69
73701	S	Ct lower extremity w/dye	0283	4.89	$248.62	$136.74	$49.72
73702	S	Ct lwr extremity w/o&w dye	0333	5.66	$287.77	$158.27	$57.55
73706	S	Ct angio lwr extr w/o&w dye	0333	5.66	$287.77	$158.27	$57.55
73718	S	Mri lower extremity w/o dye	0336	6.85	$348.27	$191.55	$69.65
73719	S	Mri lower extremity w/dye	0284	7.80	$396.57	$218.11	$79.31
73720	S	Mri lwr extremity w/o&w dye	0337	9.26	$470.80	$258.94	$94.16
73721	S	Mri joint of lwr extre w/o d	0336	6.85	$348.27	$191.55	$69.65
73722	S	Mri joint of lwr extr w/dye	0284	7.80	$396.57	$218.11	$79.31
73723	S	Mri joint lwr extr w/o&w dye	0337	9.26	$470.80	$258.94	$94.16
73725	E	Mr ang lwr ext w or w/o dye	.....	.....	.....	.....	.....
74000	X	X-ray exam of abdomen	0260	0.76	$38.64	$21.25	$7.73
74010	X	X-ray exam of abdomen	0260	0.76	$38.64	$21.25	$7.73
74020	X	X-ray exam of abdomen	0260	0.76	$38.64	$21.25	$7.73
74022	X	X-ray exam series, abdomen	0261	1.31	$66.60	$36.63	$13.32
74150	S	Ct abdomen w/o dye	0332	3.51	$178.46	$98.15	$35.69
74160	S	Ct abdomen w/dye	0283	4.89	$248.62	$136.74	$49.72
74170	S	Ct abdomen w/o&w dye	0333	5.66	$287.77	$158.27	$57.55
74175	S	Ct angio abdom w/o&w dye	0333	5.66	$287.77	$158.27	$57.55
74181	S	Mri abdomen w/o dye	0336	6.85	$348.27	$191.55	$69.65
74182	S	Mri abdomen w/dye	0284	7.80	$396.57	$218.11	$79.31
74183	S	Mri abdomen w/o&w dye	0337	9.26	$470.80	$258.94	$94.16
74185	E	Mri angio, abdom w or w/o dy	.....	.....	.....	.....	.....
74190	X	X-ray exam of peritoneum	0263	1.74	$88.47	$45.88	$17.69
74210	S	Contrst x-ray exam of throat	0276	1.63	$82.87	$45.58	$16.57
74220	S	Contrast x-ray, esophagus	0276	1.63	$82.87	$45.58	$16.57
74230	S	Cinema x-ray, throat/esoph	0276	1.63	$82.87	$45.58	$16.57
74235	S	Remove esophagus obstruction	0296	3.52	$178.96	$98.43	$35.79
74240	S	X-ray exam, upper gi tract	0276	1.63	$82.87	$45.58	$16.57
74241	S	X-ray exam, upper gi tract	0276	1.63	$82.87	$45.58	$16.57

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
74245	S	X-ray exam, upper gi tract	0277	2.35	$119.48	$65.71	$23.90
74246	S	Contrst x-ray uppr gi tract	0276	1.63	$82.87	$45.58	$16.57
74247	S	Contrst x-ray uppr gi tract	0276	1.63	$82.87	$45.58	$16.57
74249	S	Contrst x-ray uppr gi tract	0277	2.35	$119.48	$65.71	$23.90
74250	S	X-ray exam of small bowel	0276	1.63	$82.87	$45.58	$16.57
74251	S	X-ray exam of small bowel	0277	2.35	$119.48	$65.71	$23.90
74260	S	X-ray exam of small bowel	0277	2.35	$119.48	$65.71	$23.90
74270	S	Contrast x-ray exam of colon	0276	1.63	$82.87	$45.58	$16.57
74280	S	Contrast x-ray exam of colon	0277	2.35	$119.48	$65.71	$23.90
74283	S	Contrast x-ray exam of colon	0276	1.63	$82.87	$45.58	$16.57
74290	S	Contrast x-ray, gallbladder	0276	1.63	$82.87	$45.58	$16.57
74291	S	Contrast x-rays, gallbladder	0276	1.63	$82.87	$45.58	$16.57
74300	X	X-ray bile ducts/pancreas	0263	1.74	$88.47	$45.88	$17.69
74301	X	X-rays at surgery add-on	0263	1.74	$88.47	$45.88	$17.69
74305	X	X-ray bile ducts/pancreas	0263	1.74	$88.47	$45.88	$17.69
74320	X	Contrast x-ray of bile ducts	0264	2.51	$127.61	$70.19	$25.52
74327	S	X-ray bile stone removal	0296	3.52	$178.96	$98.43	$35.79
74328	N	Xray bile duct endoscopy					
74329	N	X-ray for pancreas endoscopy					
74330	N	X-ray bile/panc endoscopy					
74340	X	X-ray guide for GI tube	0272	1.47	$74.74	$39.00	$14.95
74350	T	X-ray guide, stomach tube	0187	4.54	$230.82	$113.10	$46.16
74355	T	X-ray guide, intestinal tube	0187	4.54	$230.82	$113.10	$46.16
74360	S	X-ray guide, GI dilation	0296	3.52	$178.96	$98.43	$35.79
74363	S	X-ray, bile duct dilation	0297	7.80	$396.57	$172.51	$79.31
74400	S	Contrst x-ray, urinary tract	0278	2.56	$130.16	$71.59	$26.03
74410	S	Contrst x-ray, urinary tract	0278	2.56	$130.16	$71.59	$26.03
74415	S	Contrst x-ray, urinary tract	0278	2.56	$130.16	$71.59	$26.03
74420	S	Contrst x-ray, urinary tract	0278	2.56	$130.16	$71.59	$26.03
74425	S	Contrst x-ray, urinary tract	0278	2.56	$130.16	$71.59	$26.03
74430	S	Contrast x-ray, bladder	0278	2.56	$130.16	$71.59	$26.03
74440	S	X-ray, male genital tract	0278	2.56	$130.16	$71.59	$26.03
74445	S	X-ray exam of penis	0278	2.56	$130.16	$71.59	$26.03
74450	S	X-ray, urethra/bladder	0278	2.56	$130.16	$71.59	$26.03
74455	S	X-ray, urethra/bladder	0278	2.56	$130.16	$71.59	$26.03
74470	X	X-ray exam of kidney lesion	0264	2.51	$127.61	$70.19	$25.52
74475	S	X-ray control, cath insert	0297	7.80	$396.57	$172.51	$79.31
74480	S	X-ray control, cath insert	0297	7.80	$396.57	$172.51	$79.31
74485	S	X-ray guide, GU dilation	0296	3.52	$178.96	$98.43	$35.79
74710	X	X-ray measurement of pelvis	0260	0.76	$38.64	$21.25	$7.73
74740	X	X-ray, female genital tract	0264	2.51	$127.61	$70.19	$25.52
74742	T	X-ray, fallopian tube	0187	4.54	$230.82	$113.10	$46.16
74775	S	X-ray exam of perineum	0278	2.56	$130.16	$71.59	$26.03
75552	S	Heart mri for morph w/o dye	0336	6.85	$348.27	$191.55	$69.65
75553	S	Heart mri for morph w/dye	0284	7.80	$396.57	$218.11	$79.31
75554	S	Cardiac MRI/function	0335	5.91	$300.48	$165.26	$60.10
75555	S	Cardiac MRI/limited study	0335	5.91	$300.48	$165.26	$60.10
75556	E	Cardiac MRI/flow mapping					
75600	S	Contrast x-ray exam of aorta	0280	14.40	$732.12	$373.38	$146.42
75605	S	Contrast x-ray exam of aorta	0280	14.40	$732.12	$373.38	$146.42
75625	S	Contrast x-ray exam of aorta	0280	14.40	$732.12	$373.38	$146.42
75630	S	X-ray aorta, leg arteries	0280	14.40	$732.12	$373.38	$146.42
75635	S	Ct angio abdominal arteries	0333	5.66	$287.77	$158.27	$57.55
75650	S	Artery x-rays, head & neck	0280	14.40	$732.12	$373.38	$146.42
75658	S	Artery x-rays, arm	0280	14.40	$732.12	$373.38	$146.42
75660	S	Artery x-rays, head & neck	0279	8.37	$425.55	$174.57	$85.11
75662	S	Artery x-rays, head & neck	0279	8.37	$425.55	$174.57	$85.11
75665	S	Artery x-rays, head & neck	0280	14.40	$732.12	$373.38	$146.42
75671	S	Artery x-rays, head & neck	0280	14.40	$732.12	$373.38	$146.42
75676	S	Artery x-rays, neck	0280	14.40	$732.12	$373.38	$146.42
75680	S	Artery x-rays, neck	0280	14.40	$732.12	$373.38	$146.42
75685	S	Artery x-rays, spine	0279	8.37	$425.55	$174.57	$85.11
75705	S	Artery x-rays, spine	0279	8.37	$425.55	$174.57	$85.11
75710	S	Artery x-rays, arm/leg	0280	14.40	$732.12	$373.38	$146.42
75716	S	Artery x-rays, arms/legs	0280	14.40	$732.12	$373.38	$146.42
75722	S	Artery x-rays, kidney	0280	14.40	$732.12	$373.38	$146.42
75724	S	Artery x-rays, kidneys	0280	14.40	$732.12	$373.38	$146.42
75726	S	Artery x-rays, abdomen	0280	14.40	$732.12	$373.38	$146.42
75731	S	Artery x-rays, adrenal gland	0280	14.40	$732.12	$373.38	$146.42
75733	S	Artery x-rays, adrenals	0280	14.40	$732.12	$373.38	$146.42
75736	S	Artery x-rays, pelvis	0280	14.40	$732.12	$373.38	$146.42
75741	S	Artery x-rays, lung	0279	8.37	$425.55	$174.57	$85.11
75743	S	Artery x-rays, lungs	0280	14.40	$732.12	$373.38	$146.42
75746	S	Artery x-rays, lung	0279	8.37	$425.55	$174.57	$85.11
75756	S	Artery x-rays, chest	0279	8.37	$425.55	$174.57	$85.11

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
75774	S	Artery x-ray, each vessel	0279	8.37	$425.55	$174.57	$85.11
75790	S	Visualize A-V shunt	0281	4.64	$235.91	$115.16	$47.18
75801	X	Lymph vessel x-ray, arm/leg	0264	2.51	$127.61	$70.19	$25.52
75803	X	Lymph vessel x-ray,arms/legs	0264	2.51	$127.61	$70.19	$25.52
75805	X	Lymph vessel x-ray, trunk	0264	2.51	$127.61	$70.19	$25.52
75807	X	Lymph vessel x-ray, trunk	0264	2.51	$127.61	$70.19	$25.52
75809	X	Nonvascular shunt, x-ray	0263	1.74	$88.47	$45.88	$17.69
75810	S	Vein x-ray, spleen/liver	0279	8.37	$425.55	$174.57	$85.11
75820	S	Vein x-ray, arm/leg	0281	4.64	$235.91	$115.16	$47.18
75822	S	Vein x-ray, arms/legs	0281	4.64	$235.91	$115.16	$47.18
75825	S	Vein x-ray, trunk	0279	8.37	$425.55	$174.57	$85.11
75827	S	Vein x-ray, chest	0279	8.37	$425.55	$174.57	$85.11
75831	S	Vein x-ray, kidney	0287	4.33	$220.15	$90.26	$44.03
75833	S	Vein x-ray, kidneys	0279	8.37	$425.55	$174.57	$85.11
75840	S	Vein x-ray, adrenal gland	0287	4.33	$220.15	$90.26	$44.03
75842	S	Vein x-ray, adrenal glands	0287	4.33	$220.15	$90.26	$44.03
75860	S	Vein x-ray, neck	0287	4.33	$220.15	$90.26	$44.03
75870	S	Vein x-ray, skull	0287	4.33	$220.15	$90.26	$44.03
75872	S	Vein x-ray, skull	0287	4.33	$220.15	$90.26	$44.03
75880	S	Vein x-ray, eye socket	0287	4.33	$220.15	$90.26	$44.03
75885	S	Vein x-ray, liver	0279	8.37	$425.55	$174.57	$85.11
75887	S	Vein x-ray, liver	0280	14.40	$732.12	$373.38	$146.42
75889	S	Vein x-ray, liver	0279	8.37	$425.55	$174.57	$85.11
75891	S	Vein x-ray, liver	0279	8.37	$425.55	$174.57	$85.11
75893	N	Venous sampling by catheter					
75894	S	X-rays, transcath therapy	0297	7.80	$396.57	$172.51	$79.31
75896	S	X-rays, transcath therapy	0297	7.80	$396.57	$172.51	$79.31
75898	X	Follow-up angiogram	0264	2.51	$127.61	$70.19	$25.52
75900	C	Arterial catheter exchange					
75940	T	X-ray placement, vein filter	0187	4.54	$230.82	$113.10	$46.16
75945	S	Intravascular us	0267	2.58	$131.17	$72.14	$26.23
75946	S	Intravascular us add-on	0267	2.58	$131.17	$72.14	$26.23
75952	C	Endovasc repair abdom aorta					
75953	C	Abdom aneurysm endovas rpr					
75960	S	Transcatheter intro, stent	0280	14.40	$732.12	$373.38	$146.42
75961	S	Retrieval, broken catheter	0280	14.40	$732.12	$373.38	$146.42
75962	S	Repair arterial blockage	0280	14.40	$732.12	$373.38	$146.42
75964	S	Repair artery blockage, each	0280	14.40	$732.12	$373.38	$146.42
75966	S	Repair arterial blockage	0280	14.40	$732.12	$373.38	$146.42
75968	S	Repair artery blockage, each	0280	14.40	$732.12	$373.38	$146.42
75970	S	Vascular biopsy	0280	14.40	$732.12	$373.38	$146.42
75978	S	Repair venous blockage	0280	14.40	$732.12	$373.38	$146.42
75980	S	Contrast xray exam bile duct	0297	7.80	$396.57	$172.51	$79.31
75982	S	Contrast xray exam bile duct	0297	7.80	$396.57	$172.51	$79.31
75984	S	Xray control catheter change	0296	3.52	$178.96	$98.43	$35.79
75989	N	Abscess drainage under x-ray					
75992	S	Atherectomy, x-ray exam	0280	14.40	$732.12	$373.38	$146.42
75993	T	Atherectomy, x-ray exam	0081	22.04	$1,120.56	$549.07	$224.11
75994	T	Atherectomy, x-ray exam	0081	22.04	$1,120.56	$549.07	$224.11
75995	S	Atherectomy, x-ray exam	0280	14.40	$732.12	$373.38	$146.42
75996	T	Atherectomy, x-ray exam	0081	22.04	$1,120.56	$549.07	$224.11
76000	X	Fluoroscope examination	0272	1.47	$74.74	$39.00	$14.95
76001	N	Fluoroscope exam, extensive					
76003	N	Needle localization by x-ray					
76005	N	Fluoroguide for spine inject					
76006	X	X-ray stress view	0261	1.31	$66.60	$36.63	$13.32
76010	X	X-ray, nose to rectum	0260	0.76	$38.64	$21.25	$7.73
76012	S	Percut vertebroplasty fluor	0274	5.69	$289.29	$128.12	$57.86
76013	S	Percut vertebroplasty, ct	0274	5.69	$289.29	$128.12	$57.86
76020	X	X-rays for bone age	0261	1.31	$66.60	$36.63	$13.32
76040	X	X-rays, bone evaluation	0260	0.76	$38.64	$21.25	$7.73
76061	X	X-rays, bone survey	0261	1.31	$66.60	$36.63	$13.32
76062	X	X-rays, bone survey	0261	1.31	$66.60	$36.63	$13.32
76065	X	X-rays, bone evaluation	0261	1.31	$66.60	$36.63	$13.32
76066	X	Joint(s) survey, single film	0260	0.76	$38.64	$21.25	$7.73
76070	E	CT scan, bone density study					
76075	S	Dual energy x-ray study	0971	1.42	$72.20		$14.44
76076	S	Dual energy x-ray study	0971	1.42	$72.20		$14.44
76078	X	Photodensitometry	0261	1.31	$66.60	$36.63	$13.32
76080	X	X-ray exam of fistula	0263	1.74	$88.47	$45.88	$17.69
76086	X	X-ray of mammary duct	0263	1.74	$88.47	$45.88	$17.69
76088	X	X-ray of mammary ducts	0263	1.74	$88.47	$45.88	$17.69
76090	S	Mammogram, one breast	0271	0.64	$32.54	$17.90	$6.51
76091	S	Mammogram, both breasts	0271	0.64	$32.54	$17.90	$6.51
76092	A	Mammogram, screening					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
76093	E	Magnetic image, breast					
76094	E	Magnetic image, both breasts					
76095	T	Stereotactic breast biopsy	0187	4.54	$230.82	$113.10	$46.16
76096	X	X-ray of needle wire, breast	0289	1.22	$62.03	$32.25	$12.41
76098	X	X-ray exam, breast specimen	0260	0.76	$38.64	$21.25	$7.73
76100	X	X-ray exam of body section	0261	1.31	$66.60	$36.63	$13.32
76101	X	Complex body section x-ray	0263	1.74	$88.47	$45.88	$17.69
76102	X	Complex body section x-rays	0264	2.51	$127.61	$70.19	$25.52
76120	X	Cinematic x-rays	0261	1.31	$66.60	$36.63	$13.32
76125	X	Cinematic x-rays add-on	0261	1.31	$66.60	$36.63	$13.32
76140	E	X-ray consultation					
76150	X	X-ray exam, dry process	0260	0.76	$38.64	$21.25	$7.73
76350	N	Special x-ray contrast study					
76355	S	CAT scan for localization	0283	4.89	$248.62	$136.74	$49.72
76360	S	CAT scan for needle biopsy	0283	4.89	$248.62	$136.74	$49.72
76370	S	CAT scan for therapy guide	0282	1.63	$82.87	$45.58	$16.57
76375	S	3d/holograph reconstr add-on	0282	1.63	$82.87	$45.58	$16.57
76380	S	CAT scan follow-up study	0282	1.63	$82.87	$45.58	$16.57
76390	S	Mr spectroscopy	0335	5.91	$300.48	$165.26	$60.10
76393	N	Mr guidance for needle place					
76400	S	Magnetic image, bone marrow	0335	5.91	$300.48	$165.26	$60.10
76499	X	Radiographic procedure	0260	0.76	$38.64	$21.25	$7.73
76506	S	Echo exam of head	0266	1.67	$84.91	$46.70	$16.98
76511	S	Echo exam of eye	0266	1.67	$84.91	$46.70	$16.98
76512	S	Echo exam of eye	0266	1.67	$84.91	$46.70	$16.98
76513	S	Echo exam of eye, water bath	0265	1.02	$51.86	$28.52	$10.37
76516	S	Echo exam of eye	0266	1.67	$84.91	$46.70	$16.98
76519	S	Echo exam of eye	0266	1.67	$84.91	$46.70	$16.98
76529	S	Echo exam of eye	0265	1.02	$51.86	$28.52	$10.37
76536	S	Echo exam of head and neck	0266	1.67	$84.91	$46.70	$16.98
76604	S	Echo exam of chest	0266	1.67	$84.91	$46.70	$16.98
76645	S	Echo exam of breast(s)	0265	1.02	$51.86	$28.52	$10.37
76700	S	Echo exam of abdomen	0266	1.67	$84.91	$46.70	$16.98
76705	S	Echo exam of abdomen	0266	1.67	$84.91	$46.70	$16.98
76770	S	Echo exam abdomen back wall	0266	1.67	$84.91	$46.70	$16.98
76775	S	Echo exam abdomen back wall	0266	1.67	$84.91	$46.70	$16.98
76778	S	Echo exam kidney transplant	0266	1.67	$84.91	$46.70	$16.98
76800	S	Echo exam spinal canal	0266	1.67	$84.91	$46.70	$16.98
76805	S	Echo exam of pregnant uterus	0266	1.67	$84.91	$46.70	$16.98
76810	S	Echo exam of pregnant uterus	0265	1.02	$51.86	$28.52	$10.37
76815	S	Echo exam of pregnant uterus	0265	1.02	$51.86	$28.52	$10.37
76816	S	Echo exam follow-up/repeat	0265	1.02	$51.86	$28.52	$10.37
76818	S	Fetl biophys profil w/stress	0266	1.67	$84.91	$46.70	$16.98
76819	S	Fetl biophys profil w/o strs	0266	1.67	$84.91	$46.70	$16.98
76825	S	Echo exam of fetal heart	0269	4.31	$219.13	$113.95	$43.83
76826	S	Echo exam of fetal heart	0697	2.00	$101.68	$52.88	$20.34
76827	S	Echo exam of fetal heart	0269	4.31	$219.13	$113.95	$43.83
76828	S	Echo exam of fetal heart	0697	2.00	$101.68	$52.88	$20.34
76830	S	Echo exam, transvaginal	0266	1.67	$84.91	$46.70	$16.98
76831	S	Echo exam, uterus	0266	1.67	$84.91	$46.70	$16.98
76856	S	Echo exam of pelvis	0266	1.67	$84.91	$46.70	$16.98
76857	S	Echo exam of pelvis	0265	1.02	$51.86	$28.52	$10.37
76870	S	Echo exam of scrotum	0266	1.67	$84.91	$46.70	$16.98
76872	S	Echo exam, transrectal	0266	1.67	$84.91	$46.70	$16.98
76873	N	Echograp trans r, pros study					
76880	S	Echo exam of extremity	0266	1.67	$84.91	$46.70	$16.98
76885	S	Echo exam, infant hips	0266	1.67	$84.91	$46.70	$16.98
76886	S	Echo exam, infant hips	0266	1.67	$84.91	$46.70	$16.98
76930	N	Echo guide, cardiocentesis					
76932	N	Echo guide for heart biopsy					
76936	N	Echo guide for artery repair					
76941	N	Echo guide for transfusion					
76942	N	Echo guide for biopsy					
76945	N	Echo guide, villus sampling					
76946	N	Echo guide for amniocentesis					
76948	N	Echo guide, ova aspiration					
76950	N	Echo guidance radiotherapy					
76965	N	Echo guidance radiotherapy					
76970	S	Ultrasound exam follow-up	0265	1.02	$51.86	$28.52	$10.37
76975	S	GI endoscopic ultrasound	0266	1.67	$84.91	$46.70	$16.98
76977	S	Us bone density measure	0265	1.02	$51.86	$28.52	$10.37
76986	S	Ultrasound guide intraoper	0266	1.67	$84.91	$46.70	$16.98
76999	S	Echo examination procedure	0266	1.67	$84.91	$46.70	$16.98
77261	E	Radiation therapy planning					
77262	E	Radiation therapy planning					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
77263	E	Radiation therapy planning	.....	.....	.....	.....	.....
77280	X	Set radiation therapy field	0304	1.80	$91.52	$41.52	$18.30
77285	X	Set radiation therapy field	0305	4.40	$223.70	$97.50	$44.74
77290	X	Set radiation therapy field	0305	4.40	$223.70	$97.50	$44.74
77295	X	Set radiation therapy field	0310	17.14	$871.43	$339.05	$174.29
77299	E	Radiation therapy planning	.....	.....	.....	.....	.....
77300	X	Radiation therapy dose plan	0304	1.80	$91.52	$41.52	$18.30
77305	X	Radiation therapy dose plan	0304	1.80	$91.52	$41.52	$18.30
77310	X	Radiation therapy dose plan	0304	1.80	$91.52	$41.52	$18.30
77315	X	Radiation therapy dose plan	0305	4.40	$223.70	$97.50	$44.74
77321	X	Radiation therapy port plan	0305	4.40	$223.70	$97.50	$44.74
77326	X	Radiation therapy dose plan	0305	4.40	$223.70	$97.50	$44.74
77327	X	Radiation therapy dose plan	0305	4.40	$223.70	$97.50	$44.74
77328	X	Radiation therapy dose plan	0305	4.40	$223.70	$97.50	$44.74
77331	X	Special radiation dosimetry	0304	1.80	$91.52	$41.52	$18.30
77332	X	Radiation treatment aid(s)	0303	3.98	$202.35	$69.28	$40.47
77333	X	Radiation treatment aid(s)	0303	3.98	$202.35	$69.28	$40.47
77334	X	Radiation treatment aid(s)	0303	3.98	$202.35	$69.28	$40.47
77336	X	Radiation physics consult	0304	1.80	$91.52	$41.52	$18.30
77370	X	Radiation physics consult	0305	4.40	$223.70	$97.50	$44.74
77399	X	External radiation dosimetry	0304	1.80	$91.52	$41.52	$18.30
77401	S	Radiation treatment delivery	0300	2.25	$114.39	$47.72	$22.88
77402	S	Radiation treatment delivery	0300	2.25	$114.39	$47.72	$22.88
77403	S	Radiation treatment delivery	0300	2.25	$114.39	$47.72	$22.88
77404	S	Radiation treatment delivery	0300	2.25	$114.39	$47.72	$22.88
77406	S	Radiation treatment delivery	0300	2.25	$114.39	$47.72	$22.88
77407	S	Radiation treatment delivery	0300	2.25	$114.39	$47.72	$22.88
77408	S	Radiation treatment delivery	0300	2.25	$114.39	$47.72	$22.88
77409	S	Radiation treatment delivery	0300	2.25	$114.39	$47.72	$22.88
77411	S	Radiation treatment delivery	0300	2.25	$114.39	$47.72	$22.88
77412	S	Radiation treatment delivery	0300	2.25	$114.39	$47.72	$22.88
77413	S	Radiation treatment delivery	0300	2.25	$114.39	$47.72	$22.88
77414	S	Radiation treatment delivery	0300	2.25	$114.39	$47.72	$22.88
77416	S	Radiation treatment delivery	0300	2.25	$114.39	$47.72	$22.88
77417	X	Radiology port film(s)	0260	0.76	$38.64	$21.25	$7.73
77427	E	Radiation tx management, x5	.....	.....	.....	.....	.....
77431	E	Radiation therapy management	.....	.....	.....	.....	.....
77432	E	Stereotactic radiation trmt	.....	.....	.....	.....	.....
77470	S	Special radiation treatment	0302	11.96	$608.07	$216.55	$121.61
77499	E	Radiation therapy management	.....	.....	.....	.....	.....
77520	S	Proton trmt, simple w/o comp	0974	7.57	$384.87	.....	$76.97
77522	S	Proton trmt, simple w/comp	0974	7.57	$384.87	.....	$76.97
77523	S	Proton trmt, intermediate	0976	16.56	$841.94	.....	$168.39
77525	S	Proton treatment, complex	0976	16.56	$841.94	.....	$168.39
77600	S	Hyperthermia treatment	0314	5.16	$262.34	$133.80	$52.47
77605	S	Hyperthermia treatment	0314	5.16	$262.34	$133.80	$52.47
77610	S	Hyperthermia treatment	0314	5.16	$262.34	$133.80	$52.47
77615	S	Hyperthermia treatment	0314	5.16	$262.34	$133.80	$52.47
77620	S	Hyperthermia treatment	0314	5.16	$262.34	$133.80	$52.47
77750	S	Infuse radioactive materials	0301	5.85	$297.43	$59.49	$59.49
77761	S	Apply intrcav radiat simple	0312	7.77	$395.04	$109.65	$79.01
77762	S	Apply intrcav radiat interm	0312	7.77	$395.04	$109.65	$79.01
77763	S	Apply intrcav radiat compl	0312	7.77	$395.04	$109.65	$79.01
77776	S	Apply interstit radiat simpl	0312	7.77	$395.04	$109.65	$79.01
77777	S	Apply interstit radiat inter	0312	7.77	$395.04	$109.65	$79.01
77778	S	Apply iterstit radiat compl	0312	7.77	$395.04	$109.65	$79.01
77781	S	High intensity brachytherapy	0313	16.31	$829.23	$165.85	$165.85
77782	S	High intensity brachytherapy	0313	16.31	$829.23	$165.85	$165.85
77783	S	High intensity brachytherapy	0313	16.31	$829.23	$165.85	$165.85
77784	S	High intensity brachytherapy	0313	16.31	$829.23	$165.85	$165.85
77789	S	Apply surface radiation	0300	2.25	$114.39	$47.72	$22.88
77790	N	Radiation handling	.....	.....	.....	.....	.....
77799	S	Radium/radioisotope therapy	0313	16.31	$829.23	$165.85	$165.85
78000	S	Thyroid, single uptake	0290	1.91	$97.11	$53.41	$19.42
78001	S	Thyroid, multiple uptakes	0290	1.91	$97.11	$53.41	$19.42
78003	S	Thyroid suppress/stimul	0290	1.91	$97.11	$53.41	$19.42
78006	S	Thyroid imaging with uptake	0291	3.78	$192.18	$90.20	$38.44
78007	S	Thyroid image, mult uptakes	0291	3.78	$192.18	$90.20	$38.44
78010	S	Thyroid imaging	0290	1.91	$97.11	$53.41	$19.42
78011	S	Thyroid imaging with flow	0290	1.91	$97.11	$53.41	$19.42
78015	S	Thyroid met imaging	0291	3.78	$192.18	$90.20	$38.44
78016	S	Thyroid met imaging/studies	0291	3.78	$192.18	$90.20	$38.44
78018	S	Thyroid met imaging, body	0292	4.56	$231.84	$124.85	$46.37
78020	S	Thyroid met uptake	0291	3.78	$192.18	$90.20	$38.44
78070	S	Parathyroid nuclear imaging	0291	3.78	$192.18	$90.20	$38.44

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
78075	S	Adrenal nuclear imaging	0292	4.56	$231.84	$124.85	$46.37
78099	S	Endocrine nuclear procedure	0290	1.91	$97.11	$53.41	$19.42
78102	S	Bone marrow imaging, ltd	0291	3.78	$192.18	$90.20	$38.44
78103	S	Bone marrow imaging, mult	0292	4.56	$231.84	$124.85	$46.37
78104	S	Bone marrow imaging, body	0291	3.78	$192.18	$90.20	$38.44
78110	S	Plasma volume, single	0291	3.78	$192.18	$90.20	$38.44
78111	S	Plasma volume, multiple	0291	3.78	$192.18	$90.20	$38.44
78120	S	Red cell mass, single	0291	3.78	$192.18	$90.20	$38.44
78121	S	Red cell mass, multiple	0291	3.78	$192.18	$90.20	$38.44
78122	S	Blood volume	0292	4.56	$231.84	$124.85	$46.37
78130	S	Red cell survival study	0291	3.78	$192.18	$90.20	$38.44
78135	S	Red cell survival kinetics	0292	4.56	$231.84	$124.85	$46.37
78140	S	Red cell sequestration	0291	3.78	$192.18	$90.20	$38.44
78160	S	Plasma iron turnover	0291	3.78	$192.18	$90.20	$38.44
78162	S	Iron absorption exam	0291	3.78	$192.18	$90.20	$38.44
78170	S	Red cell iron utilization	0291	3.78	$192.18	$90.20	$38.44
78172	S	Total body iron estimation	0291	3.78	$192.18	$90.20	$38.44
78185	S	Spleen imaging	0291	3.78	$192.18	$90.20	$38.44
78190	S	Platelet survival, kinetics	0291	3.78	$192.18	$90.20	$38.44
78191	S	Platelet survival	0291	3.78	$192.18	$90.20	$38.44
78195	S	Lymph system imaging	0291	3.78	$192.18	$90.20	$38.44
78199	S	Blood/lymph nuclear exam	0290	1.91	$97.11	$53.41	$19.42
78201	S	Liver imaging	0291	3.78	$192.18	$90.20	$38.44
78202	S	Liver imaging with flow	0291	3.78	$192.18	$90.20	$38.44
78205	S	Liver imaging (3D)	0292	4.56	$231.84	$124.85	$46.37
78206	S	Liver image (3d) w/flow	0292	4.56	$231.84	$124.85	$46.37
78215	S	Liver and spleen imaging	0291	3.78	$192.18	$90.20	$38.44
78216	S	Liver & spleen image/flow	0291	3.78	$192.18	$90.20	$38.44
78220	S	Liver function study	0291	3.78	$192.18	$90.20	$38.44
78223	S	Hepatobiliary imaging	0292	4.56	$231.84	$124.85	$46.37
78230	S	Salivary gland imaging	0291	3.78	$192.18	$90.20	$38.44
78231	S	Serial salivary imaging	0291	3.78	$192.18	$90.20	$38.44
78232	S	Salivary gland function exam	0291	3.78	$192.18	$90.20	$38.44
78258	S	Esophageal motility study	0291	3.78	$192.18	$90.20	$38.44
78261	S	Gastric mucosa imaging	0291	3.78	$192.18	$90.20	$38.44
78262	S	Gastroesophageal reflux exam	0291	3.78	$192.18	$90.20	$38.44
78264	S	Gastric emptying study	0291	3.78	$192.18	$90.20	$38.44
78267	A	Breath tst attain/anal c-14	.....	.....	.....	.....	.....
78268	A	Breath test analysis, c-14	.....	.....	.....	.....	.....
78270	S	Vit B-12 absorption exam	0290	1.91	$97.11	$53.41	$19.42
78271	S	Vit B-12 absorp exam, IF	0290	1.91	$97.11	$53.41	$19.42
78272	S	Vit B-12 absorp, combined	0291	3.78	$192.18	$90.20	$38.44
78278	S	Acute GI blood loss imaging	0291	3.78	$192.18	$90.20	$38.44
78282	S	GI protein loss exam	0290	1.91	$97.11	$53.41	$19.42
78290	S	Meckel's divert exam	0291	3.78	$192.18	$90.20	$38.44
78291	S	Leveen/shunt patency exam	0291	3.78	$192.18	$90.20	$38.44
78299	S	GI nuclear procedure	0290	1.91	$97.11	$53.41	$19.42
78300	S	Bone imaging, limited area	0291	3.78	$192.18	$90.20	$38.44
78305	S	Bone imaging, multiple areas	0291	3.78	$192.18	$90.20	$38.44
78306	S	Bone imaging, whole body	0291	3.78	$192.18	$90.20	$38.44
78315	S	Bone imaging, 3 phase	0292	4.56	$231.84	$124.85	$46.37
78320	S	Bone imaging (3D)	0292	4.56	$231.84	$124.85	$46.37
78350	X	Bone mineral, single photon	0261	1.31	$66.60	$36.63	$13.32
78351	E	Bone mineral, dual photon	.....	.....	.....	.....	.....
78399	S	Musculoskeletal nuclear exam	0290	1.91	$97.11	$53.41	$19.42
78414	S	Non-imaging heart function	0292	4.56	$231.84	$124.85	$46.37
78428	S	Cardiac shunt imaging	0292	4.56	$231.84	$124.85	$46.37
78445	S	Vascular flow imaging	0291	3.78	$192.18	$90.20	$38.44
78455	S	Venous thrombosis study	0291	3.78	$192.18	$90.20	$38.44
78456	S	Acute venous thrombus image	0291	3.78	$192.18	$90.20	$38.44
78457	S	Venous thrombosis imaging	0291	3.78	$192.18	$90.20	$38.44
78458	S	Ven thrombosis images, bilat	0291	3.78	$192.18	$90.20	$38.44
78459	E	Heart muscle imaging (PET)	.....	.....	.....	.....	.....
78460	S	Heart muscle blood, single	0286	5.85	$297.43	$163.58	$59.49
78461	S	Heart muscle blood, multiple	0286	5.85	$297.43	$163.58	$59.49
78464	S	Heart image (3d), single	0286	5.85	$297.43	$163.58	$59.49
78465	S	Heart image (3d), multiple	0286	5.85	$297.43	$163.58	$59.49
78466	S	Heart infarct image	0291	3.78	$192.18	$90.20	$38.44
78468	S	Heart infarct image (ef)	0292	4.56	$231.84	$124.85	$46.37
78469	S	Heart infarct image (3D)	0292	4.56	$231.84	$124.85	$46.37
78472	S	Gated heart, planar, single	0286	5.85	$297.43	$163.58	$59.49
78473	S	Gated heart, multiple	0286	5.85	$297.43	$163.58	$59.49
78478	S	Heart wall motion add-on	0286	5.85	$297.43	$163.58	$59.49
78480	S	Heart function add-on	0286	5.85	$297.43	$163.58	$59.49
78481	S	Heart first pass, single	0286	5.85	$297.43	$163.58	$59.49

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
78483	S	Heart first pass, multiple	0286	5.85	$297.43	$163.58	$59.49
78491	E	Heart image (pet), single					
78492	E	Heart image (pet), multiple					
78494	S	Heart image, spect	0296	3.52	$178.96	$98.43	$35.79
78496	S	Heart first pass add-on	0296	3.52	$178.96	$98.43	$35.79
78499	S	Cardiovascular nuclear exam	0291	3.78	$192.18	$90.20	$38.44
78580	S	Lung perfusion imaging	0291	3.78	$192.18	$90.20	$38.44
78584	S	Lung V/Q image single breath	0292	4.56	$231.84	$124.85	$46.37
78585	S	Lung V/Q imaging	0292	4.56	$231.84	$124.85	$46.37
78586	S	Aerosol lung image, single	0292	4.56	$231.84	$124.85	$46.37
78587	S	Aerosol lung image, multiple	0291	3.78	$192.18	$90.20	$38.44
78588	S	Perfusion lung image	0292	4.56	$231.84	$124.85	$46.37
78591	S	Vent image, 1 breath, 1 proj	0291	3.78	$192.18	$90.20	$38.44
78593	S	Vent image, 1 proj, gas	0292	4.56	$231.84	$124.85	$46.37
78594	S	Vent image, mult proj, gas	0292	4.56	$231.84	$124.85	$46.37
78596	S	Lung differential function	0292	4.56	$231.84	$124.85	$46.37
78599	S	Respiratory nuclear exam	0291	3.78	$192.18	$90.20	$38.44
78600	S	Brain imaging, ltd static	0292	4.56	$231.84	$124.85	$46.37
78601	S	Brain imaging, ltd w/ flow	0291	3.78	$192.18	$90.20	$38.44
78605	S	Brain imaging, complete	0291	3.78	$192.18	$90.20	$38.44
78606	S	Brain imaging, compl w/flow	0292	4.56	$231.84	$124.85	$46.37
78607	S	Brain imaging (3D)	0292	4.56	$231.84	$124.85	$46.37
78608	E	Brain imaging (PET)					
78609	E	Brain imaging (PET)					
78610	S	Brain flow imaging only	0291	3.78	$192.18	$90.20	$38.44
78615	S	Cerebral blood flow imaging	0291	3.78	$192.18	$90.20	$38.44
78630	S	Cerebrospinal fluid scan	0292	4.56	$231.84	$124.85	$46.37
78635	S	CSF ventriculography	0292	4.56	$231.84	$124.85	$46.37
78645	S	CSF shunt evaluation	0291	3.78	$192.18	$90.20	$38.44
78647	S	Cerebrospinal fluid scan	0292	4.56	$231.84	$124.85	$46.37
78650	S	CSF leakage imaging	0292	4.56	$231.84	$124.85	$46.37
78660	S	Nuclear exam of tear flow	0291	3.78	$192.18	$90.20	$38.44
78699	S	Nervous system nuclear exam	0291	3.78	$192.18	$90.20	$38.44
78700	S	Kidney imaging, static	0291	3.78	$192.18	$90.20	$38.44
78701	S	Kidney imaging with flow	0291	3.78	$192.18	$90.20	$38.44
78704	S	Imaging renogram	0291	3.78	$192.18	$90.20	$38.44
78707	S	Kidney flow/function image	0292	4.56	$231.84	$124.85	$46.37
78708	S	Kidney flow/function image	0292	4.56	$231.84	$124.85	$46.37
78709	S	Kidney flow/function image	0292	4.56	$231.84	$124.85	$46.37
78710	S	Kidney imaging (3D)	0291	3.78	$192.18	$90.20	$38.44
78715	S	Renal vascular flow exam	0291	3.78	$192.18	$90.20	$38.44
78725	S	Kidney function study	0291	3.78	$192.18	$90.20	$38.44
78730	S	Urinary bladder retention	0291	3.78	$192.18	$90.20	$38.44
78740	S	Ureteral reflux study	0291	3.78	$192.18	$90.20	$38.44
78760	S	Testicular imaging	0291	3.78	$192.18	$90.20	$38.44
78761	S	Testicular imaging/flow	0291	3.78	$192.18	$90.20	$38.44
78799	S	Genitourinary nuclear exam	0292	4.56	$231.84	$124.85	$46.37
78800	S	Tumor imaging, limited area	0291	3.78	$192.18	$90.20	$38.44
78801	S	Tumor imaging, mult areas	0292	4.56	$231.84	$124.85	$46.37
78802	S	Tumor imaging, whole body	0292	4.56	$231.84	$124.85	$46.37
78803	S	Tumor imaging (3D)	0292	4.56	$231.84	$124.85	$46.37
78805	S	Abscess imaging, ltd area	0292	4.56	$231.84	$124.85	$46.37
78806	S	Abscess imaging, whole body	0292	4.56	$231.84	$124.85	$46.37
78807	S	Nuclear localization/abscess	0292	4.56	$231.84	$124.85	$46.37
78810	E	Tumor imaging (PET)					
78890	N	Nuclear medicine data proc					
78891	N	Nuclear med data proc					
78990	N	Provide diag radionuclide(s)					
78999	S	Nuclear diagnostic exam	0291	3.78	$192.18	$90.20	$38.44
79000	S	Init hyperthyroid therapy	0294	5.45	$277.09	$144.06	$55.42
79001	S	Repeat hyperthyroid therapy	0294	5.45	$277.09	$144.06	$55.42
79020	S	Thyroid ablation	0294	5.45	$277.09	$144.06	$55.42
79030	S	Thyroid ablation, carcinoma	0294	5.45	$277.09	$144.06	$55.42
79035	S	Thyroid metastatic therapy	0294	5.45	$277.09	$144.06	$55.42
79100	S	Hematopoetic nuclear therapy	0294	5.45	$277.09	$144.06	$55.42
79200	S	Intracavitary nuclear trmt	0295	13.97	$710.26	$390.64	$142.05
79300	S	Interstitial nuclear therapy	0294	5.45	$277.09	$144.06	$55.42
79400	S	Nonhemato nuclear therapy	0295	13.97	$710.26	$390.64	$142.05
79420	S	Intravascular nuclear ther	0295	13.97	$710.26	$390.64	$142.05
79440	S	Nuclear joint therapy	0294	5.45	$277.09	$144.06	$55.42
79900	N	Provide ther radiopharm(s)					
79999	S	Nuclear medicine therapy	0294	5.45	$277.09	$144.06	$55.42
80048	A	Basic metabolic panel					
80050	A	General health panel					
80051	A	Electrolyte panel					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
80053	A	Comprehen metabolic panel					
80055	A	Obstetric panel					
80061	A	Lipid panel					
80069	A	Renal function panel					
80072	A	Arthritis panel					
80074	A	Acute hepatitis panel					
80076	A	Hepatic function panel					
80090	A	Torch antibody panel					
80100	A	Drug screen, qualitate/multi					
80101	A	Drug screen, single					
80102	A	Drug confirmation					
80103	N	Drug analysis, tissue prep					
80150	A	Assay of amikacin					
80152	A	Assay of amitriptyline					
80154	A	Assay of benzodiazepines					
80156	A	Assay, carbamazepine, total					
80157	A	Assay, carbamazepine, free					
80158	A	Assay of cyclosporine					
80160	A	Assay of desipramine					
80162	A	Assay of digoxin					
80164	A	Assay, dipropylacetic acid					
80166	A	Assay of doxepin					
80168	A	Assay of ethosuximide					
80170	A	Assay of gentamicin					
80172	A	Assay of gold					
80173	A	Assay of haloperidol					
80174	A	Assay of imipramine					
80176	A	Assay of lidocaine					
80178	A	Assay of lithium					
80182	A	Assay of nortriptyline					
80184	A	Assay of phenobarbital					
80185	A	Assay of phenytoin, total					
80186	A	Assay of phenytoin, free					
80188	A	Assay of primidone					
80190	A	Assay of procainamide					
80192	A	Assay of procainamide					
80194	A	Assay of quinidine					
80196	A	Assay of salicylate					
80197	A	Assay of tacrolimus					
80198	A	Assay of theophylline					
80200	A	Assay of tobramycin					
80201	X	Assay of topiramate	0349	0.34	$17.29	$3.46	$3.46
80202	A	Assay of vancomycin					
80299	A	Quantitative assay, drug					
80400	A	Acth stimulation panel					
80402	A	Acth stimulation panel					
80406	A	Acth stimulation panel					
80408	A	Aldosterone suppression eval					
80410	A	Calcitonin stimul panel					
80412	A	CRH stimulation panel					
80414	A	Testosterone response					
80415	A	Estradiol response panel					
80416	A	Renin stimulation panel					
80417	A	Renin stimulation panel					
80418	A	Pituitary evaluation panel					
80420	A	Dexamethasone panel					
80422	A	Glucagon tolerance panel					
80424	A	Glucagon tolerance panel					
80426	A	Gonadotropin hormone panel					
80428	A	Growth hormone panel					
80430	A	Growth hormone panel					
80432	A	Insulin suppression panel					
80434	A	Insulin tolerance panel					
80435	A	Insulin tolerance panel					
80436	A	Metyrapone panel					
80438	A	TRH stimulation panel					
80439	A	TRH stimulation panel					
80440	A	TRH stimulation panel					
80500	X	Lab pathology consultation	0343	0.42	$21.35	$11.53	$4.27
80502	X	Lab pathology consultation	0343	0.42	$21.35	$11.53	$4.27
81000	A	Urinalysis, nonauto w/scope					
81001	A	Urinalysis, auto w/scope					
81002	A	Urinalysis nonauto w/o scope					
81003	A	Urinalysis, auto, w/o scope					
81005	A	Urinalysis					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
81007	A	Urine screen for bacteria					
81015	A	Microscopic exam of urine					
81020	A	Urinalysis, glass test					
81025	A	Urine pregnancy test					
81050	A	Urinalysis, volume measure					
81099	X	Urinalysis test procedure	0349	0.34	$17.29	$3.46	$3.46
82000	A	Assay of blood acetaldehyde					
82003	A	Assay of acetaminophen					
82009	A	Test for acetone/ketones					
82010	A	Acetone assay					
82013	A	Acetylcholinesterase assay					
82016	A	Acylcarnitines, qual					
82017	A	Acylcarnitines, quant					
82024	A	Assay of acth					
82030	A	Assay of adp & amp					
82040	A	Assay of serum albumin					
82042	A	Assay of urine albumin					
82043	A	Microalbumin, quantitative					
82044	A	Microalbumin, semiquant					
82055	A	Assay of ethanol					
82075	A	Assay of breath ethanol					
82085	A	Assay of aldolase					
82088	A	Assay of aldosterone					
82101	A	Assay of urine alkaloids					
82103	A	Alpha-1-antitrypsin, total					
82104	A	Alpha-1-antitrypsin, pheno					
82105	A	Alpha-fetoprotein, serum					
82106	A	Alpha-fetoprotein, amniotic					
82108	A	Assay of aluminum					
82120	A	Amines, vaginal fluid qual					
82127	A	Amino acid, single qual					
82128	A	Amino acids, mult qual					
82131	A	Amino acids, single quant					
82135	A	Assay, aminolevulinic acid					
82136	A	Amino acids, quant, 2-5					
82139	A	Amino acids, quan, 6 or more					
82140	A	Assay of ammonia					
82143	A	Amniotic fluid scan					
82145	A	Assay of amphetamines					
82150	A	Assay of amylase					
82154	A	Androstanediol glucuronide					
82157	A	Assay of androstenedione					
82160	A	Assay of androsterone					
82163	A	Assay of angiotensin II					
82164	A	Angiotensin I enzyme test					
82172	A	Assay of apolipoprotein					
82175	A	Assay of arsenic					
82180	A	Assay of ascorbic acid					
82190	A	Atomic absorption					
82205	A	Assay of barbiturates					
82232	A	Assay of beta-2 protein					
82239	A	Bile acids, total					
82240	A	Bile acids, cholylglycine					
82247	A	Bilirubin, total					
82248	A	Bilirubin, direct					
82252	A	Fecal bilirubin test					
82261	A	Assay of biotinidase					
82270	A	Test for blood, feces					
82273	A	Test for blood, other source					
82286	A	Assay of bradykinin					
82300	A	Assay of cadmium					
82306	A	Assay of vitamin D					
82307	A	Assay of vitamin D					
82308	A	Assay of calcitonin					
82310	A	Assay of calcium					
82330	A	Assay of calcium					
82331	A	Calcium infusion test					
82340	A	Assay of calcium in urine					
82355	A	Calculus (stone) analysis					
82360	A	Calculus (stone) assay					
82365	A	Calculus (stone) assay					
82370	A	X-ray assay, calculus					
82373	A	Assay, c-d transfer measure					
82374	A	Assay, blood carbon dioxide					
82375	A	Assay, blood carbon monoxide					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
82376	A	Test for carbon monoxide					
82378	A	Carcinoembryonic antigen					
82379	A	Assay of carnitine					
82380	A	Assay of carotene					
82382	A	Assay, urine catecholamines					
82383	A	Assay, blood catecholamines					
82384	A	Assay, three catecholamines					
82387	A	Assay of cathepsin-d					
82390	A	Assay of ceruloplasmin					
82397	A	Chemiluminescent assay					
82415	A	Assay of chloramphenicol					
82435	A	Assay of blood chloride					
82436	A	Assay of urine chloride					
82438	A	Assay, other fluid chlorides					
82441	A	Test for chlorohydrocarbons					
82465	A	Assay, bld/serum cholesterol					
82480	A	Assay, serum cholinesterase					
82482	A	Assay, rbc cholinesterase					
82485	A	Assay, chondroitin sulfate					
82486	A	Gas/liquid chromatography					
82487	A	Paper chromatography					
82488	A	Paper chromatography					
82489	A	Thin layer chromatography					
82491	A	Chromotography, quant, sing					
82492	A	Chromotography, quant, mult					
82495	A	Assay of chromium					
82507	A	Assay of citrate					
82520	A	Assay of cocaine					
82523	A	Collagen crosslinks					
82525	A	Assay of copper					
82528	A	Assay of corticosterone					
82530	A	Cortisol, free					
82533	A	Total cortisol					
82540	A	Assay of creatine					
82541	A	Column chromotography, qual					
82542	A	Column chromotography, quant					
82543	A	Column chromotograph/isotope					
82544	A	Column chromotograph/isotope					
82550	A	Assay of ck (cpk)					
82552	A	Assay of cpk in blood					
82553	A	Creatine, MB fraction					
82554	A	Creatine, isoforms					
82565	A	Assay of creatinine					
82570	A	Assay of urine creatinine					
82575	A	Creatinine clearance test					
82585	A	Assay of cryofibrinogen					
82595	A	Assay of cryoglobulin					
82600	A	Assay of cyanide					
82607	A	Vitamin B-12					
82608	A	B-12 binding capacity					
82615	A	Test for urine cystines					
82626	A	Dehydroepiandrosterone					
82627	A	Dehydroepiandrosterone					
82633	A	Desoxycorticosterone					
82634	A	Deoxycortisol					
82638	A	Assay of dibucaine number					
82646	A	Assay of dihydrocodeinone					
82649	A	Assay of dihydromorphinone					
82651	A	Assay of dihydrotestosterone					
82652	A	Assay of dihydroxyvitamin d					
82654	A	Assay of dimethadione					
82657	A	Enzyme cell activity					
82658	A	Enzyme cell activity, ra					
82664	A	Electrophoretic test					
82666	A	Assay of epiandrosterone					
82668	A	Assay of erythropoietin					
82670	A	Assay of estradiol					
82671	A	Assay of estrogens					
82672	A	Assay of estrogen					
82677	A	Assay of estriol					
82679	A	Assay of estrone					
82690	A	Assay of ethchlorvynol					
82693	A	Assay of ethylene glycol					
82696	A	Assay of etiocholanolone					
82705	A	Fats/lipids, feces, qual					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
82710	A	Fats/lipids, feces, quant					
82715	A	Assay of fecal fat					
82725	A	Assay of blood fatty acids					
82726	A	Long chain fatty acids					
82728	A	Assay of ferritin					
82731	A	Assay of fetal fibronectin					
82735	A	Assay of fluoride					
82742	A	Assay of flurazepam					
82746	A	Blood folic acid serum					
82747	A	Assay of folic acid, rbc					
82757	A	Assay of semen fructose					
82759	A	Assay of rbc galactokinase					
82760	A	Assay of galactose					
82775	A	Assay galactose transferase					
82776	A	Galactose transferase test					
82784	A	Assay of gammaglobulin igm					
82785	A	Assay of gammaglobulin ige					
82787	A	Igg 1, 2, 3 or 4, each					
82800	A	Blood pH					
82803	A	Blood gases: pH, pO2 & pCO2					
82805	A	Blood gases W/02 saturation					
82810	A	Blood gases, O2 sat only					
82820	A	Hemoglobin-oxygen affinity					
82926	A	Assay of gastric acid					
82928	A	Assay of gastric acid					
82938	A	Gastrin test					
82941	A	Assay of gastrin					
82943	A	Assay of glucagon					
82945	A	Glucose other fluid					
82946	A	Glucagon tolerance test					
82947	A	Assay, glucose, blood quant					
82948	A	Reagent strip/blood glucose					
82950	A	Glucose test					
82951	A	Glucose tolerance test (GTT)					
82952	A	GTT-added samples					
82953	A	Glucose-tolbutamide test					
82955	A	Assay of g6pd enzyme					
82960	A	Test for G6PD enzyme					
82962	A	Glucose blood test					
82963	A	Assay of glucosidase					
82965	A	Assay of gdh enzyme					
82975	A	Assay of glutamine					
82977	A	Assay of GGT					
82978	A	Assay of glutathione					
82979	A	Assay, rbc glutathione					
82980	A	Assay of glutethimide					
82985	A	Glycated protein					
83001	A	Gonadotropin (FSH)					
83002	A	Gonadotropin (LH)					
83003	A	Assay, growth hormone (hgh)					
83008	A	Assay of guanosine					
83010	A	Assay of haptoglobin, quant					
83012	A	Assay of haptoglobins					
83013	A	H pylori analysis					
83014	A	H pylori drug admin/collect					
83015	A	Heavy metal screen					
83018	A	Quantitative screen, metals					
83020	A	Hemoglobin electrophoresis					
83021	A	Hemoglobin chromotography					
83026	A	Hemoglobin, copper sulfate					
83030	A	Fetal hemoglobin, chemical					
83033	A	Fetal hemoglobin assay, qual					
83036	A	Glycated hemoglobin test					
83045	A	Blood methemoglobin test					
83050	A	Blood methemoglobin assay					
83051	A	Assay of plasma hemoglobin					
83055	A	Blood sulfhemoglobin test					
83060	A	Blood sulfhemoglobin assay					
83065	A	Assay of hemoglobin heat					
83068	A	Hemoglobin stability screen					
83069	A	Assay of urine hemoglobin					
83070	A	Assay of hemosiderin, qual					
83071	A	Assay of hemosiderin, quant					
83080	A	Assay of b hexosaminidase					
83088	A	Assay of histamine					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
83090	A	Assay of homocystine					
83150	A	Assay of for hva					
83491	A	Assay of corticosteroids					
83497	A	Assay of 5-hiaa					
83498	A	Assay of progesterone					
83499	A	Assay of progesterone					
83500	A	Assay, free hydroxyproline					
83505	A	Assay, total hydroxyproline					
83516	A	Immunoassay, nonantibody					
83518	A	Immunoassay, dipstick					
83519	A	Immunoassay, nonantibody					
83520	A	Immunoassay, RIA					
83525	A	Assay of insulin					
83527	A	Assay of insulin					
83528	A	Assay of intrinsic factor					
83540	A	Assay of iron					
83550	A	Iron binding test					
83570	A	Assay of idh enzyme					
83582	A	Assay of ketogenic steroids					
83586	A	Assay 17- ketosteroids					
83593	A	Fractionation, ketosteroids					
83605	A	Assay of lactic acid					
83615	A	Lactate (LD) (LDH) enzyme					
83625	A	Assay of ldh enzymes					
83632	A	Placental lactogen					
83633	A	Test urine for lactose					
83634	A	Assay of urine for lactose					
83655	A	Assay of lead					
83661	A	L/s ratio, fetal lung					
83662	A	Foam stability, fetal lung					
83663	A	Fluoro polarize, fetal lung					
83664	A	Lamellar bdy, fetal lung					
83670	A	Assay of lap enzyme					
83690	A	Assay of lipase					
83715	A	Assay of blood lipoproteins					
83716	A	Assay of blood lipoproteins					
83718	A	Assay of lipoprotein					
83719	A	Assay of blood lipoprotein					
83721	A	Assay of blood lipoprotein					
83727	A	Assay of lrh hormone					
83735	A	Assay of magnesium					
83775	A	Assay of md enzyme					
83785	A	Assay of manganese					
83788	A	Mass spectrometry qual					
83789	A	Mass spectrometry quant					
83805	A	Assay of meprobamate					
83825	A	Assay of mercury					
83835	A	Assay of metanephrines					
83840	A	Assay of methadone					
83857	A	Assay of methemalbumin					
83858	A	Assay of methsuximide					
83864	A	Mucopolysaccharides					
83866	A	Mucopolysaccharides screen					
83872	A	Assay synovial fluid mucin					
83873	A	Assay of csf protein					
83874	A	Assay of myoglobin					
83883	A	Assay, nephelometry not spec					
83885	A	Assay of nickel					
83887	A	Assay of nicotine					
83890	A	Molecule isolate					
83891	A	Molecule isolate nucleic					
83892	A	Molecular diagnostics					
83893	A	Molecule dot/slot/blot					
83894	A	Molecule gel electrophor					
83896	A	Molecular diagnostics					
83897	A	Molecule nucleic transfer					
83898	A	Molecule nucleic ampli					
83901	A	Molecule nucleic ampli					
83902	A	Molecular diagnostics					
83903	A	Molecule mutation scan					
83904	A	Molecule mutation identify					
83905	A	Molecule mutation identify					
83906	A	Molecule mutation identify					
83912	A	Genetic examination					
83915	A	Assay of nucleotidase					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
83916	A	Oligoclonal bands					
83918	A	Organic acids, total, quant					
83919	A	Organic acids, qual, each					
83921	A	Organic acid, single, quant					
83925	A	Assay of opiates					
83930	A	Assay of blood osmolality					
83935	A	Assay of urine osmolality					
83937	A	Assay of osteocalcin					
83945	A	Assay of oxalate					
83970	A	Assay of parathormone					
83986	A	Assay of body fluid acidity					
83992	A	Assay for phencyclidine					
84022	A	Assay of phenothiazine					
84030	A	Assay of blood pku					
84035	A	Assay of phenylketones					
84060	A	Assay acid phosphatase					
84061	A	Phosphatase, forensic exam					
84066	A	Assay prostate phosphatase					
84075	A	Assay alkaline phosphatase					
84078	A	Assay alkaline phosphatase					
84080	A	Assay alkaline phosphatases					
84081	A	Amniotic fluid enzyme test					
84085	A	Assay of rbc pg6d enzyme					
84087	A	Assay phosphohexose enzymes					
84100	A	Assay of phosphorus					
84105	A	Assay of urine phosphorus					
84106	A	Test for porphobilinogen					
84110	A	Assay of porphobilinogen					
84119	A	Test urine for porphyrins					
84120	A	Assay of urine porphyrins					
84126	A	Assay of feces porphyrins					
84127	A	Assay of feces porphyrins					
84132	A	Assay of serum potassium					
84133	A	Assay of urine potassium					
84134	A	Assay of prealbumin					
84135	A	Assay of pregnanediol					
84138	A	Assay of pregnanetriol					
84140	A	Assay of pregnenolone					
84143	A	Assay of 17-hydroxypregneno					
84144	A	Assay of progesterone					
84146	A	Assay of prolactin					
84150	A	Assay of prostaglandin					
84152	A	Assay of psa, complexed					
84153	A	Assay of psa, total					
84154	A	Assay of psa, free					
84155	A	Assay of protein					
84160	A	Assay of serum protein					
84165	A	Assay of serum proteins					
84181	A	Western blot test					
84182	A	Protein, western blot test					
84202	A	Assay RBC protoporphyrin					
84203	A	Test RBC protoporphyrin					
84206	A	Assay of proinsulin					
84207	A	Assay of vitamin b-6					
84210	A	Assay of pyruvate					
84220	A	Assay of pyruvate kinase					
84228	A	Assay of quinine					
84233	A	Assay of estrogen					
84234	A	Assay of progesterone					
84235	A	Assay of endocrine hormone					
84238	A	Assay, nonendocrine receptor					
84244	A	Assay of renin					
84252	A	Assay of vitamin b-2					
84255	A	Assay of selenium					
84260	A	Assay of serotonin					
84270	A	Assay of sex hormone globul					
84275	A	Assay of sialic acid					
84285	A	Assay of silica					
84295	A	Assay of serum sodium					
84300	A	Assay of urine sodium					
84305	A	Assay of somatomedin					
84307	A	Assay of somatostatin					
84311	A	Spectrophotometry					
84315	A	Body fluid specific gravity					
84375	A	Chromatogram assay, sugars					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
84376	A	Sugars, single, qual					
84377	A	Sugars, multiple, qual					
84378	A	Sugars single quant					
84379	A	Sugars multiple quant					
84392	A	Assay of urine sulfate					
84402	A	Assay of testosterone					
84403	A	Assay of total testosterone					
84425	A	Assay of vitamin b-1					
84430	A	Assay of thiocyanate					
84432	A	Assay of thyroglobulin					
84436	A	Assay of total thyroxine					
84437	A	Assay of neonatal thyroxine					
84439	A	Assay of free thyroxine					
84442	A	Assay of thyroid activity					
84443	A	Assay thyroid stim hormone					
84445	A	Assay of tsi					
84446	A	Assay of vitamin e					
84449	A	Assay of transcortin					
84450	A	Transferase (AST) (SGOT)					
84460	A	Alanine amino (ALT) (SGPT)					
84466	A	Assay of transferrin					
84478	A	Assay of triglycerides					
84479	A	Assay of thyroid (t3 or t4)					
84480	A	Assay, triiodothyronine (t3)					
84481	A	Free assay (FT-3)					
84482	A	T3 reverse					
84484	A	Assay of troponin, quant					
84485	A	Assay duodenal fluid trypsin					
84488	A	Test feces for trypsin					
84490	A	Assay of feces for trypsin					
84510	A	Assay of tyrosine					
84512	X	Assay of troponin, qual	0349	0.34	$17.29	$3.46	$3.46
84520	A	Assay of urea nitrogen					
84525	A	Urea nitrogen semi-quant					
84540	A	Assay of urine/urea-n					
84545	A	Urea-N clearance test					
84550	A	Assay of blood/uric acid					
84560	A	Assay of urine/uric acid					
84577	A	Assay of feces/urobilinogen					
84578	A	Test urine urobilinogen					
84580	A	Assay of urine urobilinogen					
84583	A	Assay of urine urobilinogen					
84585	A	Assay of urine vma					
84586	A	Assay of vip					
84588	A	Assay of vasopressin					
84590	A	Assay of vitamin a					
84591	A	Assay of nos vitamin					
84597	A	Assay of vitamin k					
84600	A	Assay of volatiles					
84620	A	Xylose tolerance test					
84630	A	Assay of zinc					
84681	A	Assay of c-peptide					
84702	A	Chorionic gonadotropin test					
84703	A	Chorionic gonadotropin assay					
84830	A	Ovulation tests					
84999	X	Clinical chemistry test	0349	0.34	$17.29	$3.46	$3.46
85002	A	Bleeding time test					
85007	A	Differential WBC count					
85008	A	Nondifferential WBC count					
85009	A	Differential WBC count					
85013	A	Hematocrit					
85014	A	Hematocrit					
85018	A	Hemoglobin					
85021	A	Automated hemogram					
85022	A	Automated hemogram					
85023	A	Automated hemogram					
85024	A	Automated hemogram					
85025	A	Automated hemogram					
85027	A	Automated hemogram					
85031	A	Manual hemogram, cbc					
85041	A	Red blood cell (RBC) count					
85044	A	Reticulocyte count					
85045	A	Reticulocyte count					
85046	A	Reticyte/hgb concentrate					
85048	A	White blood cell (WBC) count					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
85060	X	Blood smear interpretation	0342	0.22	$11.19	$6.15	$2.24
85095	T	Bone marrow aspiration	0003	1.11	$56.43	$27.99	$11.29
85097	X	Bone marrow interpretation	0344	0.60	$30.51	$16.78	$6.10
85102	T	Bone marrow biopsy	0003	1.11	$56.43	$27.99	$11.29
85130	A	Chromogenic substrate assay					
85170	A	Blood clot retraction					
85175	A	Blood clot lysis time					
85210	A	Blood clot factor II test					
85220	A	Blood clot factor V test					
85230	A	Blood clot factor VII test					
85240	A	Blood clot factor VIII test					
85244	A	Blood clot factor VIII test					
85245	A	Blood clot factor VIII test					
85246	A	Blood clot factor VIII test					
85247	A	Blood clot factor VIII test					
85250	A	Blood clot factor IX test					
85260	A	Blood clot factor X test					
85270	A	Blood clot factor XI test					
85280	A	Blood clot factor XII test					
85290	A	Blood clot factor XIII test					
85291	A	Blood clot factor XIII test					
85292	A	Blood clot factor assay					
85293	A	Blood clot factor assay					
85300	A	Antithrombin III test					
85301	A	Antithrombin III test					
85302	A	Blood clot inhibitor antigen					
85303	A	Blood clot inhibitor test					
85305	A	Blood clot inhibitor assay					
85306	A	Blood clot inhibitor test					
85307	A	Assay activated protein c					
85335	A	Factor inhibitor test					
85337	A	Thrombomodulin					
85345	A	Coagulation time					
85347	A	Coagulation time					
85348	A	Coagulation time					
85360	A	Euglobulin lysis					
85362	A	Fibrin degradation products					
85366	A	Fibrinogen test					
85370	A	Fibrinogen test					
85378	A	Fibrin degradation					
85379	A	Fibrin degradation					
85384	A	Fibrinogen					
85385	A	Fibrinogen					
85390	A	Fibrinolysins screen					
85400	A	Fibrinolytic plasmin					
85410	A	Fibrinolytic antiplasmin					
85415	A	Fibrinolytic plasminogen					
85420	A	Fibrinolytic plasminogen					
85421	A	Fibrinolytic plasminogen					
85441	A	Heinz bodies, direct					
85445	A	Heinz bodies, induced					
85460	A	Hemoglobin, fetal					
85461	A	Hemoglobin, fetal					
85475	A	Hemolysin					
85520	A	Heparin assay					
85525	A	Heparin					
85530	A	Heparin-protamine tolerance					
85535	A	Iron stain, blood cells					
85536	A	Iron stain peripheral blood					
85540	A	Wbc alkaline phosphatase					
85547	A	RBC mechanical fragility					
85549	A	Muramidase					
85555	A	RBC osmotic fragility					
85557	A	RBC osmotic fragility					
85576	A	Blood platelet aggregation					
85585	A	Blood platelet estimation					
85590	A	Platelet count, manual					
85595	A	Platelet count, automated					
85597	A	Platelet neutralization					
85610	A	Prothrombin time					
85611	A	Prothrombin test					
85612	A	Viper venom prothrombin time					
85613	A	Russell viper venom, diluted					
85635	A	Reptilase test					
85651	A	Rbc sed rate, nonautomated					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
85652	A	Rbc sed rate, automated					
85660	A	RBC sickle cell test					
85670	A	Thrombin time, plasma					
85675	A	Thrombin time, titer					
85705	A	Thromboplastin inhibition					
85730	A	Thromboplastin time, partial					
85732	A	Thromboplastin time, partial					
85810	A	Blood viscosity examination					
85999	X	Hematology procedure	0349	0.34	$17.29	$3.46	$3.46
86000	A	Agglutinins, febrile					
86001	A	Allergen specific igg					
86003	A	Allergen specific IgE					
86005	A	Allergen specific IgE					
86021	A	WBC antibody identification					
86022	A	Platelet antibodies					
86023	A	Immunoglobulin assay					
86038	A	Antinuclear antibodies					
86039	A	Antinuclear antibodies (ANA)					
86060	A	Antistreptolysin o, titer					
86063	A	Antistreptolysin o, screen					
86077	X	Physician blood bank service	0343	0.42	$21.35	$11.53	$4.27
86078	X	Physician blood bank service	0344	0.60	$30.51	$16.78	$6.10
86079	X	Physician blood bank service	0344	0.60	$30.51	$16.78	$6.10
86140	A	C-reactive protein					
86146	A	Glycoprotein antibody					
86147	A	Cardiolipin antibody					
86148	X	Phospholipid antibody	0349	0.34	$17.29	$3.46	$3.46
86155	A	Chemotaxis assay					
86156	A	Cold agglutinin, screen					
86157	A	Cold agglutinin, titer					
86160	A	Complement, antigen					
86161	A	Complement/function activity					
86162	A	Complement, total (CH50)					
86171	A	Complement fixation, each					
86185	A	Counterimmunoelectrophoresis					
86215	A	Deoxyribonuclease, antibody					
86225	A	DNA antibody					
86226	A	DNA antibody, single strand					
86235	A	Nuclear antigen antibody					
86243	A	Fc receptor					
86255	A	Fluorescent antibody, screen					
86256	A	Fluorescent antibody, titer					
86277	A	Growth hormone antibody					
86280	A	Hemagglutination inhibition					
86294	A	Immunoassay, tumor qual					
86300	A	Immunoassay, tumor ca 15-3					
86301	A	Immunoassay, tumor, ca 19-9					
86304	A	Immunoassay, tumor ca 125					
86308	A	Heterophile antibodies					
86309	A	Heterophile antibodies					
86310	A	Heterophile antibodies					
86316	A	Immunoassay, tumor other					
86317	A	Immunoassay,infectious agent					
86318	A	Immunoassay,infectious agent					
86320	A	Serum immunoelectrophoresis					
86325	A	Other immunoelectrophoresis					
86327	A	Immunoelectrophoresis assay					
86329	A	Immunodiffusion					
86331	A	Immunodiffusion ouchterlony					
86332	A	Immune complex assay					
86334	A	Immunofixation procedure					
86337	A	Insulin antibodies					
86340	A	Intrinsic factor antibody					
86341	A	Islet cell antibody					
86343	A	Leukocyte histamine release					
86344	A	Leukocyte phagocytosis					
86353	A	Lymphocyte transformation					
86359	A	T cells, total count					
86360	A	T cell, absolute count/ratio					
86361	X	T cell, absolute count	0349	0.34	$17.29	$3.46	$3.46
86376	A	Microsomal antibody					
86378	A	Migration inhibitory factor					
86382	A	Neutralization test, viral					
86384	A	Nitroblue tetrazolium dye					
86403	A	Particle agglutination test					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
86406	A	Particle agglutination test					
86430	A	Rheumatoid factor test					
86431	A	Rheumatoid factor, quant					
86485	X	Skin test, candida	0341	0.11	$5.59	$3.08	$1.12
86490	X	Coccidioidomycosis skin test	0341	0.11	$5.59	$3.08	$1.12
86510	X	Histoplasmosis skin test	0341	0.11	$5.59	$3.08	$1.12
86580	X	TB intradermal test	0341	0.11	$5.59	$3.08	$1.12
86585	X	TB tine test	0341	0.11	$5.59	$3.08	$1.12
86586	X	Skin test, unlisted	0341	0.11	$5.59	$3.08	$1.12
86590	A	Streptokinase, antibody					
86592	A	Blood serology, qualitative					
86593	A	Blood serology, quantitative					
86602	A	Antinomyces antibody					
86603	A	Adenovirus antibody					
86606	A	Aspergillus antibody					
86609	A	Bacterium antibody					
86611	A	Bartonella antibody					
86612	A	Blastomyces antibody					
86615	A	Bordetella antibody					
86617	A	Lyme disease antibody					
86618	A	Lyme disease antibody					
86619	A	Borrelia antibody					
86622	A	Brucella antibody					
86625	A	Campylobacter antibody					
86628	A	Candida antibody					
86631	A	Chlamydia antibody					
86632	A	Chlamydia igm antibody					
86635	A	Coccidioides antibody					
86638	A	Q fever antibody					
86641	A	Cryptococcus antibody					
86644	A	CMV antibody					
86645	A	CMV antibody, IgM					
86648	A	Diphtheria antibody					
86651	A	Encephalitis antibody					
86652	A	Encephalitis antibody					
86653	A	Encephalitis antibody					
86654	A	Encephalitis antibody					
86658	A	Enterovirus antibody					
86663	A	Epstein-barr antibody					
86664	A	Epstein-barr antibody					
86665	A	Epstein-barr antibody					
86666	A	Ehrlichia antibody					
86668	A	Francisella tularensis					
86671	A	Fungus antibody					
86674	A	Giardia lamblia antibody					
86677	A	Helicobacter pylori					
86682	A	Helminth antibody					
86683	A	Hemoglobin, fecal antibody					
86684	A	Hemophilus influenza					
86687	A	Htlv-i antibody					
86688	A	Htlv-ii antibody					
86689	A	HTLV/HIV confirmatory test					
86692	A	Hepatitis, delta agent					
86694	A	Herpes simplex test					
86695	A	Herpes simplex test					
86696	A	Herpes simplex type 2					
86698	A	Histoplasma					
86701	A	HIV-1					
86702	A	HIV-2					
86703	A	HIV-1/HIV-2, single assay					
86704	A	Hep b core antibody, total					
86705	A	Hep b core antibody, igm					
86706	A	Hep b surface antibody					
86707	A	Hep be antibody					
86708	A	Hep a antibody, total					
86709	A	Hep a antibody, igm					
86710	A	Influenza virus antibody					
86713	A	Legionella antibody					
86717	A	Leishmania antibody					
86720	A	Leptospira antibody					
86723	A	Listeria monocytogenes ab					
86727	A	Lymph choriomeningitis ab					
86729	A	Lympho venereum antibody					
86732	A	Mucormycosis antibody					
86735	A	Mumps antibody					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
86738	A	Mycoplasma antibody					
86741	A	Neisseria meningitidis					
86744	A	Nocardia antibody					
86747	A	Parvovirus antibody					
86750	A	Malaria antibody					
86753	A	Protozoa antibody nos					
86756	A	Respiratory virus antibody					
86757	A	Rickettsia antibody					
86759	A	Rotavirus antibody					
86762	A	Rubella antibody					
86765	A	Rubeola antibody					
86768	A	Salmonella antibody					
86771	A	Shigella antibody					
86774	A	Tetanus antibody					
86777	A	Toxoplasma antibody					
86778	A	Toxoplasma antibody, igm					
86781	A	Treponema pallidum, confirm					
86784	A	Trichinella antibody					
86787	A	Varicella-zoster antibody					
86790	A	Virus antibody nos					
86793	A	Yersinia antibody					
86800	A	Thyroglobulin antibody					
86803	A	Hepatitis c ab test					
86804	A	Hep c ab test, confirm					
86805	A	Lymphocytotoxicity assay					
86806	A	Lymphocytotoxicity assay					
86807	A	Cytotoxic antibody screening					
86808	A	Cytotoxic antibody screening					
86812	A	HLA typing, A, B, or C					
86813	A	HLA typing, A, B, or C					
86816	A	HLA typing, DR/DQ					
86817	A	HLA typing, DR/DQ					
86821	A	Lymphocyte culture, mixed					
86822	A	Lymphocyte culture, primed					
86849	X	Immunology procedure	0349	0.34	$17.29	$3.46	$3.46
86850	X	RBC antibody screen	0345	0.29	$14.74	$5.37	$2.95
86860	X	RBC antibody elution	0345	0.29	$14.74	$5.37	$2.95
86870	X	RBC antibody identification	0346	0.83	$42.20	$12.03	$8.44
86880	A	Coombs test					
86885	A	Coombs test					
86886	A	Coombs test					
86890	X	Autologous blood process	0346	0.83	$42.20	$12.03	$8.44
86891	X	Autologous blood, op salvage	0345	0.29	$14.74	$5.37	$2.95
86900	A	Blood typing, ABO					
86901	X	Blood typing, Rh (D)	0345	0.29	$14.74	$5.37	$2.95
86903	A	Blood typing, antigen screen					
86904	A	Blood typing, patient serum					
86905	A	Blood typing, RBC antigens					
86906	A	Blood typing, Rh phenotype					
86910	E	Blood typing, paternity test					
86911	E	Blood typing, antigen system					
86915	X	Bone marrow/stem cell prep	0346	0.83	$42.20	$12.03	$8.44
86920	X	Compatibility test	0346	0.83	$42.20	$12.03	$8.44
86921	X	Compatibility test	0345	0.29	$14.74	$5.37	$2.95
86922	X	Compatibility test	0346	0.83	$42.20	$12.03	$8.44
86927	X	Plasma, fresh frozen	0346	0.83	$42.20	$12.03	$8.44
86930	X	Frozen blood prep	0347	1.73	$87.96	$20.13	$17.59
86931	X	Frozen blood thaw	0347	1.73	$87.96	$20.13	$17.59
86932	X	Frozen blood freeze/thaw	0346	0.83	$42.20	$12.03	$8.44
86940	A	Hemolysins/agglutinins, auto					
86941	A	Hemolysins/agglutinins					
86945	X	Blood product/irradiation	0345	0.29	$14.74	$5.37	$2.95
86950	X	Leukacyte transfusion	0347	1.73	$87.96	$20.13	$17.59
86965	X	Pooling blood platelets	0347	1.73	$87.96	$20.13	$17.59
86970	X	RBC pretreatment	0345	0.29	$14.74	$5.37	$2.95
86971	X	RBC pretreatment	0345	0.29	$14.74	$5.37	$2.95
86972	X	RBC pretreatment	0345	0.29	$14.74	$5.37	$2.95
86975	X	RBC pretreatment, serum	0345	0.29	$14.74	$5.37	$2.95
86976	X	RBC pretreatment, serum	0345	0.29	$14.74	$5.37	$2.95
86977	X	RBC pretreatment, serum	0345	0.29	$14.74	$5.37	$2.95
86978	X	RBC pretreatment, serum	0345	0.29	$14.74	$5.37	$2.95
86985	X	Split blood or products	0347	1.73	$87.96	$20.13	$17.59
86999	X	Transfusion procedure	0346	0.83	$42.20	$12.03	$8.44
87001	A	Small animal inoculation					
87003	A	Small animal inoculation					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
87015	A	Specimen concentration					
87040	A	Blood culture for bacteria					
87045	A	Stool culture, bacteria					
87046	A	Stool cultr, bacteria, each					
87070	A	Culture, bacteria, other					
87071	A	Culture bacteri aerobic othr					
87073	A	Culture bacteria anaerobic					
87075	A	Culture bacteria anaerobic					
87076	A	Culture anaerobe ident, each					
87077	A	Culture aerobic identify					
87081	A	Culture screen only					
87084	A	Culture of specimen by kit					
87086	A	Urine culture/colony count					
87088	A	Urine bacteria culture					
87101	A	Skin fungi culture					
87102	A	Fungus isolation culture					
87103	A	Blood fungus culture					
87106	A	Fungi identification, yeast					
87107	A	Fungi identification, mold					
87109	A	Mycoplasma					
87110	A	Chlamydia culture					
87116	A	Mycobacteria culture					
87118	A	Mycobacteric identification					
87140	A	Cultur type immunofluoresc					
87143	A	Culture typing, glc/hplc					
87147	A	Culture type, immunologic					
87149	A	Culture type, nucleic acid					
87152	A	Culture type pulse field gel					
87158	A	Culture typing, added method					
87164	A	Dark field examination					
87166	A	Dark field examination					
87168	A	Macroscopic exam arthropod					
87169	A	Macacroscopic exam parasite					
87172	A	Pinworm exam					
87176	A	Tissue homogenization, cultr					
87177	A	Ova and parasites smears					
87181	A	Microbe susceptible, diffuse					
87184	A	Microbe susceptible, disk					
87185	A	Microbe susceptible, enzyme					
87186	A	Microbe susceptible, mic					
87187	A	Microbe susceptible, mlc					
87188	A	Microbe suscept, macrobroth					
87190	A	Microbe suscept, mycobacteri					
87197	A	Bactericidal level, serum					
87205	A	Smear, gram stain					
87206	A	Smear, fluorescent/acid stai					
87207	A	Smear, special stain					
87210	A	Smear, wet mount, saline/ink					
87220	A	Tissue exam for fungi					
87230	A	Assay, toxin or antitoxin					
87250	A	Virus inoculate, eggs/animal					
87252	A	Virus inoculation, tissue					
87253	A	Virus inoculate tissue, addl					
87254	A	Virus inoculation, shell via					
87260	A	Adenovirus ag, if					
87265	A	Pertussis ag, if					
87270	A	Chlamydia trachomatis ag, if					
87272	A	Cryptosporidum/gardia ag, if					
87273	A	Herpes simplex 2, ag, if					
87274	A	Herpes simplex 1, ag, if					
87275	A	Influenza b, ag, if					
87276	A	Influenza a, ag, if					
87277	A	Legionella micdadei, ag, if					
87278	A	Legion pneumophilia ag, if					
87279	A	Parainfluenza, ag, if					
87280	A	Respiratory syncytial ag, if					
87281	A	Pneumocystis carinii, ag, if					
87283	A	Rubeola, ag, if					
87285	A	Treponema pallidum, ag, if					
87290	A	Varicella zoster, ag, if					
87299	A	Antibody detection, nos, if					
87300	A	Ag detection, polyval, if					
87301	A	Adenovirus ag, eia					
87320	A	Chylmd trach ag, eia					
87324	A	Clostridium ag, eia					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
87327	A	Cryptococcus neoform ag, eia					
87328	A	Cryptospor ag, eia					
87332	A	Cytomegalovirus ag, eia					
87335	A	E coli 0157 ag, eia					
87336	A	Entamoeb hist dispr, ag, eia					
87337	A	Entamoeb hist group, ag, eia					
87338	A	Hpylori, stool, eia					
87339	A	Hpylori ag, eia					
87340	A	Hepatitis b surface ag, eia					
87341	A	Hepatitis b surface, ag, eia					
87350	A	Hepatitis be ag, eia					
87380	A	Hepatitis delta ag, eia					
87385	A	Histoplasma capsul ag, eia					
87390	A	Hiv-1 ag, eia					
87391	A	Hiv-2 ag, eia					
87400	A	Influenza a/b, ag, eia					
87420	A	Resp syncytial ag, eia					
87425	A	Rotavirus ag, eia					
87427	A	Shiga-like toxin ag, eia					
87430	A	Strep a ag, eia					
87449	A	Ag detect nos, eia, mult					
87450	A	Ag detect nos, eia, single					
87451	A	Ag detect polyval, eia, mult					
87470	A	Bartonella, dna, dir probe					
87471	A	Bartonella, dna, amp probe					
87472	X	Bartonella, dna, quant	0349	0.34	$17.29	$3.46	$3.46
87475	A	Lyme dis, dna, dir probe					
87476	A	Lyme dis, dna, amp probe					
87477	X	Lyme dis, dna, quant	0349	0.34	$17.29	$3.46	$3.46
87480	A	Candida, dna, dir probe					
87481	A	Candida, dna, amp probe					
87482	X	Candida, dna, quant	0349	0.34	$17.29	$3.46	$3.46
87485	A	Chylmd pneum, dna, dir probe					
87486	A	Chylmd pneum, dna, amp probe					
87487	X	Chylmd pneum, dna, quant	0349	0.34	$17.29	$3.46	$3.46
87490	A	Chylmd trach, dna, dir probe					
87491	A	Chylmd trach, dna, amp probe					
87492	X	Chylmd trach, dna, quant	0349	0.34	$17.29	$3.46	$3.46
87495	A	Cytomeg, dna, dir probe					
87496	A	Cytomeg, dna, amp probe					
87497	X	Cytomeg, dna, quant	0349	0.34	$17.29	$3.46	$3.46
87510	A	Gardner vag, dna, dir probe					
87511	A	Gardner vag, dna, amp probe					
87512	X	Gardner vag, dna, quant	0349	0.34	$17.29	$3.46	$3.46
87515	A	Hepatitis b, dna, dir probe					
87516	A	Hepatitis b , dna, amp probe					
87517	X	Hepatitis b , dna, quant	0349	0.34	$17.29	$3.46	$3.46
87520	A	Hepatitis c , rna, dir probe					
87521	A	Hepatitis c , rna, amp probe					
87522	X	Hepatitis c, rna, quant	0349	0.34	$17.29	$3.46	$3.46
87525	A	Hepatitis g , dna, dir probe					
87526	A	Hepatitis g, dna, amp probe					
87527	X	Hepatitis g, dna, quant	0349	0.34	$17.29	$3.46	$3.46
87528	A	Hsv, dna, dir probe					
87529	A	Hsv, dna, amp probe					
87530	X	Hsv, dna, quant	0349	0.34	$17.29	$3.46	$3.46
87531	A	Hhv-6, dna, dir probe					
87532	A	Hhv-6, dna, amp probe					
87533	X	Hhv-6, dna, quant	0349	0.34	$17.29	$3.46	$3.46
87534	A	Hiv-1, dna, dir probe					
87535	A	Hiv-1, dna, amp probe					
87536	X	Hiv-1, dna, quant	0349	0.34	$17.29	$3.46	$3.46
87537	A	Hiv-2, dna, dir probe					
87538	A	Hiv-2, dna, amp probe					
87539	X	Hiv-2, dna, quant	0349	0.34	$17.29	$3.46	$3.46
87540	A	Legion pneumo, dna, dir prob					
87541	A	Legion pneumo, dna, amp prob					
87542	X	Legion pneumo, dna, quant	0349	0.34	$17.29	$3.46	$3.46
87550	A	Mycobacteria, dna, dir probe					
87551	A	Mycobacteria, dna, amp probe					
87552	X	Mycobacteria, dna, quant	0349	0.34	$17.29	$3.46	$3.46
87555	A	M.tuberculo, dna, dir probe					
87556	A	M.tuberculo, dna, amp probe					
87557	X	M.tuberculo, dna, quant	0349	0.34	$17.29	$3.46	$3.46
87560	A	M.avium-intra, dna, dir prob					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
87561	A	M.avium-intra, dna, amp prob					
87562	X	M.avium-intra, dna, quant	0349	0.34	$17.29	$3.46	$3.46
87580	A	M.pneumon, dna, dir probe					
87581	A	M.pneumon, dna, amp probe					
87582	X	M.pneumon, dna, quant	0349	0.34	$17.29	$3.46	$3.46
87590	A	N.gonorrhoeae, dna, dir prob					
87591	A	N.gonorrhoeae, dna, amp prob					
87592	X	N.gonorrhoeae, dna, quant	0349	0.34	$17.29	$3.46	$3.46
87620	A	Hpv, dna, dir probe					
87621	A	Hpv, dna, amp probe					
87622	X	Hpv, dna, quant	0349	0.34	$17.29	$3.46	$3.46
87650	A	Strep a, dna, dir probe					
87651	A	Strep a, dna, amp probe					
87652	X	Strep a, dna, quant	0349	0.34	$17.29	$3.46	$3.46
87797	A	Detect agent nos, dna, dir					
87798	A	Detect agent nos, dna, amp					
87799	X	Detect agent nos, dna, quant	0349	0.34	$17.29	$3.46	$3.46
87800	A	Detect agnt mult, dna, direc					
87801	A	Detect agnt mult, dna, ampli					
87810	A	Chylmd trach assay w/optic					
87850	A	N. gonorrhoeae assay w/optic					
87880	A	Strep a assay w/optic					
87899	A	Agent nos assay w/optic					
87901	A	Genotype, dna, hiv reverse t					
87903	A	Phenotype, dna hiv w/culture					
87904	A	Phenotype, dna hiv w/clt add					
87999	X	Microbiology procedure	0349	0.34	$17.29	$3.46	$3.46
88000	E	Autopsy (necropsy), gross					
88005	E	Autopsy (necropsy), gross					
88007	E	Autopsy (necropsy), gross					
88012	E	Autopsy (necropsy), gross					
88014	E	Autopsy (necropsy), gross					
88016	E	Autopsy (necropsy), gross					
88020	E	Autopsy (necropsy), complete					
88025	E	Autopsy (necropsy), complete					
88027	E	Autopsy (necropsy), complete					
88028	E	Autopsy (necropsy), complete					
88029	E	Autopsy (necropsy), complete					
88036	E	Limited autopsy					
88037	E	Limited autopsy					
88040	E	Forensic autopsy (necropsy)					
88045	E	Coroner's autopsy (necropsy)					
88099	E	Necropsy (autopsy) procedure					
88104	X	Cytopathology, fluids	0343	0.42	$21.35	$11.53	$4.27
88106	X	Cytopathology, fluids	0343	0.42	$21.35	$11.53	$4.27
88107	X	Cytopathology, fluids	0343	0.42	$21.35	$11.53	$4.27
88108	X	Cytopath, concentrate tech	0343	0.42	$21.35	$11.53	$4.27
88125	X	Forensic cytopathology	0343	0.42	$21.35	$11.53	$4.27
88130	A	Sex chromatin identification					
88140	A	Sex chromatin identification					
88141	N	Cytopath, c/v, interpret					
88142	X	Cytopath, c/v, thin layer	0349	0.34	$17.29	$3.46	$3.46
88143	A	Cytopath c/v thin layer redo					
88144	A	Cytopath, c/v thin lyr redo					
88145	A	Cytopath, c/v thin lyr sel					
88147	A	Cytopath, c/v, automated					
88148	A	Cytopath, c/v, auto rescreen					
88150	A	Cytopath, c/v, manual					
88152	A	Cytopath, c/v, auto redo					
88153	A	Cytopath, c/v, redo					
88154	A	Cytopath, c/v, select					
88155	A	Cytopath, c/v, index add-on					
88160	X	Cytopath smear, other source	0342	0.22	$11.19	$6.15	$2.24
88161	X	Cytopath smear, other source	0343	0.42	$21.35	$11.53	$4.27
88162	X	Cytopath smear, other source	0343	0.42	$21.35	$11.53	$4.27
88164	A	Cytopath tbs, c/v, manual					
88165	A	Cytopath tbs, c/v, redo					
88166	A	Cytopath tbs, c/v, auto redo					
88167	A	Cytopath tbs, c/v, select					
88170	T	Fine needle aspiration	0002	0.47	$23.90	$13.14	$4.78
88171	T	Fine needle aspiration	0004	3.00	$152.53	$32.57	$30.51
88172	X	Cytopathology eval of fna	0343	0.42	$21.35	$11.53	$4.27
88173	X	Cytopath eval, fna, report	0343	0.42	$21.35	$11.53	$4.27
88180	X	Cell marker study	0344	0.60	$30.51	$16.78	$6.10
88182	X	Cell marker study	0344	0.60	$30.51	$16.78	$6.10

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
88199	X	Cytopathology procedure	0349	0.34	$17.29	$3.46	$3.46
88230	A	Tissue culture, lymphocyte					
88233	A	Tissue culture, skin/biopsy					
88235	A	Tissue culture, placenta					
88237	A	Tissue culture, bone marrow					
88239	A	Tissue culture, tumor					
88240	A	Cell cryopreserve/storage					
88241	A	Frozen cell preparation					
88245	A	Chromosome analysis, 20-25					
88248	A	Chromosome analysis, 50-100					
88249	A	Chromosome analysis, 100					
88261	A	Chromosome analysis, 5					
88262	A	Chromosome analysis, 15-20					
88263	A	Chromosome analysis, 45					
88264	A	Chromosome analysis, 20-25					
88267	A	Chromosome analys, placenta					
88269	A	Chromosome analys, amniotic					
88271	A	Cytogenetics, dna probe					
88272	A	Cytogenetics, 3-5					
88273	A	Cytogenetics, 10-30					
88274	A	Cytogenetics, 25-99					
88275	A	Cytogenetics, 100-300					
88280	A	Chromosome karyotype study					
88283	A	Chromosome banding study					
88285	A	Chromosome count, additional					
88289	A	Chromosome study, additional					
88291	A	Cyto/molecular report					
88299	X	Cytogenetic study	0342	0.22	$11.19	$6.15	$2.24
88300	X	Surgical path, gross	0342	0.22	$11.19	$6.15	$2.24
88302	X	Tissue exam by pathologist	0342	0.22	$11.19	$6.15	$2.24
88304	X	Tissue exam by pathologist	0343	0.42	$21.35	$11.53	$4.27
88305	X	Tissue exam by pathologist	0343	0.42	$21.35	$11.53	$4.27
88307	X	Tissue exam by pathologist	0344	0.60	$30.51	$16.78	$6.10
88309	X	Tissue exam by pathologist	0344	0.60	$30.51	$16.78	$6.10
88311	X	Decalcify tissue	0342	0.22	$11.19	$6.15	$2.24
88312	X	Special stains	0343	0.42	$21.35	$11.53	$4.27
88313	X	Special stains	0342	0.22	$11.19	$6.15	$2.24
88314	X	Histochemical stain	0343	0.42	$21.35	$11.53	$4.27
88318	X	Chemical histochemistry	0343	0.42	$21.35	$11.53	$4.27
88319	X	Enzyme histochemistry	0342	0.22	$11.19	$6.15	$2.24
88321	X	Microslide consultation	0342	0.22	$11.19	$6.15	$2.24
88323	X	Microslide consultation	0343	0.42	$21.35	$11.53	$4.27
88325	X	Comprehensive review of data	0343	0.42	$21.35	$11.53	$4.27
88329	X	Path consult introp	0343	0.42	$21.35	$11.53	$4.27
88331	X	Path consult intraop, 1 bloc	0343	0.42	$21.35	$11.53	$4.27
88332	X	Path consult intraop, addl	0343	0.42	$21.35	$11.53	$4.27
88342	X	Immunocytochemistry	0344	0.60	$30.51	$16.78	$6.10
88346	X	Immunofluorescent study	0343	0.42	$21.35	$11.53	$4.27
88347	X	Immunofluorescent study	0344	0.60	$30.51	$16.78	$6.10
88348	X	Electron microscopy	0344	0.60	$30.51	$16.78	$6.10
88349	X	Scanning electron microscopy	0344	0.60	$30.51	$16.78	$6.10
88355	X	Analysis, skeletal muscle	0344	0.60	$30.51	$16.78	$6.10
88356	X	Analysis, nerve	0344	0.60	$30.51	$16.78	$6.10
88358	X	Analysis, tumor	0344	0.60	$30.51	$16.78	$6.10
88362	X	Nerve teasing preparations	0343	0.42	$21.35	$11.53	$4.27
88365	X	Tissue hybridization	0344	0.60	$30.51	$16.78	$6.10
88371	A	Protein, western blot tissue					
88372	A	Protein analysis w/probe					
88399	X	Surgical pathology procedure	0349	0.34	$17.29	$3.46	$3.46
88400	A	Bilirubin total transcut					
89050	A	Body fluid cell count					
89051	A	Body fluid cell count					
89060	A	Exam,synovial fluid crystals					
89100	X	Sample intestinal contents	0361	3.52	$178.96	$88.09	$35.79
89105	X	Sample intestinal contents	0360	1.40	$71.18	$34.75	$14.24
89125	A	Specimen fat stain					
89130	X	Sample stomach contents	0360	1.40	$71.18	$34.75	$14.24
89132	X	Sample stomach contents	0360	1.40	$71.18	$34.75	$14.24
89135	X	Sample stomach contents	0360	1.40	$71.18	$34.75	$14.24
89136	X	Sample stomach contents	0360	1.40	$71.18	$34.75	$14.24
89140	X	Sample stomach contents	0360	1.40	$71.18	$34.75	$14.24
89141	X	Sample stomach contents	0360	1.40	$71.18	$34.75	$14.24
89160	A	Exam feces for meat fibers					
89190	A	Nasal smear for eosinophils					
89250	X	Fertilization of oocyte	0348	0.85	$43.22	$8.64	$8.64

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
89251	X	Culture oocyte w/embryos	0348	0.85	$43.22	$8.64	$8.64
89252	X	Assist oocyte fertilization	0348	0.85	$43.22	$8.64	$8.64
89253	X	Embryo hatching	0348	0.85	$43.22	$8.64	$8.64
89254	X	Oocyte identification	0348	0.85	$43.22	$8.64	$8.64
89255	X	Prepare embryo for transfer	0348	0.85	$43.22	$8.64	$8.64
89256	X	Prepare cryopreserved embryo	0348	0.85	$43.22	$8.64	$8.64
89257	X	Sperm identification	0348	0.85	$43.22	$8.64	$8.64
89258	X	Cryopreservation, embryo	0348	0.85	$43.22	$8.64	$8.64
89259	X	Cryopreservation, sperm	0348	0.85	$43.22	$8.64	$8.64
89260	X	Sperm isolation, simple	0348	0.85	$43.22	$8.64	$8.64
89261	X	Sperm isolation, complex	0348	0.85	$43.22	$8.64	$8.64
89264	X	Identify sperm tissue	0348	0.85	$43.22	$8.64	$8.64
89300	A	Semen analysis					
89310	A	Semen analysis					
89320	A	Semen analysis					
89321	A	Semen analysis					
89325	A	Sperm antibody test					
89329	A	Sperm evaluation test					
89330	A	Evaluation, cervical mucus					
89350	X	Sputum specimen collection	0344	0.60	$30.51	$16.78	$6.10
89355	A	Exam feces for starch					
89360	X	Collect sweat for test	0344	0.60	$30.51	$16.78	$6.10
89365	A	Water load test					
89399	X	Pathology lab procedure	0349	0.34	$17.29	$3.46	$3.46
90281	E	Human ig, im					
90283	E	Human ig, iv					
90287	E	Botulinum antitoxin					
90288	E	Botulism ig, iv					
90291	E	Cmv ig, iv					
90296	K	Diphtheria antitoxin	0356	1.20	$61.01		$12.20
90371	K	Hep b ig, im	0356	1.20	$61.01		$12.20
90375	K	Rabies ig, im/sc	0356	1.20	$61.01		$12.20
90376	K	Rabies ig, heat treated	0356	1.20	$61.01		$12.20
90378	K	Rsv ig, im, 50mg	0356	1.20	$61.01		$12.20
90379	K	Rsv ig, iv	0356	1.20	$61.01		$12.20
90384	E	Rh ig, full-dose, im					
90385	K	Rh ig, minidose, im	0356	1.20	$61.01		$12.20
90386	E	Rh ig, iv					
90389	K	Tetanus ig, im	0356	1.20	$61.01		$12.20
90393	K	Vaccina ig, im	0356	1.20	$61.01		$12.20
90396	K	Varicella-zoster ig, im	0356	1.20	$61.01		$12.20
90399	E	Immune globulin					
90471	N	Immunization admin					
90472	N	Immunization admin, each add					
90476	K	Adenovirus vaccine, type 4	0356	1.20	$61.01		$12.20
90477	K	Adenovirus vaccine, type 7	0356	1.20	$61.01		$12.20
90581	K	Anthrax vaccine, sc	0356	1.20	$61.01		$12.20
90585	K	Bcg vaccine, percut	0356	1.20	$61.01		$12.20
90586	K	Bcg vaccine, intravesical	0356	1.20	$61.01		$12.20
90632	K	Hep a vaccine, adult im	0356	1.20	$61.01		$12.20
90633	K	Hep a vacc, ped/adol, 2 dose	0356	1.20	$61.01		$12.20
90634	K	Hep a vacc, ped/adol, 3 dose	0356	1.20	$61.01		$12.20
90636	K	Hep a/hep b vacc, adult im	0355	0.20	$10.17		$2.03
90645	K	Hib vaccine, hboc, im	0355	0.20	$10.17		$2.03
90646	K	Hib vaccine, prp-d, im	0355	0.20	$10.17		$2.03
90647	K	Hib vaccine, prp-omp, im	0355	0.20	$10.17		$2.03
90648	K	Hib vaccine, prp-t, im	0355	0.20	$10.17		$2.03
90657	K	Flu vaccine, 6-35 mo, im	0354	0.11	$5.59		
90658	K	Flu vaccine, 3 yrs, im	0354	0.11	$5.59		
90659	K	Flu vaccine, whole, im	0354	0.11	$5.59		
90660	E	Flu vaccine, nasal					
90665	K	Lyme disease vaccine, im	0356	1.20	$61.01		$12.20
90669	E	Pneumococcal vacc, ped<5					
90675	K	Rabies vaccine, im	0356	1.20	$61.01		$12.20
90676	K	Rabies vaccine, id	0356	1.20	$61.01		$12.20
90680	K	Rotovirus vaccine, oral	0356	1.20	$61.01		$12.20
90690	K	Typhoid vaccine, oral	0356	1.20	$61.01		$12.20
90691	K	Typhoid vaccine, im	0356	1.20	$61.01		$12.20
90692	K	Typhoid vaccine, h-p, sc/id	0355	0.20	$10.17		$2.03
90693	K	Typhoid vaccine, akd, sc	0356	1.20	$61.01		$12.20
90700	K	Dtap vaccine, im	0355	0.20	$10.17		$2.03
90701	K	Dtp vaccine, im	0355	0.20	$10.17		$2.03
90702	K	Dt vaccine < 7, im	0355	0.20	$10.17		$2.03
90703	K	Tetanus vaccine, im	0355	0.20	$10.17		$2.03
90704	K	Mumps vaccine, sc	0355	0.20	$10.17		$2.03

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
90705	K	Measles vaccine, sc	0356	1.20	$61.01	.....	$12.20
90706	K	Rubella vaccine, sc	0355	0.20	$10.17	.....	$2.03
90707	K	Mmr vaccine, sc	0356	1.20	$61.01	.....	$12.20
90708	K	Measles-rubella vaccine, sc	0356	1.20	$61.01	.....	$12.20
90709	K	Rubella & mumps vaccine, sc	0356	1.20	$61.01	.....	$12.20
90710	K	Mmrv vaccine, sc	0356	1.20	$61.01	.....	$12.20
90712	K	Oral poliovirus vaccine	0355	0.20	$10.17	.....	$2.03
90713	K	Poliovirus, ipv, sc	0355	0.20	$10.17	.....	$2.03
90716	K	Chicken pox vaccine, sc	0355	0.20	$10.17	.....	$2.03
90717	K	Yellow fever vaccine, sc	0356	1.20	$61.01	.....	$12.20
90718	K	Td vaccine > 7, im	0355	0.20	$10.17	.....	$2.03
90719	K	Diphtheria vaccine, im	0356	1.20	$61.01	.....	$12.20
90720	K	Dtp/hib vaccine, im	0355	0.20	$10.17	.....	$2.03
90721	K	Dtap/hib vaccine, im	0355	0.20	$10.17	.....	$2.03
90723	K	Dtap-hep b-ipv vaccine, im	0356	1.20	$61.01	.....	$12.20
90725	K	Cholera vaccine, injectable	0355	0.20	$10.17	.....	$2.03
90727	K	Plague vaccine, im	0355	0.20	$10.17	.....	$2.03
90732	K	Pneumococcal vacc, adult/ill	0354	0.11	$5.59	.....	.....
90733	K	Meningococcal vaccine, sc	0356	1.20	$61.01	.....	$12.20
90735	K	Encephalitis vaccine, sc	0356	1.20	$61.01	.....	$12.20
90740	K	Hepb vacc, ill pat 3 dose im	0356	1.20	$61.01	.....	$12.20
90743	K	Hep b vacc, adol, 2 dose, im	0356	1.20	$61.01	.....	$12.20
90744	K	Hepb vacc ped/adol 3 dose im	0356	1.20	$61.01	.....	$12.20
90746	K	Hep b vaccine, adult, im	0356	1.20	$61.01	.....	$12.20
90747	K	Hepb vacc, ill pat 4 dose im	0356	1.20	$61.01	.....	$12.20
90748	K	Hep b/hib vaccine, im	0355	0.20	$10.17	.....	$2.03
90749	K	Vaccine toxoid	0355	0.20	$10.17	.....	$2.03
90780	E	IV infusion therapy, 1 hour	.....	.....	.....	.....	.....
90781	E	IV infusion, additional hour	.....	.....	.....	.....	.....
90782	X	Injection, sc/im	0352	0.45	$22.88	$4.58	$4.58
90783	X	Injection, ia	0359	1.91	$97.11	$19.42	$19.42
90784	X	Injection, iv	0359	1.91	$97.11	$19.42	$19.42
90788	X	Injection of antibiotic	0359	1.91	$97.11	$19.42	$19.42
90799	X	Ther/prophylactic/dx inject	0352	0.45	$22.88	$4.58	$4.58
90801	S	Psy dx interview	0323	1.89	$96.09	$22.48	$19.22
90802	S	Intac psy dx interview	0323	1.89	$96.09	$22.48	$19.22
90804	S	Psytx, office, 20-30 min	0322	1.25	$63.55	$13.35	$12.71
90805	S	Psytx, off, 20-30 min w/e&m	0322	1.25	$63.55	$13.35	$12.71
90806	S	Psytx, off, 45-50 min	0323	1.89	$96.09	$22.48	$19.22
90807	S	Psytx, off, 45-50 min w/e&m	0323	1.89	$96.09	$22.48	$19.22
90808	S	Psytx, office, 75-80 min	0323	1.89	$96.09	$22.48	$19.22
90809	S	Psytx, off, 75-80, w/e&m	0323	1.89	$96.09	$22.48	$19.22
90810	S	Intac psytx, off, 20-30 min	0322	1.25	$63.55	$13.35	$12.71
90811	S	Intac psytx, 20-30, w/e&m	0322	1.25	$63.55	$13.35	$12.71
90812	S	Intac psytx, off, 45-50 min	0323	1.89	$96.09	$22.48	$19.22
90813	S	Intac psytx, 45-50 min w/e&m	0323	1.89	$96.09	$22.48	$19.22
90814	S	Intac psytx, off, 75-80 min	0323	1.89	$96.09	$22.48	$19.22
90815	S	Intac psytx, 75-80 w/e&m	0323	1.89	$96.09	$22.48	$19.22
90816	S	Psytx, hosp, 20-30 min	0322	1.25	$63.55	$13.35	$12.71
90817	S	Psytx, hosp, 20-30 min w/e&m	0322	1.25	$63.55	$13.35	$12.71
90818	S	Psytx, hosp, 45-50 min	0323	1.89	$96.09	$22.48	$19.22
90819	S	Psytx, hosp, 45-50 min w/e&m	0323	1.89	$96.09	$22.48	$19.22
90821	S	Psytx, hosp, 75-80 min	0323	1.89	$96.09	$22.48	$19.22
90822	S	Psytx, hosp, 75-80 min w/e&m	0323	1.89	$96.09	$22.48	$19.22
90823	S	Intac psytx, hosp, 20-30 min	0322	1.25	$63.55	$13.35	$12.71
90824	S	Intac psytx, hsp 20-30 w/e&m	0322	1.25	$63.55	$13.35	$12.71
90826	S	Intac psytx, hosp, 45-50 min	0323	1.89	$96.09	$22.48	$19.22
90827	S	Intac psytx, hsp 45-50 w/e&m	0323	1.89	$96.09	$22.48	$19.22
90828	S	Intac psytx, hosp, 75-80 min	0323	1.89	$96.09	$22.48	$19.22
90829	S	Intac psytx, hsp 75-80 w/e&m	0323	1.89	$96.09	$22.48	$19.22
90845	S	Psychoanalysis	0323	1.89	$96.09	$22.48	$19.22
90846	S	Family psytx w/o patient	0324	3.13	$159.14	$31.83	$31.83
90847	S	Family psytx w/patient	0324	3.13	$159.14	$31.83	$31.83
90849	S	Multiple family group psytx	0325	1.49	$75.75	$19.70	$15.15
90853	S	Group psychotherapy	0325	1.49	$75.75	$19.70	$15.15
90857	S	Intac group psytx	0325	1.49	$75.75	$19.70	$15.15
90862	X	Medication management	0374	0.96	$48.81	$10.74	$9.76
90865	S	Narcosynthesis	0323	1.89	$96.09	$22.48	$19.22
90870	S	Electroconvulsive therapy	0320	4.20	$213.54	$80.06	$42.71
90871	S	Electroconvulsive therapy	0320	4.20	$213.54	$80.06	$42.71
90875	E	Psychophysiological therapy	.....	.....	.....	.....	.....
90876	E	Psychophysiological therapy	.....	.....	.....	.....	.....
90880	S	Hypnotherapy	0323	1.89	$96.09	$22.48	$19.22
90882	E	Environmental manipulation	.....	.....	.....	.....	.....
90885	N	Psy evaluation of records	.....	.....	.....	.....	.....

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
90887	N	Consultation with family					
90889	N	Preparation of report					
90899	S	Psychiatric service/therapy	0322	1.25	$63.55	$13.35	$12.71
90901	S	Biofeedback train, any meth	0321	1.02	$51.86	$23.86	$10.37
90911	S	Biofeedback peri/uro/rectal	0321	1.02	$51.86	$23.86	$10.37
90918	A	ESRD related services, month					
90919	A	ESRD related services, month					
90920	A	ESRD related services, month					
90921	A	ESRD related services, month					
90922	A	ESRD related services, day					
90923	A	Esrd related services, day					
90924	A	Esrd related services, day					
90925	A	Esrd related services, day					
90935	S	Hemodialysis, one evaluation	0170	1.08	$54.91	$12.08	$10.98
90937	E	Hemodialysis, repeated eval					
90940	N	Hemodialysis access study					
90945	S	Dialysis, one evaluation	0170	1.08	$54.91	$12.08	$10.98
90947	E	Dialysis, repeated eval					
90989	E	Dialysis training, complete					
90993	E	Dialysis training, incompl					
90997	E	Hemoperfusion					
90999	E	Dialysis procedure					
91000	X	Esophageal intubation	0361	3.52	$178.96	$88.09	$35.79
91010	X	Esophagus motility study	0361	3.52	$178.96	$88.09	$35.79
91011	X	Esophagus motility study	0361	3.52	$178.96	$88.09	$35.79
91012	X	Esophagus motility study	0361	3.52	$178.96	$88.09	$35.79
91020	X	Gastric motility	0361	3.52	$178.96	$88.09	$35.79
91030	X	Acid perfusion of esophagus	0360	1.40	$71.18	$34.75	$14.24
91032	X	Esophagus, acid reflux test	0361	3.52	$178.96	$88.09	$35.79
91033	X	Prolonged acid reflux test	0361	3.52	$178.96	$88.09	$35.79
91052	X	Gastric analysis test	0361	3.52	$178.96	$88.09	$35.79
91055	X	Gastric intubation for smear	0360	1.40	$71.18	$34.75	$14.24
91060	X	Gastric saline load test	0360	1.40	$71.18	$34.75	$14.24
91065	X	Breath hydrogen test	0360	1.40	$71.18	$34.75	$14.24
91100	X	Pass intestine bleeding tube	0360	1.40	$71.18	$34.75	$14.24
91105	X	Gastric intubation treatment	0361	3.52	$178.96	$88.09	$35.79
91122	T	Anal pressure record	0156	2.62	$133.21	$39.96	$26.64
91132	X	Electrogastrography	0360	1.40	$71.18	$34.75	$14.24
91133	X	Electrogastrography w/test	0360	1.40	$71.18	$34.75	$14.24
91299	X	Gastroenterology procedure	0360	1.40	$71.18	$34.75	$14.24
92002	V	Eye exam, new patient	0601	1.02	$51.86	$10.37	$10.37
92004	V	Eye exam, new patient	0602	1.49	$75.75	$15.15	$15.15
92012	V	Eye exam established pat	0601	1.02	$51.86	$10.37	$10.37
92014	V	Eye exam & treatment	0602	1.49	$75.75	$15.15	$15.15
92015	E	Refraction					
92018	T	New eye exam & treatment	0699	6.91	$351.32	$158.09	$70.26
92019	S	Eye exam & treatment	0698	1.09	$55.42	$24.94	$11.08
92020	S	Special eye evaluation	0230	0.64	$32.54	$14.97	$6.51
92060	S	Special eye evaluation	0230	0.64	$32.54	$14.97	$6.51
92065	S	Orthoptic/pleoptic training	0230	0.64	$32.54	$14.97	$6.51
92070	N	Fitting of contact lens					
92081	S	Visual field examination(s)	0230	0.64	$32.54	$14.97	$6.51
92082	S	Visual field examination(s)	0698	1.09	$55.42	$24.94	$11.08
92083	S	Visual field examination(s)	0698	1.09	$55.42	$24.94	$11.08
92100	N	Serial tonometry exam(s)					
92120	S	Tonography & eye evaluation	0230	0.64	$32.54	$14.97	$6.51
92130	S	Water provocation tonography	0230	0.64	$32.54	$14.97	$6.51
92135	S	Opthalmic dx imaging	0230	0.64	$32.54	$14.97	$6.51
92140	S	Glaucoma provocative tests	0231	2.27	$115.41	$51.94	$23.08
92225	S	Special eye exam, initial	0230	0.64	$32.54	$14.97	$6.51
92226	S	Special eye exam, subsequent	0231	2.27	$115.41	$51.94	$23.08
92230	T	Eye exam with photos	0699	6.91	$351.32	$158.09	$70.26
92235	S	Eye exam with photos	0231	2.27	$115.41	$51.94	$23.08
92240	S	Icg angiography	0231	2.27	$115.41	$51.94	$23.08
92250	S	Eye exam with photos	0230	0.64	$32.54	$14.97	$6.51
92260	S	Ophthalmoscopy/dynamometry	0230	0.64	$32.54	$14.97	$6.51
92265	S	Eye muscle evaluation	0231	2.27	$115.41	$51.94	$23.08
92270	S	Electro-oculography	0698	1.09	$55.42	$24.94	$11.08
92275	S	Electroretinography	0216	2.91	$147.95	$64.69	$29.59
92283	S	Color vision examination	0230	0.64	$32.54	$14.97	$6.51
92284	S	Dark adaptation eye exam	0231	2.27	$115.41	$51.94	$23.08
92285	S	Eye photography	0230	0.64	$32.54	$14.97	$6.51
92286	S	Internal eye photography	0230	0.64	$32.54	$14.97	$6.51
92287	S	Internal eye photography	0231	2.27	$115.41	$51.94	$23.08
92310	E	Contact lens fitting					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
92311	X	Contact lens fitting	0362	0.83	$42.20	$9.63	$8.44
92312	X	Contact lens fitting	0362	0.83	$42.20	$9.63	$8.44
92313	X	Contact lens fitting	0362	0.83	$42.20	$9.63	$8.44
92314	E	Prescription of contact lens					
92315	X	Prescription of contact lens	0362	0.83	$42.20	$9.63	$8.44
92316	X	Prescription of contact lens	0362	0.83	$42.20	$9.63	$8.44
92317	X	Prescription of contact lens	0362	0.83	$42.20	$9.63	$8.44
92325	X	Modification of contact lens	0362	0.83	$42.20	$9.63	$8.44
92326	X	Replacement of contact lens	0362	0.83	$42.20	$9.63	$8.44
92330	S	Fitting of artificial eye	0230	0.64	$32.54	$14.97	$6.51
92335	N	Fitting of artificial eye					
92340	E	Fitting of spectacles					
92341	E	Fitting of spectacles					
92342	E	Fitting of spectacles					
92352	X	Special spectacles fitting	0362	0.83	$42.20	$9.63	$8.44
92353	X	Special spectacles fitting	0362	0.83	$42.20	$9.63	$8.44
92354	X	Special spectacles fitting	0362	0.83	$42.20	$9.63	$8.44
92355	X	Special spectacles fitting	0362	0.83	$42.20	$9.63	$8.44
92358	X	Eye prosthesis service	0362	0.83	$42.20	$9.63	$8.44
92370	E	Repair & adjust spectacles					
92371	X	Repair & adjust spectacles	0362	0.83	$42.20	$9.63	$8.44
92390	E	Supply of spectacles					
92391	E	Supply of contact lenses					
92392	E	Supply of low vision aids					
92393	E	Supply of artificial eye					
92395	E	Supply of spectacles					
92396	E	Supply of contact lenses					
92499	S	Eye service or procedure	0230	0.64	$32.54	$14.97	$6.51
92502	T	Ear and throat examination	0251	2.71	$137.78	$27.99	$27.56
92504	N	Ear microscopy examination					
92506	A	Speech/hearing evaluation					
92507	A	Speech/hearing therapy					
92508	A	Speech/hearing therapy					
92510	A	Rehab for ear implant					
92511	T	Nasopharyngoscopy	0071	1.08	$54.91	$14.22	$10.98
92512	X	Nasal function studies	0363	2.06	$104.73	$38.75	$20.95
92516	X	Facial nerve function test	0363	2.06	$104.73	$38.75	$20.95
92520	X	Laryngeal function studies	0363	2.06	$104.73	$38.75	$20.95
92525	A	Oral function evaluation					
92526	A	Oral function therapy					
92531	N	Spontaneous nystagmus study					
92532	N	Positional nystagmus study					
92533	N	Caloric vestibular test					
92534	N	Optokinetic nystagmus					
92541	X	Spontaneous nystagmus test	0363	2.06	$104.73	$38.75	$20.95
92542	X	Positional nystagmus test	0363	2.06	$104.73	$38.75	$20.95
92543	X	Caloric vestibular test	0363	2.06	$104.73	$38.75	$20.95
92544	X	Optokinetic nystagmus test	0363	2.06	$104.73	$38.75	$20.95
92545	X	Oscillating tracking test	0363	2.06	$104.73	$38.75	$20.95
92546	X	Sinusoidal rotational test	0363	2.06	$104.73	$38.75	$20.95
92547	X	Supplemental electrical test	0363	2.06	$104.73	$38.75	$20.95
92548	X	Posturography	0363	2.06	$104.73	$38.75	$20.95
92551	E	Pure tone hearing test, air					
92552	X	Pure tone audiometry, air	0364	0.55	$27.96	$10.91	$5.59
92553	X	Audiometry, air & bone	0365	1.42	$72.20	$21.66	$14.44
92555	X	Speech threshold audiometry	0364	0.55	$27.96	$10.91	$5.59
92556	X	Speech audiometry, complete	0364	0.55	$27.96	$10.91	$5.59
92557	X	Comprehensive hearing test	0365	1.42	$72.20	$21.66	$14.44
92559	E	Group audiometric testing					
92560	E	Bekesy audiometry, screen					
92561	X	Bekesy audiometry, diagnosis	0365	1.42	$72.20	$21.66	$14.44
92562	X	Loudness balance test	0364	0.55	$27.96	$10.91	$5.59
92563	X	Tone decay hearing test	0364	0.55	$27.96	$10.91	$5.59
92564	X	Sisi hearing test	0364	0.55	$27.96	$10.91	$5.59
92565	X	Stenger test, pure tone	0364	0.55	$27.96	$10.91	$5.59
92567	X	Tympanometry	0364	0.55	$27.96	$10.91	$5.59
92568	X	Acoustic reflex testing	0364	0.55	$27.96	$10.91	$5.59
92569	X	Acoustic reflex decay test	0364	0.55	$27.96	$10.91	$5.59
92571	X	Filtered speech hearing test	0364	0.55	$27.96	$10.91	$5.59
92572	X	Staggered spondaic word test	0364	0.55	$27.96	$10.91	$5.59
92573	X	Lombard test	0364	0.55	$27.96	$10.91	$5.59
92575	X	Sensorineural acuity test	0365	1.42	$72.20	$21.66	$14.44
92576	X	Synthetic sentence test	0364	0.55	$27.96	$10.91	$5.59
92577	X	Stenger test, speech	0365	1.42	$72.20	$21.66	$14.44
92579	X	Visual audiometry (vra)	0365	1.42	$72.20	$21.66	$14.44

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
92582	X	Conditioning play audiometry	0365	1.42	$72.20	$21.66	$14.44
92583	X	Select picture audiometry	0364	0.55	$27.96	$10.91	$5.59
92584	X	Electrocochleography	0363	2.06	$104.73	$38.75	$20.95
92585	S	Auditor evoke potent, compre	0216	2.91	$147.95	$64.69	$29.59
92586	S	Auditor evoke potent, limit	0971	1.42	$72.20	.....	$14.44
92587	X	Evoked auditory test	0363	2.06	$104.73	$38.75	$20.95
92588	X	Evoked auditory test	0363	2.06	$104.73	$38.75	$20.95
92589	X	Auditory function test(s)	0364	0.55	$27.96	$10.91	$5.59
92590	E	Hearing aid exam, one ear	.....	.....	.....	.....	.....
92591	E	Hearing aid exam, both ears	.....	.....	.....	.....	.....
92592	E	Hearing aid check, one ear	.....	.....	.....	.....	.....
92593	E	Hearing aid check, both ears	.....	.....	.....	.....	.....
92594	E	Electro hearng aid test, one	.....	.....	.....	.....	.....
92595	E	Electro hearng aid tst, both	.....	.....	.....	.....	.....
92596	X	Ear protector evaluation	0365	1.42	$72.20	$21.66	$14.44
92599	X	ENT procedure/service	0364	0.55	$27.96	$10.91	$5.59
92950	S	Heart/lung resuscitation cpr	0094	5.69	$289.29	$105.29	$57.86
92953	S	Temporary external pacing	0094	5.69	$289.29	$105.29	$57.86
92960	S	Cardioversion electric, ext	0094	5.69	$289.29	$105.29	$57.86
92961	S	Cardioversion, electric, int	0087	14.89	$757.04	$214.72	$151.41
92970	C	Cardioassist, internal	.....	.....	.....	.....	.....
92971	C	Cardioassist, external	.....	.....	.....	.....	.....
92975	C	Dissolve clot, heart vessel	.....	.....	.....	.....	.....
92977	T	Dissolve clot, heart vessel	0120	2.35	$119.48	$42.67	$23.90
92978	S	Intravasc us, heart add-on	0267	2.58	$131.17	$72.14	$26.23
92979	S	Intravasc us, heart add-on	0267	2.58	$131.17	$72.14	$26.23
92980	T	Insert intracoronary stent	0104	71.42	$3,631.14	$726.23	$726.23
92981	T	Insert intracoronary stent	0104	71.42	$3,631.14	$726.23	$726.23
92982	T	Coronary artery dilation	0083	50.15	$2,549.73	$794.30	$509.95
92984	T	Coronary artery dilation	0083	50.15	$2,549.73	$794.30	$509.95
92986	C	Revision of aortic valve	.....	.....	.....	.....	.....
92987	C	Revision of mitral valve	.....	.....	.....	.....	.....
92990	C	Revision of pulmonary valve	.....	.....	.....	.....	.....
92992	C	Revision of heart chamber	.....	.....	.....	.....	.....
92993	C	Revision of heart chamber	.....	.....	.....	.....	.....
92995	T	Coronary atherectomy	0082	130.89	$6,654.71	$1,351.74	$1,330.94
92996	T	Coronary atherectomy add-on	0082	130.89	$6,654.71	$1,351.74	$1,330.94
92997	C	Pul art balloon repr, percut	.....	.....	.....	.....	.....
92998	C	Pul art balloon repr, percut	.....	.....	.....	.....	.....
93000	E	Electrocardiogram, complete	.....	.....	.....	.....	.....
93005	S	Electrocardiogram, tracing	0099	0.38	$19.32	$10.63	$3.86
93010	S	Electrocardiogram report	.....	.....	.....	.....	.....
93012	N	Transmission of ecg	.....	.....	.....	.....	.....
93014	E	Report on transmitted ecg	.....	.....	.....	.....	.....
93015	E	Cardiovascular stress test	.....	.....	.....	.....	.....
93016	E	Cardiovascular stress test	.....	.....	.....	.....	.....
93017	X	Cardiovascular stress test	0100	1.63	$82.87	$45.58	$16.57
93018	E	Cardiovascular stress test	.....	.....	.....	.....	.....
93024	X	Cardiac drug stress test	0100	1.63	$82.87	$45.58	$16.57
93040	E	Rhythm ECG with report	.....	.....	.....	.....	.....
93041	S	Rhythm ECG, tracing	0099	0.38	$19.32	$10.63	$3.86
93042	E	Rhythm ECG, report	.....	.....	.....	.....	.....
93224	E	ECG monitor/report, 24 hrs	.....	.....	.....	.....	.....
93225	X	ECG monitor/record, 24 hrs	0100	1.63	$82.87	$45.58	$16.57
93226	X	ECG monitor/report, 24 hrs	0100	1.63	$82.87	$45.58	$16.57
93227	E	ECG monitor/review, 24 hrs	.....	.....	.....	.....	.....
93230	E	ECG monitor/report, 24 hrs	.....	.....	.....	.....	.....
93231	X	Ecg monitor/record, 24 hrs	0100	1.63	$82.87	$45.58	$16.57
93232	X	ECG monitor/report, 24 hrs	0100	1.63	$82.87	$45.58	$16.57
93233	E	ECG monitor/review, 24 hrs	.....	.....	.....	.....	.....
93235	E	ECG monitor/report, 24 hrs	.....	.....	.....	.....	.....
93236	X	ECG monitor/report, 24 hrs	0100	1.63	$82.87	$45.58	$16.57
93237	E	ECG monitor/review, 24 hrs	.....	.....	.....	.....	.....
93268	E	ECG record/review	.....	.....	.....	.....	.....
93270	X	ECG recording	0097	0.87	$44.23	$24.33	$8.85
93271	X	Ecg/monitoring and analysis	0097	0.87	$44.23	$24.33	$8.85
93272	E	Ecg/review, interpret only	.....	.....	.....	.....	.....
93278	S	ECG/signal-averaged	0099	0.38	$19.32	$10.63	$3.86
93303	S	Echo transthoracic	0269	4.31	$219.13	$113.95	$43.83
93304	S	Echo transthoracic	0697	2.00	$101.68	$52.88	$20.34
93307	S	Echo exam of heart	0269	4.31	$219.13	$113.95	$43.83
93308	S	Echo exam of heart	0697	2.00	$101.68	$52.88	$20.34
93312	S	Echo transesophageal	0270	5.83	$296.41	$150.26	$59.28
93313	S	Echo transesophageal	0270	5.83	$296.41	$150.26	$59.28
93314	N	Echo transesophageal	.....	.....	.....	.....	.....

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
93315	S	Echo transesophageal	0270	5.83	$296.41	$150.26	$59.28
93316	S	Echo transesophageal	0270	5.83	$296.41	$150.26	$59.28
93317	N	Echo transesophageal					
93318	S	Echo transesophageal intraop	0270	5.83	$296.41	$150.26	$59.28
93320	S	Doppler echo exam, heart	0269	4.31	$219.13	$113.95	$43.83
93321	S	Doppler echo exam, heart	0697	2.00	$101.68	$52.88	$20.34
93325	S	Doppler color flow add-on	0697	2.00	$101.68	$52.88	$20.34
93350	S	Echo transthoracic	0269	4.31	$219.13	$113.95	$43.83
93501	T	Right heart catheterization	0080	32.20	$1,637.11	$838.92	$327.42
93503	T	Insert/place heart catheter	0103	10.91	$554.69	$249.61	$110.94
93505	T	Biopsy of heart lining	0103	10.91	$554.69	$249.61	$110.94
93508	N	Cath placement, angiography					
93510	T	Left heart catheterization	0080	32.20	$1,637.11	$838.92	$327.42
93511	T	Left heart catheterization	0080	32.20	$1,637.11	$838.92	$327.42
93514	T	Left heart catheterization	0080	32.20	$1,637.11	$838.92	$327.42
93524	T	Left heart catheterization	0080	32.20	$1,637.11	$838.92	$327.42
93526	T	Rt & Lt heart catheters	0080	32.20	$1,637.11	$838.92	$327.42
93527	T	Rt & Lt heart catheters	0080	32.20	$1,637.11	$838.92	$327.42
93528	T	Rt & Lt heart catheters	0080	32.20	$1,637.11	$838.92	$327.42
93529	T	Rt, Lt heart catheterization	0080	32.20	$1,637.11	$838.92	$327.42
93530	T	Rt heart cath, congenital	0080	32.20	$1,637.11	$838.92	$327.42
93531	T	R & l heart cath, congenital	0080	32.20	$1,637.11	$838.92	$327.42
93532	T	R & l heart cath, congenital	0080	32.20	$1,637.11	$838.92	$327.42
93533	T	R & l heart cath, congenital	0080	32.20	$1,637.11	$838.92	$327.42
93536	T	Insert circulation assi	0103	10.91	$554.69	$249.61	$110.94
93539	N	Injection, cardiac cath					
93540	N	Injection, cardiac cath					
93541	N	Injection for lung angiogram					
93542	N	Injection for heart x-rays					
93543	N	Injection for heart x-rays					
93544	N	Injection for aortography					
93545	N	Inject for coronary x-rays					
93555	N	Imaging, cardiac cath					
93556	N	Imaging, cardiac cath					
93561	N	Cardiac output measurement					
93562	N	Cardiac output measurement					
93571	N	Heart flow reserve measure					
93572	N	Heart flow reserve measure					
93600	S	Bundle of His recording	0087	14.89	$757.04	$214.72	$151.41
93602	S	Intra-atrial recording	0087	14.89	$757.04	$214.72	$151.41
93603	S	Right ventricular recording	0087	14.89	$757.04	$214.72	$151.41
93607	S	Left ventricular recording	0087	14.89	$757.04	$214.72	$151.41
93609	S	Mapping of tachycardia	0087	14.89	$757.04	$214.72	$151.41
93610	S	Intra-atrial pacing	0087	14.89	$757.04	$214.72	$151.41
93612	S	Intraventricular pacing	0087	14.89	$757.04	$214.72	$151.41
93615	S	Esophageal recording	0087	14.89	$757.04	$214.72	$151.41
93616	S	Esophageal recording	0087	14.89	$757.04	$214.72	$151.41
93618	S	Heart rhythm pacing	0087	14.89	$757.04	$214.72	$151.41
93619	S	Electrophysiology evaluation	0085	27.39	$1,392.56	$654.48	$278.51
93620	S	Electrophysiology evaluation	0085	27.39	$1,392.56	$654.48	$278.51
93621	S	Electrophysiology evaluation	0085	27.39	$1,392.56	$654.48	$278.51
93622	S	Electrophysiology evaluation	0085	27.39	$1,392.56	$654.48	$278.51
93623	S	Stimulation, pacing heart	0087	14.89	$757.04	$214.72	$151.41
93624	S	Electrophysiologic study	0087	14.89	$757.04	$214.72	$151.41
93631	S	Heart pacing, mapping	0087	14.89	$757.04	$214.72	$151.41
93640	S	Evaluation heart device	0084	4.94	$251.16	$82.88	$50.23
93641	S	Electrophysiology evaluation	0084	4.94	$251.16	$82.88	$50.23
93642	S	Electrophysiology evaluation	0084	4.94	$251.16	$82.88	$50.23
93650	S	Ablate heart dysrhythm focus	0086	47.13	$2,396.18	$1,265.37	$479.24
93651	S	Ablate heart dysrhythm focus	0086	47.13	$2,396.18	$1,265.37	$479.24
93652	S	Ablate heart dysrhythm focus	0086	47.13	$2,396.18	$1,265.37	$479.24
93660	S	Tilt table evaluation	0101	4.03	$204.89	$112.69	$40.98
93662	S	Intracardiac ecg (ice)	0270	5.83	$296.41	$150.26	$59.28
93668	E	Peripheral vascular rehab					
93720	E	Total body plethysmography					
93721	S	Plethysmography tracing	0096	1.87	$95.07	$52.29	$19.01
93722	E	Plethysmography report					
93724	S	Analyze pacemaker system	0690	0.40	$20.34	$11.19	$4.07
93727	S	Analyze ilr system	0690	0.40	$20.34	$11.19	$4.07
93731	S	Analyze pacemaker system	0690	0.40	$20.34	$11.19	$4.07
93732	S	Analyze pacemaker system	0690	0.40	$20.34	$11.19	$4.07
93733	S	Telephone analy, pacemaker	0690	0.40	$20.34	$11.19	$4.07
93734	S	Analyze pacemaker system	0690	0.40	$20.34	$11.19	$4.07
93735	S	Analyze pacemaker system	0690	0.40	$20.34	$11.19	$4.07
93736	S	Telephone analy, pacemaker	0690	0.40	$20.34	$11.19	$4.07

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
93737	S	Analyze cardio/defibrillator	0689	0.49	$24.91	$13.70	$4.98
93738	S	Analyze cardio/defibrillator	0689	0.49	$24.91	$13.70	$4.98
93740	S	Temperature gradient studies	0096	1.87	$95.07	$52.29	$19.01
93741	S	Analyze ht pace device sngl	0689	0.49	$24.91	$13.70	$4.98
93742	S	Analyze ht pace device sngl	0689	0.49	$24.91	$13.70	$4.98
93743	S	Analyze ht pace device dual	0689	0.49	$24.91	$13.70	$4.98
93744	S	Analyze ht pace device dual	0689	0.49	$24.91	$13.70	$4.98
93760	E	Cephalic thermogram					
93762	E	Peripheral thermogram					
93770	N	Measure venous pressure					
93784	E	Ambulatory BP monitoring					
93786	E	Ambulatory BP recording					
93788	E	Ambulatory BP analysis					
93790	E	Review/report BP recording					
93797	S	Cardiac rehab	0095	0.66	$33.56	$16.98	$6.71
93798	S	Cardiac rehab/monitor	0095	0.66	$33.56	$16.98	$6.71
93799	S	Cardiovascular procedure	0096	1.87	$95.07	$52.29	$19.01
93875	S	Extracranial study	0096	1.87	$95.07	$52.29	$19.01
93880	S	Extracranial study	0267	2.58	$131.17	$72.14	$26.23
93882	S	Extracranial study	0267	2.58	$131.17	$72.14	$26.23
93886	S	Intracranial study	0267	2.58	$131.17	$72.14	$26.23
93888	S	Intracranial study	0267	2.58	$131.17	$72.14	$26.23
93922	S	Extremity study	0096	1.87	$95.07	$52.29	$19.01
93923	S	Extremity study	0096	1.87	$95.07	$52.29	$19.01
93924	S	Extremity study	0096	1.87	$95.07	$52.29	$19.01
93925	S	Lower extremity study	0267	2.58	$131.17	$72.14	$26.23
93926	S	Lower extremity study	0267	2.58	$131.17	$72.14	$26.23
93930	S	Upper extremity study	0267	2.58	$131.17	$72.14	$26.23
93931	S	Upper extremity study	0267	2.58	$131.17	$72.14	$26.23
93965	S	Extremity study	0096	1.87	$95.07	$52.29	$19.01
93970	S	Extremity study	0267	2.58	$131.17	$72.14	$26.23
93971	S	Extremity study	0267	2.58	$131.17	$72.14	$26.23
93975	S	Vascular study	0267	2.58	$131.17	$72.14	$26.23
93976	S	Vascular study	0267	2.58	$131.17	$72.14	$26.23
93978	S	Vascular study	0267	2.58	$131.17	$72.14	$26.23
93979	S	Vascular study	0267	2.58	$131.17	$72.14	$26.23
93980	S	Penile vascular study	0267	2.58	$131.17	$72.14	$26.23
93981	S	Penile vascular study	0267	2.58	$131.17	$72.14	$26.23
93990	S	Doppler flow testing	0267	2.58	$131.17	$72.14	$26.23
94010	X	Breathing capacity test	0367	0.76	$38.64	$19.32	$7.73
94014	X	Patient recorded spirometry	0367	0.76	$38.64	$19.32	$7.73
94015	X	Patient recorded spirometry	0367	0.76	$38.64	$19.32	$7.73
94016	X	Review patient spirometry	0369	3.99	$202.86	$58.50	$40.57
94060	X	Evaluation of wheezing	0368	1.53	$77.79	$39.67	$15.56
94070	X	Evaluation of wheezing	0368	1.53	$77.79	$39.67	$15.56
94150	N	Vital capacity test					
94200	X	Lung function test (MBC/MVV)	0367	0.76	$38.64	$19.32	$7.73
94240	X	Residual lung capacity	0368	1.53	$77.79	$39.67	$15.56
94250	X	Expired gas collection	0367	0.76	$38.64	$19.32	$7.73
94260	X	Thoracic gas volume	0368	1.53	$77.79	$39.67	$15.56
94350	X	Lung nitrogen washout curve	0368	1.53	$77.79	$39.67	$15.56
94360	X	Measure airflow resistance	0368	1.53	$77.79	$39.67	$15.56
94370	X	Breath airway closing volume	0368	1.53	$77.79	$39.67	$15.56
94375	X	Respiratory flow volume loop	0367	0.76	$38.64	$19.32	$7.73
94400	X	CO2 breathing response curve	0368	1.53	$77.79	$39.67	$15.56
94450	X	Hypoxia response curve	0367	0.76	$38.64	$19.32	$7.73
94620	X	Pulmonary stress test/simple	0368	1.53	$77.79	$39.67	$15.56
94621	X	Pulm stress test/complex	0369	3.99	$202.86	$58.50	$40.57
94640	S	Airway inhalation treatment	0077	0.42	$21.35	$11.74	$4.27
94642	S	Aerosol inhalation treatment	0078	0.93	$47.28	$20.33	$9.46
94650	S	Pressure breathing (IPPB)	0077	0.42	$21.35	$11.74	$4.27
94651	S	Pressure breathing (IPPB)	0077	0.42	$21.35	$11.74	$4.27
94652	C	Pressure breathing (IPPB)					
94656	S	Initial ventilator mgmt	0079	0.62	$31.52	$17.34	$6.30
94657	S	Continued ventilator mgmt	0079	0.62	$31.52	$17.34	$6.30
94660	S	Pos airway pressure, CPAP	0068	3.33	$169.30	$93.12	$33.86
94662	S	Neg press ventilation, cnp	0079	0.62	$31.52	$17.34	$6.30
94664	S	Aerosol or vapor inhalations	0077	0.42	$21.35	$11.74	$4.27
94665	S	Aerosol or vapor inhalations	0077	0.42	$21.35	$11.74	$4.27
94667	S	Chest wall manipulation	0077	0.42	$21.35	$11.74	$4.27
94668	S	Chest wall manipulation	0077	0.42	$21.35	$11.74	$4.27
94680	X	Exhaled air analysis, o2	0368	1.53	$77.79	$39.67	$15.56
94681	X	Exhaled air analysis, o2/co2	0368	1.53	$77.79	$39.67	$15.56
94690	X	Exhaled air analysis	0367	0.76	$38.64	$19.32	$7.73
94720	X	Monoxide diffusing capacity	0367	0.76	$38.64	$19.32	$7.73

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
94725	X	Membrane diffusion capacity	0368	1.53	$77.79	$39.67	$15.56
94750	X	Pulmonary compliance study	0368	1.53	$77.79	$39.67	$15.56
94760	N	Measure blood oxygen level					
94761	N	Measure blood oxygen level					
94762	N	Measure blood oxygen level					
94770	X	Exhaled carbon dioxide test	0367	0.76	$38.64	$19.32	$7.73
94772	X	Breath recording, infant	0369	3.99	$202.86	$58.50	$40.57
94799	X	Pulmonary service/procedure	0367	0.76	$38.64	$19.32	$7.73
95004	X	Allergy skin tests	0370	0.87	$44.23	$11.81	$8.85
95010	X	Sensitivity skin tests	0370	0.87	$44.23	$11.81	$8.85
95015	X	Sensitivity skin tests	0370	0.87	$44.23	$11.81	$8.85
95024	X	Allergy skin tests	0370	0.87	$44.23	$11.81	$8.85
95027	X	Skin end point titration	0370	0.87	$44.23	$11.81	$8.85
95028	X	Allergy skin tests	0370	0.87	$44.23	$11.81	$8.85
95044	X	Allergy patch tests	0370	0.87	$44.23	$11.81	$8.85
95052	X	Photo patch test	0370	0.87	$44.23	$11.81	$8.85
95056	X	Photosensitivity tests	0370	0.87	$44.23	$11.81	$8.85
95060	X	Eye allergy tests	0370	0.87	$44.23	$11.81	$8.85
95065	X	Nose allergy test	0370	0.87	$44.23	$11.81	$8.85
95070	X	Bronchial allergy tests	0369	3.99	$202.86	$58.50	$40.57
95071	X	Bronchial allergy tests	0369	3.99	$202.86	$58.50	$40.57
95075	X	Ingestion challenge test	0361	3.52	$178.96	$88.09	$35.79
95078	X	Provocative testing	0370	0.87	$44.23	$11.81	$8.85
95115	X	Immunotherapy, one injection	0353	0.27	$13.73	$2.75	$2.75
95117	X	Immunotherapy injections	0353	0.27	$13.73	$2.75	$2.75
95120	E	Immunotherapy, one injection					
95125	E	Immunotherapy, many antigens					
95130	E	Immunotherapy, insect venom					
95131	E	Immunotherapy, insect venoms					
95132	E	Immunotherapy, insect venoms					
95133	E	Immunotherapy, insect venoms					
95134	E	Immunotherapy, insect venoms					
95144	X	Antigen therapy services	0371	0.76	$38.64	$7.73	$7.73
95145	X	Antigen therapy services	0371	0.76	$38.64	$7.73	$7.73
95146	X	Antigen therapy services	0371	0.76	$38.64	$7.73	$7.73
95147	X	Antigen therapy services	0371	0.76	$38.64	$7.73	$7.73
95148	X	Antigen therapy services	0371	0.76	$38.64	$7.73	$7.73
95149	X	Antigen therapy services	0371	0.76	$38.64	$7.73	$7.73
95165	X	Antigen therapy services	0371	0.76	$38.64	$7.73	$7.73
95170	X	Antigen therapy services	0371	0.76	$38.64	$7.73	$7.73
95180	X	Rapid desensitization	0370	0.87	$44.23	$11.81	$8.85
95199	X	Allergy immunology services	0370	0.87	$44.23	$11.81	$8.85
95805	S	Multiple sleep latency test	0209	11.73	$596.38	$310.12	$119.28
95806	S	Sleep study, unattended	0213	2.95	$149.98	$77.99	$30.00
95807	S	Sleep study, attended	0209	11.73	$596.38	$310.12	$119.28
95808	S	Polysomnography, 1-3	0209	11.73	$596.38	$310.12	$119.28
95810	S	Polysomnography, 4 or more	0209	11.73	$596.38	$310.12	$119.28
95811	S	Polysomnography w/cpap	0209	11.73	$596.38	$310.12	$119.28
95812	S	Electroencephalogram (EEG)	0213	2.95	$149.98	$77.99	$30.00
95813	S	Electroencephalogram (EEG)	0213	2.95	$149.98	$77.99	$30.00
95816	S	Electroencephalogram (EEG)	0214	2.27	$115.41	$57.71	$23.08
95819	S	Electroencephalogram (EEG)	0214	2.27	$115.41	$57.71	$23.08
95822	S	Sleep electroencephalogram	0214	2.27	$115.41	$57.71	$23.08
95824	S	Electroencephalography	0214	2.27	$115.41	$57.71	$23.08
95827	S	Night electroencephalogram	0209	11.73	$596.38	$310.12	$119.28
95829	S	Surgery electrocorticogram	0214	2.27	$115.41	$57.71	$23.08
95830	E	Insert electrodes for EEG					
95831	N	Limb muscle testing, manual					
95832	N	Hand muscle testing, manual					
95833	N	Body muscle testing, manual					
95834	N	Body muscle testing, manual					
95851	N	Range of motion measurements					
95852	N	Range of motion measurements					
95857	S	Tensilon test	0218	1.09	$55.42	$23.83	$11.08
95858	S	Tensilon test & myogram	0215	0.66	$33.56	$17.45	$6.71
95860	S	Muscle test, one limb	0218	1.09	$55.42	$23.83	$11.08
95861	S	Muscle test, two limbs	0218	1.09	$55.42	$23.83	$11.08
95863	S	Muscle test, 3 limbs	0218	1.09	$55.42	$23.83	$11.08
95864	S	Muscle test, 4 limbs	0218	1.09	$55.42	$23.83	$11.08
95867	S	Muscle test, head or neck	0218	1.09	$55.42	$23.83	$11.08
95868	S	Muscle test, head or neck	0218	1.09	$55.42	$23.83	$11.08
95869	S	Muscle test, thor paraspinal	0215	0.66	$33.56	$17.45	$6.71
95870	S	Muscle test, nonparaspinal	0218	1.09	$55.42	$23.83	$11.08
95872	S	Muscle test, one fiber	0215	0.66	$33.56	$17.45	$6.71
95875	S	Limb exercise test	0215	0.66	$33.56	$17.45	$6.71

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
95900	S	Motor nerve conduction test	0218	1.09	$55.42	$23.83	$11.08
95903	S	Motor nerve conduction test	0218	1.09	$55.42	$23.83	$11.08
95904	S	Sense/mixed n conduction tst	0215	0.66	$33.56	$17.45	$6.71
95920	S	Intraop nerve test add-on	0218	1.09	$55.42	$23.83	$11.08
95921	S	Autonomic nerv function test	0215	0.66	$33.56	$17.45	$6.71
95922	S	Autonomic nerv function test	0215	0.66	$33.56	$17.45	$6.71
95923	S	Autonomic nerv function test	0215	0.66	$33.56	$17.45	$6.71
95925	S	Somatosensory testing	0216	2.91	$147.95	$64.69	$29.59
95926	S	Somatosensory testing	0216	2.91	$147.95	$64.69	$29.59
95927	S	Somatosensory testing	0216	2.91	$147.95	$64.69	$29.59
95930	S	Visual evoked potential test	0216	2.91	$147.95	$64.69	$29.59
95933	S	Blink reflex test	0215	0.66	$33.56	$17.45	$6.71
95934	S	H-reflex test	0215	0.66	$33.56	$17.45	$6.71
95936	S	H-reflex test	0215	0.66	$33.56	$17.45	$6.71
95937	S	Neuromuscular junction test	0218	1.09	$55.42	$23.83	$11.08
95950	S	Ambulatory eeg monitoring	0213	2.95	$149.98	$77.99	$30.00
95951	S	EEG monitoring/videorecord	0209	11.73	$596.38	$310.12	$119.28
95953	S	EEG monitoring/computer	0209	11.73	$596.38	$310.12	$119.28
95954	S	EEG monitoring/giving drugs	0213	2.95	$149.98	$77.99	$30.00
95955	S	EEG during surgery	0214	2.27	$115.41	$57.71	$23.08
95956	N	Eeg monitoring, cable/radio					
95957	N	EEG digital analysis					
95958	S	EEG monitoring/function test	0213	2.95	$149.98	$77.99	$30.00
95961	S	Electrode stimulation, brain	0216	2.91	$147.95	$64.69	$29.59
95962	S	Electrode stim, brain add-on	0216	2.91	$147.95	$64.69	$29.59
95970	S	Analyze neurostim, no prog	0692	1.73	$87.96	$48.38	$17.59
95971	S	Analyze neurostim, simple	0692	1.73	$87.96	$48.38	$17.59
95972	S	Analyze neurostim, complex	0692	1.73	$87.96	$48.38	$17.59
95973	S	Analyze neurostim, complex	0692	1.73	$87.96	$48.38	$17.59
95974	S	Cranial neurostim, complex	0692	1.73	$87.96	$48.38	$17.59
95975	S	Cranial neurostim, complex	0692	1.73	$87.96	$48.38	$17.59
95999	N	Neurological procedure					
96100	X	Psychological testing	0373	1.11	$56.43	$15.80	$11.29
96105	X	Assessment of aphasia	0373	1.11	$56.43	$15.80	$11.29
96110	X	Developmental test, lim	0373	1.11	$56.43	$15.80	$11.29
96111	X	Developmental test, extend	0373	1.11	$56.43	$15.80	$11.29
96115	X	Neurobehavior status exam	0373	1.11	$56.43	$15.80	$11.29
96117	X	Neuropsych test battery	0373	1.11	$56.43	$15.80	$11.29
96400	E	Chemotherapy, sc/im					
96405	E	Intralesional chemo admin					
96406	E	Intralesional chemo admin					
96408	E	Chemotherapy, push technique					
96410	E	Chemotherapy,infusion method					
96412	E	Chemo, infuse method add-on					
96414	E	Chemo, infuse method add-on					
96420	E	Chemotherapy, push technique					
96422	E	Chemotherapy,infusion method					
96423	E	Chemo, infuse method add-on					
96425	E	Chemotherapy,infusion method					
96440	E	Chemotherapy, intracavitary					
96445	E	Chemotherapy, intracavitary					
96450	E	Chemotherapy, into CNS					
96520	T	Pump refilling, maintenance	0125	3.20	$162.69		$32.54
96530	T	Pump refilling, maintenance	0125	3.20	$162.69		$32.54
96542	E	Chemotherapy injection					
96545	E	Provide chemotherapy agent					
96549	E	Chemotherapy, unspecified					
96570	T	Photodynamic tx, 30 min	0973	4.73	$240.48		$48.10
96571	T	Photodynamic tx, addl 15 min	0973	4.73	$240.48		$48.10
96900	S	Ultraviolet light therapy	0001	0.45	$22.88	$8.24	$4.58
96902	N	Trichogram					
96910	S	Photochemotherapy with UV-B	0001	0.45	$22.88	$8.24	$4.58
96912	S	Photochemotherapy with UV-A	0001	0.45	$22.88	$8.24	$4.58
96913	S	Photochemotherapy, UV-A or B	0001	0.45	$22.88	$8.24	$4.58
96999	S	Dermatological procedure	0001	0.45	$22.88	$8.24	$4.58
97001	A	Pt evaluation					
97002	A	Pt re-evaluation					
97003	A	Ot evaluation					
97004	A	Ot re-evaluation					
97010	A	Hot or cold packs therapy					
97012	A	Mechanical traction therapy					
97014	A	Electric stimulation therapy					
97016	A	Vasopneumatic device therapy					
97018	A	Paraffin bath therapy					
97020	A	Microwave therapy					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
97022	A	Whirlpool therapy					
97024	A	Diathermy treatment					
97026	A	Infrared therapy					
97028	A	Ultraviolet therapy					
97032	A	Electrical stimulation					
97033	A	Electric current therapy					
97034	A	Contrast bath therapy					
97035	A	Ultrasound therapy					
97036	A	Hydrotherapy					
97039	A	Physical therapy treatment					
97110	A	Therapeutic exercises					
97112	A	Neuromuscular reeducation					
97113	A	Aquatic therapy/exercises					
97116	A	Gait training therapy					
97124	A	Massage therapy					
97139	A	Physical medicine procedure					
97140	A	Manual therapy					
97150	A	Group therapeutic procedures					
97504	A	Orthotic training					
97520	A	Prosthetic training					
97530	A	Therapeutic activities					
97532	A	Cognitive skills development					
97533	A	Sensory integration					
97535	A	Self care mngment training					
97537	A	Community/work reintegration					
97542	A	Wheelchair mngment training					
97545	A	Work hardening					
97546	A	Work hardening add-on					
97601	A	Wound care selective					
97602	N	Wound care non-selective					
97703	A	Prosthetic checkout					
97750	A	Physical performance test					
97780	E	Acupuncture w/o stimul					
97781	E	Acupuncture w/stimul					
97799	A	Physical medicine procedure					
97802	E	Medical nutrition, indiv, in					
97803	E	Med nutrition, indiv, subseq					
97804	E	Medical nutrition, group					
98925	S	Osteopathic manipulation	0060	0.25	$12.71	$2.54	$2.54
98926	S	Osteopathic manipulation	0060	0.25	$12.71	$2.54	$2.54
98927	S	Osteopathic manipulation	0060	0.25	$12.71	$2.54	$2.54
98928	S	Osteopathic manipulation	0060	0.25	$12.71	$2.54	$2.54
98929	S	Osteopathic manipulation	0060	0.25	$12.71	$2.54	$2.54
98940	S	Chiropractic manipulation	0060	0.25	$12.71	$2.54	$2.54
98941	S	Chiropractic manipulation	0060	0.25	$12.71	$2.54	$2.54
98942	S	Chiropractic manipulation	0060	0.25	$12.71	$2.54	$2.54
98943	E	Chiropractic manipulation					
99000	E	Specimen handling					
99001	E	Specimen handling					
99002	E	Device handling					
99024	E	Postop follow-up visit					
99025	E	Initial surgical evaluation					
99050	E	Medical services after hrs					
99052	E	Medical services at night					
99054	E	Medical servcs, unusual hrs					
99056	E	Non-office medical services					
99058	E	Office emergency care					
99070	E	Special supplies					
99071	E	Patient education materials					
99075	E	Medical testimony					
99078	E	Group health education					
99080	E	Special reports or forms					
99082	E	Unusual physician travel					
99090	E	Computer data analysis					
99100	E	Special anesthesia service					
99116	E	Anesthesia with hypothermia					
99135	E	Special anesthesia procedure					
99140	E	Emergency anesthesia					
99141	N	Sedation, iv/im or inhalant					
99142	N	Sedation, oral/rectal/nasal					
99170	T	Anogenital exam, child	0191	0.27	$13.73	$3.98	$2.75
99172	E	Ocular function screen					
99173	E	Visual acuity screen					
99175	N	Induction of vomiting					
99183	E	Hyperbaric oxygen therapy					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
99185	N	Regional hypothermia					
99186	N	Total body hypothermia					
99190	C	Special pump services					
99191	C	Special pump services					
99192	C	Special pump services					
99195	X	Phlebotomy	0372	0.57	$28.98	$10.09	$5.80
99199	E	Special service/proc/report					
99201	V	Office/outpatient visit, new	0600	0.93	$47.28	$9.46	$9.46
99202	V	Office/outpatient visit, new	0600	0.93	$47.28	$9.46	$9.46
99203	V	Office/outpatient visit, new	0601	1.02	$51.86	$10.37	$10.37
99204	V	Office/outpatient visit, new	0602	1.49	$75.75	$15.15	$15.15
99205	V	Office/outpatient visit, new	0602	1.49	$75.75	$15.15	$15.15
99211	V	Office/outpatient visit, est	0600	0.93	$47.28	$9.46	$9.46
99212	V	Office/outpatient visit, est	0600	0.93	$47.28	$9.46	$9.46
99213	V	Office/outpatient visit, est	0601	1.02	$51.86	$10.37	$10.37
99214	V	Office/outpatient visit, est	0602	1.49	$75.75	$15.15	$15.15
99215	V	Office/outpatient visit, est	0602	1.49	$75.75	$15.15	$15.15
99217	N	Observation care discharge					
99218	N	Observation care					
99219	N	Observation care					
99220	N	Observation care					
99221	E	Initial hospital care					
99222	E	Initial hospital care					
99223	E	Initial hospital care					
99231	E	Subsequent hospital care					
99232	E	Subsequent hospital care					
99233	E	Subsequent hospital care					
99234	N	Observ/hosp same date					
99235	N	Observ/hosp same date					
99236	N	Observ/hosp same date					
99238	E	Hospital discharge day					
99239	E	Hospital discharge day					
99241	V	Office consultation	0600	0.93	$47.28	$9.46	$9.46
99242	V	Office consultation	0600	0.93	$47.28	$9.46	$9.46
99243	V	Office consultation	0601	1.02	$51.86	$10.37	$10.37
99244	V	Office consultation	0602	1.49	$75.75	$15.15	$15.15
99245	V	Office consultation	0602	1.49	$75.75	$15.15	$15.15
99251	C	Initial inpatient consult					
99252	C	Initial inpatient consult					
99253	C	Initial inpatient consult					
99254	C	Initial inpatient consult					
99255	C	Initial inpatient consult					
99261	C	Follow-up inpatient consult					
99262	C	Follow-up inpatient consult					
99263	C	Follow-up inpatient consult					
99271	V	Confirmatory consultation	0600	0.93	$47.28	$9.46	$9.46
99272	V	Confirmatory consultation	0600	0.93	$47.28	$9.46	$9.46
99273	V	Confirmatory consultation	0601	1.02	$51.86	$10.37	$10.37
99274	V	Confirmatory consultation	0602	1.49	$75.75	$15.15	$15.15
99275	V	Confirmatory consultation	0602	1.49	$75.75	$15.15	$15.15
99281	V	Emergency dept visit	0610	1.34	$68.13	$20.65	$13.63
99282	V	Emergency dept visit	0610	1.34	$68.13	$20.65	$13.63
99283	V	Emergency dept visit	0611	2.33	$118.46	$36.47	$23.69
99284	V	Emergency dept visit	0612	3.75	$190.66	$54.14	$38.13
99285	V	Emergency dept visit	0612	3.75	$190.66	$54.14	$38.13
99288	E	Direct advanced life support					
99291	S	Critical care, first hour	0620	9.13	$464.19	$152.78	$92.84
99292	N	Critical care, addl 30 min					
99295	C	Neonatal critical care					
99296	C	Neonatal critical care					
99297	C	Neonatal critical care					
99298	C	Neonatal critical care					
99301	E	Nursing facility care					
99302	E	Nursing facility care					
99303	E	Nursing facility care					
99311	E	Nursing fac care, subseq					
99312	E	Nursing fac care, subseq					
99313	E	Nursing fac care, subseq					
99315	E	Nursing fac discharge day					
99316	E	Nursing fac discharge day					
99321	E	Rest home visit, new patient					
99322	E	Rest home visit, new patient					
99323	E	Rest home visit, new patient					
99331	E	Rest home visit, est pat					
99332	E	Rest home visit, est pat					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
99333	E	Rest home visit, est pat					
99341	E	Home visit, new patient					
99342	E	Home visit, new patient					
99343	E	Home visit, new patient					
99344	E	Home visit, new patient					
99345	E	Home visit, new patient					
99347	E	Home visit, est patient					
99348	E	Home visit, est patient					
99349	E	Home visit, est patient					
99350	E	Home visit, est patient					
99354	N	Prolonged service, office					
99355	N	Prolonged service, office					
99356	C	Prolonged service, inpatient					
99357	C	Prolonged service, inpatient					
99358	N	Prolonged serv, w/o contact					
99359	N	Prolonged serv, w/o contact					
99360	E	Physician standby services					
99361	E	Physician/team conference					
99362	E	Physician/team conference					
99371	E	Physician phone consultation					
99372	E	Physician phone consultation					
99373	E	Physician phone consultation					
99374	E	Home health care supervision					
99377	E	Hospice care supervision					
99379	E	Nursing fac care supervision					
99380	E	Nursing fac care supervision					
99381	E	Prev visit, new, infant					
99382	E	Prev visit, new, age 1-4					
99383	E	Prev visit, new, age 5-11					
99384	E	Prev visit, new, age 12-17					
99385	E	Prev visit, new, age 18-39					
99386	E	Prev visit, new, age 40-64					
99387	E	Prev visit, new, 65 & over					
99391	E	Prev visit, est, infant					
99392	E	Prev visit, est, age 1-4					
99393	E	Prev visit, est, age 5-11					
99394	E	Prev visit, est, age 12-17					
99395	E	Prev visit, est, age 18-39					
99396	E	Prev visit, est, age 40-64					
99397	E	Prev visit, est, 65 & over					
99401	E	Preventive counseling, indiv					
99402	E	Preventive counseling, indiv					
99403	E	Preventive counseling, indiv					
99404	E	Preventive counseling, indiv					
99411	E	Preventive counseling, group					
99412	E	Preventive counseling, group					
99420	E	Health risk assessment test					
99429	E	Unlisted preventive service					
99431	N	Initial care, normal newborn					
99432	N	Newborn care, not in hosp					
99433	C	Normal newborn care/hospital					
99435	E	Newborn discharge day hosp					
99436	N	Attendance, birth					
99440	S	Newborn resuscitation	0094	5.69	$289.29	$105.29	$57.86
99450	E	Life/disability evaluation					
99455	E	Disability examination					
99456	E	Disability examination					
99499	E	Unlisted e&m service					
A0021	E	Outside state ambulance serv					
A0080	E	Noninterest escort in non er					
A0090	E	Interest escort in non er					
A0100	E	Nonemergency transport taxi					
A0110	E	Nonemergency transport bus					
A0120	E	Noner transport mini-bus					
A0130	E	Noner transport wheelch van					
A0140	E	Nonemergency transport air					
A0160	E	Noner transport case worker					
A0170	E	Noner transport parking fees					
A0180	E	Noner transport lodgng recip					
A0190	E	Noner transport meals recip					
A0200	E	Noner transport lodgng escrt					
A0210	E	Noner transport meals escort					
A0225	A	Neonatal emergency transport					
A0382	A	Basic support routine suppls					
A0384	A	Bls defibrillation supplies					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
A0392	A	Als defibrillation supplies					
A0394	A	Als IV drug therapy supplies					
A0396	A	Als esophageal intub suppls					
A0398	A	Als routine disposble suppls					
A0420	A	Ambulance waiting 1/2 hr					
A0422	A	Ambulance 02 life sustaining					
A0424	A	Extra ambulance attendant					
A0425	A	Ground mileage					
A0426	A	Als 1					
A0427	A	ALS1-emergency					
A0428	A	bls					
A0429	A	BLS-emergency					
A0430	A	Fixed wing air transport					
A0431	A	Rotary wing air transport					
A0432	A	PI volunteer ambulance co					
A0433	A	als 2					
A0434	A	Specialty care transport					
A0435	A	Fixed wing air mileage					
A0436	A	Rotary wing air mileage					
A0888	E	Noncovered ambulance mileage					
A0999	A	Unlisted ambulance service					
A4206	A	1 CC sterile syringe&needle					
A4207	A	2 CC sterile syringe&needle					
A4208	A	3 CC sterile syringe&needle					
A4209	E	5+ CC sterile syringe&needle					
A4210	E	Nonneedle injection device					
A4211	E	Supp for self-adm injections					
A4212	E	Non coring needle or stylet					
A4213	E	20+ CC syringe only					
A4214	A	30 CC sterile water/saline					
A4215	E	Sterile needle					
A4220	A	Infusion pump refill kit					
A4221	A	Maint drug infus cath per wk					
A4222	A	Drug infusion pump supplies					
A4230	A	Infus insulin pump non needl					
A4231	A	Infusion insulin pump needle					
A4232	A	Syringe w/needle insulin 3cc					
A4244	E	Alcohol or peroxide per pint					
A4245	E	Alcohol wipes per box					
A4246	E	Betadine/phisohex solution					
A4247	E	Betadine/iodine swabs/wipes					
A4250	E	Urine reagent strips/tablets					
A4253	A	Blood glucose/reagent strips					
A4254	A	Battery for glucose monitor					
A4255	A	Glucose monitor platforms					
A4256	A	Calibrator solution/chips					
A4258	A	Lancet device each					
A4259	A	Lancets per box					
A4260	E	Levonorgestrel implant					
A4261	E	Cervical cap contraceptive					
A4262	N	Temporary tear duct plug					
A4263	N	Permanent tear duct plug					
A4265	A	Paraffin					
A4270	A	Disposable endoscope sheath					
A4280	A	Brst prsths adhsv attchmnt					
A4290	N	Sacral nerve stim test lead					
A4300	A	Cath impl vasc access portal					
A4301	A	Implantable access syst perc					
A4305	A	Drug delivery system >=50 ML					
A4306	A	Drug delivery system <=5 ML					
A4310	A	Insert tray w/o bag/cath					
A4311	A	Catheter w/o bag 2-way latex					
A4312	A	Cath w/o bag 2-way silicone					
A4313	A	Catheter w/bag 3-way					
A4314	A	Cath w/drainage 2-way latex					
A4315	A	Cath w/drainage 2-way silcne					
A4316	A	Cath w/drainage 3-way					
A4319	A	Sterile H2O irrigation solut					
A4320	A	Irrigation tray					
A4321	A	Cath therapeutic irrig agent					
A4322	A	Irrigation syringe					
A4323	A	Saline irrigation solution					
A4324	A	Male ext cath w/adh coating					
A4325	A	Male ext cath w/adh strip					
A4326	A	Male external catheter					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
A4327	A	Fem urinary collect dev cup					
A4328	A	Fem urinary collect pouch					
A4329	A	External catheter start set					
A4330	A	Stool collection pouch					
A4331	A	Extension drainage tubing					
A4332	A	Lubricant for cath insertion					
A4333	A	Urinary cath anchor device					
A4334	A	Urinary cath leg strap					
A4335	A	Incontinence supply					
A4338	A	Indwelling catheter latex					
A4340	A	Indwelling catheter special					
A4344	A	Cath indw foley 2 way silicn					
A4346	A	Cath indw foley 3 way					
A4347	A	Male external catheter					
A4348	A	Male ext cath extended wear					
A4351	A	Straight tip urine catheter					
A4352	A	Coude tip urinary catheter					
A4353	A	Intermittent urinary cath					
A4354	A	Cath insertion tray w/bag					
A4355	A	Bladder irrigation tubing					
A4356	A	Ext ureth clmp or compr dvc					
A4357	A	Bedside drainage bag					
A4358	A	Urinary leg bag					
A4359	A	Urinary suspensory w/o leg b					
A4361	A	Ostomy face plate					
A4362	A	Solid skin barrier					
A4364	A	Adhesive, liquid or equal					
A4365	A	Adhesive remover wipes					
A4367	A	Ostomy belt					
A4368	A	Ostomy filter					
A4369	A	Skin barrier liquid per oz					
A4370	A	Skin barrier paste per oz					
A4371	A	Skin barrier powder per oz					
A4372	A	Skin barrier solid 4x4 equiv					
A4373	A	Skin barrier with flange					
A4374	A	Skin barrier extended wear					
A4375	A	Drainable plastic pch w fcpl					
A4376	A	Drainable rubber pch w fcplt					
A4377	A	Drainable plstic pch w/o fp					
A4378	A	Drainable rubber pch w/o fp					
A4379	A	Urinary plastic pouch w fcpl					
A4380	A	Urinary rubber pouch w fcplt					
A4381	A	Urinary plastic pouch w/o fp					
A4382	A	Urinary hvy plstc pch w/o fp					
A4383	A	Urinary rubber pouch w/o fp					
A4384	A	Ostomy faceplt/silicone ring					
A4385	A	Ost skn barrier sld ext wear					
A4386	A	Ost skn barrier w flng ex wr					
A4387	A	Ost clsd pouch w att st barr					
A4388	A	Drainable pch w ex wear barr					
A4389	A	Drainable pch w st wear barr					
A4390	A	Drainable pch ex wear convex					
A4391	A	Urinary pouch w ex wear barr					
A4392	A	Urinary pouch w st wear barr					
A4393	A	Urine pch w ex wear bar conv					
A4394	A	Ostomy pouch liq deodorant					
A4395	A	Ostomy pouch solid deodorant					
A4396	A	Peristomal hernia supprt blt					
A4397	A	Irrigation supply sleeve					
A4398	A	Ostomy irrigation bag					
A4399	A	Ostomy irrig cone/cath w brs					
A4400	A	Ostomy irrigation set					
A4402	A	Lubricant per ounce					
A4404	A	Ostomy ring each					
A4421	A	Ostomy supply misc					
A4454	A	Tape all types all sizes					
A4455	A	Adhesive remover per ounce					
A4460	A	Elastic compression bandage					
A4462	A	Abdmnl drssng holder/binder					
A4464	A	Joint support device/garment					
A4465	A	Non-elastic extremity binder					
A4470	A	Gravlee jet washer					
A4480	A	Vabra aspirator					
A4481	A	Tracheostoma filter					
A4483	A	Moisture exchanger					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
A4490	E	Above knee surgical stocking					
A4495	E	Thigh length surg stocking					
A4500	E	Below knee surgical stocking					
A4510	E	Full length surg stocking					
A4550	E	Surgical trays					
A4554	E	Disposable underpads					
A4556	A	Electrodes, pair					
A4557	A	Lead wires, pair					
A4558	A	Conductive paste or gel					
A4561	N	Pessary rubber, any type					
A4562	N	Pessary, non rubber,any type					
A4565	A	Slings					
A4570	N	Splint					
A4572	A	Rib belt					
A4575	E	Hyperbaric o2 chamber disps					
A4580	N	Cast supplies (plaster)					
A4590	N	Special casting material					
A4595	A	TENS suppl 2 lead per month					
A4608	A	Transtracheal oxygen cath					
A4611	A	Heavy duty battery					
A4612	A	Battery cables					
A4613	A	Battery charger					
A4614	A	Hand-held PEFR meter					
A4615	A	Cannula nasal					
A4616	A	Tubing (oxygen) per foot					
A4617	A	Mouth piece					
A4618	A	Breathing circuits					
A4619	A	Face tent					
A4620	A	Variable concentration mask					
A4621	A	Tracheotomy mask or collar					
A4622	A	Tracheostomy or larngectomy					
A4623	A	Tracheostomy inner cannula					
A4624	A	Tracheal suction tube					
A4625	A	Trach care kit for new trach					
A4626	A	Tracheostomy cleaning brush					
A4627	E	Spacer bag/reservoir					
A4628	A	Oropharyngeal suction cath					
A4629	A	Tracheostomy care kit					
A4630	A	Repl bat t.e.n.s. own by pt					
A4631	A	Wheelchair battery					
A4635	A	Underarm crutch pad					
A4636	A	Handgrip for cane etc					
A4637	A	Repl tip cane/crutch/walker					
A4640	A	Alternating pressure pad					
A4641	N	Diagnostic imaging agent					
A4642	G	Satumomab pendetide per dose	0704		$831.25		$119.00
A4643	N	High dose contrast MRI					
A4644	N	Contrast 100-199 MGs iodine					
A4645	N	Contrast 200-299 MGs iodine					
A4646	N	Contrast 300-399 MGs iodine					
A4647	N	Supp- paramagnetic contr mat					
A4649	A	Surgical supplies					
A4650	A	Supp esrd centrifuge					
A4655	A	Esrd syringe/needle					
A4660	A	Esrd blood pressure device					
A4663	A	Esrd blood pressure cuff					
A4670	E	Auto blood pressure monitor					
A4680	A	Activated carbon filters					
A4690	A	Dialyzers					
A4700	A	Standard dialysate solution					
A4705	A	Bicarb dialysate solution					
A4712	A	Sterile water					
A4714	A	Treated water for dialysis					
A4730	A	Fistula cannulation set dial					
A4735	A	Local/topical anesthetics					
A4740	A	Esrd shunt accessory					
A4750	A	Arterial or venous tubing					
A4755	A	Arterial and venous tubing					
A4760	A	Standard testing solution					
A4765	A	Dialysate concentrate					
A4770	A	Blood testing supplies					
A4771	A	Blood clotting time tube					
A4772	A	Dextrostick/glucose strips					
A4773	A	Hemostix					
A4774	A	Ammonia test paper					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
A4780	A	Esrd sterilizing agent					
A4790	A	Esrd cleansing agents					
A4800	A	Heparin/antidote dialysis					
A4820	A	Supplies hemodialysis kit					
A4850	A	Rubber tipped hemostats					
A4860	A	Disposable catheter caps					
A4870	A	Plumbing/electrical work					
A4880	A	Water storage tanks					
A4890	A	Contracts/repair/maintenance					
A4900	A	Capd supply kit					
A4901	A	Ccpd supply kit					
A4905	A	Ipd supply kit					
A4910	A	Esrd nonmedical supplies					
A4912	A	Gomco drain bottle					
A4913	A	Esrd supply					
A4914	A	Preparation kit					
A4918	A	Venous pressure clamp					
A4919	A	Supp dialysis dialyzer holde					
A4920	A	Harvard pressure clamp					
A4921	A	Measuring cylinder					
A4927	A	Gloves					
A5051	A	Pouch clsd w barr attached					
A5052	A	Clsd ostomy pouch w/o barr					
A5053	A	Clsd ostomy pouch faceplate					
A5054	A	Clsd ostomy pouch w/flange					
A5055	A	Stoma cap					
A5061	A	Pouch drainable w barrier at					
A5062	A	Drnble ostomy pouch w/o barr					
A5063	A	Drain ostomy pouch w/flange					
A5064	E	Drain ostomy pouch w/fceplte					
A5071	A	Urinary pouch w/barrier					
A5072	A	Urinary pouch w/o barrier					
A5073	A	Urinary pouch on barr w/flng					
A5074	E	Urinary pouch w/faceplate					
A5075	E	Urinary pouch on faceplate					
A5081	A	Continent stoma plug					
A5082	A	Continent stoma catheter					
A5093	A	Ostomy accessory convex inse					
A5102	A	Bedside drain btl w/wo tube					
A5105	A	Urinary suspensory					
A5112	A	Urinary leg bag					
A5113	A	Latex leg strap					
A5114	A	Foam/fabric leg strap					
A5119	A	Skin barrier wipes box pr 50					
A5121	A	Solid skin barrier 6x6					
A5122	A	Solid skin barrier 8x8					
A5123	A	Skin barrier with flange					
A5126	A	Disk/foam pad +or- adhesive					
A5131	A	Appliance cleaner					
A5200	A	Percutaneous catheter anchor					
A5500	A	Diab shoe for density insert					
A5501	A	Diabetic custom molded shoe					
A5502	A	Diabetic shoe density insert					
A5503	A	Diabetic shoe w/roller/rockr					
A5504	A	Diabetic shoe with wedge					
A5505	A	Diab shoe w/metatarsal bar					
A5506	A	Diabetic shoe w/off set heel					
A5507	A	Modification diabetic shoe					
A5508	A	Diabetic deluxe shoe					
A6021	A	Collagen dressing <=16 sq in					
A6022	A	Collagen drsg>6<=48 sq in					
A6023	A	Collagen dressing >48 sq in					
A6024	A	Collagen dsg wound filler					
A6025	E	Silicone gel sheet, each					
A6154	A	Wound pouch each					
A6196	A	Alginate dressing <=16 sq in					
A6197	A	Alginate drsg >16 <=48 sq in					
A6198	A	alginate dressing > 48 sq in					
A6199	A	Alginate drsg wound filler					
A6200	A	Compos drsg <=16 no border					
A6201	A	Compos drsg >16<=48 no bdr					
A6202	A	Compos drsg >48 no border					
A6203	A	Composite drsg <= 16 sq in					
A6204	A	Composite drsg >16<=48 sq in					
A6205	A	Composite drsg > 48 sq in					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
A6206	A	Contact layer <= 16 sq in					
A6207	A	Contact layer >16<= 48 sq in					
A6208	A	Contact layer > 48 sq in					
A6209	A	Foam drsg <=16 sq in w/o bdr					
A6210	A	Foam drg >16<=48 sq in w/o b					
A6211	A	Foam drg > 48 sq in w/o brdr					
A6212	A	Foam drg <=16 sq in w/border					
A6213	A	Foam drg >16<=48 sq in w/bdr					
A6214	A	Foam drg > 48 sq in w/border					
A6215	A	Foam dressing wound filler					
A6216	A	Non-sterile gauze<=16 sq in					
A6217	A	Non-sterile gauze>16<=48 sq					
A6218	A	Non-sterile gauze > 48 sq in					
A6219	A	Gauze <= 16 sq in w/border					
A6220	A	Gauze >16 <=48 sq in w/bordr					
A6221	A	Gauze > 48 sq in w/border					
A6222	A	Gauze <=16 in no w/sal w/o b					
A6223	A	Gauze >16<=48 no w/sal w/o b					
A6224	A	Gauze > 48 in no w/sal w/o b					
A6228	A	Gauze <= 16 sq in water/sal					
A6229	A	Gauze >16<=48 sq in watr/sal					
A6230	A	Gauze > 48 sq in water/salne					
A6231	A	Hydrogel dsg<=16 sq in					
A6232	A	Hydrogel dsg>16<=48 sq in					
A6233	A	Hydrogel dressing >48 sq in					
A6234	A	Hydrocolld drg <=16 w/o bdr					
A6235	A	Hydrocolld drg >16<=48 w/o b					
A6236	A	Hydrocolld drg > 48 in w/o b					
A6237	A	Hydrocolld drg <=16 in w/bdr					
A6238	A	Hydrocolld drg >16<=48 w/bdr					
A6239	A	Hydrocolld drg > 48 in w/bdr					
A6240	A	Hydrocolld drg filler paste					
A6241	A	Hydrocolloid drg filler dry					
A6242	A	Hydrogel drg <=16 in w/o bdr					
A6243	A	Hydrogel drg >16<=48 w/o bdr					
A6244	A	Hydrogel drg >48 in w/o bdr					
A6245	A	Hydrogel drg <= 16 in w/bdr					
A6246	A	Hydrogel drg >16<=48 in w/b					
A6247	A	Hydrogel drg > 48 sq in w/b					
A6248	A	Hydrogel drsg gel filler					
A6250	A	Skin seal protect moisturizr					
A6251	A	Absorpt drg <=16 sq in w/o b					
A6252	A	Absorpt drg >16 <=48 w/o bdr					
A6253	A	Absorpt drg > 48 sq in w/o b					
A6254	A	Absorpt drg <=16 sq in w/bdr					
A6255	A	Absorpt drg >16<=48 in w/bdr					
A6256	A	Absorpt drg > 48 sq in w/bdr					
A6257	A	Transparent film <= 16 sq in					
A6258	A	Transparent film >16<=48 in					
A6259	A	Transparent film > 48 sq in					
A6260	A	Wound cleanser any type/size					
A6261	A	Wound filler gel/paste /oz					
A6262	A	Wound filler dry form / gram					
A6263	A	Non-sterile elastic gauze/yd					
A6264	A	Non-sterile no elastic gauze					
A6265	A	Tape per 18 sq inches					
A6266	A	Impreg gauze no h20/sal/yard					
A6402	A	Sterile gauze <= 16 sq in					
A6403	A	Sterile gauze>16 <= 48 sq in					
A6404	A	Sterile gauze > 48 sq in					
A6405	A	Sterile elastic gauze /yd					
A6406	A	Sterile non-elastic gauze/yd					
A7000	A	Disposable canister for pump					
A7001	A	Nondisposable pump canister					
A7002	A	Tubing used w suction pump					
A7003	A	Nebulizer administration set					
A7004	A	Disposable nebulizer sml vol					
A7005	A	Nondisposable nebulizer set					
A7006	A	Filtered nebulizer admin set					
A7007	A	Lg vol nebulizer disposable					
A7008	A	Disposable nebulizer prefill					
A7009	A	Nebulizer reservoir bottle					
A7010	A	Disposable corrugated tubing					
A7011	A	Nondispos corrugated tubing					
A7012	A	Nebulizer water collec devic					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
A7013	A	Disposable compressor filter					
A7014	A	Compressor nondispos filter					
A7015	A	Aerosol mask used w nebulize					
A7016	A	Nebulizer dome & mouthpiece					
A7017	A	Nebulizer not used w oxygen					
A7018	A	Water distilled w/nebulizer					
A7019	A	Saline solution dispenser					
A7020	A	Sterile H2O or NSS w lgv neb					
A7501	A	Tracheostoma valve w diaphra					
A7502	A	Replacement diaphragm/fplate					
A7503	A	HMES filter holder or cap					
A7504	A	Tracheostoma HMES filter					
A7505	A	HMES or trach valve housing					
A7506	A	HMES/trachvalve adhesivedisk					
A7507	A	Integrated filter & holder					
A7508	A	Housing & Integrated Adhesiv					
A7509	A	Heat & moisture exchange sys					
A9150	E	Misc/exper non-prescript dru					
A9160	E	Podiatrist non-covered servi					
A9170	E	Chiropractor non-covered ser					
A9190	E	Misc/expe personal comfort i					
A9270	E	Non-covered item or service					
A9300	E	Exercise equipment					
A9500	G	Technetium TC 99m sestamibi	1600		$115.90		$16.59
A9502	G	Technetium TC99M tetrofosmin	0705		$129.96		$18.60
A9503	G	Technetium TC 99m medronate	1601		$36.46		$3.30
A9504	G	Technetium tc 99m apcitide	1602		$45.13		$6.46
A9505	G	Thallous chloride TL 201/mci	1603		$29.45		$3.78
A9507	G	Indium/111 capromab pendetid	1604		$1,128.13		$161.50
A9508	G	Iobenguane sulfate I-131	1045		$495.65		$44.87
A9510	G	Technetium TC99m Disofenin	1205		$85.50		$7.74
A9600	G	Strontium-89 chloride	0701		$963.42		$137.92
A9605	G	Samarium sm153 lexidronamm	0702		$1,020.00		$146.02
A9700	G	Echocardiography Contrast	9016		$39.58		$5.67
A9900	A	Supply/accessory/service					
A9901	A	Delivery/set up/dispensing					
B4034	A	Enter feed supkit syr by day					
B4035	A	Enteral feed supp pump per d					
B4036	A	Enteral feed sup kit grav by					
B4081	A	Enteral ng tubing w/ stylet					
B4082	A	Enteral ng tubing w/o stylet					
B4083	A	Enteral stomach tube levine					
B4084	A	Gastrostomy/jejunostomy tubi					
B4085	A	Gastrostomy tube w/ring each					
B4150	A	Enteral formulae category i					
B4151	A	Enteral formulae cat1natural					
B4152	A	Enteral formulae category ii					
B4153	A	Enteral formulae categoryIII					
B4154	A	Enteral formulae category IV					
B4155	A	Enteral formulae category v					
B4156	A	Enteral formulae category vi					
B4164	A	Parenteral 50% dextrose solu					
B4168	A	Parenteral sol amino acid 3.					
B4172	A	Parenteral sol amino acid 5.					
B4176	A	Parenteral sol amino acid 7-					
B4178	A	Parenteral sol amino acid >					
B4180	A	Parenteral sol carb > 50%					
B4184	A	Parenteral sol lipids 10%					
B4186	A	Parenteral sol lipids 20%					
B4189	A	Parenteral sol amino acid &					
B4193	A	Parenteral sol 52-73 gm prot					
B4197	A	Parenteral sol 74-100 gm pro					
B4199	A	Parenteral sol > 100gm prote					
B4216	A	Parenteral nutrition additiv					
B4220	A	Parenteral supply kit premix					
B4222	A	Parenteral supply kit homemi					
B4224	A	Parenteral administration ki					
B5000	A	Parenteral sol renal-amirosy					
B5100	A	Parenteral sol hepatic-fream					
B5200	A	Parenteral sol stres-brnch c					
B9000	A	Enter infusion pump w/o alrm					
B9002	A	Enteral infusion pump w/ ala					
B9004	A	Parenteral infus pump portab					
B9006	A	Parenteral infus pump statio					
B9998	A	Enteral supp not otherwise c					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
B9999	A	Parenteral supp not othrws c					
C1010	K	Blood, L/R, CMV-NEG	1010	2.94	$149.48		$29.90
C1011	K	Platelets, HLA-m, L/R, unit	1011	12.12	$616.21		$123.24
C1012	K	PLATELET CONC, L/R, Irrad	1012	1.96	$99.65		$19.93
C1013	K	PLATELET CONC, L/R, Unit	1013	1.20	$61.01		$12.20
C1014	K	Platelet,Aph/Pher, L/R, unit	1014	9.13	$464.19		$92.84
C1016	K	BLOOD,L/R,FROZ/DEGLY/Washed	1016	7.31	$371.66		$74.33
C1017	K	Plt, APH/PHER,L/R,CMV-NEG	1017	9.53	$484.52		$96.90
C1018	K	Blood, L/R, IRRADIATED	1018	3.20	$162.69		$32.54
C1019	K	Plt, APH/PHER, L/R, IRRAD	1019	9.85	$500.79		$100.16
C1050	S	PROSORBA Column	0976	16.56	$841.94		$168.39
C1079	G	CO 57/58 0.5 Mci	1079		$253.84		$36.34
C1087	G	I-123 per uci, dx use	1087		$.65		$.09
C1088	T	LASER OPTIC TR Sys	0980	35.49	$1,804.38		$360.88
C1090	G	IN 111 chloride, per mCi	1090		$152.00		$21.76
C1091	G	IN 111 oxyquinoline,per 5mCi	1091		$482.84		$69.12
C1092	G	IN 111 PENETATE, PER 1.5 mci	1092		$769.50		$110.16
C1094	G	TC 99M albumin aggr, per via	1094		$33.09		$4.74
C1095	G	TC 99M DEPREOTIDE, PER Vial	1095		$760.00		$108.80
C1096	G	TC 99M EXAMETAZIME, PER Dose	1096		$423.04		$60.56
C1097	G	TC 99M MEBROFENIN, PER Vial	1097		$51.43		$7.36
C1098	G	TC 99M PENTETATE, PER Vial	1098		$22.64		$2.76
C1099	G	TC 99M PYROPHOSPHATE,PER Via	1099		$42.75		$6.12
C1122	G	Tc 99M ARCITUMOMAB PER VIAL	1122		$1,235.00		$176.80
C1166	G	CYTARABINE LIPOSOMAL, 10 mg	1166		$371.45		$53.18
C1167	G	EPIRUBICIN HCL, 2 mg	1167		$24.94		$3.57
C1178	G	BUSULFAN IV, 6 Mg	1178		$26.49		$3.79
C1188	G	I-131 per uci, dx use	1188		$.78		$.10
C1200	G	TC 99M Sodium Glucoheptonat	1200		$107.40		$15.37
C1201	G	TC 99M SUCCIMER, PER Vial	1201		$135.66		$19.42
C1202	G	TC 99M SULFUR COLLOID, Vial	1202		$36.10		$3.27
C1207	G	OCTREOTIDE ACETATE DEPOT 1mg	1207		$140.37		$20.10
C1300	S	HYPERBARIC Oxygen	0971	1.42	$72.20		$14.44
C1305	G	Apligraf	1305		$1,157.81		$165.75
C1348	G	I-131 per mci sol, rx use	1348		$146.57		$20.98
C1713	H	Anchor/screw bn/bn,tis/bn	1713				
C1714	H	Cath, trans atherectomy, dir	1714				
C1715	H	Brachytherapy needle	1715				
C1716	H	Brachytx seed, Gold 198	1716				
C1717	H	Brachytx seed, HDR Ir-192	1717				
C1718	H	Brachytx seed, Iodine 125	1718				
C1719	H	Brachytx seed,Non-HDR Ir-192	1719				
C1720	H	Brachytx seed, Palladium 103	1720				
C1721	H	AICD, dual chamber	1721				
C1722	H	AICD, single chamber	1722				
C1723	H	Cath, ablation, non-cardiac	1723				
C1724	H	Cath, trans atherec,rotation	1724				
C1725	H	Cath, translumin non-laser	1725				
C1726	H	Cath, bal dil, non-vascular	1726				
C1727	H	Cath, bal tis dis, non-vas	1727				
C1728	H	Cath, brachytx seed adm	1728				
C1729	H	Cath, drainage	1729				
C1730	H	Cath, EP, 19 or few elect	1730				
C1731	H	Cath, EP, 20 or more elec	1731				
C1732	H	Cath, EP, diag/abl, 3D/vect	1732				
C1733	H	Cath, EP, othr than cool-tip	1733				
C1750	H	Cath, hemodialysis,long-term	1750				
C1751	H	Cath, inf, per/cent/midline	1751				
C1752	H	Cath,hemodialysis,short-term	1752				
C1753	H	Cath, intravas ultrasound	1753				
C1754	H	Catheter, intradiscal	1754				
C1755	H	Catheter, intraspinal	1755				
C1756	H	Cath, pacing, transesoph	1756				
C1757	H	Cath, thrombectomy/embolect	1757				
C1758	H	Catheter, ureteral	1758				
C1759	H	Cath, intra echocardiography	1759				
C1760	H	Closure dev, vasc	1760				
C1762	H	Conn tiss, human(inc fascia)	1762				
C1763	H	Conn tiss, non-human	1763				
C1764	H	Event recorder, cardiac	1764				
C1765	H	Adhesion barrier	1765				
C1766	H	Intro/sheath,strble,non-peel	1766				
C1767	H	Generator, neurostim, imp	1767				
C1768	H	Graft, vascular	1768				
C1769	H	Guide wire	1769				

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
C1770	H	Imaging coil, MR, insertable	1770				
C1771	H	Rep dev, urinary, w/sling	1771				
C1772	H	Infusion pump, programmable	1772				
C1773	H	Ret dev, insertable	1773				
C1776	H	Joint device (implantable)	1776				
C1777	H	Lead, AICD, endo single coil	1777				
C1778	H	Lead, neurostimulator	1778				
C1779	H	Lead, pmkr, transvenous VDD	1779				
C1780	H	Lens, intraocular (new tech)	1780				
C1781	H	Mesh (implantable)	1781				
C1782	H	Morcellator	1782				
C1784	H	Ocular dev, intraop, det ret	1784				
C1785	H	Pmkr, dual, rate-resp	1785				
C1786	H	Pmkr, single, rate-resp	1786				
C1787	H	Patient progr, neurostim	1787				
C1788	H	Port, indwelling, imp	1788				
C1789	H	Prosthesis, breast, imp	1789				
C1813	H	Prosthesis, penile, inflatab	1813				
C1815	H	Pros, urinary sph, imp	1815				
C1816	H	Receiver/transmitter, neuro	1816				
C1817	H	Septal defect imp sys	1817				
C1874	H	Stent, coated/cov w/del sys	1874				
C1875	H	Stent, coated/cov w/o del sy	1875				
C1876	H	Stent, non-coa/non-cov w/del	1876				
C1877	H	Stent, non-coat/cov w/o del	1877				
C1878	H	Matrl for vocal cord	1878				
C1879	H	Tissue marker, implantable	1879				
C1880	H	Vena cava filter	1880				
C1881	H	Dialysis access system	1881				
C1882	H	AICD, other than sing/dual	1882				
C1883	H	Adapt/ext, pacing/neuro lead	1883				
C1885	H	Cath, translumin angio laser	1885				
C1887	H	Catheter, guiding	1887				
C1891	H	Infusion pump,non-prog, perm	1891				
C1892	H	Intro/sheath,fixed,peel-away	1892				
C1893	H	Intro/sheath, fixed,non-peel	1893				
C1894	H	Intro/sheath, non-laser	1894				
C1895	H	Lead, AICD, endo dual coil	1895				
C1896	H	Lead, AICD, non sing/dual	1896				
C1897	H	Lead, neurostim test kit	1897				
C1898	H	Lead, pmkr, other than trans	1898				
C1899	H	Lead, pmkr/AICD combination	1899				
C2615	H	Sealant, pulmonary, liquid	2615				
C2616	H	Brachytx seed, Yttrium-90	2616				
C2617	H	Stent, non-cor, tem w/o del	2617				
C2618	H	Probe, cryoablation	2618				
C2619	H	Pmkr, dual, non rate-resp	2619				
C2620	H	Pmkr, single, non rate-resp	2620				
C2621	H	Pmkr, other than sing/dual	2621				
C2622	H	Prosthesis, penile, non-inf	2622				
C2625	H	Stent, non-cor, tem w/del sy	2625				
C2626	H	Infusion pump, non-prog,temp	2626				
C2627	H	Cath, suprapubic/cystoscopic	2627				
C2628	H	Catheter, occlusion	2628				
C2629	H	Intro/sheath, laser	2629				
C2630	H	Cath, EP, cool-tip	2630				
C2631	H	Rep dev, urinary, w/o sling	2631				
C8900	S	MRA w/cont, abd	0284	7.80	$396.57	$218.11	$79.31
C8901	S	MRA w/o cont, abd	0336	6.85	$348.27	$191.55	$69.65
C8902	S	MRA w/o fol w/cont, abd	0337	9.26	$470.80	$258.94	$94.16
C8903	S	MRI w/cont, breast, uni	0284	7.80	$396.57	$218.11	$79.31
C8904	S	MRI w/o cont, breast, uni	0336	6.85	$348.27	$191.55	$69.65
C8905	S	MRI w/o fol w/cont, brst, un	0337	9.26	$470.80	$258.94	$94.16
C8906	S	MRI w/cont, breast, bi	0284	7.80	$396.57	$218.11	$79.31
C8907	S	MRI w/o cont, breast, bi	0336	6.85	$348.27	$191.55	$69.65
C8908	S	MRI w/o fol w/cont, breast,	0337	9.26	$470.80	$258.94	$94.16
C8909	S	MRA w/cont, chest	0284	7.80	$396.57	$218.11	$79.31
C8910	S	MRA w/o cont, chest	0336	6.85	$348.27	$191.55	$69.65
C8911	S	MRA w/o fol w/cont, chest	0337	9.26	$470.80	$258.94	$94.16
C8912	S	MRA w/cont, lwr ext	0284	7.80	$396.57	$218.11	$79.31
C8913	S	MRA w/o cont, lwr ext	0336	6.85	$348.27	$191.55	$69.65
C8914	S	MRA w/o fol w/cont, lwr ext	0337	9.26	$470.80	$258.94	$94.16
C9000	G	Na chromateCr51, per 0.25mCi	9000		$.32		$.05
C9001	G	Linezolid inj, 200mg	9001		$34.14		$4.89
C9002	G	Tenecteplase, 50mg/vial	9002		$2,612.50		$374.00

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
C9003	G	Palivizumab, per 50 mg	9003		$664.49		$95.13
C9004	G	Gemtuzumab ozogamicin inj,5m	9004		$1,929.69		$276.25
C9006	G	Tacrolimus inj, per 5 mg	9006		$113.15		$16.20
C9007	G	Baclofen Intrathecal kit-1am	9007		$79.80		$11.42
C9008	G	Baclofen Refill Kit-500mcg	9008		$233.70		$33.46
C9009	G	Baclofen Refill Kit-2000mcg	9009		$491.15		$70.31
C9010	G	Baclofen Refill Kit--4000mcg	9010		$861.65		$123.35
C9011	G	Caffeine Citrate, inj, 1ml	9011		$12.22		$1.75
C9012	G	Injection, arsenic trioxide	9012		$237.50		$34.00
C9013	G	Co 57 cobaltous chloride	9013		$10.02		$1.43
C9017	E	Lomustine, 10 mg					
C9018	G	Botulinum tox B, per 100 u	9018		$8.79		$1.26
C9019	G	Caspofungin acetate, 5 mg	9019		$34.20		$4.90
C9020	G	Sirolimus tablet, 1 mg	9020		$6.51		$.89
C9100	G	Iodinated I-131 Albumin	9100		$9.84		$1.41
C9102	G	51 Na Chromate, 50mCi	9102		$.65		$.09
C9103	G	Na Iothalamate I-125, 10 uCi	9103		$11.66		$1.67
C9104	G	Anti-thymocyte globulin,25mg	9104		$251.75		$36.04
C9105	G	Hep B imm glob, per 1 ml	9105		$135.43		$12.26
C9108	G	Thyrotropin alfa, 1.1 mg	9108		$531.05		$76.02
C9109	G	Tirofliban hcl, 6.25 mg	9109		$217.64		$31.16
C9503	K	Fresh frozen plasma, ea unit	9503	1.69	$85.92		$17.18
C9700	T	Water Induced Thermo	0977	21.30	$1,082.93		$216.59
C9701	S	Stretta System	0976	16.56	$841.94		$168.39
C9702	S	Chkmate/Novost/Galileo Brach	0981	42.59	$2,165.36		$433.07
C9708	T	Preview Tx Planning Software	0975	11.83	$601.46		$120.29
D0120	E	Periodic oral evaluation					
D0140	E	Limit oral eval problm focus					
D0150	S	Comprehensve oral evaluation	0330	7.68	$390.47	$78.09	$78.09
D0160	E	Extensv oral eval prob focus					
D0170	E	Re-eval,est pt,problem focus					
D0210	E	Intraor complete film series					
D0220	E	Intraoral periapical first f					
D0230	E	Intraoral periapical ea add					
D0240	S	Intraoral occlusal film	0330	7.68	$390.47	$78.09	$78.09
D0250	S	Extraoral first film	0330	7.68	$390.47	$78.09	$78.09
D0260	S	Extraoral ea additional film	0330	7.68	$390.47	$78.09	$78.09
D0270	S	Dental bitewing single film	0330	7.68	$390.47	$78.09	$78.09
D0272	S	Dental bitewings two films	0330	7.68	$390.47	$78.09	$78.09
D0274	S	Dental bitewings four films	0330	7.68	$390.47	$78.09	$78.09
D0277	S	Vert bitewings-sev to eight	0330	7.68	$390.47	$78.09	$78.09
D0290	E	Dental film skull/facial bon					
D0310	E	Dental saliography					
D0320	E	Dental tmj arthrogram incl i					
D0321	E	Dental other tmj films					
D0322	E	Dental tomographic survey					
D0330	E	Dental panoramic film					
D0340	E	Dental cephalometric film					
D0350	E	Oral/facial images					
D0415	E	Bacteriologic study					
D0425	E	Caries susceptibility test					
D0460	S	Pulp vitality test	0330	7.68	$390.47	$78.09	$78.09
D0470	E	Diagnostic casts					
D0472	S	Gross exam, prep & report	0330	7.68	$390.47	$78.09	$78.09
D0473	S	Micro exam, prep & report	0330	7.68	$390.47	$78.09	$78.09
D0474	S	Micro w exam of surg margins	0330	7.68	$390.47	$78.09	$78.09
D0480	S	Cytopath smear prep & report	0330	7.68	$390.47	$78.09	$78.09
D0501	S	Histopathologic examinations	0330	7.68	$390.47	$78.09	$78.09
D0502	S	Other oral pathology procedu	0330	7.68	$390.47	$78.09	$78.09
D0999	S	Unspecified diagnostic proce	0330	7.68	$390.47	$78.09	$78.09
D1110	E	Dental prophylaxis adult					
D1120	E	Dental prophylaxis child					
D1201	E	Topical fluor w prophy child					
D1203	E	Topical fluor w/o prophy chi					
D1204	E	Topical fluor w/o prophy adu					
D1205	E	Topical fluoride w/ prophy a					
D1310	E	Nutri counsel-control caries					
D1320	E	Tobacco counseling					
D1330	E	Oral hygiene instruction					
D1351	E	Dental sealant per tooth					
D1510	S	Space maintainer fxd unilat	0330	7.68	$390.47	$78.09	$78.09
D1515	S	Fixed bilat space maintainer	0330	7.68	$390.47	$78.09	$78.09
D1520	S	Remove unilat space maintain	0330	7.68	$390.47	$78.09	$78.09
D1525	S	Remove bilat space maintain	0330	7.68	$390.47	$78.09	$78.09
D1550	S	Recement space maintainer	0330	7.68	$390.47	$78.09	$78.09

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
D2110	E	Amalgam one surface primary					
D2120	E	Amalgam two surfaces primary					
D2130	E	Amalgam three surfaces prima					
D2131	E	Amalgam four/more surf prima					
D2140	E	Amalgam one surface permanen					
D2150	E	Amalgam two surfaces permane					
D2160	E	Amalgam three surfaces perma					
D2161	E	Amalgam 4 or > surfaces perm					
D2330	E	Resin one surface-anterior					
D2331	E	Resin two surfaces-anterior					
D2332	E	Resin three surfaces-anterio					
D2335	E	Resin 4/> surf or w incis an					
D2336	E	Composite resin crown					
D2337	E	Compo resin crown ant-perm					
D2380	E	Resin one surf poster primar					
D2381	E	Resin two surf poster primar					
D2382	E	Resin three/more surf post p					
D2385	E	Resin one surf poster perman					
D2386	E	Resin two surf poster perman					
D2387	E	Resin three/more surf post p					
D2388	E	Resin four/more, post perm					
D2410	E	Dental gold foil one surface					
D2420	E	Dental gold foil two surface					
D2430	E	Dental gold foil three surfa					
D2510	E	Dental inlay metalic 1 surf					
D2520	E	Dental inlay metallic 2 surf					
D2530	E	Dental inlay metl 3/more sur					
D2542	E	Dental onlay metallic 2 surf					
D2543	E	Dental onlay metallic 3 surf					
D2544	E	Dental onlay metl 4/more sur					
D2610	E	Inlay porcelain/ceramic 1 su					
D2620	E	Inlay porcelain/ceramic 2 su					
D2630	E	Dental onlay porc 3/more sur					
D2642	E	Dental onlay porcelin 2 surf					
D2643	E	Dental onlay porcelin 3 surf					
D2644	E	Dental onlay porc 4/more sur					
D2650	E	Inlay composite/resin one su					
D2651	E	Inlay composite/resin two su					
D2652	E	Dental inlay resin 3/mre sur					
D2662	E	Dental onlay resin 2 surface					
D2663	E	Dental onlay resin 3 surface					
D2664	E	Dental onlay resin 4/mre sur					
D2710	E	Crown resin laboratory					
D2720	E	Crown resin w/ high noble me					
D2721	E	Crown resin w/ base metal					
D2722	E	Crown resin w/ noble metal					
D2740	E	Crown porcelain/ceramic subs					
D2750	E	Crown porcelain w/ h noble m					
D2751	E	Crown porcelain fused base m					
D2752	E	Crown porcelain w/ noble met					
D2780	E	Crown 3/4 cast hi noble met					
D2781	E	Crown 3/4 cast base metal					
D2782	E	Crown 3/4 cast noble metal					
D2783	E	Crown 3/4 porcelain/ceramic					
D2790	E	Crown full cast high noble m					
D2791	E	Crown full cast base metal					
D2792	E	Crown full cast noble metal					
D2799	E	Provisional crown					
D2910	E	Dental recement inlay					
D2920	E	Dental recement crown					
D2930	E	Prefab stnlss steel crwn pri					
D2931	E	Prefab stnlss steel crown pe					
D2932	E	Prefabricated resin crown					
D2933	E	Prefab stainless steel crown					
D2940	E	Dental sedative filling					
D2950	E	Core build-up incl any pins					
D2951	E	Tooth pin retention					
D2952	E	Post and core cast + crown					
D2953	E	Each addtnl cast post					
D2954	E	Prefab post/core + crown					
D2955	E	Post removal					
D2957	E	Each addtnl prefab post					
D2960	E	Laminate labial veneer					
D2961	E	Lab labial veneer resin					
D2962	E	Lab labial veneer porcelain					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
D2970	S	Temporary- fractured tooth	0330	7.68	$390.47	$78.09	$78.09
D2980	E	Crown repair					
D2999	S	Dental unspec restorative pr	0330	7.68	$390.47	$78.09	$78.09
D3110	E	Pulp cap direct					
D3120	E	Pulp cap indirect					
D3220	E	Therapeutic pulpotomy					
D3221	E	Gross pulpal debridement					
D3230	E	Pulpal therapy anterior prim					
D3240	E	Pulpal therapy posterior pri					
D3310	E	Anterior					
D3320	E	Root canal therapy 2 canals					
D3330	E	Root canal therapy 3 canals					
D3331	E	Non-surg tx root canal obs					
D3332	E	Incomplete endodontic tx					
D3333	E	Internal root repair					
D3346	E	Retreat root canal anterior					
D3347	E	Retreat root canal bicuspid					
D3348	E	Retreat root canal molar					
D3351	E	Apexification/recalc initial					
D3352	E	Apexification/recalc interim					
D3353	E	Apexification/recalc final					
D3410	E	Apicoect/perirad surg anter					
D3421	E	Root surgery bicuspid					
D3425	E	Root surgery molar					
D3426	E	Root surgery ea add root					
D3430	E	Retrograde filling					
D3450	E	Root amputation					
D3460	S	Endodontic endosseous implan	0330	7.68	$390.47	$78.09	$78.09
D3470	E	Intentional replantation					
D3910	E	Isolation- tooth w rubb dam					
D3920	E	Tooth splitting					
D3950	E	Canal prep/fitting of dowel					
D3999	S	Endodontic procedure	0330	7.68	$390.47	$78.09	$78.09
D4210	E	Gingivectomy/plasty per quad					
D4211	E	Gingivectomy/plasty per toot					
D4220	E	Gingival curettage per quadr					
D4240	E	Gingival flap proc w/ planin					
D4245	E	Apically positioned flap					
D4249	E	Crown lengthen hard tissue					
D4260	S	Osseous surgery per quadrant	0330	7.68	$390.47	$78.09	$78.09
D4263	S	Bone replce graft first site	0330	7.68	$390.47	$78.09	$78.09
D4264	S	Bone replce graft each add	0330	7.68	$390.47	$78.09	$78.09
D4266	E	Guided tiss regen resorble					
D4267	E	Guided tiss regen nonresorb					
D4268	S	Surgical revision procedure	0330	7.68	$390.47	$78.09	$78.09
D4270	S	Pedicle soft tissue graft pr	0330	7.68	$390.47	$78.09	$78.09
D4271	S	Free soft tissue graft proc	0330	7.68	$390.47	$78.09	$78.09
D4273	S	Subepithelial tissue graft	0330	7.68	$390.47	$78.09	$78.09
D4274	E	Distal/proximal wedge proc					
D4320	E	Provision splnt intracoronal					
D4321	E	Provisional splint extracoro					
D4341	E	Periodontal scaling & root					
D4355	S	Full mouth debridement	0330	7.68	$390.47	$78.09	$78.09
D4381	S	Localized chemo delivery	0330	7.68	$390.47	$78.09	$78.09
D4910	E	Periodontal maint procedures					
D4920	E	Unscheduled dressing change					
D4999	E	Unspecified periodontal proc					
D5110	E	Dentures complete maxillary					
D5120	E	Dentures complete mandible					
D5130	E	Dentures immediat maxillary					
D5140	E	Dentures immediat mandible					
D5211	E	Dentures maxill part resin					
D5212	E	Dentures mand part resin					
D5213	E	Dentures maxill part metal					
D5214	E	Dentures mandibl part metal					
D5281	E	Removable partial denture					
D5410	E	Dentures adjust cmplt maxil					
D5411	E	Dentures adjust cmplt mand					
D5421	E	Dentures adjust part maxill					
D5422	E	Dentures adjust part mandbl					
D5510	E	Dentur repr broken compl bas					
D5520	E	Replace denture teeth complt					
D5610	E	Dentures repair resin base					
D5620	E	Rep part denture cast frame					
D5630	E	Rep partial denture clasp					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
D5640	E	Replace part denture teeth					
D5650	E	Add tooth to partial denture					
D5660	E	Add clasp to partial denture					
D5710	E	Dentures rebase cmplt maxil					
D5711	E	Dentures rebase cmplt mand					
D5720	E	Dentures rebase part maxill					
D5721	E	Dentures rebase part mandbl					
D5730	E	Denture reln cmplt maxil ch					
D5731	E	Denture reln cmplt mand chr					
D5740	E	Denture reln part maxil chr					
D5741	E	Denture reln part mand chr					
D5750	E	Denture reln cmplt max lab					
D5751	E	Denture reln cmplt mand lab					
D5760	E	Denture reln part maxil lab					
D5761	E	Denture reln part mand lab					
D5810	E	Denture interm cmplt maxill					
D5811	E	Denture interm cmplt mandbl					
D5820	E	Denture interm part maxill					
D5821	E	Denture interm part mandbl					
D5850	E	Denture tiss conditn maxill					
D5851	E	Denture tiss condtin mandbl					
D5860	E	Overdenture complete					
D5861	E	Overdenture partial					
D5862	E	Precision attachment					
D5867	E	Replacement of precision att					
D5875	E	Prosthesis modification					
D5899	E	Removable prosthodontic proc					
D5911	S	Facial moulage sectional	0330	7.68	$390.47	$78.09	$78.09
D5912	S	Facial moulage complete	0330	7.68	$390.47	$78.09	$78.09
D5913	E	Nasal prosthesis					
D5914	E	Auricular prosthesis					
D5915	E	Orbital prosthesis					
D5916	E	Ocular prosthesis					
D5919	E	Facial prosthesis					
D5922	E	Nasal septal prosthesis					
D5923	E	Ocular prosthesis interim					
D5924	E	Cranial prosthesis					
D5925	E	Facial augmentation implant					
D5926	E	Replacement nasal prosthesis					
D5927	E	Auricular replacement					
D5928	E	Orbital replacement					
D5929	E	Facial replacement					
D5931	E	Surgical obturator					
D5932	E	Postsurgical obturator					
D5933	E	Refitting of obturator					
D5934	E	Mandibular flange prosthesis					
D5935	E	Mandibular denture prosth					
D5936	E	Temp obturator prosthesis					
D5937	E	Trismus appliance					
D5951	E	Feeding aid					
D5952	E	Pediatric speech aid					
D5953	E	Adult speech aid					
D5954	E	Superimposed prosthesis					
D5955	E	Palatal lift prosthesis					
D5958	E	Intraoral con def inter plt					
D5959	E	Intraoral con def mod palat					
D5960	E	Modify speech aid prosthesis					
D5982	E	Surgical stent					
D5983	S	Radiation applicator	0330	7.68	$390.47	$78.09	$78.09
D5984	S	Radiation shield	0330	7.68	$390.47	$78.09	$78.09
D5985	S	Radiation cone locator	0330	7.68	$390.47	$78.09	$78.09
D5986	E	Fluoride applicator					
D5987	S	Commissure splint	0330	7.68	$390.47	$78.09	$78.09
D5988	E	Surgical splint					
D5999	E	Maxillofacial prosthesis					
D6010	E	Odontics endosteal implant					
D6020	E	Odontics abutment placement					
D6040	E	Odontics eposteal implant					
D6050	E	Odontics transosteal implnt					
D6055	E	Implant connecting bar					
D6056	E	Prefabricated abutment					
D6057	E	Custom abutment					
D6058	E	Abutment supported crown					
D6059	E	Abutment supported mtl crown					
D6060	E	Abutment supported mtl crown					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
D6061	E	Abutment supported mtl crown					
D6062	E	Abutment supported mtl crown					
D6063	E	Abutment supported mtl crown					
D6064	E	Abutment supported mtl crown					
D6065	E	Implant supported crown					
D6066	E	Implant supported mtl crown					
D6067	E	Implant supported mtl crown					
D6068	E	Abutment supported retainer					
D6069	E	Abutment supported retainer					
D6070	E	Abutment supported retainer					
D6071	E	Abutment supported retainer					
D6072	E	Abutment supported retainer					
D6073	E	Abutment supported retainer					
D6074	E	Abutment supported retainer					
D6075	E	Implant supported retainer					
D6076	E	Implant supported retainer					
D6077	E	Implant supported retainer					
D6078	E	Implnt/abut suprtd fixd dent					
D6079	E	Implnt/abut suprtd fixd dent					
D6080	E	Implant maintenance					
D6090	E	Repair implant					
D6095	E	Odontics repr abutment					
D6100	E	Removal of implant					
D6199	E	Implant procedure					
D6210	E	Prosthodont high noble metal					
D6211	E	Bridge base metal cast					
D6212	E	Bridge noble metal cast					
D6240	E	Bridge porcelain high noble					
D6241	E	Bridge porcelain base metal					
D6242	E	Bridge porcelain nobel metal					
D6245	E	Bridge porcelain/ceramic					
D6250	E	Bridge resin w/high noble					
D6251	E	Bridge resin base metal					
D6252	E	Bridge resin w/noble metal					
D6519	E	Inlay/onlay porce/ceramic					
D6520	E	Dental retainer two surfaces					
D6530	E	Retainer metallic 3+ surface					
D6543	E	Dental retainr onlay 3 surf					
D6544	E	Dental retainr onlay 4/more					
D6545	E	Dental retainr cast metl					
D6548	E	Porcelain/ceramic retainer					
D6720	E	Retain crown resin w hi nble					
D6721	E	Crown resin w/base metal					
D6722	E	Crown resin w/noble metal					
D6740	E	Crown porcelain/ceramic					
D6750	E	Crown porcelain high noble					
D6751	E	Crown porcelain base metal					
D6752	E	Crown porcelain noble metal					
D6780	E	Crown 3/4 high noble metal					
D6781	E	Crown 3/4 cast based metal					
D6782	E	Crown 3/4 cast noble metal					
D6783	E	Crown 3/4 porcelain/ceramic					
D6790	E	Crown full high noble metal					
D6791	E	Crown full base metal cast					
D6792	E	Crown full noble metal cast					
D6920	S	Dental connector bar	0330	7.68	$390.47	$78.09	$78.09
D6930	E	Dental recement bridge					
D6940	E	Stress breaker					
D6950	E	Precision attachment					
D6970	E	Post & core plus retainer					
D6971	E	Cast post bridge retainer					
D6972	E	Prefab post & core plus reta					
D6973	E	Core build up for retainer					
D6975	E	Coping metal					
D6976	E	Each addtnl cast post					
D6977	E	Each addtl prefab post					
D6980	E	Bridge repair					
D6999	E	Fixed prosthodontic proc					
D7110	S	Oral surgery single tooth	0330	7.68	$390.47	$78.09	$78.09
D7120	S	Each add tooth extraction	0330	7.68	$390.47	$78.09	$78.09
D7130	S	Tooth root removal	0330	7.68	$390.47	$78.09	$78.09
D7210	S	Rem imp tooth w mucoper flp	0330	7.68	$390.47	$78.09	$78.09
D7220	S	Impact tooth remov soft tiss	0330	7.68	$390.47	$78.09	$78.09
D7230	S	Impact tooth remov part bony	0330	7.68	$390.47	$78.09	$78.09
D7240	S	Impact tooth remov comp bony	0330	7.68	$390.47	$78.09	$78.09

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
D7241	S	Impact tooth rem bony w/comp	0330	7.68	$390.47	$78.09	$78.09
D7250	S	Tooth root removal	0330	7.68	$390.47	$78.09	$78.09
D7260	S	Oral antral fistula closure	0330	7.68	$390.47	$78.09	$78.09
D7270	E	Tooth reimplantation					
D7272	E	Tooth transplantation					
D7280	E	Exposure impact tooth orthod					
D7281	E	Exposure tooth aid eruption					
D7285	E	Biopsy of oral tissue hard					
D7286	E	Biopsy of oral tissue soft					
D7290	E	Repositioning of teeth					
D7291	S	Transseptal fiberotomy	0330	7.68	$390.47	$78.09	$78.09
D7310	E	Alveoplasty w/ extraction					
D7320	E	Alveoplasty w/o extraction					
D7340	E	Vestibuloplasty ridge extens					
D7350	E	Vestibuloplasty exten graft					
D7410	E	Rad exc lesion up to 1.25 cm					
D7420	E	Lesion > 1.25 cm					
D7430	E	Exc benign tumor to 1.25 cm					
D7431	E	Benign tumor exc > 1.25 cm					
D7440	E	Malig tumor exc to 1.25 cm					
D7441	E	Malig tumor > 1.25 cm					
D7450	E	Rem odontogen cyst to 1.25cm					
D7451	E	Rem odontogen cyst > 1.25 cm					
D7460	E	Rem nonodonto cyst to 1.25cm					
D7461	E	Rem nonodonto cyst > 1.25 cm					
D7465	E	Lesion destruction					
D7471	E	Rem exostosis any site					
D7480	E	Partial ostectomy					
D7490	E	Mandible resection					
D7510	E	I&d absc intraoral soft tiss					
D7520	E	I&d abscess extraoral					
D7530	E	Removal fb skin/areolar tiss					
D7540	E	Removal of fb reaction					
D7550	E	Removal of sloughed off bone					
D7560	E	Maxillary sinusotomy					
D7610	E	Maxilla open reduct simple					
D7620	E	Clsd reduct simpl maxilla fx					
D7630	E	Open red simpl mandible fx					
D7640	E	Clsd red simpl mandible fx					
D7650	E	Open red simp malar/zygom fx					
D7660	E	Clsd red simp malar/zygom fx					
D7670	E	Closd rductn splint alveolus					
D7680	E	Reduct simple facial bone fx					
D7710	E	Maxilla open reduct compound					
D7720	E	Clsd reduct compd maxilla fx					
D7730	E	Open reduct compd mandble fx					
D7740	E	Clsd reduct compd mandble fx					
D7750	E	Open red comp malar/zygma fx					
D7760	E	Clsd red comp malar/zygma fx					
D7770	E	Open reduc compd alveolus fx					
D7780	E	Reduct compnd facial bone fx					
D7810	E	Tmj open reduct-dislocation					
D7820	E	Closed tmp manipulation					
D7830	E	Tmj manipulation under anest					
D7840	E	Removal of tmj condyle					
D7850	E	Tmj meniscectomy					
D7852	E	Tmj repair of joint disc					
D7854	E	Tmj excisn of joint membrane					
D7856	E	Tmj cutting of a muscle					
D7858	E	Tmj reconstruction					
D7860	E	Tmj cutting into joint					
D7865	E	Tmj reshaping components					
D7870	E	Tmj aspiration joint fluid					
D7871	E	Lysis + lavage w catheters					
D7872	E	Tmj diagnostic arthroscopy					
D7873	E	Tmj arthroscopy lysis adhesn					
D7874	E	Tmj arthroscopy disc reposit					
D7875	E	Tmj arthroscopy synovectomy					
D7876	E	Tmj arthroscopy discectomy					
D7877	E	Tmj arthroscopy debridement					
D7880	E	Occlusal orthotic appliance					
D7899	E	Tmj unspecified therapy					
D7910	E	Dent sutur recent wnd to 5cm					
D7911	E	Dental suture wound to 5 cm					
D7912	E	Suture complicate wnd > 5 cm					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
D7920	E	Dental skin graft					
D7940	S	Reshaping bone orthognathic	0330	7.68	$390.47	$78.09	$78.09
D7941	E	Bone cutting ramus closed					
D7943	E	Cutting ramus open w/graft					
D7944	E	Bone cutting segmented					
D7945	E	Bone cutting body mandible					
D7946	E	Reconstruction maxilla total					
D7947	E	Reconstruct maxilla segment					
D7948	E	Reconstruct midface no graft					
D7949	E	Reconstruct midface w/graft					
D7950	E	Mandible graft					
D7955	E	Repair maxillofacial defects					
D7960	E	Frenulectomy/frenulotomy					
D7970	E	Excision hyperplastic tissue					
D7971	E	Excision pericoronal gingiva					
D7980	E	Sialolithotomy					
D7981	E	Excision of salivary gland					
D7982	E	Sialodochoplasty					
D7983	E	Closure of salivary fistula					
D7990	E	Emergency tracheotomy					
D7991	E	Dental coronoidectomy					
D7995	E	Synthetic graft facial bones					
D7996	E	Implant mandible for augment					
D7997	E	Appliance removal					
D7999	E	Oral surgery procedure					
D8010	E	Limited dental tx primary					
D8020	E	Limited dental tx transition					
D8030	E	Limited dental tx adolescent					
D8040	E	Limited dental tx adult					
D8050	E	Intercep dental tx primary					
D8060	E	Intercep dental tx transitn					
D8070	E	Compre dental tx transition					
D8080	E	Compre dental tx adolescent					
D8090	E	Compre dental tx adult					
D8210	E	Orthodontic rem appliance tx					
D8220	E	Fixed appliance therapy habt					
D8660	E	Preorthodontic tx visit					
D8670	E	Periodic orthodontc tx visit					
D8680	E	Orthodontic retention					
D8690	E	Orthodontic treatment					
D8691	E	Repair ortho appliance					
D8692	E	Replacement retainer					
D8999	E	Orthodontic procedure					
D9110	N	Tx dental pain minor proc					
D9210	E	Dent anesthesia w/o surgery					
D9211	E	Regional block anesthesia					
D9212	E	Trigeminal block anesthesia					
D9215	E	Local anesthesia					
D9220	E	General anesthesia					
D9221	E	General anesthesia ea ad 15m					
D9230	N	Analgesia					
D9241	E	Intravenous sedation					
D9242	E	IV sedation ea ad 30 m					
D9248	N	Sedation (non-iv)					
D9310	E	Dental consultation					
D9410	E	Dental house call					
D9420	E	Hospital call					
D9430	E	Office visit during hours					
D9440	E	Office visit after hours					
D9610	E	Dent therapeutic drug inject					
D9630	S	Other drugs/medicaments	0330	7.68	$390.47	$78.09	$78.09
D9910	E	Dent appl desensitizing med					
D9911	E	Appl desensitizing resin					
D9920	E	Behavior management					
D9930	S	Treatment of complications	0330	7.68	$390.47	$78.09	$78.09
D9940	S	Dental occlusal guard	0330	7.68	$390.47	$78.09	$78.09
D9941	E	Fabrication athletic guard					
D9950	S	Occlusion analysis	0330	7.68	$390.47	$78.09	$78.09
D9951	S	Limited occlusal adjustment	0330	7.68	$390.47	$78.09	$78.09
D9952	S	Complete occlusal adjustment	0330	7.68	$390.47	$78.09	$78.09
D9970	E	Enamel microabrasion					
D9971	E	Odontoplasty 1-2 teeth					
D9972	E	Extrnl bleaching per arch					
D9973	E	Extrnl bleaching per tooth					
D9974	E	Intrnl bleaching per tooth					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
D9999	E	Adjunctive procedure					
E0100	A	Cane adjust/fixed with tip					
E0105	A	Cane adjust/fixed quad/3 pro					
E0110	A	Crutch forearm pair					
E0111	A	Crutch forearm each					
E0112	A	Crutch underarm pair wood					
E0113	A	Crutch underarm each wood					
E0114	A	Crutch underarm pair no wood					
E0116	A	Crutch underarm each no wood					
E0130	A	Walker rigid adjust/fixed ht					
E0135	A	Walker folding adjust/fixed					
E0141	A	Rigid walker wheeled wo seat					
E0142	A	Walker rigid wheeled with se					
E0143	A	Walker folding wheeled w/o s					
E0144	A	Enclosed walker w rear seat					
E0145	A	Walker whled seat/crutch att					
E0146	A	Folding walker wheels w seat					
E0147	A	Walker variable wheel resist					
E0148	A	Heavyduty walker no wheels					
E0149	A	Heavy duty wheeled walker					
E0153	A	Forearm crutch platform atta					
E0154	A	Walker platform attachment					
E0155	A	Walker wheel attachment,pair					
E0156	A	Walker seat attachment					
E0157	A	Walker crutch attachment					
E0158	A	Walker leg extenders set of4					
E0159	A	Brake for wheeled walker					
E0160	A	Sitz type bath or equipment					
E0161	A	Sitz bath/equipment w/faucet					
E0162	A	Sitz bath chair					
E0163	A	Commode chair stationry fxd					
E0164	A	Commode chair mobile fixed a					
E0165	A	Commode chair stationry det					
E0166	A	Commode chair mobile detach					
E0167	A	Commode chair pail or pan					
E0168	A	Heavyduty/wide commode chair					
E0175	A	Commode chair foot rest					
E0176	A	Air pressre pad/cushion nonp					
E0177	A	Water press pad/cushion nonp					
E0178	A	Gel pressre pad/cushion nonp					
E0179	A	Dry pressre pad/cushion nonp					
E0180	A	Press pad alternating w pump					
E0181	A	Press pad alternating w/ pum					
E0182	A	Pressure pad alternating pum					
E0184	A	Dry pressure mattress					
E0185	A	Gel pressure mattress pad					
E0186	A	Air pressure mattress					
E0187	A	Water pressure mattress					
E0188	E	Synthetic sheepskin pad					
E0189	E	Lambswool sheepskin pad					
E0191	A	Protector heel or elbow					
E0192	A	Pad wheelchr low press/posit					
E0193	A	Powered air flotation bed					
E0194	A	Air fluidized bed					
E0196	A	Gel pressure mattress					
E0197	A	Air pressure pad for mattres					
E0198	A	Water pressure pad for mattr					
E0199	A	Dry pressure pad for mattres					
E0200	A	Heat lamp without stand					
E0202	A	Phototherapy light w/ photom					
E0205	A	Heat lamp with stand					
E0210	A	Electric heat pad standard					
E0215	A	Electric heat pad moist					
E0217	A	Water circ heat pad w pump					
E0218	E	Water circ cold pad w pump					
E0220	A	Hot water bottle					
E0225	A	Hydrocollator unit					
E0230	A	Ice cap or collar					
E0235	A	Paraffin bath unit portable					
E0236	A	Pump for water circulating p					
E0238	A	Heat pad non-electric moist					
E0239	A	Hydrocollator unit portable					
E0241	E	Bath tub wall rail					
E0242	E	Bath tub rail floor					
E0243	E	Toilet rail					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
E0244	E	Toilet seat raised					
E0245	E	Tub stool or bench					
E0246	E	Transfer tub rail attachment					
E0249	A	Pad water circulating heat u					
E0250	A	Hosp bed fixed ht w/ mattres					
E0251	A	Hosp bed fixd ht w/o mattres					
E0255	A	Hospital bed var ht w/ mattr					
E0256	A	Hospital bed var ht w/o matt					
E0260	A	Hosp bed semi-electr w/ matt					
E0261	A	Hosp bed semi-electr w/o mat					
E0265	A	Hosp bed total electr w/ mat					
E0266	A	Hosp bed total elec w/o matt					
E0270	E	Hospital bed institutional t					
E0271	A	Mattress innerspring					
E0272	A	Mattress foam rubber					
E0273	E	Bed board					
E0274	E	Over-bed table					
E0275	A	Bed pan standard					
E0276	A	Bed pan fracture					
E0277	A	Powered pres-redu air mattrs					
E0280	A	Bed cradle					
E0290	A	Hosp bed fx ht w/o rails w/m					
E0291	A	Hosp bed fx ht w/o rail w/o					
E0292	A	Hosp bed var ht w/o rail w/o					
E0293	A	Hosp bed var ht w/o rail w/					
E0294	A	Hosp bed semi-elect w/ mattr					
E0295	A	Hosp bed semi-elect w/o matt					
E0296	A	Hosp bed total elect w/ matt					
E0297	A	Hosp bed total elect w/o mat					
E0298	E	Heavyduty/xtra wide hosp bed					
E0305	A	Rails bed side half length					
E0310	A	Rails bed side full length					
E0315	E	Bed accessory brd/tbl/supprt					
E0325	A	Urinal male jug-type					
E0326	A	Urinal female jug-type					
E0350	E	Control unit bowel system					
E0352	E	Disposable pack w/bowel syst					
E0370	E	Air elevator for heel					
E0371	A	Nonpower mattress overlay					
E0372	A	Powered air mattress overlay					
E0373	A	Nonpowered pressure mattress					
E0424	A	Stationary compressed gas 02					
E0425	E	Gas system stationary compre					
E0430	E	Oxygen system gas portable					
E0431	A	Portable gaseous 02					
E0434	A	Portable liquid 02					
E0435	E	Oxygen system liquid portabl					
E0439	A	Stationary liquid 02					
E0440	E	Oxygen system liquid station					
E0441	A	Oxygen contents, gaseous					
E0442	A	Oxygen contents, liquid					
E0443	A	Portable 02 contents, gas					
E0444	A	Portable 02 contents, liquid					
E0450	A	Volume vent stationary/porta					
E0455	A	Oxygen tent excl croup/ped t					
E0457	A	Chest shell					
E0459	A	Chest wrap					
E0460	A	Neg press vent portabl/statn					
E0462	A	Rocking bed w/ or w/o side r					
E0480	A	Percussor elect/pneum home m					
E0500	A	Ippb all types					
E0550	A	Humidif extens supple w ippb					
E0555	A	Humidifier for use w/ regula					
E0560	A	Humidifier supplemental w/ i					
E0565	A	Compressor air power source					
E0570	A	Nebulizer with compression					
E0571	A	Aerosol compressor for svneb					
E0572	A	Aerosol compressor adjust pr					
E0574	A	Ultrasonic generator w svneb					
E0575	A	Nebulizer ultrasonic					
E0580	A	Nebulizer for use w/ regulat					
E0585	A	Nebulizer w/ compressor & he					
E0590	A	Dispensing fee dme neb drug					
E0600	A	Suction pump portab hom modl					
E0601	A	Cont airway pressure device					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
E0602	E	Breast pump					
E0605	A	Vaporizer room type					
E0606	A	Drainage board postural					
E0607	A	Blood glucose monitor home					
E0608	A	Apnea monitor					
E0609	A	Blood gluc mon w/special fea					
E0610	A	Pacemaker monitr audible/vis					
E0615	A	Pacemaker monitr digital/vis					
E0616	N	Cardiac event recorder					
E0617	A	Automatic ext defibrillator					
E0621	A	Patient lift sling or seat					
E0625	E	Patient lift bathroom or toi					
E0627	A	Seat lift incorp lift-chair					
E0628	A	Seat lift for pt furn-electr					
E0629	A	Seat lift for pt furn-non-el					
E0630	A	Patient lift hydraulic					
E0635	A	Patient lift electric					
E0650	A	Pneuma compresor non-segment					
E0651	A	Pneum compressor segmental					
E0652	A	Pneum compres w/cal pressure					
E0655	A	Pneumatic appliance half arm					
E0660	A	Pneumatic appliance full leg					
E0665	A	Pneumatic appliance full arm					
E0666	A	Pneumatic appliance half leg					
E0667	A	Seg pneumatic appl full leg					
E0668	A	Seg pneumatic appl full arm					
E0669	A	Seg pneumatic appli half leg					
E0671	A	Pressure pneum appl full leg					
E0672	A	Pressure pneum appl full arm					
E0673	A	Pressure pneum appl half leg					
E0690	A	Ultraviolet cabinet					
E0700	E	Safety equipment					
E0710	E	Restraints any type					
E0720	A	Tens two lead					
E0730	A	Tens four lead					
E0731	A	Conductive garment for tens/					
E0740	E	Incontinence treatment systm					
E0744	A	Neuromuscular stim for scoli					
E0745	A	Neuromuscular stim for shock					
E0746	E	Electromyograph biofeedback					
E0747	A	Elec osteogen stim not spine					
E0748	A	Elec osteogen stim spinal					
E0749	N	Elec osteogen stim implanted					
E0753	N	Neurostimulator electrodes					
E0755	E	Electronic salivary reflex s					
E0756	A	Implantable pulse generator					
E0757	A	Implantable RF receiver					
E0758	A	External RF transmitter					
E0760	E	Osteogen ultrasound stimltor					
E0765	E	Nerve stimulator for tx n&v					
E0776	A	Iv pole					
E0779	A	Amb infusion pump mechanical					
E0780	A	Mech amb infusion pump <8hrs					
E0781	A	External ambulatory infus pu					
E0782	N	Non-programble infusion pump					
E0783	N	Programmable infusion pump					
E0784	A	Ext amb infusn pump insulin					
E0785	N	Replacement impl pump cathet					
E0786	A	Implantable pump replacement					
E0791	A	Parenteral infusion pump sta					
E0830	N	Ambulatory traction device					
E0840	A	Tract frame attach headboard					
E0850	A	Traction stand free standing					
E0855	A	Cervical traction equipment					
E0860	A	Tract equip cervical tract					
E0870	A	Tract frame attach footboard					
E0880	A	Trac stand free stand extrem					
E0890	A	Traction frame attach pelvic					
E0900	A	Trac stand free stand pelvic					
E0910	A	Trapeze bar attached to bed					
E0920	A	Fracture frame attached to b					
E0930	A	Fracture frame free standing					
E0935	A	Exercise device passive moti					
E0940	A	Trapeze bar free standing					
E0941	A	Gravity assisted traction de					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
E0942	A	Cervical head harness/halter					
E0943	A	Cervical pillow					
E0944	A	Pelvic belt/harness/boot					
E0945	A	Belt/harness extremity					
E0946	A	Fracture frame dual w cross					
E0947	A	Fracture frame attachmnts pe					
E0948	A	Fracture frame attachmnts ce					
E0950	E	Tray					
E0951	E	Loop heel					
E0952	E	Loop tie					
E0953	E	Pneumatic tire					
E0954	E	Wheelchair semi-pneumatic ca					
E0958	E	Whlchr att- conv 1 arm drive					
E0959	E	Amputee adapter					
E0961	E	Wheelchair brake extension					
E0962	A	Wheelchair 1 inch cushion					
E0963	A	Wheelchair 2 inch cushion					
E0964	A	Wheelchair 3 inch cushion					
E0965	A	Wheelchair 4 inch cushion					
E0966	E	Wheelchair head rest extensi					
E0967	E	Wheelchair hand rims					
E0968	E	Wheelchair commode seat					
E0969	E	Wheelchair narrowing device					
E0970	E	Wheelchair no. 2 footplates					
E0971	E	Wheelchair anti-tipping devi					
E0972	A	Transfer board or device					
E0973	E	Wheelchair adjustabl height					
E0974	E	Wheelchair grade-aid					
E0975	E	Wheelchair reinforced seat u					
E0976	E	Wheelchair reinforced back u					
E0977	E	Wheelchair wedge cushion					
E0978	E	Wheelchair belt w/airplane b					
E0979	E	Wheelchair belt with velcro					
E0980	E	Wheelchair safety vest					
E0990	E	Whellchair elevating leg res					
E0991	E	Wheelchair upholstry seat					
E0992	E	Wheelchair solid seat insert					
E0993	E	Wheelchair back upholstery					
E0994	E	Wheelchair arm rest					
E0995	E	Wheelchair calf rest					
E0996	E	Wheelchair tire solid					
E0997	E	Wheelchair caster w/ a fork					
E0998	E	Wheelchair caster w/o a fork					
E0999	E	Wheelchr pneumatic tire w/wh					
E1000	E	Wheelchair tire pneumatic ca					
E1001	E	Wheelchair wheel					
E1031	A	Rollabout chair with casters					
E1035	E	Patient transfer system					
E1050	E	Whelchr fxd full length arms					
E1060	E	Wheelchair detachable arms					
E1065	E	Wheelchair power attachment					
E1066	E	Wheelchair battery charger					
E1069	E	Wheelchair deep cycle batter					
E1070	E	Wheelchair detachable foot r					
E1083	E	Hemi-wheelchair fixed arms					
E1084	E	Hemi-wheelchair detachable a					
E1085	E	Hemi-wheelchair fixed arms					
E1086	E	Hemi-wheelchair detachable a					
E1087	E	Wheelchair lightwt fixed arm					
E1088	E	Wheelchair lightweight det a					
E1089	E	Wheelchair lightwt fixed arm					
E1090	E	Wheelchair lightweight det a					
E1091	E	Wheelchair youth					
E1092	E	Wheelchair wide w/ leg rests					
E1093	E	Wheelchair wide w/ foot rest					
E1100	E	Whchr s-recl fxd arm leg res					
E1110	E	Wheelchair semi-recl detach					
E1130	E	Whlchr stand fxd arm ft rest					
E1140	E	Wheelchair standard detach a					
E1150	E	Wheelchair standard w/ leg r					
E1160	E	Wheelchair fixed arms					
E1170	E	Whlchr ampu fxd arm leg rest					
E1171	E	Wheelchair amputee w/o leg r					
E1172	E	Wheelchair amputee detach ar					
E1180	E	Wheelchair amputee w/ foot r					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
E1190	E	Wheelchair amputee w/ leg re					
E1195	E	Wheelchair amputee heavy dut					
E1200	E	Wheelchair amputee fixed arm					
E1210	E	Whlchr moto ful arm leg rest					
E1211	E	Wheelchair motorized w/ det					
E1212	E	Wheelchair motorized w full					
E1213	E	Wheelchair motorized w/ det					
E1220	E	Whlchr special size/constrc					
E1221	E	Wheelchair spec size w foot					
E1222	E	Wheelchair spec size w/ leg					
E1223	E	Wheelchair spec size w foot					
E1224	E	Wheelchair spec size w/ leg					
E1225	E	Wheelchair spec sz semi-recl					
E1226	E	Wheelchair spec sz full-recl					
E1227	E	Wheelchair spec sz spec ht a					
E1228	E	Wheelchair spec sz spec ht b					
E1230	A	Power operated vehicle					
E1240	E	Whchr litwt det arm leg rest					
E1250	E	Wheelchair lightwt fixed arm					
E1260	E	Wheelchair lightwt foot rest					
E1270	E	Wheelchair lightweight leg r					
E1280	E	Whchr h-duty det arm leg res					
E1285	E	Wheelchair heavy duty fixed					
E1290	E	Wheelchair hvy duty detach a					
E1295	E	Wheelchair heavy duty fixed					
E1296	E	Wheelchair special seat heig					
E1297	E	Wheelchair special seat dept					
E1298	E	Wheelchair spec seat depth/w					
E1300	E	Whirlpool portable					
E1310	A	Whirlpool non-portable					
E1340	A	Repair for DME, per 15 min					
E1353	A	Oxygen supplies regulator					
E1355	A	Oxygen supplies stand/rack					
E1372	A	Oxy suppl heater for nebuliz					
E1390	A	Oxygen concentrator					
E1399	A	Durable medical equipment mi					
E1405	A	O2/water vapor enrich w/heat					
E1406	A	O2/water vapor enrich w/o he					
E1510	A	Kidney dialysate delivry sys					
E1520	A	Heparin infusion pump for di					
E1530	A	Air bubble detector for dial					
E1540	A	Pressure alarm for dialysis					
E1550	A	Bath conductivity meter					
E1560	A	Blood leak detector for dial					
E1570	A	Adjustable chair for esrd pt					
E1575	A	Transducer protector/fluid b					
E1580	A	Unipuncture control system					
E1590	A	Hemodialysis machine					
E1592	A	Auto interm peritoneal dialy					
E1594	A	Cycler dialysis machine					
E1600	A	Deliv/install equip for dial					
E1610	A	Reverse osmosis water purifi					
E1615	A	Deionizer water purification					
E1620	A	Blood pump for dialysis					
E1625	A	Water softening system					
E1630	A	Reciprocating peritoneal dia					
E1632	A	Wearable artificial kidney					
E1635	A	Compact travel hemodialyzer					
E1636	A	Sorbent cartridges for dialy					
E1640	A	Replacement components for d					
E1699	A	Dialysis equipment unspecifi					
E1700	A	Jaw motion rehab system					
E1701	A	Repl cushions for jaw motion					
E1702	A	Repl measr scales jaw motion					
E1800	A	Adjust elbow ext/flex device					
E1805	A	Adjust wrist ext/flex device					
E1810	A	Adjust knee ext/flex device					
E1815	A	Adjust ankle ext/flex device					
E1820	A	Soft interface material					
E1825	A	Adjust finger ext/flex devc					
E1830	A	Adjust toe ext/flex device					
E1900	A	Speech communication device					
G0001	A	Drawing blood for specimen					
G0002	N	Temporary urinary catheter					
G0004	E	ECG transm phys review & int					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
G0005	X	ECG 24 hour recording	0097	0.87	$44.23	$24.33	$8.85
G0006	X	ECG transmission & analysis	0097	0.87	$44.23	$24.33	$8.85
G0007	N	ECG phy review & interpret					
G0008	K	Admin influenza virus vac	0354	0.11	$5.59		
G0009	K	Admin pneumococcal vaccine	0354	0.11	$5.59		
G0010	N	Admin hepatitis b vaccine					
G0015	X	Post symptom ECG tracing	0097	0.87	$44.23	$24.33	$8.85
G0016	E	Post symptom ECG md review					
G0117	S	Glaucoma screen, md perform	0230	0.64	$32.54	$14.97	$6.51
G0118	S	Glaucoma screen, md supr	0230	0.64	$32.54	$14.97	$6.51
G0025	X	Collagen skin test kit	0343	0.42	$21.35	$11.53	$4.27
G0026	A	Fecal leukocyte examination					
G0027	A	Semen analysis					
G0030	S	PET imaging prev PET single	0285	20.07	$1,020.40	$415.21	$204.08
G0031	S	PET imaging prev PET multple	0285	20.07	$1,020.40	$415.21	$204.08
G0032	S	PET follow SPECT 78464 singl	0285	20.07	$1,020.40	$415.21	$204.08
G0033	S	PET follow SPECT 78464 mult	0285	20.07	$1,020.40	$415.21	$204.08
G0034	S	PET follow SPECT 76865 singl	0285	20.07	$1,020.40	$415.21	$204.08
G0035	S	PET follow SPECT 78465 mult	0285	20.07	$1,020.40	$415.21	$204.08
G0036	S	PET follow cornry angio sing	0285	20.07	$1,020.40	$415.21	$204.08
G0037	S	PET follow cornry angio mult	0285	20.07	$1,020.40	$415.21	$204.08
G0038	S	PET follow myocard perf sing	0285	20.07	$1,020.40	$415.21	$204.08
G0039	S	PET follow myocard perf mult	0285	20.07	$1,020.40	$415.21	$204.08
G0040	S	PET follow stress echo singl	0285	20.07	$1,020.40	$415.21	$204.08
G0041	S	PET follow stress echo mult	0285	20.07	$1,020.40	$415.21	$204.08
G0042	S	PET follow ventriculogm sing	0285	20.07	$1,020.40	$415.21	$204.08
G0043	S	PET follow ventriculogm mult	0285	20.07	$1,020.40	$415.21	$204.08
G0044	S	PET following rest ECG singl	0285	20.07	$1,020.40	$415.21	$204.08
G0045	S	PET following rest ECG mult	0285	20.07	$1,020.40	$415.21	$204.08
G0046	S	PET follow stress ECG singl	0285	20.07	$1,020.40	$415.21	$204.08
G0047	S	PET follow stress ECG mult	0285	20.07	$1,020.40	$415.21	$204.08
G0050	S	Residual urine by ultrasound	0265	1.02	$51.86	$28.52	$10.37
G0101	V	CA screen;pelvic/breast exam	0601	1.02	$51.86	$10.37	$10.37
G0102	N	Prostate ca screening; dre					
G0103	A	Psa, total screening					
G0104	S	CA screen;flexi sigmoidscope	0159	2.51	$127.61		$31.90
G0105	S	Colorectal scrn; hi risk ind	0158	7.00	$355.89		$88.97
G0106	S	Colon CA screen;barium enema	0157	2.14	$108.80		$27.20
G0107	A	CA screen; fecal blood test					
G0108	A	Diab manage trn per indiv					
G0109	A	Diab manage trn ind/group					
G0110	A	Nett pulm-rehab educ; ind					
G0111	A	Nett pulm-rehab educ; group					
G0112	A	Nett;nutrition guid, initial					
G0113	A	Nett;nutrition guid,subseqnt					
G0114	A	Nett; psychosocial consult					
G0115	A	Nett; psychological testing					
G0116	A	Nett; psychosocial counsel					
G0120	S	Colon ca scrn; barium enema	0157	2.14	$108.80		$27.20
G0121	E	Colon ca scrn not hi rsk ind					
G0122	S	Colon ca scrn; barium enema	0157	2.14	$108.80		$27.20
G0123	A	Screen cerv/vag thin layer					
G0124	A	Screen c/v thin layer by MD					
G0125	S	PET image pulmonary nodule	0976	16.56	$841.94		$168.39
G0126	S	Lung image (PET) staging	0976	16.56	$841.94		$168.39
G0127	T	Trim nail(s)	0009	0.68	$34.57	$8.99	$6.91
G0128	E	CORF skilled nursing service					
G0129	P	Partial hosp prog service	0033	4.17	$212.01		$42.40
G0130	X	Single energy x-ray study	0261	1.31	$66.60	$36.63	$13.32
G0131	S	CT scan, bone density study	0288	1.27	$64.57	$35.51	$12.91
G0132	S	CT scan, bone density study	0288	1.27	$64.57	$35.51	$12.91
G0141	E	Scr c/v cyto,autosys and md					
G0143	A	Scr c/v cyto,thinlayer,rescr					
G0144	A	Scr c/v cyto,thinlayer,rescr					
G0145	A	Scr c/v cyto,thinlayer,rescr					
G0147	A	Scr c/v cyto, automated sys					
G0148	A	Scr c/v cyto, autosys, rescr					
G0151	E	HHCP-serv of pt,ea 15 min					
G0152	E	HHCP-serv of ot,ea 15 min					
G0153	E	HHCP-svs of s/l path,ea 15mn					
G0154	E	HHCP-svs of rn,ea 15 min					
G0155	E	HHCP-svs of csw,ea 15 min					
G0156	E	HHCP-svs of aide,ea 15 min					
G0163	S	Pet for rec of colorectal ca	0976	16.56	$841.94		$168.39
G0164	S	Pet for lymphoma staging	0976	16.56	$841.94		$168.39

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
G0165	S	Pet,rec of melanoma/met ca	0976	16.56	$841.94	.....	$168.39
G0166	T	Extrnl counterpulse, per tx	0972	2.84	$144.39	.....	$28.88
G0167	E	Hyperbaric oz tx;no md reqrd	.....	.....	.....	.....	.....
G0168	T	Wound closure by adhesive	0970	0.47	$23.90	.....	$4.78
G0173	S	Stereo radoisurgery,complete	0302	11.96	$608.07	$216.55	$121.61
G0174	S	Intensitymodulatedradiation	0302	11.96	$608.07	$216.55	$121.61
G0175	V	OPPS Service,sched team conf	0602	1.49	$75.75	$15.15	$15.15
G0176	P	OPPS/PHP;activity therapy	0033	4.17	$212.01	.....	$42.40
G0177	P	OPPS/PHP; train & educ serv	0033	4.17	$212.01	.....	$42.40
G0178	S	Intensitymodulatedradiation	0302	11.96	$608.07	$216.55	$121.61
G0179	E	MD recertification HHA PT	.....	.....	.....	.....	.....
G0180	E	MD certification HHA patient	.....	.....	.....	.....	.....
G0181	E	Home health care supervision	.....	.....	.....	.....	.....
G0182	E	Hospice care supervision	.....	.....	.....	.....	.....
G0183	T	Ocular photodynamic therapy	0235	5.39	$274.04	$78.91	$54.81
G0184	T	Ocular photdynamicTx 2nd eye	0235	5.39	$274.04	$78.91	$54.81
G0185	T	Transpuppillary thermotx	0235	5.39	$274.04	$78.91	$54.81
G0186	T	Dstry eye lesn,fdr vssl tech	0235	5.39	$274.04	$78.91	$54.81
G0187	T	Dstry mclr drusen,photocoag	0235	5.39	$274.04	$78.91	$54.81
G0188	X	Xray lwr extrmty-full lngth	0261	1.31	$66.60	$36.63	$13.32
G0190	N	Immunization administration	.....	.....	.....	.....	.....
G0191	N	Immunization admin,each add	.....	.....	.....	.....	.....
G0192	N	Immunization oral/intranasal	.....	.....	.....	.....	.....
G0193	A	Endoscopicstudyswallowfunctn	.....	.....	.....	.....	.....
G0194	A	Sensorytestingendoscopicstud	.....	.....	.....	.....	.....
G0195	A	Clinicalevalswallowingfunct	.....	.....	.....	.....	.....
G0196	A	Evalofswallowingwithradioopa	.....	.....	.....	.....	.....
G0197	A	Evalofptforprescipspeechdevi	.....	.....	.....	.....	.....
G0198	A	Patientadapation&trainforspe	.....	.....	.....	.....	.....
G0199	A	Reevaluationofpatientusespec	.....	.....	.....	.....	.....
G0200	A	Evalofpatientprescipofvoicep	.....	.....	.....	.....	.....
G0201	A	Modifortraininginusevoicepro	.....	.....	.....	.....	.....
G0202	A	Screeningmammographydigital	.....	.....	.....	.....	.....
G0203	A	Screenmammographyfilmdigital	.....	.....	.....	.....	.....
G0204	S	Diagnosticmammographydigital	0271	0.64	$32.54	$17.90	$6.51
G0205	S	Diagnosticmammographyfilmpro	0271	0.64	$32.54	$17.90	$6.51
G0206	S	Diagnosticmammographydigital	0271	0.64	$32.54	$17.90	$6.51
G0207	S	Diagnostic mammography film	0271	0.64	$32.54	$17.90	$6.51
G0210	S	PET img wholebody dxlung ca	0976	16.56	$841.94	.....	$168.39
G0211	S	PET img wholebody init lung	0976	16.56	$841.94	.....	$168.39
G0212	S	PET img wholebod restag lung	0976	16.56	$841.94	.....	$168.39
G0213	S	PET img wholebody dx colorec	0976	16.56	$841.94	.....	$168.39
G0214	S	PET img wholebod init colore	0976	16.56	$841.94	.....	$168.39
G0215	S	PETimg wholebod restag colre	0976	16.56	$841.94	.....	$168.39
G0216	S	PET img wholebod dx melanoma	0976	16.56	$841.94	.....	$168.39
G0217	S	PET img wholebod init melano	0976	16.56	$841.94	.....	$168.39
G0218	S	PET img wholebod restag mela	0976	16.56	$841.94	.....	$168.39
G0219	S	PET img wholbod melano nonco	0976	16.56	$841.94	.....	$168.39
G0220	S	PET img wholebod dx lymphoma	0976	16.56	$841.94	.....	$168.39
G0221	S	PET imag wholbod init lympho	0976	16.56	$841.94	.....	$168.39
G0222	S	PET imag wholbod resta lymph	0976	16.56	$841.94	.....	$168.39
G0223	S	PET imag wholbod reg dx head	0976	16.56	$841.94	.....	$168.39
G0224	S	PET imag wholbod reg ini hea	0976	16.56	$841.94	.....	$168.39
G0225	S	PET whol restag headneck onl	0976	16.56	$841.94	.....	$168.39
G0226	S	PET img wholbody dx esophagl	0976	16.56	$841.94	.....	$168.39
G0227	S	PET img wholbod ini esophage	0976	16.56	$841.94	.....	$168.39
G0228	S	PET img wholbod restg esopha	0976	16.56	$841.94	.....	$168.39
G0229	S	PET img metabolic brain pres	0976	16.56	$841.94	.....	$168.39
G0230	S	PET myocard viability post s	0976	16.56	$841.94	.....	$168.39
G9001	E	MCCD, initial rate	.....	.....	.....	.....	.....
G9002	E	MCCD,maintenance rate	.....	.....	.....	.....	.....
G9003	E	MCCD, risk adj hi, initial	.....	.....	.....	.....	.....
G9004	E	MCCD, risk adj lo, initial	.....	.....	.....	.....	.....
G9005	E	MCCD, risk adj, maintenance	.....	.....	.....	.....	.....
G9006	E	MCCD, Home monitoring	.....	.....	.....	.....	.....
G9007	E	MCCD, sch team conf	.....	.....	.....	.....	.....
G9008	E	Mccd,phys coor-care ovrsght	.....	.....	.....	.....	.....
G9016	A	Demo-smoking cessation coun	.....	.....	.....	.....	.....
H0001	E	Alcohol and/or drug assess	.....	.....	.....	.....	.....
H0002	E	Alcohol and/or drug screenin	.....	.....	.....	.....	.....
H0003	E	Alcohol and/or drug screenin	.....	.....	.....	.....	.....
H0004	E	Alcohol and/or drug services	.....	.....	.....	.....	.....
H0005	E	Alcohol and/or drug services	.....	.....	.....	.....	.....
H0006	E	Alcohol and/or drug services	.....	.....	.....	.....	.....
H0007	E	Alcohol and/or drug services	.....	.....	.....	.....	.....

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
H0008	E	Alcohol and/or drug services					
H0009	E	Alcohol and/or drug services					
H0010	E	Alcohol and/or drug services					
H0011	E	Alcohol and/or drug services					
H0012	E	Alcohol and/or drug services					
H0013	E	Alcohol and/or drug services					
H0014	E	Alcohol and/or drug services					
H0015	E	Alcohol and/or drug services					
H0016	E	Alcohol and/or drug services					
H0017	E	Alcohol and/or drug services					
H0018	E	Alcohol and/or drug services					
H0019	E	Alcohol and/or drug services					
H0020	E	Alcohol and/or drug services					
H0021	E	Alcohol and/or drug training					
H0022	E	Alcohol and/or drug interven					
H0023	E	Alcohol and/or drug outreach					
H0024	E	Alcohol and/or drug preventi					
H0025	E	Alcohol and/or drug preventi					
H0026	E	Alcohol and/or drug preventi					
H0027	E	Alcohol and/or drug preventi					
H0028	E	Alcohol and/or drug preventi					
H0029	E	Alcohol and/or drug preventi					
H0030	E	Alcohol and/or drug hotline					
J0120	N	Tetracyclin injection					
J0130	G	Abciximab injection	1605		$513.02		$73.44
J0150	K	Injection adenosine 6 MG	0917	0.37	$18.81		$3.62
J0151	E	Adenosine injection					
J0170	N	Adrenalin epinephrin inject					
J0190	N	Inj biperiden lactate/5 mg					
J0200	N	Alatrofloxacin mesylate					
J0205	G	Alglucerase injection	0900		$37.53		$5.37
J0207	G	Amifostine	7000		$392.06		$56.13
J0210	N	Methyldopate hcl injection					
J0256	G	Alpha 1 proteinase inhibitor	0901		$2.09		$.30
J0270	E	Alprostadil for injection					
J0275	E	Alprostadil urethral suppos					
J0280	N	Aminophyllin 250 MG inj					
J0282	N	Amiodarone HCl					
J0285	N	Amphotericin B					
J0286	G	Amphotericin B lipid complex	7001		$109.25		$15.64
J0290	N	Ampicillin 500 MG inj					
J0295	N	Ampicillin sodium per 1.5 gm					
J0300	N	Amobarbital 125 MG inj					
J0330	N	Succinycholine chloride inj					
J0340	N	Nandrolon phenpropionate inj					
J0350	G	Injection anistreplase 30 u	1606		$2,559.11		$366.36
J0360	N	Hydralazine hcl injection					
J0380	N	Inj metaraminol bitartrate					
J0390	N	Chloroquine injection					
J0395	N	Arbutamine HCl injection					
J0400	N	Inj trimethaphan camsylate					
J0456	N	Azithromycin					
J0460	N	Atropine sulfate injection					
J0470	N	Dimecaprol injection					
J0475	N	Baclofen 10 MG injection					
J0476	E	Baclofen intrathecal trial					
J0500	N	Dicyclomine injection					
J0510	N	Benzquinamide injection					
J0515	N	Inj benztropine mesylate					
J0520	N	Bethanechol chloride inject					
J0530	N	Penicillin g benzathine inj					
J0540	N	Penicillin g benzathine inj					
J0550	N	Penicillin g benzathine inj					
J0560	N	Penicillin g benzathine inj					
J0570	N	Penicillin g benzathine inj					
J0580	N	Penicillin g benzathine inj					
J0585	G	Botulinum toxin a per unit	0902		$4.39		$.56
J0590	N	Ethylnorepinephrine hcl inj					
J0600	N	Edetate calcium disodium inj					
J0610	N	Calcium gluconate injection					
J0620	N	Calcium glycer & lact/10 ML					
J0630	N	Calcitonin salmon injection					
J0635	N	Calcitriol injection					
J0640	G	Leucovorin calcium injection	0725		$4.98		$.45
J0670	N	Inj mepivacaine HCL/10 ml					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
J0690	N	Cefazolin sodium injection					
J0694	N	Cefoxitin sodium injection					
J0695	N	Cefonocid sodium injection					
J0696	N	Ceftriaxone sodium injection					
J0697	N	Sterile cefuroxime injection					
J0698	N	Cefotaxime sodium injection					
J0702	N	Betamethasone acet&sod phosp					
J0704	N	Betamethasone sod phosp/4 MG					
J0710	N	Cephapirin sodium injection					
J0713	N	Inj ceftazidime per 500 mg					
J0715	N	Ceftizoxime sodium / 500 MG					
J0720	N	Chloramphenicol sodium injec					
J0725	N	Chorionic gonadotropin/1000u					
J0730	N	Chlorpheniramin maleate inj					
J0735	N	Clonidine hydrochloride					
J0740	N	Cidofovir injection					
J0743	N	Cilastatin sodium injection					
J0745	N	Inj codeine phosphate /30 MG					
J0760	N	Colchicine injection					
J0770	N	Colistimethate sodium inj					
J0780	N	Prochlorperazine injection					
J0800	N	Corticotropin injection					
J0810	N	Cortisone injection					
J0835	N	Inj cosyntropin per 0.25 MG					
J0850	G	Cytomegalovirus imm IV /vial	0903		$656.27		$84.28
J0895	N	Deferoxamine mesylate inj					
J0900	N	Testosterone enanthate inj					
J0945	N	Brompheniramine maleate inj					
J0970	N	Estradiol valerate injection					
J1000	N	Depo-estradiol cypionate inj					
J1020	N	Methylprednisolone 20 MG inj					
J1030	N	Methylprednisolone 40 MG inj					
J1040	N	Methylprednisolone 80 MG inj					
J1050	N	Medroxyprogesterone inj					
J1055	E	Medrxyprogester acetate inj					
J1060	N	Testosterone cypionate 1 ML					
J1070	N	Testosterone cypionat 100 MG					
J1080	N	Testosterone cypionat 200 MG					
J1090	N	Testosterone cypionate 50 MG					
J1095	N	Inj dexamethasone acetate					
J1100	N	Dexamethasone sodium phos					
J1110	N	Inj dihydroergotamine mesylt					
J1120	N	Acetazolamid sodium injectio					
J1160	N	Digoxin injection					
J1165	N	Phenytoin sodium injection					
J1170	N	Hydromorphone injection					
J1180	N	Dyphylline injection					
J1190	G	Dexrazoxane HCl injection	0726		$194.53		$27.85
J1200	N	Diphenhydramine hcl injectio					
J1205	N	Chlorothiazide sodium inj					
J1212	N	Dimethyl sulfoxide 50% 50 ML					
J1230	N	Methadone injection					
J1240	N	Dimenhydrinate injection					
J1245	K	Dipyridamole injection	0917	0.37	$18.81		$3.62
J1250	N	Inj dobutamine HCL/250 mg					
J1260	G	Dolasetron mesylate	0750		$16.45		$2.11
J1320	N	Amitriptyline injection					
J1325	G	Epoprostenol injection	7003		$17.37		$2.49
J1327	G	Eptifibatide injection	1607		$13.58		$1.94
J1330	N	Ergonovine maleate injection					
J1362	N	Erythromycin glucep / 250 MG					
J1364	N	Erythro lactobionate /500 MG					
J1380	N	Estradiol valerate 10 MG inj					
J1390	N	Estradiol valerate 20 MG inj					
J1410	N	Inj estrogen conjugate 25 MG					
J1435	N	Injection estrone per 1 MG					
J1436	G	Etidronate disodium inj	0727		$63.65		$9.11
J1438	G	Etanercept injection	1608		$140.98		$20.18
J1440	G	Filgrastim 300 mcg injeciton	0728		$179.08		$25.64
J1441	G	Filgrastim 480 mcg injection	7049		$285.38		$40.85
J1450	N	Fluconazole					
J1452	N	Intraocular Fomivirsen na					
J1455	N	Foscarnet sodium injection					
J1460	N	Gamma globulin 1 CC inj					
J1470	E	Gamma globulin 2 CC inj					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
J1480	E	Gamma globulin 3 CC inj					
J1490	E	Gamma globulin 4 CC inj					
J1500	E	Gamma globulin 5 CC inj					
J1510	E	Gamma globulin 6 CC inj					
J1520	E	Gamma globulin 7 CC inj					
J1530	E	Gamma globulin 8 CC inj					
J1540	E	Gamma globulin 9 CC inj					
J1550	E	Gamma globulin 10 CC inj					
J1560	E	Gamma globulin > 10 CC inj					
J1561	G	Immune globulin 500 mg	0905		$25.92		$3.33
J1563	N	IV immune globulin					
J1565	G	RSV-ivig	0906		$406.34		$58.17
J1570	K	Ganciclovir sodium injection	0907	0.46	$23.39		$4.51
J1580	N	Garamycin gentamicin inj					
J1600	N	Gold sodium thiomaleate inj					
J1610	N	Glucagon hydrochloride/1 MG					
J1620	G	Gonadorelin hydroch/ 100 mcg	7005		$38.47		$5.51
J1626	G	Granisetron HCl injection	0764		$18.54		$2.38
J1630	N	Haloperidol injection					
J1631	N	Haloperidol decanoate inj					
J1642	N	Inj heparin sodium per 10 u					
J1644	N	Inj heparin sodium per 1000u					
J1645	N	Dalteparin sodium					
J1650	N	Inj enoxaparin sodium					
J1670	G	Tetanus immune globulin inj	0908		$102.60		$14.69
J1690	N	Prednisolone tebutate inj					
J1700	N	Hydrocortisone acetate inj					
J1710	N	Hydrocortisone sodium ph inj					
J1720	N	Hydrocortisone sodium succ i					
J1730	N	Diazoxide injection					
J1739	N	Hydroxyprogesterone cap 125					
J1741	N	Hydroxyprogesterone cap 250					
J1742	N	Ibutilide fumarate injection					
J1745	G	Infliximab injection	7043		$63.23		$9.05
J1750	N	Iron dextran					
J1785	G	Injection imiglucerase /unit	0916		$3.75		$.54
J1790	N	Droperidol injection					
J1800	N	Propranolol injection					
J1810	G	Droperidol/fentanyl inj	7047		$6.67		$.95
J1820	N	Insulin injection					
J1825	G	Interferon beta-1a	0909		$225.23		$32.24
J1830	G	Interferon beta-1b / .25 MG	0910		$54.15		$7.75
J1840	N	Kanamycin sulfate 500 MG inj					
J1850	N	Kanamycin sulfate 75 MG inj					
J1885	N	Ketorolac tromethamine inj					
J1890	N	Cephalothin sodium injection					
J1910	N	Kutapressin injection					
J1930	N	Propiomazine injection					
J1940	N	Furosemide injection					
J1950	G	Leuprolide acetate /3.75 MG	0800		$81.60		$7.39
J1955	E	Inj levocarnitine per 1 gm					
J1956	N	Levofloxacin injection					
J1960	N	Levorphanol tartrate inj					
J1970	N	Methotrimeprazine injection					
J1980	N	Hyoscyamine sulfate inj					
J1990	N	Chlordiazepoxide injection					
J2000	N	Lidocaine injection					
J2010	N	Lincomycin injection					
J2060	N	Lorazepam injection					
J2150	N	Mannitol injection					
J2175	N	Meperidine hydrochl /100 MG					
J2180	N	Meperidine/promethazine inj					
J2210	N	Methylergonovin maleate inj					
J2240	N	Metocurine iodide injection					
J2250	N	Inj midazolam hydrochloride					
J2260	K	Inj milrinone lactate / 5 ML	7007	0.48	$24.40		$4.88
J2270	N	Morphine sulfate injection					
J2271	N	Morphine so4 injection 100mg					
J2275	G	Morphine sulfate injection	7010		$7.41		$.95
J2300	N	Inj nalbuphine hydrochloride					
J2310	N	Inj naloxone hydrochloride					
J2320	N	Nandrolone decanoate 50 MG					
J2321	N	Nandrolone decanoate 100 MG					
J2322	N	Nandrolone decanoate 200 MG					
J2330	N	Thiothixene injection					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
J2350	N	Niacinamide/niacin injection					
J2352	G	Octreotide acetate injection	7031		$125.65		$17.99
J2355	G	Oprelvekin injection	7011		$236.31		$33.83
J2360	N	Orphenadrine injection					
J2370	N	Phenylephrine hcl injection					
J2400	N	Chloroprocaine hcl injection					
J2405	G	Ondansetron hcl injection	0768		$3.92		$.50
J2410	N	Oxymorphone hcl injection					
J2430	G	Pamidronate disodium /30 MG	0730		$253.68		$32.58
J2440	N	Papaverin hcl injection					
J2460	N	Oxytetracycline injection					
J2480	N	Hydrochlorides of opium inj					
J2500	N	Paricalcitol					
J2510	N	Penicillin g procaine inj					
J2512	N	Inj pentagastrin per 2 ML					
J2515	N	Pentobarbital sodium inj					
J2540	N	Penicillin g potassium inj					
J2543	N	Piperacillin/tazobactam					
J2545	A	Pentamidine isethionte/300mg					
J2550	N	Promethazine hcl injection					
J2560	N	Phenobarbital sodium inj					
J2590	N	Oxytocin injection					
J2597	E	Inj desmopressin acetate					
J2640	N	Prednisolone sodium ph inj					
J2650	N	Prednisolone acetate inj					
J2670	N	Totazoline hcl injection					
J2675	N	Inj progesterone per 50 MG					
J2680	N	Fluphenazine decanoate 25 MG					
J2690	N	Procainamide hcl injection					
J2700	N	Oxacillin sodium injeciton					
J2710	N	Neostigmine methylslfte inj					
J2720	N	Inj protamine sulfate/10 MG					
J2725	N	Inj protirelin per 250 mcg					
J2730	N	Pralidoxime chloride inj					
J2760	N	Phentolaine mesylate inj					
J2765	G	Metoclopramide hcl injection	0754		$1.55		$.20
J2770	G	Quinupristin/dalfopristin	1024		$102.05		$14.61
J2780	N	Ranitidine hydrochloride inj					
J2790	G	Rho d immune globulin inj	0884		$34.11		$4.38
J2792	G	Rho(D) immune globulin h, sd	1609		$20.64		$2.65
J2795	N	Ropivacaine HCl injection					
J2800	N	Methocarbamol injection					
J2810	N	Inj theophylline per 40 MG					
J2820	G	Sargramostim injection	0731		$29.06		$4.16
J2860	N	Secobarbital sodium inj					
J2910	N	Aurothioglucose injeciton					
J2912	N	Sodium chloride injection					
J2915	N	NA Ferric Gluconate Complex					
J2920	N	Methylprednisolone injection					
J2930	N	Methylprednisolone injection					
J2950	N	Promazine hcl injeciton					
J2970	N	Methicillin sodium injection					
J2993	G	Reteplase injection	9005		$1,306.25		$187.00
J2995	K	Inj streptokinase /250000 IU	0911	1.80	$91.52		$17.68
J2997	K	Alteplase recombinant	7048	0.39	$19.83		$3.97
J3000	N	Streptomycin injection					
J3010	G	Fentanyl citrate injeciton	7014		$1.40		$.18
J3030	N	Sumatriptan succinate / 6 MG					
J3070	N	Pentazocine hcl injeciton					
J3080	N	Chlorprothixene injection					
J3105	N	Terbutaline sulfate inj					
J3120	N	Testosterone enanthate inj					
J3130	N	Testosterone enanthate inj					
J3140	N	Testosterone suspension inj					
J3150	N	Testosteron propionate inj					
J3230	N	Chlorpromazine hcl injection					
J3240	E	Thyrotropin injection					
J3245	G	Tirofiban hydrochloride	7041		$435.27		$62.31
J3250	N	Trimethobenzamide hcl inj					
J3260	N	Tobramycin sulfate injection					
J3265	N	Injection torsemide 10 mg/ml					
J3270	N	Imipramine hcl injection					
J3280	G	Thiethylperazine maleate inj	0755		$5.43		$.70
J3301	N	Triamcinolone acetonide inj					
J3302	N	Triamcinolone diacetate inj					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
J3303	N	Triamcinolone hexacetonl inj					
J3305	G	Inj trimetrexate glucoronate	7045		$86.09		$12.32
J3310	N	Perphenazine injeciton					
J3320	N	Spectinomycn di-hcl inj					
J3350	N	Urea injection					
J3360	N	Diazepam injection					
J3364	N	Urokinase 5000 IU injection					
J3365	K	Urokinase 250,000 IU inj	7036	6.93	$352.34		$70.47
J3370	N	Vancomycin hcl injeciton					
J3390	N	Methoxamine injection					
J3400	N	Triflupromazine hcl inj					
J3410	N	Hydroxyzine hcl injeciton					
J3420	N	Vitamin b12 injection					
J3430	N	Vitamin k phytonadione inj					
J3450	N	Mephentermine sulfate inj					
J3470	N	Hyaluronidase injection					
J3475	N	Inj magnesium sulfate					
J3480	N	Inj potassium chloride					
J3485	N	Zidovudine					
J3490	N	Drugs unclassified injection					
J3520	E	Edetate disodium per 150 mg					
J3530	N	Nasal vaccine inhalation					
J3535	E	Metered dose inhaler drug					
J3570	E	Laetrile amygdalin vit B17					
J7030	N	Normal saline solution infus					
J7040	N	Normal saline solution infus					
J7042	N	5% dextrose/normal saline					
J7050	N	Normal saline solution infus					
J7051	N	Sterile saline/water					
J7060	N	5% dextrose/water					
J7070	N	D5w infusion					
J7100	N	Dextran 40 infusion					
J7110	N	Dextran 75 infusion					
J7120	N	Ringers lactate infusion					
J7130	N	Hypertonic saline solution					
J7190	G	Factor viii	0925		$.87		$.11
J7191	G	Factor VIII (porcine)	0926		$2.09		$.30
J7192	G	Factor viii recombinant	0927		$1.19		$.15
J7194	G	Factor ix complex	0928		$.68		$.09
J7197	G	Antithrombin iii injection	0930		$1.05		$.15
J7198	G	Anti-inhibitor	0929		$1.43		$.18
J7199	E	Hemophilia clot factor noc					
J7300	E	Intraut copper contraceptive					
J7310	G	Ganciclovir long act implant	0913		$4,750.00		$680.00
J7315	G	Sodium hyaluronate injection	7315		$136.80		$19.58
J7320	G	Hylan G-F 20 injection	1611		$213.86		$30.62
J7330	G	Cultured chondrocytes implnt	1059		$14,250.00		$2,040.00
J7500	G	Azathioprine oral 50mg	0886		$1.24		$.16
J7501	G	Azathioprine parenteral	0887		$.75		$.10
J7502	G	Cyclosporine oral 100 mg	0888		$5.23		$.47
J7504	G	Lymphocyte immune globulin	0890		$249.47		$32.04
J7505	G	Monoclonal antibodies	7038		$777.31		$111.28
J7506	G	Prednisone oral	7050		$.07		$.01
J7507	G	Tacrolimus oral per 1 MG	0891		$2.91		$.42
J7508	E	Tacrolimus oral per 5 MG					
J7509	N	Methylprednisolone oral					
J7510	N	Prednisolone oral per 5 mg					
J7513	G	Daclizumab, parenteral	1612		$397.29		$56.88
J7515	N	Cyclosporine oral 25 mg					
J7516	G	Cyclosporin parenteral 250mg	0889		$25.08		$2.27
J7517	G	Mycophenolate mofetil oral	9015		$2.40		$.34
J7520	G	Sirolimus, oral	9106		$6.51		$.93
J7525	E	Tacrolimus injection					
J7599	E	Immunosuppressive drug noc					
J7608	A	Acetylcysteine inh sol u d					
J7618	A	Albuterol inh sol con					
J7619	A	Albuterol inh sol u d					
J7628	A	Bitolterol mes inhal sol con					
J7629	A	Bitolterol mes inh sol u d					
J7631	A	Cromolyn sodium inh sol u d					
J7635	A	Atropine inhal sol con					
J7636	A	Atropine inhal sol unit dose					
J7637	A	Dexamethasone inhal sol con					
J7638	A	Dexamethasone inhal sol u d					
J7639	A	Dornase alpha inhal sol u d					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
J7642	A	Glycopyrrolate inhal sol con					
J7643	A	Glycopyrrolate inhal sol u d					
J7644	A	Ipratropium brom inh sol u d					
J7648	A	Isoetharine hcl inh sol con					
J7649	A	Isoetharine hcl inh sol u d					
J7658	A	Isoproterenolhcl inh sol con					
J7659	A	Isoproterenol hcl inh sol ud					
J7668	A	Metaproterenol inh sol con					
J7669	A	Metaproterenol inh sol u d					
J7680	A	Terbutaline so4 inh sol con					
J7681	A	Terbutaline so4 inh sol u d					
J7682	A	Tobramycin inhalation sol					
J7683	A	Triamcinolone inh sol con					
J7684	A	Triamcinolone inh sol u d					
J7699	A	Inhalation solution for DME					
J7799	A	Non-inhalation drug for DME					
J8499	E	Oral prescrip drug non chemo					
J8510	G	Oral busulfan	7015		$1.81		$.23
J8520	G	Capecitabine, oral, 150 mg	7042		$2.43		$.35
J8521	N	Capecitabine, oral, 500 mg					
J8530	G	Cyclophosphamide oral 25 MG	0801		$2.23		$.32
J8560	G	Etoposide oral 50 MG	0802		$50.89		$7.29
J8600	G	Melphalan oral 2 MG	0803		$2.18		$.31
J8610	G	Methotrexate oral 2.5 MG	0826		$2.73		$.25
J8700	G	Temozolmide	1086		$5.93		$.85
J8999	E	Oral prescription drug chemo					
J9000	G	Doxorubic hcl 10 MG vl chemo	0847		$9.00		$1.29
J9001	G	Doxorubicin hcl liposome inj	7046		$358.95		$51.39
J9015	G	Aldesleukin/single use vial	0807		$641.25		$91.80
J9020	G	Asparaginase injection	0814		$59.70		$8.55
J9031	G	Bcg live intravesical vac	0809		$166.44		$21.37
J9040	G	Bleomycin sulfate injection	0857		$289.37		$41.43
J9045	G	Carboplatin injection	0811		$111.11		$15.91
J9050	G	Carmus bischl nitro inj	0812		$114.41		$16.38
J9060	G	Cisplatin 10 MG injeciton	0813		$47.12		$6.75
J9062	E	Cisplatin 50 MG injeciton					
J9065	G	Inj cladribine per 1 MG	0858		$56.08		$8.03
J9070	G	Cyclophosphamide 100 MG inj	0815		$5.98		$.77
J9080	E	Cyclophosphamide 200 MG inj					
J9090	E	Cyclophosphamide 500 MG inj					
J9091	E	Cyclophosphamide 1.0 grm inj					
J9092	E	Cyclophosphamide 2.0 grm inj					
J9093	G	Cyclophosphamide lyophilized	0816		$6.13		$.79
J9094	E	Cyclophosphamide lyophilized					
J9095	E	Cyclophosphamide lyophilized					
J9096	E	Cyclophosphamide lyophilized					
J9097	E	Cyclophosphamide lyophilized					
J9100	G	Cytarabine hcl 100 MG inj	0817		$4.75		$.43
J9110	E	Cytarabine hcl 500 MG inj					
J9120	G	Dactinomycin actinomycin d	0818		$13.23		$1.89
J9130	G	Dacarbazine 10 MG inj	0819		$11.28		$1.02
J9140	E	Dacarbazine 200 MG inj					
J9150	G	Daunorubicin	0820		$76.62		$6.94
J9151	G	Daunorubicin citrate liposom	0821		$64.60		$9.25
J9160	G	Denileukin diftitox, 300 mcg	1084		$999.88		$143.14
J9165	G	Diethylstilbestrol injection	0822		$3.99		$.57
J9170	G	Docetaxel	0823		$297.83		$42.64
J9180	E	Epirubicin HCl injection					
J9181	G	Etoposide 10 MG inj	0824		$3.86		$.35
J9182	E	Etoposide 100 MG inj					
J9185	G	Fludarabine phosphate inj	0842		$258.88		$37.06
J9190	G	Fluorouracil injection	0859		$1.48		$.13
J9200	G	Floxuridine injection	0827		$129.56		$11.73
J9201	G	Gemcitabine HCl	0828		$102.13		$14.62
J9202	G	Goserelin acetate implant	0810		$446.49		$63.92
J9206	G	Irinotecan injection	0830		$125.47		$17.96
J9208	G	Ifosfomide injection	0831		$156.65		$22.43
J9209	G	Mesna injection	0732		$40.44		$5.79
J9211	G	Idarubicin hcl injeciton	0832		$412.21		$59.01
J9212	G	Interferon alfacon-1	0833		$4.10		$.59
J9213	G	Interferon alfa-2a inj	0834		$34.87		$4.99
J9214	G	Interferon alfa-2b inj	0836		$12.98		$1.67
J9215	G	Interferon alfa-n3 inj	0865		$7.86		$1.12
J9216	G	Interferon gamma 1-b inj	0838		$285.64		$40.89
J9217	G	Leuprolide acetate suspnsion	9217		$564.92		$51.14

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
J9218	G	Leuprolide acetate injeciton	0861		$26.15		$2.37
J9219	N	Leuprolide acetate implant					
J9230	G	Mechlorethamine hcl inj	0839		$11.88		$1.70
J9245	G	Inj melphalan hydrochl 50 MG	0840		$381.65		$54.64
J9250	G	Methotrexate sodium inj	0841		$.41		$.04
J9260	E	Methotrexate sodium inj					
J9265	G	Paclitaxel injection	0863		$164.08		$21.07
J9266	G	Pegaspargase/singl dose vial	0843		$1,255.57		$179.74
J9268	G	Pentostatin injection	0844		$1,654.14		$236.80
J9270	G	Plicamycin (mithramycin) inj	0860		$93.80		$13.43
J9280	G	Mitomycin 5 MG inj	0862		$121.65		$11.01
J9290	E	Mitomycin 20 MG inj					
J9291	E	Mitomycin 40 MG inj					
J9293	G	Mitoxantrone hydrochl / 5 MG	0864		$244.20		$34.96
J9310	G	Rituximab cancer treatment	0849		$454.55		$65.07
J9320	G	Streptozocin injection	0850		$117.64		$16.84
J9340	G	Thiotepa injection	0851		$116.97		$16.75
J9350	G	Topotecan	0852		$632.56		$90.56
J9355	G	Trastuzumab	1613		$52.83		$7.56
J9357	G	Valrubicin, 200 mg	1614		$423.23		$60.59
J9360	G	Vinblastine sulfate inj	0853		$4.11		$.37
J9370	G	Vincristine sulfate 1 MG inj	0854		$30.16		$2.73
J9375	E	Vincristine sulfate 2 MG inj					
J9380	E	Vincristine sulfate 5 MG inj					
J9390	G	Vinorelbine tartrate/10 mg	0855		$79.28		$11.35
J9600	G	Porfimer sodium	0856		$2,603.67		$372.74
J9999	E	Chemotherapy drug					
K0001	A	Standard wheelchair					
K0002	A	Stnd hemi (low seat) whlchr					
K0003	A	Lightweight wheelchair					
K0004	A	High strength ltwt whlchr					
K0005	A	Ultralightweight wheelchair					
K0006	A	Heavy duty wheelchair					
K0007	A	Extra heavy duty wheelchair					
K0008	A	Cstm manual wheelchair/base					
K0009	A	Other manual wheelchair/base					
K0010	A	Stnd wt frame power whlchr					
K0011	A	Stnd wt pwr whlchr w control					
K0012	A	Ltwt portbl power whlchr					
K0013	A	Custom power whlchr base					
K0014	A	Other power whlchr base					
K0015	A	Detach non-adjus hght armrst					
K0016	A	Detach adjust armrst cmplete					
K0017	A	Detach adjust armrest base					
K0018	A	Detach adjust armrst upper					
K0019	A	Arm pad each					
K0020	A	Fixed adjust armrest pair					
K0021	A	Anti-tipping device each					
K0022	A	Reinforced back upholstery					
K0023	A	Planr back insrt foam w/strp					
K0024	A	Plnr back insrt foam w/hrdwr					
K0025	A	Hook-on headrest extension					
K0026	A	Back upholst lgtwt whlchr					
K0027	A	Back upholst other whlchr					
K0028	A	Manual fully reclining back					
K0029	A	Reinforced seat upholstery					
K0030	A	Solid plnr seat sngl dnsfoam					
K0031	A	Safety belt/pelvic strap					
K0032	A	Seat uphols lgtwt whlchr					
K0033	A	Seat upholstery other whlchr					
K0034	A	Heel loop each					
K0035	A	Heel loop with ankle strap					
K0036	A	Toe loop each					
K0037	A	High mount flip-up footrest					
K0038	A	Leg strap each					
K0039	A	Leg strap h style each					
K0040	A	Adjustable angle footplate					
K0041	A	Large size footplate each					
K0042	A	Standard size footplate each					
K0043	A	Ftrst lower extension tube					
K0044	A	Ftrst upper hanger bracket					
K0045	A	Footrest complete assembly					
K0046	A	Elevat legrst low extension					
K0047	A	Elevat legrst up hangr brack					
K0048	A	Elevate legrest complete					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
K0049	A	Calf pad each					
K0050	A	Ratchet assembly					
K0051	A	Cam relese assem ftrst/lgrst					
K0052	A	Swingaway detach footrest					
K0053	A	Elevate footrest articulate					
K0054	A	Seat wdth 10-12/15/17/20 wc					
K0055	A	Seat dpth 15/17/18 ltwt wc					
K0056	A	Seat ht 17 or =21 ltwt wc					
K0057	A	Seat wdth 19/20 hvy dty wc					
K0058	A	Seat dpth 17/18 power wc					
K0059	A	Plastic coated handrim each					
K0060	A	Steel handrim each					
K0061	A	Aluminum handrim each					
K0062	A	Handrim 8-10 vert/obliq proj					
K0063	A	Hndrm 12-16 vert/obliq proj					
K0064	A	Zero pressure tube flat free					
K0065	A	Spoke protectors					
K0066	A	Solid tire any size each					
K0067	A	Pneumatic tire any size each					
K0068	A	Pneumatic tire tube each					
K0069	A	Rear whl complete solid tire					
K0070	A	Rear whl compl pneum tire					
K0071	A	Front castr compl pneum tire					
K0072	A	Frnt cstr cmpl sem-pneum tir					
K0073	A	Caster pin lock each					
K0074	A	Pneumatic caster tire each					
K0075	A	Semi-pneumatic caster tire					
K0076	A	Solid caster tire each					
K0077	A	Front caster assem complete					
K0078	A	Pneumatic caster tire tube					
K0079	A	Wheel lock extension pair					
K0080	A	Anti-rollback device pair					
K0081	A	Wheel lock assembly complete					
K0082	A	22 nf deep cycl acid battery					
K0083	A	22 nf gel cell battery each					
K0084	A	Grp 24 deep cycl acid battry					
K0085	A	Group 24 gel cell battery					
K0086	A	U-1 lead acid battery each					
K0087	A	U-1 gel cell battery each					
K0088	A	Battry chrgr acid/gel cell					
K0089	A	Battery charger dual mode					
K0090	A	Rear tire power wheelchair					
K0091	A	Rear tire tube power whlchr					
K0092	A	Rear assem cmplt powr whlchr					
K0093	A	Rear zero pressure tire tube					
K0094	A	Wheel tire for power base					
K0095	A	Wheel tire tube each base					
K0096	A	Wheel assem powr base complt					
K0097	A	Wheel zero presure tire tube					
K0098	A	Drive belt power wheelchair					
K0099	A	Pwr wheelchair front caster					
K0100	A	Amputee adapter pair					
K0101	A	One-arm drive attachment					
K0102	A	Crutch and cane holder					
K0103	A	Transfer board < 25≧					
K0104	A	Cylinder tank carrier					
K0105	A	Iv hanger					
K0106	A	Arm trough each					
K0107	A	Wheelchair tray					
K0108	A	W/c component-accessory NOS					
K0112	A	Trunk vest supprt innr frame					
K0113	A	Trunk vest suprt w/o inr frm					
K0114	A	Whlchr back suprt inr frame					
K0115	A	Back module orthotic system					
K0116	A	Back & seat modul orthot sys					
K0183	A	Nasal application device					
K0184	A	Nasal pillows/seals pair					
K0185	A	Pos airway pressure headgear					
K0186	A	Pos airway prssure chinstrap					
K0187	A	Pos airway pressure tubing					
K0188	A	Pos airway pressure filter					
K0189	A	Filter nondisposable w PAP					
K0195	A	Elevating whlchair leg rests					
K0268	A	Humidifier nonheated w PAP					
K0415	E	RX antiemetic drg, oral NOS					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
K0416	E	Rx antiemetic drg,rectal NOS					
K0452	A	Wheelchair bearings					
K0455	A	Pump uninterrupted infusion					
K0460	A	WC power add-on joystick					
K0461	A	WC power add-on tiller cntrl					
K0462	A	Temporary replacement eqpmnt					
K0531	A	Heated humidifier used w pap					
K0532	A	Noninvasive assist wo backup					
K0533	A	Noninvasive assist w backup					
K0534	A	Invasive assist w backup					
K0538	A	Neg pressure wnd thrpy pump					
K0539	A	Neg pres wnd thrpy dsg set					
K0540	A	Neg pres wnd thrp canister					
K0541	A	Speech generating device					
K0542	A	Speech generating device					
K0543	A	Speech generating device					
K0544	A	Speech generating device					
K0545	A	Speech generating software					
K0546	A	Accessory for sgd,mntng syst					
K0547	A	Accessory for sgd,not clasfd					
K0548	A	Insulin lispro					
K0549	A	Hosp bed hvy dty xtra wide					
K0550	A	Hosp bed xtra hvy dty x wide					
K0551	A	Residual limb support system					
L0100	A	Cerv craniosten helmet mold					
L0110	A	Cerv craniostenosis hel non-					
L0120	A	Cerv flexible non-adjustable					
L0130	A	Flex thermoplastic collar mo					
L0140	A	Cervical semi-rigid adjustab					
L0150	A	Cerv semi-rig adj molded chn					
L0160	A	Cerv semi-rig wire occ/mand					
L0170	A	Cervical collar molded to pt					
L0172	A	Cerv col thermplas foam 2 pi					
L0174	A	Cerv col foam 2 piece w thor					
L0180	A	Cer post col occ/man sup adj					
L0190	A	Cerv collar supp adj cerv ba					
L0200	A	Cerv col supp adj bar & thor					
L0210	A	Thoracic rib belt					
L0220	A	Thor rib belt custom fabrica					
L0300	A	TLSO flex surgical support					
L0310	A	Tlso flexible custom fabrica					
L0315	A	Tlso flex elas rigid post pa					
L0317	A	Tlso flex hypext elas post p					
L0320	A	Tlso a-p contrl w apron frnt					
L0330	A	Tlso ant-pos-lateral control					
L0340	A	Tlso a-p-l-rotary with apron					
L0350	A	Tlso flex compress jacket cu					
L0360	A	Tlso flex compress jacket mo					
L0370	A	Tlso a-p-l-rotary hyperexten					
L0380	A	Tlso a-p-l-rot w/ pos extens					
L0390	A	Tlso a-p-l control molded					
L0400	A	Tlso a-p-l w interface mater					
L0410	A	Tlso a-p-l two piece constr					
L0420	A	Tlso a-p-l 2 piece w interfa					
L0430	A	Tlso a-p-l w interface custm					
L0440	A	Tlso a-p-l overlap frnt cust					
L0500	A	Lso flex surgical support					
L0510	A	Lso flexible custom fabricat					
L0515	A	Lso flex elas w/ rig post pa					
L0520	A	Lso a-p-l control with apron					
L0530	A	Lso ant-pos control w apron					
L0540	A	Lso lumbar flexion a-p-l					
L0550	A	Lso a-p-l control molded					
L0560	A	Lso a-p-l w interface					
L0565	A	Lso a-p-l control custom					
L0600	A	Sacroiliac flex surg support					
L0610	A	Sacroiliac flexible custm fa					
L0620	A	Sacroiliac semi-rig w apron					
L0700	A	Ctlso a-p-l control molded					
L0710	A	Ctlso a-p-l control w/ inter					
L0810	A	Halo cervical into jckt vest					
L0820	A	Halo cervical into body jack					
L0830	A	Halo cerv into milwaukee typ					
L0860	A	Magnetic resonanc image comp					
L0900	A	Torso/ptosis support					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
L0910	A	Torso & ptosis supp custm fa					
L0920	A	Torso/pendulous abd support					
L0930	A	Pendulous abdomen supp custm					
L0940	A	Torso/postsurgical support					
L0950	A	Post surg support custom fab					
L0960	A	Post surgical support pads					
L0970	A	Tlso corset front					
L0972	A	Lso corset front					
L0974	A	Tlso full corset					
L0976	A	Lso full corset					
L0978	A	Axillary crutch extension					
L0980	A	Peroneal straps pair					
L0982	A	Stocking supp grips set of f					
L0984	A	Protective body sock each					
L0999	A	Add to spinal orthosis NOS					
L1000	A	Ctlso milwauke initial model					
L1010	A	Ctlso axilla sling					
L1020	A	Kyphosis pad					
L1025	A	Kyphosis pad floating					
L1030	A	Lumbar bolster pad					
L1040	A	Lumbar or lumbar rib pad					
L1050	A	Sternal pad					
L1060	A	Thoracic pad					
L1070	A	Trapezius sling					
L1080	A	Outrigger					
L1085	A	Outrigger bil w/ vert extens					
L1090	A	Lumbar sling					
L1100	A	Ring flange plastic/leather					
L1110	A	Ring flange plas/leather mol					
L1120	A	Covers for upright each					
L1200	A	Furnsh initial orthosis only					
L1210	A	Lateral thoracic extension					
L1220	A	Anterior thoracic extension					
L1230	A	Milwaukee type superstructur					
L1240	A	Lumbar derotation pad					
L1250	A	Anterior asis pad					
L1260	A	Anterior thoracic derotation					
L1270	A	Abdominal pad					
L1280	A	Rib gusset (elastic) each					
L1290	A	Lateral trochanteric pad					
L1300	A	Body jacket mold to patient					
L1310	A	Post-operative body jacket					
L1499	A	Spinal orthosis NOS					
L1500	A	Thkao mobility frame					
L1510	A	Thkao standing frame					
L1520	A	Thkao swivel walker					
L1600	A	Abduct hip flex frejka w cvr					
L1610	A	Abduct hip flex frejka covr					
L1620	A	Abduct hip flex pavlik harne					
L1630	A	Abduct control hip semi-flex					
L1640	A	Pelv band/spread bar thigh c					
L1650	A	HO abduction hip adjustable					
L1660	A	HO abduction static plastic					
L1680	A	Pelvic & hip control thigh c					
L1685	A	Post-op hip abduct custom fa					
L1686	A	HO post-op hip abduction					
L1690	A	Combination bilateral HO					
L1700	A	Leg perthes orth toronto typ					
L1710	A	Legg perthes orth newington					
L1720	A	Legg perthes orthosis trilat					
L1730	A	Legg perthes orth scottish r					
L1750	A	Legg perthes sling					
L1755	A	Legg perthes patten bottom t					
L1800	A	Knee orthoses elas w stays					
L1810	A	Ko elastic with joints					
L1815	A	Elastic with condylar pads					
L1820	A	Ko elas w/ condyle pads & jo					
L1825	A	Ko elastic knee cap					
L1830	A	Ko immobilizer canvas longit					
L1832	A	KO adj jnt pos rigid support					
L1834	A	Ko w/0 joint rigid molded to					
L1840	A	Ko derot ant cruciate custom					
L1843	A	KO single upright custom fit					
L1844	A	Ko w/adj jt rot cntrl molded					
L1845	A	Ko w/ adj flex/ext rotat cus					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
L1846	A	Ko w adj flex/ext rotat mold					
L1847	A	KO adjustable w air chambers					
L1850	A	Ko swedish type					
L1855	A	Ko plas doub upright jnt mol					
L1858	A	Ko polycentric pneumatic pad					
L1860	A	Ko supracondylar socket mold					
L1870	A	Ko doub upright lacers molde					
L1880	A	Ko doub upright cuffs/lacers					
L1885	A	Knee upright w/resistance					
L1900	A	Afo sprng wir drsflx calf bd					
L1902	A	Afo ankle gauntlet					
L1904	A	Afo molded ankle gauntlet					
L1906	A	Afo multiligamentus ankle su					
L1910	A	Afo sing bar clasp attach sh					
L1920	A	Afo sing upright w/ adjust s					
L1930	A	Afo plastic					
L1940	A	Afo molded to patient plasti					
L1945	A	Afo molded plas rig ant tib					
L1950	A	Afo spiral molded to pt plas					
L1960	A	Afo pos solid ank plastic mo					
L1970	A	Afo plastic molded w/ankle j					
L1980	A	Afo sing solid stirrup calf					
L1990	A	Afo doub solid stirrup calf					
L2000	A	Kafo sing fre stirr thi/calf					
L2010	A	Kafo sng solid stirrup w/o j					
L2020	A	Kafo dbl solid stirrup band/					
L2030	A	Kafo dbl solid stirrup w/o j					
L2035	A	KAFO plastic pediatric size					
L2036	A	Kafo plas doub free knee mol					
L2037	A	Kafo plas sing free knee mol					
L2038	A	Kafo w/o joint multi-axis an					
L2039	A	KAFO,plstic,medlat rotat con					
L2040	A	Hkafo torsion bil rot straps					
L2050	A	Hkafo torsion cable hip pelv					
L2060	A	Hkafo torsion ball bearing j					
L2070	A	Hkafo torsion unilat rot str					
L2080	A	Hkafo unilat torsion cable					
L2090	A	Hkafo unilat torsion ball br					
L2102	A	Afo tibial fx cast plstr mol					
L2104	A	Afo tib fx cast synthetic mo					
L2106	A	Afo tib fx cast plaster mold					
L2108	A	Afo tib fx cast molded to pt					
L2112	A	Afo tibial fracture soft					
L2114	A	Afo tib fx semi-rigid					
L2116	A	Afo tibial fracture rigid					
L2122	A	Kafo fem fx cast plaster mol					
L2124	A	Kafo fem fx cast synthet mol					
L2126	A	Kafo fem fx cast thermoplas					
L2128	A	Kafo fem fx cast molded to p					
L2132	A	Kafo femoral fx cast soft					
L2134	A	Kafo fem fx cast semi-rigid					
L2136	A	Kafo femoral fx cast rigid					
L2180	A	Plas shoe insert w ank joint					
L2182	A	Drop lock knee					
L2184	A	Limited motion knee joint					
L2186	A	Adj motion knee jnt lerman t					
L2188	A	Quadrilateral brim					
L2190	A	Waist belt					
L2192	A	Pelvic band & belt thigh fla					
L2200	A	Limited ankle motion ea jnt					
L2210	A	Dorsiflexion assist each joi					
L2220	A	Dorsi & plantar flex ass/res					
L2230	A	Split flat caliper stirr & p					
L2240	A	Round caliper and plate atta					
L2250	A	Foot plate molded stirrup at					
L2260	A	Reinforced solid stirrup					
L2265	A	Long tongue stirrup					
L2270	A	Varus/valgus strap padded/li					
L2275	A	Plastic mod low ext pad/line					
L2280	A	Molded inner boot					
L2300	A	Abduction bar jointed adjust					
L2310	A	Abduction bar-straight					
L2320	A	Non-molded lacer					
L2330	A	Lacer molded to patient mode					
L2335	A	Anterior swing band					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
L2340	A	Pre-tibial shell molded to p					
L2350	A	Prosthetic type socket molde					
L2360	A	Extended steel shank					
L2370	A	Patten bottom					
L2375	A	Torsion ank & half solid sti					
L2380	A	Torsion straight knee joint					
L2385	A	Straight knee joint heavy du					
L2390	A	Offset knee joint each					
L2395	A	Offset knee joint heavy duty					
L2397	A	Suspension sleeve lower ext					
L2405	A	Knee joint drop lock ea jnt					
L2415	A	Knee joint cam lock each joi					
L2425	A	Knee disc/dial lock/adj flex					
L2430	A	Knee jnt ratchet lock ea jnt					
L2435	A	Knee joint polycentric joint					
L2492	A	Knee lift loop drop lock rin					
L2500	A	Thi/glut/ischia wgt bearing					
L2510	A	Th/wght bear quad-lat brim m					
L2520	A	Th/wght bear quad-lat brim c					
L2525	A	Th/wght bear nar m-l brim mo					
L2526	A	Th/wght bear nar m-l brim cu					
L2530	A	Thigh/wght bear lacer non-mo					
L2540	A	Thigh/wght bear lacer molded					
L2550	A	Thigh/wght bear high roll cu					
L2570	A	Hip clevis type 2 posit jnt					
L2580	A	Pelvic control pelvic sling					
L2600	A	Hip clevis/thrust bearing fr					
L2610	A	Hip clevis/thrust bearing lo					
L2620	A	Pelvic control hip heavy dut					
L2622	A	Hip joint adjustable flexion					
L2624	A	Hip adj flex ext abduct cont					
L2627	A	Plastic mold recipro hip & c					
L2628	A	Metal frame recipro hip & ca					
L2630	A	Pelvic control band & belt u					
L2640	A	Pelvic control band & belt b					
L2650	A	Pelv & thor control gluteal					
L2660	A	Thoracic control thoracic ba					
L2670	A	Thorac cont paraspinal uprig					
L2680	A	Thorac cont lat support upri					
L2750	A	Plating chrome/nickel pr bar					
L2755	A	Carbon graphite lamination					
L2760	A	Extension per extension per					
L2770	A	Low ext orthosis per bar/jnt					
L2780	A	Non-corrosive finish					
L2785	A	Drop lock retainer each					
L2795	A	Knee control full kneecap					
L2800	A	Knee cap medial or lateral p					
L2810	A	Knee control condylar pad					
L2820	A	Soft interface below knee se					
L2830	A	Soft interface above knee se					
L2840	A	Tibial length sock fx or equ					
L2850	A	Femoral lgth sock fx or equa					
L2860	A	Torsion mechanism knee/ankle					
L2999	A	Lower extremity orthosis NOS					
L3000	E	Ft insert ucb berkeley shell					
L3001	E	Foot insert removmolded spe					
L3002	E	Foot insert plastazote or eq					
L3003	E	Foot insert silicone gel eac					
L3010	E	Foot longitudinal arch suppo					
L3020	E	Foot longitud/metatarsal sup					
L3030	E	Foot arch support removprem					
L3040	E	Ft arch suprt premold longit					
L3050	E	Foot arch supp premold metat					
L3060	E	Foot arch supp longitud/meta					
L3070	E	Arch suprt att to sho longit					
L3080	E	Arch supp att to shoe metata					
L3090	E	Arch supp att to shoe long/m					
L3100	E	Hallus-valgus nght dynamic s					
L3140	E	Abduction rotation bar shoe					
L3150	E	Abduct rotation bar w/o shoe					
L3160	E	Shoe styled positioning dev					
L3170	E	Foot plastic heel stabilizer					
L3201	E	Oxford w supinat/pronat inf					
L3202	E	Oxford w/ supinat/pronator c					
L3203	E	Oxford w/ supinator/pronator					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
L3204	E	Hightop w/ supp/pronator inf					
L3206	E	Hightop w/ supp/pronator chi					
L3207	E	Hightop w/ supp/pronator jun					
L3208	E	Surgical boot each infant					
L3209	E	Surgical boot each child					
L3211	E	Surgical boot each junior					
L3212	E	Benesch boot pair infant					
L3213	E	Benesch boot pair child					
L3214	E	Benesch boot pair junior					
L3215	E	Orthopedic ftwear ladies oxf					
L3216	E	Orthoped ladies shoes dpth i					
L3217	E	Ladies shoes hightop depth i					
L3218	E	Ladies surgical boot each					
L3219	E	Orthopedic mens shoes oxford					
L3221	E	Orthopedic mens shoes dpth i					
L3222	E	Mens shoes hightop depth inl					
L3223	E	Mens surgical boot each					
L3224	A	Woman's shoe oxford brace					
L3225	A	Man's shoe oxford brace					
L3230	E	Custom shoes depth inlay					
L3250	E	Custom mold shoe remov prost					
L3251	E	Shoe molded to pt silicone s					
L3252	E	Shoe molded plastazote cust					
L3253	E	Shoe molded plastazote cust					
L3254	E	Orth foot non-stndard size/w					
L3255	E	Orth foot non-standard size/					
L3257	E	Orth foot add charge split s					
L3260	E	Ambulatory surgical boot eac					
L3265	E	Plastazote sandal each					
L3300	E	Sho lift taper to metatarsal					
L3310	E	Shoe lift elev heel/sole neo					
L3320	E	Shoe lift elev heel/sole cor					
L3330	E	Lifts elevation metal extens					
L3332	E	Shoe lifts tapered to one-ha					
L3334	E	Shoe lifts elevation heel /i					
L3340	E	Shoe wedge sach					
L3350	E	Shoe heel wedge					
L3360	E	Shoe sole wedge outside sole					
L3370	E	Shoe sole wedge between sole					
L3380	E	Shoe clubfoot wedge					
L3390	E	Shoe outflare wedge					
L3400	E	Shoe metatarsal bar wedge ro					
L3410	E	Shoe metatarsal bar between					
L3420	E	Full sole/heel wedge btween					
L3430	E	Sho heel count plast reinfor					
L3440	E	Heel leather reinforced					
L3450	E	Shoe heel sach cushion type					
L3455	E	Shoe heel new leather standa					
L3460	E	Shoe heel new rubber standar					
L3465	E	Shoe heel thomas with wedge					
L3470	E	Shoe heel thomas extend to b					
L3480	E	Shoe heel pad & depress for					
L3485	E	Shoe heel pad removable for					
L3500	E	Ortho shoe add leather insol					
L3510	E	Orthopedic shoe add rub insl					
L3520	E	O shoe add felt w leath insl					
L3530	E	Ortho shoe add half sole					
L3540	E	Ortho shoe add full sole					
L3550	E	O shoe add standard toe tap					
L3560	E	O shoe add horseshoe toe tap					
L3570	E	O shoe add instep extension					
L3580	E	O shoe add instep velcro clo					
L3590	E	O shoe convert to sof counte					
L3595	E	Ortho shoe add march bar					
L3600	E	Trans shoe calip plate exist					
L3610	E	Trans shoe caliper plate new					
L3620	E	Trans shoe solid stirrup exi					
L3630	E	Trans shoe solid stirrup new					
L3640	E	Shoe dennis browne splint bo					
L3649	E	Orthopedic shoe modifica NOS					
L3650	A	Shlder fig 8 abduct restrain					
L3660	A	Abduct restrainer canvas&web					
L3670	A	Acromio/clavicular canvas&we					
L3675	A	Canvas vest SO					
L3700	A	Elbow orthoses elas w stays					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
L3710	A	Elbow elastic with metal joi					
L3720	A	Forearm/arm cuffs free motio					
L3730	A	Forearm/arm cuffs ext/flex a					
L3740	A	Cuffs adj lock w/ active con					
L3760	E	EO withjoint, Prefabricated					
L3800	A	Whfo short opponen no attach					
L3805	A	Whfo long opponens no attach					
L3807	A	WHFO,no joint, prefabricated					
L3810	A	Whfo thumb abduction bar					
L3815	A	Whfo second m.p. abduction a					
L3820	A	Whfo ip ext asst w/ mp ext s					
L3825	A	Whfo m.p. extension stop					
L3830	A	Whfo m.p. extension assist					
L3835	A	Whfo m.p. spring extension a					
L3840	A	Whfo spring swivel thumb					
L3845	A	Whfo thumb ip ext ass w/ mp					
L3850	A	Action wrist w/ dorsiflex as					
L3855	A	Whfo adj m.p. flexion contro					
L3860	A	Whfo adj m.p. flex ctrl & i.					
L3890	E	Torsion mechanism wrist/elbo					
L3900	A	Hinge extension/flex wrist/f					
L3901	A	Hinge ext/flex wrist finger					
L3902	A	Whfo ext power compress gas					
L3904	A	Whfo electric custom fitted					
L3906	A	Wrist gauntlet molded to pt					
L3907	A	Whfo wrst gauntlt thmb spica					
L3908	A	Wrist cock-up non-molded					
L3910	A	Whfo swanson design					
L3912	A	Flex glove w/elastic finger					
L3914	A	WHO wrist extension cock-up					
L3916	A	Whfo wrist extens w/ outrigg					
L3918	A	HFO knuckle bender					
L3920	A	Knuckle bender with outrigge					
L3922	A	Knuckle bend 2 seg to flex j					
L3923	A	HFO, no joint, prefabricated					
L3924	A	Oppenheimer					
L3926	A	Thomas suspension					
L3928	A	Finger extension w/ clock sp					
L3930	A	Finger extension with wrist					
L3932	A	Safety pin spring wire					
L3934	A	Safety pin modified					
L3936	A	Palmer					
L3938	A	Dorsal wrist					
L3940	A	Dorsal wrist w/ outrigger at					
L3942	A	Reverse knuckle bender					
L3944	A	Reverse knuckle bend w/ outr					
L3946	A	HFO composite elastic					
L3948	A	Finger knuckle bender					
L3950	A	Oppenheimer w/ knuckle bend					
L3952	A	Oppenheimer w/ rev knuckle 2					
L3954	A	Spreading hand					
L3956	A	Add joint upper ext orthosis					
L3960	A	Sewho airplan desig abdu pos					
L3962	A	Sewho erbs palsey design abd					
L3963	A	Molded w/ articulating elbow					
L3964	A	Seo mobile arm sup att to wc					
L3965	A	Arm supp att to wc rancho ty					
L3966	A	Mobile arm supports reclinin					
L3968	A	Friction dampening arm supp					
L3969	A	Monosuspension arm/hand supp					
L3970	A	Elevat proximal arm support					
L3972	A	Offset/lat rocker arm w/ ela					
L3974	A	Mobile arm support supinator					
L3980	A	Upp ext fx orthosis humeral					
L3982	A	Upper ext fx orthosis rad/ul					
L3984	A	Upper ext fx orthosis wrist					
L3985	A	Forearm hand fx orth w/ wr h					
L3986	A	Humeral rad/ulna wrist fx or					
L3995	A	Sock fracture or equal each					
L3999	A	Upper limb orthosis NOS					
L4000	A	Repl girdle milwaukee orth					
L4010	A	Replace trilateral socket br					
L4020	A	Replace quadlat socket brim					
L4030	A	Replace socket brim cust fit					
L4040	A	Replace molded thigh lacer					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
L4045	A	Replace non-molded thigh lac					
L4050	A	Replace molded calf lacer					
L4055	A	Replace non-molded calf lace					
L4060	A	Replace high roll cuff					
L4070	A	Replace prox & dist upright					
L4080	A	Repl met band kafo-afo prox					
L4090	A	Repl met band kafo-afo calf/					
L4100	A	Repl leath cuff kafo prox th					
L4110	A	Repl leath cuff kafo-afo cal					
L4130	A	Replace pretibial shell					
L4205	A	Ortho dvc repair per 15 min					
L4210	A	Orth dev repair/repl minor p					
L4350	A	Pneumatic ankle cntrl splint					
L4360	A	Pneumatic walking splint					
L4370	A	Pneumatic full leg splint					
L4380	A	Pneumatic knee splint					
L4392	A	Replace AFO soft interface					
L4394	A	Replace foot drop spint					
L4396	A	Static AFO					
L4398	A	Foot drop splint recumbent					
L5000	A	Sho insert w arch toe filler					
L5010	A	Mold socket ank hgt w/ toe f					
L5020	A	Tibial tubercle hgt w/ toe f					
L5050	A	Ank symes mold sckt sach ft					
L5060	A	Symes met fr leath socket ar					
L5100	A	Molded socket shin sach foot					
L5105	A	Plast socket jts/thgh lacer					
L5150	A	Mold sckt ext knee shin sach					
L5160	A	Mold socket bent knee shin s					
L5200	A	Kne sing axis fric shin sach					
L5210	A	No knee/ankle joints w/ ft b					
L5220	A	No knee joint with artic ali					
L5230	A	Fem focal defic constant fri					
L5250	A	Hip canad sing axi cons fric					
L5270	A	Tilt table locking hip sing					
L5280	A	Hemipelvect canad sing axis					
L5300	A	Bk sach soft cover & finish					
L5310	A	Knee disart sach soft cv/fin					
L5320	A	Ak open end sach soft cv/fin					
L5330	A	Hip canadian sach sft cv/fin					
L5340	A	Hemipelvectomy canad cv/fin					
L5400	A	Postop dress & 1 cast chg bk					
L5410	A	Postop dsg bk ea add cast ch					
L5420	A	Postop dsg & 1 cast chg ak/d					
L5430	A	Postop dsg ak ea add cast ch					
L5450	A	Postop app non-wgt bear dsg					
L5460	A	Postop app non-wgt bear dsg					
L5500	A	Init bk ptb plaster direct					
L5505	A	Init ak ischal plstr direct					
L5510	A	Prep BK ptb plaster molded					
L5520	A	Perp BK ptb thermopls direct					
L5530	A	Prep BK ptb thermopls molded					
L5535	A	Prep BK ptb open end socket					
L5540	A	Prep BK ptb laminated socket					
L5560	A	Prep AK ischial plast molded					
L5570	A	Prep AK ischial direct form					
L5580	A	Prep AK ischial thermo mold					
L5585	A	Prep AK ischial open end					
L5590	A	Prep AK ischial laminated					
L5595	A	Hip disartic sach thermopls					
L5600	A	Hip disart sach laminat mold					
L5610	A	Above knee hydracadence					
L5611	A	Ak 4 bar link w/fric swing					
L5613	A	Ak 4 bar ling w/hydraul swig					
L5614	A	4-bar link above knee w/swng					
L5616	A	Ak univ multiplex sys frict					
L5617	A	AK/BK self-aligning unit ea					
L5618	A	Test socket symes					
L5620	A	Test socket below knee					
L5622	A	Test socket knee disarticula					
L5624	A	Test socket above knee					
L5626	A	Test socket hip disarticulat					
L5628	A	Test socket hemipelvectomy					
L5629	A	Below knee acrylic socket					
L5630	A	Syme typ expandabl wall sckt					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
L5631	A	Ak/knee disartic acrylic soc					
L5632	A	Symes type ptb brim design s					
L5634	A	Symes type poster opening so					
L5636	A	Symes type medial opening so					
L5637	A	Below knee total contact					
L5638	A	Below knee leather socket					
L5639	A	Below knee wood socket					
L5640	A	Knee disarticulat leather so					
L5642	A	Above knee leather socket					
L5643	A	Hip flex inner socket ext fr					
L5644	A	Above knee wood socket					
L5645	A	Bk flex inner socket ext fra					
L5646	A	Below knee air cushion socke					
L5647	A	Below knee suction socket					
L5648	A	Above knee air cushion socke					
L5649	A	Isch containmt/narrow m-l so					
L5650	A	Tot contact ak/knee disart s					
L5651	A	Ak flex inner socket ext fra					
L5652	A	Suction susp ak/knee disart					
L5653	A	Knee disart expand wall sock					
L5654	A	Socket insert symes					
L5655	A	Socket insert below knee					
L5656	A	Socket insert knee articulat					
L5658	A	Socket insert above knee					
L5660	A	Sock insrt syme silicone gel					
L5661	A	Multi-durometer symes					
L5662	A	Socket insert bk silicone ge					
L5663	A	Sock knee disartic silicone					
L5664	A	Socket insert ak silicone ge					
L5665	A	Multi-durometer below knee					
L5666	A	Below knee cuff suspension					
L5667	A	Socket insert w lock lower					
L5668	A	Socket insert w/o lock lower					
L5669	A	Below knee socket w/o lock					
L5670	A	Bk molded supracondylar susp					
L5672	A	Bk removable medial brim sus					
L5674	A	Bk suspension sleeve					
L5675	A	Bk heavy duty susp sleeve					
L5676	A	Bk knee joints single axis p					
L5677	A	Bk knee joints polycentric p					
L5678	A	Bk joint covers pair					
L5680	A	Bk thigh lacer non-molded					
L5682	A	Bk thigh lacer glut/ischia m					
L5684	A	Bk fork strap					
L5686	A	Bk back check					
L5688	A	Bk waist belt webbing					
L5690	A	Bk waist belt padded and lin					
L5692	A	Ak pelvic control belt light					
L5694	A	Ak pelvic control belt pad/l					
L5695	A	Ak sleeve susp neoprene/equa					
L5696	A	Ak/knee disartic pelvic join					
L5697	A	Ak/knee disartic pelvic band					
L5698	A	Ak/knee disartic silesian ba					
L5699	A	Shoulder harness					
L5700	A	Replace socket below knee					
L5701	A	Replace socket above knee					
L5702	A	Replace socket hip					
L5704	A	Custom shape covr below knee					
L5705	A	Custm shape cover above knee					
L5706	A	Custm shape cvr knee disart					
L5707	A	Custm shape cover hip disart					
L5710	A	Kne-shin exo sng axi mnl loc					
L5711	A	Knee-shin exo mnl lock ultra					
L5712	A	Knee-shin exo frict swg & st					
L5714	A	Knee-shin exo variable frict					
L5716	A	Knee-shin exo mech stance ph					
L5718	A	Knee-shin exo frct swg & sta					
L5722	A	Knee-shin pneum swg frct exo					
L5724	A	Knee-shin exo fluid swing ph					
L5726	A	Knee-shin ext jnts fld swg e					
L5728	A	Knee-shin fluid swg & stance					
L5780	A	Knee-shin pneum/hydra pneum					
L5785	A	Exoskeletal bk ultralt mater					
L5790	A	Exoskeletal ak ultra-light m					
L5795	A	Exoskel hip ultra-light mate					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
L5810	A	Endoskel knee-shin mnl lock					
L5811	A	Endo knee-shin mnl lck ultra					
L5812	A	Endo knee-shin frct swg & st					
L5814	A	Endo knee-shin hydral swg ph					
L5816	A	Endo knee-shin polyc mch sta					
L5818	A	Endo knee-shin frct swg & st					
L5822	A	Endo knee-shin pneum swg frc					
L5824	A	Endo knee-shin fluid swing p					
L5826	A	Miniature knee joint					
L5828	A	Endo knee-shin fluid swg/sta					
L5830	A	Endo knee-shin pneum/swg pha					
L5840	A	Multi-axial knee/shin system					
L5845	A	Knee-shin sys stance flexion					
L5846	A	Knee-shin sys microprocessor					
L5850	A	Endo ak/hip knee extens assi					
L5855	A	Mech hip extension assist					
L5910	A	Endo below knee alignable sy					
L5920	A	Endo ak/hip alignable system					
L5925	A	Above knee manual lock					
L5930	A	High activity knee frame					
L5940	A	Endo bk ultra-light material					
L5950	A	Endo ak ultra-light material					
L5960	A	Endo hip ultra-light materia					
L5962	A	Below knee flex cover system					
L5964	A	Above knee flex cover system					
L5966	A	Hip flexible cover system					
L5968	A	Multiaxial ankle w dorsiflex					
L5970	A	Foot external keel sach foot					
L5972	A	Flexible keel foot					
L5974	A	Foot single axis ankle/foot					
L5975	A	Combo ankle/foot prosthesis					
L5976	A	Energy storing foot					
L5978	A	Ft prosth multiaxial ankl/ft					
L5979	A	Multi-axial ankle/ft prosth					
L5980	A	Flex foot system					
L5981	A	Flex-walk sys low ext prosth					
L5982	A	Exoskeletal axial rotation u					
L5984	A	Endoskeletal axial rotation					
L5985	A	Lwr ext dynamic prosth pylon					
L5986	A	Multi-axial rotation unit					
L5987	A	Shank ft w vert load pylon					
L5988	A	Vertical shock reducing pylo					
L5999	A	Lowr extremity prosthes NOS					
L6000	A	Par hand robin-aids thum rem					
L6010	A	Hand robin-aids little/ring					
L6020	A	Part hand robin-aids no fing					
L6050	A	Wrst MLd sck flx hng tri pad					
L6055	A	Wrst mold sock w/exp interfa					
L6100	A	Elb mold sock flex hinge pad					
L6110	A	Elbow mold sock suspension t					
L6120	A	Elbow mold doub splt soc ste					
L6130	A	Elbow stump activated lock h					
L6200	A	Elbow mold outsid lock hinge					
L6205	A	Elbow molded w/ expand inter					
L6250	A	Elbow inter loc elbow forarm					
L6300	A	Shlder disart int lock elbow					
L6310	A	Shoulder passive restor comp					
L6320	A	Shoulder passive restor cap					
L6350	A	Thoracic intern lock elbow					
L6360	A	Thoracic passive restor comp					
L6370	A	Thoracic passive restor cap					
L6380	A	Postop dsg cast chg wrst/elb					
L6382	A	Postop dsg cast chg elb dis/					
L6384	A	Postop dsg cast chg shlder/t					
L6386	A	Postop ea cast chg & realign					
L6388	A	Postop applicat rigid dsg on					
L6400	A	Below elbow prosth tiss shap					
L6450	A	Elb disart prosth tiss shap					
L6500	A	Above elbow prosth tiss shap					
L6550	A	Shldr disar prosth tiss shap					
L6570	A	Scap thorac prosth tiss shap					
L6580	A	Wrist/elbow bowden cable mol					
L6582	A	Wrist/elbow bowden cbl dir f					
L6584	A	Elbow fair lead cable molded					
L6586	A	Elbow fair lead cable dir fo					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
L6588	A	Shdr fair lead cable molded					
L6590	A	Shdr fair lead cable direct					
L6600	A	Polycentric hinge pair					
L6605	A	Single pivot hinge pair					
L6610	A	Flexible metal hinge pair					
L6615	A	Disconnect locking wrist uni					
L6616	A	Disconnect insert locking wr					
L6620	A	Flexion-friction wrist unit					
L6623	A	Spring-ass rot wrst w/ latch					
L6625	A	Rotation wrst w/ cable lock					
L6628	A	Quick disconn hook adapter o					
L6629	A	Lamination collar w/ couplin					
L6630	A	Stainless steel any wrist					
L6632	A	Latex suspension sleeve each					
L6635	A	Lift assist for elbow					
L6637	A	Nudge control elbow lock					
L6640	A	Shoulder abduction joint pai					
L6641	A	Excursion amplifier pulley t					
L6642	A	Excursion amplifier lever ty					
L6645	A	Shoulder flexion-abduction j					
L6650	A	Shoulder universal joint					
L6655	A	Standard control cable extra					
L6660	A	Heavy duty control cable					
L6665	A	Teflon or equal cable lining					
L6670	A	Hook to hand cable adapter					
L6672	A	Harness chest/shlder saddle					
L6675	A	Harness figure of 8 sing con					
L6676	A	Harness figure of 8 dual con					
L6680	A	Test sock wrist disart/bel e					
L6682	A	Test sock elbw disart/above					
L6684	A	Test socket shldr disart/tho					
L6686	A	Suction socket					
L6687	A	Frame typ socket bel elbow/w					
L6688	A	Frame typ sock above elb/dis					
L6689	A	Frame typ socket shoulder di					
L6690	A	Frame typ sock interscap-tho					
L6691	A	Removable insert each					
L6692	A	Silicone gel insert or equal					
L6693	A	Lockingelbow forearm cntrbal					
L6700	A	Terminal device model ı3					
L6705	A	Terminal device model ı5					
L6710	A	Terminal device model ı5x					
L6715	A	Terminal device model ı5xa					
L6720	A	Terminal device model ı6					
L6725	A	Terminal device model ı7					
L6730	A	Terminal device model ı7lo					
L6735	A	Terminal device model ı8					
L6740	A	Terminal device model ı8x					
L6745	A	Terminal device model ı88x					
L6750	A	Terminal device model ı10p					
L6755	A	Terminal device model ı10x					
L6765	A	Terminal device model ı12p					
L6770	A	Terminal device model ı99x					
L6775	A	Terminal device modelı555					
L6780	A	Terminal device model ıss555					
L6790	A	Hooks-accu hook or equal					
L6795	A	Hooks-2 load or equal					
L6800	A	Hooks-aprl vc or equal					
L6805	A	Modifier wrist flexion unit					
L6806	A	Trs grip vc or equal					
L6807	A	Term device grip1/2 or equal					
L6808	A	Term device infant or child					
L6809	A	Trs super sport passive					
L6810	A	Pincher tool otto bock or eq					
L6825	A	Hands dorrance vo					
L6830	A	Hand aprl vc					
L6835	A	Hand sierra vo					
L6840	A	Hand becker imperial					
L6845	A	Hand becker lock grip					
L6850	A	Term dvc-hand becker plylite					
L6855	A	Hand robin-aids vo					
L6860	A	Hand robin-aids vo soft					
L6865	A	Hand passive hand					
L6867	A	Hand detroit infant hand					
L6868	A	Passive inf hand steeper/hos					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
L6870	A	Hand child mitt					
L6872	A	Hand nyu child hand					
L6873	A	Hand mech inf steeper or equ					
L6875	A	Hand bock vc					
L6880	A	Hand bock vo					
L6890	A	Production glove					
L6895	A	Custom glove					
L6900	A	Hand restorat thumb/1 finger					
L6905	A	Hand restoration multiple fi					
L6910	A	Hand restoration no fingers					
L6915	A	Hand restoration replacmnt g					
L6920	A	Wrist disarticul switch ctrl					
L6925	A	Wrist disart myoelectronic c					
L6930	A	Below elbow switch control					
L6935	A	Below elbow myoelectronic ct					
L6940	A	Elbow disarticulation switch					
L6945	A	Elbow disart myoelectronic c					
L6950	A	Above elbow switch control					
L6955	A	Above elbow myoelectronic ct					
L6960	A	Shldr disartic switch contro					
L6965	A	Shldr disartic myoelectronic					
L6970	A	Interscapular-thor switch ct					
L6975	A	Interscap-thor myoelectronic					
L7010	A	Hand otto back steeper/eq sw					
L7015	A	Hand sys teknik village swit					
L7020	A	Electronic greifer switch ct					
L7025	A	Electron hand myoelectronic					
L7030	A	Hand sys teknik vill myoelec					
L7035	A	Electron greifer myoelectro					
L7040	A	Prehensile actuator hosmer s					
L7045	A	Electron hook child michigan					
L7170	A	Electronic elbow hosmer swit					
L7180	A	Electronic elbow utah myoele					
L7185	A	Electron elbow adolescent sw					
L7186	A	Electron elbow child switch					
L7190	A	Elbow adolescent myoelectron					
L7191	A	Elbow child myoelectronic ct					
L7260	A	Electron wrist rotator otto					
L7261	A	Electron wrist rotator utah					
L7266	A	Servo control steeper or equ					
L7272	A	Analogue control unb or equa					
L7274	A	Proportional ctl 12 volt uta					
L7360	A	Six volt bat otto bock/eq ea					
L7362	A	Battery chrgr six volt otto					
L7364	A	Twelve volt battery utah/equ					
L7366	A	Battery chrgr 12 volt utah/e					
L7499	A	Upper extremity prosthes NOS					
L7500	A	Prosthetic dvc repair hourly					
L7510	A	Prosthetic device repair rep					
L7520	A	Repair prosthesis per 15 min					
L7900	A	Vacuum erection system					
L8000	A	Mastectomy bra					
L8010	A	Mastectomy sleeve					
L8015	A	Ext breastprosthesis garment					
L8020	A	Mastectomy form					
L8030	A	Breast prosthesis silicone/e					
L8035	A	Custom breast prosthesis					
L8039	A	Breast prosthesis NOS					
L8040	A	Nasal prosthesis					
L8041	A	Midfacial prosthesis					
L8042	A	Orbital prosthesis					
L8043	A	Upper facial prosthesis					
L8044	A	Hemi-facial prosthesis					
L8045	A	Auricular prosthesis					
L8046	A	Partial facial prosthesis					
L8047	A	Nasal septal prosthesis					
L8048	A	Unspec maxillofacial prosth					
L8049	A	Repair maxillofacial prosth					
L8100	E	Compression stocking BK18-30					
L8110	E	Compression stocking BK30-40					
L8120	E	Compression stocking BK40-50					
L8130	E	Gc stocking thighlngth 18-30					
L8140	E	Gc stocking thighlngth 30-40					
L8150	E	Gc stocking thighlngth 40-50					
L8160	E	Gc stocking full lngth 18-30					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
L8170	E	Gc stocking full lngth 30-40					
L8180	E	Gc stocking full lngth 40-50					
L8190	E	Gc stocking waistlngth 18-30					
L8195	E	Gc stocking waistlngth 30-40					
L8200	E	Gc stocking waistlngth 40-50					
L8210	E	Gc stocking custom made					
L8220	E	Gc stocking lymphedema					
L8230	E	Gc stocking garter belt					
L8239	E	G compression stocking NOS					
L8300	A	Truss single w/ standard pad					
L8310	A	Truss double w/ standard pad					
L8320	A	Truss addition to std pad wa					
L8330	A	Truss add to std pad scrotal					
L8400	A	Sheath below knee					
L8410	A	Sheath above knee					
L8415	A	Sheath upper limb					
L8417	A	Pros sheath/sock w gel cushn					
L8420	A	Prosthetic sock multi ply BK					
L8430	A	Prosthetic sock multi ply AK					
L8435	A	Pros sock multi ply upper lm					
L8440	A	Shrinker below knee					
L8460	A	Shrinker above knee					
L8465	A	Shrinker upper limb					
L8470	A	Pros sock single ply BK					
L8480	A	Pros sock single ply AK					
L8485	A	Pros sock single ply upper l					
L8490	A	Air seal suction reten systm					
L8499	A	Unlisted misc prosthetic ser					
L8500	A	Artificial larynx					
L8501	A	Tracheostomy speaking valve					
L8600	N	Implant breast silicone/eq					
L8603	N	Collagen imp urinary 2.5 ml					
L8606	A	Synthetic implnt urinary 1ml					
L8610	N	Ocular implant					
L8612	N	Aqueous shunt prosthesis					
L8613	N	Ossicular implant					
L8614	H	Cochlear device/system	1002				
L8619	A	Replace cochlear processor					
L8630	N	Metacarpophalangeal implant					
L8641	N	Metatarsal joint implant					
L8642	N	Hallux implant					
L8658	N	Interphalangeal joint implnt					
L8670	N	Vascular graft, synthetic					
L8699	N	Prosthetic implant NOS					
L9900	A	O&P supply/accessory/service					
M0064	X	Visit for drug monitoring	0374	0.96	$48.81	$10.74	$9.76
M0075	E	Cellular therapy					
M0076	E	Prolotherapy					
M0100	E	Intragastric hypothermia					
M0300	E	IV chelationtherapy					
M0301	E	Fabric wrapping of aneurysm					
M0302	T	Assessment of cardiac output	0970	0.47	$23.90		$4.78
P2028	X	Cephalin floculation test	0349	0.34	$17.29	$3.46	$3.46
P2029	X	Congo red blood test	0349	0.34	$17.29	$3.46	$3.46
P2031	E	Hair analysis					
P2033	X	Blood thymol turbidity	0349	0.34	$17.29	$3.46	$3.46
P2038	A	Blood mucoprotein					
P3000	A	Screen pap by tech w md supv					
P3001	E	Screening pap smear by phys					
P7001	E	Culture bacterial urine					
P9010	K	Whole blood for transfusion	0950	2.13	$108.29		$21.66
P9011	E	Blood split unit					
P9012	K	Cryoprecipitate each unit	0952	0.72	$36.61		$7.32
P9016	K	RBC leukocytes reduced	0954	2.89	$146.93		$29.39
P9017	K	One donor fresh frozn plasma	0955	2.31	$117.45		$23.49
P9019	K	Platelets, each unit	0957	1.00	$50.84		$10.17
P9020	K	Plaelet rich plasma unit	0958	1.19	$60.50		$12.10
P9021	K	Red blood cells unit	0959	2.09	$106.26		$21.25
P9022	K	Washed red blood cells unit	0960	3.89	$197.78		$39.56
P9023	K	Frozen plasma, pooled, sd	0949	3.00	$152.53		$30.51
P9031	K	Platelets leukocytes reduced	0954	2.89	$146.93		$29.39
P9032	K	Platelets, irradiated	9500	1.81	$92.02		$18.40
P9033	K	Platelets leukoreduced irrad	0954	2.89	$146.93		$29.39
P9034	K	Platelets, pheresis	9501	9.91	$503.84		$100.77
P9035	K	Platelet pheres leukoreduced	9501	9.91	$503.84		$100.77

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
P9036	K	Platelet pheresis irradiated	9502	10.75	$546.55		$109.31
P9037	K	Plate pheres leukoredu irrad	9501	9.91	$503.84		$100.77
P9038	K	RBC irradiated	9505	2.64	$134.22		$26.84
P9039	K	RBC deglycerolized	9504	4.45	$226.25		$45.25
P9040	K	RBC leukoreduced irradiated	9504	4.45	$226.25		$45.25
P9041	K	Albumin(human), 5%	0961	2.24	$113.89		$22.78
P9042	K	Albumin (human), 25%	0962	1.12	$56.94		$11.39
P9043	K	Plasma protein fraction	0956	1.29	$65.59		$13.12
P9044	K	Cryoprecipitatereducedplasma	1009	0.88	$44.74		$8.95
P9603	A	One-way allow prorated miles					
P9604	A	One-way allow prorated trip					
P9612	N	Catheterize for urine spec					
P9615	N	Urine specimen collect mult					
Q0035	X	Cardiokymography	0100	1.63	$82.87	$45.58	$16.57
Q0081	T	Infusion ther other than che	0120	2.35	$119.48	$42.67	$23.90
Q0083	S	Chemo by other than infusion	0116	0.98	$49.83	$9.97	$9.97
Q0084	S	Chemotherapy by infusion	0117	3.48	$176.93	$52.69	$35.39
Q0085	S	Chemo by both infusion and o	0118	3.52	$178.96	$72.03	$35.79
Q0086	A	Physical therapy evaluation/					
Q0091	T	Obtaining screen pap smear	0191	0.27	$13.73	$3.98	$2.75
Q0092	N	Set up port xray equipment					
Q0111	A	Wet mounts/ w preparations					
Q0112	A	Potassium hydroxide preps					
Q0113	A	Pinworm examinations					
Q0114	A	Fern test					
Q0115	A	Post-coital mucous exam					
Q0136	G	Non esrd epoetin alpha inj	0733		$11.85		$1.52
Q0144	E	Azithromycin dihydrate, oral					
Q0160	G	Factor IX non-recombinant	0931		$.76		$.10
Q0161	G	Factor IX recombinant	0932		$1.12		$.16
Q0163	G	Diphenhydramine HCl 50mg	1400		$.12		$.01
Q0164	G	Prochlorperazine maleate 5mg	1401		$.57		$.05
Q0165	E	Prochlorperazine maleate10mg					
Q0166	G	Granisetron HCl 1 mg oral	0765		$44.70		$5.74
Q0167	G	Dronabinol 2.5mg oral	0762		$3.28		$.42
Q0168	E	Dronabinol 5mg oral					
Q0169	G	Promethazine HCl 12.5mg oral	1402		$.03		$.00
Q0170	E	Promethazine HCl 25 mg oral					
Q0171	G	Chlorpromazine HCl 10mg oral	1403		$.07		$.01
Q0172	E	Chlorpromazine HCl 25mg oral					
Q0173	G	Trimethobenzamide HCl 250mg	1404		$.36		$.03
Q0174	G	Thiethylperazine maleate10mg	1405		$.56		$.08
Q0175	G	Perphenazine 4mg oral	1406		$.62		$.06
Q0176	E	Perphenazine 8mg oral					
Q0177	G	Hydroxyzine pamoate 25mg	1407		$.20		$.02
Q0178	E	Hydroxyzine pamoate 50mg					
Q0179	G	Ondansetron HCl 8mg oral	0769		$25.15		$3.23
Q0180	G	Dolasetron mesylate oral	0763		$69.64		$8.94
Q0181	E	Unspecified oral anti-emetic					
Q0183	N	Nonmetabolic active tissue					
Q0184	N	Metabolically active tissue					
Q0185	N	Metabolic active D/E tissue					
Q0187	G	Factor viia recombinant	1409		$1,596.00		$228.48
Q1001	E	Ntiol category 1					
Q1002	E	Ntiol category 2					
Q1003	E	Ntiol category 3					
Q1004	E	Ntiol category 4					
Q1005	E	Ntiol category 5					
Q2001	N	Oral cabergoline 0.5 mg					
Q2002	G	Elliotts b solution per ml	7022		$14.25		$2.04
Q2003	G	Aprotinin, 10,000 kiu	7019		$2.06		$.30
Q2004	G	Bladder calculi irrig sol	7023		$24.70		$3.54
Q2005	G	Corticorelin ovine triflutat	7024		$368.03		$52.69
Q2006	G	Digoxin immune fab (ovine)	7025		$551.66		$78.97
Q2007	G	Ethanolamine oleate 100 mg	7026		$39.73		$5.69
Q2008	G	Fomepizole, 15 mg	7027		$1.09		$.16
Q2009	G	Fosphenytoin, 50 mg	7028		$9.55		$1.37
Q2010	G	Glatiramer acetate, per dose	7029		$30.07		$4.30
Q2011	G	Hemin, per 1 mg	7030		$.99		$.14
Q2012	G	Pegademase bovine, 25 iu	7039		$139.33		$19.95
Q2013	G	Pentastarch 10% solution	7040		$15.11		$2.16
Q2014	G	Sermorelin acetate, 0.5 mg	7032		$15.78		$2.26
Q2015	G	Somatrem, 5 mg	7033		$209.48		$29.99
Q2016	G	Somatropin, 1 mg	7034		$39.90		$5.12
Q2017	G	Teniposide, 50 mg	7035		$216.32		$30.97

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
Q2018	G	Urofollitropin, 75 iu	7037		$73.29		$9.41
Q2019	G	Basiliximab	1615		$1,348.76		$193.09
Q2020	G	Histrelin acetate	1616		$14.16		$2.03
Q2021	G	Lepirudin	1617		$131.96		$18.89
Q2022	G	VonWillebrandFactrCmplxperIU	1618		$.95		$.14
Q3001	E	Brachytherapy Radioelements	0918				
Q3002	G	Gallium ga 67	1619		$24.38		$3.13
Q3003	G	Technetium tc99m bicisate	1620		$384.75		$55.08
Q3004	G	Xenon xe 133	1621		$29.93		$3.84
Q3005	G	Technetium tc99m mertiatide	1622		$176.53		$25.27
Q3006	G	Technetium tc99m glucepatate	1623		$22.61		$3.24
Q3007	G	Sodium phosphate p32	1624		$81.10		$11.61
Q3008	G	Indium 111-in pentetreotide	1625		$935.75		$133.96
Q3009	G	Technetium tc99m oxidronate	1626		$36.74		$5.26
Q3010	G	Technetium tc99mlabeledrbcs	1627		$40.90		$5.85
Q3011	G	Chromic phosphate p32	1628		$150.86		$21.60
Q3012	G	Cyanocobalamin cobalt co57	1089		$97.85		$14.01
Q3013	G	Verteporfin for injection	1203		$1,458.25		$208.76
Q4001	A	Cast sup body cast plaster					
Q4002	A	Cast sup body cast fiberglas					
Q4003	A	Cast sup shoulder cast plstr					
Q4004	A	Cast sup shoulder cast fbrgl					
Q4005	A	Cast sup long arm adult plst					
Q4006	A	Cast sup long arm adult fbrg					
Q4007	A	Cast sup long arm ped plster					
Q4008	A	Cast sup long arm ped fbrgls					
Q4009	A	Cast sup sht arm adult plstr					
Q4010	A	Cast sup sht arm adult fbrgl					
Q4011	A	Cast sup sht arm ped plaster					
Q4012	A	Cast sup sht arm ped fbrglas					
Q4013	A	Cast sup gauntlet plaster					
Q4014	A	Cast sup gauntlet fiberglass					
Q4015	A	Cast sup gauntlet ped plster					
Q4016	A	Cast sup gauntlet ped fbrgls					
Q4017	A	Cast sup lng arm splint plst					
Q4018	A	Cast sup lng arm splint fbrg					
Q4019	A	Cast sup lng arm splnt ped p					
Q4020	A	Cast sup lng arm splnt ped f					
Q4021	A	Cast sup sht arm splint plst					
Q4022	A	Cast sup sht arm splint fbrg					
Q4023	A	Cast sup sht arm splnt ped p					
Q4024	A	Cast sup sht arm splnt ped f					
Q4025	A	Cast sup hip spica plaster					
Q4026	A	Cast sup hip spica fiberglas					
Q4027	A	Cast sup hip spica ped plstr					
Q4028	A	Cast sup hip spica ped fbrgl					
Q4029	A	Cast sup long leg plaster					
Q4030	A	Cast sup long leg fiberglass					
Q4031	A	Cast sup lng leg ped plaster					
Q4032	A	Cast sup lng leg ped fbrgls					
Q4033	A	Cast sup lng leg cylinder pl					
Q4034	A	Cast sup lng leg cylinder fb					
Q4035	A	Cast sup lngleg cylndr ped p					
Q4036	A	Cast sup lngleg cylndr ped f					
Q4037	A	Cast sup shrt leg plaster					
Q4038	A	Cast sup shrt leg fiberglass					
Q4039	A	Cast sup shrt leg ped plster					
Q4040	A	Cast sup shrt leg ped fbrgls					
Q4041	A	Cast sup lng leg splnt plstr					
Q4042	A	Cast sup lng leg splnt fbrgl					
Q4043	A	Cast sup lng leg splnt ped p					
Q4044	A	Cast sup lng leg splnt ped f					
Q4045	A	Cast sup sht leg splnt plstr					
Q4046	A	Cast sup sht leg splnt fbrgl					
Q4047	A	Cast sup sht leg splnt ped p					
Q4048	A	Cast sup sht leg splnt ped f					
Q4049	A	Finger splint, static					
Q4050	A	Cast supplies unlisted					
Q4051	A	Splint supplies misc					
Q9920	A	Epoetin with hct <= 20					
Q9921	A	Epoetin with hct = 21					
Q9922	A	Epoetin with hct = 22					
Q9923	A	Epoetin with hct = 23					
Q9924	A	Epoetin with hct = 24					
Q9925	A	Epoetin with hct = 25					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
Q9926	A	Epoetin with hct = 26					
Q9927	A	Epoetin with hct = 27					
Q9928	A	Epoetin with hct = 28					
Q9929	A	Epoetin with hct = 29					
Q9930	A	Epoetin with hct = 30					
Q9931	A	Epoetin with hct = 31					
Q9932	A	Epoetin with hct = 32					
Q9933	A	Epoetin with hct = 33					
Q9934	A	Epoetin with hct = 34					
Q9935	A	Epoetin with hct = 35					
Q9936	A	Epoetin with hct = 36					
Q9937	A	Epoetin with hct = 37					
Q9938	A	Epoetin with hct = 38					
Q9939	A	Epoetin with hct = 39					
Q9940	A	Epoetin with hct >= 40					
R0070	N	Transport portable x-ray					
R0075	N	Transport port x-ray multipl					
R0076	N	Transport portable EKG					
V2020	A	Vision svcs frames purchases					
V2025	E	Eyeglasses delux frames					
V2100	A	Lens spher single plano 4.00					
V2101	A	Single visn sphere 4.12-7.00					
V2102	A	Singl visn sphere 7.12-20.00					
V2103	A	Spherocylindr 4.00d/12-2.00d					
V2104	A	Spherocylindr 4.00d/2.12-4d					
V2105	A	Spherocylinder 4.00d/4.25-6d					
V2106	A	Spherocylinder 4.00d/>6.00d					
V2107	A	Spherocylinder 4.25d/12-2d					
V2108	A	Spherocylinder 4.25d/2.12-4d					
V2109	A	Spherocylinder 4.25d/4.25-6d					
V2110	A	Spherocylinder 4.25d/over 6d					
V2111	A	Spherocylindr 7.25d/.25-2.25					
V2112	A	Spherocylindr 7.25d/2.25-4d					
V2113	A	Spherocylindr 7.25d/4.25-6d					
V2114	A	Spherocylinder over 12.00d					
V2115	A	Lens lenticular bifocal					
V2116	A	Nonaspheric lens bifocal					
V2117	A	Aspheric lens bifocal					
V2118	A	Lens aniseikonic single					
V2199	A	Lens single vision not oth c					
V2200	A	Lens spher bifoc plano 4.00d					
V2201	A	Lens sphere bifocal 4.12-7.0					
V2202	A	Lens sphere bifocal 7.12-20.					
V2203	A	Lens sphcyl bifocal 4.00d/.1					
V2204	A	Lens sphcy bifocal 4.00d/2.1					
V2205	A	Lens sphcy bifocal 4.00d/4.2					
V2206	A	Lens sphcy bifocal 4.00d/ove					
V2207	A	Lens sphcy bifocal 4.25-7d/.					
V2208	A	Lens sphcy bifocal 4.25-7/2.					
V2209	A	Lens sphcy bifocal 4.25-7/4.					
V2210	A	Lens sphcy bifocal 4.25-7/ov					
V2211	A	Lens sphcy bifo 7.25-12/.25-					
V2212	A	Lens sphcyl bifo 7.25-12/2.2					
V2213	A	Lens sphcyl bifo 7.25-12/4.2					
V2214	A	Lens sphcyl bifocal over 12.					
V2215	A	Lens lenticular bifocal					
V2216	A	Lens lenticular nonaspheric					
V2217	A	Lens lenticular aspheric bif					
V2218	A	Lens aniseikonic bifocal					
V2219	A	Lens bifocal seg width over					
V2220	A	Lens bifocal add over 3.25d					
V2299	A	Lens bifocal speciality					
V2300	A	Lens sphere trifocal 4.00d					
V2301	A	Lens sphere trifocal 4.12-7.					
V2302	A	Lens sphere trifocal 7.12-20					
V2303	A	Lens sphcy trifocal 4.0/.12-					
V2304	A	Lens sphcy trifocal 4.0/2.25					
V2305	A	Lens sphcy trifocal 4.0/4.25					
V2306	A	Lens sphcyl trifocal 4.00/>6					
V2307	A	Lens sphcy trifocal 4.25-7/.					
V2308	A	Lens sphc trifocal 4.25-7/2.					
V2309	A	Lens sphc trifocal 4.25-7/4.					
V2310	A	Lens sphc trifocal 4.25-7/>6					
V2311	A	Lens sphc trifo 7.25-12/.25-					
V2312	A	Lens sphc trifo 7.25-12/2.25					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
V2313	A	Lens sphc trifo 7.25-12/4.25					
V2314	A	Lens sphcyl trifocal over 12					
V2315	A	Lens lenticular trifocal					
V2316	A	Lens lenticular nonaspheric					
V2317	A	Lens lenticular aspheric tri					
V2318	A	Lens aniseikonic trifocal					
V2319	A	Lens trifocal seg width > 28					
V2320	A	Lens trifocal add over 3.25d					
V2399	A	Lens trifocal speciality					
V2410	A	Lens variab asphericity sing					
V2430	A	Lens variable asphericity bi					
V2499	A	Variable asphericity lens					
V2500	A	Contact lens pmma spherical					
V2501	A	Cntct lens pmma-toric/prism					
V2502	A	Contact lens pmma bifocal					
V2503	A	Cntct lens pmma color vision					
V2510	A	Cntct gas permeable sphericl					
V2511	A	Cntct toric prism ballast					
V2512	A	Cntct lens gas permbl bifocl					
V2513	A	Contact lens extended wear					
V2520	A	Contact lens hydrophilic					
V2521	A	Cntct lens hydrophilic toric					
V2522	A	Cntct lens hydrophil bifocl					
V2523	A	Cntct lens hydrophil extend					
V2530	A	Contact lens gas impermeable					
V2531	A	Contact lens gas permeable					
V2599	A	Contact lens/es other type					
V2600	A	Hand held low vision aids					
V2610	A	Single lens spectacle mount					
V2615	A	Telescop/othr compound lens					
V2623	A	Plastic eye prosth custom					
V2624	A	Polishing artifical eye					
V2625	A	Enlargemnt of eye prosthesis					
V2626	A	Reduction of eye prosthesis					
V2627	A	Scleral cover shell					
V2628	A	Fabrication & fitting					
V2629	A	Prosthetic eye other type					
V2630	N	Anter chamber intraocul lens					
V2631	N	Iris support intraoclr lens					
V2632	N	Post chmbr intraocular lens					
V2700	A	Balance lens					
V2710	A	Glass/plastic slab off prism					
V2715	A	Prism lens/es					
V2718	A	Fresnell prism press-on lens					
V2730	A	Special base curve					
V2740	A	Rose tint plastic					
V2741	A	Non-rose tint plastic					
V2742	A	Rose tint glass					
V2743	A	Non-rose tint glass					
V2744	A	Tint photochromatic lens/es					
V2750	A	Anti-reflective coating					
V2755	A	UV lens/es					
V2760	A	Scratch resistant coating					
V2770	A	Occluder lens/es					
V2780	A	Oversize lens/es					
V2781	E	Progressive lens per lens					
V2785	F	Corneal tissue processing					
V2790	N	Amniotic membrane					
V2799	A	Miscellaneous vision service					
V5008	E	Hearing screening					
V5010	E	Assessment for hearing aid					
V5011	E	Hearing aid fitting/checking					
V5014	E	Hearing aid repair/modifying					
V5020	E	Conformity evaluation					
V5030	E	Body-worn hearing aid air					
V5040	E	Body-worn hearing aid bone					
V5050	E	Hearing aid monaural in ear					
V5060	E	Behind ear hearing aid					
V5070	E	Glasses air conduction					
V5080	E	Glasses bone conduction					
V5090	E	Hearing aid dispensing fee					
V5100	E	Body-worn bilat hearing aid					
V5110	E	Hearing aid dispensing fee					
V5120	E	Body-worn binaur hearing aid					
V5130	E	In ear binaural hearing aid					

ADDENDUM B.—PAYMENT STATUS BY HCPCS CODE AND RELATED INFORMATION CALENDER YEAR 2002—Continued

CPT/ HCPCS	HOPD Status Indicator	Description	APC	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment
V5140	E	Behind ear binaur hearing ai					
V5150	E	Glasses binaural hearing aid					
V5160	E	Dispensing fee binaural					
V5170	E	Within ear cros hearing aid					
V5180	E	Behind ear cros hearing aid					
V5190	E	Glasses cros hearing aid					
V5200	E	Cros hearing aid dispens fee					
V5210	E	In ear bicros hearing aid					
V5220	E	Behind ear bicros hearing ai					
V5230	E	Glasses bicros hearing aid					
V5240	E	Dispensing fee bicros					
V5299	E	Hearing service					
V5336	E	Repair communication device					
V5362	A	Speech screening					
V5363	A	Language screening					
V5364	A	Dysphagia screening					

ADDENDUM E.—CPT CODES WHICH WOULD BE PAID ONLY AS INPATIENT PROCEDURES

CPT/ HCPCS	HOPD Status Indicator	Description
00174	C	Anesth, pharyngeal surgery
00176	C	Anesth, pharyngeal surgery
00192	C	Anesth, facial bone surgery
00214	C	Anesth, skull drainage
00215	C	Anesth, skull repair/fract
00404	C	Anesth, surgery of breast
00406	C	Anesth, surgery of breast
00452	C	Anesth, surgery of shoulder
00474	C	Anesth, surgery of rib(s)
00524	C	Anesth, chest drainage
00530	C	Anesth, pacemaker insertion
00540	C	Anesth, chest surgery
00542	C	Anesth, release of lung
00544	C	Anesth, chest lining removal
00546	C	Anesth, lung,chest wall surg
00560	C	Anesth, open heart surgery
00562	C	Anesth, open heart surgery
00580	C	Anesth heart/lung transplant
00604	C	Anesth, sitting procedure
00622	C	Anesth, removal of nerves
00632	C	Anesth, removal of nerves
00634	C	Anesth for chemonucleolysis
00670	C	Anesth, spine, cord surgery
00792	C	Anesth, hemorr/excise liver
00794	C	Anesth, pancreas removal
00796	C	Anesth, for liver transplant
00802	C	Anesth, fat layer removal
00844	C	Anesth, pelvis surgery
00846	C	Anesth, hysterectomy
00848	C	Anesth, pelvic organ surg
00850	C	Anesth, cesarean section
00855	C	Anesth, hysterectomy
00857	C	Analgesia, labor & c-section
00864	C	Anesth, removal of bladder
00865	C	Anesth, removal of prostate
00866	C	Anesth, removal of adrenal
00868	C	Anesth, kidney transplant
00882	C	Anesth, major vein ligation
00884	C	Anesth, major vein revision
00904	C	Anesth, perineal surgery
00908	C	Anesth, removal of prostate
00928	C	Anesth, removal of testis
00932	C	Anesth, amputation of penis
00934	C	Anesth, penis, nodes removal
00936	C	Anesth, penis, nodes removal
00944	C	Anesth, vaginal hysterectomy
00955	C	Analgesia, vaginal delivery
01140	C	Anesth, amputation at pelvis
01150	C	Anesth, pelvic tumor surgery

ADDENDUM E.—CPT CODES WHICH WOULD BE PAID ONLY AS INPATIENT PROCEDURES—Continued

CPT/ HCPCS	HOPD Status Indicator	Description
01190	C	Anesth, pelvis nerve removal
01212	C	Anesth, hip disarticulation
01214	C	Anesth, replacement of hip
01232	C	Anesth, amputation of femur
01234	C	Anesth, radical femur surg
01272	C	Anesth, femoral artery surg
01274	C	Anesth, femoral embolectomy
01402	C	Anesth, replacement of knee
01404	C	Anesth, amputation at knee
01442	C	Anesth, knee artery surg
01444	C	Anesth, knee artery repair
01486	C	Anesth, ankle replacement
01502	C	Anesth, lwr leg embolectomy
01632	C	Anesth, surgery of shoulder
01634	C	Anesth, shoulder joint amput
01636	C	Anesth, forequarter amput
01638	C	Anesth, shoulder replacement
01652	C	Anesth, shoulder vessel surg
01654	C	Anesth, shoulder vessel surg
01656	C	Anesth, arm-leg vessel surg
01756	C	Anesth, radical humerus surg
01772	C	Anesth, uppr arm embolectomy
01782	C	Anesth, uppr arm vein repair
01842	C	Anesth, lwr arm embolectomy
01852	C	Anesth, lwr arm vein repair
01904	C	Anesth, skull x-ray inject
01990	C	Support for organ donor
15756	C	Free muscle flap, microvasc
15757	C	Free skin flap, microvasc
15758	C	Free fascial flap, microvasc
16035	C	Incision of burn scab, initi
16036	C	Incise burn scab, addl incis
19200	C	Removal of breast
19220	C	Removal of breast
19271	C	Revision of chest wall
19272	C	Extensive chest wall surgery
19361	C	Breast reconstruction
19364	C	Breast reconstruction
19367	C	Breast reconstruction
19368	C	Breast reconstruction
19369	C	Breast reconstruction
20660	C	Apply,remove fixation device
20661	C	Application of head brace
20662	C	Application of pelvis brace
20663	C	Application of thigh brace
20664	C	Halo brace application
20802	C	Replantation, arm, complete
20805	C	Replant, forearm, complete
20808	C	Replantation hand, complete
20816	C	Replantation digit, complete
20822	C	Replantation digit, complete
20824	C	Replantation thumb, complete
20827	C	Replantation thumb, complete
20838	C	Replantation foot, complete
20930	C	Spinal bone allograft
20931	C	Spinal bone allograft
20936	C	Spinal bone autograft
20937	C	Spinal bone autograft
20938	C	Spinal bone autograft
20955	C	Fibula bone graft, microvasc
20956	C	Iliac bone graft, microvasc
20957	C	Mt bone graft, microvasc
20962	C	Other bone graft, microvasc
20969	C	Bone/skin graft, microvasc
20970	C	Bone/skin graft, iliac crest
20972	C	Bone/skin graft, metatarsal
20973	C	Bone/skin graft, great toe
21045	C	Extensive jaw surgery
21141	C	Reconstruct midface, lefort
21142	C	Reconstruct midface, lefort
21143	C	Reconstruct midface, lefort
21145	C	Reconstruct midface, lefort
21146	C	Reconstruct midface, lefort
21147	C	Reconstruct midface, lefort
21150	C	Reconstruct midface, lefort

ADDENDUM E.—CPT CODES WHICH WOULD BE PAID ONLY AS INPATIENT PROCEDURES—Continued

CPT/ HCPCS	HOPD Status Indicator	Description
21151	C	Reconstruct midface, lefort
21154	C	Reconstruct midface, lefort
21155	C	Reconstruct midface, lefort
21159	C	Reconstruct midface, lefort
21160	C	Reconstruct midface, lefort
21172	C	Reconstruct orbit/forehead
21175	C	Reconstruct orbit/forehead
21179	C	Reconstruct entire forehead
21180	C	Reconstruct entire forehead
21182	C	Reconstruct cranial bone
21183	C	Reconstruct cranial bone
21184	C	Reconstruct cranial bone
21188	C	Reconstruction of midface
21193	C	Reconst lwr jaw w/o graft
21194	C	Reconst lwr jaw w/graft
21195	C	Reconst lwr jaw w/o fixation
21196	C	Reconst lwr jaw w/fixation
21247	C	Reconstruct lower jaw bone
21255	C	Reconstruct lower jaw bone
21256	C	Reconstruction of orbit
21268	C	Revise eye sockets
21343	C	Treatment of sinus fracture
21344	C	Treatment of sinus fracture
21346	C	Treat nose/jaw fracture
21347	C	Treat nose/jaw fracture
21348	C	Treat nose/jaw fracture
21356	C	Treat cheek bone fracture
21360	C	Treat cheek bone fracture
21365	C	Treat cheek bone fracture
21366	C	Treat cheek bone fracture
21385	C	Treat eye socket fracture
21386	C	Treat eye socket fracture
21387	C	Treat eye socket fracture
21390	C	Treat eye socket fracture
21395	C	Treat eye socket fracture
21408	C	Treat eye socket fracture
21422	C	Treat mouth roof fracture
21423	C	Treat mouth roof fracture
21431	C	Treat craniofacial fracture
21432	C	Treat craniofacial fracture
21433	C	Treat craniofacial fracture
21435	C	Treat craniofacial fracture
21436	C	Treat craniofacial fracture
21495	C	Treat hyoid bone fracture
21510	C	Drainage of bone lesion
21557	C	Remove tumor, neck/chest
21615	C	Removal of rib
21616	C	Removal of rib and nerves
21620	C	Partial removal of sternum
21627	C	Sternal debridement
21630	C	Extensive sternum surgery
21632	C	Extensive sternum surgery
21705	C	Revision of neck muscle/rib
21740	C	Reconstruction of sternum
21750	C	Repair of sternum separation
21810	C	Treatment of rib fracture(s)
21825	C	Treat sternum fracture
22100	C	Remove part of neck vertebra
22101	C	Remove part, thorax vertebra
22102	C	Remove part, lumbar vertebra
22103	C	Remove extra spine segment
22110	C	Remove part of neck vertebra
22112	C	Remove part, thorax vertebra
22114	C	Remove part, lumbar vertebra
22116	C	Remove extra spine segment
22210	C	Revision of neck spine
22212	C	Revision of thorax spine
22214	C	Revision of lumbar spine
22216	C	Revise, extra spine segment
22220	C	Revision of neck spine
22222	C	Revision of thorax spine
22224	C	Revision of lumbar spine
22226	C	Revise, extra spine segment
22318	C	Treat odontoid fx w/o graft
22319	C	Treat odontoid fx w/graft

ADDENDUM E.—CPT CODES WHICH WOULD BE PAID ONLY AS INPATIENT PROCEDURES—Continued

CPT/ HCPCS	HOPD Status Indicator	Description
22325	C	Treat spine fracture
22326	C	Treat neck spine fracture
22327	C	Treat thorax spine fracture
22328	C	Treat each add spine fx
22548	C	Neck spine fusion
22554	C	Neck spine fusion
22556	C	Thorax spine fusion
22558	C	Lumbar spine fusion
22585	C	Additional spinal fusion
22590	C	Spine & skull spinal fusion
22595	C	Neck spinal fusion
22600	C	Neck spine fusion
22610	C	Thorax spine fusion
22612	C	Lumbar spine fusion
22614	C	Spine fusion, extra segment
22630	C	Lumbar spine fusion
22632	C	Spine fusion, extra segment
22800	C	Fusion of spine
22802	C	Fusion of spine
22804	C	Fusion of spine
22808	C	Fusion of spine
22810	C	Fusion of spine
22812	C	Fusion of spine
22818	C	Kyphectomy, 1-2 segments
22819	C	Kyphectomy, 3 or more
22830	C	Exploration of spinal fusion
22840	C	Insert spine fixation device
22841	C	Insert spine fixation device
22842	C	Insert spine fixation device
22843	C	Insert spine fixation device
22844	C	Insert spine fixation device
22845	C	Insert spine fixation device
22846	C	Insert spine fixation device
22847	C	Insert spine fixation device
22848	C	Insert pelv fixation device
22849	C	Reinsert spinal fixation
22850	C	Remove spine fixation device
22851	C	Apply spine prosth device
22852	C	Remove spine fixation device
22855	C	Remove spine fixation device
23035	C	Drain shoulder bone lesion
23125	C	Removal of collar bone
23195	C	Removal of head of humerus
23200	C	Removal of collar bone
23210	C	Removal of shoulder blade
23220	C	Partial removal of humerus
23221	C	Partial removal of humerus
23222	C	Partial removal of humerus
23332	C	Remove shoulder foreign body
23395	C	Muscle transfer,shoulder/arm
23397	C	Muscle transfers
23400	C	Fixation of shoulder blade
23440	C	Remove/transplant tendon
23470	C	Reconstruct shoulder joint
23472	C	Reconstruct shoulder joint
23900	C	Amputation of arm & girdle
23920	C	Amputation at shoulder joint
24149	C	Radical resection of elbow
24150	C	Extensive humerus surgery
24151	C	Extensive humerus surgery
24152	C	Extensive radius surgery
24153	C	Extensive radius surgery
24900	C	Amputation of upper arm
24920	C	Amputation of upper arm
24930	C	Amputation follow-up surgery
24931	C	Amputate upper arm & implant
24940	C	Revision of upper arm
25170	C	Extensive forearm surgery
25390	C	Shorten radius or ulna
25391	C	Lengthen radius or ulna
25392	C	Shorten radius & ulna
25393	C	Lengthen radius & ulna
25420	C	Repair/graft radius & ulna
25900	C	Amputation of forearm
25905	C	Amputation of forearm

ADDENDUM E.—CPT CODES WHICH WOULD BE PAID ONLY AS INPATIENT PROCEDURES—Continued

CPT/ HCPCS	HOPD Status Indicator	Description
25909	C	Amputation follow-up surgery
25915	C	Amputation of forearm
25920	C	Amputate hand at wrist
25924	C	Amputation follow-up surgery
25927	C	Amputation of hand
25931	C	Amputation follow-up surgery
26551	C	Great toe-hand transfer
26553	C	Single transfer, toe-hand
26554	C	Double transfer, toe-hand
26556	C	Toe joint transfer
26992	C	Drainage of bone lesion
27005	C	Incision of hip tendon
27006	C	Incision of hip tendons
27025	C	Incision of hip/thigh fascia
27030	C	Drainage of hip joint
27035	C	Denervation of hip joint
27036	C	Excision of hip joint/muscle
27054	C	Removal of hip joint lining
27070	C	Partial removal of hip bone
27071	C	Partial removal of hip bone
27075	C	Extensive hip surgery
27076	C	Extensive hip surgery
27077	C	Extensive hip surgery
27078	C	Extensive hip surgery
27079	C	Extensive hip surgery
27090	C	Removal of hip prosthesis
27091	C	Removal of hip prosthesis
27120	C	Reconstruction of hip socket
27122	C	Reconstruction of hip socket
27125	C	Partial hip replacement
27130	C	Total hip replacement
27132	C	Total hip replacement
27134	C	Revise hip joint replacement
27137	C	Revise hip joint replacement
27138	C	Revise hip joint replacement
27140	C	Transplant femur ridge
27146	C	Incision of hip bone
27147	C	Revision of hip bone
27151	C	Incision of hip bones
27156	C	Revision of hip bones
27158	C	Revision of pelvis
27161	C	Incision of neck of femur
27165	C	Incision/fixation of femur
27170	C	Repair/graft femur head/neck
27175	C	Treat slipped epiphysis
27176	C	Treat slipped epiphysis
27177	C	Treat slipped epiphysis
27178	C	Treat slipped epiphysis
27179	C	Revise head/neck of femur
27181	C	Treat slipped epiphysis
27185	C	Revision of femur epiphysis
27187	C	Reinforce hip bones
27215	C	Treat pelvic fracture(s)
27216	C	Treat pelvic ring fracture
27217	C	Treat pelvic ring fracture
27218	C	Treat pelvic ring fracture
27222	C	Treat hip socket fracture
27226	C	Treat hip wall fracture
27227	C	Treat hip fracture(s)
27228	C	Treat hip fracture(s)
27232	C	Treat thigh fracture
27235	C	Treat thigh fracture
27236	C	Treat thigh fracture
27240	C	Treat thigh fracture
27244	C	Treat thigh fracture
27245	C	Treat thigh fracture
27248	C	Treat thigh fracture
27253	C	Treat hip dislocation
27254	C	Treat hip dislocation
27258	C	Treat hip dislocation
27259	C	Treat hip dislocation
27280	C	Fusion of sacroiliac joint
27282	C	Fusion of pubic bones
27284	C	Fusion of hip joint
27286	C	Fusion of hip joint

ADDENDUM E.—CPT CODES WHICH WOULD BE PAID ONLY AS INPATIENT PROCEDURES—Continued

CPT/ HCPCS	HOPD Status Indicator	Description
27290	C	Amputation of leg at hip
27295	C	Amputation of leg at hip
27303	C	Drainage of bone lesion
27365	C	Extensive leg surgery
27445	C	Revision of knee joint
27447	C	Total knee replacement
27448	C	Incision of thigh
27450	C	Incision of thigh
27454	C	Realignment of thigh bone
27455	C	Realignment of knee
27457	C	Realignment of knee
27465	C	Shortening of thigh bone
27466	C	Lengthening of thigh bone
27468	C	Shorten/lengthen thighs
27470	C	Repair of thigh
27472	C	Repair/graft of thigh
27475	C	Surgery to stop leg growth
27477	C	Surgery to stop leg growth
27479	C	Surgery to stop leg growth
27485	C	Surgery to stop leg growth
27486	C	Revise/replace knee joint
27487	C	Revise/replace knee joint
27488	C	Removal of knee prosthesis
27495	C	Reinforce thigh
27506	C	Treatment of thigh fracture
27507	C	Treatment of thigh fracture
27511	C	Treatment of thigh fracture
27513	C	Treatment of thigh fracture
27514	C	Treatment of thigh fracture
27519	C	Treat thigh fx growth plate
27535	C	Treat knee fracture
27536	C	Treat knee fracture
27540	C	Treat knee fracture
27556	C	Treat knee dislocation
27557	C	Treat knee dislocation
27558	C	Treat knee dislocation
27580	C	Fusion of knee
27590	C	Amputate leg at thigh
27591	C	Amputate leg at thigh
27592	C	Amputate leg at thigh
27596	C	Amputation follow-up surgery
27598	C	Amputate lower leg at knee
27645	C	Extensive lower leg surgery
27646	C	Extensive lower leg surgery
27702	C	Reconstruct ankle joint
27703	C	Reconstruction, ankle joint
27712	C	Realignment of lower leg
27715	C	Revision of lower leg
27720	C	Repair of tibia
27722	C	Repair/graft of tibia
27724	C	Repair/graft of tibia
27725	C	Repair of lower leg
27727	C	Repair of lower leg
27880	C	Amputation of lower leg
27881	C	Amputation of lower leg
27882	C	Amputation of lower leg
27886	C	Amputation follow-up surgery
27888	C	Amputation of foot at ankle
28800	C	Amputation of midfoot
28805	C	Amputation thru metatarsal
31225	C	Removal of upper jaw
31230	C	Removal of upper jaw
31290	C	Nasal/sinus endoscopy, surg
31291	C	Nasal/sinus endoscopy, surg
31292	C	Nasal/sinus endoscopy, surg
31293	C	Nasal/sinus endoscopy, surg
31294	C	Nasal/sinus endoscopy, surg
31360	C	Removal of larynx
31365	C	Removal of larynx
31367	C	Partial removal of larynx
31368	C	Partial removal of larynx
31370	C	Partial removal of larynx
31375	C	Partial removal of larynx
31380	C	Partial removal of larynx
31382	C	Partial removal of larynx

ADDENDUM E.—CPT CODES WHICH WOULD BE PAID ONLY AS INPATIENT PROCEDURES—Continued

CPT/ HCPCS	HOPD Status Indicator	Description
31390	C	Removal of larynx & pharynx
31395	C	Reconstruct larynx & pharynx
31582	C	Revision of larynx
31584	C	Treat larynx fracture
31587	C	Revision of larynx
31725	C	Clearance of airways
31760	C	Repair of windpipe
31766	C	Reconstruction of windpipe
31770	C	Repair/graft of bronchus
31775	C	Reconstruct bronchus
31780	C	Reconstruct windpipe
31781	C	Reconstruct windpipe
31785	C	Remove windpipe lesion
31786	C	Remove windpipe lesion
31800	C	Repair of windpipe injury
31805	C	Repair of windpipe injury
32035	C	Exploration of chest
32036	C	Exploration of chest
32095	C	Biopsy through chest wall
32100	C	Exploration/biopsy of chest
32110	C	Explore/repair chest
32120	C	Re-exploration of chest
32124	C	Explore chest free adhesions
32140	C	Removal of lung lesion(s)
32141	C	Remove/treat lung lesions
32150	C	Removal of lung lesion(s)
32151	C	Remove lung foreign body
32160	C	Open chest heart massage
32200	C	Drain, open, lung lesion
32201	C	Drain, percut, lung lesion
32215	C	Treat chest lining
32220	C	Release of lung
32225	C	Partial release of lung
32310	C	Removal of chest lining
32320	C	Free/remove chest lining
32402	C	Open biopsy chest lining
32440	C	Removal of lung
32442	C	Sleeve pneumonectomy
32445	C	Removal of lung
32480	C	Partial removal of lung
32482	C	Bilobectomy
32484	C	Segmentectomy
32486	C	Sleeve lobectomy
32488	C	Completion pneumonectomy
32491	C	Lung volume reduction
32500	C	Partial removal of lung
32501	C	Repair bronchus add-on
32520	C	Remove lung & revise chest
32522	C	Remove lung & revise chest
32525	C	Remove lung & revise chest
32540	C	Removal of lung lesion
32650	C	Thoracoscopy, surgical
32651	C	Thoracoscopy, surgical
32652	C	Thoracoscopy, surgical
32653	C	Thoracoscopy, surgical
32654	C	Thoracoscopy, surgical
32655	C	Thoracoscopy, surgical
32656	C	Thoracoscopy, surgical
32657	C	Thoracoscopy, surgical
32658	C	Thoracoscopy, surgical
32659	C	Thoracoscopy, surgical
32660	C	Thoracoscopy, surgical
32661	C	Thoracoscopy, surgical
32662	C	Thoracoscopy, surgical
32663	C	Thoracoscopy, surgical
32664	C	Thoracoscopy, surgical
32665	C	Thoracoscopy, surgical
32800	C	Repair lung hernia
32810	C	Close chest after drainage
32815	C	Close bronchial fistula
32820	C	Reconstruct injured chest
32850	C	Donor pneumonectomy
32851	C	Lung transplant, single
32852	C	Lung transplant with bypass
32853	C	Lung transplant, double

ADDENDUM E.—CPT CODES WHICH WOULD BE PAID ONLY AS INPATIENT PROCEDURES—Continued

CPT/ HCPCS	HOPD Status Indicator	Description
32854	C	Lung transplant with bypass
32900	C	Removal of rib(s)
32905	C	Revise & repair chest wall
32906	C	Revise & repair chest wall
32940	C	Revision of lung
32997	C	Total lung lavage
33015	C	Incision of heart sac
33020	C	Incision of heart sac
33025	C	Incision of heart sac
33030	C	Partial removal of heart sac
33031	C	Partial removal of heart sac
33050	C	Removal of heart sac lesion
33120	C	Removal of heart lesion
33130	C	Removal of heart lesion
33140	C	Heart revascularize (tmr)
33141	C	Heart tmr w/other procedure
33200	C	Insertion of heart pacemaker
33201	C	Insertion of heart pacemaker
33236	C	Remove electrode/thoracotomy
33237	C	Remove electrode/thoracotomy
33238	C	Remove electrode/thoracotomy
33243	C	Remove eltrd/thoracotomy
33245	C	Insert epic eltrd pace-defib
33246	C	Insert epic eltrd/generator
33250	C	Ablate heart dysrhythm focus
33251	C	Ablate heart dysrhythm focus
33253	C	Reconstruct atria
33261	C	Ablate heart dysrhythm focus
33300	C	Repair of heart wound
33305	C	Repair of heart wound
33310	C	Exploratory heart surgery
33315	C	Exploratory heart surgery
33320	C	Repair major blood vessel(s)
33321	C	Repair major vessel
33322	C	Repair major blood vessel(s)
33330	C	Insert major vessel graft
33332	C	Insert major vessel graft
33335	C	Insert major vessel graft
33400	C	Repair of aortic valve
33401	C	Valvuloplasty, open
33403	C	Valvuloplasty, w/cp bypass
33404	C	Prepare heart-aorta conduit
33405	C	Replacement of aortic valve
33406	C	Replacement of aortic valve
33410	C	Replacement of aortic valve
33411	C	Replacement of aortic valve
33412	C	Replacement of aortic valve
33413	C	Replacement of aortic valve
33414	C	Repair of aortic valve
33415	C	Revision, subvalvular tissue
33416	C	Revise ventricle muscle
33417	C	Repair of aortic valve
33420	C	Revision of mitral valve
33422	C	Revision of mitral valve
33425	C	Repair of mitral valve
33426	C	Repair of mitral valve
33427	C	Repair of mitral valve
33430	C	Replacement of mitral valve
33460	C	Revision of tricuspid valve
33463	C	Valvuloplasty, tricuspid
33464	C	Valvuloplasty, tricuspid
33465	C	Replace tricuspid valve
33468	C	Revision of tricuspid valve
33470	C	Revision of pulmonary valve
33471	C	Valvotomy, pulmonary valve
33472	C	Revision of pulmonary valve
33474	C	Revision of pulmonary valve
33475	C	Replacement, pulmonary valve
33476	C	Revision of heart chamber
33478	C	Revision of heart chamber
33496	C	Repair, prosth valve clot
33500	C	Repair heart vessel fistula
33501	C	Repair heart vessel fistula
33502	C	Coronary artery correction
33503	C	Coronary artery graft

ADDENDUM E.—CPT CODES WHICH WOULD BE PAID ONLY AS INPATIENT PROCEDURES—Continued

CPT/ HCPCS	HOPD Status Indicator	Description
33504	C	Coronary artery graft
33505	C	Repair artery w/tunnel
33506	C	Repair artery, translocation
33510	C	Cabg, vein, single
33511	C	Cabg, vein, two
33512	C	Cabg, vein, three
33513	C	Cabg, vein, four
33514	C	Cabg, vein, five
33516	C	Cabg, vein, six or more
33517	C	Cabg, artery-vein, single
33518	C	Cabg, artery-vein, two
33519	C	Cabg, artery-vein, three
33521	C	Cabg, artery-vein, four
33522	C	Cabg, artery-vein, five
33523	C	Cabg, art-vein, six or more
33530	C	Coronary artery, bypass/reop
33533	C	Cabg, arterial, single
33534	C	Cabg, arterial, two
33535	C	Cabg, arterial, three
33536	C	Cabg, arterial, four or more
33542	C	Removal of heart lesion
33545	C	Repair of heart damage
33572	C	Open coronary endarterectomy
33600	C	Closure of valve
33602	C	Closure of valve
33606	C	Anastomosis/artery-aorta
33608	C	Repair anomaly w/conduit
33610	C	Repair by enlargement
33611	C	Repair double ventricle
33612	C	Repair double ventricle
33615	C	Repair, modified fontan
33617	C	Repair single ventricle
33619	C	Repair single ventricle
33641	C	Repair heart septum defect
33645	C	Revision of heart veins
33647	C	Repair heart septum defects
33660	C	Repair of heart defects
33665	C	Repair of heart defects
33670	C	Repair of heart chambers
33681	C	Repair heart septum defect
33684	C	Repair heart septum defect
33688	C	Repair heart septum defect
33690	C	Reinforce pulmonary artery
33692	C	Repair of heart defects
33694	C	Repair of heart defects
33697	C	Repair of heart defects
33702	C	Repair of heart defects
33710	C	Repair of heart defects
33720	C	Repair of heart defect
33722	C	Repair of heart defect
33730	C	Repair heart-vein defect(s)
33732	C	Repair heart-vein defect
33735	C	Revision of heart chamber
33736	C	Revision of heart chamber
33737	C	Revision of heart chamber
33750	C	Major vessel shunt
33755	C	Major vessel shunt
33762	C	Major vessel shunt
33764	C	Major vessel shunt & graft
33766	C	Major vessel shunt
33767	C	Major vessel shunt
33770	C	Repair great vessels defect
33771	C	Repair great vessels defect
33774	C	Repair great vessels defect
33775	C	Repair great vessels defect
33776	C	Repair great vessels defect
33777	C	Repair great vessels defect
33778	C	Repair great vessels defect
33779	C	Repair great vessels defect
33780	C	Repair great vessels defect
33781	C	Repair great vessels defect
33786	C	Repair arterial trunk
33788	C	Revision of pulmonary artery
33800	C	Aortic suspension
33802	C	Repair vessel defect

ADDENDUM E.—CPT CODES WHICH WOULD BE PAID ONLY AS INPATIENT PROCEDURES—Continued

CPT/ HCPCS	HOPD Status Indicator	Description
33803	C	Repair vessel defect
33813	C	Repair septal defect
33814	C	Repair septal defect
33820	C	Revise major vessel
33822	C	Revise major vessel
33824	C	Revise major vessel
33840	C	Remove aorta constriction
33845	C	Remove aorta constriction
33851	C	Remove aorta constriction
33852	C	Repair septal defect
33853	C	Repair septal defect
33860	C	Ascending aortic graft
33861	C	Ascending aortic graft
33863	C	Ascending aortic graft
33870	C	Transverse aortic arch graft
33875	C	Thoracic aortic graft
33877	C	Thoracoabdominal graft
33910	C	Remove lung artery emboli
33915	C	Remove lung artery emboli
33916	C	Surgery of great vessel
33917	C	Repair pulmonary artery
33918	C	Repair pulmonary atresia
33919	C	Repair pulmonary atresia
33920	C	Repair pulmonary atresia
33922	C	Transect pulmonary artery
33924	C	Remove pulmonary shunt
33930	C	Removal of donor heart/lung
33935	C	Transplantation, heart/lung
33940	C	Removal of donor heart
33945	C	Transplantation of heart
33960	C	External circulation assist
33961	C	External circulation assist
33968	C	Remove aortic assist device
33970	C	Aortic circulation assist
33971	C	Aortic circulation assist
33973	C	Insert balloon device
33974	C	Remove intra-aortic balloon
33975	C	Implant ventricular device
33976	C	Implant ventricular device
33977	C	Remove ventricular device
33978	C	Remove ventricular device
34001	C	Removal of artery clot
34051	C	Removal of artery clot
34151	C	Removal of artery clot
34401	C	Removal of vein clot
34451	C	Removal of vein clot
34502	C	Reconstruct vena cava
34800	C	Endovasc abdo repair w/tube
34802	C	Endovasc abdo repr w/device
34804	C	Endovasc abdo repr w/device
34808	C	Endovasc abdo occlud device
34812	C	Xpose for endoprosth, aortic
34813	C	Xpose for endoprosth, femorl
34820	C	Xpose for endoprosth, iliac
34825	C	Endovasc extend prosth, init
34826	C	Endovasc exten prosth, addl
34830	C	Open aortic tube prosth repr
34831	C	Open aortoiliac prosth repr
34832	C	Open aortofemor prosth repr
35001	C	Repair defect of artery
35002	C	Repair artery rupture, neck
35005	C	Repair defect of artery
35013	C	Repair artery rupture, arm
35021	C	Repair defect of artery
35022	C	Repair artery rupture, chest
35045	C	Repair defect of arm artery
35081	C	Repair defect of artery
35082	C	Repair artery rupture, aorta
35091	C	Repair defect of artery
35092	C	Repair artery rupture, aorta
35102	C	Repair defect of artery
35103	C	Repair artery rupture, groin
35111	C	Repair defect of artery
35112	C	Repair artery rupture,spleen
35121	C	Repair defect of artery

ADDENDUM E.—CPT CODES WHICH WOULD BE PAID ONLY AS INPATIENT PROCEDURES—Continued

CPT/ HCPCS	HOPD Status Indicator	Description
35122	C	Repair artery rupture, belly
35131	C	Repair defect of artery
35132	C	Repair artery rupture, groin
35141	C	Repair defect of artery
35142	C	Repair artery rupture, thigh
35151	C	Repair defect of artery
35152	C	Repair artery rupture, knee
35161	C	Repair defect of artery
35162	C	Repair artery rupture
35182	C	Repair blood vessel lesion
35189	C	Repair blood vessel lesion
35211	C	Repair blood vessel lesion
35216	C	Repair blood vessel lesion
35221	C	Repair blood vessel lesion
35241	C	Repair blood vessel lesion
35246	C	Repair blood vessel lesion
35251	C	Repair blood vessel lesion
35271	C	Repair blood vessel lesion
35276	C	Repair blood vessel lesion
35281	C	Repair blood vessel lesion
35301	C	Rechanneling of artery
35311	C	Rechanneling of artery
35331	C	Rechanneling of artery
35341	C	Rechanneling of artery
35351	C	Rechanneling of artery
35355	C	Rechanneling of artery
35361	C	Rechanneling of artery
35363	C	Rechanneling of artery
35371	C	Rechanneling of artery
35372	C	Rechanneling of artery
35381	C	Rechanneling of artery
35390	C	Reoperation, carotid add-on
35400	C	Angioscopy
35450	C	Repair arterial blockage
35452	C	Repair arterial blockage
35454	C	Repair arterial blockage
35456	C	Repair arterial blockage
35480	C	Atherectomy, open
35482	C	Atherectomy, open
35483	C	Atherectomy, open
35501	C	Artery bypass graft
35506	C	Artery bypass graft
35507	C	Artery bypass graft
35508	C	Artery bypass graft
35509	C	Artery bypass graft
35511	C	Artery bypass graft
35515	C	Artery bypass graft
35516	C	Artery bypass graft
35518	C	Artery bypass graft
35521	C	Artery bypass graft
35526	C	Artery bypass graft
35531	C	Artery bypass graft
35533	C	Artery bypass graft
35536	C	Artery bypass graft
35541	C	Artery bypass graft
35546	C	Artery bypass graft
35548	C	Artery bypass graft
35549	C	Artery bypass graft
35551	C	Artery bypass graft
35556	C	Artery bypass graft
35558	C	Artery bypass graft
35560	C	Artery bypass graft
35563	C	Artery bypass graft
35565	C	Artery bypass graft
35566	C	Artery bypass graft
35571	C	Artery bypass graft
35582	C	Vein bypass graft
35583	C	Vein bypass graft
35585	C	Vein bypass graft
35587	C	Vein bypass graft
35600	C	Harvest artery for cabg
35601	C	Artery bypass graft
35606	C	Artery bypass graft
35612	C	Artery bypass graft
35616	C	Artery bypass graft

ADDENDUM E.—CPT CODES WHICH WOULD BE PAID ONLY AS INPATIENT PROCEDURES—Continued

CPT/ HCPCS	HOPD Status Indicator	Description
35621	C	Artery bypass graft
35623	C	Bypass graft, not vein
35626	C	Artery bypass graft
35631	C	Artery bypass graft
35636	C	Artery bypass graft
35641	C	Artery bypass graft
35642	C	Artery bypass graft
35645	C	Artery bypass graft
35646	C	Artery bypass graft
35650	C	Artery bypass graft
35651	C	Artery bypass graft
35654	C	Artery bypass graft
35656	C	Artery bypass graft
35661	C	Artery bypass graft
35663	C	Artery bypass graft
35665	C	Artery bypass graft
35666	C	Artery bypass graft
35671	C	Artery bypass graft
35681	C	Composite bypass graft
35682	C	Composite bypass graft
35683	C	Composite bypass graft
35691	C	Arterial transposition
35693	C	Arterial transposition
35694	C	Arterial transposition
35695	C	Arterial transposition
35700	C	Reoperation, bypass graft
35701	C	Exploration, carotid artery
35721	C	Exploration, femoral artery
35741	C	Exploration popliteal artery
35800	C	Explore neck vessels
35820	C	Explore chest vessels
35840	C	Explore abdominal vessels
35870	C	Repair vessel graft defect
35901	C	Excision, graft, neck
35905	C	Excision, graft, thorax
35907	C	Excision, graft, abdomen
36510	C	Insertion of catheter, vein
36660	C	Insertion catheter, artery
36822	C	Insertion of cannula(s)
36823	C	Insertion of cannula(s)
37140	C	Revision of circulation
37145	C	Revision of circulation
37160	C	Revision of circulation
37180	C	Revision of circulation
37181	C	Splice spleen/kidney veins
37195	C	Thrombolytic therapy, stroke
37616	C	Ligation of chest artery
37617	C	Ligation of abdomen artery
37618	C	Ligation of extremity artery
37660	C	Revision of major vein
37788	C	Revascularization, penis
38100	C	Removal of spleen, total
38101	C	Removal of spleen, partial
38102	C	Removal of spleen, total
38115	C	Repair of ruptured spleen
38380	C	Thoracic duct procedure
38381	C	Thoracic duct procedure
38382	C	Thoracic duct procedure
38562	C	Removal, pelvic lymph nodes
38564	C	Removal, abdomen lymph nodes
38700	C	Removal of lymph nodes, neck
38724	C	Removal of lymph nodes, neck
38746	C	Remove thoracic lymph nodes
38747	C	Remove abdominal lymph nodes
38765	C	Remove groin lymph nodes
38770	C	Remove pelvis lymph nodes
38780	C	Remove abdomen lymph nodes
39000	C	Exploration of chest
39010	C	Exploration of chest
39200	C	Removal chest lesion
39220	C	Removal chest lesion
39499	C	Chest procedure
39501	C	Repair diaphragm laceration
39502	C	Repair paraesophageal hernia
39503	C	Repair of diaphragm hernia

ADDENDUM E.—CPT CODES WHICH WOULD BE PAID ONLY AS INPATIENT PROCEDURES—Continued

CPT/ HCPCS	HOPD Status Indicator	Description
39520	C	Repair of diaphragm hernia
39530	C	Repair of diaphragm hernia
39531	C	Repair of diaphragm hernia
39540	C	Repair of diaphragm hernia
39541	C	Repair of diaphragm hernia
39545	C	Revision of diaphragm
39560	C	Resect diaphragm, simple
39561	C	Resect diaphragm, complex
39599	C	Diaphragm surgery procedure
41130	C	Partial removal of tongue
41135	C	Tongue and neck surgery
41140	C	Removal of tongue
41145	C	Tongue removal, neck surgery
41150	C	Tongue, mouth, jaw surgery
41153	C	Tongue, mouth, neck surgery
41155	C	Tongue, jaw, & neck surgery
42426	C	Excise parotid gland/lesion
42842	C	Extensive surgery of throat
42845	C	Extensive surgery of throat
42894	C	Revision of pharyngeal walls
42953	C	Repair throat, esophagus
42961	C	Control throat bleeding
42971	C	Control nose/throat bleeding
43030	C	Throat muscle surgery
43045	C	Incision of esophagus
43100	C	Excision of esophagus lesion
43101	C	Excision of esophagus lesion
43107	C	Removal of esophagus
43108	C	Removal of esophagus
43112	C	Removal of esophagus
43113	C	Removal of esophagus
43116	C	Partial removal of esophagus
43117	C	Partial removal of esophagus
43118	C	Partial removal of esophagus
43121	C	Partial removal of esophagus
43122	C	Parital removal of esophagus
43123	C	Partial removal of esophagus
43124	C	Removal of esophagus
43135	C	Removal of esophagus pouch
43300	C	Repair of esophagus
43305	C	Repair esophagus and fistula
43310	C	Repair of esophagus
43312	C	Repair esophagus and fistula
43320	C	Fuse esophagus & stomach
43324	C	Revise esophagus & stomach
43325	C	Revise esophagus & stomach
43326	C	Revise esophagus & stomach
43330	C	Repair of esophagus
43331	C	Repair of esophagus
43340	C	Fuse esophagus & intestine
43341	C	Fuse esophagus & intestine
43350	C	Surgical opening, esophagus
43351	C	Surgical opening, esophagus
43352	C	Surgical opening, esophagus
43360	C	Gastrointestinal repair
43361	C	Gastrointestinal repair
43400	C	Ligate esophagus veins
43401	C	Esophagus surgery for veins
43405	C	Ligate/staple esophagus
43410	C	Repair esophagus wound
43415	C	Repair esophagus wound
43420	C	Repair esophagus opening
43425	C	Repair esophagus opening
43460	C	Pressure treatment esophagus
43496	C	Free jejunum flap, microvasc
43500	C	Surgical opening of stomach
43501	C	Surgical repair of stomach
43502	C	Surgical repair of stomach
43510	C	Surgical opening of stomach
43520	C	Incision of pyloric muscle
43605	C	Biopsy of stomach
43610	C	Excision of stomach lesion
43611	C	Excision of stomach lesion
43620	C	Removal of stomach
43621	C	Removal of stomach

ADDENDUM E.—CPT CODES WHICH WOULD BE PAID ONLY AS INPATIENT PROCEDURES—Continued

CPT/ HCPCS	HOPD Status Indicator	Description
43622	C	Removal of stomach
43631	C	Removal of stomach, partial
43632	C	Removal of stomach, partial
43633	C	Removal of stomach, partial
43634	C	Removal of stomach, partial
43635	C	Removal of stomach, partial
43638	C	Removal of stomach, partial
43639	C	Removal of stomach, partial
43640	C	Vagotomy & pylorus repair
43641	C	Vagotomy & pylorus repair
43800	C	Reconstruction of pylorus
43810	C	Fusion of stomach and bowel
43820	C	Fusion of stomach and bowel
43825	C	Fusion of stomach and bowel
43832	C	Place gastrostomy tube
43840	C	Repair of stomach lesion
43842	C	Gastroplasty for obesity
43843	C	Gastroplasty for obesity
43846	C	Gastric bypass for obesity
43847	C	Gastric bypass for obesity
43848	C	Revision gastroplasty
43850	C	Revise stomach-bowel fusion
43855	C	Revise stomach-bowel fusion
43860	C	Revise stomach-bowel fusion
43865	C	Revise stomach-bowel fusion
43880	C	Repair stomach-bowel fistula
44005	C	Freeing of bowel adhesion
44010	C	Incision of small bowel
44015	C	Insert needle cath bowel
44020	C	Exploration of small bowel
44021	C	Decompress small bowel
44025	C	Incision of large bowel
44050	C	Reduce bowel obstruction
44055	C	Correct malrotation of bowel
44110	C	Excision of bowel lesion(s)
44111	C	Excision of bowel lesion(s)
44120	C	Removal of small intestine
44121	C	Removal of small intestine
44125	C	Removal of small intestine
44130	C	Bowel to bowel fusion
44139	C	Mobilization of colon
44140	C	Partial removal of colon
44141	C	Partial removal of colon
44143	C	Partial removal of colon
44144	C	Partial removal of colon
44145	C	Partial removal of colon
44146	C	Partial removal of colon
44147	C	Partial removal of colon
44150	C	Removal of colon
44151	C	Removal of colon/ileostomy
44152	C	Removal of colon/ileostomy
44153	C	Removal of colon/ileostomy
44155	C	Removal of colon/ileostomy
44156	C	Removal of colon/ileostomy
44160	C	Removal of colon
44202	C	Laparo, resect intestine
44300	C	Open bowel to skin
44310	C	Ileostomy/jejunostomy
44314	C	Revision of ileostomy
44316	C	Devise bowel pouch
44320	C	Colostomy
44322	C	Colostomy with biopsies
44345	C	Revision of colostomy
44346	C	Revision of colostomy
44602	C	Suture, small intestine
44603	C	Suture, small intestine
44604	C	Suture, large intestine
44605	C	Repair of bowel lesion
44615	C	Intestinal stricturoplasty
44620	C	Repair bowel opening
44625	C	Repair bowel opening
44626	C	Repair bowel opening
44640	C	Repair bowel-skin fistula
44650	C	Repair bowel fistula
44660	C	Repair bowel-bladder fistula

ADDENDUM E.—CPT CODES WHICH WOULD BE PAID ONLY AS INPATIENT PROCEDURES—Continued

CPT/ HCPCS	HOPD Status Indicator	Description
44661	C	Repair bowel-bladder fistula
44680	C	Surgical revision, intestine
44700	C	Suspend bowel w/prosthesis
44800	C	Excision of bowel pouch
44820	C	Excision of mesentery lesion
44850	C	Repair of mesentery
44899	C	Bowel surgery procedure
44900	C	Drain app abscess, open
44901	C	Drain app abscess, percut
44950	C	Appendectomy
44955	C	Appendectomy add-on
44960	C	Appendectomy
45110	C	Removal of rectum
45111	C	Partial removal of rectum
45112	C	Removal of rectum
45113	C	Partial proctectomy
45114	C	Partial removal of rectum
45116	C	Partial removal of rectum
45119	C	Remove rectum w/reservoir
45120	C	Removal of rectum
45121	C	Removal of rectum and colon
45123	C	Partial proctectomy
45126	C	Pelvic exenteration
45130	C	Excision of rectal prolapse
45135	C	Excision of rectal prolapse
45540	C	Correct rectal prolapse
45541	C	Correct rectal prolapse
45550	C	Repair rectum/remove sigmoid
45562	C	Exploration/repair of rectum
45563	C	Exploration/repair of rectum
45800	C	Repair rect/bladder fistula
45805	C	Repair fistula w/colostomy
45820	C	Repair rectourethral fistula
45825	C	Repair fistula w/colostomy
46705	C	Repair of anal stricture
46715	C	Repair of anovaginal fistula
46716	C	Repair of anovaginal fistula
46730	C	Construction of absent anus
46735	C	Construction of absent anus
46740	C	Construction of absent anus
46742	C	Repair of imperforated anus
46744	C	Repair of cloacal anomaly
46746	C	Repair of cloacal anomaly
46748	C	Repair of cloacal anomaly
46751	C	Repair of anal sphincter
47001	C	Needle biopsy, liver add-on
47010	C	Open drainage, liver lesion
47011	C	Percut drain, liver lesion
47015	C	Inject/aspirate liver cyst
47100	C	Wedge biopsy of liver
47120	C	Partial removal of liver
47122	C	Extensive removal of liver
47125	C	Partial removal of liver
47130	C	Partial removal of liver
47133	C	Removal of donor liver
47134	C	Partial removal, donor liver
47135	C	Transplantation of liver
47136	C	Transplantation of liver
47300	C	Surgery for liver lesion
47350	C	Repair liver wound
47360	C	Repair liver wound
47361	C	Repair liver wound
47362	C	Repair liver wound
47400	C	Incision of liver duct
47420	C	Incision of bile duct
47425	C	Incision of bile duct
47460	C	Incise bile duct sphincter
47480	C	Incision of gallbladder
47490	C	Incision of gallbladder
47550	C	Bile duct endoscopy add-on
47570	C	Laparo cholecystoenterostomy
47600	C	Removal of gallbladder
47605	C	Removal of gallbladder
47610	C	Removal of gallbladder
47612	C	Removal of gallbladder

ADDENDUM E.—CPT CODES WHICH WOULD BE PAID ONLY AS INPATIENT PROCEDURES—Continued

CPT/ HCPCS	HOPD Status Indicator	Description
47620	C	Removal of gallbladder
47700	C	Exploration of bile ducts
47701	C	Bile duct revision
47711	C	Excision of bile duct tumor
47712	C	Excision of bile duct tumor
47715	C	Excision of bile duct cyst
47716	C	Fusion of bile duct cyst
47720	C	Fuse gallbladder & bowel
47721	C	Fuse upper GI structures
47740	C	Fuse gallbladder & bowel
47741	C	Fuse gallbladder & bowel
47760	C	Fuse bile ducts and bowel
47765	C	Fuse liver ducts & bowel
47780	C	Fuse bile ducts and bowel
47785	C	Fuse bile ducts and bowel
47800	C	Reconstruction of bile ducts
47801	C	Placement, bile duct support
47802	C	Fuse liver duct & intestine
47900	C	Suture bile duct injury
48000	C	Drainage of abdomen
48001	C	Placement of drain, pancreas
48005	C	Resect/debride pancreas
48020	C	Removal of pancreatic stone
48100	C	Biopsy of pancreas
48120	C	Removal of pancreas lesion
48140	C	Partial removal of pancreas
48145	C	Partial removal of pancreas
48146	C	Pancreatectomy
48148	C	Removal of pancreatic duct
48150	C	Partial removal of pancreas
48152	C	Pancreatectomy
48153	C	Pancreatectomy
48154	C	Pancreatectomy
48155	C	Removal of pancreas
48180	C	Fuse pancreas and bowel
48400	C	Injection, intraop add-on
48500	C	Surgery of pancreas cyst
48510	C	Drain pancreatic pseudocyst
48511	C	Drain pancreatic pseudocyst
48520	C	Fuse pancreas cyst and bowel
48540	C	Fuse pancreas cyst and bowel
48545	C	Pancreatorrhaphy
48547	C	Duodenal exclusion
48556	C	Removal, allograft pancreas
49000	C	Exploration of abdomen
49002	C	Reopening of abdomen
49010	C	Exploration behind abdomen
49020	C	Drain abdominal abscess
49021	C	Drain abdominal abscess
49040	C	Drain, open, abdom abscess
49041	C	Drain, percut, abdom abscess
49060	C	Drain, open, retrop abscess
49061	C	Drain, percut, retroper absc
49062	C	Drain to peritoneal cavity
49200	C	Removal of abdominal lesion
49201	C	Removal of abdominal lesion
49215	C	Excise sacral spine tumor
49220	C	Multiple surgery, abdomen
49255	C	Removal of omentum
49425	C	Insert abdomen-venous drain
49428	C	Ligation of shunt
49605	C	Repair umbilical lesion
49606	C	Repair umbilical lesion
49610	C	Repair umbilical lesion
49611	C	Repair umbilical lesion
49900	C	Repair of abdominal wall
49905	C	Omental flap
49906	C	Free omental flap, microvasc
50010	C	Exploration of kidney
50020	C	Renal abscess, open drain
50021	C	Renal abscess, percut drain
50040	C	Drainage of kidney
50045	C	Exploration of kidney
50060	C	Removal of kidney stone
50065	C	Incision of kidney

ADDENDUM E.—CPT CODES WHICH WOULD BE PAID ONLY AS INPATIENT PROCEDURES—Continued

CPT/ HCPCS	HOPD Status Indicator	Description
50070	C	Incision of kidney
50075	C	Removal of kidney stone
50100	C	Revise kidney blood vessels
50120	C	Exploration of kidney
50125	C	Explore and drain kidney
50130	C	Removal of kidney stone
50135	C	Exploration of kidney
50205	C	Biopsy of kidney
50220	C	Removal of kidney
50225	C	Removal of kidney
50230	C	Removal of kidney
50234	C	Removal of kidney & ureter
50236	C	Removal of kidney & ureter
50240	C	Partial removal of kidney
50280	C	Removal of kidney lesion
50290	C	Removal of kidney lesion
50300	C	Removal of donor kidney
50320	C	Removal of donor kidney
50340	C	Removal of kidney
50360	C	Transplantation of kidney
50365	C	Transplantation of kidney
50370	C	Remove transplanted kidney
50380	C	Reimplantation of kidney
50400	C	Revision of kidney/ureter
50405	C	Revision of kidney/ureter
50500	C	Repair of kidney wound
50520	C	Close kidney-skin fistula
50525	C	Repair renal-abdomen fistula
50526	C	Repair renal-abdomen fistula
50540	C	Revision of horseshoe kidney
50545	C	Laparo radical nephrectomy
50546	C	Laparoscopic nephrectomy
50547	C	Laparo removal donor kidney
50548	C	Laparo remove k/ureter
50570	C	Kidney endoscopy
50572	C	Kidney endoscopy
50574	C	Kidney endoscopy & biopsy
50575	C	Kidney endoscopy
50576	C	Kidney endoscopy & treatment
50578	C	Renal endoscopy/radiotracer
50580	C	Kidney endoscopy & treatment
50600	C	Exploration of ureter
50605	C	Insert ureteral support
50610	C	Removal of ureter stone
50620	C	Removal of ureter stone
50630	C	Removal of ureter stone
50650	C	Removal of ureter
50660	C	Removal of ureter
50700	C	Revision of ureter
50715	C	Release of ureter
50722	C	Release of ureter
50725	C	Release/revise ureter
50727	C	Revise ureter
50728	C	Revise ureter
50740	C	Fusion of ureter & kidney
50750	C	Fusion of ureter & kidney
50760	C	Fusion of ureters
50770	C	Splicing of ureters
50780	C	Reimplant ureter in bladder
50782	C	Reimplant ureter in bladder
50783	C	Reimplant ureter in bladder
50785	C	Reimplant ureter in bladder
50800	C	Implant ureter in bowel
50810	C	Fusion of ureter & bowel
50815	C	Urine shunt to bowel
50820	C	Construct bowel bladder
50825	C	Construct bowel bladder
50830	C	Revise urine flow
50840	C	Replace ureter by bowel
50845	C	Appendico-vesicostomy
50860	C	Transplant ureter to skin
50900	C	Repair of ureter
50920	C	Closure ureter/skin fistula
50930	C	Closure ureter/bowel fistula
50940	C	Release of ureter

ADDENDUM E.—CPT CODES WHICH WOULD BE PAID ONLY AS INPATIENT PROCEDURES—Continued

CPT/ HCPCS	HOPD Status Indicator	Description
51060	C	Removal of ureter stone
51525	C	Removal of bladder lesion
51530	C	Removal of bladder lesion
51535	C	Repair of ureter lesion
51550	C	Partial removal of bladder
51555	C	Partial removal of bladder
51565	C	Revise bladder & ureter(s)
51570	C	Removal of bladder
51575	C	Removal of bladder & nodes
51580	C	Remove bladder/revise tract
51585	C	Removal of bladder & nodes
51590	C	Remove bladder/revise tract
51595	C	Remove bladder/revise tract
51596	C	Remove bladder/create pouch
51597	C	Removal of pelvic structures
51800	C	Revision of bladder/urethra
51820	C	Revision of urinary tract
51840	C	Attach bladder/urethra
51841	C	Attach bladder/urethra
51845	C	Repair bladder neck
51860	C	Repair of bladder wound
51865	C	Repair of bladder wound
51900	C	Repair bladder/vagina lesion
51920	C	Close bladder-uterus fistula
51925	C	Hysterectomy/bladder repair
51940	C	Correction of bladder defect
51960	C	Revision of bladder & bowel
51980	C	Construct bladder opening
53085	C	Drainage of urinary leakage
53415	C	Reconstruction of urethra
53443	C	Reconstruction of urethra
54125	C	Removal of penis
54130	C	Remove penis & nodes
54135	C	Remove penis & nodes
54332	C	Revise penis/urethra
54336	C	Revise penis/urethra
54390	C	Repair penis and bladder
54430	C	Revision of penis
54535	C	Extensive testis surgery
54560	C	Exploration for testis
54650	C	Orchiopexy (fowler-stephens)
55600	C	Incise sperm duct pouch
55605	C	Incise sperm duct pouch
55650	C	Remove sperm duct pouch
55801	C	Removal of prostate
55810	C	Extensive prostate surgery
55812	C	Extensive prostate surgery
55815	C	Extensive prostate surgery
55821	C	Removal of prostate
55831	C	Removal of prostate
55840	C	Extensive prostate surgery
55842	C	Extensive prostate surgery
55845	C	Extensive prostate surgery
55862	C	Extensive prostate surgery
55865	C	Extensive prostate surgery
56630	C	Extensive vulva surgery
56631	C	Extensive vulva surgery
56632	C	Extensive vulva surgery
56633	C	Extensive vulva surgery
56634	C	Extensive vulva surgery
56637	C	Extensive vulva surgery
56640	C	Extensive vulva surgery
57110	C	Remove vagina wall, complete
57111	C	Remove vagina tissue, compl
57112	C	Vaginectomy w/nodes, compl
57270	C	Repair of bowel pouch
57280	C	Suspension of vagina
57282	C	Repair of vaginal prolapse
57292	C	Construct vagina with graft
57305	C	Repair rectum-vagina fistula
57307	C	Fistula repair & colostomy
57308	C	Fistula repair, transperine
57311	C	Repair urethrovaginal lesion
57335	C	Repair vagina
57531	C	Removal of cervix, radical

ADDENDUM E.—CPT CODES WHICH WOULD BE PAID ONLY AS INPATIENT PROCEDURES—Continued

CPT/ HCPCS	HOPD Status Indicator	Description
57540	C	Removal of residual cervix
57545	C	Remove cervix/repair pelvis
58140	C	Removal of uterus lesion
58150	C	Total hysterectomy
58152	C	Total hysterectomy
58180	C	Partial hysterectomy
58200	C	Extensive hysterectomy
58210	C	Extensive hysterectomy
58240	C	Removal of pelvis contents
58260	C	Vaginal hysterectomy
58262	C	Vaginal hysterectomy
58263	C	Vaginal hysterectomy
58267	C	Hysterectomy & vagina repair
58270	C	Hysterectomy & vagina repair
58275	C	Hysterectomy/revise vagina
58280	C	Hysterectomy/revise vagina
58285	C	Extensive hysterectomy
58400	C	Suspension of uterus
58410	C	Suspension of uterus
58520	C	Repair of ruptured uterus
58540	C	Revision of uterus
58605	C	Division of fallopian tube
58611	C	Ligate oviduct(s) add-on
58700	C	Removal of fallopian tube
58720	C	Removal of ovary/tube(s)
58740	C	Revise fallopian tube(s)
58750	C	Repair oviduct
58752	C	Revise ovarian tube(s)
58760	C	Remove tubal obstruction
58770	C	Create new tubal opening
58805	C	Drainage of ovarian cyst(s)
58822	C	Drain ovary abscess, percut
58823	C	Drain pelvic abscess, percut
58825	C	Transposition, ovary(s)
58940	C	Removal of ovary(s)
58943	C	Removal of ovary(s)
58950	C	Resect ovarian malignancy
58951	C	Resect ovarian malignancy
58952	C	Resect ovarian malignancy
58960	C	Exploration of abdomen
59100	C	Remove uterus lesion
59120	C	Treat ectopic pregnancy
59121	C	Treat ectopic pregnancy
59130	C	Treat ectopic pregnancy
59135	C	Treat ectopic pregnancy
59136	C	Treat ectopic pregnancy
59140	C	Treat ectopic pregnancy
59325	C	Revision of cervix
59350	C	Repair of uterus
59514	C	Cesarean delivery only
59525	C	Remove uterus after cesarean
59620	C	Attempted vbac delivery only
59830	C	Treat uterus infection
59850	C	Abortion
59851	C	Abortion
59852	C	Abortion
59855	C	Abortion
59856	C	Abortion
59857	C	Abortion
60254	C	Extensive thyroid surgery
60270	C	Removal of thyroid
60271	C	Removal of thyroid
60502	C	Re-explore parathyroids
60505	C	Explore parathyroid glands
60520	C	Removal of thymus gland
60521	C	Removal of thymus gland
60522	C	Removal of thymus gland
60540	C	Explore adrenal gland
60545	C	Explore adrenal gland
60600	C	Remove carotid body lesion
60605	C	Remove carotid body lesion
60650	C	Laparoscopy adrenalectomy
61105	C	Twist drill hole
61107	C	Drill skull for implantation
61108	C	Drill skull for drainage

ADDENDUM E.—CPT CODES WHICH WOULD BE PAID ONLY AS INPATIENT PROCEDURES—Continued

CPT/ HCPCS	HOPD Status Indicator	Description
61120	C	Burr hole for puncture
61140	C	Pierce skull for biopsy
61150	C	Pierce skull for drainage
61151	C	Pierce skull for drainage
61154	C	Pierce skull & remove clot
61156	C	Pierce skull for drainage
61210	C	Pierce skull, implant device
61250	C	Pierce skull & explore
61253	C	Pierce skull & explore
61304	C	Open skull for exploration
61305	C	Open skull for exploration
61312	C	Open skull for drainage
61313	C	Open skull for drainage
61314	C	Open skull for drainage
61315	C	Open skull for drainage
61320	C	Open skull for drainage
61321	C	Open skull for drainage
61332	C	Explore/biopsy eye socket
61333	C	Explore orbit/remove lesion
61334	C	Explore orbit/remove object
61340	C	Relieve cranial pressure
61343	C	Incise skull (press relief)
61345	C	Relieve cranial pressure
61440	C	Incise skull for surgery
61450	C	Incise skull for surgery
61458	C	Incise skull for brain wound
61460	C	Incise skull for surgery
61470	C	Incise skull for surgery
61480	C	Incise skull for surgery
61490	C	Incise skull for surgery
61500	C	Removal of skull lesion
61501	C	Remove infected skull bone
61510	C	Removal of brain lesion
61512	C	Remove brain lining lesion
61514	C	Removal of brain abscess
61516	C	Removal of brain lesion
61518	C	Removal of brain lesion
61519	C	Remove brain lining lesion
61520	C	Removal of brain lesion
61521	C	Removal of brain lesion
61522	C	Removal of brain abscess
61524	C	Removal of brain lesion
61526	C	Removal of brain lesion
61530	C	Removal of brain lesion
61531	C	Implant brain electrodes
61533	C	Implant brain electrodes
61534	C	Removal of brain lesion
61535	C	Remove brain electrodes
61536	C	Removal of brain lesion
61538	C	Removal of brain tissue
61539	C	Removal of brain tissue
61541	C	Incision of brain tissue
61542	C	Removal of brain tissue
61543	C	Removal of brain tissue
61544	C	Remove & treat brain lesion
61545	C	Excision of brain tumor
61546	C	Removal of pituitary gland
61548	C	Removal of pituitary gland
61550	C	Release of skull seams
61552	C	Release of skull seams
61556	C	Incise skull/sutures
61557	C	Incise skull/sutures
61558	C	Excision of skull/sutures
61559	C	Excision of skull/sutures
61563	C	Excision of skull tumor
61564	C	Excision of skull tumor
61570	C	Remove foreign body, brain
61571	C	Incise skull for brain wound
61575	C	Skull base/brainstem surgery
61576	C	Skull base/brainstem surgery
61580	C	Craniofacial approach, skull
61581	C	Craniofacial approach, skull
61582	C	Craniofacial approach, skull
61583	C	Craniofacial approach, skull
61584	C	Orbitocranial approach/skull

ADDENDUM E.—CPT CODES WHICH WOULD BE PAID ONLY AS INPATIENT PROCEDURES—Continued

CPT/ HCPCS	HOPD Status Indicator	Description
61585	C	Orbitocranial approach/skull
61586	C	Resect nasopharynx, skull
61590	C	Infratemporal approach/skull
61591	C	Infratemporal approach/skull
61592	C	Orbitocranial approach/skull
61595	C	Transtemporal approach/skull
61596	C	Transcochlear approach/skull
61597	C	Transcondylar approach/skull
61598	C	Transpetrosal approach/skull
61600	C	Resect/excise cranial lesion
61601	C	Resect/excise cranial lesion
61605	C	Resect/excise cranial lesion
61606	C	Resect/excise cranial lesion
61607	C	Resect/excise cranial lesion
61608	C	Resect/excise cranial lesion
61609	C	Transect artery, sinus
61610	C	Transect artery, sinus
61611	C	Transect artery, sinus
61612	C	Transect artery, sinus
61613	C	Remove aneurysm, sinus
61615	C	Resect/excise lesion, skull
61616	C	Resect/excise lesion, skull
61618	C	Repair dura
61619	C	Repair dura
61624	C	Occlusion/embolization cath
61626	C	Occlusion/embolization cath
61680	C	Intracranial vessel surgery
61682	C	Intracranial vessel surgery
61684	C	Intracranial vessel surgery
61686	C	Intracranial vessel surgery
61690	C	Intracranial vessel surgery
61692	C	Intracranial vessel surgery
61697	C	Brain aneurysm repr, complx
61698	C	Brain aneurysm repr, complx
61700	C	Brain aneurysm repr , simple
61702	C	Inner skull vessel surgery
61703	C	Clamp neck artery
61705	C	Revise circulation to head
61708	C	Revise circulation to head
61710	C	Revise circulation to head
61711	C	Fusion of skull arteries
61720	C	Incise skull/brain surgery
61735	C	Incise skull/brain surgery
61750	C	Incise skull/brain biopsy
61751	C	Brain biopsy w/ ct/mr guide
61760	C	Implant brain electrodes
61770	C	Incise skull for treatment
61791	C	Treat trigeminal tract
61850	C	Implant neuroelectrodes
61860	C	Implant neuroelectrodes
61862	C	Implant neurostimul, subcort
61870	C	Implant neuroelectrodes
61875	C	Implant neuroelectrodes
62000	C	Treat skull fracture
62005	C	Treat skull fracture
62010	C	Treatment of head injury
62100	C	Repair brain fluid leakage
62115	C	Reduction of skull defect
62116	C	Reduction of skull defect
62117	C	Reduction of skull defect
62120	C	Repair skull cavity lesion
62121	C	Incise skull repair
62140	C	Repair of skull defect
62141	C	Repair of skull defect
62142	C	Remove skull plate/flap
62143	C	Replace skull plate/flap
62145	C	Repair of skull & brain
62146	C	Repair of skull with graft
62147	C	Repair of skull with graft
62180	C	Establish brain cavity shunt
62190	C	Establish brain cavity shunt
62192	C	Establish brain cavity shunt
62200	C	Establish brain cavity shunt
62201	C	Establish brain cavity shunt
62220	C	Establish brain cavity shunt

ADDENDUM E.—CPT CODES WHICH WOULD BE PAID ONLY AS INPATIENT PROCEDURES—Continued

CPT/ HCPCS	HOPD Status Indicator	Description
62223	C	Establish brain cavity shunt
62256	C	Remove brain cavity shunt
62258	C	Replace brain cavity shunt
62351	C	Implant spinal canal cath
63043	C	Laminotomy, addl cervical
63044	C	Laminotomy, addl lumbar
63075	C	Neck spine disk surgery
63076	C	Neck spine disk surgery
63077	C	Spine disk surgery, thorax
63078	C	Spine disk surgery, thorax
63081	C	Removal of vertebral body
63082	C	Remove vertebral body add-on
63085	C	Removal of vertebral body
63086	C	Remove vertebral body add-on
63087	C	Removal of vertebral body
63088	C	Remove vertebral body add-on
63090	C	Removal of vertebral body
63091	C	Remove vertebral body add-on
63170	C	Incise spinal cord tract(s)
63172	C	Drainage of spinal cyst
63173	C	Drainage of spinal cyst
63180	C	Revise spinal cord ligaments
63182	C	Revise spinal cord ligaments
63185	C	Incise spinal column/nerves
63190	C	Incise spinal column/nerves
63191	C	Incise spinal column/nerves
63194	C	Incise spinal column & cord
63195	C	Incise spinal column & cord
63196	C	Incise spinal column & cord
63197	C	Incise spinal column & cord
63198	C	Incise spinal column & cord
63199	C	Incise spinal column & cord
63200	C	Release of spinal cord
63250	C	Revise spinal cord vessels
63251	C	Revise spinal cord vessels
63252	C	Revise spinal cord vessels
63265	C	Excise intraspinal lesion
63266	C	Excise intraspinal lesion
63267	C	Excise intraspinal lesion
63268	C	Excise intraspinal lesion
63270	C	Excise intraspinal lesion
63271	C	Excise intraspinal lesion
63272	C	Excise intraspinal lesion
63273	C	Excise intraspinal lesion
63275	C	Biopsy/excise spinal tumor
63276	C	Biopsy/excise spinal tumor
63277	C	Biopsy/excise spinal tumor
63278	C	Biopsy/excise spinal tumor
63280	C	Biopsy/excise spinal tumor
63281	C	Biopsy/excise spinal tumor
63282	C	Biopsy/excise spinal tumor
63283	C	Biopsy/excise spinal tumor
63285	C	Biopsy/excise spinal tumor
63286	C	Biopsy/excise spinal tumor
63287	C	Biopsy/excise spinal tumor
63290	C	Biopsy/excise spinal tumor
63300	C	Removal of vertebral body
63301	C	Removal of vertebral body
63302	C	Removal of vertebral body
63303	C	Removal of vertebral body
63304	C	Removal of vertebral body
63305	C	Removal of vertebral body
63306	C	Removal of vertebral body
63307	C	Removal of vertebral body
63308	C	Remove vertebral body add-on
63655	C	Implant neuroelectrodes
63700	C	Repair of spinal herniation
63702	C	Repair of spinal herniation
63704	C	Repair of spinal herniation
63706	C	Repair of spinal herniation
63707	C	Repair spinal fluid leakage
63709	C	Repair spinal fluid leakage
63710	C	Graft repair of spine defect
63740	C	Install spinal shunt
64752	C	Incision of vagus nerve

ADDENDUM E.—CPT CODES WHICH WOULD BE PAID ONLY AS INPATIENT PROCEDURES—Continued

CPT/ HCPCS	HOPD Status Indicator	Description
64755	C	Incision of stomach nerves
64760	C	Incision of vagus nerve
64763	C	Incise hip/thigh nerve
64766	C	Incise hip/thigh nerve
64802	C	Remove sympathetic nerves
64804	C	Remove sympathetic nerves
64809	C	Remove sympathetic nerves
64818	C	Remove sympathetic nerves
64820	C	Remove sympathetic nerves
64866	C	Fusion of facial/other nerve
64868	C	Fusion of facial/other nerve
65273	C	Repair of eye wound
69150	C	Extensive ear canal surgery
69155	C	Extensive ear/neck surgery
69502	C	Mastoidectomy
69535	C	Remove part of temporal bone
69554	C	Remove ear lesion
69950	C	Incise inner ear nerve
69970	C	Remove inner ear lesion
75900	C	Arterial catheter exchange
75952	C	Endovasc repair abdom aorta
75953	C	Abdom aneurysm endovas rpr
92970	C	Cardioassist, internal
92971	C	Cardioassist, external
92975	C	Dissolve clot, heart vessel
92986	C	Revision of aortic valve
92987	C	Revision of mitral valve
92990	C	Revision of pulmonary valve
92992	C	Revision of heart chamber
92993	C	Revision of heart chamber
92997	C	Pul art balloon repr, percut
92998	C	Pul art balloon repr, percut
94652	C	Pressure breathing (ippb)
99190	C	Special pump services
99191	C	Special pump services
99192	C	Special pump services
99251	C	Initial inpatient consult
99252	C	Initial inpatient consult
99253	C	Initial inpatient consult
99254	C	Initial inpatient consult
99255	C	Initial inpatient consult
99261	C	Follow-up inpatient consult
99262	C	Follow-up inpatient consult
99263	C	Follow-up inpatient consult
99295	C	Neonatal critical care
99296	C	Neonatal critical care
99297	C	Neonatal critical care
99298	C	Neonatal critical care
99356	C	Prolonged service, inpatient
99357	C	Prolonged service, inpatient
99433	C	Normal newborn care/hospital

ADDENDUM H.—WAGE INDEX FOR URBAN AREAS

Urban area (constituent counties)	Wage index
0040 Abilene, TX	0.8118
Taylor, TX	
0060 Aguadilla, PR	0.4738
Aguada, PR	
Aguadilla, PR	
Moca, PR	
0080 Akron, OH	0.9924
Portage, OH	
Summit, OH	
0120 Albany, GA	1.0675
Dougherty, GA	
Lee, GA	

ADDENDUM H.—WAGE INDEX FOR URBAN AREAS—Continued

Urban area (constituent counties)	Wage index
0160 Albany-Schenectady-Troy, NY	0.8597
Albany, NY	
Montgomery, NY	
Rensselaer, NY	
Saratoga, NY	
Schenectady, NY	
Schoharie, NY	
0200 Albuquerque, NM	0.9855
Bernalillo, NM	
Sandoval, NM	
Valencia, NM	
0220 Alexandria, LA	0.8137
Rapides, LA	

ADDENDUM H.—WAGE INDEX FOR URBAN AREAS—Continued

Urban area (constituent counties)	Wage index
0240 Allentown-Bethlehem-Easton, PA	0.9443
Carbon, PA	
Lehigh, PA	
Northampton, PA	
0280 Altoona, PA	0.9225
Blair, PA	
0320 Amarillo, TX	0.8706
Potter, TX	
Randall, TX	
0380 Anchorage, AK	1.2605
Anchorage, AK	
0440 Ann Arbor, MI	1.1220
Lenawee, MI	
Livingston, MI	

ADDENDUM H.—WAGE INDEX FOR URBAN AREAS—Continued

Urban area (constituent counties)	Wage index
Washtenaw, MI	
0450 Anniston, AL	0.8360
Calhoun, AL	
0460 Appleton-Oshkosh-Neenah, WI	0.9203
Calumet, WI	
Outagamie, WI	
Winnebago, WI	
0470 Arecibo, PR	0.4683
Arecibo, PR	
Camuy, PR	
Hatillo, PR	
0480 Asheville, NC	0.9307
Buncombe, NC	
Madison, NC	
0500 Athens, GA	0.9956
Clarke, GA	
Madison, GA	
Oconee, GA	
0520 [1] Atlanta, GA	1.0176
Barrow, GA	
Bartow, GA	
Carroll, GA	
Cherokee, GA	
Clayton, GA	
Cobb, GA	
Coweta, GA	
DeKalb, GA	
Douglas, GA	
Fayette, GA	
Forsyth, GA	
Fulton, GA	
Gwinnett, GA	
Henry, GA	
Newton, GA	
Paulding, GA	
Pickens, GA	
Rockdale, GA	
Spalding, GA	
Walton, GA	
0560 Atlantic-Cape May, NJ	1.1349
Atlantic, NJ	
Cape May, NJ	
0580 Auburn-Opelika, AL	0.8325
Lee, AL	
0600 Augusta-Aiken, GA–SC	1.0090
Columbia, GA	
McDuffie, GA	
Richmond, GA	
Aiken, SC	
Edgefield, SC	
0640 [1] Austin-San Marcos, TX	0.9327
Bastrop, TX	
Caldwell, TX	
Hays, TX	
Travis, TX	
Williamson, TX	
0680 [2] Bakersfield, CA	0.9870
Kern, CA	
0720 [1] Baltimore, MD	0.9723
Anne Arundel, MD	
Baltimore, MD	
Baltimore City, MD	
Carroll, MD	
Harford, MD	
Howard, MD	
Queen Anne's, MD	
0733 Bangor, ME	0.9559
Penobscot, ME	
0743 Barnstable-Yarmouth, MA	1.3539
Barnstable, MA	
0760 Baton Rouge, LA	0.8258
Ascension, LA	
East Baton Rouge, LA	
Livingston, LA	
West Baton Rouge, LA	
0840 Beaumont-Port Arthur, TX	0.8508
Hardin, TX	
Jefferson, TX	
Orange, TX	
0860 Bellingham, WA	1.1963
Whatcom, WA	
0870 [2] Benton Harbor, MI	0.9115
Berrien, MI	
0875 [1] Bergen-Passaic, NJ	1.1669
Bergen, NJ	
Passaic, NJ	
0880 Billings, MT	0.9623
Yellowstone, MT	
0920 Biloxi-Gulfport-Pascagoula, MS	0.8538
Hancock, MS	
Harrison, MS	
Jackson, MS	
0960 Binghamton, NY	0.8595
Broome, NY	
Tioga, NY	
1000 Birmingham, AL	0.8648
Blount, AL	
Jefferson, AL	
St. Clair, AL	
Shelby, AL	
1010 [2] Bismarck, ND	0.7965
Burleigh, ND	
Morton, ND	
1020 [2] Bloomington, IN	0.8757
Monroe, IN	
1040 Bloomington-Normal, IL	0.8545
McLean, IL	
1080 Boise City, ID	0.9190
Ada, ID	
Canyon, ID	
1123 [1,2] Boston-Worcester-Lawrence-Lowell-Brockton, MA–NH (MA Hospitals)	1.1586
Bristol, MA	
Essex, MA	
Middlesex, MA	
Norfolk, MA	
Plymouth, MA	
Suffolk, MA	
Worcester, MA	
Hillsborough, NH	
Merrimack, NH	
Rockingham, NH	
Strafford, NH	
1123 [1] Boston-Worcester-Lawrence-Lowell-Brockton, MA–NH (NH Hospitals)	1.1483
Bristol, MA	
Essex, MA	
Middlesex, MA	
Norfolk, MA	
Plymouth, MA	
Suffolk, MA	
Worcester, MA	
Hillsborough, NH	
Merrimack, NH	
Rockingham, NH	
Strafford, NH	
1125 Boulder-Longmont, CO	0.9836
Boulder, CO	
1145 Brazoria, TX	0.8299
Brazoria, TX	
1150 Bremerton, WA	1.0882
Kitsap, WA	
1240 Brownsville-Harlingen-San Benito, TX	0.8783
Cameron, TX	
1260 Bryan-College Station, TX	0.9296
Brazos, TX	
1280 [1] Buffalo-Niagara Falls, NY	0.9405
Erie, NY	
Niagara, NY	
1303 Burlington, VT	0.9826
Chittenden, VT	
Franklin, VT	
Grand Isle, VT	
1310 Caguas, PR	0.5158
Caguas, PR	
Cayey, PR	
Cidra, PR	
Gurabo, PR	
San Lorenzo, PR	
1320 Canton-Massillon, OH	0.9059
Carroll, OH	
Stark, OH	
1350 Casper, WY	0.9606
Natrona, WY	
1360 Cedar Rapids, IA	0.8711
Linn, IA	
1400 Champaign-Urbana, IL	0.9264
Champaign, IL	
1440 Charleston-North Charleston, SC	0.9293
Berkeley, SC	
Charleston, SC	
Dorchester, SC	
1480 Charleston, WV	0.9369
Kanawha, WV	
Putnam, WV	
1520 [1] Charlotte-Gastonia-Rock Hill, NC–SC	0.9469
Cabarrus, NC	
Gaston, NC	
Lincoln, NC	
Mecklenburg, NC	
Rowan, NC	
Stanly, NC	
Union, NC	
York, SC	
1540 Charlottesville, VA	1.0688
Albemarle, VA	
Charlottesville City, VA	
Fluvanna, VA	
Greene, VA	
1560 Chattanooga, TN–GA	0.9446
Catoosa, GA	
Dade, GA	
Walker, GA	
Hamilton, TN	
Marion, TN	
1580 [2] Cheyenne, WY	0.8855
Laramie, WY	
1600 [1] Chicago, IL	1.1011
Cook, IL	
DeKalb, IL	
DuPage, IL	
Grundy, IL	
Kane, IL	

ADDENDUM H.—WAGE INDEX FOR URBAN AREAS—Continued

Urban area (constituent counties)	Wage index
Kendall, IL	
Lake, IL	
McHenry, IL	
Will, IL	
1620 Chico-Paradise, CA	0.9909
Butte, CA	
1640 [1] Cincinnati, OH–KY–IN	0.9574
Dearborn, IN	
Ohio, IN	
Boone, KY	
Campbell, KY	
Gallatin, KY	
Grant, KY	
Kenton, KY	
Pendleton, KY	
Brown, OH	
Clermont, OH	
Hamilton, OH	
Warren, OH	
1660 Clarksville-Hopkinsville, TN–KY	0.8481
Christian, KY	
Montgomery, TN	
1680 [1] Cleveland-Lorain-Elyria, OH	0.9496
Ashtabula, OH	
Cuyahoga, OH	
Geauga, OH	
Lake, OH	
Lorain, OH	
Medina, OH	
1720 Colorado Springs, CO	0.9754
El Paso, CO	
1740 Columbia, MO	0.8787
Boone, MO	
1760 Columbia, SC	0.9589
Lexington, SC	
Richland, SC	
1800 Columbus, GA–AL Russell, AL	0.8471
Chattahoochee, GA	
Harris, GA	
Muscogee, GA	
1840 [1] Columbus, OH	0.9724
Delaware, OH	
Fairfield, OH	
Franklin, OH	
Licking, OH	
Madison, OH	
Pickaway, OH	
1880 Corpus Christi, TX	0.8203
Nueces, TX	
San Patricio, TX	
1890 Corvallis, OR	1.1781
Benton, OR	
1900 [2] Cumberland, MD–WV (MD Hospitals)	0.8962
Allegany, MD	
Mineral, WV	
1900 Cumberland, MD–WV (WV Hospital)	0.8402
Allegany, MD	
Mineral, WV	
1920 [1] Dallas, TX	0.9506
Collin, TX	
Dallas, TX	
Denton, TX	
Ellis, TX	
Henderson, TX	
Hunt, TX	
Kaufman, TX	
Rockwall, TX	
1950 Danville, VA	0.8641
Danville City, VA	
Pittsylvania, VA	
1960 Davenport-Moline-Rock Island, IA–IL	0.8790
Scott, IA	
Henry, IL	
Rock Island, IL	
2000 Dayton-Springfield, OH	0.9323
Clark, OH	
Greene, OH	
Miami, OH	
Montgomery, OH	
2020 Daytona Beach, FL	0.9069
Flagler, FL	
Volusia, FL	
2030 Decatur, AL	0.8817
Lawrence, AL	
Morgan, AL	
2040 [2] Decatur, IL	0.8140
Macon, IL	
2080 [1] Denver, CO	1.0289
Adams, CO	
Arapahoe, CO	
Denver, CO	
Douglas, CO	
Jefferson, CO	
2120 Des Moines, IA	0.8881
Dallas, IA	
Polk, IA	
Warren, IA	
2160 [1] Detroit, MI	1.0478
Lapeer, MI	
Macomb, MI	
Monroe, MI	
Oakland, MI	
St. Clair, MI	
Wayne, MI	
2180 Dothan, AL	0.8005
Dale, AL	
Houston, AL	
2190 Dover, DE	1.0453
Kent, DE	
2200 Dubuque, IA	0.8617
Dubuque, IA	
2240 Duluth-Superior, MN–WI	1.0401
St. Louis, MN	
Douglas, WI	
2281 Dutchess County, NY	1.0639
Dutchess, NY	
2290 [2] Eau Claire, WI	0.9121
Chippewa, WI	
Eau Claire, WI	
2320 El Paso, TX	0.9162
El Paso, TX	
2330 Elkhart-Goshen, IN	0.9646
Elkhart, IN	
2335 Elmira, NY	0.8530
Chemung, NY	
2340 Enid, OK	0.8454
Garfield, OK	
2360 Erie, PA	0.8911
Erie, PA	
2400 Eugene-Springfield, OR	1.1485
Lane, OR	
2440 [2] Evansville-Henderson, IN–KY (IN Hospitals)	0.8757
Posey, IN	
Vanderburgh, IN	
Warrick, IN	
Henderson, KY	
2440 [2] Evansville-Henderson, IN–KY (KY Hospitals)	0.8019
Posey, IN	
Vanderburgh, IN	
Warrick, IN	
Henderson, KY	
2520 Fargo-Moorhead, ND–MN	0.9374
Clay, MN	
Cass, ND	
2560 Fayetteville, NC	0.9132
Cumberland, NC	
2580 Fayetteville-Springdale-Rogers, AR	0.7587
Benton, AR	
Washington, AR	
2620 Flagstaff, AZ–UT	1.0678
Coconino, AZ	
Kane, UT	
2640 Flint, MI	1.0920
Genesee, MI	
2650 Florence, AL	0.7927
Colbert, AL	
Lauderdale, AL	
2655 Florence, SC	0.8843
Florence, SC	
2670 Fort Collins-Loveland, CO	1.0161
Larimer, CO	
2680 [1] Ft. Lauderdale, FL	1.0906
Broward, FL	
2700 Fort Myers-Cape Coral, FL	0.9380
Lee, FL	
2710 Fort Pierce-Port St. Lucie, FL	1.0067
Martin, FL	
St. Lucie, FL	
2720 Fort Smith, AR–OK	0.8076
Crawford, AR	
Sebastian, AR	
Sequoyah, OK	
2750 [2] Fort Walton Beach, FL	0.8733
Okaloosa, FL	
2760 Fort Wayne, IN	0.9186
Adams, IN	
Allen, IN	
De Kalb, IN	
Huntington, IN	
Wells, IN	
Whitley, IN	
2800 [1] Fort Worth-Arlington, TX	0.9452
Hood, TX	
Johnson, TX	
Parker, TX	
Tarrant, TX	
2840 Fresno, CA	0.9972
Fresno, CA	
Madera, CA	
2880 Gadsden, AL	0.8845
Etowah, AL	
2900 Gainesville, FL	1.2133
Alachua, FL	
2920 Galveston-Texas City, TX	1.0271
Galveston, TX	
2960 Gary, IN	0.9571
Lake, IN	
Porter, IN	
2975 [2] Glens Falls, NY	0.8530
Warren, NY	

ADDENDUM H.—WAGE INDEX FOR URBAN AREAS—Continued

Urban area (constituent counties)	Wage index
Washington, NY	
2980 Goldsboro, NC	0.8810
Wayne, NC	
2985 Grand Forks, ND–MN	0.9173
Polk, MN	
Grand Forks, ND	
2995 Grand Junction, CO	0.9816
Mesa, CO	
3000 [1] Grand Rapids-Muskegon-Holland, MI	1.0161
Allegan, MI	
Kent, MI	
Muskegon, MI	
Ottawa, MI	
3040 Great Falls, MT	0.9301
Cascade, MT	
3060 Greeley, CO	0.9604
Weld, CO	
3080 Green Bay, WI	0.9440
Brown, WI	
3120 [1] Greensboro-Winston-Salem-High Point, NC	0.9616
Alamance, NC	
Davidson, NC	
Davie, NC	
Forsyth, NC	
Guilford, NC	
Randolph, NC	
Stokes, NC	
Yadkin, NC	
3150 Greenville, NC	0.9963
Pitt, NC	
3160 Greenville-Spartanburg-Anderson, SC	0.9110
Anderson, SC	
Cherokee, SC	
Greenville, SC	
Pickens, SC	
Spartanburg, SC	
3180 [2] Hagerstown, MD	0.8962
Washington, MD	
3200 Hamilton-Middletown, OH	0.9269
Butler, OH	
3240 Harrisburg-Lebanon-Carlisle, PA	0.9311
Cumberland, PA	
Dauphin, PA	
Lebanon, PA	
Perry, PA	
3283 [1, 2] Hartford, CT	1.2357
Hartford, CT	
Litchfield, CT	
Middlesex, CT	
Tolland, CT	
3285 [2] Hattiesburg, MS	0.7612
Forrest, MS	
Lamar, MS	
3290 Hickory-Morganton-Lenoir, NC	0.9517
Alexander, NC	
Burke, NC	
Caldwell, NC	
Catawba, NC	
3320 Honolulu, HI	1.1658
Honolulu, HI	
3350 Houma, LA	0.8043
Lafourche, LA	
Terrebonne, LA	
3360 [1] Houston, TX	0.9604
Chambers, TX	
Fort Bend, TX	
Harris, TX	
Liberty, TX	
Montgomery, TX	
Waller, TX	
3400 Huntington-Ashland, WV–KY–OH	0.9700
Boyd, KY	
Carter, KY	
Greenup, KY	
Lawrence, OH	
Cabell, WV	
Wayne, WV	
3440 Huntsville, AL	0.8854
Limestone, AL	
Madison, AL	
3480 [1] Indianapolis, IN	0.9771
Boone, IN	
Hamilton, IN	
Hancock, IN	
Hendricks, IN	
Johnson, IN	
Madison, IN	
Marion, IN	
Morgan, IN	
Shelby, IN	
3500 Iowa City, IA	0.9973
Johnson, IA	
3520 Jackson, MI	0.9387
Jackson, MI	
3560 Jackson, MS	0.8589
Hinds, MS	
Madison, MS	
Rankin, MS	
3580 Jackson, TN	0.9117
Madison, TN	
Chester, TN	
3600 [1] Jacksonville, FL	0.9040
Clay, FL	
Duval, FL	
Nassau, FL	
St. Johns, FL	
3605 [2] Jacksonville, NC	0.8632
Onslow, NC	
3610 [2] Jamestown, NY	0.8530
Chautauqua, NY	
3620 Janesville-Beloit, WI	0.9840
Rock, WI	
3640 Jersey City, NJ	1.1216
Hudson, NJ	
3660 Johnson City-Kingsport-Bristol, TN–VA	0.8540
Carter, TN	
Hawkins, TN	
Sullivan, TN	
Unicoi, TN	
Washington, TN	
Bristol City, VA	
Scott, VA	
Washington, VA	
3680 Johnstown, PA	0.8959
Cambria, PA	
Somerset, PA	
3700 Jonesboro, AR	0.8523
Craighead, AR	
3710 Joplin, MO	0.8736
Jasper, MO	
Newton, MO	
3720 Kalamazoo-Battlecreek, MI	1.0696
Calhoun, MI	
Kalamazoo, MI	
Van Buren, MI	
3740 Kankakee, IL	0.9268
Kankakee, IL	
3760 [1] Kansas City, KS–MO	0.9430
Johnson, KS	
Leavenworth, KS	
Miami, KS	
Wyandotte, KS	
Cass, MO	
Clay, MO	
Clinton, MO	
Jackson, MO	
Lafayette, MO	
Platte, MO	
Ray, MO	
3800 Kenosha, WI	0.9678
Kenosha, WI	
3810 [2] Killeen-Temple, TX	0.7673
Bell, TX	
Coryell, TX	
3840 Knoxville, TN	0.8904
Anderson, TN	
Blount, TN	
Knox, TN	
Loudon, TN	
Sevier, TN	
Union, TN	
3850 Kokomo, IN	0.9290
Howard, IN	
Tipton, IN	
3870 La Crosse, WI–MN	0.9328
Houston, MN	
La Crosse, WI	
3880 Lafayette, LA	0.8600
Acadia, LA	
Lafayette, LA	
St. Landry, LA	
St. Martin, LA	
3920 Lafayette, IN	0.9165
Clinton, IN	
Tippecanoe, IN	
3960 Lake Charles, LA	0.7810
Calcasieu, LA	
3980 Lakeland-Winter Haven, FL	0.9167
Polk, FL	
4000 Lancaster, PA	0.9413
Lancaster, PA	
4040 Lansing-East Lansing, MI	0.9653
Clinton, MI	
Eaton, MI	
Ingham, MI	
4080 Laredo, TX	0.7877
Webb, TX	
4100 [2] Las Cruces, NM	0.8835
Dona Ana, NM	
4120 [1] Las Vegas, NV–AZ	1.1238
Mohave, AZ	
Clark, NV	
Nye, NV	
4150 Lawrence, KS	0.8756
Douglas, KS	
4200 Lawton, OK	0.8783
Comanche, OK	
4243 Lewiston-Auburn, ME	0.9451
Androscoggin, ME	
4280 Lexington, KY	0.8850
Bourbon, KY	
Clark, KY	
Fayette, KY	

ADDENDUM H.—WAGE INDEX FOR URBAN AREAS—Continued

Urban area (constituent counties)	Wage index
Jessamine, KY	
Madison, KY	
Scott, KY	
Woodford, KY	
4320 Lima, OH	0.9558
Allen, OH	
Auglaize, OH	
4360 Lincoln, NE	1.0272
Lancaster, NE	
4400 Little Rock-North Little Rock, AR	0.9053
Faulkner, AR	
Lonoke, AR	
Pulaski, AR	
Saline, AR	
4420 Longview-Marshall, TX	0.8439
Gregg, TX	
Harrison, TX	
Upshur, TX	
4480 [1] Los Angeles-Long Beach, CA	1.2071
Los Angeles, CA	
4520 [1] Louisville, KY–IN	0.9596
Clark, IN	
Floyd, IN	
Harrison, IN	
Scott, IN	
Bullitt, KY	
Jefferson, KY	
Oldham, KY	
4600 Lubbock, TX	0.8547
Lubbock, TX	
4640 Lynchburg, VA	0.9208
Amherst, VA	
Bedford, VA	
Bedford City, VA	
Campbell, VA	
Lynchburg City, VA	
4680 Macon, GA	0.9077
Bibb, GA	
Houston, GA	
Jones, GA	
Peach, GA	
Twiggs, GA	
4720 Madison, WI	1.0462
Dane, WI	
4800 Mansfield, OH	0.8827
Crawford, OH	
Richland, OH	
4840 Mayaguez, PR	0.4917
Anasco, PR	
Cabo Rojo, PR	
Hormigueros, PR	
Mayaguez, PR	
Sabana Grande, PR	
San German, PR	
4880 McAllen-Edinburg-Mission, TX	0.8433
Hidalgo, TX	
4890 Medford-Ashland, OR	1.0433
Jackson, OR	
4900 Melbourne-Titusville-Palm Bay, FL	0.9883
Brevard, FL	
4920 [1] Memphis, TN–AR–MS	0.9435
Crittenden, AR	
DeSoto, MS	
Fayette, TN	
Shelby, TN	
Tipton, TN	

ADDENDUM H.—WAGE INDEX FOR URBAN AREAS—Continued

Urban area (constituent counties)	Wage index
4940 Merced, CA	0.9870
Merced, CA	
5000 [1] Miami, FL	0.9934
Dade, FL	
5015 [1] Middlesex-Somerset-Hunterdon, NJ	1.1952
Hunterdon, NJ	
Middlesex, NJ	
Somerset, NJ	
5080 [1] Milwaukee-Waukesha, WI	0.9898
Milwaukee, WI	
Ozaukee, WI	
Washington, WI	
Waukesha, WI	
5120 [1] Minneapolis-St. Paul, MN–WI	1.1000
Anoka, MN	
Carver, MN	
Chisago, MN	
Dakota, MN	
Hennepin, MN	
Isanti, MN	
Ramsey, MN	
Scott, MN	
Sherburne, MN	
Washington, MN	
Wright, MN	
Pierce, WI	
St. Croix, WI	
5140 Missoula, MT	0.9453
Missoula, MT	
5160 Mobile, AL	0.7766
Baldwin, AL	
Mobile, AL	
5170 Modesto, CA	1.0945
Stanislaus, CA	
5190 [1] Monmouth-Ocean, NJ	1.1514
Monmouth, NJ	
Ocean, NJ	
5200 Monroe, LA	0.8296
Ouachita, LA	
5240 Montgomery, AL	0.7502
Autauga, AL	
Elmore, AL	
Montgomery, AL	
5280 Muncie, IN	0.9689
Delaware, IN	
5330 Myrtle Beach, SC	0.8855
Horry, SC	
5345 Naples, FL	0.9566
Collier, FL	
5360 [1] Nashville, TN	0.9602
Cheatham, TN	
Davidson, TN	
Dickson, TN	
Robertson, TN	
Rutherford, TN	
Sumner, TN	
Williamson, TN	
Wilson, TN	
5380 [1] Nassau-Suffolk, NY	1.3841
Nassau, NY	
Suffolk, NY	
5483 [1,2] New Haven-Bridgeport-Stamford-Waterbury	1.2357
Danbury, CT	
Fairfield, CT	
New Haven, CT	
5523 [2] New London-Norwich, CT	1.2357
New London, CT	

ADDENDUM H.—WAGE INDEX FOR URBAN AREAS—Continued

Urban area (constituent counties)	Wage index
5560 [1] New Orleans, LA	0.9054
Jefferson, LA	
Orleans, LA	
Plaquemines, LA	
St. Bernard, LA	
St. Charles, LA	
St. James, LA	
St. John The Baptist, LA	
St. Tammany, LA	
5600 [1] New York, NY	1.3923
Bronx, NY	
Kings, NY	
New York, NY	
Putnam, NY	
Queens, NY	
Richmond, NY	
Rockland, NY	
Westchester, NY	
5640 [1] Newark, NJ	1.2004
Essex, NJ	
Morris, NJ	
Sussex, NJ	
Union, NJ	
Warren, NJ	
5660 Newburgh, NY–PA	1.1235
Orange, NY	
Pike, PA	
5720 [1] Norfolk-Virginia Beach-Newport News, VA–NC	0.8630
Currituck, NC	
Chesapeake City, VA	
Gloucester, VA	
Hampton City, VA	
Isle of Wight, VA	
James City, VA	
Mathews, VA	
Newport News City, VA	
Norfolk City, VA	
Poquoson City, VA	
Portsmouth City, VA	
Suffolk City, VA	
Virginia Beach City, VA	
Williamsburg City, VA	
York, VA	
5775 [1] Oakland, CA	1.5416
Alameda, CA	
Contra Costa, CA	
5790 Ocala, FL	0.9579
Marion, FL	
5800 Odessa-Midland, TX	0.9017
Ector, TX	
Midland, TX	
5880 [1] Oklahoma City, OK	0.8728
Canadian, OK	
Cleveland, OK	
Logan, OK	
McClain, OK	
Oklahoma, OK	
Pottawatomie, OK	
5910 Olympia, WA	1.1481
Thurston, WA	
5920 Omaha, NE–IA	0.9696
Pottawattamie, IA	
Cass, NE	
Douglas, NE	
Sarpy, NE	
Washington, NE	
5945 [1] Orange County, CA	1.1354
Orange, CA	
5960 [1] Orlando, FL	0.9464

ADDENDUM H.—WAGE INDEX FOR URBAN AREAS—Continued

Urban area (constituent counties)	Wage index
Lake, FL	
Orange, FL	
Osceola, FL	
Seminole, FL	
5990 Owensboro, KY	0.8346
Daviess, KY	
6015 Panama City, FL	0.9166
Bay, FL	
6020 Parkersburg-Marietta, WV–OH (WV Hospitals)	0.8192
Washington, OH	
Wood, WV	
6020 [2] Parkersburg-Marietta, WV–OH (OH Hospitals)	0.8761
Washington, OH	
Wood, WV	
6080 [2] Pensacola, FL	0.8733
Escambia, FL	
Santa Rosa, FL	
6120 Peoria-Pekin, IL	0.8883
Peoria, IL	
Tazewell, IL	
Woodford, IL	
6160 [1] Philadelphia, PA–NJ	1.0626
Burlington, NJ	
Camden, NJ	
Gloucester, NJ	
Salem, NJ	
Bucks, PA	
Chester, PA	
Delaware, PA	
Montgomery, PA	
Philadelphia, PA	
6200 [1] Phoenix-Mesa, AZ	0.9654
Maricopa, AZ	
Pinal, AZ	
6240 Pine Bluff, AR	0.7837
Jefferson, AR	
6280 [1] Pittsburgh, PA	0.9714
Allegheny, PA	
Beaver, PA	
Butler, PA	
Fayette, PA	
Washington, PA	
Westmoreland, PA	
6323 [2] Pittsfield, MA	1.1586
Berkshire, MA	
6340 Pocatello, ID	0.9557
Bannock, ID	
6360 Ponce, PR	0.5278
Guayanilla, PR	
Juana Diaz, PR	
Penuelas, PR	
Ponce, PR	
Villalba, PR	
Yauco, PR	
6403 Portland, ME	0.9501
Cumberland, ME	
Sagadahoc, ME	
York, ME	
6440 [1] Portland-Vancouver, OR–WA	1.1291
Clackamas, OR	
Columbia, OR	
Multnomah, OR	
Washington, OR	
Yamhill, OR	
Clark, WA	
6483 [1] Providence-Warwick-Pawtucket, RI	1.0781
Bristol, RI	
Kent, RI	
Newport, RI	
Providence, RI	
Washington, RI	
6520 Provo-Orem, UT	0.9967
Utah, UT	
6560 [2] Pueblo, CO	0.8909
Pueblo, CO	
6580 Punta Gorda, FL	0.8818
Charlotte, FL	
6600 Racine, WI	0.9441
Racine, WI	
6640 [1] Raleigh-Durham-Chapel Hill, NC	0.9901
Chatham, NC	
Durham, NC	
Franklin, NC	
Johnston, NC	
Orange, NC	
Wake, NC	
6660 Rapid City, SD	0.8971
Pennington, SD	
6680 [2] Reading, PA	0.8473
Berks, PA	
6690 Redding, CA	1.1222
Shasta, CA	
6720 Reno, NV	1.0456
Washoe, NV	
6740 Richland-Kennewick-Pasco, WA	1.1086
Benton, WA	
Franklin, WA	
6760 Richmond-Petersburg, VA	0.9712
Charles City County, VA	
Chesterfield, VA	
Colonial Heights City, VA	
Dinwiddie, VA	
Goochland, VA	
Hanover, VA	
Henrico, VA	
Hopewell City, VA	
New Kent, VA	
Petersburg City, VA	
Powhatan, VA	
Prince George, VA	
Richmond City, VA	
6780 [1] Riverside-San Bernardino, CA	1.1012
Riverside, CA	
San Bernardino, CA	
6800 [2] Roanoke, VA	0.8473
Botetourt, VA	
Roanoke, VA	
Roanoke City, VA	
Salem City, VA	
6820 Rochester, MN	1.1595
Olmsted, MN	
6840 [1] Rochester, NY	0.9238
Genesee, NY	
Livingston, NY	
Monroe, NY	
Ontario, NY	
Orleans, NY	
Wayne, NY	
6880 Rockford, IL	0.9194
Boone, IL	
Ogle, IL	
Winnebago, IL	
6895 Rocky Mount, NC	0.9197
Edgecombe, NC	
Nash, NC	
6920 [1] Sacramento, CA	1.1809
El Dorado, CA	
Placer, CA	
Sacramento, CA	
6960 Saginaw-Bay City-Midland, MI	0.9662
Bay, MI	
Midland, MI	
Saginaw, MI	
6980 St. Cloud, MN	1.0040
Benton, MN	
Stearns, MN	
7000 St. Joseph, MO	0.9113
Andrew, MO	
Buchanan, MO	
7040 [1] St. Louis, MO–IL	0.9024
Clinton, IL	
Jersey, IL	
Madison, IL	
Monroe, IL	
St. Clair, IL	
Franklin, MO	
Jefferson, MO	
Lincoln, MO	
St. Charles, MO	
St. Louis, MO	
St. Louis City, MO	
Warren, MO	
7080 [2] Salem, OR	1.0156
Marion, OR	
Polk, OR	
7120 Salinas, CA	1.4854
Monterey, CA	
7160 [1] Salt Lake City-Ogden, UT	0.9976
Davis, UT	
Salt Lake, UT	
Weber, UT	
7200 San Angelo, TX	0.8288
Tom Green, TX	
7240 [1] San Antonio, TX	0.8333
Bexar, TX	
Comal, TX	
Guadalupe, TX	
Wilson, TX	
7320 [1] San Diego, CA	1.1480
San Diego, CA	
7360 [1] San Francisco, CA	1.4319
Marin, CA	
San Francisco, CA	
San Mateo, CA	
7400 [1] San Jose, CA	1.4249
Santa Clara, CA	
7440 [1] San Juan-Bayamon, PR	0.4812
Aguas Buenas, PR	
Barceloneta, PR	
Bayamon, PR	
Canovanas, PR	
Carolina, PR	
Catano, PR	
Ceiba, PR	
Comerio, PR	
Corozal, PR	
Dorado, PR	
Fajardo, PR	
Florida, PR	
Guaynabo, PR	
Humacao, PR	
Juncos, PR	

ADDENDUM H.—WAGE INDEX FOR URBAN AREAS—Continued

Urban area (constituent counties)	Wage index
Los Piedras, PR	.....
Loiza, PR	.....
Luguillo, PR	.....
Manati, PR	.....
Morovis, PR	.....
Naguabo, PR	.....
Naranjito, PR	.....
Rio Grande, PR	.....
San Juan, PR	.....
Toa Alta, PR	.....
Toa Baja, PR	.....
Trujillo Alto, PR	.....
Vega Alta, PR	.....
Vega Baja, PR	.....
Yabucoa, PR	.....
7460 San Luis Obispo-Atascadero-Paso Robles, CA	1.1117
San Luis Obispo, CA	.....
7480 Santa Barbara-Santa Maria-Lompoc, CA	1.0927
Santa Barbara, CA	.....
7485 Santa Cruz-Watsonville, CA	1.4049
Santa Cruz, CA	.....
7490 Santa Fe, NM	1.0312
Los Alamos, NM	.....
Santa Fe, NM	.....
7500 Santa Rosa, CA	1.2727
Sonoma, CA	.....
7510 Sarasota-Bradenton, FL	1.0118
Manatee, FL	.....
Sarasota, FL	.....
7520 Savannah, GA	0.9349
Bryan, GA	.....
Chatham, GA	.....
Effingham, GA	.....
7560 [2] Scranton-Wilkes-Barre-Hazleton, PA	0.8473
Columbia, PA	.....
Lackawanna, PA	.....
Luzerne, PA	.....
Wyoming, PA	.....
7600 [1] Seattle-Bellevue-Everett, WA	1.1056
Island, WA	.....
King, WA	.....
Snohomish, WA	.....
7610 [2] Sharon, PA	0.8473
Mercer, PA	.....
7620 [2] Sheboygan, WI	0.9121
Sheboygan, WI	.....
7640 Sherman-Denison, TX	0.9163
Grayson, TX	.....
7680 Shreveport-Bossier City, LA	0.9165
Bossier, LA	.....
Caddo, LA	.....
Webster, LA	.....
7720 Sioux City, IA–NE	0.8868
Woodbury, IA	.....
Dakota, NE	.....
7760 Sioux Falls, SD	0.9245
Lincoln, SD	.....
Minnehaha, SD	.....
7800 South Bend, IN	1.0303
St. Joseph, IN	.....
7840 Spokane, WA	1.0791
Spokane, WA	.....
7880 Springfield, IL	0.8502
Menard, IL	.....
Sangamon, IL	.....
7920 Springfield, MO	0.8666
Christian, MO	.....
Greene, MO	.....
Webster, MO	.....
8003 [2] Springfield, MA	1.1586
Hampden, MA	.....
Hampshire, MA	.....
8050 State College, PA	0.9239
Centre, PA	.....
8080 [2] Steubenville-Weirton, OH–WV (OH Hospitals)	0.8761
Jefferson, OH	.....
Brooke, WV	.....
Hancock, WV	.....
8080 Steubenville-Weirton, OH–WV (WV Hospitals)	0.8737
Jefferson, OH	.....
Brooke, WV	.....
Hancock, WV	.....
8120 Stockton-Lodi, CA	1.1114
San Joaquin, CA	.....
8140 [2] Sumter, SC	0.8606
Sumter, SC	.....
8160 Syracuse, NY	0.9247
Cayuga, NY	.....
Madison, NY	.....
Onondaga, NY	.....
Oswego, NY	.....
8200 Tacoma, WA	1.1751
Pierce, WA	.....
8240 [2] Tallahassee, FL	0.8733
Gadsden, FL	.....
Leon, FL	.....
8280 [1] Tampa-St. Petersburg-Clearwater, FL	0.9095
Hernando, FL	.....
Hillsborough, FL	.....
Pasco, FL	.....
Pinellas, FL	.....
8320 [2] Terre Haute, IN	0.8757
Clay, IN	.....
Vermillion, IN	.....
Vigo, IN	.....
8360 Texarkana, AR—Texarkana, TX	0.8414
Miller, AR	.....
Bowie, TX	.....
8400 Toledo, OH	0.9815
Fulton, OH	.....
Lucas, OH	.....
Wood, OH	.....
8440 Topeka, KS	0.9015
Shawnee, KS	.....
8480 Trenton, NJ	1.0172
Mercer, NJ	.....
8520 Tucson, AZ	0.9002
Pima, AZ	.....
8560 Tulsa, OK	0.8949
Creek, OK	.....
Osage, OK	.....
Rogers, OK	.....
Tulsa, OK	.....
Wagoner, OK	.....
8600 Tuscaloosa, AL	0.8265
Tuscaloosa, AL	.....
8640 Tyler, TX	0.9109
Smith, TX	.....
8680 [2] Utica-Rome, NY	0.8530
Herkimer, NY	.....
Oneida, NY	.....
8720 Vallejo-Fairfield-Napa, CA	1.3535
Napa, CA	.....
Solano, CA	.....
8735 Ventura, CA	1.1088
Ventura, CA	.....
8750 Victoria, TX	0.8354
Victoria, TX	.....
8760 Vineland-Millville-Bridgeton, NJ	1.0473
Cumberland, NJ	.....
8780 [2] Visalia-Tulare-Porterville, CA	0.9870
Tulare, CA	.....
8800 Waco, TX	0.8268
McLennan, TX	.....
8840 [1] Washington, DC–MD–VA–WV	1.1176
District of Columbia, DC	.....
Calvert, MD	.....
Charles, MD	.....
Frederick, MD	.....
Montgomery, MD	.....
Prince Georges, MD	.....
Alexandria City, VA	.....
Arlington, VA	.....
Clarke, VA	.....
Culpeper, VA	.....
Fairfax, VA	.....
Fairfax City, VA	.....
Falls Church City, VA	.....
Fauquier, VA	.....
Fredericksburg City, VA	.....
King George, VA	.....
Loudoun, VA	.....
Manassas City, VA	.....
Manassas Park City, VA	.....
Prince William, VA	.....
Spotsylvania, VA	.....
Stafford, VA	.....
Warren, VA	.....
Berkeley, WV	.....
Jefferson, WV	.....
8920 Waterloo-Cedar Falls, IA	0.8608
Black Hawk, IA	.....
8940 Wausau, WI	0.9516
Marathon, WI	.....
8960 [1] West Palm Beach-Boca Raton, FL	0.9785
Palm Beach, FL	.....
9000 [2] Wheeling, WV–OH (WV Hospitals)	0.8145
Belmont, OH	.....
Marshall, WV	.....
Ohio, WV	.....
9000 [2] Wheeling, WV–OH (OH Hospitals)	0.8761
Belmont, OH	.....
Marshall, WV	.....
Ohio, WV	.....
9040 Wichita, KS	0.9541
Butler, KS	.....
Harvey, KS	.....
Sedgwick, KS	.....
9080 Wichita Falls, TX	0.8015
Archer, TX	.....
Wichita, TX	.....
9140 Williamsport, PA	0.8503
Lycoming, PA	.....
9160 Wilmington-Newark, DE–MD	1.0757
New Castle, DE	.....

ADDENDUM H.—WAGE INDEX FOR URBAN AREAS—Continued

Urban area (constituent counties)	Wage index
Cecil, MD	.....
9200 Wilmington, NC	0.9971
New Hanover, NC	.....
Brunswick, NC	.....
9260 Yakima, WA	1.0690
Yakima, WA	.....
9270 [2] Yolo, CA	0.9870
Yolo, CA	.....
9280 [2] York, PA	0.8473
York, PA	.....
9320 Youngstown-Warren, OH	0.9480
Columbiana, OH	.....
Mahoning, OH	.....
Trumbull, OH	.....
9340 Yuba City, CA	1.0479
Sutter, CA	.....
Yuba, CA	.....
9360 Yuma, AZ	0.8904
Yuma, AZ	

[1] Large Urban Area.
[2] Hospitals geographically located in the area are assigned the statewide rural wage index for FY 2002.

ADDENDUM I.—WAGE INDEX FOR RURAL AREAS

Nonurban area	Wage index
Alabama	0.7483
Alaska	1.2006
Arizona	0.8747
Arkansas	0.7561
California	0.9870
Colorado	0.8909
Connecticut	1.2357
Delaware	0.9487
Florida	0.8733
Georgia	0.8341
Hawaii	1.1235
Idaho	0.8820
Illinois	0.8140
Indiana	0.8757
Iowa	0.8194
Kansas	0.7850
Kentucky	0.8019
Louisiana	0.7755
Maine	0.8714
Maryland	0.8962
Massachusetts	1.1586
Michigan	0.9115
Minnesota	0.9109
Mississippi	0.7612
Missouri	0.7838
Montana	0.8642
Nebraska	0.8233
Nevada	0.9785
New Hampshire	0.9914
New Jersey [1].	
New Mexico	0.8835
New York	0.8530
North Carolina	0.8632
North Dakota	0.7965
Ohio	0.8761
Oklahoma	0.7646
Oregon	1.0156
Pennsylvania	0.8473
Puerto Rico	0.4654

ADDENDUM I.—WAGE INDEX FOR RURAL AREAS—Continued

Nonurban area	Wage index
Rhode Island [1].	
South Carolina	0.8606
South Dakota	0.7934
Tennessee	0.7901
Texas	0.7673
Utah	0.9156
Vermont	0.9576
Virginia	0.8473
Washington	1.0301
West Virginia	0.8145
Wisconsin	0.9121
Wyoming	0.8855

[1] All counties within the State are classified as urban.

ADDENDUM J.—WAGE INDEX FOR HOSPITALS THAT ARE RECLASSIFIED

Area	Wage index
Abilene, TX	0.8118
Akron, OH	0.9924
Albany, GA	1.0675
Albuquerque, NM	0.9748
Alexandria, LA	0.8137
Allentown-Bethlehem-Easton, PA	0.9443
Altoona, PA	0.9225
Amarillo, TX	0.8485
Anchorage, AK	1.2605
Ann Arbor, MI	1.1220
Anniston, AL	0.7922
Asheville, NC	0.9307
Athens, GA	0.9818
Atlanta, GA	1.0066
Augusta-Aiken, GA–SC	1.0090
Austin-San Marcos, TX	0.9327
Barnstable-Yarmouth, MA	1.3415
Baton Rouge, LA	0.8258
Bellingham, WA	1.1427
Benton Harbor, MI	0.9115
Bergen-Passaic, NJ	1.1669
Billings, MT	0.9623
Biloxi-Gulfport-Pascagoula, MS	0.8198
Binghamton, NY	0.8595
Birmingham, AL	0.8648
Bismarck, ND	0.7965
Bloomington-Normal, IL	0.8545
Boise City, ID	0.9190
Boston-Worcester-Lawrence-Lowell-Brockton, MA–NH	1.1483
Burlington, VT	0.9606
Caguas, PR	0.4993
Casper, WY	0.9454
Champaign-Urbana, IL	0.9264
Charleston-North Charleston, SC	0.9293
Charleston, WV	0.8991
Charlotte-Gastonia-Rock Hill, NC–SC	0.9469
Chattanooga, TN–GA	0.9207
Chicago, IL	1.0887
Cincinnati, OH–KY–IN	0.9574
Clarksville-Hopkinsville, TN–KY	0.8481
Cleveland-Lorain-Elyria, OH	0.9496
Columbia, MO	0.8787
Columbia, SC	0.9264
Columbus, GA–AL	0.8471
Columbus, OH	0.9724
Corpus Christi, TX	0.8203

ADDENDUM J.—WAGE INDEX FOR HOSPITALS THAT ARE RECLASSIFIED—Continued

Area	Wage index
Dallas, TX	0.9506
Davenport-Moline-Rock Island, IA–IL	0.8790
Dayton-Springfield, OH	0.9323
Denver, CO	1.0289
Des Moines, IA	0.8881
Dothan, AL	0.8005
Dover, DE	0.9957
Duluth-Superior, MN–WI	1.0299
Eau Claire, WI	0.9121
Elkhart-Goshen, IN	0.9516
Erie, PA	0.8780
Eugene-Springfield, OR	1.1073
Fargo-Moorhead, ND–MN	0.9247
Fayetteville, NC	0.8970
Flagstaff, AZ–UT	1.0222
Flint, MI	1.0920
Florence, AL	0.7927
Florence, SC	0.8843
Fort Collins-Loveland, CO	1.0161
Ft. Lauderdale, FL	1.0906
Fort Pierce-Port St. Lucie, FL	1.0067
Fort Smith, AR–OK	0.7889
Fort Walton Beach, FL	0.8547
Fort Wayne, IN	0.9059
Forth Worth-Arlington, TX	0.9452
Gadsden, AL	0.8446
Gainesville, FL	1.1855
Grand Forks, ND–MN (ND Hospitals)	0.9022
Grand Forks, ND–MN (MN Hospital)	0.9109
Grand Junction, CO	0.9816
Grand Rapids-Muskegon-Holland, MI	1.0052
Great Falls, MT	0.9301
Greeley, CO	0.9604
Green Bay, WI	0.9440
Greensboro-Winston-Salem-High Point, NC	0.9474
Greenville, NC	0.9751
Greenville-Spartanburg-Anderson, SC	0.9110
Harrisburg-Lebanon-Carlisle, PA	0.9068
Hartford, CT	1.1586
Hattiesburg, MS	0.7612
Hickory-Morganton-Lenoir, NC	0.9517
Honolulu, HI	1.1658
Houston, TX	0.9604
Huntington-Ashland, WV–KY–OH	0.9286
Huntsville, AL	0.8657
Indianapolis, IN	0.9666
Iowa City, IA	0.9820
Jackson, MS	0.8589
Jackson, TN	0.8945
Jacksonville, FL	0.9040
Johnson City-Kingsport-Bristol, TN–VA	0.8540
Jonesboro, AR	0.8093
Joplin, MO	0.8560
Kalamazoo-Battlecreek, MI	1.0537
Kansas City, KS–MO	0.9430
Knoxville, TN	0.8904
Kokomo, IN	0.9290
Lafayette, LA	0.8430
Lansing-East Lansing, MI	0.9653
Las Vegas, NV–AZ	1.1238
Lawton, OK	0.8372
Lexington, KY	0.8675

ADDENDUM J.—WAGE INDEX FOR HOSPITALS THAT ARE RECLASSIFIED—Continued

Area	Wage index
Lima, OH	0.9558
Lincoln, NE	0.9945
Little Rock-North Little Rock, AR	0.8938
Longview-Marshall, TX	0.8439
Los Angeles-Long Beach, CA	1.2071
Louisville, KY–IN	0.9481
Lubbock, TX	0.8547
Lynchburg, VA	0.8897
Macon, GA	0.9077
Madison, WI	1.0462
Mansfield, OH	0.8827
Medford-Ashland, OR	1.0156
Melbourne-Titusville-Palm Bay, FL	0.9883
Memphis, TN–AR–MS	0.9152
Miami, FL	0.9934
Milwaukee-Waukesha, WI	0.9898
Minneapolis-St. Paul, MN–WI	1.1000
Missoula, MT	0.9273
Mobile, AL	0.7766
Modesto, CA	1.0945
Monmouth-Ocean, NJ	1.1514
Monroe, LA	0.8191
Montgomery, AL	0.7502
Myrtle Beach, SC	0.8663
Nashville, TN	0.9433
New Haven-Bridgeport-Stamford-Waterbury-Danbury, CT	1.2357
New London-Norwich, CT	1.1578
New Orleans, LA	0.9054
New York, NY	1.3923
Newark, NJ	1.2004
Newburgh, NY–PA	1.0838
Norfolk-Virginia Beach-Newport News, VA–NC	0.8632
Oakland, CA	1.5313
Odessa-Midland, TX (TX Hospitals)	0.8769
Odessa-Midland, TX (NM Hospitals)	0.8835
Oklahoma City, OK	0.8728
Omaha, NE–IA	0.9696
Orange County, CA	1.1354
Orlando, FL	0.9464

ADDENDUM J.—WAGE INDEX FOR HOSPITALS THAT ARE RECLASSIFIED—Continued

Area	Wage index
Peoria-Pekin, IL	0.8883
Philadelphia, PA–NJ	1.0626
Pine Bluff, AR	0.7837
Pittsburgh, PA	0.9550
Pittsfield, MA	1.0018
Pocatello, ID	0.9264
Portland, ME	0.9501
Portland-Vancouver, OR–WA	1.1291
Provo-Orem, UT	0.9840
Raleigh-Durham-Chapel Hill, NC	0.9901
Rapid City, SD	0.8849
Reading, PA	0.8473
Redding, CA	1.1222
Reno, NV	1.0456
Richland-Kennewick-Pasco, WA	1.0478
Richmond-Petersburg, VA	0.9712
Roanoke, VA	0.8468
Rochester, MN	1.1595
Rockford, IL	0.9080
Sacramento, CA	1.1809
Saginaw-Bay City-Midland, MI	0.9662
St. Cloud, MN	1.0040
St. Joseph, MO	0.8953
St. Louis, MO–IL	0.8911
Salinas, CA	1.4738
Salt Lake City-Ogden, UT	0.9976
San Diego, CA	1.1480
Santa Fe, NM	1.0013
Santa Rosa, CA	1.2408
Sarasota-Bradenton, FL	1.0118
Savannah, GA	0.9349
Seattle-Bellevue-Everett, WA	1.1056
Sherman-Denison, TX	0.8899
Shreveport-Bossier City, LA	0.9165
Sioux City, IA–NE	0.8868
Sioux Falls, SD	0.9037
South Bend, IN	1.0176
Spokane, WA	1.0663
Springfield, IL	0.8502
Springfield, MO	0.8454
Stockton-Lodi, CA	1.1114
Syracuse, NY	0.9247

ADDENDUM J.—WAGE INDEX FOR HOSPITALS THAT ARE RECLASSIFIED—Continued

Area	Wage index
Tampa-St. Petersburg-Clearwater, FL	0.9095
Texarkana, AR—Texarkana, TX	0.8414
Toledo, OH	0.9815
Topeka, KS	0.8850
Tucson, AZ	0.9002
Tulsa, OK	0.8815
Tuscaloosa, AL	0.8265
Tyler, TX	0.8905
Victoria, TX	0.8212
Waco, TX	0.8268
Washington, DC–MD–VA–WV	1.1024
Waterloo-Cedar Falls, IA	0.8608
Wausau, WI	0.9516
West Palm Beach-Boca Raton, FL	0.9785
Wichita, KS	0.9218
Wichita Falls, TX	0.8015
Wilmington-Newark, DE–MD	1.0757
Rural Alabama	0.7483
Rural Florida	0.8733
Rural Illinois (IA Hospital)	0.8194
Rural Illinois (MO Hospital)	0.8140
Rural Kentucky	0.8019
Rural Louisiana	0.7755
Rural Michigan	0.9115
Rural Minnesota	0.9109
Rural Missouri (AK Hospital)	0.7838
Rural Missouri (KS Hospital)	0.7850
Rural Montana	0.8642
Rural Nebraska	0.8233
Rural Nevada	0.9219
Rural Oregon	1.0156
Rural Texas	0.7673
Rural Washington	1.0301
Rural Wisconsin	0.9121
Rural Wyoming	0.8855

[FR Doc. 01–21213 Filed 8–20–01; 10:08 am]

BILLING CODE 4120–01–P

Federal Register

Friday,
August 24, 2001

Part III

Department of Housing and Urban Development

Federal Property Suitable as Facilities To Assist the Homeless; Notice

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR–4644–N–34]

Federal Property Suitable as Facilities To Assist the Homeless

AGENCY: Office of the Assistant Secretary for Community Planning and Development, HUD.

ACTION: Notice.

SUMMARY: This Notice identifies unutilized, underutilized, excess, and surplus Federal property reviewed by HUD for suitability for possible use to assist the homeless.

FOR FURTHER INFORMATION CONTACT: Clifford Taffet, room 7266, Department of Housing and Urban Development, 451 Seventh Street SW., Washington, DC 20410; telephone (202) 708–1234; TTY number for the hearing- and speech-impaired (202) 708–2565 (these telephone numbers are not toll-free), or call the toll-free Title V information line at 1–800–927–7588.

SUPPLEMENTARY INFORMATION: In accordance with 24 CFR part 581 and section 501 of the Stewart B. McKinney Homeless Assistance Act (42 U.S.C. 11411), as amended, HUD is publishing this Notice to identify Federal buildings and other real property that HUD has reviewed for suitability for use to assist the homeless. The properties were reviewed using information provided to HUD by Federal landholding agencies regarding unutilized and underutilized buildings and real property controlled by such agencies or by GSA regarding its inventory of excess or surplus Federal property. This Notice is also published in order to comply with the December 12, 1988 Court Order in *National Coalition for the Homeless* v. *Veterans Administration*, No. 88–2503–OG (D.D.C.).

Properties reviewed are listed in this Notice according to the following categories: Suitable/available, suitable/unavailable, suitable/to be excess, and unsuitable. The properties listed in the three suitable categories have been reviewed by the landholding agencies, and each agency has transmitted to HUD: (1) Its intention to make the property available for use to assist the homeless, (2) its intention to declare the property excess to the agency's needs, or (3) a statement of the reasons that the property cannot be declared excess or made available for use as facilities to assist the homeless.

Properties listed as suitable/available will be available exclusively for homeless use for a period of 60 days from the date of this Notice. Homeless assistance providers interested in any such property should send a written expression of interest to HHS, addressed to Brian Rooney, Division of Property Management, Program Support Center, HHS, room 5B–41, 5600 Fishers Lane, Rockville, MD 20857; (301) 443–2265. (This is not a toll-free number.) HHS will mail to the interested provider an application packet, which will include instructions for completing the application. In order to maximize the opportunity to utilize a suitable property, providers should submit their written expressions of interest as soon as possible. For complete details concerning the processing of applications, the reader is encouraged to refer to the interim rule governing this program, 24 CFR part 581.

For properties listed as suitable/to be excess, that property may, if subsequently accepted as excess by GSA, be made available for use by the homeless in accordance with applicable law, subject to screening for other Federal use. At the appropriate time, HUD will publish the property in a Notice showing it as either suitable/available or suitable/unavailable.

For properties listed as suitable/unavailable, the landholding agency has decided that the property cannot be declared excess or made available for use to assist the homeless, and the property will not be available.

Properties listed as unsuitable will not be made available for any other purpose for 20 days from the date of this Notice. Homeless assistance providers interested in a review by HUD of the determination of unsuitability should call the toll free information line at 1–800–927–7588 for detailed instructions or write a letter to Clifford Taffet at the address listed at the beginning of this Notice. Included in the request for review should be the property address (including zip code), the date of publication in the **Federal Register**, the landholding agency, and the property number.

For more information regarding particular properties identified in this Notice (*i.e.*, acreage, floor plan, existing sanitary facilities, exact street address), providers should contact the appropriate landholding agencies at the following addresses: ARMY: Mr. Jeff Holste, Military Programs, U.S. Army Corps of Engineers, Installation Support Center, Planning Branch, Attn: CEMP–IP, 441 G Street, NW., Washington, DC 20314–1000; (202) 761–5737; (These are not toll-free numbers).

Dated: August 16, 2001.

John D. Garrity,

Director, Office of Special Needs Assistance Programs.

TITLE V, FEDERAL SURPLUS PROPERTY PROGRAM FEDERAL REGISTER REPORT FOR 8/24/01

Suitable/Available Properties

Buildings (by State)

Alabama

Bldg. 60101
Shell Army Heliport
Ft. Rucker Co: Dale AL 36362–5000
Landholding Agency: Army
Property Number: 21199520152
Status: Unutilized
Comment: 6082 sq. ft., 1-story, most recent use—airfield fire station, off-site use only

Bldg. 60103
Shell Army Heliport
Ft. Rucker Co: Dale AL 36362–5000
Landholding Agency: Army
Property Number: 21199520154
Status: Unutilized
Comment: 12516 sq. ft., 2-story, most recent use—admin., off-site use only

Bldg. 60110
Shell Army Heliport
Ft. Rucker Co: Dale AL 36362–5000
Landholding Agency: Army
Property Number: 21199520155
Status: Unutilized
Comment: 8319 sq. ft., 1-story, most recent use—admin., off-site use only

Bldg. 60113
Shell Army Heliport
Ft. Rucker Co: Dale AL 36362–5000
Landholding Agency: Army
Property Number: 21199520156
Status: Unutilized
Comment: 4000 sq. ft., 1-story, most recent use—admin., off-site use only

Alaska

Bldgs. 09100, 09104–09106
Fort Richardson
Ft. Richardson Co: AK 99505–6500
Landholding Agency: Army
Property Number: 21200020158
Status: Unutilized
Comment: various sq. ft., concrete, most recent use—hazard bldg., off-site use only

5 Bldgs.
Fort Richardson
09108, 09110–09112, 09114
Ft. Richardson Co: AK 99505–6500
Landholding Agency: Army
Property Number: 21200020159
Status: Unutilized
Comment: various sq. ft., concrete, most recent use—hazard bldg., off-site use only

Bldgs. 09128, 09129 Fort Richardson
Ft. Richardson Co: AK 99505–6500
Landholding Agency: Army
Property Number: 21200020160
Status: Unutilized
Comment: various sq. ft., concrete, most recent use—hazard bldg., off-site use only

Bldgs. 09151, 09155, 09156 Fort Richardson
Ft. Richardson Co: AK 99505–6500
Landholding Agency: Army
Property Number: 21200020161
Status: Unutilized

Comment: various sq. ft., concrete, most recent use—hazard bldg., off-site use only

Bldg. 09158
Fort Richardson
Ft. Richardson Co: AK 99505–6500
Landholding Agency: Army
Property Number: 21200020162
Status: Unutilized
Comment: 672 sq. ft., most recent use—storage shed, off-site use only

Bldgs. 09160–09162
Fort Richardson
Ft. Richardson Co: AK 99505–6500
Landholding Agency: Army
Property Number: 21200020163
Status: Unutilized
Comment: 11520 sq. ft., concrete, most recent use—NCO–ENL FH, off-site use only

Bldgs. 09164, 09165
Fort Richardson
Ft. Richardson Co: AK 99505–6500
Landholding Agency: Army
Property Number: 21200020164
Status: Unutilized
Comment: 2304 & 2880 sq. ft., most recent use—storage, off-site use only

Bldg. 10100
Fort Richardson
Ft. Richardson Co: AK 99505–6500
Landholding Agency: Army
Property Number: 21200020165
Status: Unutilized
Comment: 4688 sq. ft., concrete, most recent use—hazard bldg., off-site use only

Bldg. 00390
Fort Richardson
Ft. Richardson Co: AK 99505–
Landholding Agency: Army
Property Number: 21200030067
Status: Excess
Comment: 13,632 sq. ft., off-site use only

Bldgs. 01200, 01202
Fort Richardson
Ft. Richardson Co: AK 99505–
Landholding Agency: Army
Property Number: 21200030068
Status: Excess
Comment: 4508 & 6366 sq. ft., most recent use—hazard bldg., off-site use only

Bldg. 01204
Fort Richardson
Ft. Richardson Co: AK 99505–
Landholding Agency: Army
Property Number: 21200030069
Status: Excess
Comment: 5578 sq. ft., most recent use—VOQ transient, off-site use only

Bldgs. 01205–01207
Fort Richardson
Ft. Richardson Co: AK 99505–
Landholding Agency: Army
Property Number: 21200030070
Status: Excess
Comment: various sq. ft., most recent use—hazard bldg., off-site use only

Bldgs. 01208, 01210, 01212
Fort Richardson
Ft. Richardson Co: AK 99505–
Landholding Agency: Army
Property Number: 21200030071
Status: Excess
Comment: various sq ft., most recent use—hazard bldg., off-site use only

Bldgs. 01213, 01214
Fort Richardson
Ft. Richardson Co: AK 99505–
Landholding Agency: Army
Property Number: 21200030072
Status: Excess
Comment: 11964 & 13740 sq. ft., most recent use—transient UPH, off-site use only

Bldgs. 01218, 01230
Fort Richardson
Ft. Richardson Co: AK 99505–
Landholding Agency: Army
Property Number: 21200030073
Status: Excess
Comment: 480 & 188 sq. ft., most recent use—hazard bldgs., off-site use only

Bldgs. 01231, 01232
Fort Richardson
Ft. Richardson Co: AK 99505–
Landholding Agency: Army
Property Number: 21200030074
Status: Excess
Comment: 458 & 4260 sq. ft., most recent use—hazard bldgs., off-site use only

Bldg. 01234
Fort Richardson
Ft. Richardson Co: AK 99505–
Landholding Agency: Army
Property Number: 21200030075
Status: Excess
Comment: 615 sq. ft., most recent use—admin., off-site use only

Bldg. 01237
Fort Richardson
Ft. Richardson Co: AK 99505–
Landholding Agency: Army
Property Number: 21200030076
Status: Excess
Comment: 408 sq. ft., most recent use—fuel/pol bldg., off-site use only

Bldg. 01272
Fort Richardson
Ft. Richardson Co: AK 99505–
Landholding Agency: Army
Property Number: 21200030077
Status: Excess
Comment: 308 sq. ft., most recent use—storage, off-site use only

Bldg. 08109
Fort Richardson
Ft. Richardson Co: AK 99505–
Landholding Agency: Army
Property Number: 21200030080
Status: Excess
Comment: 1920 sq. ft., most recent use—storage, off-site use only

Bldg. 21001
Fort Richardson
Ft. Richardson Co: AK 99505–
Landholding Agency: Army
Property Number: 21200030081
Status: Excess
Comment: 3200 sq. ft., most recent use—family housing, off-site use only

Bldg. 22001
Fort Richardson
Ft. Richardson Co: AK 99505–
Landholding Agency: Army
Property Number: 21200030082
Status: Excess
Comment: 1448 sq. ft., most recent use—family housing, off-site use only

Bldg. 22002
Fort Richardson
Ft. Richardson Co: AK 99505–
Landholding Agency: Army
Property Number: 21200030083
Status: Excess
Comment: 1508 sq. ft., most recent use—family housing, off-site use only

Armory
NG Noorvik
Noorvik Co: AK 99763–
Landholding Agency: Army
Property Number: 21200110075
Status: Unutilized
Comment: 1200 sq. ft., most recent use—armory, off-site use only

Bldg. 00229
Fort Richardson
Ft. Richardson Co: AK 99505–6500
Landholding Agency: Army
Property Number: 21200120085
Status: Excess
Comment: 13,056 sq. ft., off-site use only

Arizona

Bldg. 30012, Fort Huachuca
Sierra Vista Co: Cochise AZ 85635–
Landholding Agency: Army
Property Number: 21199310298
Status: Excess
Comment: 237 sq. ft., 1-story block, most recent use—storage

Bldg. S–306
Yuma Proving Ground
Yuma Co: Yuma/La Paz AZ 85365–9104
Landholding Agency: Army
Property Number: 21199420346
Status: Unutilized
Comment: 4103 sq. ft., 2-story, needs major rehab, off-site use only

Bldg. 503, Yuma Proving Ground
Yuma Co: Yuma AZ 85365–9104
Landholding Agency: Army
Property Number: 21199520073
Status: Underutilized
Comment: 3789 sq. ft., 2-story, major structural changes required to meet floor loading & fire code requirements, presence of asbestos, off-site use only

Bldgs. 12521, 13572
Fort Huachuca
Sierra Vista Co: Cochise AZ 85635–
Landholding Agency: Army
Property Number: 21199920183
Status: Unutilized
Comment: 448 sq. ft. & 54 sq. ft., off-site use only

Bldg. 72908
Fort Huachuca
Sierra Vista Co: Cochise AZ 85635–
Landholding Agency: Army
Property Number: 21200010079
Status: Unutilized
Comment: 16,491 sq. ft., presence of asbestos/lead paint, most recent use—veh. maint., off-site use only

Bldg. 63001
Fort Huachuca
Sierra Vista Co: Cochise AZ 85635–
Landholding Agency: Army
Property Number: 21200010080
Status: Unutilized
Comment: 2280 sq. ft., presence of asbestos/lead paint, most recent use—admin., off-site use only

2 Bldgs.
Fort Huachuca
Sierra Vista Co: Cochise AZ 85635–

Location: 15542, 15546
Landholding Agency: Army
Property Number: 21200010082
Status: Unutilized
Comment: 552 & 400 sq. ft., presence of asbestos/lead paint, most recent use—restrooms, off-site use only

2 Bldgs.
Fort Huachuca
Sierra Vista Co: Cochise AZ 85635–
Location: 15544, 15552
Landholding Agency: Army
Property Number: 21200010083
Status: Unutilized
Comment: 9713 & 2895 sq. ft., presence of asbestos/lead paint, most recent use—classrooms, off-site use only

Bldg. 15543
Fort Huachuca
Sierra Vista Co: Cochise AZ 85635–
Landholding Agency: Army
Property Number: 21200010084
Status: Unutilized
Comment: 416 sq. ft., presence of asbestos/lead paint, most recent use—rec. shelter, off-site use only

34 Bldgs.
Fort Huachuca
62001–62022, 64001–64012
Sierra Vista Co: Cochise AZ 85635–
Landholding Agency: Army
Property Number: 21200020166
Status: Unutilized
Comment: 658 & 587 sq. ft., presence of asbestos/lead paint, most recent use—one bedroom family housing, off-site use only

22 Bldgs.
Fort Huachuca
Sierra Vista Co: Cochise AZ 85635–
Location: #63002–63018, 64014–64018
Landholding Agency: Army
Property Number: 21200110076
Status: Excess
Comment: 2 & 3 bedroom family housing, presence of asbestos/lead paint, off-site use only

Bldg. 76910
Fort Huachuca
Sierra Vista Co: Cochise AZ 85635–
Landholding Agency: Army
Property Number: 21200110077
Status: Excess
Comment: 2001 sq. ft., presence of asbestos/lead paint, most recent use—office, off-site use only

Bldg. 22523
Fort Huachuca
Sierra Vista Co: Cochise AZ 85613–
Landholding Agency: Army
Property Number: 21200120086
Status: Excess
Comment: 63 sq ft., most recent use—storage, off-site use only

California

Bldg. 104
Presidio of Monterey
Monterey Co: CA 93944–
Landholding Agency: Army
Property Number: 21199910088
Status: Unutilized
Comment: 8039 sq. ft., presence of asbestos/lead paint, most recent use—office, off-site use only

Bldg. 106
Presidio of Monterey
Monterey Co: CA 93944–
Landholding Agency: Army
Property Number: 21199910089
Status: Unutilized
Comment: 1950 sq. ft., presence of asbestos/lead paint, most recent use—office/storage, off-site use only

Bldg. 125
Presidio of Monterey
Monterey Co: CA 93944–
Landholding Agency: Army
Property Number: 21199910090
Status: Unutilized
Comment: 371 sq. ft., presence of asbestos/lead paint, most recent use—office, off-site use only

Bldg. 340
Presidio of Monterey
Monterey Co: CA 93944–
Landholding Agency: Army
Property Number: 21199910093
Status: Unutilized
Comment: 6500 sq. ft., presence of asbestos/lead paint, most recent use—office, off-site use only

Bldg. 341
Presidio of Monterey
Monterey Co: CA 93944–
Landholding Agency: Army
Property Number: 21199910094
Status: Unutilized
Comment: 371 sq ft., presence of asbestos/lead paint, most recent use—office, off-site use only

Bldg. 4214
Presidio of Monterey
Monterey Co: CA 93944–
Landholding Agency: Army
Property Number: 21199910095
Status: Unutilized
Comment: 3168 sq. ft., presence of asbestos/lead paint, most recent use—office, off-site use only

Bldgs. 204–207, 517
Presidio of Monterey
Monterey Co: CA 93944–5006
Landholding Agency: Army
Property Number: 21200020167
Status: Unutilized
Comment: 4780 & 10950 sq. ft., presence of asbestos/lead paint, most recent use—classroom/admin/storage, off-site use only

Bldg. S251
Army Reserve
6357 Woodly Ave.
Van Nuys Co: Los Angeles CA 91406–6496
Landholding Agency: Army
Property Number: 21200040043
Status: Excess
Comment: 800 sq. ft., needs repair, presence of asbestos, most recent use—storage, off-site use only

Georgia

Bldg. 2285
Fort Benning
Fort Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199011704
Status: Unutilized
Comment: 4574 sq. ft.; most recent use—clinic; needs substantial rehabilitation; 1 floor.

Bldg. 1252, Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199220694
Status: Unutilized
Comment: 583 sq. ft., 1 story, most recent use—storehouse, needs major rehab, off-site removal only.

Bldg. 4881, Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199220707
Status: Unutilized
Comment: 2449 sq. ft., 1 story, most recent use—storehouse, need repairs, off-site removal only.

Bldg. 4963, Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199220710
Status: Unutilized
Comment: 6077 sq. ft., 1 story, most recent use—storehouse, need repairs, off-site removal only.

Bldg. 2396, Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199220712
Status: Unutilized
Comment: 9786 sq. ft., 1 story, most recent use—dining facility, needs major rehab, off-site removal only

Bldg. 4882, Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199220727
Status: Unutilized
Comment: 6077 sq. ft., 1 story, most recent use—storage, need repairs, off-site removal only

Bldg. 4967, Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199220728
Status: Unutilized
Comment: 6077 sq. ft., 1 story, most recent use—storage, need repairs, off-site removal only

Bldg. 4977, Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199220736
Status: Unutilized
Comment: 192 sq. ft., 1 story, most recent use—offices, need repairs, off-site removal only

Bldg. 4944, Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199220747
Status: Unutilized
Comment: 6400 sq. ft., 1 story, most recent use—vehicle maintenance shop, need repairs, off-site removal only

Bldg. 4960, Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199220752
Status: Unutilized
Comment: 3335 sq. ft., 1 story, most recent use—vehicle maintenance shop, off-site removal only

Bldg. 4969, Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army

Property Number: 21199220753
Status: Unutilized
Comment: 8416 sq. ft., 1 story, most recent use—vehicle maintenance shop, off-site removal only

Bldg. 4884, Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199220762
Status: Unutilized
Comment: 2000 sq. ft., 1 story, most recent use—headquarters bldg., need repairs, off-site removal only

Bldg. 4964, Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199220763
Status: Unutilized
Comment: 2000 sq. ft., 1 story, most recent use—headquarters bldg., need repairs, off-site removal only

Bldg. 4966, Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199220764
Status: Unutilized
Comment: 2000 sq. ft., 1 story, most recent use—headquarters bldg., need repairs, off-site removal only

Bldg. 4965, Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199220769
Status: Unutilized
Comment: 7713 sq. ft., 1 story, most recent use—supply bldg., need repairs, off-site removal only

Bldg. 4945, Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199220779
Status: Unutilized
Comment: 220 sq. ft., 1 story, most recent use—gas station, needs major rehab, off-site removal only

Bldg. 4979, Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199220780
Status: Unutilized
Comment: 400 sq. ft., 1 story, most recent use—oil house, need repairs, off-site removal only

Bldg. 4023, Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199310461
Status: Unutilized
Comment: 2269 sq. ft., 1-story, needs rehab, most recent use—maintenance shop, off-site use only

Bldg. 4024, Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199310462
Status: Unutilized
Comment: 3281 sq. ft., 1-story, needs rehab, most recent use—maintenance shop, off-site use only

Bldg. 4067, Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199310465
Status: Unutilized
Comment: 4406 sq. ft., 1-story, needs rehab, most recent use—admin. off-site use only

Bldg. 11813
Fort Gordon
Fort Gordon Co: Richmond GA 30905–
Landholding Agency: Army
Property Number: 21199410269
Status: Unutilized
Comment: 70 sq. ft.; 1 story; metal; needs rehab.; most recent use—storage; off-site use only

Bldg. 21314
Fort Gordon
Fort Gordon Co: Richmond GA 30905–
Landholding Agency: Army
Property Number: 21199410270
Status: Unutilized
Comment: 85 sq. ft.; 1 story; needs rehab.; most recent use—storage; off-site use only

Bldg. 12809
Fort Gordon
Fort Gordon Co: Richmond GA 30905–
Landholding Agency: Army
Property Number: 21199410272
Status: Unutilized
Comment: 2788 sq. ft.; 1 story; wood; needs rehab.; most recent use—maintenance shop; off-site use only

Bldg. 10306
Fort Gordon
Fort Gordon Co: Richmond GA 30905–
Landholding Agency: Army
Property Number: 21199410273
Status: Unutilized
Comment: 195 sq. ft.; 1 story; wood; most recent use—oil storage shed; off-site use only

Bldg 4051, Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199520175
Status: Unutilized
Comment: 967 sq. ft., 1-story, needs rehab, most recent use—storage, off-site use only

Bldg. 2141
Fort Gordon
Ft. Gordon Co: Richmond GA 30905–
Landholding Agency: Army
Property Number: 21199610655
Status: Unutilized
Comment: 2283 sq. ft., needs repair, most recent use—office, off-site use only

Bldg. 322
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199720156
Status: Unutilized
Comment: 9600 sq. ft., needs rehab, most recent use—admin., off-site use only

Bldg. 1737
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199720161
Status: Unutilized
Comment: 1500 sq. ft., needs rehab, most recent use—storage, off-site use only

Bldg. 2593
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199720167
Status: Unutilized
Comment: 13644 sq. ft., needs rehab, most recent use—parachute shop, off-site use only

Bldg. 2595
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199720168
Status: Unutilized
Comment: 3356 sq. ft., needs rehab, most recent use—chapel, off-site use only

Bldgs. 2865, 2869, 2872
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199720169
Status: Unutilized
Comment: approx. 1100 sq. ft. each, needs rehab, most recent use—shower fac., off-site use only

Bldg. 4476
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199720184
Status: Unutilized
Comment: 3148 sq. ft., needs rehab, most recent use—vehicle maint. shop, off-site use only

8 Bldgs.
Fort Benning
4700–4701, 4704–4707, 4710–4711
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199720189
Status: Unutilized
Comment: 6433 sq. ft. each, needs rehab, most recent use—unaccompanied personnel housing, off-site use only

Bldg. 4714
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199720191
Status: Unutilized
Comment: 1983 sq. ft., needs rehab, most recent use—battalion headquarters bldg., off-site use only

Bldg. 4702
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199720192
Status: Unutilized
Comment: 3690 sq. ft., needs rehab, most recent use—dining facility off-site use only

Bldgs. 4712–4713
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199720193
Status: Unutilized
Comment: 1983 sq. ft. and 10270 sq. ft., needs rehab, most recent use—company headquarters bldg., off-site use only

Bldg. 305
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199810268
Status: Unutilized
Comment: 4083 sq. ft., most recent use—recreation center, off-site use only

Bldg. 318

Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199810269
Status: Unutilized
Comment: 374 sq. ft., poor condition, most recent use—maint. shop, off-site use only

Bldg. 1792
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199810274
Status: Unutilized
Comment: 10,200 sq. ft., most recent use—storage, off-site use only

Bldg. 1836
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199810276
Status: Unutilized
Comment: 2998 sq. ft., most recent use—admin., off-site use only

Bldg. 4373
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199810286
Status: Unutilized
Comment: 409 sq. ft., poor condition, most recent use—station bldg. off-site use only

Bldg. 4628
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199810287
Status: Unutilized
Comment: 5483 sq. ft., most recent use—admin., off-site use only

Bldg. 92
Fort Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199830278
Status: Unutilized
Comment: 637 sq. ft., needs rehab, most recent use—admin., off-site use only

Bldg. 2445
Fort Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199830279
Status: Unutilized
Comment: 2385 sq. ft., needs rehab, most recent use—fire station, off-site use only

Bldg. 4232
Fort Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199830291
Status: Unutilized
Comment: 3720 sq. ft., needs rehab, most recent use—maint. bay, off-site use only

Bldg. 39720
Fort Gordon
Ft. Gordon Co: Richmond GA 30905–
Landholding Agency: Army
Property Number: 21199930119
Status: Unutilized
Comment: 1520 sq. ft., concrete block, possible asbestos/lead paint, most recent use—office, off-site use only

Bldg. 492
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199930120
Status: Unutilized
Comment: 720 sq. ft., most recent use—admin/maint, off-site use only

Bldg. 880
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199930121
Status: Unutilized
Comment: 57,110 sq. ft., most recent use—instruction, off-site use only

Bldg. 1370
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199930122
Status: Unutilized
Comment: 5204 sq. ft., most recent use—hdqts. bldg., off-site use only

Bldg. 2288
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199930123
Status: Unutilized
Comment: 2481 sq. ft., most recent use—admin., off-site use only

Bldg. 2290
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199930124
Status: Unutilized
Comment: 455 sq. ft., most recent use—storage, off-site use only

Bldg. 2293
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199930125
Status: Unutilized
Comment: 2600 sq. ft., most recent use—hdqts. bldg., off-site use only

Bldg. 2297
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199930126
Status: Unutilized
Comment: 5156 sq. ft., most recent use—admin.

Bldg. 2505
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199930127
Status: Unutilized
Comment: 10,257 sq. ft., most recent use—repair shop, off-site use only

Bldg. 2508
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199930128
Status: Unutilized
Comment: 2434 sq. ft., most recent use—storage, off-site use only

Bldg. 2815
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199930129
Status: Unutilized
Comment: 2578 sq. ft., most recent use—hdqts. bldg., off-site use only

Bldg. 3815
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199930130
Status: Unutilized
Comment: 7575 sq. ft., most recent use—storage, off-site use only

Bldg. 3816
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199930131
Status: Unutilized
Comment: 7514 sq. ft., most recent use—storage, off-site use only

Bldg. 5886
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199930134
Status: Unutilized
Comment: 67 sq. ft., most recent use—maint/storage, off-site use only

Bldgs. 5974–5978
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199930135
Status: Unutilized
Comment: 400 sq. ft., most recent use—storage, off-site use only

Bldg. 5993
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199930136
Status: Unutilized
Comment: 960 sq. ft., most recent use—storage, off-site use only

Bldg. 5994
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199930137
Status: Unutilized
Comment: 2016 sq. ft., most recent use—storage, off-site use only

Bldg. 2214
Fort Gordon
Ft. Gordon Co: Richmond GA 30905–
Landholding Agency: Army
Property Number: 21200020171
Status: Unutilized
Comment: 13,508 sq. ft., possible asbestos/lead paint, most recent use—storage/admin., off-site use only

Bldg. 2233
Fort Gordon
Ft. Gordon Co: Richmond GA 30905–
Landholding Agency: Army
Property Number: 21200020172
Status: Unutilized
Comment: 1720 sq. ft., possible asbestos/lead paint, most recent use—admin., off-site use only

Bldg. T–1003
Fort Stewart
Hinesville Co: Liberty GA 31514–
Landholding Agency: Army
Property Number: 21200030085
Status: Excess
Comment: 9267 sq. ft., poor condition, most recent use—admin., off-site use only

Bldgs. T–1005, T–1006, T–1007
Fort Stewart
Hinesville Co: Liberty GA 31514–
Landholding Agency: Army
Property Number: 21200030086
Status: Excess
Comment: 9267 sq. ft., poor condition, most recent use—storage, off-site use only

Bldgs. T–1015, T–1016, T–1017
Fort Stewart
Hinesville Co: Liberty GA 31514–
Landholding Agency: Army
Property Number: 21200030087
Status: Excess
Comment: 7496 sq ft., poor condition, most recent use—storage, off-site use only

Bldgs. T–1018, T–1019
Fort Stewart
Hinesville Co: Liberty GA 31514–
Landholding Agency: Army
Property Number: 21200030088
Status: Excess
Comment: 9267 sq. ft., poor condition, most recent use—storage, off-site use only

Bldgs. T–1020, T–1021
Fort Stewart
Hinesville Co: Liberty GA 31514–
Landholding Agency: Army
Property Number: 21200030089
Status: Excess
Comment: 9267 sq. ft., poor condition, most recent use—storage, off-site use only

Bldg. T–1022
Fort Stewart
Hinesville Co: Liberty GA 31514–
Landholding Agency: Army
Property Number: 21200030090
Status: Excess
Comment: 9267 sq. ft., poor condition, most recent use—supply center, off-site use only

Bldg. T–1027
Fort Stewart
Hinesville Co: Liberty GA 31514–
Landholding Agency: Army
Property Number: 21200030091
Status: Excess
Comment: 9024 sq ft., poor condition, most recent use—storage, off-site use only

Bldg. T–1028
Fort Stewart
Hinesville Co: Liberty GA 31514–
Landholding Agency: Army
Property Number: 21200030092
Status: Excess
Comment: 7496 sq. ft., poor condition, most recent use—storage, off-site use only

Bldgs. T–1035, T–1036, T–1037
Fort Stewart
Hinesville Co: Liberty GA 31514–
Landholding Agency: Army
Property Number: 21200030093
Status: Excess
Comment: 1626 sq ft., poor condition, most recent use—storage, off-site use only

Bldgs. T–1038, T–1039
Fort Stewart
Hinesville Co: Liberty GA 31514–
Landholding Agency: Army
Property Number: 21200030094
Status: Excess
Comment: 1626 sq. ft., poor condition, most recent use—storage, off-site use only

Bldgs. T–1040, T–1042
Fort Stewart
Hinesville Co: Liberty GA 31514–
Landholding Agency: Army
Property Number: 21200030095
Status: Excess
Comment: 1626 sq. ft., poor condition, most recent use—storage, off-site use only

Bldgs. T–1086, T–1087, T–1088
Fort Stewart
Hinesville Co: Liberty GA 31514–
Landholding Agency: Army
Property Number: 21200030096
Status: Excess
Comment: 7680 sq. ft., poor condition, most recent use—storage, off-site use only

Bldg. P–7751
Fort Stewart
Hinesville Co: Liberty GA 31514–
Landholding Agency: Army
Property Number: 21200030097
Status: Excess
Comment: 192 sq. ft., poor condition, off-site use only

Bldg. 223
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21200040044
Status: Unutilized
Comment: 21,556 sq. ft., most recent use—gen. purpose

Bldg. 228
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21200040045
Status: Unutilized
Comment: 20,220 sq. ft., most recent use—gen. purpose

Bldg. 2051
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21200040046
Status: Unutilized
Comment: 6077 sq. ft., most recent use—storage

Bldg. 2053
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21200040047
Status: Unutilized
Comment: 14,520 sq. ft., most recent use—storage

Bldg. 2677
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21200040048
Status: Unutilized
Comment: 19,326 sq. ft., most recent use—maint. shop

Hawaii

P–88
Aliamanu Military Reservation
Honolulu Co: Honolulu HI 96818–
Location: Approximately 600 feet from Main Gate on Aliamanu Drive
Landholding Agency: Army
Property Number: 21199030324
Status: Unutilized
Comment: 45,216 sq. ft. underground tunnel complex, pres. of asbestos clean-up required of contamination, use of respirator required by those entering property, use limitations

Bldg. T–337
Fort Shafter
Honolulu Co: Honolulu HI 96819–
Landholding Agency: Army
Property Number: 21199640203
Status: Unutilized
Comment: 132 sq. ft., most recent use—storage, off-site use only

Illinois

Bldg. 54
Rock Island Arsenal
Rock Island Co: Rock Island IL 61299–
Landholding Agency: Army
Property Number: 21199620666
Status: Unutilized
Comment: 2000 sq. ft., most recent use—oil storage, needs repair, off-site use only

Bldg. AR112
Sheridan Reserve
Arlington Heights Co: IL 60052–2475
Landholding Agency: Army
Property Number: 21200110081
Status: Unutilized
Comment: 1000 sq. ft., off-site use only

Kansas

Bldg. P–390
Fort Leavenworth
Leavenworth KS 66027–
Landholding Agency: Army
Property Number: 21199740295
Status: Unutilized
Comment: 4713 sq. ft., presence of lead based paint, most recent use—swine house, off-site use only

Bldg. P–68
Fort Leavenworth
Leavenworth KS 66027–
Landholding Agency: Army
Property Number: 21199820153
Status: Unutilized
Comment: 2236 sq. ft., most recent use—vehicle storage, off-site use only

Bldg. P–321
Fort Leavenworth
Leavenworth KS 66027–
Landholding Agency: Army
Property Number: 21199820157
Status: Unutilized
Comment: 600 sq. ft., most recent use—picnic shelter, off-site use only

Bldg. S–809
Fort Leavenworth
Leavenworth KS 66027–
Landholding Agency: Army
Property Number: 21199820160
Status: Unutilized
Comment: 39 sq. ft., most recent use—access control, off-site use only

Bldg. S–830
Fort Leavenworth
Leavenworth KS 66027–
Landholding Agency: Army
Property Number: 21199820161
Status: Unutilized
Comment: 5789 sq. ft., most recent use—underground storage, off-site use only

Bldg. S–831
Fort Leavenworth
Leavenworth KS 66027–
Landholding Agency: Army
Property Number: 21199820162

Status: Unutilized
Comment: 5789 sq. ft., most recent use—underground storage, off-site use only

Bldg. P–243
Fort Leavenworth
Leavenworth KS 66027–
Landholding Agency: Army
Property Number: 21199830321
Status: Unutilized
Comment: 242 sq. ft., most recent use—industrial, off-site use only

Bldg. P–242
Fort Leavenworth
Leavenworth Co: KS 66027–
Landholding Agency: Army
Property Number: 21199920202
Status: Unutilized
Comment: 4680 sq. ft., most recent use—storage, off-site use only

Bldg. P–75
Fort Leavenworth
Leavenworth Co: KS 66027
Landholding Agency: Army
Property Number: 21199930140
Status: Unutilized
Comment: 12,129 sq. ft., most recent use—storage, off-site use only

Bldg. P–223
Fort Leavenworth
Leavenworth Co: KS 66027
Landholding Agency: Army
Property Number: 21199930146
Status: Unutilized
Comment: 7,174 sq. ft., most recent use—storage, off-site use only

Bldg. T–236
Fort Leavenworth
Leavenworth Co: KS 66027
Landholding Agency: Army
Property Number: 21199930147
Status: Unutilized
Comment: 4563 sq. ft., most recent use—storage, off-site use only

Bldg. P–241
Fort Leavenworth
Leavenworth Co: KS 66027
Landholding Agency: Army
Property Number: 21199930148
Status: Unutilized
Comment: 5920 sq. ft., most recent use—storage, off-site use only

Bldg. T–257
Fort Leavenworth
Leavenworth Co: KS 66027
Landholding Agency: Army
Property Number: 21199930149
Status: Unutilized
Comment: 5920 sq. ft., most recent use—storage, off-site use only

Kentucky

Bldg. 02813
Fort Knox
Ft. Knox Co: Hardin KY 40121
Landholding Agency: Army
Property Number: 21200030102
Status: Unutilized
Comment: 60 sq. ft., needs rehab, possible asbestos/lead paint, most recent use—shed, off-site use only

Louisiana

Bldg. 8405, Fort Polk
Ft. Polk Co: Vernon Parish LA 71459
Landholding Agency: Army
Property Number: 21199640524
Status: Underutilized
Comment: 1029 sq. ft., most recent use—office

Bldg. 8407, Fort Polk
Ft. Polk Co: Vernon Parish LA 71459
Landholding Agency: Army
Property Number: 21199640525
Status: Underutilized
Comment: 2055 sq. ft., most recent use—admin.

Bldg. 8408, Fort Polk
Ft. Polk Co: Vernon Parish LA 71459
Landholding Agency: Army
Property Number: 21199640526
Status: Underutilized
Comment: 2055 sq. ft., most recent use—admin.

Bldg. 8414, Fort Polk
Ft. Polk Co: Vernon Parish LA 71459
Landholding Agency: Army
Property Number: 21199640527
Status: Underutilized
Comment: 4172 sq. ft., most recent use—barracks

Bldg. 8423, Fort Polk
Ft. Polk Co: Vernon Parish LA 71459
Landholding Agency: Army
Property Number: 21199640528
Status: Underutilized
Comment: 4172 sq. ft., most recent use—barracks

Bldg. 8424, Fort Polk
Ft. Polk Co: Vernon Parish LA 71459
Landholding Agency: Army
Property Number: 21199640529
Status: Underutilized
Comment: 4172 sq. ft., most recent use—barracks

Bldg. 8426, Fort Polk
Ft. Polk Co: Vernon Parish LA 71459
Landholding Agency: Army
Property Number: 21199640530
Status: Underutilized
Comment: 4172 sq. ft., most recent use—barracks

Bldg. 8427, Fort Polk
Ft. Polk Co: Vernon Parish LA 71459
Landholding Agency: Army
Property Number: 21199640531
Status: Underutilized
Comment: 4172 sq. ft., most recent use—barracks

Bldg. 8428, Fort Polk
Ft. Polk Co: Vernon Parish LA 71459
Landholding Agency: Army
Property Number: 21199640532
Status: Underutilized
Comment: 4172 sq. ft., most recent use—barracks

Bldg. 8429, Fort Polk
Ft. Polk Co: Vernon Parish LA 71459
Landholding Agency: Army
Property Number: 21199640533
Status: Underutilized
Comment: 4172 sq. ft., most recent use—barracks

Bldg. 8430, Fort Polk
Ft. Polk Co: Vernon Parish LA 71459
Landholding Agency: Army
Property Number: 21199640534
Status: Underutilized
Comment: 4172 sq. ft., most recent use—barracks

Bldg. 8431, Fort Polk
Ft. Polk Co: Vernon Parish LA 71459
Landholding Agency: Army
Property Number: 21199640535
Status: Underutilized
Comment: 4172 sq. ft., most recent use—barracks

Bldg. 8432, Fort Polk
Ft. Polk Co: Vernon Parish LA 71459
Landholding Agency: Army
Property Number: 21199640536
Status: Underutilized
Comment: 4172 sq. ft., most recent use—barracks

Bldg. 8433, Fort Polk
Ft. Polk Co: Vernon Parish LA 71459
Landholding Agency: Army
Property Number: 21199640537
Status: Underutilized
Comment: 4172 sq. ft., most recent use—barracks

Bldg. 8446, Fort Polk
Ft. Polk Co: Vernon Parish LA 71459
Landholding Agency: Army
Property Number: 21199640538
Status: Underutilized
Comment: 2093 sq. ft., most recent use—admin.

Bldg. 8449, Fort Polk
Ft. Polk Co: Vernon Parish LA 71459
Landholding Agency: Army
Property Number: 21199640539
Status: Underutilized
Comment: 2093 sq. ft., most recent use—office

Bldg. 8450, Fort Polk
Ft. Polk Co: Vernon Parish LA 71459
Landholding Agency: Army
Property Number: 21199640540
Status: Underutilized
Comment: 2093 sq. ft., most recent use—admin.

Bldg. 8458, Fort Polk
Ft. Polk Co: Vernon Parish LA 71459
Landholding Agency: Army
Property Number: 21199640542
Status: Underutilized
Comment: 4172 sq. ft., most recent use—barracks

Bldg. 8459, Fort Polk
Ft. Polk Co: Vernon Parish LA 71459
Landholding Agency: Army
Property Number: 21199640543
Status: Underutilized
Comment: 4172 sq. ft., most recent use—barracks

Bldg. 8460, Fort Polk
Ft. Polk Co: Vernon Parish LA 71459
Landholding Agency: Army
Property Number: 21199640544
Status: Underutilized
Comment: 4172 sq. ft., most recent use—barracks

Bldg. 8461, Fort Polk
Ft. Polk Co: Vernon Parish LA 71459
Landholding Agency: Army
Property Number: 21199640545
Status: Underutilized
Comment: 4172 sq. ft., most recent use—barracks

Bldg. 8462, Fort Polk
Ft. Polk Co: Vernon Parish LA 71459
Landholding Agency: Army
Property Number: 21199640546

Status: Underutilized
Comment: 4172 sq. ft., most recent use—barracks

Bldg. 8463, Fort Polk
Ft. Polk Co: Vernon Parish LA 71459
Landholding Agency: Army
Property Number: 21199640547
Status: Underutilized
Comment: 4172 sq. ft., most recent use—barracks

Bldg. 8501, Fort Polk
Ft. Polk Co: Vernon Parish LA 71459
Landholding Agency: Army
Property Number: 21199640548
Status: Underutilized
Comment: 1687 sq. ft., most recent use—office

Bldg. 8502, Fort Polk
Ft. Polk Co: Vernon Parish LA 71459
Landholding Agency: Army
Property Number: 21199640549
Status: Underutilized
Comment: 1029 sq. ft., most recent use—office

Bldg. 8541, Fort Polk
Ft. Polk Co: Vernon Parish LA 71459
Landholding Agency: Army
Property Number: 21199640551
Status: Underutilized
Comment: 4172 sq. ft., most recent use—barracks

Bldg. 8542, Fort Polk
Ft. Polk Co: Vernon Parish LA 71459
Landholding Agency: Army
Property Number: 21199640552
Status: Underutilized
Comment: 4172 sq. ft., most recent use—barracks

Bldg. 8543, Fort Polk
Ft. Polk Co: Vernon Parish LA 71459
Landholding Agency: Army
Property Number: 21199640553
Status: Underutilized
Comment: 4172 sq. ft., most recent use—barracks

Bldg. 8545, Fort Polk
Ft. Polk Co: Vernon Parish LA 71459–
Landholding Agency: Army
Property Number: 21199640555
Status: Underutilized
Comment: 4172 sq. ft., most recent use—barracks

Bldg. 8546, Fort Polk
Ft. Polk Co: Vernon Parish LA 71459–
Landholding Agency: Army
Property Number: 21199640556
Status: Underutilized
Comment: 4172 sq. ft., most recent use—barracks

Bldg. 8547, Fort Polk
Ft. Polk Co: Vernon Parish LA 71459–
Landholding Agency: Army
Property Number: 21199640557
Status: Underutilized
Comment: 4172 sq. ft., most recent use—barracks

Bldg. 8548, Fort Polk
Ft. Polk Co: Vernon Parish LA 71459–
Landholding Agency: Army
Property Number: 21199640558
Status: Underutilized
Comment: 4172 sq. ft., most recent use—barracks

Bldg. 8549, Fort Polk
Ft. Polk Co: Vernon Parish LA 71459–
Landholding Agency: Army
Property Number: 21199640559
Status: Underutilized
Comment: 4172 sq. ft., most recent use—barracks

Maryland

Bldg. 2831
Ft. George G. Meade
Ft. Meade Co: Anne Arundel MD 20755–5115
Landholding Agency: Army
Property Number: 21200030103
Status: Unutilized
Comment: 9652 sq. ft., presence of asbestos/lead paint, most recent use—dental clinic, off-site use only

Bldg. 618A
Fort George G. Meade
Ft. Meade Co: Anne Arundel MD 20755–5115
Landholding Agency: Army
Property Number: 21200120087
Status: Unutilized
Comment: 400 sq. ft., presence of asbestos/lead paint, most recent use—heat plant bldg., off-site use only

Bldg. 901
Fort George G. Meade
Ft. Meade Co: Anne Arundel MD 20755–5115
Landholding Agency: Army
Property Number: 21200120088
Status: Unutilized
Comment: 2740 sq. ft., presence of asbestos/lead paint, most recent use—storage, off-site use only

Bldgs. 902, 932, 937
Fort George G. Meade
Ft. Meade Co: Anne Arundel MD 20755–5115
Landholding Agency: Army
Property Number: 21200120089
Status: Unutilized
Comment: 2208 sq. ft., presence of asbestos/lead paint, most recent use—admin/dining, off-site use only

4 Bldgs.
Fort George G. Meade
#903, 906, 933, 936
Ft. Meade Co: Anne Arundel MD 20755–5115
Landholding Agency: Army
Property Number: 21200120090
Status: Unutilized
Comment: 1144 sq. ft., presence of asbestos/lead paint, most recent use—admin/storage/dayroom, off-site use only

10 Bldgs.
Fort George G. Meade
#904, 905, 913, 916, 923–926, 934, 935
Ft. Meade Co: Anne Arundel MD 20755–5115
Landholding Agency: Army
Property Number: 21200120091
Status: Unutilized
Comment: 4720 sq. ft., presence of asbestos/lead paint, most recent use—admin., off-site use only

Bldg. 907
Fort George G. Meade
Ft. Meade Co: Anne Arundel MD 20755–5115
Landholding Agency: Army
Property Number: 21200120092
Status: Unutilized
Comment: 2306 sq. ft., presence of asbestos/lead paint, most recent use—storage, off-site use only

Bldg. 908
Fort George G. Meade
Ft. Meade Co: Anne Arundel MD 20755–5115
Landholding Agency: Army
Property Number: 21200120093
Status: Unutilized
Comment: 3663 sq. ft., presence of asbestos/lead paint, most recent use—admin., off-site use only

Bldgs. 912, 917, 922, 927
Fort George G. Meade
Ft. Meade Co: Anne Arundel MD 20755–5115
Landholding Agency: Army
Property Number: 21200120094
Status: Unutilized
Comment: 1297 sq. ft., presence of asbestos/lead paint, most recent use—admin/storage, off-site use only

Bldg. 918
Fort George G. Meade
Ft. Meade Co: Anne Arundel MD 20755–5115
Landholding Agency: Army
Property Number: 21200120095
Status: Unutilized
Comment: 2331 sq. ft., presence of asbestos/lead paint, most recent use—admin/classroom, off-site use only

4 Bldgs.
Fort George G. Meade
#928, 929, 2832, 2834
Ft. Meade Co: Anne Arundel MD 20755–5115
Landholding Agency: Army
Property Number: 21200120096
Status: Unutilized
Comment: 2284 sq. ft., presence of asbestos/lead paint, most recent use—admin., off-site use only

Bldg. 930
Fort George G. Meade
Ft. Meade Co: Anne Arundel MD 20755–5115
Landholding Agency: Army
Property Number: 21200120097
Status: Unutilized
Comment: 3108 sq. ft., presence of asbestos/lead paint, most recent use—storage, off-site use only

Bldg. 938
Fort George G. Meade
Ft. Meade Co: Anne Arundel MD 20755–5115
Landholding Agency: Army
Property Number: 21200120098
Status: Unutilized
Comment: 1676 sq. ft., presence of asbestos/lead paint, most recent use—admin., off-site use only

Bldg. 2810
Fort George G. Meade
Ft. Meade Co: Anne Arundel MD 20755–5115
Landholding Agency: Army
Property Number: 21200120099
Status: Unutilized
Comment: 2441 sq. ft., poor condition, presence of asbestos/lead paint, most recent use—admin., off-site use only

Bldg. 2811
Fort George G. Meade
Ft. Meade Co: Anne Arundel MD 20755–5115
Landholding Agency: Army
Property Number: 21200120100
Status: Unutilized
Comment: 4720 sq. ft., poor condition, presence of asbestos/lead paint, most recent use—admin., off-site use only

Bldg. 2837
Fort George G. Meade
Ft. Meade Co: Anne Arundel MD 20755–5115

Landholding Agency: Army
Property Number: 21200120101
Status: Unutilized
Comment: 7670 sq. ft., presence of asbestos/lead paint, most recent use—admin., off-site use only

Bldg. 00262
Aberdeen Proving Ground
Aberdeen Co: Harford MD 21005–5001
Landholding Agency: Army
Property Number: 21200120102
Status: Unutilized
Comment: 24 sq. ft., presence of asbestos/lead paint, most recent use—access control facility, off-site use only

Bldg. 0310A
Aberdeen Proving Ground
Aberdeen Co: Harford MD 21005–5001
Landholding Agency: Army
Property Number: 21200120103
Status: Unutilized
Comment: 120 sq. ft., poor condition, presence of asbestos/lead paint, most recent use—storage, off-site use only

Bldg. 00313
Aberdeen Proving Ground
Aberdeen Co: Harford MD 21005–5001
Landholding Agency: Army
Property Number: 21200120104
Status: Unutilized
Comment: 983 sq. ft., most recent use—storage, off-site use only

Bldg. 00340
Aberdeen Proving Ground
Aberdeen Co: Harford MD 21005–5001
Landholding Agency: Army
Property Number: 21200120105
Status: Unutilized
Comment: 384 sq. ft., most recent use—storage, off-site use only

Bldg. 0459B
Aberdeen Proving Ground
Aberdeen Co: Harford MD 21005–5001
Landholding Agency: Army
Property Number: 21200120106
Status: Unutilized
Comment: 225 sq. ft., poor condition, most recent use—equipment bldg., off-site use only

Bldg. 00785
Aberdeen Proving Ground
Aberdeen Co: Harford MD 21005–5001
Landholding Agency: Army
Property Number: 21200120107
Status: Unutilized
Comment: 160 sq. ft., poor condition, most recent use—shelter, off-site use only

Bldg. E3325
Aberdeen Proving Ground
Aberdeen Co: Harford MD 21005–5001
Landholding Agency: Army
Property Number: 21200120108
Status: Unutilized
Comment: 452 sq. ft., poor condition, possible contamination, most recent use—lab, off-site use only

Bldg. E3728
Aberdeen Proving Ground
Aberdeen Co: Harford MD 21005–5001
Landholding Agency: Army
Property Number: 21200120109
Status: Unutilized
Comment: 2596 sq. ft., presence of asbestos/lead paint, most recent use—testing facility, off-site use only

Bldg. E3870
Aberdeen Proving Ground
Aberdeen Co: Harford MD 21005–5001
Landholding Agency: Army
Property Number: 21200120110
Status: Unutilized
Comment: 1208 sq. ft., presence of asbestos/lead paint, most recent use—lab/test facility, off-site use only

Bldg. E3948
Aberdeen Proving Ground
Aberdeen Co: Harford MD 21005–5001
Landholding Agency: Army
Property Number: 21200120111
Status: Unutilized
Comment: 1416 sq. ft., presence of asbestos/lead paint, most recent use—utility bldg., off-site use only

Bldg. 05213
Aberdeen Proving Ground
Aberdeen Co: Harford MD 21005–5001
Landholding Agency: Army
Property Number: 21200120112
Status: Unutilized
Comment: 200 sq. ft., poor condition, most recent use—storage, off-site use only

Bldg. E5239
Aberdeen Proving Ground
Aberdeen Co: Harford MD 21005–5001
Landholding Agency: Army
Property Number: 21200120113
Status: Unutilized
Comment: 230 sq. ft., most recent use—storage, off-site use only

Bldg. E5317
Aberdeen Proving Ground
Aberdeen Co: Harford MD 21005–5001
Landholding Agency: Army
Property Number: 21200120114
Status: Unutilized
Comment: 3158 sq. ft., presence of asbestos/lead paint, most recent use—lab, off-site use only

Bldg. E5637
Aberdeen Proving Ground
Aberdeen Co: Harford MD 21005–5001
Landholding Agency: Army
Property Number: 21200120115
Status: Unutilized
Comment: 312 sq. ft., presence of asbestos/lead paint, most recent use—lab, off-site use only

Missouri

Bldg. T599
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199230260
Status: Underutilized
Comment: 18270 sq. ft., 1-story, presence of asbestos, most recent use—storehouse, off-site use only

Bldg. T2171
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199340212
Status: Unutilized
Comment: 1296 sq. ft., 1-story wood frame, most recent use—administrative, no handicap fixtures, lead base paint, off-site use only

Bldg. T6822
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199340219
Status: Underutilized
Comment: 4000 sq. ft., 1-story wood frame, most recent use—storage, no handicap fixtures, off-site use only

Bldg. T1497
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199420441
Status: Underutilized
Comment: 4720 sq. ft., 2-story, presence of lead base paint, most recent use—admin/gen. purpose, off-site use only

Bldg. T2139
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199420446
Status: Underutilized
Comment: 3663 sq. ft., 1-story, presence of lead base paint, most recent use—admin/gen. purpose, off-site use only

Bldg. T–2191
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199440334
Status: Excess
Comment: 4720 sq. ft., 2 story wood frame, off-site removal only, to be vacated 8/95, lead based paint, most recent use—barracks

Bldg. T–2197
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199440335
Status: Excess
Comment: 4720 sq. ft., 2 story wood frame, off-site removal only, to be vacated 8/95, lead based paint, most recent use—barracks

Bldg. T590
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–
Landholding Agency: Army
Property Number: 21199510110
Status: Excess
Comment: 3263 sq. ft., 1-story, wood frame, most recent use—admin., to be vacated 8/95, off-site use only

Bldg. T2385
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–
Landholding Agency: Army
Property Number: 21199510115
Status: Excess
Comment: 3158 sq. ft., 1-story, wood frame, most recent use—admin., to be vacated 8/95, off-site use only

Bldgs. T–2340 thru T2343
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army

Property Number: 21199710138
Status: Underutilized
Comment: 9267 sq. ft. each, most recent use—storage/general purpose

Bldg. 1226
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199730275
Status: Unutilized
Comment: 1600 sq. ft., presence of asbestos/lad paint, most recent use—admin., off-site use only

Bldg. 1271
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199730276
Status: Unutilized
Comment: 2360 sq. ft., presence of asbestos/lead paint, most recent use—storage, off-site use only

Bldg. 1280
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199730277
Status: Unutilized
Comment: 1144 sq. ft., presence of asbestos/lead paint, most recent use—classroom, off-site use only

Bldg. 1281
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199730278
Status: Unutilized
Comment: 2360 sq. ft., presence of asbestos/lead paint, most recent use—classroom, off-site use only

Bldg. 1282
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199730279
Status: Unutilized
Comment: 4720 sq. ft., presence of asbestos/lead paint, most recent use—barracks, off-site use only

Bldg. 1283
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199730280
Status: Unutilized
Comment: 1296 sq. ft., presence of asbestos/lead paint, most recent use—storage, off-site use only

Bldg. 1284
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199730281
Status: Unutilized
Comment: 4720 sq. ft., presence of asbestos/lead paint, most recent use—admin., off-site use only

Bldg. 1285
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199730282
Status: Unutilized
Comment: 4720 sq. ft., presence of asbestos/lead paint, most recent use—barracks, off-site use only

Bldg. 1286
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199730283
Status: Unutilized
Comment: 1296 sq. ft., presence of asbestos/lead paint, most recent use—admin., off-site use only

Bldg. 1287
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199730284
Status: Unutilized
Comment: 4720 sq. ft., presence of asbestos/lead paint, most recent use—barracks, off-site use only

Bldg. 1288
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199730285
Status: Unutilized
Comment: 2360 sq. ft., presence of asbestos/lead paint, most recent use—dining facility, off-site use only

Bldg. 1289
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199730286
Status: Unutilized
Comment: 1144 sq. ft., presence of asbestos/lead paint, most recent use—classroom, off-site use only

Bldg. 430
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199810305
Status: Unutilized
Comment: 4100 sq. ft., presence of asbestos/lead paint, most recent use—Red Cross facility, off-site use only

Bldg. 758
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199810306
Status: Unutilized
Comment: 2400 sq. ft., presence of asbestos/lead paint, most recent use—classroom, off-site use only

Bldg. 759
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199810307
Status: Unutilized
Comment: 2400 sq. ft., presence of asbestos/lead paint, most recent use—classroom, off-site use only

Bldg. 760
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199810308
Status: Unutilized
Comment: 2400 sq. ft., presence of asbestos/lead paint, off-site use only

Bldgs. 761–766
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199810309
Status: Unutilized
Comment: 2400 sq. ft. each, presence of asbestos/lead paint, most recent use—classroom, off-site use only

Bldg. 1650
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199810311
Status: Unutilized
Comment: 1676 sq. ft., presence of asbestos/lead paint, most recent use—union hall, off-site use only

Bldg. 2111
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199810312
Status: Unutilized
Comment: 1600 sq. ft., presence of asbestos/lead paint, most recent use—union hall, off-site use only

Bldg. 2170
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199810313
Status: Unutilized
Comment: 1296 sq. ft., presence of asbestos/lead paint, most recent use—admin., off-site use only

Bldg. 2204
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199810315
Status: Unutilized
Comment: 3525 sq. ft., presence of asbestos/lead paint, most recent use—admin., off-site use only

Bldg. 2225
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199810316
Status: Unutilized
Comment: 820 sq. ft., presence of lead paint, most recent use—storage, off-site use only

Bldg. 2271
Fort Leonard Wood

Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199810317
Status: Unutilized
Comment: 256 sq. ft., presence of lead paint, most recent use—storage, off-site use only

Bldg. 2275
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199810318
Status: Unutilized
Comment: 225 sq. ft., presence of lead paint, most recent use—storage, off-site use only

Bldg. 2318
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199810322
Status: Unutilized
Comment: 9267 sq. ft., presence of asbestos/lead paint, most recent use—storage, off-site use only

Bldg. 4199
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199810327
Status: Unutilized
Comment: 2400 sq. ft., presence of asbestos/lead paint, most recent use—storage, off-site use only

Bldg. 401
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199820164
Status: Unutilized
Comment: 9567 sq. ft., presence of asbestos/lead paint, most recent use—admin., off-site use only

Bldg. 856
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199820166
Status: Unutilized
Comment: 2400 sq. ft., presence of asbestos/lead paint, most recent use—storage, off-site use only

Bldg. 859
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199820167
Status: Unutilized
Comment: 2400 sq. ft., presence of asbestos/lead paint, most recent use—storage, off-site use only

Bldg. 1242
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199820168
Status: Unutilized
Comment: 2360 sq. ft., presence of asbestos/lead paint, most recent use—storage, off-site use only

Bldg. 1265
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199820169
Status: Unutilized
Comment: 2360 sq. ft., presence of asbestos/lead paint, most recent use—storage, off-site use only

Bldg. 1267
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199820170
Status: Unutilized
Comment: 1144 sq. ft., presence of asbestos/lead paint, most recent use—admin., off-site use only

Bldg. 1272
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199820171
Status: Unutilized
Comment: 1144 sq. ft., presence of asbestos/lead paint, most recent use—admin., off-site use only

Bldg. 1277
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199820172
Status: Unutilized
Comment: 1144 sq. ft., presence of asbestos/lead paint, most recent use—admin., off-site use only

Bldgs. 2142, 2145, 2151–2153
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199820174
Status: Unutilized
Comment: 4720 sq. ft., presence of asbestos/lead paint, most recent use—barracks, off-site use only

Bldg. 2150
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199820175
Status: Unutilized
Comment: 2892 sq. ft., presence of asbestos/lead paint, most recent use—dayroom, off-site use only

Bldg. 2155
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199820176
Status: Unutilized
Comment: 1296 sq. ft., presence of asbestos/lead paint, most recent use—admin., off-site use only

Bldgs. 2156, 2157, 2163, 2164
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency:Army
Property Number: 21199820177
Status: Unutilized
Comment: 4720 sq. ft., presence of asbestos/lead paint, most recent use—barracks, off-site use only

Bldg. 2165
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency:Army
Property Number: 21199820178
Status: Unutilized
Comment: 2892 sq. ft., presence of asbestos/lead paint, most recent use—dayroom, off-site use only

Bldg. 2167
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199820179
Status: Unutilized
Comment: 1296 sq. ft., presence of asbestos/lead paint, most recent use—admin., off-site use only

Bldgs. 2169, 2181, 2182, 2183
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199820180
Status: Unutilized
Comment: 4720 sq. ft., presence of asbestos/lead paint, most recent use—barracks, off-site use only

Bldg. 2186
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199820181
Status: Unutilized
Comment: 1296 sq. ft., presence of asbestos/lead paint, most recent use—admin., off-site use only

Bldg. 2187
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199820182
Status: Unutilized
Comment: 2892 sq. ft., presence of asbestos/lead paint, most recent use—dayroom, off-site use only

Bldgs. 2192, 2196, 2198
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199820183
Status: Unutilized
Comment: 4720 sq. ft., presence of asbestos/lead paint, most recent use—barracks, off-site use only

Bldgs. 2304, 2306
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199820184

Status: Unutilized
Comment: 1625 sq. ft., presence of asbestos/lead paint, most recent use—storage, off-site use only

Bldg. 12651
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199820186
Status: Unutilized
Comment: 240 sq. ft., presence of lead paint, off-site use only

Bldg. 1448
Fort Leonard Wood
Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199830327
Status: Unutilized
Comment: 8450 sq. ft., presence of asbestos/lead paint, most recent use—training, off-site use only

Bldg. 2210
Fort Leonard Wood
Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199830328
Status: Unutilized
Comment: 808 sq. ft., concrete, presence of asbestos/lead paint, most recent use—storage, off-site use only

Bldg. 2270
Fort Leonard Wood
Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 21199830329
Status: Unutilized
Comment: 256 sq. ft., concrete, presence of asbestos/lead paint, most recent use—storage, off-site use only

Bldg. 6036
Fort Leonard Wood
Pulaski Co: MO 65473–8994
Landholding Agency: Army
Property Number: 21199910101
Status: Underutilized
Comment: 240 sq. ft., off-site use only

Bldg. 9110
Fort Leonard Wood
Pulaski Co: MO 65473–8994
Landholding Agency: Army
Property Number: 21199910108
Status: Underutilized
Comment: 6498 sq. ft., presence of asbestos/lead paint, most recent use—family quarters, off-site use only

Bldgs. 9113, 9115, 9117
Fort Leonard Wood
Pulaski Co: MO 65473–8994
Landholding Agency: Army
Property Number: 21199910109
Status: Underutilized
Comment: 4332 sq. ft., presence of asbestos/lead paint, most recent use—family quarters, off-site use only

Bldg. 493
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–
Landholding Agency: Army
Property Number: 21199930158
Status: Unutilized
Comment: 26,936 sq. ft., concrete, presence of asbestos/lead paint, most recent use—store, off-site use only

Bldg. 1178
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–8994
Landholding Agency: Army
Property Number: 21200040058
Status: Unutilized
Comment: 3203 sq. ft., most recent use—fire station, off-site use only

New Hampshire

Bldg. KG001
Grenier Field USARC
Manchester Co: Rockingham NH 03103–7474
Landholding Agency: Army
Property Number: 21200030104
Status: Excess
Comment: 18,994 sq. ft., presence of asbestos, most recent use—classroom, off-site use only

Bldg. KG002
Grenier Field USARC
Manchester Co: Rockingham NH 03103–7474
Landholding Agency: Army
Property Number: 21200030105
Status: Excess
Comment: 20,014 sq. ft., presence of asbestos, most recent use—storage/store, off-site use only

Bldg. KG003
Grenier Field USARC
Manchester Co: Rockingham NH 03103–7474
Landholding Agency: Army
Property Number: 21200030106
Status: Excess
Comment: 3458 sq. ft., presence of asbestos, most recent use—veh. maint., off-site use only

New Jersey

Bldg. 178
Armament R&D Engineering Center
Picatinny Arsenal Co: Morris NJ 07806–5000
Landholding Agency: Army
Property Number: 21199740312
Status: Unutilized
Comment: 2067 sq. ft., most recent use—research, off-site use only

Bldg. 642
Armament R&D Engineering Center
Picatinny Arsenal Co: Morris NJ 07806–5000
Landholding Agency: Army
Property Number: 21199740314
Status: Unutilized
Comment: 280 sq. ft., most recent use—explosives testing, off-site use only

Bldg. 732
Armament R&D Engineering Center
Picatinny Arsenal Co: Morris NJ 07806–5000
Landholding Agency: Army
Property Number: 21199740315
Status: Unutilized
Comment: 9077 sq. ft., needs rehab, most recent use—storage, off-site use only

Bldg. 3117
Armament R&D Engineering Center
Picatinny Arsenal Co: Morris NJ 07806–5000
Landholding Agency: Army
Property Number: 21199740322
Status: Unutilized
Comment: 100 sq. ft., most recent use—sentry station, off-site use only

Bldg. 3219
Armament R&D Engineering Center
Picatinny Arsenal Co: Morris NJ 07806–5000
Landholding Agency: Army
Property Number: 21199740326
Status: Unutilized
Comment: 288 sq. ft., most recent use—snack bar, off-site use only

New Mexico

9 MFH Units
White Sands Missile Range
White Sands Co: Dona Ana NM 88002–
Location: 11201, 12210, 11214, 11217, 11220, 11223, 11244, 11247, 11264
Landholding Agency: Army
Property Number: 21200040062
Status: Unutilized
Comment: 1620 sq. ft. each, major repairs required, presence of asbestos, most recent use—housing, off-site use only

19 MFH Units
White Sands Missile Range
White Sands Co: Dona Ana NM 88002–
Location: 11202, 11209, 11212, 11216, 11219, 11222, 11224, 11227, 11236, 11241, 11242, 11245, 11249, 11253, 11257, 11260, 11263, 11270, 11273
Landholding Agency: Army
Property Number: 21200040063
Status: Unutilized
Comment: 1606 sq. ft. each, major repairs required, presence of asbestos, most recent use—housing, off-site use only

34 MFU Units
White Sands Missile Range
White Sands Co: Dona Ana NM 88002–
Landholding Agency: Army
Status: Unutilized
Comment: 1512 sq. ft. each, major repairs required, presence of osbestos, most recent use—housing, off-site use only

12 MFH Units
White Sands Missile Range
White Sands Co: Dona Ana NM 88002–
Location: 11204, 11207, 11226, 11229, 11232, 11235, 11238, 11251, 11255, 11258, 11261, 11266
Landholding Agency: Army
Property Number: 21200040065
Status: Unutilized
Comment: 1590 sq. ft. each, major repairs required, presence of asbestos, most recent use—housing, off-site use only

New York

Bldg. 801
US Military Academy
Highlands Co: Orange NY 10996–1592
Landholding Agency: Army
Property Number: 21200030108
Status: Unutilized
Comment: 27,726 sq. ft., needs repair, possible lead paint, most recent use—warehouse, off-site use only

Bldg. T–2276
Fort Drum
Ft. Drum Co: Jefferson NY 13602–
Landholding Agency: Army
Property Number: 21200040069
Status: Unutilized
Comment: 5310 sq. ft., needs repair, most recent use—officer's quarters, off-site use only

Bldg. T–251
Fort Drum
Ft. Drum Co: Jefferson NY 13602–
Landholding Agency: Army
Property Number: 21200110083
Status: Unutilized

Comment: 4720 sq. ft., needs repair, most recent use—barracks, off-site use only

Bldg. T–791
Fort Drum
Ft. Drum Co: Jefferson NY 13602–
Landholding Agency: Army
Property Number: 21200110084
Status: Unutilized
Comment: 1372 sq. ft., needs repair, most recent use—storage, off-site use only

Bldg. 267
Fort Drum
Ft. Drum Co: Jefferson NY 13602–
Landholding Agency: Army
Property Number: 21200120116
Status: Unutilized
Comment: 1144 sq. ft., most recent use—hq. bldg., off-site use only

Bldg. 268
Fort Drum
Ft. Drum Co: Jefferson NY 13602–
Landholding Agency: Army
Property Number: 21200120117
Status: Unutilized
Comment: 1144 sq. ft., most recent use—hq. bldg., off-site use only

Bldg. 269
Fort Drum
Ft. Drum Co: Jefferson NY 13602–
Landholding Agency: Army
Property Number: 21200120118
Status: Unutilized
Comment: 2731 sq. ft., most recent use—hq. bldg., off-site use only

North Carolina

Bldgs. A2864, A3164
Fort Bragg
Ft. Bragg Co: Cumberland NC 28310–5000
Landholding Agency: Army
Property Number: 21200110085
Status: Excess
Comment: 3056 sq. ft., needs rehab, presence of asbestos/lead paint, most recent use—admin., off-site use only

Bldgs. O–3551, O–3552
Fort Bragg
Ft. Bragg Co: Cumberland NC 28310–5000
Landholding Agency: Army
Property Number: 21200110086
Status: Excess
Comment: 1584 sq. ft., presence of asbestos/lead paint, most recent use—barracks, off-site use only

3 Bldgs.
Fort Bragg
#8–7003, 2–7404, 0–9030
Ft. Bragg Co: Cumberland NC 28310–5000
Landholding Agency: Army
Property Number: 21200110087
Status: Excess
Comment: small bldgs., needs rehab, presence of asbestos/lead paint, most recent use—storage/pumphouse, off-site use only

Ohio

Bldg. 304
Defense Supply Center
Columbus Co: Franklin OH 43216–5000
Landholding Agency: Army
Property Number: 21200120131
Status: Unutilized
Comment: 219 sq. ft., most recent use—storage, off-site use only

Oklahoma

Bldg. T–838, Fort Sill
838 Macomb Road
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199220609
Status: Unutilized
Comment: 151 sq. ft., wood frame, 1 story, off-site removal only, most recent use—vet facility (quarantine stable)

Bldg. T–954, Fort Sill
954 Quinette Road
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199240659
Status: Unutilized
Comment: 3571 sq. ft., 1 story wood frame, needs rehab, off-site use only, most recent use—motor repair shop

Bldg. T–3325, Fort Sill
3325 Naylor Road
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199240681
Status: Unutilized
Comment: 8832 sq. ft., 1 story wood frame, needs rehab, off-site use only, most recent use—warehouse

Bldg. T1652, Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199330380
Status: Unutilized
Comment: 1505 sq. ft., 1-story wood, possible asbestos, most recent use—storage, off-site use only

Bldg. T5637 Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199330419
Status: Unutilized
Comment: 1606 sq. ft., 1 story, possible asbestos, most recent use—storage, off-site use only

Bldg. T–4226
Fort Sill
Lawton Co: Comanche OK 73503–
Landholding Agency: Army
Property Number: 21199440384
Status: Unutilized
Comment: 114 sq. ft., 1-story wood frame, possible asbestos and lead paint, most recent use—storage, off-site use only

Bldg. P–1015, Fort Sill
Lawton Co: Comanche OK 73501–5100
Landholding Agency: Army
Property Number: 21199520197
Status: Unutilized
Comment: 15402 sq. ft., 1-story, most recent use—storage, off-site use only

Bldg. P–366, Fort Sill
Lawton Co: Comanche OK 73503–
Landholding Agency: Army
Property Number: 21199610740
Status: Unutilized
Comment: 482 sq. ft., possible asbestos, most recent use—storage, off-site use only

Building T–2952
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199710047
Status: Unutilized
Comment: 4,327 sq. ft., possible asbestos and leadpaint, most recent use—motor repair shop, off-site use only

Building P–5042
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199710066
Status: Unutilized
Comment: 119 sq. ft., possible asbestos and leadpaint, most recent use—heatplant, off-site use only

4 Buildings
Fort Sill
Lawton Co: Comanche OK 73503–5100
Location: T–6465, T–6466, T–6467, T–6468
Landholding Agency: Army
Property Number: 21199710086
Status: Unutilized
Comment: various sq. ft., possible asbestos and leadpaint, most recent use—range support, off site use only

Building P–6539
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199710087
Status: Unutilized
Comment: 1,483 sq. ft., possible asbestos and leadpaint, most recent use—office, off-site use only

Bldg. T–208
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730344
Status: Unutilized
Comment: 20525 sq. ft., possible asbestos/lead paint, most recent use—training center, off-site use only

Bldg. T–214
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730346
Status: Unutilized
Comment: 6332 sq. ft., possible asbestos/lead paint, most recent use—training center, off-site use only

Bldgs. T–215, T–216
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730347
Status: Unutilized
Comment: 6300 sq. ft. each, possible asbestos/lead paint, most recent use—storage, off-site use only

Bldg. T–217
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730348
Status: Unutilized
Comment: 6394 sq. ft., possible asbestos/lead paint, most recent use—training center, off-site use only

Bldg. T–810
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730350
Status: Unutilized

Comment: 7205 sq. ft., possible asbestos/lead paint, most recent use—hay storage, off-site use only

Bldgs. T–837, T–839
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730351
Status: Unutilized
Comment: approx. 100 sq. ft. each, possible asbestos/lead paint, most recent use—storage, off-site use only

Bldg. P–934
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730353
Status: Unutilized
Comment: 402 sq. ft., possible asbestos/lead paint, most recent use—storage, off-site use only

Bldg. T–1177
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730356
Status: Unutilized
Comment: 183 sq. ft., possible asbestos/lead paint, most recent use—snack bar, off-site use only

Bldgs. T–1468, T–1469
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730357
Status: Unutilized
Comment: 114 sq. ft., possible asbestos/lead paint, most recent use—storage, off-site use only

Bldg. T–1470
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730358
Status: Unutilized
Comment: 3120 sq. ft., possible asbestos/lead paint, most recent use—storage, off-site use only

Bldg. T–1940
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730360
Status: Unutilized
Comment: 1400 sq. ft., possible asbestos/lead paint, most recent use—storage, off-site use only

Bldgs. T–1954, T–2022
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730362
Status: Unutilized
Comment: approx. 100 sq. ft. each, possible asbestos/lead paint, most recent use—storage, off-site use only

Bldg. T–2184
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730364
Status: Unutilized
Comment: 454 sq. ft., possible asbestos/lead paint, most recent use—storage, off-site use only

Bldg. T–2185
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730365
Status: Unutilized
Comment: 151 sq. ft., possible asbestos/lead paint, most recent use—fuel storage, off-site use only

Bldgs. T–2186, T–2188, T–2189
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730366
Status: Unutilized
Comment: 1656—3583 sq. ft., possible asbestos/lead paint, most recent use—vehicle maint. shop, off-site use only

Bldg. T–2187
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730367
Status: Unutilized
Comment: 1673 sq. ft., possible asbestos/lead paint, most recent use—storage, off-site use only

Bldg. T–2209
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730368
Status: Unutilized
Comment: 1257 sq. ft., possible asbestos/lead paint, most recent use—storage, off-site use only

Bldgs. T–2240, T–2241
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730369
Status: Unutilized
Comment: approx. 9500 sq. ft., possible asbestos/lead paint, most recent use—storage, off-site use only

Bldgs. T–2262, T–2263
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730370
Status: Unutilized
Comment: approx. 3100 sq. ft., possible asbestos/lead paint, most recent use—maint. shop, off-site use only

Bldgs. T–2271, T–2272
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730371
Status: Unutilized
Comment: 232 sq. ft., possible asbestos/lead paint, most recent use—storage, off-site use only

Bldgs. T–2291 thru T–2296
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730372
Status: Unutilized
Comment: 400 sq. ft. each, possible asbestos/lead paint, most recent use—storage, off-site use only

Bldgs. T–3001, T–3006
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730383
Status: Unutilized
Comment: approx. 9300 sq. ft., possible asbestos/lead paint, most recent use—storage, off-site use only

Bldg. T–3025
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730384
Status: Unutilized
Comment: 5259 sq. ft., possible asbestos/lead paint, most recent use—museum, off-site use only

Bldg. T–3314
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730385
Status: Unutilized
Comment: 229 sq. ft., possible asbestos/lead paint, most recent use—office, off-site use only

Bldg. T–3323
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730387
Status: Unutilized
Comment: 8832 sq. ft., possible asbestos/lead paint, most recent use—office, off-site use only

Bldg. T–4281
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730392
Status: Unutilized
Comment: 9405 sq. ft., possible asbestos/lead paint, most recent use—storage, off-site use only

Bldgs. T–4401, T–4402
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730393
Status: Unutilized
Comment: 2260 sq. ft., possible asbestos/lead paint, most recent use—office, off-site use only

Bldg. T–4407
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730395
Status: Unutilized
Comment: 3070 sq. ft., possible asbestos/lead paint, most recent use—dining facility, off-site use only

4 Bldgs.
Fort Sill
#T–4410, T–4414, T–4415, T–4418
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730396
Status: Unutilized
Comment: 1311 sq. ft., possible asbestos/lead paint, most recent use—office, off-site use only

5 Bldgs.
Fort Sill
#T–4411 thru T–4413, T–4416 thru T–4417

Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730397
Status: Unutilized
Comment: 1244 sq. ft., possible asbestos/lead paint, most recent use—showers, off-site use only

Bldg. T–4421
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730398
Status: Unutilized
Comment: 3070 sq. ft., possible asbestos/lead paint, most recent use—dining, off-site use only

10 Bldgs.
Fort Sill
#T–4422 thru T–4427, T–4431 thru T–4434
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730399
Status: Unutilized
Comment: 2263 sq. ft., possible asbestos/lead paint, most recent use—barracks, off-site use only

6 Bldgs.
Fort Sill
Lawton Co: Comanche OK 73503–5100
Location: #T–4436, T–4440, T–4444, T–4445, T–4448, T–4449
Landholding Agency: Army
Property Number: 21199730400
Status: Unutilized
Comment: 1311–2263 sq. ft., possible asbestos/lead paint, most recent use—office, off-site use only

5 Bldgs.
Fort Sill
Lawton Co: Comanche OK 73503–5100
Location: #T–4441, T–4442, T–4443, T–4446, T–4447
Landholding Agency: Army
Property Number: 21199730401
Status: Unutilized
Comment: 1244 sq. ft., possible asbestos/lead paint, most recent use—showers, off-site use only

Bldg. T–5041
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730409
Status: Unutilized
Comment: 763 sq. ft., possible asbestos/lead paint, most recent use—storage, off-site use only

Bldgs. T–5044, T–5045
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730410
Status: Unutilized
Comment: 1798/1806 sq. ft., possible asbestos/lead paint, most recent use—class rooms, off-site use only

Bldg. T–5420
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730414
Status: Unutilized
Comment: 189 sq. ft., possible asbestos/lead paint, most recent use—fuel storage, off-site use only

Bldgs. T–7290, T–7291
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730417
Status: Unutilized
Comment: 224/840 sq. ft., possible asbestos/lead paint, most recent use—kennel, off-site use only

Bldg. T–7775
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199730419
Status: Unutilized
Comment: 1452 sq. ft., possible asbestos/lead paint, most recent use—private club, off-site use only

Bldg. T–207
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199910130
Status: Unutilized
Comment: 19,531 sq. ft., possible asbestos/lead paint, most recent use—office, off-site use only

Bldg. P–599
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199910132
Status: Unutilized
Comment: 1400 sq. ft., possible asbestos/lead paint, most recent use—clubhouse, off-site use only

4 Bldgs.
Fort Sill
P–617, P–1114, P–1386, P–1608
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199910133
Status: Unutilized
Comment: 106 sq. ft., possible asbestos/lead paint, most recent use—utility plant, off-site use only

Bldg. P–746
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199910135
Status: Unutilized
Comment: 6299 sq. ft., possible asbestos/lead paint, most recent use—admin., off-site use only

Bldg. T–2183
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199910139
Status: Unutilized
Comment: 14,530 sq. ft., possible asbestos/lead paint, most recent use—repair shop, off-site use only

Bldgs. P–2581, P–2773
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199910140
Status: Unutilized
Comment: 4093 and 4129 sq. ft., possible asbestos/lead paint, most recent use—office, off-site use only

Bldg. P–2582
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199910141
Status: Unutilized
Comment: 3672 sq. ft., possible asbestos/lead paint, most recent use—admin., off-site use only

Bldgs. P–2912, P–2921, P–2944
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199910144
Status: Unutilized
Comment: 1390 sq. ft., possible asbestos/lead paint, most recent use—office, off-site use only

Bldg. S–3169
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199910145
Status: Unutilized
Comment: 6437 sq. ft., possible asbestos/lead paint, most recent use—office, off-site use only

Bldg. P–2914
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199910146
Status: Unutilized
Comment: 1236 sq. ft., possible asbestos/lead paint, most recent use—storage, off-site use only

Bldg. P–3469
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199910147
Status: Unutilized
Comment: 3930 sq. ft., possible asbestos/lead paint, most recent use—car wash, off-site use only

Bldg. S–3559
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199910148
Status: Unutilized
Comment: 9462 sq. ft., possible asbestos/lead paint, most recent use—classroom, off-site use only

Bldg. S–4064
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199910149
Status: Unutilized
Comment: 1389 sq. ft., possible asbestos/lead paint, off-site use only

Bldg. S–5086
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199910152
Status: Unutilized
Comment: 6453 sq. ft., possible asbestos/lead paint, most recent use—maintenance shop, off-site use only

Bldg. P–5101
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army

Property Number: 21199910153
Status: Unutilized
Comment: 82 sq. ft., possible asbestos/lead paint, most recent use—gas station, off-site use only

Bldg. S–6430
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199910156
Status: Unutilized
Comment: 2080 sq. ft., possible asbestos/lead paint, most recent use—range support, off-site use only

Bldg. T–6461
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199910157
Status: Unutilized
Comment: 200 sq. ft., possible asbestos/lead paint, most recent use—range support, off-site use only

Bldg. T–6462
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199910158
Status: Unutilized
Comment: 64 sq. ft., possible asbestos/lead paint, most recent use—control tower, off-site use only

Bldg. P–7230
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21199910159
Status: Unutilized
Comment: 160 sq. ft., possible asbestos/lead paint, most recent use—transmitter bldg., off-site use only

Bldg. S–4023
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21200010128
Status: Unutilized
Comment: 1200 sq. ft., possible asbestos/lead paint, most recent use—storage, off-site use only

Bldg. P–706
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21200120119
Status: Unutilized
Comment: 103 sq. ft., possible asbestos/lead paint, most recent use—storage, off-site use only

Bldg. P–747
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21200120120
Status: Unutilized
Comment: 9232 sq. ft., possible asbestos/lead paint, most recent use—lab, off-site use only

Bldg. S–830
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21200120121
Status: Unutilized
Comment: 7356 sq. ft., possible asbestos/lead paint, most recent use—vehicle maint., off-site use only

Bldg. S–831
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21200120122
Status: Unutilized
Comment: 7344 sq. ft., possible asbestos/lead paint, most recent use—classroom, off-site use only

Bldg. P–842
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21200120123
Status: Unutilized
Comment: 192 sq. ft., possible asbestos/lead paint, most recent use—storage, off-site use only

Bldg. T–911
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21200120124
Status: Unutilized
Comment: 3080 sq. ft., possible asbestos/lead paint, most recent use—office, off-site use only

Bldg. P–1390
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21200120125
Status: Unutilized
Comment: 106 sq. ft., possible asbestos/lead paint, most recent use—utility plant, off-site use only

Bldg. P–1672
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21200120126
Status: Unutilized
Comment: 1056 sq. ft., possible asbestos/lead paint, most recent use—storage, off-site use only

Bldg. S–2362
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21200120127
Status: Unutilized
Comment: 64 sq. ft., possible asbestos/lead paint, most recent use—gatehouse, off-site use only

Bldg. P–2421
Fort Sill
Lawton Co: Comanche OK 73505–5100
Landholding Agency: Army
Property Number: 21200120128
Status: Unutilized
Comment: 100 sq. ft., most recent use—storage, off-site use only

Bldg. P–2589
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21200120129
Status: Unutilized
Comment: 3672 sq. ft., possible asbestos/lead paint, most recent use—storage, off-site use only

Bldg. T–3043
Fort Sill
Lawton Co: Comanche OK 73503–5100
Landholding Agency: Army
Property Number: 21200120130
Status: Unutilized
Comment: 80 sq. ft., possible asbestos/lead paint, most recent use—guard shack, off-site use only

South Carolina

Bldg. 3499
Fort Jackson
Ft. Jackson Co: Richland SC 29207–
Landholding Agency: Army
Property Number: 21199730310
Status: Unutilized
Comment: 3724 sq. ft., needs repair, most recent use—admin.

Bldg. 2441
Fort Jackson
Ft. Jackson Co: Richland SC 29207–
Landholding Agency: Army
Property Number: 21199820187
Status: Unutilized
Comment: 2160 sq. ft., needs repair, most recent use—admin.

Bldg. 3605
Fort Jackson
Ft. Jackson Co: Richland SC 29207–
Landholding Agency: Army
Property Number: 21199820188
Status: Unutilized
Comment: 711 sq. ft., needs repair, most recent use—storage

Bldg. 1765
Fort Jackson
Ft. Jackson Co: Richland SC 29207–
Landholding Agency: Army
Property Number: 21200030109
Status: Unutilized
Comment: 1700 sq. ft., need repairs, presence of asbestos/lead paint, most recent use—training bldg., off-site use only

Texas

Bldg. T–5901
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199330486
Status: Unutilized
Comment: 742 sq. ft., 1-story wood frame, most recent use—admin., off-site use only.

Bldg. P–6615
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199440454
Status: Excess
Comment: 400 sq. ft., 1 story concrete frame, off-site removal only, most recent use—detached garage

Bldg. 4201, Fort Hood
Ft. Hood Co: Bell TX 76544–
Landholding Agency: Army
Property Number: 21199520201
Status: Unutilized
Comment: 9000 sq. ft., 1-story, off-site use only

Bldg. 7137, Fort Bliss
El Paso Co: El Paso TX 79916–
Landholding Agency: Army
Property Number: 21199640564
Status: Unutilized

Comment: 35,736 sq. ft., 3-story, most recent use—housing, off-site use only

Building 4630
Fort Hood
Fort Hood Co: Bell TX 76544–
Landholding Agency: Army
Property Number: 21199710088
Status: Unutilized
Comment: 21,833 sq. ft., most recent use—Admin., off-site use only

Bldgs. P–605A & P–606A
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199730316
Status: Unutilized
Comment: 2418 sq. ft., poor condition, presence of asbestos/lead paint, historical category, most recent use—indoor firing range, off-site use only

Bldg. T–5122
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199730331
Status: Unutilized
Comment: 3602 sq. ft., presence of asbestos/lead paint, historical category, most recent use—instruction bldg., off-site use only

Bldg. T–5903
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199730332
Status: Unutilized
Comment: 5200 sq. ft., presence of asbestos/lead paint, historical category, most recent use—admin., off-site use only

Bldg. T–5907
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199730333
Status: Unutilized
Comment: 570 sq. ft., presence of asbestos/lead paint, historical category, most recent use—admin., off-site use only

Bldg. T–5906
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199730420
Status: Unutilized
Comment: 570 sq. ft., presence of asbestos/lead paint, most recent use—admin., off-site use only

Bldg. P–1382
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199810365
Status: Unutilized
Comment: 30,082 sq. ft., presence of asbestos/lead paint, most recent use—housing, off-site use only

Bldg. T–5123
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199830350
Status: Unutilized
Comment: 2596 sq. ft., fair, hazard abatement required, most recent use—instruction, off-site use only, historical significance

Bldg. P–6150
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199830351
Status: Unutilized
Comment: 48 sq. ft., fair, hazard abatement required, most recent use—pumphouse, off-site use only

Bldgs. P–6331, P–6335, P–6495
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199830353
Status: Unutilized
Comment: 36 sq. ft., fair, hazard abatement required, most recent use—pumping station, off-site use only

Bldg. P–8000
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199830354
Status: Unutilized
Comment: 1766 sq. ft., fair, hazard abatement required, most recent use—housing, off-site use only

9 Bldgs.
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Location: #P8001, P8008, 8014, 8027, 8033, 8035, 8127, 8229, 8265
Landholding Agency: Army
Property Number: 21199830355
Status: Unutilized
Comment: 2456 sq. ft., fair, hazard abatement required, most recent use—housing, off-site use only

11 Bldgs.
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Location: #P8003, P8011, 8012, 8019, 8043, 8202, 8204, 8216, 8235, 8241, 8261
Landholding Agency: Army
Property Number: 21199830356
Status: Unutilized
Comment: 2358 sq. ft., fair, hazard abatement required, most recent use—housing, off-site use only

Bldgs. P–8003C, P–8220C
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199830357
Status: Unutilized
Comment: 1174 sq. ft., fair, hazard abatement required, most recent use—detached garage, off-site use only

Bldg. P–8004
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199830358
Status: Unutilized
Comment: 2243 sq. ft., fair, hazard abatement required, most recent use—housing, off-site use only

7 Bldgs.
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Location: #P8005, 8101, 8107, 8141, 8143, 8146, 8150
Landholding Agency: Army
Property Number: 21199830359
Status: Unutilized
Comment: 1804 sq. ft., fair, hazard abatement required, most recent use—housing, off-site use only

7 Bldgs.
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Location: #P8009, 8024, 8207, 8214, 8217, 8226, 8256
Landholding Agency: Army
Property Number: 21199830361
Status: Unutilized
Comment: 2253 sq. ft., fair, hazard abatement required, most recent use—housing, off-site use only

4 Bldgs.
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Location: #P8009C, 8027C, 8248C, 8256C
Landholding Agency: Army
Property Number: 21199830362
Status: Unutilized
Comment: 681 sq. ft., fair, hazard abatement required, most recent use—detached garage, off-site use only

3 Bldgs.
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Location: #P8012C, 8039C, 8224C
Landholding Agency: Army
Property Number: 21199830363
Status: Unutilized
Comment: 1185 sq. ft., fair, hazard abatement required, most recent use—detached garage, off-site use only

Bldg. P8016
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199830364
Status: Unutilized
Comment: 2347 sq. ft., fair, hazard abatement required, most recent use—housing, off-site use only

8 Bldgs.
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Location: #P8021, 8211, 8244, 8270, 8213, 8223, 8243. 8266
Landholding Agency: Army
Property Number: 21199830365
Status: Unutilized
Comment: 249 sq. ft., fair, hazard abatement required, most recent use—housing, off-site use only

Bldg. P–8022
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199830366
Status: Unutilized
Comment: 1849 sq. ft., fair, hazard abatement required, most recent use—housing, off-site use only

5 Bldgs.
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Location: #8022C, 8023C, 8106C, 8127C, 8206C
Landholding Agency: Army
Property Number: 21199830367
Status: Unutilized
Comment: 513 sq. ft., fair, hazard abatement required, most recent use—detached garage, off-site use only

Bldgs. P8026, P8028

Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199830369
Status: Unutilized
Comment: approx. 1850 sq. ft., fair, hazard abatement required, most recent use—housing, off-site use only

3 Bldgs.
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Location: #P8028C, P8143C, P8150C
Landholding Agency: Army
Property Number: 21199830370
Status: Unutilized
Comment: 838 sq. ft., fair, hazard abatement required, most recent use—detached garage, off-site use only

3 Bldgs.
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Location: #P8035C, P8104C, 8236C
Landholding Agency: Army
Property Number: 21199830372
Status: Unutilized
Comment: 1017 sq. ft., fair, hazard abatement required, most recent use—detached garage, off-site use only

3 Bldgs.
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Location: #P8102, 8106, 8108
Landholding Agency: Army
Property Number: 21199830375
Status: Unutilized
Comment: approx. 2700 sq. ft., fair, hazard abatement required, most recent use—housing, off-site use only

Bldgs. P8109, P8137
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199830376
Status: Unutilized
Comment: 1540 sq. ft., fair, hazard abatement required, most recent use—housing, off-site use only

Bldgs. P8112, P8228
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199830378
Status: Unutilized
Comment: 1807 sq. ft., fair, hazard abatement required, most recent use—housing, off-site use only

3 Bldgs.
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Location: P8116, 8151, 8158
Landholding Agency: Army
Property Number: 21199830380
Status: Unutilized
Comment: 1691 sq. ft., fair, hazard abatement required, most recent use—housing, off-site use only

Bldg. P8117
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199830381
Status: Unutilized
Comment: 1581 sq. ft., fair, hazard abatement required, most recent use—housing, off-site use only

8 Bldgs.
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Location: #P8118, 8121, 8125, 8153, 8119, 8120, 8124, 8168
Landholding Agency: Army
Property Number: 21199830382
Status: Unutilized
Comment: various sq. ft., fair, hazard abatement required, most recent use—housing, off-site use only

Bldgs. P8122, P8123
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199830383
Status: Unutilized
Comment: approx. 1400 sq. ft., fair, hazard abatement required, most recent use—housing, off-site use only

Bldg. P8126
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199830384
Status: Unutilized
Comment: 1331 sq. ft., fair, hazard abatement required, most recent use—housing, off-site use only

8 Bldgs.
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Location: P8131C, 8139C, 8203C, 8211C, 8231C, 8243C, 8249C, 8261C
Landholding Agency: Army
Property Number: 21199830386
Status: Unutilized
Comment: 849 sq. ft., fair, hazard abatement required, most recent use—detached garage, off-site use only

Bldgs. P8133, P8134
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199830387
Status: Unutilized
Comment: approx. 2000 sq. ft., fair, hazard abatement required, most recent use—housing, off-site use only

Bldgs. P8135, P8136
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199830388
Status: Unutilized
Comment: approx. 1500 sq. ft., fair, hazard abatement required, most recent use—housing, off-site use only

4 Bldgs.
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Location: #P8144, 8267, 8148, 8149
Landholding Agency: Army
Property Number: 21199830389
Status: Unutilized
Comment: approx. 2200 sq. ft., fair, hazard abatement required, most recent use—housing, off-site use only

Bldg. P8171
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199830392
Status: Unutilized
Comment: 1289 sq. ft., fair, hazard abatement required, most recent use—housing, off-site use only

Bldg. P8172
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199830393
Status: Unutilized
Comment: 1597 sq. ft., fair, hazard abatement required, most recent use—housing, off-site use only

Bldgs. P8173, P8174
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199830394
Status: Unutilized
Comment: approx. 2200 sq. ft., fair, hazard abatement required, most recent use—housing, off-site use only

Bldg. P8174C
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199830395
Status: Unutilized
Comment: 670 sq. ft., fair, hazard abatement required, most recent use—detached garage, off-site use only

Bldg. P8175
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199830396
Status: Unutilized
Comment: 2220 sq. ft., fair, hazard abatement required, most recent use—housing, off-site use only

Bldg. P8200
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199830397
Status: Unutilized
Comment: 892 sq. ft., fair, hazard abatement required, most recent use—officers quarters, off-site use only

Bldg. P8205
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199830399
Status: Unutilized
Comment: 1745 sq. ft., fair, hazard abatement required, most recent use—housing, off-site use only

3 Bldgs.
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Location: #P8206, 8232, 8233
Landholding Agency: Army
Property Number: 21199830400
Status: Unutilized
Comment: approx. 2400 sq. ft., fair, hazard abatement required, most recent use—housing, off-site use only

Bldg. P8245
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199830401
Status: Unutilized

Comment: 2876 sq. ft., fair, hazard abatement required, most recent use—housing, off-site use only

Bldgs. P8262C, 8271C
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199830403
Status: Unutilized
Comment: 1006 sq. ft., fair, hazard abatement required, most recent use—detached garage, off-site use only

Bldg. P8269
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199830404
Status: Unutilized
Comment: 2396 sq. ft., fair, hazard abatement required, most recent use—housing, off-site use only

20 Bldgs.
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Location: #P8271, 8002, 8018, 8025, 8037, 8100, 8130, 8132, 8138, 8140, 8142, 8145, 8147, 8210, 8212, 8221, 8242, 8247, 8264, 8257
Landholding Agency: Army
Property Number: 21199830405
Status: Unutilized
Comment: 2777 sq. ft., fair, hazard abatement required, most recent use—housing, off-site use only

Bldg. 41
Fort Hood
Ft. Hood Co: Coryell TX 76544–
Landholding Agency: Army
Property Number: 21199920208
Status: Unutilized
Comment: 1750 sq. ft., needs repair, most recent use—admin., off-site use only

Bldg. 919
Fort Hood
Ft. Hood Co: Coryell TX 76544–
Landholding Agency: Army
Property Number: 21199920212
Status: Unutilized
Comment: 11,800 sq. ft., needs repair, most recent use—Bde. Hq. Bldg., off-site use only

Bldg. 3959
Fort Hood
Ft. Hood Co: Coryell TX 76544–
Landholding Agency: Army
Property Number: 21199920224
Status: Unutilized
Comment: 3373 sq. ft., needs repair, most recent use—admin., off-site use only

Bldgs. 3967–3969
Fort Hood
Ft. Hood Co: Coryell TX 76544–
Landholding Agency: Army
Property Number: 21199920228
Status: Unutilized
Comment: 5310 sq. ft., needs repair, most recent use—admin., off-site use only

Bldgs. 3970–3971
Fort Hood
Ft. Hood Co: Coryell TX 76544–
Landholding Agency: Army
Property Number: 21199920229
Status: Unutilized
Comment: 3241 sq. ft., needs repair, most recent use—admin., off-site use only

4 Bldgs.
Fort Sam Houston
S6161, S6162, S6167, S6168
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21200010132
Status: Unutilized
Comment: 900 sq. ft., needs major repairs, most recent use—admin., off-site use only

Bldg. S1448
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21200010133
Status: Unutilized
Comment: 4200 sq. ft., possible asbestos/lead paint, most recent use—admin., off-site use only

Bldg. T5001
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21200010134
Status: Unutilized
Comment: 1186 sq. ft., needs major repairs, possible asbestos/lead paint, most recent use—admin., off-site use only

Bldg. S6163
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21200010136
Status: Unutilized
Comment: 3200 sq. ft., needs major repairs, most recent use—admin., off-site use only

Bldg. S6169
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21200010137
Status: Unutilized
Comment: 1800 sq. ft., needs major repairs, most recent use—admin., off-site use only

Bldg. P–2375A
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21200020202
Status: Unutilized
Comment: 108 sq. ft., presence of lead paint, most recent use—storage, off-site use only

Bldg. T–5004
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21200020203
Status: Unutilized
Comment: 4489 sq. ft., presence of asbestos/lead paint, most recent use—storage, off-site use only

Bldg. 92043
Fort Hood
Ft. Hood Co: Bell TX 76544–
Landholding Agency: Army
Property Number: 21200020206
Status: Unutilized
Comment: 450 sq. ft., most recent use—storage, off-site use only

Bldg. 92044
Fort Hood
Ft. Hood Co: Bell TX 76544–
Landholding Agency: Army
Property Number: 21200020207
Status: Unutilized
Comment: 1920 sq. ft., most recent use—admin., off-site use only

Bldg. 92045
Fort Hood
Ft. Hood Co: Bell TX 76544–
Landholding Agency: Army
Property Number: 21200020208
Status: Unutilized
Comment: 2108 sq. ft., most recent use—maint., off-site use only

Bldg. P–8219
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21200030110
Status: Excess
Comment: 2456 sq. ft., presence of asbestos/lead paint, most recent use—family house, off-site use only

Bldg. 4422
Fort Hood
Ft. Hood Co: Bell TX 76544–
Landholding Agency: Army
Property Number: 21200030111
Status: Unutilized
Comment: 5310 sq. ft., most recent use—barracks, off-site use only

Bldg. 4423
Fort Hood
Ft. Hood Co: Bell TX 76544–
Landholding Agency: Army
Property Number: 21200030112
Status: Unutilized
Comment: 5310 sq. ft., most recent use—barracks, off-site use only

Bldg. 4462
Fort Hood
Ft. Hood Co: Bell TX 76544–
Landholding Agency: Army
Property Number: 21200030113
Status: Unutilized
Comment: 5310 sq. ft., most recent use—barracks, off-site use only

Bldg. 4463
Fort Hood
Ft. Hood Co: Bell TX 76544–
Landholding Agency: Army
Property Number: 21200030114
Status: Unutilized
Comment: 5310 sq. ft., most recent use—barracks, off-site use only

Bldg. 4464
Fort Hood
Ft. Hood Co: Bell TX 76544–
Landholding Agency: Army
Property Number: 21200030115
Status: Unutilized
Comment: 5310 sq. ft., most recent use—barracks, off-site use only

Bldg. 4469
Fort Hood
Ft. Hood Co: Bell TX 76544–
Landholding Agency: Army
Property Number: 21200030116
Status: Unutilized
Comment: 5310 sq. ft., most recent use—barracks, off-site use only

Bldg. P–376
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21200110090
Status: Excess
Comment: 2529 sq. ft., presence of asbestos/lead paint, most recent use—post exchange

services, historic preservation requirements, off-site use only
Bldg. 1281
Fort Bliss
El Paso Co: TX 79916–
Landholding Agency: Army
Property Number: 21200110091
Status: Unutilized
Comment: 25,027 sq. ft., most recent use—cold storage, off-site use only
Bldg. 2542
Fort Bliss
El Paso Co: TX 79916–
Landholding Agency: Army
Property Number: 21200110092
Status: Unutilized
Comment: 3103 sq. ft., most recent use—gen. purpose, off-site use only
Bldg. 3656
Fort Bliss
El Paso Co: TX 79916–
Landholding Agency: Army
Property Number: 21200110093
Status: Unutilized
Comment: 1806 sq. ft., most recent use—igloo str. inst., off-site use only
Bldg. 7113
Fort Bliss
El Paso Co: TX 79916–
Landholding Agency: Army
Property Number: 21200110094
Status: Unutilized
Comment: 14,807 sq. ft., most recent use—nursery school, off-site use only
Bldg. 7133
Fort Bliss
El Paso Co: TX 79916–
Landholding Agency: Army
Property Number: 21200110095
Status: Unutilized
Comment: 11,650 sq. ft., most recent use—storage, off-site use only
Bldg. 7136
Fort Bliss
El Paso Co: TX 79916–
Landholding Agency: Army
Property Number: 21200110096
Status: Unutilized
Comment: 11,755 sq. ft., most recent use—vet facility, off-site use only
Bldg. 7146
Fort Bliss
El Paso Co: TX 79916–
Landholding Agency: Army
Property Number: 21200110097
Status: Unutilized
Comment: most recent use—oil storage, off-site use only
Bldg. 7147
Fort Bliss
El Paso Co: TX 79916–
Landholding Agency: Army
Property Number: 21200110098
Status: Unutilized
Comment: most recent use—oil storage, off-site use only
Bldg. 7153
Fort Bliss
El Paso Co: TX 79916–
Landholding Agency: Army
Property Number: 21200110099
Status: Unutilized
Comment: 11924 sq. ft., most recent use—bowling center, off-site use only
Bldg. 7162
Fort Bliss
El Paso Co: TX 79916–
Landholding Agency: Army
Property Number: 21200110100
Status: Unutilized
Comment: 3956 sq. ft., most recent use—development center, off-site use only
Bldg. 11116
Fort Bliss
El Paso Co: TX 79916–
Landholding Agency: Army
Property Number: 21200110101
Status: Unutilized
Comment: 20,100 sq. ft., most recent use—storage, off-site use only
Bldg. 11127
Fort Bliss
El Paso Co: TX 79916–
Landholding Agency: Army
Property Number: 21200110102
Status: Unutilized
Comment: 9172 sq. ft., most recent use—storage, off-site use only

Virginia

Bldg. 178
Fort Monroe
Ft. Monroe Co: VA 23651–
Landholding Agency: Army
Property Number: 21199940046
Status: Unutilized
Comment: 1180 sq. ft., needs repair, most recent use—storage, off-site use only
Bldg. T246
Fort Monroe
Ft. Monroe Co: VA 23651–
Landholding Agency: Army
Property Number: 21199940047
Status: Unutilized
Comment: 756 sq. ft., needs repair, possible lead paint, most recent use—scout meetings, off-site use only
Bldgs. 1630, 1633, 1636
Fort Eustis
Ft. Eustis Co: VA 23604–
Landholding Agency: Army
Property Number: 21200030119
Status: Unutilized
Comment: 720 sq. ft., most recent use—storehouse, off-site use only
Bldgs. SS0305, SS0306
Fort A.P. Hill
Bowling Green Co: Caroline VA 22428–
Landholding Agency: Army
Property Number: 21200120132
Status: Unutilized
Comment: 1250 sq. ft., concrete block, off-site use only
Bldg. 16
Defense Supply Center
Richmond Co: Chesterfield VA 23297–
Landholding Agency: Army
Property Number: 21200120133
Status: Unutilized
Comment: 165 sq. ft., most recent use—sewage lift station bldg., off-site use only
Bldg. 46
Defense Supply Center
Richmond Co: Chesterfield VA 23297–
Landholding Agency: Army
Property Number: 21200120134
Status: Unutilized
Comment: 124 sq. ft., most recent use—storage, off-site use only
Bldg. 52
Defense Supply Center
Richmond Co: Chesterfield VA 23297–
Landholding Agency: Army
Property Number: 21200120135
Status: Unutilized
Comment: 240 sq. ft., presence of lead paint, most recent use—storage, off-site use only
Bldg. 68
Defense Supply Center
Richmond Co: Chesterfield VA 23297–
Landholding Agency: Army
Property Number: 21200120136
Status: Unutilized
Comment: 400 sq. ft., most recent use—storage, off-site use only
Bldg. 75
Defense Supply Center
Richmond Co: Chesterfield VA 23297–
Landholding Agency: Army
Property Number: 21200120137
Status: Unutilized
Comment: 1010 sq. ft., site contamination, most recent use—storage, off-site use only
Bldg. 112
Defense Supply Center
Richmond Co: Chesterfield VA 23297–
Landholding Agency: Army
Property Number: 21200120138
Status: Unutilized
Comment: 1744 sq. ft., presence of pesticides/asbestos, most recent use—storage, off-site use only

Washington

13 Bldgs., Fort Lewis
A0402, CO723, CO726, CO727, CO902, CO903, CO906, CO907, CO922, CO923, CO926, CO927, C1250
Ft. Lewis Co: Pierce WA 98433–9500
Landholding Agency: Army
Property Number: 21199630199
Status: Unutilized
Comment: 2360 sq. ft., possible asbestos/lead paint, most recent use—barracks, off-site use only
7 Bldgs., Fort Lewis
AO438, AO439, CO901, CO910, CO911, CO918, CO919
Ft. Lewis Co: Pierce WA 98433–9500
Landholding Agency: Army
Property Number: 21199630200
Status: Unutilized
Comment: 1144 sq. ft., possible asbestos/lead paint, most recent use—dayroom bldgs., off-site use only
6 Bldgs., Fort Lewis
CO908, CO728, CO921, CO928, C1008, C1108
Ft. Lewis Co: Pierce WA 98433–9500
Landholding Agency: Army
Property Number: 21199630204
Status: Unutilized
Comment: 2207 sq. ft., possible asbestos/lead paint, most recent use—dining, off-site use only
Bldg. CO909, Fort Lewis
Ft. Lewis Co: Pierce WA 98433–9500
Landholding Agency: Army
Property Number: 21199630205
Status: Unutilized
Comment: 1984 sq. ft., possible asbestos/lead paint, most recent use—admin., off-site use only
Bldg. CO920, Fort Lewis
Ft. Lewis Co: Pierce WA 98433–9500

Landholding Agency: Army
Property Number: 21199630206
Status: Unutilized
Comment: 1984 sq. ft., possible asbestos/lead paint, most recent use—admin., off-site use only

Bldg. C1249, Fort Lewis
Ft. Lewis Co: Pierce WA 98433–9500
Landholding Agency: Army
Property Number: 21199630207
Status: Unutilized
Comment: 992 sq. ft., possible asbestos/lead paint, most recent use—storage, off-site use only

Bldg. 1164, Fort Lewis
Ft. Lewis Co: Pierce WA 98433–9500
Landholding Agency: Army
Property Number: 21199630213
Status: Unutilized
Comment: 230 sq. ft., possible asbestos/lead paint, most recent use—storehouse, off-site use only

Bldg. 1307, Fort Lewis
Ft. Lewis Co: Pierce WA 98433–9500
Landholding Agency: Army
Property Number: 21199630216
Status: Unutilized
Comment: 1092 sq. ft., possible asbestos/lead paint, most recent use—storage, off-site use only

Bldg. 1309, Fort Lewis
Ft. Lewis Co: Pierce WA 98433–9500
Landholding Agency: Army
Property Number: 21199630217
Status: Unutilized
Comment: 1092 sq. ft., possible asbestos/lead paint, most recent use—storage, off-site use only

Bldg. 2167, Fort Lewis
Ft. Lewis Co: Pierce WA 98433–9500
Landholding Agency: Army
Property Number: 21199630218
Status: Unutilized
Comment: 288 sq. ft., possible asbestos/lead paint, most recent use—warehouse, off-site use only

Bldg. 4078, Fort Lewis
Ft. Lewis Co: Pierce WA 98433–9500
Landholding Agency: Army
Property Number: 21199630219
Status: Unutilized
Comment: 10200 sq. ft., needs rehab, possible asbestos/lead paint, most recent use—warehouse, off-site use only

Bldg. 9599, Fort Lewis
Ft. Lewis Co: Pierce WA 98433–9500
Landholding Agency: Army
Property Number: 21199630220
Status: Unutilized
Comment: 12366 sq. ft., possible asbestos/lead paint, most recent use—warehouse, off-site use only

Bldg. A1404, Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199640570
Status: Unutilized
Comment: 557 sq. ft., needs rehab, most recent use—storage, off-site use only

Bldg. A1419, Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199640571
Status: Unutilized
Comment: 1307 sq. ft., needs rehab, most recent use—storage, off-site use only

Bldg. EO202
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199710149
Status: Unutilized
Comment: 992 sq. ft., possible asbestos/lead paint, most recent use—office, off-site use only

Bldg. EO347
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199710156
Status: Unutilized
Comment: 1800 sq. ft., possible asbestos/lead paint, most recent use—office, off-site use only

Bldg. B1008, Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199720216
Status: Unutilized
Comment: 7387 sq. ft., 2-story, needs rehab, possible asbestos/lead paint, most recent use—medical clinic, off-site use only

Bldgs. B1011-B1012, Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199720217
Status: Unutilized
Comment: 992 sq. ft. and 1144 sq. ft., needs rehab, possible asbestos/lead paint, most recent use—office, off-site use only

Bldgs. CO509, CO709, CO720
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199810372
Status: Unutilized
Comment: 1984 sq. ft., possible asbestos/lead paint, needs rehab, most recent use—storage, off-site use only

4 Bldgs.
Fort Lewis
CO511, CO710, CO711, CO719
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199810373
Status: Unutilized
Comment: 1,144 sq. ft., possible asbestos/lead paint, needs rehab, most recent use—dayrooms, off-site use only

11 Bldgs.
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Location: CO528, CO701, CO708, CO721, CO526, CO527, CO702, CO703, CO706, CO707, CO722
Landholding Agency: Army
Property Number: 21199810374
Status: Unutilized
Comment: 2207 sq. ft., possible asbestos/lead paint, needs rehab, most recent use—dining, off-site use only

Bldg. 5162
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199830419
Status: Unutilized
Comment: 2360 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—office, off-site use only

Bldg. A0631
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199830422
Status: Unutilized
Comment: 2207 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—dayroom, off-site use only

Bldg. B0813
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199830427
Status: Unutilized
Comment: 1144 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—office, off-site use only

Bldg. B0812
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199830428
Status: Unutilized
Comment: 1144 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—dayroom, off-site use only

Bldg. 5224
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199830433
Status: Unutilized
Comment: 2360 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—educ. fac., off-site use only

Bldg. U001B
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920237
Status: Excess
Comment: 54 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—control tower, off-site use only

Bldg. U001C
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920238
Status: Unutilized
Comment: 960 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—supply, off-site use only

10 Bldgs.
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Location: U002B, U002C, U005C, U015I, U016E, U019C, U022A, U028B, 0091A, U093C
Landholding Agency: Army
Property Number: 21199920239
Status: Excess
Comment: 600 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—range house, off-site use only

6 Bldgs.
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Location: U003A, U004B, U006C, U015B, U016B, U019B

Landholding Agency: Army
Property Number: 21199920240
Status: Unutilized
Comment: 54 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—control tower, off-site use only
Bldg. U004D
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920241
Status: Unutilized
Comment: 960 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—supply, off-site use only
Bldg. U005A
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920242
Status: Unutilized
Comment: 360 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—control tower, off-site use only
Bldgs. U006A, U024A
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920243
Status: Excess
Comment: 1440 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—shelter, off-site use only
Bldgs. U007A, U021A
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920244
Status: Excess
Comment: 100 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—control tower, off-site use only
7 Bldgs.
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Location: U014A, U022B, U023A, U043B, U059B, U060A, U101A
Landholding Agency: Army
Property Number: 21199920245
Status: Excess
Comment: needs repair, presence of asbestos/lead paint, most recent use—ofc/tower/support, off-site use only
Bldg. U015J
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920246
Status: Excess
Comment: 144 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—tower, off-site use only
Bldg. U018B
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920247
Status: Unutilized
Comment: 121 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—range house, off-site use only
Bldg. U018C
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920248
Status: Unutilized
Comment: 48 sq. ft., needs repair, presence of asbestos/lead paint, off-site use only
Bldg. U024B
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920249
Status: Unutilized
Comment: 168 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—control tower, off-site use only
Bldg. U024D
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920250
Status: Unutilized
Comment: 120 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—ammo bldg., off-site use only
Bldg. U027A
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920251
Status: Excess
Comment: 64 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—tire house, off-site use only
Bldgs. U028A–U032A
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920252
Status: Unutilized
Comment: 72 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—control tower, off-site use only
Bldg. U031A
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920253
Status: Excess
Comment: 3456 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—line shed, off-site use only
Bldg. U031C
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920254
Status: Unutilized
Comment: 32 sq. ft., needs repair, presence of asbestos/lead paint, off-site use only
Bldg. U040D
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920255
Status: Excess
Comment: 800 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—range house, off-site use only
Bldgs. U052C, U052H
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920256
Status: Excess
Comment: various sq. ft., needs repair, presence of asbestos/lead paint, most recent use—range house, off-site use only
Bldgs. U035A, U035B
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920257
Status: Excess
Comment: 192 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—shelter, off-site use only
Bldg. U035C
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920258
Status: Excess
Comment: 242 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—range house, off-site use only
Bldg. U039A
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920259
Status: Excess
Comment: 36 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—control tower, off-site use only
Bldg. U039B
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920260
Status: Excess
Comment: 1600 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—grandstand/bleachers, off-site use only
Bldg. U039C
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920261
Status: Excess
Comment: 600 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—support, off-site use only
Bldg. U043A
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920262
Status: Excess
Comment: 132 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—range house, off-site use only
Bldg. U052A
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920263
Status: Excess
Comment: 69 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—tower, off-site use only
Bldg. U052E
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920264
Status: Excess
Comment: 600 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—storage, off-site use only
Bldg. U052G
Fort Lewis

Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920265
Status: Excess
Comment: 1600 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—shelter, off-site use only

3 Bldgs.
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Location: U058A, U103A, U018A
Landholding Agency: Army
Property Number: 21199920266
Status: Excess
Comment: 36 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—control tower, off-site use only

Bldg. U059A
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920267
Status: Excess
Comment: 16 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—tower, off-site use only

Bldg. U093B
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920268
Status: Excess
Comment: 680 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—range house, off-site use only

4 Bldgs.
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Location: U101B, U101C, U507B, U557A
Landholding Agency: Army
Property Number: 21199920269
Status: Excess
Comment: 400 sq. ft., needs repair, presence of asbestos/lead paint, off-site use only

Bldg. U102B
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920270
Status: Excess
Comment: 1058 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—shelter, off-site use only

Bldg. U108A
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920271
Status: Excess
Comment: 31,320 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—line shed, off-site use only

Bldg. U110B
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920272
Status: Excess
Comment: 138 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—support, off-site use only

6 Bldgs.
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Location: U111A, U015A, U024E, U052F, U109A, U110A
Landholding Agency: Army
Property Number: 21199920273
Status: Excess
Comment: 1000 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—support/shelter/mess, off-site use only

Bldg. U112A
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920274
Status: Excess
Comment: 1600 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—shelter, off-site use only

Bldg. U115A
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920275
Status: Excess
Comment: 36 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—tower, off-site use only

Bldg. U507A
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920276
Status: Excess
Comment: 400 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—support, off-site use only

Bldg. U516B
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920277
Status: Excess
Comment: 5000 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—shed, off-site use only

Bldg. F0022A
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920279
Status: Excess
Comment: 4373 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—gen. inst., off-site use only

Bldg. F0022B
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920280
Status: Excess
Comment: 3100 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—storage, off-site use only

Bldg. C0120
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920281
Status: Excess
Comment: 384 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—scale house, off-site use only

Bldg. A0220
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920282
Status: Excess
Comment: 2284 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—club facility, off-site use only

Bldg. A0334
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920284
Status: Excess
Comment: 1092 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—sentry station, off-site use only.

12 Bldgs.
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Location: C1002, C1003, C1006, C1007, C1022, C1023, C1026, C1027, C1207, C1301, C13333, C1334
Landholding Agency: Army
Property Number: 21199920287
Status: Excess
Comment: 2360 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—barracks, off-site use only

Bldg. D1154
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920289
Status: Excess
Comment: 1165 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—day room, off-site use only

Bldg. 01205
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920290
Status: Excess
Comment: 87 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—storehouse, off-site use only

Bldg. 01259
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920291
Status: Excess
Comment: 16 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—storage, off-site use only

Bldg. 01266
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920292
Status: Excess
Comment: 45 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—shelter, off-site use only

Bldg. 1445
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920294
Status: Excess
Comment: 144 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—generator bldg., off-site use only

Bldg. 02082
Fort Lewis

Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920295
Status: Excess
Comment: 16 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—storage, off-site use only

Bldgs. 03091, 03099
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920296
Status: Excess
Comment: various sq. ft., needs repair, presence of asbestos/lead paint, most recent use—sentry station, off-site use only

Bldgs. 03100, 3101
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920297
Status: Excess
Comment: various sq. ft., needs repair, presence of asbestos/lead paint, most recent use—storage, off-site use only

Bldg. 4040
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920298
Status: Excess
Comment: 8326 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—shed, off-site use only

Bldgs. 4072, 5104
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920299
Status: Excess
Comment: 24/36 sq. ft., needs repair, presence of asbestos/lead paint, off-site use only

Bldg. 4295
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920300
Status: Excess
Comment: 48 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—storage, off-site use only

Bldg. 5170
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920301
Status: Excess
Comment: 19,411 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—store, off-site use only

Bldg. 6191
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920303
Status: Excess
Comment: 3663 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—exchange branch, off-site use only

Bldgs. 08076, 08080
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920304
Status: Excess
Comment: 3660/412 sq. ft., needs repair, presence of asbestos/lead paint, off-site use only

Bldg. 08093
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920305
Status: Excess
Comment: 289 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—boat storage, off-site use only

Bldg. 8279
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920306
Status: Excess
Comment: 210 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—fuel disp. fac., off-site use only

Bldgs. 8280, 8291
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920307
Status: Excess
Comment: 800/464 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—storage, off-site use only

Bldg. 8956
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920308
Status: Excess
Comment: 100 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—storage, off-site use only

Bldg. 9530
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920309
Status: Excess
Comment: 64 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—sentry station, off-site use only

Bldg. 9574
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920310
Status: Excess
Comment: 6005 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—veh. shop., off-site use only

Bldg. 9596
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920311
Status: Excess
Comment: 36 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—gas station, off-site use only

Bldg. 9939
Fort Lewis
Ft. Lewis Co: Pierce WA 98433–
Landholding Agency: Army
Property Number: 21199920313
Status: Excess
Comment: 600 sq. ft., needs repair, presence of asbestos/lead paint, most recent use—recreation, off-site use only

Land (by State)

Georgia

Land (Railbed)
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199440440
Status: Unutilized
Comment: 17.3 acres extending 1.24 miles, no known utilities potential

New York

Land—6.965 Acres
Dix Avenue
Queensbury Co: Warren NY 12801–
Landholding Agency: Army
Property Number: 21199540018
Status: Unutilized
Comment: 6.96 acres of vacant land, located in industrial area, potential utilities

300 acres
U.S. Military Academy
Highlands Co: Orange NY 10996–1592
Landholding Agency: Army
Property Number: 21200040070
Status: Unutilized
Comment: approx. 300 acres, contains wetlands and rare flora

South Carolina

One Acre
Fort Jackson
Columbia Co: Richland SC 29207–
Landholding Agency: Army
Property Number: 21200110089
Status: Underutilized
Comment: approx. 1 acre

Texas

Old Camp Bullis Road
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199420461
Status: Unutilized
Comment: 7.16 acres, rural gravel road

Suitable/Unavailable Properties

Buildings (by State)

Georgia

Bldg. 4090
Fort Benning
Ft. Benning Co: Muscogee GA 31905–
Landholding Agency: Army
Property Number: 21199630007
Status: Underutilized
Comment: 3530 sq. ft., most recent use—chapel, off-site use only

Kansas

Bldg. P–295
Fort Leavenworth
Leavenworth Co: Leavenworth KS 66027–
Landholding Agency: Army
Property Number: 21199810296
Status: Unutilized
Comment: 3480 sq. ft., concrete, most recent use—underground storage, off-site use only

Missouri

Bldg. 2172
Fort Leonard Wood

Ft. Leonard Wood Co: Pulaski MO 65473–8994
Landholding Agency: Army
Property Number: 21200040059
Status: Unutilized
Comment: 2892 sq. ft., most recent use—operations, off-site use only

Bldg. 5041
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–8994
Landholding Agency: Army
Property Number: 21200040060
Status: Unutilized
Comment: 1000 sq. ft., most recent use—classroom, off-site use only

Texas

Bldg. P–2000, Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199220389
Status: Underutilized
Comment: 49,542 sq. ft., 3-story brick structure, within National Landmark Historic District

Bldg. P–2001, Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 21199220390
Status: Underutilized
Comment: 16,539 sq. ft., 4-story brick structure, within National Landmark Historic District

Land (by State)

North Carolina

.92 Acre—Land
Military Ocean Terminal, Sunny Point
Southport Co: Brunswick NC 28461–5000
Landholding Agency: Army
Property Number: 21199610728
Status: Underutilized
Comment: municipal drinking waterwell, restricted by explosive safety regs., New Hanover County Buffer Zone

10 Acre—Land
Military Ocean Terminal, Sunny Point
Southport Co: Brunswick NC 28461–5000
Landholding Agency: Army
Property Number: 21199610729
Status: Underutilized
Comment: municipal park, restricted by explosive safety regs., New Hanover County Buffer Zone

257 Acre—Land
Military Ocean Terminal, Sunny Point
Southport Co: Brunswick NC 28461–5000
Landholding Agency: Army
Property Number: 21199610730
Status: Underutilized
Comment: state park, restricted by explosive safety regs., New Hanover County Buffer Zone

24.83 acres—Tract of Land
Military Ocean Terminal, Sunny Point
Southport Co: Brunswick NC 28461–5000
Landholding Agency: Army
Property Number: 21199620685
Status: Underutilized
Comment: 24.83 acres, municipal park, most recent use—New Hanover County explosive buffer zone

Unsuitable Properties

Buildings (by State)

Alabama

13 Bldgs.
Redstone Arsenal
Redstone Arsenal Co: Madison AL 35898–
Landholding Agency: Army
Property Number: 21200040001–21200040012, 21200120018
Status: Unutilized
Reason: Secured Area Extensive deterioration

22 Bldgs., Fort Rucker
Ft. Rucker Co: Dale AL 36362
Landholding Agency: Army
Property Number: 219330003, 219410022, 219520057–219520058, 219740004, 219740006, 219830002, 21199930019, 21200040013, 21200130001
Status: Unutilized
Reason: Extensive deterioration

Bldgs. 25203, 25205–25207, 25209
Fort Rucker
Stagefield Areas
Ft. Rucker Co: Dale AL 36362–5138
Landholding Agency: Army
Property Number: 219410020
Status: Unutilized
Reason: Secured area

Alaska

8 Bldgs., Fort Wainwright
Ft. Wainwright AK 99703
Landholding Agency: Army
Property Number: 219710090, 219710195–219710198, 219810002, 219810007, 21199920001
Status: Unutilized
Reason: Within 2000 ft. of flammable or explosive material; Secured area; Floodway (Some are extensively deteriorated)

Arizona

32 Bldgs.
Navajo Depot Activity
Bellemont Co: Coconino AZ 86015–
Location: 12 miles west of Flagstaff, Arizona on I–40
Landholding Agency: Army
Property Number: 219014560–219014591
Status: Underutilized
Reason: Secured Area

10 properties: 753 earth covered igloos; above ground standard magazines
Navajo Depot Activity
Bellemont Co: Coconino AZ 86015–
Location: 12 miles west of Flagstaff, Arizona on I–40
Landholding Agency: Army
Property Number: 219014592–219014601
Status: Underutilized
Reason: Secured Area

7 Bldgs.
Navajo Depot Activity
Bellemont Co: Coconino AZ 86015–5000
Location: 12 miles west of Flagstaff on I–40
Landholding Agency: Army
Property Number: 219030273–219030274, 219120177–219120181
Status: Unutilized
Reason: Secured Area

Bldgs. S–2003, S–2093
Yuma Proving Ground
Yuma Co: La Paz AZ 85365–9104
Landholding Agency: Army
Property Number: 21200120027–21200120028
Status: Excess
Reason: Extensive deterioration

Arkansas

177 Bldgs., Fort Chaffee
Ft. Chaffee Co: Sebastian AR 72905–5000
Landholding Agency: Army
Property Number: 219630019–219630029, 219640462–219640477
Status: Unutilized
Reason: Extensive deterioration

88 Bldgs.
Ft. Chaffee Maneuver Training Center
Ft. Chaffee Co: Sebastian AR 72905–1370
Landholding Agency: Army
Property Number: 21200110001–21200110017
Status: Unutilized
Reason: Extensive deterioration

California

Bldg. 18
Riverbank Army Ammunition Plant
5300 Claus Road
Riverbank Co: Stanislaus CA 95367–
Landholding Agency: Army
Property Number: 219012554
Status: Unutilized
Reason: Within 2000 ft. of flammable or explosive material; Secured Area

11 Bldgs., Nos. 2–8, 156, 1, 120, 181
Riverbank Army Ammunition Plant
Riverbank Co: Stanislaus CA 95367–
Landholding Agency: Army
Property Number: 219013582–219013588, 219013590, 219240444–219240446
Status: Underutilized
Reason: Secured Area

Bldgs. 13, 171, 178 Riverbank Ammun Plant
5300 Claus Road
Riverbank Co: Stanislaus CA 95367–
Landholding Agency: Army
Property Number: 219120162–219120164
Status: Underutilized
Reason: Secured Area

32 Bldgs.
DDDRW Sharpe Facility
Tracy Co: San Joaquin CA 95331
Landholding Agency: Army
Property Number: 219610289, 219610291, 21199930021, 21200020028–21200020030, 21200030004–21200030015, 21200040015, 21200120029–21200120040, 21200130004
Status: Unutilized
Reason: Secured Area

Bldgs. 29, 39, 73, 154, 155, 193, 204, 257
Los Alamitos Co: Orange CA 90720–5001
Landholding Agency: Army
Property Number: 219520040
Status: Unutilized
Reason: Extensive deterioration

Bldgs. 1103, 1131, 1120, 341, 1160
Parks Reserve Forces Training Area
Dublin Co: Alameda CA 94568–5201
Landholding Agency: Army
Property Number: 219520056, 219830010, 21200110021–21200110022
Status: Unutilized
Reason: Extensive deterioration

10 Bldgs.
Sierra Army Depot
Herlong Co: Lassen CA 96113
Landholding Agency: Army

Property Number: 21199840015
21199920033–21199920036,
21199940052–21199940056
Status: Underutilized
Reason: Within 2000 ft. of flammable or explosive material; Secured Area

449 Bldgs.
Camp Roberts
Camp Roberts Co: San Obispo CA
Landholding Agency: Army
Property Number: 21199730014, 219820192–219820235
Status: Excess
Reason: Secured Area Extensive deterioration

33 Bldgs.
Presidio of Monterey Annex
Seaside Co: Monterey CA 93944
Landholding Agency: Army
Property Number: 219810380–219810381, 21199930106–21199930108, 21199940050–21199940051, 21200130005
Status: Unutilized
Reason: Extensive deterioration

34 Bldgs.
Fort Irwin
Ft. Irwin Co: San Bernardino CA 92310
Landholding Agency: Army
Property Number: 21199920037–21199920038, 21200030016–21200030018, 21200040014, 21200110018–21200110020, 21200130002–21200130003
Status: Unutilized
Reason: Secured Area; Extensive deterioration

Colorado

Bldgs. T–317, T–412, 431, 433
Rocky Mountain Arsenal
Commerce Co: Adams CO 80022–2180
Landholding Agency: Army
Property Number: 219320013–219320016
Status: Unutilized
Reason: Within 2000 ft. of flammable or explosive material; Secured Area; Extensive deterioration

40 Bldgs. Fort Carson
Ft. Carson Co: El Paso CO 80913–5023
Landholding Agency: Army
Property Number: 219830020–219830030, 21199910008, 21199930022,21199930025, 21200130006–21200130011
Status: Unutilized
Reason: Extensive deterioration

Bldgs. 00087, 00088, 00096
Pueblo Chemical Depot
Pueblo CO 81006–9330
Landholding Agency: Army
Property Number: 21200030019–21200030021
Status: Unutilized
Reason: Extensive deterioration

Georgia

Fort Stewart
Sewage Treatment Plant
Ft. Stewart Co: Hinesville GA 31314–
Landholding Agency: Army
Property Number: 219013922
Status: Unutilized
Reason: Sewage treatment

Facility 12304
Fort Gordon
Augusta Co: Richmond GA 30905–
Location: Located off Lane Avenue
Landholding Agency: Army
Property Number: 219014787
Status: Unutilized
Reason: Wheeled vehicle grease/inspection rack

123 Bldgs.
Fort Gordon
Augusta Co: Richmond GA 30905–
Landholding Agency: Army
Property Number: 219220269, 219320026, 219410050–219410060, 219410071–219410072, 219410100, 219410109, 219630044–219630063, 219640011–219640037, 219710094, 219730020, 219830034–219830067, 21199910012, 21200120041
Status: Unutilized
Reason: Extensive deterioration

3 Bldgs., Fort Benning
Ft. Benning Co: Muscogee GA 31905
Landholding Agency: Army
Property Number: 219220335–219220337
Status: Unutilized
Reason: Detached lavatory

23 Bldgs., Fort Benning
Ft. Benning Co: Muscogee GA 31905
Landholding Agency: Army
Property Number: 219520150, 219610320, 219720017–219720020, 219810028–219810031, 219810035, 219830073–219830076, 21199930031–21199930037, 21200030023–21200030028
Status: Unutilized
Reason: Extensive deterioration

18 Bldgs.
Fort Gillem
Forest Park Co: Clayton GA 30050
Landholding Agency: Army
Property Number: 219620815, 21199920044–21199920051, 21199930026, 21200040019–21200040021
Status: Unutilized
Reason: Extensive deterioration; Secured Area

Bldg. P8121, Fort Stewart
Hinesville Co: Liberty GA 31314
Landholding Agency: Army
Property Number: 21199940060
Status: Unutilized
Reason: Extensive Deterioration

5 Bldgs., Hunter Army Airfield
Savannah Co: Chatham GA 31409
Landholding Agency: Army
Property Number: 219630034, 219830068, 21200020031, 21200120042
Status: Unutilized
Reason: Extensive deterioration

3 Bldgs., Fort McPherson
Ft. McPherson Co: Fulton GA 30330–5000
Landholding Agency: Army
Property Number: 21200040016–21200040018
Status: Unutilized
Reason: Secured Area

Hawaii

17 Bldgs.
Schofield Barracks
Wahiawa Co: Wahiawa HI 96786–
Landholding Agency: Army
Property Number: 219014836–219014837, 219030361, 21200130015–21200130016
Status: Unutilized
Reason: Secured Area; (Most are extensively deteriorated)

Bldg. T–1305
Wheeler Army Airfield
Wahiawa HI 96857
Landholding Agency: Army
Property Number: 219610348
Status: Unutilized
Reason: Extensive deterioration

5 Bldgs.
Fort Shafter
Honolulu Co: HI 96819
Landholding Agency: Army
Property Number: 21200030029–21200030031, 21200130013–21200130014
Status: Unutilized
Reason: Extensive deterioration

Bldg. P–25
Dillingham Military Reservation
Honolulu Co: HI
Landholding Agency: Army
Property Number: 21200130012
Status: Unutilized
Reason: Extensive deterioration

Illinois

Bldgs. 58, 59 and 72, 69, 64, 105, 135
Rock Island Arsenal
Rock Island Co: Rock Island IL 61299–5000
Landholding Agency: Army
Property Number: 219110104–219110108, 219620427
Status: Unutilized
Reason: Secured Area

Bldgs. 133, 141 Rock Island Arsenal
Gillespie Avenue
Rock Island Co: Rock Island IL 61299–
Landholding Agency: Army
Property Number: 219210100, 219620428
Status: Unutilized
Reason: Extensive deterioration

16 Bldgs.
Charles Melvin Price Support Center
Granite City Co: Madison IL 62040
Landholding Agency: Army
Property Number: 219820027, 21199930042–21199930053
Status: Unutilized
Reason: Secured Area; Extensive deterioration; Floodway

Indiana

181 Bldgs.
Newport Army Ammunition Plant
Newport Co: Vermillion IN 47966–
Landholding Agency: Army
Property Number: 219011584, 219011586–219011587, 219011589–219011590, 219011592–219011627, 219011629–219011636, 219011638–219011641, 219210149–219210151, 219220220, 219230032–219230033, 219430336–219430338, 219520033, 219520042, 219530075–219530097, 219740021–219740026, 219820031–219820032, 21199920063
Status: Unutilized
Reason: Secured Area; (Some are extensively deteriorated.)

2 Bldgs.
Atterbury Reserve Forces Training Area
Edinburgh Co: Johnson IN 46124–1096
Landholding Agency: Army
Property Number: 219230030–219230031
Status: Unutilized
Reason: Extensive deterioration

Iowa

96 Bldgs.
Iowa Army Ammunition Plant

Middletown Co: Des Moines IA 52638–
Landholding Agency: Army
Property Number: 219012605–219012607, 219012609, 219012611, 219012613, 219012615, 219012620, 219012622, 219012624, 219013706–219013738, 219120172–219120174, 219440112–219440158, 219520002, 219520070, 219610414, 219740027
Status: Unutilized
Reason: (Many are in a Secured Area); (Most are within 2000 ft. of flammable or explosive material.)

27 Bldgs., Iowa Army Ammunition Plant
Middletown Co: Des Moines IA 52638
Landholding Agency: Army
Property Number: 219230005–219230029, 219310017, 219340091
Status: Unutilized
Reason: Extensive deterioration

Bldg. P003
Cedar Rapids AFRC
Cedar Rapids Co: Linn IA 52402–3799
Landholding Agency: Army
Property Number: 21200130017
Status: Unutilized
Reason: Extensive deterioration

Kansas

37 Bldgs.
Kansas Army Ammunition Plant
Production Area
Parsons Co: Labette KS 67357–
Landholding Agency: Army
Property Number: 219011909–219011945
Status: Unutilized
Reason: Secured Area; (Most are within 2000 ft. of flammable or explosive material)

10 Bldgs.
Fort Riley
Ft. Riley Co: Geary KS 66442–
Landholding Agency: Army
Property Number: 21200130018–21200130023
Status: Unutilized
Reason: Extensive deterioration

121 Bldgs.
Kansas Army Ammunition Plant
Parsons Co: Labette KS 67357
Landholding Agency: Army
Property Number: 219620518–219620638
Status: Unutilized
Reason: Secured Area

Bldg. P–417
Fort Leavenworth
Leavenworth KS 66027
Landholding Agency: Army
Property Number: 219740029
Status: Unutilized
Reason: Extensive deterioration; Sewage pump station

Kentucky

Bldg. 126
Lexington-Blue Grass Army Depot
Lexington Co: Fayette KY 40511–
Location: 12 miles northeast of Lexington, Kentucky
Landholding Agency: Army
Property Number: 219011661
Status: Unutilized
Reason: Secured Area; Sewage treatment facility

Bldg. 12
Lexington-Blue Grass Army Depot
Lexington Co: Fayette KY 40511–
Location: 12 miles Northeast of Lexington Kentucky
Landholding Agency: Army
Property Number: 219011663
Status: Unutilized
Reason: Industrial waste treatment plant

64 Bldgs., Fort Knox
Ft. Knox Co: Hardin KY 40121–
Landholding Agency: Army
Property Number: 21200110028, 21200130024–21200130029
Status: Unutilized
Reason: Extensive deterioration

20 Bldgs., Fort Campbell
Ft. Campbell Co: Christian KY 42223
Landholding Agency: Army
Property Number: 21200110030–21200110049
Status: Unutilized
Reason: Extensive deterioration

Louisiana

528 Bldgs.
Louisiana Army Ammunition Plant
Doylin Co: Webster LA 71023–
Landholding Agency: Army
Property Number: 219011714–219011716, 219011735–219011737, 219012112, 219013863–219013869, 219110131, 219240138–219240147, 219420332, 219610049–219610263, 219620002–219620200, 219620749–219620801, 219820047–219820078
Status: Unutilized
Reason: Secured Area; (Most are within 2000 ft. of flammable or explosive material); (Some are extensively deteriorated)

46 Bldgs., Fort Polk
Ft. Polk Co: Vernon Parish LA 71459–7100
Landholding Agency: Army
Property Number: 21199920070, 21199920078, 21199940074, 21199940075, 21200030044, 21200040025–21200040029, 21200110050–21200110051, 21200120058, 21200130030–21200130043
Status: Unutilized
Reason: Extensive deterioration; (Some are in Floodway)

Maryland

45 Bldgs.
Aberdeen Proving Ground
Aberdeen City Co: Harford MD 21005–5001
Landholding Agency: Army
Property Number: 219011417, 219012610, 219012637–219012642, 219012649, 219012650, 219012658–219012662, 219013773, 219014711, 219610480, 219610489–219610490, 219730077–219730078, 219810070–219810121, 219820090–219820096, 21200120059–21200120060
Status: Unutilized
Reason: Most are in a secured area. (Some are within 2000 ft. of flammable or explosive material); (Some are in a floodway); (Some are extensively deteriorated)

12 Bldgs. Ft. George G. Meade
Ft. Meade Co: Anne Arundel MD 20755–
Landholding Agency: Army
Property Number: 219710186, 219710192, 219740068–219740076, 219810065, 219810069, 21199910019, 21199940084, 21199940086
Status: Unutilized
Reason: Extensive deterioration

12 Bldgs.
Woodstock Military Rsv
Granite Co: Baltimore MD 22163
Landholding Agency: Army
Property Number: 21200130044–21200130052
Status: Unutilized
Reason: Extensive deterioration

Massachusetts

Bldg. 3462, Camp Edwards
Massachusetts Military Reservation
Bourne Co: Barnstable MA 024620–5003
Landholding Agency: Army
Property Number: 219230095
Status: Unutilized
Reason: Secured Area; Extensive deterioration

Bldgs. 3596, 1209–1211 Camp Edwards
Massachusetts Military Reservation
Bourne Co: Barnstable MA 02462–5003
Landholding Agency: Army
Property Number: 219230096, 219310018–219310020
Status: Unutilized
Reason: Secured Area

Facility No. 0G001
LTA Granby
Granby Co: Hampshire MA
Landholding Agency: Army
Property Number: 219810062
Status: Unutilized
Reason: Extensive deterioration

Michigan

Bldgs. 5755–5756
Newport Weekend Training Site
Carleton Co: Monroe MI 48166
Landholding Agency: Army
Property Number: 219310060–219310061
Status: Unutilized
Reason: Secured Area; Extensive deterioration

25 Bldgs.
Fort Custer Training Center
2501 26th Street
Augusta Co: Kalamazoo MI 49102–9205
Landholding Agency: Army
Property Number: 219014947–219014963, 219140447–219140454
Status: Unutilized
Reason: Secured Area

10 Bldgs.
Selfridge ANG Base
Selfridge Co: MI 48045
Landholding Agency: Army
Property Number: 21199930059, 21199940089–21199940093, 21200110052–21200110055
Status: Unutilized
Reason: Secured Area

Minnesota

173 Bldgs.
Twin Cities Army Ammunition Plant
New Brighton Co: Ramsey MN 55112–
Landholding Agency: Army
Property Number: 219120165–219120166, 219210014–219210015, 219220227–219220235, 219240328, 219310055–219310056, 219320145–219320156, 219330096–219330108, 219340015, 219410159–219410189, 219420195–219420283, 219430059–219430064, 21199840060, 21200130053–21200130054
Status: Unutilized

Reason: Secured Area; (Most are within 2000 ft. of flammable or explosive material.) (Some are extensively deteriorated)

Missouri

83 Bldgs.
Lake City Army Ammo. Plant
Independence Co: Jackson MO 64050–
Landholding Agency: Army
Property Number: 219013666–219013669, 219530134–219530138, 21199910023–21199910035, 21199920082, 21200030049
Status: Unutilized
Reason: Secured Area; (Some are within 2000 ft. of flammable or explosive material)

9 Bldgs.
St. Louis Army Ammunition Plant
4800 Goodfellow Blvd.
St. Louis Co: St. Louis MO 63120–1798
Landholding Agency: Army
Property Number: 219120067–219120068, 219610469–219610475
Status: Unutilized
Reason: Secured Area; (Some are extensively deteriorated.)

10 Bldgs.
Fort Leonard Wood
Ft. Leonard Wood Co: Pulaski MO 65473–5000
Landholding Agency: Army
Property Number: 219430070–219430075, 219830115–219830116, 21199910020–21199910021, 21200120063
Status: Unutilized
Reason: Within 2000 ft. of flammable or explosive material; (Some are extensively deteriorated.)

Montana

19 Bldgs.
Fort Harrison
Ft. Harrison Co: Lewis/Clark MT 59636
Landholding Agency: Army
Property Number: 219620473–219620475, 219740093–219740101
Status: Unutilized
Reason: Within 2000 ft. of flammable or explosive material; Extensive deterioration

Nevada

Bldg. 292
Hawthorne Army Ammunition Plant
Hawthorne Co: Mineral NV 89415–
Landholding Agency: Army
Property Number: 219013614
Status: Unutilized
Reason: Secured Area

Bldg. 396
Hawthorne Army Ammunition Plant
Bachelor Enlisted Qtrs W/Dining Facilities
Hawthorne Co: Mineral NV 89415–
Location: East side of Decatur Street—North of Maine Avenue
Landholding Agency: Army
Property Number: 219011997
Status: Unutilized
Reason: Within airport runway clear zone; Secured Area

39 Bldgs.
Hawthorne Army Ammunition Plant
Hawthorne Co: Mineral NV 89415–
Landholding Agency: Army
Property Number: 219012013, 219013615–219013643,
Status: Underutilized
Reason: Secured Area; (Some within airport runway clear zone; many within 2000 ft. of flammable or explosive material)

Group 101, 34 Bldgs.
Hawthorne Army Ammunition Plant Co: Mineral NV 89415–0015
Landholding Agency: Army
Property Number: 219830132
Status: Unutilized
Reason: Within 2000 ft. of flammable or explosive material; Secured Area

New Jersey

173 Bldgs.
Armament Res. Dev. & Eng. Ctr.
Picatinny Arsenal Co: Morris NJ 07806–5000
Landholding Agency: Army
Property Number: 219010440–219010474, 219010476, 219010478, 219010639–219010665, 219010671–219010721, 219012424, 219012427–219012428, 219012430, 219012433–219012466, 219012469–219012472, 219012475, 219012760, 219012763–219012767, 219014306–219014307, 219014311, 219014313–219014321, 219140617, 219230121–219230125, 219420001–219420002, 219420006–219420008, 219530144–219530150, 219540002–219540007, 219740110–219740127, 21200130055–21200130064
Status: Excess
Reason: Secured Area (Most are within 2000 ft. of flammable or explosive material.) (Some are extensively deteriorated); (Some are in a floodway)

Structure 403B
Armament Research, Dev. & Eng. Center
Picatinny Arsenal Co: Morris NJ 07806–5000
Landholding Agency: Army
Property Number: 219510001
Status: Unutilized
Reason: Drop Tower

9 Bldgs.
Armament Research
Picatinny Arsenal Co: Morris NJ 07806–5000
Landholding Agency: Army
Property Number: 21199940094–21199940099
Status: Unutilized
Reasons: unexploded ordnance; Extensive deterioration

Bldg. S05216
Fort Dix
Ft. Dix Co: Burlington NJ 08640–5505
Landholding Agency: Army
Property Number: 21200130065
Status: Unutilized
Reason: Extensive deterioration

Bldgs. 432, 899
Ft. Monmouth
Ft. Monmouth Co: NJ 07703
Landholding Agency: Army
Property Number: 21200110056–21200110057
Status: Unutilized
Reason: Extensive deterioration

New Mexico

Bldg. 23644
White Sands Missile Range
White Sands Co: Dona Ana NM 88002
Landholding Agency: Army
Property Number: 21200030057
Status: Unutilized
Reason: Extensive deterioration

New York

Bldgs. 110, 143, 2084, 2105, 2110
Seneca Army Depot
Romulus Co: Seneca NY 14541–5001
Landholding Agency: Army
Property Number: 219240439, 219240440–219240443
Status: Unutilized
Reason: Secured Area; Extensive deterioration

Parcel 19
Stewart Army Subpost, U.S. Military Academy
New Windsor Co: Orange NY 12553
Landholding Agency: Army
Property Number: 219730098
Status: Unutilized
Reason: Within airport runway clear zone

Bldg. 12
Watervliet Arsenal
Watervliet NY
Landholding Agency: Army
Property Number: 219730099
Status: Unutilized
Reason: Extensive deterioration

Bldg. 134
Watervliet Arsenal Co: Albany NY 12189–4050
Landholding Agency: Army
Property Number: 21199840068
Status: Unutilized
Reason: Secured Area

Bldgs. 4056, 4275
Stewart Army Subpost
New Windsor Co: Orange NY 12553
Landholding Agency: Army
Property Number: 21199930061
Status: Unutilized
Reason: Sewage pump station

North Carolina

85 Bldgs. Fort Bragg
Ft. Bragg Co: Cumberland NC 28307
Landholding Agency: Army
Property Number: 219620478, 219620480, 219640064, 219640074, 219710102–219710111, 219710224, 219810167, 219830117, 219830120, 21199930062–21199930067, 21200040032–21200040037
Status: Unutilized
Reason: Extensive deterioration

Bldgs. 16, 139, 261, 273
Military Ocean Terminal
Southport Co: Brunswick NC 28461–5000
Landholding Agency: Army
Property Number: 219530155, 219810158–219810160
Status: Unutilized
Reason: Secured Area

North Dakota

Bldgs. 440, 455, 456, 3101, 3110
Stanley R. Mickelsen
Nekoma Co: Cavalier ND 58355
Landholding Agency: Army
Property Number: 21199940103–21199940107
Status: Unutilized
Reason: Extensive deterioration

Ohio

190 Bldgs.
Ravenna Army Ammunition Plant
Ravenna Co: Portage OH 44266–9297
Landholding Agency: Army
Property Number: 219012476–219012507, 219012509–219012513, 219012515,

219012517–219012518, 219012520, 219012522–219012523, 219012525–219012528, 219012530–219012532, 219012534–219012535, 219012537, 219013670–219013677, 219013781, 219210148, 21199840069–21199840104, 21199930070–21199930072
Status: Unutilized
Reason: Secured Area

7 Bldgs.
Lima Army Tank Plant
Lima OH 45804–1898
Landholding Agency: Army
Property Number: 219730104–219730110
Status: Unutilized
Reason: Secured Area

9 Bldgs.
Defense Supply Center
Columbus Co: Franklin OH 43216–5000
Landholding Agency: Army
Property Number: 219830134, 21199910037, 21199930068, 21200020052, 21200110088, 21200130066–21200130069
Status: Unutilized
Reason: Extensive deterioration

Oklahoma

548 Bldgs.
McAlester Army Ammunition Plant
McAlester Co: Pittsburg OK 74501–5000
Landholding Agency: Army
Property Number: 219011674, 219011680, 219011684, 219011687, 219012113, 219013981–219013991, 219013994, 219014081–219014102, 219014104, 219014107–219014137, 219014141–219014159, 219014162, 219014165–219014216, 219014218–219014274, 219014336–219014559, 219030007–219030127, 219040004, 21199910039–21199910040
Status: Underutilized
Reason: Secured Area, (Some are within 2000 ft. of flammable or explosive material)

5 Bldgs.
Fort Sill
Lawton Co: Comanche OK 73503–
Landholding Agency: Army
Property Number: 219140550, 219510023, 219730342
Status: Unutilized
Reason: Extensive deterioration

33 Bldgs.
McAlester Army Ammunition Plant
McAlester Co: Pittsburg OK 74501
Landholding Agency: Army
Property Number: 219310050–219310052, 219320170–219320171, 219330149–219330160, 219430123–219430125, 219620485–219620490, 219630110–219630111, 219810174
Status: Unutilized
Reason: Secured Area; (Some are extensively deteriorated)

Oregon

11 Bldgs.
Tooele Army Depot
Umatilla Depot Activity
Hermiston Co: Morrow/Umatilla OR 97838–
Landholding Agency: Army
Property Number: 219012174–219012176, 219012178–219012179, 219012190–219012191, 219012197–219012198, 219012217, 219012229
Status: Underutilized
Reason: Secured Area

34 Bldgs.
Tooele Army Depot
Umatilla Depot Activity
Hermiston Co: Morrow/Umatilla OR 97838–
Landholding Agency: Army
Property Number: 219012177, 219012185–219012186, 219012189, 219012195–219012196, 219012199–219012205, 219012207–219012208, 219012225, 219012279, 219014304–219014305, 219014782, 219030362–219030363, 219120032, 21199840107–21199840110, 21199920084–21199920090
Status: Unutilized
Reason: Secured Area

Pennsylvania

59 Bldgs.
Fort Indiantown Gap
Annville Co: Lebanon PA 17003–5011
Landholding Agency: Army
Property Number: 219640337, 219730122–219730128, 219740137, 219810178–219810193
Status: Unutilized
Reason: Extensive deterioration

18 Bldgs.
Defense Distribution Depot
New Cumberland Co: York PA 17070–5001
Landholding Agency: Army
Property Number: 219830135, 21199940108–21199940112, 21200030060, 21200110058–21200110063, 21200130070–21200130072
Status: Unutilized
Reason: Secured Area

Rhode Island

Bldg. 104
Army Aviation
North Kingstown Co: Washington RI 02852
Landholding Agency: Army
Property Number: 21200120064
Status: Unutilized
Reason: Extensive deterioration

South Carolina

40 Bldgs., Fort Jackson
Ft. Jackson Co: Richland SC 29207
Landholding Agency: Army
Property Number: 219440237, 219440239, 219620312, 219620317, 219620348–219620351, 219640138–219640139, 21199640148–21199640149, 219720095, 219720097, 219730130, 219730132, 219730145–219730157, 219740138, 219820102–219820111, 219830139–219830157
Status: Unutilized
Reason: Extensive deterioration

Tennessee

33 Bldgs.
Holston Army Ammunition Plant
Kingsport Co: Hawkins TN 61299–6000
Landholding Agency: Army
Property Number: 219012304–219012309,219012311–219012312, 219012314, 219012316–219012317, 219012319, 219012325, 219012328, 219012330, 219012332, 219012334–219012335, 219012337, 219013789–219013790, 219030266, 219140613, 219330178, 219440212–219440216, 219510025–219510028, 21200040038
Status: Unutilized
Reason: Secured Area; (Some are within 2000 ft. of flammable or explosive material)

10 Bldgs.
Milan Army Ammunition Plant
Milan Co: Gibson TN 38358
Landholding Agency: Army
Property Number: 219240447–219240449, 219320182–219320184, 219330176–219330177, 219520034, 219740139
Status: Unutilized
Reason: Secured Area

Bldg. Z–183A
Milan Army Ammunition Plant
Milan Co: Gibson TN 38358
Landholding Agency: Army
Property Number: 219240783
Status: Unutilized
Reason: Within 2000 ft. of flammable or explosive material

Texas

20 Bldgs.
Lone Star Army Ammunition Plant
Highway 82 West
Texarkana Co: Bowie TX 75505–9100
Landholding Agency: Army
Property Number: 219012524, 219012529, 219012533, 219012536, 219012539–219012540, 219012542, 219012544–219012545, 219030337–219030345
Status: Unutilized
Reason: Within 2000 ft. of flammable or explosive material; Secured Area

225 Bldgs.
Longhorn Army Ammunition Plant
Karnack Co: Harrison TX 75661–
Location: State highway 43 north
Landholding Agency: Army
Property Number: 219012546, 219012548, 219610555-219610584, 219610635, 219620244–219620287, 219620827–219620837, 21200020054–21200020070
Status: Unutilized
Reason: Secured Area (Most are within 2000 ft. of flammable or explosive material)

16 Bldgs., Red River Army Depot
Texarkana Co: Bowie TX 75507–5000
Landholding Agency: Army
Property Number: 219420314–219420327, 219430094–219430097
Status: Unutilized
Reason: Secured Area (Some are extensively deteriorated)

3 Bldgs., Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 219640172, 219640177, 219640182
Status: Unutilized
Reason: Extensive Deterioration

Bldgs. T–2916, T–3180, T–3192, T–3398, T–2915
Fort Sam Houston
San Antonio Co: Bexar TX 78234–5000
Landholding Agency: Army
Property Number: 219330476–219330479, 219640181
Status: Unutilized
Reason: Detached latrines

80 Bldgs. Fort Bliss
El Paso Co: El Paso TX 79916
Landholding Agency: Army
Property Number: 219730160–219730186, 219830161–219830197
Status: Unutilized

Reason: Extensive deterioration

Starr Ranch, Bldg. 703B
Longhorn Army Ammunition Plant
Karnack Co: Harrison TX 75661
Landholding Agency: Army
Property Number: 219640186, 219640494
Status: Unutilized
Reason: Floodway

Utah

Bldgs. 4555, 4554
Tooele Army Depot
Tooele Co: Tooele UT 84074–5008
Landholding Agency: Army
Property Number: 219012166, 219030366,
Status: Unutilized
Reason: Secured Area

Bldg. S–4301
Tooele Army Depot
Tooele Co: Tooele UT 84074–5008
Landholding Agency: Army
Property Number: 219012751
Status: Underutilized
Reason: Secured Area

4 Bldgs.
Dugway Proving Ground
Dugway Co: Toole UT 84022–
Landholding Agency: Army
Property Number: 219013997, 219130012, 219130015, 21200120065
Status: Underutilized
Reason: Secured Area

51 Bldgs.
Dugway Proving Ground
Dugway Co: Toole UT 84022–
Landholding Agency: Army
Property Number: 219330181–219330182, 219330185, 219420328–219420329, 21199920091–21199920101
Status: Unutilized
Reason: Secured Area

Bldgs. 3102, 5145, 8030
Deseret Chemical Depot
Tooele UT 84074
Landholding Agency: Army
Property Number: 219820119–219820121
Status: Unutilized
Reason: Secured Area; Extensive deterioration

Virginia

323 Bldgs.
Radford Army Ammunition Plant
Radford Co: Montgomery VA 24141
Landholding Agency: Army
Property Number: 219010833, 219010836, 219010839, 219010842, 219010844, 219010847–219010890, 219010892–219010912, 219011521–219011577, 219011581–219011583, 219011585, 219011588, 219011591, 219013559–219013570, 219110142–219110143, 219120071, 219140618–219140633, 219440219–219440225, 219510031–219510033, 219610607–219610608, 219830223–219830267, 21200020079–21200020081
Status: Unutilized
Reason: Within 2000 ft. of flammable or explosive material; Secured Area

13 Bldgs.
Radford Army Ammunition Plant
Radford Co: Montgomery VA 24141
Landholding Agency: Army
Property Number: 219010834–219010835, 219010837–219010838, 219010840–219010841, 219010843, 219010845–219010846, 219010891, 219011578–219011580
Status: Unutilized
Reason: Within 2000 ft. of flammable or explosive material; Secured Area; Latrine, detached structure

40 Bldgs.
U.S. Army Combined Arms Support Command
Fort Lee Co: Prince George VA 23801–
Landholding Agency: Army
Property Number: 219240107, 219330210, 2129330219–219330220, 219330225–219330228, 219520062, 219610597, 219620497, 219620866–219620876, 219630115, 219740156, 219830208–219830210, 21199920117, 21199940128–21199940131, 21200030062, 21200040040, 21200110064-21200110066, 21200120067, 21200130078–21200130079
Status: Unutilized
Reason: Extensive deterioration (Some are in a secured area.)

16 Bldgs.
Radford Army Ammunition Plant
Radford VA 24141
Landholding Agency: Army
Property Number: 219220210–219220218, 219230100–219230103, 219520037
Status: Unutilized
Reason: Secured Area

Bldg. B7103–01, Motor House
Radford Army Ammunition Plant
Radford VA 24141
Landholding Agency: Army
Property Number: 219240324
Status: Unutilized
Reason: Secured Area, Within 2000 ft. of flammable or explosive material; Extensive deterioration

56 Bldgs.
Red Water Field Office
Radford Army Ammunition Plant
Radford VA 24141
Landholding Agency: Army
Property Number: 219430341–219430396
Status: Unutilized
Reason: Within 2000 ft. of flammable or explosive material; Secured Area

17 Bldgs.
Fort A.P. Hill
Bowling Green Co: Caroline VA 22427
Landholding Agency: Army
Property Number: 219510030, 219610588, 21199930079, 21200020073, 21200040041–21200040042, 21200110067–21200110069, 21200120066, 21200130074
Status: Unutilized
Reason: Secured Area; Extensive deterioration

Bldgs. 2013–00, B2013–00, A1601–00
Radford Army Ammunition Plant
Radford VA 24141
Landholding Agency: Army
Property Number: 219520052, 219530194
Status: Unutilized
Reason: Extensive deterioration

11 Bldgs.
Fort Belvoir
Ft. Belvoir Co: Fairfax VA 22060–5116
Landholding Agency: Army
Property Number: 21199910050–21199910051, 21199920107, 21199940117–21199940120, 21200030063–21200030064, 21200130075–21200130077
Status: Unutilized
Reason: Extensive deterioration

8 Bldgs.
Fort Story
Ft. Story Co: Princess Ann VA 23459
Landholding Agency: Army
Property Number: 219640506, 219710193, 21200040039
Status: Unutilized
Reason: Extensive deterioration

5 Bldgs., Fort Eustis
Ft. Eustis Co. VA 23604
Landholding Agency: Army
Property Number: 21199930074
Status: Unutilized
Reason: Extensive deterioration

Bldg. 448, Fort Myer
Ft. Myer Co: Arlington VA 22211–1199
Landholding Agency: Army
Property Number: 21200010069
Status: Underutilized
Reason: Extensive deterioration

Washington

656 Bldgs., Fort Lewis
Ft. Lewis Co: Pierce WA 98433–5000
Landholding Agency: Army
Property Number: 219610006–219610007, 219610009–219610010, 219610012, 219610042–219610046, 219620512–219620517, 219640193, 219720142–219720151, 219810205–219810242, 219820130–219820132, 21199840118, 21199910063–21199910080, 21199920125–21199920181, 21199930080–21199930105, 21199940134, 21200120068, 21200130080
Status: Unutilized
Reason: Secured Area; Extensive deterioration

10 Bldgs., Fort Lewis
Huckleberry Creek Mountain Training Site
Co: Pierce WA
Landholding Agency: Army
Property Number: 219740162–219740171
Status: Unutilized
Reason: Extensive deterioration

Bldg. 415, Fort Worden
Port Angeles Co: Clallam WA 98362
Landholding Agency: Army
Property Number: 21199910062
Status: Excess
Reason: Extensive deterioration

Bldg. U515A, Fort Lewis
Ft. Lewis Co: Pierce WA 98433
Landholding Agency: Army
Property Number: 21199920124
Status: Excess
Reason: gas chamber

12 Bldgs.
Yakima Training Center
Yakima Co: WA 98901
Landholding Agency: Army
Property Number: 21200010074, 21200120069–21200120076, 21200120084
Status: Unutilized
Reason: Extensive deterioration

Wisconsin

6 Bldgs.
Badger Army Ammunition Plant
Baraboo Co: Sauk WI 53913–
Landholding Agency: Army

Property Number: 219011094, 219011209–219011212, 219011217
Status: Underutilized
Reason: Within 2000 ft. of flammable or explosive material; Friable asbestos; Secured Area

153 Bldgs.
Badger Army Ammunition Plant
Baraboo Co: Sauk WI 53913–
Landholding Agency: Army
Property Number: 219011104, 219011106, 219011108–219011113, 219011115–219011117, 219011119–219011120, 219011122–219011139, 219011141–219011142, 219011144, 219011148–219011208, 219011213–219011216, 219011218–219011234, 219011236, 219011238, 219011240, 219011242, 219011244, 219011247, 219011249, 219011251, 219011256, 19011259, 219011263, 219011265, 219011268, 219011270, 219011275, 219011277, 219011280, 219011282, 219011284, 219011286, 219011290, 219011293, 219011295, 219011297, 219011300, 219011302, 219011304– 219011311, 219011317, 219011319–219011321, 219011323
Status: Unutilized
Reason: Within 2000 ft. of flammable or explosive material; Friable asbestos; Secured Area

4 Bldgs.
Badger Army Ammunition Plant
Baraboo Co: Sauk WI
Landholding Agency: Army
Property Number: 219013871–219013873, 219013875
Status: Underutilized
Reason: Secured Area

22 Bldgs.
Badger Army Ammunition Plant
Baraboo Co: Sauk WI
Landholding Agency: Army
Property Number: 219013876–219013878, 219220295–219220311, 219510065, 219510067
Status: Unutilized
Reason: Secured Area

743 Bldgs.
Badger Army Ammunition Plant
Baraboo Co: Sauk WI 53913–
Landholding Agency: Army
Property Number: 219210097–219210099, 219740184–219740271, 21200020083–21200020155
Status: Unutilized
Reason: Within 2000 ft. of flammable or explosive material; Secured Area

124 Bldgs.
Badger Army Ammunition Plant
Baraboo Co: Sauk WI 53913
Landholding Agency: Army
Property Number: 219510069–219510077
Status: Unutilized
Reason: Secured Area; Extensive deterioration

Land (By State)

Alabama

23 acres and 2284 acres
Alabama Army Ammunition Plant
110 Hwy. 235
Childersburg Co: Talladega AL 35044–
Landholding Agency: Army
Property Number: 219210095–219210096
Status: Excess
Reason: Secured Area

Indiana

Newport Army Ammunition Plant
East of 14th St. & North of S. Blvd.
Newport Co: Vermillion IN 47966–
Landholding Agency: Army
Property Number: 219012360
Status: Unutilized
Reason: Within 2000 ft. of flammable or explosive material; Secured Area

Maryland

Carroll Island, Graces Quarters
Aberdeen Proving Ground
Edgewood Area
Aberdeen City Co: Harford MD 21010–5425
Landholding Agency: Army
Property Number: 219012630, 219012632
Status: Underutilized
Reason: Floodway; Secured Area

Minnesota

Portion of R.R. Spur
Twin Cities Army Ammunition Plant
New Brighton Co: Ramsey MN 55112
Landholding Agency: Army
Property Number: 219620472
Status: Unutilized
Reason: landlocked

New Jersey

Land
Armament Research Development & Eng. Center
Route 15 North
Picatinny Arsenal Co: Morris NJ 07806–
Landholding Agency: Army
Property Number: 219013788
Status: Unutilized
Reason: Secured Area

Spur Line/Right of Way
Armament Rsch., Dev., & Eng. Center
Picatinny Arsenal Co: Morris NJ 07806–5000
Landholding Agency: Army
Property Number: 219530143
Status: Unutilized
Reason: Floodway

2.0 Acres, Berkshire Trail
Armament Rsch., Dev., & Eng. Center
Picatinny Arsenal Co: Morris NJ 07806–5000
Landholding Agency: Army
Property Number: 21199910036
Status: Underutilized
Reasons: Within 2000 ft. of flammable or explosive material; Secured Area

Ohio

0.4051 acres, Lot 40 & 41
Ravenna Army Ammunition Plant
Ravenna Co: Portage OH 44266–9297
Landholding Agency: Army
Property Number: 219630109
Status: Excess
Reason: Within 2000 ft. of flammable or explosive material

Oklahoma

McAlester Army Ammunition Plant
McAlester Co: Pittsburg OK 74501–
Landholding Agency: Army
Property Number: 219014603
Status: Underutilized
Reason: Within 2000 ft. of flammable or explosive material

Texas

Land—Approx. 50 acres
Lone Star Army Ammunition Plant
Texarkana Co: Bowie TX 75505–9100
Landholding Agency: Army
Property Number: 219420308
Status: Unutilized
Reason: Secured Area

Training Land (3.764 acres)
Camp Swift Military Rsv.
Bastrop Co: TX
Landholding Agency: Army
Property Number: 21200130073
Status: Unutilized
Reason: Secured Area

Wisconsin

Land
Badger Army Ammunition Plant
Baraboo Co: Sauk WI 53913–
Location: Vacant land within plant boundaries
Landholding Agency: Army
Property Number: 219013783
Status: Unutilized
Reason: Secured Area

[FR Doc. 01–21215 Filed 8–23–01; 8:45 am]
BILLING CODE 4210–29–P

Reader Aids

Federal Register

Vol. 66, No. 165

Friday, August 24, 2001

CUSTOMER SERVICE AND INFORMATION

Federal Register/Code of Federal Regulations

General Information, indexes and other finding aids — **202–523–5227**

Laws — **523–5227**

Presidential Documents

Executive orders and proclamations — **523–5227**

The United States Government Manual — **523–5227**

Other Services

Electronic and on-line services (voice) — **523–4534**

Privacy Act Compilation — **523–3187**

Public Laws Update Service (numbers, dates, etc.) — **523–6641**

TTY for the deaf-and-hard-of-hearing — **523–5229**

ELECTRONIC RESEARCH

World Wide Web

Full text of the daily Federal Register, CFR and other publications:

http://www.access.gpo.gov/nara

Federal Register information and research tools, including Public Inspection List, indexes, and links to GPO Access:

http://www.nara.gov/fedreg

E-mail

PENS (Public Law Electronic Notification Service) is an E-mail service for notification of recently enacted Public Laws. To subscribe, send E-mail to

listserv@listserv.gsa.gov

with the text message:

subscribe PUBLAWS-L your name

Use listserv@www.gsa.gov only to subscribe or unsubscribe to PENS. We cannot respond to specific inquiries.

Reference questions. Send questions and comments about the Federal Register system to:

info@fedreg.nara.gov

The Federal Register staff cannot interpret specific documents or regulations.

FEDERAL REGISTER PAGES AND DATE, AUGUST

39615–40106 1
40107–40572 2
40573–40838 3
40839–41128 6
41129–41438 7
41439–41754 8
41755–42104 9
42105–42412 10
42413–42597 13
42587–42728 14
42729–42928 15
42929–43064 16
43065–43460 17
43461–43760 20
43761–44024 21
44025–44290 22
44291–44520 23
44521–44944 24

CFR PARTS AFFECTED DURING AUGUST

At the end of each month, the Office of the Federal Register publishes separately a List of CFR Sections Affected (LSA), which lists parts and sections affected by documents published since the revision date of each title.

1 CFR

11 44523

3 CFR

Executive Orders:

12002 (See EO 13222) 44025
12214 (See EO 13222) 44025
12722 (See Notice of July 31, 2001) 40105
12724 (See Notice of July 31, 2001) 40105
12735 (See EO 13222) 44025
12755 (See EO 13222) 44025
12851 (See Eo 13222) 44025
13026 (See EO 13222) 44025
13221 40571
13222 44025

Administrative Orders:

Presidential Determinations:
No. 2001-22 of July 26, 2001 40107
No. 2001-23 of August 9, 2001 44521
Notices:
Notice of July 31, 2001 40105

5 CFR

1605 44276
1606 44276
1650 43461

7 CFR

20 44291
301 ..... 40573, 40923, 41439, 43065
457 42729
916 39615
917 39615
924 42413
959 39621
989 39623
1744 41755
1755 ..... 43310, 43314

Proposed Rules:

56 42456
58 42458
70 42456
246 40152
911 40923
916 39690
944 ..... 40845, 40923
948 ..... 40153, 40155
966 40158
982 44086
993 43534
1205 42464
1230 42469

8 CFR

212 42587
214 42587
245 42587
248 42587
274a 42587

Proposed Rules:

103 41456

9 CFR

54 43964
79 43964
94 42595
95 42595
130 39628
317 40843
381 40843

Proposed Rules:

317 41160
327 ..... 41160, 42472

10 CFR

72 43761

Proposed Rules:

50 40626
72 43810
430 43123

12 CFR

202 41439
205 41439
208 42929
213 41439
220 44525
226 ..... 41439, 43463
230 41439
709 40574
712 40575
721 40845
749 40578
1411 44027

Proposed Rules:

611 43536
614 43536
701 40641
702 40642
741 40642
925 ..... 41462, 43961
930 ..... 41462, 41474, 43961
931 ..... 41462, 43961
932 ..... 41462, 41474, 43961
933 ..... 41462, 43961

14 CFR

23 40580
39 ..... 39632, 40109, 40582, 40850, 40860, 40863, 40864, 40867, 40869, 40870, 40872,

REMINDERS

The items in this list were editorially compiled as an aid to Federal Register users. Inclusion or exclusion from this list has no legal significance.

RULES GOING INTO EFFECT AUGUST 24, 2001

AGRICULTURE DEPARTMENT

Export sales reporting requirements:
- Beef and pork; published 7-25-01

COMMERCE DEPARTMENT

National Oceanic and Atmospheric Administration

Endangered and threatened species:
- Sea turtle conservation—
  - Leatherback sea turtles incidentally captured by California/Oregon drift gillnet fishery; published 8-24-01

COMMERCE DEPARTMENT

Patent and Trademark Office

Registration of agents; interpretation; published 8-24-01

ENVIRONMENTAL PROTECTION AGENCY

Air quality implementation plans; approval and promulgation; various States:
- Arizona; published 7-25-01
- California; published 7-25-01
- Pennsylvania; published 6-25-01

HEALTH AND HUMAN SERVICES DEPARTMENT

Health Care Financing Administration

Medicaid:
- State Children's Health Insurance Program; implementation; published 6-25-01

SMALL BUSINESS ADMINISTRATION

Disaster loan program:
- Military reservist economic injury disaster loans; published 7-25-01

TRANSPORTATION DEPARTMENT

Federal Aviation Administration

Airworthiness directives:
- Boeing; published 7-20-01

TREASURY DEPARTMENT

Fiscal Service

Book-entry Treasury bonds, notes, and bills:
- Uniform Commercial Code; substantially indentical State statute determinations—
  - South Carolina; published 8-24-01

VETERANS AFFAIRS DEPARTMENT

Adjudication; pensions, compensation, dependency, etc.; and disabilities rating schedule:
- Adaptive equipment for automobiles or other conveyances; eligibility certification; published 8-24-01

COMMENTS DUE NEXT WEEK

AGRICULTURE DEPARTMENT

Agricultural Marketing Service

Cherries (tart) grown in—
- Michigan et al.; comments due by 8-30-01; published 7-31-01

Hass Avocado Promotion, Research, and Consumer Information Order; industry-funded research, promotion and information program; comments due by 8-27-01; published 7-13-01

Hass Avocado Promotion, Research, and Information Order; referendum procedures; comments due by 8-27-01; published 7-13-01

Nectarines grown in—
- California; comments due by 8-31-01; published 8-1-01

Raisins produced from grapes grown in—
- California; comments due by 8-31-01; published 8-1-01

AGRICULTURE DEPARTMENT

Natural Resources Conservation Service

Conservation operations:
- Private grazing land resources; technical assistance; comments due by 8-28-01; published 6-29-01

COMMERCE DEPARTMENT

National Oceanic and Atmospheric Administration

Endangered and threatened species:
- Atlantic Ocean and Gulf of Mexico; sea turtle interactions with fishing activities; environmental impact statement; comments due by 8-30-01; published 7-31-01

Fishery conservation and management:
- Atlantic coastal fisheries cooperative management—
  - Horeshoe crabs; comments due by 8-30-01; published 8-15-01
- West Coast States and Western Pacific fisheries—
  - Salmon; comments due by 8-28-01; published 8-13-01
  - Western Pacific Community Development Program and western Pacific demonstration projects; eligibility criteria and definitions; comments due by 8-27-01; published 7-27-01

ENVIRONMENTAL PROTECTION AGENCY

Air pollution control:
- State operating permits programs—
  - Alaska; comments due by 8-27-01; published 7-26-01
  - Alaska; comments due by 8-27-01; published 7-26-01
  - Florida; comments due by 8-31-01; published 7-2-01
  - Indiana; comments due by 8-29-01; published 7-30-01

Air pollution control; new motor vehicles and engines:
- Light-duty vehicles and trucks and heavy duty vehicles and engines; on-board diagnostic systems and emission-related repairs; comments due by 8-27-01; published 8-6-01

Air quality implementation plans; approval and promulgation; various States:
- Maryland; comments due by 8-30-01; published 7-31-01
- New Hampshire; comments due by 8-27-01; published 7-27-01

Air quality planning purposes; designation of areas:
- Oregon; comments due by 8-27-01; published 7-26-01

Hazardous waste:
- Identification and listing—
  - Exclusions; comments due by 8-27-01; published 7-13-01

Pesticides; tolerances in food, animal feeds, and raw agricultural commodities:
- Bifenazate; comments due by 8-28-01; published 6-29-01

Superfund program:
- National oil and hazardous substances contingency plan—
  - National priorities list update; comments due by 8-29-01; published 7-30-01
  - National priorities list update; comments due by 8-29-01; published 7-30-01
  - National priorities list update; comments due by 8-29-01; published 7-30-01
  - National priorities list update; comments due by 8-29-01; published 7-30-01

Water pollution control:
- Marine sanitation devices—
  - Florida Keys National Marine Sanctuary, FL; no discharge zone; comments due by 8-27-01; published 7-26-01

Water pollution; effluent guidelines for point source categories:
- Coal mining; comments due by 8-29-01; published 7-30-01

FEDERAL COMMUNICATIONS COMMISSION

Common carrier services:
- Individuals with hearing and speech disabilities; telecommunications relay services
  - Correction; comments due by 8-30-01; published 8-3-01

Radio frequency devices:
- Spread spectrum systems operating in 2.4 GHz band; spectrum sharing and new digital transmission technologies introduction; comments due by 8-27-01; published 6-12-01

Radio stations; table of assignments:
- Texas; comments due by 8-27-01; published 7-19-01

Television stations; table of assignments:
- Kentucky; comments due by 8-27-01; published 7-18-01

HEALTH AND HUMAN SERVICES DEPARTMENT

Food and Drug Administration

Human drugs:
- Topical antifungal products (OTC); final monograph

amendment; comments due by 8-27-01; published 5-29-01

HOUSING AND URBAN DEVELOPMENT DEPARTMENT

Mortgage and loan insurance programs:

Multifamily housing programs; mortgage insurance premiums; comments due by 8-31-01; published 7-2-01

INTERIOR DEPARTMENT

Surface Mining Reclamation and Enforcement Office

Permanent program and abandoned mine land reclamation plan submissions:

Kentucky; comments due by 8-30-01; published 8-15-01

JUSTICE DEPARTMENT

DNA Analysis Backlog Elimination Act of 2000; implementation; comments due by 8-27-01; published 6-28-01

STATE DEPARTMENT

Visas; immigrant documentation:

Diversity Immigration Program; comments due by 8-30-01; published 7-31-01

TRANSPORTATION DEPARTMENT

Coast Guard

Boating safety:

Personal flotation devices for children; Federal requirements for wearing aboard recreational vessels; comments due by 8-29-01; published 5-1-01

TRANSPORTATION DEPARTMENT

Federal Aviation Administration

Airworthiness directives:

Boeing; comments due by 8-27-01; published 6-27-01

British Aerospace; comments due by 8-30-01; published 7-18-01

Eurocopter France; comments due by 8-27-01; published 6-27-01

Raytheon; comments due by 8-30-01; published 7-11-01

Class E airspace; comments due by 8-30-01; published 7-16-01

TREASURY DEPARTMENT

Comptroller of the Currency

Bank activities and operations:

Electronic banking; comments due by 8-31-01; published 7-2-01

VETERANS AFFAIRS DEPARTMENT

Construction or acquisition of State homes; grants to States; comments due by 8-27-01; published 6-26-01

LIST OF PUBLIC LAWS

This is a continuing list of public bills from the current session of Congress which have become Federal laws. It may be used in conjunction with ''P L U S'' (Public Laws Update Service) on 202–523–6641. This list is also available online at http://www.nara.gov/fedreg.

The text of laws is not published in the **Federal Register** but may be ordered in ''slip law'' (individual pamphlet) form from the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402 (phone, 202–512–1808). The text will also be made available on the Internet from GPO Access at http://www.access.gpo.gov/nara/index.html. Some laws may not yet be available.

H.R. 2213/P.L. 107–25

To respond to the continuing economic crisis adversely affecting American agricultural producers. (Aug. 13, 2001; 115 Stat. 201)

H.R. 2131/P.L. 107–26

To reauthorize the Tropical Forest Conservation Act of 1998 through fiscal year 2004, and for other purposes. (Aug. 17, 2001; 115 Stat. 206)

Last List August 7, 2001

Public Laws Electronic Notification Service (PENS)

PENS is a free electronic mail notification service of newly enacted public laws. To subscribe, go to http://hydra.gsa.gov/archives/publaws-l.html or send E-mail to **listserv@listserv.gsa.gov** with the following text message:

SUBSCRIBE PUBLAWS-L Your Name.

Note: This service is strictly for E-mail notification of new laws. The text of laws is not available through this service. **PENS** cannot respond to specific inquiries sent to this address.